{"docstore/data": {"2b35cef7-27ec-4c77-8741-7536e1b99e5c": {"__data__": {"id_": "2b35cef7-27ec-4c77-8741-7536e1b99e5c", "embedding": null, "metadata": {"window": " \nPage 1 of 19 \n \nQ2 FY24 Cardinal Health, Inc.  Earnings \nConference Call  \nFebruary 1, 2024 , 8:30AM Eastern  \n \nOperator :  Good day , and welcome to today's Second Quarter Financial Year 2024 Cardinal Health \nEarnings Conference Call.  This meeting is being recorded.  At this time, I'd like to hand the call over to \nMatt Sims, Vice President of Investor Relations. ", "original_text": " \nPage 1 of 19 \n \nQ2 FY24 Cardinal Health, Inc. ", "page_label": "1", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "a4414d54-6710-431a-9934-c424ca18a68a", "node_type": "4", "metadata": {"page_label": "1", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "db9341b5ca61c774614e85db93e9685d87e88c142ca1cdb509ea4c52d573440c", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "53c01b19-2681-45a7-9265-bb1f9166ed3e", "node_type": "1", "metadata": {"window": " \nPage 1 of 19 \n \nQ2 FY24 Cardinal Health, Inc.  Earnings \nConference Call  \nFebruary 1, 2024 , 8:30AM Eastern  \n \nOperator :  Good day , and welcome to today's Second Quarter Financial Year 2024 Cardinal Health \nEarnings Conference Call.  This meeting is being recorded.  At this time, I'd like to hand the call over to \nMatt Sims, Vice President of Investor Relations.  Please go ahead, sir.  \n \n", "original_text": "Earnings \nConference Call  \nFebruary 1, 2024 , 8:30AM Eastern  \n \nOperator :  Good day , and welcome to today's Second Quarter Financial Year 2024 Cardinal Health \nEarnings Conference Call. "}, "hash": "3491e24d92e785b389de41369df849686f98e408c7b2dff7dd38429cdd6d74ab", "class_name": "RelatedNodeInfo"}}, "text": " \nPage 1 of 19 \n \nQ2 FY24 Cardinal Health, Inc. ", "start_char_idx": 0, "end_char_idx": 48, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "53c01b19-2681-45a7-9265-bb1f9166ed3e": {"__data__": {"id_": "53c01b19-2681-45a7-9265-bb1f9166ed3e", "embedding": null, "metadata": {"window": " \nPage 1 of 19 \n \nQ2 FY24 Cardinal Health, Inc.  Earnings \nConference Call  \nFebruary 1, 2024 , 8:30AM Eastern  \n \nOperator :  Good day , and welcome to today's Second Quarter Financial Year 2024 Cardinal Health \nEarnings Conference Call.  This meeting is being recorded.  At this time, I'd like to hand the call over to \nMatt Sims, Vice President of Investor Relations.  Please go ahead, sir.  \n \n", "original_text": "Earnings \nConference Call  \nFebruary 1, 2024 , 8:30AM Eastern  \n \nOperator :  Good day , and welcome to today's Second Quarter Financial Year 2024 Cardinal Health \nEarnings Conference Call. ", "page_label": "1", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "a4414d54-6710-431a-9934-c424ca18a68a", "node_type": "4", "metadata": {"page_label": "1", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "db9341b5ca61c774614e85db93e9685d87e88c142ca1cdb509ea4c52d573440c", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "2b35cef7-27ec-4c77-8741-7536e1b99e5c", "node_type": "1", "metadata": {"window": " \nPage 1 of 19 \n \nQ2 FY24 Cardinal Health, Inc.  Earnings \nConference Call  \nFebruary 1, 2024 , 8:30AM Eastern  \n \nOperator :  Good day , and welcome to today's Second Quarter Financial Year 2024 Cardinal Health \nEarnings Conference Call.  This meeting is being recorded.  At this time, I'd like to hand the call over to \nMatt Sims, Vice President of Investor Relations. ", "original_text": " \nPage 1 of 19 \n \nQ2 FY24 Cardinal Health, Inc. ", "page_label": "1", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "5885b3ee05bdef57a81dcf35e5f40b2e2baa987f12dc97197cfd431cc53d13f9", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "24cde944-6af4-4357-9a9d-9b91e6aa55a6", "node_type": "1", "metadata": {"window": " \nPage 1 of 19 \n \nQ2 FY24 Cardinal Health, Inc.  Earnings \nConference Call  \nFebruary 1, 2024 , 8:30AM Eastern  \n \nOperator :  Good day , and welcome to today's Second Quarter Financial Year 2024 Cardinal Health \nEarnings Conference Call.  This meeting is being recorded.  At this time, I'd like to hand the call over to \nMatt Sims, Vice President of Investor Relations.  Please go ahead, sir.  \n \n Matt Sims :  Welcome to this morning\u2019s Cardinal Health Second -Quarter Fiscal 2024 Earnings \nconference call and thank you for joining us. ", "original_text": "This meeting is being recorded. "}, "hash": "44abbb66ddafd3a0c948db63406f65bbbb15eb5a5b7dd901fe28728459131960", "class_name": "RelatedNodeInfo"}}, "text": "Earnings \nConference Call  \nFebruary 1, 2024 , 8:30AM Eastern  \n \nOperator :  Good day , and welcome to today's Second Quarter Financial Year 2024 Cardinal Health \nEarnings Conference Call. ", "start_char_idx": 48, "end_char_idx": 238, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "24cde944-6af4-4357-9a9d-9b91e6aa55a6": {"__data__": {"id_": "24cde944-6af4-4357-9a9d-9b91e6aa55a6", "embedding": null, "metadata": {"window": " \nPage 1 of 19 \n \nQ2 FY24 Cardinal Health, Inc.  Earnings \nConference Call  \nFebruary 1, 2024 , 8:30AM Eastern  \n \nOperator :  Good day , and welcome to today's Second Quarter Financial Year 2024 Cardinal Health \nEarnings Conference Call.  This meeting is being recorded.  At this time, I'd like to hand the call over to \nMatt Sims, Vice President of Investor Relations.  Please go ahead, sir.  \n \n Matt Sims :  Welcome to this morning\u2019s Cardinal Health Second -Quarter Fiscal 2024 Earnings \nconference call and thank you for joining us. ", "original_text": "This meeting is being recorded. ", "page_label": "1", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "a4414d54-6710-431a-9934-c424ca18a68a", "node_type": "4", "metadata": {"page_label": "1", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "db9341b5ca61c774614e85db93e9685d87e88c142ca1cdb509ea4c52d573440c", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "53c01b19-2681-45a7-9265-bb1f9166ed3e", "node_type": "1", "metadata": {"window": " \nPage 1 of 19 \n \nQ2 FY24 Cardinal Health, Inc.  Earnings \nConference Call  \nFebruary 1, 2024 , 8:30AM Eastern  \n \nOperator :  Good day , and welcome to today's Second Quarter Financial Year 2024 Cardinal Health \nEarnings Conference Call.  This meeting is being recorded.  At this time, I'd like to hand the call over to \nMatt Sims, Vice President of Investor Relations.  Please go ahead, sir.  \n \n", "original_text": "Earnings \nConference Call  \nFebruary 1, 2024 , 8:30AM Eastern  \n \nOperator :  Good day , and welcome to today's Second Quarter Financial Year 2024 Cardinal Health \nEarnings Conference Call. ", "page_label": "1", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "f3d4911e66b0f663f8639b0bc9ae3abf3c54393ee026af5a0121028d0edc5405", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "e91ab319-1bc7-40c3-9b80-2d2fb51957a3", "node_type": "1", "metadata": {"window": " \nPage 1 of 19 \n \nQ2 FY24 Cardinal Health, Inc.  Earnings \nConference Call  \nFebruary 1, 2024 , 8:30AM Eastern  \n \nOperator :  Good day , and welcome to today's Second Quarter Financial Year 2024 Cardinal Health \nEarnings Conference Call.  This meeting is being recorded.  At this time, I'd like to hand the call over to \nMatt Sims, Vice President of Investor Relations.  Please go ahead, sir.  \n \n Matt Sims :  Welcome to this morning\u2019s Cardinal Health Second -Quarter Fiscal 2024 Earnings \nconference call and thank you for joining us.  With me today are Cardinal Health\u2019s CEO, Jason Hollar, \nand our CFO, Aaron Alt .  \n \n", "original_text": "At this time, I'd like to hand the call over to \nMatt Sims, Vice President of Investor Relations. "}, "hash": "89cc88d7295af6c18db30188119720782d8b510abbf845eb3cb7d604e7f44a0c", "class_name": "RelatedNodeInfo"}}, "text": "This meeting is being recorded. ", "start_char_idx": 238, "end_char_idx": 270, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "e91ab319-1bc7-40c3-9b80-2d2fb51957a3": {"__data__": {"id_": "e91ab319-1bc7-40c3-9b80-2d2fb51957a3", "embedding": null, "metadata": {"window": " \nPage 1 of 19 \n \nQ2 FY24 Cardinal Health, Inc.  Earnings \nConference Call  \nFebruary 1, 2024 , 8:30AM Eastern  \n \nOperator :  Good day , and welcome to today's Second Quarter Financial Year 2024 Cardinal Health \nEarnings Conference Call.  This meeting is being recorded.  At this time, I'd like to hand the call over to \nMatt Sims, Vice President of Investor Relations.  Please go ahead, sir.  \n \n Matt Sims :  Welcome to this morning\u2019s Cardinal Health Second -Quarter Fiscal 2024 Earnings \nconference call and thank you for joining us.  With me today are Cardinal Health\u2019s CEO, Jason Hollar, \nand our CFO, Aaron Alt .  \n \n", "original_text": "At this time, I'd like to hand the call over to \nMatt Sims, Vice President of Investor Relations. ", "page_label": "1", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "a4414d54-6710-431a-9934-c424ca18a68a", "node_type": "4", "metadata": {"page_label": "1", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "db9341b5ca61c774614e85db93e9685d87e88c142ca1cdb509ea4c52d573440c", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "24cde944-6af4-4357-9a9d-9b91e6aa55a6", "node_type": "1", "metadata": {"window": " \nPage 1 of 19 \n \nQ2 FY24 Cardinal Health, Inc.  Earnings \nConference Call  \nFebruary 1, 2024 , 8:30AM Eastern  \n \nOperator :  Good day , and welcome to today's Second Quarter Financial Year 2024 Cardinal Health \nEarnings Conference Call.  This meeting is being recorded.  At this time, I'd like to hand the call over to \nMatt Sims, Vice President of Investor Relations.  Please go ahead, sir.  \n \n Matt Sims :  Welcome to this morning\u2019s Cardinal Health Second -Quarter Fiscal 2024 Earnings \nconference call and thank you for joining us. ", "original_text": "This meeting is being recorded. ", "page_label": "1", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "da2c2a392694e2b87f703b8934245aaf91b73b81feba4bbff97100e121d7b80e", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "a0d3e3d1-e0ef-4ae0-b22f-afc8bf26f8da", "node_type": "1", "metadata": {"window": "Earnings \nConference Call  \nFebruary 1, 2024 , 8:30AM Eastern  \n \nOperator :  Good day , and welcome to today's Second Quarter Financial Year 2024 Cardinal Health \nEarnings Conference Call.  This meeting is being recorded.  At this time, I'd like to hand the call over to \nMatt Sims, Vice President of Investor Relations.  Please go ahead, sir.  \n \n Matt Sims :  Welcome to this morning\u2019s Cardinal Health Second -Quarter Fiscal 2024 Earnings \nconference call and thank you for joining us.  With me today are Cardinal Health\u2019s CEO, Jason Hollar, \nand our CFO, Aaron Alt .  \n \n You can find t his morning\u2019s press release and investor  presentation on the investor relations  section \nof our website at ir.cardinalhealth.com . ", "original_text": "Please go ahead, sir.  \n \n"}, "hash": "05346f99c031f85aa524766344681db4d8fc617370351a9e67cdd4320fc48e7f", "class_name": "RelatedNodeInfo"}}, "text": "At this time, I'd like to hand the call over to \nMatt Sims, Vice President of Investor Relations. ", "start_char_idx": 270, "end_char_idx": 368, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "a0d3e3d1-e0ef-4ae0-b22f-afc8bf26f8da": {"__data__": {"id_": "a0d3e3d1-e0ef-4ae0-b22f-afc8bf26f8da", "embedding": null, "metadata": {"window": "Earnings \nConference Call  \nFebruary 1, 2024 , 8:30AM Eastern  \n \nOperator :  Good day , and welcome to today's Second Quarter Financial Year 2024 Cardinal Health \nEarnings Conference Call.  This meeting is being recorded.  At this time, I'd like to hand the call over to \nMatt Sims, Vice President of Investor Relations.  Please go ahead, sir.  \n \n Matt Sims :  Welcome to this morning\u2019s Cardinal Health Second -Quarter Fiscal 2024 Earnings \nconference call and thank you for joining us.  With me today are Cardinal Health\u2019s CEO, Jason Hollar, \nand our CFO, Aaron Alt .  \n \n You can find t his morning\u2019s press release and investor  presentation on the investor relations  section \nof our website at ir.cardinalhealth.com . ", "original_text": "Please go ahead, sir.  \n \n", "page_label": "1", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "a4414d54-6710-431a-9934-c424ca18a68a", "node_type": "4", "metadata": {"page_label": "1", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "db9341b5ca61c774614e85db93e9685d87e88c142ca1cdb509ea4c52d573440c", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "e91ab319-1bc7-40c3-9b80-2d2fb51957a3", "node_type": "1", "metadata": {"window": " \nPage 1 of 19 \n \nQ2 FY24 Cardinal Health, Inc.  Earnings \nConference Call  \nFebruary 1, 2024 , 8:30AM Eastern  \n \nOperator :  Good day , and welcome to today's Second Quarter Financial Year 2024 Cardinal Health \nEarnings Conference Call.  This meeting is being recorded.  At this time, I'd like to hand the call over to \nMatt Sims, Vice President of Investor Relations.  Please go ahead, sir.  \n \n Matt Sims :  Welcome to this morning\u2019s Cardinal Health Second -Quarter Fiscal 2024 Earnings \nconference call and thank you for joining us.  With me today are Cardinal Health\u2019s CEO, Jason Hollar, \nand our CFO, Aaron Alt .  \n \n", "original_text": "At this time, I'd like to hand the call over to \nMatt Sims, Vice President of Investor Relations. ", "page_label": "1", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "2439fb859f3d60ec28944ca473f9aaab9929df5dea19204fa9ff40afa9876e7d", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "1196d81d-6394-4c13-9b9f-480c3a22c0b9", "node_type": "1", "metadata": {"window": "This meeting is being recorded.  At this time, I'd like to hand the call over to \nMatt Sims, Vice President of Investor Relations.  Please go ahead, sir.  \n \n Matt Sims :  Welcome to this morning\u2019s Cardinal Health Second -Quarter Fiscal 2024 Earnings \nconference call and thank you for joining us.  With me today are Cardinal Health\u2019s CEO, Jason Hollar, \nand our CFO, Aaron Alt .  \n \n You can find t his morning\u2019s press release and investor  presentation on the investor relations  section \nof our website at ir.cardinalhealth.com .  Before I turn the call over to Jaso n, since we will be  making \nforward -looking statements  let me remind you that t he matters addressed in the statements are \nsubject to risks and uncertainties that could cause actual results to differ materially from those \nprojected or implied. ", "original_text": "Matt Sims :  Welcome to this morning\u2019s Cardinal Health Second -Quarter Fiscal 2024 Earnings \nconference call and thank you for joining us. "}, "hash": "a59ad877b45957c4256af9d3044866ea9e8531d797a82d792134ae4e2e73abbb", "class_name": "RelatedNodeInfo"}}, "text": "Please go ahead, sir.  \n \n", "start_char_idx": 368, "end_char_idx": 394, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "1196d81d-6394-4c13-9b9f-480c3a22c0b9": {"__data__": {"id_": "1196d81d-6394-4c13-9b9f-480c3a22c0b9", "embedding": null, "metadata": {"window": "This meeting is being recorded.  At this time, I'd like to hand the call over to \nMatt Sims, Vice President of Investor Relations.  Please go ahead, sir.  \n \n Matt Sims :  Welcome to this morning\u2019s Cardinal Health Second -Quarter Fiscal 2024 Earnings \nconference call and thank you for joining us.  With me today are Cardinal Health\u2019s CEO, Jason Hollar, \nand our CFO, Aaron Alt .  \n \n You can find t his morning\u2019s press release and investor  presentation on the investor relations  section \nof our website at ir.cardinalhealth.com .  Before I turn the call over to Jaso n, since we will be  making \nforward -looking statements  let me remind you that t he matters addressed in the statements are \nsubject to risks and uncertainties that could cause actual results to differ materially from those \nprojected or implied. ", "original_text": "Matt Sims :  Welcome to this morning\u2019s Cardinal Health Second -Quarter Fiscal 2024 Earnings \nconference call and thank you for joining us. ", "page_label": "1", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "a4414d54-6710-431a-9934-c424ca18a68a", "node_type": "4", "metadata": {"page_label": "1", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "db9341b5ca61c774614e85db93e9685d87e88c142ca1cdb509ea4c52d573440c", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "a0d3e3d1-e0ef-4ae0-b22f-afc8bf26f8da", "node_type": "1", "metadata": {"window": "Earnings \nConference Call  \nFebruary 1, 2024 , 8:30AM Eastern  \n \nOperator :  Good day , and welcome to today's Second Quarter Financial Year 2024 Cardinal Health \nEarnings Conference Call.  This meeting is being recorded.  At this time, I'd like to hand the call over to \nMatt Sims, Vice President of Investor Relations.  Please go ahead, sir.  \n \n Matt Sims :  Welcome to this morning\u2019s Cardinal Health Second -Quarter Fiscal 2024 Earnings \nconference call and thank you for joining us.  With me today are Cardinal Health\u2019s CEO, Jason Hollar, \nand our CFO, Aaron Alt .  \n \n You can find t his morning\u2019s press release and investor  presentation on the investor relations  section \nof our website at ir.cardinalhealth.com . ", "original_text": "Please go ahead, sir.  \n \n", "page_label": "1", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "23e4adbffb4bff3dbb436febb68bdc627acb82ba1dc3698c59904e1362879196", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "4008df93-4537-40d8-91ae-415cfaa5a9b1", "node_type": "1", "metadata": {"window": "At this time, I'd like to hand the call over to \nMatt Sims, Vice President of Investor Relations.  Please go ahead, sir.  \n \n Matt Sims :  Welcome to this morning\u2019s Cardinal Health Second -Quarter Fiscal 2024 Earnings \nconference call and thank you for joining us.  With me today are Cardinal Health\u2019s CEO, Jason Hollar, \nand our CFO, Aaron Alt .  \n \n You can find t his morning\u2019s press release and investor  presentation on the investor relations  section \nof our website at ir.cardinalhealth.com .  Before I turn the call over to Jaso n, since we will be  making \nforward -looking statements  let me remind you that t he matters addressed in the statements are \nsubject to risks and uncertainties that could cause actual results to differ materially from those \nprojected or implied.  Please refer to our SEC filings and the forward -looking statement slide at the \nbeginning of our presentation for a description of these risks and uncertainties.  \n \n", "original_text": "With me today are Cardinal Health\u2019s CEO, Jason Hollar, \nand our CFO, Aaron Alt .  \n \n"}, "hash": "ac47542e0776bfd7c24c039582d5a7f16c9dd688204ad8083d996d8cab051cb3", "class_name": "RelatedNodeInfo"}}, "text": "Matt Sims :  Welcome to this morning\u2019s Cardinal Health Second -Quarter Fiscal 2024 Earnings \nconference call and thank you for joining us. ", "start_char_idx": 394, "end_char_idx": 533, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "4008df93-4537-40d8-91ae-415cfaa5a9b1": {"__data__": {"id_": "4008df93-4537-40d8-91ae-415cfaa5a9b1", "embedding": null, "metadata": {"window": "At this time, I'd like to hand the call over to \nMatt Sims, Vice President of Investor Relations.  Please go ahead, sir.  \n \n Matt Sims :  Welcome to this morning\u2019s Cardinal Health Second -Quarter Fiscal 2024 Earnings \nconference call and thank you for joining us.  With me today are Cardinal Health\u2019s CEO, Jason Hollar, \nand our CFO, Aaron Alt .  \n \n You can find t his morning\u2019s press release and investor  presentation on the investor relations  section \nof our website at ir.cardinalhealth.com .  Before I turn the call over to Jaso n, since we will be  making \nforward -looking statements  let me remind you that t he matters addressed in the statements are \nsubject to risks and uncertainties that could cause actual results to differ materially from those \nprojected or implied.  Please refer to our SEC filings and the forward -looking statement slide at the \nbeginning of our presentation for a description of these risks and uncertainties.  \n \n", "original_text": "With me today are Cardinal Health\u2019s CEO, Jason Hollar, \nand our CFO, Aaron Alt .  \n \n", "page_label": "1", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "a4414d54-6710-431a-9934-c424ca18a68a", "node_type": "4", "metadata": {"page_label": "1", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "db9341b5ca61c774614e85db93e9685d87e88c142ca1cdb509ea4c52d573440c", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "1196d81d-6394-4c13-9b9f-480c3a22c0b9", "node_type": "1", "metadata": {"window": "This meeting is being recorded.  At this time, I'd like to hand the call over to \nMatt Sims, Vice President of Investor Relations.  Please go ahead, sir.  \n \n Matt Sims :  Welcome to this morning\u2019s Cardinal Health Second -Quarter Fiscal 2024 Earnings \nconference call and thank you for joining us.  With me today are Cardinal Health\u2019s CEO, Jason Hollar, \nand our CFO, Aaron Alt .  \n \n You can find t his morning\u2019s press release and investor  presentation on the investor relations  section \nof our website at ir.cardinalhealth.com .  Before I turn the call over to Jaso n, since we will be  making \nforward -looking statements  let me remind you that t he matters addressed in the statements are \nsubject to risks and uncertainties that could cause actual results to differ materially from those \nprojected or implied. ", "original_text": "Matt Sims :  Welcome to this morning\u2019s Cardinal Health Second -Quarter Fiscal 2024 Earnings \nconference call and thank you for joining us. ", "page_label": "1", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "e6a7d239b193e1a9f4e8442f08f2dbf30011efc9e03ebb1cf2af3913d48d085c", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "e46986a0-30bf-4a26-80ba-59f84910c16f", "node_type": "1", "metadata": {"window": "Please go ahead, sir.  \n \n Matt Sims :  Welcome to this morning\u2019s Cardinal Health Second -Quarter Fiscal 2024 Earnings \nconference call and thank you for joining us.  With me today are Cardinal Health\u2019s CEO, Jason Hollar, \nand our CFO, Aaron Alt .  \n \n You can find t his morning\u2019s press release and investor  presentation on the investor relations  section \nof our website at ir.cardinalhealth.com .  Before I turn the call over to Jaso n, since we will be  making \nforward -looking statements  let me remind you that t he matters addressed in the statements are \nsubject to risks and uncertainties that could cause actual results to differ materially from those \nprojected or implied.  Please refer to our SEC filings and the forward -looking statement slide at the \nbeginning of our presentation for a description of these risks and uncertainties.  \n \n Please note, that during the discussion today, the comments will be on a non -GAAP basis unless \nthey are specifically called out as GAAP. ", "original_text": "You can find t his morning\u2019s press release and investor  presentation on the investor relations  section \nof our website at ir.cardinalhealth.com . "}, "hash": "735cb9458aa10c51cdbd871da151c60d9933dfe20c047a0a2e5eda68109e46d3", "class_name": "RelatedNodeInfo"}}, "text": "With me today are Cardinal Health\u2019s CEO, Jason Hollar, \nand our CFO, Aaron Alt .  \n \n", "start_char_idx": 533, "end_char_idx": 618, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "e46986a0-30bf-4a26-80ba-59f84910c16f": {"__data__": {"id_": "e46986a0-30bf-4a26-80ba-59f84910c16f", "embedding": null, "metadata": {"window": "Please go ahead, sir.  \n \n Matt Sims :  Welcome to this morning\u2019s Cardinal Health Second -Quarter Fiscal 2024 Earnings \nconference call and thank you for joining us.  With me today are Cardinal Health\u2019s CEO, Jason Hollar, \nand our CFO, Aaron Alt .  \n \n You can find t his morning\u2019s press release and investor  presentation on the investor relations  section \nof our website at ir.cardinalhealth.com .  Before I turn the call over to Jaso n, since we will be  making \nforward -looking statements  let me remind you that t he matters addressed in the statements are \nsubject to risks and uncertainties that could cause actual results to differ materially from those \nprojected or implied.  Please refer to our SEC filings and the forward -looking statement slide at the \nbeginning of our presentation for a description of these risks and uncertainties.  \n \n Please note, that during the discussion today, the comments will be on a non -GAAP basis unless \nthey are specifically called out as GAAP. ", "original_text": "You can find t his morning\u2019s press release and investor  presentation on the investor relations  section \nof our website at ir.cardinalhealth.com . ", "page_label": "1", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "a4414d54-6710-431a-9934-c424ca18a68a", "node_type": "4", "metadata": {"page_label": "1", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "db9341b5ca61c774614e85db93e9685d87e88c142ca1cdb509ea4c52d573440c", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "4008df93-4537-40d8-91ae-415cfaa5a9b1", "node_type": "1", "metadata": {"window": "At this time, I'd like to hand the call over to \nMatt Sims, Vice President of Investor Relations.  Please go ahead, sir.  \n \n Matt Sims :  Welcome to this morning\u2019s Cardinal Health Second -Quarter Fiscal 2024 Earnings \nconference call and thank you for joining us.  With me today are Cardinal Health\u2019s CEO, Jason Hollar, \nand our CFO, Aaron Alt .  \n \n You can find t his morning\u2019s press release and investor  presentation on the investor relations  section \nof our website at ir.cardinalhealth.com .  Before I turn the call over to Jaso n, since we will be  making \nforward -looking statements  let me remind you that t he matters addressed in the statements are \nsubject to risks and uncertainties that could cause actual results to differ materially from those \nprojected or implied.  Please refer to our SEC filings and the forward -looking statement slide at the \nbeginning of our presentation for a description of these risks and uncertainties.  \n \n", "original_text": "With me today are Cardinal Health\u2019s CEO, Jason Hollar, \nand our CFO, Aaron Alt .  \n \n", "page_label": "1", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "4bfeffd624f1b533a23cf4514f8f15a7181965c76f04f2c321941e5f0830141a", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "5cf2fec5-897e-46dc-93e9-e0e4cf2073d2", "node_type": "1", "metadata": {"window": "Matt Sims :  Welcome to this morning\u2019s Cardinal Health Second -Quarter Fiscal 2024 Earnings \nconference call and thank you for joining us.  With me today are Cardinal Health\u2019s CEO, Jason Hollar, \nand our CFO, Aaron Alt .  \n \n You can find t his morning\u2019s press release and investor  presentation on the investor relations  section \nof our website at ir.cardinalhealth.com .  Before I turn the call over to Jaso n, since we will be  making \nforward -looking statements  let me remind you that t he matters addressed in the statements are \nsubject to risks and uncertainties that could cause actual results to differ materially from those \nprojected or implied.  Please refer to our SEC filings and the forward -looking statement slide at the \nbeginning of our presentation for a description of these risks and uncertainties.  \n \n Please note, that during the discussion today, the comments will be on a non -GAAP basis unless \nthey are specifically called out as GAAP.  GAAP to non -GAAP reconciliations for all relevant periods \ncan be found in the supporting schedules attached to our press release.  \n \n", "original_text": "Before I turn the call over to Jaso n, since we will be  making \nforward -looking statements  let me remind you that t he matters addressed in the statements are \nsubject to risks and uncertainties that could cause actual results to differ materially from those \nprojected or implied. "}, "hash": "75f70c2411b993b600c278a50b142454b32719a1f97a3a26880da3636367e8da", "class_name": "RelatedNodeInfo"}}, "text": "You can find t his morning\u2019s press release and investor  presentation on the investor relations  section \nof our website at ir.cardinalhealth.com . ", "start_char_idx": 618, "end_char_idx": 766, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "5cf2fec5-897e-46dc-93e9-e0e4cf2073d2": {"__data__": {"id_": "5cf2fec5-897e-46dc-93e9-e0e4cf2073d2", "embedding": null, "metadata": {"window": "Matt Sims :  Welcome to this morning\u2019s Cardinal Health Second -Quarter Fiscal 2024 Earnings \nconference call and thank you for joining us.  With me today are Cardinal Health\u2019s CEO, Jason Hollar, \nand our CFO, Aaron Alt .  \n \n You can find t his morning\u2019s press release and investor  presentation on the investor relations  section \nof our website at ir.cardinalhealth.com .  Before I turn the call over to Jaso n, since we will be  making \nforward -looking statements  let me remind you that t he matters addressed in the statements are \nsubject to risks and uncertainties that could cause actual results to differ materially from those \nprojected or implied.  Please refer to our SEC filings and the forward -looking statement slide at the \nbeginning of our presentation for a description of these risks and uncertainties.  \n \n Please note, that during the discussion today, the comments will be on a non -GAAP basis unless \nthey are specifically called out as GAAP.  GAAP to non -GAAP reconciliations for all relevant periods \ncan be found in the supporting schedules attached to our press release.  \n \n", "original_text": "Before I turn the call over to Jaso n, since we will be  making \nforward -looking statements  let me remind you that t he matters addressed in the statements are \nsubject to risks and uncertainties that could cause actual results to differ materially from those \nprojected or implied. ", "page_label": "1", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "a4414d54-6710-431a-9934-c424ca18a68a", "node_type": "4", "metadata": {"page_label": "1", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "db9341b5ca61c774614e85db93e9685d87e88c142ca1cdb509ea4c52d573440c", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "e46986a0-30bf-4a26-80ba-59f84910c16f", "node_type": "1", "metadata": {"window": "Please go ahead, sir.  \n \n Matt Sims :  Welcome to this morning\u2019s Cardinal Health Second -Quarter Fiscal 2024 Earnings \nconference call and thank you for joining us.  With me today are Cardinal Health\u2019s CEO, Jason Hollar, \nand our CFO, Aaron Alt .  \n \n You can find t his morning\u2019s press release and investor  presentation on the investor relations  section \nof our website at ir.cardinalhealth.com .  Before I turn the call over to Jaso n, since we will be  making \nforward -looking statements  let me remind you that t he matters addressed in the statements are \nsubject to risks and uncertainties that could cause actual results to differ materially from those \nprojected or implied.  Please refer to our SEC filings and the forward -looking statement slide at the \nbeginning of our presentation for a description of these risks and uncertainties.  \n \n Please note, that during the discussion today, the comments will be on a non -GAAP basis unless \nthey are specifically called out as GAAP. ", "original_text": "You can find t his morning\u2019s press release and investor  presentation on the investor relations  section \nof our website at ir.cardinalhealth.com . ", "page_label": "1", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "b605c81e035d07996a6758829dff119b52b9b292175801870b2df6309fe4784a", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "967afa49-7711-4b8c-99a9-115f90bbf988", "node_type": "1", "metadata": {"window": "With me today are Cardinal Health\u2019s CEO, Jason Hollar, \nand our CFO, Aaron Alt .  \n \n You can find t his morning\u2019s press release and investor  presentation on the investor relations  section \nof our website at ir.cardinalhealth.com .  Before I turn the call over to Jaso n, since we will be  making \nforward -looking statements  let me remind you that t he matters addressed in the statements are \nsubject to risks and uncertainties that could cause actual results to differ materially from those \nprojected or implied.  Please refer to our SEC filings and the forward -looking statement slide at the \nbeginning of our presentation for a description of these risks and uncertainties.  \n \n Please note, that during the discussion today, the comments will be on a non -GAAP basis unless \nthey are specifically called out as GAAP.  GAAP to non -GAAP reconciliations for all relevant periods \ncan be found in the supporting schedules attached to our press release.  \n \n For the Q&A portion of today\u2019s call, we kindly ask that you limit questions to one per participant, so \nthat we can try and give everyone an opportunity. ", "original_text": "Please refer to our SEC filings and the forward -looking statement slide at the \nbeginning of our presentation for a description of these risks and uncertainties.  \n \n"}, "hash": "1f07df06cce8f1d04c2c34c09b8b3075fdfaae5143929cf58e86e38e3b1cc8fd", "class_name": "RelatedNodeInfo"}}, "text": "Before I turn the call over to Jaso n, since we will be  making \nforward -looking statements  let me remind you that t he matters addressed in the statements are \nsubject to risks and uncertainties that could cause actual results to differ materially from those \nprojected or implied. ", "start_char_idx": 766, "end_char_idx": 1051, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "967afa49-7711-4b8c-99a9-115f90bbf988": {"__data__": {"id_": "967afa49-7711-4b8c-99a9-115f90bbf988", "embedding": null, "metadata": {"window": "With me today are Cardinal Health\u2019s CEO, Jason Hollar, \nand our CFO, Aaron Alt .  \n \n You can find t his morning\u2019s press release and investor  presentation on the investor relations  section \nof our website at ir.cardinalhealth.com .  Before I turn the call over to Jaso n, since we will be  making \nforward -looking statements  let me remind you that t he matters addressed in the statements are \nsubject to risks and uncertainties that could cause actual results to differ materially from those \nprojected or implied.  Please refer to our SEC filings and the forward -looking statement slide at the \nbeginning of our presentation for a description of these risks and uncertainties.  \n \n Please note, that during the discussion today, the comments will be on a non -GAAP basis unless \nthey are specifically called out as GAAP.  GAAP to non -GAAP reconciliations for all relevant periods \ncan be found in the supporting schedules attached to our press release.  \n \n For the Q&A portion of today\u2019s call, we kindly ask that you limit questions to one per participant, so \nthat we can try and give everyone an opportunity. ", "original_text": "Please refer to our SEC filings and the forward -looking statement slide at the \nbeginning of our presentation for a description of these risks and uncertainties.  \n \n", "page_label": "1", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "a4414d54-6710-431a-9934-c424ca18a68a", "node_type": "4", "metadata": {"page_label": "1", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "db9341b5ca61c774614e85db93e9685d87e88c142ca1cdb509ea4c52d573440c", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "5cf2fec5-897e-46dc-93e9-e0e4cf2073d2", "node_type": "1", "metadata": {"window": "Matt Sims :  Welcome to this morning\u2019s Cardinal Health Second -Quarter Fiscal 2024 Earnings \nconference call and thank you for joining us.  With me today are Cardinal Health\u2019s CEO, Jason Hollar, \nand our CFO, Aaron Alt .  \n \n You can find t his morning\u2019s press release and investor  presentation on the investor relations  section \nof our website at ir.cardinalhealth.com .  Before I turn the call over to Jaso n, since we will be  making \nforward -looking statements  let me remind you that t he matters addressed in the statements are \nsubject to risks and uncertainties that could cause actual results to differ materially from those \nprojected or implied.  Please refer to our SEC filings and the forward -looking statement slide at the \nbeginning of our presentation for a description of these risks and uncertainties.  \n \n Please note, that during the discussion today, the comments will be on a non -GAAP basis unless \nthey are specifically called out as GAAP.  GAAP to non -GAAP reconciliations for all relevant periods \ncan be found in the supporting schedules attached to our press release.  \n \n", "original_text": "Before I turn the call over to Jaso n, since we will be  making \nforward -looking statements  let me remind you that t he matters addressed in the statements are \nsubject to risks and uncertainties that could cause actual results to differ materially from those \nprojected or implied. ", "page_label": "1", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "ba489be32d08ba5357dad166ee72d96a437cdbed1c4a21718db968b7b5285a2d", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "e79bc945-1e39-4012-86ed-5c9e820d4aaa", "node_type": "1", "metadata": {"window": "You can find t his morning\u2019s press release and investor  presentation on the investor relations  section \nof our website at ir.cardinalhealth.com .  Before I turn the call over to Jaso n, since we will be  making \nforward -looking statements  let me remind you that t he matters addressed in the statements are \nsubject to risks and uncertainties that could cause actual results to differ materially from those \nprojected or implied.  Please refer to our SEC filings and the forward -looking statement slide at the \nbeginning of our presentation for a description of these risks and uncertainties.  \n \n Please note, that during the discussion today, the comments will be on a non -GAAP basis unless \nthey are specifically called out as GAAP.  GAAP to non -GAAP reconciliations for all relevant periods \ncan be found in the supporting schedules attached to our press release.  \n \n For the Q&A portion of today\u2019s call, we kindly ask that you limit questions to one per participant, so \nthat we can try and give everyone an opportunity.  With that, I will now turn the call over to Jason.  \n \n", "original_text": "Please note, that during the discussion today, the comments will be on a non -GAAP basis unless \nthey are specifically called out as GAAP. "}, "hash": "1cfff2208cbe10808e3696b3fbc9835c4fe867b1d40293480592ec577cc88af7", "class_name": "RelatedNodeInfo"}}, "text": "Please refer to our SEC filings and the forward -looking statement slide at the \nbeginning of our presentation for a description of these risks and uncertainties.  \n \n", "start_char_idx": 1051, "end_char_idx": 1218, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "e79bc945-1e39-4012-86ed-5c9e820d4aaa": {"__data__": {"id_": "e79bc945-1e39-4012-86ed-5c9e820d4aaa", "embedding": null, "metadata": {"window": "You can find t his morning\u2019s press release and investor  presentation on the investor relations  section \nof our website at ir.cardinalhealth.com .  Before I turn the call over to Jaso n, since we will be  making \nforward -looking statements  let me remind you that t he matters addressed in the statements are \nsubject to risks and uncertainties that could cause actual results to differ materially from those \nprojected or implied.  Please refer to our SEC filings and the forward -looking statement slide at the \nbeginning of our presentation for a description of these risks and uncertainties.  \n \n Please note, that during the discussion today, the comments will be on a non -GAAP basis unless \nthey are specifically called out as GAAP.  GAAP to non -GAAP reconciliations for all relevant periods \ncan be found in the supporting schedules attached to our press release.  \n \n For the Q&A portion of today\u2019s call, we kindly ask that you limit questions to one per participant, so \nthat we can try and give everyone an opportunity.  With that, I will now turn the call over to Jason.  \n \n", "original_text": "Please note, that during the discussion today, the comments will be on a non -GAAP basis unless \nthey are specifically called out as GAAP. ", "page_label": "1", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "a4414d54-6710-431a-9934-c424ca18a68a", "node_type": "4", "metadata": {"page_label": "1", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "db9341b5ca61c774614e85db93e9685d87e88c142ca1cdb509ea4c52d573440c", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "967afa49-7711-4b8c-99a9-115f90bbf988", "node_type": "1", "metadata": {"window": "With me today are Cardinal Health\u2019s CEO, Jason Hollar, \nand our CFO, Aaron Alt .  \n \n You can find t his morning\u2019s press release and investor  presentation on the investor relations  section \nof our website at ir.cardinalhealth.com .  Before I turn the call over to Jaso n, since we will be  making \nforward -looking statements  let me remind you that t he matters addressed in the statements are \nsubject to risks and uncertainties that could cause actual results to differ materially from those \nprojected or implied.  Please refer to our SEC filings and the forward -looking statement slide at the \nbeginning of our presentation for a description of these risks and uncertainties.  \n \n Please note, that during the discussion today, the comments will be on a non -GAAP basis unless \nthey are specifically called out as GAAP.  GAAP to non -GAAP reconciliations for all relevant periods \ncan be found in the supporting schedules attached to our press release.  \n \n For the Q&A portion of today\u2019s call, we kindly ask that you limit questions to one per participant, so \nthat we can try and give everyone an opportunity. ", "original_text": "Please refer to our SEC filings and the forward -looking statement slide at the \nbeginning of our presentation for a description of these risks and uncertainties.  \n \n", "page_label": "1", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "cf01f64ac21530ff1fd1e0d8d346a44bd232a19abee63c1d67a707b65e409763", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "09e57fcf-706b-4cb2-a4b9-3813e5addea2", "node_type": "1", "metadata": {"window": "Before I turn the call over to Jaso n, since we will be  making \nforward -looking statements  let me remind you that t he matters addressed in the statements are \nsubject to risks and uncertainties that could cause actual results to differ materially from those \nprojected or implied.  Please refer to our SEC filings and the forward -looking statement slide at the \nbeginning of our presentation for a description of these risks and uncertainties.  \n \n Please note, that during the discussion today, the comments will be on a non -GAAP basis unless \nthey are specifically called out as GAAP.  GAAP to non -GAAP reconciliations for all relevant periods \ncan be found in the supporting schedules attached to our press release.  \n \n For the Q&A portion of today\u2019s call, we kindly ask that you limit questions to one per participant, so \nthat we can try and give everyone an opportunity.  With that, I will now turn the call over to Jason.  \n \n Jason Hollar :  Good morning, everyone.  \n \n", "original_text": "GAAP to non -GAAP reconciliations for all relevant periods \ncan be found in the supporting schedules attached to our press release.  \n \n"}, "hash": "5e627366bd3e557a759980fc9604472086597dde90cf80616c57e1de1c9ad84a", "class_name": "RelatedNodeInfo"}}, "text": "Please note, that during the discussion today, the comments will be on a non -GAAP basis unless \nthey are specifically called out as GAAP. ", "start_char_idx": 1218, "end_char_idx": 1357, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "09e57fcf-706b-4cb2-a4b9-3813e5addea2": {"__data__": {"id_": "09e57fcf-706b-4cb2-a4b9-3813e5addea2", "embedding": null, "metadata": {"window": "Before I turn the call over to Jaso n, since we will be  making \nforward -looking statements  let me remind you that t he matters addressed in the statements are \nsubject to risks and uncertainties that could cause actual results to differ materially from those \nprojected or implied.  Please refer to our SEC filings and the forward -looking statement slide at the \nbeginning of our presentation for a description of these risks and uncertainties.  \n \n Please note, that during the discussion today, the comments will be on a non -GAAP basis unless \nthey are specifically called out as GAAP.  GAAP to non -GAAP reconciliations for all relevant periods \ncan be found in the supporting schedules attached to our press release.  \n \n For the Q&A portion of today\u2019s call, we kindly ask that you limit questions to one per participant, so \nthat we can try and give everyone an opportunity.  With that, I will now turn the call over to Jason.  \n \n Jason Hollar :  Good morning, everyone.  \n \n", "original_text": "GAAP to non -GAAP reconciliations for all relevant periods \ncan be found in the supporting schedules attached to our press release.  \n \n", "page_label": "1", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "a4414d54-6710-431a-9934-c424ca18a68a", "node_type": "4", "metadata": {"page_label": "1", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "db9341b5ca61c774614e85db93e9685d87e88c142ca1cdb509ea4c52d573440c", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "e79bc945-1e39-4012-86ed-5c9e820d4aaa", "node_type": "1", "metadata": {"window": "You can find t his morning\u2019s press release and investor  presentation on the investor relations  section \nof our website at ir.cardinalhealth.com .  Before I turn the call over to Jaso n, since we will be  making \nforward -looking statements  let me remind you that t he matters addressed in the statements are \nsubject to risks and uncertainties that could cause actual results to differ materially from those \nprojected or implied.  Please refer to our SEC filings and the forward -looking statement slide at the \nbeginning of our presentation for a description of these risks and uncertainties.  \n \n Please note, that during the discussion today, the comments will be on a non -GAAP basis unless \nthey are specifically called out as GAAP.  GAAP to non -GAAP reconciliations for all relevant periods \ncan be found in the supporting schedules attached to our press release.  \n \n For the Q&A portion of today\u2019s call, we kindly ask that you limit questions to one per participant, so \nthat we can try and give everyone an opportunity.  With that, I will now turn the call over to Jason.  \n \n", "original_text": "Please note, that during the discussion today, the comments will be on a non -GAAP basis unless \nthey are specifically called out as GAAP. ", "page_label": "1", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "57dc1949405e678f0557bbfc91f14dbcf6e784b41ccd0d65067fb3f7580314af", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "274bc5da-dda3-48c6-8987-840e2328437c", "node_type": "1", "metadata": {"window": "Please refer to our SEC filings and the forward -looking statement slide at the \nbeginning of our presentation for a description of these risks and uncertainties.  \n \n Please note, that during the discussion today, the comments will be on a non -GAAP basis unless \nthey are specifically called out as GAAP.  GAAP to non -GAAP reconciliations for all relevant periods \ncan be found in the supporting schedules attached to our press release.  \n \n For the Q&A portion of today\u2019s call, we kindly ask that you limit questions to one per participant, so \nthat we can try and give everyone an opportunity.  With that, I will now turn the call over to Jason.  \n \n Jason Hollar :  Good morning, everyone.  \n \n In the last few weeks, we\u2019ve made several notable announcements regarding our company\u2019s \ncontinued progress, including yesterday\u2019s news on our agreement to acquire Specialty Networks, \nwhich will further our specialty growth strategy and create value for spe cialty providers, \nmanufacturers,  and patients in exciting new ways.  \n \n", "original_text": "For the Q&A portion of today\u2019s call, we kindly ask that you limit questions to one per participant, so \nthat we can try and give everyone an opportunity. "}, "hash": "965627ca9aecfd0a8962f5cd81555d96af55b9ce043c143d3f38a853c81a1025", "class_name": "RelatedNodeInfo"}}, "text": "GAAP to non -GAAP reconciliations for all relevant periods \ncan be found in the supporting schedules attached to our press release.  \n \n", "start_char_idx": 1357, "end_char_idx": 1493, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "274bc5da-dda3-48c6-8987-840e2328437c": {"__data__": {"id_": "274bc5da-dda3-48c6-8987-840e2328437c", "embedding": null, "metadata": {"window": "Please refer to our SEC filings and the forward -looking statement slide at the \nbeginning of our presentation for a description of these risks and uncertainties.  \n \n Please note, that during the discussion today, the comments will be on a non -GAAP basis unless \nthey are specifically called out as GAAP.  GAAP to non -GAAP reconciliations for all relevant periods \ncan be found in the supporting schedules attached to our press release.  \n \n For the Q&A portion of today\u2019s call, we kindly ask that you limit questions to one per participant, so \nthat we can try and give everyone an opportunity.  With that, I will now turn the call over to Jason.  \n \n Jason Hollar :  Good morning, everyone.  \n \n In the last few weeks, we\u2019ve made several notable announcements regarding our company\u2019s \ncontinued progress, including yesterday\u2019s news on our agreement to acquire Specialty Networks, \nwhich will further our specialty growth strategy and create value for spe cialty providers, \nmanufacturers,  and patients in exciting new ways.  \n \n", "original_text": "For the Q&A portion of today\u2019s call, we kindly ask that you limit questions to one per participant, so \nthat we can try and give everyone an opportunity. ", "page_label": "1", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "a4414d54-6710-431a-9934-c424ca18a68a", "node_type": "4", "metadata": {"page_label": "1", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "db9341b5ca61c774614e85db93e9685d87e88c142ca1cdb509ea4c52d573440c", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "09e57fcf-706b-4cb2-a4b9-3813e5addea2", "node_type": "1", "metadata": {"window": "Before I turn the call over to Jaso n, since we will be  making \nforward -looking statements  let me remind you that t he matters addressed in the statements are \nsubject to risks and uncertainties that could cause actual results to differ materially from those \nprojected or implied.  Please refer to our SEC filings and the forward -looking statement slide at the \nbeginning of our presentation for a description of these risks and uncertainties.  \n \n Please note, that during the discussion today, the comments will be on a non -GAAP basis unless \nthey are specifically called out as GAAP.  GAAP to non -GAAP reconciliations for all relevant periods \ncan be found in the supporting schedules attached to our press release.  \n \n For the Q&A portion of today\u2019s call, we kindly ask that you limit questions to one per participant, so \nthat we can try and give everyone an opportunity.  With that, I will now turn the call over to Jason.  \n \n Jason Hollar :  Good morning, everyone.  \n \n", "original_text": "GAAP to non -GAAP reconciliations for all relevant periods \ncan be found in the supporting schedules attached to our press release.  \n \n", "page_label": "1", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "acf796e25cceb2f1a8259d9f93b4a2e1f521a094cf1d319cc214c0f047b729aa", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "a3e1ec3a-bfd0-4115-8490-2dcb20fd628c", "node_type": "1", "metadata": {"window": "Please note, that during the discussion today, the comments will be on a non -GAAP basis unless \nthey are specifically called out as GAAP.  GAAP to non -GAAP reconciliations for all relevant periods \ncan be found in the supporting schedules attached to our press release.  \n \n For the Q&A portion of today\u2019s call, we kindly ask that you limit questions to one per participant, so \nthat we can try and give everyone an opportunity.  With that, I will now turn the call over to Jason.  \n \n Jason Hollar :  Good morning, everyone.  \n \n In the last few weeks, we\u2019ve made several notable announcements regarding our company\u2019s \ncontinued progress, including yesterday\u2019s news on our agreement to acquire Specialty Networks, \nwhich will further our specialty growth strategy and create value for spe cialty providers, \nmanufacturers,  and patients in exciting new ways.  \n \n And, as we highlighted at a recent industry conference, we\u2019re continuing to take actions to become a \nsimplified and more focused company, with further progress achieved on our ongoing business and \nportfolio review and our updated enterprise operating and s egment reporting structure, which will be \nreflected in our financial reporting beginning next quarter. ", "original_text": "With that, I will now turn the call over to Jason.  \n \n"}, "hash": "1a24072aa4c43f96d9ca9d1e020db72081ffd63a3485a8258de1f42e250d3476", "class_name": "RelatedNodeInfo"}}, "text": "For the Q&A portion of today\u2019s call, we kindly ask that you limit questions to one per participant, so \nthat we can try and give everyone an opportunity. ", "start_char_idx": 1493, "end_char_idx": 1647, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "a3e1ec3a-bfd0-4115-8490-2dcb20fd628c": {"__data__": {"id_": "a3e1ec3a-bfd0-4115-8490-2dcb20fd628c", "embedding": null, "metadata": {"window": "Please note, that during the discussion today, the comments will be on a non -GAAP basis unless \nthey are specifically called out as GAAP.  GAAP to non -GAAP reconciliations for all relevant periods \ncan be found in the supporting schedules attached to our press release.  \n \n For the Q&A portion of today\u2019s call, we kindly ask that you limit questions to one per participant, so \nthat we can try and give everyone an opportunity.  With that, I will now turn the call over to Jason.  \n \n Jason Hollar :  Good morning, everyone.  \n \n In the last few weeks, we\u2019ve made several notable announcements regarding our company\u2019s \ncontinued progress, including yesterday\u2019s news on our agreement to acquire Specialty Networks, \nwhich will further our specialty growth strategy and create value for spe cialty providers, \nmanufacturers,  and patients in exciting new ways.  \n \n And, as we highlighted at a recent industry conference, we\u2019re continuing to take actions to become a \nsimplified and more focused company, with further progress achieved on our ongoing business and \nportfolio review and our updated enterprise operating and s egment reporting structure, which will be \nreflected in our financial reporting beginning next quarter. ", "original_text": "With that, I will now turn the call over to Jason.  \n \n", "page_label": "1", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "a4414d54-6710-431a-9934-c424ca18a68a", "node_type": "4", "metadata": {"page_label": "1", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "db9341b5ca61c774614e85db93e9685d87e88c142ca1cdb509ea4c52d573440c", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "274bc5da-dda3-48c6-8987-840e2328437c", "node_type": "1", "metadata": {"window": "Please refer to our SEC filings and the forward -looking statement slide at the \nbeginning of our presentation for a description of these risks and uncertainties.  \n \n Please note, that during the discussion today, the comments will be on a non -GAAP basis unless \nthey are specifically called out as GAAP.  GAAP to non -GAAP reconciliations for all relevant periods \ncan be found in the supporting schedules attached to our press release.  \n \n For the Q&A portion of today\u2019s call, we kindly ask that you limit questions to one per participant, so \nthat we can try and give everyone an opportunity.  With that, I will now turn the call over to Jason.  \n \n Jason Hollar :  Good morning, everyone.  \n \n In the last few weeks, we\u2019ve made several notable announcements regarding our company\u2019s \ncontinued progress, including yesterday\u2019s news on our agreement to acquire Specialty Networks, \nwhich will further our specialty growth strategy and create value for spe cialty providers, \nmanufacturers,  and patients in exciting new ways.  \n \n", "original_text": "For the Q&A portion of today\u2019s call, we kindly ask that you limit questions to one per participant, so \nthat we can try and give everyone an opportunity. ", "page_label": "1", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "b2b801745b5f06216cb5caf1c40c5cc8fea7bdadfa934edd2cd29068331a7a5e", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "dd1de457-b343-4ca4-80a4-73f4381940c9", "node_type": "1", "metadata": {"window": "GAAP to non -GAAP reconciliations for all relevant periods \ncan be found in the supporting schedules attached to our press release.  \n \n For the Q&A portion of today\u2019s call, we kindly ask that you limit questions to one per participant, so \nthat we can try and give everyone an opportunity.  With that, I will now turn the call over to Jason.  \n \n Jason Hollar :  Good morning, everyone.  \n \n In the last few weeks, we\u2019ve made several notable announcements regarding our company\u2019s \ncontinued progress, including yesterday\u2019s news on our agreement to acquire Specialty Networks, \nwhich will further our specialty growth strategy and create value for spe cialty providers, \nmanufacturers,  and patients in exciting new ways.  \n \n And, as we highlighted at a recent industry conference, we\u2019re continuing to take actions to become a \nsimplified and more focused company, with further progress achieved on our ongoing business and \nportfolio review and our updated enterprise operating and s egment reporting structure, which will be \nreflected in our financial reporting beginning next quarter.  We plan to go further into our recent \nupdates with you today, but first, let me begin with a few brief comments on our results.  \n \n", "original_text": "Jason Hollar :  Good morning, everyone.  \n \n"}, "hash": "cf719d3ddb13d56e316c67e107960d88bfca12d871dc8a5fd515c4f1f29c60b3", "class_name": "RelatedNodeInfo"}}, "text": "With that, I will now turn the call over to Jason.  \n \n", "start_char_idx": 1647, "end_char_idx": 1702, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "dd1de457-b343-4ca4-80a4-73f4381940c9": {"__data__": {"id_": "dd1de457-b343-4ca4-80a4-73f4381940c9", "embedding": null, "metadata": {"window": "GAAP to non -GAAP reconciliations for all relevant periods \ncan be found in the supporting schedules attached to our press release.  \n \n For the Q&A portion of today\u2019s call, we kindly ask that you limit questions to one per participant, so \nthat we can try and give everyone an opportunity.  With that, I will now turn the call over to Jason.  \n \n Jason Hollar :  Good morning, everyone.  \n \n In the last few weeks, we\u2019ve made several notable announcements regarding our company\u2019s \ncontinued progress, including yesterday\u2019s news on our agreement to acquire Specialty Networks, \nwhich will further our specialty growth strategy and create value for spe cialty providers, \nmanufacturers,  and patients in exciting new ways.  \n \n And, as we highlighted at a recent industry conference, we\u2019re continuing to take actions to become a \nsimplified and more focused company, with further progress achieved on our ongoing business and \nportfolio review and our updated enterprise operating and s egment reporting structure, which will be \nreflected in our financial reporting beginning next quarter.  We plan to go further into our recent \nupdates with you today, but first, let me begin with a few brief comments on our results.  \n \n", "original_text": "Jason Hollar :  Good morning, everyone.  \n \n", "page_label": "1", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "a4414d54-6710-431a-9934-c424ca18a68a", "node_type": "4", "metadata": {"page_label": "1", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "db9341b5ca61c774614e85db93e9685d87e88c142ca1cdb509ea4c52d573440c", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "a3e1ec3a-bfd0-4115-8490-2dcb20fd628c", "node_type": "1", "metadata": {"window": "Please note, that during the discussion today, the comments will be on a non -GAAP basis unless \nthey are specifically called out as GAAP.  GAAP to non -GAAP reconciliations for all relevant periods \ncan be found in the supporting schedules attached to our press release.  \n \n For the Q&A portion of today\u2019s call, we kindly ask that you limit questions to one per participant, so \nthat we can try and give everyone an opportunity.  With that, I will now turn the call over to Jason.  \n \n Jason Hollar :  Good morning, everyone.  \n \n In the last few weeks, we\u2019ve made several notable announcements regarding our company\u2019s \ncontinued progress, including yesterday\u2019s news on our agreement to acquire Specialty Networks, \nwhich will further our specialty growth strategy and create value for spe cialty providers, \nmanufacturers,  and patients in exciting new ways.  \n \n And, as we highlighted at a recent industry conference, we\u2019re continuing to take actions to become a \nsimplified and more focused company, with further progress achieved on our ongoing business and \nportfolio review and our updated enterprise operating and s egment reporting structure, which will be \nreflected in our financial reporting beginning next quarter. ", "original_text": "With that, I will now turn the call over to Jason.  \n \n", "page_label": "1", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "ec9fa38f6eb1c84572fe5263bcda77bad4d95274ed37d45c3fad8d8743013e80", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "4590692e-1b0d-486c-a06b-0a6895dfe8f3", "node_type": "1", "metadata": {"window": "For the Q&A portion of today\u2019s call, we kindly ask that you limit questions to one per participant, so \nthat we can try and give everyone an opportunity.  With that, I will now turn the call over to Jason.  \n \n Jason Hollar :  Good morning, everyone.  \n \n In the last few weeks, we\u2019ve made several notable announcements regarding our company\u2019s \ncontinued progress, including yesterday\u2019s news on our agreement to acquire Specialty Networks, \nwhich will further our specialty growth strategy and create value for spe cialty providers, \nmanufacturers,  and patients in exciting new ways.  \n \n And, as we highlighted at a recent industry conference, we\u2019re continuing to take actions to become a \nsimplified and more focused company, with further progress achieved on our ongoing business and \nportfolio review and our updated enterprise operating and s egment reporting structure, which will be \nreflected in our financial reporting beginning next quarter.  We plan to go further into our recent \nupdates with you today, but first, let me begin with a few brief comments on our results.  \n \n In Q2, we delivered strong profit growth in both segments, demonstrating continued operating \nmomentum and execution against our strategic priorities.  \n ", "original_text": "In the last few weeks, we\u2019ve made several notable announcements regarding our company\u2019s \ncontinued progress, including yesterday\u2019s news on our agreement to acquire Specialty Networks, \nwhich will further our specialty growth strategy and create value for spe cialty providers, \nmanufacturers,  and patients in exciting new ways.  \n \n"}, "hash": "9a4e448085277c8866ef3972b3a7582f941cb4a97e55466aee814ca42b7f2058", "class_name": "RelatedNodeInfo"}}, "text": "Jason Hollar :  Good morning, everyone.  \n \n", "start_char_idx": 1702, "end_char_idx": 1746, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "4590692e-1b0d-486c-a06b-0a6895dfe8f3": {"__data__": {"id_": "4590692e-1b0d-486c-a06b-0a6895dfe8f3", "embedding": null, "metadata": {"window": "For the Q&A portion of today\u2019s call, we kindly ask that you limit questions to one per participant, so \nthat we can try and give everyone an opportunity.  With that, I will now turn the call over to Jason.  \n \n Jason Hollar :  Good morning, everyone.  \n \n In the last few weeks, we\u2019ve made several notable announcements regarding our company\u2019s \ncontinued progress, including yesterday\u2019s news on our agreement to acquire Specialty Networks, \nwhich will further our specialty growth strategy and create value for spe cialty providers, \nmanufacturers,  and patients in exciting new ways.  \n \n And, as we highlighted at a recent industry conference, we\u2019re continuing to take actions to become a \nsimplified and more focused company, with further progress achieved on our ongoing business and \nportfolio review and our updated enterprise operating and s egment reporting structure, which will be \nreflected in our financial reporting beginning next quarter.  We plan to go further into our recent \nupdates with you today, but first, let me begin with a few brief comments on our results.  \n \n In Q2, we delivered strong profit growth in both segments, demonstrating continued operating \nmomentum and execution against our strategic priorities.  \n ", "original_text": "In the last few weeks, we\u2019ve made several notable announcements regarding our company\u2019s \ncontinued progress, including yesterday\u2019s news on our agreement to acquire Specialty Networks, \nwhich will further our specialty growth strategy and create value for spe cialty providers, \nmanufacturers,  and patients in exciting new ways.  \n \n", "page_label": "1", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "a4414d54-6710-431a-9934-c424ca18a68a", "node_type": "4", "metadata": {"page_label": "1", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "db9341b5ca61c774614e85db93e9685d87e88c142ca1cdb509ea4c52d573440c", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "dd1de457-b343-4ca4-80a4-73f4381940c9", "node_type": "1", "metadata": {"window": "GAAP to non -GAAP reconciliations for all relevant periods \ncan be found in the supporting schedules attached to our press release.  \n \n For the Q&A portion of today\u2019s call, we kindly ask that you limit questions to one per participant, so \nthat we can try and give everyone an opportunity.  With that, I will now turn the call over to Jason.  \n \n Jason Hollar :  Good morning, everyone.  \n \n In the last few weeks, we\u2019ve made several notable announcements regarding our company\u2019s \ncontinued progress, including yesterday\u2019s news on our agreement to acquire Specialty Networks, \nwhich will further our specialty growth strategy and create value for spe cialty providers, \nmanufacturers,  and patients in exciting new ways.  \n \n And, as we highlighted at a recent industry conference, we\u2019re continuing to take actions to become a \nsimplified and more focused company, with further progress achieved on our ongoing business and \nportfolio review and our updated enterprise operating and s egment reporting structure, which will be \nreflected in our financial reporting beginning next quarter.  We plan to go further into our recent \nupdates with you today, but first, let me begin with a few brief comments on our results.  \n \n", "original_text": "Jason Hollar :  Good morning, everyone.  \n \n", "page_label": "1", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "d4aeb3df3fd1bc3b6433eaa0e06d615f2a9a4d60b2b3c98207d3475d59b73be8", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "11b83ae2-f338-4180-a308-8be35d719626", "node_type": "1", "metadata": {"window": "With that, I will now turn the call over to Jason.  \n \n Jason Hollar :  Good morning, everyone.  \n \n In the last few weeks, we\u2019ve made several notable announcements regarding our company\u2019s \ncontinued progress, including yesterday\u2019s news on our agreement to acquire Specialty Networks, \nwhich will further our specialty growth strategy and create value for spe cialty providers, \nmanufacturers,  and patients in exciting new ways.  \n \n And, as we highlighted at a recent industry conference, we\u2019re continuing to take actions to become a \nsimplified and more focused company, with further progress achieved on our ongoing business and \nportfolio review and our updated enterprise operating and s egment reporting structure, which will be \nreflected in our financial reporting beginning next quarter.  We plan to go further into our recent \nupdates with you today, but first, let me begin with a few brief comments on our results.  \n \n In Q2, we delivered strong profit growth in both segments, demonstrating continued operating \nmomentum and execution against our strategic priorities.  \n ", "original_text": "And, as we highlighted at a recent industry conference, we\u2019re continuing to take actions to become a \nsimplified and more focused company, with further progress achieved on our ongoing business and \nportfolio review and our updated enterprise operating and s egment reporting structure, which will be \nreflected in our financial reporting beginning next quarter. "}, "hash": "1b66be410f5cac2cc737aadf6351e522c7f8eb40b3ce69c0edad81db049d5dcf", "class_name": "RelatedNodeInfo"}}, "text": "In the last few weeks, we\u2019ve made several notable announcements regarding our company\u2019s \ncontinued progress, including yesterday\u2019s news on our agreement to acquire Specialty Networks, \nwhich will further our specialty growth strategy and create value for spe cialty providers, \nmanufacturers,  and patients in exciting new ways.  \n \n", "start_char_idx": 1746, "end_char_idx": 2079, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "11b83ae2-f338-4180-a308-8be35d719626": {"__data__": {"id_": "11b83ae2-f338-4180-a308-8be35d719626", "embedding": null, "metadata": {"window": "With that, I will now turn the call over to Jason.  \n \n Jason Hollar :  Good morning, everyone.  \n \n In the last few weeks, we\u2019ve made several notable announcements regarding our company\u2019s \ncontinued progress, including yesterday\u2019s news on our agreement to acquire Specialty Networks, \nwhich will further our specialty growth strategy and create value for spe cialty providers, \nmanufacturers,  and patients in exciting new ways.  \n \n And, as we highlighted at a recent industry conference, we\u2019re continuing to take actions to become a \nsimplified and more focused company, with further progress achieved on our ongoing business and \nportfolio review and our updated enterprise operating and s egment reporting structure, which will be \nreflected in our financial reporting beginning next quarter.  We plan to go further into our recent \nupdates with you today, but first, let me begin with a few brief comments on our results.  \n \n In Q2, we delivered strong profit growth in both segments, demonstrating continued operating \nmomentum and execution against our strategic priorities.  \n ", "original_text": "And, as we highlighted at a recent industry conference, we\u2019re continuing to take actions to become a \nsimplified and more focused company, with further progress achieved on our ongoing business and \nportfolio review and our updated enterprise operating and s egment reporting structure, which will be \nreflected in our financial reporting beginning next quarter. ", "page_label": "1", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "a4414d54-6710-431a-9934-c424ca18a68a", "node_type": "4", "metadata": {"page_label": "1", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "db9341b5ca61c774614e85db93e9685d87e88c142ca1cdb509ea4c52d573440c", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "4590692e-1b0d-486c-a06b-0a6895dfe8f3", "node_type": "1", "metadata": {"window": "For the Q&A portion of today\u2019s call, we kindly ask that you limit questions to one per participant, so \nthat we can try and give everyone an opportunity.  With that, I will now turn the call over to Jason.  \n \n Jason Hollar :  Good morning, everyone.  \n \n In the last few weeks, we\u2019ve made several notable announcements regarding our company\u2019s \ncontinued progress, including yesterday\u2019s news on our agreement to acquire Specialty Networks, \nwhich will further our specialty growth strategy and create value for spe cialty providers, \nmanufacturers,  and patients in exciting new ways.  \n \n And, as we highlighted at a recent industry conference, we\u2019re continuing to take actions to become a \nsimplified and more focused company, with further progress achieved on our ongoing business and \nportfolio review and our updated enterprise operating and s egment reporting structure, which will be \nreflected in our financial reporting beginning next quarter.  We plan to go further into our recent \nupdates with you today, but first, let me begin with a few brief comments on our results.  \n \n In Q2, we delivered strong profit growth in both segments, demonstrating continued operating \nmomentum and execution against our strategic priorities.  \n ", "original_text": "In the last few weeks, we\u2019ve made several notable announcements regarding our company\u2019s \ncontinued progress, including yesterday\u2019s news on our agreement to acquire Specialty Networks, \nwhich will further our specialty growth strategy and create value for spe cialty providers, \nmanufacturers,  and patients in exciting new ways.  \n \n", "page_label": "1", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "ef2b4aa31ef771593f5d2b7f39e05b494b4356d841658050a341ab3c5930c933", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "e52c54aa-0a67-432f-90da-19c152aa1675", "node_type": "1", "metadata": {"window": "Jason Hollar :  Good morning, everyone.  \n \n In the last few weeks, we\u2019ve made several notable announcements regarding our company\u2019s \ncontinued progress, including yesterday\u2019s news on our agreement to acquire Specialty Networks, \nwhich will further our specialty growth strategy and create value for spe cialty providers, \nmanufacturers,  and patients in exciting new ways.  \n \n And, as we highlighted at a recent industry conference, we\u2019re continuing to take actions to become a \nsimplified and more focused company, with further progress achieved on our ongoing business and \nportfolio review and our updated enterprise operating and s egment reporting structure, which will be \nreflected in our financial reporting beginning next quarter.  We plan to go further into our recent \nupdates with you today, but first, let me begin with a few brief comments on our results.  \n \n In Q2, we delivered strong profit growth in both segments, demonstrating continued operating \nmomentum and execution against our strategic priorities.  \n ", "original_text": "We plan to go further into our recent \nupdates with you today, but first, let me begin with a few brief comments on our results.  \n \n"}, "hash": "27a658bc5c43802fe124a8a1235cfb9750beba6bbd0b802e963abe799ed76181", "class_name": "RelatedNodeInfo"}}, "text": "And, as we highlighted at a recent industry conference, we\u2019re continuing to take actions to become a \nsimplified and more focused company, with further progress achieved on our ongoing business and \nportfolio review and our updated enterprise operating and s egment reporting structure, which will be \nreflected in our financial reporting beginning next quarter. ", "start_char_idx": 2079, "end_char_idx": 2442, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "e52c54aa-0a67-432f-90da-19c152aa1675": {"__data__": {"id_": "e52c54aa-0a67-432f-90da-19c152aa1675", "embedding": null, "metadata": {"window": "Jason Hollar :  Good morning, everyone.  \n \n In the last few weeks, we\u2019ve made several notable announcements regarding our company\u2019s \ncontinued progress, including yesterday\u2019s news on our agreement to acquire Specialty Networks, \nwhich will further our specialty growth strategy and create value for spe cialty providers, \nmanufacturers,  and patients in exciting new ways.  \n \n And, as we highlighted at a recent industry conference, we\u2019re continuing to take actions to become a \nsimplified and more focused company, with further progress achieved on our ongoing business and \nportfolio review and our updated enterprise operating and s egment reporting structure, which will be \nreflected in our financial reporting beginning next quarter.  We plan to go further into our recent \nupdates with you today, but first, let me begin with a few brief comments on our results.  \n \n In Q2, we delivered strong profit growth in both segments, demonstrating continued operating \nmomentum and execution against our strategic priorities.  \n ", "original_text": "We plan to go further into our recent \nupdates with you today, but first, let me begin with a few brief comments on our results.  \n \n", "page_label": "1", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "a4414d54-6710-431a-9934-c424ca18a68a", "node_type": "4", "metadata": {"page_label": "1", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "db9341b5ca61c774614e85db93e9685d87e88c142ca1cdb509ea4c52d573440c", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "11b83ae2-f338-4180-a308-8be35d719626", "node_type": "1", "metadata": {"window": "With that, I will now turn the call over to Jason.  \n \n Jason Hollar :  Good morning, everyone.  \n \n In the last few weeks, we\u2019ve made several notable announcements regarding our company\u2019s \ncontinued progress, including yesterday\u2019s news on our agreement to acquire Specialty Networks, \nwhich will further our specialty growth strategy and create value for spe cialty providers, \nmanufacturers,  and patients in exciting new ways.  \n \n And, as we highlighted at a recent industry conference, we\u2019re continuing to take actions to become a \nsimplified and more focused company, with further progress achieved on our ongoing business and \nportfolio review and our updated enterprise operating and s egment reporting structure, which will be \nreflected in our financial reporting beginning next quarter.  We plan to go further into our recent \nupdates with you today, but first, let me begin with a few brief comments on our results.  \n \n In Q2, we delivered strong profit growth in both segments, demonstrating continued operating \nmomentum and execution against our strategic priorities.  \n ", "original_text": "And, as we highlighted at a recent industry conference, we\u2019re continuing to take actions to become a \nsimplified and more focused company, with further progress achieved on our ongoing business and \nportfolio review and our updated enterprise operating and s egment reporting structure, which will be \nreflected in our financial reporting beginning next quarter. ", "page_label": "1", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "d69db7f79393b5b9605b9979640e90d45bbf8cb8889e7c333b2803f0534cb08e", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "c86e8138-f341-46f7-bd9e-228d5ec6da37", "node_type": "1", "metadata": {"window": "In the last few weeks, we\u2019ve made several notable announcements regarding our company\u2019s \ncontinued progress, including yesterday\u2019s news on our agreement to acquire Specialty Networks, \nwhich will further our specialty growth strategy and create value for spe cialty providers, \nmanufacturers,  and patients in exciting new ways.  \n \n And, as we highlighted at a recent industry conference, we\u2019re continuing to take actions to become a \nsimplified and more focused company, with further progress achieved on our ongoing business and \nportfolio review and our updated enterprise operating and s egment reporting structure, which will be \nreflected in our financial reporting beginning next quarter.  We plan to go further into our recent \nupdates with you today, but first, let me begin with a few brief comments on our results.  \n \n In Q2, we delivered strong profit growth in both segments, demonstrating continued operating \nmomentum and execution against our strategic priorities.  \n ", "original_text": "In Q2, we delivered strong profit growth in both segments, demonstrating continued operating \nmomentum and execution against our strategic priorities.  \n "}, "hash": "faa1cf8318876754b5e121a43700eede2d70492d752a0a0a1c261d0a66f4367f", "class_name": "RelatedNodeInfo"}}, "text": "We plan to go further into our recent \nupdates with you today, but first, let me begin with a few brief comments on our results.  \n \n", "start_char_idx": 2442, "end_char_idx": 2575, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "c86e8138-f341-46f7-bd9e-228d5ec6da37": {"__data__": {"id_": "c86e8138-f341-46f7-bd9e-228d5ec6da37", "embedding": null, "metadata": {"window": "In the last few weeks, we\u2019ve made several notable announcements regarding our company\u2019s \ncontinued progress, including yesterday\u2019s news on our agreement to acquire Specialty Networks, \nwhich will further our specialty growth strategy and create value for spe cialty providers, \nmanufacturers,  and patients in exciting new ways.  \n \n And, as we highlighted at a recent industry conference, we\u2019re continuing to take actions to become a \nsimplified and more focused company, with further progress achieved on our ongoing business and \nportfolio review and our updated enterprise operating and s egment reporting structure, which will be \nreflected in our financial reporting beginning next quarter.  We plan to go further into our recent \nupdates with you today, but first, let me begin with a few brief comments on our results.  \n \n In Q2, we delivered strong profit growth in both segments, demonstrating continued operating \nmomentum and execution against our strategic priorities.  \n ", "original_text": "In Q2, we delivered strong profit growth in both segments, demonstrating continued operating \nmomentum and execution against our strategic priorities.  \n ", "page_label": "1", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "a4414d54-6710-431a-9934-c424ca18a68a", "node_type": "4", "metadata": {"page_label": "1", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "db9341b5ca61c774614e85db93e9685d87e88c142ca1cdb509ea4c52d573440c", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "e52c54aa-0a67-432f-90da-19c152aa1675", "node_type": "1", "metadata": {"window": "Jason Hollar :  Good morning, everyone.  \n \n In the last few weeks, we\u2019ve made several notable announcements regarding our company\u2019s \ncontinued progress, including yesterday\u2019s news on our agreement to acquire Specialty Networks, \nwhich will further our specialty growth strategy and create value for spe cialty providers, \nmanufacturers,  and patients in exciting new ways.  \n \n And, as we highlighted at a recent industry conference, we\u2019re continuing to take actions to become a \nsimplified and more focused company, with further progress achieved on our ongoing business and \nportfolio review and our updated enterprise operating and s egment reporting structure, which will be \nreflected in our financial reporting beginning next quarter.  We plan to go further into our recent \nupdates with you today, but first, let me begin with a few brief comments on our results.  \n \n In Q2, we delivered strong profit growth in both segments, demonstrating continued operating \nmomentum and execution against our strategic priorities.  \n ", "original_text": "We plan to go further into our recent \nupdates with you today, but first, let me begin with a few brief comments on our results.  \n \n", "page_label": "1", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "0671975c17b4d2a4be467d347f10883327047640ce2fe77c486fae5713ead4d5", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "80d29dbf-ec98-4263-90d8-4bfb52bc361d", "node_type": "1", "metadata": {"window": " \nPage 2 of 19 \n \nPharma again delivered strong performance.  Overall, the business is performing consistent with our \nexpectations, and we\u2019re pleased to reiterate our outlook for 7% to 9% segment profit growth in fiscal \n\u201824. \n \n We\u2019ve seen ongoing stability in macro trends, including in our generics program, and continued \nbroad -based strength in overall pharmaceutical demand.  \n \n Our Specialty Distribution business also continued to see strong demand, including with COVID -19 \nvaccines in the first part of the quarter.  \n \n", "original_text": " \nPage 2 of 19 \n \nPharma again delivered strong performance. "}, "hash": "e4821de9c5f919726995afdbbda66e15ba307ce74db37cccfb7c19aaaeaa48f8", "class_name": "RelatedNodeInfo"}}, "text": "In Q2, we delivered strong profit growth in both segments, demonstrating continued operating \nmomentum and execution against our strategic priorities.  \n ", "start_char_idx": 2575, "end_char_idx": 2729, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "80d29dbf-ec98-4263-90d8-4bfb52bc361d": {"__data__": {"id_": "80d29dbf-ec98-4263-90d8-4bfb52bc361d", "embedding": null, "metadata": {"window": " \nPage 2 of 19 \n \nPharma again delivered strong performance.  Overall, the business is performing consistent with our \nexpectations, and we\u2019re pleased to reiterate our outlook for 7% to 9% segment profit growth in fiscal \n\u201824. \n \n We\u2019ve seen ongoing stability in macro trends, including in our generics program, and continued \nbroad -based strength in overall pharmaceutical demand.  \n \n Our Specialty Distribution business also continued to see strong demand, including with COVID -19 \nvaccines in the first part of the quarter.  \n \n", "original_text": " \nPage 2 of 19 \n \nPharma again delivered strong performance. ", "page_label": "2", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "af1efd63-b407-4e15-8b8e-7fdf94ed494d", "node_type": "4", "metadata": {"page_label": "2", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "401b4c01251e89f37825f9162d3daf2147390f8c3172f8fb25970737b79da56e", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "c86e8138-f341-46f7-bd9e-228d5ec6da37", "node_type": "1", "metadata": {"window": "In the last few weeks, we\u2019ve made several notable announcements regarding our company\u2019s \ncontinued progress, including yesterday\u2019s news on our agreement to acquire Specialty Networks, \nwhich will further our specialty growth strategy and create value for spe cialty providers, \nmanufacturers,  and patients in exciting new ways.  \n \n And, as we highlighted at a recent industry conference, we\u2019re continuing to take actions to become a \nsimplified and more focused company, with further progress achieved on our ongoing business and \nportfolio review and our updated enterprise operating and s egment reporting structure, which will be \nreflected in our financial reporting beginning next quarter.  We plan to go further into our recent \nupdates with you today, but first, let me begin with a few brief comments on our results.  \n \n In Q2, we delivered strong profit growth in both segments, demonstrating continued operating \nmomentum and execution against our strategic priorities.  \n ", "original_text": "In Q2, we delivered strong profit growth in both segments, demonstrating continued operating \nmomentum and execution against our strategic priorities.  \n ", "page_label": "1", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "4de43c82590fca1a7f23175dd96d9f8de70b588930d0157428989527edfa1a78", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "8f0d3214-ac5b-429d-b6fc-02705e9e0bcc", "node_type": "1", "metadata": {"window": " \nPage 2 of 19 \n \nPharma again delivered strong performance.  Overall, the business is performing consistent with our \nexpectations, and we\u2019re pleased to reiterate our outlook for 7% to 9% segment profit growth in fiscal \n\u201824. \n \n We\u2019ve seen ongoing stability in macro trends, including in our generics program, and continued \nbroad -based strength in overall pharmaceutical demand.  \n \n Our Specialty Distribution business also continued to see strong demand, including with COVID -19 \nvaccines in the first part of the quarter.  \n \n Turning to Medical, Q2 segment profit was consistent with Q1, despite some non -recurring \nadjustments in the second quarter, which we\u2019ve reflected in our updated fiscal \u201824 outlook for the \nformer Medical segment.  \n \n", "original_text": "Overall, the business is performing consistent with our \nexpectations, and we\u2019re pleased to reiterate our outlook for 7% to 9% segment profit growth in fiscal \n\u201824. \n \n"}, "hash": "728ab6e770f386bb3fcb5f3381a723bdd74e1c3eb579124cab05102088df7eb1", "class_name": "RelatedNodeInfo"}}, "text": " \nPage 2 of 19 \n \nPharma again delivered strong performance. ", "start_char_idx": 0, "end_char_idx": 61, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "8f0d3214-ac5b-429d-b6fc-02705e9e0bcc": {"__data__": {"id_": "8f0d3214-ac5b-429d-b6fc-02705e9e0bcc", "embedding": null, "metadata": {"window": " \nPage 2 of 19 \n \nPharma again delivered strong performance.  Overall, the business is performing consistent with our \nexpectations, and we\u2019re pleased to reiterate our outlook for 7% to 9% segment profit growth in fiscal \n\u201824. \n \n We\u2019ve seen ongoing stability in macro trends, including in our generics program, and continued \nbroad -based strength in overall pharmaceutical demand.  \n \n Our Specialty Distribution business also continued to see strong demand, including with COVID -19 \nvaccines in the first part of the quarter.  \n \n Turning to Medical, Q2 segment profit was consistent with Q1, despite some non -recurring \nadjustments in the second quarter, which we\u2019ve reflected in our updated fiscal \u201824 outlook for the \nformer Medical segment.  \n \n", "original_text": "Overall, the business is performing consistent with our \nexpectations, and we\u2019re pleased to reiterate our outlook for 7% to 9% segment profit growth in fiscal \n\u201824. \n \n", "page_label": "2", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "af1efd63-b407-4e15-8b8e-7fdf94ed494d", "node_type": "4", "metadata": {"page_label": "2", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "401b4c01251e89f37825f9162d3daf2147390f8c3172f8fb25970737b79da56e", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "80d29dbf-ec98-4263-90d8-4bfb52bc361d", "node_type": "1", "metadata": {"window": " \nPage 2 of 19 \n \nPharma again delivered strong performance.  Overall, the business is performing consistent with our \nexpectations, and we\u2019re pleased to reiterate our outlook for 7% to 9% segment profit growth in fiscal \n\u201824. \n \n We\u2019ve seen ongoing stability in macro trends, including in our generics program, and continued \nbroad -based strength in overall pharmaceutical demand.  \n \n Our Specialty Distribution business also continued to see strong demand, including with COVID -19 \nvaccines in the first part of the quarter.  \n \n", "original_text": " \nPage 2 of 19 \n \nPharma again delivered strong performance. ", "page_label": "2", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "ca6940624b2d998d12ea0c686f737a5917408dcf2629fbb0bb196501afb24a45", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "cd18a014-c4a5-4969-b568-746db62905d4", "node_type": "1", "metadata": {"window": " \nPage 2 of 19 \n \nPharma again delivered strong performance.  Overall, the business is performing consistent with our \nexpectations, and we\u2019re pleased to reiterate our outlook for 7% to 9% segment profit growth in fiscal \n\u201824. \n \n We\u2019ve seen ongoing stability in macro trends, including in our generics program, and continued \nbroad -based strength in overall pharmaceutical demand.  \n \n Our Specialty Distribution business also continued to see strong demand, including with COVID -19 \nvaccines in the first part of the quarter.  \n \n Turning to Medical, Q2 segment profit was consistent with Q1, despite some non -recurring \nadjustments in the second quarter, which we\u2019ve reflected in our updated fiscal \u201824 outlook for the \nformer Medical segment.  \n \n We\u2019re encouraged by the underlying improvements in operating performance, reflecting further \nprogress with our Medical Improvement Plan efforts, focused on our Global Medical Products and \nDistribution business.  \n \n", "original_text": "We\u2019ve seen ongoing stability in macro trends, including in our generics program, and continued \nbroad -based strength in overall pharmaceutical demand.  \n \n"}, "hash": "83d2b4f201773075af1fa129892d705561491279a09954ab81d2e9e9f1a2fcb1", "class_name": "RelatedNodeInfo"}}, "text": "Overall, the business is performing consistent with our \nexpectations, and we\u2019re pleased to reiterate our outlook for 7% to 9% segment profit growth in fiscal \n\u201824. \n \n", "start_char_idx": 61, "end_char_idx": 229, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "cd18a014-c4a5-4969-b568-746db62905d4": {"__data__": {"id_": "cd18a014-c4a5-4969-b568-746db62905d4", "embedding": null, "metadata": {"window": " \nPage 2 of 19 \n \nPharma again delivered strong performance.  Overall, the business is performing consistent with our \nexpectations, and we\u2019re pleased to reiterate our outlook for 7% to 9% segment profit growth in fiscal \n\u201824. \n \n We\u2019ve seen ongoing stability in macro trends, including in our generics program, and continued \nbroad -based strength in overall pharmaceutical demand.  \n \n Our Specialty Distribution business also continued to see strong demand, including with COVID -19 \nvaccines in the first part of the quarter.  \n \n Turning to Medical, Q2 segment profit was consistent with Q1, despite some non -recurring \nadjustments in the second quarter, which we\u2019ve reflected in our updated fiscal \u201824 outlook for the \nformer Medical segment.  \n \n We\u2019re encouraged by the underlying improvements in operating performance, reflecting further \nprogress with our Medical Improvement Plan efforts, focused on our Global Medical Products and \nDistribution business.  \n \n", "original_text": "We\u2019ve seen ongoing stability in macro trends, including in our generics program, and continued \nbroad -based strength in overall pharmaceutical demand.  \n \n", "page_label": "2", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "af1efd63-b407-4e15-8b8e-7fdf94ed494d", "node_type": "4", "metadata": {"page_label": "2", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "401b4c01251e89f37825f9162d3daf2147390f8c3172f8fb25970737b79da56e", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "8f0d3214-ac5b-429d-b6fc-02705e9e0bcc", "node_type": "1", "metadata": {"window": " \nPage 2 of 19 \n \nPharma again delivered strong performance.  Overall, the business is performing consistent with our \nexpectations, and we\u2019re pleased to reiterate our outlook for 7% to 9% segment profit growth in fiscal \n\u201824. \n \n We\u2019ve seen ongoing stability in macro trends, including in our generics program, and continued \nbroad -based strength in overall pharmaceutical demand.  \n \n Our Specialty Distribution business also continued to see strong demand, including with COVID -19 \nvaccines in the first part of the quarter.  \n \n Turning to Medical, Q2 segment profit was consistent with Q1, despite some non -recurring \nadjustments in the second quarter, which we\u2019ve reflected in our updated fiscal \u201824 outlook for the \nformer Medical segment.  \n \n", "original_text": "Overall, the business is performing consistent with our \nexpectations, and we\u2019re pleased to reiterate our outlook for 7% to 9% segment profit growth in fiscal \n\u201824. \n \n", "page_label": "2", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "c9b9bcf0a84b66af173cdaf1d8ec0a0488e5a606175b960ff6078b370e1f0186", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "318d0436-6633-4dba-b681-532a2164ab96", "node_type": "1", "metadata": {"window": " \nPage 2 of 19 \n \nPharma again delivered strong performance.  Overall, the business is performing consistent with our \nexpectations, and we\u2019re pleased to reiterate our outlook for 7% to 9% segment profit growth in fiscal \n\u201824. \n \n We\u2019ve seen ongoing stability in macro trends, including in our generics program, and continued \nbroad -based strength in overall pharmaceutical demand.  \n \n Our Specialty Distribution business also continued to see strong demand, including with COVID -19 \nvaccines in the first part of the quarter.  \n \n Turning to Medical, Q2 segment profit was consistent with Q1, despite some non -recurring \nadjustments in the second quarter, which we\u2019ve reflected in our updated fiscal \u201824 outlook for the \nformer Medical segment.  \n \n We\u2019re encouraged by the underlying improvements in operating performance, reflecting further \nprogress with our Medical Improvement Plan efforts, focused on our Global Medical Products and \nDistribution business.  \n \n Notably, we saw a change in trend in revenue growth for the Medical segment in the second quarter. \n", "original_text": "Our Specialty Distribution business also continued to see strong demand, including with COVID -19 \nvaccines in the first part of the quarter.  \n \n"}, "hash": "1dd9f49f2d2c326c638aa15983f59ccf800f19e553f1b7f686000ce2c4a4e577", "class_name": "RelatedNodeInfo"}}, "text": "We\u2019ve seen ongoing stability in macro trends, including in our generics program, and continued \nbroad -based strength in overall pharmaceutical demand.  \n \n", "start_char_idx": 229, "end_char_idx": 385, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "318d0436-6633-4dba-b681-532a2164ab96": {"__data__": {"id_": "318d0436-6633-4dba-b681-532a2164ab96", "embedding": null, "metadata": {"window": " \nPage 2 of 19 \n \nPharma again delivered strong performance.  Overall, the business is performing consistent with our \nexpectations, and we\u2019re pleased to reiterate our outlook for 7% to 9% segment profit growth in fiscal \n\u201824. \n \n We\u2019ve seen ongoing stability in macro trends, including in our generics program, and continued \nbroad -based strength in overall pharmaceutical demand.  \n \n Our Specialty Distribution business also continued to see strong demand, including with COVID -19 \nvaccines in the first part of the quarter.  \n \n Turning to Medical, Q2 segment profit was consistent with Q1, despite some non -recurring \nadjustments in the second quarter, which we\u2019ve reflected in our updated fiscal \u201824 outlook for the \nformer Medical segment.  \n \n We\u2019re encouraged by the underlying improvements in operating performance, reflecting further \nprogress with our Medical Improvement Plan efforts, focused on our Global Medical Products and \nDistribution business.  \n \n Notably, we saw a change in trend in revenue growth for the Medical segment in the second quarter. \n", "original_text": "Our Specialty Distribution business also continued to see strong demand, including with COVID -19 \nvaccines in the first part of the quarter.  \n \n", "page_label": "2", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "af1efd63-b407-4e15-8b8e-7fdf94ed494d", "node_type": "4", "metadata": {"page_label": "2", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "401b4c01251e89f37825f9162d3daf2147390f8c3172f8fb25970737b79da56e", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "cd18a014-c4a5-4969-b568-746db62905d4", "node_type": "1", "metadata": {"window": " \nPage 2 of 19 \n \nPharma again delivered strong performance.  Overall, the business is performing consistent with our \nexpectations, and we\u2019re pleased to reiterate our outlook for 7% to 9% segment profit growth in fiscal \n\u201824. \n \n We\u2019ve seen ongoing stability in macro trends, including in our generics program, and continued \nbroad -based strength in overall pharmaceutical demand.  \n \n Our Specialty Distribution business also continued to see strong demand, including with COVID -19 \nvaccines in the first part of the quarter.  \n \n Turning to Medical, Q2 segment profit was consistent with Q1, despite some non -recurring \nadjustments in the second quarter, which we\u2019ve reflected in our updated fiscal \u201824 outlook for the \nformer Medical segment.  \n \n We\u2019re encouraged by the underlying improvements in operating performance, reflecting further \nprogress with our Medical Improvement Plan efforts, focused on our Global Medical Products and \nDistribution business.  \n \n", "original_text": "We\u2019ve seen ongoing stability in macro trends, including in our generics program, and continued \nbroad -based strength in overall pharmaceutical demand.  \n \n", "page_label": "2", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "1f414a457adf451242f787ebc84ef9c99fb4c1640dfa752c33579750b2b35d04", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "c2b7f78f-aa18-4197-afcd-c1f9505155b3", "node_type": "1", "metadata": {"window": "Overall, the business is performing consistent with our \nexpectations, and we\u2019re pleased to reiterate our outlook for 7% to 9% segment profit growth in fiscal \n\u201824. \n \n We\u2019ve seen ongoing stability in macro trends, including in our generics program, and continued \nbroad -based strength in overall pharmaceutical demand.  \n \n Our Specialty Distribution business also continued to see strong demand, including with COVID -19 \nvaccines in the first part of the quarter.  \n \n Turning to Medical, Q2 segment profit was consistent with Q1, despite some non -recurring \nadjustments in the second quarter, which we\u2019ve reflected in our updated fiscal \u201824 outlook for the \nformer Medical segment.  \n \n We\u2019re encouraged by the underlying improvements in operating performance, reflecting further \nprogress with our Medical Improvement Plan efforts, focused on our Global Medical Products and \nDistribution business.  \n \n Notably, we saw a change in trend in revenue growth for the Medical segment in the second quarter. \n Along with continued growth from at -Home Solutions, we\u2019re seeing the effects of our 5 -point plan to \ngrow Cardinal Health Brand volumes yield positive results .  \n \n", "original_text": "Turning to Medical, Q2 segment profit was consistent with Q1, despite some non -recurring \nadjustments in the second quarter, which we\u2019ve reflected in our updated fiscal \u201824 outlook for the \nformer Medical segment.  \n \n"}, "hash": "15785008d96377611f05f63abcdded6dc69f7cae9c2e14bb77d771b6ce5d2d1e", "class_name": "RelatedNodeInfo"}}, "text": "Our Specialty Distribution business also continued to see strong demand, including with COVID -19 \nvaccines in the first part of the quarter.  \n \n", "start_char_idx": 385, "end_char_idx": 531, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "c2b7f78f-aa18-4197-afcd-c1f9505155b3": {"__data__": {"id_": "c2b7f78f-aa18-4197-afcd-c1f9505155b3", "embedding": null, "metadata": {"window": "Overall, the business is performing consistent with our \nexpectations, and we\u2019re pleased to reiterate our outlook for 7% to 9% segment profit growth in fiscal \n\u201824. \n \n We\u2019ve seen ongoing stability in macro trends, including in our generics program, and continued \nbroad -based strength in overall pharmaceutical demand.  \n \n Our Specialty Distribution business also continued to see strong demand, including with COVID -19 \nvaccines in the first part of the quarter.  \n \n Turning to Medical, Q2 segment profit was consistent with Q1, despite some non -recurring \nadjustments in the second quarter, which we\u2019ve reflected in our updated fiscal \u201824 outlook for the \nformer Medical segment.  \n \n We\u2019re encouraged by the underlying improvements in operating performance, reflecting further \nprogress with our Medical Improvement Plan efforts, focused on our Global Medical Products and \nDistribution business.  \n \n Notably, we saw a change in trend in revenue growth for the Medical segment in the second quarter. \n Along with continued growth from at -Home Solutions, we\u2019re seeing the effects of our 5 -point plan to \ngrow Cardinal Health Brand volumes yield positive results .  \n \n", "original_text": "Turning to Medical, Q2 segment profit was consistent with Q1, despite some non -recurring \nadjustments in the second quarter, which we\u2019ve reflected in our updated fiscal \u201824 outlook for the \nformer Medical segment.  \n \n", "page_label": "2", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "af1efd63-b407-4e15-8b8e-7fdf94ed494d", "node_type": "4", "metadata": {"page_label": "2", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "401b4c01251e89f37825f9162d3daf2147390f8c3172f8fb25970737b79da56e", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "318d0436-6633-4dba-b681-532a2164ab96", "node_type": "1", "metadata": {"window": " \nPage 2 of 19 \n \nPharma again delivered strong performance.  Overall, the business is performing consistent with our \nexpectations, and we\u2019re pleased to reiterate our outlook for 7% to 9% segment profit growth in fiscal \n\u201824. \n \n We\u2019ve seen ongoing stability in macro trends, including in our generics program, and continued \nbroad -based strength in overall pharmaceutical demand.  \n \n Our Specialty Distribution business also continued to see strong demand, including with COVID -19 \nvaccines in the first part of the quarter.  \n \n Turning to Medical, Q2 segment profit was consistent with Q1, despite some non -recurring \nadjustments in the second quarter, which we\u2019ve reflected in our updated fiscal \u201824 outlook for the \nformer Medical segment.  \n \n We\u2019re encouraged by the underlying improvements in operating performance, reflecting further \nprogress with our Medical Improvement Plan efforts, focused on our Global Medical Products and \nDistribution business.  \n \n Notably, we saw a change in trend in revenue growth for the Medical segment in the second quarter. \n", "original_text": "Our Specialty Distribution business also continued to see strong demand, including with COVID -19 \nvaccines in the first part of the quarter.  \n \n", "page_label": "2", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "ee5e2f57c4cc7e1fa2036fccbce3ed7a1f54797740aa405be53f81477a7a4608", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "177cb92a-0319-41d5-a36e-14c0b22250d4", "node_type": "1", "metadata": {"window": "We\u2019ve seen ongoing stability in macro trends, including in our generics program, and continued \nbroad -based strength in overall pharmaceutical demand.  \n \n Our Specialty Distribution business also continued to see strong demand, including with COVID -19 \nvaccines in the first part of the quarter.  \n \n Turning to Medical, Q2 segment profit was consistent with Q1, despite some non -recurring \nadjustments in the second quarter, which we\u2019ve reflected in our updated fiscal \u201824 outlook for the \nformer Medical segment.  \n \n We\u2019re encouraged by the underlying improvements in operating performance, reflecting further \nprogress with our Medical Improvement Plan efforts, focused on our Global Medical Products and \nDistribution business.  \n \n Notably, we saw a change in trend in revenue growth for the Medical segment in the second quarter. \n Along with continued growth from at -Home Solutions, we\u2019re seeing the effects of our 5 -point plan to \ngrow Cardinal Health Brand volumes yield positive results .  \n \n And, as we continue to optimize not only the performance of our businesses, but also the financial \nstrength of the broader enterprise, we\u2019re generating robust cash flow and seeing meaningful benefits \nbelow the operating line.  \n \n", "original_text": "We\u2019re encouraged by the underlying improvements in operating performance, reflecting further \nprogress with our Medical Improvement Plan efforts, focused on our Global Medical Products and \nDistribution business.  \n \n"}, "hash": "c3456b099cddae23d64abbb333887b1b578a6c729739eac000f64ba4f793d359", "class_name": "RelatedNodeInfo"}}, "text": "Turning to Medical, Q2 segment profit was consistent with Q1, despite some non -recurring \nadjustments in the second quarter, which we\u2019ve reflected in our updated fiscal \u201824 outlook for the \nformer Medical segment.  \n \n", "start_char_idx": 531, "end_char_idx": 750, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "177cb92a-0319-41d5-a36e-14c0b22250d4": {"__data__": {"id_": "177cb92a-0319-41d5-a36e-14c0b22250d4", "embedding": null, "metadata": {"window": "We\u2019ve seen ongoing stability in macro trends, including in our generics program, and continued \nbroad -based strength in overall pharmaceutical demand.  \n \n Our Specialty Distribution business also continued to see strong demand, including with COVID -19 \nvaccines in the first part of the quarter.  \n \n Turning to Medical, Q2 segment profit was consistent with Q1, despite some non -recurring \nadjustments in the second quarter, which we\u2019ve reflected in our updated fiscal \u201824 outlook for the \nformer Medical segment.  \n \n We\u2019re encouraged by the underlying improvements in operating performance, reflecting further \nprogress with our Medical Improvement Plan efforts, focused on our Global Medical Products and \nDistribution business.  \n \n Notably, we saw a change in trend in revenue growth for the Medical segment in the second quarter. \n Along with continued growth from at -Home Solutions, we\u2019re seeing the effects of our 5 -point plan to \ngrow Cardinal Health Brand volumes yield positive results .  \n \n And, as we continue to optimize not only the performance of our businesses, but also the financial \nstrength of the broader enterprise, we\u2019re generating robust cash flow and seeing meaningful benefits \nbelow the operating line.  \n \n", "original_text": "We\u2019re encouraged by the underlying improvements in operating performance, reflecting further \nprogress with our Medical Improvement Plan efforts, focused on our Global Medical Products and \nDistribution business.  \n \n", "page_label": "2", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "af1efd63-b407-4e15-8b8e-7fdf94ed494d", "node_type": "4", "metadata": {"page_label": "2", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "401b4c01251e89f37825f9162d3daf2147390f8c3172f8fb25970737b79da56e", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "c2b7f78f-aa18-4197-afcd-c1f9505155b3", "node_type": "1", "metadata": {"window": "Overall, the business is performing consistent with our \nexpectations, and we\u2019re pleased to reiterate our outlook for 7% to 9% segment profit growth in fiscal \n\u201824. \n \n We\u2019ve seen ongoing stability in macro trends, including in our generics program, and continued \nbroad -based strength in overall pharmaceutical demand.  \n \n Our Specialty Distribution business also continued to see strong demand, including with COVID -19 \nvaccines in the first part of the quarter.  \n \n Turning to Medical, Q2 segment profit was consistent with Q1, despite some non -recurring \nadjustments in the second quarter, which we\u2019ve reflected in our updated fiscal \u201824 outlook for the \nformer Medical segment.  \n \n We\u2019re encouraged by the underlying improvements in operating performance, reflecting further \nprogress with our Medical Improvement Plan efforts, focused on our Global Medical Products and \nDistribution business.  \n \n Notably, we saw a change in trend in revenue growth for the Medical segment in the second quarter. \n Along with continued growth from at -Home Solutions, we\u2019re seeing the effects of our 5 -point plan to \ngrow Cardinal Health Brand volumes yield positive results .  \n \n", "original_text": "Turning to Medical, Q2 segment profit was consistent with Q1, despite some non -recurring \nadjustments in the second quarter, which we\u2019ve reflected in our updated fiscal \u201824 outlook for the \nformer Medical segment.  \n \n", "page_label": "2", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "e1cc633cc487f5520b9e774dfdf063b1750a832eea2fd84e435cb28b96091d46", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "7d704305-bc7c-40ff-ae2e-e9ef20103ddc", "node_type": "1", "metadata": {"window": "Our Specialty Distribution business also continued to see strong demand, including with COVID -19 \nvaccines in the first part of the quarter.  \n \n Turning to Medical, Q2 segment profit was consistent with Q1, despite some non -recurring \nadjustments in the second quarter, which we\u2019ve reflected in our updated fiscal \u201824 outlook for the \nformer Medical segment.  \n \n We\u2019re encouraged by the underlying improvements in operating performance, reflecting further \nprogress with our Medical Improvement Plan efforts, focused on our Global Medical Products and \nDistribution business.  \n \n Notably, we saw a change in trend in revenue growth for the Medical segment in the second quarter. \n Along with continued growth from at -Home Solutions, we\u2019re seeing the effects of our 5 -point plan to \ngrow Cardinal Health Brand volumes yield positive results .  \n \n And, as we continue to optimize not only the performance of our businesses, but also the financial \nstrength of the broader enterprise, we\u2019re generating robust cash flow and seeing meaningful benefits \nbelow the operating line.  \n \n As a result of our first half performance, and increased confidence as we look ahead, we\u2019re pleased \nto raise our fiscal \u201824 EPS guidance and our outlook for adjusted free cash flow.  \n \n", "original_text": "Notably, we saw a change in trend in revenue growth for the Medical segment in the second quarter. \n"}, "hash": "da46d3c0114d7f4547b69a6a6673d31f614efabc26e970e8fcd58380593aecad", "class_name": "RelatedNodeInfo"}}, "text": "We\u2019re encouraged by the underlying improvements in operating performance, reflecting further \nprogress with our Medical Improvement Plan efforts, focused on our Global Medical Products and \nDistribution business.  \n \n", "start_char_idx": 750, "end_char_idx": 967, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "7d704305-bc7c-40ff-ae2e-e9ef20103ddc": {"__data__": {"id_": "7d704305-bc7c-40ff-ae2e-e9ef20103ddc", "embedding": null, "metadata": {"window": "Our Specialty Distribution business also continued to see strong demand, including with COVID -19 \nvaccines in the first part of the quarter.  \n \n Turning to Medical, Q2 segment profit was consistent with Q1, despite some non -recurring \nadjustments in the second quarter, which we\u2019ve reflected in our updated fiscal \u201824 outlook for the \nformer Medical segment.  \n \n We\u2019re encouraged by the underlying improvements in operating performance, reflecting further \nprogress with our Medical Improvement Plan efforts, focused on our Global Medical Products and \nDistribution business.  \n \n Notably, we saw a change in trend in revenue growth for the Medical segment in the second quarter. \n Along with continued growth from at -Home Solutions, we\u2019re seeing the effects of our 5 -point plan to \ngrow Cardinal Health Brand volumes yield positive results .  \n \n And, as we continue to optimize not only the performance of our businesses, but also the financial \nstrength of the broader enterprise, we\u2019re generating robust cash flow and seeing meaningful benefits \nbelow the operating line.  \n \n As a result of our first half performance, and increased confidence as we look ahead, we\u2019re pleased \nto raise our fiscal \u201824 EPS guidance and our outlook for adjusted free cash flow.  \n \n", "original_text": "Notably, we saw a change in trend in revenue growth for the Medical segment in the second quarter. \n", "page_label": "2", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "af1efd63-b407-4e15-8b8e-7fdf94ed494d", "node_type": "4", "metadata": {"page_label": "2", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "401b4c01251e89f37825f9162d3daf2147390f8c3172f8fb25970737b79da56e", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "177cb92a-0319-41d5-a36e-14c0b22250d4", "node_type": "1", "metadata": {"window": "We\u2019ve seen ongoing stability in macro trends, including in our generics program, and continued \nbroad -based strength in overall pharmaceutical demand.  \n \n Our Specialty Distribution business also continued to see strong demand, including with COVID -19 \nvaccines in the first part of the quarter.  \n \n Turning to Medical, Q2 segment profit was consistent with Q1, despite some non -recurring \nadjustments in the second quarter, which we\u2019ve reflected in our updated fiscal \u201824 outlook for the \nformer Medical segment.  \n \n We\u2019re encouraged by the underlying improvements in operating performance, reflecting further \nprogress with our Medical Improvement Plan efforts, focused on our Global Medical Products and \nDistribution business.  \n \n Notably, we saw a change in trend in revenue growth for the Medical segment in the second quarter. \n Along with continued growth from at -Home Solutions, we\u2019re seeing the effects of our 5 -point plan to \ngrow Cardinal Health Brand volumes yield positive results .  \n \n And, as we continue to optimize not only the performance of our businesses, but also the financial \nstrength of the broader enterprise, we\u2019re generating robust cash flow and seeing meaningful benefits \nbelow the operating line.  \n \n", "original_text": "We\u2019re encouraged by the underlying improvements in operating performance, reflecting further \nprogress with our Medical Improvement Plan efforts, focused on our Global Medical Products and \nDistribution business.  \n \n", "page_label": "2", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "2fc02489cf58a43067016ee45396b4f7c9b899ce0f482243873dd31e9282ba99", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "e97e4010-193f-4cfa-966a-6b5b2abcf674", "node_type": "1", "metadata": {"window": "Turning to Medical, Q2 segment profit was consistent with Q1, despite some non -recurring \nadjustments in the second quarter, which we\u2019ve reflected in our updated fiscal \u201824 outlook for the \nformer Medical segment.  \n \n We\u2019re encouraged by the underlying improvements in operating performance, reflecting further \nprogress with our Medical Improvement Plan efforts, focused on our Global Medical Products and \nDistribution business.  \n \n Notably, we saw a change in trend in revenue growth for the Medical segment in the second quarter. \n Along with continued growth from at -Home Solutions, we\u2019re seeing the effects of our 5 -point plan to \ngrow Cardinal Health Brand volumes yield positive results .  \n \n And, as we continue to optimize not only the performance of our businesses, but also the financial \nstrength of the broader enterprise, we\u2019re generating robust cash flow and seeing meaningful benefits \nbelow the operating line.  \n \n As a result of our first half performance, and increased confidence as we look ahead, we\u2019re pleased \nto raise our fiscal \u201824 EPS guidance and our outlook for adjusted free cash flow.  \n \n Of course, our customers remain at the center of everything we do, and our team continues to \nprioritize core operational execution to best serve them and their patients with essential products and \nservices, as we drive our company forward.   \n \n", "original_text": "Along with continued growth from at -Home Solutions, we\u2019re seeing the effects of our 5 -point plan to \ngrow Cardinal Health Brand volumes yield positive results .  \n \n"}, "hash": "be16ad6b7311776c2cf3d06d081dacbfdd05e7b1844e6d6b260093b655ef30ae", "class_name": "RelatedNodeInfo"}}, "text": "Notably, we saw a change in trend in revenue growth for the Medical segment in the second quarter. \n", "start_char_idx": 967, "end_char_idx": 1067, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "e97e4010-193f-4cfa-966a-6b5b2abcf674": {"__data__": {"id_": "e97e4010-193f-4cfa-966a-6b5b2abcf674", "embedding": null, "metadata": {"window": "Turning to Medical, Q2 segment profit was consistent with Q1, despite some non -recurring \nadjustments in the second quarter, which we\u2019ve reflected in our updated fiscal \u201824 outlook for the \nformer Medical segment.  \n \n We\u2019re encouraged by the underlying improvements in operating performance, reflecting further \nprogress with our Medical Improvement Plan efforts, focused on our Global Medical Products and \nDistribution business.  \n \n Notably, we saw a change in trend in revenue growth for the Medical segment in the second quarter. \n Along with continued growth from at -Home Solutions, we\u2019re seeing the effects of our 5 -point plan to \ngrow Cardinal Health Brand volumes yield positive results .  \n \n And, as we continue to optimize not only the performance of our businesses, but also the financial \nstrength of the broader enterprise, we\u2019re generating robust cash flow and seeing meaningful benefits \nbelow the operating line.  \n \n As a result of our first half performance, and increased confidence as we look ahead, we\u2019re pleased \nto raise our fiscal \u201824 EPS guidance and our outlook for adjusted free cash flow.  \n \n Of course, our customers remain at the center of everything we do, and our team continues to \nprioritize core operational execution to best serve them and their patients with essential products and \nservices, as we drive our company forward.   \n \n", "original_text": "Along with continued growth from at -Home Solutions, we\u2019re seeing the effects of our 5 -point plan to \ngrow Cardinal Health Brand volumes yield positive results .  \n \n", "page_label": "2", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "af1efd63-b407-4e15-8b8e-7fdf94ed494d", "node_type": "4", "metadata": {"page_label": "2", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "401b4c01251e89f37825f9162d3daf2147390f8c3172f8fb25970737b79da56e", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "7d704305-bc7c-40ff-ae2e-e9ef20103ddc", "node_type": "1", "metadata": {"window": "Our Specialty Distribution business also continued to see strong demand, including with COVID -19 \nvaccines in the first part of the quarter.  \n \n Turning to Medical, Q2 segment profit was consistent with Q1, despite some non -recurring \nadjustments in the second quarter, which we\u2019ve reflected in our updated fiscal \u201824 outlook for the \nformer Medical segment.  \n \n We\u2019re encouraged by the underlying improvements in operating performance, reflecting further \nprogress with our Medical Improvement Plan efforts, focused on our Global Medical Products and \nDistribution business.  \n \n Notably, we saw a change in trend in revenue growth for the Medical segment in the second quarter. \n Along with continued growth from at -Home Solutions, we\u2019re seeing the effects of our 5 -point plan to \ngrow Cardinal Health Brand volumes yield positive results .  \n \n And, as we continue to optimize not only the performance of our businesses, but also the financial \nstrength of the broader enterprise, we\u2019re generating robust cash flow and seeing meaningful benefits \nbelow the operating line.  \n \n As a result of our first half performance, and increased confidence as we look ahead, we\u2019re pleased \nto raise our fiscal \u201824 EPS guidance and our outlook for adjusted free cash flow.  \n \n", "original_text": "Notably, we saw a change in trend in revenue growth for the Medical segment in the second quarter. \n", "page_label": "2", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "730782c0b03b80ed2ba97f9839744156678c47c01075c5ee6b523409fd0a0698", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "c728b342-573c-4be8-b137-48d1ebf80374", "node_type": "1", "metadata": {"window": "We\u2019re encouraged by the underlying improvements in operating performance, reflecting further \nprogress with our Medical Improvement Plan efforts, focused on our Global Medical Products and \nDistribution business.  \n \n Notably, we saw a change in trend in revenue growth for the Medical segment in the second quarter. \n Along with continued growth from at -Home Solutions, we\u2019re seeing the effects of our 5 -point plan to \ngrow Cardinal Health Brand volumes yield positive results .  \n \n And, as we continue to optimize not only the performance of our businesses, but also the financial \nstrength of the broader enterprise, we\u2019re generating robust cash flow and seeing meaningful benefits \nbelow the operating line.  \n \n As a result of our first half performance, and increased confidence as we look ahead, we\u2019re pleased \nto raise our fiscal \u201824 EPS guidance and our outlook for adjusted free cash flow.  \n \n Of course, our customers remain at the center of everything we do, and our team continues to \nprioritize core operational execution to best serve them and their patients with essential products and \nservices, as we drive our company forward.   \n \n Now, let me turn it over to Aaron to review our results and updated guidance in more detail.  \n \n", "original_text": "And, as we continue to optimize not only the performance of our businesses, but also the financial \nstrength of the broader enterprise, we\u2019re generating robust cash flow and seeing meaningful benefits \nbelow the operating line.  \n \n"}, "hash": "628807241f2a5d26c02ec7b556742e623734a567a7dc9be8df960cbe37683ff9", "class_name": "RelatedNodeInfo"}}, "text": "Along with continued growth from at -Home Solutions, we\u2019re seeing the effects of our 5 -point plan to \ngrow Cardinal Health Brand volumes yield positive results .  \n \n", "start_char_idx": 1067, "end_char_idx": 1234, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "c728b342-573c-4be8-b137-48d1ebf80374": {"__data__": {"id_": "c728b342-573c-4be8-b137-48d1ebf80374", "embedding": null, "metadata": {"window": "We\u2019re encouraged by the underlying improvements in operating performance, reflecting further \nprogress with our Medical Improvement Plan efforts, focused on our Global Medical Products and \nDistribution business.  \n \n Notably, we saw a change in trend in revenue growth for the Medical segment in the second quarter. \n Along with continued growth from at -Home Solutions, we\u2019re seeing the effects of our 5 -point plan to \ngrow Cardinal Health Brand volumes yield positive results .  \n \n And, as we continue to optimize not only the performance of our businesses, but also the financial \nstrength of the broader enterprise, we\u2019re generating robust cash flow and seeing meaningful benefits \nbelow the operating line.  \n \n As a result of our first half performance, and increased confidence as we look ahead, we\u2019re pleased \nto raise our fiscal \u201824 EPS guidance and our outlook for adjusted free cash flow.  \n \n Of course, our customers remain at the center of everything we do, and our team continues to \nprioritize core operational execution to best serve them and their patients with essential products and \nservices, as we drive our company forward.   \n \n Now, let me turn it over to Aaron to review our results and updated guidance in more detail.  \n \n", "original_text": "And, as we continue to optimize not only the performance of our businesses, but also the financial \nstrength of the broader enterprise, we\u2019re generating robust cash flow and seeing meaningful benefits \nbelow the operating line.  \n \n", "page_label": "2", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "af1efd63-b407-4e15-8b8e-7fdf94ed494d", "node_type": "4", "metadata": {"page_label": "2", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "401b4c01251e89f37825f9162d3daf2147390f8c3172f8fb25970737b79da56e", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "e97e4010-193f-4cfa-966a-6b5b2abcf674", "node_type": "1", "metadata": {"window": "Turning to Medical, Q2 segment profit was consistent with Q1, despite some non -recurring \nadjustments in the second quarter, which we\u2019ve reflected in our updated fiscal \u201824 outlook for the \nformer Medical segment.  \n \n We\u2019re encouraged by the underlying improvements in operating performance, reflecting further \nprogress with our Medical Improvement Plan efforts, focused on our Global Medical Products and \nDistribution business.  \n \n Notably, we saw a change in trend in revenue growth for the Medical segment in the second quarter. \n Along with continued growth from at -Home Solutions, we\u2019re seeing the effects of our 5 -point plan to \ngrow Cardinal Health Brand volumes yield positive results .  \n \n And, as we continue to optimize not only the performance of our businesses, but also the financial \nstrength of the broader enterprise, we\u2019re generating robust cash flow and seeing meaningful benefits \nbelow the operating line.  \n \n As a result of our first half performance, and increased confidence as we look ahead, we\u2019re pleased \nto raise our fiscal \u201824 EPS guidance and our outlook for adjusted free cash flow.  \n \n Of course, our customers remain at the center of everything we do, and our team continues to \nprioritize core operational execution to best serve them and their patients with essential products and \nservices, as we drive our company forward.   \n \n", "original_text": "Along with continued growth from at -Home Solutions, we\u2019re seeing the effects of our 5 -point plan to \ngrow Cardinal Health Brand volumes yield positive results .  \n \n", "page_label": "2", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "47a327c967bbe06fae86cbbb104f624266041d935d6a0db41527a296c956adea", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "51a565bd-a823-4759-bc5b-294bd6433331", "node_type": "1", "metadata": {"window": "Notably, we saw a change in trend in revenue growth for the Medical segment in the second quarter. \n Along with continued growth from at -Home Solutions, we\u2019re seeing the effects of our 5 -point plan to \ngrow Cardinal Health Brand volumes yield positive results .  \n \n And, as we continue to optimize not only the performance of our businesses, but also the financial \nstrength of the broader enterprise, we\u2019re generating robust cash flow and seeing meaningful benefits \nbelow the operating line.  \n \n As a result of our first half performance, and increased confidence as we look ahead, we\u2019re pleased \nto raise our fiscal \u201824 EPS guidance and our outlook for adjusted free cash flow.  \n \n Of course, our customers remain at the center of everything we do, and our team continues to \nprioritize core operational execution to best serve them and their patients with essential products and \nservices, as we drive our company forward.   \n \n Now, let me turn it over to Aaron to review our results and updated guidance in more detail.  \n \n Aaron Alt:   Thanks Jason, and good morning.  \n \n", "original_text": "As a result of our first half performance, and increased confidence as we look ahead, we\u2019re pleased \nto raise our fiscal \u201824 EPS guidance and our outlook for adjusted free cash flow.  \n \n"}, "hash": "3a224d993428817668a54058abb069765d4497c9fc148394b55bdcec8084bbff", "class_name": "RelatedNodeInfo"}}, "text": "And, as we continue to optimize not only the performance of our businesses, but also the financial \nstrength of the broader enterprise, we\u2019re generating robust cash flow and seeing meaningful benefits \nbelow the operating line.  \n \n", "start_char_idx": 1234, "end_char_idx": 1466, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "51a565bd-a823-4759-bc5b-294bd6433331": {"__data__": {"id_": "51a565bd-a823-4759-bc5b-294bd6433331", "embedding": null, "metadata": {"window": "Notably, we saw a change in trend in revenue growth for the Medical segment in the second quarter. \n Along with continued growth from at -Home Solutions, we\u2019re seeing the effects of our 5 -point plan to \ngrow Cardinal Health Brand volumes yield positive results .  \n \n And, as we continue to optimize not only the performance of our businesses, but also the financial \nstrength of the broader enterprise, we\u2019re generating robust cash flow and seeing meaningful benefits \nbelow the operating line.  \n \n As a result of our first half performance, and increased confidence as we look ahead, we\u2019re pleased \nto raise our fiscal \u201824 EPS guidance and our outlook for adjusted free cash flow.  \n \n Of course, our customers remain at the center of everything we do, and our team continues to \nprioritize core operational execution to best serve them and their patients with essential products and \nservices, as we drive our company forward.   \n \n Now, let me turn it over to Aaron to review our results and updated guidance in more detail.  \n \n Aaron Alt:   Thanks Jason, and good morning.  \n \n", "original_text": "As a result of our first half performance, and increased confidence as we look ahead, we\u2019re pleased \nto raise our fiscal \u201824 EPS guidance and our outlook for adjusted free cash flow.  \n \n", "page_label": "2", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "af1efd63-b407-4e15-8b8e-7fdf94ed494d", "node_type": "4", "metadata": {"page_label": "2", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "401b4c01251e89f37825f9162d3daf2147390f8c3172f8fb25970737b79da56e", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "c728b342-573c-4be8-b137-48d1ebf80374", "node_type": "1", "metadata": {"window": "We\u2019re encouraged by the underlying improvements in operating performance, reflecting further \nprogress with our Medical Improvement Plan efforts, focused on our Global Medical Products and \nDistribution business.  \n \n Notably, we saw a change in trend in revenue growth for the Medical segment in the second quarter. \n Along with continued growth from at -Home Solutions, we\u2019re seeing the effects of our 5 -point plan to \ngrow Cardinal Health Brand volumes yield positive results .  \n \n And, as we continue to optimize not only the performance of our businesses, but also the financial \nstrength of the broader enterprise, we\u2019re generating robust cash flow and seeing meaningful benefits \nbelow the operating line.  \n \n As a result of our first half performance, and increased confidence as we look ahead, we\u2019re pleased \nto raise our fiscal \u201824 EPS guidance and our outlook for adjusted free cash flow.  \n \n Of course, our customers remain at the center of everything we do, and our team continues to \nprioritize core operational execution to best serve them and their patients with essential products and \nservices, as we drive our company forward.   \n \n Now, let me turn it over to Aaron to review our results and updated guidance in more detail.  \n \n", "original_text": "And, as we continue to optimize not only the performance of our businesses, but also the financial \nstrength of the broader enterprise, we\u2019re generating robust cash flow and seeing meaningful benefits \nbelow the operating line.  \n \n", "page_label": "2", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "b9753973a2e73e28b14e5af735d133de8b9c34cddaa44b200c661375e87f455a", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "569a3639-3901-41ed-98e1-576e40a12866", "node_type": "1", "metadata": {"window": "Along with continued growth from at -Home Solutions, we\u2019re seeing the effects of our 5 -point plan to \ngrow Cardinal Health Brand volumes yield positive results .  \n \n And, as we continue to optimize not only the performance of our businesses, but also the financial \nstrength of the broader enterprise, we\u2019re generating robust cash flow and seeing meaningful benefits \nbelow the operating line.  \n \n As a result of our first half performance, and increased confidence as we look ahead, we\u2019re pleased \nto raise our fiscal \u201824 EPS guidance and our outlook for adjusted free cash flow.  \n \n Of course, our customers remain at the center of everything we do, and our team continues to \nprioritize core operational execution to best serve them and their patients with essential products and \nservices, as we drive our company forward.   \n \n Now, let me turn it over to Aaron to review our results and updated guidance in more detail.  \n \n Aaron Alt:   Thanks Jason, and good morning.  \n \n Before we begin, let me remind you that our Q2 segment commentary will be according to our former \nsegment structure, Pharma and Medical.  \n \n", "original_text": "Of course, our customers remain at the center of everything we do, and our team continues to \nprioritize core operational execution to best serve them and their patients with essential products and \nservices, as we drive our company forward.   \n \n"}, "hash": "1897a021516d9d554d563bf1ea9cb2317b8bdf504daf15ae835a5efffe5afd61", "class_name": "RelatedNodeInfo"}}, "text": "As a result of our first half performance, and increased confidence as we look ahead, we\u2019re pleased \nto raise our fiscal \u201824 EPS guidance and our outlook for adjusted free cash flow.  \n \n", "start_char_idx": 1466, "end_char_idx": 1653, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "569a3639-3901-41ed-98e1-576e40a12866": {"__data__": {"id_": "569a3639-3901-41ed-98e1-576e40a12866", "embedding": null, "metadata": {"window": "Along with continued growth from at -Home Solutions, we\u2019re seeing the effects of our 5 -point plan to \ngrow Cardinal Health Brand volumes yield positive results .  \n \n And, as we continue to optimize not only the performance of our businesses, but also the financial \nstrength of the broader enterprise, we\u2019re generating robust cash flow and seeing meaningful benefits \nbelow the operating line.  \n \n As a result of our first half performance, and increased confidence as we look ahead, we\u2019re pleased \nto raise our fiscal \u201824 EPS guidance and our outlook for adjusted free cash flow.  \n \n Of course, our customers remain at the center of everything we do, and our team continues to \nprioritize core operational execution to best serve them and their patients with essential products and \nservices, as we drive our company forward.   \n \n Now, let me turn it over to Aaron to review our results and updated guidance in more detail.  \n \n Aaron Alt:   Thanks Jason, and good morning.  \n \n Before we begin, let me remind you that our Q2 segment commentary will be according to our former \nsegment structure, Pharma and Medical.  \n \n", "original_text": "Of course, our customers remain at the center of everything we do, and our team continues to \nprioritize core operational execution to best serve them and their patients with essential products and \nservices, as we drive our company forward.   \n \n", "page_label": "2", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "af1efd63-b407-4e15-8b8e-7fdf94ed494d", "node_type": "4", "metadata": {"page_label": "2", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "401b4c01251e89f37825f9162d3daf2147390f8c3172f8fb25970737b79da56e", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "51a565bd-a823-4759-bc5b-294bd6433331", "node_type": "1", "metadata": {"window": "Notably, we saw a change in trend in revenue growth for the Medical segment in the second quarter. \n Along with continued growth from at -Home Solutions, we\u2019re seeing the effects of our 5 -point plan to \ngrow Cardinal Health Brand volumes yield positive results .  \n \n And, as we continue to optimize not only the performance of our businesses, but also the financial \nstrength of the broader enterprise, we\u2019re generating robust cash flow and seeing meaningful benefits \nbelow the operating line.  \n \n As a result of our first half performance, and increased confidence as we look ahead, we\u2019re pleased \nto raise our fiscal \u201824 EPS guidance and our outlook for adjusted free cash flow.  \n \n Of course, our customers remain at the center of everything we do, and our team continues to \nprioritize core operational execution to best serve them and their patients with essential products and \nservices, as we drive our company forward.   \n \n Now, let me turn it over to Aaron to review our results and updated guidance in more detail.  \n \n Aaron Alt:   Thanks Jason, and good morning.  \n \n", "original_text": "As a result of our first half performance, and increased confidence as we look ahead, we\u2019re pleased \nto raise our fiscal \u201824 EPS guidance and our outlook for adjusted free cash flow.  \n \n", "page_label": "2", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "33d722573cb11d59025527cd594ccb7e9486121a36574a4e0dfe589a9543a2d8", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "0bf3b072-85eb-47ee-a21e-69474ff15fe4", "node_type": "1", "metadata": {"window": "And, as we continue to optimize not only the performance of our businesses, but also the financial \nstrength of the broader enterprise, we\u2019re generating robust cash flow and seeing meaningful benefits \nbelow the operating line.  \n \n As a result of our first half performance, and increased confidence as we look ahead, we\u2019re pleased \nto raise our fiscal \u201824 EPS guidance and our outlook for adjusted free cash flow.  \n \n Of course, our customers remain at the center of everything we do, and our team continues to \nprioritize core operational execution to best serve them and their patients with essential products and \nservices, as we drive our company forward.   \n \n Now, let me turn it over to Aaron to review our results and updated guidance in more detail.  \n \n Aaron Alt:   Thanks Jason, and good morning.  \n \n Before we begin, let me remind you that our Q2 segment commentary will be according to our former \nsegment structure, Pharma and Medical.  \n \n Let\u2019s start with total company results for the second quarter.  \n \n", "original_text": "Now, let me turn it over to Aaron to review our results and updated guidance in more detail.  \n \n"}, "hash": "cf01a9bd521c669bd509c9c9cfb9405ad3698d065bc4f052bde52c1d66c43d48", "class_name": "RelatedNodeInfo"}}, "text": "Of course, our customers remain at the center of everything we do, and our team continues to \nprioritize core operational execution to best serve them and their patients with essential products and \nservices, as we drive our company forward.   \n \n", "start_char_idx": 1653, "end_char_idx": 1900, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "0bf3b072-85eb-47ee-a21e-69474ff15fe4": {"__data__": {"id_": "0bf3b072-85eb-47ee-a21e-69474ff15fe4", "embedding": null, "metadata": {"window": "And, as we continue to optimize not only the performance of our businesses, but also the financial \nstrength of the broader enterprise, we\u2019re generating robust cash flow and seeing meaningful benefits \nbelow the operating line.  \n \n As a result of our first half performance, and increased confidence as we look ahead, we\u2019re pleased \nto raise our fiscal \u201824 EPS guidance and our outlook for adjusted free cash flow.  \n \n Of course, our customers remain at the center of everything we do, and our team continues to \nprioritize core operational execution to best serve them and their patients with essential products and \nservices, as we drive our company forward.   \n \n Now, let me turn it over to Aaron to review our results and updated guidance in more detail.  \n \n Aaron Alt:   Thanks Jason, and good morning.  \n \n Before we begin, let me remind you that our Q2 segment commentary will be according to our former \nsegment structure, Pharma and Medical.  \n \n Let\u2019s start with total company results for the second quarter.  \n \n", "original_text": "Now, let me turn it over to Aaron to review our results and updated guidance in more detail.  \n \n", "page_label": "2", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "af1efd63-b407-4e15-8b8e-7fdf94ed494d", "node_type": "4", "metadata": {"page_label": "2", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "401b4c01251e89f37825f9162d3daf2147390f8c3172f8fb25970737b79da56e", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "569a3639-3901-41ed-98e1-576e40a12866", "node_type": "1", "metadata": {"window": "Along with continued growth from at -Home Solutions, we\u2019re seeing the effects of our 5 -point plan to \ngrow Cardinal Health Brand volumes yield positive results .  \n \n And, as we continue to optimize not only the performance of our businesses, but also the financial \nstrength of the broader enterprise, we\u2019re generating robust cash flow and seeing meaningful benefits \nbelow the operating line.  \n \n As a result of our first half performance, and increased confidence as we look ahead, we\u2019re pleased \nto raise our fiscal \u201824 EPS guidance and our outlook for adjusted free cash flow.  \n \n Of course, our customers remain at the center of everything we do, and our team continues to \nprioritize core operational execution to best serve them and their patients with essential products and \nservices, as we drive our company forward.   \n \n Now, let me turn it over to Aaron to review our results and updated guidance in more detail.  \n \n Aaron Alt:   Thanks Jason, and good morning.  \n \n Before we begin, let me remind you that our Q2 segment commentary will be according to our former \nsegment structure, Pharma and Medical.  \n \n", "original_text": "Of course, our customers remain at the center of everything we do, and our team continues to \nprioritize core operational execution to best serve them and their patients with essential products and \nservices, as we drive our company forward.   \n \n", "page_label": "2", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "a65bfaf03f50f03856a78ecf9fe4c2a690871719188478f41c0b8fd7530f3b03", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "54a85354-6242-4d48-90e3-38c742368493", "node_type": "1", "metadata": {"window": "As a result of our first half performance, and increased confidence as we look ahead, we\u2019re pleased \nto raise our fiscal \u201824 EPS guidance and our outlook for adjusted free cash flow.  \n \n Of course, our customers remain at the center of everything we do, and our team continues to \nprioritize core operational execution to best serve them and their patients with essential products and \nservices, as we drive our company forward.   \n \n Now, let me turn it over to Aaron to review our results and updated guidance in more detail.  \n \n Aaron Alt:   Thanks Jason, and good morning.  \n \n Before we begin, let me remind you that our Q2 segment commentary will be according to our former \nsegment structure, Pharma and Medical.  \n \n Let\u2019s start with total company results for the second quarter.  \n \n Q2 delivered another strong quarter across the enterprise, with EPS of $1.82, growth of 38%, which \nincluded operating earnings growth of 20%.  \n ", "original_text": "Aaron Alt:   Thanks Jason, and good morning.  \n \n"}, "hash": "5faeb55c504337053b129dfc26e97fcd561ad4d216772581a5f5bb2545cd5928", "class_name": "RelatedNodeInfo"}}, "text": "Now, let me turn it over to Aaron to review our results and updated guidance in more detail.  \n \n", "start_char_idx": 1900, "end_char_idx": 1997, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "54a85354-6242-4d48-90e3-38c742368493": {"__data__": {"id_": "54a85354-6242-4d48-90e3-38c742368493", "embedding": null, "metadata": {"window": "As a result of our first half performance, and increased confidence as we look ahead, we\u2019re pleased \nto raise our fiscal \u201824 EPS guidance and our outlook for adjusted free cash flow.  \n \n Of course, our customers remain at the center of everything we do, and our team continues to \nprioritize core operational execution to best serve them and their patients with essential products and \nservices, as we drive our company forward.   \n \n Now, let me turn it over to Aaron to review our results and updated guidance in more detail.  \n \n Aaron Alt:   Thanks Jason, and good morning.  \n \n Before we begin, let me remind you that our Q2 segment commentary will be according to our former \nsegment structure, Pharma and Medical.  \n \n Let\u2019s start with total company results for the second quarter.  \n \n Q2 delivered another strong quarter across the enterprise, with EPS of $1.82, growth of 38%, which \nincluded operating earnings growth of 20%.  \n ", "original_text": "Aaron Alt:   Thanks Jason, and good morning.  \n \n", "page_label": "2", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "af1efd63-b407-4e15-8b8e-7fdf94ed494d", "node_type": "4", "metadata": {"page_label": "2", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "401b4c01251e89f37825f9162d3daf2147390f8c3172f8fb25970737b79da56e", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "0bf3b072-85eb-47ee-a21e-69474ff15fe4", "node_type": "1", "metadata": {"window": "And, as we continue to optimize not only the performance of our businesses, but also the financial \nstrength of the broader enterprise, we\u2019re generating robust cash flow and seeing meaningful benefits \nbelow the operating line.  \n \n As a result of our first half performance, and increased confidence as we look ahead, we\u2019re pleased \nto raise our fiscal \u201824 EPS guidance and our outlook for adjusted free cash flow.  \n \n Of course, our customers remain at the center of everything we do, and our team continues to \nprioritize core operational execution to best serve them and their patients with essential products and \nservices, as we drive our company forward.   \n \n Now, let me turn it over to Aaron to review our results and updated guidance in more detail.  \n \n Aaron Alt:   Thanks Jason, and good morning.  \n \n Before we begin, let me remind you that our Q2 segment commentary will be according to our former \nsegment structure, Pharma and Medical.  \n \n Let\u2019s start with total company results for the second quarter.  \n \n", "original_text": "Now, let me turn it over to Aaron to review our results and updated guidance in more detail.  \n \n", "page_label": "2", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "d0b786e5807e200305b4b065307f7e489aec5cd0a6008b418826ede90431a540", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "54700922-67e0-469f-91dc-556eba18af73", "node_type": "1", "metadata": {"window": "Of course, our customers remain at the center of everything we do, and our team continues to \nprioritize core operational execution to best serve them and their patients with essential products and \nservices, as we drive our company forward.   \n \n Now, let me turn it over to Aaron to review our results and updated guidance in more detail.  \n \n Aaron Alt:   Thanks Jason, and good morning.  \n \n Before we begin, let me remind you that our Q2 segment commentary will be according to our former \nsegment structure, Pharma and Medical.  \n \n Let\u2019s start with total company results for the second quarter.  \n \n Q2 delivered another strong quarter across the enterprise, with EPS of $1.82, growth of 38%, which \nincluded operating earnings growth of 20%.  \n ", "original_text": "Before we begin, let me remind you that our Q2 segment commentary will be according to our former \nsegment structure, Pharma and Medical.  \n \n"}, "hash": "96054c28ce868b739de221d28fd49cb738c80088273ac64fe216505679a915c0", "class_name": "RelatedNodeInfo"}}, "text": "Aaron Alt:   Thanks Jason, and good morning.  \n \n", "start_char_idx": 1997, "end_char_idx": 2046, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "54700922-67e0-469f-91dc-556eba18af73": {"__data__": {"id_": "54700922-67e0-469f-91dc-556eba18af73", "embedding": null, "metadata": {"window": "Of course, our customers remain at the center of everything we do, and our team continues to \nprioritize core operational execution to best serve them and their patients with essential products and \nservices, as we drive our company forward.   \n \n Now, let me turn it over to Aaron to review our results and updated guidance in more detail.  \n \n Aaron Alt:   Thanks Jason, and good morning.  \n \n Before we begin, let me remind you that our Q2 segment commentary will be according to our former \nsegment structure, Pharma and Medical.  \n \n Let\u2019s start with total company results for the second quarter.  \n \n Q2 delivered another strong quarter across the enterprise, with EPS of $1.82, growth of 38%, which \nincluded operating earnings growth of 20%.  \n ", "original_text": "Before we begin, let me remind you that our Q2 segment commentary will be according to our former \nsegment structure, Pharma and Medical.  \n \n", "page_label": "2", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "af1efd63-b407-4e15-8b8e-7fdf94ed494d", "node_type": "4", "metadata": {"page_label": "2", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "401b4c01251e89f37825f9162d3daf2147390f8c3172f8fb25970737b79da56e", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "54a85354-6242-4d48-90e3-38c742368493", "node_type": "1", "metadata": {"window": "As a result of our first half performance, and increased confidence as we look ahead, we\u2019re pleased \nto raise our fiscal \u201824 EPS guidance and our outlook for adjusted free cash flow.  \n \n Of course, our customers remain at the center of everything we do, and our team continues to \nprioritize core operational execution to best serve them and their patients with essential products and \nservices, as we drive our company forward.   \n \n Now, let me turn it over to Aaron to review our results and updated guidance in more detail.  \n \n Aaron Alt:   Thanks Jason, and good morning.  \n \n Before we begin, let me remind you that our Q2 segment commentary will be according to our former \nsegment structure, Pharma and Medical.  \n \n Let\u2019s start with total company results for the second quarter.  \n \n Q2 delivered another strong quarter across the enterprise, with EPS of $1.82, growth of 38%, which \nincluded operating earnings growth of 20%.  \n ", "original_text": "Aaron Alt:   Thanks Jason, and good morning.  \n \n", "page_label": "2", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "b48eb9c6f232bcd340c7e98ee7a26f3c4ec9c7d88395caf9693ee10b2c3a3ca2", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "9e0f4328-cd45-4fb0-9d26-0922be4544d1", "node_type": "1", "metadata": {"window": "Now, let me turn it over to Aaron to review our results and updated guidance in more detail.  \n \n Aaron Alt:   Thanks Jason, and good morning.  \n \n Before we begin, let me remind you that our Q2 segment commentary will be according to our former \nsegment structure, Pharma and Medical.  \n \n Let\u2019s start with total company results for the second quarter.  \n \n Q2 delivered another strong quarter across the enterprise, with EPS of $1.82, growth of 38%, which \nincluded operating earnings growth of 20%.  \n ", "original_text": "Let\u2019s start with total company results for the second quarter.  \n \n"}, "hash": "d299b1d6984d59a8773832624324a7c54bf25e0e70f9246eb7c00414392186a4", "class_name": "RelatedNodeInfo"}}, "text": "Before we begin, let me remind you that our Q2 segment commentary will be according to our former \nsegment structure, Pharma and Medical.  \n \n", "start_char_idx": 2046, "end_char_idx": 2188, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "9e0f4328-cd45-4fb0-9d26-0922be4544d1": {"__data__": {"id_": "9e0f4328-cd45-4fb0-9d26-0922be4544d1", "embedding": null, "metadata": {"window": "Now, let me turn it over to Aaron to review our results and updated guidance in more detail.  \n \n Aaron Alt:   Thanks Jason, and good morning.  \n \n Before we begin, let me remind you that our Q2 segment commentary will be according to our former \nsegment structure, Pharma and Medical.  \n \n Let\u2019s start with total company results for the second quarter.  \n \n Q2 delivered another strong quarter across the enterprise, with EPS of $1.82, growth of 38%, which \nincluded operating earnings growth of 20%.  \n ", "original_text": "Let\u2019s start with total company results for the second quarter.  \n \n", "page_label": "2", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "af1efd63-b407-4e15-8b8e-7fdf94ed494d", "node_type": "4", "metadata": {"page_label": "2", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "401b4c01251e89f37825f9162d3daf2147390f8c3172f8fb25970737b79da56e", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "54700922-67e0-469f-91dc-556eba18af73", "node_type": "1", "metadata": {"window": "Of course, our customers remain at the center of everything we do, and our team continues to \nprioritize core operational execution to best serve them and their patients with essential products and \nservices, as we drive our company forward.   \n \n Now, let me turn it over to Aaron to review our results and updated guidance in more detail.  \n \n Aaron Alt:   Thanks Jason, and good morning.  \n \n Before we begin, let me remind you that our Q2 segment commentary will be according to our former \nsegment structure, Pharma and Medical.  \n \n Let\u2019s start with total company results for the second quarter.  \n \n Q2 delivered another strong quarter across the enterprise, with EPS of $1.82, growth of 38%, which \nincluded operating earnings growth of 20%.  \n ", "original_text": "Before we begin, let me remind you that our Q2 segment commentary will be according to our former \nsegment structure, Pharma and Medical.  \n \n", "page_label": "2", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "2eb937cd7ee2251a2f727f6e24b0780695b10887734b0bbcaaf9e3dfe053d067", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "54702bd4-4c68-4a9a-866b-09341a069377", "node_type": "1", "metadata": {"window": "Aaron Alt:   Thanks Jason, and good morning.  \n \n Before we begin, let me remind you that our Q2 segment commentary will be according to our former \nsegment structure, Pharma and Medical.  \n \n Let\u2019s start with total company results for the second quarter.  \n \n Q2 delivered another strong quarter across the enterprise, with EPS of $1.82, growth of 38%, which \nincluded operating earnings growth of 20%.  \n ", "original_text": "Q2 delivered another strong quarter across the enterprise, with EPS of $1.82, growth of 38%, which \nincluded operating earnings growth of 20%.  \n "}, "hash": "946f318c0b2b3b0de4b9f8d17b2d7656f6f82f32a37407f267e7abc3b96c0016", "class_name": "RelatedNodeInfo"}}, "text": "Let\u2019s start with total company results for the second quarter.  \n \n", "start_char_idx": 2188, "end_char_idx": 2255, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "54702bd4-4c68-4a9a-866b-09341a069377": {"__data__": {"id_": "54702bd4-4c68-4a9a-866b-09341a069377", "embedding": null, "metadata": {"window": "Aaron Alt:   Thanks Jason, and good morning.  \n \n Before we begin, let me remind you that our Q2 segment commentary will be according to our former \nsegment structure, Pharma and Medical.  \n \n Let\u2019s start with total company results for the second quarter.  \n \n Q2 delivered another strong quarter across the enterprise, with EPS of $1.82, growth of 38%, which \nincluded operating earnings growth of 20%.  \n ", "original_text": "Q2 delivered another strong quarter across the enterprise, with EPS of $1.82, growth of 38%, which \nincluded operating earnings growth of 20%.  \n ", "page_label": "2", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "af1efd63-b407-4e15-8b8e-7fdf94ed494d", "node_type": "4", "metadata": {"page_label": "2", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "401b4c01251e89f37825f9162d3daf2147390f8c3172f8fb25970737b79da56e", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "9e0f4328-cd45-4fb0-9d26-0922be4544d1", "node_type": "1", "metadata": {"window": "Now, let me turn it over to Aaron to review our results and updated guidance in more detail.  \n \n Aaron Alt:   Thanks Jason, and good morning.  \n \n Before we begin, let me remind you that our Q2 segment commentary will be according to our former \nsegment structure, Pharma and Medical.  \n \n Let\u2019s start with total company results for the second quarter.  \n \n Q2 delivered another strong quarter across the enterprise, with EPS of $1.82, growth of 38%, which \nincluded operating earnings growth of 20%.  \n ", "original_text": "Let\u2019s start with total company results for the second quarter.  \n \n", "page_label": "2", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "cbae4509d8d381c46ea4becbc22187c6660a8b8aed5d8c94d28b17a1ed62e15f", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "b9db02c7-8674-4358-bb73-1eb1f7de88c4", "node_type": "1", "metadata": {"window": " \nPage 3 of 19 \n \nWe also delivered strong cash flow and ended the quarter with $4.6  billion  of cash, even following \nincremental share repurchase activity in the quarter.  \n \n As seen on slide 4 , total company revenue increased 12% to $57.4 billion, reflecting growth in both \nthe Pharma and Medical segments.  \n \n We drove operating leverage for the enterprise, despite incremental investments in the business and \nhigher costs to support sales growth.  \n \n Gross margin increased 11% to $1.8 billion, driven by both segments, and consolidated SG&A \nincreased 8% to $1.3 billion.   \n \n", "original_text": " \nPage 3 of 19 \n \nWe also delivered strong cash flow and ended the quarter with $4.6  billion  of cash, even following \nincremental share repurchase activity in the quarter.  \n \n"}, "hash": "79814d575008932b70b3e627dc92e54674d73f6e80fc7ee7d3a466d47e4a894d", "class_name": "RelatedNodeInfo"}}, "text": "Q2 delivered another strong quarter across the enterprise, with EPS of $1.82, growth of 38%, which \nincluded operating earnings growth of 20%.  \n ", "start_char_idx": 2255, "end_char_idx": 2401, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "b9db02c7-8674-4358-bb73-1eb1f7de88c4": {"__data__": {"id_": "b9db02c7-8674-4358-bb73-1eb1f7de88c4", "embedding": null, "metadata": {"window": " \nPage 3 of 19 \n \nWe also delivered strong cash flow and ended the quarter with $4.6  billion  of cash, even following \nincremental share repurchase activity in the quarter.  \n \n As seen on slide 4 , total company revenue increased 12% to $57.4 billion, reflecting growth in both \nthe Pharma and Medical segments.  \n \n We drove operating leverage for the enterprise, despite incremental investments in the business and \nhigher costs to support sales growth.  \n \n Gross margin increased 11% to $1.8 billion, driven by both segments, and consolidated SG&A \nincreased 8% to $1.3 billion.   \n \n", "original_text": " \nPage 3 of 19 \n \nWe also delivered strong cash flow and ended the quarter with $4.6  billion  of cash, even following \nincremental share repurchase activity in the quarter.  \n \n", "page_label": "3", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "2122bb61-73c3-4261-85c0-fd8e84992ea1", "node_type": "4", "metadata": {"page_label": "3", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "f98687a89f26084d26a47edc3cd31551f3f6fd6e2047c95d14693d1c9dfdc292", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "54702bd4-4c68-4a9a-866b-09341a069377", "node_type": "1", "metadata": {"window": "Aaron Alt:   Thanks Jason, and good morning.  \n \n Before we begin, let me remind you that our Q2 segment commentary will be according to our former \nsegment structure, Pharma and Medical.  \n \n Let\u2019s start with total company results for the second quarter.  \n \n Q2 delivered another strong quarter across the enterprise, with EPS of $1.82, growth of 38%, which \nincluded operating earnings growth of 20%.  \n ", "original_text": "Q2 delivered another strong quarter across the enterprise, with EPS of $1.82, growth of 38%, which \nincluded operating earnings growth of 20%.  \n ", "page_label": "2", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "be1114c2f831703790447142a19a011803b0c032182ea0fc52501e809e39f198", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "fbcbb01a-e3e2-439a-9c9b-4c15ccf177fa", "node_type": "1", "metadata": {"window": " \nPage 3 of 19 \n \nWe also delivered strong cash flow and ended the quarter with $4.6  billion  of cash, even following \nincremental share repurchase activity in the quarter.  \n \n As seen on slide 4 , total company revenue increased 12% to $57.4 billion, reflecting growth in both \nthe Pharma and Medical segments.  \n \n We drove operating leverage for the enterprise, despite incremental investments in the business and \nhigher costs to support sales growth.  \n \n Gross margin increased 11% to $1.8 billion, driven by both segments, and consolidated SG&A \nincreased 8% to $1.3 billion.   \n \n With the strong profit growth in both segments, we delivered operating earnings of $562 million, 20% \nhigher than a year ago.  \n \n", "original_text": "As seen on slide 4 , total company revenue increased 12% to $57.4 billion, reflecting growth in both \nthe Pharma and Medical segments.  \n \n"}, "hash": "e764e4fd864bde40e20b4786b7f7d5d642336ffba07acf7506c02c112c8d6504", "class_name": "RelatedNodeInfo"}}, "text": " \nPage 3 of 19 \n \nWe also delivered strong cash flow and ended the quarter with $4.6  billion  of cash, even following \nincremental share repurchase activity in the quarter.  \n \n", "start_char_idx": 0, "end_char_idx": 178, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "fbcbb01a-e3e2-439a-9c9b-4c15ccf177fa": {"__data__": {"id_": "fbcbb01a-e3e2-439a-9c9b-4c15ccf177fa", "embedding": null, "metadata": {"window": " \nPage 3 of 19 \n \nWe also delivered strong cash flow and ended the quarter with $4.6  billion  of cash, even following \nincremental share repurchase activity in the quarter.  \n \n As seen on slide 4 , total company revenue increased 12% to $57.4 billion, reflecting growth in both \nthe Pharma and Medical segments.  \n \n We drove operating leverage for the enterprise, despite incremental investments in the business and \nhigher costs to support sales growth.  \n \n Gross margin increased 11% to $1.8 billion, driven by both segments, and consolidated SG&A \nincreased 8% to $1.3 billion.   \n \n With the strong profit growth in both segments, we delivered operating earnings of $562 million, 20% \nhigher than a year ago.  \n \n", "original_text": "As seen on slide 4 , total company revenue increased 12% to $57.4 billion, reflecting growth in both \nthe Pharma and Medical segments.  \n \n", "page_label": "3", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "2122bb61-73c3-4261-85c0-fd8e84992ea1", "node_type": "4", "metadata": {"page_label": "3", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "f98687a89f26084d26a47edc3cd31551f3f6fd6e2047c95d14693d1c9dfdc292", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "b9db02c7-8674-4358-bb73-1eb1f7de88c4", "node_type": "1", "metadata": {"window": " \nPage 3 of 19 \n \nWe also delivered strong cash flow and ended the quarter with $4.6  billion  of cash, even following \nincremental share repurchase activity in the quarter.  \n \n As seen on slide 4 , total company revenue increased 12% to $57.4 billion, reflecting growth in both \nthe Pharma and Medical segments.  \n \n We drove operating leverage for the enterprise, despite incremental investments in the business and \nhigher costs to support sales growth.  \n \n Gross margin increased 11% to $1.8 billion, driven by both segments, and consolidated SG&A \nincreased 8% to $1.3 billion.   \n \n", "original_text": " \nPage 3 of 19 \n \nWe also delivered strong cash flow and ended the quarter with $4.6  billion  of cash, even following \nincremental share repurchase activity in the quarter.  \n \n", "page_label": "3", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "e7674b5c7eb7f9bff2933e28db081eb3f3b59817349e11a2d28ec776a36c62c0", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "85445337-5676-4544-a161-7696b355e4e2", "node_type": "1", "metadata": {"window": " \nPage 3 of 19 \n \nWe also delivered strong cash flow and ended the quarter with $4.6  billion  of cash, even following \nincremental share repurchase activity in the quarter.  \n \n As seen on slide 4 , total company revenue increased 12% to $57.4 billion, reflecting growth in both \nthe Pharma and Medical segments.  \n \n We drove operating leverage for the enterprise, despite incremental investments in the business and \nhigher costs to support sales growth.  \n \n Gross margin increased 11% to $1.8 billion, driven by both segments, and consolidated SG&A \nincreased 8% to $1.3 billion.   \n \n With the strong profit growth in both segments, we delivered operating earnings of $562 million, 20% \nhigher than a year ago.  \n \n Moving below the line, interest and other decreased by $26 million to $8 million in income, due to \nincreased interest income on cash and equivalents from higher cash balances and higher rates. ", "original_text": "We drove operating leverage for the enterprise, despite incremental investments in the business and \nhigher costs to support sales growth.  \n \n"}, "hash": "880e695df0cc139eb2f84f0de05a99b040cddcf800cf13264d93cdf2a3ce88b3", "class_name": "RelatedNodeInfo"}}, "text": "As seen on slide 4 , total company revenue increased 12% to $57.4 billion, reflecting growth in both \nthe Pharma and Medical segments.  \n \n", "start_char_idx": 178, "end_char_idx": 317, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "85445337-5676-4544-a161-7696b355e4e2": {"__data__": {"id_": "85445337-5676-4544-a161-7696b355e4e2", "embedding": null, "metadata": {"window": " \nPage 3 of 19 \n \nWe also delivered strong cash flow and ended the quarter with $4.6  billion  of cash, even following \nincremental share repurchase activity in the quarter.  \n \n As seen on slide 4 , total company revenue increased 12% to $57.4 billion, reflecting growth in both \nthe Pharma and Medical segments.  \n \n We drove operating leverage for the enterprise, despite incremental investments in the business and \nhigher costs to support sales growth.  \n \n Gross margin increased 11% to $1.8 billion, driven by both segments, and consolidated SG&A \nincreased 8% to $1.3 billion.   \n \n With the strong profit growth in both segments, we delivered operating earnings of $562 million, 20% \nhigher than a year ago.  \n \n Moving below the line, interest and other decreased by $26 million to $8 million in income, due to \nincreased interest income on cash and equivalents from higher cash balances and higher rates. ", "original_text": "We drove operating leverage for the enterprise, despite incremental investments in the business and \nhigher costs to support sales growth.  \n \n", "page_label": "3", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "2122bb61-73c3-4261-85c0-fd8e84992ea1", "node_type": "4", "metadata": {"page_label": "3", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "f98687a89f26084d26a47edc3cd31551f3f6fd6e2047c95d14693d1c9dfdc292", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "fbcbb01a-e3e2-439a-9c9b-4c15ccf177fa", "node_type": "1", "metadata": {"window": " \nPage 3 of 19 \n \nWe also delivered strong cash flow and ended the quarter with $4.6  billion  of cash, even following \nincremental share repurchase activity in the quarter.  \n \n As seen on slide 4 , total company revenue increased 12% to $57.4 billion, reflecting growth in both \nthe Pharma and Medical segments.  \n \n We drove operating leverage for the enterprise, despite incremental investments in the business and \nhigher costs to support sales growth.  \n \n Gross margin increased 11% to $1.8 billion, driven by both segments, and consolidated SG&A \nincreased 8% to $1.3 billion.   \n \n With the strong profit growth in both segments, we delivered operating earnings of $562 million, 20% \nhigher than a year ago.  \n \n", "original_text": "As seen on slide 4 , total company revenue increased 12% to $57.4 billion, reflecting growth in both \nthe Pharma and Medical segments.  \n \n", "page_label": "3", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "80b843d21803e6aa20c7cbabce8224d3068ad5bd67fba5dbf4cd274c31db4991", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "a7a62310-92aa-46eb-9ff3-25983a54528f", "node_type": "1", "metadata": {"window": " \nPage 3 of 19 \n \nWe also delivered strong cash flow and ended the quarter with $4.6  billion  of cash, even following \nincremental share repurchase activity in the quarter.  \n \n As seen on slide 4 , total company revenue increased 12% to $57.4 billion, reflecting growth in both \nthe Pharma and Medical segments.  \n \n We drove operating leverage for the enterprise, despite incremental investments in the business and \nhigher costs to support sales growth.  \n \n Gross margin increased 11% to $1.8 billion, driven by both segments, and consolidated SG&A \nincreased 8% to $1.3 billion.   \n \n With the strong profit growth in both segments, we delivered operating earnings of $562 million, 20% \nhigher than a year ago.  \n \n Moving below the line, interest and other decreased by $26 million to $8 million in income, due to \nincreased interest income on cash and equivalents from higher cash balances and higher rates.  As \nwe\u2019ve noted, our debt is largely fixed rate, resulting in a net benefit from rising interest rates in the \nnear term. ", "original_text": "Gross margin increased 11% to $1.8 billion, driven by both segments, and consolidated SG&A \nincreased 8% to $1.3 billion.   \n \n"}, "hash": "a5a120f0cbd7e6c9430639ebd312ec269d4aef334b55443d7d3655f5d2a198b1", "class_name": "RelatedNodeInfo"}}, "text": "We drove operating leverage for the enterprise, despite incremental investments in the business and \nhigher costs to support sales growth.  \n \n", "start_char_idx": 317, "end_char_idx": 460, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "a7a62310-92aa-46eb-9ff3-25983a54528f": {"__data__": {"id_": "a7a62310-92aa-46eb-9ff3-25983a54528f", "embedding": null, "metadata": {"window": " \nPage 3 of 19 \n \nWe also delivered strong cash flow and ended the quarter with $4.6  billion  of cash, even following \nincremental share repurchase activity in the quarter.  \n \n As seen on slide 4 , total company revenue increased 12% to $57.4 billion, reflecting growth in both \nthe Pharma and Medical segments.  \n \n We drove operating leverage for the enterprise, despite incremental investments in the business and \nhigher costs to support sales growth.  \n \n Gross margin increased 11% to $1.8 billion, driven by both segments, and consolidated SG&A \nincreased 8% to $1.3 billion.   \n \n With the strong profit growth in both segments, we delivered operating earnings of $562 million, 20% \nhigher than a year ago.  \n \n Moving below the line, interest and other decreased by $26 million to $8 million in income, due to \nincreased interest income on cash and equivalents from higher cash balances and higher rates.  As \nwe\u2019ve noted, our debt is largely fixed rate, resulting in a net benefit from rising interest rates in the \nnear term. ", "original_text": "Gross margin increased 11% to $1.8 billion, driven by both segments, and consolidated SG&A \nincreased 8% to $1.3 billion.   \n \n", "page_label": "3", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "2122bb61-73c3-4261-85c0-fd8e84992ea1", "node_type": "4", "metadata": {"page_label": "3", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "f98687a89f26084d26a47edc3cd31551f3f6fd6e2047c95d14693d1c9dfdc292", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "85445337-5676-4544-a161-7696b355e4e2", "node_type": "1", "metadata": {"window": " \nPage 3 of 19 \n \nWe also delivered strong cash flow and ended the quarter with $4.6  billion  of cash, even following \nincremental share repurchase activity in the quarter.  \n \n As seen on slide 4 , total company revenue increased 12% to $57.4 billion, reflecting growth in both \nthe Pharma and Medical segments.  \n \n We drove operating leverage for the enterprise, despite incremental investments in the business and \nhigher costs to support sales growth.  \n \n Gross margin increased 11% to $1.8 billion, driven by both segments, and consolidated SG&A \nincreased 8% to $1.3 billion.   \n \n With the strong profit growth in both segments, we delivered operating earnings of $562 million, 20% \nhigher than a year ago.  \n \n Moving below the line, interest and other decreased by $26 million to $8 million in income, due to \nincreased interest income on cash and equivalents from higher cash balances and higher rates. ", "original_text": "We drove operating leverage for the enterprise, despite incremental investments in the business and \nhigher costs to support sales growth.  \n \n", "page_label": "3", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "9e244f17d9d72c3a4af5b6632d02d0109f7c0f31f1015b0e8f3a979a5f9ca7ea", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "2fb1baaa-0fb9-4468-bef1-512693d62a5c", "node_type": "1", "metadata": {"window": "As seen on slide 4 , total company revenue increased 12% to $57.4 billion, reflecting growth in both \nthe Pharma and Medical segments.  \n \n We drove operating leverage for the enterprise, despite incremental investments in the business and \nhigher costs to support sales growth.  \n \n Gross margin increased 11% to $1.8 billion, driven by both segments, and consolidated SG&A \nincreased 8% to $1.3 billion.   \n \n With the strong profit growth in both segments, we delivered operating earnings of $562 million, 20% \nhigher than a year ago.  \n \n Moving below the line, interest and other decreased by $26 million to $8 million in income, due to \nincreased interest income on cash and equivalents from higher cash balances and higher rates.  As \nwe\u2019ve noted, our debt is largely fixed rate, resulting in a net benefit from rising interest rates in the \nnear term.  Additionally, Q2 interest and other benefitted from nearly $10 million in income from the \nquarterly revaluation of our company\u2019s deferred compensation plan investments, which as a reminder \nhas a matc hing offset above -the-line. \n \n", "original_text": "With the strong profit growth in both segments, we delivered operating earnings of $562 million, 20% \nhigher than a year ago.  \n \n"}, "hash": "40b042c1a5500b1354e3650c0040d2d9489f9a7115278759d695ed90e4d166bb", "class_name": "RelatedNodeInfo"}}, "text": "Gross margin increased 11% to $1.8 billion, driven by both segments, and consolidated SG&A \nincreased 8% to $1.3 billion.   \n \n", "start_char_idx": 460, "end_char_idx": 587, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "2fb1baaa-0fb9-4468-bef1-512693d62a5c": {"__data__": {"id_": "2fb1baaa-0fb9-4468-bef1-512693d62a5c", "embedding": null, "metadata": {"window": "As seen on slide 4 , total company revenue increased 12% to $57.4 billion, reflecting growth in both \nthe Pharma and Medical segments.  \n \n We drove operating leverage for the enterprise, despite incremental investments in the business and \nhigher costs to support sales growth.  \n \n Gross margin increased 11% to $1.8 billion, driven by both segments, and consolidated SG&A \nincreased 8% to $1.3 billion.   \n \n With the strong profit growth in both segments, we delivered operating earnings of $562 million, 20% \nhigher than a year ago.  \n \n Moving below the line, interest and other decreased by $26 million to $8 million in income, due to \nincreased interest income on cash and equivalents from higher cash balances and higher rates.  As \nwe\u2019ve noted, our debt is largely fixed rate, resulting in a net benefit from rising interest rates in the \nnear term.  Additionally, Q2 interest and other benefitted from nearly $10 million in income from the \nquarterly revaluation of our company\u2019s deferred compensation plan investments, which as a reminder \nhas a matc hing offset above -the-line. \n \n", "original_text": "With the strong profit growth in both segments, we delivered operating earnings of $562 million, 20% \nhigher than a year ago.  \n \n", "page_label": "3", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "2122bb61-73c3-4261-85c0-fd8e84992ea1", "node_type": "4", "metadata": {"page_label": "3", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "f98687a89f26084d26a47edc3cd31551f3f6fd6e2047c95d14693d1c9dfdc292", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "a7a62310-92aa-46eb-9ff3-25983a54528f", "node_type": "1", "metadata": {"window": " \nPage 3 of 19 \n \nWe also delivered strong cash flow and ended the quarter with $4.6  billion  of cash, even following \nincremental share repurchase activity in the quarter.  \n \n As seen on slide 4 , total company revenue increased 12% to $57.4 billion, reflecting growth in both \nthe Pharma and Medical segments.  \n \n We drove operating leverage for the enterprise, despite incremental investments in the business and \nhigher costs to support sales growth.  \n \n Gross margin increased 11% to $1.8 billion, driven by both segments, and consolidated SG&A \nincreased 8% to $1.3 billion.   \n \n With the strong profit growth in both segments, we delivered operating earnings of $562 million, 20% \nhigher than a year ago.  \n \n Moving below the line, interest and other decreased by $26 million to $8 million in income, due to \nincreased interest income on cash and equivalents from higher cash balances and higher rates.  As \nwe\u2019ve noted, our debt is largely fixed rate, resulting in a net benefit from rising interest rates in the \nnear term. ", "original_text": "Gross margin increased 11% to $1.8 billion, driven by both segments, and consolidated SG&A \nincreased 8% to $1.3 billion.   \n \n", "page_label": "3", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "b8448cbfcd64914878f09665784c90e999dbc51f1fdcfaedd9cedeab9e7d1ebb", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "3baca8c7-8b24-4a8b-b306-78907a252595", "node_type": "1", "metadata": {"window": "We drove operating leverage for the enterprise, despite incremental investments in the business and \nhigher costs to support sales growth.  \n \n Gross margin increased 11% to $1.8 billion, driven by both segments, and consolidated SG&A \nincreased 8% to $1.3 billion.   \n \n With the strong profit growth in both segments, we delivered operating earnings of $562 million, 20% \nhigher than a year ago.  \n \n Moving below the line, interest and other decreased by $26 million to $8 million in income, due to \nincreased interest income on cash and equivalents from higher cash balances and higher rates.  As \nwe\u2019ve noted, our debt is largely fixed rate, resulting in a net benefit from rising interest rates in the \nnear term.  Additionally, Q2 interest and other benefitted from nearly $10 million in income from the \nquarterly revaluation of our company\u2019s deferred compensation plan investments, which as a reminder \nhas a matc hing offset above -the-line. \n \n Our second quarter effective tax rate of 21.3 % was 1.7 percentage points lower than a year ago and \nbetter than we anticipated, due to positive discrete items in the period.  \n \n", "original_text": "Moving below the line, interest and other decreased by $26 million to $8 million in income, due to \nincreased interest income on cash and equivalents from higher cash balances and higher rates. "}, "hash": "400d3f93979d0c607e693de9bc2e06891cd641fc77a6e3137dcd0b2c8ec050c8", "class_name": "RelatedNodeInfo"}}, "text": "With the strong profit growth in both segments, we delivered operating earnings of $562 million, 20% \nhigher than a year ago.  \n \n", "start_char_idx": 587, "end_char_idx": 717, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "3baca8c7-8b24-4a8b-b306-78907a252595": {"__data__": {"id_": "3baca8c7-8b24-4a8b-b306-78907a252595", "embedding": null, "metadata": {"window": "We drove operating leverage for the enterprise, despite incremental investments in the business and \nhigher costs to support sales growth.  \n \n Gross margin increased 11% to $1.8 billion, driven by both segments, and consolidated SG&A \nincreased 8% to $1.3 billion.   \n \n With the strong profit growth in both segments, we delivered operating earnings of $562 million, 20% \nhigher than a year ago.  \n \n Moving below the line, interest and other decreased by $26 million to $8 million in income, due to \nincreased interest income on cash and equivalents from higher cash balances and higher rates.  As \nwe\u2019ve noted, our debt is largely fixed rate, resulting in a net benefit from rising interest rates in the \nnear term.  Additionally, Q2 interest and other benefitted from nearly $10 million in income from the \nquarterly revaluation of our company\u2019s deferred compensation plan investments, which as a reminder \nhas a matc hing offset above -the-line. \n \n Our second quarter effective tax rate of 21.3 % was 1.7 percentage points lower than a year ago and \nbetter than we anticipated, due to positive discrete items in the period.  \n \n", "original_text": "Moving below the line, interest and other decreased by $26 million to $8 million in income, due to \nincreased interest income on cash and equivalents from higher cash balances and higher rates. ", "page_label": "3", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "2122bb61-73c3-4261-85c0-fd8e84992ea1", "node_type": "4", "metadata": {"page_label": "3", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "f98687a89f26084d26a47edc3cd31551f3f6fd6e2047c95d14693d1c9dfdc292", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "2fb1baaa-0fb9-4468-bef1-512693d62a5c", "node_type": "1", "metadata": {"window": "As seen on slide 4 , total company revenue increased 12% to $57.4 billion, reflecting growth in both \nthe Pharma and Medical segments.  \n \n We drove operating leverage for the enterprise, despite incremental investments in the business and \nhigher costs to support sales growth.  \n \n Gross margin increased 11% to $1.8 billion, driven by both segments, and consolidated SG&A \nincreased 8% to $1.3 billion.   \n \n With the strong profit growth in both segments, we delivered operating earnings of $562 million, 20% \nhigher than a year ago.  \n \n Moving below the line, interest and other decreased by $26 million to $8 million in income, due to \nincreased interest income on cash and equivalents from higher cash balances and higher rates.  As \nwe\u2019ve noted, our debt is largely fixed rate, resulting in a net benefit from rising interest rates in the \nnear term.  Additionally, Q2 interest and other benefitted from nearly $10 million in income from the \nquarterly revaluation of our company\u2019s deferred compensation plan investments, which as a reminder \nhas a matc hing offset above -the-line. \n \n", "original_text": "With the strong profit growth in both segments, we delivered operating earnings of $562 million, 20% \nhigher than a year ago.  \n \n", "page_label": "3", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "a726a8e9bac5cd7ddc7f12a1e5ce3322f18242e2bf5a5bc609d67d45b4101218", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "7bb4c23a-8a23-48a2-b691-3bc70a1fa455", "node_type": "1", "metadata": {"window": "Gross margin increased 11% to $1.8 billion, driven by both segments, and consolidated SG&A \nincreased 8% to $1.3 billion.   \n \n With the strong profit growth in both segments, we delivered operating earnings of $562 million, 20% \nhigher than a year ago.  \n \n Moving below the line, interest and other decreased by $26 million to $8 million in income, due to \nincreased interest income on cash and equivalents from higher cash balances and higher rates.  As \nwe\u2019ve noted, our debt is largely fixed rate, resulting in a net benefit from rising interest rates in the \nnear term.  Additionally, Q2 interest and other benefitted from nearly $10 million in income from the \nquarterly revaluation of our company\u2019s deferred compensation plan investments, which as a reminder \nhas a matc hing offset above -the-line. \n \n Our second quarter effective tax rate of 21.3 % was 1.7 percentage points lower than a year ago and \nbetter than we anticipated, due to positive discrete items in the period.  \n \n Q2 average diluted shares outstanding were 246 million, 6% lower than a year ago due to share \nrepurchases in each of the last four quarters.  \n \n", "original_text": "As \nwe\u2019ve noted, our debt is largely fixed rate, resulting in a net benefit from rising interest rates in the \nnear term. "}, "hash": "dbbe6c129e6b5d90bb5407c83513767999b1b9da90cefbb2c9258c6601afc80f", "class_name": "RelatedNodeInfo"}}, "text": "Moving below the line, interest and other decreased by $26 million to $8 million in income, due to \nincreased interest income on cash and equivalents from higher cash balances and higher rates. ", "start_char_idx": 717, "end_char_idx": 911, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "7bb4c23a-8a23-48a2-b691-3bc70a1fa455": {"__data__": {"id_": "7bb4c23a-8a23-48a2-b691-3bc70a1fa455", "embedding": null, "metadata": {"window": "Gross margin increased 11% to $1.8 billion, driven by both segments, and consolidated SG&A \nincreased 8% to $1.3 billion.   \n \n With the strong profit growth in both segments, we delivered operating earnings of $562 million, 20% \nhigher than a year ago.  \n \n Moving below the line, interest and other decreased by $26 million to $8 million in income, due to \nincreased interest income on cash and equivalents from higher cash balances and higher rates.  As \nwe\u2019ve noted, our debt is largely fixed rate, resulting in a net benefit from rising interest rates in the \nnear term.  Additionally, Q2 interest and other benefitted from nearly $10 million in income from the \nquarterly revaluation of our company\u2019s deferred compensation plan investments, which as a reminder \nhas a matc hing offset above -the-line. \n \n Our second quarter effective tax rate of 21.3 % was 1.7 percentage points lower than a year ago and \nbetter than we anticipated, due to positive discrete items in the period.  \n \n Q2 average diluted shares outstanding were 246 million, 6% lower than a year ago due to share \nrepurchases in each of the last four quarters.  \n \n", "original_text": "As \nwe\u2019ve noted, our debt is largely fixed rate, resulting in a net benefit from rising interest rates in the \nnear term. ", "page_label": "3", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "2122bb61-73c3-4261-85c0-fd8e84992ea1", "node_type": "4", "metadata": {"page_label": "3", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "f98687a89f26084d26a47edc3cd31551f3f6fd6e2047c95d14693d1c9dfdc292", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "3baca8c7-8b24-4a8b-b306-78907a252595", "node_type": "1", "metadata": {"window": "We drove operating leverage for the enterprise, despite incremental investments in the business and \nhigher costs to support sales growth.  \n \n Gross margin increased 11% to $1.8 billion, driven by both segments, and consolidated SG&A \nincreased 8% to $1.3 billion.   \n \n With the strong profit growth in both segments, we delivered operating earnings of $562 million, 20% \nhigher than a year ago.  \n \n Moving below the line, interest and other decreased by $26 million to $8 million in income, due to \nincreased interest income on cash and equivalents from higher cash balances and higher rates.  As \nwe\u2019ve noted, our debt is largely fixed rate, resulting in a net benefit from rising interest rates in the \nnear term.  Additionally, Q2 interest and other benefitted from nearly $10 million in income from the \nquarterly revaluation of our company\u2019s deferred compensation plan investments, which as a reminder \nhas a matc hing offset above -the-line. \n \n Our second quarter effective tax rate of 21.3 % was 1.7 percentage points lower than a year ago and \nbetter than we anticipated, due to positive discrete items in the period.  \n \n", "original_text": "Moving below the line, interest and other decreased by $26 million to $8 million in income, due to \nincreased interest income on cash and equivalents from higher cash balances and higher rates. ", "page_label": "3", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "2cb5eb0f4cf779067b36f91a5af6dd6bd2a8615bb6f81ea7919f7066f636eed3", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "6a39ae9e-bb88-44e8-8eaf-8ce398f2dde6", "node_type": "1", "metadata": {"window": "With the strong profit growth in both segments, we delivered operating earnings of $562 million, 20% \nhigher than a year ago.  \n \n Moving below the line, interest and other decreased by $26 million to $8 million in income, due to \nincreased interest income on cash and equivalents from higher cash balances and higher rates.  As \nwe\u2019ve noted, our debt is largely fixed rate, resulting in a net benefit from rising interest rates in the \nnear term.  Additionally, Q2 interest and other benefitted from nearly $10 million in income from the \nquarterly revaluation of our company\u2019s deferred compensation plan investments, which as a reminder \nhas a matc hing offset above -the-line. \n \n Our second quarter effective tax rate of 21.3 % was 1.7 percentage points lower than a year ago and \nbetter than we anticipated, due to positive discrete items in the period.  \n \n Q2 average diluted shares outstanding were 246 million, 6% lower than a year ago due to share \nrepurchases in each of the last four quarters.  \n \n And as I mentioned earlier, the net result for Q2 was EPS of $1.82, reflecting growth of 38%.  \n \n", "original_text": "Additionally, Q2 interest and other benefitted from nearly $10 million in income from the \nquarterly revaluation of our company\u2019s deferred compensation plan investments, which as a reminder \nhas a matc hing offset above -the-line. \n \n"}, "hash": "c33e253f71b002e7429c0eeacbeac999641ecdabacb27669f70c5728a163b3e5", "class_name": "RelatedNodeInfo"}}, "text": "As \nwe\u2019ve noted, our debt is largely fixed rate, resulting in a net benefit from rising interest rates in the \nnear term. ", "start_char_idx": 911, "end_char_idx": 1033, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "6a39ae9e-bb88-44e8-8eaf-8ce398f2dde6": {"__data__": {"id_": "6a39ae9e-bb88-44e8-8eaf-8ce398f2dde6", "embedding": null, "metadata": {"window": "With the strong profit growth in both segments, we delivered operating earnings of $562 million, 20% \nhigher than a year ago.  \n \n Moving below the line, interest and other decreased by $26 million to $8 million in income, due to \nincreased interest income on cash and equivalents from higher cash balances and higher rates.  As \nwe\u2019ve noted, our debt is largely fixed rate, resulting in a net benefit from rising interest rates in the \nnear term.  Additionally, Q2 interest and other benefitted from nearly $10 million in income from the \nquarterly revaluation of our company\u2019s deferred compensation plan investments, which as a reminder \nhas a matc hing offset above -the-line. \n \n Our second quarter effective tax rate of 21.3 % was 1.7 percentage points lower than a year ago and \nbetter than we anticipated, due to positive discrete items in the period.  \n \n Q2 average diluted shares outstanding were 246 million, 6% lower than a year ago due to share \nrepurchases in each of the last four quarters.  \n \n And as I mentioned earlier, the net result for Q2 was EPS of $1.82, reflecting growth of 38%.  \n \n", "original_text": "Additionally, Q2 interest and other benefitted from nearly $10 million in income from the \nquarterly revaluation of our company\u2019s deferred compensation plan investments, which as a reminder \nhas a matc hing offset above -the-line. \n \n", "page_label": "3", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "2122bb61-73c3-4261-85c0-fd8e84992ea1", "node_type": "4", "metadata": {"page_label": "3", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "f98687a89f26084d26a47edc3cd31551f3f6fd6e2047c95d14693d1c9dfdc292", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "7bb4c23a-8a23-48a2-b691-3bc70a1fa455", "node_type": "1", "metadata": {"window": "Gross margin increased 11% to $1.8 billion, driven by both segments, and consolidated SG&A \nincreased 8% to $1.3 billion.   \n \n With the strong profit growth in both segments, we delivered operating earnings of $562 million, 20% \nhigher than a year ago.  \n \n Moving below the line, interest and other decreased by $26 million to $8 million in income, due to \nincreased interest income on cash and equivalents from higher cash balances and higher rates.  As \nwe\u2019ve noted, our debt is largely fixed rate, resulting in a net benefit from rising interest rates in the \nnear term.  Additionally, Q2 interest and other benefitted from nearly $10 million in income from the \nquarterly revaluation of our company\u2019s deferred compensation plan investments, which as a reminder \nhas a matc hing offset above -the-line. \n \n Our second quarter effective tax rate of 21.3 % was 1.7 percentage points lower than a year ago and \nbetter than we anticipated, due to positive discrete items in the period.  \n \n Q2 average diluted shares outstanding were 246 million, 6% lower than a year ago due to share \nrepurchases in each of the last four quarters.  \n \n", "original_text": "As \nwe\u2019ve noted, our debt is largely fixed rate, resulting in a net benefit from rising interest rates in the \nnear term. ", "page_label": "3", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "624123dc98b99f1a24e59a9574349e097cba952e1670195bd1fb1c7376b307c2", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "ebb3a8d1-f6c1-47a3-a8b0-891c7f93e772", "node_type": "1", "metadata": {"window": "Moving below the line, interest and other decreased by $26 million to $8 million in income, due to \nincreased interest income on cash and equivalents from higher cash balances and higher rates.  As \nwe\u2019ve noted, our debt is largely fixed rate, resulting in a net benefit from rising interest rates in the \nnear term.  Additionally, Q2 interest and other benefitted from nearly $10 million in income from the \nquarterly revaluation of our company\u2019s deferred compensation plan investments, which as a reminder \nhas a matc hing offset above -the-line. \n \n Our second quarter effective tax rate of 21.3 % was 1.7 percentage points lower than a year ago and \nbetter than we anticipated, due to positive discrete items in the period.  \n \n Q2 average diluted shares outstanding were 246 million, 6% lower than a year ago due to share \nrepurchases in each of the last four quarters.  \n \n And as I mentioned earlier, the net result for Q2 was EPS of $1.82, reflecting growth of 38%.  \n \n Let\u2019s turn to the Pharma segment on slide 5 . \n \n", "original_text": "Our second quarter effective tax rate of 21.3 % was 1.7 percentage points lower than a year ago and \nbetter than we anticipated, due to positive discrete items in the period.  \n \n"}, "hash": "bfcf7641837a280451a7211e7299d1c38112c8bfdc0c571c3a581d22bf778237", "class_name": "RelatedNodeInfo"}}, "text": "Additionally, Q2 interest and other benefitted from nearly $10 million in income from the \nquarterly revaluation of our company\u2019s deferred compensation plan investments, which as a reminder \nhas a matc hing offset above -the-line. \n \n", "start_char_idx": 1033, "end_char_idx": 1267, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "ebb3a8d1-f6c1-47a3-a8b0-891c7f93e772": {"__data__": {"id_": "ebb3a8d1-f6c1-47a3-a8b0-891c7f93e772", "embedding": null, "metadata": {"window": "Moving below the line, interest and other decreased by $26 million to $8 million in income, due to \nincreased interest income on cash and equivalents from higher cash balances and higher rates.  As \nwe\u2019ve noted, our debt is largely fixed rate, resulting in a net benefit from rising interest rates in the \nnear term.  Additionally, Q2 interest and other benefitted from nearly $10 million in income from the \nquarterly revaluation of our company\u2019s deferred compensation plan investments, which as a reminder \nhas a matc hing offset above -the-line. \n \n Our second quarter effective tax rate of 21.3 % was 1.7 percentage points lower than a year ago and \nbetter than we anticipated, due to positive discrete items in the period.  \n \n Q2 average diluted shares outstanding were 246 million, 6% lower than a year ago due to share \nrepurchases in each of the last four quarters.  \n \n And as I mentioned earlier, the net result for Q2 was EPS of $1.82, reflecting growth of 38%.  \n \n Let\u2019s turn to the Pharma segment on slide 5 . \n \n", "original_text": "Our second quarter effective tax rate of 21.3 % was 1.7 percentage points lower than a year ago and \nbetter than we anticipated, due to positive discrete items in the period.  \n \n", "page_label": "3", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "2122bb61-73c3-4261-85c0-fd8e84992ea1", "node_type": "4", "metadata": {"page_label": "3", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "f98687a89f26084d26a47edc3cd31551f3f6fd6e2047c95d14693d1c9dfdc292", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "6a39ae9e-bb88-44e8-8eaf-8ce398f2dde6", "node_type": "1", "metadata": {"window": "With the strong profit growth in both segments, we delivered operating earnings of $562 million, 20% \nhigher than a year ago.  \n \n Moving below the line, interest and other decreased by $26 million to $8 million in income, due to \nincreased interest income on cash and equivalents from higher cash balances and higher rates.  As \nwe\u2019ve noted, our debt is largely fixed rate, resulting in a net benefit from rising interest rates in the \nnear term.  Additionally, Q2 interest and other benefitted from nearly $10 million in income from the \nquarterly revaluation of our company\u2019s deferred compensation plan investments, which as a reminder \nhas a matc hing offset above -the-line. \n \n Our second quarter effective tax rate of 21.3 % was 1.7 percentage points lower than a year ago and \nbetter than we anticipated, due to positive discrete items in the period.  \n \n Q2 average diluted shares outstanding were 246 million, 6% lower than a year ago due to share \nrepurchases in each of the last four quarters.  \n \n And as I mentioned earlier, the net result for Q2 was EPS of $1.82, reflecting growth of 38%.  \n \n", "original_text": "Additionally, Q2 interest and other benefitted from nearly $10 million in income from the \nquarterly revaluation of our company\u2019s deferred compensation plan investments, which as a reminder \nhas a matc hing offset above -the-line. \n \n", "page_label": "3", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "6efa672e7410b2e8a78eb6ae02820d9934716da459f7aa5e79fdfb20ded25f5c", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "f68fdfaa-a54e-4e67-910e-5f58d594c53a", "node_type": "1", "metadata": {"window": "As \nwe\u2019ve noted, our debt is largely fixed rate, resulting in a net benefit from rising interest rates in the \nnear term.  Additionally, Q2 interest and other benefitted from nearly $10 million in income from the \nquarterly revaluation of our company\u2019s deferred compensation plan investments, which as a reminder \nhas a matc hing offset above -the-line. \n \n Our second quarter effective tax rate of 21.3 % was 1.7 percentage points lower than a year ago and \nbetter than we anticipated, due to positive discrete items in the period.  \n \n Q2 average diluted shares outstanding were 246 million, 6% lower than a year ago due to share \nrepurchases in each of the last four quarters.  \n \n And as I mentioned earlier, the net result for Q2 was EPS of $1.82, reflecting growth of 38%.  \n \n Let\u2019s turn to the Pharma segment on slide 5 . \n \n Second quarter revenue increased 12% to $53.5 billion, driven by brand and specialty pharmaceutical \nsales growth from existing customers. ", "original_text": "Q2 average diluted shares outstanding were 246 million, 6% lower than a year ago due to share \nrepurchases in each of the last four quarters.  \n \n"}, "hash": "7280c0b73f44262de587d1dbad5404e52d7837b8837d6f84c950f4b6d299da40", "class_name": "RelatedNodeInfo"}}, "text": "Our second quarter effective tax rate of 21.3 % was 1.7 percentage points lower than a year ago and \nbetter than we anticipated, due to positive discrete items in the period.  \n \n", "start_char_idx": 1267, "end_char_idx": 1446, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "f68fdfaa-a54e-4e67-910e-5f58d594c53a": {"__data__": {"id_": "f68fdfaa-a54e-4e67-910e-5f58d594c53a", "embedding": null, "metadata": {"window": "As \nwe\u2019ve noted, our debt is largely fixed rate, resulting in a net benefit from rising interest rates in the \nnear term.  Additionally, Q2 interest and other benefitted from nearly $10 million in income from the \nquarterly revaluation of our company\u2019s deferred compensation plan investments, which as a reminder \nhas a matc hing offset above -the-line. \n \n Our second quarter effective tax rate of 21.3 % was 1.7 percentage points lower than a year ago and \nbetter than we anticipated, due to positive discrete items in the period.  \n \n Q2 average diluted shares outstanding were 246 million, 6% lower than a year ago due to share \nrepurchases in each of the last four quarters.  \n \n And as I mentioned earlier, the net result for Q2 was EPS of $1.82, reflecting growth of 38%.  \n \n Let\u2019s turn to the Pharma segment on slide 5 . \n \n Second quarter revenue increased 12% to $53.5 billion, driven by brand and specialty pharmaceutical \nsales growth from existing customers. ", "original_text": "Q2 average diluted shares outstanding were 246 million, 6% lower than a year ago due to share \nrepurchases in each of the last four quarters.  \n \n", "page_label": "3", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "2122bb61-73c3-4261-85c0-fd8e84992ea1", "node_type": "4", "metadata": {"page_label": "3", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "f98687a89f26084d26a47edc3cd31551f3f6fd6e2047c95d14693d1c9dfdc292", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "ebb3a8d1-f6c1-47a3-a8b0-891c7f93e772", "node_type": "1", "metadata": {"window": "Moving below the line, interest and other decreased by $26 million to $8 million in income, due to \nincreased interest income on cash and equivalents from higher cash balances and higher rates.  As \nwe\u2019ve noted, our debt is largely fixed rate, resulting in a net benefit from rising interest rates in the \nnear term.  Additionally, Q2 interest and other benefitted from nearly $10 million in income from the \nquarterly revaluation of our company\u2019s deferred compensation plan investments, which as a reminder \nhas a matc hing offset above -the-line. \n \n Our second quarter effective tax rate of 21.3 % was 1.7 percentage points lower than a year ago and \nbetter than we anticipated, due to positive discrete items in the period.  \n \n Q2 average diluted shares outstanding were 246 million, 6% lower than a year ago due to share \nrepurchases in each of the last four quarters.  \n \n And as I mentioned earlier, the net result for Q2 was EPS of $1.82, reflecting growth of 38%.  \n \n Let\u2019s turn to the Pharma segment on slide 5 . \n \n", "original_text": "Our second quarter effective tax rate of 21.3 % was 1.7 percentage points lower than a year ago and \nbetter than we anticipated, due to positive discrete items in the period.  \n \n", "page_label": "3", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "5fc955e8aa48f0d7549ae416226c7c4e762ae8e32415163dc28c8a6aae8a468b", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "20afa8b3-5b25-4805-9f52-3c22c3e1a93c", "node_type": "1", "metadata": {"window": "Additionally, Q2 interest and other benefitted from nearly $10 million in income from the \nquarterly revaluation of our company\u2019s deferred compensation plan investments, which as a reminder \nhas a matc hing offset above -the-line. \n \n Our second quarter effective tax rate of 21.3 % was 1.7 percentage points lower than a year ago and \nbetter than we anticipated, due to positive discrete items in the period.  \n \n Q2 average diluted shares outstanding were 246 million, 6% lower than a year ago due to share \nrepurchases in each of the last four quarters.  \n \n And as I mentioned earlier, the net result for Q2 was EPS of $1.82, reflecting growth of 38%.  \n \n Let\u2019s turn to the Pharma segment on slide 5 . \n \n Second quarter revenue increased 12% to $53.5 billion, driven by brand and specialty pharmaceutical \nsales growth from existing customers.  We saw strong pharmaceutical demand across product \ncategories: brand, specialty, consumer health, and generics, and from our largest customers. ", "original_text": "And as I mentioned earlier, the net result for Q2 was EPS of $1.82, reflecting growth of 38%.  \n \n"}, "hash": "c3669b0684bbfa490d1d4687463d3dc446312159a8845244fecadbe1d6768681", "class_name": "RelatedNodeInfo"}}, "text": "Q2 average diluted shares outstanding were 246 million, 6% lower than a year ago due to share \nrepurchases in each of the last four quarters.  \n \n", "start_char_idx": 1446, "end_char_idx": 1592, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "20afa8b3-5b25-4805-9f52-3c22c3e1a93c": {"__data__": {"id_": "20afa8b3-5b25-4805-9f52-3c22c3e1a93c", "embedding": null, "metadata": {"window": "Additionally, Q2 interest and other benefitted from nearly $10 million in income from the \nquarterly revaluation of our company\u2019s deferred compensation plan investments, which as a reminder \nhas a matc hing offset above -the-line. \n \n Our second quarter effective tax rate of 21.3 % was 1.7 percentage points lower than a year ago and \nbetter than we anticipated, due to positive discrete items in the period.  \n \n Q2 average diluted shares outstanding were 246 million, 6% lower than a year ago due to share \nrepurchases in each of the last four quarters.  \n \n And as I mentioned earlier, the net result for Q2 was EPS of $1.82, reflecting growth of 38%.  \n \n Let\u2019s turn to the Pharma segment on slide 5 . \n \n Second quarter revenue increased 12% to $53.5 billion, driven by brand and specialty pharmaceutical \nsales growth from existing customers.  We saw strong pharmaceutical demand across product \ncategories: brand, specialty, consumer health, and generics, and from our largest customers. ", "original_text": "And as I mentioned earlier, the net result for Q2 was EPS of $1.82, reflecting growth of 38%.  \n \n", "page_label": "3", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "2122bb61-73c3-4261-85c0-fd8e84992ea1", "node_type": "4", "metadata": {"page_label": "3", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "f98687a89f26084d26a47edc3cd31551f3f6fd6e2047c95d14693d1c9dfdc292", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "f68fdfaa-a54e-4e67-910e-5f58d594c53a", "node_type": "1", "metadata": {"window": "As \nwe\u2019ve noted, our debt is largely fixed rate, resulting in a net benefit from rising interest rates in the \nnear term.  Additionally, Q2 interest and other benefitted from nearly $10 million in income from the \nquarterly revaluation of our company\u2019s deferred compensation plan investments, which as a reminder \nhas a matc hing offset above -the-line. \n \n Our second quarter effective tax rate of 21.3 % was 1.7 percentage points lower than a year ago and \nbetter than we anticipated, due to positive discrete items in the period.  \n \n Q2 average diluted shares outstanding were 246 million, 6% lower than a year ago due to share \nrepurchases in each of the last four quarters.  \n \n And as I mentioned earlier, the net result for Q2 was EPS of $1.82, reflecting growth of 38%.  \n \n Let\u2019s turn to the Pharma segment on slide 5 . \n \n Second quarter revenue increased 12% to $53.5 billion, driven by brand and specialty pharmaceutical \nsales growth from existing customers. ", "original_text": "Q2 average diluted shares outstanding were 246 million, 6% lower than a year ago due to share \nrepurchases in each of the last four quarters.  \n \n", "page_label": "3", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "9e54fd5873eac0558272939ad93df73b16be4f36ec8beaa0515714d964255c4e", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "7c26fc13-57e5-4d66-a324-05bd3fa4e265", "node_type": "1", "metadata": {"window": "Our second quarter effective tax rate of 21.3 % was 1.7 percentage points lower than a year ago and \nbetter than we anticipated, due to positive discrete items in the period.  \n \n Q2 average diluted shares outstanding were 246 million, 6% lower than a year ago due to share \nrepurchases in each of the last four quarters.  \n \n And as I mentioned earlier, the net result for Q2 was EPS of $1.82, reflecting growth of 38%.  \n \n Let\u2019s turn to the Pharma segment on slide 5 . \n \n Second quarter revenue increased 12% to $53.5 billion, driven by brand and specialty pharmaceutical \nsales growth from existing customers.  We saw strong pharmaceutical demand across product \ncategories: brand, specialty, consumer health, and generics, and from our largest customers.  We also \ncontinued to see robust demand for GLP -1 medications, which provided a revenue tailwind in th e \nquarter.  \n \n", "original_text": "Let\u2019s turn to the Pharma segment on slide 5 . \n \n"}, "hash": "8b5aeb55b96b87ee1ae8279f8f8ba03fd6e6fb713367afb5bbe8cd633aa03a29", "class_name": "RelatedNodeInfo"}}, "text": "And as I mentioned earlier, the net result for Q2 was EPS of $1.82, reflecting growth of 38%.  \n \n", "start_char_idx": 1592, "end_char_idx": 1690, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "7c26fc13-57e5-4d66-a324-05bd3fa4e265": {"__data__": {"id_": "7c26fc13-57e5-4d66-a324-05bd3fa4e265", "embedding": null, "metadata": {"window": "Our second quarter effective tax rate of 21.3 % was 1.7 percentage points lower than a year ago and \nbetter than we anticipated, due to positive discrete items in the period.  \n \n Q2 average diluted shares outstanding were 246 million, 6% lower than a year ago due to share \nrepurchases in each of the last four quarters.  \n \n And as I mentioned earlier, the net result for Q2 was EPS of $1.82, reflecting growth of 38%.  \n \n Let\u2019s turn to the Pharma segment on slide 5 . \n \n Second quarter revenue increased 12% to $53.5 billion, driven by brand and specialty pharmaceutical \nsales growth from existing customers.  We saw strong pharmaceutical demand across product \ncategories: brand, specialty, consumer health, and generics, and from our largest customers.  We also \ncontinued to see robust demand for GLP -1 medications, which provided a revenue tailwind in th e \nquarter.  \n \n", "original_text": "Let\u2019s turn to the Pharma segment on slide 5 . \n \n", "page_label": "3", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "2122bb61-73c3-4261-85c0-fd8e84992ea1", "node_type": "4", "metadata": {"page_label": "3", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "f98687a89f26084d26a47edc3cd31551f3f6fd6e2047c95d14693d1c9dfdc292", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "20afa8b3-5b25-4805-9f52-3c22c3e1a93c", "node_type": "1", "metadata": {"window": "Additionally, Q2 interest and other benefitted from nearly $10 million in income from the \nquarterly revaluation of our company\u2019s deferred compensation plan investments, which as a reminder \nhas a matc hing offset above -the-line. \n \n Our second quarter effective tax rate of 21.3 % was 1.7 percentage points lower than a year ago and \nbetter than we anticipated, due to positive discrete items in the period.  \n \n Q2 average diluted shares outstanding were 246 million, 6% lower than a year ago due to share \nrepurchases in each of the last four quarters.  \n \n And as I mentioned earlier, the net result for Q2 was EPS of $1.82, reflecting growth of 38%.  \n \n Let\u2019s turn to the Pharma segment on slide 5 . \n \n Second quarter revenue increased 12% to $53.5 billion, driven by brand and specialty pharmaceutical \nsales growth from existing customers.  We saw strong pharmaceutical demand across product \ncategories: brand, specialty, consumer health, and generics, and from our largest customers. ", "original_text": "And as I mentioned earlier, the net result for Q2 was EPS of $1.82, reflecting growth of 38%.  \n \n", "page_label": "3", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "d2a0d0fca58324e22efbd7b65b41e5f4f4b9597e34f36eeed30061a5723af4da", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "e70b5174-1312-4a64-99b0-c0aa1e9e5ea6", "node_type": "1", "metadata": {"window": "Q2 average diluted shares outstanding were 246 million, 6% lower than a year ago due to share \nrepurchases in each of the last four quarters.  \n \n And as I mentioned earlier, the net result for Q2 was EPS of $1.82, reflecting growth of 38%.  \n \n Let\u2019s turn to the Pharma segment on slide 5 . \n \n Second quarter revenue increased 12% to $53.5 billion, driven by brand and specialty pharmaceutical \nsales growth from existing customers.  We saw strong pharmaceutical demand across product \ncategories: brand, specialty, consumer health, and generics, and from our largest customers.  We also \ncontinued to see robust demand for GLP -1 medications, which provided a revenue tailwind in th e \nquarter.  \n \n Segment profit increased 12% to $518 million in the second quarter, driven by positive generics \nprogram performance and a higher contribution from brand and specialty products, including \ndistribution of COVID -19 vaccines.  \n \n", "original_text": "Second quarter revenue increased 12% to $53.5 billion, driven by brand and specialty pharmaceutical \nsales growth from existing customers. "}, "hash": "04a96eab65c9baaa7e69eac8d4414c929c1118f04fb730c462f2943e089923db", "class_name": "RelatedNodeInfo"}}, "text": "Let\u2019s turn to the Pharma segment on slide 5 . \n \n", "start_char_idx": 1690, "end_char_idx": 1739, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "e70b5174-1312-4a64-99b0-c0aa1e9e5ea6": {"__data__": {"id_": "e70b5174-1312-4a64-99b0-c0aa1e9e5ea6", "embedding": null, "metadata": {"window": "Q2 average diluted shares outstanding were 246 million, 6% lower than a year ago due to share \nrepurchases in each of the last four quarters.  \n \n And as I mentioned earlier, the net result for Q2 was EPS of $1.82, reflecting growth of 38%.  \n \n Let\u2019s turn to the Pharma segment on slide 5 . \n \n Second quarter revenue increased 12% to $53.5 billion, driven by brand and specialty pharmaceutical \nsales growth from existing customers.  We saw strong pharmaceutical demand across product \ncategories: brand, specialty, consumer health, and generics, and from our largest customers.  We also \ncontinued to see robust demand for GLP -1 medications, which provided a revenue tailwind in th e \nquarter.  \n \n Segment profit increased 12% to $518 million in the second quarter, driven by positive generics \nprogram performance and a higher contribution from brand and specialty products, including \ndistribution of COVID -19 vaccines.  \n \n", "original_text": "Second quarter revenue increased 12% to $53.5 billion, driven by brand and specialty pharmaceutical \nsales growth from existing customers. ", "page_label": "3", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "2122bb61-73c3-4261-85c0-fd8e84992ea1", "node_type": "4", "metadata": {"page_label": "3", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "f98687a89f26084d26a47edc3cd31551f3f6fd6e2047c95d14693d1c9dfdc292", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "7c26fc13-57e5-4d66-a324-05bd3fa4e265", "node_type": "1", "metadata": {"window": "Our second quarter effective tax rate of 21.3 % was 1.7 percentage points lower than a year ago and \nbetter than we anticipated, due to positive discrete items in the period.  \n \n Q2 average diluted shares outstanding were 246 million, 6% lower than a year ago due to share \nrepurchases in each of the last four quarters.  \n \n And as I mentioned earlier, the net result for Q2 was EPS of $1.82, reflecting growth of 38%.  \n \n Let\u2019s turn to the Pharma segment on slide 5 . \n \n Second quarter revenue increased 12% to $53.5 billion, driven by brand and specialty pharmaceutical \nsales growth from existing customers.  We saw strong pharmaceutical demand across product \ncategories: brand, specialty, consumer health, and generics, and from our largest customers.  We also \ncontinued to see robust demand for GLP -1 medications, which provided a revenue tailwind in th e \nquarter.  \n \n", "original_text": "Let\u2019s turn to the Pharma segment on slide 5 . \n \n", "page_label": "3", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "a1241867f3b97f189c1cd5c724ae46d2e5b799f6d0aee0f125da7529d5e53d2b", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "0a6a206f-0137-4f43-89e6-7e83f68a9a7e", "node_type": "1", "metadata": {"window": "And as I mentioned earlier, the net result for Q2 was EPS of $1.82, reflecting growth of 38%.  \n \n Let\u2019s turn to the Pharma segment on slide 5 . \n \n Second quarter revenue increased 12% to $53.5 billion, driven by brand and specialty pharmaceutical \nsales growth from existing customers.  We saw strong pharmaceutical demand across product \ncategories: brand, specialty, consumer health, and generics, and from our largest customers.  We also \ncontinued to see robust demand for GLP -1 medications, which provided a revenue tailwind in th e \nquarter.  \n \n Segment profit increased 12% to $518 million in the second quarter, driven by positive generics \nprogram performance and a higher contribution from brand and specialty products, including \ndistribution of COVID -19 vaccines.  \n \n Our positive generics program performance continued to reflect volume growth and consistent market \ndynamics.  \n ", "original_text": "We saw strong pharmaceutical demand across product \ncategories: brand, specialty, consumer health, and generics, and from our largest customers. "}, "hash": "5141e57adcfa42077bf432105f1ab8996c5db47f9555dedece9807872b05dac7", "class_name": "RelatedNodeInfo"}}, "text": "Second quarter revenue increased 12% to $53.5 billion, driven by brand and specialty pharmaceutical \nsales growth from existing customers. ", "start_char_idx": 1739, "end_char_idx": 1878, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "0a6a206f-0137-4f43-89e6-7e83f68a9a7e": {"__data__": {"id_": "0a6a206f-0137-4f43-89e6-7e83f68a9a7e", "embedding": null, "metadata": {"window": "And as I mentioned earlier, the net result for Q2 was EPS of $1.82, reflecting growth of 38%.  \n \n Let\u2019s turn to the Pharma segment on slide 5 . \n \n Second quarter revenue increased 12% to $53.5 billion, driven by brand and specialty pharmaceutical \nsales growth from existing customers.  We saw strong pharmaceutical demand across product \ncategories: brand, specialty, consumer health, and generics, and from our largest customers.  We also \ncontinued to see robust demand for GLP -1 medications, which provided a revenue tailwind in th e \nquarter.  \n \n Segment profit increased 12% to $518 million in the second quarter, driven by positive generics \nprogram performance and a higher contribution from brand and specialty products, including \ndistribution of COVID -19 vaccines.  \n \n Our positive generics program performance continued to reflect volume growth and consistent market \ndynamics.  \n ", "original_text": "We saw strong pharmaceutical demand across product \ncategories: brand, specialty, consumer health, and generics, and from our largest customers. ", "page_label": "3", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "2122bb61-73c3-4261-85c0-fd8e84992ea1", "node_type": "4", "metadata": {"page_label": "3", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "f98687a89f26084d26a47edc3cd31551f3f6fd6e2047c95d14693d1c9dfdc292", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "e70b5174-1312-4a64-99b0-c0aa1e9e5ea6", "node_type": "1", "metadata": {"window": "Q2 average diluted shares outstanding were 246 million, 6% lower than a year ago due to share \nrepurchases in each of the last four quarters.  \n \n And as I mentioned earlier, the net result for Q2 was EPS of $1.82, reflecting growth of 38%.  \n \n Let\u2019s turn to the Pharma segment on slide 5 . \n \n Second quarter revenue increased 12% to $53.5 billion, driven by brand and specialty pharmaceutical \nsales growth from existing customers.  We saw strong pharmaceutical demand across product \ncategories: brand, specialty, consumer health, and generics, and from our largest customers.  We also \ncontinued to see robust demand for GLP -1 medications, which provided a revenue tailwind in th e \nquarter.  \n \n Segment profit increased 12% to $518 million in the second quarter, driven by positive generics \nprogram performance and a higher contribution from brand and specialty products, including \ndistribution of COVID -19 vaccines.  \n \n", "original_text": "Second quarter revenue increased 12% to $53.5 billion, driven by brand and specialty pharmaceutical \nsales growth from existing customers. ", "page_label": "3", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "18d0108d3c47d7002dd0ae9af7233a67a0ee60dc728dcfc128616da9e23b6c97", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "f222a1fc-f336-4364-bfff-4d3c1508e67f", "node_type": "1", "metadata": {"window": "Let\u2019s turn to the Pharma segment on slide 5 . \n \n Second quarter revenue increased 12% to $53.5 billion, driven by brand and specialty pharmaceutical \nsales growth from existing customers.  We saw strong pharmaceutical demand across product \ncategories: brand, specialty, consumer health, and generics, and from our largest customers.  We also \ncontinued to see robust demand for GLP -1 medications, which provided a revenue tailwind in th e \nquarter.  \n \n Segment profit increased 12% to $518 million in the second quarter, driven by positive generics \nprogram performance and a higher contribution from brand and specialty products, including \ndistribution of COVID -19 vaccines.  \n \n Our positive generics program performance continued to reflect volume growth and consistent market \ndynamics.  \n ", "original_text": "We also \ncontinued to see robust demand for GLP -1 medications, which provided a revenue tailwind in th e \nquarter.  \n \n"}, "hash": "effb2eaa7c84c635a8deec7b48430a1e470b546a6a05857e1f5e3d6412907122", "class_name": "RelatedNodeInfo"}}, "text": "We saw strong pharmaceutical demand across product \ncategories: brand, specialty, consumer health, and generics, and from our largest customers. ", "start_char_idx": 1878, "end_char_idx": 2023, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "f222a1fc-f336-4364-bfff-4d3c1508e67f": {"__data__": {"id_": "f222a1fc-f336-4364-bfff-4d3c1508e67f", "embedding": null, "metadata": {"window": "Let\u2019s turn to the Pharma segment on slide 5 . \n \n Second quarter revenue increased 12% to $53.5 billion, driven by brand and specialty pharmaceutical \nsales growth from existing customers.  We saw strong pharmaceutical demand across product \ncategories: brand, specialty, consumer health, and generics, and from our largest customers.  We also \ncontinued to see robust demand for GLP -1 medications, which provided a revenue tailwind in th e \nquarter.  \n \n Segment profit increased 12% to $518 million in the second quarter, driven by positive generics \nprogram performance and a higher contribution from brand and specialty products, including \ndistribution of COVID -19 vaccines.  \n \n Our positive generics program performance continued to reflect volume growth and consistent market \ndynamics.  \n ", "original_text": "We also \ncontinued to see robust demand for GLP -1 medications, which provided a revenue tailwind in th e \nquarter.  \n \n", "page_label": "3", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "2122bb61-73c3-4261-85c0-fd8e84992ea1", "node_type": "4", "metadata": {"page_label": "3", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "f98687a89f26084d26a47edc3cd31551f3f6fd6e2047c95d14693d1c9dfdc292", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "0a6a206f-0137-4f43-89e6-7e83f68a9a7e", "node_type": "1", "metadata": {"window": "And as I mentioned earlier, the net result for Q2 was EPS of $1.82, reflecting growth of 38%.  \n \n Let\u2019s turn to the Pharma segment on slide 5 . \n \n Second quarter revenue increased 12% to $53.5 billion, driven by brand and specialty pharmaceutical \nsales growth from existing customers.  We saw strong pharmaceutical demand across product \ncategories: brand, specialty, consumer health, and generics, and from our largest customers.  We also \ncontinued to see robust demand for GLP -1 medications, which provided a revenue tailwind in th e \nquarter.  \n \n Segment profit increased 12% to $518 million in the second quarter, driven by positive generics \nprogram performance and a higher contribution from brand and specialty products, including \ndistribution of COVID -19 vaccines.  \n \n Our positive generics program performance continued to reflect volume growth and consistent market \ndynamics.  \n ", "original_text": "We saw strong pharmaceutical demand across product \ncategories: brand, specialty, consumer health, and generics, and from our largest customers. ", "page_label": "3", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "f473c97fdb28c37993a199bbf1a5795922114e5de80a97c1199f7d426ec44359", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "65c867c2-3756-4791-a720-5d9a93794014", "node_type": "1", "metadata": {"window": "Second quarter revenue increased 12% to $53.5 billion, driven by brand and specialty pharmaceutical \nsales growth from existing customers.  We saw strong pharmaceutical demand across product \ncategories: brand, specialty, consumer health, and generics, and from our largest customers.  We also \ncontinued to see robust demand for GLP -1 medications, which provided a revenue tailwind in th e \nquarter.  \n \n Segment profit increased 12% to $518 million in the second quarter, driven by positive generics \nprogram performance and a higher contribution from brand and specialty products, including \ndistribution of COVID -19 vaccines.  \n \n Our positive generics program performance continued to reflect volume growth and consistent market \ndynamics.  \n ", "original_text": "Segment profit increased 12% to $518 million in the second quarter, driven by positive generics \nprogram performance and a higher contribution from brand and specialty products, including \ndistribution of COVID -19 vaccines.  \n \n"}, "hash": "f0c810687572b21b4edd7fe3d2d3bf6f1189f64154b765766a596eb4a6c153b7", "class_name": "RelatedNodeInfo"}}, "text": "We also \ncontinued to see robust demand for GLP -1 medications, which provided a revenue tailwind in th e \nquarter.  \n \n", "start_char_idx": 2023, "end_char_idx": 2143, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "65c867c2-3756-4791-a720-5d9a93794014": {"__data__": {"id_": "65c867c2-3756-4791-a720-5d9a93794014", "embedding": null, "metadata": {"window": "Second quarter revenue increased 12% to $53.5 billion, driven by brand and specialty pharmaceutical \nsales growth from existing customers.  We saw strong pharmaceutical demand across product \ncategories: brand, specialty, consumer health, and generics, and from our largest customers.  We also \ncontinued to see robust demand for GLP -1 medications, which provided a revenue tailwind in th e \nquarter.  \n \n Segment profit increased 12% to $518 million in the second quarter, driven by positive generics \nprogram performance and a higher contribution from brand and specialty products, including \ndistribution of COVID -19 vaccines.  \n \n Our positive generics program performance continued to reflect volume growth and consistent market \ndynamics.  \n ", "original_text": "Segment profit increased 12% to $518 million in the second quarter, driven by positive generics \nprogram performance and a higher contribution from brand and specialty products, including \ndistribution of COVID -19 vaccines.  \n \n", "page_label": "3", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "2122bb61-73c3-4261-85c0-fd8e84992ea1", "node_type": "4", "metadata": {"page_label": "3", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "f98687a89f26084d26a47edc3cd31551f3f6fd6e2047c95d14693d1c9dfdc292", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "f222a1fc-f336-4364-bfff-4d3c1508e67f", "node_type": "1", "metadata": {"window": "Let\u2019s turn to the Pharma segment on slide 5 . \n \n Second quarter revenue increased 12% to $53.5 billion, driven by brand and specialty pharmaceutical \nsales growth from existing customers.  We saw strong pharmaceutical demand across product \ncategories: brand, specialty, consumer health, and generics, and from our largest customers.  We also \ncontinued to see robust demand for GLP -1 medications, which provided a revenue tailwind in th e \nquarter.  \n \n Segment profit increased 12% to $518 million in the second quarter, driven by positive generics \nprogram performance and a higher contribution from brand and specialty products, including \ndistribution of COVID -19 vaccines.  \n \n Our positive generics program performance continued to reflect volume growth and consistent market \ndynamics.  \n ", "original_text": "We also \ncontinued to see robust demand for GLP -1 medications, which provided a revenue tailwind in th e \nquarter.  \n \n", "page_label": "3", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "0a8f24af471c01c0bab75654488b3993986deba6fc94871afe4abfff397a65bb", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "329bf0ef-b5d2-42c6-9bc7-888b9d4160e7", "node_type": "1", "metadata": {"window": "We saw strong pharmaceutical demand across product \ncategories: brand, specialty, consumer health, and generics, and from our largest customers.  We also \ncontinued to see robust demand for GLP -1 medications, which provided a revenue tailwind in th e \nquarter.  \n \n Segment profit increased 12% to $518 million in the second quarter, driven by positive generics \nprogram performance and a higher contribution from brand and specialty products, including \ndistribution of COVID -19 vaccines.  \n \n Our positive generics program performance continued to reflect volume growth and consistent market \ndynamics.  \n ", "original_text": "Our positive generics program performance continued to reflect volume growth and consistent market \ndynamics.  \n "}, "hash": "cd8c0c97fb9dcbcee2ed9a204cfc2ce6da80765afb61dbf6a623ba3fd993bdb3", "class_name": "RelatedNodeInfo"}}, "text": "Segment profit increased 12% to $518 million in the second quarter, driven by positive generics \nprogram performance and a higher contribution from brand and specialty products, including \ndistribution of COVID -19 vaccines.  \n \n", "start_char_idx": 2143, "end_char_idx": 2372, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "329bf0ef-b5d2-42c6-9bc7-888b9d4160e7": {"__data__": {"id_": "329bf0ef-b5d2-42c6-9bc7-888b9d4160e7", "embedding": null, "metadata": {"window": "We saw strong pharmaceutical demand across product \ncategories: brand, specialty, consumer health, and generics, and from our largest customers.  We also \ncontinued to see robust demand for GLP -1 medications, which provided a revenue tailwind in th e \nquarter.  \n \n Segment profit increased 12% to $518 million in the second quarter, driven by positive generics \nprogram performance and a higher contribution from brand and specialty products, including \ndistribution of COVID -19 vaccines.  \n \n Our positive generics program performance continued to reflect volume growth and consistent market \ndynamics.  \n ", "original_text": "Our positive generics program performance continued to reflect volume growth and consistent market \ndynamics.  \n ", "page_label": "3", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "2122bb61-73c3-4261-85c0-fd8e84992ea1", "node_type": "4", "metadata": {"page_label": "3", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "f98687a89f26084d26a47edc3cd31551f3f6fd6e2047c95d14693d1c9dfdc292", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "65c867c2-3756-4791-a720-5d9a93794014", "node_type": "1", "metadata": {"window": "Second quarter revenue increased 12% to $53.5 billion, driven by brand and specialty pharmaceutical \nsales growth from existing customers.  We saw strong pharmaceutical demand across product \ncategories: brand, specialty, consumer health, and generics, and from our largest customers.  We also \ncontinued to see robust demand for GLP -1 medications, which provided a revenue tailwind in th e \nquarter.  \n \n Segment profit increased 12% to $518 million in the second quarter, driven by positive generics \nprogram performance and a higher contribution from brand and specialty products, including \ndistribution of COVID -19 vaccines.  \n \n Our positive generics program performance continued to reflect volume growth and consistent market \ndynamics.  \n ", "original_text": "Segment profit increased 12% to $518 million in the second quarter, driven by positive generics \nprogram performance and a higher contribution from brand and specialty products, including \ndistribution of COVID -19 vaccines.  \n \n", "page_label": "3", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "1f34709443d4ed08585615acf77634f50162305567458524676d0ccaf6473755", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "6c28b2fe-9db4-4844-8b46-f59b5a7118e5", "node_type": "1", "metadata": {"window": " \nPage 4 of 19 \n \nWith respect to COVID -19 vaccines, we saw the strength in demand from September for the fall \nimmunization season carry into October, before peaking mid -month and trending to a much lower run \nrate as we exited the second quarter.  \n \n The Q2 increase in segment profit includes a partial offset from higher costs to support sales growth, \ndriven by increased pharmaceutical volumes.  \n \n Turning to the Medical segment on slide 6 . \n \n Second quarter revenue increased 3% to $3.9 billion, which as Jason alluded to, reflects quarterly \nrevenue growth for the Medical segment for the first time in over two years. ", "original_text": " \nPage 4 of 19 \n \nWith respect to COVID -19 vaccines, we saw the strength in demand from September for the fall \nimmunization season carry into October, before peaking mid -month and trending to a much lower run \nrate as we exited the second quarter.  \n \n"}, "hash": "80084b6762093f8b99d292c1369874b3bd0cc29b08650d5d0b6ab4f50a1360ba", "class_name": "RelatedNodeInfo"}}, "text": "Our positive generics program performance continued to reflect volume growth and consistent market \ndynamics.  \n ", "start_char_idx": 2372, "end_char_idx": 2485, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "6c28b2fe-9db4-4844-8b46-f59b5a7118e5": {"__data__": {"id_": "6c28b2fe-9db4-4844-8b46-f59b5a7118e5", "embedding": null, "metadata": {"window": " \nPage 4 of 19 \n \nWith respect to COVID -19 vaccines, we saw the strength in demand from September for the fall \nimmunization season carry into October, before peaking mid -month and trending to a much lower run \nrate as we exited the second quarter.  \n \n The Q2 increase in segment profit includes a partial offset from higher costs to support sales growth, \ndriven by increased pharmaceutical volumes.  \n \n Turning to the Medical segment on slide 6 . \n \n Second quarter revenue increased 3% to $3.9 billion, which as Jason alluded to, reflects quarterly \nrevenue growth for the Medical segment for the first time in over two years. ", "original_text": " \nPage 4 of 19 \n \nWith respect to COVID -19 vaccines, we saw the strength in demand from September for the fall \nimmunization season carry into October, before peaking mid -month and trending to a much lower run \nrate as we exited the second quarter.  \n \n", "page_label": "4", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "51bcdcef-b372-404b-848b-774d2abd5d5e", "node_type": "4", "metadata": {"page_label": "4", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "bd01f15c5527440c508d2605336d5f3491f12c6e1d25f19b4e5680375c034961", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "329bf0ef-b5d2-42c6-9bc7-888b9d4160e7", "node_type": "1", "metadata": {"window": "We saw strong pharmaceutical demand across product \ncategories: brand, specialty, consumer health, and generics, and from our largest customers.  We also \ncontinued to see robust demand for GLP -1 medications, which provided a revenue tailwind in th e \nquarter.  \n \n Segment profit increased 12% to $518 million in the second quarter, driven by positive generics \nprogram performance and a higher contribution from brand and specialty products, including \ndistribution of COVID -19 vaccines.  \n \n Our positive generics program performance continued to reflect volume growth and consistent market \ndynamics.  \n ", "original_text": "Our positive generics program performance continued to reflect volume growth and consistent market \ndynamics.  \n ", "page_label": "3", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "c1d06ab1aeef390e56468d365e116cf217f81a06bda6d6b691e0c8badca4812d", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "0b96bdc3-ca6f-40ab-b4e1-57d54e9c8665", "node_type": "1", "metadata": {"window": " \nPage 4 of 19 \n \nWith respect to COVID -19 vaccines, we saw the strength in demand from September for the fall \nimmunization season carry into October, before peaking mid -month and trending to a much lower run \nrate as we exited the second quarter.  \n \n The Q2 increase in segment profit includes a partial offset from higher costs to support sales growth, \ndriven by increased pharmaceutical volumes.  \n \n Turning to the Medical segment on slide 6 . \n \n Second quarter revenue increased 3% to $3.9 billion, which as Jason alluded to, reflects quarterly \nrevenue growth for the Medical segment for the first time in over two years.  This increase was driven \nby growth in both at -Home Solutions and Global Medical Products and Distribution, with the GMPD \ngrowth primarily related to higher Cardinal Health Brand volumes.  \n \n", "original_text": "The Q2 increase in segment profit includes a partial offset from higher costs to support sales growth, \ndriven by increased pharmaceutical volumes.  \n \n"}, "hash": "e5594901f78af39aa0cc087f689026550d5f0ac05e85527d86bab4e2248f7ac2", "class_name": "RelatedNodeInfo"}}, "text": " \nPage 4 of 19 \n \nWith respect to COVID -19 vaccines, we saw the strength in demand from September for the fall \nimmunization season carry into October, before peaking mid -month and trending to a much lower run \nrate as we exited the second quarter.  \n \n", "start_char_idx": 0, "end_char_idx": 255, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "0b96bdc3-ca6f-40ab-b4e1-57d54e9c8665": {"__data__": {"id_": "0b96bdc3-ca6f-40ab-b4e1-57d54e9c8665", "embedding": null, "metadata": {"window": " \nPage 4 of 19 \n \nWith respect to COVID -19 vaccines, we saw the strength in demand from September for the fall \nimmunization season carry into October, before peaking mid -month and trending to a much lower run \nrate as we exited the second quarter.  \n \n The Q2 increase in segment profit includes a partial offset from higher costs to support sales growth, \ndriven by increased pharmaceutical volumes.  \n \n Turning to the Medical segment on slide 6 . \n \n Second quarter revenue increased 3% to $3.9 billion, which as Jason alluded to, reflects quarterly \nrevenue growth for the Medical segment for the first time in over two years.  This increase was driven \nby growth in both at -Home Solutions and Global Medical Products and Distribution, with the GMPD \ngrowth primarily related to higher Cardinal Health Brand volumes.  \n \n", "original_text": "The Q2 increase in segment profit includes a partial offset from higher costs to support sales growth, \ndriven by increased pharmaceutical volumes.  \n \n", "page_label": "4", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "51bcdcef-b372-404b-848b-774d2abd5d5e", "node_type": "4", "metadata": {"page_label": "4", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "bd01f15c5527440c508d2605336d5f3491f12c6e1d25f19b4e5680375c034961", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "6c28b2fe-9db4-4844-8b46-f59b5a7118e5", "node_type": "1", "metadata": {"window": " \nPage 4 of 19 \n \nWith respect to COVID -19 vaccines, we saw the strength in demand from September for the fall \nimmunization season carry into October, before peaking mid -month and trending to a much lower run \nrate as we exited the second quarter.  \n \n The Q2 increase in segment profit includes a partial offset from higher costs to support sales growth, \ndriven by increased pharmaceutical volumes.  \n \n Turning to the Medical segment on slide 6 . \n \n Second quarter revenue increased 3% to $3.9 billion, which as Jason alluded to, reflects quarterly \nrevenue growth for the Medical segment for the first time in over two years. ", "original_text": " \nPage 4 of 19 \n \nWith respect to COVID -19 vaccines, we saw the strength in demand from September for the fall \nimmunization season carry into October, before peaking mid -month and trending to a much lower run \nrate as we exited the second quarter.  \n \n", "page_label": "4", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "4027da73881eb5857cecb94cedb697219ac739d3d934c3b45a2fe881bfd7474b", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "af324dab-1977-4096-a25b-7d45113c31a9", "node_type": "1", "metadata": {"window": " \nPage 4 of 19 \n \nWith respect to COVID -19 vaccines, we saw the strength in demand from September for the fall \nimmunization season carry into October, before peaking mid -month and trending to a much lower run \nrate as we exited the second quarter.  \n \n The Q2 increase in segment profit includes a partial offset from higher costs to support sales growth, \ndriven by increased pharmaceutical volumes.  \n \n Turning to the Medical segment on slide 6 . \n \n Second quarter revenue increased 3% to $3.9 billion, which as Jason alluded to, reflects quarterly \nrevenue growth for the Medical segment for the first time in over two years.  This increase was driven \nby growth in both at -Home Solutions and Global Medical Products and Distribution, with the GMPD \ngrowth primarily related to higher Cardinal Health Brand volumes.  \n \n Medical delivered segment profit of $71 million, a $54 million year -over-year increase, driven by an \nimprovement in net inflationary impacts, including our mitigation initiatives.  \n \n", "original_text": "Turning to the Medical segment on slide 6 . \n \n"}, "hash": "59fca992fbaa8f12d2bc0a402de1f78ff099f4cfdc680e53fdef9321f7a52554", "class_name": "RelatedNodeInfo"}}, "text": "The Q2 increase in segment profit includes a partial offset from higher costs to support sales growth, \ndriven by increased pharmaceutical volumes.  \n \n", "start_char_idx": 255, "end_char_idx": 407, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "af324dab-1977-4096-a25b-7d45113c31a9": {"__data__": {"id_": "af324dab-1977-4096-a25b-7d45113c31a9", "embedding": null, "metadata": {"window": " \nPage 4 of 19 \n \nWith respect to COVID -19 vaccines, we saw the strength in demand from September for the fall \nimmunization season carry into October, before peaking mid -month and trending to a much lower run \nrate as we exited the second quarter.  \n \n The Q2 increase in segment profit includes a partial offset from higher costs to support sales growth, \ndriven by increased pharmaceutical volumes.  \n \n Turning to the Medical segment on slide 6 . \n \n Second quarter revenue increased 3% to $3.9 billion, which as Jason alluded to, reflects quarterly \nrevenue growth for the Medical segment for the first time in over two years.  This increase was driven \nby growth in both at -Home Solutions and Global Medical Products and Distribution, with the GMPD \ngrowth primarily related to higher Cardinal Health Brand volumes.  \n \n Medical delivered segment profit of $71 million, a $54 million year -over-year increase, driven by an \nimprovement in net inflationary impacts, including our mitigation initiatives.  \n \n", "original_text": "Turning to the Medical segment on slide 6 . \n \n", "page_label": "4", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "51bcdcef-b372-404b-848b-774d2abd5d5e", "node_type": "4", "metadata": {"page_label": "4", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "bd01f15c5527440c508d2605336d5f3491f12c6e1d25f19b4e5680375c034961", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "0b96bdc3-ca6f-40ab-b4e1-57d54e9c8665", "node_type": "1", "metadata": {"window": " \nPage 4 of 19 \n \nWith respect to COVID -19 vaccines, we saw the strength in demand from September for the fall \nimmunization season carry into October, before peaking mid -month and trending to a much lower run \nrate as we exited the second quarter.  \n \n The Q2 increase in segment profit includes a partial offset from higher costs to support sales growth, \ndriven by increased pharmaceutical volumes.  \n \n Turning to the Medical segment on slide 6 . \n \n Second quarter revenue increased 3% to $3.9 billion, which as Jason alluded to, reflects quarterly \nrevenue growth for the Medical segment for the first time in over two years.  This increase was driven \nby growth in both at -Home Solutions and Global Medical Products and Distribution, with the GMPD \ngrowth primarily related to higher Cardinal Health Brand volumes.  \n \n", "original_text": "The Q2 increase in segment profit includes a partial offset from higher costs to support sales growth, \ndriven by increased pharmaceutical volumes.  \n \n", "page_label": "4", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "fe98e773b7a267fc61d549ceb23701966e810ec4bfb8cda78d7418fd668dd21d", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "1e89ed48-e4be-42bd-bb93-1b6caf1dbe81", "node_type": "1", "metadata": {"window": " \nPage 4 of 19 \n \nWith respect to COVID -19 vaccines, we saw the strength in demand from September for the fall \nimmunization season carry into October, before peaking mid -month and trending to a much lower run \nrate as we exited the second quarter.  \n \n The Q2 increase in segment profit includes a partial offset from higher costs to support sales growth, \ndriven by increased pharmaceutical volumes.  \n \n Turning to the Medical segment on slide 6 . \n \n Second quarter revenue increased 3% to $3.9 billion, which as Jason alluded to, reflects quarterly \nrevenue growth for the Medical segment for the first time in over two years.  This increase was driven \nby growth in both at -Home Solutions and Global Medical Products and Distribution, with the GMPD \ngrowth primarily related to higher Cardinal Health Brand volumes.  \n \n Medical delivered segment profit of $71 million, a $54 million year -over-year increase, driven by an \nimprovement in net inflationary impacts, including our mitigation initiatives.  \n \n Consistent with the expectations communicated a few weeks ago, segment profit was \u2019generally \nconsistent\u2019 with Q1, despite some non -recurring adjustments in the quarter. ", "original_text": "Second quarter revenue increased 3% to $3.9 billion, which as Jason alluded to, reflects quarterly \nrevenue growth for the Medical segment for the first time in over two years. "}, "hash": "4d91a6ac926c5084dd56aac03fb5de7e8ee96f15fc02c976519dca2fc9615024", "class_name": "RelatedNodeInfo"}}, "text": "Turning to the Medical segment on slide 6 . \n \n", "start_char_idx": 407, "end_char_idx": 454, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "1e89ed48-e4be-42bd-bb93-1b6caf1dbe81": {"__data__": {"id_": "1e89ed48-e4be-42bd-bb93-1b6caf1dbe81", "embedding": null, "metadata": {"window": " \nPage 4 of 19 \n \nWith respect to COVID -19 vaccines, we saw the strength in demand from September for the fall \nimmunization season carry into October, before peaking mid -month and trending to a much lower run \nrate as we exited the second quarter.  \n \n The Q2 increase in segment profit includes a partial offset from higher costs to support sales growth, \ndriven by increased pharmaceutical volumes.  \n \n Turning to the Medical segment on slide 6 . \n \n Second quarter revenue increased 3% to $3.9 billion, which as Jason alluded to, reflects quarterly \nrevenue growth for the Medical segment for the first time in over two years.  This increase was driven \nby growth in both at -Home Solutions and Global Medical Products and Distribution, with the GMPD \ngrowth primarily related to higher Cardinal Health Brand volumes.  \n \n Medical delivered segment profit of $71 million, a $54 million year -over-year increase, driven by an \nimprovement in net inflationary impacts, including our mitigation initiatives.  \n \n Consistent with the expectations communicated a few weeks ago, segment profit was \u2019generally \nconsistent\u2019 with Q1, despite some non -recurring adjustments in the quarter. ", "original_text": "Second quarter revenue increased 3% to $3.9 billion, which as Jason alluded to, reflects quarterly \nrevenue growth for the Medical segment for the first time in over two years. ", "page_label": "4", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "51bcdcef-b372-404b-848b-774d2abd5d5e", "node_type": "4", "metadata": {"page_label": "4", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "bd01f15c5527440c508d2605336d5f3491f12c6e1d25f19b4e5680375c034961", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "af324dab-1977-4096-a25b-7d45113c31a9", "node_type": "1", "metadata": {"window": " \nPage 4 of 19 \n \nWith respect to COVID -19 vaccines, we saw the strength in demand from September for the fall \nimmunization season carry into October, before peaking mid -month and trending to a much lower run \nrate as we exited the second quarter.  \n \n The Q2 increase in segment profit includes a partial offset from higher costs to support sales growth, \ndriven by increased pharmaceutical volumes.  \n \n Turning to the Medical segment on slide 6 . \n \n Second quarter revenue increased 3% to $3.9 billion, which as Jason alluded to, reflects quarterly \nrevenue growth for the Medical segment for the first time in over two years.  This increase was driven \nby growth in both at -Home Solutions and Global Medical Products and Distribution, with the GMPD \ngrowth primarily related to higher Cardinal Health Brand volumes.  \n \n Medical delivered segment profit of $71 million, a $54 million year -over-year increase, driven by an \nimprovement in net inflationary impacts, including our mitigation initiatives.  \n \n", "original_text": "Turning to the Medical segment on slide 6 . \n \n", "page_label": "4", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "bb1fdf2a26477ee396d0a211c41a4e8adba92d7205577d54ae64d7aab93f6924", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "d31cacf4-758c-4c4a-a6ad-52d8a4941119", "node_type": "1", "metadata": {"window": "The Q2 increase in segment profit includes a partial offset from higher costs to support sales growth, \ndriven by increased pharmaceutical volumes.  \n \n Turning to the Medical segment on slide 6 . \n \n Second quarter revenue increased 3% to $3.9 billion, which as Jason alluded to, reflects quarterly \nrevenue growth for the Medical segment for the first time in over two years.  This increase was driven \nby growth in both at -Home Solutions and Global Medical Products and Distribution, with the GMPD \ngrowth primarily related to higher Cardinal Health Brand volumes.  \n \n Medical delivered segment profit of $71 million, a $54 million year -over-year increase, driven by an \nimprovement in net inflationary impacts, including our mitigation initiatives.  \n \n Consistent with the expectations communicated a few weeks ago, segment profit was \u2019generally \nconsistent\u2019 with Q1, despite some non -recurring adjustments in the quarter.  We continue to be \nencouraged by the underlying performance of the business, which throu gh the first two quarters of the \nyear, has tracked consistent with our original plans.  \n \n", "original_text": "This increase was driven \nby growth in both at -Home Solutions and Global Medical Products and Distribution, with the GMPD \ngrowth primarily related to higher Cardinal Health Brand volumes.  \n \n"}, "hash": "2e1eba5252c80949a820bc611bc812b1dcdabd24e61cdb4a551b4bb11bb76a06", "class_name": "RelatedNodeInfo"}}, "text": "Second quarter revenue increased 3% to $3.9 billion, which as Jason alluded to, reflects quarterly \nrevenue growth for the Medical segment for the first time in over two years. ", "start_char_idx": 454, "end_char_idx": 631, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "d31cacf4-758c-4c4a-a6ad-52d8a4941119": {"__data__": {"id_": "d31cacf4-758c-4c4a-a6ad-52d8a4941119", "embedding": null, "metadata": {"window": "The Q2 increase in segment profit includes a partial offset from higher costs to support sales growth, \ndriven by increased pharmaceutical volumes.  \n \n Turning to the Medical segment on slide 6 . \n \n Second quarter revenue increased 3% to $3.9 billion, which as Jason alluded to, reflects quarterly \nrevenue growth for the Medical segment for the first time in over two years.  This increase was driven \nby growth in both at -Home Solutions and Global Medical Products and Distribution, with the GMPD \ngrowth primarily related to higher Cardinal Health Brand volumes.  \n \n Medical delivered segment profit of $71 million, a $54 million year -over-year increase, driven by an \nimprovement in net inflationary impacts, including our mitigation initiatives.  \n \n Consistent with the expectations communicated a few weeks ago, segment profit was \u2019generally \nconsistent\u2019 with Q1, despite some non -recurring adjustments in the quarter.  We continue to be \nencouraged by the underlying performance of the business, which throu gh the first two quarters of the \nyear, has tracked consistent with our original plans.  \n \n", "original_text": "This increase was driven \nby growth in both at -Home Solutions and Global Medical Products and Distribution, with the GMPD \ngrowth primarily related to higher Cardinal Health Brand volumes.  \n \n", "page_label": "4", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "51bcdcef-b372-404b-848b-774d2abd5d5e", "node_type": "4", "metadata": {"page_label": "4", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "bd01f15c5527440c508d2605336d5f3491f12c6e1d25f19b4e5680375c034961", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "1e89ed48-e4be-42bd-bb93-1b6caf1dbe81", "node_type": "1", "metadata": {"window": " \nPage 4 of 19 \n \nWith respect to COVID -19 vaccines, we saw the strength in demand from September for the fall \nimmunization season carry into October, before peaking mid -month and trending to a much lower run \nrate as we exited the second quarter.  \n \n The Q2 increase in segment profit includes a partial offset from higher costs to support sales growth, \ndriven by increased pharmaceutical volumes.  \n \n Turning to the Medical segment on slide 6 . \n \n Second quarter revenue increased 3% to $3.9 billion, which as Jason alluded to, reflects quarterly \nrevenue growth for the Medical segment for the first time in over two years.  This increase was driven \nby growth in both at -Home Solutions and Global Medical Products and Distribution, with the GMPD \ngrowth primarily related to higher Cardinal Health Brand volumes.  \n \n Medical delivered segment profit of $71 million, a $54 million year -over-year increase, driven by an \nimprovement in net inflationary impacts, including our mitigation initiatives.  \n \n Consistent with the expectations communicated a few weeks ago, segment profit was \u2019generally \nconsistent\u2019 with Q1, despite some non -recurring adjustments in the quarter. ", "original_text": "Second quarter revenue increased 3% to $3.9 billion, which as Jason alluded to, reflects quarterly \nrevenue growth for the Medical segment for the first time in over two years. ", "page_label": "4", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "b3deed9d28a3f507b1a5aa6330d706f37638703681ec8c7cd31778d51e319d6d", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "f5268ec7-350b-477d-9200-de8b834ff2b4", "node_type": "1", "metadata": {"window": "Turning to the Medical segment on slide 6 . \n \n Second quarter revenue increased 3% to $3.9 billion, which as Jason alluded to, reflects quarterly \nrevenue growth for the Medical segment for the first time in over two years.  This increase was driven \nby growth in both at -Home Solutions and Global Medical Products and Distribution, with the GMPD \ngrowth primarily related to higher Cardinal Health Brand volumes.  \n \n Medical delivered segment profit of $71 million, a $54 million year -over-year increase, driven by an \nimprovement in net inflationary impacts, including our mitigation initiatives.  \n \n Consistent with the expectations communicated a few weeks ago, segment profit was \u2019generally \nconsistent\u2019 with Q1, despite some non -recurring adjustments in the quarter.  We continue to be \nencouraged by the underlying performance of the business, which throu gh the first two quarters of the \nyear, has tracked consistent with our original plans.  \n \n Now, turning to the balance sheet . \n \n", "original_text": "Medical delivered segment profit of $71 million, a $54 million year -over-year increase, driven by an \nimprovement in net inflationary impacts, including our mitigation initiatives.  \n \n"}, "hash": "12460cdca187973f1ced5205329944de666dfde9065b7102904772701610746a", "class_name": "RelatedNodeInfo"}}, "text": "This increase was driven \nby growth in both at -Home Solutions and Global Medical Products and Distribution, with the GMPD \ngrowth primarily related to higher Cardinal Health Brand volumes.  \n \n", "start_char_idx": 631, "end_char_idx": 825, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "f5268ec7-350b-477d-9200-de8b834ff2b4": {"__data__": {"id_": "f5268ec7-350b-477d-9200-de8b834ff2b4", "embedding": null, "metadata": {"window": "Turning to the Medical segment on slide 6 . \n \n Second quarter revenue increased 3% to $3.9 billion, which as Jason alluded to, reflects quarterly \nrevenue growth for the Medical segment for the first time in over two years.  This increase was driven \nby growth in both at -Home Solutions and Global Medical Products and Distribution, with the GMPD \ngrowth primarily related to higher Cardinal Health Brand volumes.  \n \n Medical delivered segment profit of $71 million, a $54 million year -over-year increase, driven by an \nimprovement in net inflationary impacts, including our mitigation initiatives.  \n \n Consistent with the expectations communicated a few weeks ago, segment profit was \u2019generally \nconsistent\u2019 with Q1, despite some non -recurring adjustments in the quarter.  We continue to be \nencouraged by the underlying performance of the business, which throu gh the first two quarters of the \nyear, has tracked consistent with our original plans.  \n \n Now, turning to the balance sheet . \n \n", "original_text": "Medical delivered segment profit of $71 million, a $54 million year -over-year increase, driven by an \nimprovement in net inflationary impacts, including our mitigation initiatives.  \n \n", "page_label": "4", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "51bcdcef-b372-404b-848b-774d2abd5d5e", "node_type": "4", "metadata": {"page_label": "4", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "bd01f15c5527440c508d2605336d5f3491f12c6e1d25f19b4e5680375c034961", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "d31cacf4-758c-4c4a-a6ad-52d8a4941119", "node_type": "1", "metadata": {"window": "The Q2 increase in segment profit includes a partial offset from higher costs to support sales growth, \ndriven by increased pharmaceutical volumes.  \n \n Turning to the Medical segment on slide 6 . \n \n Second quarter revenue increased 3% to $3.9 billion, which as Jason alluded to, reflects quarterly \nrevenue growth for the Medical segment for the first time in over two years.  This increase was driven \nby growth in both at -Home Solutions and Global Medical Products and Distribution, with the GMPD \ngrowth primarily related to higher Cardinal Health Brand volumes.  \n \n Medical delivered segment profit of $71 million, a $54 million year -over-year increase, driven by an \nimprovement in net inflationary impacts, including our mitigation initiatives.  \n \n Consistent with the expectations communicated a few weeks ago, segment profit was \u2019generally \nconsistent\u2019 with Q1, despite some non -recurring adjustments in the quarter.  We continue to be \nencouraged by the underlying performance of the business, which throu gh the first two quarters of the \nyear, has tracked consistent with our original plans.  \n \n", "original_text": "This increase was driven \nby growth in both at -Home Solutions and Global Medical Products and Distribution, with the GMPD \ngrowth primarily related to higher Cardinal Health Brand volumes.  \n \n", "page_label": "4", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "9697047d923f0c146ee719e584f899a06b26b64e399caa5b2ba5613dd056573b", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "9e2a6610-8446-42d7-8a65-c4259a34cc69", "node_type": "1", "metadata": {"window": "Second quarter revenue increased 3% to $3.9 billion, which as Jason alluded to, reflects quarterly \nrevenue growth for the Medical segment for the first time in over two years.  This increase was driven \nby growth in both at -Home Solutions and Global Medical Products and Distribution, with the GMPD \ngrowth primarily related to higher Cardinal Health Brand volumes.  \n \n Medical delivered segment profit of $71 million, a $54 million year -over-year increase, driven by an \nimprovement in net inflationary impacts, including our mitigation initiatives.  \n \n Consistent with the expectations communicated a few weeks ago, segment profit was \u2019generally \nconsistent\u2019 with Q1, despite some non -recurring adjustments in the quarter.  We continue to be \nencouraged by the underlying performance of the business, which throu gh the first two quarters of the \nyear, has tracked consistent with our original plans.  \n \n Now, turning to the balance sheet . \n \n We generated robust adjusted free cash flow of $1  billion  in Q2, bringing our year -to-date adjusted \nfree cash flow to $2  billion , and as I noted earlier, ended the quarter with $4.6 billion of cash on hand.  \n \n", "original_text": "Consistent with the expectations communicated a few weeks ago, segment profit was \u2019generally \nconsistent\u2019 with Q1, despite some non -recurring adjustments in the quarter. "}, "hash": "9d394690c1a8258bf0d4df430db5f9913d3cfaae05a3466a01d88625fabc1c0e", "class_name": "RelatedNodeInfo"}}, "text": "Medical delivered segment profit of $71 million, a $54 million year -over-year increase, driven by an \nimprovement in net inflationary impacts, including our mitigation initiatives.  \n \n", "start_char_idx": 825, "end_char_idx": 1011, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "9e2a6610-8446-42d7-8a65-c4259a34cc69": {"__data__": {"id_": "9e2a6610-8446-42d7-8a65-c4259a34cc69", "embedding": null, "metadata": {"window": "Second quarter revenue increased 3% to $3.9 billion, which as Jason alluded to, reflects quarterly \nrevenue growth for the Medical segment for the first time in over two years.  This increase was driven \nby growth in both at -Home Solutions and Global Medical Products and Distribution, with the GMPD \ngrowth primarily related to higher Cardinal Health Brand volumes.  \n \n Medical delivered segment profit of $71 million, a $54 million year -over-year increase, driven by an \nimprovement in net inflationary impacts, including our mitigation initiatives.  \n \n Consistent with the expectations communicated a few weeks ago, segment profit was \u2019generally \nconsistent\u2019 with Q1, despite some non -recurring adjustments in the quarter.  We continue to be \nencouraged by the underlying performance of the business, which throu gh the first two quarters of the \nyear, has tracked consistent with our original plans.  \n \n Now, turning to the balance sheet . \n \n We generated robust adjusted free cash flow of $1  billion  in Q2, bringing our year -to-date adjusted \nfree cash flow to $2  billion , and as I noted earlier, ended the quarter with $4.6 billion of cash on hand.  \n \n", "original_text": "Consistent with the expectations communicated a few weeks ago, segment profit was \u2019generally \nconsistent\u2019 with Q1, despite some non -recurring adjustments in the quarter. ", "page_label": "4", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "51bcdcef-b372-404b-848b-774d2abd5d5e", "node_type": "4", "metadata": {"page_label": "4", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "bd01f15c5527440c508d2605336d5f3491f12c6e1d25f19b4e5680375c034961", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "f5268ec7-350b-477d-9200-de8b834ff2b4", "node_type": "1", "metadata": {"window": "Turning to the Medical segment on slide 6 . \n \n Second quarter revenue increased 3% to $3.9 billion, which as Jason alluded to, reflects quarterly \nrevenue growth for the Medical segment for the first time in over two years.  This increase was driven \nby growth in both at -Home Solutions and Global Medical Products and Distribution, with the GMPD \ngrowth primarily related to higher Cardinal Health Brand volumes.  \n \n Medical delivered segment profit of $71 million, a $54 million year -over-year increase, driven by an \nimprovement in net inflationary impacts, including our mitigation initiatives.  \n \n Consistent with the expectations communicated a few weeks ago, segment profit was \u2019generally \nconsistent\u2019 with Q1, despite some non -recurring adjustments in the quarter.  We continue to be \nencouraged by the underlying performance of the business, which throu gh the first two quarters of the \nyear, has tracked consistent with our original plans.  \n \n Now, turning to the balance sheet . \n \n", "original_text": "Medical delivered segment profit of $71 million, a $54 million year -over-year increase, driven by an \nimprovement in net inflationary impacts, including our mitigation initiatives.  \n \n", "page_label": "4", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "f647de7f4c34dfbfffbbd4867b70e0e7a5ae193acdd57dfe1e67225308258b8c", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "46f78cd2-c7c3-4138-bdfc-ba91d6eb1f91", "node_type": "1", "metadata": {"window": "This increase was driven \nby growth in both at -Home Solutions and Global Medical Products and Distribution, with the GMPD \ngrowth primarily related to higher Cardinal Health Brand volumes.  \n \n Medical delivered segment profit of $71 million, a $54 million year -over-year increase, driven by an \nimprovement in net inflationary impacts, including our mitigation initiatives.  \n \n Consistent with the expectations communicated a few weeks ago, segment profit was \u2019generally \nconsistent\u2019 with Q1, despite some non -recurring adjustments in the quarter.  We continue to be \nencouraged by the underlying performance of the business, which throu gh the first two quarters of the \nyear, has tracked consistent with our original plans.  \n \n Now, turning to the balance sheet . \n \n We generated robust adjusted free cash flow of $1  billion  in Q2, bringing our year -to-date adjusted \nfree cash flow to $2  billion , and as I noted earlier, ended the quarter with $4.6 billion of cash on hand.  \n \n We remain focused on doing what we said we would, deploying capital according to our disciplined \ncapital allocation framework.  \n \n", "original_text": "We continue to be \nencouraged by the underlying performance of the business, which throu gh the first two quarters of the \nyear, has tracked consistent with our original plans.  \n \n"}, "hash": "c94e5f9829d7aac0348ca453cec83b1f93eec41a0ea375f5733a184a31cdd4fc", "class_name": "RelatedNodeInfo"}}, "text": "Consistent with the expectations communicated a few weeks ago, segment profit was \u2019generally \nconsistent\u2019 with Q1, despite some non -recurring adjustments in the quarter. ", "start_char_idx": 1011, "end_char_idx": 1182, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "46f78cd2-c7c3-4138-bdfc-ba91d6eb1f91": {"__data__": {"id_": "46f78cd2-c7c3-4138-bdfc-ba91d6eb1f91", "embedding": null, "metadata": {"window": "This increase was driven \nby growth in both at -Home Solutions and Global Medical Products and Distribution, with the GMPD \ngrowth primarily related to higher Cardinal Health Brand volumes.  \n \n Medical delivered segment profit of $71 million, a $54 million year -over-year increase, driven by an \nimprovement in net inflationary impacts, including our mitigation initiatives.  \n \n Consistent with the expectations communicated a few weeks ago, segment profit was \u2019generally \nconsistent\u2019 with Q1, despite some non -recurring adjustments in the quarter.  We continue to be \nencouraged by the underlying performance of the business, which throu gh the first two quarters of the \nyear, has tracked consistent with our original plans.  \n \n Now, turning to the balance sheet . \n \n We generated robust adjusted free cash flow of $1  billion  in Q2, bringing our year -to-date adjusted \nfree cash flow to $2  billion , and as I noted earlier, ended the quarter with $4.6 billion of cash on hand.  \n \n We remain focused on doing what we said we would, deploying capital according to our disciplined \ncapital allocation framework.  \n \n", "original_text": "We continue to be \nencouraged by the underlying performance of the business, which throu gh the first two quarters of the \nyear, has tracked consistent with our original plans.  \n \n", "page_label": "4", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "51bcdcef-b372-404b-848b-774d2abd5d5e", "node_type": "4", "metadata": {"page_label": "4", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "bd01f15c5527440c508d2605336d5f3491f12c6e1d25f19b4e5680375c034961", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "9e2a6610-8446-42d7-8a65-c4259a34cc69", "node_type": "1", "metadata": {"window": "Second quarter revenue increased 3% to $3.9 billion, which as Jason alluded to, reflects quarterly \nrevenue growth for the Medical segment for the first time in over two years.  This increase was driven \nby growth in both at -Home Solutions and Global Medical Products and Distribution, with the GMPD \ngrowth primarily related to higher Cardinal Health Brand volumes.  \n \n Medical delivered segment profit of $71 million, a $54 million year -over-year increase, driven by an \nimprovement in net inflationary impacts, including our mitigation initiatives.  \n \n Consistent with the expectations communicated a few weeks ago, segment profit was \u2019generally \nconsistent\u2019 with Q1, despite some non -recurring adjustments in the quarter.  We continue to be \nencouraged by the underlying performance of the business, which throu gh the first two quarters of the \nyear, has tracked consistent with our original plans.  \n \n Now, turning to the balance sheet . \n \n We generated robust adjusted free cash flow of $1  billion  in Q2, bringing our year -to-date adjusted \nfree cash flow to $2  billion , and as I noted earlier, ended the quarter with $4.6 billion of cash on hand.  \n \n", "original_text": "Consistent with the expectations communicated a few weeks ago, segment profit was \u2019generally \nconsistent\u2019 with Q1, despite some non -recurring adjustments in the quarter. ", "page_label": "4", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "c8b2d908a14475abd3bd0d8d098dc0361833cb234f0d54c2b021e2a4633bb71c", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "e925b52e-478e-4246-96fa-fd5a30ca965a", "node_type": "1", "metadata": {"window": "Medical delivered segment profit of $71 million, a $54 million year -over-year increase, driven by an \nimprovement in net inflationary impacts, including our mitigation initiatives.  \n \n Consistent with the expectations communicated a few weeks ago, segment profit was \u2019generally \nconsistent\u2019 with Q1, despite some non -recurring adjustments in the quarter.  We continue to be \nencouraged by the underlying performance of the business, which throu gh the first two quarters of the \nyear, has tracked consistent with our original plans.  \n \n Now, turning to the balance sheet . \n \n We generated robust adjusted free cash flow of $1  billion  in Q2, bringing our year -to-date adjusted \nfree cash flow to $2  billion , and as I noted earlier, ended the quarter with $4.6 billion of cash on hand.  \n \n We remain focused on doing what we said we would, deploying capital according to our disciplined \ncapital allocation framework.  \n \n Thus far, through the first half of fiscal \u201824 we\u2019ve continued to invest against our highest priorities, \nincluding investing back into the businesses to drive organic growth, with over $200 million in year -to-\ndate capex.  \n \n", "original_text": "Now, turning to the balance sheet . \n \n"}, "hash": "64a766529b28d1d67fef6a3f1c4c1ed7880a763309556711c21397e081a38bb0", "class_name": "RelatedNodeInfo"}}, "text": "We continue to be \nencouraged by the underlying performance of the business, which throu gh the first two quarters of the \nyear, has tracked consistent with our original plans.  \n \n", "start_char_idx": 1182, "end_char_idx": 1363, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "e925b52e-478e-4246-96fa-fd5a30ca965a": {"__data__": {"id_": "e925b52e-478e-4246-96fa-fd5a30ca965a", "embedding": null, "metadata": {"window": "Medical delivered segment profit of $71 million, a $54 million year -over-year increase, driven by an \nimprovement in net inflationary impacts, including our mitigation initiatives.  \n \n Consistent with the expectations communicated a few weeks ago, segment profit was \u2019generally \nconsistent\u2019 with Q1, despite some non -recurring adjustments in the quarter.  We continue to be \nencouraged by the underlying performance of the business, which throu gh the first two quarters of the \nyear, has tracked consistent with our original plans.  \n \n Now, turning to the balance sheet . \n \n We generated robust adjusted free cash flow of $1  billion  in Q2, bringing our year -to-date adjusted \nfree cash flow to $2  billion , and as I noted earlier, ended the quarter with $4.6 billion of cash on hand.  \n \n We remain focused on doing what we said we would, deploying capital according to our disciplined \ncapital allocation framework.  \n \n Thus far, through the first half of fiscal \u201824 we\u2019ve continued to invest against our highest priorities, \nincluding investing back into the businesses to drive organic growth, with over $200 million in year -to-\ndate capex.  \n \n", "original_text": "Now, turning to the balance sheet . \n \n", "page_label": "4", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "51bcdcef-b372-404b-848b-774d2abd5d5e", "node_type": "4", "metadata": {"page_label": "4", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "bd01f15c5527440c508d2605336d5f3491f12c6e1d25f19b4e5680375c034961", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "46f78cd2-c7c3-4138-bdfc-ba91d6eb1f91", "node_type": "1", "metadata": {"window": "This increase was driven \nby growth in both at -Home Solutions and Global Medical Products and Distribution, with the GMPD \ngrowth primarily related to higher Cardinal Health Brand volumes.  \n \n Medical delivered segment profit of $71 million, a $54 million year -over-year increase, driven by an \nimprovement in net inflationary impacts, including our mitigation initiatives.  \n \n Consistent with the expectations communicated a few weeks ago, segment profit was \u2019generally \nconsistent\u2019 with Q1, despite some non -recurring adjustments in the quarter.  We continue to be \nencouraged by the underlying performance of the business, which throu gh the first two quarters of the \nyear, has tracked consistent with our original plans.  \n \n Now, turning to the balance sheet . \n \n We generated robust adjusted free cash flow of $1  billion  in Q2, bringing our year -to-date adjusted \nfree cash flow to $2  billion , and as I noted earlier, ended the quarter with $4.6 billion of cash on hand.  \n \n We remain focused on doing what we said we would, deploying capital according to our disciplined \ncapital allocation framework.  \n \n", "original_text": "We continue to be \nencouraged by the underlying performance of the business, which throu gh the first two quarters of the \nyear, has tracked consistent with our original plans.  \n \n", "page_label": "4", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "2343c6e995b820f1fccba2f0ec8214471d8ef833cc0531f4760d1e843082d98b", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "100fe8a3-fb7d-4c06-b8ac-0001a8df6441", "node_type": "1", "metadata": {"window": "Consistent with the expectations communicated a few weeks ago, segment profit was \u2019generally \nconsistent\u2019 with Q1, despite some non -recurring adjustments in the quarter.  We continue to be \nencouraged by the underlying performance of the business, which throu gh the first two quarters of the \nyear, has tracked consistent with our original plans.  \n \n Now, turning to the balance sheet . \n \n We generated robust adjusted free cash flow of $1  billion  in Q2, bringing our year -to-date adjusted \nfree cash flow to $2  billion , and as I noted earlier, ended the quarter with $4.6 billion of cash on hand.  \n \n We remain focused on doing what we said we would, deploying capital according to our disciplined \ncapital allocation framework.  \n \n Thus far, through the first half of fiscal \u201824 we\u2019ve continued to invest against our highest priorities, \nincluding investing back into the businesses to drive organic growth, with over $200 million in year -to-\ndate capex.  \n \n In the first half, we have returned $1  billion  total to shareholders, which includes our quarterly \ndividend payments and $750 million in year -to-date share repurchases. ", "original_text": "We generated robust adjusted free cash flow of $1  billion  in Q2, bringing our year -to-date adjusted \nfree cash flow to $2  billion , and as I noted earlier, ended the quarter with $4.6 billion of cash on hand.  \n \n"}, "hash": "758a523ee6feb730a3b54bba86df162bc882200a253cf0f9b9005a76557882bf", "class_name": "RelatedNodeInfo"}}, "text": "Now, turning to the balance sheet . \n \n", "start_char_idx": 1363, "end_char_idx": 1402, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "100fe8a3-fb7d-4c06-b8ac-0001a8df6441": {"__data__": {"id_": "100fe8a3-fb7d-4c06-b8ac-0001a8df6441", "embedding": null, "metadata": {"window": "Consistent with the expectations communicated a few weeks ago, segment profit was \u2019generally \nconsistent\u2019 with Q1, despite some non -recurring adjustments in the quarter.  We continue to be \nencouraged by the underlying performance of the business, which throu gh the first two quarters of the \nyear, has tracked consistent with our original plans.  \n \n Now, turning to the balance sheet . \n \n We generated robust adjusted free cash flow of $1  billion  in Q2, bringing our year -to-date adjusted \nfree cash flow to $2  billion , and as I noted earlier, ended the quarter with $4.6 billion of cash on hand.  \n \n We remain focused on doing what we said we would, deploying capital according to our disciplined \ncapital allocation framework.  \n \n Thus far, through the first half of fiscal \u201824 we\u2019ve continued to invest against our highest priorities, \nincluding investing back into the businesses to drive organic growth, with over $200 million in year -to-\ndate capex.  \n \n In the first half, we have returned $1  billion  total to shareholders, which includes our quarterly \ndividend payments and $750 million in year -to-date share repurchases. ", "original_text": "We generated robust adjusted free cash flow of $1  billion  in Q2, bringing our year -to-date adjusted \nfree cash flow to $2  billion , and as I noted earlier, ended the quarter with $4.6 billion of cash on hand.  \n \n", "page_label": "4", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "51bcdcef-b372-404b-848b-774d2abd5d5e", "node_type": "4", "metadata": {"page_label": "4", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "bd01f15c5527440c508d2605336d5f3491f12c6e1d25f19b4e5680375c034961", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "e925b52e-478e-4246-96fa-fd5a30ca965a", "node_type": "1", "metadata": {"window": "Medical delivered segment profit of $71 million, a $54 million year -over-year increase, driven by an \nimprovement in net inflationary impacts, including our mitigation initiatives.  \n \n Consistent with the expectations communicated a few weeks ago, segment profit was \u2019generally \nconsistent\u2019 with Q1, despite some non -recurring adjustments in the quarter.  We continue to be \nencouraged by the underlying performance of the business, which throu gh the first two quarters of the \nyear, has tracked consistent with our original plans.  \n \n Now, turning to the balance sheet . \n \n We generated robust adjusted free cash flow of $1  billion  in Q2, bringing our year -to-date adjusted \nfree cash flow to $2  billion , and as I noted earlier, ended the quarter with $4.6 billion of cash on hand.  \n \n We remain focused on doing what we said we would, deploying capital according to our disciplined \ncapital allocation framework.  \n \n Thus far, through the first half of fiscal \u201824 we\u2019ve continued to invest against our highest priorities, \nincluding investing back into the businesses to drive organic growth, with over $200 million in year -to-\ndate capex.  \n \n", "original_text": "Now, turning to the balance sheet . \n \n", "page_label": "4", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "7d00260477e323e802bc4fb3932067b342dafbc5db3c5e04ae15d6b4e410d700", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "fdd8b160-64c4-4ecc-b50a-6e8a9cae9229", "node_type": "1", "metadata": {"window": "We continue to be \nencouraged by the underlying performance of the business, which throu gh the first two quarters of the \nyear, has tracked consistent with our original plans.  \n \n Now, turning to the balance sheet . \n \n We generated robust adjusted free cash flow of $1  billion  in Q2, bringing our year -to-date adjusted \nfree cash flow to $2  billion , and as I noted earlier, ended the quarter with $4.6 billion of cash on hand.  \n \n We remain focused on doing what we said we would, deploying capital according to our disciplined \ncapital allocation framework.  \n \n Thus far, through the first half of fiscal \u201824 we\u2019ve continued to invest against our highest priorities, \nincluding investing back into the businesses to drive organic growth, with over $200 million in year -to-\ndate capex.  \n \n In the first half, we have returned $1  billion  total to shareholders, which includes our quarterly \ndividend payments and $750 million in year -to-date share repurchases.  These share repurchases are \nin excess of our committed baseline repurchases of $500 million.  \n \n", "original_text": "We remain focused on doing what we said we would, deploying capital according to our disciplined \ncapital allocation framework.  \n \n"}, "hash": "5426f4ac997efedb83d94ae4db7b8f2f084e2cbc7436515552447934297ef382", "class_name": "RelatedNodeInfo"}}, "text": "We generated robust adjusted free cash flow of $1  billion  in Q2, bringing our year -to-date adjusted \nfree cash flow to $2  billion , and as I noted earlier, ended the quarter with $4.6 billion of cash on hand.  \n \n", "start_char_idx": 1402, "end_char_idx": 1619, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "fdd8b160-64c4-4ecc-b50a-6e8a9cae9229": {"__data__": {"id_": "fdd8b160-64c4-4ecc-b50a-6e8a9cae9229", "embedding": null, "metadata": {"window": "We continue to be \nencouraged by the underlying performance of the business, which throu gh the first two quarters of the \nyear, has tracked consistent with our original plans.  \n \n Now, turning to the balance sheet . \n \n We generated robust adjusted free cash flow of $1  billion  in Q2, bringing our year -to-date adjusted \nfree cash flow to $2  billion , and as I noted earlier, ended the quarter with $4.6 billion of cash on hand.  \n \n We remain focused on doing what we said we would, deploying capital according to our disciplined \ncapital allocation framework.  \n \n Thus far, through the first half of fiscal \u201824 we\u2019ve continued to invest against our highest priorities, \nincluding investing back into the businesses to drive organic growth, with over $200 million in year -to-\ndate capex.  \n \n In the first half, we have returned $1  billion  total to shareholders, which includes our quarterly \ndividend payments and $750 million in year -to-date share repurchases.  These share repurchases are \nin excess of our committed baseline repurchases of $500 million.  \n \n", "original_text": "We remain focused on doing what we said we would, deploying capital according to our disciplined \ncapital allocation framework.  \n \n", "page_label": "4", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "51bcdcef-b372-404b-848b-774d2abd5d5e", "node_type": "4", "metadata": {"page_label": "4", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "bd01f15c5527440c508d2605336d5f3491f12c6e1d25f19b4e5680375c034961", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "100fe8a3-fb7d-4c06-b8ac-0001a8df6441", "node_type": "1", "metadata": {"window": "Consistent with the expectations communicated a few weeks ago, segment profit was \u2019generally \nconsistent\u2019 with Q1, despite some non -recurring adjustments in the quarter.  We continue to be \nencouraged by the underlying performance of the business, which throu gh the first two quarters of the \nyear, has tracked consistent with our original plans.  \n \n Now, turning to the balance sheet . \n \n We generated robust adjusted free cash flow of $1  billion  in Q2, bringing our year -to-date adjusted \nfree cash flow to $2  billion , and as I noted earlier, ended the quarter with $4.6 billion of cash on hand.  \n \n We remain focused on doing what we said we would, deploying capital according to our disciplined \ncapital allocation framework.  \n \n Thus far, through the first half of fiscal \u201824 we\u2019ve continued to invest against our highest priorities, \nincluding investing back into the businesses to drive organic growth, with over $200 million in year -to-\ndate capex.  \n \n In the first half, we have returned $1  billion  total to shareholders, which includes our quarterly \ndividend payments and $750 million in year -to-date share repurchases. ", "original_text": "We generated robust adjusted free cash flow of $1  billion  in Q2, bringing our year -to-date adjusted \nfree cash flow to $2  billion , and as I noted earlier, ended the quarter with $4.6 billion of cash on hand.  \n \n", "page_label": "4", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "b659eeebfd276ba16f4bf0382c86f16720a76bc6bf1da868b17ef4ad746a4643", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "7ce4eff2-694d-4a81-9819-a222670a7016", "node_type": "1", "metadata": {"window": "Now, turning to the balance sheet . \n \n We generated robust adjusted free cash flow of $1  billion  in Q2, bringing our year -to-date adjusted \nfree cash flow to $2  billion , and as I noted earlier, ended the quarter with $4.6 billion of cash on hand.  \n \n We remain focused on doing what we said we would, deploying capital according to our disciplined \ncapital allocation framework.  \n \n Thus far, through the first half of fiscal \u201824 we\u2019ve continued to invest against our highest priorities, \nincluding investing back into the businesses to drive organic growth, with over $200 million in year -to-\ndate capex.  \n \n In the first half, we have returned $1  billion  total to shareholders, which includes our quarterly \ndividend payments and $750 million in year -to-date share repurchases.  These share repurchases are \nin excess of our committed baseline repurchases of $500 million.  \n \n And in January we made certain opioid settlement prepayments of $238 million at a pre -negotiated \ndiscount, which is expected to result in a GAAP -only gain of approximately $100 million in the third \nquarter.  \n \n", "original_text": "Thus far, through the first half of fiscal \u201824 we\u2019ve continued to invest against our highest priorities, \nincluding investing back into the businesses to drive organic growth, with over $200 million in year -to-\ndate capex.  \n \n"}, "hash": "7069630285ab7eb7f398330aaa68039ffb5031178b476d697ef0e807a4b6948c", "class_name": "RelatedNodeInfo"}}, "text": "We remain focused on doing what we said we would, deploying capital according to our disciplined \ncapital allocation framework.  \n \n", "start_char_idx": 1619, "end_char_idx": 1751, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "7ce4eff2-694d-4a81-9819-a222670a7016": {"__data__": {"id_": "7ce4eff2-694d-4a81-9819-a222670a7016", "embedding": null, "metadata": {"window": "Now, turning to the balance sheet . \n \n We generated robust adjusted free cash flow of $1  billion  in Q2, bringing our year -to-date adjusted \nfree cash flow to $2  billion , and as I noted earlier, ended the quarter with $4.6 billion of cash on hand.  \n \n We remain focused on doing what we said we would, deploying capital according to our disciplined \ncapital allocation framework.  \n \n Thus far, through the first half of fiscal \u201824 we\u2019ve continued to invest against our highest priorities, \nincluding investing back into the businesses to drive organic growth, with over $200 million in year -to-\ndate capex.  \n \n In the first half, we have returned $1  billion  total to shareholders, which includes our quarterly \ndividend payments and $750 million in year -to-date share repurchases.  These share repurchases are \nin excess of our committed baseline repurchases of $500 million.  \n \n And in January we made certain opioid settlement prepayments of $238 million at a pre -negotiated \ndiscount, which is expected to result in a GAAP -only gain of approximately $100 million in the third \nquarter.  \n \n", "original_text": "Thus far, through the first half of fiscal \u201824 we\u2019ve continued to invest against our highest priorities, \nincluding investing back into the businesses to drive organic growth, with over $200 million in year -to-\ndate capex.  \n \n", "page_label": "4", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "51bcdcef-b372-404b-848b-774d2abd5d5e", "node_type": "4", "metadata": {"page_label": "4", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "bd01f15c5527440c508d2605336d5f3491f12c6e1d25f19b4e5680375c034961", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "fdd8b160-64c4-4ecc-b50a-6e8a9cae9229", "node_type": "1", "metadata": {"window": "We continue to be \nencouraged by the underlying performance of the business, which throu gh the first two quarters of the \nyear, has tracked consistent with our original plans.  \n \n Now, turning to the balance sheet . \n \n We generated robust adjusted free cash flow of $1  billion  in Q2, bringing our year -to-date adjusted \nfree cash flow to $2  billion , and as I noted earlier, ended the quarter with $4.6 billion of cash on hand.  \n \n We remain focused on doing what we said we would, deploying capital according to our disciplined \ncapital allocation framework.  \n \n Thus far, through the first half of fiscal \u201824 we\u2019ve continued to invest against our highest priorities, \nincluding investing back into the businesses to drive organic growth, with over $200 million in year -to-\ndate capex.  \n \n In the first half, we have returned $1  billion  total to shareholders, which includes our quarterly \ndividend payments and $750 million in year -to-date share repurchases.  These share repurchases are \nin excess of our committed baseline repurchases of $500 million.  \n \n", "original_text": "We remain focused on doing what we said we would, deploying capital according to our disciplined \ncapital allocation framework.  \n \n", "page_label": "4", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "81a3380f3969e73975b4832b5282ebc31aca4c4b86127017f66bac0c2d77db39", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "142bb824-5ad1-4276-8bec-90b909ce04a4", "node_type": "1", "metadata": {"window": "We generated robust adjusted free cash flow of $1  billion  in Q2, bringing our year -to-date adjusted \nfree cash flow to $2  billion , and as I noted earlier, ended the quarter with $4.6 billion of cash on hand.  \n \n We remain focused on doing what we said we would, deploying capital according to our disciplined \ncapital allocation framework.  \n \n Thus far, through the first half of fiscal \u201824 we\u2019ve continued to invest against our highest priorities, \nincluding investing back into the businesses to drive organic growth, with over $200 million in year -to-\ndate capex.  \n \n In the first half, we have returned $1  billion  total to shareholders, which includes our quarterly \ndividend payments and $750 million in year -to-date share repurchases.  These share repurchases are \nin excess of our committed baseline repurchases of $500 million.  \n \n And in January we made certain opioid settlement prepayments of $238 million at a pre -negotiated \ndiscount, which is expected to result in a GAAP -only gain of approximately $100 million in the third \nquarter.  \n \n Now, for our updated fiscal \u201824 guidance on slide 8, beginning with the enterprise . \n ", "original_text": "In the first half, we have returned $1  billion  total to shareholders, which includes our quarterly \ndividend payments and $750 million in year -to-date share repurchases. "}, "hash": "b650676efe1c643717f92cfffa7671ed42e9245fa2be5e6b6d3f573253a8f3e2", "class_name": "RelatedNodeInfo"}}, "text": "Thus far, through the first half of fiscal \u201824 we\u2019ve continued to invest against our highest priorities, \nincluding investing back into the businesses to drive organic growth, with over $200 million in year -to-\ndate capex.  \n \n", "start_char_idx": 1751, "end_char_idx": 1979, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "142bb824-5ad1-4276-8bec-90b909ce04a4": {"__data__": {"id_": "142bb824-5ad1-4276-8bec-90b909ce04a4", "embedding": null, "metadata": {"window": "We generated robust adjusted free cash flow of $1  billion  in Q2, bringing our year -to-date adjusted \nfree cash flow to $2  billion , and as I noted earlier, ended the quarter with $4.6 billion of cash on hand.  \n \n We remain focused on doing what we said we would, deploying capital according to our disciplined \ncapital allocation framework.  \n \n Thus far, through the first half of fiscal \u201824 we\u2019ve continued to invest against our highest priorities, \nincluding investing back into the businesses to drive organic growth, with over $200 million in year -to-\ndate capex.  \n \n In the first half, we have returned $1  billion  total to shareholders, which includes our quarterly \ndividend payments and $750 million in year -to-date share repurchases.  These share repurchases are \nin excess of our committed baseline repurchases of $500 million.  \n \n And in January we made certain opioid settlement prepayments of $238 million at a pre -negotiated \ndiscount, which is expected to result in a GAAP -only gain of approximately $100 million in the third \nquarter.  \n \n Now, for our updated fiscal \u201824 guidance on slide 8, beginning with the enterprise . \n ", "original_text": "In the first half, we have returned $1  billion  total to shareholders, which includes our quarterly \ndividend payments and $750 million in year -to-date share repurchases. ", "page_label": "4", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "51bcdcef-b372-404b-848b-774d2abd5d5e", "node_type": "4", "metadata": {"page_label": "4", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "bd01f15c5527440c508d2605336d5f3491f12c6e1d25f19b4e5680375c034961", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "7ce4eff2-694d-4a81-9819-a222670a7016", "node_type": "1", "metadata": {"window": "Now, turning to the balance sheet . \n \n We generated robust adjusted free cash flow of $1  billion  in Q2, bringing our year -to-date adjusted \nfree cash flow to $2  billion , and as I noted earlier, ended the quarter with $4.6 billion of cash on hand.  \n \n We remain focused on doing what we said we would, deploying capital according to our disciplined \ncapital allocation framework.  \n \n Thus far, through the first half of fiscal \u201824 we\u2019ve continued to invest against our highest priorities, \nincluding investing back into the businesses to drive organic growth, with over $200 million in year -to-\ndate capex.  \n \n In the first half, we have returned $1  billion  total to shareholders, which includes our quarterly \ndividend payments and $750 million in year -to-date share repurchases.  These share repurchases are \nin excess of our committed baseline repurchases of $500 million.  \n \n And in January we made certain opioid settlement prepayments of $238 million at a pre -negotiated \ndiscount, which is expected to result in a GAAP -only gain of approximately $100 million in the third \nquarter.  \n \n", "original_text": "Thus far, through the first half of fiscal \u201824 we\u2019ve continued to invest against our highest priorities, \nincluding investing back into the businesses to drive organic growth, with over $200 million in year -to-\ndate capex.  \n \n", "page_label": "4", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "e1b4584a1fff67b82341f2a5c4b690ae038b0bfcdf0d41a38e14ca7fc86d99b2", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "8cf35c63-710f-4195-9cd1-f5b72a74a031", "node_type": "1", "metadata": {"window": "We remain focused on doing what we said we would, deploying capital according to our disciplined \ncapital allocation framework.  \n \n Thus far, through the first half of fiscal \u201824 we\u2019ve continued to invest against our highest priorities, \nincluding investing back into the businesses to drive organic growth, with over $200 million in year -to-\ndate capex.  \n \n In the first half, we have returned $1  billion  total to shareholders, which includes our quarterly \ndividend payments and $750 million in year -to-date share repurchases.  These share repurchases are \nin excess of our committed baseline repurchases of $500 million.  \n \n And in January we made certain opioid settlement prepayments of $238 million at a pre -negotiated \ndiscount, which is expected to result in a GAAP -only gain of approximately $100 million in the third \nquarter.  \n \n Now, for our updated fiscal \u201824 guidance on slide 8, beginning with the enterprise . \n ", "original_text": "These share repurchases are \nin excess of our committed baseline repurchases of $500 million.  \n \n"}, "hash": "9308d61901834cd7d9ec087e2408e4c78ae874c8807a50ad018933f9bf06099e", "class_name": "RelatedNodeInfo"}}, "text": "In the first half, we have returned $1  billion  total to shareholders, which includes our quarterly \ndividend payments and $750 million in year -to-date share repurchases. ", "start_char_idx": 1979, "end_char_idx": 2152, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "8cf35c63-710f-4195-9cd1-f5b72a74a031": {"__data__": {"id_": "8cf35c63-710f-4195-9cd1-f5b72a74a031", "embedding": null, "metadata": {"window": "We remain focused on doing what we said we would, deploying capital according to our disciplined \ncapital allocation framework.  \n \n Thus far, through the first half of fiscal \u201824 we\u2019ve continued to invest against our highest priorities, \nincluding investing back into the businesses to drive organic growth, with over $200 million in year -to-\ndate capex.  \n \n In the first half, we have returned $1  billion  total to shareholders, which includes our quarterly \ndividend payments and $750 million in year -to-date share repurchases.  These share repurchases are \nin excess of our committed baseline repurchases of $500 million.  \n \n And in January we made certain opioid settlement prepayments of $238 million at a pre -negotiated \ndiscount, which is expected to result in a GAAP -only gain of approximately $100 million in the third \nquarter.  \n \n Now, for our updated fiscal \u201824 guidance on slide 8, beginning with the enterprise . \n ", "original_text": "These share repurchases are \nin excess of our committed baseline repurchases of $500 million.  \n \n", "page_label": "4", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "51bcdcef-b372-404b-848b-774d2abd5d5e", "node_type": "4", "metadata": {"page_label": "4", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "bd01f15c5527440c508d2605336d5f3491f12c6e1d25f19b4e5680375c034961", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "142bb824-5ad1-4276-8bec-90b909ce04a4", "node_type": "1", "metadata": {"window": "We generated robust adjusted free cash flow of $1  billion  in Q2, bringing our year -to-date adjusted \nfree cash flow to $2  billion , and as I noted earlier, ended the quarter with $4.6 billion of cash on hand.  \n \n We remain focused on doing what we said we would, deploying capital according to our disciplined \ncapital allocation framework.  \n \n Thus far, through the first half of fiscal \u201824 we\u2019ve continued to invest against our highest priorities, \nincluding investing back into the businesses to drive organic growth, with over $200 million in year -to-\ndate capex.  \n \n In the first half, we have returned $1  billion  total to shareholders, which includes our quarterly \ndividend payments and $750 million in year -to-date share repurchases.  These share repurchases are \nin excess of our committed baseline repurchases of $500 million.  \n \n And in January we made certain opioid settlement prepayments of $238 million at a pre -negotiated \ndiscount, which is expected to result in a GAAP -only gain of approximately $100 million in the third \nquarter.  \n \n Now, for our updated fiscal \u201824 guidance on slide 8, beginning with the enterprise . \n ", "original_text": "In the first half, we have returned $1  billion  total to shareholders, which includes our quarterly \ndividend payments and $750 million in year -to-date share repurchases. ", "page_label": "4", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "4a60a27a3e0b9f31d64a237d27523a6ba9c41897784c2f0b52e4dea7c264af4b", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "fc9cd0e3-9257-436b-8135-16618a3f52c2", "node_type": "1", "metadata": {"window": "Thus far, through the first half of fiscal \u201824 we\u2019ve continued to invest against our highest priorities, \nincluding investing back into the businesses to drive organic growth, with over $200 million in year -to-\ndate capex.  \n \n In the first half, we have returned $1  billion  total to shareholders, which includes our quarterly \ndividend payments and $750 million in year -to-date share repurchases.  These share repurchases are \nin excess of our committed baseline repurchases of $500 million.  \n \n And in January we made certain opioid settlement prepayments of $238 million at a pre -negotiated \ndiscount, which is expected to result in a GAAP -only gain of approximately $100 million in the third \nquarter.  \n \n Now, for our updated fiscal \u201824 guidance on slide 8, beginning with the enterprise . \n ", "original_text": "And in January we made certain opioid settlement prepayments of $238 million at a pre -negotiated \ndiscount, which is expected to result in a GAAP -only gain of approximately $100 million in the third \nquarter.  \n \n"}, "hash": "2b70db94796a82fcfb3ace7a3d155a7e0c7206264ece81c2fe45e86e638c3a6d", "class_name": "RelatedNodeInfo"}}, "text": "These share repurchases are \nin excess of our committed baseline repurchases of $500 million.  \n \n", "start_char_idx": 2152, "end_char_idx": 2250, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "fc9cd0e3-9257-436b-8135-16618a3f52c2": {"__data__": {"id_": "fc9cd0e3-9257-436b-8135-16618a3f52c2", "embedding": null, "metadata": {"window": "Thus far, through the first half of fiscal \u201824 we\u2019ve continued to invest against our highest priorities, \nincluding investing back into the businesses to drive organic growth, with over $200 million in year -to-\ndate capex.  \n \n In the first half, we have returned $1  billion  total to shareholders, which includes our quarterly \ndividend payments and $750 million in year -to-date share repurchases.  These share repurchases are \nin excess of our committed baseline repurchases of $500 million.  \n \n And in January we made certain opioid settlement prepayments of $238 million at a pre -negotiated \ndiscount, which is expected to result in a GAAP -only gain of approximately $100 million in the third \nquarter.  \n \n Now, for our updated fiscal \u201824 guidance on slide 8, beginning with the enterprise . \n ", "original_text": "And in January we made certain opioid settlement prepayments of $238 million at a pre -negotiated \ndiscount, which is expected to result in a GAAP -only gain of approximately $100 million in the third \nquarter.  \n \n", "page_label": "4", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "51bcdcef-b372-404b-848b-774d2abd5d5e", "node_type": "4", "metadata": {"page_label": "4", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "bd01f15c5527440c508d2605336d5f3491f12c6e1d25f19b4e5680375c034961", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "8cf35c63-710f-4195-9cd1-f5b72a74a031", "node_type": "1", "metadata": {"window": "We remain focused on doing what we said we would, deploying capital according to our disciplined \ncapital allocation framework.  \n \n Thus far, through the first half of fiscal \u201824 we\u2019ve continued to invest against our highest priorities, \nincluding investing back into the businesses to drive organic growth, with over $200 million in year -to-\ndate capex.  \n \n In the first half, we have returned $1  billion  total to shareholders, which includes our quarterly \ndividend payments and $750 million in year -to-date share repurchases.  These share repurchases are \nin excess of our committed baseline repurchases of $500 million.  \n \n And in January we made certain opioid settlement prepayments of $238 million at a pre -negotiated \ndiscount, which is expected to result in a GAAP -only gain of approximately $100 million in the third \nquarter.  \n \n Now, for our updated fiscal \u201824 guidance on slide 8, beginning with the enterprise . \n ", "original_text": "These share repurchases are \nin excess of our committed baseline repurchases of $500 million.  \n \n", "page_label": "4", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "96d7f33421bd0a5e22646f34eb3792dd8d5e36e6407493c11268b506ffcd36a0", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "6cd6e370-3396-4492-94e7-eea8f8d3b7a8", "node_type": "1", "metadata": {"window": "In the first half, we have returned $1  billion  total to shareholders, which includes our quarterly \ndividend payments and $750 million in year -to-date share repurchases.  These share repurchases are \nin excess of our committed baseline repurchases of $500 million.  \n \n And in January we made certain opioid settlement prepayments of $238 million at a pre -negotiated \ndiscount, which is expected to result in a GAAP -only gain of approximately $100 million in the third \nquarter.  \n \n Now, for our updated fiscal \u201824 guidance on slide 8, beginning with the enterprise . \n ", "original_text": "Now, for our updated fiscal \u201824 guidance on slide 8, beginning with the enterprise . \n "}, "hash": "54e749a2447170ba357075790cab8f351ef77ebc1673353893c1753ed735153c", "class_name": "RelatedNodeInfo"}}, "text": "And in January we made certain opioid settlement prepayments of $238 million at a pre -negotiated \ndiscount, which is expected to result in a GAAP -only gain of approximately $100 million in the third \nquarter.  \n \n", "start_char_idx": 2250, "end_char_idx": 2465, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "6cd6e370-3396-4492-94e7-eea8f8d3b7a8": {"__data__": {"id_": "6cd6e370-3396-4492-94e7-eea8f8d3b7a8", "embedding": null, "metadata": {"window": "In the first half, we have returned $1  billion  total to shareholders, which includes our quarterly \ndividend payments and $750 million in year -to-date share repurchases.  These share repurchases are \nin excess of our committed baseline repurchases of $500 million.  \n \n And in January we made certain opioid settlement prepayments of $238 million at a pre -negotiated \ndiscount, which is expected to result in a GAAP -only gain of approximately $100 million in the third \nquarter.  \n \n Now, for our updated fiscal \u201824 guidance on slide 8, beginning with the enterprise . \n ", "original_text": "Now, for our updated fiscal \u201824 guidance on slide 8, beginning with the enterprise . \n ", "page_label": "4", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "51bcdcef-b372-404b-848b-774d2abd5d5e", "node_type": "4", "metadata": {"page_label": "4", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "bd01f15c5527440c508d2605336d5f3491f12c6e1d25f19b4e5680375c034961", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "fc9cd0e3-9257-436b-8135-16618a3f52c2", "node_type": "1", "metadata": {"window": "Thus far, through the first half of fiscal \u201824 we\u2019ve continued to invest against our highest priorities, \nincluding investing back into the businesses to drive organic growth, with over $200 million in year -to-\ndate capex.  \n \n In the first half, we have returned $1  billion  total to shareholders, which includes our quarterly \ndividend payments and $750 million in year -to-date share repurchases.  These share repurchases are \nin excess of our committed baseline repurchases of $500 million.  \n \n And in January we made certain opioid settlement prepayments of $238 million at a pre -negotiated \ndiscount, which is expected to result in a GAAP -only gain of approximately $100 million in the third \nquarter.  \n \n Now, for our updated fiscal \u201824 guidance on slide 8, beginning with the enterprise . \n ", "original_text": "And in January we made certain opioid settlement prepayments of $238 million at a pre -negotiated \ndiscount, which is expected to result in a GAAP -only gain of approximately $100 million in the third \nquarter.  \n \n", "page_label": "4", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "03a0a7b8b9685346746731d3a4ab195f8e9c1184492dc67d764187704197e146", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "51447f56-c89d-426b-9ebb-f47b55070fb8", "node_type": "1", "metadata": {"window": " \nPage 5 of 19 \n \nWith our strong first half performance and positive outlook, we are again raising our fiscal \u2018 24 EPS \nguidance.  Our new range of $7.20 to $7.35 reflects a $0.45 increase at the bottom end and $0.35 \nincrease at the top end from our Q1 guidance range, and a mid -point which is 26% above our fiscal \n\u201823 EPS results.  We are encouraged by the operating performance of our businesses, and our strong \ncash flow generation, which is certainly contributing to the improvements below the line.  \n \n Interest and Other is reduced to a range of $50  million  to $65 million, which primarily reflects \nincreased interest income from higher -than-anticipated cash balances. ", "original_text": " \nPage 5 of 19 \n \nWith our strong first half performance and positive outlook, we are again raising our fiscal \u2018 24 EPS \nguidance. "}, "hash": "e3333f20b59079b3dd88be31392bc2448f6eaafd173a693b99ff47a3445c6a8b", "class_name": "RelatedNodeInfo"}}, "text": "Now, for our updated fiscal \u201824 guidance on slide 8, beginning with the enterprise . \n ", "start_char_idx": 2465, "end_char_idx": 2552, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "51447f56-c89d-426b-9ebb-f47b55070fb8": {"__data__": {"id_": "51447f56-c89d-426b-9ebb-f47b55070fb8", "embedding": null, "metadata": {"window": " \nPage 5 of 19 \n \nWith our strong first half performance and positive outlook, we are again raising our fiscal \u2018 24 EPS \nguidance.  Our new range of $7.20 to $7.35 reflects a $0.45 increase at the bottom end and $0.35 \nincrease at the top end from our Q1 guidance range, and a mid -point which is 26% above our fiscal \n\u201823 EPS results.  We are encouraged by the operating performance of our businesses, and our strong \ncash flow generation, which is certainly contributing to the improvements below the line.  \n \n Interest and Other is reduced to a range of $50  million  to $65 million, which primarily reflects \nincreased interest income from higher -than-anticipated cash balances. ", "original_text": " \nPage 5 of 19 \n \nWith our strong first half performance and positive outlook, we are again raising our fiscal \u2018 24 EPS \nguidance. ", "page_label": "5", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "62106fa2-0df0-4578-a53e-51fe39997eca", "node_type": "4", "metadata": {"page_label": "5", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "b770202d0f8dda4341d593cc59f6ec168a6c077e1794494b0e47e3483f1dd844", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "6cd6e370-3396-4492-94e7-eea8f8d3b7a8", "node_type": "1", "metadata": {"window": "In the first half, we have returned $1  billion  total to shareholders, which includes our quarterly \ndividend payments and $750 million in year -to-date share repurchases.  These share repurchases are \nin excess of our committed baseline repurchases of $500 million.  \n \n And in January we made certain opioid settlement prepayments of $238 million at a pre -negotiated \ndiscount, which is expected to result in a GAAP -only gain of approximately $100 million in the third \nquarter.  \n \n Now, for our updated fiscal \u201824 guidance on slide 8, beginning with the enterprise . \n ", "original_text": "Now, for our updated fiscal \u201824 guidance on slide 8, beginning with the enterprise . \n ", "page_label": "4", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "852149fc175d550c8d53d64bdec443cdc75907b3964c125b8d4fa8d9f18fcadf", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "3f9525f0-c979-46da-bc32-6d4316b606f0", "node_type": "1", "metadata": {"window": " \nPage 5 of 19 \n \nWith our strong first half performance and positive outlook, we are again raising our fiscal \u2018 24 EPS \nguidance.  Our new range of $7.20 to $7.35 reflects a $0.45 increase at the bottom end and $0.35 \nincrease at the top end from our Q1 guidance range, and a mid -point which is 26% above our fiscal \n\u201823 EPS results.  We are encouraged by the operating performance of our businesses, and our strong \ncash flow generation, which is certainly contributing to the improvements below the line.  \n \n Interest and Other is reduced to a range of $50  million  to $65 million, which primarily reflects \nincreased interest income from higher -than-anticipated cash balances.  We expect lower average \ncash balances in the second half of the year, due in part to the seasonal timing of anticipated cash \nflows. ", "original_text": "Our new range of $7.20 to $7.35 reflects a $0.45 increase at the bottom end and $0.35 \nincrease at the top end from our Q1 guidance range, and a mid -point which is 26% above our fiscal \n\u201823 EPS results. "}, "hash": "dc8cc37e6f2ab8a09f92f6b13a676692b3a020157eea58f41731e4486c029d09", "class_name": "RelatedNodeInfo"}}, "text": " \nPage 5 of 19 \n \nWith our strong first half performance and positive outlook, we are again raising our fiscal \u2018 24 EPS \nguidance. ", "start_char_idx": 0, "end_char_idx": 131, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "3f9525f0-c979-46da-bc32-6d4316b606f0": {"__data__": {"id_": "3f9525f0-c979-46da-bc32-6d4316b606f0", "embedding": null, "metadata": {"window": " \nPage 5 of 19 \n \nWith our strong first half performance and positive outlook, we are again raising our fiscal \u2018 24 EPS \nguidance.  Our new range of $7.20 to $7.35 reflects a $0.45 increase at the bottom end and $0.35 \nincrease at the top end from our Q1 guidance range, and a mid -point which is 26% above our fiscal \n\u201823 EPS results.  We are encouraged by the operating performance of our businesses, and our strong \ncash flow generation, which is certainly contributing to the improvements below the line.  \n \n Interest and Other is reduced to a range of $50  million  to $65 million, which primarily reflects \nincreased interest income from higher -than-anticipated cash balances.  We expect lower average \ncash balances in the second half of the year, due in part to the seasonal timing of anticipated cash \nflows. ", "original_text": "Our new range of $7.20 to $7.35 reflects a $0.45 increase at the bottom end and $0.35 \nincrease at the top end from our Q1 guidance range, and a mid -point which is 26% above our fiscal \n\u201823 EPS results. ", "page_label": "5", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "62106fa2-0df0-4578-a53e-51fe39997eca", "node_type": "4", "metadata": {"page_label": "5", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "b770202d0f8dda4341d593cc59f6ec168a6c077e1794494b0e47e3483f1dd844", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "51447f56-c89d-426b-9ebb-f47b55070fb8", "node_type": "1", "metadata": {"window": " \nPage 5 of 19 \n \nWith our strong first half performance and positive outlook, we are again raising our fiscal \u2018 24 EPS \nguidance.  Our new range of $7.20 to $7.35 reflects a $0.45 increase at the bottom end and $0.35 \nincrease at the top end from our Q1 guidance range, and a mid -point which is 26% above our fiscal \n\u201823 EPS results.  We are encouraged by the operating performance of our businesses, and our strong \ncash flow generation, which is certainly contributing to the improvements below the line.  \n \n Interest and Other is reduced to a range of $50  million  to $65 million, which primarily reflects \nincreased interest income from higher -than-anticipated cash balances. ", "original_text": " \nPage 5 of 19 \n \nWith our strong first half performance and positive outlook, we are again raising our fiscal \u2018 24 EPS \nguidance. ", "page_label": "5", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "0c91f072d7fdc47271bd4d2e3fa7c1d3e8dd76cb0d0a434b25c6cbdd5d2b663c", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "845b711d-e7c3-4266-a749-e55edef2018d", "node_type": "1", "metadata": {"window": " \nPage 5 of 19 \n \nWith our strong first half performance and positive outlook, we are again raising our fiscal \u2018 24 EPS \nguidance.  Our new range of $7.20 to $7.35 reflects a $0.45 increase at the bottom end and $0.35 \nincrease at the top end from our Q1 guidance range, and a mid -point which is 26% above our fiscal \n\u201823 EPS results.  We are encouraged by the operating performance of our businesses, and our strong \ncash flow generation, which is certainly contributing to the improvements below the line.  \n \n Interest and Other is reduced to a range of $50  million  to $65 million, which primarily reflects \nincreased interest income from higher -than-anticipated cash balances.  We expect lower average \ncash balances in the second half of the year, due in part to the seasonal timing of anticipated cash \nflows.  We are evalu ating opportunities to refinance our upcoming 2024 debt maturities in the back \nhalf of the year.  \n \n", "original_text": "We are encouraged by the operating performance of our businesses, and our strong \ncash flow generation, which is certainly contributing to the improvements below the line.  \n \n"}, "hash": "22c8a74c9ae6b2210bbda9d9c546c1a714f9845caf65bb800add2e6543fe8e9c", "class_name": "RelatedNodeInfo"}}, "text": "Our new range of $7.20 to $7.35 reflects a $0.45 increase at the bottom end and $0.35 \nincrease at the top end from our Q1 guidance range, and a mid -point which is 26% above our fiscal \n\u201823 EPS results. ", "start_char_idx": 131, "end_char_idx": 335, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "845b711d-e7c3-4266-a749-e55edef2018d": {"__data__": {"id_": "845b711d-e7c3-4266-a749-e55edef2018d", "embedding": null, "metadata": {"window": " \nPage 5 of 19 \n \nWith our strong first half performance and positive outlook, we are again raising our fiscal \u2018 24 EPS \nguidance.  Our new range of $7.20 to $7.35 reflects a $0.45 increase at the bottom end and $0.35 \nincrease at the top end from our Q1 guidance range, and a mid -point which is 26% above our fiscal \n\u201823 EPS results.  We are encouraged by the operating performance of our businesses, and our strong \ncash flow generation, which is certainly contributing to the improvements below the line.  \n \n Interest and Other is reduced to a range of $50  million  to $65 million, which primarily reflects \nincreased interest income from higher -than-anticipated cash balances.  We expect lower average \ncash balances in the second half of the year, due in part to the seasonal timing of anticipated cash \nflows.  We are evalu ating opportunities to refinance our upcoming 2024 debt maturities in the back \nhalf of the year.  \n \n", "original_text": "We are encouraged by the operating performance of our businesses, and our strong \ncash flow generation, which is certainly contributing to the improvements below the line.  \n \n", "page_label": "5", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "62106fa2-0df0-4578-a53e-51fe39997eca", "node_type": "4", "metadata": {"page_label": "5", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "b770202d0f8dda4341d593cc59f6ec168a6c077e1794494b0e47e3483f1dd844", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "3f9525f0-c979-46da-bc32-6d4316b606f0", "node_type": "1", "metadata": {"window": " \nPage 5 of 19 \n \nWith our strong first half performance and positive outlook, we are again raising our fiscal \u2018 24 EPS \nguidance.  Our new range of $7.20 to $7.35 reflects a $0.45 increase at the bottom end and $0.35 \nincrease at the top end from our Q1 guidance range, and a mid -point which is 26% above our fiscal \n\u201823 EPS results.  We are encouraged by the operating performance of our businesses, and our strong \ncash flow generation, which is certainly contributing to the improvements below the line.  \n \n Interest and Other is reduced to a range of $50  million  to $65 million, which primarily reflects \nincreased interest income from higher -than-anticipated cash balances.  We expect lower average \ncash balances in the second half of the year, due in part to the seasonal timing of anticipated cash \nflows. ", "original_text": "Our new range of $7.20 to $7.35 reflects a $0.45 increase at the bottom end and $0.35 \nincrease at the top end from our Q1 guidance range, and a mid -point which is 26% above our fiscal \n\u201823 EPS results. ", "page_label": "5", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "f9583e3adef90be40c7fdfe9d83942c429dee58273c5f7d37fdce363857b722f", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "50bbe4bf-3394-4964-b6e0-777e431d8be2", "node_type": "1", "metadata": {"window": " \nPage 5 of 19 \n \nWith our strong first half performance and positive outlook, we are again raising our fiscal \u2018 24 EPS \nguidance.  Our new range of $7.20 to $7.35 reflects a $0.45 increase at the bottom end and $0.35 \nincrease at the top end from our Q1 guidance range, and a mid -point which is 26% above our fiscal \n\u201823 EPS results.  We are encouraged by the operating performance of our businesses, and our strong \ncash flow generation, which is certainly contributing to the improvements below the line.  \n \n Interest and Other is reduced to a range of $50  million  to $65 million, which primarily reflects \nincreased interest income from higher -than-anticipated cash balances.  We expect lower average \ncash balances in the second half of the year, due in part to the seasonal timing of anticipated cash \nflows.  We are evalu ating opportunities to refinance our upcoming 2024 debt maturities in the back \nhalf of the year.  \n \n We are lowering the top end of our effective tax rate guidance to a new range of 23% to 24% to \nreflect the positive discrete items we\u2019ve seen in the first half of the year.  \n \n", "original_text": "Interest and Other is reduced to a range of $50  million  to $65 million, which primarily reflects \nincreased interest income from higher -than-anticipated cash balances. "}, "hash": "acaacf9318248ea169a4491a3c1c31ea68eca4d3fa88873681ccece2c91d313b", "class_name": "RelatedNodeInfo"}}, "text": "We are encouraged by the operating performance of our businesses, and our strong \ncash flow generation, which is certainly contributing to the improvements below the line.  \n \n", "start_char_idx": 335, "end_char_idx": 511, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "50bbe4bf-3394-4964-b6e0-777e431d8be2": {"__data__": {"id_": "50bbe4bf-3394-4964-b6e0-777e431d8be2", "embedding": null, "metadata": {"window": " \nPage 5 of 19 \n \nWith our strong first half performance and positive outlook, we are again raising our fiscal \u2018 24 EPS \nguidance.  Our new range of $7.20 to $7.35 reflects a $0.45 increase at the bottom end and $0.35 \nincrease at the top end from our Q1 guidance range, and a mid -point which is 26% above our fiscal \n\u201823 EPS results.  We are encouraged by the operating performance of our businesses, and our strong \ncash flow generation, which is certainly contributing to the improvements below the line.  \n \n Interest and Other is reduced to a range of $50  million  to $65 million, which primarily reflects \nincreased interest income from higher -than-anticipated cash balances.  We expect lower average \ncash balances in the second half of the year, due in part to the seasonal timing of anticipated cash \nflows.  We are evalu ating opportunities to refinance our upcoming 2024 debt maturities in the back \nhalf of the year.  \n \n We are lowering the top end of our effective tax rate guidance to a new range of 23% to 24% to \nreflect the positive discrete items we\u2019ve seen in the first half of the year.  \n \n", "original_text": "Interest and Other is reduced to a range of $50  million  to $65 million, which primarily reflects \nincreased interest income from higher -than-anticipated cash balances. ", "page_label": "5", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "62106fa2-0df0-4578-a53e-51fe39997eca", "node_type": "4", "metadata": {"page_label": "5", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "b770202d0f8dda4341d593cc59f6ec168a6c077e1794494b0e47e3483f1dd844", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "845b711d-e7c3-4266-a749-e55edef2018d", "node_type": "1", "metadata": {"window": " \nPage 5 of 19 \n \nWith our strong first half performance and positive outlook, we are again raising our fiscal \u2018 24 EPS \nguidance.  Our new range of $7.20 to $7.35 reflects a $0.45 increase at the bottom end and $0.35 \nincrease at the top end from our Q1 guidance range, and a mid -point which is 26% above our fiscal \n\u201823 EPS results.  We are encouraged by the operating performance of our businesses, and our strong \ncash flow generation, which is certainly contributing to the improvements below the line.  \n \n Interest and Other is reduced to a range of $50  million  to $65 million, which primarily reflects \nincreased interest income from higher -than-anticipated cash balances.  We expect lower average \ncash balances in the second half of the year, due in part to the seasonal timing of anticipated cash \nflows.  We are evalu ating opportunities to refinance our upcoming 2024 debt maturities in the back \nhalf of the year.  \n \n", "original_text": "We are encouraged by the operating performance of our businesses, and our strong \ncash flow generation, which is certainly contributing to the improvements below the line.  \n \n", "page_label": "5", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "ccdb0eec17e1cd844980854bf1fdc0a3781b89ab9c097b7afb0cba6e80af45eb", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "c3300713-1e8a-4a75-9a5c-5cd03f601d1b", "node_type": "1", "metadata": {"window": "Our new range of $7.20 to $7.35 reflects a $0.45 increase at the bottom end and $0.35 \nincrease at the top end from our Q1 guidance range, and a mid -point which is 26% above our fiscal \n\u201823 EPS results.  We are encouraged by the operating performance of our businesses, and our strong \ncash flow generation, which is certainly contributing to the improvements below the line.  \n \n Interest and Other is reduced to a range of $50  million  to $65 million, which primarily reflects \nincreased interest income from higher -than-anticipated cash balances.  We expect lower average \ncash balances in the second half of the year, due in part to the seasonal timing of anticipated cash \nflows.  We are evalu ating opportunities to refinance our upcoming 2024 debt maturities in the back \nhalf of the year.  \n \n We are lowering the top end of our effective tax rate guidance to a new range of 23% to 24% to \nreflect the positive discrete items we\u2019ve seen in the first half of the year.  \n \n We also are lowering our shares outlook to approximately 247 million, which reflects the $250  million  \naccelerated share repurchase program we completed in Q2. ", "original_text": "We expect lower average \ncash balances in the second half of the year, due in part to the seasonal timing of anticipated cash \nflows. "}, "hash": "6061b5db47dcae41a678ac738d265c6d74f5f2e9eaf0755a455e9631e716031b", "class_name": "RelatedNodeInfo"}}, "text": "Interest and Other is reduced to a range of $50  million  to $65 million, which primarily reflects \nincreased interest income from higher -than-anticipated cash balances. ", "start_char_idx": 511, "end_char_idx": 682, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "c3300713-1e8a-4a75-9a5c-5cd03f601d1b": {"__data__": {"id_": "c3300713-1e8a-4a75-9a5c-5cd03f601d1b", "embedding": null, "metadata": {"window": "Our new range of $7.20 to $7.35 reflects a $0.45 increase at the bottom end and $0.35 \nincrease at the top end from our Q1 guidance range, and a mid -point which is 26% above our fiscal \n\u201823 EPS results.  We are encouraged by the operating performance of our businesses, and our strong \ncash flow generation, which is certainly contributing to the improvements below the line.  \n \n Interest and Other is reduced to a range of $50  million  to $65 million, which primarily reflects \nincreased interest income from higher -than-anticipated cash balances.  We expect lower average \ncash balances in the second half of the year, due in part to the seasonal timing of anticipated cash \nflows.  We are evalu ating opportunities to refinance our upcoming 2024 debt maturities in the back \nhalf of the year.  \n \n We are lowering the top end of our effective tax rate guidance to a new range of 23% to 24% to \nreflect the positive discrete items we\u2019ve seen in the first half of the year.  \n \n We also are lowering our shares outlook to approximately 247 million, which reflects the $250  million  \naccelerated share repurchase program we completed in Q2. ", "original_text": "We expect lower average \ncash balances in the second half of the year, due in part to the seasonal timing of anticipated cash \nflows. ", "page_label": "5", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "62106fa2-0df0-4578-a53e-51fe39997eca", "node_type": "4", "metadata": {"page_label": "5", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "b770202d0f8dda4341d593cc59f6ec168a6c077e1794494b0e47e3483f1dd844", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "50bbe4bf-3394-4964-b6e0-777e431d8be2", "node_type": "1", "metadata": {"window": " \nPage 5 of 19 \n \nWith our strong first half performance and positive outlook, we are again raising our fiscal \u2018 24 EPS \nguidance.  Our new range of $7.20 to $7.35 reflects a $0.45 increase at the bottom end and $0.35 \nincrease at the top end from our Q1 guidance range, and a mid -point which is 26% above our fiscal \n\u201823 EPS results.  We are encouraged by the operating performance of our businesses, and our strong \ncash flow generation, which is certainly contributing to the improvements below the line.  \n \n Interest and Other is reduced to a range of $50  million  to $65 million, which primarily reflects \nincreased interest income from higher -than-anticipated cash balances.  We expect lower average \ncash balances in the second half of the year, due in part to the seasonal timing of anticipated cash \nflows.  We are evalu ating opportunities to refinance our upcoming 2024 debt maturities in the back \nhalf of the year.  \n \n We are lowering the top end of our effective tax rate guidance to a new range of 23% to 24% to \nreflect the positive discrete items we\u2019ve seen in the first half of the year.  \n \n", "original_text": "Interest and Other is reduced to a range of $50  million  to $65 million, which primarily reflects \nincreased interest income from higher -than-anticipated cash balances. ", "page_label": "5", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "1f8540678635b75e0ce02c9255e9385ebf57d482a72731c1769452c0b4f607cf", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "8ed0be0e-8c45-47d2-998e-7fc2b18f4c1e", "node_type": "1", "metadata": {"window": "We are encouraged by the operating performance of our businesses, and our strong \ncash flow generation, which is certainly contributing to the improvements below the line.  \n \n Interest and Other is reduced to a range of $50  million  to $65 million, which primarily reflects \nincreased interest income from higher -than-anticipated cash balances.  We expect lower average \ncash balances in the second half of the year, due in part to the seasonal timing of anticipated cash \nflows.  We are evalu ating opportunities to refinance our upcoming 2024 debt maturities in the back \nhalf of the year.  \n \n We are lowering the top end of our effective tax rate guidance to a new range of 23% to 24% to \nreflect the positive discrete items we\u2019ve seen in the first half of the year.  \n \n We also are lowering our shares outlook to approximately 247 million, which reflects the $250  million  \naccelerated share repurchase program we completed in Q2.  No additional share repurchases are \nassumed in our updated guidance for  fiscal year \u2018 24. \n \n", "original_text": "We are evalu ating opportunities to refinance our upcoming 2024 debt maturities in the back \nhalf of the year.  \n \n"}, "hash": "c1f4d7bfc993a8cb257a831750f03389de404f6b8255d6a2c7c3269004b54874", "class_name": "RelatedNodeInfo"}}, "text": "We expect lower average \ncash balances in the second half of the year, due in part to the seasonal timing of anticipated cash \nflows. ", "start_char_idx": 682, "end_char_idx": 816, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "8ed0be0e-8c45-47d2-998e-7fc2b18f4c1e": {"__data__": {"id_": "8ed0be0e-8c45-47d2-998e-7fc2b18f4c1e", "embedding": null, "metadata": {"window": "We are encouraged by the operating performance of our businesses, and our strong \ncash flow generation, which is certainly contributing to the improvements below the line.  \n \n Interest and Other is reduced to a range of $50  million  to $65 million, which primarily reflects \nincreased interest income from higher -than-anticipated cash balances.  We expect lower average \ncash balances in the second half of the year, due in part to the seasonal timing of anticipated cash \nflows.  We are evalu ating opportunities to refinance our upcoming 2024 debt maturities in the back \nhalf of the year.  \n \n We are lowering the top end of our effective tax rate guidance to a new range of 23% to 24% to \nreflect the positive discrete items we\u2019ve seen in the first half of the year.  \n \n We also are lowering our shares outlook to approximately 247 million, which reflects the $250  million  \naccelerated share repurchase program we completed in Q2.  No additional share repurchases are \nassumed in our updated guidance for  fiscal year \u2018 24. \n \n", "original_text": "We are evalu ating opportunities to refinance our upcoming 2024 debt maturities in the back \nhalf of the year.  \n \n", "page_label": "5", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "62106fa2-0df0-4578-a53e-51fe39997eca", "node_type": "4", "metadata": {"page_label": "5", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "b770202d0f8dda4341d593cc59f6ec168a6c077e1794494b0e47e3483f1dd844", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "c3300713-1e8a-4a75-9a5c-5cd03f601d1b", "node_type": "1", "metadata": {"window": "Our new range of $7.20 to $7.35 reflects a $0.45 increase at the bottom end and $0.35 \nincrease at the top end from our Q1 guidance range, and a mid -point which is 26% above our fiscal \n\u201823 EPS results.  We are encouraged by the operating performance of our businesses, and our strong \ncash flow generation, which is certainly contributing to the improvements below the line.  \n \n Interest and Other is reduced to a range of $50  million  to $65 million, which primarily reflects \nincreased interest income from higher -than-anticipated cash balances.  We expect lower average \ncash balances in the second half of the year, due in part to the seasonal timing of anticipated cash \nflows.  We are evalu ating opportunities to refinance our upcoming 2024 debt maturities in the back \nhalf of the year.  \n \n We are lowering the top end of our effective tax rate guidance to a new range of 23% to 24% to \nreflect the positive discrete items we\u2019ve seen in the first half of the year.  \n \n We also are lowering our shares outlook to approximately 247 million, which reflects the $250  million  \naccelerated share repurchase program we completed in Q2. ", "original_text": "We expect lower average \ncash balances in the second half of the year, due in part to the seasonal timing of anticipated cash \nflows. ", "page_label": "5", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "38419f4a7047b5bfd0bd88583fb55e43294aabd544a926177bbc9ec60d59f47f", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "d99c283d-39fb-4ede-ad2b-761d0ff95a09", "node_type": "1", "metadata": {"window": "Interest and Other is reduced to a range of $50  million  to $65 million, which primarily reflects \nincreased interest income from higher -than-anticipated cash balances.  We expect lower average \ncash balances in the second half of the year, due in part to the seasonal timing of anticipated cash \nflows.  We are evalu ating opportunities to refinance our upcoming 2024 debt maturities in the back \nhalf of the year.  \n \n We are lowering the top end of our effective tax rate guidance to a new range of 23% to 24% to \nreflect the positive discrete items we\u2019ve seen in the first half of the year.  \n \n We also are lowering our shares outlook to approximately 247 million, which reflects the $250  million  \naccelerated share repurchase program we completed in Q2.  No additional share repurchases are \nassumed in our updated guidance for  fiscal year \u2018 24. \n \n Now, turning to the fiscal \u201824 outlook for our segments.  \n \n", "original_text": "We are lowering the top end of our effective tax rate guidance to a new range of 23% to 24% to \nreflect the positive discrete items we\u2019ve seen in the first half of the year.  \n \n"}, "hash": "6ac828f4a156bab8b29eb4fe06b3a37c5faab056c0b3e2419bcc491dfba45e98", "class_name": "RelatedNodeInfo"}}, "text": "We are evalu ating opportunities to refinance our upcoming 2024 debt maturities in the back \nhalf of the year.  \n \n", "start_char_idx": 816, "end_char_idx": 931, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "d99c283d-39fb-4ede-ad2b-761d0ff95a09": {"__data__": {"id_": "d99c283d-39fb-4ede-ad2b-761d0ff95a09", "embedding": null, "metadata": {"window": "Interest and Other is reduced to a range of $50  million  to $65 million, which primarily reflects \nincreased interest income from higher -than-anticipated cash balances.  We expect lower average \ncash balances in the second half of the year, due in part to the seasonal timing of anticipated cash \nflows.  We are evalu ating opportunities to refinance our upcoming 2024 debt maturities in the back \nhalf of the year.  \n \n We are lowering the top end of our effective tax rate guidance to a new range of 23% to 24% to \nreflect the positive discrete items we\u2019ve seen in the first half of the year.  \n \n We also are lowering our shares outlook to approximately 247 million, which reflects the $250  million  \naccelerated share repurchase program we completed in Q2.  No additional share repurchases are \nassumed in our updated guidance for  fiscal year \u2018 24. \n \n Now, turning to the fiscal \u201824 outlook for our segments.  \n \n", "original_text": "We are lowering the top end of our effective tax rate guidance to a new range of 23% to 24% to \nreflect the positive discrete items we\u2019ve seen in the first half of the year.  \n \n", "page_label": "5", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "62106fa2-0df0-4578-a53e-51fe39997eca", "node_type": "4", "metadata": {"page_label": "5", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "b770202d0f8dda4341d593cc59f6ec168a6c077e1794494b0e47e3483f1dd844", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "8ed0be0e-8c45-47d2-998e-7fc2b18f4c1e", "node_type": "1", "metadata": {"window": "We are encouraged by the operating performance of our businesses, and our strong \ncash flow generation, which is certainly contributing to the improvements below the line.  \n \n Interest and Other is reduced to a range of $50  million  to $65 million, which primarily reflects \nincreased interest income from higher -than-anticipated cash balances.  We expect lower average \ncash balances in the second half of the year, due in part to the seasonal timing of anticipated cash \nflows.  We are evalu ating opportunities to refinance our upcoming 2024 debt maturities in the back \nhalf of the year.  \n \n We are lowering the top end of our effective tax rate guidance to a new range of 23% to 24% to \nreflect the positive discrete items we\u2019ve seen in the first half of the year.  \n \n We also are lowering our shares outlook to approximately 247 million, which reflects the $250  million  \naccelerated share repurchase program we completed in Q2.  No additional share repurchases are \nassumed in our updated guidance for  fiscal year \u2018 24. \n \n", "original_text": "We are evalu ating opportunities to refinance our upcoming 2024 debt maturities in the back \nhalf of the year.  \n \n", "page_label": "5", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "07d927f0e735adf8d4483ebeb40995dbf0751d50a3762527f25b65fffa13084b", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "f505ce80-d147-4e10-9208-8cfde73127c6", "node_type": "1", "metadata": {"window": "We expect lower average \ncash balances in the second half of the year, due in part to the seasonal timing of anticipated cash \nflows.  We are evalu ating opportunities to refinance our upcoming 2024 debt maturities in the back \nhalf of the year.  \n \n We are lowering the top end of our effective tax rate guidance to a new range of 23% to 24% to \nreflect the positive discrete items we\u2019ve seen in the first half of the year.  \n \n We also are lowering our shares outlook to approximately 247 million, which reflects the $250  million  \naccelerated share repurchase program we completed in Q2.  No additional share repurchases are \nassumed in our updated guidance for  fiscal year \u2018 24. \n \n Now, turning to the fiscal \u201824 outlook for our segments.  \n \n While we will be transitioning to our new segment reporting structure beginning in Q3, let me start \nwith our former segments as a comparison point for the updated structure.  \n \n", "original_text": "We also are lowering our shares outlook to approximately 247 million, which reflects the $250  million  \naccelerated share repurchase program we completed in Q2. "}, "hash": "ed8e170556f19b109374580b4677571a0ca632d6b475147fba909babe7f9061f", "class_name": "RelatedNodeInfo"}}, "text": "We are lowering the top end of our effective tax rate guidance to a new range of 23% to 24% to \nreflect the positive discrete items we\u2019ve seen in the first half of the year.  \n \n", "start_char_idx": 931, "end_char_idx": 1109, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "f505ce80-d147-4e10-9208-8cfde73127c6": {"__data__": {"id_": "f505ce80-d147-4e10-9208-8cfde73127c6", "embedding": null, "metadata": {"window": "We expect lower average \ncash balances in the second half of the year, due in part to the seasonal timing of anticipated cash \nflows.  We are evalu ating opportunities to refinance our upcoming 2024 debt maturities in the back \nhalf of the year.  \n \n We are lowering the top end of our effective tax rate guidance to a new range of 23% to 24% to \nreflect the positive discrete items we\u2019ve seen in the first half of the year.  \n \n We also are lowering our shares outlook to approximately 247 million, which reflects the $250  million  \naccelerated share repurchase program we completed in Q2.  No additional share repurchases are \nassumed in our updated guidance for  fiscal year \u2018 24. \n \n Now, turning to the fiscal \u201824 outlook for our segments.  \n \n While we will be transitioning to our new segment reporting structure beginning in Q3, let me start \nwith our former segments as a comparison point for the updated structure.  \n \n", "original_text": "We also are lowering our shares outlook to approximately 247 million, which reflects the $250  million  \naccelerated share repurchase program we completed in Q2. ", "page_label": "5", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "62106fa2-0df0-4578-a53e-51fe39997eca", "node_type": "4", "metadata": {"page_label": "5", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "b770202d0f8dda4341d593cc59f6ec168a6c077e1794494b0e47e3483f1dd844", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "d99c283d-39fb-4ede-ad2b-761d0ff95a09", "node_type": "1", "metadata": {"window": "Interest and Other is reduced to a range of $50  million  to $65 million, which primarily reflects \nincreased interest income from higher -than-anticipated cash balances.  We expect lower average \ncash balances in the second half of the year, due in part to the seasonal timing of anticipated cash \nflows.  We are evalu ating opportunities to refinance our upcoming 2024 debt maturities in the back \nhalf of the year.  \n \n We are lowering the top end of our effective tax rate guidance to a new range of 23% to 24% to \nreflect the positive discrete items we\u2019ve seen in the first half of the year.  \n \n We also are lowering our shares outlook to approximately 247 million, which reflects the $250  million  \naccelerated share repurchase program we completed in Q2.  No additional share repurchases are \nassumed in our updated guidance for  fiscal year \u2018 24. \n \n Now, turning to the fiscal \u201824 outlook for our segments.  \n \n", "original_text": "We are lowering the top end of our effective tax rate guidance to a new range of 23% to 24% to \nreflect the positive discrete items we\u2019ve seen in the first half of the year.  \n \n", "page_label": "5", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "4774ad50a94740bd28269ebe0191f3239b1f5b950970af1b2f038600cfa825ab", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "8aced6b5-70df-4f2f-90a0-dec3434d1674", "node_type": "1", "metadata": {"window": "We are evalu ating opportunities to refinance our upcoming 2024 debt maturities in the back \nhalf of the year.  \n \n We are lowering the top end of our effective tax rate guidance to a new range of 23% to 24% to \nreflect the positive discrete items we\u2019ve seen in the first half of the year.  \n \n We also are lowering our shares outlook to approximately 247 million, which reflects the $250  million  \naccelerated share repurchase program we completed in Q2.  No additional share repurchases are \nassumed in our updated guidance for  fiscal year \u2018 24. \n \n Now, turning to the fiscal \u201824 outlook for our segments.  \n \n While we will be transitioning to our new segment reporting structure beginning in Q3, let me start \nwith our former segments as a comparison point for the updated structure.  \n \n No changes to the outlook for the former Pharma segment, we are reiterating the 10% to 12% \nrevenue growth and 7% to 9% segment profit growth.  \n \n", "original_text": "No additional share repurchases are \nassumed in our updated guidance for  fiscal year \u2018 24. \n \n"}, "hash": "42d7deadf2fbec6db19375f560d615fe6cc0686ac7fa3b2eb11a8471c5c69b47", "class_name": "RelatedNodeInfo"}}, "text": "We also are lowering our shares outlook to approximately 247 million, which reflects the $250  million  \naccelerated share repurchase program we completed in Q2. ", "start_char_idx": 1109, "end_char_idx": 1271, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "8aced6b5-70df-4f2f-90a0-dec3434d1674": {"__data__": {"id_": "8aced6b5-70df-4f2f-90a0-dec3434d1674", "embedding": null, "metadata": {"window": "We are evalu ating opportunities to refinance our upcoming 2024 debt maturities in the back \nhalf of the year.  \n \n We are lowering the top end of our effective tax rate guidance to a new range of 23% to 24% to \nreflect the positive discrete items we\u2019ve seen in the first half of the year.  \n \n We also are lowering our shares outlook to approximately 247 million, which reflects the $250  million  \naccelerated share repurchase program we completed in Q2.  No additional share repurchases are \nassumed in our updated guidance for  fiscal year \u2018 24. \n \n Now, turning to the fiscal \u201824 outlook for our segments.  \n \n While we will be transitioning to our new segment reporting structure beginning in Q3, let me start \nwith our former segments as a comparison point for the updated structure.  \n \n No changes to the outlook for the former Pharma segment, we are reiterating the 10% to 12% \nrevenue growth and 7% to 9% segment profit growth.  \n \n", "original_text": "No additional share repurchases are \nassumed in our updated guidance for  fiscal year \u2018 24. \n \n", "page_label": "5", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "62106fa2-0df0-4578-a53e-51fe39997eca", "node_type": "4", "metadata": {"page_label": "5", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "b770202d0f8dda4341d593cc59f6ec168a6c077e1794494b0e47e3483f1dd844", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "f505ce80-d147-4e10-9208-8cfde73127c6", "node_type": "1", "metadata": {"window": "We expect lower average \ncash balances in the second half of the year, due in part to the seasonal timing of anticipated cash \nflows.  We are evalu ating opportunities to refinance our upcoming 2024 debt maturities in the back \nhalf of the year.  \n \n We are lowering the top end of our effective tax rate guidance to a new range of 23% to 24% to \nreflect the positive discrete items we\u2019ve seen in the first half of the year.  \n \n We also are lowering our shares outlook to approximately 247 million, which reflects the $250  million  \naccelerated share repurchase program we completed in Q2.  No additional share repurchases are \nassumed in our updated guidance for  fiscal year \u2018 24. \n \n Now, turning to the fiscal \u201824 outlook for our segments.  \n \n While we will be transitioning to our new segment reporting structure beginning in Q3, let me start \nwith our former segments as a comparison point for the updated structure.  \n \n", "original_text": "We also are lowering our shares outlook to approximately 247 million, which reflects the $250  million  \naccelerated share repurchase program we completed in Q2. ", "page_label": "5", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "0220bcb0d0a86a11758e98d374a05284f3308ed6285f38f3b2e71b7296f8bd3c", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "84891518-fc6a-440d-9b0e-3062fe707d85", "node_type": "1", "metadata": {"window": "We are lowering the top end of our effective tax rate guidance to a new range of 23% to 24% to \nreflect the positive discrete items we\u2019ve seen in the first half of the year.  \n \n We also are lowering our shares outlook to approximately 247 million, which reflects the $250  million  \naccelerated share repurchase program we completed in Q2.  No additional share repurchases are \nassumed in our updated guidance for  fiscal year \u2018 24. \n \n Now, turning to the fiscal \u201824 outlook for our segments.  \n \n While we will be transitioning to our new segment reporting structure beginning in Q3, let me start \nwith our former segments as a comparison point for the updated structure.  \n \n No changes to the outlook for the former Pharma segment, we are reiterating the 10% to 12% \nrevenue growth and 7% to 9% segment profit growth.  \n \n For the former Medical segment, the fiscal \u201824 outlook is updated to approximately $380 million of \nsegment profit to reflect the net impact of Q2 non -recurring adjustments. ", "original_text": "Now, turning to the fiscal \u201824 outlook for our segments.  \n \n"}, "hash": "a118e4028a899c891a47fd7e5ca76ef07e65eb7e95da90cf2abe502f3477c660", "class_name": "RelatedNodeInfo"}}, "text": "No additional share repurchases are \nassumed in our updated guidance for  fiscal year \u2018 24. \n \n", "start_char_idx": 1271, "end_char_idx": 1366, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "84891518-fc6a-440d-9b0e-3062fe707d85": {"__data__": {"id_": "84891518-fc6a-440d-9b0e-3062fe707d85", "embedding": null, "metadata": {"window": "We are lowering the top end of our effective tax rate guidance to a new range of 23% to 24% to \nreflect the positive discrete items we\u2019ve seen in the first half of the year.  \n \n We also are lowering our shares outlook to approximately 247 million, which reflects the $250  million  \naccelerated share repurchase program we completed in Q2.  No additional share repurchases are \nassumed in our updated guidance for  fiscal year \u2018 24. \n \n Now, turning to the fiscal \u201824 outlook for our segments.  \n \n While we will be transitioning to our new segment reporting structure beginning in Q3, let me start \nwith our former segments as a comparison point for the updated structure.  \n \n No changes to the outlook for the former Pharma segment, we are reiterating the 10% to 12% \nrevenue growth and 7% to 9% segment profit growth.  \n \n For the former Medical segment, the fiscal \u201824 outlook is updated to approximately $380 million of \nsegment profit to reflect the net impact of Q2 non -recurring adjustments. ", "original_text": "Now, turning to the fiscal \u201824 outlook for our segments.  \n \n", "page_label": "5", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "62106fa2-0df0-4578-a53e-51fe39997eca", "node_type": "4", "metadata": {"page_label": "5", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "b770202d0f8dda4341d593cc59f6ec168a6c077e1794494b0e47e3483f1dd844", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "8aced6b5-70df-4f2f-90a0-dec3434d1674", "node_type": "1", "metadata": {"window": "We are evalu ating opportunities to refinance our upcoming 2024 debt maturities in the back \nhalf of the year.  \n \n We are lowering the top end of our effective tax rate guidance to a new range of 23% to 24% to \nreflect the positive discrete items we\u2019ve seen in the first half of the year.  \n \n We also are lowering our shares outlook to approximately 247 million, which reflects the $250  million  \naccelerated share repurchase program we completed in Q2.  No additional share repurchases are \nassumed in our updated guidance for  fiscal year \u2018 24. \n \n Now, turning to the fiscal \u201824 outlook for our segments.  \n \n While we will be transitioning to our new segment reporting structure beginning in Q3, let me start \nwith our former segments as a comparison point for the updated structure.  \n \n No changes to the outlook for the former Pharma segment, we are reiterating the 10% to 12% \nrevenue growth and 7% to 9% segment profit growth.  \n \n", "original_text": "No additional share repurchases are \nassumed in our updated guidance for  fiscal year \u2018 24. \n \n", "page_label": "5", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "d5d48417cb82ea749c69fe3969d792bbd82c4ef121ae633208cfc1ea872a3d23", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "259ae151-bf33-4e47-b5e6-b80de93b2640", "node_type": "1", "metadata": {"window": "We also are lowering our shares outlook to approximately 247 million, which reflects the $250  million  \naccelerated share repurchase program we completed in Q2.  No additional share repurchases are \nassumed in our updated guidance for  fiscal year \u2018 24. \n \n Now, turning to the fiscal \u201824 outlook for our segments.  \n \n While we will be transitioning to our new segment reporting structure beginning in Q3, let me start \nwith our former segments as a comparison point for the updated structure.  \n \n No changes to the outlook for the former Pharma segment, we are reiterating the 10% to 12% \nrevenue growth and 7% to 9% segment profit growth.  \n \n For the former Medical segment, the fiscal \u201824 outlook is updated to approximately $380 million of \nsegment profit to reflect the net impact of Q2 non -recurring adjustments.  Outside of these, our overall \noperational expectations are consistent with delivering the prior $400 million in segment profit for the \nyear, as well as the corresponding prior expectation of $650 million in segment profit for fiscal year \n\u201926. ", "original_text": "While we will be transitioning to our new segment reporting structure beginning in Q3, let me start \nwith our former segments as a comparison point for the updated structure.  \n \n"}, "hash": "a177c6604b416bff85d1c07a7fb0bde4c827747dcbfd9b757b9f88c39cef3635", "class_name": "RelatedNodeInfo"}}, "text": "Now, turning to the fiscal \u201824 outlook for our segments.  \n \n", "start_char_idx": 1366, "end_char_idx": 1427, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "259ae151-bf33-4e47-b5e6-b80de93b2640": {"__data__": {"id_": "259ae151-bf33-4e47-b5e6-b80de93b2640", "embedding": null, "metadata": {"window": "We also are lowering our shares outlook to approximately 247 million, which reflects the $250  million  \naccelerated share repurchase program we completed in Q2.  No additional share repurchases are \nassumed in our updated guidance for  fiscal year \u2018 24. \n \n Now, turning to the fiscal \u201824 outlook for our segments.  \n \n While we will be transitioning to our new segment reporting structure beginning in Q3, let me start \nwith our former segments as a comparison point for the updated structure.  \n \n No changes to the outlook for the former Pharma segment, we are reiterating the 10% to 12% \nrevenue growth and 7% to 9% segment profit growth.  \n \n For the former Medical segment, the fiscal \u201824 outlook is updated to approximately $380 million of \nsegment profit to reflect the net impact of Q2 non -recurring adjustments.  Outside of these, our overall \noperational expectations are consistent with delivering the prior $400 million in segment profit for the \nyear, as well as the corresponding prior expectation of $650 million in segment profit for fiscal year \n\u201926. ", "original_text": "While we will be transitioning to our new segment reporting structure beginning in Q3, let me start \nwith our former segments as a comparison point for the updated structure.  \n \n", "page_label": "5", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "62106fa2-0df0-4578-a53e-51fe39997eca", "node_type": "4", "metadata": {"page_label": "5", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "b770202d0f8dda4341d593cc59f6ec168a6c077e1794494b0e47e3483f1dd844", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "84891518-fc6a-440d-9b0e-3062fe707d85", "node_type": "1", "metadata": {"window": "We are lowering the top end of our effective tax rate guidance to a new range of 23% to 24% to \nreflect the positive discrete items we\u2019ve seen in the first half of the year.  \n \n We also are lowering our shares outlook to approximately 247 million, which reflects the $250  million  \naccelerated share repurchase program we completed in Q2.  No additional share repurchases are \nassumed in our updated guidance for  fiscal year \u2018 24. \n \n Now, turning to the fiscal \u201824 outlook for our segments.  \n \n While we will be transitioning to our new segment reporting structure beginning in Q3, let me start \nwith our former segments as a comparison point for the updated structure.  \n \n No changes to the outlook for the former Pharma segment, we are reiterating the 10% to 12% \nrevenue growth and 7% to 9% segment profit growth.  \n \n For the former Medical segment, the fiscal \u201824 outlook is updated to approximately $380 million of \nsegment profit to reflect the net impact of Q2 non -recurring adjustments. ", "original_text": "Now, turning to the fiscal \u201824 outlook for our segments.  \n \n", "page_label": "5", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "55930f4924fa6fb0630b53603859984f76d55b8e3386aadfc60afff6a9f98454", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "0b065238-292f-42a7-b83b-ad904a6d0e35", "node_type": "1", "metadata": {"window": "No additional share repurchases are \nassumed in our updated guidance for  fiscal year \u2018 24. \n \n Now, turning to the fiscal \u201824 outlook for our segments.  \n \n While we will be transitioning to our new segment reporting structure beginning in Q3, let me start \nwith our former segments as a comparison point for the updated structure.  \n \n No changes to the outlook for the former Pharma segment, we are reiterating the 10% to 12% \nrevenue growth and 7% to 9% segment profit growth.  \n \n For the former Medical segment, the fiscal \u201824 outlook is updated to approximately $380 million of \nsegment profit to reflect the net impact of Q2 non -recurring adjustments.  Outside of these, our overall \noperational expectations are consistent with delivering the prior $400 million in segment profit for the \nyear, as well as the corresponding prior expectation of $650 million in segment profit for fiscal year \n\u201926.  We have consistently highlighted the back -half weighting of the Medical guidance, driven by \nprogress within GMPD on Cardinal Health Brand volume growth, the cumulative impact of inflation \nmitigation, and some business -specific seasonality. ", "original_text": "No changes to the outlook for the former Pharma segment, we are reiterating the 10% to 12% \nrevenue growth and 7% to 9% segment profit growth.  \n \n"}, "hash": "811a9323a28b11db964893ea358d6e31af6164d68e27711fe790ddd09f912b44", "class_name": "RelatedNodeInfo"}}, "text": "While we will be transitioning to our new segment reporting structure beginning in Q3, let me start \nwith our former segments as a comparison point for the updated structure.  \n \n", "start_char_idx": 1427, "end_char_idx": 1606, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "0b065238-292f-42a7-b83b-ad904a6d0e35": {"__data__": {"id_": "0b065238-292f-42a7-b83b-ad904a6d0e35", "embedding": null, "metadata": {"window": "No additional share repurchases are \nassumed in our updated guidance for  fiscal year \u2018 24. \n \n Now, turning to the fiscal \u201824 outlook for our segments.  \n \n While we will be transitioning to our new segment reporting structure beginning in Q3, let me start \nwith our former segments as a comparison point for the updated structure.  \n \n No changes to the outlook for the former Pharma segment, we are reiterating the 10% to 12% \nrevenue growth and 7% to 9% segment profit growth.  \n \n For the former Medical segment, the fiscal \u201824 outlook is updated to approximately $380 million of \nsegment profit to reflect the net impact of Q2 non -recurring adjustments.  Outside of these, our overall \noperational expectations are consistent with delivering the prior $400 million in segment profit for the \nyear, as well as the corresponding prior expectation of $650 million in segment profit for fiscal year \n\u201926.  We have consistently highlighted the back -half weighting of the Medical guidance, driven by \nprogress within GMPD on Cardinal Health Brand volume growth, the cumulative impact of inflation \nmitigation, and some business -specific seasonality. ", "original_text": "No changes to the outlook for the former Pharma segment, we are reiterating the 10% to 12% \nrevenue growth and 7% to 9% segment profit growth.  \n \n", "page_label": "5", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "62106fa2-0df0-4578-a53e-51fe39997eca", "node_type": "4", "metadata": {"page_label": "5", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "b770202d0f8dda4341d593cc59f6ec168a6c077e1794494b0e47e3483f1dd844", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "259ae151-bf33-4e47-b5e6-b80de93b2640", "node_type": "1", "metadata": {"window": "We also are lowering our shares outlook to approximately 247 million, which reflects the $250  million  \naccelerated share repurchase program we completed in Q2.  No additional share repurchases are \nassumed in our updated guidance for  fiscal year \u2018 24. \n \n Now, turning to the fiscal \u201824 outlook for our segments.  \n \n While we will be transitioning to our new segment reporting structure beginning in Q3, let me start \nwith our former segments as a comparison point for the updated structure.  \n \n No changes to the outlook for the former Pharma segment, we are reiterating the 10% to 12% \nrevenue growth and 7% to 9% segment profit growth.  \n \n For the former Medical segment, the fiscal \u201824 outlook is updated to approximately $380 million of \nsegment profit to reflect the net impact of Q2 non -recurring adjustments.  Outside of these, our overall \noperational expectations are consistent with delivering the prior $400 million in segment profit for the \nyear, as well as the corresponding prior expectation of $650 million in segment profit for fiscal year \n\u201926. ", "original_text": "While we will be transitioning to our new segment reporting structure beginning in Q3, let me start \nwith our former segments as a comparison point for the updated structure.  \n \n", "page_label": "5", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "6f5d491174201db6d65ae56a197c9c61e175d3262d7bd49bbcb2badbdaaefb01", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "444d3782-2c0f-45f3-b8a6-efa202d674ac", "node_type": "1", "metadata": {"window": "Now, turning to the fiscal \u201824 outlook for our segments.  \n \n While we will be transitioning to our new segment reporting structure beginning in Q3, let me start \nwith our former segments as a comparison point for the updated structure.  \n \n No changes to the outlook for the former Pharma segment, we are reiterating the 10% to 12% \nrevenue growth and 7% to 9% segment profit growth.  \n \n For the former Medical segment, the fiscal \u201824 outlook is updated to approximately $380 million of \nsegment profit to reflect the net impact of Q2 non -recurring adjustments.  Outside of these, our overall \noperational expectations are consistent with delivering the prior $400 million in segment profit for the \nyear, as well as the corresponding prior expectation of $650 million in segment profit for fiscal year \n\u201926.  We have consistently highlighted the back -half weighting of the Medical guidance, driven by \nprogress within GMPD on Cardinal Health Brand volume growth, the cumulative impact of inflation \nmitigation, and some business -specific seasonality.  Our expectations there continue.  \n \n", "original_text": "For the former Medical segment, the fiscal \u201824 outlook is updated to approximately $380 million of \nsegment profit to reflect the net impact of Q2 non -recurring adjustments. "}, "hash": "16d3e4dca515bf2fa43327a85e53d6a26715b07560cc55fe3bcffce2cf3057f3", "class_name": "RelatedNodeInfo"}}, "text": "No changes to the outlook for the former Pharma segment, we are reiterating the 10% to 12% \nrevenue growth and 7% to 9% segment profit growth.  \n \n", "start_char_idx": 1606, "end_char_idx": 1753, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "444d3782-2c0f-45f3-b8a6-efa202d674ac": {"__data__": {"id_": "444d3782-2c0f-45f3-b8a6-efa202d674ac", "embedding": null, "metadata": {"window": "Now, turning to the fiscal \u201824 outlook for our segments.  \n \n While we will be transitioning to our new segment reporting structure beginning in Q3, let me start \nwith our former segments as a comparison point for the updated structure.  \n \n No changes to the outlook for the former Pharma segment, we are reiterating the 10% to 12% \nrevenue growth and 7% to 9% segment profit growth.  \n \n For the former Medical segment, the fiscal \u201824 outlook is updated to approximately $380 million of \nsegment profit to reflect the net impact of Q2 non -recurring adjustments.  Outside of these, our overall \noperational expectations are consistent with delivering the prior $400 million in segment profit for the \nyear, as well as the corresponding prior expectation of $650 million in segment profit for fiscal year \n\u201926.  We have consistently highlighted the back -half weighting of the Medical guidance, driven by \nprogress within GMPD on Cardinal Health Brand volume growth, the cumulative impact of inflation \nmitigation, and some business -specific seasonality.  Our expectations there continue.  \n \n", "original_text": "For the former Medical segment, the fiscal \u201824 outlook is updated to approximately $380 million of \nsegment profit to reflect the net impact of Q2 non -recurring adjustments. ", "page_label": "5", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "62106fa2-0df0-4578-a53e-51fe39997eca", "node_type": "4", "metadata": {"page_label": "5", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "b770202d0f8dda4341d593cc59f6ec168a6c077e1794494b0e47e3483f1dd844", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "0b065238-292f-42a7-b83b-ad904a6d0e35", "node_type": "1", "metadata": {"window": "No additional share repurchases are \nassumed in our updated guidance for  fiscal year \u2018 24. \n \n Now, turning to the fiscal \u201824 outlook for our segments.  \n \n While we will be transitioning to our new segment reporting structure beginning in Q3, let me start \nwith our former segments as a comparison point for the updated structure.  \n \n No changes to the outlook for the former Pharma segment, we are reiterating the 10% to 12% \nrevenue growth and 7% to 9% segment profit growth.  \n \n For the former Medical segment, the fiscal \u201824 outlook is updated to approximately $380 million of \nsegment profit to reflect the net impact of Q2 non -recurring adjustments.  Outside of these, our overall \noperational expectations are consistent with delivering the prior $400 million in segment profit for the \nyear, as well as the corresponding prior expectation of $650 million in segment profit for fiscal year \n\u201926.  We have consistently highlighted the back -half weighting of the Medical guidance, driven by \nprogress within GMPD on Cardinal Health Brand volume growth, the cumulative impact of inflation \nmitigation, and some business -specific seasonality. ", "original_text": "No changes to the outlook for the former Pharma segment, we are reiterating the 10% to 12% \nrevenue growth and 7% to 9% segment profit growth.  \n \n", "page_label": "5", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "65d2fcbf8f2ac1a1d45319ceb86040c5e5496b8d87376a9938b2c422259e82aa", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "97a7d4ed-7b2e-4b13-b635-5630ea1fbde8", "node_type": "1", "metadata": {"window": "While we will be transitioning to our new segment reporting structure beginning in Q3, let me start \nwith our former segments as a comparison point for the updated structure.  \n \n No changes to the outlook for the former Pharma segment, we are reiterating the 10% to 12% \nrevenue growth and 7% to 9% segment profit growth.  \n \n For the former Medical segment, the fiscal \u201824 outlook is updated to approximately $380 million of \nsegment profit to reflect the net impact of Q2 non -recurring adjustments.  Outside of these, our overall \noperational expectations are consistent with delivering the prior $400 million in segment profit for the \nyear, as well as the corresponding prior expectation of $650 million in segment profit for fiscal year \n\u201926.  We have consistently highlighted the back -half weighting of the Medical guidance, driven by \nprogress within GMPD on Cardinal Health Brand volume growth, the cumulative impact of inflation \nmitigation, and some business -specific seasonality.  Our expectations there continue.  \n \n For example, with inflation mitigation, we have strong visibility to overall cost improvements in the \nsecond half of the year, driven by reductions we\u2019ve observed in international freight, which as a \nreminder reflect in our income statement on a two to thr ee quarter delay. ", "original_text": "Outside of these, our overall \noperational expectations are consistent with delivering the prior $400 million in segment profit for the \nyear, as well as the corresponding prior expectation of $650 million in segment profit for fiscal year \n\u201926. "}, "hash": "feae91a5891053fddf167f4291b19e2a6e1763bc9227c77379fe5c66621ac1b9", "class_name": "RelatedNodeInfo"}}, "text": "For the former Medical segment, the fiscal \u201824 outlook is updated to approximately $380 million of \nsegment profit to reflect the net impact of Q2 non -recurring adjustments. ", "start_char_idx": 1753, "end_char_idx": 1928, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "97a7d4ed-7b2e-4b13-b635-5630ea1fbde8": {"__data__": {"id_": "97a7d4ed-7b2e-4b13-b635-5630ea1fbde8", "embedding": null, "metadata": {"window": "While we will be transitioning to our new segment reporting structure beginning in Q3, let me start \nwith our former segments as a comparison point for the updated structure.  \n \n No changes to the outlook for the former Pharma segment, we are reiterating the 10% to 12% \nrevenue growth and 7% to 9% segment profit growth.  \n \n For the former Medical segment, the fiscal \u201824 outlook is updated to approximately $380 million of \nsegment profit to reflect the net impact of Q2 non -recurring adjustments.  Outside of these, our overall \noperational expectations are consistent with delivering the prior $400 million in segment profit for the \nyear, as well as the corresponding prior expectation of $650 million in segment profit for fiscal year \n\u201926.  We have consistently highlighted the back -half weighting of the Medical guidance, driven by \nprogress within GMPD on Cardinal Health Brand volume growth, the cumulative impact of inflation \nmitigation, and some business -specific seasonality.  Our expectations there continue.  \n \n For example, with inflation mitigation, we have strong visibility to overall cost improvements in the \nsecond half of the year, driven by reductions we\u2019ve observed in international freight, which as a \nreminder reflect in our income statement on a two to thr ee quarter delay. ", "original_text": "Outside of these, our overall \noperational expectations are consistent with delivering the prior $400 million in segment profit for the \nyear, as well as the corresponding prior expectation of $650 million in segment profit for fiscal year \n\u201926. ", "page_label": "5", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "62106fa2-0df0-4578-a53e-51fe39997eca", "node_type": "4", "metadata": {"page_label": "5", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "b770202d0f8dda4341d593cc59f6ec168a6c077e1794494b0e47e3483f1dd844", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "444d3782-2c0f-45f3-b8a6-efa202d674ac", "node_type": "1", "metadata": {"window": "Now, turning to the fiscal \u201824 outlook for our segments.  \n \n While we will be transitioning to our new segment reporting structure beginning in Q3, let me start \nwith our former segments as a comparison point for the updated structure.  \n \n No changes to the outlook for the former Pharma segment, we are reiterating the 10% to 12% \nrevenue growth and 7% to 9% segment profit growth.  \n \n For the former Medical segment, the fiscal \u201824 outlook is updated to approximately $380 million of \nsegment profit to reflect the net impact of Q2 non -recurring adjustments.  Outside of these, our overall \noperational expectations are consistent with delivering the prior $400 million in segment profit for the \nyear, as well as the corresponding prior expectation of $650 million in segment profit for fiscal year \n\u201926.  We have consistently highlighted the back -half weighting of the Medical guidance, driven by \nprogress within GMPD on Cardinal Health Brand volume growth, the cumulative impact of inflation \nmitigation, and some business -specific seasonality.  Our expectations there continue.  \n \n", "original_text": "For the former Medical segment, the fiscal \u201824 outlook is updated to approximately $380 million of \nsegment profit to reflect the net impact of Q2 non -recurring adjustments. ", "page_label": "5", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "0cd58bc5d8ac6672dbb5ef66dbc60f20e729856ef114ad32f888444bdffd6f53", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "f0431abd-d0d2-4bb0-8e12-76be35f49076", "node_type": "1", "metadata": {"window": "No changes to the outlook for the former Pharma segment, we are reiterating the 10% to 12% \nrevenue growth and 7% to 9% segment profit growth.  \n \n For the former Medical segment, the fiscal \u201824 outlook is updated to approximately $380 million of \nsegment profit to reflect the net impact of Q2 non -recurring adjustments.  Outside of these, our overall \noperational expectations are consistent with delivering the prior $400 million in segment profit for the \nyear, as well as the corresponding prior expectation of $650 million in segment profit for fiscal year \n\u201926.  We have consistently highlighted the back -half weighting of the Medical guidance, driven by \nprogress within GMPD on Cardinal Health Brand volume growth, the cumulative impact of inflation \nmitigation, and some business -specific seasonality.  Our expectations there continue.  \n \n For example, with inflation mitigation, we have strong visibility to overall cost improvements in the \nsecond half of the year, driven by reductions we\u2019ve observed in international freight, which as a \nreminder reflect in our income statement on a two to thr ee quarter delay.  And as we exit January, the \nmitigation initiatives necessary to achieve our year -end target are now largely in place.  \n \n", "original_text": "We have consistently highlighted the back -half weighting of the Medical guidance, driven by \nprogress within GMPD on Cardinal Health Brand volume growth, the cumulative impact of inflation \nmitigation, and some business -specific seasonality. "}, "hash": "acdced4bf84dd4b3a7334460bc27884d80bf0bf0b9c1298712aa5286e83e2040", "class_name": "RelatedNodeInfo"}}, "text": "Outside of these, our overall \noperational expectations are consistent with delivering the prior $400 million in segment profit for the \nyear, as well as the corresponding prior expectation of $650 million in segment profit for fiscal year \n\u201926. ", "start_char_idx": 1928, "end_char_idx": 2174, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "f0431abd-d0d2-4bb0-8e12-76be35f49076": {"__data__": {"id_": "f0431abd-d0d2-4bb0-8e12-76be35f49076", "embedding": null, "metadata": {"window": "No changes to the outlook for the former Pharma segment, we are reiterating the 10% to 12% \nrevenue growth and 7% to 9% segment profit growth.  \n \n For the former Medical segment, the fiscal \u201824 outlook is updated to approximately $380 million of \nsegment profit to reflect the net impact of Q2 non -recurring adjustments.  Outside of these, our overall \noperational expectations are consistent with delivering the prior $400 million in segment profit for the \nyear, as well as the corresponding prior expectation of $650 million in segment profit for fiscal year \n\u201926.  We have consistently highlighted the back -half weighting of the Medical guidance, driven by \nprogress within GMPD on Cardinal Health Brand volume growth, the cumulative impact of inflation \nmitigation, and some business -specific seasonality.  Our expectations there continue.  \n \n For example, with inflation mitigation, we have strong visibility to overall cost improvements in the \nsecond half of the year, driven by reductions we\u2019ve observed in international freight, which as a \nreminder reflect in our income statement on a two to thr ee quarter delay.  And as we exit January, the \nmitigation initiatives necessary to achieve our year -end target are now largely in place.  \n \n", "original_text": "We have consistently highlighted the back -half weighting of the Medical guidance, driven by \nprogress within GMPD on Cardinal Health Brand volume growth, the cumulative impact of inflation \nmitigation, and some business -specific seasonality. ", "page_label": "5", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "62106fa2-0df0-4578-a53e-51fe39997eca", "node_type": "4", "metadata": {"page_label": "5", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "b770202d0f8dda4341d593cc59f6ec168a6c077e1794494b0e47e3483f1dd844", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "97a7d4ed-7b2e-4b13-b635-5630ea1fbde8", "node_type": "1", "metadata": {"window": "While we will be transitioning to our new segment reporting structure beginning in Q3, let me start \nwith our former segments as a comparison point for the updated structure.  \n \n No changes to the outlook for the former Pharma segment, we are reiterating the 10% to 12% \nrevenue growth and 7% to 9% segment profit growth.  \n \n For the former Medical segment, the fiscal \u201824 outlook is updated to approximately $380 million of \nsegment profit to reflect the net impact of Q2 non -recurring adjustments.  Outside of these, our overall \noperational expectations are consistent with delivering the prior $400 million in segment profit for the \nyear, as well as the corresponding prior expectation of $650 million in segment profit for fiscal year \n\u201926.  We have consistently highlighted the back -half weighting of the Medical guidance, driven by \nprogress within GMPD on Cardinal Health Brand volume growth, the cumulative impact of inflation \nmitigation, and some business -specific seasonality.  Our expectations there continue.  \n \n For example, with inflation mitigation, we have strong visibility to overall cost improvements in the \nsecond half of the year, driven by reductions we\u2019ve observed in international freight, which as a \nreminder reflect in our income statement on a two to thr ee quarter delay. ", "original_text": "Outside of these, our overall \noperational expectations are consistent with delivering the prior $400 million in segment profit for the \nyear, as well as the corresponding prior expectation of $650 million in segment profit for fiscal year \n\u201926. ", "page_label": "5", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "b81b1e22e652c13d1999e751f1f8e472eb13ed3e2b38dc184caf458f42268917", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "c1e144ad-3728-4823-b118-610959f97a50", "node_type": "1", "metadata": {"window": "For the former Medical segment, the fiscal \u201824 outlook is updated to approximately $380 million of \nsegment profit to reflect the net impact of Q2 non -recurring adjustments.  Outside of these, our overall \noperational expectations are consistent with delivering the prior $400 million in segment profit for the \nyear, as well as the corresponding prior expectation of $650 million in segment profit for fiscal year \n\u201926.  We have consistently highlighted the back -half weighting of the Medical guidance, driven by \nprogress within GMPD on Cardinal Health Brand volume growth, the cumulative impact of inflation \nmitigation, and some business -specific seasonality.  Our expectations there continue.  \n \n For example, with inflation mitigation, we have strong visibility to overall cost improvements in the \nsecond half of the year, driven by reductions we\u2019ve observed in international freight, which as a \nreminder reflect in our income statement on a two to thr ee quarter delay.  And as we exit January, the \nmitigation initiatives necessary to achieve our year -end target are now largely in place.  \n \n Now, as seen on slide 10, let me comment on how this fiscal year \u2018 24 guidance translates to our \nupdated segment structure, to go along with the preliminary recast fiscal \u201823 actuals and long -term \ntargets we provided a few weeks back. ", "original_text": "Our expectations there continue.  \n \n"}, "hash": "f9b51aebd98e46f862c89d70889bffe7764fde61e8794ef71eb1bfa0fe1e34e8", "class_name": "RelatedNodeInfo"}}, "text": "We have consistently highlighted the back -half weighting of the Medical guidance, driven by \nprogress within GMPD on Cardinal Health Brand volume growth, the cumulative impact of inflation \nmitigation, and some business -specific seasonality. ", "start_char_idx": 2174, "end_char_idx": 2418, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "c1e144ad-3728-4823-b118-610959f97a50": {"__data__": {"id_": "c1e144ad-3728-4823-b118-610959f97a50", "embedding": null, "metadata": {"window": "For the former Medical segment, the fiscal \u201824 outlook is updated to approximately $380 million of \nsegment profit to reflect the net impact of Q2 non -recurring adjustments.  Outside of these, our overall \noperational expectations are consistent with delivering the prior $400 million in segment profit for the \nyear, as well as the corresponding prior expectation of $650 million in segment profit for fiscal year \n\u201926.  We have consistently highlighted the back -half weighting of the Medical guidance, driven by \nprogress within GMPD on Cardinal Health Brand volume growth, the cumulative impact of inflation \nmitigation, and some business -specific seasonality.  Our expectations there continue.  \n \n For example, with inflation mitigation, we have strong visibility to overall cost improvements in the \nsecond half of the year, driven by reductions we\u2019ve observed in international freight, which as a \nreminder reflect in our income statement on a two to thr ee quarter delay.  And as we exit January, the \nmitigation initiatives necessary to achieve our year -end target are now largely in place.  \n \n Now, as seen on slide 10, let me comment on how this fiscal year \u2018 24 guidance translates to our \nupdated segment structure, to go along with the preliminary recast fiscal \u201823 actuals and long -term \ntargets we provided a few weeks back. ", "original_text": "Our expectations there continue.  \n \n", "page_label": "5", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "62106fa2-0df0-4578-a53e-51fe39997eca", "node_type": "4", "metadata": {"page_label": "5", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "b770202d0f8dda4341d593cc59f6ec168a6c077e1794494b0e47e3483f1dd844", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "f0431abd-d0d2-4bb0-8e12-76be35f49076", "node_type": "1", "metadata": {"window": "No changes to the outlook for the former Pharma segment, we are reiterating the 10% to 12% \nrevenue growth and 7% to 9% segment profit growth.  \n \n For the former Medical segment, the fiscal \u201824 outlook is updated to approximately $380 million of \nsegment profit to reflect the net impact of Q2 non -recurring adjustments.  Outside of these, our overall \noperational expectations are consistent with delivering the prior $400 million in segment profit for the \nyear, as well as the corresponding prior expectation of $650 million in segment profit for fiscal year \n\u201926.  We have consistently highlighted the back -half weighting of the Medical guidance, driven by \nprogress within GMPD on Cardinal Health Brand volume growth, the cumulative impact of inflation \nmitigation, and some business -specific seasonality.  Our expectations there continue.  \n \n For example, with inflation mitigation, we have strong visibility to overall cost improvements in the \nsecond half of the year, driven by reductions we\u2019ve observed in international freight, which as a \nreminder reflect in our income statement on a two to thr ee quarter delay.  And as we exit January, the \nmitigation initiatives necessary to achieve our year -end target are now largely in place.  \n \n", "original_text": "We have consistently highlighted the back -half weighting of the Medical guidance, driven by \nprogress within GMPD on Cardinal Health Brand volume growth, the cumulative impact of inflation \nmitigation, and some business -specific seasonality. ", "page_label": "5", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "b673d1c76f11b23856846e47764f48f8e15196f196ee121e696ba537a695cd1c", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "f4559797-4e0e-4ca1-84d0-7dac65822cd9", "node_type": "1", "metadata": {"window": "Outside of these, our overall \noperational expectations are consistent with delivering the prior $400 million in segment profit for the \nyear, as well as the corresponding prior expectation of $650 million in segment profit for fiscal year \n\u201926.  We have consistently highlighted the back -half weighting of the Medical guidance, driven by \nprogress within GMPD on Cardinal Health Brand volume growth, the cumulative impact of inflation \nmitigation, and some business -specific seasonality.  Our expectations there continue.  \n \n For example, with inflation mitigation, we have strong visibility to overall cost improvements in the \nsecond half of the year, driven by reductions we\u2019ve observed in international freight, which as a \nreminder reflect in our income statement on a two to thr ee quarter delay.  And as we exit January, the \nmitigation initiatives necessary to achieve our year -end target are now largely in place.  \n \n Now, as seen on slide 10, let me comment on how this fiscal year \u2018 24 guidance translates to our \nupdated segment structure, to go along with the preliminary recast fiscal \u201823 actuals and long -term \ntargets we provided a few weeks back.  Our new structure went into effect January 1st, so beginning \nin Q3, we will report results and provide drivers according to the new segment structure, \nPharmaceutical and Specialty Solutions and  GMPD, and separate from these two segments, Nuclear, ", "original_text": "For example, with inflation mitigation, we have strong visibility to overall cost improvements in the \nsecond half of the year, driven by reductions we\u2019ve observed in international freight, which as a \nreminder reflect in our income statement on a two to thr ee quarter delay. "}, "hash": "285e01b7816b7de5b59fc7649a9aa62b2f2b58b3a4734d87dd6210b4a8148681", "class_name": "RelatedNodeInfo"}}, "text": "Our expectations there continue.  \n \n", "start_char_idx": 2418, "end_char_idx": 2455, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "f4559797-4e0e-4ca1-84d0-7dac65822cd9": {"__data__": {"id_": "f4559797-4e0e-4ca1-84d0-7dac65822cd9", "embedding": null, "metadata": {"window": "Outside of these, our overall \noperational expectations are consistent with delivering the prior $400 million in segment profit for the \nyear, as well as the corresponding prior expectation of $650 million in segment profit for fiscal year \n\u201926.  We have consistently highlighted the back -half weighting of the Medical guidance, driven by \nprogress within GMPD on Cardinal Health Brand volume growth, the cumulative impact of inflation \nmitigation, and some business -specific seasonality.  Our expectations there continue.  \n \n For example, with inflation mitigation, we have strong visibility to overall cost improvements in the \nsecond half of the year, driven by reductions we\u2019ve observed in international freight, which as a \nreminder reflect in our income statement on a two to thr ee quarter delay.  And as we exit January, the \nmitigation initiatives necessary to achieve our year -end target are now largely in place.  \n \n Now, as seen on slide 10, let me comment on how this fiscal year \u2018 24 guidance translates to our \nupdated segment structure, to go along with the preliminary recast fiscal \u201823 actuals and long -term \ntargets we provided a few weeks back.  Our new structure went into effect January 1st, so beginning \nin Q3, we will report results and provide drivers according to the new segment structure, \nPharmaceutical and Specialty Solutions and  GMPD, and separate from these two segments, Nuclear, ", "original_text": "For example, with inflation mitigation, we have strong visibility to overall cost improvements in the \nsecond half of the year, driven by reductions we\u2019ve observed in international freight, which as a \nreminder reflect in our income statement on a two to thr ee quarter delay. ", "page_label": "5", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "62106fa2-0df0-4578-a53e-51fe39997eca", "node_type": "4", "metadata": {"page_label": "5", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "b770202d0f8dda4341d593cc59f6ec168a6c077e1794494b0e47e3483f1dd844", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "c1e144ad-3728-4823-b118-610959f97a50", "node_type": "1", "metadata": {"window": "For the former Medical segment, the fiscal \u201824 outlook is updated to approximately $380 million of \nsegment profit to reflect the net impact of Q2 non -recurring adjustments.  Outside of these, our overall \noperational expectations are consistent with delivering the prior $400 million in segment profit for the \nyear, as well as the corresponding prior expectation of $650 million in segment profit for fiscal year \n\u201926.  We have consistently highlighted the back -half weighting of the Medical guidance, driven by \nprogress within GMPD on Cardinal Health Brand volume growth, the cumulative impact of inflation \nmitigation, and some business -specific seasonality.  Our expectations there continue.  \n \n For example, with inflation mitigation, we have strong visibility to overall cost improvements in the \nsecond half of the year, driven by reductions we\u2019ve observed in international freight, which as a \nreminder reflect in our income statement on a two to thr ee quarter delay.  And as we exit January, the \nmitigation initiatives necessary to achieve our year -end target are now largely in place.  \n \n Now, as seen on slide 10, let me comment on how this fiscal year \u2018 24 guidance translates to our \nupdated segment structure, to go along with the preliminary recast fiscal \u201823 actuals and long -term \ntargets we provided a few weeks back. ", "original_text": "Our expectations there continue.  \n \n", "page_label": "5", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "a45768c56ece803f01ba32f2a805189fd9bb55eff3f599cf4ba597529639ae77", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "99ecc5ee-0622-4ac5-9dd0-90959df9d26e", "node_type": "1", "metadata": {"window": "We have consistently highlighted the back -half weighting of the Medical guidance, driven by \nprogress within GMPD on Cardinal Health Brand volume growth, the cumulative impact of inflation \nmitigation, and some business -specific seasonality.  Our expectations there continue.  \n \n For example, with inflation mitigation, we have strong visibility to overall cost improvements in the \nsecond half of the year, driven by reductions we\u2019ve observed in international freight, which as a \nreminder reflect in our income statement on a two to thr ee quarter delay.  And as we exit January, the \nmitigation initiatives necessary to achieve our year -end target are now largely in place.  \n \n Now, as seen on slide 10, let me comment on how this fiscal year \u2018 24 guidance translates to our \nupdated segment structure, to go along with the preliminary recast fiscal \u201823 actuals and long -term \ntargets we provided a few weeks back.  Our new structure went into effect January 1st, so beginning \nin Q3, we will report results and provide drivers according to the new segment structure, \nPharmaceutical and Specialty Solutions and  GMPD, and separate from these two segments, Nuclear, ", "original_text": "And as we exit January, the \nmitigation initiatives necessary to achieve our year -end target are now largely in place.  \n \n"}, "hash": "b532ddd3a693fd99402df44bdef9bdf0780dc1c12e04248af120a8b934e8e6c5", "class_name": "RelatedNodeInfo"}}, "text": "For example, with inflation mitigation, we have strong visibility to overall cost improvements in the \nsecond half of the year, driven by reductions we\u2019ve observed in international freight, which as a \nreminder reflect in our income statement on a two to thr ee quarter delay. ", "start_char_idx": 2455, "end_char_idx": 2732, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "99ecc5ee-0622-4ac5-9dd0-90959df9d26e": {"__data__": {"id_": "99ecc5ee-0622-4ac5-9dd0-90959df9d26e", "embedding": null, "metadata": {"window": "We have consistently highlighted the back -half weighting of the Medical guidance, driven by \nprogress within GMPD on Cardinal Health Brand volume growth, the cumulative impact of inflation \nmitigation, and some business -specific seasonality.  Our expectations there continue.  \n \n For example, with inflation mitigation, we have strong visibility to overall cost improvements in the \nsecond half of the year, driven by reductions we\u2019ve observed in international freight, which as a \nreminder reflect in our income statement on a two to thr ee quarter delay.  And as we exit January, the \nmitigation initiatives necessary to achieve our year -end target are now largely in place.  \n \n Now, as seen on slide 10, let me comment on how this fiscal year \u2018 24 guidance translates to our \nupdated segment structure, to go along with the preliminary recast fiscal \u201823 actuals and long -term \ntargets we provided a few weeks back.  Our new structure went into effect January 1st, so beginning \nin Q3, we will report results and provide drivers according to the new segment structure, \nPharmaceutical and Specialty Solutions and  GMPD, and separate from these two segments, Nuclear, ", "original_text": "And as we exit January, the \nmitigation initiatives necessary to achieve our year -end target are now largely in place.  \n \n", "page_label": "5", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "62106fa2-0df0-4578-a53e-51fe39997eca", "node_type": "4", "metadata": {"page_label": "5", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "b770202d0f8dda4341d593cc59f6ec168a6c077e1794494b0e47e3483f1dd844", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "f4559797-4e0e-4ca1-84d0-7dac65822cd9", "node_type": "1", "metadata": {"window": "Outside of these, our overall \noperational expectations are consistent with delivering the prior $400 million in segment profit for the \nyear, as well as the corresponding prior expectation of $650 million in segment profit for fiscal year \n\u201926.  We have consistently highlighted the back -half weighting of the Medical guidance, driven by \nprogress within GMPD on Cardinal Health Brand volume growth, the cumulative impact of inflation \nmitigation, and some business -specific seasonality.  Our expectations there continue.  \n \n For example, with inflation mitigation, we have strong visibility to overall cost improvements in the \nsecond half of the year, driven by reductions we\u2019ve observed in international freight, which as a \nreminder reflect in our income statement on a two to thr ee quarter delay.  And as we exit January, the \nmitigation initiatives necessary to achieve our year -end target are now largely in place.  \n \n Now, as seen on slide 10, let me comment on how this fiscal year \u2018 24 guidance translates to our \nupdated segment structure, to go along with the preliminary recast fiscal \u201823 actuals and long -term \ntargets we provided a few weeks back.  Our new structure went into effect January 1st, so beginning \nin Q3, we will report results and provide drivers according to the new segment structure, \nPharmaceutical and Specialty Solutions and  GMPD, and separate from these two segments, Nuclear, ", "original_text": "For example, with inflation mitigation, we have strong visibility to overall cost improvements in the \nsecond half of the year, driven by reductions we\u2019ve observed in international freight, which as a \nreminder reflect in our income statement on a two to thr ee quarter delay. ", "page_label": "5", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "516682f25b55c31945f8b9d0523a6a58d9b785a36abbc4b980ca5a49fdf91b48", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "35a4c3d9-7aa2-4a29-9409-d3131eed678e", "node_type": "1", "metadata": {"window": "Our expectations there continue.  \n \n For example, with inflation mitigation, we have strong visibility to overall cost improvements in the \nsecond half of the year, driven by reductions we\u2019ve observed in international freight, which as a \nreminder reflect in our income statement on a two to thr ee quarter delay.  And as we exit January, the \nmitigation initiatives necessary to achieve our year -end target are now largely in place.  \n \n Now, as seen on slide 10, let me comment on how this fiscal year \u2018 24 guidance translates to our \nupdated segment structure, to go along with the preliminary recast fiscal \u201823 actuals and long -term \ntargets we provided a few weeks back.  Our new structure went into effect January 1st, so beginning \nin Q3, we will report results and provide drivers according to the new segment structure, \nPharmaceutical and Specialty Solutions and  GMPD, and separate from these two segments, Nuclear, ", "original_text": "Now, as seen on slide 10, let me comment on how this fiscal year \u2018 24 guidance translates to our \nupdated segment structure, to go along with the preliminary recast fiscal \u201823 actuals and long -term \ntargets we provided a few weeks back. "}, "hash": "472e083d5b2cbe617e8eb2b31da662d6f7f9f3a9f06e649258296c6b10a9a773", "class_name": "RelatedNodeInfo"}}, "text": "And as we exit January, the \nmitigation initiatives necessary to achieve our year -end target are now largely in place.  \n \n", "start_char_idx": 2732, "end_char_idx": 2856, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "35a4c3d9-7aa2-4a29-9409-d3131eed678e": {"__data__": {"id_": "35a4c3d9-7aa2-4a29-9409-d3131eed678e", "embedding": null, "metadata": {"window": "Our expectations there continue.  \n \n For example, with inflation mitigation, we have strong visibility to overall cost improvements in the \nsecond half of the year, driven by reductions we\u2019ve observed in international freight, which as a \nreminder reflect in our income statement on a two to thr ee quarter delay.  And as we exit January, the \nmitigation initiatives necessary to achieve our year -end target are now largely in place.  \n \n Now, as seen on slide 10, let me comment on how this fiscal year \u2018 24 guidance translates to our \nupdated segment structure, to go along with the preliminary recast fiscal \u201823 actuals and long -term \ntargets we provided a few weeks back.  Our new structure went into effect January 1st, so beginning \nin Q3, we will report results and provide drivers according to the new segment structure, \nPharmaceutical and Specialty Solutions and  GMPD, and separate from these two segments, Nuclear, ", "original_text": "Now, as seen on slide 10, let me comment on how this fiscal year \u2018 24 guidance translates to our \nupdated segment structure, to go along with the preliminary recast fiscal \u201823 actuals and long -term \ntargets we provided a few weeks back. ", "page_label": "5", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "62106fa2-0df0-4578-a53e-51fe39997eca", "node_type": "4", "metadata": {"page_label": "5", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "b770202d0f8dda4341d593cc59f6ec168a6c077e1794494b0e47e3483f1dd844", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "99ecc5ee-0622-4ac5-9dd0-90959df9d26e", "node_type": "1", "metadata": {"window": "We have consistently highlighted the back -half weighting of the Medical guidance, driven by \nprogress within GMPD on Cardinal Health Brand volume growth, the cumulative impact of inflation \nmitigation, and some business -specific seasonality.  Our expectations there continue.  \n \n For example, with inflation mitigation, we have strong visibility to overall cost improvements in the \nsecond half of the year, driven by reductions we\u2019ve observed in international freight, which as a \nreminder reflect in our income statement on a two to thr ee quarter delay.  And as we exit January, the \nmitigation initiatives necessary to achieve our year -end target are now largely in place.  \n \n Now, as seen on slide 10, let me comment on how this fiscal year \u2018 24 guidance translates to our \nupdated segment structure, to go along with the preliminary recast fiscal \u201823 actuals and long -term \ntargets we provided a few weeks back.  Our new structure went into effect January 1st, so beginning \nin Q3, we will report results and provide drivers according to the new segment structure, \nPharmaceutical and Specialty Solutions and  GMPD, and separate from these two segments, Nuclear, ", "original_text": "And as we exit January, the \nmitigation initiatives necessary to achieve our year -end target are now largely in place.  \n \n", "page_label": "5", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "721f43b152300d33ddb5b2d1066eef411f07e55210fed408fa49a692ce420015", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "9e7b4c27-a664-49b6-aeb1-73c837d86154", "node_type": "1", "metadata": {"window": "For example, with inflation mitigation, we have strong visibility to overall cost improvements in the \nsecond half of the year, driven by reductions we\u2019ve observed in international freight, which as a \nreminder reflect in our income statement on a two to thr ee quarter delay.  And as we exit January, the \nmitigation initiatives necessary to achieve our year -end target are now largely in place.  \n \n Now, as seen on slide 10, let me comment on how this fiscal year \u2018 24 guidance translates to our \nupdated segment structure, to go along with the preliminary recast fiscal \u201823 actuals and long -term \ntargets we provided a few weeks back.  Our new structure went into effect January 1st, so beginning \nin Q3, we will report results and provide drivers according to the new segment structure, \nPharmaceutical and Specialty Solutions and  GMPD, and separate from these two segments, Nuclear, ", "original_text": "Our new structure went into effect January 1st, so beginning \nin Q3, we will report results and provide drivers according to the new segment structure, \nPharmaceutical and Specialty Solutions and  GMPD, and separate from these two segments, Nuclear, "}, "hash": "2f78fce1b4394accda40fe8957fe569f1c4f2f003fcd9566b4bca6abab6e9836", "class_name": "RelatedNodeInfo"}}, "text": "Now, as seen on slide 10, let me comment on how this fiscal year \u2018 24 guidance translates to our \nupdated segment structure, to go along with the preliminary recast fiscal \u201823 actuals and long -term \ntargets we provided a few weeks back. ", "start_char_idx": 2856, "end_char_idx": 3094, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "9e7b4c27-a664-49b6-aeb1-73c837d86154": {"__data__": {"id_": "9e7b4c27-a664-49b6-aeb1-73c837d86154", "embedding": null, "metadata": {"window": "For example, with inflation mitigation, we have strong visibility to overall cost improvements in the \nsecond half of the year, driven by reductions we\u2019ve observed in international freight, which as a \nreminder reflect in our income statement on a two to thr ee quarter delay.  And as we exit January, the \nmitigation initiatives necessary to achieve our year -end target are now largely in place.  \n \n Now, as seen on slide 10, let me comment on how this fiscal year \u2018 24 guidance translates to our \nupdated segment structure, to go along with the preliminary recast fiscal \u201823 actuals and long -term \ntargets we provided a few weeks back.  Our new structure went into effect January 1st, so beginning \nin Q3, we will report results and provide drivers according to the new segment structure, \nPharmaceutical and Specialty Solutions and  GMPD, and separate from these two segments, Nuclear, ", "original_text": "Our new structure went into effect January 1st, so beginning \nin Q3, we will report results and provide drivers according to the new segment structure, \nPharmaceutical and Specialty Solutions and  GMPD, and separate from these two segments, Nuclear, ", "page_label": "5", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "62106fa2-0df0-4578-a53e-51fe39997eca", "node_type": "4", "metadata": {"page_label": "5", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "b770202d0f8dda4341d593cc59f6ec168a6c077e1794494b0e47e3483f1dd844", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "35a4c3d9-7aa2-4a29-9409-d3131eed678e", "node_type": "1", "metadata": {"window": "Our expectations there continue.  \n \n For example, with inflation mitigation, we have strong visibility to overall cost improvements in the \nsecond half of the year, driven by reductions we\u2019ve observed in international freight, which as a \nreminder reflect in our income statement on a two to thr ee quarter delay.  And as we exit January, the \nmitigation initiatives necessary to achieve our year -end target are now largely in place.  \n \n Now, as seen on slide 10, let me comment on how this fiscal year \u2018 24 guidance translates to our \nupdated segment structure, to go along with the preliminary recast fiscal \u201823 actuals and long -term \ntargets we provided a few weeks back.  Our new structure went into effect January 1st, so beginning \nin Q3, we will report results and provide drivers according to the new segment structure, \nPharmaceutical and Specialty Solutions and  GMPD, and separate from these two segments, Nuclear, ", "original_text": "Now, as seen on slide 10, let me comment on how this fiscal year \u2018 24 guidance translates to our \nupdated segment structure, to go along with the preliminary recast fiscal \u201823 actuals and long -term \ntargets we provided a few weeks back. ", "page_label": "5", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "8ffb3bbc1189754cb7957b298e0f6adff4d59d4c63b2b1639fd0997b9ac66dc4", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "cd9ffd1c-3051-43c8-8973-0721d0ed2a41", "node_type": "1", "metadata": {"window": " \nPage 6 of 19 \n \nat-Home and OptiFreight\u00ae aggregated in Other.  At that time,  we also plan to provide a recast of the \nresults for fiscals \u201822 to \u201824 on the new segmentation.  \n \n Beginning with the Pharmaceutical and Specialty Solutions segment, the guidance ranges are \nconsistent with the former Pharma segment, even excluding our higher -growth Nuclear business.  We \nexpect 10% to 12% revenue growth and 7% to 9% segment profit outlook  for fiscal \u201824, and a 4% to \n6% segment profit growth CAGR over the long term.  \n \n", "original_text": " \nPage 6 of 19 \n \nat-Home and OptiFreight\u00ae aggregated in Other. "}, "hash": "b4c6f2b80ca6e210431126eda142daab17477da4552dba3947d3319d4a382ee2", "class_name": "RelatedNodeInfo"}}, "text": "Our new structure went into effect January 1st, so beginning \nin Q3, we will report results and provide drivers according to the new segment structure, \nPharmaceutical and Specialty Solutions and  GMPD, and separate from these two segments, Nuclear, ", "start_char_idx": 3094, "end_char_idx": 3344, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "cd9ffd1c-3051-43c8-8973-0721d0ed2a41": {"__data__": {"id_": "cd9ffd1c-3051-43c8-8973-0721d0ed2a41", "embedding": null, "metadata": {"window": " \nPage 6 of 19 \n \nat-Home and OptiFreight\u00ae aggregated in Other.  At that time,  we also plan to provide a recast of the \nresults for fiscals \u201822 to \u201824 on the new segmentation.  \n \n Beginning with the Pharmaceutical and Specialty Solutions segment, the guidance ranges are \nconsistent with the former Pharma segment, even excluding our higher -growth Nuclear business.  We \nexpect 10% to 12% revenue growth and 7% to 9% segment profit outlook  for fiscal \u201824, and a 4% to \n6% segment profit growth CAGR over the long term.  \n \n", "original_text": " \nPage 6 of 19 \n \nat-Home and OptiFreight\u00ae aggregated in Other. ", "page_label": "6", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "46b2014a-9df1-4279-a34f-4fd4570310ad", "node_type": "4", "metadata": {"page_label": "6", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "32f6d1d774e204e51e9df5608bd9058cced7a672874c5398480b3538effc8b45", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "9e7b4c27-a664-49b6-aeb1-73c837d86154", "node_type": "1", "metadata": {"window": "For example, with inflation mitigation, we have strong visibility to overall cost improvements in the \nsecond half of the year, driven by reductions we\u2019ve observed in international freight, which as a \nreminder reflect in our income statement on a two to thr ee quarter delay.  And as we exit January, the \nmitigation initiatives necessary to achieve our year -end target are now largely in place.  \n \n Now, as seen on slide 10, let me comment on how this fiscal year \u2018 24 guidance translates to our \nupdated segment structure, to go along with the preliminary recast fiscal \u201823 actuals and long -term \ntargets we provided a few weeks back.  Our new structure went into effect January 1st, so beginning \nin Q3, we will report results and provide drivers according to the new segment structure, \nPharmaceutical and Specialty Solutions and  GMPD, and separate from these two segments, Nuclear, ", "original_text": "Our new structure went into effect January 1st, so beginning \nin Q3, we will report results and provide drivers according to the new segment structure, \nPharmaceutical and Specialty Solutions and  GMPD, and separate from these two segments, Nuclear, ", "page_label": "5", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "3f32eb072b465a8f39d091030277175f7b44516f344f471f257b8183f1946bc6", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "7b13b2d1-a32a-429a-9adc-a33549f9c50a", "node_type": "1", "metadata": {"window": " \nPage 6 of 19 \n \nat-Home and OptiFreight\u00ae aggregated in Other.  At that time,  we also plan to provide a recast of the \nresults for fiscals \u201822 to \u201824 on the new segmentation.  \n \n Beginning with the Pharmaceutical and Specialty Solutions segment, the guidance ranges are \nconsistent with the former Pharma segment, even excluding our higher -growth Nuclear business.  We \nexpect 10% to 12% revenue growth and 7% to 9% segment profit outlook  for fiscal \u201824, and a 4% to \n6% segment profit growth CAGR over the long term.  \n \n Turning to GMPD, where we remain encouraged by the improvements in this business.  \n \n", "original_text": "At that time,  we also plan to provide a recast of the \nresults for fiscals \u201822 to \u201824 on the new segmentation.  \n \n"}, "hash": "15177108a65123eee324d3945182efcb96a5e3151ca58b199c7b3c5a52e67905", "class_name": "RelatedNodeInfo"}}, "text": " \nPage 6 of 19 \n \nat-Home and OptiFreight\u00ae aggregated in Other. ", "start_char_idx": 0, "end_char_idx": 64, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "7b13b2d1-a32a-429a-9adc-a33549f9c50a": {"__data__": {"id_": "7b13b2d1-a32a-429a-9adc-a33549f9c50a", "embedding": null, "metadata": {"window": " \nPage 6 of 19 \n \nat-Home and OptiFreight\u00ae aggregated in Other.  At that time,  we also plan to provide a recast of the \nresults for fiscals \u201822 to \u201824 on the new segmentation.  \n \n Beginning with the Pharmaceutical and Specialty Solutions segment, the guidance ranges are \nconsistent with the former Pharma segment, even excluding our higher -growth Nuclear business.  We \nexpect 10% to 12% revenue growth and 7% to 9% segment profit outlook  for fiscal \u201824, and a 4% to \n6% segment profit growth CAGR over the long term.  \n \n Turning to GMPD, where we remain encouraged by the improvements in this business.  \n \n", "original_text": "At that time,  we also plan to provide a recast of the \nresults for fiscals \u201822 to \u201824 on the new segmentation.  \n \n", "page_label": "6", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "46b2014a-9df1-4279-a34f-4fd4570310ad", "node_type": "4", "metadata": {"page_label": "6", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "32f6d1d774e204e51e9df5608bd9058cced7a672874c5398480b3538effc8b45", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "cd9ffd1c-3051-43c8-8973-0721d0ed2a41", "node_type": "1", "metadata": {"window": " \nPage 6 of 19 \n \nat-Home and OptiFreight\u00ae aggregated in Other.  At that time,  we also plan to provide a recast of the \nresults for fiscals \u201822 to \u201824 on the new segmentation.  \n \n Beginning with the Pharmaceutical and Specialty Solutions segment, the guidance ranges are \nconsistent with the former Pharma segment, even excluding our higher -growth Nuclear business.  We \nexpect 10% to 12% revenue growth and 7% to 9% segment profit outlook  for fiscal \u201824, and a 4% to \n6% segment profit growth CAGR over the long term.  \n \n", "original_text": " \nPage 6 of 19 \n \nat-Home and OptiFreight\u00ae aggregated in Other. ", "page_label": "6", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "75a6f6fe6d06c35b780d6dc17064eeea97ecfb871efb362f2b3aae0dda2a6e0b", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "ae6163ac-8069-4006-9dd6-8e2b56faf487", "node_type": "1", "metadata": {"window": " \nPage 6 of 19 \n \nat-Home and OptiFreight\u00ae aggregated in Other.  At that time,  we also plan to provide a recast of the \nresults for fiscals \u201822 to \u201824 on the new segmentation.  \n \n Beginning with the Pharmaceutical and Specialty Solutions segment, the guidance ranges are \nconsistent with the former Pharma segment, even excluding our higher -growth Nuclear business.  We \nexpect 10% to 12% revenue growth and 7% to 9% segment profit outlook  for fiscal \u201824, and a 4% to \n6% segment profit growth CAGR over the long term.  \n \n Turning to GMPD, where we remain encouraged by the improvements in this business.  \n \n Through the execution of the Medical Improvement Plan initiatives, we expect to drive GMPD from an \noperating loss of approximately $165 million in fiscal \u201823 to operating income of approximately $65 \nmillion in fiscal \u201824. ", "original_text": "Beginning with the Pharmaceutical and Specialty Solutions segment, the guidance ranges are \nconsistent with the former Pharma segment, even excluding our higher -growth Nuclear business. "}, "hash": "0f75607db0135dc6408ff0018adf690c668e570d0098add189d044797eeb1f69", "class_name": "RelatedNodeInfo"}}, "text": "At that time,  we also plan to provide a recast of the \nresults for fiscals \u201822 to \u201824 on the new segmentation.  \n \n", "start_char_idx": 64, "end_char_idx": 180, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "ae6163ac-8069-4006-9dd6-8e2b56faf487": {"__data__": {"id_": "ae6163ac-8069-4006-9dd6-8e2b56faf487", "embedding": null, "metadata": {"window": " \nPage 6 of 19 \n \nat-Home and OptiFreight\u00ae aggregated in Other.  At that time,  we also plan to provide a recast of the \nresults for fiscals \u201822 to \u201824 on the new segmentation.  \n \n Beginning with the Pharmaceutical and Specialty Solutions segment, the guidance ranges are \nconsistent with the former Pharma segment, even excluding our higher -growth Nuclear business.  We \nexpect 10% to 12% revenue growth and 7% to 9% segment profit outlook  for fiscal \u201824, and a 4% to \n6% segment profit growth CAGR over the long term.  \n \n Turning to GMPD, where we remain encouraged by the improvements in this business.  \n \n Through the execution of the Medical Improvement Plan initiatives, we expect to drive GMPD from an \noperating loss of approximately $165 million in fiscal \u201823 to operating income of approximately $65 \nmillion in fiscal \u201824. ", "original_text": "Beginning with the Pharmaceutical and Specialty Solutions segment, the guidance ranges are \nconsistent with the former Pharma segment, even excluding our higher -growth Nuclear business. ", "page_label": "6", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "46b2014a-9df1-4279-a34f-4fd4570310ad", "node_type": "4", "metadata": {"page_label": "6", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "32f6d1d774e204e51e9df5608bd9058cced7a672874c5398480b3538effc8b45", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "7b13b2d1-a32a-429a-9adc-a33549f9c50a", "node_type": "1", "metadata": {"window": " \nPage 6 of 19 \n \nat-Home and OptiFreight\u00ae aggregated in Other.  At that time,  we also plan to provide a recast of the \nresults for fiscals \u201822 to \u201824 on the new segmentation.  \n \n Beginning with the Pharmaceutical and Specialty Solutions segment, the guidance ranges are \nconsistent with the former Pharma segment, even excluding our higher -growth Nuclear business.  We \nexpect 10% to 12% revenue growth and 7% to 9% segment profit outlook  for fiscal \u201824, and a 4% to \n6% segment profit growth CAGR over the long term.  \n \n Turning to GMPD, where we remain encouraged by the improvements in this business.  \n \n", "original_text": "At that time,  we also plan to provide a recast of the \nresults for fiscals \u201822 to \u201824 on the new segmentation.  \n \n", "page_label": "6", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "3bf754a91a71ffec39797fdc6fd353c07e4b48c0a64e0240a95b961ea13ce766", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "5446d953-c24c-47fe-ac1b-aeae0abed8d8", "node_type": "1", "metadata": {"window": " \nPage 6 of 19 \n \nat-Home and OptiFreight\u00ae aggregated in Other.  At that time,  we also plan to provide a recast of the \nresults for fiscals \u201822 to \u201824 on the new segmentation.  \n \n Beginning with the Pharmaceutical and Specialty Solutions segment, the guidance ranges are \nconsistent with the former Pharma segment, even excluding our higher -growth Nuclear business.  We \nexpect 10% to 12% revenue growth and 7% to 9% segment profit outlook  for fiscal \u201824, and a 4% to \n6% segment profit growth CAGR over the long term.  \n \n Turning to GMPD, where we remain encouraged by the improvements in this business.  \n \n Through the execution of the Medical Improvement Plan initiatives, we expect to drive GMPD from an \noperating loss of approximately $165 million in fiscal \u201823 to operating income of approximately $65 \nmillion in fiscal \u201824.  From the fiscal \u201823 low point, this $230 million year -over-year improvement would \nposition us roughly half -way towards our fiscal \u201826 target of approximately $300 million of segment \nprofit.  \n \n", "original_text": "We \nexpect 10% to 12% revenue growth and 7% to 9% segment profit outlook  for fiscal \u201824, and a 4% to \n6% segment profit growth CAGR over the long term.  \n \n"}, "hash": "df4ab2859ae76e84afe13def1133b09bae96f42366ea942d4163e129682eaf74", "class_name": "RelatedNodeInfo"}}, "text": "Beginning with the Pharmaceutical and Specialty Solutions segment, the guidance ranges are \nconsistent with the former Pharma segment, even excluding our higher -growth Nuclear business. ", "start_char_idx": 180, "end_char_idx": 367, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "5446d953-c24c-47fe-ac1b-aeae0abed8d8": {"__data__": {"id_": "5446d953-c24c-47fe-ac1b-aeae0abed8d8", "embedding": null, "metadata": {"window": " \nPage 6 of 19 \n \nat-Home and OptiFreight\u00ae aggregated in Other.  At that time,  we also plan to provide a recast of the \nresults for fiscals \u201822 to \u201824 on the new segmentation.  \n \n Beginning with the Pharmaceutical and Specialty Solutions segment, the guidance ranges are \nconsistent with the former Pharma segment, even excluding our higher -growth Nuclear business.  We \nexpect 10% to 12% revenue growth and 7% to 9% segment profit outlook  for fiscal \u201824, and a 4% to \n6% segment profit growth CAGR over the long term.  \n \n Turning to GMPD, where we remain encouraged by the improvements in this business.  \n \n Through the execution of the Medical Improvement Plan initiatives, we expect to drive GMPD from an \noperating loss of approximately $165 million in fiscal \u201823 to operating income of approximately $65 \nmillion in fiscal \u201824.  From the fiscal \u201823 low point, this $230 million year -over-year improvement would \nposition us roughly half -way towards our fiscal \u201826 target of approximately $300 million of segment \nprofit.  \n \n", "original_text": "We \nexpect 10% to 12% revenue growth and 7% to 9% segment profit outlook  for fiscal \u201824, and a 4% to \n6% segment profit growth CAGR over the long term.  \n \n", "page_label": "6", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "46b2014a-9df1-4279-a34f-4fd4570310ad", "node_type": "4", "metadata": {"page_label": "6", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "32f6d1d774e204e51e9df5608bd9058cced7a672874c5398480b3538effc8b45", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "ae6163ac-8069-4006-9dd6-8e2b56faf487", "node_type": "1", "metadata": {"window": " \nPage 6 of 19 \n \nat-Home and OptiFreight\u00ae aggregated in Other.  At that time,  we also plan to provide a recast of the \nresults for fiscals \u201822 to \u201824 on the new segmentation.  \n \n Beginning with the Pharmaceutical and Specialty Solutions segment, the guidance ranges are \nconsistent with the former Pharma segment, even excluding our higher -growth Nuclear business.  We \nexpect 10% to 12% revenue growth and 7% to 9% segment profit outlook  for fiscal \u201824, and a 4% to \n6% segment profit growth CAGR over the long term.  \n \n Turning to GMPD, where we remain encouraged by the improvements in this business.  \n \n Through the execution of the Medical Improvement Plan initiatives, we expect to drive GMPD from an \noperating loss of approximately $165 million in fiscal \u201823 to operating income of approximately $65 \nmillion in fiscal \u201824. ", "original_text": "Beginning with the Pharmaceutical and Specialty Solutions segment, the guidance ranges are \nconsistent with the former Pharma segment, even excluding our higher -growth Nuclear business. ", "page_label": "6", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "c06e693f0d71448d6302840931f883f4d23882825c5694c0bec1139d323b6330", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "c7af42ad-d22e-4f3c-a1d0-4763722b42ff", "node_type": "1", "metadata": {"window": "At that time,  we also plan to provide a recast of the \nresults for fiscals \u201822 to \u201824 on the new segmentation.  \n \n Beginning with the Pharmaceutical and Specialty Solutions segment, the guidance ranges are \nconsistent with the former Pharma segment, even excluding our higher -growth Nuclear business.  We \nexpect 10% to 12% revenue growth and 7% to 9% segment profit outlook  for fiscal \u201824, and a 4% to \n6% segment profit growth CAGR over the long term.  \n \n Turning to GMPD, where we remain encouraged by the improvements in this business.  \n \n Through the execution of the Medical Improvement Plan initiatives, we expect to drive GMPD from an \noperating loss of approximately $165 million in fiscal \u201823 to operating income of approximately $65 \nmillion in fiscal \u201824.  From the fiscal \u201823 low point, this $230 million year -over-year improvement would \nposition us roughly half -way towards our fiscal \u201826 target of approximately $300 million of segment \nprofit.  \n \n Finally, we expect the businesses included in Other, at -Home Solutions, Nuclear & Precision Health \nSolutions, and OptiFreight\u00ae Logistics to collectively deliver 6% to 8% segment profit growth in fiscal \n\u201824. ", "original_text": "Turning to GMPD, where we remain encouraged by the improvements in this business.  \n \n"}, "hash": "c614a93d3e92999e5be2b361837d3a23466fa8210a054025a9e993cdc849842a", "class_name": "RelatedNodeInfo"}}, "text": "We \nexpect 10% to 12% revenue growth and 7% to 9% segment profit outlook  for fiscal \u201824, and a 4% to \n6% segment profit growth CAGR over the long term.  \n \n", "start_char_idx": 367, "end_char_idx": 524, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "c7af42ad-d22e-4f3c-a1d0-4763722b42ff": {"__data__": {"id_": "c7af42ad-d22e-4f3c-a1d0-4763722b42ff", "embedding": null, "metadata": {"window": "At that time,  we also plan to provide a recast of the \nresults for fiscals \u201822 to \u201824 on the new segmentation.  \n \n Beginning with the Pharmaceutical and Specialty Solutions segment, the guidance ranges are \nconsistent with the former Pharma segment, even excluding our higher -growth Nuclear business.  We \nexpect 10% to 12% revenue growth and 7% to 9% segment profit outlook  for fiscal \u201824, and a 4% to \n6% segment profit growth CAGR over the long term.  \n \n Turning to GMPD, where we remain encouraged by the improvements in this business.  \n \n Through the execution of the Medical Improvement Plan initiatives, we expect to drive GMPD from an \noperating loss of approximately $165 million in fiscal \u201823 to operating income of approximately $65 \nmillion in fiscal \u201824.  From the fiscal \u201823 low point, this $230 million year -over-year improvement would \nposition us roughly half -way towards our fiscal \u201826 target of approximately $300 million of segment \nprofit.  \n \n Finally, we expect the businesses included in Other, at -Home Solutions, Nuclear & Precision Health \nSolutions, and OptiFreight\u00ae Logistics to collectively deliver 6% to 8% segment profit growth in fiscal \n\u201824. ", "original_text": "Turning to GMPD, where we remain encouraged by the improvements in this business.  \n \n", "page_label": "6", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "46b2014a-9df1-4279-a34f-4fd4570310ad", "node_type": "4", "metadata": {"page_label": "6", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "32f6d1d774e204e51e9df5608bd9058cced7a672874c5398480b3538effc8b45", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "5446d953-c24c-47fe-ac1b-aeae0abed8d8", "node_type": "1", "metadata": {"window": " \nPage 6 of 19 \n \nat-Home and OptiFreight\u00ae aggregated in Other.  At that time,  we also plan to provide a recast of the \nresults for fiscals \u201822 to \u201824 on the new segmentation.  \n \n Beginning with the Pharmaceutical and Specialty Solutions segment, the guidance ranges are \nconsistent with the former Pharma segment, even excluding our higher -growth Nuclear business.  We \nexpect 10% to 12% revenue growth and 7% to 9% segment profit outlook  for fiscal \u201824, and a 4% to \n6% segment profit growth CAGR over the long term.  \n \n Turning to GMPD, where we remain encouraged by the improvements in this business.  \n \n Through the execution of the Medical Improvement Plan initiatives, we expect to drive GMPD from an \noperating loss of approximately $165 million in fiscal \u201823 to operating income of approximately $65 \nmillion in fiscal \u201824.  From the fiscal \u201823 low point, this $230 million year -over-year improvement would \nposition us roughly half -way towards our fiscal \u201826 target of approximately $300 million of segment \nprofit.  \n \n", "original_text": "We \nexpect 10% to 12% revenue growth and 7% to 9% segment profit outlook  for fiscal \u201824, and a 4% to \n6% segment profit growth CAGR over the long term.  \n \n", "page_label": "6", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "57eb502fc9773416e8114905ea600cb67c01cf9dbf3e4598ff10d04b3e1e5e77", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "95f3cf67-4d72-4239-aaf7-d941f75ba82c", "node_type": "1", "metadata": {"window": "Beginning with the Pharmaceutical and Specialty Solutions segment, the guidance ranges are \nconsistent with the former Pharma segment, even excluding our higher -growth Nuclear business.  We \nexpect 10% to 12% revenue growth and 7% to 9% segment profit outlook  for fiscal \u201824, and a 4% to \n6% segment profit growth CAGR over the long term.  \n \n Turning to GMPD, where we remain encouraged by the improvements in this business.  \n \n Through the execution of the Medical Improvement Plan initiatives, we expect to drive GMPD from an \noperating loss of approximately $165 million in fiscal \u201823 to operating income of approximately $65 \nmillion in fiscal \u201824.  From the fiscal \u201823 low point, this $230 million year -over-year improvement would \nposition us roughly half -way towards our fiscal \u201826 target of approximately $300 million of segment \nprofit.  \n \n Finally, we expect the businesses included in Other, at -Home Solutions, Nuclear & Precision Health \nSolutions, and OptiFreight\u00ae Logistics to collectively deliver 6% to 8% segment profit growth in fiscal \n\u201824.  The difference between this fiscal \u201824 growth rate and the long -term CAGR of 8% to 10% for \nfiscal \u201824 to \u201826 reflects the portion of the Q2 non -recurring adjustments within at -Home Solutions, \nwith the remainder residing in GMPD.  \n \n", "original_text": "Through the execution of the Medical Improvement Plan initiatives, we expect to drive GMPD from an \noperating loss of approximately $165 million in fiscal \u201823 to operating income of approximately $65 \nmillion in fiscal \u201824. "}, "hash": "459c31e0622cf9f711daec80ce09adc84ee8db694917f4678becb0129cc31921", "class_name": "RelatedNodeInfo"}}, "text": "Turning to GMPD, where we remain encouraged by the improvements in this business.  \n \n", "start_char_idx": 524, "end_char_idx": 610, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "95f3cf67-4d72-4239-aaf7-d941f75ba82c": {"__data__": {"id_": "95f3cf67-4d72-4239-aaf7-d941f75ba82c", "embedding": null, "metadata": {"window": "Beginning with the Pharmaceutical and Specialty Solutions segment, the guidance ranges are \nconsistent with the former Pharma segment, even excluding our higher -growth Nuclear business.  We \nexpect 10% to 12% revenue growth and 7% to 9% segment profit outlook  for fiscal \u201824, and a 4% to \n6% segment profit growth CAGR over the long term.  \n \n Turning to GMPD, where we remain encouraged by the improvements in this business.  \n \n Through the execution of the Medical Improvement Plan initiatives, we expect to drive GMPD from an \noperating loss of approximately $165 million in fiscal \u201823 to operating income of approximately $65 \nmillion in fiscal \u201824.  From the fiscal \u201823 low point, this $230 million year -over-year improvement would \nposition us roughly half -way towards our fiscal \u201826 target of approximately $300 million of segment \nprofit.  \n \n Finally, we expect the businesses included in Other, at -Home Solutions, Nuclear & Precision Health \nSolutions, and OptiFreight\u00ae Logistics to collectively deliver 6% to 8% segment profit growth in fiscal \n\u201824.  The difference between this fiscal \u201824 growth rate and the long -term CAGR of 8% to 10% for \nfiscal \u201824 to \u201826 reflects the portion of the Q2 non -recurring adjustments within at -Home Solutions, \nwith the remainder residing in GMPD.  \n \n", "original_text": "Through the execution of the Medical Improvement Plan initiatives, we expect to drive GMPD from an \noperating loss of approximately $165 million in fiscal \u201823 to operating income of approximately $65 \nmillion in fiscal \u201824. ", "page_label": "6", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "46b2014a-9df1-4279-a34f-4fd4570310ad", "node_type": "4", "metadata": {"page_label": "6", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "32f6d1d774e204e51e9df5608bd9058cced7a672874c5398480b3538effc8b45", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "c7af42ad-d22e-4f3c-a1d0-4763722b42ff", "node_type": "1", "metadata": {"window": "At that time,  we also plan to provide a recast of the \nresults for fiscals \u201822 to \u201824 on the new segmentation.  \n \n Beginning with the Pharmaceutical and Specialty Solutions segment, the guidance ranges are \nconsistent with the former Pharma segment, even excluding our higher -growth Nuclear business.  We \nexpect 10% to 12% revenue growth and 7% to 9% segment profit outlook  for fiscal \u201824, and a 4% to \n6% segment profit growth CAGR over the long term.  \n \n Turning to GMPD, where we remain encouraged by the improvements in this business.  \n \n Through the execution of the Medical Improvement Plan initiatives, we expect to drive GMPD from an \noperating loss of approximately $165 million in fiscal \u201823 to operating income of approximately $65 \nmillion in fiscal \u201824.  From the fiscal \u201823 low point, this $230 million year -over-year improvement would \nposition us roughly half -way towards our fiscal \u201826 target of approximately $300 million of segment \nprofit.  \n \n Finally, we expect the businesses included in Other, at -Home Solutions, Nuclear & Precision Health \nSolutions, and OptiFreight\u00ae Logistics to collectively deliver 6% to 8% segment profit growth in fiscal \n\u201824. ", "original_text": "Turning to GMPD, where we remain encouraged by the improvements in this business.  \n \n", "page_label": "6", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "3b039db82a5bbb4234f8082b7ea79595c47de1ee95314c80053b573e1a3bd9d1", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "d9a6e026-62f5-4aee-9629-39693977650d", "node_type": "1", "metadata": {"window": "We \nexpect 10% to 12% revenue growth and 7% to 9% segment profit outlook  for fiscal \u201824, and a 4% to \n6% segment profit growth CAGR over the long term.  \n \n Turning to GMPD, where we remain encouraged by the improvements in this business.  \n \n Through the execution of the Medical Improvement Plan initiatives, we expect to drive GMPD from an \noperating loss of approximately $165 million in fiscal \u201823 to operating income of approximately $65 \nmillion in fiscal \u201824.  From the fiscal \u201823 low point, this $230 million year -over-year improvement would \nposition us roughly half -way towards our fiscal \u201826 target of approximately $300 million of segment \nprofit.  \n \n Finally, we expect the businesses included in Other, at -Home Solutions, Nuclear & Precision Health \nSolutions, and OptiFreight\u00ae Logistics to collectively deliver 6% to 8% segment profit growth in fiscal \n\u201824.  The difference between this fiscal \u201824 growth rate and the long -term CAGR of 8% to 10% for \nfiscal \u201824 to \u201826 reflects the portion of the Q2 non -recurring adjustments within at -Home Solutions, \nwith the remainder residing in GMPD.  \n \n Before I close, a couple comments on our recently announced acquisition . ", "original_text": "From the fiscal \u201823 low point, this $230 million year -over-year improvement would \nposition us roughly half -way towards our fiscal \u201826 target of approximately $300 million of segment \nprofit.  \n \n"}, "hash": "06a62e42796dfe6e34a9a3e7f47daeaf06626b75f520561d1804d8b130ab761e", "class_name": "RelatedNodeInfo"}}, "text": "Through the execution of the Medical Improvement Plan initiatives, we expect to drive GMPD from an \noperating loss of approximately $165 million in fiscal \u201823 to operating income of approximately $65 \nmillion in fiscal \u201824. ", "start_char_idx": 610, "end_char_idx": 834, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "d9a6e026-62f5-4aee-9629-39693977650d": {"__data__": {"id_": "d9a6e026-62f5-4aee-9629-39693977650d", "embedding": null, "metadata": {"window": "We \nexpect 10% to 12% revenue growth and 7% to 9% segment profit outlook  for fiscal \u201824, and a 4% to \n6% segment profit growth CAGR over the long term.  \n \n Turning to GMPD, where we remain encouraged by the improvements in this business.  \n \n Through the execution of the Medical Improvement Plan initiatives, we expect to drive GMPD from an \noperating loss of approximately $165 million in fiscal \u201823 to operating income of approximately $65 \nmillion in fiscal \u201824.  From the fiscal \u201823 low point, this $230 million year -over-year improvement would \nposition us roughly half -way towards our fiscal \u201826 target of approximately $300 million of segment \nprofit.  \n \n Finally, we expect the businesses included in Other, at -Home Solutions, Nuclear & Precision Health \nSolutions, and OptiFreight\u00ae Logistics to collectively deliver 6% to 8% segment profit growth in fiscal \n\u201824.  The difference between this fiscal \u201824 growth rate and the long -term CAGR of 8% to 10% for \nfiscal \u201824 to \u201826 reflects the portion of the Q2 non -recurring adjustments within at -Home Solutions, \nwith the remainder residing in GMPD.  \n \n Before I close, a couple comments on our recently announced acquisition . ", "original_text": "From the fiscal \u201823 low point, this $230 million year -over-year improvement would \nposition us roughly half -way towards our fiscal \u201826 target of approximately $300 million of segment \nprofit.  \n \n", "page_label": "6", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "46b2014a-9df1-4279-a34f-4fd4570310ad", "node_type": "4", "metadata": {"page_label": "6", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "32f6d1d774e204e51e9df5608bd9058cced7a672874c5398480b3538effc8b45", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "95f3cf67-4d72-4239-aaf7-d941f75ba82c", "node_type": "1", "metadata": {"window": "Beginning with the Pharmaceutical and Specialty Solutions segment, the guidance ranges are \nconsistent with the former Pharma segment, even excluding our higher -growth Nuclear business.  We \nexpect 10% to 12% revenue growth and 7% to 9% segment profit outlook  for fiscal \u201824, and a 4% to \n6% segment profit growth CAGR over the long term.  \n \n Turning to GMPD, where we remain encouraged by the improvements in this business.  \n \n Through the execution of the Medical Improvement Plan initiatives, we expect to drive GMPD from an \noperating loss of approximately $165 million in fiscal \u201823 to operating income of approximately $65 \nmillion in fiscal \u201824.  From the fiscal \u201823 low point, this $230 million year -over-year improvement would \nposition us roughly half -way towards our fiscal \u201826 target of approximately $300 million of segment \nprofit.  \n \n Finally, we expect the businesses included in Other, at -Home Solutions, Nuclear & Precision Health \nSolutions, and OptiFreight\u00ae Logistics to collectively deliver 6% to 8% segment profit growth in fiscal \n\u201824.  The difference between this fiscal \u201824 growth rate and the long -term CAGR of 8% to 10% for \nfiscal \u201824 to \u201826 reflects the portion of the Q2 non -recurring adjustments within at -Home Solutions, \nwith the remainder residing in GMPD.  \n \n", "original_text": "Through the execution of the Medical Improvement Plan initiatives, we expect to drive GMPD from an \noperating loss of approximately $165 million in fiscal \u201823 to operating income of approximately $65 \nmillion in fiscal \u201824. ", "page_label": "6", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "cb4b21848f926167cc6b536f5bab9834ea512291d743dda8807ea626644f152a", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "1aabddb0-4bf0-4325-bdd2-fe279f7dc2c4", "node_type": "1", "metadata": {"window": "Turning to GMPD, where we remain encouraged by the improvements in this business.  \n \n Through the execution of the Medical Improvement Plan initiatives, we expect to drive GMPD from an \noperating loss of approximately $165 million in fiscal \u201823 to operating income of approximately $65 \nmillion in fiscal \u201824.  From the fiscal \u201823 low point, this $230 million year -over-year improvement would \nposition us roughly half -way towards our fiscal \u201826 target of approximately $300 million of segment \nprofit.  \n \n Finally, we expect the businesses included in Other, at -Home Solutions, Nuclear & Precision Health \nSolutions, and OptiFreight\u00ae Logistics to collectively deliver 6% to 8% segment profit growth in fiscal \n\u201824.  The difference between this fiscal \u201824 growth rate and the long -term CAGR of 8% to 10% for \nfiscal \u201824 to \u201826 reflects the portion of the Q2 non -recurring adjustments within at -Home Solutions, \nwith the remainder residing in GMPD.  \n \n Before I close, a couple comments on our recently announced acquisition .  We\u2019ve noted that the \nspecialty category has been our highest priority for potential M&A and a primary consideration for our \nopportunistic capital deployment as part of our disciplined capital allocation framework. ", "original_text": "Finally, we expect the businesses included in Other, at -Home Solutions, Nuclear & Precision Health \nSolutions, and OptiFreight\u00ae Logistics to collectively deliver 6% to 8% segment profit growth in fiscal \n\u201824. "}, "hash": "ec9874c8298fd7859613bd554eadfb904668ccb8d72cae135caa69fdc15c9812", "class_name": "RelatedNodeInfo"}}, "text": "From the fiscal \u201823 low point, this $230 million year -over-year improvement would \nposition us roughly half -way towards our fiscal \u201826 target of approximately $300 million of segment \nprofit.  \n \n", "start_char_idx": 834, "end_char_idx": 1032, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "1aabddb0-4bf0-4325-bdd2-fe279f7dc2c4": {"__data__": {"id_": "1aabddb0-4bf0-4325-bdd2-fe279f7dc2c4", "embedding": null, "metadata": {"window": "Turning to GMPD, where we remain encouraged by the improvements in this business.  \n \n Through the execution of the Medical Improvement Plan initiatives, we expect to drive GMPD from an \noperating loss of approximately $165 million in fiscal \u201823 to operating income of approximately $65 \nmillion in fiscal \u201824.  From the fiscal \u201823 low point, this $230 million year -over-year improvement would \nposition us roughly half -way towards our fiscal \u201826 target of approximately $300 million of segment \nprofit.  \n \n Finally, we expect the businesses included in Other, at -Home Solutions, Nuclear & Precision Health \nSolutions, and OptiFreight\u00ae Logistics to collectively deliver 6% to 8% segment profit growth in fiscal \n\u201824.  The difference between this fiscal \u201824 growth rate and the long -term CAGR of 8% to 10% for \nfiscal \u201824 to \u201826 reflects the portion of the Q2 non -recurring adjustments within at -Home Solutions, \nwith the remainder residing in GMPD.  \n \n Before I close, a couple comments on our recently announced acquisition .  We\u2019ve noted that the \nspecialty category has been our highest priority for potential M&A and a primary consideration for our \nopportunistic capital deployment as part of our disciplined capital allocation framework. ", "original_text": "Finally, we expect the businesses included in Other, at -Home Solutions, Nuclear & Precision Health \nSolutions, and OptiFreight\u00ae Logistics to collectively deliver 6% to 8% segment profit growth in fiscal \n\u201824. ", "page_label": "6", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "46b2014a-9df1-4279-a34f-4fd4570310ad", "node_type": "4", "metadata": {"page_label": "6", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "32f6d1d774e204e51e9df5608bd9058cced7a672874c5398480b3538effc8b45", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "d9a6e026-62f5-4aee-9629-39693977650d", "node_type": "1", "metadata": {"window": "We \nexpect 10% to 12% revenue growth and 7% to 9% segment profit outlook  for fiscal \u201824, and a 4% to \n6% segment profit growth CAGR over the long term.  \n \n Turning to GMPD, where we remain encouraged by the improvements in this business.  \n \n Through the execution of the Medical Improvement Plan initiatives, we expect to drive GMPD from an \noperating loss of approximately $165 million in fiscal \u201823 to operating income of approximately $65 \nmillion in fiscal \u201824.  From the fiscal \u201823 low point, this $230 million year -over-year improvement would \nposition us roughly half -way towards our fiscal \u201826 target of approximately $300 million of segment \nprofit.  \n \n Finally, we expect the businesses included in Other, at -Home Solutions, Nuclear & Precision Health \nSolutions, and OptiFreight\u00ae Logistics to collectively deliver 6% to 8% segment profit growth in fiscal \n\u201824.  The difference between this fiscal \u201824 growth rate and the long -term CAGR of 8% to 10% for \nfiscal \u201824 to \u201826 reflects the portion of the Q2 non -recurring adjustments within at -Home Solutions, \nwith the remainder residing in GMPD.  \n \n Before I close, a couple comments on our recently announced acquisition . ", "original_text": "From the fiscal \u201823 low point, this $230 million year -over-year improvement would \nposition us roughly half -way towards our fiscal \u201826 target of approximately $300 million of segment \nprofit.  \n \n", "page_label": "6", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "402fa908dc7b35a82a2bfc2ae7a00172311c131944b1a84c175a9e97a232b92f", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "e2921bc5-1dbd-4321-a278-af9075c70edc", "node_type": "1", "metadata": {"window": "Through the execution of the Medical Improvement Plan initiatives, we expect to drive GMPD from an \noperating loss of approximately $165 million in fiscal \u201823 to operating income of approximately $65 \nmillion in fiscal \u201824.  From the fiscal \u201823 low point, this $230 million year -over-year improvement would \nposition us roughly half -way towards our fiscal \u201826 target of approximately $300 million of segment \nprofit.  \n \n Finally, we expect the businesses included in Other, at -Home Solutions, Nuclear & Precision Health \nSolutions, and OptiFreight\u00ae Logistics to collectively deliver 6% to 8% segment profit growth in fiscal \n\u201824.  The difference between this fiscal \u201824 growth rate and the long -term CAGR of 8% to 10% for \nfiscal \u201824 to \u201826 reflects the portion of the Q2 non -recurring adjustments within at -Home Solutions, \nwith the remainder residing in GMPD.  \n \n Before I close, a couple comments on our recently announced acquisition .  We\u2019ve noted that the \nspecialty category has been our highest priority for potential M&A and a primary consideration for our \nopportunistic capital deployment as part of our disciplined capital allocation framework.  Given our \nfinancial flexibility and stro ng presence in the other 60% of the specialty market in therapeutic areas \noutside of oncology, we have evaluated a range of potential acquisition candidates to further \naccelerate our Sp ecialty strategy.  \n \n", "original_text": "The difference between this fiscal \u201824 growth rate and the long -term CAGR of 8% to 10% for \nfiscal \u201824 to \u201826 reflects the portion of the Q2 non -recurring adjustments within at -Home Solutions, \nwith the remainder residing in GMPD.  \n \n"}, "hash": "688ca889075ccc41d749f091905d0d227afd83e44aec318d5d178c73f526d9a4", "class_name": "RelatedNodeInfo"}}, "text": "Finally, we expect the businesses included in Other, at -Home Solutions, Nuclear & Precision Health \nSolutions, and OptiFreight\u00ae Logistics to collectively deliver 6% to 8% segment profit growth in fiscal \n\u201824. ", "start_char_idx": 1032, "end_char_idx": 1242, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "e2921bc5-1dbd-4321-a278-af9075c70edc": {"__data__": {"id_": "e2921bc5-1dbd-4321-a278-af9075c70edc", "embedding": null, "metadata": {"window": "Through the execution of the Medical Improvement Plan initiatives, we expect to drive GMPD from an \noperating loss of approximately $165 million in fiscal \u201823 to operating income of approximately $65 \nmillion in fiscal \u201824.  From the fiscal \u201823 low point, this $230 million year -over-year improvement would \nposition us roughly half -way towards our fiscal \u201826 target of approximately $300 million of segment \nprofit.  \n \n Finally, we expect the businesses included in Other, at -Home Solutions, Nuclear & Precision Health \nSolutions, and OptiFreight\u00ae Logistics to collectively deliver 6% to 8% segment profit growth in fiscal \n\u201824.  The difference between this fiscal \u201824 growth rate and the long -term CAGR of 8% to 10% for \nfiscal \u201824 to \u201826 reflects the portion of the Q2 non -recurring adjustments within at -Home Solutions, \nwith the remainder residing in GMPD.  \n \n Before I close, a couple comments on our recently announced acquisition .  We\u2019ve noted that the \nspecialty category has been our highest priority for potential M&A and a primary consideration for our \nopportunistic capital deployment as part of our disciplined capital allocation framework.  Given our \nfinancial flexibility and stro ng presence in the other 60% of the specialty market in therapeutic areas \noutside of oncology, we have evaluated a range of potential acquisition candidates to further \naccelerate our Sp ecialty strategy.  \n \n", "original_text": "The difference between this fiscal \u201824 growth rate and the long -term CAGR of 8% to 10% for \nfiscal \u201824 to \u201826 reflects the portion of the Q2 non -recurring adjustments within at -Home Solutions, \nwith the remainder residing in GMPD.  \n \n", "page_label": "6", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "46b2014a-9df1-4279-a34f-4fd4570310ad", "node_type": "4", "metadata": {"page_label": "6", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "32f6d1d774e204e51e9df5608bd9058cced7a672874c5398480b3538effc8b45", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "1aabddb0-4bf0-4325-bdd2-fe279f7dc2c4", "node_type": "1", "metadata": {"window": "Turning to GMPD, where we remain encouraged by the improvements in this business.  \n \n Through the execution of the Medical Improvement Plan initiatives, we expect to drive GMPD from an \noperating loss of approximately $165 million in fiscal \u201823 to operating income of approximately $65 \nmillion in fiscal \u201824.  From the fiscal \u201823 low point, this $230 million year -over-year improvement would \nposition us roughly half -way towards our fiscal \u201826 target of approximately $300 million of segment \nprofit.  \n \n Finally, we expect the businesses included in Other, at -Home Solutions, Nuclear & Precision Health \nSolutions, and OptiFreight\u00ae Logistics to collectively deliver 6% to 8% segment profit growth in fiscal \n\u201824.  The difference between this fiscal \u201824 growth rate and the long -term CAGR of 8% to 10% for \nfiscal \u201824 to \u201826 reflects the portion of the Q2 non -recurring adjustments within at -Home Solutions, \nwith the remainder residing in GMPD.  \n \n Before I close, a couple comments on our recently announced acquisition .  We\u2019ve noted that the \nspecialty category has been our highest priority for potential M&A and a primary consideration for our \nopportunistic capital deployment as part of our disciplined capital allocation framework. ", "original_text": "Finally, we expect the businesses included in Other, at -Home Solutions, Nuclear & Precision Health \nSolutions, and OptiFreight\u00ae Logistics to collectively deliver 6% to 8% segment profit growth in fiscal \n\u201824. ", "page_label": "6", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "6e8305b0f175f2552edac0994f3c0df9e39325a78e8d552c56e10ef8385367f9", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "263863e6-1476-467c-8b8c-378eb99caafc", "node_type": "1", "metadata": {"window": "From the fiscal \u201823 low point, this $230 million year -over-year improvement would \nposition us roughly half -way towards our fiscal \u201826 target of approximately $300 million of segment \nprofit.  \n \n Finally, we expect the businesses included in Other, at -Home Solutions, Nuclear & Precision Health \nSolutions, and OptiFreight\u00ae Logistics to collectively deliver 6% to 8% segment profit growth in fiscal \n\u201824.  The difference between this fiscal \u201824 growth rate and the long -term CAGR of 8% to 10% for \nfiscal \u201824 to \u201826 reflects the portion of the Q2 non -recurring adjustments within at -Home Solutions, \nwith the remainder residing in GMPD.  \n \n Before I close, a couple comments on our recently announced acquisition .  We\u2019ve noted that the \nspecialty category has been our highest priority for potential M&A and a primary consideration for our \nopportunistic capital deployment as part of our disciplined capital allocation framework.  Given our \nfinancial flexibility and stro ng presence in the other 60% of the specialty market in therapeutic areas \noutside of oncology, we have evaluated a range of potential acquisition candidates to further \naccelerate our Sp ecialty strategy.  \n \n We are thrilled to reach an agreement for Specialty Networks to become a part of the Cardinal Health \nfamily. ", "original_text": "Before I close, a couple comments on our recently announced acquisition . "}, "hash": "60da0cb26fa3d8fa16bfd91654c4efcdbad4f254af9916031a819a93f48eab7b", "class_name": "RelatedNodeInfo"}}, "text": "The difference between this fiscal \u201824 growth rate and the long -term CAGR of 8% to 10% for \nfiscal \u201824 to \u201826 reflects the portion of the Q2 non -recurring adjustments within at -Home Solutions, \nwith the remainder residing in GMPD.  \n \n", "start_char_idx": 1242, "end_char_idx": 1480, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "263863e6-1476-467c-8b8c-378eb99caafc": {"__data__": {"id_": "263863e6-1476-467c-8b8c-378eb99caafc", "embedding": null, "metadata": {"window": "From the fiscal \u201823 low point, this $230 million year -over-year improvement would \nposition us roughly half -way towards our fiscal \u201826 target of approximately $300 million of segment \nprofit.  \n \n Finally, we expect the businesses included in Other, at -Home Solutions, Nuclear & Precision Health \nSolutions, and OptiFreight\u00ae Logistics to collectively deliver 6% to 8% segment profit growth in fiscal \n\u201824.  The difference between this fiscal \u201824 growth rate and the long -term CAGR of 8% to 10% for \nfiscal \u201824 to \u201826 reflects the portion of the Q2 non -recurring adjustments within at -Home Solutions, \nwith the remainder residing in GMPD.  \n \n Before I close, a couple comments on our recently announced acquisition .  We\u2019ve noted that the \nspecialty category has been our highest priority for potential M&A and a primary consideration for our \nopportunistic capital deployment as part of our disciplined capital allocation framework.  Given our \nfinancial flexibility and stro ng presence in the other 60% of the specialty market in therapeutic areas \noutside of oncology, we have evaluated a range of potential acquisition candidates to further \naccelerate our Sp ecialty strategy.  \n \n We are thrilled to reach an agreement for Specialty Networks to become a part of the Cardinal Health \nfamily. ", "original_text": "Before I close, a couple comments on our recently announced acquisition . ", "page_label": "6", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "46b2014a-9df1-4279-a34f-4fd4570310ad", "node_type": "4", "metadata": {"page_label": "6", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "32f6d1d774e204e51e9df5608bd9058cced7a672874c5398480b3538effc8b45", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "e2921bc5-1dbd-4321-a278-af9075c70edc", "node_type": "1", "metadata": {"window": "Through the execution of the Medical Improvement Plan initiatives, we expect to drive GMPD from an \noperating loss of approximately $165 million in fiscal \u201823 to operating income of approximately $65 \nmillion in fiscal \u201824.  From the fiscal \u201823 low point, this $230 million year -over-year improvement would \nposition us roughly half -way towards our fiscal \u201826 target of approximately $300 million of segment \nprofit.  \n \n Finally, we expect the businesses included in Other, at -Home Solutions, Nuclear & Precision Health \nSolutions, and OptiFreight\u00ae Logistics to collectively deliver 6% to 8% segment profit growth in fiscal \n\u201824.  The difference between this fiscal \u201824 growth rate and the long -term CAGR of 8% to 10% for \nfiscal \u201824 to \u201826 reflects the portion of the Q2 non -recurring adjustments within at -Home Solutions, \nwith the remainder residing in GMPD.  \n \n Before I close, a couple comments on our recently announced acquisition .  We\u2019ve noted that the \nspecialty category has been our highest priority for potential M&A and a primary consideration for our \nopportunistic capital deployment as part of our disciplined capital allocation framework.  Given our \nfinancial flexibility and stro ng presence in the other 60% of the specialty market in therapeutic areas \noutside of oncology, we have evaluated a range of potential acquisition candidates to further \naccelerate our Sp ecialty strategy.  \n \n", "original_text": "The difference between this fiscal \u201824 growth rate and the long -term CAGR of 8% to 10% for \nfiscal \u201824 to \u201826 reflects the portion of the Q2 non -recurring adjustments within at -Home Solutions, \nwith the remainder residing in GMPD.  \n \n", "page_label": "6", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "edc022f6ffd2ca0dd8b65b6bf6f4501529158bbb0d2c3a0d5dbf4d2999873a70", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "5b35f39e-be52-4d19-a5e3-d34eca4912e8", "node_type": "1", "metadata": {"window": "Finally, we expect the businesses included in Other, at -Home Solutions, Nuclear & Precision Health \nSolutions, and OptiFreight\u00ae Logistics to collectively deliver 6% to 8% segment profit growth in fiscal \n\u201824.  The difference between this fiscal \u201824 growth rate and the long -term CAGR of 8% to 10% for \nfiscal \u201824 to \u201826 reflects the portion of the Q2 non -recurring adjustments within at -Home Solutions, \nwith the remainder residing in GMPD.  \n \n Before I close, a couple comments on our recently announced acquisition .  We\u2019ve noted that the \nspecialty category has been our highest priority for potential M&A and a primary consideration for our \nopportunistic capital deployment as part of our disciplined capital allocation framework.  Given our \nfinancial flexibility and stro ng presence in the other 60% of the specialty market in therapeutic areas \noutside of oncology, we have evaluated a range of potential acquisition candidates to further \naccelerate our Sp ecialty strategy.  \n \n We are thrilled to reach an agreement for Specialty Networks to become a part of the Cardinal Health \nfamily.  Jason will elaborate on the strategic aspects of the deal, but we plan to include the expected \nfinancial impacts of the transaction in our guidance  upon closing, which of course is subject to the \nsatisfaction of customary closing conditions, including receipt of required regulatory approvals. ", "original_text": "We\u2019ve noted that the \nspecialty category has been our highest priority for potential M&A and a primary consideration for our \nopportunistic capital deployment as part of our disciplined capital allocation framework. "}, "hash": "9dfda8b06f86ca158306678fa9b9f0386e696bf3f134779bd4b61fb827b99f6a", "class_name": "RelatedNodeInfo"}}, "text": "Before I close, a couple comments on our recently announced acquisition . ", "start_char_idx": 1480, "end_char_idx": 1554, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "5b35f39e-be52-4d19-a5e3-d34eca4912e8": {"__data__": {"id_": "5b35f39e-be52-4d19-a5e3-d34eca4912e8", "embedding": null, "metadata": {"window": "Finally, we expect the businesses included in Other, at -Home Solutions, Nuclear & Precision Health \nSolutions, and OptiFreight\u00ae Logistics to collectively deliver 6% to 8% segment profit growth in fiscal \n\u201824.  The difference between this fiscal \u201824 growth rate and the long -term CAGR of 8% to 10% for \nfiscal \u201824 to \u201826 reflects the portion of the Q2 non -recurring adjustments within at -Home Solutions, \nwith the remainder residing in GMPD.  \n \n Before I close, a couple comments on our recently announced acquisition .  We\u2019ve noted that the \nspecialty category has been our highest priority for potential M&A and a primary consideration for our \nopportunistic capital deployment as part of our disciplined capital allocation framework.  Given our \nfinancial flexibility and stro ng presence in the other 60% of the specialty market in therapeutic areas \noutside of oncology, we have evaluated a range of potential acquisition candidates to further \naccelerate our Sp ecialty strategy.  \n \n We are thrilled to reach an agreement for Specialty Networks to become a part of the Cardinal Health \nfamily.  Jason will elaborate on the strategic aspects of the deal, but we plan to include the expected \nfinancial impacts of the transaction in our guidance  upon closing, which of course is subject to the \nsatisfaction of customary closing conditions, including receipt of required regulatory approvals. ", "original_text": "We\u2019ve noted that the \nspecialty category has been our highest priority for potential M&A and a primary consideration for our \nopportunistic capital deployment as part of our disciplined capital allocation framework. ", "page_label": "6", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "46b2014a-9df1-4279-a34f-4fd4570310ad", "node_type": "4", "metadata": {"page_label": "6", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "32f6d1d774e204e51e9df5608bd9058cced7a672874c5398480b3538effc8b45", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "263863e6-1476-467c-8b8c-378eb99caafc", "node_type": "1", "metadata": {"window": "From the fiscal \u201823 low point, this $230 million year -over-year improvement would \nposition us roughly half -way towards our fiscal \u201826 target of approximately $300 million of segment \nprofit.  \n \n Finally, we expect the businesses included in Other, at -Home Solutions, Nuclear & Precision Health \nSolutions, and OptiFreight\u00ae Logistics to collectively deliver 6% to 8% segment profit growth in fiscal \n\u201824.  The difference between this fiscal \u201824 growth rate and the long -term CAGR of 8% to 10% for \nfiscal \u201824 to \u201826 reflects the portion of the Q2 non -recurring adjustments within at -Home Solutions, \nwith the remainder residing in GMPD.  \n \n Before I close, a couple comments on our recently announced acquisition .  We\u2019ve noted that the \nspecialty category has been our highest priority for potential M&A and a primary consideration for our \nopportunistic capital deployment as part of our disciplined capital allocation framework.  Given our \nfinancial flexibility and stro ng presence in the other 60% of the specialty market in therapeutic areas \noutside of oncology, we have evaluated a range of potential acquisition candidates to further \naccelerate our Sp ecialty strategy.  \n \n We are thrilled to reach an agreement for Specialty Networks to become a part of the Cardinal Health \nfamily. ", "original_text": "Before I close, a couple comments on our recently announced acquisition . ", "page_label": "6", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "a6960a79479edaecb298dad49eba064f7e72eeffefa9fdd2173f9e60e9e5e325", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "e69f4c27-e107-447b-a9cc-047ac7eb4ce7", "node_type": "1", "metadata": {"window": "The difference between this fiscal \u201824 growth rate and the long -term CAGR of 8% to 10% for \nfiscal \u201824 to \u201826 reflects the portion of the Q2 non -recurring adjustments within at -Home Solutions, \nwith the remainder residing in GMPD.  \n \n Before I close, a couple comments on our recently announced acquisition .  We\u2019ve noted that the \nspecialty category has been our highest priority for potential M&A and a primary consideration for our \nopportunistic capital deployment as part of our disciplined capital allocation framework.  Given our \nfinancial flexibility and stro ng presence in the other 60% of the specialty market in therapeutic areas \noutside of oncology, we have evaluated a range of potential acquisition candidates to further \naccelerate our Sp ecialty strategy.  \n \n We are thrilled to reach an agreement for Specialty Networks to become a part of the Cardinal Health \nfamily.  Jason will elaborate on the strategic aspects of the deal, but we plan to include the expected \nfinancial impacts of the transaction in our guidance  upon closing, which of course is subject to the \nsatisfaction of customary closing conditions, including receipt of required regulatory approvals.  For \ngeneral modeling purposes, we expect the deal to be accretive 12 months following close.  \n \n", "original_text": "Given our \nfinancial flexibility and stro ng presence in the other 60% of the specialty market in therapeutic areas \noutside of oncology, we have evaluated a range of potential acquisition candidates to further \naccelerate our Sp ecialty strategy.  \n \n"}, "hash": "72cdfd17859afe3204963abd375f04d2bc190e1e69bf11ccd5d2abddcb63f0d5", "class_name": "RelatedNodeInfo"}}, "text": "We\u2019ve noted that the \nspecialty category has been our highest priority for potential M&A and a primary consideration for our \nopportunistic capital deployment as part of our disciplined capital allocation framework. ", "start_char_idx": 1554, "end_char_idx": 1770, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "e69f4c27-e107-447b-a9cc-047ac7eb4ce7": {"__data__": {"id_": "e69f4c27-e107-447b-a9cc-047ac7eb4ce7", "embedding": null, "metadata": {"window": "The difference between this fiscal \u201824 growth rate and the long -term CAGR of 8% to 10% for \nfiscal \u201824 to \u201826 reflects the portion of the Q2 non -recurring adjustments within at -Home Solutions, \nwith the remainder residing in GMPD.  \n \n Before I close, a couple comments on our recently announced acquisition .  We\u2019ve noted that the \nspecialty category has been our highest priority for potential M&A and a primary consideration for our \nopportunistic capital deployment as part of our disciplined capital allocation framework.  Given our \nfinancial flexibility and stro ng presence in the other 60% of the specialty market in therapeutic areas \noutside of oncology, we have evaluated a range of potential acquisition candidates to further \naccelerate our Sp ecialty strategy.  \n \n We are thrilled to reach an agreement for Specialty Networks to become a part of the Cardinal Health \nfamily.  Jason will elaborate on the strategic aspects of the deal, but we plan to include the expected \nfinancial impacts of the transaction in our guidance  upon closing, which of course is subject to the \nsatisfaction of customary closing conditions, including receipt of required regulatory approvals.  For \ngeneral modeling purposes, we expect the deal to be accretive 12 months following close.  \n \n", "original_text": "Given our \nfinancial flexibility and stro ng presence in the other 60% of the specialty market in therapeutic areas \noutside of oncology, we have evaluated a range of potential acquisition candidates to further \naccelerate our Sp ecialty strategy.  \n \n", "page_label": "6", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "46b2014a-9df1-4279-a34f-4fd4570310ad", "node_type": "4", "metadata": {"page_label": "6", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "32f6d1d774e204e51e9df5608bd9058cced7a672874c5398480b3538effc8b45", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "5b35f39e-be52-4d19-a5e3-d34eca4912e8", "node_type": "1", "metadata": {"window": "Finally, we expect the businesses included in Other, at -Home Solutions, Nuclear & Precision Health \nSolutions, and OptiFreight\u00ae Logistics to collectively deliver 6% to 8% segment profit growth in fiscal \n\u201824.  The difference between this fiscal \u201824 growth rate and the long -term CAGR of 8% to 10% for \nfiscal \u201824 to \u201826 reflects the portion of the Q2 non -recurring adjustments within at -Home Solutions, \nwith the remainder residing in GMPD.  \n \n Before I close, a couple comments on our recently announced acquisition .  We\u2019ve noted that the \nspecialty category has been our highest priority for potential M&A and a primary consideration for our \nopportunistic capital deployment as part of our disciplined capital allocation framework.  Given our \nfinancial flexibility and stro ng presence in the other 60% of the specialty market in therapeutic areas \noutside of oncology, we have evaluated a range of potential acquisition candidates to further \naccelerate our Sp ecialty strategy.  \n \n We are thrilled to reach an agreement for Specialty Networks to become a part of the Cardinal Health \nfamily.  Jason will elaborate on the strategic aspects of the deal, but we plan to include the expected \nfinancial impacts of the transaction in our guidance  upon closing, which of course is subject to the \nsatisfaction of customary closing conditions, including receipt of required regulatory approvals. ", "original_text": "We\u2019ve noted that the \nspecialty category has been our highest priority for potential M&A and a primary consideration for our \nopportunistic capital deployment as part of our disciplined capital allocation framework. ", "page_label": "6", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "c98820b525630f346084d541731a219cb320b2d40719c1008e2d2fe65d62f2de", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "72bdbffe-4370-40a8-8f76-17ddf47a4ca3", "node_type": "1", "metadata": {"window": "Before I close, a couple comments on our recently announced acquisition .  We\u2019ve noted that the \nspecialty category has been our highest priority for potential M&A and a primary consideration for our \nopportunistic capital deployment as part of our disciplined capital allocation framework.  Given our \nfinancial flexibility and stro ng presence in the other 60% of the specialty market in therapeutic areas \noutside of oncology, we have evaluated a range of potential acquisition candidates to further \naccelerate our Sp ecialty strategy.  \n \n We are thrilled to reach an agreement for Specialty Networks to become a part of the Cardinal Health \nfamily.  Jason will elaborate on the strategic aspects of the deal, but we plan to include the expected \nfinancial impacts of the transaction in our guidance  upon closing, which of course is subject to the \nsatisfaction of customary closing conditions, including receipt of required regulatory approvals.  For \ngeneral modeling purposes, we expect the deal to be accretive 12 months following close.  \n \n So, to wrap up, tremendous progress in the first half of the year, with exciting value creation \nopportunities still in front of us. ", "original_text": "We are thrilled to reach an agreement for Specialty Networks to become a part of the Cardinal Health \nfamily. "}, "hash": "c9c97bc9eb33eca5b5a41508bf3047debe1a27d02308e3fba9ec7180e681a538", "class_name": "RelatedNodeInfo"}}, "text": "Given our \nfinancial flexibility and stro ng presence in the other 60% of the specialty market in therapeutic areas \noutside of oncology, we have evaluated a range of potential acquisition candidates to further \naccelerate our Sp ecialty strategy.  \n \n", "start_char_idx": 1770, "end_char_idx": 2022, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "72bdbffe-4370-40a8-8f76-17ddf47a4ca3": {"__data__": {"id_": "72bdbffe-4370-40a8-8f76-17ddf47a4ca3", "embedding": null, "metadata": {"window": "Before I close, a couple comments on our recently announced acquisition .  We\u2019ve noted that the \nspecialty category has been our highest priority for potential M&A and a primary consideration for our \nopportunistic capital deployment as part of our disciplined capital allocation framework.  Given our \nfinancial flexibility and stro ng presence in the other 60% of the specialty market in therapeutic areas \noutside of oncology, we have evaluated a range of potential acquisition candidates to further \naccelerate our Sp ecialty strategy.  \n \n We are thrilled to reach an agreement for Specialty Networks to become a part of the Cardinal Health \nfamily.  Jason will elaborate on the strategic aspects of the deal, but we plan to include the expected \nfinancial impacts of the transaction in our guidance  upon closing, which of course is subject to the \nsatisfaction of customary closing conditions, including receipt of required regulatory approvals.  For \ngeneral modeling purposes, we expect the deal to be accretive 12 months following close.  \n \n So, to wrap up, tremendous progress in the first half of the year, with exciting value creation \nopportunities still in front of us. ", "original_text": "We are thrilled to reach an agreement for Specialty Networks to become a part of the Cardinal Health \nfamily. ", "page_label": "6", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "46b2014a-9df1-4279-a34f-4fd4570310ad", "node_type": "4", "metadata": {"page_label": "6", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "32f6d1d774e204e51e9df5608bd9058cced7a672874c5398480b3538effc8b45", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "e69f4c27-e107-447b-a9cc-047ac7eb4ce7", "node_type": "1", "metadata": {"window": "The difference between this fiscal \u201824 growth rate and the long -term CAGR of 8% to 10% for \nfiscal \u201824 to \u201826 reflects the portion of the Q2 non -recurring adjustments within at -Home Solutions, \nwith the remainder residing in GMPD.  \n \n Before I close, a couple comments on our recently announced acquisition .  We\u2019ve noted that the \nspecialty category has been our highest priority for potential M&A and a primary consideration for our \nopportunistic capital deployment as part of our disciplined capital allocation framework.  Given our \nfinancial flexibility and stro ng presence in the other 60% of the specialty market in therapeutic areas \noutside of oncology, we have evaluated a range of potential acquisition candidates to further \naccelerate our Sp ecialty strategy.  \n \n We are thrilled to reach an agreement for Specialty Networks to become a part of the Cardinal Health \nfamily.  Jason will elaborate on the strategic aspects of the deal, but we plan to include the expected \nfinancial impacts of the transaction in our guidance  upon closing, which of course is subject to the \nsatisfaction of customary closing conditions, including receipt of required regulatory approvals.  For \ngeneral modeling purposes, we expect the deal to be accretive 12 months following close.  \n \n", "original_text": "Given our \nfinancial flexibility and stro ng presence in the other 60% of the specialty market in therapeutic areas \noutside of oncology, we have evaluated a range of potential acquisition candidates to further \naccelerate our Sp ecialty strategy.  \n \n", "page_label": "6", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "6e09ce18206feaf59d657c6be966f3569dcca9321c79bd264a2ef80c651510ba", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "a9b343e5-cc6a-4b4d-962e-27a7a7f9fbb4", "node_type": "1", "metadata": {"window": "We\u2019ve noted that the \nspecialty category has been our highest priority for potential M&A and a primary consideration for our \nopportunistic capital deployment as part of our disciplined capital allocation framework.  Given our \nfinancial flexibility and stro ng presence in the other 60% of the specialty market in therapeutic areas \noutside of oncology, we have evaluated a range of potential acquisition candidates to further \naccelerate our Sp ecialty strategy.  \n \n We are thrilled to reach an agreement for Specialty Networks to become a part of the Cardinal Health \nfamily.  Jason will elaborate on the strategic aspects of the deal, but we plan to include the expected \nfinancial impacts of the transaction in our guidance  upon closing, which of course is subject to the \nsatisfaction of customary closing conditions, including receipt of required regulatory approvals.  For \ngeneral modeling purposes, we expect the deal to be accretive 12 months following close.  \n \n So, to wrap up, tremendous progress in the first half of the year, with exciting value creation \nopportunities still in front of us.  We are confident in our plans, and grateful for the efforts of our team, \nwho continue to drive our ongoing initiatives and p rioritize the needs of our customers. ", "original_text": "Jason will elaborate on the strategic aspects of the deal, but we plan to include the expected \nfinancial impacts of the transaction in our guidance  upon closing, which of course is subject to the \nsatisfaction of customary closing conditions, including receipt of required regulatory approvals. "}, "hash": "d035d4536cd73e4d774b5829fa76560add2d7a253ce0393b85e7ee5c6bc1e8c9", "class_name": "RelatedNodeInfo"}}, "text": "We are thrilled to reach an agreement for Specialty Networks to become a part of the Cardinal Health \nfamily. ", "start_char_idx": 2022, "end_char_idx": 2132, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "a9b343e5-cc6a-4b4d-962e-27a7a7f9fbb4": {"__data__": {"id_": "a9b343e5-cc6a-4b4d-962e-27a7a7f9fbb4", "embedding": null, "metadata": {"window": "We\u2019ve noted that the \nspecialty category has been our highest priority for potential M&A and a primary consideration for our \nopportunistic capital deployment as part of our disciplined capital allocation framework.  Given our \nfinancial flexibility and stro ng presence in the other 60% of the specialty market in therapeutic areas \noutside of oncology, we have evaluated a range of potential acquisition candidates to further \naccelerate our Sp ecialty strategy.  \n \n We are thrilled to reach an agreement for Specialty Networks to become a part of the Cardinal Health \nfamily.  Jason will elaborate on the strategic aspects of the deal, but we plan to include the expected \nfinancial impacts of the transaction in our guidance  upon closing, which of course is subject to the \nsatisfaction of customary closing conditions, including receipt of required regulatory approvals.  For \ngeneral modeling purposes, we expect the deal to be accretive 12 months following close.  \n \n So, to wrap up, tremendous progress in the first half of the year, with exciting value creation \nopportunities still in front of us.  We are confident in our plans, and grateful for the efforts of our team, \nwho continue to drive our ongoing initiatives and p rioritize the needs of our customers. ", "original_text": "Jason will elaborate on the strategic aspects of the deal, but we plan to include the expected \nfinancial impacts of the transaction in our guidance  upon closing, which of course is subject to the \nsatisfaction of customary closing conditions, including receipt of required regulatory approvals. ", "page_label": "6", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "46b2014a-9df1-4279-a34f-4fd4570310ad", "node_type": "4", "metadata": {"page_label": "6", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "32f6d1d774e204e51e9df5608bd9058cced7a672874c5398480b3538effc8b45", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "72bdbffe-4370-40a8-8f76-17ddf47a4ca3", "node_type": "1", "metadata": {"window": "Before I close, a couple comments on our recently announced acquisition .  We\u2019ve noted that the \nspecialty category has been our highest priority for potential M&A and a primary consideration for our \nopportunistic capital deployment as part of our disciplined capital allocation framework.  Given our \nfinancial flexibility and stro ng presence in the other 60% of the specialty market in therapeutic areas \noutside of oncology, we have evaluated a range of potential acquisition candidates to further \naccelerate our Sp ecialty strategy.  \n \n We are thrilled to reach an agreement for Specialty Networks to become a part of the Cardinal Health \nfamily.  Jason will elaborate on the strategic aspects of the deal, but we plan to include the expected \nfinancial impacts of the transaction in our guidance  upon closing, which of course is subject to the \nsatisfaction of customary closing conditions, including receipt of required regulatory approvals.  For \ngeneral modeling purposes, we expect the deal to be accretive 12 months following close.  \n \n So, to wrap up, tremendous progress in the first half of the year, with exciting value creation \nopportunities still in front of us. ", "original_text": "We are thrilled to reach an agreement for Specialty Networks to become a part of the Cardinal Health \nfamily. ", "page_label": "6", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "252e748ba69cf66047ef33ab78a579997863699897ec44903470a6c32fd6c9e3", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "0a41d06e-0eac-41ed-aeda-ed197836524c", "node_type": "1", "metadata": {"window": "Given our \nfinancial flexibility and stro ng presence in the other 60% of the specialty market in therapeutic areas \noutside of oncology, we have evaluated a range of potential acquisition candidates to further \naccelerate our Sp ecialty strategy.  \n \n We are thrilled to reach an agreement for Specialty Networks to become a part of the Cardinal Health \nfamily.  Jason will elaborate on the strategic aspects of the deal, but we plan to include the expected \nfinancial impacts of the transaction in our guidance  upon closing, which of course is subject to the \nsatisfaction of customary closing conditions, including receipt of required regulatory approvals.  For \ngeneral modeling purposes, we expect the deal to be accretive 12 months following close.  \n \n So, to wrap up, tremendous progress in the first half of the year, with exciting value creation \nopportunities still in front of us.  We are confident in our plans, and grateful for the efforts of our team, \nwho continue to drive our ongoing initiatives and p rioritize the needs of our customers.  With that, I will \nturn it back over to Jason.  \n \n", "original_text": "For \ngeneral modeling purposes, we expect the deal to be accretive 12 months following close.  \n \n"}, "hash": "88ec45bb6ae40ac1312ef1af1abdb85c133c6d8a4adb12fd24d5b0c1e85ca315", "class_name": "RelatedNodeInfo"}}, "text": "Jason will elaborate on the strategic aspects of the deal, but we plan to include the expected \nfinancial impacts of the transaction in our guidance  upon closing, which of course is subject to the \nsatisfaction of customary closing conditions, including receipt of required regulatory approvals. ", "start_char_idx": 2132, "end_char_idx": 2429, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "0a41d06e-0eac-41ed-aeda-ed197836524c": {"__data__": {"id_": "0a41d06e-0eac-41ed-aeda-ed197836524c", "embedding": null, "metadata": {"window": "Given our \nfinancial flexibility and stro ng presence in the other 60% of the specialty market in therapeutic areas \noutside of oncology, we have evaluated a range of potential acquisition candidates to further \naccelerate our Sp ecialty strategy.  \n \n We are thrilled to reach an agreement for Specialty Networks to become a part of the Cardinal Health \nfamily.  Jason will elaborate on the strategic aspects of the deal, but we plan to include the expected \nfinancial impacts of the transaction in our guidance  upon closing, which of course is subject to the \nsatisfaction of customary closing conditions, including receipt of required regulatory approvals.  For \ngeneral modeling purposes, we expect the deal to be accretive 12 months following close.  \n \n So, to wrap up, tremendous progress in the first half of the year, with exciting value creation \nopportunities still in front of us.  We are confident in our plans, and grateful for the efforts of our team, \nwho continue to drive our ongoing initiatives and p rioritize the needs of our customers.  With that, I will \nturn it back over to Jason.  \n \n", "original_text": "For \ngeneral modeling purposes, we expect the deal to be accretive 12 months following close.  \n \n", "page_label": "6", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "46b2014a-9df1-4279-a34f-4fd4570310ad", "node_type": "4", "metadata": {"page_label": "6", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "32f6d1d774e204e51e9df5608bd9058cced7a672874c5398480b3538effc8b45", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "a9b343e5-cc6a-4b4d-962e-27a7a7f9fbb4", "node_type": "1", "metadata": {"window": "We\u2019ve noted that the \nspecialty category has been our highest priority for potential M&A and a primary consideration for our \nopportunistic capital deployment as part of our disciplined capital allocation framework.  Given our \nfinancial flexibility and stro ng presence in the other 60% of the specialty market in therapeutic areas \noutside of oncology, we have evaluated a range of potential acquisition candidates to further \naccelerate our Sp ecialty strategy.  \n \n We are thrilled to reach an agreement for Specialty Networks to become a part of the Cardinal Health \nfamily.  Jason will elaborate on the strategic aspects of the deal, but we plan to include the expected \nfinancial impacts of the transaction in our guidance  upon closing, which of course is subject to the \nsatisfaction of customary closing conditions, including receipt of required regulatory approvals.  For \ngeneral modeling purposes, we expect the deal to be accretive 12 months following close.  \n \n So, to wrap up, tremendous progress in the first half of the year, with exciting value creation \nopportunities still in front of us.  We are confident in our plans, and grateful for the efforts of our team, \nwho continue to drive our ongoing initiatives and p rioritize the needs of our customers. ", "original_text": "Jason will elaborate on the strategic aspects of the deal, but we plan to include the expected \nfinancial impacts of the transaction in our guidance  upon closing, which of course is subject to the \nsatisfaction of customary closing conditions, including receipt of required regulatory approvals. ", "page_label": "6", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "6156c3c852a3022be5811ac986f77f92b04d092d091b99aa06966a22fb8411f7", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "97cd6209-6d07-4d02-b974-5a85cd437508", "node_type": "1", "metadata": {"window": "We are thrilled to reach an agreement for Specialty Networks to become a part of the Cardinal Health \nfamily.  Jason will elaborate on the strategic aspects of the deal, but we plan to include the expected \nfinancial impacts of the transaction in our guidance  upon closing, which of course is subject to the \nsatisfaction of customary closing conditions, including receipt of required regulatory approvals.  For \ngeneral modeling purposes, we expect the deal to be accretive 12 months following close.  \n \n So, to wrap up, tremendous progress in the first half of the year, with exciting value creation \nopportunities still in front of us.  We are confident in our plans, and grateful for the efforts of our team, \nwho continue to drive our ongoing initiatives and p rioritize the needs of our customers.  With that, I will \nturn it back over to Jason.  \n \n Jason Hollar:  Thanks, Aaron. ", "original_text": "So, to wrap up, tremendous progress in the first half of the year, with exciting value creation \nopportunities still in front of us. "}, "hash": "4989b92894548ec40a29831b6b59af31101edaa6701e67dc6226ddcafba4028c", "class_name": "RelatedNodeInfo"}}, "text": "For \ngeneral modeling purposes, we expect the deal to be accretive 12 months following close.  \n \n", "start_char_idx": 2429, "end_char_idx": 2527, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "97cd6209-6d07-4d02-b974-5a85cd437508": {"__data__": {"id_": "97cd6209-6d07-4d02-b974-5a85cd437508", "embedding": null, "metadata": {"window": "We are thrilled to reach an agreement for Specialty Networks to become a part of the Cardinal Health \nfamily.  Jason will elaborate on the strategic aspects of the deal, but we plan to include the expected \nfinancial impacts of the transaction in our guidance  upon closing, which of course is subject to the \nsatisfaction of customary closing conditions, including receipt of required regulatory approvals.  For \ngeneral modeling purposes, we expect the deal to be accretive 12 months following close.  \n \n So, to wrap up, tremendous progress in the first half of the year, with exciting value creation \nopportunities still in front of us.  We are confident in our plans, and grateful for the efforts of our team, \nwho continue to drive our ongoing initiatives and p rioritize the needs of our customers.  With that, I will \nturn it back over to Jason.  \n \n Jason Hollar:  Thanks, Aaron. ", "original_text": "So, to wrap up, tremendous progress in the first half of the year, with exciting value creation \nopportunities still in front of us. ", "page_label": "6", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "46b2014a-9df1-4279-a34f-4fd4570310ad", "node_type": "4", "metadata": {"page_label": "6", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "32f6d1d774e204e51e9df5608bd9058cced7a672874c5398480b3538effc8b45", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "0a41d06e-0eac-41ed-aeda-ed197836524c", "node_type": "1", "metadata": {"window": "Given our \nfinancial flexibility and stro ng presence in the other 60% of the specialty market in therapeutic areas \noutside of oncology, we have evaluated a range of potential acquisition candidates to further \naccelerate our Sp ecialty strategy.  \n \n We are thrilled to reach an agreement for Specialty Networks to become a part of the Cardinal Health \nfamily.  Jason will elaborate on the strategic aspects of the deal, but we plan to include the expected \nfinancial impacts of the transaction in our guidance  upon closing, which of course is subject to the \nsatisfaction of customary closing conditions, including receipt of required regulatory approvals.  For \ngeneral modeling purposes, we expect the deal to be accretive 12 months following close.  \n \n So, to wrap up, tremendous progress in the first half of the year, with exciting value creation \nopportunities still in front of us.  We are confident in our plans, and grateful for the efforts of our team, \nwho continue to drive our ongoing initiatives and p rioritize the needs of our customers.  With that, I will \nturn it back over to Jason.  \n \n", "original_text": "For \ngeneral modeling purposes, we expect the deal to be accretive 12 months following close.  \n \n", "page_label": "6", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "8b765916286c351030bc4ddb0fbc4a629ddc8b6d2acb327bb49f4feec0a63b11", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "ad9d6ef1-7c96-4a27-8281-7a9dc5149181", "node_type": "1", "metadata": {"window": "Jason will elaborate on the strategic aspects of the deal, but we plan to include the expected \nfinancial impacts of the transaction in our guidance  upon closing, which of course is subject to the \nsatisfaction of customary closing conditions, including receipt of required regulatory approvals.  For \ngeneral modeling purposes, we expect the deal to be accretive 12 months following close.  \n \n So, to wrap up, tremendous progress in the first half of the year, with exciting value creation \nopportunities still in front of us.  We are confident in our plans, and grateful for the efforts of our team, \nwho continue to drive our ongoing initiatives and p rioritize the needs of our customers.  With that, I will \nturn it back over to Jason.  \n \n Jason Hollar:  Thanks, Aaron.  Now, for some additional perspective on our strategic priorities, \nbeginning with priority number one  and building upon the growth of Pharma and Specialty Solutions, \nour largest and most significant business.  \n \n ", "original_text": "We are confident in our plans, and grateful for the efforts of our team, \nwho continue to drive our ongoing initiatives and p rioritize the needs of our customers. "}, "hash": "13265e8bb30d38c6b36e5d532309663e2c0c99e889e9afe42b87680e66c9ef97", "class_name": "RelatedNodeInfo"}}, "text": "So, to wrap up, tremendous progress in the first half of the year, with exciting value creation \nopportunities still in front of us. ", "start_char_idx": 2527, "end_char_idx": 2660, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "ad9d6ef1-7c96-4a27-8281-7a9dc5149181": {"__data__": {"id_": "ad9d6ef1-7c96-4a27-8281-7a9dc5149181", "embedding": null, "metadata": {"window": "Jason will elaborate on the strategic aspects of the deal, but we plan to include the expected \nfinancial impacts of the transaction in our guidance  upon closing, which of course is subject to the \nsatisfaction of customary closing conditions, including receipt of required regulatory approvals.  For \ngeneral modeling purposes, we expect the deal to be accretive 12 months following close.  \n \n So, to wrap up, tremendous progress in the first half of the year, with exciting value creation \nopportunities still in front of us.  We are confident in our plans, and grateful for the efforts of our team, \nwho continue to drive our ongoing initiatives and p rioritize the needs of our customers.  With that, I will \nturn it back over to Jason.  \n \n Jason Hollar:  Thanks, Aaron.  Now, for some additional perspective on our strategic priorities, \nbeginning with priority number one  and building upon the growth of Pharma and Specialty Solutions, \nour largest and most significant business.  \n \n ", "original_text": "We are confident in our plans, and grateful for the efforts of our team, \nwho continue to drive our ongoing initiatives and p rioritize the needs of our customers. ", "page_label": "6", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "46b2014a-9df1-4279-a34f-4fd4570310ad", "node_type": "4", "metadata": {"page_label": "6", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "32f6d1d774e204e51e9df5608bd9058cced7a672874c5398480b3538effc8b45", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "97cd6209-6d07-4d02-b974-5a85cd437508", "node_type": "1", "metadata": {"window": "We are thrilled to reach an agreement for Specialty Networks to become a part of the Cardinal Health \nfamily.  Jason will elaborate on the strategic aspects of the deal, but we plan to include the expected \nfinancial impacts of the transaction in our guidance  upon closing, which of course is subject to the \nsatisfaction of customary closing conditions, including receipt of required regulatory approvals.  For \ngeneral modeling purposes, we expect the deal to be accretive 12 months following close.  \n \n So, to wrap up, tremendous progress in the first half of the year, with exciting value creation \nopportunities still in front of us.  We are confident in our plans, and grateful for the efforts of our team, \nwho continue to drive our ongoing initiatives and p rioritize the needs of our customers.  With that, I will \nturn it back over to Jason.  \n \n Jason Hollar:  Thanks, Aaron. ", "original_text": "So, to wrap up, tremendous progress in the first half of the year, with exciting value creation \nopportunities still in front of us. ", "page_label": "6", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "7ed5c2ec4bf5fa50acda4336d6b4e402e1cc2f5b656a2a32507ac8a31578b897", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "2a71b444-048a-462c-ba74-d888f19a31b5", "node_type": "1", "metadata": {"window": "For \ngeneral modeling purposes, we expect the deal to be accretive 12 months following close.  \n \n So, to wrap up, tremendous progress in the first half of the year, with exciting value creation \nopportunities still in front of us.  We are confident in our plans, and grateful for the efforts of our team, \nwho continue to drive our ongoing initiatives and p rioritize the needs of our customers.  With that, I will \nturn it back over to Jason.  \n \n Jason Hollar:  Thanks, Aaron.  Now, for some additional perspective on our strategic priorities, \nbeginning with priority number one  and building upon the growth of Pharma and Specialty Solutions, \nour largest and most significant business.  \n \n ", "original_text": "With that, I will \nturn it back over to Jason.  \n \n"}, "hash": "7a7f4fe7dca6b9520a6b7607f12a2704ac6bf2017b11d4cce7e06ddd5fcf246d", "class_name": "RelatedNodeInfo"}}, "text": "We are confident in our plans, and grateful for the efforts of our team, \nwho continue to drive our ongoing initiatives and p rioritize the needs of our customers. ", "start_char_idx": 2660, "end_char_idx": 2824, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "2a71b444-048a-462c-ba74-d888f19a31b5": {"__data__": {"id_": "2a71b444-048a-462c-ba74-d888f19a31b5", "embedding": null, "metadata": {"window": "For \ngeneral modeling purposes, we expect the deal to be accretive 12 months following close.  \n \n So, to wrap up, tremendous progress in the first half of the year, with exciting value creation \nopportunities still in front of us.  We are confident in our plans, and grateful for the efforts of our team, \nwho continue to drive our ongoing initiatives and p rioritize the needs of our customers.  With that, I will \nturn it back over to Jason.  \n \n Jason Hollar:  Thanks, Aaron.  Now, for some additional perspective on our strategic priorities, \nbeginning with priority number one  and building upon the growth of Pharma and Specialty Solutions, \nour largest and most significant business.  \n \n ", "original_text": "With that, I will \nturn it back over to Jason.  \n \n", "page_label": "6", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "46b2014a-9df1-4279-a34f-4fd4570310ad", "node_type": "4", "metadata": {"page_label": "6", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "32f6d1d774e204e51e9df5608bd9058cced7a672874c5398480b3538effc8b45", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "ad9d6ef1-7c96-4a27-8281-7a9dc5149181", "node_type": "1", "metadata": {"window": "Jason will elaborate on the strategic aspects of the deal, but we plan to include the expected \nfinancial impacts of the transaction in our guidance  upon closing, which of course is subject to the \nsatisfaction of customary closing conditions, including receipt of required regulatory approvals.  For \ngeneral modeling purposes, we expect the deal to be accretive 12 months following close.  \n \n So, to wrap up, tremendous progress in the first half of the year, with exciting value creation \nopportunities still in front of us.  We are confident in our plans, and grateful for the efforts of our team, \nwho continue to drive our ongoing initiatives and p rioritize the needs of our customers.  With that, I will \nturn it back over to Jason.  \n \n Jason Hollar:  Thanks, Aaron.  Now, for some additional perspective on our strategic priorities, \nbeginning with priority number one  and building upon the growth of Pharma and Specialty Solutions, \nour largest and most significant business.  \n \n ", "original_text": "We are confident in our plans, and grateful for the efforts of our team, \nwho continue to drive our ongoing initiatives and p rioritize the needs of our customers. ", "page_label": "6", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "64a9e1f5528733be273630cacc790c3982005eac5e1bae110789b20e5cd567c7", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "9d10591e-f12b-4a3b-b537-a4c0749764bd", "node_type": "1", "metadata": {"window": "So, to wrap up, tremendous progress in the first half of the year, with exciting value creation \nopportunities still in front of us.  We are confident in our plans, and grateful for the efforts of our team, \nwho continue to drive our ongoing initiatives and p rioritize the needs of our customers.  With that, I will \nturn it back over to Jason.  \n \n Jason Hollar:  Thanks, Aaron.  Now, for some additional perspective on our strategic priorities, \nbeginning with priority number one  and building upon the growth of Pharma and Specialty Solutions, \nour largest and most significant business.  \n \n ", "original_text": "Jason Hollar:  Thanks, Aaron. "}, "hash": "a401ba38b0fa2e454516cc88bb32d6cb500fcf68b469305fb5a5a8a0a6a91dbf", "class_name": "RelatedNodeInfo"}}, "text": "With that, I will \nturn it back over to Jason.  \n \n", "start_char_idx": 2824, "end_char_idx": 2875, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "9d10591e-f12b-4a3b-b537-a4c0749764bd": {"__data__": {"id_": "9d10591e-f12b-4a3b-b537-a4c0749764bd", "embedding": null, "metadata": {"window": "So, to wrap up, tremendous progress in the first half of the year, with exciting value creation \nopportunities still in front of us.  We are confident in our plans, and grateful for the efforts of our team, \nwho continue to drive our ongoing initiatives and p rioritize the needs of our customers.  With that, I will \nturn it back over to Jason.  \n \n Jason Hollar:  Thanks, Aaron.  Now, for some additional perspective on our strategic priorities, \nbeginning with priority number one  and building upon the growth of Pharma and Specialty Solutions, \nour largest and most significant business.  \n \n ", "original_text": "Jason Hollar:  Thanks, Aaron. ", "page_label": "6", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "46b2014a-9df1-4279-a34f-4fd4570310ad", "node_type": "4", "metadata": {"page_label": "6", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "32f6d1d774e204e51e9df5608bd9058cced7a672874c5398480b3538effc8b45", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "2a71b444-048a-462c-ba74-d888f19a31b5", "node_type": "1", "metadata": {"window": "For \ngeneral modeling purposes, we expect the deal to be accretive 12 months following close.  \n \n So, to wrap up, tremendous progress in the first half of the year, with exciting value creation \nopportunities still in front of us.  We are confident in our plans, and grateful for the efforts of our team, \nwho continue to drive our ongoing initiatives and p rioritize the needs of our customers.  With that, I will \nturn it back over to Jason.  \n \n Jason Hollar:  Thanks, Aaron.  Now, for some additional perspective on our strategic priorities, \nbeginning with priority number one  and building upon the growth of Pharma and Specialty Solutions, \nour largest and most significant business.  \n \n ", "original_text": "With that, I will \nturn it back over to Jason.  \n \n", "page_label": "6", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "e16adc6643b15aac97ddd6c886ad45a9bd7712e77341edc5b512321f891171a1", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "63307908-cd19-4691-b35f-5935607f9bd7", "node_type": "1", "metadata": {"window": "We are confident in our plans, and grateful for the efforts of our team, \nwho continue to drive our ongoing initiatives and p rioritize the needs of our customers.  With that, I will \nturn it back over to Jason.  \n \n Jason Hollar:  Thanks, Aaron.  Now, for some additional perspective on our strategic priorities, \nbeginning with priority number one  and building upon the growth of Pharma and Specialty Solutions, \nour largest and most significant business.  \n \n ", "original_text": "Now, for some additional perspective on our strategic priorities, \nbeginning with priority number one  and building upon the growth of Pharma and Specialty Solutions, \nour largest and most significant business.  \n \n "}, "hash": "77a679f1613128496346b47c0b671b762d7b539f4b8f48b3dbc6063bdf10ce40", "class_name": "RelatedNodeInfo"}}, "text": "Jason Hollar:  Thanks, Aaron. ", "start_char_idx": 2875, "end_char_idx": 2905, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "63307908-cd19-4691-b35f-5935607f9bd7": {"__data__": {"id_": "63307908-cd19-4691-b35f-5935607f9bd7", "embedding": null, "metadata": {"window": "We are confident in our plans, and grateful for the efforts of our team, \nwho continue to drive our ongoing initiatives and p rioritize the needs of our customers.  With that, I will \nturn it back over to Jason.  \n \n Jason Hollar:  Thanks, Aaron.  Now, for some additional perspective on our strategic priorities, \nbeginning with priority number one  and building upon the growth of Pharma and Specialty Solutions, \nour largest and most significant business.  \n \n ", "original_text": "Now, for some additional perspective on our strategic priorities, \nbeginning with priority number one  and building upon the growth of Pharma and Specialty Solutions, \nour largest and most significant business.  \n \n ", "page_label": "6", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "46b2014a-9df1-4279-a34f-4fd4570310ad", "node_type": "4", "metadata": {"page_label": "6", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "32f6d1d774e204e51e9df5608bd9058cced7a672874c5398480b3538effc8b45", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "9d10591e-f12b-4a3b-b537-a4c0749764bd", "node_type": "1", "metadata": {"window": "So, to wrap up, tremendous progress in the first half of the year, with exciting value creation \nopportunities still in front of us.  We are confident in our plans, and grateful for the efforts of our team, \nwho continue to drive our ongoing initiatives and p rioritize the needs of our customers.  With that, I will \nturn it back over to Jason.  \n \n Jason Hollar:  Thanks, Aaron.  Now, for some additional perspective on our strategic priorities, \nbeginning with priority number one  and building upon the growth of Pharma and Specialty Solutions, \nour largest and most significant business.  \n \n ", "original_text": "Jason Hollar:  Thanks, Aaron. ", "page_label": "6", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "52bb0f4ac94cdc856ea0dcf50c7982e64ef0db4b7887797b15b0ddd3ca9c7ab3", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "9311ff59-9c98-412a-af59-fd30396a3efb", "node_type": "1", "metadata": {"window": " \nPage 7 of 19 \n \nThough this segment\u2019s structure has slightly changed, our focus on executing in the core remains . \n We\u2019re building upon our strong foundation, while investing to accelerate growth in Specialty both \ndownstream and upstream.  \n \n We believe that this new segment structure further enables those efforts, by enhancing management \nfocus, leveraging the connectivity between Pharmaceutical Distribution and Specialty,  and positioning \nthe business for long -term growth and investment.  More on that front shortly.       \n \n", "original_text": " \nPage 7 of 19 \n \nThough this segment\u2019s structure has slightly changed, our focus on executing in the core remains . \n"}, "hash": "281788edbfc9d45a6886b0a341fc032de553cd1609bdd228cee2fc4a2671371b", "class_name": "RelatedNodeInfo"}}, "text": "Now, for some additional perspective on our strategic priorities, \nbeginning with priority number one  and building upon the growth of Pharma and Specialty Solutions, \nour largest and most significant business.  \n \n ", "start_char_idx": 2905, "end_char_idx": 3121, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "9311ff59-9c98-412a-af59-fd30396a3efb": {"__data__": {"id_": "9311ff59-9c98-412a-af59-fd30396a3efb", "embedding": null, "metadata": {"window": " \nPage 7 of 19 \n \nThough this segment\u2019s structure has slightly changed, our focus on executing in the core remains . \n We\u2019re building upon our strong foundation, while investing to accelerate growth in Specialty both \ndownstream and upstream.  \n \n We believe that this new segment structure further enables those efforts, by enhancing management \nfocus, leveraging the connectivity between Pharmaceutical Distribution and Specialty,  and positioning \nthe business for long -term growth and investment.  More on that front shortly.       \n \n", "original_text": " \nPage 7 of 19 \n \nThough this segment\u2019s structure has slightly changed, our focus on executing in the core remains . \n", "page_label": "7", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "1b974c9c-bb8b-435a-a421-b84d1956e255", "node_type": "4", "metadata": {"page_label": "7", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "9028abcf421a057a34aae556f51e61d45492e0e39012a6e17756157dd506e3f9", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "63307908-cd19-4691-b35f-5935607f9bd7", "node_type": "1", "metadata": {"window": "We are confident in our plans, and grateful for the efforts of our team, \nwho continue to drive our ongoing initiatives and p rioritize the needs of our customers.  With that, I will \nturn it back over to Jason.  \n \n Jason Hollar:  Thanks, Aaron.  Now, for some additional perspective on our strategic priorities, \nbeginning with priority number one  and building upon the growth of Pharma and Specialty Solutions, \nour largest and most significant business.  \n \n ", "original_text": "Now, for some additional perspective on our strategic priorities, \nbeginning with priority number one  and building upon the growth of Pharma and Specialty Solutions, \nour largest and most significant business.  \n \n ", "page_label": "6", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "d6b4de7e97d72a590ebd974ebf65da8ad84d13b3d6c63c2a4691493e34503e26", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "c5bbf16b-6a43-44f4-b569-d5218dd4e002", "node_type": "1", "metadata": {"window": " \nPage 7 of 19 \n \nThough this segment\u2019s structure has slightly changed, our focus on executing in the core remains . \n We\u2019re building upon our strong foundation, while investing to accelerate growth in Specialty both \ndownstream and upstream.  \n \n We believe that this new segment structure further enables those efforts, by enhancing management \nfocus, leveraging the connectivity between Pharmaceutical Distribution and Specialty,  and positioning \nthe business for long -term growth and investment.  More on that front shortly.       \n \n A key component of our strong core foundation is our generics program, anchored by Red Oak, which \ncontinues to do an excellent job fulfilling its dual mandate , managing both cost and supply. ", "original_text": "We\u2019re building upon our strong foundation, while investing to accelerate growth in Specialty both \ndownstream and upstream.  \n \n"}, "hash": "708b2eb5ffb85d5f04c537fd1c1ba7a1dde01b77692c99a35e42fd45460a3b67", "class_name": "RelatedNodeInfo"}}, "text": " \nPage 7 of 19 \n \nThough this segment\u2019s structure has slightly changed, our focus on executing in the core remains . \n", "start_char_idx": 0, "end_char_idx": 118, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "c5bbf16b-6a43-44f4-b569-d5218dd4e002": {"__data__": {"id_": "c5bbf16b-6a43-44f4-b569-d5218dd4e002", "embedding": null, "metadata": {"window": " \nPage 7 of 19 \n \nThough this segment\u2019s structure has slightly changed, our focus on executing in the core remains . \n We\u2019re building upon our strong foundation, while investing to accelerate growth in Specialty both \ndownstream and upstream.  \n \n We believe that this new segment structure further enables those efforts, by enhancing management \nfocus, leveraging the connectivity between Pharmaceutical Distribution and Specialty,  and positioning \nthe business for long -term growth and investment.  More on that front shortly.       \n \n A key component of our strong core foundation is our generics program, anchored by Red Oak, which \ncontinues to do an excellent job fulfilling its dual mandate , managing both cost and supply. ", "original_text": "We\u2019re building upon our strong foundation, while investing to accelerate growth in Specialty both \ndownstream and upstream.  \n \n", "page_label": "7", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "1b974c9c-bb8b-435a-a421-b84d1956e255", "node_type": "4", "metadata": {"page_label": "7", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "9028abcf421a057a34aae556f51e61d45492e0e39012a6e17756157dd506e3f9", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "9311ff59-9c98-412a-af59-fd30396a3efb", "node_type": "1", "metadata": {"window": " \nPage 7 of 19 \n \nThough this segment\u2019s structure has slightly changed, our focus on executing in the core remains . \n We\u2019re building upon our strong foundation, while investing to accelerate growth in Specialty both \ndownstream and upstream.  \n \n We believe that this new segment structure further enables those efforts, by enhancing management \nfocus, leveraging the connectivity between Pharmaceutical Distribution and Specialty,  and positioning \nthe business for long -term growth and investment.  More on that front shortly.       \n \n", "original_text": " \nPage 7 of 19 \n \nThough this segment\u2019s structure has slightly changed, our focus on executing in the core remains . \n", "page_label": "7", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "17b406abb0c8dfa7ce48862a121c18924b1ced0eee0e73d6f1699cdb73e2357a", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "555af6c8-b890-43f8-bd19-f70e84e98f81", "node_type": "1", "metadata": {"window": " \nPage 7 of 19 \n \nThough this segment\u2019s structure has slightly changed, our focus on executing in the core remains . \n We\u2019re building upon our strong foundation, while investing to accelerate growth in Specialty both \ndownstream and upstream.  \n \n We believe that this new segment structure further enables those efforts, by enhancing management \nfocus, leveraging the connectivity between Pharmaceutical Distribution and Specialty,  and positioning \nthe business for long -term growth and investment.  More on that front shortly.       \n \n A key component of our strong core foundation is our generics program, anchored by Red Oak, which \ncontinues to do an excellent job fulfilling its dual mandate , managing both cost and supply.  Red Oak \nleverages proprietary analytical tools and their deep industry expertise to help maximize service \ndelivery for customers.  \n \n", "original_text": "We believe that this new segment structure further enables those efforts, by enhancing management \nfocus, leveraging the connectivity between Pharmaceutical Distribution and Specialty,  and positioning \nthe business for long -term growth and investment. "}, "hash": "1c141d00fa331b4f7fe84c8e3ad9a51d10059af05539a736e4b1c10662770f2c", "class_name": "RelatedNodeInfo"}}, "text": "We\u2019re building upon our strong foundation, while investing to accelerate growth in Specialty both \ndownstream and upstream.  \n \n", "start_char_idx": 118, "end_char_idx": 246, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "555af6c8-b890-43f8-bd19-f70e84e98f81": {"__data__": {"id_": "555af6c8-b890-43f8-bd19-f70e84e98f81", "embedding": null, "metadata": {"window": " \nPage 7 of 19 \n \nThough this segment\u2019s structure has slightly changed, our focus on executing in the core remains . \n We\u2019re building upon our strong foundation, while investing to accelerate growth in Specialty both \ndownstream and upstream.  \n \n We believe that this new segment structure further enables those efforts, by enhancing management \nfocus, leveraging the connectivity between Pharmaceutical Distribution and Specialty,  and positioning \nthe business for long -term growth and investment.  More on that front shortly.       \n \n A key component of our strong core foundation is our generics program, anchored by Red Oak, which \ncontinues to do an excellent job fulfilling its dual mandate , managing both cost and supply.  Red Oak \nleverages proprietary analytical tools and their deep industry expertise to help maximize service \ndelivery for customers.  \n \n", "original_text": "We believe that this new segment structure further enables those efforts, by enhancing management \nfocus, leveraging the connectivity between Pharmaceutical Distribution and Specialty,  and positioning \nthe business for long -term growth and investment. ", "page_label": "7", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "1b974c9c-bb8b-435a-a421-b84d1956e255", "node_type": "4", "metadata": {"page_label": "7", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "9028abcf421a057a34aae556f51e61d45492e0e39012a6e17756157dd506e3f9", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "c5bbf16b-6a43-44f4-b569-d5218dd4e002", "node_type": "1", "metadata": {"window": " \nPage 7 of 19 \n \nThough this segment\u2019s structure has slightly changed, our focus on executing in the core remains . \n We\u2019re building upon our strong foundation, while investing to accelerate growth in Specialty both \ndownstream and upstream.  \n \n We believe that this new segment structure further enables those efforts, by enhancing management \nfocus, leveraging the connectivity between Pharmaceutical Distribution and Specialty,  and positioning \nthe business for long -term growth and investment.  More on that front shortly.       \n \n A key component of our strong core foundation is our generics program, anchored by Red Oak, which \ncontinues to do an excellent job fulfilling its dual mandate , managing both cost and supply. ", "original_text": "We\u2019re building upon our strong foundation, while investing to accelerate growth in Specialty both \ndownstream and upstream.  \n \n", "page_label": "7", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "abf79b81e399cf8f376368783eee6bb6f9f134f57ce0eaff30afa78601d54bc4", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "32f990db-1f0d-4a5c-a7f1-d8bdbe511d8d", "node_type": "1", "metadata": {"window": " \nPage 7 of 19 \n \nThough this segment\u2019s structure has slightly changed, our focus on executing in the core remains . \n We\u2019re building upon our strong foundation, while investing to accelerate growth in Specialty both \ndownstream and upstream.  \n \n We believe that this new segment structure further enables those efforts, by enhancing management \nfocus, leveraging the connectivity between Pharmaceutical Distribution and Specialty,  and positioning \nthe business for long -term growth and investment.  More on that front shortly.       \n \n A key component of our strong core foundation is our generics program, anchored by Red Oak, which \ncontinues to do an excellent job fulfilling its dual mandate , managing both cost and supply.  Red Oak \nleverages proprietary analytical tools and their deep industry expertise to help maximize service \ndelivery for customers.  \n \n We\u2019re continuing to invest in our business to provide customer -focused solutions and evolve our \ncommercial engagement strategies to prioritize addressing the complex challenges our customers \nface every day.  \n \n", "original_text": "More on that front shortly.       \n \n"}, "hash": "beed0681f01bcec84293747471329274e03d35541409349c08276d89af22676e", "class_name": "RelatedNodeInfo"}}, "text": "We believe that this new segment structure further enables those efforts, by enhancing management \nfocus, leveraging the connectivity between Pharmaceutical Distribution and Specialty,  and positioning \nthe business for long -term growth and investment. ", "start_char_idx": 246, "end_char_idx": 500, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "32f990db-1f0d-4a5c-a7f1-d8bdbe511d8d": {"__data__": {"id_": "32f990db-1f0d-4a5c-a7f1-d8bdbe511d8d", "embedding": null, "metadata": {"window": " \nPage 7 of 19 \n \nThough this segment\u2019s structure has slightly changed, our focus on executing in the core remains . \n We\u2019re building upon our strong foundation, while investing to accelerate growth in Specialty both \ndownstream and upstream.  \n \n We believe that this new segment structure further enables those efforts, by enhancing management \nfocus, leveraging the connectivity between Pharmaceutical Distribution and Specialty,  and positioning \nthe business for long -term growth and investment.  More on that front shortly.       \n \n A key component of our strong core foundation is our generics program, anchored by Red Oak, which \ncontinues to do an excellent job fulfilling its dual mandate , managing both cost and supply.  Red Oak \nleverages proprietary analytical tools and their deep industry expertise to help maximize service \ndelivery for customers.  \n \n We\u2019re continuing to invest in our business to provide customer -focused solutions and evolve our \ncommercial engagement strategies to prioritize addressing the complex challenges our customers \nface every day.  \n \n", "original_text": "More on that front shortly.       \n \n", "page_label": "7", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "1b974c9c-bb8b-435a-a421-b84d1956e255", "node_type": "4", "metadata": {"page_label": "7", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "9028abcf421a057a34aae556f51e61d45492e0e39012a6e17756157dd506e3f9", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "555af6c8-b890-43f8-bd19-f70e84e98f81", "node_type": "1", "metadata": {"window": " \nPage 7 of 19 \n \nThough this segment\u2019s structure has slightly changed, our focus on executing in the core remains . \n We\u2019re building upon our strong foundation, while investing to accelerate growth in Specialty both \ndownstream and upstream.  \n \n We believe that this new segment structure further enables those efforts, by enhancing management \nfocus, leveraging the connectivity between Pharmaceutical Distribution and Specialty,  and positioning \nthe business for long -term growth and investment.  More on that front shortly.       \n \n A key component of our strong core foundation is our generics program, anchored by Red Oak, which \ncontinues to do an excellent job fulfilling its dual mandate , managing both cost and supply.  Red Oak \nleverages proprietary analytical tools and their deep industry expertise to help maximize service \ndelivery for customers.  \n \n", "original_text": "We believe that this new segment structure further enables those efforts, by enhancing management \nfocus, leveraging the connectivity between Pharmaceutical Distribution and Specialty,  and positioning \nthe business for long -term growth and investment. ", "page_label": "7", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "209e70a8084d0b88100ab77728a4b2ba81a3578e2e739dc576ba469c8dfff975", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "b23e0dca-b34b-4549-bbfa-c2b29152ded9", "node_type": "1", "metadata": {"window": "We\u2019re building upon our strong foundation, while investing to accelerate growth in Specialty both \ndownstream and upstream.  \n \n We believe that this new segment structure further enables those efforts, by enhancing management \nfocus, leveraging the connectivity between Pharmaceutical Distribution and Specialty,  and positioning \nthe business for long -term growth and investment.  More on that front shortly.       \n \n A key component of our strong core foundation is our generics program, anchored by Red Oak, which \ncontinues to do an excellent job fulfilling its dual mandate , managing both cost and supply.  Red Oak \nleverages proprietary analytical tools and their deep industry expertise to help maximize service \ndelivery for customers.  \n \n We\u2019re continuing to invest in our business to provide customer -focused solutions and evolve our \ncommercial engagement strategies to prioritize addressing the complex challenges our customers \nface every day.  \n \n For example, at Investor Day we highlighted our first -to-market clinically -integrated supply chain, the \nCardinal Health Intelogix \u2122 Platform. ", "original_text": "A key component of our strong core foundation is our generics program, anchored by Red Oak, which \ncontinues to do an excellent job fulfilling its dual mandate , managing both cost and supply. "}, "hash": "11440e9c5571654ff4218101e04b5a4d2287056760d45391766023224bc2e434", "class_name": "RelatedNodeInfo"}}, "text": "More on that front shortly.       \n \n", "start_char_idx": 500, "end_char_idx": 537, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "b23e0dca-b34b-4549-bbfa-c2b29152ded9": {"__data__": {"id_": "b23e0dca-b34b-4549-bbfa-c2b29152ded9", "embedding": null, "metadata": {"window": "We\u2019re building upon our strong foundation, while investing to accelerate growth in Specialty both \ndownstream and upstream.  \n \n We believe that this new segment structure further enables those efforts, by enhancing management \nfocus, leveraging the connectivity between Pharmaceutical Distribution and Specialty,  and positioning \nthe business for long -term growth and investment.  More on that front shortly.       \n \n A key component of our strong core foundation is our generics program, anchored by Red Oak, which \ncontinues to do an excellent job fulfilling its dual mandate , managing both cost and supply.  Red Oak \nleverages proprietary analytical tools and their deep industry expertise to help maximize service \ndelivery for customers.  \n \n We\u2019re continuing to invest in our business to provide customer -focused solutions and evolve our \ncommercial engagement strategies to prioritize addressing the complex challenges our customers \nface every day.  \n \n For example, at Investor Day we highlighted our first -to-market clinically -integrated supply chain, the \nCardinal Health Intelogix \u2122 Platform. ", "original_text": "A key component of our strong core foundation is our generics program, anchored by Red Oak, which \ncontinues to do an excellent job fulfilling its dual mandate , managing both cost and supply. ", "page_label": "7", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "1b974c9c-bb8b-435a-a421-b84d1956e255", "node_type": "4", "metadata": {"page_label": "7", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "9028abcf421a057a34aae556f51e61d45492e0e39012a6e17756157dd506e3f9", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "32f990db-1f0d-4a5c-a7f1-d8bdbe511d8d", "node_type": "1", "metadata": {"window": " \nPage 7 of 19 \n \nThough this segment\u2019s structure has slightly changed, our focus on executing in the core remains . \n We\u2019re building upon our strong foundation, while investing to accelerate growth in Specialty both \ndownstream and upstream.  \n \n We believe that this new segment structure further enables those efforts, by enhancing management \nfocus, leveraging the connectivity between Pharmaceutical Distribution and Specialty,  and positioning \nthe business for long -term growth and investment.  More on that front shortly.       \n \n A key component of our strong core foundation is our generics program, anchored by Red Oak, which \ncontinues to do an excellent job fulfilling its dual mandate , managing both cost and supply.  Red Oak \nleverages proprietary analytical tools and their deep industry expertise to help maximize service \ndelivery for customers.  \n \n We\u2019re continuing to invest in our business to provide customer -focused solutions and evolve our \ncommercial engagement strategies to prioritize addressing the complex challenges our customers \nface every day.  \n \n", "original_text": "More on that front shortly.       \n \n", "page_label": "7", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "c0c575a2a7eae74106318ac7cabf7969acb8af02a49ad8597b77b1d21fbaaf99", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "43c9c340-ad6b-4c38-a400-5dd92022bcde", "node_type": "1", "metadata": {"window": "We believe that this new segment structure further enables those efforts, by enhancing management \nfocus, leveraging the connectivity between Pharmaceutical Distribution and Specialty,  and positioning \nthe business for long -term growth and investment.  More on that front shortly.       \n \n A key component of our strong core foundation is our generics program, anchored by Red Oak, which \ncontinues to do an excellent job fulfilling its dual mandate , managing both cost and supply.  Red Oak \nleverages proprietary analytical tools and their deep industry expertise to help maximize service \ndelivery for customers.  \n \n We\u2019re continuing to invest in our business to provide customer -focused solutions and evolve our \ncommercial engagement strategies to prioritize addressing the complex challenges our customers \nface every day.  \n \n For example, at Investor Day we highlighted our first -to-market clinically -integrated supply chain, the \nCardinal Health Intelogix \u2122 Platform.  This innovative solution leverages artificial intelligence and \nmachine learning through the Palantir Foundry platform to help providers reduce costs, optimize drug \ninventories,  and generate actionable insights to simplify and streamline medication supply. ", "original_text": "Red Oak \nleverages proprietary analytical tools and their deep industry expertise to help maximize service \ndelivery for customers.  \n \n"}, "hash": "2fb89a63b3702d3d48dc4f4293196962573fb91b8c8b87da1ba39fefedd41455", "class_name": "RelatedNodeInfo"}}, "text": "A key component of our strong core foundation is our generics program, anchored by Red Oak, which \ncontinues to do an excellent job fulfilling its dual mandate , managing both cost and supply. ", "start_char_idx": 537, "end_char_idx": 730, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "43c9c340-ad6b-4c38-a400-5dd92022bcde": {"__data__": {"id_": "43c9c340-ad6b-4c38-a400-5dd92022bcde", "embedding": null, "metadata": {"window": "We believe that this new segment structure further enables those efforts, by enhancing management \nfocus, leveraging the connectivity between Pharmaceutical Distribution and Specialty,  and positioning \nthe business for long -term growth and investment.  More on that front shortly.       \n \n A key component of our strong core foundation is our generics program, anchored by Red Oak, which \ncontinues to do an excellent job fulfilling its dual mandate , managing both cost and supply.  Red Oak \nleverages proprietary analytical tools and their deep industry expertise to help maximize service \ndelivery for customers.  \n \n We\u2019re continuing to invest in our business to provide customer -focused solutions and evolve our \ncommercial engagement strategies to prioritize addressing the complex challenges our customers \nface every day.  \n \n For example, at Investor Day we highlighted our first -to-market clinically -integrated supply chain, the \nCardinal Health Intelogix \u2122 Platform.  This innovative solution leverages artificial intelligence and \nmachine learning through the Palantir Foundry platform to help providers reduce costs, optimize drug \ninventories,  and generate actionable insights to simplify and streamline medication supply. ", "original_text": "Red Oak \nleverages proprietary analytical tools and their deep industry expertise to help maximize service \ndelivery for customers.  \n \n", "page_label": "7", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "1b974c9c-bb8b-435a-a421-b84d1956e255", "node_type": "4", "metadata": {"page_label": "7", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "9028abcf421a057a34aae556f51e61d45492e0e39012a6e17756157dd506e3f9", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "b23e0dca-b34b-4549-bbfa-c2b29152ded9", "node_type": "1", "metadata": {"window": "We\u2019re building upon our strong foundation, while investing to accelerate growth in Specialty both \ndownstream and upstream.  \n \n We believe that this new segment structure further enables those efforts, by enhancing management \nfocus, leveraging the connectivity between Pharmaceutical Distribution and Specialty,  and positioning \nthe business for long -term growth and investment.  More on that front shortly.       \n \n A key component of our strong core foundation is our generics program, anchored by Red Oak, which \ncontinues to do an excellent job fulfilling its dual mandate , managing both cost and supply.  Red Oak \nleverages proprietary analytical tools and their deep industry expertise to help maximize service \ndelivery for customers.  \n \n We\u2019re continuing to invest in our business to provide customer -focused solutions and evolve our \ncommercial engagement strategies to prioritize addressing the complex challenges our customers \nface every day.  \n \n For example, at Investor Day we highlighted our first -to-market clinically -integrated supply chain, the \nCardinal Health Intelogix \u2122 Platform. ", "original_text": "A key component of our strong core foundation is our generics program, anchored by Red Oak, which \ncontinues to do an excellent job fulfilling its dual mandate , managing both cost and supply. ", "page_label": "7", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "159606b89bd0de3298e3ff09e56397a90d2533fc4e9661fd431aeeac70543618", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "db807c40-67e7-414e-8cca-6e520497267f", "node_type": "1", "metadata": {"window": "More on that front shortly.       \n \n A key component of our strong core foundation is our generics program, anchored by Red Oak, which \ncontinues to do an excellent job fulfilling its dual mandate , managing both cost and supply.  Red Oak \nleverages proprietary analytical tools and their deep industry expertise to help maximize service \ndelivery for customers.  \n \n We\u2019re continuing to invest in our business to provide customer -focused solutions and evolve our \ncommercial engagement strategies to prioritize addressing the complex challenges our customers \nface every day.  \n \n For example, at Investor Day we highlighted our first -to-market clinically -integrated supply chain, the \nCardinal Health Intelogix \u2122 Platform.  This innovative solution leverages artificial intelligence and \nmachine learning through the Palantir Foundry platform to help providers reduce costs, optimize drug \ninventories,  and generate actionable insights to simplify and streamline medication supply.  We\u2019ve \ncontinued to develop our offerings, such as the Contract Optimizer tool, which drives savings and \nvalue throu gh contract compliance, cost controls and product alternatives like brand -to-generics, \nblood plasma and more. ", "original_text": "We\u2019re continuing to invest in our business to provide customer -focused solutions and evolve our \ncommercial engagement strategies to prioritize addressing the complex challenges our customers \nface every day.  \n \n"}, "hash": "bd931fa26a7ad3c606278a1223c01a1371b1944362503c3d97647027c4206e10", "class_name": "RelatedNodeInfo"}}, "text": "Red Oak \nleverages proprietary analytical tools and their deep industry expertise to help maximize service \ndelivery for customers.  \n \n", "start_char_idx": 730, "end_char_idx": 866, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "db807c40-67e7-414e-8cca-6e520497267f": {"__data__": {"id_": "db807c40-67e7-414e-8cca-6e520497267f", "embedding": null, "metadata": {"window": "More on that front shortly.       \n \n A key component of our strong core foundation is our generics program, anchored by Red Oak, which \ncontinues to do an excellent job fulfilling its dual mandate , managing both cost and supply.  Red Oak \nleverages proprietary analytical tools and their deep industry expertise to help maximize service \ndelivery for customers.  \n \n We\u2019re continuing to invest in our business to provide customer -focused solutions and evolve our \ncommercial engagement strategies to prioritize addressing the complex challenges our customers \nface every day.  \n \n For example, at Investor Day we highlighted our first -to-market clinically -integrated supply chain, the \nCardinal Health Intelogix \u2122 Platform.  This innovative solution leverages artificial intelligence and \nmachine learning through the Palantir Foundry platform to help providers reduce costs, optimize drug \ninventories,  and generate actionable insights to simplify and streamline medication supply.  We\u2019ve \ncontinued to develop our offerings, such as the Contract Optimizer tool, which drives savings and \nvalue throu gh contract compliance, cost controls and product alternatives like brand -to-generics, \nblood plasma and more. ", "original_text": "We\u2019re continuing to invest in our business to provide customer -focused solutions and evolve our \ncommercial engagement strategies to prioritize addressing the complex challenges our customers \nface every day.  \n \n", "page_label": "7", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "1b974c9c-bb8b-435a-a421-b84d1956e255", "node_type": "4", "metadata": {"page_label": "7", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "9028abcf421a057a34aae556f51e61d45492e0e39012a6e17756157dd506e3f9", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "43c9c340-ad6b-4c38-a400-5dd92022bcde", "node_type": "1", "metadata": {"window": "We believe that this new segment structure further enables those efforts, by enhancing management \nfocus, leveraging the connectivity between Pharmaceutical Distribution and Specialty,  and positioning \nthe business for long -term growth and investment.  More on that front shortly.       \n \n A key component of our strong core foundation is our generics program, anchored by Red Oak, which \ncontinues to do an excellent job fulfilling its dual mandate , managing both cost and supply.  Red Oak \nleverages proprietary analytical tools and their deep industry expertise to help maximize service \ndelivery for customers.  \n \n We\u2019re continuing to invest in our business to provide customer -focused solutions and evolve our \ncommercial engagement strategies to prioritize addressing the complex challenges our customers \nface every day.  \n \n For example, at Investor Day we highlighted our first -to-market clinically -integrated supply chain, the \nCardinal Health Intelogix \u2122 Platform.  This innovative solution leverages artificial intelligence and \nmachine learning through the Palantir Foundry platform to help providers reduce costs, optimize drug \ninventories,  and generate actionable insights to simplify and streamline medication supply. ", "original_text": "Red Oak \nleverages proprietary analytical tools and their deep industry expertise to help maximize service \ndelivery for customers.  \n \n", "page_label": "7", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "52e72ef8464b8877925a786dd7bbc881f6d2d87d6af3ace4a69de60ba457b8e0", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "84ec9b09-9ab2-4292-9ed6-8bd5278c659a", "node_type": "1", "metadata": {"window": "A key component of our strong core foundation is our generics program, anchored by Red Oak, which \ncontinues to do an excellent job fulfilling its dual mandate , managing both cost and supply.  Red Oak \nleverages proprietary analytical tools and their deep industry expertise to help maximize service \ndelivery for customers.  \n \n We\u2019re continuing to invest in our business to provide customer -focused solutions and evolve our \ncommercial engagement strategies to prioritize addressing the complex challenges our customers \nface every day.  \n \n For example, at Investor Day we highlighted our first -to-market clinically -integrated supply chain, the \nCardinal Health Intelogix \u2122 Platform.  This innovative solution leverages artificial intelligence and \nmachine learning through the Palantir Foundry platform to help providers reduce costs, optimize drug \ninventories,  and generate actionable insights to simplify and streamline medication supply.  We\u2019ve \ncontinued to develop our offerings, such as the Contract Optimizer tool, which drives savings and \nvalue throu gh contract compliance, cost controls and product alternatives like brand -to-generics, \nblood plasma and more.  Key health system customers are already benefiting from these capabilities, \nand we see opportunities for further future expansion.  \n \n", "original_text": "For example, at Investor Day we highlighted our first -to-market clinically -integrated supply chain, the \nCardinal Health Intelogix \u2122 Platform. "}, "hash": "0df08f9930ef94756f009ad0dafdde0a3e3f9475a3279eaaec1a59056bf6d36d", "class_name": "RelatedNodeInfo"}}, "text": "We\u2019re continuing to invest in our business to provide customer -focused solutions and evolve our \ncommercial engagement strategies to prioritize addressing the complex challenges our customers \nface every day.  \n \n", "start_char_idx": 866, "end_char_idx": 1080, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "84ec9b09-9ab2-4292-9ed6-8bd5278c659a": {"__data__": {"id_": "84ec9b09-9ab2-4292-9ed6-8bd5278c659a", "embedding": null, "metadata": {"window": "A key component of our strong core foundation is our generics program, anchored by Red Oak, which \ncontinues to do an excellent job fulfilling its dual mandate , managing both cost and supply.  Red Oak \nleverages proprietary analytical tools and their deep industry expertise to help maximize service \ndelivery for customers.  \n \n We\u2019re continuing to invest in our business to provide customer -focused solutions and evolve our \ncommercial engagement strategies to prioritize addressing the complex challenges our customers \nface every day.  \n \n For example, at Investor Day we highlighted our first -to-market clinically -integrated supply chain, the \nCardinal Health Intelogix \u2122 Platform.  This innovative solution leverages artificial intelligence and \nmachine learning through the Palantir Foundry platform to help providers reduce costs, optimize drug \ninventories,  and generate actionable insights to simplify and streamline medication supply.  We\u2019ve \ncontinued to develop our offerings, such as the Contract Optimizer tool, which drives savings and \nvalue throu gh contract compliance, cost controls and product alternatives like brand -to-generics, \nblood plasma and more.  Key health system customers are already benefiting from these capabilities, \nand we see opportunities for further future expansion.  \n \n", "original_text": "For example, at Investor Day we highlighted our first -to-market clinically -integrated supply chain, the \nCardinal Health Intelogix \u2122 Platform. ", "page_label": "7", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "1b974c9c-bb8b-435a-a421-b84d1956e255", "node_type": "4", "metadata": {"page_label": "7", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "9028abcf421a057a34aae556f51e61d45492e0e39012a6e17756157dd506e3f9", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "db807c40-67e7-414e-8cca-6e520497267f", "node_type": "1", "metadata": {"window": "More on that front shortly.       \n \n A key component of our strong core foundation is our generics program, anchored by Red Oak, which \ncontinues to do an excellent job fulfilling its dual mandate , managing both cost and supply.  Red Oak \nleverages proprietary analytical tools and their deep industry expertise to help maximize service \ndelivery for customers.  \n \n We\u2019re continuing to invest in our business to provide customer -focused solutions and evolve our \ncommercial engagement strategies to prioritize addressing the complex challenges our customers \nface every day.  \n \n For example, at Investor Day we highlighted our first -to-market clinically -integrated supply chain, the \nCardinal Health Intelogix \u2122 Platform.  This innovative solution leverages artificial intelligence and \nmachine learning through the Palantir Foundry platform to help providers reduce costs, optimize drug \ninventories,  and generate actionable insights to simplify and streamline medication supply.  We\u2019ve \ncontinued to develop our offerings, such as the Contract Optimizer tool, which drives savings and \nvalue throu gh contract compliance, cost controls and product alternatives like brand -to-generics, \nblood plasma and more. ", "original_text": "We\u2019re continuing to invest in our business to provide customer -focused solutions and evolve our \ncommercial engagement strategies to prioritize addressing the complex challenges our customers \nface every day.  \n \n", "page_label": "7", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "74c2fca4a9e40e282dec23eae2ea8d48a52bbb55699304f1a40749f51c3b2b55", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "90c0d51f-d87d-4bab-8c9b-eaa7b87c5748", "node_type": "1", "metadata": {"window": "Red Oak \nleverages proprietary analytical tools and their deep industry expertise to help maximize service \ndelivery for customers.  \n \n We\u2019re continuing to invest in our business to provide customer -focused solutions and evolve our \ncommercial engagement strategies to prioritize addressing the complex challenges our customers \nface every day.  \n \n For example, at Investor Day we highlighted our first -to-market clinically -integrated supply chain, the \nCardinal Health Intelogix \u2122 Platform.  This innovative solution leverages artificial intelligence and \nmachine learning through the Palantir Foundry platform to help providers reduce costs, optimize drug \ninventories,  and generate actionable insights to simplify and streamline medication supply.  We\u2019ve \ncontinued to develop our offerings, such as the Contract Optimizer tool, which drives savings and \nvalue throu gh contract compliance, cost controls and product alternatives like brand -to-generics, \nblood plasma and more.  Key health system customers are already benefiting from these capabilities, \nand we see opportunities for further future expansion.  \n \n Shifting to Specialty, where we have also been investing to expand our offering into complementary \nareas . \n \n", "original_text": "This innovative solution leverages artificial intelligence and \nmachine learning through the Palantir Foundry platform to help providers reduce costs, optimize drug \ninventories,  and generate actionable insights to simplify and streamline medication supply. "}, "hash": "def87208169fbf6b7dbdf4e511c379cccf750af8f6b4e4b992bcb4c00462ff77", "class_name": "RelatedNodeInfo"}}, "text": "For example, at Investor Day we highlighted our first -to-market clinically -integrated supply chain, the \nCardinal Health Intelogix \u2122 Platform. ", "start_char_idx": 1080, "end_char_idx": 1225, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "90c0d51f-d87d-4bab-8c9b-eaa7b87c5748": {"__data__": {"id_": "90c0d51f-d87d-4bab-8c9b-eaa7b87c5748", "embedding": null, "metadata": {"window": "Red Oak \nleverages proprietary analytical tools and their deep industry expertise to help maximize service \ndelivery for customers.  \n \n We\u2019re continuing to invest in our business to provide customer -focused solutions and evolve our \ncommercial engagement strategies to prioritize addressing the complex challenges our customers \nface every day.  \n \n For example, at Investor Day we highlighted our first -to-market clinically -integrated supply chain, the \nCardinal Health Intelogix \u2122 Platform.  This innovative solution leverages artificial intelligence and \nmachine learning through the Palantir Foundry platform to help providers reduce costs, optimize drug \ninventories,  and generate actionable insights to simplify and streamline medication supply.  We\u2019ve \ncontinued to develop our offerings, such as the Contract Optimizer tool, which drives savings and \nvalue throu gh contract compliance, cost controls and product alternatives like brand -to-generics, \nblood plasma and more.  Key health system customers are already benefiting from these capabilities, \nand we see opportunities for further future expansion.  \n \n Shifting to Specialty, where we have also been investing to expand our offering into complementary \nareas . \n \n", "original_text": "This innovative solution leverages artificial intelligence and \nmachine learning through the Palantir Foundry platform to help providers reduce costs, optimize drug \ninventories,  and generate actionable insights to simplify and streamline medication supply. ", "page_label": "7", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "1b974c9c-bb8b-435a-a421-b84d1956e255", "node_type": "4", "metadata": {"page_label": "7", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "9028abcf421a057a34aae556f51e61d45492e0e39012a6e17756157dd506e3f9", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "84ec9b09-9ab2-4292-9ed6-8bd5278c659a", "node_type": "1", "metadata": {"window": "A key component of our strong core foundation is our generics program, anchored by Red Oak, which \ncontinues to do an excellent job fulfilling its dual mandate , managing both cost and supply.  Red Oak \nleverages proprietary analytical tools and their deep industry expertise to help maximize service \ndelivery for customers.  \n \n We\u2019re continuing to invest in our business to provide customer -focused solutions and evolve our \ncommercial engagement strategies to prioritize addressing the complex challenges our customers \nface every day.  \n \n For example, at Investor Day we highlighted our first -to-market clinically -integrated supply chain, the \nCardinal Health Intelogix \u2122 Platform.  This innovative solution leverages artificial intelligence and \nmachine learning through the Palantir Foundry platform to help providers reduce costs, optimize drug \ninventories,  and generate actionable insights to simplify and streamline medication supply.  We\u2019ve \ncontinued to develop our offerings, such as the Contract Optimizer tool, which drives savings and \nvalue throu gh contract compliance, cost controls and product alternatives like brand -to-generics, \nblood plasma and more.  Key health system customers are already benefiting from these capabilities, \nand we see opportunities for further future expansion.  \n \n", "original_text": "For example, at Investor Day we highlighted our first -to-market clinically -integrated supply chain, the \nCardinal Health Intelogix \u2122 Platform. ", "page_label": "7", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "89b5d5c88f41a72c76c3e2f023d952bfb942a9e92fb8a93fd46f5f60317a05d2", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "58fd92b4-fe36-4a8a-8069-136bcfce7545", "node_type": "1", "metadata": {"window": "We\u2019re continuing to invest in our business to provide customer -focused solutions and evolve our \ncommercial engagement strategies to prioritize addressing the complex challenges our customers \nface every day.  \n \n For example, at Investor Day we highlighted our first -to-market clinically -integrated supply chain, the \nCardinal Health Intelogix \u2122 Platform.  This innovative solution leverages artificial intelligence and \nmachine learning through the Palantir Foundry platform to help providers reduce costs, optimize drug \ninventories,  and generate actionable insights to simplify and streamline medication supply.  We\u2019ve \ncontinued to develop our offerings, such as the Contract Optimizer tool, which drives savings and \nvalue throu gh contract compliance, cost controls and product alternatives like brand -to-generics, \nblood plasma and more.  Key health system customers are already benefiting from these capabilities, \nand we see opportunities for further future expansion.  \n \n Shifting to Specialty, where we have also been investing to expand our offering into complementary \nareas . \n \n The acquisition of Specialty Networks is exciting to us on a number of  fronts. ", "original_text": "We\u2019ve \ncontinued to develop our offerings, such as the Contract Optimizer tool, which drives savings and \nvalue throu gh contract compliance, cost controls and product alternatives like brand -to-generics, \nblood plasma and more. "}, "hash": "cb1b2c1ff787ba3237856ff7ee58aee2d3429b90f88883ef77f5ec9e3b7960a8", "class_name": "RelatedNodeInfo"}}, "text": "This innovative solution leverages artificial intelligence and \nmachine learning through the Palantir Foundry platform to help providers reduce costs, optimize drug \ninventories,  and generate actionable insights to simplify and streamline medication supply. ", "start_char_idx": 1225, "end_char_idx": 1484, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "58fd92b4-fe36-4a8a-8069-136bcfce7545": {"__data__": {"id_": "58fd92b4-fe36-4a8a-8069-136bcfce7545", "embedding": null, "metadata": {"window": "We\u2019re continuing to invest in our business to provide customer -focused solutions and evolve our \ncommercial engagement strategies to prioritize addressing the complex challenges our customers \nface every day.  \n \n For example, at Investor Day we highlighted our first -to-market clinically -integrated supply chain, the \nCardinal Health Intelogix \u2122 Platform.  This innovative solution leverages artificial intelligence and \nmachine learning through the Palantir Foundry platform to help providers reduce costs, optimize drug \ninventories,  and generate actionable insights to simplify and streamline medication supply.  We\u2019ve \ncontinued to develop our offerings, such as the Contract Optimizer tool, which drives savings and \nvalue throu gh contract compliance, cost controls and product alternatives like brand -to-generics, \nblood plasma and more.  Key health system customers are already benefiting from these capabilities, \nand we see opportunities for further future expansion.  \n \n Shifting to Specialty, where we have also been investing to expand our offering into complementary \nareas . \n \n The acquisition of Specialty Networks is exciting to us on a number of  fronts. ", "original_text": "We\u2019ve \ncontinued to develop our offerings, such as the Contract Optimizer tool, which drives savings and \nvalue throu gh contract compliance, cost controls and product alternatives like brand -to-generics, \nblood plasma and more. ", "page_label": "7", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "1b974c9c-bb8b-435a-a421-b84d1956e255", "node_type": "4", "metadata": {"page_label": "7", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "9028abcf421a057a34aae556f51e61d45492e0e39012a6e17756157dd506e3f9", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "90c0d51f-d87d-4bab-8c9b-eaa7b87c5748", "node_type": "1", "metadata": {"window": "Red Oak \nleverages proprietary analytical tools and their deep industry expertise to help maximize service \ndelivery for customers.  \n \n We\u2019re continuing to invest in our business to provide customer -focused solutions and evolve our \ncommercial engagement strategies to prioritize addressing the complex challenges our customers \nface every day.  \n \n For example, at Investor Day we highlighted our first -to-market clinically -integrated supply chain, the \nCardinal Health Intelogix \u2122 Platform.  This innovative solution leverages artificial intelligence and \nmachine learning through the Palantir Foundry platform to help providers reduce costs, optimize drug \ninventories,  and generate actionable insights to simplify and streamline medication supply.  We\u2019ve \ncontinued to develop our offerings, such as the Contract Optimizer tool, which drives savings and \nvalue throu gh contract compliance, cost controls and product alternatives like brand -to-generics, \nblood plasma and more.  Key health system customers are already benefiting from these capabilities, \nand we see opportunities for further future expansion.  \n \n Shifting to Specialty, where we have also been investing to expand our offering into complementary \nareas . \n \n", "original_text": "This innovative solution leverages artificial intelligence and \nmachine learning through the Palantir Foundry platform to help providers reduce costs, optimize drug \ninventories,  and generate actionable insights to simplify and streamline medication supply. ", "page_label": "7", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "bb21efee6c2794f038c786b067d550305fd894a7e76c3ed20ef00b9dff708cbf", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "46b4ddac-e273-4879-8fb3-22a7003d1469", "node_type": "1", "metadata": {"window": "For example, at Investor Day we highlighted our first -to-market clinically -integrated supply chain, the \nCardinal Health Intelogix \u2122 Platform.  This innovative solution leverages artificial intelligence and \nmachine learning through the Palantir Foundry platform to help providers reduce costs, optimize drug \ninventories,  and generate actionable insights to simplify and streamline medication supply.  We\u2019ve \ncontinued to develop our offerings, such as the Contract Optimizer tool, which drives savings and \nvalue throu gh contract compliance, cost controls and product alternatives like brand -to-generics, \nblood plasma and more.  Key health system customers are already benefiting from these capabilities, \nand we see opportunities for further future expansion.  \n \n Shifting to Specialty, where we have also been investing to expand our offering into complementary \nareas . \n \n The acquisition of Specialty Networks is exciting to us on a number of  fronts.  This is a business with \nwhich we were already very familiar, given the long -standing partnership to service their members \nthrough our Specialty Distribution.  \n \n", "original_text": "Key health system customers are already benefiting from these capabilities, \nand we see opportunities for further future expansion.  \n \n"}, "hash": "ba3d14c96f6f8344091a21cf607f4cc7ebe7b7fd68546b6f085a0aca167d6dc6", "class_name": "RelatedNodeInfo"}}, "text": "We\u2019ve \ncontinued to develop our offerings, such as the Contract Optimizer tool, which drives savings and \nvalue throu gh contract compliance, cost controls and product alternatives like brand -to-generics, \nblood plasma and more. ", "start_char_idx": 1484, "end_char_idx": 1714, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "46b4ddac-e273-4879-8fb3-22a7003d1469": {"__data__": {"id_": "46b4ddac-e273-4879-8fb3-22a7003d1469", "embedding": null, "metadata": {"window": "For example, at Investor Day we highlighted our first -to-market clinically -integrated supply chain, the \nCardinal Health Intelogix \u2122 Platform.  This innovative solution leverages artificial intelligence and \nmachine learning through the Palantir Foundry platform to help providers reduce costs, optimize drug \ninventories,  and generate actionable insights to simplify and streamline medication supply.  We\u2019ve \ncontinued to develop our offerings, such as the Contract Optimizer tool, which drives savings and \nvalue throu gh contract compliance, cost controls and product alternatives like brand -to-generics, \nblood plasma and more.  Key health system customers are already benefiting from these capabilities, \nand we see opportunities for further future expansion.  \n \n Shifting to Specialty, where we have also been investing to expand our offering into complementary \nareas . \n \n The acquisition of Specialty Networks is exciting to us on a number of  fronts.  This is a business with \nwhich we were already very familiar, given the long -standing partnership to service their members \nthrough our Specialty Distribution.  \n \n", "original_text": "Key health system customers are already benefiting from these capabilities, \nand we see opportunities for further future expansion.  \n \n", "page_label": "7", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "1b974c9c-bb8b-435a-a421-b84d1956e255", "node_type": "4", "metadata": {"page_label": "7", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "9028abcf421a057a34aae556f51e61d45492e0e39012a6e17756157dd506e3f9", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "58fd92b4-fe36-4a8a-8069-136bcfce7545", "node_type": "1", "metadata": {"window": "We\u2019re continuing to invest in our business to provide customer -focused solutions and evolve our \ncommercial engagement strategies to prioritize addressing the complex challenges our customers \nface every day.  \n \n For example, at Investor Day we highlighted our first -to-market clinically -integrated supply chain, the \nCardinal Health Intelogix \u2122 Platform.  This innovative solution leverages artificial intelligence and \nmachine learning through the Palantir Foundry platform to help providers reduce costs, optimize drug \ninventories,  and generate actionable insights to simplify and streamline medication supply.  We\u2019ve \ncontinued to develop our offerings, such as the Contract Optimizer tool, which drives savings and \nvalue throu gh contract compliance, cost controls and product alternatives like brand -to-generics, \nblood plasma and more.  Key health system customers are already benefiting from these capabilities, \nand we see opportunities for further future expansion.  \n \n Shifting to Specialty, where we have also been investing to expand our offering into complementary \nareas . \n \n The acquisition of Specialty Networks is exciting to us on a number of  fronts. ", "original_text": "We\u2019ve \ncontinued to develop our offerings, such as the Contract Optimizer tool, which drives savings and \nvalue throu gh contract compliance, cost controls and product alternatives like brand -to-generics, \nblood plasma and more. ", "page_label": "7", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "9ebe884344b5914adb6a694bd6c48e3f0cbeff897e56849308876a28d9723a3f", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "40f76173-5e11-4d91-bdaf-4ad7a4a47228", "node_type": "1", "metadata": {"window": "This innovative solution leverages artificial intelligence and \nmachine learning through the Palantir Foundry platform to help providers reduce costs, optimize drug \ninventories,  and generate actionable insights to simplify and streamline medication supply.  We\u2019ve \ncontinued to develop our offerings, such as the Contract Optimizer tool, which drives savings and \nvalue throu gh contract compliance, cost controls and product alternatives like brand -to-generics, \nblood plasma and more.  Key health system customers are already benefiting from these capabilities, \nand we see opportunities for further future expansion.  \n \n Shifting to Specialty, where we have also been investing to expand our offering into complementary \nareas . \n \n The acquisition of Specialty Networks is exciting to us on a number of  fronts.  This is a business with \nwhich we were already very familiar, given the long -standing partnership to service their members \nthrough our Specialty Distribution.  \n \n Specialty Networks is a technology -enabled multi -specialty group purchasing and practice \nenhancement organization, serving 11,500 total providers today, including more than 7,000 \nphysicians across 1,200 independent urology, gastroenterology,  and rheumatology practices. ", "original_text": "Shifting to Specialty, where we have also been investing to expand our offering into complementary \nareas . \n \n"}, "hash": "dbbc698a36504f736140f10cce3730451020844346fd43b5ddbb8abdf83b11b0", "class_name": "RelatedNodeInfo"}}, "text": "Key health system customers are already benefiting from these capabilities, \nand we see opportunities for further future expansion.  \n \n", "start_char_idx": 1714, "end_char_idx": 1850, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "40f76173-5e11-4d91-bdaf-4ad7a4a47228": {"__data__": {"id_": "40f76173-5e11-4d91-bdaf-4ad7a4a47228", "embedding": null, "metadata": {"window": "This innovative solution leverages artificial intelligence and \nmachine learning through the Palantir Foundry platform to help providers reduce costs, optimize drug \ninventories,  and generate actionable insights to simplify and streamline medication supply.  We\u2019ve \ncontinued to develop our offerings, such as the Contract Optimizer tool, which drives savings and \nvalue throu gh contract compliance, cost controls and product alternatives like brand -to-generics, \nblood plasma and more.  Key health system customers are already benefiting from these capabilities, \nand we see opportunities for further future expansion.  \n \n Shifting to Specialty, where we have also been investing to expand our offering into complementary \nareas . \n \n The acquisition of Specialty Networks is exciting to us on a number of  fronts.  This is a business with \nwhich we were already very familiar, given the long -standing partnership to service their members \nthrough our Specialty Distribution.  \n \n Specialty Networks is a technology -enabled multi -specialty group purchasing and practice \nenhancement organization, serving 11,500 total providers today, including more than 7,000 \nphysicians across 1,200 independent urology, gastroenterology,  and rheumatology practices. ", "original_text": "Shifting to Specialty, where we have also been investing to expand our offering into complementary \nareas . \n \n", "page_label": "7", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "1b974c9c-bb8b-435a-a421-b84d1956e255", "node_type": "4", "metadata": {"page_label": "7", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "9028abcf421a057a34aae556f51e61d45492e0e39012a6e17756157dd506e3f9", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "46b4ddac-e273-4879-8fb3-22a7003d1469", "node_type": "1", "metadata": {"window": "For example, at Investor Day we highlighted our first -to-market clinically -integrated supply chain, the \nCardinal Health Intelogix \u2122 Platform.  This innovative solution leverages artificial intelligence and \nmachine learning through the Palantir Foundry platform to help providers reduce costs, optimize drug \ninventories,  and generate actionable insights to simplify and streamline medication supply.  We\u2019ve \ncontinued to develop our offerings, such as the Contract Optimizer tool, which drives savings and \nvalue throu gh contract compliance, cost controls and product alternatives like brand -to-generics, \nblood plasma and more.  Key health system customers are already benefiting from these capabilities, \nand we see opportunities for further future expansion.  \n \n Shifting to Specialty, where we have also been investing to expand our offering into complementary \nareas . \n \n The acquisition of Specialty Networks is exciting to us on a number of  fronts.  This is a business with \nwhich we were already very familiar, given the long -standing partnership to service their members \nthrough our Specialty Distribution.  \n \n", "original_text": "Key health system customers are already benefiting from these capabilities, \nand we see opportunities for further future expansion.  \n \n", "page_label": "7", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "ebd3e20c32af0c3c2793039baf4d1dd49090aa39aa320e90085236b366cfc5f4", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "63206695-382c-4390-ab68-6767f4a298b4", "node_type": "1", "metadata": {"window": "We\u2019ve \ncontinued to develop our offerings, such as the Contract Optimizer tool, which drives savings and \nvalue throu gh contract compliance, cost controls and product alternatives like brand -to-generics, \nblood plasma and more.  Key health system customers are already benefiting from these capabilities, \nand we see opportunities for further future expansion.  \n \n Shifting to Specialty, where we have also been investing to expand our offering into complementary \nareas . \n \n The acquisition of Specialty Networks is exciting to us on a number of  fronts.  This is a business with \nwhich we were already very familiar, given the long -standing partnership to service their members \nthrough our Specialty Distribution.  \n \n Specialty Networks is a technology -enabled multi -specialty group purchasing and practice \nenhancement organization, serving 11,500 total providers today, including more than 7,000 \nphysicians across 1,200 independent urology, gastroenterology,  and rheumatology practices.  We see \ntheir service capabilities as accelerating our efforts in critical ways:  \n \nFirst, f urther extending our reach, expertise, and offerings in key therapeutic areas to provide \nincreased clinical and economic value for specialty providers. ", "original_text": "The acquisition of Specialty Networks is exciting to us on a number of  fronts. "}, "hash": "41a5748c08873082ac35aa53f706db76e084d1e7529b0b2e079a9c2bbab08bb4", "class_name": "RelatedNodeInfo"}}, "text": "Shifting to Specialty, where we have also been investing to expand our offering into complementary \nareas . \n \n", "start_char_idx": 1850, "end_char_idx": 1961, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "63206695-382c-4390-ab68-6767f4a298b4": {"__data__": {"id_": "63206695-382c-4390-ab68-6767f4a298b4", "embedding": null, "metadata": {"window": "We\u2019ve \ncontinued to develop our offerings, such as the Contract Optimizer tool, which drives savings and \nvalue throu gh contract compliance, cost controls and product alternatives like brand -to-generics, \nblood plasma and more.  Key health system customers are already benefiting from these capabilities, \nand we see opportunities for further future expansion.  \n \n Shifting to Specialty, where we have also been investing to expand our offering into complementary \nareas . \n \n The acquisition of Specialty Networks is exciting to us on a number of  fronts.  This is a business with \nwhich we were already very familiar, given the long -standing partnership to service their members \nthrough our Specialty Distribution.  \n \n Specialty Networks is a technology -enabled multi -specialty group purchasing and practice \nenhancement organization, serving 11,500 total providers today, including more than 7,000 \nphysicians across 1,200 independent urology, gastroenterology,  and rheumatology practices.  We see \ntheir service capabilities as accelerating our efforts in critical ways:  \n \nFirst, f urther extending our reach, expertise, and offerings in key therapeutic areas to provide \nincreased clinical and economic value for specialty providers. ", "original_text": "The acquisition of Specialty Networks is exciting to us on a number of  fronts. ", "page_label": "7", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "1b974c9c-bb8b-435a-a421-b84d1956e255", "node_type": "4", "metadata": {"page_label": "7", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "9028abcf421a057a34aae556f51e61d45492e0e39012a6e17756157dd506e3f9", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "40f76173-5e11-4d91-bdaf-4ad7a4a47228", "node_type": "1", "metadata": {"window": "This innovative solution leverages artificial intelligence and \nmachine learning through the Palantir Foundry platform to help providers reduce costs, optimize drug \ninventories,  and generate actionable insights to simplify and streamline medication supply.  We\u2019ve \ncontinued to develop our offerings, such as the Contract Optimizer tool, which drives savings and \nvalue throu gh contract compliance, cost controls and product alternatives like brand -to-generics, \nblood plasma and more.  Key health system customers are already benefiting from these capabilities, \nand we see opportunities for further future expansion.  \n \n Shifting to Specialty, where we have also been investing to expand our offering into complementary \nareas . \n \n The acquisition of Specialty Networks is exciting to us on a number of  fronts.  This is a business with \nwhich we were already very familiar, given the long -standing partnership to service their members \nthrough our Specialty Distribution.  \n \n Specialty Networks is a technology -enabled multi -specialty group purchasing and practice \nenhancement organization, serving 11,500 total providers today, including more than 7,000 \nphysicians across 1,200 independent urology, gastroenterology,  and rheumatology practices. ", "original_text": "Shifting to Specialty, where we have also been investing to expand our offering into complementary \nareas . \n \n", "page_label": "7", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "75d30462b21e1b788e0e9e6f9b38382807f348bf2850f44b2e98f68e7cef2c58", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "130dbcf6-273c-4d68-bd50-976970d187b5", "node_type": "1", "metadata": {"window": "Key health system customers are already benefiting from these capabilities, \nand we see opportunities for further future expansion.  \n \n Shifting to Specialty, where we have also been investing to expand our offering into complementary \nareas . \n \n The acquisition of Specialty Networks is exciting to us on a number of  fronts.  This is a business with \nwhich we were already very familiar, given the long -standing partnership to service their members \nthrough our Specialty Distribution.  \n \n Specialty Networks is a technology -enabled multi -specialty group purchasing and practice \nenhancement organization, serving 11,500 total providers today, including more than 7,000 \nphysicians across 1,200 independent urology, gastroenterology,  and rheumatology practices.  We see \ntheir service capabilities as accelerating our efforts in critical ways:  \n \nFirst, f urther extending our reach, expertise, and offerings in key therapeutic areas to provide \nincreased clinical and economic value for specialty providers.  Specialty Networks is a leader in \nspecialty practice management, research and technologies that support physicians in lowering costs, \noperating more efficiently, and delivering best -in-class care to their patients. ", "original_text": "This is a business with \nwhich we were already very familiar, given the long -standing partnership to service their members \nthrough our Specialty Distribution.  \n \n"}, "hash": "ad7b53c05b5c139aacd64ae4582c6d51cb63c022e62bf14c837472ae6199cca0", "class_name": "RelatedNodeInfo"}}, "text": "The acquisition of Specialty Networks is exciting to us on a number of  fronts. ", "start_char_idx": 1961, "end_char_idx": 2041, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "130dbcf6-273c-4d68-bd50-976970d187b5": {"__data__": {"id_": "130dbcf6-273c-4d68-bd50-976970d187b5", "embedding": null, "metadata": {"window": "Key health system customers are already benefiting from these capabilities, \nand we see opportunities for further future expansion.  \n \n Shifting to Specialty, where we have also been investing to expand our offering into complementary \nareas . \n \n The acquisition of Specialty Networks is exciting to us on a number of  fronts.  This is a business with \nwhich we were already very familiar, given the long -standing partnership to service their members \nthrough our Specialty Distribution.  \n \n Specialty Networks is a technology -enabled multi -specialty group purchasing and practice \nenhancement organization, serving 11,500 total providers today, including more than 7,000 \nphysicians across 1,200 independent urology, gastroenterology,  and rheumatology practices.  We see \ntheir service capabilities as accelerating our efforts in critical ways:  \n \nFirst, f urther extending our reach, expertise, and offerings in key therapeutic areas to provide \nincreased clinical and economic value for specialty providers.  Specialty Networks is a leader in \nspecialty practice management, research and technologies that support physicians in lowering costs, \noperating more efficiently, and delivering best -in-class care to their patients. ", "original_text": "This is a business with \nwhich we were already very familiar, given the long -standing partnership to service their members \nthrough our Specialty Distribution.  \n \n", "page_label": "7", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "1b974c9c-bb8b-435a-a421-b84d1956e255", "node_type": "4", "metadata": {"page_label": "7", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "9028abcf421a057a34aae556f51e61d45492e0e39012a6e17756157dd506e3f9", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "63206695-382c-4390-ab68-6767f4a298b4", "node_type": "1", "metadata": {"window": "We\u2019ve \ncontinued to develop our offerings, such as the Contract Optimizer tool, which drives savings and \nvalue throu gh contract compliance, cost controls and product alternatives like brand -to-generics, \nblood plasma and more.  Key health system customers are already benefiting from these capabilities, \nand we see opportunities for further future expansion.  \n \n Shifting to Specialty, where we have also been investing to expand our offering into complementary \nareas . \n \n The acquisition of Specialty Networks is exciting to us on a number of  fronts.  This is a business with \nwhich we were already very familiar, given the long -standing partnership to service their members \nthrough our Specialty Distribution.  \n \n Specialty Networks is a technology -enabled multi -specialty group purchasing and practice \nenhancement organization, serving 11,500 total providers today, including more than 7,000 \nphysicians across 1,200 independent urology, gastroenterology,  and rheumatology practices.  We see \ntheir service capabilities as accelerating our efforts in critical ways:  \n \nFirst, f urther extending our reach, expertise, and offerings in key therapeutic areas to provide \nincreased clinical and economic value for specialty providers. ", "original_text": "The acquisition of Specialty Networks is exciting to us on a number of  fronts. ", "page_label": "7", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "dc71940f6428422aa1f639ad887c0f2d950bc7b59f5fc93f3fb664af84928ec8", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "7e1af22d-b54b-482f-94b9-c3d133b1afe4", "node_type": "1", "metadata": {"window": "Shifting to Specialty, where we have also been investing to expand our offering into complementary \nareas . \n \n The acquisition of Specialty Networks is exciting to us on a number of  fronts.  This is a business with \nwhich we were already very familiar, given the long -standing partnership to service their members \nthrough our Specialty Distribution.  \n \n Specialty Networks is a technology -enabled multi -specialty group purchasing and practice \nenhancement organization, serving 11,500 total providers today, including more than 7,000 \nphysicians across 1,200 independent urology, gastroenterology,  and rheumatology practices.  We see \ntheir service capabilities as accelerating our efforts in critical ways:  \n \nFirst, f urther extending our reach, expertise, and offerings in key therapeutic areas to provide \nincreased clinical and economic value for specialty providers.  Specialty Networks is a leader in \nspecialty practice management, research and technologies that support physicians in lowering costs, \noperating more efficiently, and delivering best -in-class care to their patients.  For example, the \ncompany provides solutions that improve clinical and economic outcomes to over 3,000 urologists \nthrough its leading UroG PO. \n ", "original_text": "Specialty Networks is a technology -enabled multi -specialty group purchasing and practice \nenhancement organization, serving 11,500 total providers today, including more than 7,000 \nphysicians across 1,200 independent urology, gastroenterology,  and rheumatology practices. "}, "hash": "6c03e700a0103ac247d74f520b6fd3e119b0bb932458831f1adc667d061f296c", "class_name": "RelatedNodeInfo"}}, "text": "This is a business with \nwhich we were already very familiar, given the long -standing partnership to service their members \nthrough our Specialty Distribution.  \n \n", "start_char_idx": 2041, "end_char_idx": 2206, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "7e1af22d-b54b-482f-94b9-c3d133b1afe4": {"__data__": {"id_": "7e1af22d-b54b-482f-94b9-c3d133b1afe4", "embedding": null, "metadata": {"window": "Shifting to Specialty, where we have also been investing to expand our offering into complementary \nareas . \n \n The acquisition of Specialty Networks is exciting to us on a number of  fronts.  This is a business with \nwhich we were already very familiar, given the long -standing partnership to service their members \nthrough our Specialty Distribution.  \n \n Specialty Networks is a technology -enabled multi -specialty group purchasing and practice \nenhancement organization, serving 11,500 total providers today, including more than 7,000 \nphysicians across 1,200 independent urology, gastroenterology,  and rheumatology practices.  We see \ntheir service capabilities as accelerating our efforts in critical ways:  \n \nFirst, f urther extending our reach, expertise, and offerings in key therapeutic areas to provide \nincreased clinical and economic value for specialty providers.  Specialty Networks is a leader in \nspecialty practice management, research and technologies that support physicians in lowering costs, \noperating more efficiently, and delivering best -in-class care to their patients.  For example, the \ncompany provides solutions that improve clinical and economic outcomes to over 3,000 urologists \nthrough its leading UroG PO. \n ", "original_text": "Specialty Networks is a technology -enabled multi -specialty group purchasing and practice \nenhancement organization, serving 11,500 total providers today, including more than 7,000 \nphysicians across 1,200 independent urology, gastroenterology,  and rheumatology practices. ", "page_label": "7", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "1b974c9c-bb8b-435a-a421-b84d1956e255", "node_type": "4", "metadata": {"page_label": "7", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "9028abcf421a057a34aae556f51e61d45492e0e39012a6e17756157dd506e3f9", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "130dbcf6-273c-4d68-bd50-976970d187b5", "node_type": "1", "metadata": {"window": "Key health system customers are already benefiting from these capabilities, \nand we see opportunities for further future expansion.  \n \n Shifting to Specialty, where we have also been investing to expand our offering into complementary \nareas . \n \n The acquisition of Specialty Networks is exciting to us on a number of  fronts.  This is a business with \nwhich we were already very familiar, given the long -standing partnership to service their members \nthrough our Specialty Distribution.  \n \n Specialty Networks is a technology -enabled multi -specialty group purchasing and practice \nenhancement organization, serving 11,500 total providers today, including more than 7,000 \nphysicians across 1,200 independent urology, gastroenterology,  and rheumatology practices.  We see \ntheir service capabilities as accelerating our efforts in critical ways:  \n \nFirst, f urther extending our reach, expertise, and offerings in key therapeutic areas to provide \nincreased clinical and economic value for specialty providers.  Specialty Networks is a leader in \nspecialty practice management, research and technologies that support physicians in lowering costs, \noperating more efficiently, and delivering best -in-class care to their patients. ", "original_text": "This is a business with \nwhich we were already very familiar, given the long -standing partnership to service their members \nthrough our Specialty Distribution.  \n \n", "page_label": "7", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "bba9bae95bc8b1b07dbe59bf8e6421bd24f0956d2dac5d777261b27494c5564d", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "c33602cb-89eb-451f-94bf-70ab19a4d642", "node_type": "1", "metadata": {"window": "The acquisition of Specialty Networks is exciting to us on a number of  fronts.  This is a business with \nwhich we were already very familiar, given the long -standing partnership to service their members \nthrough our Specialty Distribution.  \n \n Specialty Networks is a technology -enabled multi -specialty group purchasing and practice \nenhancement organization, serving 11,500 total providers today, including more than 7,000 \nphysicians across 1,200 independent urology, gastroenterology,  and rheumatology practices.  We see \ntheir service capabilities as accelerating our efforts in critical ways:  \n \nFirst, f urther extending our reach, expertise, and offerings in key therapeutic areas to provide \nincreased clinical and economic value for specialty providers.  Specialty Networks is a leader in \nspecialty practice management, research and technologies that support physicians in lowering costs, \noperating more efficiently, and delivering best -in-class care to their patients.  For example, the \ncompany provides solutions that improve clinical and economic outcomes to over 3,000 urologists \nthrough its leading UroG PO. \n ", "original_text": "We see \ntheir service capabilities as accelerating our efforts in critical ways:  \n \nFirst, f urther extending our reach, expertise, and offerings in key therapeutic areas to provide \nincreased clinical and economic value for specialty providers. "}, "hash": "36731aa417a63557c3d10831127a094f976f2e9cd5c37edf446e843f6a82768d", "class_name": "RelatedNodeInfo"}}, "text": "Specialty Networks is a technology -enabled multi -specialty group purchasing and practice \nenhancement organization, serving 11,500 total providers today, including more than 7,000 \nphysicians across 1,200 independent urology, gastroenterology,  and rheumatology practices. ", "start_char_idx": 2206, "end_char_idx": 2481, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "c33602cb-89eb-451f-94bf-70ab19a4d642": {"__data__": {"id_": "c33602cb-89eb-451f-94bf-70ab19a4d642", "embedding": null, "metadata": {"window": "The acquisition of Specialty Networks is exciting to us on a number of  fronts.  This is a business with \nwhich we were already very familiar, given the long -standing partnership to service their members \nthrough our Specialty Distribution.  \n \n Specialty Networks is a technology -enabled multi -specialty group purchasing and practice \nenhancement organization, serving 11,500 total providers today, including more than 7,000 \nphysicians across 1,200 independent urology, gastroenterology,  and rheumatology practices.  We see \ntheir service capabilities as accelerating our efforts in critical ways:  \n \nFirst, f urther extending our reach, expertise, and offerings in key therapeutic areas to provide \nincreased clinical and economic value for specialty providers.  Specialty Networks is a leader in \nspecialty practice management, research and technologies that support physicians in lowering costs, \noperating more efficiently, and delivering best -in-class care to their patients.  For example, the \ncompany provides solutions that improve clinical and economic outcomes to over 3,000 urologists \nthrough its leading UroG PO. \n ", "original_text": "We see \ntheir service capabilities as accelerating our efforts in critical ways:  \n \nFirst, f urther extending our reach, expertise, and offerings in key therapeutic areas to provide \nincreased clinical and economic value for specialty providers. ", "page_label": "7", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "1b974c9c-bb8b-435a-a421-b84d1956e255", "node_type": "4", "metadata": {"page_label": "7", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "9028abcf421a057a34aae556f51e61d45492e0e39012a6e17756157dd506e3f9", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "7e1af22d-b54b-482f-94b9-c3d133b1afe4", "node_type": "1", "metadata": {"window": "Shifting to Specialty, where we have also been investing to expand our offering into complementary \nareas . \n \n The acquisition of Specialty Networks is exciting to us on a number of  fronts.  This is a business with \nwhich we were already very familiar, given the long -standing partnership to service their members \nthrough our Specialty Distribution.  \n \n Specialty Networks is a technology -enabled multi -specialty group purchasing and practice \nenhancement organization, serving 11,500 total providers today, including more than 7,000 \nphysicians across 1,200 independent urology, gastroenterology,  and rheumatology practices.  We see \ntheir service capabilities as accelerating our efforts in critical ways:  \n \nFirst, f urther extending our reach, expertise, and offerings in key therapeutic areas to provide \nincreased clinical and economic value for specialty providers.  Specialty Networks is a leader in \nspecialty practice management, research and technologies that support physicians in lowering costs, \noperating more efficiently, and delivering best -in-class care to their patients.  For example, the \ncompany provides solutions that improve clinical and economic outcomes to over 3,000 urologists \nthrough its leading UroG PO. \n ", "original_text": "Specialty Networks is a technology -enabled multi -specialty group purchasing and practice \nenhancement organization, serving 11,500 total providers today, including more than 7,000 \nphysicians across 1,200 independent urology, gastroenterology,  and rheumatology practices. ", "page_label": "7", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "6b527b47c944a8b05dd694cecca666d6c1be28a8052ac74ac999ab2b68f828bf", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "652887f1-8aa3-4232-9fdb-42fd4cd75192", "node_type": "1", "metadata": {"window": "This is a business with \nwhich we were already very familiar, given the long -standing partnership to service their members \nthrough our Specialty Distribution.  \n \n Specialty Networks is a technology -enabled multi -specialty group purchasing and practice \nenhancement organization, serving 11,500 total providers today, including more than 7,000 \nphysicians across 1,200 independent urology, gastroenterology,  and rheumatology practices.  We see \ntheir service capabilities as accelerating our efforts in critical ways:  \n \nFirst, f urther extending our reach, expertise, and offerings in key therapeutic areas to provide \nincreased clinical and economic value for specialty providers.  Specialty Networks is a leader in \nspecialty practice management, research and technologies that support physicians in lowering costs, \noperating more efficiently, and delivering best -in-class care to their patients.  For example, the \ncompany provides solutions that improve clinical and economic outcomes to over 3,000 urologists \nthrough its leading UroG PO. \n ", "original_text": "Specialty Networks is a leader in \nspecialty practice management, research and technologies that support physicians in lowering costs, \noperating more efficiently, and delivering best -in-class care to their patients. "}, "hash": "7b39c75a920249506704bf2880257a0428ea776b1fe2fec626ebd00e589132e3", "class_name": "RelatedNodeInfo"}}, "text": "We see \ntheir service capabilities as accelerating our efforts in critical ways:  \n \nFirst, f urther extending our reach, expertise, and offerings in key therapeutic areas to provide \nincreased clinical and economic value for specialty providers. ", "start_char_idx": 2481, "end_char_idx": 2728, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "652887f1-8aa3-4232-9fdb-42fd4cd75192": {"__data__": {"id_": "652887f1-8aa3-4232-9fdb-42fd4cd75192", "embedding": null, "metadata": {"window": "This is a business with \nwhich we were already very familiar, given the long -standing partnership to service their members \nthrough our Specialty Distribution.  \n \n Specialty Networks is a technology -enabled multi -specialty group purchasing and practice \nenhancement organization, serving 11,500 total providers today, including more than 7,000 \nphysicians across 1,200 independent urology, gastroenterology,  and rheumatology practices.  We see \ntheir service capabilities as accelerating our efforts in critical ways:  \n \nFirst, f urther extending our reach, expertise, and offerings in key therapeutic areas to provide \nincreased clinical and economic value for specialty providers.  Specialty Networks is a leader in \nspecialty practice management, research and technologies that support physicians in lowering costs, \noperating more efficiently, and delivering best -in-class care to their patients.  For example, the \ncompany provides solutions that improve clinical and economic outcomes to over 3,000 urologists \nthrough its leading UroG PO. \n ", "original_text": "Specialty Networks is a leader in \nspecialty practice management, research and technologies that support physicians in lowering costs, \noperating more efficiently, and delivering best -in-class care to their patients. ", "page_label": "7", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "1b974c9c-bb8b-435a-a421-b84d1956e255", "node_type": "4", "metadata": {"page_label": "7", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "9028abcf421a057a34aae556f51e61d45492e0e39012a6e17756157dd506e3f9", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "c33602cb-89eb-451f-94bf-70ab19a4d642", "node_type": "1", "metadata": {"window": "The acquisition of Specialty Networks is exciting to us on a number of  fronts.  This is a business with \nwhich we were already very familiar, given the long -standing partnership to service their members \nthrough our Specialty Distribution.  \n \n Specialty Networks is a technology -enabled multi -specialty group purchasing and practice \nenhancement organization, serving 11,500 total providers today, including more than 7,000 \nphysicians across 1,200 independent urology, gastroenterology,  and rheumatology practices.  We see \ntheir service capabilities as accelerating our efforts in critical ways:  \n \nFirst, f urther extending our reach, expertise, and offerings in key therapeutic areas to provide \nincreased clinical and economic value for specialty providers.  Specialty Networks is a leader in \nspecialty practice management, research and technologies that support physicians in lowering costs, \noperating more efficiently, and delivering best -in-class care to their patients.  For example, the \ncompany provides solutions that improve clinical and economic outcomes to over 3,000 urologists \nthrough its leading UroG PO. \n ", "original_text": "We see \ntheir service capabilities as accelerating our efforts in critical ways:  \n \nFirst, f urther extending our reach, expertise, and offerings in key therapeutic areas to provide \nincreased clinical and economic value for specialty providers. ", "page_label": "7", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "bd8605272fc4ceca734a8ebbcb141464dacd99c3ab1753eb770a4f5152209479", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "b23c1a75-8def-4517-a27c-2dc6b7461557", "node_type": "1", "metadata": {"window": "Specialty Networks is a technology -enabled multi -specialty group purchasing and practice \nenhancement organization, serving 11,500 total providers today, including more than 7,000 \nphysicians across 1,200 independent urology, gastroenterology,  and rheumatology practices.  We see \ntheir service capabilities as accelerating our efforts in critical ways:  \n \nFirst, f urther extending our reach, expertise, and offerings in key therapeutic areas to provide \nincreased clinical and economic value for specialty providers.  Specialty Networks is a leader in \nspecialty practice management, research and technologies that support physicians in lowering costs, \noperating more efficiently, and delivering best -in-class care to their patients.  For example, the \ncompany provides solutions that improve clinical and economic outcomes to over 3,000 urologists \nthrough its leading UroG PO. \n ", "original_text": "For example, the \ncompany provides solutions that improve clinical and economic outcomes to over 3,000 urologists \nthrough its leading UroG PO. \n "}, "hash": "da0a019059496a0324b3bbdf7f97ef0c654f95cc3751ca8d5e86193942a01d52", "class_name": "RelatedNodeInfo"}}, "text": "Specialty Networks is a leader in \nspecialty practice management, research and technologies that support physicians in lowering costs, \noperating more efficiently, and delivering best -in-class care to their patients. ", "start_char_idx": 2728, "end_char_idx": 2946, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "b23c1a75-8def-4517-a27c-2dc6b7461557": {"__data__": {"id_": "b23c1a75-8def-4517-a27c-2dc6b7461557", "embedding": null, "metadata": {"window": "Specialty Networks is a technology -enabled multi -specialty group purchasing and practice \nenhancement organization, serving 11,500 total providers today, including more than 7,000 \nphysicians across 1,200 independent urology, gastroenterology,  and rheumatology practices.  We see \ntheir service capabilities as accelerating our efforts in critical ways:  \n \nFirst, f urther extending our reach, expertise, and offerings in key therapeutic areas to provide \nincreased clinical and economic value for specialty providers.  Specialty Networks is a leader in \nspecialty practice management, research and technologies that support physicians in lowering costs, \noperating more efficiently, and delivering best -in-class care to their patients.  For example, the \ncompany provides solutions that improve clinical and economic outcomes to over 3,000 urologists \nthrough its leading UroG PO. \n ", "original_text": "For example, the \ncompany provides solutions that improve clinical and economic outcomes to over 3,000 urologists \nthrough its leading UroG PO. \n ", "page_label": "7", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "1b974c9c-bb8b-435a-a421-b84d1956e255", "node_type": "4", "metadata": {"page_label": "7", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "9028abcf421a057a34aae556f51e61d45492e0e39012a6e17756157dd506e3f9", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "652887f1-8aa3-4232-9fdb-42fd4cd75192", "node_type": "1", "metadata": {"window": "This is a business with \nwhich we were already very familiar, given the long -standing partnership to service their members \nthrough our Specialty Distribution.  \n \n Specialty Networks is a technology -enabled multi -specialty group purchasing and practice \nenhancement organization, serving 11,500 total providers today, including more than 7,000 \nphysicians across 1,200 independent urology, gastroenterology,  and rheumatology practices.  We see \ntheir service capabilities as accelerating our efforts in critical ways:  \n \nFirst, f urther extending our reach, expertise, and offerings in key therapeutic areas to provide \nincreased clinical and economic value for specialty providers.  Specialty Networks is a leader in \nspecialty practice management, research and technologies that support physicians in lowering costs, \noperating more efficiently, and delivering best -in-class care to their patients.  For example, the \ncompany provides solutions that improve clinical and economic outcomes to over 3,000 urologists \nthrough its leading UroG PO. \n ", "original_text": "Specialty Networks is a leader in \nspecialty practice management, research and technologies that support physicians in lowering costs, \noperating more efficiently, and delivering best -in-class care to their patients. ", "page_label": "7", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "98764b1849d00c2b1ed229fe9ffae8cc7560bc9471457ea36024ca3176f48e37", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "50e5df59-c1a0-4d5a-ac2e-b392237e6679", "node_type": "1", "metadata": {"window": " \nPage 8 of 19 \n \nSecond, c reating a platform for our expansion across specialty therapeutic areas.  The company\u2019s \nPPS Analytics solution is a subscription -based advanced technology platform that utilizes artificial \nintelligence, such as continuous learning algorithms and natural lan guage processing, to analyze data \nfrom electronic medical records, practice management, imaging and dispensing systems and \ntransform it into actionable insights for providers and other stakeholders.  We see this complementing \nour suite of clinical,  practice management and distribution solutions to specialty practices nationwide. \n Specialty Networks experience and capabilities in clinical engagement are robust, which also \naccelerates our upstream data and research opportunities with biopharma manufact urers.    \n \n", "original_text": " \nPage 8 of 19 \n \nSecond, c reating a platform for our expansion across specialty therapeutic areas. "}, "hash": "9bb16d79a04b0fd1dcdbc53e8e72a273332fa7553a83d9265268e7e78f133dc8", "class_name": "RelatedNodeInfo"}}, "text": "For example, the \ncompany provides solutions that improve clinical and economic outcomes to over 3,000 urologists \nthrough its leading UroG PO. \n ", "start_char_idx": 2946, "end_char_idx": 3092, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "50e5df59-c1a0-4d5a-ac2e-b392237e6679": {"__data__": {"id_": "50e5df59-c1a0-4d5a-ac2e-b392237e6679", "embedding": null, "metadata": {"window": " \nPage 8 of 19 \n \nSecond, c reating a platform for our expansion across specialty therapeutic areas.  The company\u2019s \nPPS Analytics solution is a subscription -based advanced technology platform that utilizes artificial \nintelligence, such as continuous learning algorithms and natural lan guage processing, to analyze data \nfrom electronic medical records, practice management, imaging and dispensing systems and \ntransform it into actionable insights for providers and other stakeholders.  We see this complementing \nour suite of clinical,  practice management and distribution solutions to specialty practices nationwide. \n Specialty Networks experience and capabilities in clinical engagement are robust, which also \naccelerates our upstream data and research opportunities with biopharma manufact urers.    \n \n", "original_text": " \nPage 8 of 19 \n \nSecond, c reating a platform for our expansion across specialty therapeutic areas. ", "page_label": "8", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "cb248949-64fc-498f-a357-322668a33cd9", "node_type": "4", "metadata": {"page_label": "8", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "e7b8c2a5dcb80575f7d8228fbd3e727bd9f5cdac723c24e2c276fa2bff980b35", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "b23c1a75-8def-4517-a27c-2dc6b7461557", "node_type": "1", "metadata": {"window": "Specialty Networks is a technology -enabled multi -specialty group purchasing and practice \nenhancement organization, serving 11,500 total providers today, including more than 7,000 \nphysicians across 1,200 independent urology, gastroenterology,  and rheumatology practices.  We see \ntheir service capabilities as accelerating our efforts in critical ways:  \n \nFirst, f urther extending our reach, expertise, and offerings in key therapeutic areas to provide \nincreased clinical and economic value for specialty providers.  Specialty Networks is a leader in \nspecialty practice management, research and technologies that support physicians in lowering costs, \noperating more efficiently, and delivering best -in-class care to their patients.  For example, the \ncompany provides solutions that improve clinical and economic outcomes to over 3,000 urologists \nthrough its leading UroG PO. \n ", "original_text": "For example, the \ncompany provides solutions that improve clinical and economic outcomes to over 3,000 urologists \nthrough its leading UroG PO. \n ", "page_label": "7", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "229680a5e4ad84cc2d3abe72decaa60824478eca5bb528716687b6bbae93046f", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "0168fae5-1479-4543-8914-0603c1531c2a", "node_type": "1", "metadata": {"window": " \nPage 8 of 19 \n \nSecond, c reating a platform for our expansion across specialty therapeutic areas.  The company\u2019s \nPPS Analytics solution is a subscription -based advanced technology platform that utilizes artificial \nintelligence, such as continuous learning algorithms and natural lan guage processing, to analyze data \nfrom electronic medical records, practice management, imaging and dispensing systems and \ntransform it into actionable insights for providers and other stakeholders.  We see this complementing \nour suite of clinical,  practice management and distribution solutions to specialty practices nationwide. \n Specialty Networks experience and capabilities in clinical engagement are robust, which also \naccelerates our upstream data and research opportunities with biopharma manufact urers.    \n \n Third, e nhancing the capabilities of our Specialty business, including supporting the ongoing build of \nthe Navista \u2122 Network. ", "original_text": "The company\u2019s \nPPS Analytics solution is a subscription -based advanced technology platform that utilizes artificial \nintelligence, such as continuous learning algorithms and natural lan guage processing, to analyze data \nfrom electronic medical records, practice management, imaging and dispensing systems and \ntransform it into actionable insights for providers and other stakeholders. "}, "hash": "036ac8b179191bfaa1b938061941b320ed9e2a15b493350194d0e7e16c6bc837", "class_name": "RelatedNodeInfo"}}, "text": " \nPage 8 of 19 \n \nSecond, c reating a platform for our expansion across specialty therapeutic areas. ", "start_char_idx": 0, "end_char_idx": 101, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "0168fae5-1479-4543-8914-0603c1531c2a": {"__data__": {"id_": "0168fae5-1479-4543-8914-0603c1531c2a", "embedding": null, "metadata": {"window": " \nPage 8 of 19 \n \nSecond, c reating a platform for our expansion across specialty therapeutic areas.  The company\u2019s \nPPS Analytics solution is a subscription -based advanced technology platform that utilizes artificial \nintelligence, such as continuous learning algorithms and natural lan guage processing, to analyze data \nfrom electronic medical records, practice management, imaging and dispensing systems and \ntransform it into actionable insights for providers and other stakeholders.  We see this complementing \nour suite of clinical,  practice management and distribution solutions to specialty practices nationwide. \n Specialty Networks experience and capabilities in clinical engagement are robust, which also \naccelerates our upstream data and research opportunities with biopharma manufact urers.    \n \n Third, e nhancing the capabilities of our Specialty business, including supporting the ongoing build of \nthe Navista \u2122 Network. ", "original_text": "The company\u2019s \nPPS Analytics solution is a subscription -based advanced technology platform that utilizes artificial \nintelligence, such as continuous learning algorithms and natural lan guage processing, to analyze data \nfrom electronic medical records, practice management, imaging and dispensing systems and \ntransform it into actionable insights for providers and other stakeholders. ", "page_label": "8", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "cb248949-64fc-498f-a357-322668a33cd9", "node_type": "4", "metadata": {"page_label": "8", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "e7b8c2a5dcb80575f7d8228fbd3e727bd9f5cdac723c24e2c276fa2bff980b35", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "50e5df59-c1a0-4d5a-ac2e-b392237e6679", "node_type": "1", "metadata": {"window": " \nPage 8 of 19 \n \nSecond, c reating a platform for our expansion across specialty therapeutic areas.  The company\u2019s \nPPS Analytics solution is a subscription -based advanced technology platform that utilizes artificial \nintelligence, such as continuous learning algorithms and natural lan guage processing, to analyze data \nfrom electronic medical records, practice management, imaging and dispensing systems and \ntransform it into actionable insights for providers and other stakeholders.  We see this complementing \nour suite of clinical,  practice management and distribution solutions to specialty practices nationwide. \n Specialty Networks experience and capabilities in clinical engagement are robust, which also \naccelerates our upstream data and research opportunities with biopharma manufact urers.    \n \n", "original_text": " \nPage 8 of 19 \n \nSecond, c reating a platform for our expansion across specialty therapeutic areas. ", "page_label": "8", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "ee98fc848fdbda87c4e1393898b778b744f75bb97ebd4fe54275f9efb94bce19", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "fac20d16-66f2-4c74-ab36-21cb576bc156", "node_type": "1", "metadata": {"window": " \nPage 8 of 19 \n \nSecond, c reating a platform for our expansion across specialty therapeutic areas.  The company\u2019s \nPPS Analytics solution is a subscription -based advanced technology platform that utilizes artificial \nintelligence, such as continuous learning algorithms and natural lan guage processing, to analyze data \nfrom electronic medical records, practice management, imaging and dispensing systems and \ntransform it into actionable insights for providers and other stakeholders.  We see this complementing \nour suite of clinical,  practice management and distribution solutions to specialty practices nationwide. \n Specialty Networks experience and capabilities in clinical engagement are robust, which also \naccelerates our upstream data and research opportunities with biopharma manufact urers.    \n \n Third, e nhancing the capabilities of our Specialty business, including supporting the ongoing build of \nthe Navista \u2122 Network.  Specialty Networks has a deep understanding of independent physician \npractices, and we see capabilities and expertise that will accelerate our ongoing development of the \nNavista \u2122 Network, which is focused on supporting the clinical and operational needs of independent \ncommunity oncologists.  \n \n", "original_text": "We see this complementing \nour suite of clinical,  practice management and distribution solutions to specialty practices nationwide. \n"}, "hash": "67771755279eb18c35968c21f69a261ddea92eb9ff6fa0c779f238432a21543d", "class_name": "RelatedNodeInfo"}}, "text": "The company\u2019s \nPPS Analytics solution is a subscription -based advanced technology platform that utilizes artificial \nintelligence, such as continuous learning algorithms and natural lan guage processing, to analyze data \nfrom electronic medical records, practice management, imaging and dispensing systems and \ntransform it into actionable insights for providers and other stakeholders. ", "start_char_idx": 101, "end_char_idx": 489, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "fac20d16-66f2-4c74-ab36-21cb576bc156": {"__data__": {"id_": "fac20d16-66f2-4c74-ab36-21cb576bc156", "embedding": null, "metadata": {"window": " \nPage 8 of 19 \n \nSecond, c reating a platform for our expansion across specialty therapeutic areas.  The company\u2019s \nPPS Analytics solution is a subscription -based advanced technology platform that utilizes artificial \nintelligence, such as continuous learning algorithms and natural lan guage processing, to analyze data \nfrom electronic medical records, practice management, imaging and dispensing systems and \ntransform it into actionable insights for providers and other stakeholders.  We see this complementing \nour suite of clinical,  practice management and distribution solutions to specialty practices nationwide. \n Specialty Networks experience and capabilities in clinical engagement are robust, which also \naccelerates our upstream data and research opportunities with biopharma manufact urers.    \n \n Third, e nhancing the capabilities of our Specialty business, including supporting the ongoing build of \nthe Navista \u2122 Network.  Specialty Networks has a deep understanding of independent physician \npractices, and we see capabilities and expertise that will accelerate our ongoing development of the \nNavista \u2122 Network, which is focused on supporting the clinical and operational needs of independent \ncommunity oncologists.  \n \n", "original_text": "We see this complementing \nour suite of clinical,  practice management and distribution solutions to specialty practices nationwide. \n", "page_label": "8", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "cb248949-64fc-498f-a357-322668a33cd9", "node_type": "4", "metadata": {"page_label": "8", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "e7b8c2a5dcb80575f7d8228fbd3e727bd9f5cdac723c24e2c276fa2bff980b35", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "0168fae5-1479-4543-8914-0603c1531c2a", "node_type": "1", "metadata": {"window": " \nPage 8 of 19 \n \nSecond, c reating a platform for our expansion across specialty therapeutic areas.  The company\u2019s \nPPS Analytics solution is a subscription -based advanced technology platform that utilizes artificial \nintelligence, such as continuous learning algorithms and natural lan guage processing, to analyze data \nfrom electronic medical records, practice management, imaging and dispensing systems and \ntransform it into actionable insights for providers and other stakeholders.  We see this complementing \nour suite of clinical,  practice management and distribution solutions to specialty practices nationwide. \n Specialty Networks experience and capabilities in clinical engagement are robust, which also \naccelerates our upstream data and research opportunities with biopharma manufact urers.    \n \n Third, e nhancing the capabilities of our Specialty business, including supporting the ongoing build of \nthe Navista \u2122 Network. ", "original_text": "The company\u2019s \nPPS Analytics solution is a subscription -based advanced technology platform that utilizes artificial \nintelligence, such as continuous learning algorithms and natural lan guage processing, to analyze data \nfrom electronic medical records, practice management, imaging and dispensing systems and \ntransform it into actionable insights for providers and other stakeholders. ", "page_label": "8", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "ea77144fd59020a832fce5c68ad7268f176005965b5bc40538852cb24c8ffc81", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "fef2fae6-e748-4e2e-89d6-932a0c437e4a", "node_type": "1", "metadata": {"window": " \nPage 8 of 19 \n \nSecond, c reating a platform for our expansion across specialty therapeutic areas.  The company\u2019s \nPPS Analytics solution is a subscription -based advanced technology platform that utilizes artificial \nintelligence, such as continuous learning algorithms and natural lan guage processing, to analyze data \nfrom electronic medical records, practice management, imaging and dispensing systems and \ntransform it into actionable insights for providers and other stakeholders.  We see this complementing \nour suite of clinical,  practice management and distribution solutions to specialty practices nationwide. \n Specialty Networks experience and capabilities in clinical engagement are robust, which also \naccelerates our upstream data and research opportunities with biopharma manufact urers.    \n \n Third, e nhancing the capabilities of our Specialty business, including supporting the ongoing build of \nthe Navista \u2122 Network.  Specialty Networks has a deep understanding of independent physician \npractices, and we see capabilities and expertise that will accelerate our ongoing development of the \nNavista \u2122 Network, which is focused on supporting the clinical and operational needs of independent \ncommunity oncologists.  \n \n In summary, this transaction enhances our specialty strategy by providing new capabilities that \nstrengthen the link between our downstream and upstream services, enabling us to create further \nvalue for customers, manufacturer partners and patients.  \n \n", "original_text": "Specialty Networks experience and capabilities in clinical engagement are robust, which also \naccelerates our upstream data and research opportunities with biopharma manufact urers.    \n \n"}, "hash": "dfac5cb505b2982c4e520e9992e2f769159d21447b331bd412743e785ea53096", "class_name": "RelatedNodeInfo"}}, "text": "We see this complementing \nour suite of clinical,  practice management and distribution solutions to specialty practices nationwide. \n", "start_char_idx": 489, "end_char_idx": 623, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "fef2fae6-e748-4e2e-89d6-932a0c437e4a": {"__data__": {"id_": "fef2fae6-e748-4e2e-89d6-932a0c437e4a", "embedding": null, "metadata": {"window": " \nPage 8 of 19 \n \nSecond, c reating a platform for our expansion across specialty therapeutic areas.  The company\u2019s \nPPS Analytics solution is a subscription -based advanced technology platform that utilizes artificial \nintelligence, such as continuous learning algorithms and natural lan guage processing, to analyze data \nfrom electronic medical records, practice management, imaging and dispensing systems and \ntransform it into actionable insights for providers and other stakeholders.  We see this complementing \nour suite of clinical,  practice management and distribution solutions to specialty practices nationwide. \n Specialty Networks experience and capabilities in clinical engagement are robust, which also \naccelerates our upstream data and research opportunities with biopharma manufact urers.    \n \n Third, e nhancing the capabilities of our Specialty business, including supporting the ongoing build of \nthe Navista \u2122 Network.  Specialty Networks has a deep understanding of independent physician \npractices, and we see capabilities and expertise that will accelerate our ongoing development of the \nNavista \u2122 Network, which is focused on supporting the clinical and operational needs of independent \ncommunity oncologists.  \n \n In summary, this transaction enhances our specialty strategy by providing new capabilities that \nstrengthen the link between our downstream and upstream services, enabling us to create further \nvalue for customers, manufacturer partners and patients.  \n \n", "original_text": "Specialty Networks experience and capabilities in clinical engagement are robust, which also \naccelerates our upstream data and research opportunities with biopharma manufact urers.    \n \n", "page_label": "8", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "cb248949-64fc-498f-a357-322668a33cd9", "node_type": "4", "metadata": {"page_label": "8", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "e7b8c2a5dcb80575f7d8228fbd3e727bd9f5cdac723c24e2c276fa2bff980b35", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "fac20d16-66f2-4c74-ab36-21cb576bc156", "node_type": "1", "metadata": {"window": " \nPage 8 of 19 \n \nSecond, c reating a platform for our expansion across specialty therapeutic areas.  The company\u2019s \nPPS Analytics solution is a subscription -based advanced technology platform that utilizes artificial \nintelligence, such as continuous learning algorithms and natural lan guage processing, to analyze data \nfrom electronic medical records, practice management, imaging and dispensing systems and \ntransform it into actionable insights for providers and other stakeholders.  We see this complementing \nour suite of clinical,  practice management and distribution solutions to specialty practices nationwide. \n Specialty Networks experience and capabilities in clinical engagement are robust, which also \naccelerates our upstream data and research opportunities with biopharma manufact urers.    \n \n Third, e nhancing the capabilities of our Specialty business, including supporting the ongoing build of \nthe Navista \u2122 Network.  Specialty Networks has a deep understanding of independent physician \npractices, and we see capabilities and expertise that will accelerate our ongoing development of the \nNavista \u2122 Network, which is focused on supporting the clinical and operational needs of independent \ncommunity oncologists.  \n \n", "original_text": "We see this complementing \nour suite of clinical,  practice management and distribution solutions to specialty practices nationwide. \n", "page_label": "8", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "ad2e6a3333ea3b199a57e5a24565343552869eccb490023f8891369d972d853a", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "70f9f2dc-967c-4d32-96e8-a68529ef5810", "node_type": "1", "metadata": {"window": "The company\u2019s \nPPS Analytics solution is a subscription -based advanced technology platform that utilizes artificial \nintelligence, such as continuous learning algorithms and natural lan guage processing, to analyze data \nfrom electronic medical records, practice management, imaging and dispensing systems and \ntransform it into actionable insights for providers and other stakeholders.  We see this complementing \nour suite of clinical,  practice management and distribution solutions to specialty practices nationwide. \n Specialty Networks experience and capabilities in clinical engagement are robust, which also \naccelerates our upstream data and research opportunities with biopharma manufact urers.    \n \n Third, e nhancing the capabilities of our Specialty business, including supporting the ongoing build of \nthe Navista \u2122 Network.  Specialty Networks has a deep understanding of independent physician \npractices, and we see capabilities and expertise that will accelerate our ongoing development of the \nNavista \u2122 Network, which is focused on supporting the clinical and operational needs of independent \ncommunity oncologists.  \n \n In summary, this transaction enhances our specialty strategy by providing new capabilities that \nstrengthen the link between our downstream and upstream services, enabling us to create further \nvalue for customers, manufacturer partners and patients.  \n \n Turning to priority number two , and the GMPD business, where we\u2019re executing the Medical \nImprovement Plan . \n \n", "original_text": "Third, e nhancing the capabilities of our Specialty business, including supporting the ongoing build of \nthe Navista \u2122 Network. "}, "hash": "389c954acf15f311ce5682ae0816dc4484a1443231852b83bb2f522a3e49cf10", "class_name": "RelatedNodeInfo"}}, "text": "Specialty Networks experience and capabilities in clinical engagement are robust, which also \naccelerates our upstream data and research opportunities with biopharma manufact urers.    \n \n", "start_char_idx": 623, "end_char_idx": 811, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "70f9f2dc-967c-4d32-96e8-a68529ef5810": {"__data__": {"id_": "70f9f2dc-967c-4d32-96e8-a68529ef5810", "embedding": null, "metadata": {"window": "The company\u2019s \nPPS Analytics solution is a subscription -based advanced technology platform that utilizes artificial \nintelligence, such as continuous learning algorithms and natural lan guage processing, to analyze data \nfrom electronic medical records, practice management, imaging and dispensing systems and \ntransform it into actionable insights for providers and other stakeholders.  We see this complementing \nour suite of clinical,  practice management and distribution solutions to specialty practices nationwide. \n Specialty Networks experience and capabilities in clinical engagement are robust, which also \naccelerates our upstream data and research opportunities with biopharma manufact urers.    \n \n Third, e nhancing the capabilities of our Specialty business, including supporting the ongoing build of \nthe Navista \u2122 Network.  Specialty Networks has a deep understanding of independent physician \npractices, and we see capabilities and expertise that will accelerate our ongoing development of the \nNavista \u2122 Network, which is focused on supporting the clinical and operational needs of independent \ncommunity oncologists.  \n \n In summary, this transaction enhances our specialty strategy by providing new capabilities that \nstrengthen the link between our downstream and upstream services, enabling us to create further \nvalue for customers, manufacturer partners and patients.  \n \n Turning to priority number two , and the GMPD business, where we\u2019re executing the Medical \nImprovement Plan . \n \n", "original_text": "Third, e nhancing the capabilities of our Specialty business, including supporting the ongoing build of \nthe Navista \u2122 Network. ", "page_label": "8", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "cb248949-64fc-498f-a357-322668a33cd9", "node_type": "4", "metadata": {"page_label": "8", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "e7b8c2a5dcb80575f7d8228fbd3e727bd9f5cdac723c24e2c276fa2bff980b35", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "fef2fae6-e748-4e2e-89d6-932a0c437e4a", "node_type": "1", "metadata": {"window": " \nPage 8 of 19 \n \nSecond, c reating a platform for our expansion across specialty therapeutic areas.  The company\u2019s \nPPS Analytics solution is a subscription -based advanced technology platform that utilizes artificial \nintelligence, such as continuous learning algorithms and natural lan guage processing, to analyze data \nfrom electronic medical records, practice management, imaging and dispensing systems and \ntransform it into actionable insights for providers and other stakeholders.  We see this complementing \nour suite of clinical,  practice management and distribution solutions to specialty practices nationwide. \n Specialty Networks experience and capabilities in clinical engagement are robust, which also \naccelerates our upstream data and research opportunities with biopharma manufact urers.    \n \n Third, e nhancing the capabilities of our Specialty business, including supporting the ongoing build of \nthe Navista \u2122 Network.  Specialty Networks has a deep understanding of independent physician \npractices, and we see capabilities and expertise that will accelerate our ongoing development of the \nNavista \u2122 Network, which is focused on supporting the clinical and operational needs of independent \ncommunity oncologists.  \n \n In summary, this transaction enhances our specialty strategy by providing new capabilities that \nstrengthen the link between our downstream and upstream services, enabling us to create further \nvalue for customers, manufacturer partners and patients.  \n \n", "original_text": "Specialty Networks experience and capabilities in clinical engagement are robust, which also \naccelerates our upstream data and research opportunities with biopharma manufact urers.    \n \n", "page_label": "8", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "8f8288b4b661de3c4073e9ea3a689a5deaf5da943158d9e6b08936f90e237cc1", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "cf63d8bb-5614-4279-9b1a-a22515f68f70", "node_type": "1", "metadata": {"window": "We see this complementing \nour suite of clinical,  practice management and distribution solutions to specialty practices nationwide. \n Specialty Networks experience and capabilities in clinical engagement are robust, which also \naccelerates our upstream data and research opportunities with biopharma manufact urers.    \n \n Third, e nhancing the capabilities of our Specialty business, including supporting the ongoing build of \nthe Navista \u2122 Network.  Specialty Networks has a deep understanding of independent physician \npractices, and we see capabilities and expertise that will accelerate our ongoing development of the \nNavista \u2122 Network, which is focused on supporting the clinical and operational needs of independent \ncommunity oncologists.  \n \n In summary, this transaction enhances our specialty strategy by providing new capabilities that \nstrengthen the link between our downstream and upstream services, enabling us to create further \nvalue for customers, manufacturer partners and patients.  \n \n Turning to priority number two , and the GMPD business, where we\u2019re executing the Medical \nImprovement Plan . \n \n While the business and portfolio review of GMPD continues, the team continues to prioritize and \nmake significant progress on turning around the operational performance of this business, as Aaron \nindicated with our expectation that the business returns to p rofitability in fiscal \u201824.  \n \n", "original_text": "Specialty Networks has a deep understanding of independent physician \npractices, and we see capabilities and expertise that will accelerate our ongoing development of the \nNavista \u2122 Network, which is focused on supporting the clinical and operational needs of independent \ncommunity oncologists.  \n \n"}, "hash": "66efa2c44aa9bed31c599a010f65181753a1cc074fa8270fdc8a2c46c0e73f7c", "class_name": "RelatedNodeInfo"}}, "text": "Third, e nhancing the capabilities of our Specialty business, including supporting the ongoing build of \nthe Navista \u2122 Network. ", "start_char_idx": 811, "end_char_idx": 939, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "cf63d8bb-5614-4279-9b1a-a22515f68f70": {"__data__": {"id_": "cf63d8bb-5614-4279-9b1a-a22515f68f70", "embedding": null, "metadata": {"window": "We see this complementing \nour suite of clinical,  practice management and distribution solutions to specialty practices nationwide. \n Specialty Networks experience and capabilities in clinical engagement are robust, which also \naccelerates our upstream data and research opportunities with biopharma manufact urers.    \n \n Third, e nhancing the capabilities of our Specialty business, including supporting the ongoing build of \nthe Navista \u2122 Network.  Specialty Networks has a deep understanding of independent physician \npractices, and we see capabilities and expertise that will accelerate our ongoing development of the \nNavista \u2122 Network, which is focused on supporting the clinical and operational needs of independent \ncommunity oncologists.  \n \n In summary, this transaction enhances our specialty strategy by providing new capabilities that \nstrengthen the link between our downstream and upstream services, enabling us to create further \nvalue for customers, manufacturer partners and patients.  \n \n Turning to priority number two , and the GMPD business, where we\u2019re executing the Medical \nImprovement Plan . \n \n While the business and portfolio review of GMPD continues, the team continues to prioritize and \nmake significant progress on turning around the operational performance of this business, as Aaron \nindicated with our expectation that the business returns to p rofitability in fiscal \u201824.  \n \n", "original_text": "Specialty Networks has a deep understanding of independent physician \npractices, and we see capabilities and expertise that will accelerate our ongoing development of the \nNavista \u2122 Network, which is focused on supporting the clinical and operational needs of independent \ncommunity oncologists.  \n \n", "page_label": "8", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "cb248949-64fc-498f-a357-322668a33cd9", "node_type": "4", "metadata": {"page_label": "8", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "e7b8c2a5dcb80575f7d8228fbd3e727bd9f5cdac723c24e2c276fa2bff980b35", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "70f9f2dc-967c-4d32-96e8-a68529ef5810", "node_type": "1", "metadata": {"window": "The company\u2019s \nPPS Analytics solution is a subscription -based advanced technology platform that utilizes artificial \nintelligence, such as continuous learning algorithms and natural lan guage processing, to analyze data \nfrom electronic medical records, practice management, imaging and dispensing systems and \ntransform it into actionable insights for providers and other stakeholders.  We see this complementing \nour suite of clinical,  practice management and distribution solutions to specialty practices nationwide. \n Specialty Networks experience and capabilities in clinical engagement are robust, which also \naccelerates our upstream data and research opportunities with biopharma manufact urers.    \n \n Third, e nhancing the capabilities of our Specialty business, including supporting the ongoing build of \nthe Navista \u2122 Network.  Specialty Networks has a deep understanding of independent physician \npractices, and we see capabilities and expertise that will accelerate our ongoing development of the \nNavista \u2122 Network, which is focused on supporting the clinical and operational needs of independent \ncommunity oncologists.  \n \n In summary, this transaction enhances our specialty strategy by providing new capabilities that \nstrengthen the link between our downstream and upstream services, enabling us to create further \nvalue for customers, manufacturer partners and patients.  \n \n Turning to priority number two , and the GMPD business, where we\u2019re executing the Medical \nImprovement Plan . \n \n", "original_text": "Third, e nhancing the capabilities of our Specialty business, including supporting the ongoing build of \nthe Navista \u2122 Network. ", "page_label": "8", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "08015cc2af2287b23e460002d567744cb8183638af969c68f66a5ada19e40114", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "1e571f78-4a3b-4f2d-b96f-e70ce603ce9a", "node_type": "1", "metadata": {"window": "Specialty Networks experience and capabilities in clinical engagement are robust, which also \naccelerates our upstream data and research opportunities with biopharma manufact urers.    \n \n Third, e nhancing the capabilities of our Specialty business, including supporting the ongoing build of \nthe Navista \u2122 Network.  Specialty Networks has a deep understanding of independent physician \npractices, and we see capabilities and expertise that will accelerate our ongoing development of the \nNavista \u2122 Network, which is focused on supporting the clinical and operational needs of independent \ncommunity oncologists.  \n \n In summary, this transaction enhances our specialty strategy by providing new capabilities that \nstrengthen the link between our downstream and upstream services, enabling us to create further \nvalue for customers, manufacturer partners and patients.  \n \n Turning to priority number two , and the GMPD business, where we\u2019re executing the Medical \nImprovement Plan . \n \n While the business and portfolio review of GMPD continues, the team continues to prioritize and \nmake significant progress on turning around the operational performance of this business, as Aaron \nindicated with our expectation that the business returns to p rofitability in fiscal \u201824.  \n \n The number one priority remains mitigating supply chain inflation, where we remain on track to \naddress the impact by the time we exit fiscal \u201824. ", "original_text": "In summary, this transaction enhances our specialty strategy by providing new capabilities that \nstrengthen the link between our downstream and upstream services, enabling us to create further \nvalue for customers, manufacturer partners and patients.  \n \n"}, "hash": "56b03631af5f820ee971db7f891f98d2afcade8dbaf204039b142353c3d1ec5e", "class_name": "RelatedNodeInfo"}}, "text": "Specialty Networks has a deep understanding of independent physician \npractices, and we see capabilities and expertise that will accelerate our ongoing development of the \nNavista \u2122 Network, which is focused on supporting the clinical and operational needs of independent \ncommunity oncologists.  \n \n", "start_char_idx": 939, "end_char_idx": 1239, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "1e571f78-4a3b-4f2d-b96f-e70ce603ce9a": {"__data__": {"id_": "1e571f78-4a3b-4f2d-b96f-e70ce603ce9a", "embedding": null, "metadata": {"window": "Specialty Networks experience and capabilities in clinical engagement are robust, which also \naccelerates our upstream data and research opportunities with biopharma manufact urers.    \n \n Third, e nhancing the capabilities of our Specialty business, including supporting the ongoing build of \nthe Navista \u2122 Network.  Specialty Networks has a deep understanding of independent physician \npractices, and we see capabilities and expertise that will accelerate our ongoing development of the \nNavista \u2122 Network, which is focused on supporting the clinical and operational needs of independent \ncommunity oncologists.  \n \n In summary, this transaction enhances our specialty strategy by providing new capabilities that \nstrengthen the link between our downstream and upstream services, enabling us to create further \nvalue for customers, manufacturer partners and patients.  \n \n Turning to priority number two , and the GMPD business, where we\u2019re executing the Medical \nImprovement Plan . \n \n While the business and portfolio review of GMPD continues, the team continues to prioritize and \nmake significant progress on turning around the operational performance of this business, as Aaron \nindicated with our expectation that the business returns to p rofitability in fiscal \u201824.  \n \n The number one priority remains mitigating supply chain inflation, where we remain on track to \naddress the impact by the time we exit fiscal \u201824. ", "original_text": "In summary, this transaction enhances our specialty strategy by providing new capabilities that \nstrengthen the link between our downstream and upstream services, enabling us to create further \nvalue for customers, manufacturer partners and patients.  \n \n", "page_label": "8", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "cb248949-64fc-498f-a357-322668a33cd9", "node_type": "4", "metadata": {"page_label": "8", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "e7b8c2a5dcb80575f7d8228fbd3e727bd9f5cdac723c24e2c276fa2bff980b35", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "cf63d8bb-5614-4279-9b1a-a22515f68f70", "node_type": "1", "metadata": {"window": "We see this complementing \nour suite of clinical,  practice management and distribution solutions to specialty practices nationwide. \n Specialty Networks experience and capabilities in clinical engagement are robust, which also \naccelerates our upstream data and research opportunities with biopharma manufact urers.    \n \n Third, e nhancing the capabilities of our Specialty business, including supporting the ongoing build of \nthe Navista \u2122 Network.  Specialty Networks has a deep understanding of independent physician \npractices, and we see capabilities and expertise that will accelerate our ongoing development of the \nNavista \u2122 Network, which is focused on supporting the clinical and operational needs of independent \ncommunity oncologists.  \n \n In summary, this transaction enhances our specialty strategy by providing new capabilities that \nstrengthen the link between our downstream and upstream services, enabling us to create further \nvalue for customers, manufacturer partners and patients.  \n \n Turning to priority number two , and the GMPD business, where we\u2019re executing the Medical \nImprovement Plan . \n \n While the business and portfolio review of GMPD continues, the team continues to prioritize and \nmake significant progress on turning around the operational performance of this business, as Aaron \nindicated with our expectation that the business returns to p rofitability in fiscal \u201824.  \n \n", "original_text": "Specialty Networks has a deep understanding of independent physician \npractices, and we see capabilities and expertise that will accelerate our ongoing development of the \nNavista \u2122 Network, which is focused on supporting the clinical and operational needs of independent \ncommunity oncologists.  \n \n", "page_label": "8", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "026ea339ea765ad9634451d7ddabc655221a6d6b99b8e789c67981add696daec", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "be104b7c-4278-4375-9ab8-849b1958bb4e", "node_type": "1", "metadata": {"window": "Third, e nhancing the capabilities of our Specialty business, including supporting the ongoing build of \nthe Navista \u2122 Network.  Specialty Networks has a deep understanding of independent physician \npractices, and we see capabilities and expertise that will accelerate our ongoing development of the \nNavista \u2122 Network, which is focused on supporting the clinical and operational needs of independent \ncommunity oncologists.  \n \n In summary, this transaction enhances our specialty strategy by providing new capabilities that \nstrengthen the link between our downstream and upstream services, enabling us to create further \nvalue for customers, manufacturer partners and patients.  \n \n Turning to priority number two , and the GMPD business, where we\u2019re executing the Medical \nImprovement Plan . \n \n While the business and portfolio review of GMPD continues, the team continues to prioritize and \nmake significant progress on turning around the operational performance of this business, as Aaron \nindicated with our expectation that the business returns to p rofitability in fiscal \u201824.  \n \n The number one priority remains mitigating supply chain inflation, where we remain on track to \naddress the impact by the time we exit fiscal \u201824.  As of Q2, we\u2019re approximately 75% to target.   \n \n", "original_text": "Turning to priority number two , and the GMPD business, where we\u2019re executing the Medical \nImprovement Plan . \n \n"}, "hash": "c56823fdf87d305fff924de698e5d3658420751de06b796088f231d310a4eb68", "class_name": "RelatedNodeInfo"}}, "text": "In summary, this transaction enhances our specialty strategy by providing new capabilities that \nstrengthen the link between our downstream and upstream services, enabling us to create further \nvalue for customers, manufacturer partners and patients.  \n \n", "start_char_idx": 1239, "end_char_idx": 1494, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "be104b7c-4278-4375-9ab8-849b1958bb4e": {"__data__": {"id_": "be104b7c-4278-4375-9ab8-849b1958bb4e", "embedding": null, "metadata": {"window": "Third, e nhancing the capabilities of our Specialty business, including supporting the ongoing build of \nthe Navista \u2122 Network.  Specialty Networks has a deep understanding of independent physician \npractices, and we see capabilities and expertise that will accelerate our ongoing development of the \nNavista \u2122 Network, which is focused on supporting the clinical and operational needs of independent \ncommunity oncologists.  \n \n In summary, this transaction enhances our specialty strategy by providing new capabilities that \nstrengthen the link between our downstream and upstream services, enabling us to create further \nvalue for customers, manufacturer partners and patients.  \n \n Turning to priority number two , and the GMPD business, where we\u2019re executing the Medical \nImprovement Plan . \n \n While the business and portfolio review of GMPD continues, the team continues to prioritize and \nmake significant progress on turning around the operational performance of this business, as Aaron \nindicated with our expectation that the business returns to p rofitability in fiscal \u201824.  \n \n The number one priority remains mitigating supply chain inflation, where we remain on track to \naddress the impact by the time we exit fiscal \u201824.  As of Q2, we\u2019re approximately 75% to target.   \n \n", "original_text": "Turning to priority number two , and the GMPD business, where we\u2019re executing the Medical \nImprovement Plan . \n \n", "page_label": "8", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "cb248949-64fc-498f-a357-322668a33cd9", "node_type": "4", "metadata": {"page_label": "8", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "e7b8c2a5dcb80575f7d8228fbd3e727bd9f5cdac723c24e2c276fa2bff980b35", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "1e571f78-4a3b-4f2d-b96f-e70ce603ce9a", "node_type": "1", "metadata": {"window": "Specialty Networks experience and capabilities in clinical engagement are robust, which also \naccelerates our upstream data and research opportunities with biopharma manufact urers.    \n \n Third, e nhancing the capabilities of our Specialty business, including supporting the ongoing build of \nthe Navista \u2122 Network.  Specialty Networks has a deep understanding of independent physician \npractices, and we see capabilities and expertise that will accelerate our ongoing development of the \nNavista \u2122 Network, which is focused on supporting the clinical and operational needs of independent \ncommunity oncologists.  \n \n In summary, this transaction enhances our specialty strategy by providing new capabilities that \nstrengthen the link between our downstream and upstream services, enabling us to create further \nvalue for customers, manufacturer partners and patients.  \n \n Turning to priority number two , and the GMPD business, where we\u2019re executing the Medical \nImprovement Plan . \n \n While the business and portfolio review of GMPD continues, the team continues to prioritize and \nmake significant progress on turning around the operational performance of this business, as Aaron \nindicated with our expectation that the business returns to p rofitability in fiscal \u201824.  \n \n The number one priority remains mitigating supply chain inflation, where we remain on track to \naddress the impact by the time we exit fiscal \u201824. ", "original_text": "In summary, this transaction enhances our specialty strategy by providing new capabilities that \nstrengthen the link between our downstream and upstream services, enabling us to create further \nvalue for customers, manufacturer partners and patients.  \n \n", "page_label": "8", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "97c77f3bc1e5c4df80e4b63c70ca8eef60c8c31a6a37425b633b7b7b183324f6", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "3c290084-9a7a-43a9-93bb-3f3b237848fa", "node_type": "1", "metadata": {"window": "Specialty Networks has a deep understanding of independent physician \npractices, and we see capabilities and expertise that will accelerate our ongoing development of the \nNavista \u2122 Network, which is focused on supporting the clinical and operational needs of independent \ncommunity oncologists.  \n \n In summary, this transaction enhances our specialty strategy by providing new capabilities that \nstrengthen the link between our downstream and upstream services, enabling us to create further \nvalue for customers, manufacturer partners and patients.  \n \n Turning to priority number two , and the GMPD business, where we\u2019re executing the Medical \nImprovement Plan . \n \n While the business and portfolio review of GMPD continues, the team continues to prioritize and \nmake significant progress on turning around the operational performance of this business, as Aaron \nindicated with our expectation that the business returns to p rofitability in fiscal \u201824.  \n \n The number one priority remains mitigating supply chain inflation, where we remain on track to \naddress the impact by the time we exit fiscal \u201824.  As of Q2, we\u2019re approximately 75% to target.   \n \n On the cost side, while overall still elevated, we\u2019ve seen lower international freight costs reflected in \nour results, as anticipated, and we have strong line of sight to continued improvement in the second \nhalf of the fiscal year. ", "original_text": "While the business and portfolio review of GMPD continues, the team continues to prioritize and \nmake significant progress on turning around the operational performance of this business, as Aaron \nindicated with our expectation that the business returns to p rofitability in fiscal \u201824.  \n \n"}, "hash": "f182c856888aaa53b0a982ca9d00c4e2131e8ba3ec906bbe971824c5003990be", "class_name": "RelatedNodeInfo"}}, "text": "Turning to priority number two , and the GMPD business, where we\u2019re executing the Medical \nImprovement Plan . \n \n", "start_char_idx": 1494, "end_char_idx": 1607, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "3c290084-9a7a-43a9-93bb-3f3b237848fa": {"__data__": {"id_": "3c290084-9a7a-43a9-93bb-3f3b237848fa", "embedding": null, "metadata": {"window": "Specialty Networks has a deep understanding of independent physician \npractices, and we see capabilities and expertise that will accelerate our ongoing development of the \nNavista \u2122 Network, which is focused on supporting the clinical and operational needs of independent \ncommunity oncologists.  \n \n In summary, this transaction enhances our specialty strategy by providing new capabilities that \nstrengthen the link between our downstream and upstream services, enabling us to create further \nvalue for customers, manufacturer partners and patients.  \n \n Turning to priority number two , and the GMPD business, where we\u2019re executing the Medical \nImprovement Plan . \n \n While the business and portfolio review of GMPD continues, the team continues to prioritize and \nmake significant progress on turning around the operational performance of this business, as Aaron \nindicated with our expectation that the business returns to p rofitability in fiscal \u201824.  \n \n The number one priority remains mitigating supply chain inflation, where we remain on track to \naddress the impact by the time we exit fiscal \u201824.  As of Q2, we\u2019re approximately 75% to target.   \n \n On the cost side, while overall still elevated, we\u2019ve seen lower international freight costs reflected in \nour results, as anticipated, and we have strong line of sight to continued improvement in the second \nhalf of the fiscal year. ", "original_text": "While the business and portfolio review of GMPD continues, the team continues to prioritize and \nmake significant progress on turning around the operational performance of this business, as Aaron \nindicated with our expectation that the business returns to p rofitability in fiscal \u201824.  \n \n", "page_label": "8", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "cb248949-64fc-498f-a357-322668a33cd9", "node_type": "4", "metadata": {"page_label": "8", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "e7b8c2a5dcb80575f7d8228fbd3e727bd9f5cdac723c24e2c276fa2bff980b35", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "be104b7c-4278-4375-9ab8-849b1958bb4e", "node_type": "1", "metadata": {"window": "Third, e nhancing the capabilities of our Specialty business, including supporting the ongoing build of \nthe Navista \u2122 Network.  Specialty Networks has a deep understanding of independent physician \npractices, and we see capabilities and expertise that will accelerate our ongoing development of the \nNavista \u2122 Network, which is focused on supporting the clinical and operational needs of independent \ncommunity oncologists.  \n \n In summary, this transaction enhances our specialty strategy by providing new capabilities that \nstrengthen the link between our downstream and upstream services, enabling us to create further \nvalue for customers, manufacturer partners and patients.  \n \n Turning to priority number two , and the GMPD business, where we\u2019re executing the Medical \nImprovement Plan . \n \n While the business and portfolio review of GMPD continues, the team continues to prioritize and \nmake significant progress on turning around the operational performance of this business, as Aaron \nindicated with our expectation that the business returns to p rofitability in fiscal \u201824.  \n \n The number one priority remains mitigating supply chain inflation, where we remain on track to \naddress the impact by the time we exit fiscal \u201824.  As of Q2, we\u2019re approximately 75% to target.   \n \n", "original_text": "Turning to priority number two , and the GMPD business, where we\u2019re executing the Medical \nImprovement Plan . \n \n", "page_label": "8", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "05d05dcd5a924c6bf07090d43eb5dbedd6f035c888195e52eb47af837816dcc4", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "8f8cc612-ecf4-4442-b705-62e0522aa90b", "node_type": "1", "metadata": {"window": "In summary, this transaction enhances our specialty strategy by providing new capabilities that \nstrengthen the link between our downstream and upstream services, enabling us to create further \nvalue for customers, manufacturer partners and patients.  \n \n Turning to priority number two , and the GMPD business, where we\u2019re executing the Medical \nImprovement Plan . \n \n While the business and portfolio review of GMPD continues, the team continues to prioritize and \nmake significant progress on turning around the operational performance of this business, as Aaron \nindicated with our expectation that the business returns to p rofitability in fiscal \u201824.  \n \n The number one priority remains mitigating supply chain inflation, where we remain on track to \naddress the impact by the time we exit fiscal \u201824.  As of Q2, we\u2019re approximately 75% to target.   \n \n On the cost side, while overall still elevated, we\u2019ve seen lower international freight costs reflected in \nour results, as anticipated, and we have strong line of sight to continued improvement in the second \nhalf of the fiscal year.  We\u2019ve continued to make progress with our mitigation initiatives and \ncommercial contracting efforts and  are continually taking additional actions to offset elevated inflation, \nsuch as through sourcing initiatives.  \n \n", "original_text": "The number one priority remains mitigating supply chain inflation, where we remain on track to \naddress the impact by the time we exit fiscal \u201824. "}, "hash": "8d4466a555509d7977f645ef5bbdb49fd039fdd1b0e2945d676a289d2292d6db", "class_name": "RelatedNodeInfo"}}, "text": "While the business and portfolio review of GMPD continues, the team continues to prioritize and \nmake significant progress on turning around the operational performance of this business, as Aaron \nindicated with our expectation that the business returns to p rofitability in fiscal \u201824.  \n \n", "start_char_idx": 1607, "end_char_idx": 1898, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "8f8cc612-ecf4-4442-b705-62e0522aa90b": {"__data__": {"id_": "8f8cc612-ecf4-4442-b705-62e0522aa90b", "embedding": null, "metadata": {"window": "In summary, this transaction enhances our specialty strategy by providing new capabilities that \nstrengthen the link between our downstream and upstream services, enabling us to create further \nvalue for customers, manufacturer partners and patients.  \n \n Turning to priority number two , and the GMPD business, where we\u2019re executing the Medical \nImprovement Plan . \n \n While the business and portfolio review of GMPD continues, the team continues to prioritize and \nmake significant progress on turning around the operational performance of this business, as Aaron \nindicated with our expectation that the business returns to p rofitability in fiscal \u201824.  \n \n The number one priority remains mitigating supply chain inflation, where we remain on track to \naddress the impact by the time we exit fiscal \u201824.  As of Q2, we\u2019re approximately 75% to target.   \n \n On the cost side, while overall still elevated, we\u2019ve seen lower international freight costs reflected in \nour results, as anticipated, and we have strong line of sight to continued improvement in the second \nhalf of the fiscal year.  We\u2019ve continued to make progress with our mitigation initiatives and \ncommercial contracting efforts and  are continually taking additional actions to offset elevated inflation, \nsuch as through sourcing initiatives.  \n \n", "original_text": "The number one priority remains mitigating supply chain inflation, where we remain on track to \naddress the impact by the time we exit fiscal \u201824. ", "page_label": "8", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "cb248949-64fc-498f-a357-322668a33cd9", "node_type": "4", "metadata": {"page_label": "8", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "e7b8c2a5dcb80575f7d8228fbd3e727bd9f5cdac723c24e2c276fa2bff980b35", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "3c290084-9a7a-43a9-93bb-3f3b237848fa", "node_type": "1", "metadata": {"window": "Specialty Networks has a deep understanding of independent physician \npractices, and we see capabilities and expertise that will accelerate our ongoing development of the \nNavista \u2122 Network, which is focused on supporting the clinical and operational needs of independent \ncommunity oncologists.  \n \n In summary, this transaction enhances our specialty strategy by providing new capabilities that \nstrengthen the link between our downstream and upstream services, enabling us to create further \nvalue for customers, manufacturer partners and patients.  \n \n Turning to priority number two , and the GMPD business, where we\u2019re executing the Medical \nImprovement Plan . \n \n While the business and portfolio review of GMPD continues, the team continues to prioritize and \nmake significant progress on turning around the operational performance of this business, as Aaron \nindicated with our expectation that the business returns to p rofitability in fiscal \u201824.  \n \n The number one priority remains mitigating supply chain inflation, where we remain on track to \naddress the impact by the time we exit fiscal \u201824.  As of Q2, we\u2019re approximately 75% to target.   \n \n On the cost side, while overall still elevated, we\u2019ve seen lower international freight costs reflected in \nour results, as anticipated, and we have strong line of sight to continued improvement in the second \nhalf of the fiscal year. ", "original_text": "While the business and portfolio review of GMPD continues, the team continues to prioritize and \nmake significant progress on turning around the operational performance of this business, as Aaron \nindicated with our expectation that the business returns to p rofitability in fiscal \u201824.  \n \n", "page_label": "8", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "f314bc8dbd347d15f7d8066c34d216144b6369839bdd7f0770fda11ac8cd5cc2", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "5d079ed4-7dc3-4f4b-9ea1-fc1a99f369af", "node_type": "1", "metadata": {"window": "Turning to priority number two , and the GMPD business, where we\u2019re executing the Medical \nImprovement Plan . \n \n While the business and portfolio review of GMPD continues, the team continues to prioritize and \nmake significant progress on turning around the operational performance of this business, as Aaron \nindicated with our expectation that the business returns to p rofitability in fiscal \u201824.  \n \n The number one priority remains mitigating supply chain inflation, where we remain on track to \naddress the impact by the time we exit fiscal \u201824.  As of Q2, we\u2019re approximately 75% to target.   \n \n On the cost side, while overall still elevated, we\u2019ve seen lower international freight costs reflected in \nour results, as anticipated, and we have strong line of sight to continued improvement in the second \nhalf of the fiscal year.  We\u2019ve continued to make progress with our mitigation initiatives and \ncommercial contracting efforts and  are continually taking additional actions to offset elevated inflation, \nsuch as through sourcing initiatives.  \n \n As Aaron indicated, the work we\u2019ve accomplished to -date provides increased confidence in achieving \nour fiscal year -end target, as overall cost improvements continue to reflect in our second half results.  \n \n", "original_text": "As of Q2, we\u2019re approximately 75% to target.   \n \n"}, "hash": "3fcadd472cfb720f02d16ba10e5410ef8c08102fc71997b76541375b2ba64b8c", "class_name": "RelatedNodeInfo"}}, "text": "The number one priority remains mitigating supply chain inflation, where we remain on track to \naddress the impact by the time we exit fiscal \u201824. ", "start_char_idx": 1898, "end_char_idx": 2045, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "5d079ed4-7dc3-4f4b-9ea1-fc1a99f369af": {"__data__": {"id_": "5d079ed4-7dc3-4f4b-9ea1-fc1a99f369af", "embedding": null, "metadata": {"window": "Turning to priority number two , and the GMPD business, where we\u2019re executing the Medical \nImprovement Plan . \n \n While the business and portfolio review of GMPD continues, the team continues to prioritize and \nmake significant progress on turning around the operational performance of this business, as Aaron \nindicated with our expectation that the business returns to p rofitability in fiscal \u201824.  \n \n The number one priority remains mitigating supply chain inflation, where we remain on track to \naddress the impact by the time we exit fiscal \u201824.  As of Q2, we\u2019re approximately 75% to target.   \n \n On the cost side, while overall still elevated, we\u2019ve seen lower international freight costs reflected in \nour results, as anticipated, and we have strong line of sight to continued improvement in the second \nhalf of the fiscal year.  We\u2019ve continued to make progress with our mitigation initiatives and \ncommercial contracting efforts and  are continually taking additional actions to offset elevated inflation, \nsuch as through sourcing initiatives.  \n \n As Aaron indicated, the work we\u2019ve accomplished to -date provides increased confidence in achieving \nour fiscal year -end target, as overall cost improvements continue to reflect in our second half results.  \n \n", "original_text": "As of Q2, we\u2019re approximately 75% to target.   \n \n", "page_label": "8", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "cb248949-64fc-498f-a357-322668a33cd9", "node_type": "4", "metadata": {"page_label": "8", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "e7b8c2a5dcb80575f7d8228fbd3e727bd9f5cdac723c24e2c276fa2bff980b35", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "8f8cc612-ecf4-4442-b705-62e0522aa90b", "node_type": "1", "metadata": {"window": "In summary, this transaction enhances our specialty strategy by providing new capabilities that \nstrengthen the link between our downstream and upstream services, enabling us to create further \nvalue for customers, manufacturer partners and patients.  \n \n Turning to priority number two , and the GMPD business, where we\u2019re executing the Medical \nImprovement Plan . \n \n While the business and portfolio review of GMPD continues, the team continues to prioritize and \nmake significant progress on turning around the operational performance of this business, as Aaron \nindicated with our expectation that the business returns to p rofitability in fiscal \u201824.  \n \n The number one priority remains mitigating supply chain inflation, where we remain on track to \naddress the impact by the time we exit fiscal \u201824.  As of Q2, we\u2019re approximately 75% to target.   \n \n On the cost side, while overall still elevated, we\u2019ve seen lower international freight costs reflected in \nour results, as anticipated, and we have strong line of sight to continued improvement in the second \nhalf of the fiscal year.  We\u2019ve continued to make progress with our mitigation initiatives and \ncommercial contracting efforts and  are continually taking additional actions to offset elevated inflation, \nsuch as through sourcing initiatives.  \n \n", "original_text": "The number one priority remains mitigating supply chain inflation, where we remain on track to \naddress the impact by the time we exit fiscal \u201824. ", "page_label": "8", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "4035847f797162a82cf8c207d815be469569e9fccb3bcca3cb7c22c823b3ab40", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "b58873c8-367d-452f-a56c-fce70ecbbce2", "node_type": "1", "metadata": {"window": "While the business and portfolio review of GMPD continues, the team continues to prioritize and \nmake significant progress on turning around the operational performance of this business, as Aaron \nindicated with our expectation that the business returns to p rofitability in fiscal \u201824.  \n \n The number one priority remains mitigating supply chain inflation, where we remain on track to \naddress the impact by the time we exit fiscal \u201824.  As of Q2, we\u2019re approximately 75% to target.   \n \n On the cost side, while overall still elevated, we\u2019ve seen lower international freight costs reflected in \nour results, as anticipated, and we have strong line of sight to continued improvement in the second \nhalf of the fiscal year.  We\u2019ve continued to make progress with our mitigation initiatives and \ncommercial contracting efforts and  are continually taking additional actions to offset elevated inflation, \nsuch as through sourcing initiatives.  \n \n As Aaron indicated, the work we\u2019ve accomplished to -date provides increased confidence in achieving \nour fiscal year -end target, as overall cost improvements continue to reflect in our second half results.  \n \n We\u2019re continuing to invest in the resiliency of our supply chain and our manufacturing and distribution \ncapacity. ", "original_text": "On the cost side, while overall still elevated, we\u2019ve seen lower international freight costs reflected in \nour results, as anticipated, and we have strong line of sight to continued improvement in the second \nhalf of the fiscal year. "}, "hash": "fccb032f5873d1e1e92a3a660785f73b87c57f60f822f40620a6c6ff4356528a", "class_name": "RelatedNodeInfo"}}, "text": "As of Q2, we\u2019re approximately 75% to target.   \n \n", "start_char_idx": 2045, "end_char_idx": 2095, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "b58873c8-367d-452f-a56c-fce70ecbbce2": {"__data__": {"id_": "b58873c8-367d-452f-a56c-fce70ecbbce2", "embedding": null, "metadata": {"window": "While the business and portfolio review of GMPD continues, the team continues to prioritize and \nmake significant progress on turning around the operational performance of this business, as Aaron \nindicated with our expectation that the business returns to p rofitability in fiscal \u201824.  \n \n The number one priority remains mitigating supply chain inflation, where we remain on track to \naddress the impact by the time we exit fiscal \u201824.  As of Q2, we\u2019re approximately 75% to target.   \n \n On the cost side, while overall still elevated, we\u2019ve seen lower international freight costs reflected in \nour results, as anticipated, and we have strong line of sight to continued improvement in the second \nhalf of the fiscal year.  We\u2019ve continued to make progress with our mitigation initiatives and \ncommercial contracting efforts and  are continually taking additional actions to offset elevated inflation, \nsuch as through sourcing initiatives.  \n \n As Aaron indicated, the work we\u2019ve accomplished to -date provides increased confidence in achieving \nour fiscal year -end target, as overall cost improvements continue to reflect in our second half results.  \n \n We\u2019re continuing to invest in the resiliency of our supply chain and our manufacturing and distribution \ncapacity. ", "original_text": "On the cost side, while overall still elevated, we\u2019ve seen lower international freight costs reflected in \nour results, as anticipated, and we have strong line of sight to continued improvement in the second \nhalf of the fiscal year. ", "page_label": "8", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "cb248949-64fc-498f-a357-322668a33cd9", "node_type": "4", "metadata": {"page_label": "8", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "e7b8c2a5dcb80575f7d8228fbd3e727bd9f5cdac723c24e2c276fa2bff980b35", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "5d079ed4-7dc3-4f4b-9ea1-fc1a99f369af", "node_type": "1", "metadata": {"window": "Turning to priority number two , and the GMPD business, where we\u2019re executing the Medical \nImprovement Plan . \n \n While the business and portfolio review of GMPD continues, the team continues to prioritize and \nmake significant progress on turning around the operational performance of this business, as Aaron \nindicated with our expectation that the business returns to p rofitability in fiscal \u201824.  \n \n The number one priority remains mitigating supply chain inflation, where we remain on track to \naddress the impact by the time we exit fiscal \u201824.  As of Q2, we\u2019re approximately 75% to target.   \n \n On the cost side, while overall still elevated, we\u2019ve seen lower international freight costs reflected in \nour results, as anticipated, and we have strong line of sight to continued improvement in the second \nhalf of the fiscal year.  We\u2019ve continued to make progress with our mitigation initiatives and \ncommercial contracting efforts and  are continually taking additional actions to offset elevated inflation, \nsuch as through sourcing initiatives.  \n \n As Aaron indicated, the work we\u2019ve accomplished to -date provides increased confidence in achieving \nour fiscal year -end target, as overall cost improvements continue to reflect in our second half results.  \n \n", "original_text": "As of Q2, we\u2019re approximately 75% to target.   \n \n", "page_label": "8", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "72d14e0214a697c4c0fc8000832d96aa9017a90654e2b2f2601d8853636b6f5e", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "a73a1c4e-bd86-475b-b6be-4b4366cdddcf", "node_type": "1", "metadata": {"window": "The number one priority remains mitigating supply chain inflation, where we remain on track to \naddress the impact by the time we exit fiscal \u201824.  As of Q2, we\u2019re approximately 75% to target.   \n \n On the cost side, while overall still elevated, we\u2019ve seen lower international freight costs reflected in \nour results, as anticipated, and we have strong line of sight to continued improvement in the second \nhalf of the fiscal year.  We\u2019ve continued to make progress with our mitigation initiatives and \ncommercial contracting efforts and  are continually taking additional actions to offset elevated inflation, \nsuch as through sourcing initiatives.  \n \n As Aaron indicated, the work we\u2019ve accomplished to -date provides increased confidence in achieving \nour fiscal year -end target, as overall cost improvements continue to reflect in our second half results.  \n \n We\u2019re continuing to invest in the resiliency of our supply chain and our manufacturing and distribution \ncapacity.  We have opened three new distribution centers in the past year, adding capacity for growth \nwhile featuring state -of-the-art automation technology to streamline operations. ", "original_text": "We\u2019ve continued to make progress with our mitigation initiatives and \ncommercial contracting efforts and  are continually taking additional actions to offset elevated inflation, \nsuch as through sourcing initiatives.  \n \n"}, "hash": "eeae597b22926c33fe6d4f6200cc5f80aa022d3694ec7139386abae3753ddbb9", "class_name": "RelatedNodeInfo"}}, "text": "On the cost side, while overall still elevated, we\u2019ve seen lower international freight costs reflected in \nour results, as anticipated, and we have strong line of sight to continued improvement in the second \nhalf of the fiscal year. ", "start_char_idx": 2095, "end_char_idx": 2329, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "a73a1c4e-bd86-475b-b6be-4b4366cdddcf": {"__data__": {"id_": "a73a1c4e-bd86-475b-b6be-4b4366cdddcf", "embedding": null, "metadata": {"window": "The number one priority remains mitigating supply chain inflation, where we remain on track to \naddress the impact by the time we exit fiscal \u201824.  As of Q2, we\u2019re approximately 75% to target.   \n \n On the cost side, while overall still elevated, we\u2019ve seen lower international freight costs reflected in \nour results, as anticipated, and we have strong line of sight to continued improvement in the second \nhalf of the fiscal year.  We\u2019ve continued to make progress with our mitigation initiatives and \ncommercial contracting efforts and  are continually taking additional actions to offset elevated inflation, \nsuch as through sourcing initiatives.  \n \n As Aaron indicated, the work we\u2019ve accomplished to -date provides increased confidence in achieving \nour fiscal year -end target, as overall cost improvements continue to reflect in our second half results.  \n \n We\u2019re continuing to invest in the resiliency of our supply chain and our manufacturing and distribution \ncapacity.  We have opened three new distribution centers in the past year, adding capacity for growth \nwhile featuring state -of-the-art automation technology to streamline operations. ", "original_text": "We\u2019ve continued to make progress with our mitigation initiatives and \ncommercial contracting efforts and  are continually taking additional actions to offset elevated inflation, \nsuch as through sourcing initiatives.  \n \n", "page_label": "8", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "cb248949-64fc-498f-a357-322668a33cd9", "node_type": "4", "metadata": {"page_label": "8", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "e7b8c2a5dcb80575f7d8228fbd3e727bd9f5cdac723c24e2c276fa2bff980b35", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "b58873c8-367d-452f-a56c-fce70ecbbce2", "node_type": "1", "metadata": {"window": "While the business and portfolio review of GMPD continues, the team continues to prioritize and \nmake significant progress on turning around the operational performance of this business, as Aaron \nindicated with our expectation that the business returns to p rofitability in fiscal \u201824.  \n \n The number one priority remains mitigating supply chain inflation, where we remain on track to \naddress the impact by the time we exit fiscal \u201824.  As of Q2, we\u2019re approximately 75% to target.   \n \n On the cost side, while overall still elevated, we\u2019ve seen lower international freight costs reflected in \nour results, as anticipated, and we have strong line of sight to continued improvement in the second \nhalf of the fiscal year.  We\u2019ve continued to make progress with our mitigation initiatives and \ncommercial contracting efforts and  are continually taking additional actions to offset elevated inflation, \nsuch as through sourcing initiatives.  \n \n As Aaron indicated, the work we\u2019ve accomplished to -date provides increased confidence in achieving \nour fiscal year -end target, as overall cost improvements continue to reflect in our second half results.  \n \n We\u2019re continuing to invest in the resiliency of our supply chain and our manufacturing and distribution \ncapacity. ", "original_text": "On the cost side, while overall still elevated, we\u2019ve seen lower international freight costs reflected in \nour results, as anticipated, and we have strong line of sight to continued improvement in the second \nhalf of the fiscal year. ", "page_label": "8", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "5a5094911ce155a78fbb5179435a5b1ad5a85177ef6145fd4a5a59ee7092f54f", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "cf35929c-ff61-4f37-875c-986901a68dc4", "node_type": "1", "metadata": {"window": "As of Q2, we\u2019re approximately 75% to target.   \n \n On the cost side, while overall still elevated, we\u2019ve seen lower international freight costs reflected in \nour results, as anticipated, and we have strong line of sight to continued improvement in the second \nhalf of the fiscal year.  We\u2019ve continued to make progress with our mitigation initiatives and \ncommercial contracting efforts and  are continually taking additional actions to offset elevated inflation, \nsuch as through sourcing initiatives.  \n \n As Aaron indicated, the work we\u2019ve accomplished to -date provides increased confidence in achieving \nour fiscal year -end target, as overall cost improvements continue to reflect in our second half results.  \n \n We\u2019re continuing to invest in the resiliency of our supply chain and our manufacturing and distribution \ncapacity.  We have opened three new distribution centers in the past year, adding capacity for growth \nwhile featuring state -of-the-art automation technology to streamline operations.  For example, our new \nGreater Toronto Area DC expands capacity to serve Car dinal Health Canada customers, while \nleveraging autonomous mobile robots to increase picking and packing accuracy and drive \nefficiencies.  \n ", "original_text": "As Aaron indicated, the work we\u2019ve accomplished to -date provides increased confidence in achieving \nour fiscal year -end target, as overall cost improvements continue to reflect in our second half results.  \n \n"}, "hash": "04535761e136de2058d62bae97decd275b7b1abc29dc9f79d06006411648dc6f", "class_name": "RelatedNodeInfo"}}, "text": "We\u2019ve continued to make progress with our mitigation initiatives and \ncommercial contracting efforts and  are continually taking additional actions to offset elevated inflation, \nsuch as through sourcing initiatives.  \n \n", "start_char_idx": 2329, "end_char_idx": 2550, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "cf35929c-ff61-4f37-875c-986901a68dc4": {"__data__": {"id_": "cf35929c-ff61-4f37-875c-986901a68dc4", "embedding": null, "metadata": {"window": "As of Q2, we\u2019re approximately 75% to target.   \n \n On the cost side, while overall still elevated, we\u2019ve seen lower international freight costs reflected in \nour results, as anticipated, and we have strong line of sight to continued improvement in the second \nhalf of the fiscal year.  We\u2019ve continued to make progress with our mitigation initiatives and \ncommercial contracting efforts and  are continually taking additional actions to offset elevated inflation, \nsuch as through sourcing initiatives.  \n \n As Aaron indicated, the work we\u2019ve accomplished to -date provides increased confidence in achieving \nour fiscal year -end target, as overall cost improvements continue to reflect in our second half results.  \n \n We\u2019re continuing to invest in the resiliency of our supply chain and our manufacturing and distribution \ncapacity.  We have opened three new distribution centers in the past year, adding capacity for growth \nwhile featuring state -of-the-art automation technology to streamline operations.  For example, our new \nGreater Toronto Area DC expands capacity to serve Car dinal Health Canada customers, while \nleveraging autonomous mobile robots to increase picking and packing accuracy and drive \nefficiencies.  \n ", "original_text": "As Aaron indicated, the work we\u2019ve accomplished to -date provides increased confidence in achieving \nour fiscal year -end target, as overall cost improvements continue to reflect in our second half results.  \n \n", "page_label": "8", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "cb248949-64fc-498f-a357-322668a33cd9", "node_type": "4", "metadata": {"page_label": "8", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "e7b8c2a5dcb80575f7d8228fbd3e727bd9f5cdac723c24e2c276fa2bff980b35", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "a73a1c4e-bd86-475b-b6be-4b4366cdddcf", "node_type": "1", "metadata": {"window": "The number one priority remains mitigating supply chain inflation, where we remain on track to \naddress the impact by the time we exit fiscal \u201824.  As of Q2, we\u2019re approximately 75% to target.   \n \n On the cost side, while overall still elevated, we\u2019ve seen lower international freight costs reflected in \nour results, as anticipated, and we have strong line of sight to continued improvement in the second \nhalf of the fiscal year.  We\u2019ve continued to make progress with our mitigation initiatives and \ncommercial contracting efforts and  are continually taking additional actions to offset elevated inflation, \nsuch as through sourcing initiatives.  \n \n As Aaron indicated, the work we\u2019ve accomplished to -date provides increased confidence in achieving \nour fiscal year -end target, as overall cost improvements continue to reflect in our second half results.  \n \n We\u2019re continuing to invest in the resiliency of our supply chain and our manufacturing and distribution \ncapacity.  We have opened three new distribution centers in the past year, adding capacity for growth \nwhile featuring state -of-the-art automation technology to streamline operations. ", "original_text": "We\u2019ve continued to make progress with our mitigation initiatives and \ncommercial contracting efforts and  are continually taking additional actions to offset elevated inflation, \nsuch as through sourcing initiatives.  \n \n", "page_label": "8", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "a43f47dda48086ebd46d1e7938ccf0dea91651e6c901bd259b620129fc0d0d9f", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "ee05a25c-dbb9-4803-a0a1-4def30f01f77", "node_type": "1", "metadata": {"window": "On the cost side, while overall still elevated, we\u2019ve seen lower international freight costs reflected in \nour results, as anticipated, and we have strong line of sight to continued improvement in the second \nhalf of the fiscal year.  We\u2019ve continued to make progress with our mitigation initiatives and \ncommercial contracting efforts and  are continually taking additional actions to offset elevated inflation, \nsuch as through sourcing initiatives.  \n \n As Aaron indicated, the work we\u2019ve accomplished to -date provides increased confidence in achieving \nour fiscal year -end target, as overall cost improvements continue to reflect in our second half results.  \n \n We\u2019re continuing to invest in the resiliency of our supply chain and our manufacturing and distribution \ncapacity.  We have opened three new distribution centers in the past year, adding capacity for growth \nwhile featuring state -of-the-art automation technology to streamline operations.  For example, our new \nGreater Toronto Area DC expands capacity to serve Car dinal Health Canada customers, while \nleveraging autonomous mobile robots to increase picking and packing accuracy and drive \nefficiencies.  \n ", "original_text": "We\u2019re continuing to invest in the resiliency of our supply chain and our manufacturing and distribution \ncapacity. "}, "hash": "208bd2de1b21a27b285d56dfde496fb164929a570be34315d0e6cb4b1c7a113a", "class_name": "RelatedNodeInfo"}}, "text": "As Aaron indicated, the work we\u2019ve accomplished to -date provides increased confidence in achieving \nour fiscal year -end target, as overall cost improvements continue to reflect in our second half results.  \n \n", "start_char_idx": 2550, "end_char_idx": 2761, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "ee05a25c-dbb9-4803-a0a1-4def30f01f77": {"__data__": {"id_": "ee05a25c-dbb9-4803-a0a1-4def30f01f77", "embedding": null, "metadata": {"window": "On the cost side, while overall still elevated, we\u2019ve seen lower international freight costs reflected in \nour results, as anticipated, and we have strong line of sight to continued improvement in the second \nhalf of the fiscal year.  We\u2019ve continued to make progress with our mitigation initiatives and \ncommercial contracting efforts and  are continually taking additional actions to offset elevated inflation, \nsuch as through sourcing initiatives.  \n \n As Aaron indicated, the work we\u2019ve accomplished to -date provides increased confidence in achieving \nour fiscal year -end target, as overall cost improvements continue to reflect in our second half results.  \n \n We\u2019re continuing to invest in the resiliency of our supply chain and our manufacturing and distribution \ncapacity.  We have opened three new distribution centers in the past year, adding capacity for growth \nwhile featuring state -of-the-art automation technology to streamline operations.  For example, our new \nGreater Toronto Area DC expands capacity to serve Car dinal Health Canada customers, while \nleveraging autonomous mobile robots to increase picking and packing accuracy and drive \nefficiencies.  \n ", "original_text": "We\u2019re continuing to invest in the resiliency of our supply chain and our manufacturing and distribution \ncapacity. ", "page_label": "8", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "cb248949-64fc-498f-a357-322668a33cd9", "node_type": "4", "metadata": {"page_label": "8", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "e7b8c2a5dcb80575f7d8228fbd3e727bd9f5cdac723c24e2c276fa2bff980b35", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "cf35929c-ff61-4f37-875c-986901a68dc4", "node_type": "1", "metadata": {"window": "As of Q2, we\u2019re approximately 75% to target.   \n \n On the cost side, while overall still elevated, we\u2019ve seen lower international freight costs reflected in \nour results, as anticipated, and we have strong line of sight to continued improvement in the second \nhalf of the fiscal year.  We\u2019ve continued to make progress with our mitigation initiatives and \ncommercial contracting efforts and  are continually taking additional actions to offset elevated inflation, \nsuch as through sourcing initiatives.  \n \n As Aaron indicated, the work we\u2019ve accomplished to -date provides increased confidence in achieving \nour fiscal year -end target, as overall cost improvements continue to reflect in our second half results.  \n \n We\u2019re continuing to invest in the resiliency of our supply chain and our manufacturing and distribution \ncapacity.  We have opened three new distribution centers in the past year, adding capacity for growth \nwhile featuring state -of-the-art automation technology to streamline operations.  For example, our new \nGreater Toronto Area DC expands capacity to serve Car dinal Health Canada customers, while \nleveraging autonomous mobile robots to increase picking and packing accuracy and drive \nefficiencies.  \n ", "original_text": "As Aaron indicated, the work we\u2019ve accomplished to -date provides increased confidence in achieving \nour fiscal year -end target, as overall cost improvements continue to reflect in our second half results.  \n \n", "page_label": "8", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "8ca5a1b9f53c46076d5ab4a5880be38947d0f06d7d703c4f046ba54e898f996a", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "3946df4e-2014-4b39-9403-1767aaed4df7", "node_type": "1", "metadata": {"window": "We\u2019ve continued to make progress with our mitigation initiatives and \ncommercial contracting efforts and  are continually taking additional actions to offset elevated inflation, \nsuch as through sourcing initiatives.  \n \n As Aaron indicated, the work we\u2019ve accomplished to -date provides increased confidence in achieving \nour fiscal year -end target, as overall cost improvements continue to reflect in our second half results.  \n \n We\u2019re continuing to invest in the resiliency of our supply chain and our manufacturing and distribution \ncapacity.  We have opened three new distribution centers in the past year, adding capacity for growth \nwhile featuring state -of-the-art automation technology to streamline operations.  For example, our new \nGreater Toronto Area DC expands capacity to serve Car dinal Health Canada customers, while \nleveraging autonomous mobile robots to increase picking and packing accuracy and drive \nefficiencies.  \n ", "original_text": "We have opened three new distribution centers in the past year, adding capacity for growth \nwhile featuring state -of-the-art automation technology to streamline operations. "}, "hash": "39f9e40917254c58005ab6a0049a200d9a73c15562055cb32f8ce7a43049aa40", "class_name": "RelatedNodeInfo"}}, "text": "We\u2019re continuing to invest in the resiliency of our supply chain and our manufacturing and distribution \ncapacity. ", "start_char_idx": 2761, "end_char_idx": 2876, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "3946df4e-2014-4b39-9403-1767aaed4df7": {"__data__": {"id_": "3946df4e-2014-4b39-9403-1767aaed4df7", "embedding": null, "metadata": {"window": "We\u2019ve continued to make progress with our mitigation initiatives and \ncommercial contracting efforts and  are continually taking additional actions to offset elevated inflation, \nsuch as through sourcing initiatives.  \n \n As Aaron indicated, the work we\u2019ve accomplished to -date provides increased confidence in achieving \nour fiscal year -end target, as overall cost improvements continue to reflect in our second half results.  \n \n We\u2019re continuing to invest in the resiliency of our supply chain and our manufacturing and distribution \ncapacity.  We have opened three new distribution centers in the past year, adding capacity for growth \nwhile featuring state -of-the-art automation technology to streamline operations.  For example, our new \nGreater Toronto Area DC expands capacity to serve Car dinal Health Canada customers, while \nleveraging autonomous mobile robots to increase picking and packing accuracy and drive \nefficiencies.  \n ", "original_text": "We have opened three new distribution centers in the past year, adding capacity for growth \nwhile featuring state -of-the-art automation technology to streamline operations. ", "page_label": "8", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "cb248949-64fc-498f-a357-322668a33cd9", "node_type": "4", "metadata": {"page_label": "8", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "e7b8c2a5dcb80575f7d8228fbd3e727bd9f5cdac723c24e2c276fa2bff980b35", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "ee05a25c-dbb9-4803-a0a1-4def30f01f77", "node_type": "1", "metadata": {"window": "On the cost side, while overall still elevated, we\u2019ve seen lower international freight costs reflected in \nour results, as anticipated, and we have strong line of sight to continued improvement in the second \nhalf of the fiscal year.  We\u2019ve continued to make progress with our mitigation initiatives and \ncommercial contracting efforts and  are continually taking additional actions to offset elevated inflation, \nsuch as through sourcing initiatives.  \n \n As Aaron indicated, the work we\u2019ve accomplished to -date provides increased confidence in achieving \nour fiscal year -end target, as overall cost improvements continue to reflect in our second half results.  \n \n We\u2019re continuing to invest in the resiliency of our supply chain and our manufacturing and distribution \ncapacity.  We have opened three new distribution centers in the past year, adding capacity for growth \nwhile featuring state -of-the-art automation technology to streamline operations.  For example, our new \nGreater Toronto Area DC expands capacity to serve Car dinal Health Canada customers, while \nleveraging autonomous mobile robots to increase picking and packing accuracy and drive \nefficiencies.  \n ", "original_text": "We\u2019re continuing to invest in the resiliency of our supply chain and our manufacturing and distribution \ncapacity. ", "page_label": "8", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "429dd17055d1b74864dafec8c6e9fa30c18982e58d98f38a9fcdf998dc97c27d", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "47895c88-6bc4-43aa-8edf-9adc38447bd9", "node_type": "1", "metadata": {"window": "As Aaron indicated, the work we\u2019ve accomplished to -date provides increased confidence in achieving \nour fiscal year -end target, as overall cost improvements continue to reflect in our second half results.  \n \n We\u2019re continuing to invest in the resiliency of our supply chain and our manufacturing and distribution \ncapacity.  We have opened three new distribution centers in the past year, adding capacity for growth \nwhile featuring state -of-the-art automation technology to streamline operations.  For example, our new \nGreater Toronto Area DC expands capacity to serve Car dinal Health Canada customers, while \nleveraging autonomous mobile robots to increase picking and packing accuracy and drive \nefficiencies.  \n ", "original_text": "For example, our new \nGreater Toronto Area DC expands capacity to serve Car dinal Health Canada customers, while \nleveraging autonomous mobile robots to increase picking and packing accuracy and drive \nefficiencies.  \n "}, "hash": "88f43508d0a814d41eaf1dca87871b3a050e6228e02180c19fa6e1dfc0fdf054", "class_name": "RelatedNodeInfo"}}, "text": "We have opened three new distribution centers in the past year, adding capacity for growth \nwhile featuring state -of-the-art automation technology to streamline operations. ", "start_char_idx": 2876, "end_char_idx": 3050, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "47895c88-6bc4-43aa-8edf-9adc38447bd9": {"__data__": {"id_": "47895c88-6bc4-43aa-8edf-9adc38447bd9", "embedding": null, "metadata": {"window": "As Aaron indicated, the work we\u2019ve accomplished to -date provides increased confidence in achieving \nour fiscal year -end target, as overall cost improvements continue to reflect in our second half results.  \n \n We\u2019re continuing to invest in the resiliency of our supply chain and our manufacturing and distribution \ncapacity.  We have opened three new distribution centers in the past year, adding capacity for growth \nwhile featuring state -of-the-art automation technology to streamline operations.  For example, our new \nGreater Toronto Area DC expands capacity to serve Car dinal Health Canada customers, while \nleveraging autonomous mobile robots to increase picking and packing accuracy and drive \nefficiencies.  \n ", "original_text": "For example, our new \nGreater Toronto Area DC expands capacity to serve Car dinal Health Canada customers, while \nleveraging autonomous mobile robots to increase picking and packing accuracy and drive \nefficiencies.  \n ", "page_label": "8", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "cb248949-64fc-498f-a357-322668a33cd9", "node_type": "4", "metadata": {"page_label": "8", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "e7b8c2a5dcb80575f7d8228fbd3e727bd9f5cdac723c24e2c276fa2bff980b35", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "3946df4e-2014-4b39-9403-1767aaed4df7", "node_type": "1", "metadata": {"window": "We\u2019ve continued to make progress with our mitigation initiatives and \ncommercial contracting efforts and  are continually taking additional actions to offset elevated inflation, \nsuch as through sourcing initiatives.  \n \n As Aaron indicated, the work we\u2019ve accomplished to -date provides increased confidence in achieving \nour fiscal year -end target, as overall cost improvements continue to reflect in our second half results.  \n \n We\u2019re continuing to invest in the resiliency of our supply chain and our manufacturing and distribution \ncapacity.  We have opened three new distribution centers in the past year, adding capacity for growth \nwhile featuring state -of-the-art automation technology to streamline operations.  For example, our new \nGreater Toronto Area DC expands capacity to serve Car dinal Health Canada customers, while \nleveraging autonomous mobile robots to increase picking and packing accuracy and drive \nefficiencies.  \n ", "original_text": "We have opened three new distribution centers in the past year, adding capacity for growth \nwhile featuring state -of-the-art automation technology to streamline operations. ", "page_label": "8", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "b2626f029b127747d218680f0f90b13f2b5b453bcbe349dadaadce4e591c7b4d", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "af491530-c3ad-45bf-ace6-d7d2671965b9", "node_type": "1", "metadata": {"window": " \nPage 9 of 19 \n \nWe are also continuing to invest in new product innovation and portfolio expansion in key categories, \nin alignment with our disciplined portfolio management approach.  \n \n As a result of our team\u2019s collective efforts, we\u2019re seeing our 5 -point plan to grow Cardinal Health \nBrand volume result in improvements in our leading indicators, and most importantly, strong customer \nretention and product volume growth.  \n \n Finally, we continue to drive simplification and optimize our cost structure by exiting non -core product \nlines, rationalizing our network , and streamlining our international footprint.  \n \n We believe our new structure will further enable our Medical Improvement Plan efforts, as we \ncontinue to execute the plan and deliver value for customers.  \n \n", "original_text": " \nPage 9 of 19 \n \nWe are also continuing to invest in new product innovation and portfolio expansion in key categories, \nin alignment with our disciplined portfolio management approach.  \n \n"}, "hash": "333c9e6dcd38286741bcc81a464bdeecf5b65be678990403166fd166f23ec083", "class_name": "RelatedNodeInfo"}}, "text": "For example, our new \nGreater Toronto Area DC expands capacity to serve Car dinal Health Canada customers, while \nleveraging autonomous mobile robots to increase picking and packing accuracy and drive \nefficiencies.  \n ", "start_char_idx": 3050, "end_char_idx": 3269, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "af491530-c3ad-45bf-ace6-d7d2671965b9": {"__data__": {"id_": "af491530-c3ad-45bf-ace6-d7d2671965b9", "embedding": null, "metadata": {"window": " \nPage 9 of 19 \n \nWe are also continuing to invest in new product innovation and portfolio expansion in key categories, \nin alignment with our disciplined portfolio management approach.  \n \n As a result of our team\u2019s collective efforts, we\u2019re seeing our 5 -point plan to grow Cardinal Health \nBrand volume result in improvements in our leading indicators, and most importantly, strong customer \nretention and product volume growth.  \n \n Finally, we continue to drive simplification and optimize our cost structure by exiting non -core product \nlines, rationalizing our network , and streamlining our international footprint.  \n \n We believe our new structure will further enable our Medical Improvement Plan efforts, as we \ncontinue to execute the plan and deliver value for customers.  \n \n", "original_text": " \nPage 9 of 19 \n \nWe are also continuing to invest in new product innovation and portfolio expansion in key categories, \nin alignment with our disciplined portfolio management approach.  \n \n", "page_label": "9", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "dd0c036b-c7ea-4c12-b21f-2c88607b8c5c", "node_type": "4", "metadata": {"page_label": "9", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "5d4f5ac995aa0b111e65496903626588b23de8b22bcf9a511a093abb894b19ef", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "47895c88-6bc4-43aa-8edf-9adc38447bd9", "node_type": "1", "metadata": {"window": "As Aaron indicated, the work we\u2019ve accomplished to -date provides increased confidence in achieving \nour fiscal year -end target, as overall cost improvements continue to reflect in our second half results.  \n \n We\u2019re continuing to invest in the resiliency of our supply chain and our manufacturing and distribution \ncapacity.  We have opened three new distribution centers in the past year, adding capacity for growth \nwhile featuring state -of-the-art automation technology to streamline operations.  For example, our new \nGreater Toronto Area DC expands capacity to serve Car dinal Health Canada customers, while \nleveraging autonomous mobile robots to increase picking and packing accuracy and drive \nefficiencies.  \n ", "original_text": "For example, our new \nGreater Toronto Area DC expands capacity to serve Car dinal Health Canada customers, while \nleveraging autonomous mobile robots to increase picking and packing accuracy and drive \nefficiencies.  \n ", "page_label": "8", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "01d46006db9536e0ab1fd6c5af30b0dc6996c09434092ffc11ccf30d3334f2fa", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "8a90e4e0-eacd-4a83-8ae2-0cf30c0bab42", "node_type": "1", "metadata": {"window": " \nPage 9 of 19 \n \nWe are also continuing to invest in new product innovation and portfolio expansion in key categories, \nin alignment with our disciplined portfolio management approach.  \n \n As a result of our team\u2019s collective efforts, we\u2019re seeing our 5 -point plan to grow Cardinal Health \nBrand volume result in improvements in our leading indicators, and most importantly, strong customer \nretention and product volume growth.  \n \n Finally, we continue to drive simplification and optimize our cost structure by exiting non -core product \nlines, rationalizing our network , and streamlining our international footprint.  \n \n We believe our new structure will further enable our Medical Improvement Plan efforts, as we \ncontinue to execute the plan and deliver value for customers.  \n \n Now, priority number three , accelerating growth in key areas . \n \n", "original_text": "As a result of our team\u2019s collective efforts, we\u2019re seeing our 5 -point plan to grow Cardinal Health \nBrand volume result in improvements in our leading indicators, and most importantly, strong customer \nretention and product volume growth.  \n \n"}, "hash": "8316aae231357a251d0bc42f9cb8cb0a8fa9d889b366b0bf9be6617f43ade36a", "class_name": "RelatedNodeInfo"}}, "text": " \nPage 9 of 19 \n \nWe are also continuing to invest in new product innovation and portfolio expansion in key categories, \nin alignment with our disciplined portfolio management approach.  \n \n", "start_char_idx": 0, "end_char_idx": 190, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "8a90e4e0-eacd-4a83-8ae2-0cf30c0bab42": {"__data__": {"id_": "8a90e4e0-eacd-4a83-8ae2-0cf30c0bab42", "embedding": null, "metadata": {"window": " \nPage 9 of 19 \n \nWe are also continuing to invest in new product innovation and portfolio expansion in key categories, \nin alignment with our disciplined portfolio management approach.  \n \n As a result of our team\u2019s collective efforts, we\u2019re seeing our 5 -point plan to grow Cardinal Health \nBrand volume result in improvements in our leading indicators, and most importantly, strong customer \nretention and product volume growth.  \n \n Finally, we continue to drive simplification and optimize our cost structure by exiting non -core product \nlines, rationalizing our network , and streamlining our international footprint.  \n \n We believe our new structure will further enable our Medical Improvement Plan efforts, as we \ncontinue to execute the plan and deliver value for customers.  \n \n Now, priority number three , accelerating growth in key areas . \n \n", "original_text": "As a result of our team\u2019s collective efforts, we\u2019re seeing our 5 -point plan to grow Cardinal Health \nBrand volume result in improvements in our leading indicators, and most importantly, strong customer \nretention and product volume growth.  \n \n", "page_label": "9", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "dd0c036b-c7ea-4c12-b21f-2c88607b8c5c", "node_type": "4", "metadata": {"page_label": "9", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "5d4f5ac995aa0b111e65496903626588b23de8b22bcf9a511a093abb894b19ef", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "af491530-c3ad-45bf-ace6-d7d2671965b9", "node_type": "1", "metadata": {"window": " \nPage 9 of 19 \n \nWe are also continuing to invest in new product innovation and portfolio expansion in key categories, \nin alignment with our disciplined portfolio management approach.  \n \n As a result of our team\u2019s collective efforts, we\u2019re seeing our 5 -point plan to grow Cardinal Health \nBrand volume result in improvements in our leading indicators, and most importantly, strong customer \nretention and product volume growth.  \n \n Finally, we continue to drive simplification and optimize our cost structure by exiting non -core product \nlines, rationalizing our network , and streamlining our international footprint.  \n \n We believe our new structure will further enable our Medical Improvement Plan efforts, as we \ncontinue to execute the plan and deliver value for customers.  \n \n", "original_text": " \nPage 9 of 19 \n \nWe are also continuing to invest in new product innovation and portfolio expansion in key categories, \nin alignment with our disciplined portfolio management approach.  \n \n", "page_label": "9", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "6d8b1f70372dd042ccc9f774036021b98dae81ada3ca41ed5f5beb63467ad35a", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "304ac4bc-a541-4424-9b4c-b8b64313dcd6", "node_type": "1", "metadata": {"window": " \nPage 9 of 19 \n \nWe are also continuing to invest in new product innovation and portfolio expansion in key categories, \nin alignment with our disciplined portfolio management approach.  \n \n As a result of our team\u2019s collective efforts, we\u2019re seeing our 5 -point plan to grow Cardinal Health \nBrand volume result in improvements in our leading indicators, and most importantly, strong customer \nretention and product volume growth.  \n \n Finally, we continue to drive simplification and optimize our cost structure by exiting non -core product \nlines, rationalizing our network , and streamlining our international footprint.  \n \n We believe our new structure will further enable our Medical Improvement Plan efforts, as we \ncontinue to execute the plan and deliver value for customers.  \n \n Now, priority number three , accelerating growth in key areas . \n \n We are excited about the strong demand we are seeing in our at -Home Solutions and OptiFreight\u00ae \nbusinesses, and our recent determination to further invest in and develop these businesses for long -\nterm value creation as part of our portfolio.  \n \n", "original_text": "Finally, we continue to drive simplification and optimize our cost structure by exiting non -core product \nlines, rationalizing our network , and streamlining our international footprint.  \n \n"}, "hash": "4c0120ba1b50a096d8f81158c4b143fc6e9c93d6d2be827177c946220ad4f00e", "class_name": "RelatedNodeInfo"}}, "text": "As a result of our team\u2019s collective efforts, we\u2019re seeing our 5 -point plan to grow Cardinal Health \nBrand volume result in improvements in our leading indicators, and most importantly, strong customer \nretention and product volume growth.  \n \n", "start_char_idx": 190, "end_char_idx": 435, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "304ac4bc-a541-4424-9b4c-b8b64313dcd6": {"__data__": {"id_": "304ac4bc-a541-4424-9b4c-b8b64313dcd6", "embedding": null, "metadata": {"window": " \nPage 9 of 19 \n \nWe are also continuing to invest in new product innovation and portfolio expansion in key categories, \nin alignment with our disciplined portfolio management approach.  \n \n As a result of our team\u2019s collective efforts, we\u2019re seeing our 5 -point plan to grow Cardinal Health \nBrand volume result in improvements in our leading indicators, and most importantly, strong customer \nretention and product volume growth.  \n \n Finally, we continue to drive simplification and optimize our cost structure by exiting non -core product \nlines, rationalizing our network , and streamlining our international footprint.  \n \n We believe our new structure will further enable our Medical Improvement Plan efforts, as we \ncontinue to execute the plan and deliver value for customers.  \n \n Now, priority number three , accelerating growth in key areas . \n \n We are excited about the strong demand we are seeing in our at -Home Solutions and OptiFreight\u00ae \nbusinesses, and our recent determination to further invest in and develop these businesses for long -\nterm value creation as part of our portfolio.  \n \n", "original_text": "Finally, we continue to drive simplification and optimize our cost structure by exiting non -core product \nlines, rationalizing our network , and streamlining our international footprint.  \n \n", "page_label": "9", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "dd0c036b-c7ea-4c12-b21f-2c88607b8c5c", "node_type": "4", "metadata": {"page_label": "9", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "5d4f5ac995aa0b111e65496903626588b23de8b22bcf9a511a093abb894b19ef", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "8a90e4e0-eacd-4a83-8ae2-0cf30c0bab42", "node_type": "1", "metadata": {"window": " \nPage 9 of 19 \n \nWe are also continuing to invest in new product innovation and portfolio expansion in key categories, \nin alignment with our disciplined portfolio management approach.  \n \n As a result of our team\u2019s collective efforts, we\u2019re seeing our 5 -point plan to grow Cardinal Health \nBrand volume result in improvements in our leading indicators, and most importantly, strong customer \nretention and product volume growth.  \n \n Finally, we continue to drive simplification and optimize our cost structure by exiting non -core product \nlines, rationalizing our network , and streamlining our international footprint.  \n \n We believe our new structure will further enable our Medical Improvement Plan efforts, as we \ncontinue to execute the plan and deliver value for customers.  \n \n Now, priority number three , accelerating growth in key areas . \n \n", "original_text": "As a result of our team\u2019s collective efforts, we\u2019re seeing our 5 -point plan to grow Cardinal Health \nBrand volume result in improvements in our leading indicators, and most importantly, strong customer \nretention and product volume growth.  \n \n", "page_label": "9", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "dca7a57a33f043665f452411972cb9ffa9c8189c0e2062084048aa26e63d42ed", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "b37b57a5-942d-4a57-b3f4-412b40b20176", "node_type": "1", "metadata": {"window": " \nPage 9 of 19 \n \nWe are also continuing to invest in new product innovation and portfolio expansion in key categories, \nin alignment with our disciplined portfolio management approach.  \n \n As a result of our team\u2019s collective efforts, we\u2019re seeing our 5 -point plan to grow Cardinal Health \nBrand volume result in improvements in our leading indicators, and most importantly, strong customer \nretention and product volume growth.  \n \n Finally, we continue to drive simplification and optimize our cost structure by exiting non -core product \nlines, rationalizing our network , and streamlining our international footprint.  \n \n We believe our new structure will further enable our Medical Improvement Plan efforts, as we \ncontinue to execute the plan and deliver value for customers.  \n \n Now, priority number three , accelerating growth in key areas . \n \n We are excited about the strong demand we are seeing in our at -Home Solutions and OptiFreight\u00ae \nbusinesses, and our recent determination to further invest in and develop these businesses for long -\nterm value creation as part of our portfolio.  \n \n In at-Home Solutions, we continue to focus on enabling and supporting comfortable, home -based \ncare for patients with acute and chronic conditions. ", "original_text": "We believe our new structure will further enable our Medical Improvement Plan efforts, as we \ncontinue to execute the plan and deliver value for customers.  \n \n"}, "hash": "c77667ac0776d0575214bdb841c8c36c6588edcf84f30a6b0cf6babf9f75a58f", "class_name": "RelatedNodeInfo"}}, "text": "Finally, we continue to drive simplification and optimize our cost structure by exiting non -core product \nlines, rationalizing our network , and streamlining our international footprint.  \n \n", "start_char_idx": 435, "end_char_idx": 627, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "b37b57a5-942d-4a57-b3f4-412b40b20176": {"__data__": {"id_": "b37b57a5-942d-4a57-b3f4-412b40b20176", "embedding": null, "metadata": {"window": " \nPage 9 of 19 \n \nWe are also continuing to invest in new product innovation and portfolio expansion in key categories, \nin alignment with our disciplined portfolio management approach.  \n \n As a result of our team\u2019s collective efforts, we\u2019re seeing our 5 -point plan to grow Cardinal Health \nBrand volume result in improvements in our leading indicators, and most importantly, strong customer \nretention and product volume growth.  \n \n Finally, we continue to drive simplification and optimize our cost structure by exiting non -core product \nlines, rationalizing our network , and streamlining our international footprint.  \n \n We believe our new structure will further enable our Medical Improvement Plan efforts, as we \ncontinue to execute the plan and deliver value for customers.  \n \n Now, priority number three , accelerating growth in key areas . \n \n We are excited about the strong demand we are seeing in our at -Home Solutions and OptiFreight\u00ae \nbusinesses, and our recent determination to further invest in and develop these businesses for long -\nterm value creation as part of our portfolio.  \n \n In at-Home Solutions, we continue to focus on enabling and supporting comfortable, home -based \ncare for patients with acute and chronic conditions. ", "original_text": "We believe our new structure will further enable our Medical Improvement Plan efforts, as we \ncontinue to execute the plan and deliver value for customers.  \n \n", "page_label": "9", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "dd0c036b-c7ea-4c12-b21f-2c88607b8c5c", "node_type": "4", "metadata": {"page_label": "9", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "5d4f5ac995aa0b111e65496903626588b23de8b22bcf9a511a093abb894b19ef", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "304ac4bc-a541-4424-9b4c-b8b64313dcd6", "node_type": "1", "metadata": {"window": " \nPage 9 of 19 \n \nWe are also continuing to invest in new product innovation and portfolio expansion in key categories, \nin alignment with our disciplined portfolio management approach.  \n \n As a result of our team\u2019s collective efforts, we\u2019re seeing our 5 -point plan to grow Cardinal Health \nBrand volume result in improvements in our leading indicators, and most importantly, strong customer \nretention and product volume growth.  \n \n Finally, we continue to drive simplification and optimize our cost structure by exiting non -core product \nlines, rationalizing our network , and streamlining our international footprint.  \n \n We believe our new structure will further enable our Medical Improvement Plan efforts, as we \ncontinue to execute the plan and deliver value for customers.  \n \n Now, priority number three , accelerating growth in key areas . \n \n We are excited about the strong demand we are seeing in our at -Home Solutions and OptiFreight\u00ae \nbusinesses, and our recent determination to further invest in and develop these businesses for long -\nterm value creation as part of our portfolio.  \n \n", "original_text": "Finally, we continue to drive simplification and optimize our cost structure by exiting non -core product \nlines, rationalizing our network , and streamlining our international footprint.  \n \n", "page_label": "9", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "1178ff741f47e457ee590e531310901a89873544c83ac84ce249d32310f2d37c", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "3a1862bc-a495-4847-b59d-66aad3b43d88", "node_type": "1", "metadata": {"window": "As a result of our team\u2019s collective efforts, we\u2019re seeing our 5 -point plan to grow Cardinal Health \nBrand volume result in improvements in our leading indicators, and most importantly, strong customer \nretention and product volume growth.  \n \n Finally, we continue to drive simplification and optimize our cost structure by exiting non -core product \nlines, rationalizing our network , and streamlining our international footprint.  \n \n We believe our new structure will further enable our Medical Improvement Plan efforts, as we \ncontinue to execute the plan and deliver value for customers.  \n \n Now, priority number three , accelerating growth in key areas . \n \n We are excited about the strong demand we are seeing in our at -Home Solutions and OptiFreight\u00ae \nbusinesses, and our recent determination to further invest in and develop these businesses for long -\nterm value creation as part of our portfolio.  \n \n In at-Home Solutions, we continue to focus on enabling and supporting comfortable, home -based \ncare for patients with acute and chronic conditions.  To support the growing demand for home \nhealthcare, we\u2019re investing to expand the capacity of our network, the breadth of our offering, and in \nnew technology to drive operating efficiencies. ", "original_text": "Now, priority number three , accelerating growth in key areas . \n \n"}, "hash": "f53dcced84db7fba26b3c34390f078c5d73e51b1b3f514700c8ebad91f669598", "class_name": "RelatedNodeInfo"}}, "text": "We believe our new structure will further enable our Medical Improvement Plan efforts, as we \ncontinue to execute the plan and deliver value for customers.  \n \n", "start_char_idx": 627, "end_char_idx": 787, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "3a1862bc-a495-4847-b59d-66aad3b43d88": {"__data__": {"id_": "3a1862bc-a495-4847-b59d-66aad3b43d88", "embedding": null, "metadata": {"window": "As a result of our team\u2019s collective efforts, we\u2019re seeing our 5 -point plan to grow Cardinal Health \nBrand volume result in improvements in our leading indicators, and most importantly, strong customer \nretention and product volume growth.  \n \n Finally, we continue to drive simplification and optimize our cost structure by exiting non -core product \nlines, rationalizing our network , and streamlining our international footprint.  \n \n We believe our new structure will further enable our Medical Improvement Plan efforts, as we \ncontinue to execute the plan and deliver value for customers.  \n \n Now, priority number three , accelerating growth in key areas . \n \n We are excited about the strong demand we are seeing in our at -Home Solutions and OptiFreight\u00ae \nbusinesses, and our recent determination to further invest in and develop these businesses for long -\nterm value creation as part of our portfolio.  \n \n In at-Home Solutions, we continue to focus on enabling and supporting comfortable, home -based \ncare for patients with acute and chronic conditions.  To support the growing demand for home \nhealthcare, we\u2019re investing to expand the capacity of our network, the breadth of our offering, and in \nnew technology to drive operating efficiencies. ", "original_text": "Now, priority number three , accelerating growth in key areas . \n \n", "page_label": "9", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "dd0c036b-c7ea-4c12-b21f-2c88607b8c5c", "node_type": "4", "metadata": {"page_label": "9", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "5d4f5ac995aa0b111e65496903626588b23de8b22bcf9a511a093abb894b19ef", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "b37b57a5-942d-4a57-b3f4-412b40b20176", "node_type": "1", "metadata": {"window": " \nPage 9 of 19 \n \nWe are also continuing to invest in new product innovation and portfolio expansion in key categories, \nin alignment with our disciplined portfolio management approach.  \n \n As a result of our team\u2019s collective efforts, we\u2019re seeing our 5 -point plan to grow Cardinal Health \nBrand volume result in improvements in our leading indicators, and most importantly, strong customer \nretention and product volume growth.  \n \n Finally, we continue to drive simplification and optimize our cost structure by exiting non -core product \nlines, rationalizing our network , and streamlining our international footprint.  \n \n We believe our new structure will further enable our Medical Improvement Plan efforts, as we \ncontinue to execute the plan and deliver value for customers.  \n \n Now, priority number three , accelerating growth in key areas . \n \n We are excited about the strong demand we are seeing in our at -Home Solutions and OptiFreight\u00ae \nbusinesses, and our recent determination to further invest in and develop these businesses for long -\nterm value creation as part of our portfolio.  \n \n In at-Home Solutions, we continue to focus on enabling and supporting comfortable, home -based \ncare for patients with acute and chronic conditions. ", "original_text": "We believe our new structure will further enable our Medical Improvement Plan efforts, as we \ncontinue to execute the plan and deliver value for customers.  \n \n", "page_label": "9", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "f8a11e928cb209a78412ef348e8046cef18ebaea8746c0e9651f4051c856e489", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "9f9bc403-b149-4043-90c5-9634d43a9840", "node_type": "1", "metadata": {"window": "Finally, we continue to drive simplification and optimize our cost structure by exiting non -core product \nlines, rationalizing our network , and streamlining our international footprint.  \n \n We believe our new structure will further enable our Medical Improvement Plan efforts, as we \ncontinue to execute the plan and deliver value for customers.  \n \n Now, priority number three , accelerating growth in key areas . \n \n We are excited about the strong demand we are seeing in our at -Home Solutions and OptiFreight\u00ae \nbusinesses, and our recent determination to further invest in and develop these businesses for long -\nterm value creation as part of our portfolio.  \n \n In at-Home Solutions, we continue to focus on enabling and supporting comfortable, home -based \ncare for patients with acute and chronic conditions.  To support the growing demand for home \nhealthcare, we\u2019re investing to expand the capacity of our network, the breadth of our offering, and in \nnew technology to drive operating efficiencies.  We recently announced plans for a new distribution \ncenter to be built in Texas, with increased capacity, advanced automation technology and robotic s \nwithin the facility. ", "original_text": "We are excited about the strong demand we are seeing in our at -Home Solutions and OptiFreight\u00ae \nbusinesses, and our recent determination to further invest in and develop these businesses for long -\nterm value creation as part of our portfolio.  \n \n"}, "hash": "39cb351434fbd1a051ec5695573c7737563ea3ea2021c5e5d0b6b8d6198408bf", "class_name": "RelatedNodeInfo"}}, "text": "Now, priority number three , accelerating growth in key areas . \n \n", "start_char_idx": 787, "end_char_idx": 854, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "9f9bc403-b149-4043-90c5-9634d43a9840": {"__data__": {"id_": "9f9bc403-b149-4043-90c5-9634d43a9840", "embedding": null, "metadata": {"window": "Finally, we continue to drive simplification and optimize our cost structure by exiting non -core product \nlines, rationalizing our network , and streamlining our international footprint.  \n \n We believe our new structure will further enable our Medical Improvement Plan efforts, as we \ncontinue to execute the plan and deliver value for customers.  \n \n Now, priority number three , accelerating growth in key areas . \n \n We are excited about the strong demand we are seeing in our at -Home Solutions and OptiFreight\u00ae \nbusinesses, and our recent determination to further invest in and develop these businesses for long -\nterm value creation as part of our portfolio.  \n \n In at-Home Solutions, we continue to focus on enabling and supporting comfortable, home -based \ncare for patients with acute and chronic conditions.  To support the growing demand for home \nhealthcare, we\u2019re investing to expand the capacity of our network, the breadth of our offering, and in \nnew technology to drive operating efficiencies.  We recently announced plans for a new distribution \ncenter to be built in Texas, with increased capacity, advanced automation technology and robotic s \nwithin the facility. ", "original_text": "We are excited about the strong demand we are seeing in our at -Home Solutions and OptiFreight\u00ae \nbusinesses, and our recent determination to further invest in and develop these businesses for long -\nterm value creation as part of our portfolio.  \n \n", "page_label": "9", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "dd0c036b-c7ea-4c12-b21f-2c88607b8c5c", "node_type": "4", "metadata": {"page_label": "9", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "5d4f5ac995aa0b111e65496903626588b23de8b22bcf9a511a093abb894b19ef", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "3a1862bc-a495-4847-b59d-66aad3b43d88", "node_type": "1", "metadata": {"window": "As a result of our team\u2019s collective efforts, we\u2019re seeing our 5 -point plan to grow Cardinal Health \nBrand volume result in improvements in our leading indicators, and most importantly, strong customer \nretention and product volume growth.  \n \n Finally, we continue to drive simplification and optimize our cost structure by exiting non -core product \nlines, rationalizing our network , and streamlining our international footprint.  \n \n We believe our new structure will further enable our Medical Improvement Plan efforts, as we \ncontinue to execute the plan and deliver value for customers.  \n \n Now, priority number three , accelerating growth in key areas . \n \n We are excited about the strong demand we are seeing in our at -Home Solutions and OptiFreight\u00ae \nbusinesses, and our recent determination to further invest in and develop these businesses for long -\nterm value creation as part of our portfolio.  \n \n In at-Home Solutions, we continue to focus on enabling and supporting comfortable, home -based \ncare for patients with acute and chronic conditions.  To support the growing demand for home \nhealthcare, we\u2019re investing to expand the capacity of our network, the breadth of our offering, and in \nnew technology to drive operating efficiencies. ", "original_text": "Now, priority number three , accelerating growth in key areas . \n \n", "page_label": "9", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "5974e8456bd661a39cb32234b3f9348aea85afb1c491a8f40452386e1ac35465", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "fbff49a6-910a-448d-a85a-f02c8e203f8d", "node_type": "1", "metadata": {"window": "We believe our new structure will further enable our Medical Improvement Plan efforts, as we \ncontinue to execute the plan and deliver value for customers.  \n \n Now, priority number three , accelerating growth in key areas . \n \n We are excited about the strong demand we are seeing in our at -Home Solutions and OptiFreight\u00ae \nbusinesses, and our recent determination to further invest in and develop these businesses for long -\nterm value creation as part of our portfolio.  \n \n In at-Home Solutions, we continue to focus on enabling and supporting comfortable, home -based \ncare for patients with acute and chronic conditions.  To support the growing demand for home \nhealthcare, we\u2019re investing to expand the capacity of our network, the breadth of our offering, and in \nnew technology to drive operating efficiencies.  We recently announced plans for a new distribution \ncenter to be built in Texas, with increased capacity, advanced automation technology and robotic s \nwithin the facility.  And our previously announced 350,000 sq uare foot facility being built in South \nCarolina is on track to open this calendar year.  \n \n", "original_text": "In at-Home Solutions, we continue to focus on enabling and supporting comfortable, home -based \ncare for patients with acute and chronic conditions. "}, "hash": "77135c40972781078fa9996eae79c79c1c20f56790dfbe08049773e09b1e4b01", "class_name": "RelatedNodeInfo"}}, "text": "We are excited about the strong demand we are seeing in our at -Home Solutions and OptiFreight\u00ae \nbusinesses, and our recent determination to further invest in and develop these businesses for long -\nterm value creation as part of our portfolio.  \n \n", "start_char_idx": 854, "end_char_idx": 1103, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "fbff49a6-910a-448d-a85a-f02c8e203f8d": {"__data__": {"id_": "fbff49a6-910a-448d-a85a-f02c8e203f8d", "embedding": null, "metadata": {"window": "We believe our new structure will further enable our Medical Improvement Plan efforts, as we \ncontinue to execute the plan and deliver value for customers.  \n \n Now, priority number three , accelerating growth in key areas . \n \n We are excited about the strong demand we are seeing in our at -Home Solutions and OptiFreight\u00ae \nbusinesses, and our recent determination to further invest in and develop these businesses for long -\nterm value creation as part of our portfolio.  \n \n In at-Home Solutions, we continue to focus on enabling and supporting comfortable, home -based \ncare for patients with acute and chronic conditions.  To support the growing demand for home \nhealthcare, we\u2019re investing to expand the capacity of our network, the breadth of our offering, and in \nnew technology to drive operating efficiencies.  We recently announced plans for a new distribution \ncenter to be built in Texas, with increased capacity, advanced automation technology and robotic s \nwithin the facility.  And our previously announced 350,000 sq uare foot facility being built in South \nCarolina is on track to open this calendar year.  \n \n", "original_text": "In at-Home Solutions, we continue to focus on enabling and supporting comfortable, home -based \ncare for patients with acute and chronic conditions. ", "page_label": "9", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "dd0c036b-c7ea-4c12-b21f-2c88607b8c5c", "node_type": "4", "metadata": {"page_label": "9", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "5d4f5ac995aa0b111e65496903626588b23de8b22bcf9a511a093abb894b19ef", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "9f9bc403-b149-4043-90c5-9634d43a9840", "node_type": "1", "metadata": {"window": "Finally, we continue to drive simplification and optimize our cost structure by exiting non -core product \nlines, rationalizing our network , and streamlining our international footprint.  \n \n We believe our new structure will further enable our Medical Improvement Plan efforts, as we \ncontinue to execute the plan and deliver value for customers.  \n \n Now, priority number three , accelerating growth in key areas . \n \n We are excited about the strong demand we are seeing in our at -Home Solutions and OptiFreight\u00ae \nbusinesses, and our recent determination to further invest in and develop these businesses for long -\nterm value creation as part of our portfolio.  \n \n In at-Home Solutions, we continue to focus on enabling and supporting comfortable, home -based \ncare for patients with acute and chronic conditions.  To support the growing demand for home \nhealthcare, we\u2019re investing to expand the capacity of our network, the breadth of our offering, and in \nnew technology to drive operating efficiencies.  We recently announced plans for a new distribution \ncenter to be built in Texas, with increased capacity, advanced automation technology and robotic s \nwithin the facility. ", "original_text": "We are excited about the strong demand we are seeing in our at -Home Solutions and OptiFreight\u00ae \nbusinesses, and our recent determination to further invest in and develop these businesses for long -\nterm value creation as part of our portfolio.  \n \n", "page_label": "9", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "76f16f8163ad6ff33b122ed14d01ac3ebbed981d7d5c812dd30af51ad79f1a77", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "70600a73-fa6b-40b3-ae8c-c00996535c0a", "node_type": "1", "metadata": {"window": "Now, priority number three , accelerating growth in key areas . \n \n We are excited about the strong demand we are seeing in our at -Home Solutions and OptiFreight\u00ae \nbusinesses, and our recent determination to further invest in and develop these businesses for long -\nterm value creation as part of our portfolio.  \n \n In at-Home Solutions, we continue to focus on enabling and supporting comfortable, home -based \ncare for patients with acute and chronic conditions.  To support the growing demand for home \nhealthcare, we\u2019re investing to expand the capacity of our network, the breadth of our offering, and in \nnew technology to drive operating efficiencies.  We recently announced plans for a new distribution \ncenter to be built in Texas, with increased capacity, advanced automation technology and robotic s \nwithin the facility.  And our previously announced 350,000 sq uare foot facility being built in South \nCarolina is on track to open this calendar year.  \n \n In OptiFreight\u00ae Logistics, we\u2019re continuing to invest in digital tools to enable healthcare supply chain \nleaders to better manage their shipping spend and support the core volume growth in our business. \n", "original_text": "To support the growing demand for home \nhealthcare, we\u2019re investing to expand the capacity of our network, the breadth of our offering, and in \nnew technology to drive operating efficiencies. "}, "hash": "0012471db672546b388aa3f3c3e772c4a745bdb24a9eaa255f65a1e5c94d7cb1", "class_name": "RelatedNodeInfo"}}, "text": "In at-Home Solutions, we continue to focus on enabling and supporting comfortable, home -based \ncare for patients with acute and chronic conditions. ", "start_char_idx": 1103, "end_char_idx": 1252, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "70600a73-fa6b-40b3-ae8c-c00996535c0a": {"__data__": {"id_": "70600a73-fa6b-40b3-ae8c-c00996535c0a", "embedding": null, "metadata": {"window": "Now, priority number three , accelerating growth in key areas . \n \n We are excited about the strong demand we are seeing in our at -Home Solutions and OptiFreight\u00ae \nbusinesses, and our recent determination to further invest in and develop these businesses for long -\nterm value creation as part of our portfolio.  \n \n In at-Home Solutions, we continue to focus on enabling and supporting comfortable, home -based \ncare for patients with acute and chronic conditions.  To support the growing demand for home \nhealthcare, we\u2019re investing to expand the capacity of our network, the breadth of our offering, and in \nnew technology to drive operating efficiencies.  We recently announced plans for a new distribution \ncenter to be built in Texas, with increased capacity, advanced automation technology and robotic s \nwithin the facility.  And our previously announced 350,000 sq uare foot facility being built in South \nCarolina is on track to open this calendar year.  \n \n In OptiFreight\u00ae Logistics, we\u2019re continuing to invest in digital tools to enable healthcare supply chain \nleaders to better manage their shipping spend and support the core volume growth in our business. \n", "original_text": "To support the growing demand for home \nhealthcare, we\u2019re investing to expand the capacity of our network, the breadth of our offering, and in \nnew technology to drive operating efficiencies. ", "page_label": "9", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "dd0c036b-c7ea-4c12-b21f-2c88607b8c5c", "node_type": "4", "metadata": {"page_label": "9", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "5d4f5ac995aa0b111e65496903626588b23de8b22bcf9a511a093abb894b19ef", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "fbff49a6-910a-448d-a85a-f02c8e203f8d", "node_type": "1", "metadata": {"window": "We believe our new structure will further enable our Medical Improvement Plan efforts, as we \ncontinue to execute the plan and deliver value for customers.  \n \n Now, priority number three , accelerating growth in key areas . \n \n We are excited about the strong demand we are seeing in our at -Home Solutions and OptiFreight\u00ae \nbusinesses, and our recent determination to further invest in and develop these businesses for long -\nterm value creation as part of our portfolio.  \n \n In at-Home Solutions, we continue to focus on enabling and supporting comfortable, home -based \ncare for patients with acute and chronic conditions.  To support the growing demand for home \nhealthcare, we\u2019re investing to expand the capacity of our network, the breadth of our offering, and in \nnew technology to drive operating efficiencies.  We recently announced plans for a new distribution \ncenter to be built in Texas, with increased capacity, advanced automation technology and robotic s \nwithin the facility.  And our previously announced 350,000 sq uare foot facility being built in South \nCarolina is on track to open this calendar year.  \n \n", "original_text": "In at-Home Solutions, we continue to focus on enabling and supporting comfortable, home -based \ncare for patients with acute and chronic conditions. ", "page_label": "9", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "18f1536aed49f4e27b114874f86f02934a39392bd682c3c94b53f85263945242", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "e3c4e1d9-0abe-423f-a6f2-4bce556e2ea9", "node_type": "1", "metadata": {"window": "We are excited about the strong demand we are seeing in our at -Home Solutions and OptiFreight\u00ae \nbusinesses, and our recent determination to further invest in and develop these businesses for long -\nterm value creation as part of our portfolio.  \n \n In at-Home Solutions, we continue to focus on enabling and supporting comfortable, home -based \ncare for patients with acute and chronic conditions.  To support the growing demand for home \nhealthcare, we\u2019re investing to expand the capacity of our network, the breadth of our offering, and in \nnew technology to drive operating efficiencies.  We recently announced plans for a new distribution \ncenter to be built in Texas, with increased capacity, advanced automation technology and robotic s \nwithin the facility.  And our previously announced 350,000 sq uare foot facility being built in South \nCarolina is on track to open this calendar year.  \n \n In OptiFreight\u00ae Logistics, we\u2019re continuing to invest in digital tools to enable healthcare supply chain \nleaders to better manage their shipping spend and support the core volume growth in our business. \n We\u2019ve launched new offerings to give our customers mo re supply chain visibility, and we are \nreceiving great feedback. ", "original_text": "We recently announced plans for a new distribution \ncenter to be built in Texas, with increased capacity, advanced automation technology and robotic s \nwithin the facility. "}, "hash": "2ebf04d798cb235bc6e1762fd5c2cb89b8a3a4cf94e951ff839b0cb6cbd45464", "class_name": "RelatedNodeInfo"}}, "text": "To support the growing demand for home \nhealthcare, we\u2019re investing to expand the capacity of our network, the breadth of our offering, and in \nnew technology to drive operating efficiencies. ", "start_char_idx": 1252, "end_char_idx": 1444, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "e3c4e1d9-0abe-423f-a6f2-4bce556e2ea9": {"__data__": {"id_": "e3c4e1d9-0abe-423f-a6f2-4bce556e2ea9", "embedding": null, "metadata": {"window": "We are excited about the strong demand we are seeing in our at -Home Solutions and OptiFreight\u00ae \nbusinesses, and our recent determination to further invest in and develop these businesses for long -\nterm value creation as part of our portfolio.  \n \n In at-Home Solutions, we continue to focus on enabling and supporting comfortable, home -based \ncare for patients with acute and chronic conditions.  To support the growing demand for home \nhealthcare, we\u2019re investing to expand the capacity of our network, the breadth of our offering, and in \nnew technology to drive operating efficiencies.  We recently announced plans for a new distribution \ncenter to be built in Texas, with increased capacity, advanced automation technology and robotic s \nwithin the facility.  And our previously announced 350,000 sq uare foot facility being built in South \nCarolina is on track to open this calendar year.  \n \n In OptiFreight\u00ae Logistics, we\u2019re continuing to invest in digital tools to enable healthcare supply chain \nleaders to better manage their shipping spend and support the core volume growth in our business. \n We\u2019ve launched new offerings to give our customers mo re supply chain visibility, and we are \nreceiving great feedback. ", "original_text": "We recently announced plans for a new distribution \ncenter to be built in Texas, with increased capacity, advanced automation technology and robotic s \nwithin the facility. ", "page_label": "9", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "dd0c036b-c7ea-4c12-b21f-2c88607b8c5c", "node_type": "4", "metadata": {"page_label": "9", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "5d4f5ac995aa0b111e65496903626588b23de8b22bcf9a511a093abb894b19ef", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "70600a73-fa6b-40b3-ae8c-c00996535c0a", "node_type": "1", "metadata": {"window": "Now, priority number three , accelerating growth in key areas . \n \n We are excited about the strong demand we are seeing in our at -Home Solutions and OptiFreight\u00ae \nbusinesses, and our recent determination to further invest in and develop these businesses for long -\nterm value creation as part of our portfolio.  \n \n In at-Home Solutions, we continue to focus on enabling and supporting comfortable, home -based \ncare for patients with acute and chronic conditions.  To support the growing demand for home \nhealthcare, we\u2019re investing to expand the capacity of our network, the breadth of our offering, and in \nnew technology to drive operating efficiencies.  We recently announced plans for a new distribution \ncenter to be built in Texas, with increased capacity, advanced automation technology and robotic s \nwithin the facility.  And our previously announced 350,000 sq uare foot facility being built in South \nCarolina is on track to open this calendar year.  \n \n In OptiFreight\u00ae Logistics, we\u2019re continuing to invest in digital tools to enable healthcare supply chain \nleaders to better manage their shipping spend and support the core volume growth in our business. \n", "original_text": "To support the growing demand for home \nhealthcare, we\u2019re investing to expand the capacity of our network, the breadth of our offering, and in \nnew technology to drive operating efficiencies. ", "page_label": "9", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "09ec19e069ecac43c68a8d22dc561af5f422d1b84d24a752b649d68952877e5b", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "2a79b74f-9962-4f38-bc50-7da567f207ee", "node_type": "1", "metadata": {"window": "In at-Home Solutions, we continue to focus on enabling and supporting comfortable, home -based \ncare for patients with acute and chronic conditions.  To support the growing demand for home \nhealthcare, we\u2019re investing to expand the capacity of our network, the breadth of our offering, and in \nnew technology to drive operating efficiencies.  We recently announced plans for a new distribution \ncenter to be built in Texas, with increased capacity, advanced automation technology and robotic s \nwithin the facility.  And our previously announced 350,000 sq uare foot facility being built in South \nCarolina is on track to open this calendar year.  \n \n In OptiFreight\u00ae Logistics, we\u2019re continuing to invest in digital tools to enable healthcare supply chain \nleaders to better manage their shipping spend and support the core volume growth in our business. \n We\u2019ve launched new offerings to give our customers mo re supply chain visibility, and we are \nreceiving great feedback.  For example, we now have more than 1,000 healthcare providers \nleveraging our TotalVue \u2122 Insights platform to gain valuable insights on their operations.   \n \n", "original_text": "And our previously announced 350,000 sq uare foot facility being built in South \nCarolina is on track to open this calendar year.  \n \n"}, "hash": "37d98a254e04f02b0bff7f89037789aba83ab2213d16607d383727a286fde090", "class_name": "RelatedNodeInfo"}}, "text": "We recently announced plans for a new distribution \ncenter to be built in Texas, with increased capacity, advanced automation technology and robotic s \nwithin the facility. ", "start_char_idx": 1444, "end_char_idx": 1617, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "2a79b74f-9962-4f38-bc50-7da567f207ee": {"__data__": {"id_": "2a79b74f-9962-4f38-bc50-7da567f207ee", "embedding": null, "metadata": {"window": "In at-Home Solutions, we continue to focus on enabling and supporting comfortable, home -based \ncare for patients with acute and chronic conditions.  To support the growing demand for home \nhealthcare, we\u2019re investing to expand the capacity of our network, the breadth of our offering, and in \nnew technology to drive operating efficiencies.  We recently announced plans for a new distribution \ncenter to be built in Texas, with increased capacity, advanced automation technology and robotic s \nwithin the facility.  And our previously announced 350,000 sq uare foot facility being built in South \nCarolina is on track to open this calendar year.  \n \n In OptiFreight\u00ae Logistics, we\u2019re continuing to invest in digital tools to enable healthcare supply chain \nleaders to better manage their shipping spend and support the core volume growth in our business. \n We\u2019ve launched new offerings to give our customers mo re supply chain visibility, and we are \nreceiving great feedback.  For example, we now have more than 1,000 healthcare providers \nleveraging our TotalVue \u2122 Insights platform to gain valuable insights on their operations.   \n \n", "original_text": "And our previously announced 350,000 sq uare foot facility being built in South \nCarolina is on track to open this calendar year.  \n \n", "page_label": "9", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "dd0c036b-c7ea-4c12-b21f-2c88607b8c5c", "node_type": "4", "metadata": {"page_label": "9", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "5d4f5ac995aa0b111e65496903626588b23de8b22bcf9a511a093abb894b19ef", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "e3c4e1d9-0abe-423f-a6f2-4bce556e2ea9", "node_type": "1", "metadata": {"window": "We are excited about the strong demand we are seeing in our at -Home Solutions and OptiFreight\u00ae \nbusinesses, and our recent determination to further invest in and develop these businesses for long -\nterm value creation as part of our portfolio.  \n \n In at-Home Solutions, we continue to focus on enabling and supporting comfortable, home -based \ncare for patients with acute and chronic conditions.  To support the growing demand for home \nhealthcare, we\u2019re investing to expand the capacity of our network, the breadth of our offering, and in \nnew technology to drive operating efficiencies.  We recently announced plans for a new distribution \ncenter to be built in Texas, with increased capacity, advanced automation technology and robotic s \nwithin the facility.  And our previously announced 350,000 sq uare foot facility being built in South \nCarolina is on track to open this calendar year.  \n \n In OptiFreight\u00ae Logistics, we\u2019re continuing to invest in digital tools to enable healthcare supply chain \nleaders to better manage their shipping spend and support the core volume growth in our business. \n We\u2019ve launched new offerings to give our customers mo re supply chain visibility, and we are \nreceiving great feedback. ", "original_text": "We recently announced plans for a new distribution \ncenter to be built in Texas, with increased capacity, advanced automation technology and robotic s \nwithin the facility. ", "page_label": "9", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "32fd531b1f67af411ead8f43c47345d548a8770a6a3710731d97d40bd7663b85", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "951bda90-1220-4014-8f81-a3412d4a53aa", "node_type": "1", "metadata": {"window": "To support the growing demand for home \nhealthcare, we\u2019re investing to expand the capacity of our network, the breadth of our offering, and in \nnew technology to drive operating efficiencies.  We recently announced plans for a new distribution \ncenter to be built in Texas, with increased capacity, advanced automation technology and robotic s \nwithin the facility.  And our previously announced 350,000 sq uare foot facility being built in South \nCarolina is on track to open this calendar year.  \n \n In OptiFreight\u00ae Logistics, we\u2019re continuing to invest in digital tools to enable healthcare supply chain \nleaders to better manage their shipping spend and support the core volume growth in our business. \n We\u2019ve launched new offerings to give our customers mo re supply chain visibility, and we are \nreceiving great feedback.  For example, we now have more than 1,000 healthcare providers \nleveraging our TotalVue \u2122 Insights platform to gain valuable insights on their operations.   \n \n In Nuclear and Precision Health Solutions, we\u2019re continuing to see above -market growth in both our \ncore business and theranostics, as we\u2019re a premier partner of choice due to our strong core \nfoundation and differentiation with pharmaceutical manufacturers looking for commercialization \nsuccess of their future radiopharmaceutical portfolios. ", "original_text": "In OptiFreight\u00ae Logistics, we\u2019re continuing to invest in digital tools to enable healthcare supply chain \nleaders to better manage their shipping spend and support the core volume growth in our business. \n"}, "hash": "c4193814f14d2edb1b794cf034e1ca7fd1f9f4791868d63ee80b234fd42fb049", "class_name": "RelatedNodeInfo"}}, "text": "And our previously announced 350,000 sq uare foot facility being built in South \nCarolina is on track to open this calendar year.  \n \n", "start_char_idx": 1617, "end_char_idx": 1751, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "951bda90-1220-4014-8f81-a3412d4a53aa": {"__data__": {"id_": "951bda90-1220-4014-8f81-a3412d4a53aa", "embedding": null, "metadata": {"window": "To support the growing demand for home \nhealthcare, we\u2019re investing to expand the capacity of our network, the breadth of our offering, and in \nnew technology to drive operating efficiencies.  We recently announced plans for a new distribution \ncenter to be built in Texas, with increased capacity, advanced automation technology and robotic s \nwithin the facility.  And our previously announced 350,000 sq uare foot facility being built in South \nCarolina is on track to open this calendar year.  \n \n In OptiFreight\u00ae Logistics, we\u2019re continuing to invest in digital tools to enable healthcare supply chain \nleaders to better manage their shipping spend and support the core volume growth in our business. \n We\u2019ve launched new offerings to give our customers mo re supply chain visibility, and we are \nreceiving great feedback.  For example, we now have more than 1,000 healthcare providers \nleveraging our TotalVue \u2122 Insights platform to gain valuable insights on their operations.   \n \n In Nuclear and Precision Health Solutions, we\u2019re continuing to see above -market growth in both our \ncore business and theranostics, as we\u2019re a premier partner of choice due to our strong core \nfoundation and differentiation with pharmaceutical manufacturers looking for commercialization \nsuccess of their future radiopharmaceutical portfolios. ", "original_text": "In OptiFreight\u00ae Logistics, we\u2019re continuing to invest in digital tools to enable healthcare supply chain \nleaders to better manage their shipping spend and support the core volume growth in our business. \n", "page_label": "9", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "dd0c036b-c7ea-4c12-b21f-2c88607b8c5c", "node_type": "4", "metadata": {"page_label": "9", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "5d4f5ac995aa0b111e65496903626588b23de8b22bcf9a511a093abb894b19ef", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "2a79b74f-9962-4f38-bc50-7da567f207ee", "node_type": "1", "metadata": {"window": "In at-Home Solutions, we continue to focus on enabling and supporting comfortable, home -based \ncare for patients with acute and chronic conditions.  To support the growing demand for home \nhealthcare, we\u2019re investing to expand the capacity of our network, the breadth of our offering, and in \nnew technology to drive operating efficiencies.  We recently announced plans for a new distribution \ncenter to be built in Texas, with increased capacity, advanced automation technology and robotic s \nwithin the facility.  And our previously announced 350,000 sq uare foot facility being built in South \nCarolina is on track to open this calendar year.  \n \n In OptiFreight\u00ae Logistics, we\u2019re continuing to invest in digital tools to enable healthcare supply chain \nleaders to better manage their shipping spend and support the core volume growth in our business. \n We\u2019ve launched new offerings to give our customers mo re supply chain visibility, and we are \nreceiving great feedback.  For example, we now have more than 1,000 healthcare providers \nleveraging our TotalVue \u2122 Insights platform to gain valuable insights on their operations.   \n \n", "original_text": "And our previously announced 350,000 sq uare foot facility being built in South \nCarolina is on track to open this calendar year.  \n \n", "page_label": "9", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "09249753275511519cbf344ab2356f47c1aff88546896d06143580255dc0e51a", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "cc01a675-e4e0-41c8-a5b2-6b3b3b99c275", "node_type": "1", "metadata": {"window": "We recently announced plans for a new distribution \ncenter to be built in Texas, with increased capacity, advanced automation technology and robotic s \nwithin the facility.  And our previously announced 350,000 sq uare foot facility being built in South \nCarolina is on track to open this calendar year.  \n \n In OptiFreight\u00ae Logistics, we\u2019re continuing to invest in digital tools to enable healthcare supply chain \nleaders to better manage their shipping spend and support the core volume growth in our business. \n We\u2019ve launched new offerings to give our customers mo re supply chain visibility, and we are \nreceiving great feedback.  For example, we now have more than 1,000 healthcare providers \nleveraging our TotalVue \u2122 Insights platform to gain valuable insights on their operations.   \n \n In Nuclear and Precision Health Solutions, we\u2019re continuing to see above -market growth in both our \ncore business and theranostics, as we\u2019re a premier partner of choice due to our strong core \nfoundation and differentiation with pharmaceutical manufacturers looking for commercialization \nsuccess of their future radiopharmaceutical portfolios.  For example, in theranostics, prostate cancer \nradiodiagnostics are important tools for healthcare providers to assess and properly treat the disease. \n", "original_text": "We\u2019ve launched new offerings to give our customers mo re supply chain visibility, and we are \nreceiving great feedback. "}, "hash": "d6efee966173773949db6de3415f3b1eaf52c1a6821a797eb2d7c883bc251eeb", "class_name": "RelatedNodeInfo"}}, "text": "In OptiFreight\u00ae Logistics, we\u2019re continuing to invest in digital tools to enable healthcare supply chain \nleaders to better manage their shipping spend and support the core volume growth in our business. \n", "start_char_idx": 1751, "end_char_idx": 1956, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "cc01a675-e4e0-41c8-a5b2-6b3b3b99c275": {"__data__": {"id_": "cc01a675-e4e0-41c8-a5b2-6b3b3b99c275", "embedding": null, "metadata": {"window": "We recently announced plans for a new distribution \ncenter to be built in Texas, with increased capacity, advanced automation technology and robotic s \nwithin the facility.  And our previously announced 350,000 sq uare foot facility being built in South \nCarolina is on track to open this calendar year.  \n \n In OptiFreight\u00ae Logistics, we\u2019re continuing to invest in digital tools to enable healthcare supply chain \nleaders to better manage their shipping spend and support the core volume growth in our business. \n We\u2019ve launched new offerings to give our customers mo re supply chain visibility, and we are \nreceiving great feedback.  For example, we now have more than 1,000 healthcare providers \nleveraging our TotalVue \u2122 Insights platform to gain valuable insights on their operations.   \n \n In Nuclear and Precision Health Solutions, we\u2019re continuing to see above -market growth in both our \ncore business and theranostics, as we\u2019re a premier partner of choice due to our strong core \nfoundation and differentiation with pharmaceutical manufacturers looking for commercialization \nsuccess of their future radiopharmaceutical portfolios.  For example, in theranostics, prostate cancer \nradiodiagnostics are important tools for healthcare providers to assess and properly treat the disease. \n", "original_text": "We\u2019ve launched new offerings to give our customers mo re supply chain visibility, and we are \nreceiving great feedback. ", "page_label": "9", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "dd0c036b-c7ea-4c12-b21f-2c88607b8c5c", "node_type": "4", "metadata": {"page_label": "9", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "5d4f5ac995aa0b111e65496903626588b23de8b22bcf9a511a093abb894b19ef", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "951bda90-1220-4014-8f81-a3412d4a53aa", "node_type": "1", "metadata": {"window": "To support the growing demand for home \nhealthcare, we\u2019re investing to expand the capacity of our network, the breadth of our offering, and in \nnew technology to drive operating efficiencies.  We recently announced plans for a new distribution \ncenter to be built in Texas, with increased capacity, advanced automation technology and robotic s \nwithin the facility.  And our previously announced 350,000 sq uare foot facility being built in South \nCarolina is on track to open this calendar year.  \n \n In OptiFreight\u00ae Logistics, we\u2019re continuing to invest in digital tools to enable healthcare supply chain \nleaders to better manage their shipping spend and support the core volume growth in our business. \n We\u2019ve launched new offerings to give our customers mo re supply chain visibility, and we are \nreceiving great feedback.  For example, we now have more than 1,000 healthcare providers \nleveraging our TotalVue \u2122 Insights platform to gain valuable insights on their operations.   \n \n In Nuclear and Precision Health Solutions, we\u2019re continuing to see above -market growth in both our \ncore business and theranostics, as we\u2019re a premier partner of choice due to our strong core \nfoundation and differentiation with pharmaceutical manufacturers looking for commercialization \nsuccess of their future radiopharmaceutical portfolios. ", "original_text": "In OptiFreight\u00ae Logistics, we\u2019re continuing to invest in digital tools to enable healthcare supply chain \nleaders to better manage their shipping spend and support the core volume growth in our business. \n", "page_label": "9", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "650a2eeaaf422ea5a740ccc13cc16968fcc87ac6de27cbde79812a9f6fcd967f", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "31223a1c-a92c-4967-bff0-460eca6132b7", "node_type": "1", "metadata": {"window": "And our previously announced 350,000 sq uare foot facility being built in South \nCarolina is on track to open this calendar year.  \n \n In OptiFreight\u00ae Logistics, we\u2019re continuing to invest in digital tools to enable healthcare supply chain \nleaders to better manage their shipping spend and support the core volume growth in our business. \n We\u2019ve launched new offerings to give our customers mo re supply chain visibility, and we are \nreceiving great feedback.  For example, we now have more than 1,000 healthcare providers \nleveraging our TotalVue \u2122 Insights platform to gain valuable insights on their operations.   \n \n In Nuclear and Precision Health Solutions, we\u2019re continuing to see above -market growth in both our \ncore business and theranostics, as we\u2019re a premier partner of choice due to our strong core \nfoundation and differentiation with pharmaceutical manufacturers looking for commercialization \nsuccess of their future radiopharmaceutical portfolios.  For example, in theranostics, prostate cancer \nradiodiagnostics are important tools for healthcare providers to assess and properly treat the disease. \n We saw meaningful ye ar-over-year revenue growth in the first half of fiscal \u201824 from the ramp -up in \ndemand of these diagnostics. ", "original_text": "For example, we now have more than 1,000 healthcare providers \nleveraging our TotalVue \u2122 Insights platform to gain valuable insights on their operations.   \n \n"}, "hash": "a7ae7a3770e665be74443da0db6d2d2447304d8b33bb5f944f21c1393f9c020f", "class_name": "RelatedNodeInfo"}}, "text": "We\u2019ve launched new offerings to give our customers mo re supply chain visibility, and we are \nreceiving great feedback. ", "start_char_idx": 1956, "end_char_idx": 2076, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "31223a1c-a92c-4967-bff0-460eca6132b7": {"__data__": {"id_": "31223a1c-a92c-4967-bff0-460eca6132b7", "embedding": null, "metadata": {"window": "And our previously announced 350,000 sq uare foot facility being built in South \nCarolina is on track to open this calendar year.  \n \n In OptiFreight\u00ae Logistics, we\u2019re continuing to invest in digital tools to enable healthcare supply chain \nleaders to better manage their shipping spend and support the core volume growth in our business. \n We\u2019ve launched new offerings to give our customers mo re supply chain visibility, and we are \nreceiving great feedback.  For example, we now have more than 1,000 healthcare providers \nleveraging our TotalVue \u2122 Insights platform to gain valuable insights on their operations.   \n \n In Nuclear and Precision Health Solutions, we\u2019re continuing to see above -market growth in both our \ncore business and theranostics, as we\u2019re a premier partner of choice due to our strong core \nfoundation and differentiation with pharmaceutical manufacturers looking for commercialization \nsuccess of their future radiopharmaceutical portfolios.  For example, in theranostics, prostate cancer \nradiodiagnostics are important tools for healthcare providers to assess and properly treat the disease. \n We saw meaningful ye ar-over-year revenue growth in the first half of fiscal \u201824 from the ramp -up in \ndemand of these diagnostics. ", "original_text": "For example, we now have more than 1,000 healthcare providers \nleveraging our TotalVue \u2122 Insights platform to gain valuable insights on their operations.   \n \n", "page_label": "9", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "dd0c036b-c7ea-4c12-b21f-2c88607b8c5c", "node_type": "4", "metadata": {"page_label": "9", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "5d4f5ac995aa0b111e65496903626588b23de8b22bcf9a511a093abb894b19ef", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "cc01a675-e4e0-41c8-a5b2-6b3b3b99c275", "node_type": "1", "metadata": {"window": "We recently announced plans for a new distribution \ncenter to be built in Texas, with increased capacity, advanced automation technology and robotic s \nwithin the facility.  And our previously announced 350,000 sq uare foot facility being built in South \nCarolina is on track to open this calendar year.  \n \n In OptiFreight\u00ae Logistics, we\u2019re continuing to invest in digital tools to enable healthcare supply chain \nleaders to better manage their shipping spend and support the core volume growth in our business. \n We\u2019ve launched new offerings to give our customers mo re supply chain visibility, and we are \nreceiving great feedback.  For example, we now have more than 1,000 healthcare providers \nleveraging our TotalVue \u2122 Insights platform to gain valuable insights on their operations.   \n \n In Nuclear and Precision Health Solutions, we\u2019re continuing to see above -market growth in both our \ncore business and theranostics, as we\u2019re a premier partner of choice due to our strong core \nfoundation and differentiation with pharmaceutical manufacturers looking for commercialization \nsuccess of their future radiopharmaceutical portfolios.  For example, in theranostics, prostate cancer \nradiodiagnostics are important tools for healthcare providers to assess and properly treat the disease. \n", "original_text": "We\u2019ve launched new offerings to give our customers mo re supply chain visibility, and we are \nreceiving great feedback. ", "page_label": "9", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "0a3b38916f165c1c17e334d9898f1bb5bee9631720fa1d5367d122b609d23b22", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "77180a31-af95-41e7-b5b3-5cd49290594f", "node_type": "1", "metadata": {"window": "In OptiFreight\u00ae Logistics, we\u2019re continuing to invest in digital tools to enable healthcare supply chain \nleaders to better manage their shipping spend and support the core volume growth in our business. \n We\u2019ve launched new offerings to give our customers mo re supply chain visibility, and we are \nreceiving great feedback.  For example, we now have more than 1,000 healthcare providers \nleveraging our TotalVue \u2122 Insights platform to gain valuable insights on their operations.   \n \n In Nuclear and Precision Health Solutions, we\u2019re continuing to see above -market growth in both our \ncore business and theranostics, as we\u2019re a premier partner of choice due to our strong core \nfoundation and differentiation with pharmaceutical manufacturers looking for commercialization \nsuccess of their future radiopharmaceutical portfolios.  For example, in theranostics, prostate cancer \nradiodiagnostics are important tools for healthcare providers to assess and properly treat the disease. \n We saw meaningful ye ar-over-year revenue growth in the first half of fiscal \u201824 from the ramp -up in \ndemand of these diagnostics.  From a pipeline perspective, we\u2019re investing to expand our Center for \nTheranostics Advancement, with demand from pharmaceutical manufacturer partners currently \noversubscribed. ", "original_text": "In Nuclear and Precision Health Solutions, we\u2019re continuing to see above -market growth in both our \ncore business and theranostics, as we\u2019re a premier partner of choice due to our strong core \nfoundation and differentiation with pharmaceutical manufacturers looking for commercialization \nsuccess of their future radiopharmaceutical portfolios. "}, "hash": "b8371fe1e774f7a21ec298034c3be2f9add42e4f0a35d1035b4e82e74830ea5c", "class_name": "RelatedNodeInfo"}}, "text": "For example, we now have more than 1,000 healthcare providers \nleveraging our TotalVue \u2122 Insights platform to gain valuable insights on their operations.   \n \n", "start_char_idx": 2076, "end_char_idx": 2235, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "77180a31-af95-41e7-b5b3-5cd49290594f": {"__data__": {"id_": "77180a31-af95-41e7-b5b3-5cd49290594f", "embedding": null, "metadata": {"window": "In OptiFreight\u00ae Logistics, we\u2019re continuing to invest in digital tools to enable healthcare supply chain \nleaders to better manage their shipping spend and support the core volume growth in our business. \n We\u2019ve launched new offerings to give our customers mo re supply chain visibility, and we are \nreceiving great feedback.  For example, we now have more than 1,000 healthcare providers \nleveraging our TotalVue \u2122 Insights platform to gain valuable insights on their operations.   \n \n In Nuclear and Precision Health Solutions, we\u2019re continuing to see above -market growth in both our \ncore business and theranostics, as we\u2019re a premier partner of choice due to our strong core \nfoundation and differentiation with pharmaceutical manufacturers looking for commercialization \nsuccess of their future radiopharmaceutical portfolios.  For example, in theranostics, prostate cancer \nradiodiagnostics are important tools for healthcare providers to assess and properly treat the disease. \n We saw meaningful ye ar-over-year revenue growth in the first half of fiscal \u201824 from the ramp -up in \ndemand of these diagnostics.  From a pipeline perspective, we\u2019re investing to expand our Center for \nTheranostics Advancement, with demand from pharmaceutical manufacturer partners currently \noversubscribed. ", "original_text": "In Nuclear and Precision Health Solutions, we\u2019re continuing to see above -market growth in both our \ncore business and theranostics, as we\u2019re a premier partner of choice due to our strong core \nfoundation and differentiation with pharmaceutical manufacturers looking for commercialization \nsuccess of their future radiopharmaceutical portfolios. ", "page_label": "9", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "dd0c036b-c7ea-4c12-b21f-2c88607b8c5c", "node_type": "4", "metadata": {"page_label": "9", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "5d4f5ac995aa0b111e65496903626588b23de8b22bcf9a511a093abb894b19ef", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "31223a1c-a92c-4967-bff0-460eca6132b7", "node_type": "1", "metadata": {"window": "And our previously announced 350,000 sq uare foot facility being built in South \nCarolina is on track to open this calendar year.  \n \n In OptiFreight\u00ae Logistics, we\u2019re continuing to invest in digital tools to enable healthcare supply chain \nleaders to better manage their shipping spend and support the core volume growth in our business. \n We\u2019ve launched new offerings to give our customers mo re supply chain visibility, and we are \nreceiving great feedback.  For example, we now have more than 1,000 healthcare providers \nleveraging our TotalVue \u2122 Insights platform to gain valuable insights on their operations.   \n \n In Nuclear and Precision Health Solutions, we\u2019re continuing to see above -market growth in both our \ncore business and theranostics, as we\u2019re a premier partner of choice due to our strong core \nfoundation and differentiation with pharmaceutical manufacturers looking for commercialization \nsuccess of their future radiopharmaceutical portfolios.  For example, in theranostics, prostate cancer \nradiodiagnostics are important tools for healthcare providers to assess and properly treat the disease. \n We saw meaningful ye ar-over-year revenue growth in the first half of fiscal \u201824 from the ramp -up in \ndemand of these diagnostics. ", "original_text": "For example, we now have more than 1,000 healthcare providers \nleveraging our TotalVue \u2122 Insights platform to gain valuable insights on their operations.   \n \n", "page_label": "9", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "774689fe49a49c682a745830c8c123ffa30f33fa832293bc460485334879c941", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "69c10b64-a513-48d0-886b-9224b26b8499", "node_type": "1", "metadata": {"window": "We\u2019ve launched new offerings to give our customers mo re supply chain visibility, and we are \nreceiving great feedback.  For example, we now have more than 1,000 healthcare providers \nleveraging our TotalVue \u2122 Insights platform to gain valuable insights on their operations.   \n \n In Nuclear and Precision Health Solutions, we\u2019re continuing to see above -market growth in both our \ncore business and theranostics, as we\u2019re a premier partner of choice due to our strong core \nfoundation and differentiation with pharmaceutical manufacturers looking for commercialization \nsuccess of their future radiopharmaceutical portfolios.  For example, in theranostics, prostate cancer \nradiodiagnostics are important tools for healthcare providers to assess and properly treat the disease. \n We saw meaningful ye ar-over-year revenue growth in the first half of fiscal \u201824 from the ramp -up in \ndemand of these diagnostics.  From a pipeline perspective, we\u2019re investing to expand our Center for \nTheranostics Advancement, with demand from pharmaceutical manufacturer partners currently \noversubscribed.  And we\u2019re investing to expan d the capabilities and resiliency of our PET \nmanufacturing network to enable portfolio diversification and accommodate growth from the \nincreasing demand for PET agents. ", "original_text": "For example, in theranostics, prostate cancer \nradiodiagnostics are important tools for healthcare providers to assess and properly treat the disease. \n"}, "hash": "1b5cec0dad5d971bda69b881c143ca7668bb43e19ff9fe9bc0280d1fb07b2234", "class_name": "RelatedNodeInfo"}}, "text": "In Nuclear and Precision Health Solutions, we\u2019re continuing to see above -market growth in both our \ncore business and theranostics, as we\u2019re a premier partner of choice due to our strong core \nfoundation and differentiation with pharmaceutical manufacturers looking for commercialization \nsuccess of their future radiopharmaceutical portfolios. ", "start_char_idx": 2235, "end_char_idx": 2581, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "69c10b64-a513-48d0-886b-9224b26b8499": {"__data__": {"id_": "69c10b64-a513-48d0-886b-9224b26b8499", "embedding": null, "metadata": {"window": "We\u2019ve launched new offerings to give our customers mo re supply chain visibility, and we are \nreceiving great feedback.  For example, we now have more than 1,000 healthcare providers \nleveraging our TotalVue \u2122 Insights platform to gain valuable insights on their operations.   \n \n In Nuclear and Precision Health Solutions, we\u2019re continuing to see above -market growth in both our \ncore business and theranostics, as we\u2019re a premier partner of choice due to our strong core \nfoundation and differentiation with pharmaceutical manufacturers looking for commercialization \nsuccess of their future radiopharmaceutical portfolios.  For example, in theranostics, prostate cancer \nradiodiagnostics are important tools for healthcare providers to assess and properly treat the disease. \n We saw meaningful ye ar-over-year revenue growth in the first half of fiscal \u201824 from the ramp -up in \ndemand of these diagnostics.  From a pipeline perspective, we\u2019re investing to expand our Center for \nTheranostics Advancement, with demand from pharmaceutical manufacturer partners currently \noversubscribed.  And we\u2019re investing to expan d the capabilities and resiliency of our PET \nmanufacturing network to enable portfolio diversification and accommodate growth from the \nincreasing demand for PET agents. ", "original_text": "For example, in theranostics, prostate cancer \nradiodiagnostics are important tools for healthcare providers to assess and properly treat the disease. \n", "page_label": "9", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "dd0c036b-c7ea-4c12-b21f-2c88607b8c5c", "node_type": "4", "metadata": {"page_label": "9", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "5d4f5ac995aa0b111e65496903626588b23de8b22bcf9a511a093abb894b19ef", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "77180a31-af95-41e7-b5b3-5cd49290594f", "node_type": "1", "metadata": {"window": "In OptiFreight\u00ae Logistics, we\u2019re continuing to invest in digital tools to enable healthcare supply chain \nleaders to better manage their shipping spend and support the core volume growth in our business. \n We\u2019ve launched new offerings to give our customers mo re supply chain visibility, and we are \nreceiving great feedback.  For example, we now have more than 1,000 healthcare providers \nleveraging our TotalVue \u2122 Insights platform to gain valuable insights on their operations.   \n \n In Nuclear and Precision Health Solutions, we\u2019re continuing to see above -market growth in both our \ncore business and theranostics, as we\u2019re a premier partner of choice due to our strong core \nfoundation and differentiation with pharmaceutical manufacturers looking for commercialization \nsuccess of their future radiopharmaceutical portfolios.  For example, in theranostics, prostate cancer \nradiodiagnostics are important tools for healthcare providers to assess and properly treat the disease. \n We saw meaningful ye ar-over-year revenue growth in the first half of fiscal \u201824 from the ramp -up in \ndemand of these diagnostics.  From a pipeline perspective, we\u2019re investing to expand our Center for \nTheranostics Advancement, with demand from pharmaceutical manufacturer partners currently \noversubscribed. ", "original_text": "In Nuclear and Precision Health Solutions, we\u2019re continuing to see above -market growth in both our \ncore business and theranostics, as we\u2019re a premier partner of choice due to our strong core \nfoundation and differentiation with pharmaceutical manufacturers looking for commercialization \nsuccess of their future radiopharmaceutical portfolios. ", "page_label": "9", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "0bd50164cb540c5d7d5c789a7c73f1c872963ab982a688c903e4e51ffb961714", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "c6f577c9-834a-4a47-9a77-4edd826aa38a", "node_type": "1", "metadata": {"window": "For example, we now have more than 1,000 healthcare providers \nleveraging our TotalVue \u2122 Insights platform to gain valuable insights on their operations.   \n \n In Nuclear and Precision Health Solutions, we\u2019re continuing to see above -market growth in both our \ncore business and theranostics, as we\u2019re a premier partner of choice due to our strong core \nfoundation and differentiation with pharmaceutical manufacturers looking for commercialization \nsuccess of their future radiopharmaceutical portfolios.  For example, in theranostics, prostate cancer \nradiodiagnostics are important tools for healthcare providers to assess and properly treat the disease. \n We saw meaningful ye ar-over-year revenue growth in the first half of fiscal \u201824 from the ramp -up in \ndemand of these diagnostics.  From a pipeline perspective, we\u2019re investing to expand our Center for \nTheranostics Advancement, with demand from pharmaceutical manufacturer partners currently \noversubscribed.  And we\u2019re investing to expan d the capabilities and resiliency of our PET \nmanufacturing network to enable portfolio diversification and accommodate growth from the \nincreasing demand for PET agents.  This is driven by trends such as an aging population, cancer ", "original_text": "We saw meaningful ye ar-over-year revenue growth in the first half of fiscal \u201824 from the ramp -up in \ndemand of these diagnostics. "}, "hash": "9021c52c782f3751dfcebe70211ad32858ae9fb24ffcf02b3c095f358d454c72", "class_name": "RelatedNodeInfo"}}, "text": "For example, in theranostics, prostate cancer \nradiodiagnostics are important tools for healthcare providers to assess and properly treat the disease. \n", "start_char_idx": 2581, "end_char_idx": 2733, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "c6f577c9-834a-4a47-9a77-4edd826aa38a": {"__data__": {"id_": "c6f577c9-834a-4a47-9a77-4edd826aa38a", "embedding": null, "metadata": {"window": "For example, we now have more than 1,000 healthcare providers \nleveraging our TotalVue \u2122 Insights platform to gain valuable insights on their operations.   \n \n In Nuclear and Precision Health Solutions, we\u2019re continuing to see above -market growth in both our \ncore business and theranostics, as we\u2019re a premier partner of choice due to our strong core \nfoundation and differentiation with pharmaceutical manufacturers looking for commercialization \nsuccess of their future radiopharmaceutical portfolios.  For example, in theranostics, prostate cancer \nradiodiagnostics are important tools for healthcare providers to assess and properly treat the disease. \n We saw meaningful ye ar-over-year revenue growth in the first half of fiscal \u201824 from the ramp -up in \ndemand of these diagnostics.  From a pipeline perspective, we\u2019re investing to expand our Center for \nTheranostics Advancement, with demand from pharmaceutical manufacturer partners currently \noversubscribed.  And we\u2019re investing to expan d the capabilities and resiliency of our PET \nmanufacturing network to enable portfolio diversification and accommodate growth from the \nincreasing demand for PET agents.  This is driven by trends such as an aging population, cancer ", "original_text": "We saw meaningful ye ar-over-year revenue growth in the first half of fiscal \u201824 from the ramp -up in \ndemand of these diagnostics. ", "page_label": "9", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "dd0c036b-c7ea-4c12-b21f-2c88607b8c5c", "node_type": "4", "metadata": {"page_label": "9", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "5d4f5ac995aa0b111e65496903626588b23de8b22bcf9a511a093abb894b19ef", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "69c10b64-a513-48d0-886b-9224b26b8499", "node_type": "1", "metadata": {"window": "We\u2019ve launched new offerings to give our customers mo re supply chain visibility, and we are \nreceiving great feedback.  For example, we now have more than 1,000 healthcare providers \nleveraging our TotalVue \u2122 Insights platform to gain valuable insights on their operations.   \n \n In Nuclear and Precision Health Solutions, we\u2019re continuing to see above -market growth in both our \ncore business and theranostics, as we\u2019re a premier partner of choice due to our strong core \nfoundation and differentiation with pharmaceutical manufacturers looking for commercialization \nsuccess of their future radiopharmaceutical portfolios.  For example, in theranostics, prostate cancer \nradiodiagnostics are important tools for healthcare providers to assess and properly treat the disease. \n We saw meaningful ye ar-over-year revenue growth in the first half of fiscal \u201824 from the ramp -up in \ndemand of these diagnostics.  From a pipeline perspective, we\u2019re investing to expand our Center for \nTheranostics Advancement, with demand from pharmaceutical manufacturer partners currently \noversubscribed.  And we\u2019re investing to expan d the capabilities and resiliency of our PET \nmanufacturing network to enable portfolio diversification and accommodate growth from the \nincreasing demand for PET agents. ", "original_text": "For example, in theranostics, prostate cancer \nradiodiagnostics are important tools for healthcare providers to assess and properly treat the disease. \n", "page_label": "9", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "255f3f9f4b95a92a03a78bff415a3995387498bfc9cad9649a3a483885be8e4e", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "b1e4b3b3-3aaa-4055-89c1-aa346bfc7db7", "node_type": "1", "metadata": {"window": "In Nuclear and Precision Health Solutions, we\u2019re continuing to see above -market growth in both our \ncore business and theranostics, as we\u2019re a premier partner of choice due to our strong core \nfoundation and differentiation with pharmaceutical manufacturers looking for commercialization \nsuccess of their future radiopharmaceutical portfolios.  For example, in theranostics, prostate cancer \nradiodiagnostics are important tools for healthcare providers to assess and properly treat the disease. \n We saw meaningful ye ar-over-year revenue growth in the first half of fiscal \u201824 from the ramp -up in \ndemand of these diagnostics.  From a pipeline perspective, we\u2019re investing to expand our Center for \nTheranostics Advancement, with demand from pharmaceutical manufacturer partners currently \noversubscribed.  And we\u2019re investing to expan d the capabilities and resiliency of our PET \nmanufacturing network to enable portfolio diversification and accommodate growth from the \nincreasing demand for PET agents.  This is driven by trends such as an aging population, cancer ", "original_text": "From a pipeline perspective, we\u2019re investing to expand our Center for \nTheranostics Advancement, with demand from pharmaceutical manufacturer partners currently \noversubscribed. "}, "hash": "e468a6b388b66cb17d7fba3214c391d66968ca932e74b32b5bd1ca069ae176f0", "class_name": "RelatedNodeInfo"}}, "text": "We saw meaningful ye ar-over-year revenue growth in the first half of fiscal \u201824 from the ramp -up in \ndemand of these diagnostics. ", "start_char_idx": 2733, "end_char_idx": 2865, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "b1e4b3b3-3aaa-4055-89c1-aa346bfc7db7": {"__data__": {"id_": "b1e4b3b3-3aaa-4055-89c1-aa346bfc7db7", "embedding": null, "metadata": {"window": "In Nuclear and Precision Health Solutions, we\u2019re continuing to see above -market growth in both our \ncore business and theranostics, as we\u2019re a premier partner of choice due to our strong core \nfoundation and differentiation with pharmaceutical manufacturers looking for commercialization \nsuccess of their future radiopharmaceutical portfolios.  For example, in theranostics, prostate cancer \nradiodiagnostics are important tools for healthcare providers to assess and properly treat the disease. \n We saw meaningful ye ar-over-year revenue growth in the first half of fiscal \u201824 from the ramp -up in \ndemand of these diagnostics.  From a pipeline perspective, we\u2019re investing to expand our Center for \nTheranostics Advancement, with demand from pharmaceutical manufacturer partners currently \noversubscribed.  And we\u2019re investing to expan d the capabilities and resiliency of our PET \nmanufacturing network to enable portfolio diversification and accommodate growth from the \nincreasing demand for PET agents.  This is driven by trends such as an aging population, cancer ", "original_text": "From a pipeline perspective, we\u2019re investing to expand our Center for \nTheranostics Advancement, with demand from pharmaceutical manufacturer partners currently \noversubscribed. ", "page_label": "9", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "dd0c036b-c7ea-4c12-b21f-2c88607b8c5c", "node_type": "4", "metadata": {"page_label": "9", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "5d4f5ac995aa0b111e65496903626588b23de8b22bcf9a511a093abb894b19ef", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "c6f577c9-834a-4a47-9a77-4edd826aa38a", "node_type": "1", "metadata": {"window": "For example, we now have more than 1,000 healthcare providers \nleveraging our TotalVue \u2122 Insights platform to gain valuable insights on their operations.   \n \n In Nuclear and Precision Health Solutions, we\u2019re continuing to see above -market growth in both our \ncore business and theranostics, as we\u2019re a premier partner of choice due to our strong core \nfoundation and differentiation with pharmaceutical manufacturers looking for commercialization \nsuccess of their future radiopharmaceutical portfolios.  For example, in theranostics, prostate cancer \nradiodiagnostics are important tools for healthcare providers to assess and properly treat the disease. \n We saw meaningful ye ar-over-year revenue growth in the first half of fiscal \u201824 from the ramp -up in \ndemand of these diagnostics.  From a pipeline perspective, we\u2019re investing to expand our Center for \nTheranostics Advancement, with demand from pharmaceutical manufacturer partners currently \noversubscribed.  And we\u2019re investing to expan d the capabilities and resiliency of our PET \nmanufacturing network to enable portfolio diversification and accommodate growth from the \nincreasing demand for PET agents.  This is driven by trends such as an aging population, cancer ", "original_text": "We saw meaningful ye ar-over-year revenue growth in the first half of fiscal \u201824 from the ramp -up in \ndemand of these diagnostics. ", "page_label": "9", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "d608faf7e5e1adcdefd2fe5ebde4909ab84f9f5ae85a26ef5077cbed49416527", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "cee6f8f3-e90f-4ee9-bd47-b2dcca2dc6c2", "node_type": "1", "metadata": {"window": "For example, in theranostics, prostate cancer \nradiodiagnostics are important tools for healthcare providers to assess and properly treat the disease. \n We saw meaningful ye ar-over-year revenue growth in the first half of fiscal \u201824 from the ramp -up in \ndemand of these diagnostics.  From a pipeline perspective, we\u2019re investing to expand our Center for \nTheranostics Advancement, with demand from pharmaceutical manufacturer partners currently \noversubscribed.  And we\u2019re investing to expan d the capabilities and resiliency of our PET \nmanufacturing network to enable portfolio diversification and accommodate growth from the \nincreasing demand for PET agents.  This is driven by trends such as an aging population, cancer ", "original_text": "And we\u2019re investing to expan d the capabilities and resiliency of our PET \nmanufacturing network to enable portfolio diversification and accommodate growth from the \nincreasing demand for PET agents. "}, "hash": "88d2b06c573a4ff7e427bf16f367dbea5f3c5d88ba5199f7ab3360ffcc93f947", "class_name": "RelatedNodeInfo"}}, "text": "From a pipeline perspective, we\u2019re investing to expand our Center for \nTheranostics Advancement, with demand from pharmaceutical manufacturer partners currently \noversubscribed. ", "start_char_idx": 2865, "end_char_idx": 3043, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "cee6f8f3-e90f-4ee9-bd47-b2dcca2dc6c2": {"__data__": {"id_": "cee6f8f3-e90f-4ee9-bd47-b2dcca2dc6c2", "embedding": null, "metadata": {"window": "For example, in theranostics, prostate cancer \nradiodiagnostics are important tools for healthcare providers to assess and properly treat the disease. \n We saw meaningful ye ar-over-year revenue growth in the first half of fiscal \u201824 from the ramp -up in \ndemand of these diagnostics.  From a pipeline perspective, we\u2019re investing to expand our Center for \nTheranostics Advancement, with demand from pharmaceutical manufacturer partners currently \noversubscribed.  And we\u2019re investing to expan d the capabilities and resiliency of our PET \nmanufacturing network to enable portfolio diversification and accommodate growth from the \nincreasing demand for PET agents.  This is driven by trends such as an aging population, cancer ", "original_text": "And we\u2019re investing to expan d the capabilities and resiliency of our PET \nmanufacturing network to enable portfolio diversification and accommodate growth from the \nincreasing demand for PET agents. ", "page_label": "9", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "dd0c036b-c7ea-4c12-b21f-2c88607b8c5c", "node_type": "4", "metadata": {"page_label": "9", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "5d4f5ac995aa0b111e65496903626588b23de8b22bcf9a511a093abb894b19ef", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "b1e4b3b3-3aaa-4055-89c1-aa346bfc7db7", "node_type": "1", "metadata": {"window": "In Nuclear and Precision Health Solutions, we\u2019re continuing to see above -market growth in both our \ncore business and theranostics, as we\u2019re a premier partner of choice due to our strong core \nfoundation and differentiation with pharmaceutical manufacturers looking for commercialization \nsuccess of their future radiopharmaceutical portfolios.  For example, in theranostics, prostate cancer \nradiodiagnostics are important tools for healthcare providers to assess and properly treat the disease. \n We saw meaningful ye ar-over-year revenue growth in the first half of fiscal \u201824 from the ramp -up in \ndemand of these diagnostics.  From a pipeline perspective, we\u2019re investing to expand our Center for \nTheranostics Advancement, with demand from pharmaceutical manufacturer partners currently \noversubscribed.  And we\u2019re investing to expan d the capabilities and resiliency of our PET \nmanufacturing network to enable portfolio diversification and accommodate growth from the \nincreasing demand for PET agents.  This is driven by trends such as an aging population, cancer ", "original_text": "From a pipeline perspective, we\u2019re investing to expand our Center for \nTheranostics Advancement, with demand from pharmaceutical manufacturer partners currently \noversubscribed. ", "page_label": "9", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "7cde88442d1251de4d35a1c0211e38c28ca91cc8c0fb21ade602da19f5ac856e", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "c0bfa657-e3c6-4f06-9052-a0603618d961", "node_type": "1", "metadata": {"window": "We saw meaningful ye ar-over-year revenue growth in the first half of fiscal \u201824 from the ramp -up in \ndemand of these diagnostics.  From a pipeline perspective, we\u2019re investing to expand our Center for \nTheranostics Advancement, with demand from pharmaceutical manufacturer partners currently \noversubscribed.  And we\u2019re investing to expan d the capabilities and resiliency of our PET \nmanufacturing network to enable portfolio diversification and accommodate growth from the \nincreasing demand for PET agents.  This is driven by trends such as an aging population, cancer ", "original_text": "This is driven by trends such as an aging population, cancer "}, "hash": "a23549013098e22a87150e58a1e5bad1b1db7f4f528297ca08a6aed7b294be92", "class_name": "RelatedNodeInfo"}}, "text": "And we\u2019re investing to expan d the capabilities and resiliency of our PET \nmanufacturing network to enable portfolio diversification and accommodate growth from the \nincreasing demand for PET agents. ", "start_char_idx": 3043, "end_char_idx": 3243, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "c0bfa657-e3c6-4f06-9052-a0603618d961": {"__data__": {"id_": "c0bfa657-e3c6-4f06-9052-a0603618d961", "embedding": null, "metadata": {"window": "We saw meaningful ye ar-over-year revenue growth in the first half of fiscal \u201824 from the ramp -up in \ndemand of these diagnostics.  From a pipeline perspective, we\u2019re investing to expand our Center for \nTheranostics Advancement, with demand from pharmaceutical manufacturer partners currently \noversubscribed.  And we\u2019re investing to expan d the capabilities and resiliency of our PET \nmanufacturing network to enable portfolio diversification and accommodate growth from the \nincreasing demand for PET agents.  This is driven by trends such as an aging population, cancer ", "original_text": "This is driven by trends such as an aging population, cancer ", "page_label": "9", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "dd0c036b-c7ea-4c12-b21f-2c88607b8c5c", "node_type": "4", "metadata": {"page_label": "9", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "5d4f5ac995aa0b111e65496903626588b23de8b22bcf9a511a093abb894b19ef", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "cee6f8f3-e90f-4ee9-bd47-b2dcca2dc6c2", "node_type": "1", "metadata": {"window": "For example, in theranostics, prostate cancer \nradiodiagnostics are important tools for healthcare providers to assess and properly treat the disease. \n We saw meaningful ye ar-over-year revenue growth in the first half of fiscal \u201824 from the ramp -up in \ndemand of these diagnostics.  From a pipeline perspective, we\u2019re investing to expand our Center for \nTheranostics Advancement, with demand from pharmaceutical manufacturer partners currently \noversubscribed.  And we\u2019re investing to expan d the capabilities and resiliency of our PET \nmanufacturing network to enable portfolio diversification and accommodate growth from the \nincreasing demand for PET agents.  This is driven by trends such as an aging population, cancer ", "original_text": "And we\u2019re investing to expan d the capabilities and resiliency of our PET \nmanufacturing network to enable portfolio diversification and accommodate growth from the \nincreasing demand for PET agents. ", "page_label": "9", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "5895ee01e72afa798f2c43af820ae1d85bb9159b74b99a123bbe68ec3837f78e", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "3aed3ca6-89b2-46ee-923d-6c9579add71d", "node_type": "1", "metadata": {"window": " \nPage 10 of 19 \n \nprevalence, emerging Alzheimer\u2019s therapy availability and reimbursement, and increasing clinical trial \nneeds.  \n \n Finally, priority number four , maximizing shareholder value creation . \n \n We\u2019re continuing to maximize shareholder value creation through our improved operational \nperformance, robust cash flow and responsible allocation of capital.  \n   \n As Aaron noted, our robust cash flow generation is not only driving benefits below the operating line, \nit is enabling our opportunistic capital deployment , with additional share repurchases in the quarter \nbeyond our baseline plan and our ability to pursue value -creating M&A in Specialty.   \n \n", "original_text": " \nPage 10 of 19 \n \nprevalence, emerging Alzheimer\u2019s therapy availability and reimbursement, and increasing clinical trial \nneeds.  \n \n"}, "hash": "8917107b59ac102dd5d4d8e26a61bfe8797ced0bb7e63b2a0df6a7045d57bc09", "class_name": "RelatedNodeInfo"}}, "text": "This is driven by trends such as an aging population, cancer ", "start_char_idx": 3243, "end_char_idx": 3304, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "3aed3ca6-89b2-46ee-923d-6c9579add71d": {"__data__": {"id_": "3aed3ca6-89b2-46ee-923d-6c9579add71d", "embedding": null, "metadata": {"window": " \nPage 10 of 19 \n \nprevalence, emerging Alzheimer\u2019s therapy availability and reimbursement, and increasing clinical trial \nneeds.  \n \n Finally, priority number four , maximizing shareholder value creation . \n \n We\u2019re continuing to maximize shareholder value creation through our improved operational \nperformance, robust cash flow and responsible allocation of capital.  \n   \n As Aaron noted, our robust cash flow generation is not only driving benefits below the operating line, \nit is enabling our opportunistic capital deployment , with additional share repurchases in the quarter \nbeyond our baseline plan and our ability to pursue value -creating M&A in Specialty.   \n \n", "original_text": " \nPage 10 of 19 \n \nprevalence, emerging Alzheimer\u2019s therapy availability and reimbursement, and increasing clinical trial \nneeds.  \n \n", "page_label": "10", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "0be51136-ae11-430d-b0c4-8d03b6d16d4c", "node_type": "4", "metadata": {"page_label": "10", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "e4d3538a4609d0f51019a25623c590d5938685f2ab449c6d5fc681dad0fd35b4", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "c0bfa657-e3c6-4f06-9052-a0603618d961", "node_type": "1", "metadata": {"window": "We saw meaningful ye ar-over-year revenue growth in the first half of fiscal \u201824 from the ramp -up in \ndemand of these diagnostics.  From a pipeline perspective, we\u2019re investing to expand our Center for \nTheranostics Advancement, with demand from pharmaceutical manufacturer partners currently \noversubscribed.  And we\u2019re investing to expan d the capabilities and resiliency of our PET \nmanufacturing network to enable portfolio diversification and accommodate growth from the \nincreasing demand for PET agents.  This is driven by trends such as an aging population, cancer ", "original_text": "This is driven by trends such as an aging population, cancer ", "page_label": "9", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "a53bd68646b287458f8d2cd370b410fa2dca01d3bfeb8d34da01f8d5f0d59a7f", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "35182a77-950e-40b7-a41c-1143adcc3c0e", "node_type": "1", "metadata": {"window": " \nPage 10 of 19 \n \nprevalence, emerging Alzheimer\u2019s therapy availability and reimbursement, and increasing clinical trial \nneeds.  \n \n Finally, priority number four , maximizing shareholder value creation . \n \n We\u2019re continuing to maximize shareholder value creation through our improved operational \nperformance, robust cash flow and responsible allocation of capital.  \n   \n As Aaron noted, our robust cash flow generation is not only driving benefits below the operating line, \nit is enabling our opportunistic capital deployment , with additional share repurchases in the quarter \nbeyond our baseline plan and our ability to pursue value -creating M&A in Specialty.   \n \n We remain well-positioned with the financial flexibility to continue opportunistically evaluating \ndisciplined M&A not only in Specialty but in our other growth areas, and potential additional share \nrepurchases.  \n \n", "original_text": "Finally, priority number four , maximizing shareholder value creation . \n \n"}, "hash": "3c0ed5008059dc4f7e2a76799a9fabd58153e9ef23749fc01abfbb404136fa24", "class_name": "RelatedNodeInfo"}}, "text": " \nPage 10 of 19 \n \nprevalence, emerging Alzheimer\u2019s therapy availability and reimbursement, and increasing clinical trial \nneeds.  \n \n", "start_char_idx": 0, "end_char_idx": 134, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "35182a77-950e-40b7-a41c-1143adcc3c0e": {"__data__": {"id_": "35182a77-950e-40b7-a41c-1143adcc3c0e", "embedding": null, "metadata": {"window": " \nPage 10 of 19 \n \nprevalence, emerging Alzheimer\u2019s therapy availability and reimbursement, and increasing clinical trial \nneeds.  \n \n Finally, priority number four , maximizing shareholder value creation . \n \n We\u2019re continuing to maximize shareholder value creation through our improved operational \nperformance, robust cash flow and responsible allocation of capital.  \n   \n As Aaron noted, our robust cash flow generation is not only driving benefits below the operating line, \nit is enabling our opportunistic capital deployment , with additional share repurchases in the quarter \nbeyond our baseline plan and our ability to pursue value -creating M&A in Specialty.   \n \n We remain well-positioned with the financial flexibility to continue opportunistically evaluating \ndisciplined M&A not only in Specialty but in our other growth areas, and potential additional share \nrepurchases.  \n \n", "original_text": "Finally, priority number four , maximizing shareholder value creation . \n \n", "page_label": "10", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "0be51136-ae11-430d-b0c4-8d03b6d16d4c", "node_type": "4", "metadata": {"page_label": "10", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "e4d3538a4609d0f51019a25623c590d5938685f2ab449c6d5fc681dad0fd35b4", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "3aed3ca6-89b2-46ee-923d-6c9579add71d", "node_type": "1", "metadata": {"window": " \nPage 10 of 19 \n \nprevalence, emerging Alzheimer\u2019s therapy availability and reimbursement, and increasing clinical trial \nneeds.  \n \n Finally, priority number four , maximizing shareholder value creation . \n \n We\u2019re continuing to maximize shareholder value creation through our improved operational \nperformance, robust cash flow and responsible allocation of capital.  \n   \n As Aaron noted, our robust cash flow generation is not only driving benefits below the operating line, \nit is enabling our opportunistic capital deployment , with additional share repurchases in the quarter \nbeyond our baseline plan and our ability to pursue value -creating M&A in Specialty.   \n \n", "original_text": " \nPage 10 of 19 \n \nprevalence, emerging Alzheimer\u2019s therapy availability and reimbursement, and increasing clinical trial \nneeds.  \n \n", "page_label": "10", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "dce149408e7caa373e9f062d6b5f770ec896280f4766b29c2ca93a1321afb7ed", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "d03b695a-7b1a-48db-88cc-b7c26078cbcd", "node_type": "1", "metadata": {"window": " \nPage 10 of 19 \n \nprevalence, emerging Alzheimer\u2019s therapy availability and reimbursement, and increasing clinical trial \nneeds.  \n \n Finally, priority number four , maximizing shareholder value creation . \n \n We\u2019re continuing to maximize shareholder value creation through our improved operational \nperformance, robust cash flow and responsible allocation of capital.  \n   \n As Aaron noted, our robust cash flow generation is not only driving benefits below the operating line, \nit is enabling our opportunistic capital deployment , with additional share repurchases in the quarter \nbeyond our baseline plan and our ability to pursue value -creating M&A in Specialty.   \n \n We remain well-positioned with the financial flexibility to continue opportunistically evaluating \ndisciplined M&A not only in Specialty but in our other growth areas, and potential additional share \nrepurchases.  \n \n With our recent conclusions on our business and portfolio review, we do not have further updates to \nshare today, but plan to keep you apprised of our progress.  \n \n", "original_text": "We\u2019re continuing to maximize shareholder value creation through our improved operational \nperformance, robust cash flow and responsible allocation of capital.  \n   \n"}, "hash": "5de2f08290ec5f93857930aa70e2f82cb23bc47cb3aa14162f17f460b764daa1", "class_name": "RelatedNodeInfo"}}, "text": "Finally, priority number four , maximizing shareholder value creation . \n \n", "start_char_idx": 134, "end_char_idx": 209, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "d03b695a-7b1a-48db-88cc-b7c26078cbcd": {"__data__": {"id_": "d03b695a-7b1a-48db-88cc-b7c26078cbcd", "embedding": null, "metadata": {"window": " \nPage 10 of 19 \n \nprevalence, emerging Alzheimer\u2019s therapy availability and reimbursement, and increasing clinical trial \nneeds.  \n \n Finally, priority number four , maximizing shareholder value creation . \n \n We\u2019re continuing to maximize shareholder value creation through our improved operational \nperformance, robust cash flow and responsible allocation of capital.  \n   \n As Aaron noted, our robust cash flow generation is not only driving benefits below the operating line, \nit is enabling our opportunistic capital deployment , with additional share repurchases in the quarter \nbeyond our baseline plan and our ability to pursue value -creating M&A in Specialty.   \n \n We remain well-positioned with the financial flexibility to continue opportunistically evaluating \ndisciplined M&A not only in Specialty but in our other growth areas, and potential additional share \nrepurchases.  \n \n With our recent conclusions on our business and portfolio review, we do not have further updates to \nshare today, but plan to keep you apprised of our progress.  \n \n", "original_text": "We\u2019re continuing to maximize shareholder value creation through our improved operational \nperformance, robust cash flow and responsible allocation of capital.  \n   \n", "page_label": "10", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "0be51136-ae11-430d-b0c4-8d03b6d16d4c", "node_type": "4", "metadata": {"page_label": "10", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "e4d3538a4609d0f51019a25623c590d5938685f2ab449c6d5fc681dad0fd35b4", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "35182a77-950e-40b7-a41c-1143adcc3c0e", "node_type": "1", "metadata": {"window": " \nPage 10 of 19 \n \nprevalence, emerging Alzheimer\u2019s therapy availability and reimbursement, and increasing clinical trial \nneeds.  \n \n Finally, priority number four , maximizing shareholder value creation . \n \n We\u2019re continuing to maximize shareholder value creation through our improved operational \nperformance, robust cash flow and responsible allocation of capital.  \n   \n As Aaron noted, our robust cash flow generation is not only driving benefits below the operating line, \nit is enabling our opportunistic capital deployment , with additional share repurchases in the quarter \nbeyond our baseline plan and our ability to pursue value -creating M&A in Specialty.   \n \n We remain well-positioned with the financial flexibility to continue opportunistically evaluating \ndisciplined M&A not only in Specialty but in our other growth areas, and potential additional share \nrepurchases.  \n \n", "original_text": "Finally, priority number four , maximizing shareholder value creation . \n \n", "page_label": "10", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "0a360f7b3c7cc1740dccffafbe754ed2cea1929eafa98fd22e8d0ff1926c8fa8", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "f0476995-35cc-4a40-b7ea-6891e8a891bd", "node_type": "1", "metadata": {"window": " \nPage 10 of 19 \n \nprevalence, emerging Alzheimer\u2019s therapy availability and reimbursement, and increasing clinical trial \nneeds.  \n \n Finally, priority number four , maximizing shareholder value creation . \n \n We\u2019re continuing to maximize shareholder value creation through our improved operational \nperformance, robust cash flow and responsible allocation of capital.  \n   \n As Aaron noted, our robust cash flow generation is not only driving benefits below the operating line, \nit is enabling our opportunistic capital deployment , with additional share repurchases in the quarter \nbeyond our baseline plan and our ability to pursue value -creating M&A in Specialty.   \n \n We remain well-positioned with the financial flexibility to continue opportunistically evaluating \ndisciplined M&A not only in Specialty but in our other growth areas, and potential additional share \nrepurchases.  \n \n With our recent conclusions on our business and portfolio review, we do not have further updates to \nshare today, but plan to keep you apprised of our progress.  \n \n To close, we had a strong first half of the year and are excited about the many initiatives underway to \nbuild upon our momentum. ", "original_text": "As Aaron noted, our robust cash flow generation is not only driving benefits below the operating line, \nit is enabling our opportunistic capital deployment , with additional share repurchases in the quarter \nbeyond our baseline plan and our ability to pursue value -creating M&A in Specialty.   \n \n"}, "hash": "24b8bcf93d69274f6661032c2af17a121c230dcd6759572671259907bd16b6af", "class_name": "RelatedNodeInfo"}}, "text": "We\u2019re continuing to maximize shareholder value creation through our improved operational \nperformance, robust cash flow and responsible allocation of capital.  \n   \n", "start_char_idx": 209, "end_char_idx": 374, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "f0476995-35cc-4a40-b7ea-6891e8a891bd": {"__data__": {"id_": "f0476995-35cc-4a40-b7ea-6891e8a891bd", "embedding": null, "metadata": {"window": " \nPage 10 of 19 \n \nprevalence, emerging Alzheimer\u2019s therapy availability and reimbursement, and increasing clinical trial \nneeds.  \n \n Finally, priority number four , maximizing shareholder value creation . \n \n We\u2019re continuing to maximize shareholder value creation through our improved operational \nperformance, robust cash flow and responsible allocation of capital.  \n   \n As Aaron noted, our robust cash flow generation is not only driving benefits below the operating line, \nit is enabling our opportunistic capital deployment , with additional share repurchases in the quarter \nbeyond our baseline plan and our ability to pursue value -creating M&A in Specialty.   \n \n We remain well-positioned with the financial flexibility to continue opportunistically evaluating \ndisciplined M&A not only in Specialty but in our other growth areas, and potential additional share \nrepurchases.  \n \n With our recent conclusions on our business and portfolio review, we do not have further updates to \nshare today, but plan to keep you apprised of our progress.  \n \n To close, we had a strong first half of the year and are excited about the many initiatives underway to \nbuild upon our momentum. ", "original_text": "As Aaron noted, our robust cash flow generation is not only driving benefits below the operating line, \nit is enabling our opportunistic capital deployment , with additional share repurchases in the quarter \nbeyond our baseline plan and our ability to pursue value -creating M&A in Specialty.   \n \n", "page_label": "10", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "0be51136-ae11-430d-b0c4-8d03b6d16d4c", "node_type": "4", "metadata": {"page_label": "10", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "e4d3538a4609d0f51019a25623c590d5938685f2ab449c6d5fc681dad0fd35b4", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "d03b695a-7b1a-48db-88cc-b7c26078cbcd", "node_type": "1", "metadata": {"window": " \nPage 10 of 19 \n \nprevalence, emerging Alzheimer\u2019s therapy availability and reimbursement, and increasing clinical trial \nneeds.  \n \n Finally, priority number four , maximizing shareholder value creation . \n \n We\u2019re continuing to maximize shareholder value creation through our improved operational \nperformance, robust cash flow and responsible allocation of capital.  \n   \n As Aaron noted, our robust cash flow generation is not only driving benefits below the operating line, \nit is enabling our opportunistic capital deployment , with additional share repurchases in the quarter \nbeyond our baseline plan and our ability to pursue value -creating M&A in Specialty.   \n \n We remain well-positioned with the financial flexibility to continue opportunistically evaluating \ndisciplined M&A not only in Specialty but in our other growth areas, and potential additional share \nrepurchases.  \n \n With our recent conclusions on our business and portfolio review, we do not have further updates to \nshare today, but plan to keep you apprised of our progress.  \n \n", "original_text": "We\u2019re continuing to maximize shareholder value creation through our improved operational \nperformance, robust cash flow and responsible allocation of capital.  \n   \n", "page_label": "10", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "ac6bbc449855e8b7f8ed3542156da961391ed2928f5fdced687fe18bea5f360e", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "886dcbad-98e1-4c45-9054-2b18d1274bb8", "node_type": "1", "metadata": {"window": "Finally, priority number four , maximizing shareholder value creation . \n \n We\u2019re continuing to maximize shareholder value creation through our improved operational \nperformance, robust cash flow and responsible allocation of capital.  \n   \n As Aaron noted, our robust cash flow generation is not only driving benefits below the operating line, \nit is enabling our opportunistic capital deployment , with additional share repurchases in the quarter \nbeyond our baseline plan and our ability to pursue value -creating M&A in Specialty.   \n \n We remain well-positioned with the financial flexibility to continue opportunistically evaluating \ndisciplined M&A not only in Specialty but in our other growth areas, and potential additional share \nrepurchases.  \n \n With our recent conclusions on our business and portfolio review, we do not have further updates to \nshare today, but plan to keep you apprised of our progress.  \n \n To close, we had a strong first half of the year and are excited about the many initiatives underway to \nbuild upon our momentum.  I would like to thank our highly -engaged and talented team for driving our \nprogress and prioritizing our customers, as we fulfi ll our critical role as healthcare\u2019s most trusted \npartner.   \n \n", "original_text": "We remain well-positioned with the financial flexibility to continue opportunistically evaluating \ndisciplined M&A not only in Specialty but in our other growth areas, and potential additional share \nrepurchases.  \n \n"}, "hash": "43e28e6d47fd4164f859a9ed78db85885135b3e5952be2c7a6712d217786d334", "class_name": "RelatedNodeInfo"}}, "text": "As Aaron noted, our robust cash flow generation is not only driving benefits below the operating line, \nit is enabling our opportunistic capital deployment , with additional share repurchases in the quarter \nbeyond our baseline plan and our ability to pursue value -creating M&A in Specialty.   \n \n", "start_char_idx": 374, "end_char_idx": 672, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "886dcbad-98e1-4c45-9054-2b18d1274bb8": {"__data__": {"id_": "886dcbad-98e1-4c45-9054-2b18d1274bb8", "embedding": null, "metadata": {"window": "Finally, priority number four , maximizing shareholder value creation . \n \n We\u2019re continuing to maximize shareholder value creation through our improved operational \nperformance, robust cash flow and responsible allocation of capital.  \n   \n As Aaron noted, our robust cash flow generation is not only driving benefits below the operating line, \nit is enabling our opportunistic capital deployment , with additional share repurchases in the quarter \nbeyond our baseline plan and our ability to pursue value -creating M&A in Specialty.   \n \n We remain well-positioned with the financial flexibility to continue opportunistically evaluating \ndisciplined M&A not only in Specialty but in our other growth areas, and potential additional share \nrepurchases.  \n \n With our recent conclusions on our business and portfolio review, we do not have further updates to \nshare today, but plan to keep you apprised of our progress.  \n \n To close, we had a strong first half of the year and are excited about the many initiatives underway to \nbuild upon our momentum.  I would like to thank our highly -engaged and talented team for driving our \nprogress and prioritizing our customers, as we fulfi ll our critical role as healthcare\u2019s most trusted \npartner.   \n \n", "original_text": "We remain well-positioned with the financial flexibility to continue opportunistically evaluating \ndisciplined M&A not only in Specialty but in our other growth areas, and potential additional share \nrepurchases.  \n \n", "page_label": "10", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "0be51136-ae11-430d-b0c4-8d03b6d16d4c", "node_type": "4", "metadata": {"page_label": "10", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "e4d3538a4609d0f51019a25623c590d5938685f2ab449c6d5fc681dad0fd35b4", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "f0476995-35cc-4a40-b7ea-6891e8a891bd", "node_type": "1", "metadata": {"window": " \nPage 10 of 19 \n \nprevalence, emerging Alzheimer\u2019s therapy availability and reimbursement, and increasing clinical trial \nneeds.  \n \n Finally, priority number four , maximizing shareholder value creation . \n \n We\u2019re continuing to maximize shareholder value creation through our improved operational \nperformance, robust cash flow and responsible allocation of capital.  \n   \n As Aaron noted, our robust cash flow generation is not only driving benefits below the operating line, \nit is enabling our opportunistic capital deployment , with additional share repurchases in the quarter \nbeyond our baseline plan and our ability to pursue value -creating M&A in Specialty.   \n \n We remain well-positioned with the financial flexibility to continue opportunistically evaluating \ndisciplined M&A not only in Specialty but in our other growth areas, and potential additional share \nrepurchases.  \n \n With our recent conclusions on our business and portfolio review, we do not have further updates to \nshare today, but plan to keep you apprised of our progress.  \n \n To close, we had a strong first half of the year and are excited about the many initiatives underway to \nbuild upon our momentum. ", "original_text": "As Aaron noted, our robust cash flow generation is not only driving benefits below the operating line, \nit is enabling our opportunistic capital deployment , with additional share repurchases in the quarter \nbeyond our baseline plan and our ability to pursue value -creating M&A in Specialty.   \n \n", "page_label": "10", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "834f46fbeaedad716a425d058347e0496f77ed0bf7472abb52ce14f86ac4111f", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "1dff6ac6-9a19-4836-8cb6-0ad19efec4cf", "node_type": "1", "metadata": {"window": "We\u2019re continuing to maximize shareholder value creation through our improved operational \nperformance, robust cash flow and responsible allocation of capital.  \n   \n As Aaron noted, our robust cash flow generation is not only driving benefits below the operating line, \nit is enabling our opportunistic capital deployment , with additional share repurchases in the quarter \nbeyond our baseline plan and our ability to pursue value -creating M&A in Specialty.   \n \n We remain well-positioned with the financial flexibility to continue opportunistically evaluating \ndisciplined M&A not only in Specialty but in our other growth areas, and potential additional share \nrepurchases.  \n \n With our recent conclusions on our business and portfolio review, we do not have further updates to \nshare today, but plan to keep you apprised of our progress.  \n \n To close, we had a strong first half of the year and are excited about the many initiatives underway to \nbuild upon our momentum.  I would like to thank our highly -engaged and talented team for driving our \nprogress and prioritizing our customers, as we fulfi ll our critical role as healthcare\u2019s most trusted \npartner.   \n \n With that, we will take your questions.  \n \n", "original_text": "With our recent conclusions on our business and portfolio review, we do not have further updates to \nshare today, but plan to keep you apprised of our progress.  \n \n"}, "hash": "bcdd7dfe2d6ae3fc2555cd14723f0d84495390aecf39a18840d1e9d50a59ffc0", "class_name": "RelatedNodeInfo"}}, "text": "We remain well-positioned with the financial flexibility to continue opportunistically evaluating \ndisciplined M&A not only in Specialty but in our other growth areas, and potential additional share \nrepurchases.  \n \n", "start_char_idx": 672, "end_char_idx": 889, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "1dff6ac6-9a19-4836-8cb6-0ad19efec4cf": {"__data__": {"id_": "1dff6ac6-9a19-4836-8cb6-0ad19efec4cf", "embedding": null, "metadata": {"window": "We\u2019re continuing to maximize shareholder value creation through our improved operational \nperformance, robust cash flow and responsible allocation of capital.  \n   \n As Aaron noted, our robust cash flow generation is not only driving benefits below the operating line, \nit is enabling our opportunistic capital deployment , with additional share repurchases in the quarter \nbeyond our baseline plan and our ability to pursue value -creating M&A in Specialty.   \n \n We remain well-positioned with the financial flexibility to continue opportunistically evaluating \ndisciplined M&A not only in Specialty but in our other growth areas, and potential additional share \nrepurchases.  \n \n With our recent conclusions on our business and portfolio review, we do not have further updates to \nshare today, but plan to keep you apprised of our progress.  \n \n To close, we had a strong first half of the year and are excited about the many initiatives underway to \nbuild upon our momentum.  I would like to thank our highly -engaged and talented team for driving our \nprogress and prioritizing our customers, as we fulfi ll our critical role as healthcare\u2019s most trusted \npartner.   \n \n With that, we will take your questions.  \n \n", "original_text": "With our recent conclusions on our business and portfolio review, we do not have further updates to \nshare today, but plan to keep you apprised of our progress.  \n \n", "page_label": "10", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "0be51136-ae11-430d-b0c4-8d03b6d16d4c", "node_type": "4", "metadata": {"page_label": "10", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "e4d3538a4609d0f51019a25623c590d5938685f2ab449c6d5fc681dad0fd35b4", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "886dcbad-98e1-4c45-9054-2b18d1274bb8", "node_type": "1", "metadata": {"window": "Finally, priority number four , maximizing shareholder value creation . \n \n We\u2019re continuing to maximize shareholder value creation through our improved operational \nperformance, robust cash flow and responsible allocation of capital.  \n   \n As Aaron noted, our robust cash flow generation is not only driving benefits below the operating line, \nit is enabling our opportunistic capital deployment , with additional share repurchases in the quarter \nbeyond our baseline plan and our ability to pursue value -creating M&A in Specialty.   \n \n We remain well-positioned with the financial flexibility to continue opportunistically evaluating \ndisciplined M&A not only in Specialty but in our other growth areas, and potential additional share \nrepurchases.  \n \n With our recent conclusions on our business and portfolio review, we do not have further updates to \nshare today, but plan to keep you apprised of our progress.  \n \n To close, we had a strong first half of the year and are excited about the many initiatives underway to \nbuild upon our momentum.  I would like to thank our highly -engaged and talented team for driving our \nprogress and prioritizing our customers, as we fulfi ll our critical role as healthcare\u2019s most trusted \npartner.   \n \n", "original_text": "We remain well-positioned with the financial flexibility to continue opportunistically evaluating \ndisciplined M&A not only in Specialty but in our other growth areas, and potential additional share \nrepurchases.  \n \n", "page_label": "10", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "419d1a332f236142790394c4550e421603632e243ce489e8edb5596776665d8d", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "2e5006eb-a0b6-48fd-9f66-61d790060772", "node_type": "1", "metadata": {"window": "As Aaron noted, our robust cash flow generation is not only driving benefits below the operating line, \nit is enabling our opportunistic capital deployment , with additional share repurchases in the quarter \nbeyond our baseline plan and our ability to pursue value -creating M&A in Specialty.   \n \n We remain well-positioned with the financial flexibility to continue opportunistically evaluating \ndisciplined M&A not only in Specialty but in our other growth areas, and potential additional share \nrepurchases.  \n \n With our recent conclusions on our business and portfolio review, we do not have further updates to \nshare today, but plan to keep you apprised of our progress.  \n \n To close, we had a strong first half of the year and are excited about the many initiatives underway to \nbuild upon our momentum.  I would like to thank our highly -engaged and talented team for driving our \nprogress and prioritizing our customers, as we fulfi ll our critical role as healthcare\u2019s most trusted \npartner.   \n \n With that, we will take your questions.  \n \n Operator :  Thank you very much, sir. ", "original_text": "To close, we had a strong first half of the year and are excited about the many initiatives underway to \nbuild upon our momentum. "}, "hash": "b7ef3889d84361837f29400e7c6cadef6e84de39b0b18320d2c85ecd9ac14033", "class_name": "RelatedNodeInfo"}}, "text": "With our recent conclusions on our business and portfolio review, we do not have further updates to \nshare today, but plan to keep you apprised of our progress.  \n \n", "start_char_idx": 889, "end_char_idx": 1054, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "2e5006eb-a0b6-48fd-9f66-61d790060772": {"__data__": {"id_": "2e5006eb-a0b6-48fd-9f66-61d790060772", "embedding": null, "metadata": {"window": "As Aaron noted, our robust cash flow generation is not only driving benefits below the operating line, \nit is enabling our opportunistic capital deployment , with additional share repurchases in the quarter \nbeyond our baseline plan and our ability to pursue value -creating M&A in Specialty.   \n \n We remain well-positioned with the financial flexibility to continue opportunistically evaluating \ndisciplined M&A not only in Specialty but in our other growth areas, and potential additional share \nrepurchases.  \n \n With our recent conclusions on our business and portfolio review, we do not have further updates to \nshare today, but plan to keep you apprised of our progress.  \n \n To close, we had a strong first half of the year and are excited about the many initiatives underway to \nbuild upon our momentum.  I would like to thank our highly -engaged and talented team for driving our \nprogress and prioritizing our customers, as we fulfi ll our critical role as healthcare\u2019s most trusted \npartner.   \n \n With that, we will take your questions.  \n \n Operator :  Thank you very much, sir. ", "original_text": "To close, we had a strong first half of the year and are excited about the many initiatives underway to \nbuild upon our momentum. ", "page_label": "10", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "0be51136-ae11-430d-b0c4-8d03b6d16d4c", "node_type": "4", "metadata": {"page_label": "10", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "e4d3538a4609d0f51019a25623c590d5938685f2ab449c6d5fc681dad0fd35b4", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "1dff6ac6-9a19-4836-8cb6-0ad19efec4cf", "node_type": "1", "metadata": {"window": "We\u2019re continuing to maximize shareholder value creation through our improved operational \nperformance, robust cash flow and responsible allocation of capital.  \n   \n As Aaron noted, our robust cash flow generation is not only driving benefits below the operating line, \nit is enabling our opportunistic capital deployment , with additional share repurchases in the quarter \nbeyond our baseline plan and our ability to pursue value -creating M&A in Specialty.   \n \n We remain well-positioned with the financial flexibility to continue opportunistically evaluating \ndisciplined M&A not only in Specialty but in our other growth areas, and potential additional share \nrepurchases.  \n \n With our recent conclusions on our business and portfolio review, we do not have further updates to \nshare today, but plan to keep you apprised of our progress.  \n \n To close, we had a strong first half of the year and are excited about the many initiatives underway to \nbuild upon our momentum.  I would like to thank our highly -engaged and talented team for driving our \nprogress and prioritizing our customers, as we fulfi ll our critical role as healthcare\u2019s most trusted \npartner.   \n \n With that, we will take your questions.  \n \n", "original_text": "With our recent conclusions on our business and portfolio review, we do not have further updates to \nshare today, but plan to keep you apprised of our progress.  \n \n", "page_label": "10", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "bf5134b284202e7d117093e352cc29f691aabb5923a90badad0b0cdb8c251d47", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "7c2a3a7f-3b94-4533-8b92-ec86c669eaa8", "node_type": "1", "metadata": {"window": "We remain well-positioned with the financial flexibility to continue opportunistically evaluating \ndisciplined M&A not only in Specialty but in our other growth areas, and potential additional share \nrepurchases.  \n \n With our recent conclusions on our business and portfolio review, we do not have further updates to \nshare today, but plan to keep you apprised of our progress.  \n \n To close, we had a strong first half of the year and are excited about the many initiatives underway to \nbuild upon our momentum.  I would like to thank our highly -engaged and talented team for driving our \nprogress and prioritizing our customers, as we fulfi ll our critical role as healthcare\u2019s most trusted \npartner.   \n \n With that, we will take your questions.  \n \n Operator :  Thank you very much, sir.  Ladies and gentlemen as a reminder, if you have any questions,  \nplease press star one on your telephone keypad.  ", "original_text": "I would like to thank our highly -engaged and talented team for driving our \nprogress and prioritizing our customers, as we fulfi ll our critical role as healthcare\u2019s most trusted \npartner.   \n \n"}, "hash": "4541e36887acae72b1e78e58f2a4b1c5ed30c8143fee336834ff39041d0814bf", "class_name": "RelatedNodeInfo"}}, "text": "To close, we had a strong first half of the year and are excited about the many initiatives underway to \nbuild upon our momentum. ", "start_char_idx": 1054, "end_char_idx": 1184, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "7c2a3a7f-3b94-4533-8b92-ec86c669eaa8": {"__data__": {"id_": "7c2a3a7f-3b94-4533-8b92-ec86c669eaa8", "embedding": null, "metadata": {"window": "We remain well-positioned with the financial flexibility to continue opportunistically evaluating \ndisciplined M&A not only in Specialty but in our other growth areas, and potential additional share \nrepurchases.  \n \n With our recent conclusions on our business and portfolio review, we do not have further updates to \nshare today, but plan to keep you apprised of our progress.  \n \n To close, we had a strong first half of the year and are excited about the many initiatives underway to \nbuild upon our momentum.  I would like to thank our highly -engaged and talented team for driving our \nprogress and prioritizing our customers, as we fulfi ll our critical role as healthcare\u2019s most trusted \npartner.   \n \n With that, we will take your questions.  \n \n Operator :  Thank you very much, sir.  Ladies and gentlemen as a reminder, if you have any questions,  \nplease press star one on your telephone keypad.  ", "original_text": "I would like to thank our highly -engaged and talented team for driving our \nprogress and prioritizing our customers, as we fulfi ll our critical role as healthcare\u2019s most trusted \npartner.   \n \n", "page_label": "10", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "0be51136-ae11-430d-b0c4-8d03b6d16d4c", "node_type": "4", "metadata": {"page_label": "10", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "e4d3538a4609d0f51019a25623c590d5938685f2ab449c6d5fc681dad0fd35b4", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "2e5006eb-a0b6-48fd-9f66-61d790060772", "node_type": "1", "metadata": {"window": "As Aaron noted, our robust cash flow generation is not only driving benefits below the operating line, \nit is enabling our opportunistic capital deployment , with additional share repurchases in the quarter \nbeyond our baseline plan and our ability to pursue value -creating M&A in Specialty.   \n \n We remain well-positioned with the financial flexibility to continue opportunistically evaluating \ndisciplined M&A not only in Specialty but in our other growth areas, and potential additional share \nrepurchases.  \n \n With our recent conclusions on our business and portfolio review, we do not have further updates to \nshare today, but plan to keep you apprised of our progress.  \n \n To close, we had a strong first half of the year and are excited about the many initiatives underway to \nbuild upon our momentum.  I would like to thank our highly -engaged and talented team for driving our \nprogress and prioritizing our customers, as we fulfi ll our critical role as healthcare\u2019s most trusted \npartner.   \n \n With that, we will take your questions.  \n \n Operator :  Thank you very much, sir. ", "original_text": "To close, we had a strong first half of the year and are excited about the many initiatives underway to \nbuild upon our momentum. ", "page_label": "10", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "2d7219aa1674aa73ba29a518112f58a374c2b88125c5b01bc47ab5761248e834", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "62176bcb-4113-4dbe-bd59-063def3f2b1a", "node_type": "1", "metadata": {"window": "With our recent conclusions on our business and portfolio review, we do not have further updates to \nshare today, but plan to keep you apprised of our progress.  \n \n To close, we had a strong first half of the year and are excited about the many initiatives underway to \nbuild upon our momentum.  I would like to thank our highly -engaged and talented team for driving our \nprogress and prioritizing our customers, as we fulfi ll our critical role as healthcare\u2019s most trusted \npartner.   \n \n With that, we will take your questions.  \n \n Operator :  Thank you very much, sir.  Ladies and gentlemen as a reminder, if you have any questions,  \nplease press star one on your telephone keypad.   Our first question is coming from Stephanie Davis, \ncalling f rom Barclays. ", "original_text": "With that, we will take your questions.  \n \n"}, "hash": "5f43f77a4029e3abc73c687627f6970fbbd54e9b50016b08271252b03b84abb0", "class_name": "RelatedNodeInfo"}}, "text": "I would like to thank our highly -engaged and talented team for driving our \nprogress and prioritizing our customers, as we fulfi ll our critical role as healthcare\u2019s most trusted \npartner.   \n \n", "start_char_idx": 1184, "end_char_idx": 1379, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "62176bcb-4113-4dbe-bd59-063def3f2b1a": {"__data__": {"id_": "62176bcb-4113-4dbe-bd59-063def3f2b1a", "embedding": null, "metadata": {"window": "With our recent conclusions on our business and portfolio review, we do not have further updates to \nshare today, but plan to keep you apprised of our progress.  \n \n To close, we had a strong first half of the year and are excited about the many initiatives underway to \nbuild upon our momentum.  I would like to thank our highly -engaged and talented team for driving our \nprogress and prioritizing our customers, as we fulfi ll our critical role as healthcare\u2019s most trusted \npartner.   \n \n With that, we will take your questions.  \n \n Operator :  Thank you very much, sir.  Ladies and gentlemen as a reminder, if you have any questions,  \nplease press star one on your telephone keypad.   Our first question is coming from Stephanie Davis, \ncalling f rom Barclays. ", "original_text": "With that, we will take your questions.  \n \n", "page_label": "10", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "0be51136-ae11-430d-b0c4-8d03b6d16d4c", "node_type": "4", "metadata": {"page_label": "10", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "e4d3538a4609d0f51019a25623c590d5938685f2ab449c6d5fc681dad0fd35b4", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "7c2a3a7f-3b94-4533-8b92-ec86c669eaa8", "node_type": "1", "metadata": {"window": "We remain well-positioned with the financial flexibility to continue opportunistically evaluating \ndisciplined M&A not only in Specialty but in our other growth areas, and potential additional share \nrepurchases.  \n \n With our recent conclusions on our business and portfolio review, we do not have further updates to \nshare today, but plan to keep you apprised of our progress.  \n \n To close, we had a strong first half of the year and are excited about the many initiatives underway to \nbuild upon our momentum.  I would like to thank our highly -engaged and talented team for driving our \nprogress and prioritizing our customers, as we fulfi ll our critical role as healthcare\u2019s most trusted \npartner.   \n \n With that, we will take your questions.  \n \n Operator :  Thank you very much, sir.  Ladies and gentlemen as a reminder, if you have any questions,  \nplease press star one on your telephone keypad.  ", "original_text": "I would like to thank our highly -engaged and talented team for driving our \nprogress and prioritizing our customers, as we fulfi ll our critical role as healthcare\u2019s most trusted \npartner.   \n \n", "page_label": "10", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "e0eca3f0f96fc77b545a3c78556b55b4b4e4001755c909046d5081ea41aeda5e", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "9cf1b625-527a-4cfe-af44-9b91586cc312", "node_type": "1", "metadata": {"window": "To close, we had a strong first half of the year and are excited about the many initiatives underway to \nbuild upon our momentum.  I would like to thank our highly -engaged and talented team for driving our \nprogress and prioritizing our customers, as we fulfi ll our critical role as healthcare\u2019s most trusted \npartner.   \n \n With that, we will take your questions.  \n \n Operator :  Thank you very much, sir.  Ladies and gentlemen as a reminder, if you have any questions,  \nplease press star one on your telephone keypad.   Our first question is coming from Stephanie Davis, \ncalling f rom Barclays.  Please go ahead.  \n \n", "original_text": "Operator :  Thank you very much, sir. "}, "hash": "2c6460d7f310e9bcfbd321f8dc18ed05c62c29edf8ae76252d3946cabd5ea2ad", "class_name": "RelatedNodeInfo"}}, "text": "With that, we will take your questions.  \n \n", "start_char_idx": 1379, "end_char_idx": 1423, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "9cf1b625-527a-4cfe-af44-9b91586cc312": {"__data__": {"id_": "9cf1b625-527a-4cfe-af44-9b91586cc312", "embedding": null, "metadata": {"window": "To close, we had a strong first half of the year and are excited about the many initiatives underway to \nbuild upon our momentum.  I would like to thank our highly -engaged and talented team for driving our \nprogress and prioritizing our customers, as we fulfi ll our critical role as healthcare\u2019s most trusted \npartner.   \n \n With that, we will take your questions.  \n \n Operator :  Thank you very much, sir.  Ladies and gentlemen as a reminder, if you have any questions,  \nplease press star one on your telephone keypad.   Our first question is coming from Stephanie Davis, \ncalling f rom Barclays.  Please go ahead.  \n \n", "original_text": "Operator :  Thank you very much, sir. ", "page_label": "10", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "0be51136-ae11-430d-b0c4-8d03b6d16d4c", "node_type": "4", "metadata": {"page_label": "10", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "e4d3538a4609d0f51019a25623c590d5938685f2ab449c6d5fc681dad0fd35b4", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "62176bcb-4113-4dbe-bd59-063def3f2b1a", "node_type": "1", "metadata": {"window": "With our recent conclusions on our business and portfolio review, we do not have further updates to \nshare today, but plan to keep you apprised of our progress.  \n \n To close, we had a strong first half of the year and are excited about the many initiatives underway to \nbuild upon our momentum.  I would like to thank our highly -engaged and talented team for driving our \nprogress and prioritizing our customers, as we fulfi ll our critical role as healthcare\u2019s most trusted \npartner.   \n \n With that, we will take your questions.  \n \n Operator :  Thank you very much, sir.  Ladies and gentlemen as a reminder, if you have any questions,  \nplease press star one on your telephone keypad.   Our first question is coming from Stephanie Davis, \ncalling f rom Barclays. ", "original_text": "With that, we will take your questions.  \n \n", "page_label": "10", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "632fb3962416f3cec95b6c6fd1db80763febff0637baaf55db4ad2ac8180499a", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "e3e87f39-2f8c-4161-a3a6-0b73b52ffc0b", "node_type": "1", "metadata": {"window": "I would like to thank our highly -engaged and talented team for driving our \nprogress and prioritizing our customers, as we fulfi ll our critical role as healthcare\u2019s most trusted \npartner.   \n \n With that, we will take your questions.  \n \n Operator :  Thank you very much, sir.  Ladies and gentlemen as a reminder, if you have any questions,  \nplease press star one on your telephone keypad.   Our first question is coming from Stephanie Davis, \ncalling f rom Barclays.  Please go ahead.  \n \n Stephanie Davis:   Hey, guys. ", "original_text": "Ladies and gentlemen as a reminder, if you have any questions,  \nplease press star one on your telephone keypad.  "}, "hash": "43fc8b9ae8655af3d1f36ee5e36a92900d25b6a97d32fdc87fe8d0b0779cad8e", "class_name": "RelatedNodeInfo"}}, "text": "Operator :  Thank you very much, sir. ", "start_char_idx": 1423, "end_char_idx": 1461, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "e3e87f39-2f8c-4161-a3a6-0b73b52ffc0b": {"__data__": {"id_": "e3e87f39-2f8c-4161-a3a6-0b73b52ffc0b", "embedding": null, "metadata": {"window": "I would like to thank our highly -engaged and talented team for driving our \nprogress and prioritizing our customers, as we fulfi ll our critical role as healthcare\u2019s most trusted \npartner.   \n \n With that, we will take your questions.  \n \n Operator :  Thank you very much, sir.  Ladies and gentlemen as a reminder, if you have any questions,  \nplease press star one on your telephone keypad.   Our first question is coming from Stephanie Davis, \ncalling f rom Barclays.  Please go ahead.  \n \n Stephanie Davis:   Hey, guys. ", "original_text": "Ladies and gentlemen as a reminder, if you have any questions,  \nplease press star one on your telephone keypad.  ", "page_label": "10", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "0be51136-ae11-430d-b0c4-8d03b6d16d4c", "node_type": "4", "metadata": {"page_label": "10", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "e4d3538a4609d0f51019a25623c590d5938685f2ab449c6d5fc681dad0fd35b4", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "9cf1b625-527a-4cfe-af44-9b91586cc312", "node_type": "1", "metadata": {"window": "To close, we had a strong first half of the year and are excited about the many initiatives underway to \nbuild upon our momentum.  I would like to thank our highly -engaged and talented team for driving our \nprogress and prioritizing our customers, as we fulfi ll our critical role as healthcare\u2019s most trusted \npartner.   \n \n With that, we will take your questions.  \n \n Operator :  Thank you very much, sir.  Ladies and gentlemen as a reminder, if you have any questions,  \nplease press star one on your telephone keypad.   Our first question is coming from Stephanie Davis, \ncalling f rom Barclays.  Please go ahead.  \n \n", "original_text": "Operator :  Thank you very much, sir. ", "page_label": "10", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "345c1a515140a1ad5a6a0e8e0f38639cbf14d88c9515b38293df1f8c623f477f", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "1d5099cc-e8c8-4b54-993f-3454efabda9d", "node_type": "1", "metadata": {"window": "With that, we will take your questions.  \n \n Operator :  Thank you very much, sir.  Ladies and gentlemen as a reminder, if you have any questions,  \nplease press star one on your telephone keypad.   Our first question is coming from Stephanie Davis, \ncalling f rom Barclays.  Please go ahead.  \n \n Stephanie Davis:   Hey, guys.  Thank you for taking my questions and congrats on the continued \nprogress. ", "original_text": "Our first question is coming from Stephanie Davis, \ncalling f rom Barclays. "}, "hash": "452cde7b832ed6ba71133a71fbcc491de3957a9166ee7fc36442dcd3b25d2d8d", "class_name": "RelatedNodeInfo"}}, "text": "Ladies and gentlemen as a reminder, if you have any questions,  \nplease press star one on your telephone keypad.  ", "start_char_idx": 1461, "end_char_idx": 1575, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "1d5099cc-e8c8-4b54-993f-3454efabda9d": {"__data__": {"id_": "1d5099cc-e8c8-4b54-993f-3454efabda9d", "embedding": null, "metadata": {"window": "With that, we will take your questions.  \n \n Operator :  Thank you very much, sir.  Ladies and gentlemen as a reminder, if you have any questions,  \nplease press star one on your telephone keypad.   Our first question is coming from Stephanie Davis, \ncalling f rom Barclays.  Please go ahead.  \n \n Stephanie Davis:   Hey, guys.  Thank you for taking my questions and congrats on the continued \nprogress. ", "original_text": "Our first question is coming from Stephanie Davis, \ncalling f rom Barclays. ", "page_label": "10", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "0be51136-ae11-430d-b0c4-8d03b6d16d4c", "node_type": "4", "metadata": {"page_label": "10", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "e4d3538a4609d0f51019a25623c590d5938685f2ab449c6d5fc681dad0fd35b4", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "e3e87f39-2f8c-4161-a3a6-0b73b52ffc0b", "node_type": "1", "metadata": {"window": "I would like to thank our highly -engaged and talented team for driving our \nprogress and prioritizing our customers, as we fulfi ll our critical role as healthcare\u2019s most trusted \npartner.   \n \n With that, we will take your questions.  \n \n Operator :  Thank you very much, sir.  Ladies and gentlemen as a reminder, if you have any questions,  \nplease press star one on your telephone keypad.   Our first question is coming from Stephanie Davis, \ncalling f rom Barclays.  Please go ahead.  \n \n Stephanie Davis:   Hey, guys. ", "original_text": "Ladies and gentlemen as a reminder, if you have any questions,  \nplease press star one on your telephone keypad.  ", "page_label": "10", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "cc41d4d91bdb92c9ae79ac10c4532e2d33ccb99478f75a732db98a9f186e5d37", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "19fa639b-9bae-4312-ba26-a23e7e3945e7", "node_type": "1", "metadata": {"window": "Operator :  Thank you very much, sir.  Ladies and gentlemen as a reminder, if you have any questions,  \nplease press star one on your telephone keypad.   Our first question is coming from Stephanie Davis, \ncalling f rom Barclays.  Please go ahead.  \n \n Stephanie Davis:   Hey, guys.  Thank you for taking my questions and congrats on the continued \nprogress.  Jason, you already shared a lot of color around the acquisition, but I was hoping you could \ndig in just a little bit further on Specialty Networks  of mix and capabilities , just given the higher margin \nnature of both GPO and analytics solutions. ", "original_text": "Please go ahead.  \n \n"}, "hash": "ea3a9c5bf5bbbee05409d623747a4ce55d43620859d4a95ff8f9ffe406f89faa", "class_name": "RelatedNodeInfo"}}, "text": "Our first question is coming from Stephanie Davis, \ncalling f rom Barclays. ", "start_char_idx": 1575, "end_char_idx": 1651, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "19fa639b-9bae-4312-ba26-a23e7e3945e7": {"__data__": {"id_": "19fa639b-9bae-4312-ba26-a23e7e3945e7", "embedding": null, "metadata": {"window": "Operator :  Thank you very much, sir.  Ladies and gentlemen as a reminder, if you have any questions,  \nplease press star one on your telephone keypad.   Our first question is coming from Stephanie Davis, \ncalling f rom Barclays.  Please go ahead.  \n \n Stephanie Davis:   Hey, guys.  Thank you for taking my questions and congrats on the continued \nprogress.  Jason, you already shared a lot of color around the acquisition, but I was hoping you could \ndig in just a little bit further on Specialty Networks  of mix and capabilities , just given the higher margin \nnature of both GPO and analytics solutions. ", "original_text": "Please go ahead.  \n \n", "page_label": "10", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "0be51136-ae11-430d-b0c4-8d03b6d16d4c", "node_type": "4", "metadata": {"page_label": "10", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "e4d3538a4609d0f51019a25623c590d5938685f2ab449c6d5fc681dad0fd35b4", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "1d5099cc-e8c8-4b54-993f-3454efabda9d", "node_type": "1", "metadata": {"window": "With that, we will take your questions.  \n \n Operator :  Thank you very much, sir.  Ladies and gentlemen as a reminder, if you have any questions,  \nplease press star one on your telephone keypad.   Our first question is coming from Stephanie Davis, \ncalling f rom Barclays.  Please go ahead.  \n \n Stephanie Davis:   Hey, guys.  Thank you for taking my questions and congrats on the continued \nprogress. ", "original_text": "Our first question is coming from Stephanie Davis, \ncalling f rom Barclays. ", "page_label": "10", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "4dfb2e12d151c9e18cd7b328a64cc29e54b50731d8e4c5ab7f98d4b13705dc3a", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "00d6f413-0d3a-4dfe-ae32-c4f468cc1746", "node_type": "1", "metadata": {"window": "Ladies and gentlemen as a reminder, if you have any questions,  \nplease press star one on your telephone keypad.   Our first question is coming from Stephanie Davis, \ncalling f rom Barclays.  Please go ahead.  \n \n Stephanie Davis:   Hey, guys.  Thank you for taking my questions and congrats on the continued \nprogress.  Jason, you already shared a lot of color around the acquisition, but I was hoping you could \ndig in just a little bit further on Specialty Networks  of mix and capabilities , just given the higher margin \nnature of both GPO and analytics solutions.  And then just following up, given the pipeline that you \nmentioned, I was hoping you could share some thoughts on hurdle rates for future deals as that \nbecomes a bigger part of the st ory. ", "original_text": "Stephanie Davis:   Hey, guys. "}, "hash": "dc39225511bc0b7e9283938be2fb485279021330d17da070b52616c6c3ea4918", "class_name": "RelatedNodeInfo"}}, "text": "Please go ahead.  \n \n", "start_char_idx": 1651, "end_char_idx": 1672, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "00d6f413-0d3a-4dfe-ae32-c4f468cc1746": {"__data__": {"id_": "00d6f413-0d3a-4dfe-ae32-c4f468cc1746", "embedding": null, "metadata": {"window": "Ladies and gentlemen as a reminder, if you have any questions,  \nplease press star one on your telephone keypad.   Our first question is coming from Stephanie Davis, \ncalling f rom Barclays.  Please go ahead.  \n \n Stephanie Davis:   Hey, guys.  Thank you for taking my questions and congrats on the continued \nprogress.  Jason, you already shared a lot of color around the acquisition, but I was hoping you could \ndig in just a little bit further on Specialty Networks  of mix and capabilities , just given the higher margin \nnature of both GPO and analytics solutions.  And then just following up, given the pipeline that you \nmentioned, I was hoping you could share some thoughts on hurdle rates for future deals as that \nbecomes a bigger part of the st ory. ", "original_text": "Stephanie Davis:   Hey, guys. ", "page_label": "10", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "0be51136-ae11-430d-b0c4-8d03b6d16d4c", "node_type": "4", "metadata": {"page_label": "10", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "e4d3538a4609d0f51019a25623c590d5938685f2ab449c6d5fc681dad0fd35b4", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "19fa639b-9bae-4312-ba26-a23e7e3945e7", "node_type": "1", "metadata": {"window": "Operator :  Thank you very much, sir.  Ladies and gentlemen as a reminder, if you have any questions,  \nplease press star one on your telephone keypad.   Our first question is coming from Stephanie Davis, \ncalling f rom Barclays.  Please go ahead.  \n \n Stephanie Davis:   Hey, guys.  Thank you for taking my questions and congrats on the continued \nprogress.  Jason, you already shared a lot of color around the acquisition, but I was hoping you could \ndig in just a little bit further on Specialty Networks  of mix and capabilities , just given the higher margin \nnature of both GPO and analytics solutions. ", "original_text": "Please go ahead.  \n \n", "page_label": "10", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "1c4ad9c0fdbcceb46bcc474413cfc559733cae54c654d421de7e45a33401008d", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "7efe25dc-48fc-42f2-b2a8-15752901612b", "node_type": "1", "metadata": {"window": "Our first question is coming from Stephanie Davis, \ncalling f rom Barclays.  Please go ahead.  \n \n Stephanie Davis:   Hey, guys.  Thank you for taking my questions and congrats on the continued \nprogress.  Jason, you already shared a lot of color around the acquisition, but I was hoping you could \ndig in just a little bit further on Specialty Networks  of mix and capabilities , just given the higher margin \nnature of both GPO and analytics solutions.  And then just following up, given the pipeline that you \nmentioned, I was hoping you could share some thoughts on hurdle rates for future deals as that \nbecomes a bigger part of the st ory.  Thank you.  \n", "original_text": "Thank you for taking my questions and congrats on the continued \nprogress. "}, "hash": "efe53994bfe01ce2826ced60961511acb3e26cc12ecd1c7a64f8de99c6a1b565", "class_name": "RelatedNodeInfo"}}, "text": "Stephanie Davis:   Hey, guys. ", "start_char_idx": 1672, "end_char_idx": 1702, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "7efe25dc-48fc-42f2-b2a8-15752901612b": {"__data__": {"id_": "7efe25dc-48fc-42f2-b2a8-15752901612b", "embedding": null, "metadata": {"window": "Our first question is coming from Stephanie Davis, \ncalling f rom Barclays.  Please go ahead.  \n \n Stephanie Davis:   Hey, guys.  Thank you for taking my questions and congrats on the continued \nprogress.  Jason, you already shared a lot of color around the acquisition, but I was hoping you could \ndig in just a little bit further on Specialty Networks  of mix and capabilities , just given the higher margin \nnature of both GPO and analytics solutions.  And then just following up, given the pipeline that you \nmentioned, I was hoping you could share some thoughts on hurdle rates for future deals as that \nbecomes a bigger part of the st ory.  Thank you.  \n", "original_text": "Thank you for taking my questions and congrats on the continued \nprogress. ", "page_label": "10", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "0be51136-ae11-430d-b0c4-8d03b6d16d4c", "node_type": "4", "metadata": {"page_label": "10", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "e4d3538a4609d0f51019a25623c590d5938685f2ab449c6d5fc681dad0fd35b4", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "00d6f413-0d3a-4dfe-ae32-c4f468cc1746", "node_type": "1", "metadata": {"window": "Ladies and gentlemen as a reminder, if you have any questions,  \nplease press star one on your telephone keypad.   Our first question is coming from Stephanie Davis, \ncalling f rom Barclays.  Please go ahead.  \n \n Stephanie Davis:   Hey, guys.  Thank you for taking my questions and congrats on the continued \nprogress.  Jason, you already shared a lot of color around the acquisition, but I was hoping you could \ndig in just a little bit further on Specialty Networks  of mix and capabilities , just given the higher margin \nnature of both GPO and analytics solutions.  And then just following up, given the pipeline that you \nmentioned, I was hoping you could share some thoughts on hurdle rates for future deals as that \nbecomes a bigger part of the st ory. ", "original_text": "Stephanie Davis:   Hey, guys. ", "page_label": "10", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "69b3c929553824232eea2b9f8397ef34f97239a7e08e989f3b93aaa1b6aac055", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "e013b527-1b94-4fc2-a7ae-b35abc2b6eae", "node_type": "1", "metadata": {"window": "Please go ahead.  \n \n Stephanie Davis:   Hey, guys.  Thank you for taking my questions and congrats on the continued \nprogress.  Jason, you already shared a lot of color around the acquisition, but I was hoping you could \ndig in just a little bit further on Specialty Networks  of mix and capabilities , just given the higher margin \nnature of both GPO and analytics solutions.  And then just following up, given the pipeline that you \nmentioned, I was hoping you could share some thoughts on hurdle rates for future deals as that \nbecomes a bigger part of the st ory.  Thank you.  \n Jason Hollar:  Great. ", "original_text": "Jason, you already shared a lot of color around the acquisition, but I was hoping you could \ndig in just a little bit further on Specialty Networks  of mix and capabilities , just given the higher margin \nnature of both GPO and analytics solutions. "}, "hash": "f00ca2d2f166b004fa7533a5915527fe24a2b8702dac7e9a3a6d2c1000a5554d", "class_name": "RelatedNodeInfo"}}, "text": "Thank you for taking my questions and congrats on the continued \nprogress. ", "start_char_idx": 1702, "end_char_idx": 1777, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "e013b527-1b94-4fc2-a7ae-b35abc2b6eae": {"__data__": {"id_": "e013b527-1b94-4fc2-a7ae-b35abc2b6eae", "embedding": null, "metadata": {"window": "Please go ahead.  \n \n Stephanie Davis:   Hey, guys.  Thank you for taking my questions and congrats on the continued \nprogress.  Jason, you already shared a lot of color around the acquisition, but I was hoping you could \ndig in just a little bit further on Specialty Networks  of mix and capabilities , just given the higher margin \nnature of both GPO and analytics solutions.  And then just following up, given the pipeline that you \nmentioned, I was hoping you could share some thoughts on hurdle rates for future deals as that \nbecomes a bigger part of the st ory.  Thank you.  \n Jason Hollar:  Great. ", "original_text": "Jason, you already shared a lot of color around the acquisition, but I was hoping you could \ndig in just a little bit further on Specialty Networks  of mix and capabilities , just given the higher margin \nnature of both GPO and analytics solutions. ", "page_label": "10", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "0be51136-ae11-430d-b0c4-8d03b6d16d4c", "node_type": "4", "metadata": {"page_label": "10", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "e4d3538a4609d0f51019a25623c590d5938685f2ab449c6d5fc681dad0fd35b4", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "7efe25dc-48fc-42f2-b2a8-15752901612b", "node_type": "1", "metadata": {"window": "Our first question is coming from Stephanie Davis, \ncalling f rom Barclays.  Please go ahead.  \n \n Stephanie Davis:   Hey, guys.  Thank you for taking my questions and congrats on the continued \nprogress.  Jason, you already shared a lot of color around the acquisition, but I was hoping you could \ndig in just a little bit further on Specialty Networks  of mix and capabilities , just given the higher margin \nnature of both GPO and analytics solutions.  And then just following up, given the pipeline that you \nmentioned, I was hoping you could share some thoughts on hurdle rates for future deals as that \nbecomes a bigger part of the st ory.  Thank you.  \n", "original_text": "Thank you for taking my questions and congrats on the continued \nprogress. ", "page_label": "10", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "11b9dd2cb5b500c317182f54f93571fcb0e8ce1bad3f7842ed1eb94d8af05dd0", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "75bbcc61-ac12-4770-8da9-5fb27af869f7", "node_type": "1", "metadata": {"window": "Stephanie Davis:   Hey, guys.  Thank you for taking my questions and congrats on the continued \nprogress.  Jason, you already shared a lot of color around the acquisition, but I was hoping you could \ndig in just a little bit further on Specialty Networks  of mix and capabilities , just given the higher margin \nnature of both GPO and analytics solutions.  And then just following up, given the pipeline that you \nmentioned, I was hoping you could share some thoughts on hurdle rates for future deals as that \nbecomes a bigger part of the st ory.  Thank you.  \n Jason Hollar:  Great.  Thanks. ", "original_text": "And then just following up, given the pipeline that you \nmentioned, I was hoping you could share some thoughts on hurdle rates for future deals as that \nbecomes a bigger part of the st ory. "}, "hash": "f23372885bc7d462dd025a6901aefcb2f7b1ae9e000b04c49c4b1e4c892d4fa9", "class_name": "RelatedNodeInfo"}}, "text": "Jason, you already shared a lot of color around the acquisition, but I was hoping you could \ndig in just a little bit further on Specialty Networks  of mix and capabilities , just given the higher margin \nnature of both GPO and analytics solutions. ", "start_char_idx": 1777, "end_char_idx": 2026, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "75bbcc61-ac12-4770-8da9-5fb27af869f7": {"__data__": {"id_": "75bbcc61-ac12-4770-8da9-5fb27af869f7", "embedding": null, "metadata": {"window": "Stephanie Davis:   Hey, guys.  Thank you for taking my questions and congrats on the continued \nprogress.  Jason, you already shared a lot of color around the acquisition, but I was hoping you could \ndig in just a little bit further on Specialty Networks  of mix and capabilities , just given the higher margin \nnature of both GPO and analytics solutions.  And then just following up, given the pipeline that you \nmentioned, I was hoping you could share some thoughts on hurdle rates for future deals as that \nbecomes a bigger part of the st ory.  Thank you.  \n Jason Hollar:  Great.  Thanks. ", "original_text": "And then just following up, given the pipeline that you \nmentioned, I was hoping you could share some thoughts on hurdle rates for future deals as that \nbecomes a bigger part of the st ory. ", "page_label": "10", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "0be51136-ae11-430d-b0c4-8d03b6d16d4c", "node_type": "4", "metadata": {"page_label": "10", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "e4d3538a4609d0f51019a25623c590d5938685f2ab449c6d5fc681dad0fd35b4", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "e013b527-1b94-4fc2-a7ae-b35abc2b6eae", "node_type": "1", "metadata": {"window": "Please go ahead.  \n \n Stephanie Davis:   Hey, guys.  Thank you for taking my questions and congrats on the continued \nprogress.  Jason, you already shared a lot of color around the acquisition, but I was hoping you could \ndig in just a little bit further on Specialty Networks  of mix and capabilities , just given the higher margin \nnature of both GPO and analytics solutions.  And then just following up, given the pipeline that you \nmentioned, I was hoping you could share some thoughts on hurdle rates for future deals as that \nbecomes a bigger part of the st ory.  Thank you.  \n Jason Hollar:  Great. ", "original_text": "Jason, you already shared a lot of color around the acquisition, but I was hoping you could \ndig in just a little bit further on Specialty Networks  of mix and capabilities , just given the higher margin \nnature of both GPO and analytics solutions. ", "page_label": "10", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "fbe3295230f94624091cb4070e33c79a6b37ff20d6eec2346fa1af20ccc4418c", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "e5e8352a-8e14-4201-8c26-a96be3fa17e0", "node_type": "1", "metadata": {"window": "Thank you for taking my questions and congrats on the continued \nprogress.  Jason, you already shared a lot of color around the acquisition, but I was hoping you could \ndig in just a little bit further on Specialty Networks  of mix and capabilities , just given the higher margin \nnature of both GPO and analytics solutions.  And then just following up, given the pipeline that you \nmentioned, I was hoping you could share some thoughts on hurdle rates for future deals as that \nbecomes a bigger part of the st ory.  Thank you.  \n Jason Hollar:  Great.  Thanks.  Good morning, Stephanie. ", "original_text": "Thank you.  \n"}, "hash": "eb7661c977d556a4061ac5f42695dfd7e38340a37b6c7a536ca348527abb806b", "class_name": "RelatedNodeInfo"}}, "text": "And then just following up, given the pipeline that you \nmentioned, I was hoping you could share some thoughts on hurdle rates for future deals as that \nbecomes a bigger part of the st ory. ", "start_char_idx": 2026, "end_char_idx": 2216, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "e5e8352a-8e14-4201-8c26-a96be3fa17e0": {"__data__": {"id_": "e5e8352a-8e14-4201-8c26-a96be3fa17e0", "embedding": null, "metadata": {"window": "Thank you for taking my questions and congrats on the continued \nprogress.  Jason, you already shared a lot of color around the acquisition, but I was hoping you could \ndig in just a little bit further on Specialty Networks  of mix and capabilities , just given the higher margin \nnature of both GPO and analytics solutions.  And then just following up, given the pipeline that you \nmentioned, I was hoping you could share some thoughts on hurdle rates for future deals as that \nbecomes a bigger part of the st ory.  Thank you.  \n Jason Hollar:  Great.  Thanks.  Good morning, Stephanie. ", "original_text": "Thank you.  \n", "page_label": "10", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "0be51136-ae11-430d-b0c4-8d03b6d16d4c", "node_type": "4", "metadata": {"page_label": "10", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "e4d3538a4609d0f51019a25623c590d5938685f2ab449c6d5fc681dad0fd35b4", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "75bbcc61-ac12-4770-8da9-5fb27af869f7", "node_type": "1", "metadata": {"window": "Stephanie Davis:   Hey, guys.  Thank you for taking my questions and congrats on the continued \nprogress.  Jason, you already shared a lot of color around the acquisition, but I was hoping you could \ndig in just a little bit further on Specialty Networks  of mix and capabilities , just given the higher margin \nnature of both GPO and analytics solutions.  And then just following up, given the pipeline that you \nmentioned, I was hoping you could share some thoughts on hurdle rates for future deals as that \nbecomes a bigger part of the st ory.  Thank you.  \n Jason Hollar:  Great.  Thanks. ", "original_text": "And then just following up, given the pipeline that you \nmentioned, I was hoping you could share some thoughts on hurdle rates for future deals as that \nbecomes a bigger part of the st ory. ", "page_label": "10", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "0993022e19c75663b7b9dac0e5909a85dbac7ca24d0962f53c28cf393a01d4aa", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "588b9c19-8c10-456d-ab55-ea023d7d318d", "node_type": "1", "metadata": {"window": "Jason, you already shared a lot of color around the acquisition, but I was hoping you could \ndig in just a little bit further on Specialty Networks  of mix and capabilities , just given the higher margin \nnature of both GPO and analytics solutions.  And then just following up, given the pipeline that you \nmentioned, I was hoping you could share some thoughts on hurdle rates for future deals as that \nbecomes a bigger part of the st ory.  Thank you.  \n Jason Hollar:  Great.  Thanks.  Good morning, Stephanie.  Yeah, we're really excited about Specialty \nNetworks. ", "original_text": "Jason Hollar:  Great. "}, "hash": "84d2cbcb3aee08669d7c3cee2b9918acc4d66232ca97ff232bb4308e82088870", "class_name": "RelatedNodeInfo"}}, "text": "Thank you.  \n", "start_char_idx": 2216, "end_char_idx": 2229, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "588b9c19-8c10-456d-ab55-ea023d7d318d": {"__data__": {"id_": "588b9c19-8c10-456d-ab55-ea023d7d318d", "embedding": null, "metadata": {"window": "Jason, you already shared a lot of color around the acquisition, but I was hoping you could \ndig in just a little bit further on Specialty Networks  of mix and capabilities , just given the higher margin \nnature of both GPO and analytics solutions.  And then just following up, given the pipeline that you \nmentioned, I was hoping you could share some thoughts on hurdle rates for future deals as that \nbecomes a bigger part of the st ory.  Thank you.  \n Jason Hollar:  Great.  Thanks.  Good morning, Stephanie.  Yeah, we're really excited about Specialty \nNetworks. ", "original_text": "Jason Hollar:  Great. ", "page_label": "10", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "0be51136-ae11-430d-b0c4-8d03b6d16d4c", "node_type": "4", "metadata": {"page_label": "10", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "e4d3538a4609d0f51019a25623c590d5938685f2ab449c6d5fc681dad0fd35b4", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "e5e8352a-8e14-4201-8c26-a96be3fa17e0", "node_type": "1", "metadata": {"window": "Thank you for taking my questions and congrats on the continued \nprogress.  Jason, you already shared a lot of color around the acquisition, but I was hoping you could \ndig in just a little bit further on Specialty Networks  of mix and capabilities , just given the higher margin \nnature of both GPO and analytics solutions.  And then just following up, given the pipeline that you \nmentioned, I was hoping you could share some thoughts on hurdle rates for future deals as that \nbecomes a bigger part of the st ory.  Thank you.  \n Jason Hollar:  Great.  Thanks.  Good morning, Stephanie. ", "original_text": "Thank you.  \n", "page_label": "10", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "7a69bc3a01396f63495aa642db77921bb77f0d6442c5fae0e1ef1a0ce1c25d09", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "da5dc87a-5381-4245-ac99-f47e3baa2b9f", "node_type": "1", "metadata": {"window": "And then just following up, given the pipeline that you \nmentioned, I was hoping you could share some thoughts on hurdle rates for future deals as that \nbecomes a bigger part of the st ory.  Thank you.  \n Jason Hollar:  Great.  Thanks.  Good morning, Stephanie.  Yeah, we're really excited about Specialty \nNetworks.  And I love how you asked the question, Stephanie, because it's , there's a lot that goes into \nthis business, and we love all of it . ", "original_text": "Thanks. "}, "hash": "6fdb96500e6a3c3ea07ade46a275f62bb301a81b95638cb16fc490efa7337b53", "class_name": "RelatedNodeInfo"}}, "text": "Jason Hollar:  Great. ", "start_char_idx": 2229, "end_char_idx": 2251, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "da5dc87a-5381-4245-ac99-f47e3baa2b9f": {"__data__": {"id_": "da5dc87a-5381-4245-ac99-f47e3baa2b9f", "embedding": null, "metadata": {"window": "And then just following up, given the pipeline that you \nmentioned, I was hoping you could share some thoughts on hurdle rates for future deals as that \nbecomes a bigger part of the st ory.  Thank you.  \n Jason Hollar:  Great.  Thanks.  Good morning, Stephanie.  Yeah, we're really excited about Specialty \nNetworks.  And I love how you asked the question, Stephanie, because it's , there's a lot that goes into \nthis business, and we love all of it . ", "original_text": "Thanks. ", "page_label": "10", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "0be51136-ae11-430d-b0c4-8d03b6d16d4c", "node_type": "4", "metadata": {"page_label": "10", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "e4d3538a4609d0f51019a25623c590d5938685f2ab449c6d5fc681dad0fd35b4", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "588b9c19-8c10-456d-ab55-ea023d7d318d", "node_type": "1", "metadata": {"window": "Jason, you already shared a lot of color around the acquisition, but I was hoping you could \ndig in just a little bit further on Specialty Networks  of mix and capabilities , just given the higher margin \nnature of both GPO and analytics solutions.  And then just following up, given the pipeline that you \nmentioned, I was hoping you could share some thoughts on hurdle rates for future deals as that \nbecomes a bigger part of the st ory.  Thank you.  \n Jason Hollar:  Great.  Thanks.  Good morning, Stephanie.  Yeah, we're really excited about Specialty \nNetworks. ", "original_text": "Jason Hollar:  Great. ", "page_label": "10", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "58ef2805ce0d2ae8d3fe3302931c55d93eaf37c0bfe6387538e9910f89162800", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "cd7454c5-91b8-442d-b376-8e74bb217dc4", "node_type": "1", "metadata": {"window": "Thank you.  \n Jason Hollar:  Great.  Thanks.  Good morning, Stephanie.  Yeah, we're really excited about Specialty \nNetworks.  And I love how you asked the question, Stephanie, because it's , there's a lot that goes into \nthis business, and we love all of it .  Whether it's the GPO or the analytics and technology behind it, \nspecifically PPS analytics is something we thought was really special, not just in terms of how this \nteam has created this capability for their original primary business of urology, but then ho w they've \nextend ed into other therapeutic areas. ", "original_text": "Good morning, Stephanie. "}, "hash": "713f4edd30020d7e12acd891623d2a024c2e06912b6df2454c7127e3e0b89506", "class_name": "RelatedNodeInfo"}}, "text": "Thanks. ", "start_char_idx": 2251, "end_char_idx": 2259, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "cd7454c5-91b8-442d-b376-8e74bb217dc4": {"__data__": {"id_": "cd7454c5-91b8-442d-b376-8e74bb217dc4", "embedding": null, "metadata": {"window": "Thank you.  \n Jason Hollar:  Great.  Thanks.  Good morning, Stephanie.  Yeah, we're really excited about Specialty \nNetworks.  And I love how you asked the question, Stephanie, because it's , there's a lot that goes into \nthis business, and we love all of it .  Whether it's the GPO or the analytics and technology behind it, \nspecifically PPS analytics is something we thought was really special, not just in terms of how this \nteam has created this capability for their original primary business of urology, but then ho w they've \nextend ed into other therapeutic areas. ", "original_text": "Good morning, Stephanie. ", "page_label": "10", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "0be51136-ae11-430d-b0c4-8d03b6d16d4c", "node_type": "4", "metadata": {"page_label": "10", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "e4d3538a4609d0f51019a25623c590d5938685f2ab449c6d5fc681dad0fd35b4", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "da5dc87a-5381-4245-ac99-f47e3baa2b9f", "node_type": "1", "metadata": {"window": "And then just following up, given the pipeline that you \nmentioned, I was hoping you could share some thoughts on hurdle rates for future deals as that \nbecomes a bigger part of the st ory.  Thank you.  \n Jason Hollar:  Great.  Thanks.  Good morning, Stephanie.  Yeah, we're really excited about Specialty \nNetworks.  And I love how you asked the question, Stephanie, because it's , there's a lot that goes into \nthis business, and we love all of it . ", "original_text": "Thanks. ", "page_label": "10", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "26faebbd5b68f6a0809787abea5a1a985e148e90c6ee2bf50ce5b893da89e020", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "9a77fa52-81e9-43f7-b119-832f43f6201e", "node_type": "1", "metadata": {"window": "Jason Hollar:  Great.  Thanks.  Good morning, Stephanie.  Yeah, we're really excited about Specialty \nNetworks.  And I love how you asked the question, Stephanie, because it's , there's a lot that goes into \nthis business, and we love all of it .  Whether it's the GPO or the analytics and technology behind it, \nspecifically PPS analytics is something we thought was really special, not just in terms of how this \nteam has created this capability for their original primary business of urology, but then ho w they've \nextend ed into other therapeutic areas.  And we felt we could learn from that further and use that \ntechnology across potentially other therapeutic areas beyond the three that they're in today.  ", "original_text": "Yeah, we're really excited about Specialty \nNetworks. "}, "hash": "a5839fda6847419b91200fe88bbbd952d359d591c6a3e222b9dec15482ddf39a", "class_name": "RelatedNodeInfo"}}, "text": "Good morning, Stephanie. ", "start_char_idx": 2259, "end_char_idx": 2284, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "9a77fa52-81e9-43f7-b119-832f43f6201e": {"__data__": {"id_": "9a77fa52-81e9-43f7-b119-832f43f6201e", "embedding": null, "metadata": {"window": "Jason Hollar:  Great.  Thanks.  Good morning, Stephanie.  Yeah, we're really excited about Specialty \nNetworks.  And I love how you asked the question, Stephanie, because it's , there's a lot that goes into \nthis business, and we love all of it .  Whether it's the GPO or the analytics and technology behind it, \nspecifically PPS analytics is something we thought was really special, not just in terms of how this \nteam has created this capability for their original primary business of urology, but then ho w they've \nextend ed into other therapeutic areas.  And we felt we could learn from that further and use that \ntechnology across potentially other therapeutic areas beyond the three that they're in today.  ", "original_text": "Yeah, we're really excited about Specialty \nNetworks. ", "page_label": "10", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "0be51136-ae11-430d-b0c4-8d03b6d16d4c", "node_type": "4", "metadata": {"page_label": "10", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "e4d3538a4609d0f51019a25623c590d5938685f2ab449c6d5fc681dad0fd35b4", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "cd7454c5-91b8-442d-b376-8e74bb217dc4", "node_type": "1", "metadata": {"window": "Thank you.  \n Jason Hollar:  Great.  Thanks.  Good morning, Stephanie.  Yeah, we're really excited about Specialty \nNetworks.  And I love how you asked the question, Stephanie, because it's , there's a lot that goes into \nthis business, and we love all of it .  Whether it's the GPO or the analytics and technology behind it, \nspecifically PPS analytics is something we thought was really special, not just in terms of how this \nteam has created this capability for their original primary business of urology, but then ho w they've \nextend ed into other therapeutic areas. ", "original_text": "Good morning, Stephanie. ", "page_label": "10", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "c26e1e9333168db52bfb4b30a6f5e38876b1ccc76bced6fceeea1ade069ac13f", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "de100211-e95f-48b2-8829-e9daea52cede", "node_type": "1", "metadata": {"window": "Thanks.  Good morning, Stephanie.  Yeah, we're really excited about Specialty \nNetworks.  And I love how you asked the question, Stephanie, because it's , there's a lot that goes into \nthis business, and we love all of it .  Whether it's the GPO or the analytics and technology behind it, \nspecifically PPS analytics is something we thought was really special, not just in terms of how this \nteam has created this capability for their original primary business of urology, but then ho w they've \nextend ed into other therapeutic areas.  And we felt we could learn from that further and use that \ntechnology across potentially other therapeutic areas beyond the three that they're in today.  ", "original_text": "And I love how you asked the question, Stephanie, because it's , there's a lot that goes into \nthis business, and we love all of it . "}, "hash": "be81b0be51ea439df8521c5059f91e18d0a6d5df44b3702bdea9f7617d0ae8d1", "class_name": "RelatedNodeInfo"}}, "text": "Yeah, we're really excited about Specialty \nNetworks. ", "start_char_idx": 2284, "end_char_idx": 2338, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "de100211-e95f-48b2-8829-e9daea52cede": {"__data__": {"id_": "de100211-e95f-48b2-8829-e9daea52cede", "embedding": null, "metadata": {"window": "Thanks.  Good morning, Stephanie.  Yeah, we're really excited about Specialty \nNetworks.  And I love how you asked the question, Stephanie, because it's , there's a lot that goes into \nthis business, and we love all of it .  Whether it's the GPO or the analytics and technology behind it, \nspecifically PPS analytics is something we thought was really special, not just in terms of how this \nteam has created this capability for their original primary business of urology, but then ho w they've \nextend ed into other therapeutic areas.  And we felt we could learn from that further and use that \ntechnology across potentially other therapeutic areas beyond the three that they're in today.  ", "original_text": "And I love how you asked the question, Stephanie, because it's , there's a lot that goes into \nthis business, and we love all of it . ", "page_label": "10", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "0be51136-ae11-430d-b0c4-8d03b6d16d4c", "node_type": "4", "metadata": {"page_label": "10", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "e4d3538a4609d0f51019a25623c590d5938685f2ab449c6d5fc681dad0fd35b4", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "9a77fa52-81e9-43f7-b119-832f43f6201e", "node_type": "1", "metadata": {"window": "Jason Hollar:  Great.  Thanks.  Good morning, Stephanie.  Yeah, we're really excited about Specialty \nNetworks.  And I love how you asked the question, Stephanie, because it's , there's a lot that goes into \nthis business, and we love all of it .  Whether it's the GPO or the analytics and technology behind it, \nspecifically PPS analytics is something we thought was really special, not just in terms of how this \nteam has created this capability for their original primary business of urology, but then ho w they've \nextend ed into other therapeutic areas.  And we felt we could learn from that further and use that \ntechnology across potentially other therapeutic areas beyond the three that they're in today.  ", "original_text": "Yeah, we're really excited about Specialty \nNetworks. ", "page_label": "10", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "1c7cf4e4f899807b79098c086fb9c9631e9289c12fb4bf96fc0796355e120ddf", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "01a973ec-6ff2-440a-92db-8fa255c01bbc", "node_type": "1", "metadata": {"window": "Good morning, Stephanie.  Yeah, we're really excited about Specialty \nNetworks.  And I love how you asked the question, Stephanie, because it's , there's a lot that goes into \nthis business, and we love all of it .  Whether it's the GPO or the analytics and technology behind it, \nspecifically PPS analytics is something we thought was really special, not just in terms of how this \nteam has created this capability for their original primary business of urology, but then ho w they've \nextend ed into other therapeutic areas.  And we felt we could learn from that further and use that \ntechnology across potentially other therapeutic areas beyond the three that they're in today.  ", "original_text": "Whether it's the GPO or the analytics and technology behind it, \nspecifically PPS analytics is something we thought was really special, not just in terms of how this \nteam has created this capability for their original primary business of urology, but then ho w they've \nextend ed into other therapeutic areas. "}, "hash": "6f5f2e5d84c943fcc45c3c398041e839893d02851ee71d9a9b02296eedae6d59", "class_name": "RelatedNodeInfo"}}, "text": "And I love how you asked the question, Stephanie, because it's , there's a lot that goes into \nthis business, and we love all of it . ", "start_char_idx": 2338, "end_char_idx": 2472, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "01a973ec-6ff2-440a-92db-8fa255c01bbc": {"__data__": {"id_": "01a973ec-6ff2-440a-92db-8fa255c01bbc", "embedding": null, "metadata": {"window": "Good morning, Stephanie.  Yeah, we're really excited about Specialty \nNetworks.  And I love how you asked the question, Stephanie, because it's , there's a lot that goes into \nthis business, and we love all of it .  Whether it's the GPO or the analytics and technology behind it, \nspecifically PPS analytics is something we thought was really special, not just in terms of how this \nteam has created this capability for their original primary business of urology, but then ho w they've \nextend ed into other therapeutic areas.  And we felt we could learn from that further and use that \ntechnology across potentially other therapeutic areas beyond the three that they're in today.  ", "original_text": "Whether it's the GPO or the analytics and technology behind it, \nspecifically PPS analytics is something we thought was really special, not just in terms of how this \nteam has created this capability for their original primary business of urology, but then ho w they've \nextend ed into other therapeutic areas. ", "page_label": "10", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "0be51136-ae11-430d-b0c4-8d03b6d16d4c", "node_type": "4", "metadata": {"page_label": "10", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "e4d3538a4609d0f51019a25623c590d5938685f2ab449c6d5fc681dad0fd35b4", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "de100211-e95f-48b2-8829-e9daea52cede", "node_type": "1", "metadata": {"window": "Thanks.  Good morning, Stephanie.  Yeah, we're really excited about Specialty \nNetworks.  And I love how you asked the question, Stephanie, because it's , there's a lot that goes into \nthis business, and we love all of it .  Whether it's the GPO or the analytics and technology behind it, \nspecifically PPS analytics is something we thought was really special, not just in terms of how this \nteam has created this capability for their original primary business of urology, but then ho w they've \nextend ed into other therapeutic areas.  And we felt we could learn from that further and use that \ntechnology across potentially other therapeutic areas beyond the three that they're in today.  ", "original_text": "And I love how you asked the question, Stephanie, because it's , there's a lot that goes into \nthis business, and we love all of it . ", "page_label": "10", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "132a544f72e083023bf906662fd5c7bd52c838c0a9308eadc7ae0464867b540f", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "1742b17b-20ce-43a7-bb47-274ab10fc2bf", "node_type": "1", "metadata": {"window": "Yeah, we're really excited about Specialty \nNetworks.  And I love how you asked the question, Stephanie, because it's , there's a lot that goes into \nthis business, and we love all of it .  Whether it's the GPO or the analytics and technology behind it, \nspecifically PPS analytics is something we thought was really special, not just in terms of how this \nteam has created this capability for their original primary business of urology, but then ho w they've \nextend ed into other therapeutic areas.  And we felt we could learn from that further and use that \ntechnology across potentially other therapeutic areas beyond the three that they're in today.  ", "original_text": "And we felt we could learn from that further and use that \ntechnology across potentially other therapeutic areas beyond the three that they're in today.  "}, "hash": "fbcc4d96a91a2df7ec317060b50209aabc6d21e40f676513efe91337d141b986", "class_name": "RelatedNodeInfo"}}, "text": "Whether it's the GPO or the analytics and technology behind it, \nspecifically PPS analytics is something we thought was really special, not just in terms of how this \nteam has created this capability for their original primary business of urology, but then ho w they've \nextend ed into other therapeutic areas. ", "start_char_idx": 2472, "end_char_idx": 2783, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "1742b17b-20ce-43a7-bb47-274ab10fc2bf": {"__data__": {"id_": "1742b17b-20ce-43a7-bb47-274ab10fc2bf", "embedding": null, "metadata": {"window": "Yeah, we're really excited about Specialty \nNetworks.  And I love how you asked the question, Stephanie, because it's , there's a lot that goes into \nthis business, and we love all of it .  Whether it's the GPO or the analytics and technology behind it, \nspecifically PPS analytics is something we thought was really special, not just in terms of how this \nteam has created this capability for their original primary business of urology, but then ho w they've \nextend ed into other therapeutic areas.  And we felt we could learn from that further and use that \ntechnology across potentially other therapeutic areas beyond the three that they're in today.  ", "original_text": "And we felt we could learn from that further and use that \ntechnology across potentially other therapeutic areas beyond the three that they're in today.  ", "page_label": "10", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "0be51136-ae11-430d-b0c4-8d03b6d16d4c", "node_type": "4", "metadata": {"page_label": "10", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "e4d3538a4609d0f51019a25623c590d5938685f2ab449c6d5fc681dad0fd35b4", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "01a973ec-6ff2-440a-92db-8fa255c01bbc", "node_type": "1", "metadata": {"window": "Good morning, Stephanie.  Yeah, we're really excited about Specialty \nNetworks.  And I love how you asked the question, Stephanie, because it's , there's a lot that goes into \nthis business, and we love all of it .  Whether it's the GPO or the analytics and technology behind it, \nspecifically PPS analytics is something we thought was really special, not just in terms of how this \nteam has created this capability for their original primary business of urology, but then ho w they've \nextend ed into other therapeutic areas.  And we felt we could learn from that further and use that \ntechnology across potentially other therapeutic areas beyond the three that they're in today.  ", "original_text": "Whether it's the GPO or the analytics and technology behind it, \nspecifically PPS analytics is something we thought was really special, not just in terms of how this \nteam has created this capability for their original primary business of urology, but then ho w they've \nextend ed into other therapeutic areas. ", "page_label": "10", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "6e6c36cb434cc0d44baa11d962d6f7d6761ba460a9605a8df19f7d2840e358fa", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "da8c225f-2dc1-4dab-9bb7-0d2d0aa6adc6", "node_type": "1", "metadata": {"window": " \nPage 11 of 19 \n \nSo, that was really exciting to us and it's certainly a key part of the value.  So, we definitely attributed \ngood value to that technology and where we believe that can go.  And not only is that good for our \nbusiness, but importantly, we see that technology is really solving a lot of customer, both provider and \nmanufacturer challenges , and ultimately giving a much better solutions to the end patient.  \n So, it's a win -win across the industry and one that plugs in nicely to our strategy and to be throughout \nthe specialty space. ", "original_text": " \nPage 11 of 19 \n \nSo, that was really exciting to us and it's certainly a key part of the value. "}, "hash": "45af653230ea76fd043dfa2fb949690524cbc6865ac784bb0e263024c4c55939", "class_name": "RelatedNodeInfo"}}, "text": "And we felt we could learn from that further and use that \ntechnology across potentially other therapeutic areas beyond the three that they're in today.  ", "start_char_idx": 2783, "end_char_idx": 2937, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "da8c225f-2dc1-4dab-9bb7-0d2d0aa6adc6": {"__data__": {"id_": "da8c225f-2dc1-4dab-9bb7-0d2d0aa6adc6", "embedding": null, "metadata": {"window": " \nPage 11 of 19 \n \nSo, that was really exciting to us and it's certainly a key part of the value.  So, we definitely attributed \ngood value to that technology and where we believe that can go.  And not only is that good for our \nbusiness, but importantly, we see that technology is really solving a lot of customer, both provider and \nmanufacturer challenges , and ultimately giving a much better solutions to the end patient.  \n So, it's a win -win across the industry and one that plugs in nicely to our strategy and to be throughout \nthe specialty space. ", "original_text": " \nPage 11 of 19 \n \nSo, that was really exciting to us and it's certainly a key part of the value. ", "page_label": "11", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "b4407d4d-b563-4c08-aa98-9c55aec1911f", "node_type": "4", "metadata": {"page_label": "11", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "2e734cba32afda1e64007d444339da8b484d595b5b4674519061166904641ae7", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "1742b17b-20ce-43a7-bb47-274ab10fc2bf", "node_type": "1", "metadata": {"window": "Yeah, we're really excited about Specialty \nNetworks.  And I love how you asked the question, Stephanie, because it's , there's a lot that goes into \nthis business, and we love all of it .  Whether it's the GPO or the analytics and technology behind it, \nspecifically PPS analytics is something we thought was really special, not just in terms of how this \nteam has created this capability for their original primary business of urology, but then ho w they've \nextend ed into other therapeutic areas.  And we felt we could learn from that further and use that \ntechnology across potentially other therapeutic areas beyond the three that they're in today.  ", "original_text": "And we felt we could learn from that further and use that \ntechnology across potentially other therapeutic areas beyond the three that they're in today.  ", "page_label": "10", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "988d9068f4155c33231dcc47bd89daa91d9312db6d4fcc65596b2c2a1c764466", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "7897b9a9-e59a-4e0d-94aa-4f66487a6334", "node_type": "1", "metadata": {"window": " \nPage 11 of 19 \n \nSo, that was really exciting to us and it's certainly a key part of the value.  So, we definitely attributed \ngood value to that technology and where we believe that can go.  And not only is that good for our \nbusiness, but importantly, we see that technology is really solving a lot of customer, both provider and \nmanufacturer challenges , and ultimately giving a much better solutions to the end patient.  \n So, it's a win -win across the industry and one that plugs in nicely to our strategy and to be throughout \nthe specialty space.  So, we feel great about that. ", "original_text": "So, we definitely attributed \ngood value to that technology and where we believe that can go. "}, "hash": "e525f990a48f8910b47ffd00505869c7633e50cce3588db93270d063448fe218", "class_name": "RelatedNodeInfo"}}, "text": " \nPage 11 of 19 \n \nSo, that was really exciting to us and it's certainly a key part of the value. ", "start_char_idx": 0, "end_char_idx": 98, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "7897b9a9-e59a-4e0d-94aa-4f66487a6334": {"__data__": {"id_": "7897b9a9-e59a-4e0d-94aa-4f66487a6334", "embedding": null, "metadata": {"window": " \nPage 11 of 19 \n \nSo, that was really exciting to us and it's certainly a key part of the value.  So, we definitely attributed \ngood value to that technology and where we believe that can go.  And not only is that good for our \nbusiness, but importantly, we see that technology is really solving a lot of customer, both provider and \nmanufacturer challenges , and ultimately giving a much better solutions to the end patient.  \n So, it's a win -win across the industry and one that plugs in nicely to our strategy and to be throughout \nthe specialty space.  So, we feel great about that. ", "original_text": "So, we definitely attributed \ngood value to that technology and where we believe that can go. ", "page_label": "11", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "b4407d4d-b563-4c08-aa98-9c55aec1911f", "node_type": "4", "metadata": {"page_label": "11", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "2e734cba32afda1e64007d444339da8b484d595b5b4674519061166904641ae7", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "da8c225f-2dc1-4dab-9bb7-0d2d0aa6adc6", "node_type": "1", "metadata": {"window": " \nPage 11 of 19 \n \nSo, that was really exciting to us and it's certainly a key part of the value.  So, we definitely attributed \ngood value to that technology and where we believe that can go.  And not only is that good for our \nbusiness, but importantly, we see that technology is really solving a lot of customer, both provider and \nmanufacturer challenges , and ultimately giving a much better solutions to the end patient.  \n So, it's a win -win across the industry and one that plugs in nicely to our strategy and to be throughout \nthe specialty space. ", "original_text": " \nPage 11 of 19 \n \nSo, that was really exciting to us and it's certainly a key part of the value. ", "page_label": "11", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "3df1d88d39e4ac89155633903ed8e7eb3026692cc7d9a3d546761e5b4766a665", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "d6b208c8-07c9-4624-8baf-63f6c6ced31f", "node_type": "1", "metadata": {"window": " \nPage 11 of 19 \n \nSo, that was really exciting to us and it's certainly a key part of the value.  So, we definitely attributed \ngood value to that technology and where we believe that can go.  And not only is that good for our \nbusiness, but importantly, we see that technology is really solving a lot of customer, both provider and \nmanufacturer challenges , and ultimately giving a much better solutions to the end patient.  \n So, it's a win -win across the industry and one that plugs in nicely to our strategy and to be throughout \nthe specialty space.  So, we feel great about that.  And I certainly don't want to miss that we are also \nthrough this transaction, acquiring a fantastic leadership team that will plug in very nicely to our own \nexisting team. ", "original_text": "And not only is that good for our \nbusiness, but importantly, we see that technology is really solving a lot of customer, both provider and \nmanufacturer challenges , and ultimately giving a much better solutions to the end patient.  \n"}, "hash": "975e0247c88119da23c75d1a9f65a64cfd6b4f94314e4376630f1f1cad1e27b9", "class_name": "RelatedNodeInfo"}}, "text": "So, we definitely attributed \ngood value to that technology and where we believe that can go. ", "start_char_idx": 98, "end_char_idx": 192, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "d6b208c8-07c9-4624-8baf-63f6c6ced31f": {"__data__": {"id_": "d6b208c8-07c9-4624-8baf-63f6c6ced31f", "embedding": null, "metadata": {"window": " \nPage 11 of 19 \n \nSo, that was really exciting to us and it's certainly a key part of the value.  So, we definitely attributed \ngood value to that technology and where we believe that can go.  And not only is that good for our \nbusiness, but importantly, we see that technology is really solving a lot of customer, both provider and \nmanufacturer challenges , and ultimately giving a much better solutions to the end patient.  \n So, it's a win -win across the industry and one that plugs in nicely to our strategy and to be throughout \nthe specialty space.  So, we feel great about that.  And I certainly don't want to miss that we are also \nthrough this transaction, acquiring a fantastic leadership team that will plug in very nicely to our own \nexisting team. ", "original_text": "And not only is that good for our \nbusiness, but importantly, we see that technology is really solving a lot of customer, both provider and \nmanufacturer challenges , and ultimately giving a much better solutions to the end patient.  \n", "page_label": "11", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "b4407d4d-b563-4c08-aa98-9c55aec1911f", "node_type": "4", "metadata": {"page_label": "11", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "2e734cba32afda1e64007d444339da8b484d595b5b4674519061166904641ae7", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "7897b9a9-e59a-4e0d-94aa-4f66487a6334", "node_type": "1", "metadata": {"window": " \nPage 11 of 19 \n \nSo, that was really exciting to us and it's certainly a key part of the value.  So, we definitely attributed \ngood value to that technology and where we believe that can go.  And not only is that good for our \nbusiness, but importantly, we see that technology is really solving a lot of customer, both provider and \nmanufacturer challenges , and ultimately giving a much better solutions to the end patient.  \n So, it's a win -win across the industry and one that plugs in nicely to our strategy and to be throughout \nthe specialty space.  So, we feel great about that. ", "original_text": "So, we definitely attributed \ngood value to that technology and where we believe that can go. ", "page_label": "11", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "e74a6d43a8bbf637233184fb7055fd006c81cdfa6b52a3a3b5346fe957f9c30f", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "41da7205-52a9-45ed-b750-0c39e3b0a248", "node_type": "1", "metadata": {"window": " \nPage 11 of 19 \n \nSo, that was really exciting to us and it's certainly a key part of the value.  So, we definitely attributed \ngood value to that technology and where we believe that can go.  And not only is that good for our \nbusiness, but importantly, we see that technology is really solving a lot of customer, both provider and \nmanufacturer challenges , and ultimately giving a much better solutions to the end patient.  \n So, it's a win -win across the industry and one that plugs in nicely to our strategy and to be throughout \nthe specialty space.  So, we feel great about that.  And I certainly don't want to miss that we are also \nthrough this transaction, acquiring a fantastic leadership team that will plug in very nicely to our own \nexisting team.  And so, it's a culture that I think will work very well together. ", "original_text": "So, it's a win -win across the industry and one that plugs in nicely to our strategy and to be throughout \nthe specialty space. "}, "hash": "9c9558ba9072714f45f4ac3b5c789caf78048f2cea026dc96f63ffdcb0fb174a", "class_name": "RelatedNodeInfo"}}, "text": "And not only is that good for our \nbusiness, but importantly, we see that technology is really solving a lot of customer, both provider and \nmanufacturer challenges , and ultimately giving a much better solutions to the end patient.  \n", "start_char_idx": 192, "end_char_idx": 427, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "41da7205-52a9-45ed-b750-0c39e3b0a248": {"__data__": {"id_": "41da7205-52a9-45ed-b750-0c39e3b0a248", "embedding": null, "metadata": {"window": " \nPage 11 of 19 \n \nSo, that was really exciting to us and it's certainly a key part of the value.  So, we definitely attributed \ngood value to that technology and where we believe that can go.  And not only is that good for our \nbusiness, but importantly, we see that technology is really solving a lot of customer, both provider and \nmanufacturer challenges , and ultimately giving a much better solutions to the end patient.  \n So, it's a win -win across the industry and one that plugs in nicely to our strategy and to be throughout \nthe specialty space.  So, we feel great about that.  And I certainly don't want to miss that we are also \nthrough this transaction, acquiring a fantastic leadership team that will plug in very nicely to our own \nexisting team.  And so, it's a culture that I think will work very well together. ", "original_text": "So, it's a win -win across the industry and one that plugs in nicely to our strategy and to be throughout \nthe specialty space. ", "page_label": "11", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "b4407d4d-b563-4c08-aa98-9c55aec1911f", "node_type": "4", "metadata": {"page_label": "11", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "2e734cba32afda1e64007d444339da8b484d595b5b4674519061166904641ae7", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "d6b208c8-07c9-4624-8baf-63f6c6ced31f", "node_type": "1", "metadata": {"window": " \nPage 11 of 19 \n \nSo, that was really exciting to us and it's certainly a key part of the value.  So, we definitely attributed \ngood value to that technology and where we believe that can go.  And not only is that good for our \nbusiness, but importantly, we see that technology is really solving a lot of customer, both provider and \nmanufacturer challenges , and ultimately giving a much better solutions to the end patient.  \n So, it's a win -win across the industry and one that plugs in nicely to our strategy and to be throughout \nthe specialty space.  So, we feel great about that.  And I certainly don't want to miss that we are also \nthrough this transaction, acquiring a fantastic leadership team that will plug in very nicely to our own \nexisting team. ", "original_text": "And not only is that good for our \nbusiness, but importantly, we see that technology is really solving a lot of customer, both provider and \nmanufacturer challenges , and ultimately giving a much better solutions to the end patient.  \n", "page_label": "11", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "ceb6dcfc5ef987eb14970f590f3d711c0d7078cd447e2a4d968902fecfea353c", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "0ebbb8aa-93ef-4691-b413-d9e82728b5c5", "node_type": "1", "metadata": {"window": "So, we definitely attributed \ngood value to that technology and where we believe that can go.  And not only is that good for our \nbusiness, but importantly, we see that technology is really solving a lot of customer, both provider and \nmanufacturer challenges , and ultimately giving a much better solutions to the end patient.  \n So, it's a win -win across the industry and one that plugs in nicely to our strategy and to be throughout \nthe specialty space.  So, we feel great about that.  And I certainly don't want to miss that we are also \nthrough this transaction, acquiring a fantastic leadership team that will plug in very nicely to our own \nexisting team.  And so, it's a culture that I think will work very well together.  And we've had a fantastic, \nvery quick process. ", "original_text": "So, we feel great about that. "}, "hash": "ce8290385fc35bd3e12b4f6e8e6d78155a76d9fe79dcd557677432b3319b8e88", "class_name": "RelatedNodeInfo"}}, "text": "So, it's a win -win across the industry and one that plugs in nicely to our strategy and to be throughout \nthe specialty space. ", "start_char_idx": 427, "end_char_idx": 555, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "0ebbb8aa-93ef-4691-b413-d9e82728b5c5": {"__data__": {"id_": "0ebbb8aa-93ef-4691-b413-d9e82728b5c5", "embedding": null, "metadata": {"window": "So, we definitely attributed \ngood value to that technology and where we believe that can go.  And not only is that good for our \nbusiness, but importantly, we see that technology is really solving a lot of customer, both provider and \nmanufacturer challenges , and ultimately giving a much better solutions to the end patient.  \n So, it's a win -win across the industry and one that plugs in nicely to our strategy and to be throughout \nthe specialty space.  So, we feel great about that.  And I certainly don't want to miss that we are also \nthrough this transaction, acquiring a fantastic leadership team that will plug in very nicely to our own \nexisting team.  And so, it's a culture that I think will work very well together.  And we've had a fantastic, \nvery quick process. ", "original_text": "So, we feel great about that. ", "page_label": "11", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "b4407d4d-b563-4c08-aa98-9c55aec1911f", "node_type": "4", "metadata": {"page_label": "11", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "2e734cba32afda1e64007d444339da8b484d595b5b4674519061166904641ae7", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "41da7205-52a9-45ed-b750-0c39e3b0a248", "node_type": "1", "metadata": {"window": " \nPage 11 of 19 \n \nSo, that was really exciting to us and it's certainly a key part of the value.  So, we definitely attributed \ngood value to that technology and where we believe that can go.  And not only is that good for our \nbusiness, but importantly, we see that technology is really solving a lot of customer, both provider and \nmanufacturer challenges , and ultimately giving a much better solutions to the end patient.  \n So, it's a win -win across the industry and one that plugs in nicely to our strategy and to be throughout \nthe specialty space.  So, we feel great about that.  And I certainly don't want to miss that we are also \nthrough this transaction, acquiring a fantastic leadership team that will plug in very nicely to our own \nexisting team.  And so, it's a culture that I think will work very well together. ", "original_text": "So, it's a win -win across the industry and one that plugs in nicely to our strategy and to be throughout \nthe specialty space. ", "page_label": "11", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "b57050467d8f8c54bfb7a2defe845865043a9624e06b55c8d36a84bc111fb17e", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "7525efe1-c12b-441c-9624-b8865f30aa32", "node_type": "1", "metadata": {"window": "And not only is that good for our \nbusiness, but importantly, we see that technology is really solving a lot of customer, both provider and \nmanufacturer challenges , and ultimately giving a much better solutions to the end patient.  \n So, it's a win -win across the industry and one that plugs in nicely to our strategy and to be throughout \nthe specialty space.  So, we feel great about that.  And I certainly don't want to miss that we are also \nthrough this transaction, acquiring a fantastic leadership team that will plug in very nicely to our own \nexisting team.  And so, it's a culture that I think will work very well together.  And we've had a fantastic, \nvery quick process.  We \u2019ve known Specialty Networks for quite a while, but from the point th at we \nstarted talking about a possible tie up, we went from the beginning to the end, of course, going deep \nand thorough diligence. ", "original_text": "And I certainly don't want to miss that we are also \nthrough this transaction, acquiring a fantastic leadership team that will plug in very nicely to our own \nexisting team. "}, "hash": "d2b07349ec04c4b3852d5a06717450d5ee96cc7e95eafc91f00a9d71fb186bcc", "class_name": "RelatedNodeInfo"}}, "text": "So, we feel great about that. ", "start_char_idx": 555, "end_char_idx": 585, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "7525efe1-c12b-441c-9624-b8865f30aa32": {"__data__": {"id_": "7525efe1-c12b-441c-9624-b8865f30aa32", "embedding": null, "metadata": {"window": "And not only is that good for our \nbusiness, but importantly, we see that technology is really solving a lot of customer, both provider and \nmanufacturer challenges , and ultimately giving a much better solutions to the end patient.  \n So, it's a win -win across the industry and one that plugs in nicely to our strategy and to be throughout \nthe specialty space.  So, we feel great about that.  And I certainly don't want to miss that we are also \nthrough this transaction, acquiring a fantastic leadership team that will plug in very nicely to our own \nexisting team.  And so, it's a culture that I think will work very well together.  And we've had a fantastic, \nvery quick process.  We \u2019ve known Specialty Networks for quite a while, but from the point th at we \nstarted talking about a possible tie up, we went from the beginning to the end, of course, going deep \nand thorough diligence. ", "original_text": "And I certainly don't want to miss that we are also \nthrough this transaction, acquiring a fantastic leadership team that will plug in very nicely to our own \nexisting team. ", "page_label": "11", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "b4407d4d-b563-4c08-aa98-9c55aec1911f", "node_type": "4", "metadata": {"page_label": "11", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "2e734cba32afda1e64007d444339da8b484d595b5b4674519061166904641ae7", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "0ebbb8aa-93ef-4691-b413-d9e82728b5c5", "node_type": "1", "metadata": {"window": "So, we definitely attributed \ngood value to that technology and where we believe that can go.  And not only is that good for our \nbusiness, but importantly, we see that technology is really solving a lot of customer, both provider and \nmanufacturer challenges , and ultimately giving a much better solutions to the end patient.  \n So, it's a win -win across the industry and one that plugs in nicely to our strategy and to be throughout \nthe specialty space.  So, we feel great about that.  And I certainly don't want to miss that we are also \nthrough this transaction, acquiring a fantastic leadership team that will plug in very nicely to our own \nexisting team.  And so, it's a culture that I think will work very well together.  And we've had a fantastic, \nvery quick process. ", "original_text": "So, we feel great about that. ", "page_label": "11", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "b0b70f32d97b39c587dd73b30d5de0dd19c73c0ec9b434c1a266dee9898308cf", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "db85f13a-5c9f-4676-b788-eeb119826fe2", "node_type": "1", "metadata": {"window": "So, it's a win -win across the industry and one that plugs in nicely to our strategy and to be throughout \nthe specialty space.  So, we feel great about that.  And I certainly don't want to miss that we are also \nthrough this transaction, acquiring a fantastic leadership team that will plug in very nicely to our own \nexisting team.  And so, it's a culture that I think will work very well together.  And we've had a fantastic, \nvery quick process.  We \u2019ve known Specialty Networks for quite a while, but from the point th at we \nstarted talking about a possible tie up, we went from the beginning to the end, of course, going deep \nand thorough diligence.  But, nonetheless, knowing the business well so that we could quickly \nunderstand the value for us.  \n", "original_text": "And so, it's a culture that I think will work very well together. "}, "hash": "3f0d44c0e7dd7f6a8972880997ebd47a8311b02a0c0908cafd146dcba2fefdfd", "class_name": "RelatedNodeInfo"}}, "text": "And I certainly don't want to miss that we are also \nthrough this transaction, acquiring a fantastic leadership team that will plug in very nicely to our own \nexisting team. ", "start_char_idx": 585, "end_char_idx": 759, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "db85f13a-5c9f-4676-b788-eeb119826fe2": {"__data__": {"id_": "db85f13a-5c9f-4676-b788-eeb119826fe2", "embedding": null, "metadata": {"window": "So, it's a win -win across the industry and one that plugs in nicely to our strategy and to be throughout \nthe specialty space.  So, we feel great about that.  And I certainly don't want to miss that we are also \nthrough this transaction, acquiring a fantastic leadership team that will plug in very nicely to our own \nexisting team.  And so, it's a culture that I think will work very well together.  And we've had a fantastic, \nvery quick process.  We \u2019ve known Specialty Networks for quite a while, but from the point th at we \nstarted talking about a possible tie up, we went from the beginning to the end, of course, going deep \nand thorough diligence.  But, nonetheless, knowing the business well so that we could quickly \nunderstand the value for us.  \n", "original_text": "And so, it's a culture that I think will work very well together. ", "page_label": "11", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "b4407d4d-b563-4c08-aa98-9c55aec1911f", "node_type": "4", "metadata": {"page_label": "11", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "2e734cba32afda1e64007d444339da8b484d595b5b4674519061166904641ae7", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "7525efe1-c12b-441c-9624-b8865f30aa32", "node_type": "1", "metadata": {"window": "And not only is that good for our \nbusiness, but importantly, we see that technology is really solving a lot of customer, both provider and \nmanufacturer challenges , and ultimately giving a much better solutions to the end patient.  \n So, it's a win -win across the industry and one that plugs in nicely to our strategy and to be throughout \nthe specialty space.  So, we feel great about that.  And I certainly don't want to miss that we are also \nthrough this transaction, acquiring a fantastic leadership team that will plug in very nicely to our own \nexisting team.  And so, it's a culture that I think will work very well together.  And we've had a fantastic, \nvery quick process.  We \u2019ve known Specialty Networks for quite a while, but from the point th at we \nstarted talking about a possible tie up, we went from the beginning to the end, of course, going deep \nand thorough diligence. ", "original_text": "And I certainly don't want to miss that we are also \nthrough this transaction, acquiring a fantastic leadership team that will plug in very nicely to our own \nexisting team. ", "page_label": "11", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "a5ccde625ec2c9c6599052a99cee36cb984d2904b17c2012db7c0f0816c1e7e4", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "481dd25a-a48f-467d-abc8-8c7f00c10400", "node_type": "1", "metadata": {"window": "So, we feel great about that.  And I certainly don't want to miss that we are also \nthrough this transaction, acquiring a fantastic leadership team that will plug in very nicely to our own \nexisting team.  And so, it's a culture that I think will work very well together.  And we've had a fantastic, \nvery quick process.  We \u2019ve known Specialty Networks for quite a while, but from the point th at we \nstarted talking about a possible tie up, we went from the beginning to the end, of course, going deep \nand thorough diligence.  But, nonetheless, knowing the business well so that we could quickly \nunderstand the value for us.  \n As it relates to your second question on hurdle rates, I'm not sure exactly, which part of the business \nyou're referring to. ", "original_text": "And we've had a fantastic, \nvery quick process. "}, "hash": "53c85c8779b794550139c034ae5edee04bdd645291c09b79c03884bde6edf6a7", "class_name": "RelatedNodeInfo"}}, "text": "And so, it's a culture that I think will work very well together. ", "start_char_idx": 759, "end_char_idx": 825, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "481dd25a-a48f-467d-abc8-8c7f00c10400": {"__data__": {"id_": "481dd25a-a48f-467d-abc8-8c7f00c10400", "embedding": null, "metadata": {"window": "So, we feel great about that.  And I certainly don't want to miss that we are also \nthrough this transaction, acquiring a fantastic leadership team that will plug in very nicely to our own \nexisting team.  And so, it's a culture that I think will work very well together.  And we've had a fantastic, \nvery quick process.  We \u2019ve known Specialty Networks for quite a while, but from the point th at we \nstarted talking about a possible tie up, we went from the beginning to the end, of course, going deep \nand thorough diligence.  But, nonetheless, knowing the business well so that we could quickly \nunderstand the value for us.  \n As it relates to your second question on hurdle rates, I'm not sure exactly, which part of the business \nyou're referring to. ", "original_text": "And we've had a fantastic, \nvery quick process. ", "page_label": "11", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "b4407d4d-b563-4c08-aa98-9c55aec1911f", "node_type": "4", "metadata": {"page_label": "11", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "2e734cba32afda1e64007d444339da8b484d595b5b4674519061166904641ae7", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "db85f13a-5c9f-4676-b788-eeb119826fe2", "node_type": "1", "metadata": {"window": "So, it's a win -win across the industry and one that plugs in nicely to our strategy and to be throughout \nthe specialty space.  So, we feel great about that.  And I certainly don't want to miss that we are also \nthrough this transaction, acquiring a fantastic leadership team that will plug in very nicely to our own \nexisting team.  And so, it's a culture that I think will work very well together.  And we've had a fantastic, \nvery quick process.  We \u2019ve known Specialty Networks for quite a while, but from the point th at we \nstarted talking about a possible tie up, we went from the beginning to the end, of course, going deep \nand thorough diligence.  But, nonetheless, knowing the business well so that we could quickly \nunderstand the value for us.  \n", "original_text": "And so, it's a culture that I think will work very well together. ", "page_label": "11", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "a81128588c22555cd5f111f7ac5605eb809cbac235d6f2495c0a7878ba3dda15", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "e05c2758-a557-4cc8-95f7-8721e3831a4e", "node_type": "1", "metadata": {"window": "And I certainly don't want to miss that we are also \nthrough this transaction, acquiring a fantastic leadership team that will plug in very nicely to our own \nexisting team.  And so, it's a culture that I think will work very well together.  And we've had a fantastic, \nvery quick process.  We \u2019ve known Specialty Networks for quite a while, but from the point th at we \nstarted talking about a possible tie up, we went from the beginning to the end, of course, going deep \nand thorough diligence.  But, nonetheless, knowing the business well so that we could quickly \nunderstand the value for us.  \n As it relates to your second question on hurdle rates, I'm not sure exactly, which part of the business \nyou're referring to.  But generally speaking, I think no matter what part of our business we're talking \nabout, it's a competitive and stable type of envi ronment. ", "original_text": "We \u2019ve known Specialty Networks for quite a while, but from the point th at we \nstarted talking about a possible tie up, we went from the beginning to the end, of course, going deep \nand thorough diligence. "}, "hash": "b1463ca7dec380c0c8ee4268bc07b120c55dc2b9bb4b15ddeec85e93f3c28d73", "class_name": "RelatedNodeInfo"}}, "text": "And we've had a fantastic, \nvery quick process. ", "start_char_idx": 825, "end_char_idx": 873, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "e05c2758-a557-4cc8-95f7-8721e3831a4e": {"__data__": {"id_": "e05c2758-a557-4cc8-95f7-8721e3831a4e", "embedding": null, "metadata": {"window": "And I certainly don't want to miss that we are also \nthrough this transaction, acquiring a fantastic leadership team that will plug in very nicely to our own \nexisting team.  And so, it's a culture that I think will work very well together.  And we've had a fantastic, \nvery quick process.  We \u2019ve known Specialty Networks for quite a while, but from the point th at we \nstarted talking about a possible tie up, we went from the beginning to the end, of course, going deep \nand thorough diligence.  But, nonetheless, knowing the business well so that we could quickly \nunderstand the value for us.  \n As it relates to your second question on hurdle rates, I'm not sure exactly, which part of the business \nyou're referring to.  But generally speaking, I think no matter what part of our business we're talking \nabout, it's a competitive and stable type of envi ronment. ", "original_text": "We \u2019ve known Specialty Networks for quite a while, but from the point th at we \nstarted talking about a possible tie up, we went from the beginning to the end, of course, going deep \nand thorough diligence. ", "page_label": "11", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "b4407d4d-b563-4c08-aa98-9c55aec1911f", "node_type": "4", "metadata": {"page_label": "11", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "2e734cba32afda1e64007d444339da8b484d595b5b4674519061166904641ae7", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "481dd25a-a48f-467d-abc8-8c7f00c10400", "node_type": "1", "metadata": {"window": "So, we feel great about that.  And I certainly don't want to miss that we are also \nthrough this transaction, acquiring a fantastic leadership team that will plug in very nicely to our own \nexisting team.  And so, it's a culture that I think will work very well together.  And we've had a fantastic, \nvery quick process.  We \u2019ve known Specialty Networks for quite a while, but from the point th at we \nstarted talking about a possible tie up, we went from the beginning to the end, of course, going deep \nand thorough diligence.  But, nonetheless, knowing the business well so that we could quickly \nunderstand the value for us.  \n As it relates to your second question on hurdle rates, I'm not sure exactly, which part of the business \nyou're referring to. ", "original_text": "And we've had a fantastic, \nvery quick process. ", "page_label": "11", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "dcc5d3a8595a9cbc9e462340759b2ad2e27f187012e661df46658f8beb83dd0b", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "4f673dfa-ee43-4082-9091-67651040c039", "node_type": "1", "metadata": {"window": "And so, it's a culture that I think will work very well together.  And we've had a fantastic, \nvery quick process.  We \u2019ve known Specialty Networks for quite a while, but from the point th at we \nstarted talking about a possible tie up, we went from the beginning to the end, of course, going deep \nand thorough diligence.  But, nonetheless, knowing the business well so that we could quickly \nunderstand the value for us.  \n As it relates to your second question on hurdle rates, I'm not sure exactly, which part of the business \nyou're referring to.  But generally speaking, I think no matter what part of our business we're talking \nabout, it's a competitive and stable type of envi ronment.  So, I'm not normally going to go deeper into \nthat anyways, but generally speaking, we're not really calling out anything from an overall market \nperspective today regardless of what our business we're talking about, utilization continues to be \nquite good and predictable. ", "original_text": "But, nonetheless, knowing the business well so that we could quickly \nunderstand the value for us.  \n"}, "hash": "7d17ed5448c351122b179b6b9ca82b0a200067bcaa25433d2421c5612c83a801", "class_name": "RelatedNodeInfo"}}, "text": "We \u2019ve known Specialty Networks for quite a while, but from the point th at we \nstarted talking about a possible tie up, we went from the beginning to the end, of course, going deep \nand thorough diligence. ", "start_char_idx": 873, "end_char_idx": 1080, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "4f673dfa-ee43-4082-9091-67651040c039": {"__data__": {"id_": "4f673dfa-ee43-4082-9091-67651040c039", "embedding": null, "metadata": {"window": "And so, it's a culture that I think will work very well together.  And we've had a fantastic, \nvery quick process.  We \u2019ve known Specialty Networks for quite a while, but from the point th at we \nstarted talking about a possible tie up, we went from the beginning to the end, of course, going deep \nand thorough diligence.  But, nonetheless, knowing the business well so that we could quickly \nunderstand the value for us.  \n As it relates to your second question on hurdle rates, I'm not sure exactly, which part of the business \nyou're referring to.  But generally speaking, I think no matter what part of our business we're talking \nabout, it's a competitive and stable type of envi ronment.  So, I'm not normally going to go deeper into \nthat anyways, but generally speaking, we're not really calling out anything from an overall market \nperspective today regardless of what our business we're talking about, utilization continues to be \nquite good and predictable. ", "original_text": "But, nonetheless, knowing the business well so that we could quickly \nunderstand the value for us.  \n", "page_label": "11", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "b4407d4d-b563-4c08-aa98-9c55aec1911f", "node_type": "4", "metadata": {"page_label": "11", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "2e734cba32afda1e64007d444339da8b484d595b5b4674519061166904641ae7", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "e05c2758-a557-4cc8-95f7-8721e3831a4e", "node_type": "1", "metadata": {"window": "And I certainly don't want to miss that we are also \nthrough this transaction, acquiring a fantastic leadership team that will plug in very nicely to our own \nexisting team.  And so, it's a culture that I think will work very well together.  And we've had a fantastic, \nvery quick process.  We \u2019ve known Specialty Networks for quite a while, but from the point th at we \nstarted talking about a possible tie up, we went from the beginning to the end, of course, going deep \nand thorough diligence.  But, nonetheless, knowing the business well so that we could quickly \nunderstand the value for us.  \n As it relates to your second question on hurdle rates, I'm not sure exactly, which part of the business \nyou're referring to.  But generally speaking, I think no matter what part of our business we're talking \nabout, it's a competitive and stable type of envi ronment. ", "original_text": "We \u2019ve known Specialty Networks for quite a while, but from the point th at we \nstarted talking about a possible tie up, we went from the beginning to the end, of course, going deep \nand thorough diligence. ", "page_label": "11", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "6fabe046b51d1f0399994d89641799e42b5d9c936df663e8dd193b14f9604eb7", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "458dbdf3-09fa-4c9e-ba92-8519ea6a1df5", "node_type": "1", "metadata": {"window": "And we've had a fantastic, \nvery quick process.  We \u2019ve known Specialty Networks for quite a while, but from the point th at we \nstarted talking about a possible tie up, we went from the beginning to the end, of course, going deep \nand thorough diligence.  But, nonetheless, knowing the business well so that we could quickly \nunderstand the value for us.  \n As it relates to your second question on hurdle rates, I'm not sure exactly, which part of the business \nyou're referring to.  But generally speaking, I think no matter what part of our business we're talking \nabout, it's a competitive and stable type of envi ronment.  So, I'm not normally going to go deeper into \nthat anyways, but generally speaking, we're not really calling out anything from an overall market \nperspective today regardless of what our business we're talking about, utilization continues to be \nquite good and predictable.  So, we're in a nice environment for ongoing growth, both organically as \nwell as then able to look opportunistically at transactions like this.  \n \n", "original_text": "As it relates to your second question on hurdle rates, I'm not sure exactly, which part of the business \nyou're referring to. "}, "hash": "92ca36b9f1e1e61a4e383f7cf42f27246c47075af7655b1d5bbd2ec566503634", "class_name": "RelatedNodeInfo"}}, "text": "But, nonetheless, knowing the business well so that we could quickly \nunderstand the value for us.  \n", "start_char_idx": 1080, "end_char_idx": 1181, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "458dbdf3-09fa-4c9e-ba92-8519ea6a1df5": {"__data__": {"id_": "458dbdf3-09fa-4c9e-ba92-8519ea6a1df5", "embedding": null, "metadata": {"window": "And we've had a fantastic, \nvery quick process.  We \u2019ve known Specialty Networks for quite a while, but from the point th at we \nstarted talking about a possible tie up, we went from the beginning to the end, of course, going deep \nand thorough diligence.  But, nonetheless, knowing the business well so that we could quickly \nunderstand the value for us.  \n As it relates to your second question on hurdle rates, I'm not sure exactly, which part of the business \nyou're referring to.  But generally speaking, I think no matter what part of our business we're talking \nabout, it's a competitive and stable type of envi ronment.  So, I'm not normally going to go deeper into \nthat anyways, but generally speaking, we're not really calling out anything from an overall market \nperspective today regardless of what our business we're talking about, utilization continues to be \nquite good and predictable.  So, we're in a nice environment for ongoing growth, both organically as \nwell as then able to look opportunistically at transactions like this.  \n \n", "original_text": "As it relates to your second question on hurdle rates, I'm not sure exactly, which part of the business \nyou're referring to. ", "page_label": "11", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "b4407d4d-b563-4c08-aa98-9c55aec1911f", "node_type": "4", "metadata": {"page_label": "11", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "2e734cba32afda1e64007d444339da8b484d595b5b4674519061166904641ae7", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "4f673dfa-ee43-4082-9091-67651040c039", "node_type": "1", "metadata": {"window": "And so, it's a culture that I think will work very well together.  And we've had a fantastic, \nvery quick process.  We \u2019ve known Specialty Networks for quite a while, but from the point th at we \nstarted talking about a possible tie up, we went from the beginning to the end, of course, going deep \nand thorough diligence.  But, nonetheless, knowing the business well so that we could quickly \nunderstand the value for us.  \n As it relates to your second question on hurdle rates, I'm not sure exactly, which part of the business \nyou're referring to.  But generally speaking, I think no matter what part of our business we're talking \nabout, it's a competitive and stable type of envi ronment.  So, I'm not normally going to go deeper into \nthat anyways, but generally speaking, we're not really calling out anything from an overall market \nperspective today regardless of what our business we're talking about, utilization continues to be \nquite good and predictable. ", "original_text": "But, nonetheless, knowing the business well so that we could quickly \nunderstand the value for us.  \n", "page_label": "11", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "1972e5eed8da13e47d86388c96a6cabc92618d7e30d466c8cd1972a576502afc", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "46667162-05bd-4bce-be1d-abd52f201488", "node_type": "1", "metadata": {"window": "We \u2019ve known Specialty Networks for quite a while, but from the point th at we \nstarted talking about a possible tie up, we went from the beginning to the end, of course, going deep \nand thorough diligence.  But, nonetheless, knowing the business well so that we could quickly \nunderstand the value for us.  \n As it relates to your second question on hurdle rates, I'm not sure exactly, which part of the business \nyou're referring to.  But generally speaking, I think no matter what part of our business we're talking \nabout, it's a competitive and stable type of envi ronment.  So, I'm not normally going to go deeper into \nthat anyways, but generally speaking, we're not really calling out anything from an overall market \nperspective today regardless of what our business we're talking about, utilization continues to be \nquite good and predictable.  So, we're in a nice environment for ongoing growth, both organically as \nwell as then able to look opportunistically at transactions like this.  \n \n Aaron Alt:  Probably worth noting that it is a profitable business today. ", "original_text": "But generally speaking, I think no matter what part of our business we're talking \nabout, it's a competitive and stable type of envi ronment. "}, "hash": "5f84d199d81923bdb0be01b8936ecc57af8df24c66c866a885a6ce3d44070476", "class_name": "RelatedNodeInfo"}}, "text": "As it relates to your second question on hurdle rates, I'm not sure exactly, which part of the business \nyou're referring to. ", "start_char_idx": 1181, "end_char_idx": 1307, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "46667162-05bd-4bce-be1d-abd52f201488": {"__data__": {"id_": "46667162-05bd-4bce-be1d-abd52f201488", "embedding": null, "metadata": {"window": "We \u2019ve known Specialty Networks for quite a while, but from the point th at we \nstarted talking about a possible tie up, we went from the beginning to the end, of course, going deep \nand thorough diligence.  But, nonetheless, knowing the business well so that we could quickly \nunderstand the value for us.  \n As it relates to your second question on hurdle rates, I'm not sure exactly, which part of the business \nyou're referring to.  But generally speaking, I think no matter what part of our business we're talking \nabout, it's a competitive and stable type of envi ronment.  So, I'm not normally going to go deeper into \nthat anyways, but generally speaking, we're not really calling out anything from an overall market \nperspective today regardless of what our business we're talking about, utilization continues to be \nquite good and predictable.  So, we're in a nice environment for ongoing growth, both organically as \nwell as then able to look opportunistically at transactions like this.  \n \n Aaron Alt:  Probably worth noting that it is a profitable business today. ", "original_text": "But generally speaking, I think no matter what part of our business we're talking \nabout, it's a competitive and stable type of envi ronment. ", "page_label": "11", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "b4407d4d-b563-4c08-aa98-9c55aec1911f", "node_type": "4", "metadata": {"page_label": "11", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "2e734cba32afda1e64007d444339da8b484d595b5b4674519061166904641ae7", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "458dbdf3-09fa-4c9e-ba92-8519ea6a1df5", "node_type": "1", "metadata": {"window": "And we've had a fantastic, \nvery quick process.  We \u2019ve known Specialty Networks for quite a while, but from the point th at we \nstarted talking about a possible tie up, we went from the beginning to the end, of course, going deep \nand thorough diligence.  But, nonetheless, knowing the business well so that we could quickly \nunderstand the value for us.  \n As it relates to your second question on hurdle rates, I'm not sure exactly, which part of the business \nyou're referring to.  But generally speaking, I think no matter what part of our business we're talking \nabout, it's a competitive and stable type of envi ronment.  So, I'm not normally going to go deeper into \nthat anyways, but generally speaking, we're not really calling out anything from an overall market \nperspective today regardless of what our business we're talking about, utilization continues to be \nquite good and predictable.  So, we're in a nice environment for ongoing growth, both organically as \nwell as then able to look opportunistically at transactions like this.  \n \n", "original_text": "As it relates to your second question on hurdle rates, I'm not sure exactly, which part of the business \nyou're referring to. ", "page_label": "11", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "c38e357de1b3325e587c3bd44b67b213b6ac82f9e7bfb9d39c7f97eb09cd1133", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "ca2880cd-622f-4084-9382-3ceb3e291910", "node_type": "1", "metadata": {"window": "But, nonetheless, knowing the business well so that we could quickly \nunderstand the value for us.  \n As it relates to your second question on hurdle rates, I'm not sure exactly, which part of the business \nyou're referring to.  But generally speaking, I think no matter what part of our business we're talking \nabout, it's a competitive and stable type of envi ronment.  So, I'm not normally going to go deeper into \nthat anyways, but generally speaking, we're not really calling out anything from an overall market \nperspective today regardless of what our business we're talking about, utilization continues to be \nquite good and predictable.  So, we're in a nice environment for ongoing growth, both organically as \nwell as then able to look opportunistically at transactions like this.  \n \n Aaron Alt:  Probably worth noting that it is a profitable business today.  And as Jason highlighted, we \ndo intend to invest in the business early on to expand the scope of what they are doing across not \nonly their own initiatives, but our initiatives within Specialty as well.  \n \n", "original_text": "So, I'm not normally going to go deeper into \nthat anyways, but generally speaking, we're not really calling out anything from an overall market \nperspective today regardless of what our business we're talking about, utilization continues to be \nquite good and predictable. "}, "hash": "654c16f73a55b55eef97b30d1dd7a521852826a7810a1dcb126b86b3f1496888", "class_name": "RelatedNodeInfo"}}, "text": "But generally speaking, I think no matter what part of our business we're talking \nabout, it's a competitive and stable type of envi ronment. ", "start_char_idx": 1307, "end_char_idx": 1449, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "ca2880cd-622f-4084-9382-3ceb3e291910": {"__data__": {"id_": "ca2880cd-622f-4084-9382-3ceb3e291910", "embedding": null, "metadata": {"window": "But, nonetheless, knowing the business well so that we could quickly \nunderstand the value for us.  \n As it relates to your second question on hurdle rates, I'm not sure exactly, which part of the business \nyou're referring to.  But generally speaking, I think no matter what part of our business we're talking \nabout, it's a competitive and stable type of envi ronment.  So, I'm not normally going to go deeper into \nthat anyways, but generally speaking, we're not really calling out anything from an overall market \nperspective today regardless of what our business we're talking about, utilization continues to be \nquite good and predictable.  So, we're in a nice environment for ongoing growth, both organically as \nwell as then able to look opportunistically at transactions like this.  \n \n Aaron Alt:  Probably worth noting that it is a profitable business today.  And as Jason highlighted, we \ndo intend to invest in the business early on to expand the scope of what they are doing across not \nonly their own initiatives, but our initiatives within Specialty as well.  \n \n", "original_text": "So, I'm not normally going to go deeper into \nthat anyways, but generally speaking, we're not really calling out anything from an overall market \nperspective today regardless of what our business we're talking about, utilization continues to be \nquite good and predictable. ", "page_label": "11", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "b4407d4d-b563-4c08-aa98-9c55aec1911f", "node_type": "4", "metadata": {"page_label": "11", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "2e734cba32afda1e64007d444339da8b484d595b5b4674519061166904641ae7", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "46667162-05bd-4bce-be1d-abd52f201488", "node_type": "1", "metadata": {"window": "We \u2019ve known Specialty Networks for quite a while, but from the point th at we \nstarted talking about a possible tie up, we went from the beginning to the end, of course, going deep \nand thorough diligence.  But, nonetheless, knowing the business well so that we could quickly \nunderstand the value for us.  \n As it relates to your second question on hurdle rates, I'm not sure exactly, which part of the business \nyou're referring to.  But generally speaking, I think no matter what part of our business we're talking \nabout, it's a competitive and stable type of envi ronment.  So, I'm not normally going to go deeper into \nthat anyways, but generally speaking, we're not really calling out anything from an overall market \nperspective today regardless of what our business we're talking about, utilization continues to be \nquite good and predictable.  So, we're in a nice environment for ongoing growth, both organically as \nwell as then able to look opportunistically at transactions like this.  \n \n Aaron Alt:  Probably worth noting that it is a profitable business today. ", "original_text": "But generally speaking, I think no matter what part of our business we're talking \nabout, it's a competitive and stable type of envi ronment. ", "page_label": "11", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "228c7d659c210b3bcc7741e2f8fcc7524741ab1e00c7d32f9776bbadcc9263ca", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "b62b2866-0edf-4585-bf8a-04fa73151984", "node_type": "1", "metadata": {"window": "As it relates to your second question on hurdle rates, I'm not sure exactly, which part of the business \nyou're referring to.  But generally speaking, I think no matter what part of our business we're talking \nabout, it's a competitive and stable type of envi ronment.  So, I'm not normally going to go deeper into \nthat anyways, but generally speaking, we're not really calling out anything from an overall market \nperspective today regardless of what our business we're talking about, utilization continues to be \nquite good and predictable.  So, we're in a nice environment for ongoing growth, both organically as \nwell as then able to look opportunistically at transactions like this.  \n \n Aaron Alt:  Probably worth noting that it is a profitable business today.  And as Jason highlighted, we \ndo intend to invest in the business early on to expand the scope of what they are doing across not \nonly their own initiatives, but our initiatives within Specialty as well.  \n \n Operator:  Ladies and gentlemen, our next question is going to be  coming from  Lisa Gill calling from \nJPMorgan. ", "original_text": "So, we're in a nice environment for ongoing growth, both organically as \nwell as then able to look opportunistically at transactions like this.  \n \n"}, "hash": "40832660412639b942036e4344756c240b329d9372f907aeb5b0cfcf35d208c9", "class_name": "RelatedNodeInfo"}}, "text": "So, I'm not normally going to go deeper into \nthat anyways, but generally speaking, we're not really calling out anything from an overall market \nperspective today regardless of what our business we're talking about, utilization continues to be \nquite good and predictable. ", "start_char_idx": 1449, "end_char_idx": 1723, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "b62b2866-0edf-4585-bf8a-04fa73151984": {"__data__": {"id_": "b62b2866-0edf-4585-bf8a-04fa73151984", "embedding": null, "metadata": {"window": "As it relates to your second question on hurdle rates, I'm not sure exactly, which part of the business \nyou're referring to.  But generally speaking, I think no matter what part of our business we're talking \nabout, it's a competitive and stable type of envi ronment.  So, I'm not normally going to go deeper into \nthat anyways, but generally speaking, we're not really calling out anything from an overall market \nperspective today regardless of what our business we're talking about, utilization continues to be \nquite good and predictable.  So, we're in a nice environment for ongoing growth, both organically as \nwell as then able to look opportunistically at transactions like this.  \n \n Aaron Alt:  Probably worth noting that it is a profitable business today.  And as Jason highlighted, we \ndo intend to invest in the business early on to expand the scope of what they are doing across not \nonly their own initiatives, but our initiatives within Specialty as well.  \n \n Operator:  Ladies and gentlemen, our next question is going to be  coming from  Lisa Gill calling from \nJPMorgan. ", "original_text": "So, we're in a nice environment for ongoing growth, both organically as \nwell as then able to look opportunistically at transactions like this.  \n \n", "page_label": "11", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "b4407d4d-b563-4c08-aa98-9c55aec1911f", "node_type": "4", "metadata": {"page_label": "11", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "2e734cba32afda1e64007d444339da8b484d595b5b4674519061166904641ae7", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "ca2880cd-622f-4084-9382-3ceb3e291910", "node_type": "1", "metadata": {"window": "But, nonetheless, knowing the business well so that we could quickly \nunderstand the value for us.  \n As it relates to your second question on hurdle rates, I'm not sure exactly, which part of the business \nyou're referring to.  But generally speaking, I think no matter what part of our business we're talking \nabout, it's a competitive and stable type of envi ronment.  So, I'm not normally going to go deeper into \nthat anyways, but generally speaking, we're not really calling out anything from an overall market \nperspective today regardless of what our business we're talking about, utilization continues to be \nquite good and predictable.  So, we're in a nice environment for ongoing growth, both organically as \nwell as then able to look opportunistically at transactions like this.  \n \n Aaron Alt:  Probably worth noting that it is a profitable business today.  And as Jason highlighted, we \ndo intend to invest in the business early on to expand the scope of what they are doing across not \nonly their own initiatives, but our initiatives within Specialty as well.  \n \n", "original_text": "So, I'm not normally going to go deeper into \nthat anyways, but generally speaking, we're not really calling out anything from an overall market \nperspective today regardless of what our business we're talking about, utilization continues to be \nquite good and predictable. ", "page_label": "11", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "310d5d1f864162a8d4cc930aa8c3098f8e4443cf40750fc27bea650273dda69a", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "3d832961-1de6-41df-b9f7-8fcee26e3bc9", "node_type": "1", "metadata": {"window": "But generally speaking, I think no matter what part of our business we're talking \nabout, it's a competitive and stable type of envi ronment.  So, I'm not normally going to go deeper into \nthat anyways, but generally speaking, we're not really calling out anything from an overall market \nperspective today regardless of what our business we're talking about, utilization continues to be \nquite good and predictable.  So, we're in a nice environment for ongoing growth, both organically as \nwell as then able to look opportunistically at transactions like this.  \n \n Aaron Alt:  Probably worth noting that it is a profitable business today.  And as Jason highlighted, we \ndo intend to invest in the business early on to expand the scope of what they are doing across not \nonly their own initiatives, but our initiatives within Specialty as well.  \n \n Operator:  Ladies and gentlemen, our next question is going to be  coming from  Lisa Gill calling from \nJPMorgan.  Please go ahead.  \n \n", "original_text": "Aaron Alt:  Probably worth noting that it is a profitable business today. "}, "hash": "64d20fde586dbb57ea84a817fdc0264837a3b9a254587f245345fa6867fb2749", "class_name": "RelatedNodeInfo"}}, "text": "So, we're in a nice environment for ongoing growth, both organically as \nwell as then able to look opportunistically at transactions like this.  \n \n", "start_char_idx": 1723, "end_char_idx": 1871, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "3d832961-1de6-41df-b9f7-8fcee26e3bc9": {"__data__": {"id_": "3d832961-1de6-41df-b9f7-8fcee26e3bc9", "embedding": null, "metadata": {"window": "But generally speaking, I think no matter what part of our business we're talking \nabout, it's a competitive and stable type of envi ronment.  So, I'm not normally going to go deeper into \nthat anyways, but generally speaking, we're not really calling out anything from an overall market \nperspective today regardless of what our business we're talking about, utilization continues to be \nquite good and predictable.  So, we're in a nice environment for ongoing growth, both organically as \nwell as then able to look opportunistically at transactions like this.  \n \n Aaron Alt:  Probably worth noting that it is a profitable business today.  And as Jason highlighted, we \ndo intend to invest in the business early on to expand the scope of what they are doing across not \nonly their own initiatives, but our initiatives within Specialty as well.  \n \n Operator:  Ladies and gentlemen, our next question is going to be  coming from  Lisa Gill calling from \nJPMorgan.  Please go ahead.  \n \n", "original_text": "Aaron Alt:  Probably worth noting that it is a profitable business today. ", "page_label": "11", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "b4407d4d-b563-4c08-aa98-9c55aec1911f", "node_type": "4", "metadata": {"page_label": "11", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "2e734cba32afda1e64007d444339da8b484d595b5b4674519061166904641ae7", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "b62b2866-0edf-4585-bf8a-04fa73151984", "node_type": "1", "metadata": {"window": "As it relates to your second question on hurdle rates, I'm not sure exactly, which part of the business \nyou're referring to.  But generally speaking, I think no matter what part of our business we're talking \nabout, it's a competitive and stable type of envi ronment.  So, I'm not normally going to go deeper into \nthat anyways, but generally speaking, we're not really calling out anything from an overall market \nperspective today regardless of what our business we're talking about, utilization continues to be \nquite good and predictable.  So, we're in a nice environment for ongoing growth, both organically as \nwell as then able to look opportunistically at transactions like this.  \n \n Aaron Alt:  Probably worth noting that it is a profitable business today.  And as Jason highlighted, we \ndo intend to invest in the business early on to expand the scope of what they are doing across not \nonly their own initiatives, but our initiatives within Specialty as well.  \n \n Operator:  Ladies and gentlemen, our next question is going to be  coming from  Lisa Gill calling from \nJPMorgan. ", "original_text": "So, we're in a nice environment for ongoing growth, both organically as \nwell as then able to look opportunistically at transactions like this.  \n \n", "page_label": "11", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "23239473814768b2f4b681b9fbdf24220c0474669427fa61f16ccf9a7f976e94", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "ec908560-986a-4256-9e9e-fa0292bd2a3c", "node_type": "1", "metadata": {"window": "So, I'm not normally going to go deeper into \nthat anyways, but generally speaking, we're not really calling out anything from an overall market \nperspective today regardless of what our business we're talking about, utilization continues to be \nquite good and predictable.  So, we're in a nice environment for ongoing growth, both organically as \nwell as then able to look opportunistically at transactions like this.  \n \n Aaron Alt:  Probably worth noting that it is a profitable business today.  And as Jason highlighted, we \ndo intend to invest in the business early on to expand the scope of what they are doing across not \nonly their own initiatives, but our initiatives within Specialty as well.  \n \n Operator:  Ladies and gentlemen, our next question is going to be  coming from  Lisa Gill calling from \nJPMorgan.  Please go ahead.  \n \n Lisa Gill:   Thanks very much for taking my question, and good morning. ", "original_text": "And as Jason highlighted, we \ndo intend to invest in the business early on to expand the scope of what they are doing across not \nonly their own initiatives, but our initiatives within Specialty as well.  \n \n"}, "hash": "ebc53efc4a21825a471b5a879645e3a7150fdaec580c4e54e0dc4fe4dbbbb8d9", "class_name": "RelatedNodeInfo"}}, "text": "Aaron Alt:  Probably worth noting that it is a profitable business today. ", "start_char_idx": 1871, "end_char_idx": 1945, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "ec908560-986a-4256-9e9e-fa0292bd2a3c": {"__data__": {"id_": "ec908560-986a-4256-9e9e-fa0292bd2a3c", "embedding": null, "metadata": {"window": "So, I'm not normally going to go deeper into \nthat anyways, but generally speaking, we're not really calling out anything from an overall market \nperspective today regardless of what our business we're talking about, utilization continues to be \nquite good and predictable.  So, we're in a nice environment for ongoing growth, both organically as \nwell as then able to look opportunistically at transactions like this.  \n \n Aaron Alt:  Probably worth noting that it is a profitable business today.  And as Jason highlighted, we \ndo intend to invest in the business early on to expand the scope of what they are doing across not \nonly their own initiatives, but our initiatives within Specialty as well.  \n \n Operator:  Ladies and gentlemen, our next question is going to be  coming from  Lisa Gill calling from \nJPMorgan.  Please go ahead.  \n \n Lisa Gill:   Thanks very much for taking my question, and good morning. ", "original_text": "And as Jason highlighted, we \ndo intend to invest in the business early on to expand the scope of what they are doing across not \nonly their own initiatives, but our initiatives within Specialty as well.  \n \n", "page_label": "11", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "b4407d4d-b563-4c08-aa98-9c55aec1911f", "node_type": "4", "metadata": {"page_label": "11", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "2e734cba32afda1e64007d444339da8b484d595b5b4674519061166904641ae7", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "3d832961-1de6-41df-b9f7-8fcee26e3bc9", "node_type": "1", "metadata": {"window": "But generally speaking, I think no matter what part of our business we're talking \nabout, it's a competitive and stable type of envi ronment.  So, I'm not normally going to go deeper into \nthat anyways, but generally speaking, we're not really calling out anything from an overall market \nperspective today regardless of what our business we're talking about, utilization continues to be \nquite good and predictable.  So, we're in a nice environment for ongoing growth, both organically as \nwell as then able to look opportunistically at transactions like this.  \n \n Aaron Alt:  Probably worth noting that it is a profitable business today.  And as Jason highlighted, we \ndo intend to invest in the business early on to expand the scope of what they are doing across not \nonly their own initiatives, but our initiatives within Specialty as well.  \n \n Operator:  Ladies and gentlemen, our next question is going to be  coming from  Lisa Gill calling from \nJPMorgan.  Please go ahead.  \n \n", "original_text": "Aaron Alt:  Probably worth noting that it is a profitable business today. ", "page_label": "11", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "0a2f2a58a8547d1be29451589932a17e071d5d6f06b0eda4bb9c6cef9cf57321", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "03ab3e2f-3931-41b6-b691-1718e5d2ede2", "node_type": "1", "metadata": {"window": "So, we're in a nice environment for ongoing growth, both organically as \nwell as then able to look opportunistically at transactions like this.  \n \n Aaron Alt:  Probably worth noting that it is a profitable business today.  And as Jason highlighted, we \ndo intend to invest in the business early on to expand the scope of what they are doing across not \nonly their own initiatives, but our initiatives within Specialty as well.  \n \n Operator:  Ladies and gentlemen, our next question is going to be  coming from  Lisa Gill calling from \nJPMorgan.  Please go ahead.  \n \n Lisa Gill:   Thanks very much for taking my question, and good morning.  Just really wanted to ask two \nthings, Jason. ", "original_text": "Operator:  Ladies and gentlemen, our next question is going to be  coming from  Lisa Gill calling from \nJPMorgan. "}, "hash": "732b68e35a5835812b9b2041248f17054534f68ece3cbae04570af1eb18abb2a", "class_name": "RelatedNodeInfo"}}, "text": "And as Jason highlighted, we \ndo intend to invest in the business early on to expand the scope of what they are doing across not \nonly their own initiatives, but our initiatives within Specialty as well.  \n \n", "start_char_idx": 1945, "end_char_idx": 2153, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "03ab3e2f-3931-41b6-b691-1718e5d2ede2": {"__data__": {"id_": "03ab3e2f-3931-41b6-b691-1718e5d2ede2", "embedding": null, "metadata": {"window": "So, we're in a nice environment for ongoing growth, both organically as \nwell as then able to look opportunistically at transactions like this.  \n \n Aaron Alt:  Probably worth noting that it is a profitable business today.  And as Jason highlighted, we \ndo intend to invest in the business early on to expand the scope of what they are doing across not \nonly their own initiatives, but our initiatives within Specialty as well.  \n \n Operator:  Ladies and gentlemen, our next question is going to be  coming from  Lisa Gill calling from \nJPMorgan.  Please go ahead.  \n \n Lisa Gill:   Thanks very much for taking my question, and good morning.  Just really wanted to ask two \nthings, Jason. ", "original_text": "Operator:  Ladies and gentlemen, our next question is going to be  coming from  Lisa Gill calling from \nJPMorgan. ", "page_label": "11", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "b4407d4d-b563-4c08-aa98-9c55aec1911f", "node_type": "4", "metadata": {"page_label": "11", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "2e734cba32afda1e64007d444339da8b484d595b5b4674519061166904641ae7", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "ec908560-986a-4256-9e9e-fa0292bd2a3c", "node_type": "1", "metadata": {"window": "So, I'm not normally going to go deeper into \nthat anyways, but generally speaking, we're not really calling out anything from an overall market \nperspective today regardless of what our business we're talking about, utilization continues to be \nquite good and predictable.  So, we're in a nice environment for ongoing growth, both organically as \nwell as then able to look opportunistically at transactions like this.  \n \n Aaron Alt:  Probably worth noting that it is a profitable business today.  And as Jason highlighted, we \ndo intend to invest in the business early on to expand the scope of what they are doing across not \nonly their own initiatives, but our initiatives within Specialty as well.  \n \n Operator:  Ladies and gentlemen, our next question is going to be  coming from  Lisa Gill calling from \nJPMorgan.  Please go ahead.  \n \n Lisa Gill:   Thanks very much for taking my question, and good morning. ", "original_text": "And as Jason highlighted, we \ndo intend to invest in the business early on to expand the scope of what they are doing across not \nonly their own initiatives, but our initiatives within Specialty as well.  \n \n", "page_label": "11", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "1c9ab20088110d25280247c9e142893123b643c2820cadef1e3753a26b90793f", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "b3304d79-f196-409e-b3a8-fbe621a7a113", "node_type": "1", "metadata": {"window": "Aaron Alt:  Probably worth noting that it is a profitable business today.  And as Jason highlighted, we \ndo intend to invest in the business early on to expand the scope of what they are doing across not \nonly their own initiatives, but our initiatives within Specialty as well.  \n \n Operator:  Ladies and gentlemen, our next question is going to be  coming from  Lisa Gill calling from \nJPMorgan.  Please go ahead.  \n \n Lisa Gill:   Thanks very much for taking my question, and good morning.  Just really wanted to ask two \nthings, Jason.  One, on the strategic side as we think about your core Medical business. ", "original_text": "Please go ahead.  \n \n"}, "hash": "9ca727116eedeb4357bebbe7a3941b2d0c0c5a3bc033b8637df663e8150b7bad", "class_name": "RelatedNodeInfo"}}, "text": "Operator:  Ladies and gentlemen, our next question is going to be  coming from  Lisa Gill calling from \nJPMorgan. ", "start_char_idx": 2153, "end_char_idx": 2267, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "b3304d79-f196-409e-b3a8-fbe621a7a113": {"__data__": {"id_": "b3304d79-f196-409e-b3a8-fbe621a7a113", "embedding": null, "metadata": {"window": "Aaron Alt:  Probably worth noting that it is a profitable business today.  And as Jason highlighted, we \ndo intend to invest in the business early on to expand the scope of what they are doing across not \nonly their own initiatives, but our initiatives within Specialty as well.  \n \n Operator:  Ladies and gentlemen, our next question is going to be  coming from  Lisa Gill calling from \nJPMorgan.  Please go ahead.  \n \n Lisa Gill:   Thanks very much for taking my question, and good morning.  Just really wanted to ask two \nthings, Jason.  One, on the strategic side as we think about your core Medical business. ", "original_text": "Please go ahead.  \n \n", "page_label": "11", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "b4407d4d-b563-4c08-aa98-9c55aec1911f", "node_type": "4", "metadata": {"page_label": "11", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "2e734cba32afda1e64007d444339da8b484d595b5b4674519061166904641ae7", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "03ab3e2f-3931-41b6-b691-1718e5d2ede2", "node_type": "1", "metadata": {"window": "So, we're in a nice environment for ongoing growth, both organically as \nwell as then able to look opportunistically at transactions like this.  \n \n Aaron Alt:  Probably worth noting that it is a profitable business today.  And as Jason highlighted, we \ndo intend to invest in the business early on to expand the scope of what they are doing across not \nonly their own initiatives, but our initiatives within Specialty as well.  \n \n Operator:  Ladies and gentlemen, our next question is going to be  coming from  Lisa Gill calling from \nJPMorgan.  Please go ahead.  \n \n Lisa Gill:   Thanks very much for taking my question, and good morning.  Just really wanted to ask two \nthings, Jason. ", "original_text": "Operator:  Ladies and gentlemen, our next question is going to be  coming from  Lisa Gill calling from \nJPMorgan. ", "page_label": "11", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "ddf24e8056a8649d950ecbb7612940f97b3d1bfb1e4dbc99f722ed2349b0a2a4", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "b647a521-8609-4b97-ae49-6af447026582", "node_type": "1", "metadata": {"window": "And as Jason highlighted, we \ndo intend to invest in the business early on to expand the scope of what they are doing across not \nonly their own initiatives, but our initiatives within Specialty as well.  \n \n Operator:  Ladies and gentlemen, our next question is going to be  coming from  Lisa Gill calling from \nJPMorgan.  Please go ahead.  \n \n Lisa Gill:   Thanks very much for taking my question, and good morning.  Just really wanted to ask two \nthings, Jason.  One, on the strategic side as we think about your core Medical business.  One, do you \nstill feel a commitment to that business going forward?  ", "original_text": "Lisa Gill:   Thanks very much for taking my question, and good morning. "}, "hash": "df0efedcc546696bf6fc62b9ac098fd7236fb9c457a14a42593fc5e840a68f45", "class_name": "RelatedNodeInfo"}}, "text": "Please go ahead.  \n \n", "start_char_idx": 2267, "end_char_idx": 2288, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "b647a521-8609-4b97-ae49-6af447026582": {"__data__": {"id_": "b647a521-8609-4b97-ae49-6af447026582", "embedding": null, "metadata": {"window": "And as Jason highlighted, we \ndo intend to invest in the business early on to expand the scope of what they are doing across not \nonly their own initiatives, but our initiatives within Specialty as well.  \n \n Operator:  Ladies and gentlemen, our next question is going to be  coming from  Lisa Gill calling from \nJPMorgan.  Please go ahead.  \n \n Lisa Gill:   Thanks very much for taking my question, and good morning.  Just really wanted to ask two \nthings, Jason.  One, on the strategic side as we think about your core Medical business.  One, do you \nstill feel a commitment to that business going forward?  ", "original_text": "Lisa Gill:   Thanks very much for taking my question, and good morning. ", "page_label": "11", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "b4407d4d-b563-4c08-aa98-9c55aec1911f", "node_type": "4", "metadata": {"page_label": "11", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "2e734cba32afda1e64007d444339da8b484d595b5b4674519061166904641ae7", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "b3304d79-f196-409e-b3a8-fbe621a7a113", "node_type": "1", "metadata": {"window": "Aaron Alt:  Probably worth noting that it is a profitable business today.  And as Jason highlighted, we \ndo intend to invest in the business early on to expand the scope of what they are doing across not \nonly their own initiatives, but our initiatives within Specialty as well.  \n \n Operator:  Ladies and gentlemen, our next question is going to be  coming from  Lisa Gill calling from \nJPMorgan.  Please go ahead.  \n \n Lisa Gill:   Thanks very much for taking my question, and good morning.  Just really wanted to ask two \nthings, Jason.  One, on the strategic side as we think about your core Medical business. ", "original_text": "Please go ahead.  \n \n", "page_label": "11", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "68daa7217ffc185ef6a9690c1015862bdbb11a048009028166656fc25d70edd6", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "cca5ad36-2127-463f-be4b-4ad243e9df99", "node_type": "1", "metadata": {"window": "Operator:  Ladies and gentlemen, our next question is going to be  coming from  Lisa Gill calling from \nJPMorgan.  Please go ahead.  \n \n Lisa Gill:   Thanks very much for taking my question, and good morning.  Just really wanted to ask two \nthings, Jason.  One, on the strategic side as we think about your core Medical business.  One, do you \nstill feel a commitment to that business going forward?   And then secondly, as we think about the shift \nand the new reporting structure, it does look like you're taking down the margin on the core business. \n", "original_text": "Just really wanted to ask two \nthings, Jason. "}, "hash": "116fde0b39446ef43164bf4a32b21bd5835382a81d7388ba536b4d7e4a5007b9", "class_name": "RelatedNodeInfo"}}, "text": "Lisa Gill:   Thanks very much for taking my question, and good morning. ", "start_char_idx": 2288, "end_char_idx": 2360, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "cca5ad36-2127-463f-be4b-4ad243e9df99": {"__data__": {"id_": "cca5ad36-2127-463f-be4b-4ad243e9df99", "embedding": null, "metadata": {"window": "Operator:  Ladies and gentlemen, our next question is going to be  coming from  Lisa Gill calling from \nJPMorgan.  Please go ahead.  \n \n Lisa Gill:   Thanks very much for taking my question, and good morning.  Just really wanted to ask two \nthings, Jason.  One, on the strategic side as we think about your core Medical business.  One, do you \nstill feel a commitment to that business going forward?   And then secondly, as we think about the shift \nand the new reporting structure, it does look like you're taking down the margin on the core business. \n", "original_text": "Just really wanted to ask two \nthings, Jason. ", "page_label": "11", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "b4407d4d-b563-4c08-aa98-9c55aec1911f", "node_type": "4", "metadata": {"page_label": "11", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "2e734cba32afda1e64007d444339da8b484d595b5b4674519061166904641ae7", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "b647a521-8609-4b97-ae49-6af447026582", "node_type": "1", "metadata": {"window": "And as Jason highlighted, we \ndo intend to invest in the business early on to expand the scope of what they are doing across not \nonly their own initiatives, but our initiatives within Specialty as well.  \n \n Operator:  Ladies and gentlemen, our next question is going to be  coming from  Lisa Gill calling from \nJPMorgan.  Please go ahead.  \n \n Lisa Gill:   Thanks very much for taking my question, and good morning.  Just really wanted to ask two \nthings, Jason.  One, on the strategic side as we think about your core Medical business.  One, do you \nstill feel a commitment to that business going forward?  ", "original_text": "Lisa Gill:   Thanks very much for taking my question, and good morning. ", "page_label": "11", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "81f2f069f1416e62f369a70c8622ca50db70c1b490e0f913d9c5ae6db6623491", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "9b99e806-62e9-434d-9ae5-9a6fdb561630", "node_type": "1", "metadata": {"window": "Please go ahead.  \n \n Lisa Gill:   Thanks very much for taking my question, and good morning.  Just really wanted to ask two \nthings, Jason.  One, on the strategic side as we think about your core Medical business.  One, do you \nstill feel a commitment to that business going forward?   And then secondly, as we think about the shift \nand the new reporting structure, it does look like you're taking down the margin on the core business. \n Is there something that's either changing and the timeline  of the turnaround? ", "original_text": "One, on the strategic side as we think about your core Medical business. "}, "hash": "eeac7ac16323be404fdc1325f57296be96fff1f8650143239ddc8b622d4a43e8", "class_name": "RelatedNodeInfo"}}, "text": "Just really wanted to ask two \nthings, Jason. ", "start_char_idx": 2360, "end_char_idx": 2406, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "9b99e806-62e9-434d-9ae5-9a6fdb561630": {"__data__": {"id_": "9b99e806-62e9-434d-9ae5-9a6fdb561630", "embedding": null, "metadata": {"window": "Please go ahead.  \n \n Lisa Gill:   Thanks very much for taking my question, and good morning.  Just really wanted to ask two \nthings, Jason.  One, on the strategic side as we think about your core Medical business.  One, do you \nstill feel a commitment to that business going forward?   And then secondly, as we think about the shift \nand the new reporting structure, it does look like you're taking down the margin on the core business. \n Is there something that's either changing and the timeline  of the turnaround? ", "original_text": "One, on the strategic side as we think about your core Medical business. ", "page_label": "11", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "b4407d4d-b563-4c08-aa98-9c55aec1911f", "node_type": "4", "metadata": {"page_label": "11", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "2e734cba32afda1e64007d444339da8b484d595b5b4674519061166904641ae7", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "cca5ad36-2127-463f-be4b-4ad243e9df99", "node_type": "1", "metadata": {"window": "Operator:  Ladies and gentlemen, our next question is going to be  coming from  Lisa Gill calling from \nJPMorgan.  Please go ahead.  \n \n Lisa Gill:   Thanks very much for taking my question, and good morning.  Just really wanted to ask two \nthings, Jason.  One, on the strategic side as we think about your core Medical business.  One, do you \nstill feel a commitment to that business going forward?   And then secondly, as we think about the shift \nand the new reporting structure, it does look like you're taking down the margin on the core business. \n", "original_text": "Just really wanted to ask two \nthings, Jason. ", "page_label": "11", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "9a897515bcc2900d2a06dab2fc5ed8116d596d768bdeb1af990bf341317f9a69", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "6a73f8c1-43fa-49ea-8528-5ad6dea2421e", "node_type": "1", "metadata": {"window": "Lisa Gill:   Thanks very much for taking my question, and good morning.  Just really wanted to ask two \nthings, Jason.  One, on the strategic side as we think about your core Medical business.  One, do you \nstill feel a commitment to that business going forward?   And then secondly, as we think about the shift \nand the new reporting structure, it does look like you're taking down the margin on the core business. \n Is there something that's either changing and the timeline  of the turnaround?  Is there something else \nthat's shifting competitively or incremental costs? ", "original_text": "One, do you \nstill feel a commitment to that business going forward?  "}, "hash": "c70899b1fefded70ecc78c5499b323f1a0f67523a6588da1816c58da612cb4b8", "class_name": "RelatedNodeInfo"}}, "text": "One, on the strategic side as we think about your core Medical business. ", "start_char_idx": 2406, "end_char_idx": 2479, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "6a73f8c1-43fa-49ea-8528-5ad6dea2421e": {"__data__": {"id_": "6a73f8c1-43fa-49ea-8528-5ad6dea2421e", "embedding": null, "metadata": {"window": "Lisa Gill:   Thanks very much for taking my question, and good morning.  Just really wanted to ask two \nthings, Jason.  One, on the strategic side as we think about your core Medical business.  One, do you \nstill feel a commitment to that business going forward?   And then secondly, as we think about the shift \nand the new reporting structure, it does look like you're taking down the margin on the core business. \n Is there something that's either changing and the timeline  of the turnaround?  Is there something else \nthat's shifting competitively or incremental costs? ", "original_text": "One, do you \nstill feel a commitment to that business going forward?  ", "page_label": "11", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "b4407d4d-b563-4c08-aa98-9c55aec1911f", "node_type": "4", "metadata": {"page_label": "11", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "2e734cba32afda1e64007d444339da8b484d595b5b4674519061166904641ae7", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "9b99e806-62e9-434d-9ae5-9a6fdb561630", "node_type": "1", "metadata": {"window": "Please go ahead.  \n \n Lisa Gill:   Thanks very much for taking my question, and good morning.  Just really wanted to ask two \nthings, Jason.  One, on the strategic side as we think about your core Medical business.  One, do you \nstill feel a commitment to that business going forward?   And then secondly, as we think about the shift \nand the new reporting structure, it does look like you're taking down the margin on the core business. \n Is there something that's either changing and the timeline  of the turnaround? ", "original_text": "One, on the strategic side as we think about your core Medical business. ", "page_label": "11", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "ec0461296a6b385125800a2c718f5b4d47ed4db42ca5db7d6cd952db398eacb7", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "4d028826-cb65-4f5c-8b3d-51a1ccc5f21e", "node_type": "1", "metadata": {"window": "Just really wanted to ask two \nthings, Jason.  One, on the strategic side as we think about your core Medical business.  One, do you \nstill feel a commitment to that business going forward?   And then secondly, as we think about the shift \nand the new reporting structure, it does look like you're taking down the margin on the core business. \n Is there something that's either changing and the timeline  of the turnaround?  Is there something else \nthat's shifting competitively or incremental costs?  If you could just help us understand that. ", "original_text": "And then secondly, as we think about the shift \nand the new reporting structure, it does look like you're taking down the margin on the core business. \n"}, "hash": "ecc7553c6c25f585ef9f04dc5f767e27a04f0761216a0055ef5330bbeb98d306", "class_name": "RelatedNodeInfo"}}, "text": "One, do you \nstill feel a commitment to that business going forward?  ", "start_char_idx": 2479, "end_char_idx": 2549, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "4d028826-cb65-4f5c-8b3d-51a1ccc5f21e": {"__data__": {"id_": "4d028826-cb65-4f5c-8b3d-51a1ccc5f21e", "embedding": null, "metadata": {"window": "Just really wanted to ask two \nthings, Jason.  One, on the strategic side as we think about your core Medical business.  One, do you \nstill feel a commitment to that business going forward?   And then secondly, as we think about the shift \nand the new reporting structure, it does look like you're taking down the margin on the core business. \n Is there something that's either changing and the timeline  of the turnaround?  Is there something else \nthat's shifting competitively or incremental costs?  If you could just help us understand that. ", "original_text": "And then secondly, as we think about the shift \nand the new reporting structure, it does look like you're taking down the margin on the core business. \n", "page_label": "11", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "b4407d4d-b563-4c08-aa98-9c55aec1911f", "node_type": "4", "metadata": {"page_label": "11", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "2e734cba32afda1e64007d444339da8b484d595b5b4674519061166904641ae7", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "6a73f8c1-43fa-49ea-8528-5ad6dea2421e", "node_type": "1", "metadata": {"window": "Lisa Gill:   Thanks very much for taking my question, and good morning.  Just really wanted to ask two \nthings, Jason.  One, on the strategic side as we think about your core Medical business.  One, do you \nstill feel a commitment to that business going forward?   And then secondly, as we think about the shift \nand the new reporting structure, it does look like you're taking down the margin on the core business. \n Is there something that's either changing and the timeline  of the turnaround?  Is there something else \nthat's shifting competitively or incremental costs? ", "original_text": "One, do you \nstill feel a commitment to that business going forward?  ", "page_label": "11", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "f0f5292fb00b214dea7d15d90f2351529587cd5891c9b4774a55e5bd42959ab8", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "11c2f803-5bdf-450e-834f-eca7bfaec6ff", "node_type": "1", "metadata": {"window": "One, on the strategic side as we think about your core Medical business.  One, do you \nstill feel a commitment to that business going forward?   And then secondly, as we think about the shift \nand the new reporting structure, it does look like you're taking down the margin on the core business. \n Is there something that's either changing and the timeline  of the turnaround?  Is there something else \nthat's shifting competitively or incremental costs?  If you could just help us understand that.  Thanks so \nmuch.  \n \n", "original_text": "Is there something that's either changing and the timeline  of the turnaround? "}, "hash": "0ddbe763206177f2f474ca4664376f2d43f903d2babdb6d92f011b04bbc56de2", "class_name": "RelatedNodeInfo"}}, "text": "And then secondly, as we think about the shift \nand the new reporting structure, it does look like you're taking down the margin on the core business. \n", "start_char_idx": 2549, "end_char_idx": 2701, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "11c2f803-5bdf-450e-834f-eca7bfaec6ff": {"__data__": {"id_": "11c2f803-5bdf-450e-834f-eca7bfaec6ff", "embedding": null, "metadata": {"window": "One, on the strategic side as we think about your core Medical business.  One, do you \nstill feel a commitment to that business going forward?   And then secondly, as we think about the shift \nand the new reporting structure, it does look like you're taking down the margin on the core business. \n Is there something that's either changing and the timeline  of the turnaround?  Is there something else \nthat's shifting competitively or incremental costs?  If you could just help us understand that.  Thanks so \nmuch.  \n \n", "original_text": "Is there something that's either changing and the timeline  of the turnaround? ", "page_label": "11", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "b4407d4d-b563-4c08-aa98-9c55aec1911f", "node_type": "4", "metadata": {"page_label": "11", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "2e734cba32afda1e64007d444339da8b484d595b5b4674519061166904641ae7", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "4d028826-cb65-4f5c-8b3d-51a1ccc5f21e", "node_type": "1", "metadata": {"window": "Just really wanted to ask two \nthings, Jason.  One, on the strategic side as we think about your core Medical business.  One, do you \nstill feel a commitment to that business going forward?   And then secondly, as we think about the shift \nand the new reporting structure, it does look like you're taking down the margin on the core business. \n Is there something that's either changing and the timeline  of the turnaround?  Is there something else \nthat's shifting competitively or incremental costs?  If you could just help us understand that. ", "original_text": "And then secondly, as we think about the shift \nand the new reporting structure, it does look like you're taking down the margin on the core business. \n", "page_label": "11", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "6cd6c95a657a4a268f682836d0788f4178dd2aca794caa3d651a226fdbe9acf2", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "6051638b-89fb-4e3d-9d88-ccce6b72047b", "node_type": "1", "metadata": {"window": "One, do you \nstill feel a commitment to that business going forward?   And then secondly, as we think about the shift \nand the new reporting structure, it does look like you're taking down the margin on the core business. \n Is there something that's either changing and the timeline  of the turnaround?  Is there something else \nthat's shifting competitively or incremental costs?  If you could just help us understand that.  Thanks so \nmuch.  \n \n Jason Hollar:  Sure, Lisa. ", "original_text": "Is there something else \nthat's shifting competitively or incremental costs? "}, "hash": "284ce11a1962e3ab76da46850339091342b5bf7313f2f96e6a29287c3655a871", "class_name": "RelatedNodeInfo"}}, "text": "Is there something that's either changing and the timeline  of the turnaround? ", "start_char_idx": 2701, "end_char_idx": 2780, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "6051638b-89fb-4e3d-9d88-ccce6b72047b": {"__data__": {"id_": "6051638b-89fb-4e3d-9d88-ccce6b72047b", "embedding": null, "metadata": {"window": "One, do you \nstill feel a commitment to that business going forward?   And then secondly, as we think about the shift \nand the new reporting structure, it does look like you're taking down the margin on the core business. \n Is there something that's either changing and the timeline  of the turnaround?  Is there something else \nthat's shifting competitively or incremental costs?  If you could just help us understand that.  Thanks so \nmuch.  \n \n Jason Hollar:  Sure, Lisa. ", "original_text": "Is there something else \nthat's shifting competitively or incremental costs? ", "page_label": "11", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "b4407d4d-b563-4c08-aa98-9c55aec1911f", "node_type": "4", "metadata": {"page_label": "11", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "2e734cba32afda1e64007d444339da8b484d595b5b4674519061166904641ae7", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "11c2f803-5bdf-450e-834f-eca7bfaec6ff", "node_type": "1", "metadata": {"window": "One, on the strategic side as we think about your core Medical business.  One, do you \nstill feel a commitment to that business going forward?   And then secondly, as we think about the shift \nand the new reporting structure, it does look like you're taking down the margin on the core business. \n Is there something that's either changing and the timeline  of the turnaround?  Is there something else \nthat's shifting competitively or incremental costs?  If you could just help us understand that.  Thanks so \nmuch.  \n \n", "original_text": "Is there something that's either changing and the timeline  of the turnaround? ", "page_label": "11", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "a6c4d46c20a3e93dd0e3d014ba1ebb319489540c39f25c64323a34d28d030657", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "6f3fce4d-c647-4c1b-9960-0b518a758cb3", "node_type": "1", "metadata": {"window": "And then secondly, as we think about the shift \nand the new reporting structure, it does look like you're taking down the margin on the core business. \n Is there something that's either changing and the timeline  of the turnaround?  Is there something else \nthat's shifting competitively or incremental costs?  If you could just help us understand that.  Thanks so \nmuch.  \n \n Jason Hollar:  Sure, Lisa.  Very clear here. ", "original_text": "If you could just help us understand that. "}, "hash": "fd59c0268b15c98f32169c25321f45ebf05fc0ea48cf1ae5efe3f0c985363e6b", "class_name": "RelatedNodeInfo"}}, "text": "Is there something else \nthat's shifting competitively or incremental costs? ", "start_char_idx": 2780, "end_char_idx": 2857, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "6f3fce4d-c647-4c1b-9960-0b518a758cb3": {"__data__": {"id_": "6f3fce4d-c647-4c1b-9960-0b518a758cb3", "embedding": null, "metadata": {"window": "And then secondly, as we think about the shift \nand the new reporting structure, it does look like you're taking down the margin on the core business. \n Is there something that's either changing and the timeline  of the turnaround?  Is there something else \nthat's shifting competitively or incremental costs?  If you could just help us understand that.  Thanks so \nmuch.  \n \n Jason Hollar:  Sure, Lisa.  Very clear here. ", "original_text": "If you could just help us understand that. ", "page_label": "11", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "b4407d4d-b563-4c08-aa98-9c55aec1911f", "node_type": "4", "metadata": {"page_label": "11", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "2e734cba32afda1e64007d444339da8b484d595b5b4674519061166904641ae7", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "6051638b-89fb-4e3d-9d88-ccce6b72047b", "node_type": "1", "metadata": {"window": "One, do you \nstill feel a commitment to that business going forward?   And then secondly, as we think about the shift \nand the new reporting structure, it does look like you're taking down the margin on the core business. \n Is there something that's either changing and the timeline  of the turnaround?  Is there something else \nthat's shifting competitively or incremental costs?  If you could just help us understand that.  Thanks so \nmuch.  \n \n Jason Hollar:  Sure, Lisa. ", "original_text": "Is there something else \nthat's shifting competitively or incremental costs? ", "page_label": "11", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "830ff2112a5625b8adc5d4bc740deeb8335e9d7b0d6be19498735027a498a473", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "7ff8ca1a-21e3-40f3-b3d1-eaed2971ef62", "node_type": "1", "metadata": {"window": "Is there something that's either changing and the timeline  of the turnaround?  Is there something else \nthat's shifting competitively or incremental costs?  If you could just help us understand that.  Thanks so \nmuch.  \n \n Jason Hollar:  Sure, Lisa.  Very clear here.  No, there's no change in our commitment to this business. \n", "original_text": "Thanks so \nmuch.  \n \n"}, "hash": "a8b4c799c505e6d47faf62396039770049064fc174ea66f28b6be512bcc47289", "class_name": "RelatedNodeInfo"}}, "text": "If you could just help us understand that. ", "start_char_idx": 2857, "end_char_idx": 2900, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "7ff8ca1a-21e3-40f3-b3d1-eaed2971ef62": {"__data__": {"id_": "7ff8ca1a-21e3-40f3-b3d1-eaed2971ef62", "embedding": null, "metadata": {"window": "Is there something that's either changing and the timeline  of the turnaround?  Is there something else \nthat's shifting competitively or incremental costs?  If you could just help us understand that.  Thanks so \nmuch.  \n \n Jason Hollar:  Sure, Lisa.  Very clear here.  No, there's no change in our commitment to this business. \n", "original_text": "Thanks so \nmuch.  \n \n", "page_label": "11", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "b4407d4d-b563-4c08-aa98-9c55aec1911f", "node_type": "4", "metadata": {"page_label": "11", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "2e734cba32afda1e64007d444339da8b484d595b5b4674519061166904641ae7", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "6f3fce4d-c647-4c1b-9960-0b518a758cb3", "node_type": "1", "metadata": {"window": "And then secondly, as we think about the shift \nand the new reporting structure, it does look like you're taking down the margin on the core business. \n Is there something that's either changing and the timeline  of the turnaround?  Is there something else \nthat's shifting competitively or incremental costs?  If you could just help us understand that.  Thanks so \nmuch.  \n \n Jason Hollar:  Sure, Lisa.  Very clear here. ", "original_text": "If you could just help us understand that. ", "page_label": "11", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "0a05330a96dbdde7a411b6a13bd7fb7ee597fe1873ff93c247ceedab98bfe560", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "5cab21a6-25a8-4e3a-9b70-c66ac5a3edc5", "node_type": "1", "metadata": {"window": "Is there something else \nthat's shifting competitively or incremental costs?  If you could just help us understand that.  Thanks so \nmuch.  \n \n Jason Hollar:  Sure, Lisa.  Very clear here.  No, there's no change in our commitment to this business. \n It has been there from the very beginning and continues to be . ", "original_text": "Jason Hollar:  Sure, Lisa. "}, "hash": "5f06cdc9195673483e0282c9fb457b0e2c2ca05ec0ab106093fb277e0ea12d45", "class_name": "RelatedNodeInfo"}}, "text": "Thanks so \nmuch.  \n \n", "start_char_idx": 2900, "end_char_idx": 2921, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "5cab21a6-25a8-4e3a-9b70-c66ac5a3edc5": {"__data__": {"id_": "5cab21a6-25a8-4e3a-9b70-c66ac5a3edc5", "embedding": null, "metadata": {"window": "Is there something else \nthat's shifting competitively or incremental costs?  If you could just help us understand that.  Thanks so \nmuch.  \n \n Jason Hollar:  Sure, Lisa.  Very clear here.  No, there's no change in our commitment to this business. \n It has been there from the very beginning and continues to be . ", "original_text": "Jason Hollar:  Sure, Lisa. ", "page_label": "11", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "b4407d4d-b563-4c08-aa98-9c55aec1911f", "node_type": "4", "metadata": {"page_label": "11", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "2e734cba32afda1e64007d444339da8b484d595b5b4674519061166904641ae7", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "7ff8ca1a-21e3-40f3-b3d1-eaed2971ef62", "node_type": "1", "metadata": {"window": "Is there something that's either changing and the timeline  of the turnaround?  Is there something else \nthat's shifting competitively or incremental costs?  If you could just help us understand that.  Thanks so \nmuch.  \n \n Jason Hollar:  Sure, Lisa.  Very clear here.  No, there's no change in our commitment to this business. \n", "original_text": "Thanks so \nmuch.  \n \n", "page_label": "11", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "7846e6912e215b7aafc3cb604ae93f4e8005fe4ea6061f06c2d34ae126762b89", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "ce4ae115-06fa-4dcf-ac79-41aa04c03004", "node_type": "1", "metadata": {"window": "If you could just help us understand that.  Thanks so \nmuch.  \n \n Jason Hollar:  Sure, Lisa.  Very clear here.  No, there's no change in our commitment to this business. \n It has been there from the very beginning and continues to be .  As I highlighted from the first moment \nwhen we talk about Medical in the context of the business and portfolio review, our number one \npriority has always been and continues to be turning the business around.  \n \n", "original_text": "Very clear here. "}, "hash": "86032b0f2ea64c3fa2f573b78e33270c58579ee12a0a7aca06fde19f5ca23e89", "class_name": "RelatedNodeInfo"}}, "text": "Jason Hollar:  Sure, Lisa. ", "start_char_idx": 2921, "end_char_idx": 2948, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "ce4ae115-06fa-4dcf-ac79-41aa04c03004": {"__data__": {"id_": "ce4ae115-06fa-4dcf-ac79-41aa04c03004", "embedding": null, "metadata": {"window": "If you could just help us understand that.  Thanks so \nmuch.  \n \n Jason Hollar:  Sure, Lisa.  Very clear here.  No, there's no change in our commitment to this business. \n It has been there from the very beginning and continues to be .  As I highlighted from the first moment \nwhen we talk about Medical in the context of the business and portfolio review, our number one \npriority has always been and continues to be turning the business around.  \n \n", "original_text": "Very clear here. ", "page_label": "11", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "b4407d4d-b563-4c08-aa98-9c55aec1911f", "node_type": "4", "metadata": {"page_label": "11", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "2e734cba32afda1e64007d444339da8b484d595b5b4674519061166904641ae7", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "5cab21a6-25a8-4e3a-9b70-c66ac5a3edc5", "node_type": "1", "metadata": {"window": "Is there something else \nthat's shifting competitively or incremental costs?  If you could just help us understand that.  Thanks so \nmuch.  \n \n Jason Hollar:  Sure, Lisa.  Very clear here.  No, there's no change in our commitment to this business. \n It has been there from the very beginning and continues to be . ", "original_text": "Jason Hollar:  Sure, Lisa. ", "page_label": "11", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "b38b00b26eb644b1503974bfbdfa9ed7a4d4e8740d15c9cf3bdec9a3b9c84cec", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "4e802994-243b-44e0-95c5-5c6a0a563285", "node_type": "1", "metadata": {"window": "Thanks so \nmuch.  \n \n Jason Hollar:  Sure, Lisa.  Very clear here.  No, there's no change in our commitment to this business. \n It has been there from the very beginning and continues to be .  As I highlighted from the first moment \nwhen we talk about Medical in the context of the business and portfolio review, our number one \npriority has always been and continues to be turning the business around.  \n \n Everything that we are working on has been in service of, first of all, the 5-point plan to drive Cardinal \nHealth B rand volumes to mitigate inflation and drive additional value through simplification and cost \nreductions . ", "original_text": "No, there's no change in our commitment to this business. \n"}, "hash": "aaa418199bdd5e0d92144cecc74d04bfa4c83471d921f29e98d932d6df1ff968", "class_name": "RelatedNodeInfo"}}, "text": "Very clear here. ", "start_char_idx": 2948, "end_char_idx": 2965, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "4e802994-243b-44e0-95c5-5c6a0a563285": {"__data__": {"id_": "4e802994-243b-44e0-95c5-5c6a0a563285", "embedding": null, "metadata": {"window": "Thanks so \nmuch.  \n \n Jason Hollar:  Sure, Lisa.  Very clear here.  No, there's no change in our commitment to this business. \n It has been there from the very beginning and continues to be .  As I highlighted from the first moment \nwhen we talk about Medical in the context of the business and portfolio review, our number one \npriority has always been and continues to be turning the business around.  \n \n Everything that we are working on has been in service of, first of all, the 5-point plan to drive Cardinal \nHealth B rand volumes to mitigate inflation and drive additional value through simplification and cost \nreductions . ", "original_text": "No, there's no change in our commitment to this business. \n", "page_label": "11", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "b4407d4d-b563-4c08-aa98-9c55aec1911f", "node_type": "4", "metadata": {"page_label": "11", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "2e734cba32afda1e64007d444339da8b484d595b5b4674519061166904641ae7", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "ce4ae115-06fa-4dcf-ac79-41aa04c03004", "node_type": "1", "metadata": {"window": "If you could just help us understand that.  Thanks so \nmuch.  \n \n Jason Hollar:  Sure, Lisa.  Very clear here.  No, there's no change in our commitment to this business. \n It has been there from the very beginning and continues to be .  As I highlighted from the first moment \nwhen we talk about Medical in the context of the business and portfolio review, our number one \npriority has always been and continues to be turning the business around.  \n \n", "original_text": "Very clear here. ", "page_label": "11", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "2502b43ba07440363176a67152fb687194ce815e33c467a2bf34d2a2d0e2c5d2", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "87f572ce-aa8f-45db-8e49-184000e38a43", "node_type": "1", "metadata": {"window": "Jason Hollar:  Sure, Lisa.  Very clear here.  No, there's no change in our commitment to this business. \n It has been there from the very beginning and continues to be .  As I highlighted from the first moment \nwhen we talk about Medical in the context of the business and portfolio review, our number one \npriority has always been and continues to be turning the business around.  \n \n Everything that we are working on has been in service of, first of all, the 5-point plan to drive Cardinal \nHealth B rand volumes to mitigate inflation and drive additional value through simplification and cost \nreductions .  That message and the progress we've made is entirely consistent with that. ", "original_text": "It has been there from the very beginning and continues to be . "}, "hash": "95e568f717e6f0ab7dbcf1af7d5b60f619a7c2396e2d32b0e6b8a4517557171d", "class_name": "RelatedNodeInfo"}}, "text": "No, there's no change in our commitment to this business. \n", "start_char_idx": 2965, "end_char_idx": 3024, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "87f572ce-aa8f-45db-8e49-184000e38a43": {"__data__": {"id_": "87f572ce-aa8f-45db-8e49-184000e38a43", "embedding": null, "metadata": {"window": "Jason Hollar:  Sure, Lisa.  Very clear here.  No, there's no change in our commitment to this business. \n It has been there from the very beginning and continues to be .  As I highlighted from the first moment \nwhen we talk about Medical in the context of the business and portfolio review, our number one \npriority has always been and continues to be turning the business around.  \n \n Everything that we are working on has been in service of, first of all, the 5-point plan to drive Cardinal \nHealth B rand volumes to mitigate inflation and drive additional value through simplification and cost \nreductions .  That message and the progress we've made is entirely consistent with that. ", "original_text": "It has been there from the very beginning and continues to be . ", "page_label": "11", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "b4407d4d-b563-4c08-aa98-9c55aec1911f", "node_type": "4", "metadata": {"page_label": "11", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "2e734cba32afda1e64007d444339da8b484d595b5b4674519061166904641ae7", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "4e802994-243b-44e0-95c5-5c6a0a563285", "node_type": "1", "metadata": {"window": "Thanks so \nmuch.  \n \n Jason Hollar:  Sure, Lisa.  Very clear here.  No, there's no change in our commitment to this business. \n It has been there from the very beginning and continues to be .  As I highlighted from the first moment \nwhen we talk about Medical in the context of the business and portfolio review, our number one \npriority has always been and continues to be turning the business around.  \n \n Everything that we are working on has been in service of, first of all, the 5-point plan to drive Cardinal \nHealth B rand volumes to mitigate inflation and drive additional value through simplification and cost \nreductions . ", "original_text": "No, there's no change in our commitment to this business. \n", "page_label": "11", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "23462e14e8eef49477fd6756d308018ca66244f824b74d4ff7c15e18ce648f24", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "59085e65-3a54-4079-9170-ad230a2b1dea", "node_type": "1", "metadata": {"window": "Very clear here.  No, there's no change in our commitment to this business. \n It has been there from the very beginning and continues to be .  As I highlighted from the first moment \nwhen we talk about Medical in the context of the business and portfolio review, our number one \npriority has always been and continues to be turning the business around.  \n \n Everything that we are working on has been in service of, first of all, the 5-point plan to drive Cardinal \nHealth B rand volumes to mitigate inflation and drive additional value through simplification and cost \nreductions .  That message and the progress we've made is entirely consistent with that.  The core ", "original_text": "As I highlighted from the first moment \nwhen we talk about Medical in the context of the business and portfolio review, our number one \npriority has always been and continues to be turning the business around.  \n \n"}, "hash": "ce25fdd9c50d67eca0c93c1840602c616ee642e09e21687201e65a88c9137bce", "class_name": "RelatedNodeInfo"}}, "text": "It has been there from the very beginning and continues to be . ", "start_char_idx": 3024, "end_char_idx": 3088, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "59085e65-3a54-4079-9170-ad230a2b1dea": {"__data__": {"id_": "59085e65-3a54-4079-9170-ad230a2b1dea", "embedding": null, "metadata": {"window": "Very clear here.  No, there's no change in our commitment to this business. \n It has been there from the very beginning and continues to be .  As I highlighted from the first moment \nwhen we talk about Medical in the context of the business and portfolio review, our number one \npriority has always been and continues to be turning the business around.  \n \n Everything that we are working on has been in service of, first of all, the 5-point plan to drive Cardinal \nHealth B rand volumes to mitigate inflation and drive additional value through simplification and cost \nreductions .  That message and the progress we've made is entirely consistent with that.  The core ", "original_text": "As I highlighted from the first moment \nwhen we talk about Medical in the context of the business and portfolio review, our number one \npriority has always been and continues to be turning the business around.  \n \n", "page_label": "11", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "b4407d4d-b563-4c08-aa98-9c55aec1911f", "node_type": "4", "metadata": {"page_label": "11", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "2e734cba32afda1e64007d444339da8b484d595b5b4674519061166904641ae7", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "87f572ce-aa8f-45db-8e49-184000e38a43", "node_type": "1", "metadata": {"window": "Jason Hollar:  Sure, Lisa.  Very clear here.  No, there's no change in our commitment to this business. \n It has been there from the very beginning and continues to be .  As I highlighted from the first moment \nwhen we talk about Medical in the context of the business and portfolio review, our number one \npriority has always been and continues to be turning the business around.  \n \n Everything that we are working on has been in service of, first of all, the 5-point plan to drive Cardinal \nHealth B rand volumes to mitigate inflation and drive additional value through simplification and cost \nreductions .  That message and the progress we've made is entirely consistent with that. ", "original_text": "It has been there from the very beginning and continues to be . ", "page_label": "11", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "7b7d13b8c40100451a8fcfb6c8a90b114fee29cfa21ca65cc50f3d60c628edfb", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "72b690d9-0331-4411-9347-932df9e5a9ef", "node_type": "1", "metadata": {"window": "No, there's no change in our commitment to this business. \n It has been there from the very beginning and continues to be .  As I highlighted from the first moment \nwhen we talk about Medical in the context of the business and portfolio review, our number one \npriority has always been and continues to be turning the business around.  \n \n Everything that we are working on has been in service of, first of all, the 5-point plan to drive Cardinal \nHealth B rand volumes to mitigate inflation and drive additional value through simplification and cost \nreductions .  That message and the progress we've made is entirely consistent with that.  The core ", "original_text": "Everything that we are working on has been in service of, first of all, the 5-point plan to drive Cardinal \nHealth B rand volumes to mitigate inflation and drive additional value through simplification and cost \nreductions . "}, "hash": "f5ca869d8d9ab8f76063ae996ffa5a03f17c512285081a40a4f344bc8afd3106", "class_name": "RelatedNodeInfo"}}, "text": "As I highlighted from the first moment \nwhen we talk about Medical in the context of the business and portfolio review, our number one \npriority has always been and continues to be turning the business around.  \n \n", "start_char_idx": 3088, "end_char_idx": 3302, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "72b690d9-0331-4411-9347-932df9e5a9ef": {"__data__": {"id_": "72b690d9-0331-4411-9347-932df9e5a9ef", "embedding": null, "metadata": {"window": "No, there's no change in our commitment to this business. \n It has been there from the very beginning and continues to be .  As I highlighted from the first moment \nwhen we talk about Medical in the context of the business and portfolio review, our number one \npriority has always been and continues to be turning the business around.  \n \n Everything that we are working on has been in service of, first of all, the 5-point plan to drive Cardinal \nHealth B rand volumes to mitigate inflation and drive additional value through simplification and cost \nreductions .  That message and the progress we've made is entirely consistent with that.  The core ", "original_text": "Everything that we are working on has been in service of, first of all, the 5-point plan to drive Cardinal \nHealth B rand volumes to mitigate inflation and drive additional value through simplification and cost \nreductions . ", "page_label": "11", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "b4407d4d-b563-4c08-aa98-9c55aec1911f", "node_type": "4", "metadata": {"page_label": "11", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "2e734cba32afda1e64007d444339da8b484d595b5b4674519061166904641ae7", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "59085e65-3a54-4079-9170-ad230a2b1dea", "node_type": "1", "metadata": {"window": "Very clear here.  No, there's no change in our commitment to this business. \n It has been there from the very beginning and continues to be .  As I highlighted from the first moment \nwhen we talk about Medical in the context of the business and portfolio review, our number one \npriority has always been and continues to be turning the business around.  \n \n Everything that we are working on has been in service of, first of all, the 5-point plan to drive Cardinal \nHealth B rand volumes to mitigate inflation and drive additional value through simplification and cost \nreductions .  That message and the progress we've made is entirely consistent with that.  The core ", "original_text": "As I highlighted from the first moment \nwhen we talk about Medical in the context of the business and portfolio review, our number one \npriority has always been and continues to be turning the business around.  \n \n", "page_label": "11", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "d9e6af86e8ce320a04b32d144ea0a60bcab10381a8113ee11eecfaf780b102f7", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "a9c7e98d-0b9d-4c98-ad09-8c94ce597237", "node_type": "1", "metadata": {"window": "It has been there from the very beginning and continues to be .  As I highlighted from the first moment \nwhen we talk about Medical in the context of the business and portfolio review, our number one \npriority has always been and continues to be turning the business around.  \n \n Everything that we are working on has been in service of, first of all, the 5-point plan to drive Cardinal \nHealth B rand volumes to mitigate inflation and drive additional value through simplification and cost \nreductions .  That message and the progress we've made is entirely consistent with that.  The core ", "original_text": "That message and the progress we've made is entirely consistent with that. "}, "hash": "90799afeeece3306f186d4145be95f070cdc5946fd7f4f5231372efe9608bbb5", "class_name": "RelatedNodeInfo"}}, "text": "Everything that we are working on has been in service of, first of all, the 5-point plan to drive Cardinal \nHealth B rand volumes to mitigate inflation and drive additional value through simplification and cost \nreductions . ", "start_char_idx": 3302, "end_char_idx": 3527, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "a9c7e98d-0b9d-4c98-ad09-8c94ce597237": {"__data__": {"id_": "a9c7e98d-0b9d-4c98-ad09-8c94ce597237", "embedding": null, "metadata": {"window": "It has been there from the very beginning and continues to be .  As I highlighted from the first moment \nwhen we talk about Medical in the context of the business and portfolio review, our number one \npriority has always been and continues to be turning the business around.  \n \n Everything that we are working on has been in service of, first of all, the 5-point plan to drive Cardinal \nHealth B rand volumes to mitigate inflation and drive additional value through simplification and cost \nreductions .  That message and the progress we've made is entirely consistent with that.  The core ", "original_text": "That message and the progress we've made is entirely consistent with that. ", "page_label": "11", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "b4407d4d-b563-4c08-aa98-9c55aec1911f", "node_type": "4", "metadata": {"page_label": "11", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "2e734cba32afda1e64007d444339da8b484d595b5b4674519061166904641ae7", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "72b690d9-0331-4411-9347-932df9e5a9ef", "node_type": "1", "metadata": {"window": "No, there's no change in our commitment to this business. \n It has been there from the very beginning and continues to be .  As I highlighted from the first moment \nwhen we talk about Medical in the context of the business and portfolio review, our number one \npriority has always been and continues to be turning the business around.  \n \n Everything that we are working on has been in service of, first of all, the 5-point plan to drive Cardinal \nHealth B rand volumes to mitigate inflation and drive additional value through simplification and cost \nreductions .  That message and the progress we've made is entirely consistent with that.  The core ", "original_text": "Everything that we are working on has been in service of, first of all, the 5-point plan to drive Cardinal \nHealth B rand volumes to mitigate inflation and drive additional value through simplification and cost \nreductions . ", "page_label": "11", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "e3f5fe0dfb3bd837292647416c9f67f33d8a18a93a504afdc419cac5ae55edce", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "16a1d2e2-21e3-42cf-8377-47742de8a75b", "node_type": "1", "metadata": {"window": "As I highlighted from the first moment \nwhen we talk about Medical in the context of the business and portfolio review, our number one \npriority has always been and continues to be turning the business around.  \n \n Everything that we are working on has been in service of, first of all, the 5-point plan to drive Cardinal \nHealth B rand volumes to mitigate inflation and drive additional value through simplification and cost \nreductions .  That message and the progress we've made is entirely consistent with that.  The core ", "original_text": "The core "}, "hash": "9838b03cc8cb776c1af1902c17d5f99f82de7a64f109da4ea840efe0d53d11a0", "class_name": "RelatedNodeInfo"}}, "text": "That message and the progress we've made is entirely consistent with that. ", "start_char_idx": 3527, "end_char_idx": 3602, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "16a1d2e2-21e3-42cf-8377-47742de8a75b": {"__data__": {"id_": "16a1d2e2-21e3-42cf-8377-47742de8a75b", "embedding": null, "metadata": {"window": "As I highlighted from the first moment \nwhen we talk about Medical in the context of the business and portfolio review, our number one \npriority has always been and continues to be turning the business around.  \n \n Everything that we are working on has been in service of, first of all, the 5-point plan to drive Cardinal \nHealth B rand volumes to mitigate inflation and drive additional value through simplification and cost \nreductions .  That message and the progress we've made is entirely consistent with that.  The core ", "original_text": "The core ", "page_label": "11", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "b4407d4d-b563-4c08-aa98-9c55aec1911f", "node_type": "4", "metadata": {"page_label": "11", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "2e734cba32afda1e64007d444339da8b484d595b5b4674519061166904641ae7", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "a9c7e98d-0b9d-4c98-ad09-8c94ce597237", "node_type": "1", "metadata": {"window": "It has been there from the very beginning and continues to be .  As I highlighted from the first moment \nwhen we talk about Medical in the context of the business and portfolio review, our number one \npriority has always been and continues to be turning the business around.  \n \n Everything that we are working on has been in service of, first of all, the 5-point plan to drive Cardinal \nHealth B rand volumes to mitigate inflation and drive additional value through simplification and cost \nreductions .  That message and the progress we've made is entirely consistent with that.  The core ", "original_text": "That message and the progress we've made is entirely consistent with that. ", "page_label": "11", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "cce879c02c7c9bef0a107b874e34c59c6d10ad8b15561e99d903f439adb06cd3", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "7eab7704-61ea-4c02-9f86-416fac68fee1", "node_type": "1", "metadata": {"window": " \nPage 12 of 19 \n \noperational performance of the business is exactly how we've laid it out.  So, the only update that \nwe've had today were in recognition of some of those non -recurring items.  But the plan in the fiscal \nyear \u201826 aggregate targets that we're going after are absolutely unchanged to this re -segmentation.  \n \n We did have to bucket the Medical Improvement Plan into the various buckets because we did have \nthe growth businesses that were a component of that. ", "original_text": " \nPage 12 of 19 \n \noperational performance of the business is exactly how we've laid it out. "}, "hash": "ad0d10346761490bcf0ad2e68d607d624cd410828e69c6d1d82b93aeb115c5bf", "class_name": "RelatedNodeInfo"}}, "text": "The core ", "start_char_idx": 3602, "end_char_idx": 3611, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "7eab7704-61ea-4c02-9f86-416fac68fee1": {"__data__": {"id_": "7eab7704-61ea-4c02-9f86-416fac68fee1", "embedding": null, "metadata": {"window": " \nPage 12 of 19 \n \noperational performance of the business is exactly how we've laid it out.  So, the only update that \nwe've had today were in recognition of some of those non -recurring items.  But the plan in the fiscal \nyear \u201826 aggregate targets that we're going after are absolutely unchanged to this re -segmentation.  \n \n We did have to bucket the Medical Improvement Plan into the various buckets because we did have \nthe growth businesses that were a component of that. ", "original_text": " \nPage 12 of 19 \n \noperational performance of the business is exactly how we've laid it out. ", "page_label": "12", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "f6aa5062-6f6b-48ce-b783-7a0df37afe92", "node_type": "4", "metadata": {"page_label": "12", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "22984b0b58240c211588ed6c0cd5e35a4a51583c2f3bfe772345b964ca16208b", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "16a1d2e2-21e3-42cf-8377-47742de8a75b", "node_type": "1", "metadata": {"window": "As I highlighted from the first moment \nwhen we talk about Medical in the context of the business and portfolio review, our number one \npriority has always been and continues to be turning the business around.  \n \n Everything that we are working on has been in service of, first of all, the 5-point plan to drive Cardinal \nHealth B rand volumes to mitigate inflation and drive additional value through simplification and cost \nreductions .  That message and the progress we've made is entirely consistent with that.  The core ", "original_text": "The core ", "page_label": "11", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "1301ffbfb9177893acec81b838cec230905ca4d0bc1b3e33c2939631d01f7ed8", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "6c9340db-3e8e-4ab4-a8ba-625ed62d3398", "node_type": "1", "metadata": {"window": " \nPage 12 of 19 \n \noperational performance of the business is exactly how we've laid it out.  So, the only update that \nwe've had today were in recognition of some of those non -recurring items.  But the plan in the fiscal \nyear \u201826 aggregate targets that we're going after are absolutely unchanged to this re -segmentation.  \n \n We did have to bucket the Medical Improvement Plan into the various buckets because we did have \nthe growth businesses that were a component of that.  But that was just moving the pieces. ", "original_text": "So, the only update that \nwe've had today were in recognition of some of those non -recurring items. "}, "hash": "b12d7251841d306a1accccc62b4372636edf8d327e6ce2901a8a4c777d096010", "class_name": "RelatedNodeInfo"}}, "text": " \nPage 12 of 19 \n \noperational performance of the business is exactly how we've laid it out. ", "start_char_idx": 0, "end_char_idx": 93, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "6c9340db-3e8e-4ab4-a8ba-625ed62d3398": {"__data__": {"id_": "6c9340db-3e8e-4ab4-a8ba-625ed62d3398", "embedding": null, "metadata": {"window": " \nPage 12 of 19 \n \noperational performance of the business is exactly how we've laid it out.  So, the only update that \nwe've had today were in recognition of some of those non -recurring items.  But the plan in the fiscal \nyear \u201826 aggregate targets that we're going after are absolutely unchanged to this re -segmentation.  \n \n We did have to bucket the Medical Improvement Plan into the various buckets because we did have \nthe growth businesses that were a component of that.  But that was just moving the pieces. ", "original_text": "So, the only update that \nwe've had today were in recognition of some of those non -recurring items. ", "page_label": "12", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "f6aa5062-6f6b-48ce-b783-7a0df37afe92", "node_type": "4", "metadata": {"page_label": "12", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "22984b0b58240c211588ed6c0cd5e35a4a51583c2f3bfe772345b964ca16208b", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "7eab7704-61ea-4c02-9f86-416fac68fee1", "node_type": "1", "metadata": {"window": " \nPage 12 of 19 \n \noperational performance of the business is exactly how we've laid it out.  So, the only update that \nwe've had today were in recognition of some of those non -recurring items.  But the plan in the fiscal \nyear \u201826 aggregate targets that we're going after are absolutely unchanged to this re -segmentation.  \n \n We did have to bucket the Medical Improvement Plan into the various buckets because we did have \nthe growth businesses that were a component of that. ", "original_text": " \nPage 12 of 19 \n \noperational performance of the business is exactly how we've laid it out. ", "page_label": "12", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "21954772aca0b56db1706aa421a2dd1923c7eba427a0c38af17e6c255a063664", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "8a18a009-f699-4f8b-b756-23a321d8e9ed", "node_type": "1", "metadata": {"window": " \nPage 12 of 19 \n \noperational performance of the business is exactly how we've laid it out.  So, the only update that \nwe've had today were in recognition of some of those non -recurring items.  But the plan in the fiscal \nyear \u201826 aggregate targets that we're going after are absolutely unchanged to this re -segmentation.  \n \n We did have to bucket the Medical Improvement Plan into the various buckets because we did have \nthe growth businesses that were a component of that.  But that was just moving the pieces.  The \npieces are absolutely unchanged, and the overall aggregate profitability in that long -term plan is \nabsolutely unc hanged, and our commitment is absolutely unchanged to this business. ", "original_text": "But the plan in the fiscal \nyear \u201826 aggregate targets that we're going after are absolutely unchanged to this re -segmentation.  \n \n"}, "hash": "43dfde5c1a802294b87f11500d3380f1d6c54f290287ddfa2e6e150fab48c0f1", "class_name": "RelatedNodeInfo"}}, "text": "So, the only update that \nwe've had today were in recognition of some of those non -recurring items. ", "start_char_idx": 93, "end_char_idx": 194, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "8a18a009-f699-4f8b-b756-23a321d8e9ed": {"__data__": {"id_": "8a18a009-f699-4f8b-b756-23a321d8e9ed", "embedding": null, "metadata": {"window": " \nPage 12 of 19 \n \noperational performance of the business is exactly how we've laid it out.  So, the only update that \nwe've had today were in recognition of some of those non -recurring items.  But the plan in the fiscal \nyear \u201826 aggregate targets that we're going after are absolutely unchanged to this re -segmentation.  \n \n We did have to bucket the Medical Improvement Plan into the various buckets because we did have \nthe growth businesses that were a component of that.  But that was just moving the pieces.  The \npieces are absolutely unchanged, and the overall aggregate profitability in that long -term plan is \nabsolutely unc hanged, and our commitment is absolutely unchanged to this business. ", "original_text": "But the plan in the fiscal \nyear \u201826 aggregate targets that we're going after are absolutely unchanged to this re -segmentation.  \n \n", "page_label": "12", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "f6aa5062-6f6b-48ce-b783-7a0df37afe92", "node_type": "4", "metadata": {"page_label": "12", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "22984b0b58240c211588ed6c0cd5e35a4a51583c2f3bfe772345b964ca16208b", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "6c9340db-3e8e-4ab4-a8ba-625ed62d3398", "node_type": "1", "metadata": {"window": " \nPage 12 of 19 \n \noperational performance of the business is exactly how we've laid it out.  So, the only update that \nwe've had today were in recognition of some of those non -recurring items.  But the plan in the fiscal \nyear \u201826 aggregate targets that we're going after are absolutely unchanged to this re -segmentation.  \n \n We did have to bucket the Medical Improvement Plan into the various buckets because we did have \nthe growth businesses that were a component of that.  But that was just moving the pieces. ", "original_text": "So, the only update that \nwe've had today were in recognition of some of those non -recurring items. ", "page_label": "12", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "5bea363f7aeabe641ed42b8888b85cfb23c0a78fff7da3013f38e02d6ad13d7b", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "9629e9ef-fe06-41bf-bb6d-1fe5be376d7a", "node_type": "1", "metadata": {"window": " \nPage 12 of 19 \n \noperational performance of the business is exactly how we've laid it out.  So, the only update that \nwe've had today were in recognition of some of those non -recurring items.  But the plan in the fiscal \nyear \u201826 aggregate targets that we're going after are absolutely unchanged to this re -segmentation.  \n \n We did have to bucket the Medical Improvement Plan into the various buckets because we did have \nthe growth businesses that were a component of that.  But that was just moving the pieces.  The \npieces are absolutely unchanged, and the overall aggregate profitability in that long -term plan is \nabsolutely unc hanged, and our commitment is absolutely unchanged to this business.  And I'm really \nexcited about the progress that the team is making in service of all those goals.  \n \n", "original_text": "We did have to bucket the Medical Improvement Plan into the various buckets because we did have \nthe growth businesses that were a component of that. "}, "hash": "34b2d6dff27101e4403b0a736ca8b3ea5365564ea0b0a3169231929ab9e68756", "class_name": "RelatedNodeInfo"}}, "text": "But the plan in the fiscal \nyear \u201826 aggregate targets that we're going after are absolutely unchanged to this re -segmentation.  \n \n", "start_char_idx": 194, "end_char_idx": 327, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "9629e9ef-fe06-41bf-bb6d-1fe5be376d7a": {"__data__": {"id_": "9629e9ef-fe06-41bf-bb6d-1fe5be376d7a", "embedding": null, "metadata": {"window": " \nPage 12 of 19 \n \noperational performance of the business is exactly how we've laid it out.  So, the only update that \nwe've had today were in recognition of some of those non -recurring items.  But the plan in the fiscal \nyear \u201826 aggregate targets that we're going after are absolutely unchanged to this re -segmentation.  \n \n We did have to bucket the Medical Improvement Plan into the various buckets because we did have \nthe growth businesses that were a component of that.  But that was just moving the pieces.  The \npieces are absolutely unchanged, and the overall aggregate profitability in that long -term plan is \nabsolutely unc hanged, and our commitment is absolutely unchanged to this business.  And I'm really \nexcited about the progress that the team is making in service of all those goals.  \n \n", "original_text": "We did have to bucket the Medical Improvement Plan into the various buckets because we did have \nthe growth businesses that were a component of that. ", "page_label": "12", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "f6aa5062-6f6b-48ce-b783-7a0df37afe92", "node_type": "4", "metadata": {"page_label": "12", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "22984b0b58240c211588ed6c0cd5e35a4a51583c2f3bfe772345b964ca16208b", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "8a18a009-f699-4f8b-b756-23a321d8e9ed", "node_type": "1", "metadata": {"window": " \nPage 12 of 19 \n \noperational performance of the business is exactly how we've laid it out.  So, the only update that \nwe've had today were in recognition of some of those non -recurring items.  But the plan in the fiscal \nyear \u201826 aggregate targets that we're going after are absolutely unchanged to this re -segmentation.  \n \n We did have to bucket the Medical Improvement Plan into the various buckets because we did have \nthe growth businesses that were a component of that.  But that was just moving the pieces.  The \npieces are absolutely unchanged, and the overall aggregate profitability in that long -term plan is \nabsolutely unc hanged, and our commitment is absolutely unchanged to this business. ", "original_text": "But the plan in the fiscal \nyear \u201826 aggregate targets that we're going after are absolutely unchanged to this re -segmentation.  \n \n", "page_label": "12", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "46158e27d14929f11d5da7fd48e76d4e70a15ab786337b197f69bf2a0f20f9e8", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "6fbaf010-4d69-403d-9007-f0c00a132875", "node_type": "1", "metadata": {"window": "So, the only update that \nwe've had today were in recognition of some of those non -recurring items.  But the plan in the fiscal \nyear \u201826 aggregate targets that we're going after are absolutely unchanged to this re -segmentation.  \n \n We did have to bucket the Medical Improvement Plan into the various buckets because we did have \nthe growth businesses that were a component of that.  But that was just moving the pieces.  The \npieces are absolutely unchanged, and the overall aggregate profitability in that long -term plan is \nabsolutely unc hanged, and our commitment is absolutely unchanged to this business.  And I'm really \nexcited about the progress that the team is making in service of all those goals.  \n \n Matt Sims:  Next question, please.  \n \n", "original_text": "But that was just moving the pieces. "}, "hash": "de002cd944438a527406cd9ec88df0faf41759b16946a3ec3177b23c544387c1", "class_name": "RelatedNodeInfo"}}, "text": "We did have to bucket the Medical Improvement Plan into the various buckets because we did have \nthe growth businesses that were a component of that. ", "start_char_idx": 327, "end_char_idx": 477, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "6fbaf010-4d69-403d-9007-f0c00a132875": {"__data__": {"id_": "6fbaf010-4d69-403d-9007-f0c00a132875", "embedding": null, "metadata": {"window": "So, the only update that \nwe've had today were in recognition of some of those non -recurring items.  But the plan in the fiscal \nyear \u201826 aggregate targets that we're going after are absolutely unchanged to this re -segmentation.  \n \n We did have to bucket the Medical Improvement Plan into the various buckets because we did have \nthe growth businesses that were a component of that.  But that was just moving the pieces.  The \npieces are absolutely unchanged, and the overall aggregate profitability in that long -term plan is \nabsolutely unc hanged, and our commitment is absolutely unchanged to this business.  And I'm really \nexcited about the progress that the team is making in service of all those goals.  \n \n Matt Sims:  Next question, please.  \n \n", "original_text": "But that was just moving the pieces. ", "page_label": "12", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "f6aa5062-6f6b-48ce-b783-7a0df37afe92", "node_type": "4", "metadata": {"page_label": "12", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "22984b0b58240c211588ed6c0cd5e35a4a51583c2f3bfe772345b964ca16208b", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "9629e9ef-fe06-41bf-bb6d-1fe5be376d7a", "node_type": "1", "metadata": {"window": " \nPage 12 of 19 \n \noperational performance of the business is exactly how we've laid it out.  So, the only update that \nwe've had today were in recognition of some of those non -recurring items.  But the plan in the fiscal \nyear \u201826 aggregate targets that we're going after are absolutely unchanged to this re -segmentation.  \n \n We did have to bucket the Medical Improvement Plan into the various buckets because we did have \nthe growth businesses that were a component of that.  But that was just moving the pieces.  The \npieces are absolutely unchanged, and the overall aggregate profitability in that long -term plan is \nabsolutely unc hanged, and our commitment is absolutely unchanged to this business.  And I'm really \nexcited about the progress that the team is making in service of all those goals.  \n \n", "original_text": "We did have to bucket the Medical Improvement Plan into the various buckets because we did have \nthe growth businesses that were a component of that. ", "page_label": "12", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "aba6b249245323bbac07333c9fabfcba4a98d46133c9ae0575866952839ed7ba", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "67c3b1a7-1db3-464c-86d3-3e7271c18d23", "node_type": "1", "metadata": {"window": "But the plan in the fiscal \nyear \u201826 aggregate targets that we're going after are absolutely unchanged to this re -segmentation.  \n \n We did have to bucket the Medical Improvement Plan into the various buckets because we did have \nthe growth businesses that were a component of that.  But that was just moving the pieces.  The \npieces are absolutely unchanged, and the overall aggregate profitability in that long -term plan is \nabsolutely unc hanged, and our commitment is absolutely unchanged to this business.  And I'm really \nexcited about the progress that the team is making in service of all those goals.  \n \n Matt Sims:  Next question, please.  \n \n Operator:  Thanks so much, sir. ", "original_text": "The \npieces are absolutely unchanged, and the overall aggregate profitability in that long -term plan is \nabsolutely unc hanged, and our commitment is absolutely unchanged to this business. "}, "hash": "608354afe2f07d0e4f4bac7a355805bbe11482f21529c576da4b82d8802fa912", "class_name": "RelatedNodeInfo"}}, "text": "But that was just moving the pieces. ", "start_char_idx": 477, "end_char_idx": 514, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "67c3b1a7-1db3-464c-86d3-3e7271c18d23": {"__data__": {"id_": "67c3b1a7-1db3-464c-86d3-3e7271c18d23", "embedding": null, "metadata": {"window": "But the plan in the fiscal \nyear \u201826 aggregate targets that we're going after are absolutely unchanged to this re -segmentation.  \n \n We did have to bucket the Medical Improvement Plan into the various buckets because we did have \nthe growth businesses that were a component of that.  But that was just moving the pieces.  The \npieces are absolutely unchanged, and the overall aggregate profitability in that long -term plan is \nabsolutely unc hanged, and our commitment is absolutely unchanged to this business.  And I'm really \nexcited about the progress that the team is making in service of all those goals.  \n \n Matt Sims:  Next question, please.  \n \n Operator:  Thanks so much, sir. ", "original_text": "The \npieces are absolutely unchanged, and the overall aggregate profitability in that long -term plan is \nabsolutely unc hanged, and our commitment is absolutely unchanged to this business. ", "page_label": "12", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "f6aa5062-6f6b-48ce-b783-7a0df37afe92", "node_type": "4", "metadata": {"page_label": "12", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "22984b0b58240c211588ed6c0cd5e35a4a51583c2f3bfe772345b964ca16208b", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "6fbaf010-4d69-403d-9007-f0c00a132875", "node_type": "1", "metadata": {"window": "So, the only update that \nwe've had today were in recognition of some of those non -recurring items.  But the plan in the fiscal \nyear \u201826 aggregate targets that we're going after are absolutely unchanged to this re -segmentation.  \n \n We did have to bucket the Medical Improvement Plan into the various buckets because we did have \nthe growth businesses that were a component of that.  But that was just moving the pieces.  The \npieces are absolutely unchanged, and the overall aggregate profitability in that long -term plan is \nabsolutely unc hanged, and our commitment is absolutely unchanged to this business.  And I'm really \nexcited about the progress that the team is making in service of all those goals.  \n \n Matt Sims:  Next question, please.  \n \n", "original_text": "But that was just moving the pieces. ", "page_label": "12", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "a45fc755c4a9cd6fbb69f94d4568c12b850b508c6fb4098d991d2465c27c17aa", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "ae89a610-3160-48d5-b8ae-bd508f2defff", "node_type": "1", "metadata": {"window": "We did have to bucket the Medical Improvement Plan into the various buckets because we did have \nthe growth businesses that were a component of that.  But that was just moving the pieces.  The \npieces are absolutely unchanged, and the overall aggregate profitability in that long -term plan is \nabsolutely unc hanged, and our commitment is absolutely unchanged to this business.  And I'm really \nexcited about the progress that the team is making in service of all those goals.  \n \n Matt Sims:  Next question, please.  \n \n Operator:  Thanks so much, sir.  And our next question will be coming from Elizabeth Anderson, \ncalling from Evercore ISI. ", "original_text": "And I'm really \nexcited about the progress that the team is making in service of all those goals.  \n \n"}, "hash": "0aa0fa1dff4398670b3a46a296d309730c50e756ee66a6df4cdfe7ae4a943968", "class_name": "RelatedNodeInfo"}}, "text": "The \npieces are absolutely unchanged, and the overall aggregate profitability in that long -term plan is \nabsolutely unc hanged, and our commitment is absolutely unchanged to this business. ", "start_char_idx": 514, "end_char_idx": 704, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "ae89a610-3160-48d5-b8ae-bd508f2defff": {"__data__": {"id_": "ae89a610-3160-48d5-b8ae-bd508f2defff", "embedding": null, "metadata": {"window": "We did have to bucket the Medical Improvement Plan into the various buckets because we did have \nthe growth businesses that were a component of that.  But that was just moving the pieces.  The \npieces are absolutely unchanged, and the overall aggregate profitability in that long -term plan is \nabsolutely unc hanged, and our commitment is absolutely unchanged to this business.  And I'm really \nexcited about the progress that the team is making in service of all those goals.  \n \n Matt Sims:  Next question, please.  \n \n Operator:  Thanks so much, sir.  And our next question will be coming from Elizabeth Anderson, \ncalling from Evercore ISI. ", "original_text": "And I'm really \nexcited about the progress that the team is making in service of all those goals.  \n \n", "page_label": "12", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "f6aa5062-6f6b-48ce-b783-7a0df37afe92", "node_type": "4", "metadata": {"page_label": "12", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "22984b0b58240c211588ed6c0cd5e35a4a51583c2f3bfe772345b964ca16208b", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "67c3b1a7-1db3-464c-86d3-3e7271c18d23", "node_type": "1", "metadata": {"window": "But the plan in the fiscal \nyear \u201826 aggregate targets that we're going after are absolutely unchanged to this re -segmentation.  \n \n We did have to bucket the Medical Improvement Plan into the various buckets because we did have \nthe growth businesses that were a component of that.  But that was just moving the pieces.  The \npieces are absolutely unchanged, and the overall aggregate profitability in that long -term plan is \nabsolutely unc hanged, and our commitment is absolutely unchanged to this business.  And I'm really \nexcited about the progress that the team is making in service of all those goals.  \n \n Matt Sims:  Next question, please.  \n \n Operator:  Thanks so much, sir. ", "original_text": "The \npieces are absolutely unchanged, and the overall aggregate profitability in that long -term plan is \nabsolutely unc hanged, and our commitment is absolutely unchanged to this business. ", "page_label": "12", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "81f46bfc82552d34d3c96f9af7f10239d5323efb80ccbe5ec79fcad8b6728d95", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "167dc050-c078-48f9-b264-69ae17ca8ab8", "node_type": "1", "metadata": {"window": "But that was just moving the pieces.  The \npieces are absolutely unchanged, and the overall aggregate profitability in that long -term plan is \nabsolutely unc hanged, and our commitment is absolutely unchanged to this business.  And I'm really \nexcited about the progress that the team is making in service of all those goals.  \n \n Matt Sims:  Next question, please.  \n \n Operator:  Thanks so much, sir.  And our next question will be coming from Elizabeth Anderson, \ncalling from Evercore ISI.  Please go ahead. ", "original_text": "Matt Sims:  Next question, please.  \n \n"}, "hash": "dc555a3b2fb24e3e57d37f735d90ac842145b1e8069d9c31ac801173ff424eed", "class_name": "RelatedNodeInfo"}}, "text": "And I'm really \nexcited about the progress that the team is making in service of all those goals.  \n \n", "start_char_idx": 704, "end_char_idx": 806, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "167dc050-c078-48f9-b264-69ae17ca8ab8": {"__data__": {"id_": "167dc050-c078-48f9-b264-69ae17ca8ab8", "embedding": null, "metadata": {"window": "But that was just moving the pieces.  The \npieces are absolutely unchanged, and the overall aggregate profitability in that long -term plan is \nabsolutely unc hanged, and our commitment is absolutely unchanged to this business.  And I'm really \nexcited about the progress that the team is making in service of all those goals.  \n \n Matt Sims:  Next question, please.  \n \n Operator:  Thanks so much, sir.  And our next question will be coming from Elizabeth Anderson, \ncalling from Evercore ISI.  Please go ahead. ", "original_text": "Matt Sims:  Next question, please.  \n \n", "page_label": "12", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "f6aa5062-6f6b-48ce-b783-7a0df37afe92", "node_type": "4", "metadata": {"page_label": "12", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "22984b0b58240c211588ed6c0cd5e35a4a51583c2f3bfe772345b964ca16208b", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "ae89a610-3160-48d5-b8ae-bd508f2defff", "node_type": "1", "metadata": {"window": "We did have to bucket the Medical Improvement Plan into the various buckets because we did have \nthe growth businesses that were a component of that.  But that was just moving the pieces.  The \npieces are absolutely unchanged, and the overall aggregate profitability in that long -term plan is \nabsolutely unc hanged, and our commitment is absolutely unchanged to this business.  And I'm really \nexcited about the progress that the team is making in service of all those goals.  \n \n Matt Sims:  Next question, please.  \n \n Operator:  Thanks so much, sir.  And our next question will be coming from Elizabeth Anderson, \ncalling from Evercore ISI. ", "original_text": "And I'm really \nexcited about the progress that the team is making in service of all those goals.  \n \n", "page_label": "12", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "60f11f9b45aba76a0312d5f4289aa127f4a4b46fd8a1d5239b2f1803da2d2985", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "bf4e18c6-44e8-4231-be5b-b8ce6fae391b", "node_type": "1", "metadata": {"window": "The \npieces are absolutely unchanged, and the overall aggregate profitability in that long -term plan is \nabsolutely unc hanged, and our commitment is absolutely unchanged to this business.  And I'm really \nexcited about the progress that the team is making in service of all those goals.  \n \n Matt Sims:  Next question, please.  \n \n Operator:  Thanks so much, sir.  And our next question will be coming from Elizabeth Anderson, \ncalling from Evercore ISI.  Please go ahead.  Your line is open.  \n \n", "original_text": "Operator:  Thanks so much, sir. "}, "hash": "106ab27662f7114cae438f8a25dcb0db9c2b1f021712e9085ae493ca36beb2e1", "class_name": "RelatedNodeInfo"}}, "text": "Matt Sims:  Next question, please.  \n \n", "start_char_idx": 806, "end_char_idx": 845, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "bf4e18c6-44e8-4231-be5b-b8ce6fae391b": {"__data__": {"id_": "bf4e18c6-44e8-4231-be5b-b8ce6fae391b", "embedding": null, "metadata": {"window": "The \npieces are absolutely unchanged, and the overall aggregate profitability in that long -term plan is \nabsolutely unc hanged, and our commitment is absolutely unchanged to this business.  And I'm really \nexcited about the progress that the team is making in service of all those goals.  \n \n Matt Sims:  Next question, please.  \n \n Operator:  Thanks so much, sir.  And our next question will be coming from Elizabeth Anderson, \ncalling from Evercore ISI.  Please go ahead.  Your line is open.  \n \n", "original_text": "Operator:  Thanks so much, sir. ", "page_label": "12", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "f6aa5062-6f6b-48ce-b783-7a0df37afe92", "node_type": "4", "metadata": {"page_label": "12", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "22984b0b58240c211588ed6c0cd5e35a4a51583c2f3bfe772345b964ca16208b", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "167dc050-c078-48f9-b264-69ae17ca8ab8", "node_type": "1", "metadata": {"window": "But that was just moving the pieces.  The \npieces are absolutely unchanged, and the overall aggregate profitability in that long -term plan is \nabsolutely unc hanged, and our commitment is absolutely unchanged to this business.  And I'm really \nexcited about the progress that the team is making in service of all those goals.  \n \n Matt Sims:  Next question, please.  \n \n Operator:  Thanks so much, sir.  And our next question will be coming from Elizabeth Anderson, \ncalling from Evercore ISI.  Please go ahead. ", "original_text": "Matt Sims:  Next question, please.  \n \n", "page_label": "12", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "3d23145931840d0eb2a48188d5737a1ad827272986397090f9fe52c41bc3054c", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "b2d2c856-c1a9-4be6-8c70-290dcc72c675", "node_type": "1", "metadata": {"window": "And I'm really \nexcited about the progress that the team is making in service of all those goals.  \n \n Matt Sims:  Next question, please.  \n \n Operator:  Thanks so much, sir.  And our next question will be coming from Elizabeth Anderson, \ncalling from Evercore ISI.  Please go ahead.  Your line is open.  \n \n Elizabeth Anderson:   Hi, guys. ", "original_text": "And our next question will be coming from Elizabeth Anderson, \ncalling from Evercore ISI. "}, "hash": "ba826d347198b8d3dece2316cf790d0fcf6b5e8519e04856addc54493acf5179", "class_name": "RelatedNodeInfo"}}, "text": "Operator:  Thanks so much, sir. ", "start_char_idx": 845, "end_char_idx": 877, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "b2d2c856-c1a9-4be6-8c70-290dcc72c675": {"__data__": {"id_": "b2d2c856-c1a9-4be6-8c70-290dcc72c675", "embedding": null, "metadata": {"window": "And I'm really \nexcited about the progress that the team is making in service of all those goals.  \n \n Matt Sims:  Next question, please.  \n \n Operator:  Thanks so much, sir.  And our next question will be coming from Elizabeth Anderson, \ncalling from Evercore ISI.  Please go ahead.  Your line is open.  \n \n Elizabeth Anderson:   Hi, guys. ", "original_text": "And our next question will be coming from Elizabeth Anderson, \ncalling from Evercore ISI. ", "page_label": "12", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "f6aa5062-6f6b-48ce-b783-7a0df37afe92", "node_type": "4", "metadata": {"page_label": "12", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "22984b0b58240c211588ed6c0cd5e35a4a51583c2f3bfe772345b964ca16208b", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "bf4e18c6-44e8-4231-be5b-b8ce6fae391b", "node_type": "1", "metadata": {"window": "The \npieces are absolutely unchanged, and the overall aggregate profitability in that long -term plan is \nabsolutely unc hanged, and our commitment is absolutely unchanged to this business.  And I'm really \nexcited about the progress that the team is making in service of all those goals.  \n \n Matt Sims:  Next question, please.  \n \n Operator:  Thanks so much, sir.  And our next question will be coming from Elizabeth Anderson, \ncalling from Evercore ISI.  Please go ahead.  Your line is open.  \n \n", "original_text": "Operator:  Thanks so much, sir. ", "page_label": "12", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "66abeb5cd8a25b94a2aca0e36168f274b340c19f65648633dcd46c63d295ee20", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "4840c105-9d65-4c00-bee1-8624d6039756", "node_type": "1", "metadata": {"window": "Matt Sims:  Next question, please.  \n \n Operator:  Thanks so much, sir.  And our next question will be coming from Elizabeth Anderson, \ncalling from Evercore ISI.  Please go ahead.  Your line is open.  \n \n Elizabeth Anderson:   Hi, guys.  Thanks so much for the question. ", "original_text": "Please go ahead. "}, "hash": "3428622798b9853064e9be8be22ec82a8661c2e718c223b0e5ea00bfd3b30c41", "class_name": "RelatedNodeInfo"}}, "text": "And our next question will be coming from Elizabeth Anderson, \ncalling from Evercore ISI. ", "start_char_idx": 877, "end_char_idx": 967, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "4840c105-9d65-4c00-bee1-8624d6039756": {"__data__": {"id_": "4840c105-9d65-4c00-bee1-8624d6039756", "embedding": null, "metadata": {"window": "Matt Sims:  Next question, please.  \n \n Operator:  Thanks so much, sir.  And our next question will be coming from Elizabeth Anderson, \ncalling from Evercore ISI.  Please go ahead.  Your line is open.  \n \n Elizabeth Anderson:   Hi, guys.  Thanks so much for the question. ", "original_text": "Please go ahead. ", "page_label": "12", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "f6aa5062-6f6b-48ce-b783-7a0df37afe92", "node_type": "4", "metadata": {"page_label": "12", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "22984b0b58240c211588ed6c0cd5e35a4a51583c2f3bfe772345b964ca16208b", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "b2d2c856-c1a9-4be6-8c70-290dcc72c675", "node_type": "1", "metadata": {"window": "And I'm really \nexcited about the progress that the team is making in service of all those goals.  \n \n Matt Sims:  Next question, please.  \n \n Operator:  Thanks so much, sir.  And our next question will be coming from Elizabeth Anderson, \ncalling from Evercore ISI.  Please go ahead.  Your line is open.  \n \n Elizabeth Anderson:   Hi, guys. ", "original_text": "And our next question will be coming from Elizabeth Anderson, \ncalling from Evercore ISI. ", "page_label": "12", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "0ecff71b7f9fe7419e115480d3437942666d4c7bda6b605227e2f63364e90572", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "600de59c-58aa-422d-a43c-d19840fa4c8f", "node_type": "1", "metadata": {"window": "Operator:  Thanks so much, sir.  And our next question will be coming from Elizabeth Anderson, \ncalling from Evercore ISI.  Please go ahead.  Your line is open.  \n \n Elizabeth Anderson:   Hi, guys.  Thanks so much for the question.  I had two sort of maybe more \nfinancial questions going forward. ", "original_text": "Your line is open.  \n \n"}, "hash": "b1b604a6a7c031847d52fa0cea05f1f32471888c68011c6db92a25d78df8c407", "class_name": "RelatedNodeInfo"}}, "text": "Please go ahead. ", "start_char_idx": 967, "end_char_idx": 984, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "600de59c-58aa-422d-a43c-d19840fa4c8f": {"__data__": {"id_": "600de59c-58aa-422d-a43c-d19840fa4c8f", "embedding": null, "metadata": {"window": "Operator:  Thanks so much, sir.  And our next question will be coming from Elizabeth Anderson, \ncalling from Evercore ISI.  Please go ahead.  Your line is open.  \n \n Elizabeth Anderson:   Hi, guys.  Thanks so much for the question.  I had two sort of maybe more \nfinancial questions going forward. ", "original_text": "Your line is open.  \n \n", "page_label": "12", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "f6aa5062-6f6b-48ce-b783-7a0df37afe92", "node_type": "4", "metadata": {"page_label": "12", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "22984b0b58240c211588ed6c0cd5e35a4a51583c2f3bfe772345b964ca16208b", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "4840c105-9d65-4c00-bee1-8624d6039756", "node_type": "1", "metadata": {"window": "Matt Sims:  Next question, please.  \n \n Operator:  Thanks so much, sir.  And our next question will be coming from Elizabeth Anderson, \ncalling from Evercore ISI.  Please go ahead.  Your line is open.  \n \n Elizabeth Anderson:   Hi, guys.  Thanks so much for the question. ", "original_text": "Please go ahead. ", "page_label": "12", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "19f781c258fceba070da8d8462b7e8b54b41f7f5e7a63a53857f7d262153bbdf", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "364ea9e2-e7a6-461b-ae2d-a0cdaa895fe2", "node_type": "1", "metadata": {"window": "And our next question will be coming from Elizabeth Anderson, \ncalling from Evercore ISI.  Please go ahead.  Your line is open.  \n \n Elizabeth Anderson:   Hi, guys.  Thanks so much for the question.  I had two sort of maybe more \nfinancial questions going forward.  Can you talk to us about sort of the interest expense, obviously, \nyou had a pretty big step down. ", "original_text": "Elizabeth Anderson:   Hi, guys. "}, "hash": "b625fb274a99cfb3e17c5e69c0033033d427b80b02eea1f172dd2901448e2cbb", "class_name": "RelatedNodeInfo"}}, "text": "Your line is open.  \n \n", "start_char_idx": 984, "end_char_idx": 1007, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "364ea9e2-e7a6-461b-ae2d-a0cdaa895fe2": {"__data__": {"id_": "364ea9e2-e7a6-461b-ae2d-a0cdaa895fe2", "embedding": null, "metadata": {"window": "And our next question will be coming from Elizabeth Anderson, \ncalling from Evercore ISI.  Please go ahead.  Your line is open.  \n \n Elizabeth Anderson:   Hi, guys.  Thanks so much for the question.  I had two sort of maybe more \nfinancial questions going forward.  Can you talk to us about sort of the interest expense, obviously, \nyou had a pretty big step down. ", "original_text": "Elizabeth Anderson:   Hi, guys. ", "page_label": "12", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "f6aa5062-6f6b-48ce-b783-7a0df37afe92", "node_type": "4", "metadata": {"page_label": "12", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "22984b0b58240c211588ed6c0cd5e35a4a51583c2f3bfe772345b964ca16208b", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "600de59c-58aa-422d-a43c-d19840fa4c8f", "node_type": "1", "metadata": {"window": "Operator:  Thanks so much, sir.  And our next question will be coming from Elizabeth Anderson, \ncalling from Evercore ISI.  Please go ahead.  Your line is open.  \n \n Elizabeth Anderson:   Hi, guys.  Thanks so much for the question.  I had two sort of maybe more \nfinancial questions going forward. ", "original_text": "Your line is open.  \n \n", "page_label": "12", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "818470980633cfd1d18831bff77edb16d7c7828887e0e8cd209ed1570deabf04", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "63b97613-ed15-43de-9ba6-6394455b8cab", "node_type": "1", "metadata": {"window": "Please go ahead.  Your line is open.  \n \n Elizabeth Anderson:   Hi, guys.  Thanks so much for the question.  I had two sort of maybe more \nfinancial questions going forward.  Can you talk to us about sort of the interest expense, obviously, \nyou had a pretty big step down.  I just wanted to understand that in terms of that a nd your sort of \nongoing thoughts on the capital structure. ", "original_text": "Thanks so much for the question. "}, "hash": "568b1c222ac98bbf0ef9fc1b9a30cdd87254f6ad44706a7a87104693885d69af", "class_name": "RelatedNodeInfo"}}, "text": "Elizabeth Anderson:   Hi, guys. ", "start_char_idx": 1007, "end_char_idx": 1039, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "63b97613-ed15-43de-9ba6-6394455b8cab": {"__data__": {"id_": "63b97613-ed15-43de-9ba6-6394455b8cab", "embedding": null, "metadata": {"window": "Please go ahead.  Your line is open.  \n \n Elizabeth Anderson:   Hi, guys.  Thanks so much for the question.  I had two sort of maybe more \nfinancial questions going forward.  Can you talk to us about sort of the interest expense, obviously, \nyou had a pretty big step down.  I just wanted to understand that in terms of that a nd your sort of \nongoing thoughts on the capital structure. ", "original_text": "Thanks so much for the question. ", "page_label": "12", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "f6aa5062-6f6b-48ce-b783-7a0df37afe92", "node_type": "4", "metadata": {"page_label": "12", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "22984b0b58240c211588ed6c0cd5e35a4a51583c2f3bfe772345b964ca16208b", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "364ea9e2-e7a6-461b-ae2d-a0cdaa895fe2", "node_type": "1", "metadata": {"window": "And our next question will be coming from Elizabeth Anderson, \ncalling from Evercore ISI.  Please go ahead.  Your line is open.  \n \n Elizabeth Anderson:   Hi, guys.  Thanks so much for the question.  I had two sort of maybe more \nfinancial questions going forward.  Can you talk to us about sort of the interest expense, obviously, \nyou had a pretty big step down. ", "original_text": "Elizabeth Anderson:   Hi, guys. ", "page_label": "12", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "9e2a63917114ff95ed87e51538dc286689ac105759e445c40a70530174479e75", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "72f07ada-7aee-4d9b-9da4-82b9adbead4b", "node_type": "1", "metadata": {"window": "Your line is open.  \n \n Elizabeth Anderson:   Hi, guys.  Thanks so much for the question.  I had two sort of maybe more \nfinancial questions going forward.  Can you talk to us about sort of the interest expense, obviously, \nyou had a pretty big step down.  I just wanted to understand that in terms of that a nd your sort of \nongoing thoughts on the capital structure.  And can you also talk about why the,  about the free cash \nflow improvement ? ", "original_text": "I had two sort of maybe more \nfinancial questions going forward. "}, "hash": "a4cb411af5c15b49b10373f2f958ec6174d12d91e3ef228ef2ac87b6981445c6", "class_name": "RelatedNodeInfo"}}, "text": "Thanks so much for the question. ", "start_char_idx": 1039, "end_char_idx": 1072, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "72f07ada-7aee-4d9b-9da4-82b9adbead4b": {"__data__": {"id_": "72f07ada-7aee-4d9b-9da4-82b9adbead4b", "embedding": null, "metadata": {"window": "Your line is open.  \n \n Elizabeth Anderson:   Hi, guys.  Thanks so much for the question.  I had two sort of maybe more \nfinancial questions going forward.  Can you talk to us about sort of the interest expense, obviously, \nyou had a pretty big step down.  I just wanted to understand that in terms of that a nd your sort of \nongoing thoughts on the capital structure.  And can you also talk about why the,  about the free cash \nflow improvement ? ", "original_text": "I had two sort of maybe more \nfinancial questions going forward. ", "page_label": "12", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "f6aa5062-6f6b-48ce-b783-7a0df37afe92", "node_type": "4", "metadata": {"page_label": "12", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "22984b0b58240c211588ed6c0cd5e35a4a51583c2f3bfe772345b964ca16208b", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "63b97613-ed15-43de-9ba6-6394455b8cab", "node_type": "1", "metadata": {"window": "Please go ahead.  Your line is open.  \n \n Elizabeth Anderson:   Hi, guys.  Thanks so much for the question.  I had two sort of maybe more \nfinancial questions going forward.  Can you talk to us about sort of the interest expense, obviously, \nyou had a pretty big step down.  I just wanted to understand that in terms of that a nd your sort of \nongoing thoughts on the capital structure. ", "original_text": "Thanks so much for the question. ", "page_label": "12", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "5c154c8cd8126bd998dbd3325f214aae5d1bdb7ccff652fec642bc8dae6f1e9d", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "16149aa9-a975-411f-a12b-96ad49e97df0", "node_type": "1", "metadata": {"window": "Elizabeth Anderson:   Hi, guys.  Thanks so much for the question.  I had two sort of maybe more \nfinancial questions going forward.  Can you talk to us about sort of the interest expense, obviously, \nyou had a pretty big step down.  I just wanted to understand that in terms of that a nd your sort of \nongoing thoughts on the capital structure.  And can you also talk about why the,  about the free cash \nflow improvement ?  That was nice to see that step up in the quarter as well in terms of the guidance . \n \n", "original_text": "Can you talk to us about sort of the interest expense, obviously, \nyou had a pretty big step down. "}, "hash": "63990d3011b552fe53a47f791ce9c095ea4eccad03af78f7fa138f96e8284459", "class_name": "RelatedNodeInfo"}}, "text": "I had two sort of maybe more \nfinancial questions going forward. ", "start_char_idx": 1072, "end_char_idx": 1137, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "16149aa9-a975-411f-a12b-96ad49e97df0": {"__data__": {"id_": "16149aa9-a975-411f-a12b-96ad49e97df0", "embedding": null, "metadata": {"window": "Elizabeth Anderson:   Hi, guys.  Thanks so much for the question.  I had two sort of maybe more \nfinancial questions going forward.  Can you talk to us about sort of the interest expense, obviously, \nyou had a pretty big step down.  I just wanted to understand that in terms of that a nd your sort of \nongoing thoughts on the capital structure.  And can you also talk about why the,  about the free cash \nflow improvement ?  That was nice to see that step up in the quarter as well in terms of the guidance . \n \n", "original_text": "Can you talk to us about sort of the interest expense, obviously, \nyou had a pretty big step down. ", "page_label": "12", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "f6aa5062-6f6b-48ce-b783-7a0df37afe92", "node_type": "4", "metadata": {"page_label": "12", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "22984b0b58240c211588ed6c0cd5e35a4a51583c2f3bfe772345b964ca16208b", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "72f07ada-7aee-4d9b-9da4-82b9adbead4b", "node_type": "1", "metadata": {"window": "Your line is open.  \n \n Elizabeth Anderson:   Hi, guys.  Thanks so much for the question.  I had two sort of maybe more \nfinancial questions going forward.  Can you talk to us about sort of the interest expense, obviously, \nyou had a pretty big step down.  I just wanted to understand that in terms of that a nd your sort of \nongoing thoughts on the capital structure.  And can you also talk about why the,  about the free cash \nflow improvement ? ", "original_text": "I had two sort of maybe more \nfinancial questions going forward. ", "page_label": "12", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "d770ab2a3127cf624e024de19fd0dd986a8cb67a93fee2e181f4ff94a843714f", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "3bca1532-55b2-443e-9585-cd8bf53c8bf7", "node_type": "1", "metadata": {"window": "Thanks so much for the question.  I had two sort of maybe more \nfinancial questions going forward.  Can you talk to us about sort of the interest expense, obviously, \nyou had a pretty big step down.  I just wanted to understand that in terms of that a nd your sort of \nongoing thoughts on the capital structure.  And can you also talk about why the,  about the free cash \nflow improvement ?  That was nice to see that step up in the quarter as well in terms of the guidance . \n \n Aaron Alt :  We're happy to offer some perspective. ", "original_text": "I just wanted to understand that in terms of that a nd your sort of \nongoing thoughts on the capital structure. "}, "hash": "7032027fc99ebe779701bd4410a6e8e49d2e5b344e66926551e912abab1f7877", "class_name": "RelatedNodeInfo"}}, "text": "Can you talk to us about sort of the interest expense, obviously, \nyou had a pretty big step down. ", "start_char_idx": 1137, "end_char_idx": 1236, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "3bca1532-55b2-443e-9585-cd8bf53c8bf7": {"__data__": {"id_": "3bca1532-55b2-443e-9585-cd8bf53c8bf7", "embedding": null, "metadata": {"window": "Thanks so much for the question.  I had two sort of maybe more \nfinancial questions going forward.  Can you talk to us about sort of the interest expense, obviously, \nyou had a pretty big step down.  I just wanted to understand that in terms of that a nd your sort of \nongoing thoughts on the capital structure.  And can you also talk about why the,  about the free cash \nflow improvement ?  That was nice to see that step up in the quarter as well in terms of the guidance . \n \n Aaron Alt :  We're happy to offer some perspective. ", "original_text": "I just wanted to understand that in terms of that a nd your sort of \nongoing thoughts on the capital structure. ", "page_label": "12", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "f6aa5062-6f6b-48ce-b783-7a0df37afe92", "node_type": "4", "metadata": {"page_label": "12", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "22984b0b58240c211588ed6c0cd5e35a4a51583c2f3bfe772345b964ca16208b", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "16149aa9-a975-411f-a12b-96ad49e97df0", "node_type": "1", "metadata": {"window": "Elizabeth Anderson:   Hi, guys.  Thanks so much for the question.  I had two sort of maybe more \nfinancial questions going forward.  Can you talk to us about sort of the interest expense, obviously, \nyou had a pretty big step down.  I just wanted to understand that in terms of that a nd your sort of \nongoing thoughts on the capital structure.  And can you also talk about why the,  about the free cash \nflow improvement ?  That was nice to see that step up in the quarter as well in terms of the guidance . \n \n", "original_text": "Can you talk to us about sort of the interest expense, obviously, \nyou had a pretty big step down. ", "page_label": "12", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "9043d058ff021ffe91e4984e326f7b2fffb28ffcbdd607be7ad9d5dd0e229751", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "eb93f940-44f9-4914-80a9-5845b2f7e70c", "node_type": "1", "metadata": {"window": "I had two sort of maybe more \nfinancial questions going forward.  Can you talk to us about sort of the interest expense, obviously, \nyou had a pretty big step down.  I just wanted to understand that in terms of that a nd your sort of \nongoing thoughts on the capital structure.  And can you also talk about why the,  about the free cash \nflow improvement ?  That was nice to see that step up in the quarter as well in terms of the guidance . \n \n Aaron Alt :  We're happy to offer some perspective.  We're quite pleased with the below -the-line \nresults, of course, for the quarter. ", "original_text": "And can you also talk about why the,  about the free cash \nflow improvement ? "}, "hash": "5bc13260879fb562cc535a4b16d0eabc422b86fc56951e029d79e9b39b919551", "class_name": "RelatedNodeInfo"}}, "text": "I just wanted to understand that in terms of that a nd your sort of \nongoing thoughts on the capital structure. ", "start_char_idx": 1236, "end_char_idx": 1348, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "eb93f940-44f9-4914-80a9-5845b2f7e70c": {"__data__": {"id_": "eb93f940-44f9-4914-80a9-5845b2f7e70c", "embedding": null, "metadata": {"window": "I had two sort of maybe more \nfinancial questions going forward.  Can you talk to us about sort of the interest expense, obviously, \nyou had a pretty big step down.  I just wanted to understand that in terms of that a nd your sort of \nongoing thoughts on the capital structure.  And can you also talk about why the,  about the free cash \nflow improvement ?  That was nice to see that step up in the quarter as well in terms of the guidance . \n \n Aaron Alt :  We're happy to offer some perspective.  We're quite pleased with the below -the-line \nresults, of course, for the quarter. ", "original_text": "And can you also talk about why the,  about the free cash \nflow improvement ? ", "page_label": "12", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "f6aa5062-6f6b-48ce-b783-7a0df37afe92", "node_type": "4", "metadata": {"page_label": "12", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "22984b0b58240c211588ed6c0cd5e35a4a51583c2f3bfe772345b964ca16208b", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "3bca1532-55b2-443e-9585-cd8bf53c8bf7", "node_type": "1", "metadata": {"window": "Thanks so much for the question.  I had two sort of maybe more \nfinancial questions going forward.  Can you talk to us about sort of the interest expense, obviously, \nyou had a pretty big step down.  I just wanted to understand that in terms of that a nd your sort of \nongoing thoughts on the capital structure.  And can you also talk about why the,  about the free cash \nflow improvement ?  That was nice to see that step up in the quarter as well in terms of the guidance . \n \n Aaron Alt :  We're happy to offer some perspective. ", "original_text": "I just wanted to understand that in terms of that a nd your sort of \nongoing thoughts on the capital structure. ", "page_label": "12", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "bd186d0b162bac45be971eec71da19ec1b93503ebb929e8397f3d94e342f6c38", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "b843e5c0-4471-45d5-a108-da28578569d4", "node_type": "1", "metadata": {"window": "Can you talk to us about sort of the interest expense, obviously, \nyou had a pretty big step down.  I just wanted to understand that in terms of that a nd your sort of \nongoing thoughts on the capital structure.  And can you also talk about why the,  about the free cash \nflow improvement ?  That was nice to see that step up in the quarter as well in terms of the guidance . \n \n Aaron Alt :  We're happy to offer some perspective.  We're quite pleased with the below -the-line \nresults, of course, for the quarter.  I'm going to start with the fact that as we announced, we ended the \nquarter with $4.6 billion of cash on hand. ", "original_text": "That was nice to see that step up in the quarter as well in terms of the guidance . \n \n"}, "hash": "ab0f0738e59ae34a2fd3b612d84619e59156a9603b2332f21b029aeaf0901d27", "class_name": "RelatedNodeInfo"}}, "text": "And can you also talk about why the,  about the free cash \nflow improvement ? ", "start_char_idx": 1348, "end_char_idx": 1426, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "b843e5c0-4471-45d5-a108-da28578569d4": {"__data__": {"id_": "b843e5c0-4471-45d5-a108-da28578569d4", "embedding": null, "metadata": {"window": "Can you talk to us about sort of the interest expense, obviously, \nyou had a pretty big step down.  I just wanted to understand that in terms of that a nd your sort of \nongoing thoughts on the capital structure.  And can you also talk about why the,  about the free cash \nflow improvement ?  That was nice to see that step up in the quarter as well in terms of the guidance . \n \n Aaron Alt :  We're happy to offer some perspective.  We're quite pleased with the below -the-line \nresults, of course, for the quarter.  I'm going to start with the fact that as we announced, we ended the \nquarter with $4.6 billion of cash on hand. ", "original_text": "That was nice to see that step up in the quarter as well in terms of the guidance . \n \n", "page_label": "12", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "f6aa5062-6f6b-48ce-b783-7a0df37afe92", "node_type": "4", "metadata": {"page_label": "12", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "22984b0b58240c211588ed6c0cd5e35a4a51583c2f3bfe772345b964ca16208b", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "eb93f940-44f9-4914-80a9-5845b2f7e70c", "node_type": "1", "metadata": {"window": "I had two sort of maybe more \nfinancial questions going forward.  Can you talk to us about sort of the interest expense, obviously, \nyou had a pretty big step down.  I just wanted to understand that in terms of that a nd your sort of \nongoing thoughts on the capital structure.  And can you also talk about why the,  about the free cash \nflow improvement ?  That was nice to see that step up in the quarter as well in terms of the guidance . \n \n Aaron Alt :  We're happy to offer some perspective.  We're quite pleased with the below -the-line \nresults, of course, for the quarter. ", "original_text": "And can you also talk about why the,  about the free cash \nflow improvement ? ", "page_label": "12", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "df2c724a7f6be3a5f3fbc8ad69fc4e6ba8c4b7637fda91e55e00670b18a95f13", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "c01ccf74-6dd5-47fa-b795-4d40809dbd96", "node_type": "1", "metadata": {"window": "I just wanted to understand that in terms of that a nd your sort of \nongoing thoughts on the capital structure.  And can you also talk about why the,  about the free cash \nflow improvement ?  That was nice to see that step up in the quarter as well in terms of the guidance . \n \n Aaron Alt :  We're happy to offer some perspective.  We're quite pleased with the below -the-line \nresults, of course, for the quarter.  I'm going to start with the fact that as we announced, we ended the \nquarter with $4.6 billion of cash on hand.  And of course, that's dri ven by the strong cash generation, \nwhich was the end part of your question. ", "original_text": "Aaron Alt :  We're happy to offer some perspective. "}, "hash": "a4be240df1cfb49b56a8111aac7b24f3cca09d763ed10722f443b4c189712bdf", "class_name": "RelatedNodeInfo"}}, "text": "That was nice to see that step up in the quarter as well in terms of the guidance . \n \n", "start_char_idx": 1426, "end_char_idx": 1513, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "c01ccf74-6dd5-47fa-b795-4d40809dbd96": {"__data__": {"id_": "c01ccf74-6dd5-47fa-b795-4d40809dbd96", "embedding": null, "metadata": {"window": "I just wanted to understand that in terms of that a nd your sort of \nongoing thoughts on the capital structure.  And can you also talk about why the,  about the free cash \nflow improvement ?  That was nice to see that step up in the quarter as well in terms of the guidance . \n \n Aaron Alt :  We're happy to offer some perspective.  We're quite pleased with the below -the-line \nresults, of course, for the quarter.  I'm going to start with the fact that as we announced, we ended the \nquarter with $4.6 billion of cash on hand.  And of course, that's dri ven by the strong cash generation, \nwhich was the end part of your question. ", "original_text": "Aaron Alt :  We're happy to offer some perspective. ", "page_label": "12", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "f6aa5062-6f6b-48ce-b783-7a0df37afe92", "node_type": "4", "metadata": {"page_label": "12", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "22984b0b58240c211588ed6c0cd5e35a4a51583c2f3bfe772345b964ca16208b", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "b843e5c0-4471-45d5-a108-da28578569d4", "node_type": "1", "metadata": {"window": "Can you talk to us about sort of the interest expense, obviously, \nyou had a pretty big step down.  I just wanted to understand that in terms of that a nd your sort of \nongoing thoughts on the capital structure.  And can you also talk about why the,  about the free cash \nflow improvement ?  That was nice to see that step up in the quarter as well in terms of the guidance . \n \n Aaron Alt :  We're happy to offer some perspective.  We're quite pleased with the below -the-line \nresults, of course, for the quarter.  I'm going to start with the fact that as we announced, we ended the \nquarter with $4.6 billion of cash on hand. ", "original_text": "That was nice to see that step up in the quarter as well in terms of the guidance . \n \n", "page_label": "12", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "6ca96bc4285de00ae0f35eb295862570098ab01c03263d2599992a210b9513fc", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "20654277-bde5-4825-b8a7-739f3512ad7c", "node_type": "1", "metadata": {"window": "And can you also talk about why the,  about the free cash \nflow improvement ?  That was nice to see that step up in the quarter as well in terms of the guidance . \n \n Aaron Alt :  We're happy to offer some perspective.  We're quite pleased with the below -the-line \nresults, of course, for the quarter.  I'm going to start with the fact that as we announced, we ended the \nquarter with $4.6 billion of cash on hand.  And of course, that's dri ven by the strong cash generation, \nwhich was the end part of your question.  If you think back to our Investor Day, we had highlighted that \nfurther optimization of our cash flow position was something we were focused on doing. ", "original_text": "We're quite pleased with the below -the-line \nresults, of course, for the quarter. "}, "hash": "f5d206515991a197560d2aa9eea62aaa86c4e9bdf204a6f0f602f85939bd3230", "class_name": "RelatedNodeInfo"}}, "text": "Aaron Alt :  We're happy to offer some perspective. ", "start_char_idx": 1513, "end_char_idx": 1565, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "20654277-bde5-4825-b8a7-739f3512ad7c": {"__data__": {"id_": "20654277-bde5-4825-b8a7-739f3512ad7c", "embedding": null, "metadata": {"window": "And can you also talk about why the,  about the free cash \nflow improvement ?  That was nice to see that step up in the quarter as well in terms of the guidance . \n \n Aaron Alt :  We're happy to offer some perspective.  We're quite pleased with the below -the-line \nresults, of course, for the quarter.  I'm going to start with the fact that as we announced, we ended the \nquarter with $4.6 billion of cash on hand.  And of course, that's dri ven by the strong cash generation, \nwhich was the end part of your question.  If you think back to our Investor Day, we had highlighted that \nfurther optimization of our cash flow position was something we were focused on doing. ", "original_text": "We're quite pleased with the below -the-line \nresults, of course, for the quarter. ", "page_label": "12", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "f6aa5062-6f6b-48ce-b783-7a0df37afe92", "node_type": "4", "metadata": {"page_label": "12", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "22984b0b58240c211588ed6c0cd5e35a4a51583c2f3bfe772345b964ca16208b", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "c01ccf74-6dd5-47fa-b795-4d40809dbd96", "node_type": "1", "metadata": {"window": "I just wanted to understand that in terms of that a nd your sort of \nongoing thoughts on the capital structure.  And can you also talk about why the,  about the free cash \nflow improvement ?  That was nice to see that step up in the quarter as well in terms of the guidance . \n \n Aaron Alt :  We're happy to offer some perspective.  We're quite pleased with the below -the-line \nresults, of course, for the quarter.  I'm going to start with the fact that as we announced, we ended the \nquarter with $4.6 billion of cash on hand.  And of course, that's dri ven by the strong cash generation, \nwhich was the end part of your question. ", "original_text": "Aaron Alt :  We're happy to offer some perspective. ", "page_label": "12", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "957074bc6d79418f6fb31dcff26a155a0ab9350a1ae322a4cc5efa89d5e00880", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "c2a29d29-99ce-4ba1-a30e-b10420669489", "node_type": "1", "metadata": {"window": "That was nice to see that step up in the quarter as well in terms of the guidance . \n \n Aaron Alt :  We're happy to offer some perspective.  We're quite pleased with the below -the-line \nresults, of course, for the quarter.  I'm going to start with the fact that as we announced, we ended the \nquarter with $4.6 billion of cash on hand.  And of course, that's dri ven by the strong cash generation, \nwhich was the end part of your question.  If you think back to our Investor Day, we had highlighted that \nfurther optimization of our cash flow position was something we were focused on doing.  And the team \nhas d elivered against those efforts internally and generated strong cash flow in the first half for the \nbusiness, thus the balance . ", "original_text": "I'm going to start with the fact that as we announced, we ended the \nquarter with $4.6 billion of cash on hand. "}, "hash": "41d0bbb057803c1ce90528496409e2ed03a6f32cc750e4618b42fa3d05868214", "class_name": "RelatedNodeInfo"}}, "text": "We're quite pleased with the below -the-line \nresults, of course, for the quarter. ", "start_char_idx": 1565, "end_char_idx": 1648, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "c2a29d29-99ce-4ba1-a30e-b10420669489": {"__data__": {"id_": "c2a29d29-99ce-4ba1-a30e-b10420669489", "embedding": null, "metadata": {"window": "That was nice to see that step up in the quarter as well in terms of the guidance . \n \n Aaron Alt :  We're happy to offer some perspective.  We're quite pleased with the below -the-line \nresults, of course, for the quarter.  I'm going to start with the fact that as we announced, we ended the \nquarter with $4.6 billion of cash on hand.  And of course, that's dri ven by the strong cash generation, \nwhich was the end part of your question.  If you think back to our Investor Day, we had highlighted that \nfurther optimization of our cash flow position was something we were focused on doing.  And the team \nhas d elivered against those efforts internally and generated strong cash flow in the first half for the \nbusiness, thus the balance . ", "original_text": "I'm going to start with the fact that as we announced, we ended the \nquarter with $4.6 billion of cash on hand. ", "page_label": "12", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "f6aa5062-6f6b-48ce-b783-7a0df37afe92", "node_type": "4", "metadata": {"page_label": "12", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "22984b0b58240c211588ed6c0cd5e35a4a51583c2f3bfe772345b964ca16208b", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "20654277-bde5-4825-b8a7-739f3512ad7c", "node_type": "1", "metadata": {"window": "And can you also talk about why the,  about the free cash \nflow improvement ?  That was nice to see that step up in the quarter as well in terms of the guidance . \n \n Aaron Alt :  We're happy to offer some perspective.  We're quite pleased with the below -the-line \nresults, of course, for the quarter.  I'm going to start with the fact that as we announced, we ended the \nquarter with $4.6 billion of cash on hand.  And of course, that's dri ven by the strong cash generation, \nwhich was the end part of your question.  If you think back to our Investor Day, we had highlighted that \nfurther optimization of our cash flow position was something we were focused on doing. ", "original_text": "We're quite pleased with the below -the-line \nresults, of course, for the quarter. ", "page_label": "12", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "53ece92250d881271813e2f3c92d49d07485c7b7a0d75824ce30e403cf367141", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "daf05f0c-1d53-4e7b-8b84-5a08476fd49d", "node_type": "1", "metadata": {"window": "Aaron Alt :  We're happy to offer some perspective.  We're quite pleased with the below -the-line \nresults, of course, for the quarter.  I'm going to start with the fact that as we announced, we ended the \nquarter with $4.6 billion of cash on hand.  And of course, that's dri ven by the strong cash generation, \nwhich was the end part of your question.  If you think back to our Investor Day, we had highlighted that \nfurther optimization of our cash flow position was something we were focused on doing.  And the team \nhas d elivered against those efforts internally and generated strong cash flow in the first half for the \nbusiness, thus the balance .  Of course, the knock -on consequence of that is where we have more \ncash on hand, particularly in the higher interest rate environment, which we've been operating, we'll \nget a higher return, right?  ", "original_text": "And of course, that's dri ven by the strong cash generation, \nwhich was the end part of your question. "}, "hash": "d3df8f3d91498d46c95fe81414be5b7984c06ee0a782218c8c240e16989a38fd", "class_name": "RelatedNodeInfo"}}, "text": "I'm going to start with the fact that as we announced, we ended the \nquarter with $4.6 billion of cash on hand. ", "start_char_idx": 1648, "end_char_idx": 1760, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "daf05f0c-1d53-4e7b-8b84-5a08476fd49d": {"__data__": {"id_": "daf05f0c-1d53-4e7b-8b84-5a08476fd49d", "embedding": null, "metadata": {"window": "Aaron Alt :  We're happy to offer some perspective.  We're quite pleased with the below -the-line \nresults, of course, for the quarter.  I'm going to start with the fact that as we announced, we ended the \nquarter with $4.6 billion of cash on hand.  And of course, that's dri ven by the strong cash generation, \nwhich was the end part of your question.  If you think back to our Investor Day, we had highlighted that \nfurther optimization of our cash flow position was something we were focused on doing.  And the team \nhas d elivered against those efforts internally and generated strong cash flow in the first half for the \nbusiness, thus the balance .  Of course, the knock -on consequence of that is where we have more \ncash on hand, particularly in the higher interest rate environment, which we've been operating, we'll \nget a higher return, right?  ", "original_text": "And of course, that's dri ven by the strong cash generation, \nwhich was the end part of your question. ", "page_label": "12", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "f6aa5062-6f6b-48ce-b783-7a0df37afe92", "node_type": "4", "metadata": {"page_label": "12", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "22984b0b58240c211588ed6c0cd5e35a4a51583c2f3bfe772345b964ca16208b", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "c2a29d29-99ce-4ba1-a30e-b10420669489", "node_type": "1", "metadata": {"window": "That was nice to see that step up in the quarter as well in terms of the guidance . \n \n Aaron Alt :  We're happy to offer some perspective.  We're quite pleased with the below -the-line \nresults, of course, for the quarter.  I'm going to start with the fact that as we announced, we ended the \nquarter with $4.6 billion of cash on hand.  And of course, that's dri ven by the strong cash generation, \nwhich was the end part of your question.  If you think back to our Investor Day, we had highlighted that \nfurther optimization of our cash flow position was something we were focused on doing.  And the team \nhas d elivered against those efforts internally and generated strong cash flow in the first half for the \nbusiness, thus the balance . ", "original_text": "I'm going to start with the fact that as we announced, we ended the \nquarter with $4.6 billion of cash on hand. ", "page_label": "12", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "d70ce440692385382c3213c4a97841691e309327e393d906a83fa3fe6b599d34", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "6ce3c768-7bad-480d-aea6-0082550df34c", "node_type": "1", "metadata": {"window": "We're quite pleased with the below -the-line \nresults, of course, for the quarter.  I'm going to start with the fact that as we announced, we ended the \nquarter with $4.6 billion of cash on hand.  And of course, that's dri ven by the strong cash generation, \nwhich was the end part of your question.  If you think back to our Investor Day, we had highlighted that \nfurther optimization of our cash flow position was something we were focused on doing.  And the team \nhas d elivered against those efforts internally and generated strong cash flow in the first half for the \nbusiness, thus the balance .  Of course, the knock -on consequence of that is where we have more \ncash on hand, particularly in the higher interest rate environment, which we've been operating, we'll \nget a higher return, right?   And we have indeed benefited from a greater rate of return on the larger \ncash balances that we've had in place. ", "original_text": "If you think back to our Investor Day, we had highlighted that \nfurther optimization of our cash flow position was something we were focused on doing. "}, "hash": "0d2d1491ebc2543255c5659c341a01bdde2d7792416d12c0e395cd446fa49b40", "class_name": "RelatedNodeInfo"}}, "text": "And of course, that's dri ven by the strong cash generation, \nwhich was the end part of your question. ", "start_char_idx": 1760, "end_char_idx": 1863, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "6ce3c768-7bad-480d-aea6-0082550df34c": {"__data__": {"id_": "6ce3c768-7bad-480d-aea6-0082550df34c", "embedding": null, "metadata": {"window": "We're quite pleased with the below -the-line \nresults, of course, for the quarter.  I'm going to start with the fact that as we announced, we ended the \nquarter with $4.6 billion of cash on hand.  And of course, that's dri ven by the strong cash generation, \nwhich was the end part of your question.  If you think back to our Investor Day, we had highlighted that \nfurther optimization of our cash flow position was something we were focused on doing.  And the team \nhas d elivered against those efforts internally and generated strong cash flow in the first half for the \nbusiness, thus the balance .  Of course, the knock -on consequence of that is where we have more \ncash on hand, particularly in the higher interest rate environment, which we've been operating, we'll \nget a higher return, right?   And we have indeed benefited from a greater rate of return on the larger \ncash balances that we've had in place. ", "original_text": "If you think back to our Investor Day, we had highlighted that \nfurther optimization of our cash flow position was something we were focused on doing. ", "page_label": "12", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "f6aa5062-6f6b-48ce-b783-7a0df37afe92", "node_type": "4", "metadata": {"page_label": "12", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "22984b0b58240c211588ed6c0cd5e35a4a51583c2f3bfe772345b964ca16208b", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "daf05f0c-1d53-4e7b-8b84-5a08476fd49d", "node_type": "1", "metadata": {"window": "Aaron Alt :  We're happy to offer some perspective.  We're quite pleased with the below -the-line \nresults, of course, for the quarter.  I'm going to start with the fact that as we announced, we ended the \nquarter with $4.6 billion of cash on hand.  And of course, that's dri ven by the strong cash generation, \nwhich was the end part of your question.  If you think back to our Investor Day, we had highlighted that \nfurther optimization of our cash flow position was something we were focused on doing.  And the team \nhas d elivered against those efforts internally and generated strong cash flow in the first half for the \nbusiness, thus the balance .  Of course, the knock -on consequence of that is where we have more \ncash on hand, particularly in the higher interest rate environment, which we've been operating, we'll \nget a higher return, right?  ", "original_text": "And of course, that's dri ven by the strong cash generation, \nwhich was the end part of your question. ", "page_label": "12", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "32a44fb5c135618ebd6476fe398f35c8e31d82d7d814cb7b97f703f036bdc07a", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "39229aaf-89d2-4a27-a73c-56c3931ebbe8", "node_type": "1", "metadata": {"window": "I'm going to start with the fact that as we announced, we ended the \nquarter with $4.6 billion of cash on hand.  And of course, that's dri ven by the strong cash generation, \nwhich was the end part of your question.  If you think back to our Investor Day, we had highlighted that \nfurther optimization of our cash flow position was something we were focused on doing.  And the team \nhas d elivered against those efforts internally and generated strong cash flow in the first half for the \nbusiness, thus the balance .  Of course, the knock -on consequence of that is where we have more \ncash on hand, particularly in the higher interest rate environment, which we've been operating, we'll \nget a higher return, right?   And we have indeed benefited from a greater rate of return on the larger \ncash balances that we've had in place.  It's also the case that there is some geography within our \nstatement because deferred comp was a positive for us below the line. ", "original_text": "And the team \nhas d elivered against those efforts internally and generated strong cash flow in the first half for the \nbusiness, thus the balance . "}, "hash": "61f0fbd5bf00619cf4d1e32ea0b06ae15edcb7402ff2fb62c53e7ef21cb36480", "class_name": "RelatedNodeInfo"}}, "text": "If you think back to our Investor Day, we had highlighted that \nfurther optimization of our cash flow position was something we were focused on doing. ", "start_char_idx": 1863, "end_char_idx": 2014, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "39229aaf-89d2-4a27-a73c-56c3931ebbe8": {"__data__": {"id_": "39229aaf-89d2-4a27-a73c-56c3931ebbe8", "embedding": null, "metadata": {"window": "I'm going to start with the fact that as we announced, we ended the \nquarter with $4.6 billion of cash on hand.  And of course, that's dri ven by the strong cash generation, \nwhich was the end part of your question.  If you think back to our Investor Day, we had highlighted that \nfurther optimization of our cash flow position was something we were focused on doing.  And the team \nhas d elivered against those efforts internally and generated strong cash flow in the first half for the \nbusiness, thus the balance .  Of course, the knock -on consequence of that is where we have more \ncash on hand, particularly in the higher interest rate environment, which we've been operating, we'll \nget a higher return, right?   And we have indeed benefited from a greater rate of return on the larger \ncash balances that we've had in place.  It's also the case that there is some geography within our \nstatement because deferred comp was a positive for us below the line. ", "original_text": "And the team \nhas d elivered against those efforts internally and generated strong cash flow in the first half for the \nbusiness, thus the balance . ", "page_label": "12", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "f6aa5062-6f6b-48ce-b783-7a0df37afe92", "node_type": "4", "metadata": {"page_label": "12", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "22984b0b58240c211588ed6c0cd5e35a4a51583c2f3bfe772345b964ca16208b", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "6ce3c768-7bad-480d-aea6-0082550df34c", "node_type": "1", "metadata": {"window": "We're quite pleased with the below -the-line \nresults, of course, for the quarter.  I'm going to start with the fact that as we announced, we ended the \nquarter with $4.6 billion of cash on hand.  And of course, that's dri ven by the strong cash generation, \nwhich was the end part of your question.  If you think back to our Investor Day, we had highlighted that \nfurther optimization of our cash flow position was something we were focused on doing.  And the team \nhas d elivered against those efforts internally and generated strong cash flow in the first half for the \nbusiness, thus the balance .  Of course, the knock -on consequence of that is where we have more \ncash on hand, particularly in the higher interest rate environment, which we've been operating, we'll \nget a higher return, right?   And we have indeed benefited from a greater rate of return on the larger \ncash balances that we've had in place. ", "original_text": "If you think back to our Investor Day, we had highlighted that \nfurther optimization of our cash flow position was something we were focused on doing. ", "page_label": "12", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "e766bc2b76ffc3e8b410a9bd5f953f86b1c4e827cdea6b603fe41896a08df8ee", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "224eb121-5ae3-48c8-b111-a421cc33b0f9", "node_type": "1", "metadata": {"window": "And of course, that's dri ven by the strong cash generation, \nwhich was the end part of your question.  If you think back to our Investor Day, we had highlighted that \nfurther optimization of our cash flow position was something we were focused on doing.  And the team \nhas d elivered against those efforts internally and generated strong cash flow in the first half for the \nbusiness, thus the balance .  Of course, the knock -on consequence of that is where we have more \ncash on hand, particularly in the higher interest rate environment, which we've been operating, we'll \nget a higher return, right?   And we have indeed benefited from a greater rate of return on the larger \ncash balances that we've had in place.  It's also the case that there is some geography within our \nstatement because deferred comp was a positive for us below the line.  That's an offsetting negative \nabove the line in the quarter as well. ", "original_text": "Of course, the knock -on consequence of that is where we have more \ncash on hand, particularly in the higher interest rate environment, which we've been operating, we'll \nget a higher return, right?  "}, "hash": "0fb63ba88e3c23aba14b67bcc2c9dd0aab01da55b9d6bf1d3b47210073966f61", "class_name": "RelatedNodeInfo"}}, "text": "And the team \nhas d elivered against those efforts internally and generated strong cash flow in the first half for the \nbusiness, thus the balance . ", "start_char_idx": 2014, "end_char_idx": 2163, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "224eb121-5ae3-48c8-b111-a421cc33b0f9": {"__data__": {"id_": "224eb121-5ae3-48c8-b111-a421cc33b0f9", "embedding": null, "metadata": {"window": "And of course, that's dri ven by the strong cash generation, \nwhich was the end part of your question.  If you think back to our Investor Day, we had highlighted that \nfurther optimization of our cash flow position was something we were focused on doing.  And the team \nhas d elivered against those efforts internally and generated strong cash flow in the first half for the \nbusiness, thus the balance .  Of course, the knock -on consequence of that is where we have more \ncash on hand, particularly in the higher interest rate environment, which we've been operating, we'll \nget a higher return, right?   And we have indeed benefited from a greater rate of return on the larger \ncash balances that we've had in place.  It's also the case that there is some geography within our \nstatement because deferred comp was a positive for us below the line.  That's an offsetting negative \nabove the line in the quarter as well. ", "original_text": "Of course, the knock -on consequence of that is where we have more \ncash on hand, particularly in the higher interest rate environment, which we've been operating, we'll \nget a higher return, right?  ", "page_label": "12", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "f6aa5062-6f6b-48ce-b783-7a0df37afe92", "node_type": "4", "metadata": {"page_label": "12", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "22984b0b58240c211588ed6c0cd5e35a4a51583c2f3bfe772345b964ca16208b", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "39229aaf-89d2-4a27-a73c-56c3931ebbe8", "node_type": "1", "metadata": {"window": "I'm going to start with the fact that as we announced, we ended the \nquarter with $4.6 billion of cash on hand.  And of course, that's dri ven by the strong cash generation, \nwhich was the end part of your question.  If you think back to our Investor Day, we had highlighted that \nfurther optimization of our cash flow position was something we were focused on doing.  And the team \nhas d elivered against those efforts internally and generated strong cash flow in the first half for the \nbusiness, thus the balance .  Of course, the knock -on consequence of that is where we have more \ncash on hand, particularly in the higher interest rate environment, which we've been operating, we'll \nget a higher return, right?   And we have indeed benefited from a greater rate of return on the larger \ncash balances that we've had in place.  It's also the case that there is some geography within our \nstatement because deferred comp was a positive for us below the line. ", "original_text": "And the team \nhas d elivered against those efforts internally and generated strong cash flow in the first half for the \nbusiness, thus the balance . ", "page_label": "12", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "389f07ccb4caa96a58f55228a4b9d45ed55be201f7b1e9ccb897282b961cbb55", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "7f1fbbd9-bace-4242-b340-6c1929f61d16", "node_type": "1", "metadata": {"window": "If you think back to our Investor Day, we had highlighted that \nfurther optimization of our cash flow position was something we were focused on doing.  And the team \nhas d elivered against those efforts internally and generated strong cash flow in the first half for the \nbusiness, thus the balance .  Of course, the knock -on consequence of that is where we have more \ncash on hand, particularly in the higher interest rate environment, which we've been operating, we'll \nget a higher return, right?   And we have indeed benefited from a greater rate of return on the larger \ncash balances that we've had in place.  It's also the case that there is some geography within our \nstatement because deferred comp was a positive for us below the line.  That's an offsetting negative \nabove the line in the quarter as well.  And so, it's really the aggregation of those three things , of those \nseveral things, which led to the results for the quarter.  \n \n", "original_text": "And we have indeed benefited from a greater rate of return on the larger \ncash balances that we've had in place. "}, "hash": "31a0c5108ba06be7e644f57bf4380dece624bb0b72567332f4bdb749ca3ab589", "class_name": "RelatedNodeInfo"}}, "text": "Of course, the knock -on consequence of that is where we have more \ncash on hand, particularly in the higher interest rate environment, which we've been operating, we'll \nget a higher return, right?  ", "start_char_idx": 2163, "end_char_idx": 2363, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "7f1fbbd9-bace-4242-b340-6c1929f61d16": {"__data__": {"id_": "7f1fbbd9-bace-4242-b340-6c1929f61d16", "embedding": null, "metadata": {"window": "If you think back to our Investor Day, we had highlighted that \nfurther optimization of our cash flow position was something we were focused on doing.  And the team \nhas d elivered against those efforts internally and generated strong cash flow in the first half for the \nbusiness, thus the balance .  Of course, the knock -on consequence of that is where we have more \ncash on hand, particularly in the higher interest rate environment, which we've been operating, we'll \nget a higher return, right?   And we have indeed benefited from a greater rate of return on the larger \ncash balances that we've had in place.  It's also the case that there is some geography within our \nstatement because deferred comp was a positive for us below the line.  That's an offsetting negative \nabove the line in the quarter as well.  And so, it's really the aggregation of those three things , of those \nseveral things, which led to the results for the quarter.  \n \n", "original_text": "And we have indeed benefited from a greater rate of return on the larger \ncash balances that we've had in place. ", "page_label": "12", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "f6aa5062-6f6b-48ce-b783-7a0df37afe92", "node_type": "4", "metadata": {"page_label": "12", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "22984b0b58240c211588ed6c0cd5e35a4a51583c2f3bfe772345b964ca16208b", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "224eb121-5ae3-48c8-b111-a421cc33b0f9", "node_type": "1", "metadata": {"window": "And of course, that's dri ven by the strong cash generation, \nwhich was the end part of your question.  If you think back to our Investor Day, we had highlighted that \nfurther optimization of our cash flow position was something we were focused on doing.  And the team \nhas d elivered against those efforts internally and generated strong cash flow in the first half for the \nbusiness, thus the balance .  Of course, the knock -on consequence of that is where we have more \ncash on hand, particularly in the higher interest rate environment, which we've been operating, we'll \nget a higher return, right?   And we have indeed benefited from a greater rate of return on the larger \ncash balances that we've had in place.  It's also the case that there is some geography within our \nstatement because deferred comp was a positive for us below the line.  That's an offsetting negative \nabove the line in the quarter as well. ", "original_text": "Of course, the knock -on consequence of that is where we have more \ncash on hand, particularly in the higher interest rate environment, which we've been operating, we'll \nget a higher return, right?  ", "page_label": "12", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "cbf7de343d27e364ffc497e04aafd7ba4b646f87180d82aee4920d43be285b91", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "bf21d441-4922-4ec7-8b35-6b7c66115a5c", "node_type": "1", "metadata": {"window": "And the team \nhas d elivered against those efforts internally and generated strong cash flow in the first half for the \nbusiness, thus the balance .  Of course, the knock -on consequence of that is where we have more \ncash on hand, particularly in the higher interest rate environment, which we've been operating, we'll \nget a higher return, right?   And we have indeed benefited from a greater rate of return on the larger \ncash balances that we've had in place.  It's also the case that there is some geography within our \nstatement because deferred comp was a positive for us below the line.  That's an offsetting negative \nabove the line in the quarter as well.  And so, it's really the aggregation of those three things , of those \nseveral things, which led to the results for the quarter.  \n \n And you asked about the financing as well, and I should be clear on a couple of things, just as we \nthink about our models going forward.  ", "original_text": "It's also the case that there is some geography within our \nstatement because deferred comp was a positive for us below the line. "}, "hash": "69e1b134dcea4a082cc2e685f5044a71633b9e708f65167efafd23920627b210", "class_name": "RelatedNodeInfo"}}, "text": "And we have indeed benefited from a greater rate of return on the larger \ncash balances that we've had in place. ", "start_char_idx": 2363, "end_char_idx": 2476, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "bf21d441-4922-4ec7-8b35-6b7c66115a5c": {"__data__": {"id_": "bf21d441-4922-4ec7-8b35-6b7c66115a5c", "embedding": null, "metadata": {"window": "And the team \nhas d elivered against those efforts internally and generated strong cash flow in the first half for the \nbusiness, thus the balance .  Of course, the knock -on consequence of that is where we have more \ncash on hand, particularly in the higher interest rate environment, which we've been operating, we'll \nget a higher return, right?   And we have indeed benefited from a greater rate of return on the larger \ncash balances that we've had in place.  It's also the case that there is some geography within our \nstatement because deferred comp was a positive for us below the line.  That's an offsetting negative \nabove the line in the quarter as well.  And so, it's really the aggregation of those three things , of those \nseveral things, which led to the results for the quarter.  \n \n And you asked about the financing as well, and I should be clear on a couple of things, just as we \nthink about our models going forward.  ", "original_text": "It's also the case that there is some geography within our \nstatement because deferred comp was a positive for us below the line. ", "page_label": "12", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "f6aa5062-6f6b-48ce-b783-7a0df37afe92", "node_type": "4", "metadata": {"page_label": "12", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "22984b0b58240c211588ed6c0cd5e35a4a51583c2f3bfe772345b964ca16208b", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "7f1fbbd9-bace-4242-b340-6c1929f61d16", "node_type": "1", "metadata": {"window": "If you think back to our Investor Day, we had highlighted that \nfurther optimization of our cash flow position was something we were focused on doing.  And the team \nhas d elivered against those efforts internally and generated strong cash flow in the first half for the \nbusiness, thus the balance .  Of course, the knock -on consequence of that is where we have more \ncash on hand, particularly in the higher interest rate environment, which we've been operating, we'll \nget a higher return, right?   And we have indeed benefited from a greater rate of return on the larger \ncash balances that we've had in place.  It's also the case that there is some geography within our \nstatement because deferred comp was a positive for us below the line.  That's an offsetting negative \nabove the line in the quarter as well.  And so, it's really the aggregation of those three things , of those \nseveral things, which led to the results for the quarter.  \n \n", "original_text": "And we have indeed benefited from a greater rate of return on the larger \ncash balances that we've had in place. ", "page_label": "12", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "76c1e2104275b9fac2f166278b8bd08eedc79203f2a042cabe24ac40f729d730", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "8c048a3c-f8ea-4b9a-94f0-b96222c3a02a", "node_type": "1", "metadata": {"window": "Of course, the knock -on consequence of that is where we have more \ncash on hand, particularly in the higher interest rate environment, which we've been operating, we'll \nget a higher return, right?   And we have indeed benefited from a greater rate of return on the larger \ncash balances that we've had in place.  It's also the case that there is some geography within our \nstatement because deferred comp was a positive for us below the line.  That's an offsetting negative \nabove the line in the quarter as well.  And so, it's really the aggregation of those three things , of those \nseveral things, which led to the results for the quarter.  \n \n And you asked about the financing as well, and I should be clear on a couple of things, just as we \nthink about our models going forward.   We do have maturities coming in June and November. ", "original_text": "That's an offsetting negative \nabove the line in the quarter as well. "}, "hash": "c6524b73dee32aaffee5d159f1be099b1bdfcce2c85bce1e5c7af7acdd0d792d", "class_name": "RelatedNodeInfo"}}, "text": "It's also the case that there is some geography within our \nstatement because deferred comp was a positive for us below the line. ", "start_char_idx": 2476, "end_char_idx": 2606, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "8c048a3c-f8ea-4b9a-94f0-b96222c3a02a": {"__data__": {"id_": "8c048a3c-f8ea-4b9a-94f0-b96222c3a02a", "embedding": null, "metadata": {"window": "Of course, the knock -on consequence of that is where we have more \ncash on hand, particularly in the higher interest rate environment, which we've been operating, we'll \nget a higher return, right?   And we have indeed benefited from a greater rate of return on the larger \ncash balances that we've had in place.  It's also the case that there is some geography within our \nstatement because deferred comp was a positive for us below the line.  That's an offsetting negative \nabove the line in the quarter as well.  And so, it's really the aggregation of those three things , of those \nseveral things, which led to the results for the quarter.  \n \n And you asked about the financing as well, and I should be clear on a couple of things, just as we \nthink about our models going forward.   We do have maturities coming in June and November. ", "original_text": "That's an offsetting negative \nabove the line in the quarter as well. ", "page_label": "12", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "f6aa5062-6f6b-48ce-b783-7a0df37afe92", "node_type": "4", "metadata": {"page_label": "12", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "22984b0b58240c211588ed6c0cd5e35a4a51583c2f3bfe772345b964ca16208b", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "bf21d441-4922-4ec7-8b35-6b7c66115a5c", "node_type": "1", "metadata": {"window": "And the team \nhas d elivered against those efforts internally and generated strong cash flow in the first half for the \nbusiness, thus the balance .  Of course, the knock -on consequence of that is where we have more \ncash on hand, particularly in the higher interest rate environment, which we've been operating, we'll \nget a higher return, right?   And we have indeed benefited from a greater rate of return on the larger \ncash balances that we've had in place.  It's also the case that there is some geography within our \nstatement because deferred comp was a positive for us below the line.  That's an offsetting negative \nabove the line in the quarter as well.  And so, it's really the aggregation of those three things , of those \nseveral things, which led to the results for the quarter.  \n \n And you asked about the financing as well, and I should be clear on a couple of things, just as we \nthink about our models going forward.  ", "original_text": "It's also the case that there is some geography within our \nstatement because deferred comp was a positive for us below the line. ", "page_label": "12", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "303641badcebdadf045bd9daca05aa066f734899e63b002554720f26231dc26a", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "07dff0cf-9e28-4f4d-a388-cc54d670d1ec", "node_type": "1", "metadata": {"window": "And we have indeed benefited from a greater rate of return on the larger \ncash balances that we've had in place.  It's also the case that there is some geography within our \nstatement because deferred comp was a positive for us below the line.  That's an offsetting negative \nabove the line in the quarter as well.  And so, it's really the aggregation of those three things , of those \nseveral things, which led to the results for the quarter.  \n \n And you asked about the financing as well, and I should be clear on a couple of things, just as we \nthink about our models going forward.   We do have maturities coming in June and November.  We're \nassessing what our opportunities are there, nothing to announce today in that respect, but we will \naddress that at some point as we carry forward. ", "original_text": "And so, it's really the aggregation of those three things , of those \nseveral things, which led to the results for the quarter.  \n \n"}, "hash": "647b20c543c1695be907d64124ac729708c9e6b928d6dcdf48b049dcfb87abfd", "class_name": "RelatedNodeInfo"}}, "text": "That's an offsetting negative \nabove the line in the quarter as well. ", "start_char_idx": 2606, "end_char_idx": 2676, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "07dff0cf-9e28-4f4d-a388-cc54d670d1ec": {"__data__": {"id_": "07dff0cf-9e28-4f4d-a388-cc54d670d1ec", "embedding": null, "metadata": {"window": "And we have indeed benefited from a greater rate of return on the larger \ncash balances that we've had in place.  It's also the case that there is some geography within our \nstatement because deferred comp was a positive for us below the line.  That's an offsetting negative \nabove the line in the quarter as well.  And so, it's really the aggregation of those three things , of those \nseveral things, which led to the results for the quarter.  \n \n And you asked about the financing as well, and I should be clear on a couple of things, just as we \nthink about our models going forward.   We do have maturities coming in June and November.  We're \nassessing what our opportunities are there, nothing to announce today in that respect, but we will \naddress that at some point as we carry forward. ", "original_text": "And so, it's really the aggregation of those three things , of those \nseveral things, which led to the results for the quarter.  \n \n", "page_label": "12", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "f6aa5062-6f6b-48ce-b783-7a0df37afe92", "node_type": "4", "metadata": {"page_label": "12", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "22984b0b58240c211588ed6c0cd5e35a4a51583c2f3bfe772345b964ca16208b", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "8c048a3c-f8ea-4b9a-94f0-b96222c3a02a", "node_type": "1", "metadata": {"window": "Of course, the knock -on consequence of that is where we have more \ncash on hand, particularly in the higher interest rate environment, which we've been operating, we'll \nget a higher return, right?   And we have indeed benefited from a greater rate of return on the larger \ncash balances that we've had in place.  It's also the case that there is some geography within our \nstatement because deferred comp was a positive for us below the line.  That's an offsetting negative \nabove the line in the quarter as well.  And so, it's really the aggregation of those three things , of those \nseveral things, which led to the results for the quarter.  \n \n And you asked about the financing as well, and I should be clear on a couple of things, just as we \nthink about our models going forward.   We do have maturities coming in June and November. ", "original_text": "That's an offsetting negative \nabove the line in the quarter as well. ", "page_label": "12", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "a7f2d1d41ee1b0d27fb6803fe8acee2719052a680e08d5c7d976162ada727899", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "a47431fd-b28e-4608-968b-fcea260d5b5f", "node_type": "1", "metadata": {"window": "It's also the case that there is some geography within our \nstatement because deferred comp was a positive for us below the line.  That's an offsetting negative \nabove the line in the quarter as well.  And so, it's really the aggregation of those three things , of those \nseveral things, which led to the results for the quarter.  \n \n And you asked about the financing as well, and I should be clear on a couple of things, just as we \nthink about our models going forward.   We do have maturities coming in June and November.  We're \nassessing what our opportunities are there, nothing to announce today in that respect, but we will \naddress that at some point as we carry forward.  And it is also the case that our cash balances \nfluctuate seasonally in the back half as well. ", "original_text": "And you asked about the financing as well, and I should be clear on a couple of things, just as we \nthink about our models going forward.  "}, "hash": "dc6dd64aa965846277b79224b605a8b4a4920c76302532fb4b7471fdf54d0073", "class_name": "RelatedNodeInfo"}}, "text": "And so, it's really the aggregation of those three things , of those \nseveral things, which led to the results for the quarter.  \n \n", "start_char_idx": 2676, "end_char_idx": 2808, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "a47431fd-b28e-4608-968b-fcea260d5b5f": {"__data__": {"id_": "a47431fd-b28e-4608-968b-fcea260d5b5f", "embedding": null, "metadata": {"window": "It's also the case that there is some geography within our \nstatement because deferred comp was a positive for us below the line.  That's an offsetting negative \nabove the line in the quarter as well.  And so, it's really the aggregation of those three things , of those \nseveral things, which led to the results for the quarter.  \n \n And you asked about the financing as well, and I should be clear on a couple of things, just as we \nthink about our models going forward.   We do have maturities coming in June and November.  We're \nassessing what our opportunities are there, nothing to announce today in that respect, but we will \naddress that at some point as we carry forward.  And it is also the case that our cash balances \nfluctuate seasonally in the back half as well. ", "original_text": "And you asked about the financing as well, and I should be clear on a couple of things, just as we \nthink about our models going forward.  ", "page_label": "12", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "f6aa5062-6f6b-48ce-b783-7a0df37afe92", "node_type": "4", "metadata": {"page_label": "12", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "22984b0b58240c211588ed6c0cd5e35a4a51583c2f3bfe772345b964ca16208b", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "07dff0cf-9e28-4f4d-a388-cc54d670d1ec", "node_type": "1", "metadata": {"window": "And we have indeed benefited from a greater rate of return on the larger \ncash balances that we've had in place.  It's also the case that there is some geography within our \nstatement because deferred comp was a positive for us below the line.  That's an offsetting negative \nabove the line in the quarter as well.  And so, it's really the aggregation of those three things , of those \nseveral things, which led to the results for the quarter.  \n \n And you asked about the financing as well, and I should be clear on a couple of things, just as we \nthink about our models going forward.   We do have maturities coming in June and November.  We're \nassessing what our opportunities are there, nothing to announce today in that respect, but we will \naddress that at some point as we carry forward. ", "original_text": "And so, it's really the aggregation of those three things , of those \nseveral things, which led to the results for the quarter.  \n \n", "page_label": "12", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "032a6dc7e3e6eacdcdda126f7c7a24394c19dc1692459dfd85b39adb90cd9dd1", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "0bfe42aa-9cd0-4f01-b1c1-0e67b9f7fe0b", "node_type": "1", "metadata": {"window": "That's an offsetting negative \nabove the line in the quarter as well.  And so, it's really the aggregation of those three things , of those \nseveral things, which led to the results for the quarter.  \n \n And you asked about the financing as well, and I should be clear on a couple of things, just as we \nthink about our models going forward.   We do have maturities coming in June and November.  We're \nassessing what our opportunities are there, nothing to announce today in that respect, but we will \naddress that at some point as we carry forward.  And it is also the case that our cash balances \nfluctuate seasonally in the back half as well.  And so, we wouldn't expect the high balance to remain \nwhere it is, just given  the seasonal demands on the business . \n \n", "original_text": "We do have maturities coming in June and November. "}, "hash": "a52193953d632733870e14e0eec8f80ed155e62739b157ba665e6ca86f9e2029", "class_name": "RelatedNodeInfo"}}, "text": "And you asked about the financing as well, and I should be clear on a couple of things, just as we \nthink about our models going forward.  ", "start_char_idx": 2808, "end_char_idx": 2947, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "0bfe42aa-9cd0-4f01-b1c1-0e67b9f7fe0b": {"__data__": {"id_": "0bfe42aa-9cd0-4f01-b1c1-0e67b9f7fe0b", "embedding": null, "metadata": {"window": "That's an offsetting negative \nabove the line in the quarter as well.  And so, it's really the aggregation of those three things , of those \nseveral things, which led to the results for the quarter.  \n \n And you asked about the financing as well, and I should be clear on a couple of things, just as we \nthink about our models going forward.   We do have maturities coming in June and November.  We're \nassessing what our opportunities are there, nothing to announce today in that respect, but we will \naddress that at some point as we carry forward.  And it is also the case that our cash balances \nfluctuate seasonally in the back half as well.  And so, we wouldn't expect the high balance to remain \nwhere it is, just given  the seasonal demands on the business . \n \n", "original_text": "We do have maturities coming in June and November. ", "page_label": "12", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "f6aa5062-6f6b-48ce-b783-7a0df37afe92", "node_type": "4", "metadata": {"page_label": "12", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "22984b0b58240c211588ed6c0cd5e35a4a51583c2f3bfe772345b964ca16208b", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "a47431fd-b28e-4608-968b-fcea260d5b5f", "node_type": "1", "metadata": {"window": "It's also the case that there is some geography within our \nstatement because deferred comp was a positive for us below the line.  That's an offsetting negative \nabove the line in the quarter as well.  And so, it's really the aggregation of those three things , of those \nseveral things, which led to the results for the quarter.  \n \n And you asked about the financing as well, and I should be clear on a couple of things, just as we \nthink about our models going forward.   We do have maturities coming in June and November.  We're \nassessing what our opportunities are there, nothing to announce today in that respect, but we will \naddress that at some point as we carry forward.  And it is also the case that our cash balances \nfluctuate seasonally in the back half as well. ", "original_text": "And you asked about the financing as well, and I should be clear on a couple of things, just as we \nthink about our models going forward.  ", "page_label": "12", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "06db9544f41f31d56a2a3f4a6d9d8965214d046442f90a06a5c943edd19ccd81", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "87633704-e563-448c-959d-19a29304ef42", "node_type": "1", "metadata": {"window": "And so, it's really the aggregation of those three things , of those \nseveral things, which led to the results for the quarter.  \n \n And you asked about the financing as well, and I should be clear on a couple of things, just as we \nthink about our models going forward.   We do have maturities coming in June and November.  We're \nassessing what our opportunities are there, nothing to announce today in that respect, but we will \naddress that at some point as we carry forward.  And it is also the case that our cash balances \nfluctuate seasonally in the back half as well.  And so, we wouldn't expect the high balance to remain \nwhere it is, just given  the seasonal demands on the business . \n \n Matt Sims:  Next question, please.  \n ", "original_text": "We're \nassessing what our opportunities are there, nothing to announce today in that respect, but we will \naddress that at some point as we carry forward. "}, "hash": "5f4e9fe467d8fa1c50d958243f40735cdddbd4771f4f47980dd8d8ff8d54695f", "class_name": "RelatedNodeInfo"}}, "text": "We do have maturities coming in June and November. ", "start_char_idx": 2947, "end_char_idx": 2998, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "87633704-e563-448c-959d-19a29304ef42": {"__data__": {"id_": "87633704-e563-448c-959d-19a29304ef42", "embedding": null, "metadata": {"window": "And so, it's really the aggregation of those three things , of those \nseveral things, which led to the results for the quarter.  \n \n And you asked about the financing as well, and I should be clear on a couple of things, just as we \nthink about our models going forward.   We do have maturities coming in June and November.  We're \nassessing what our opportunities are there, nothing to announce today in that respect, but we will \naddress that at some point as we carry forward.  And it is also the case that our cash balances \nfluctuate seasonally in the back half as well.  And so, we wouldn't expect the high balance to remain \nwhere it is, just given  the seasonal demands on the business . \n \n Matt Sims:  Next question, please.  \n ", "original_text": "We're \nassessing what our opportunities are there, nothing to announce today in that respect, but we will \naddress that at some point as we carry forward. ", "page_label": "12", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "f6aa5062-6f6b-48ce-b783-7a0df37afe92", "node_type": "4", "metadata": {"page_label": "12", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "22984b0b58240c211588ed6c0cd5e35a4a51583c2f3bfe772345b964ca16208b", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "0bfe42aa-9cd0-4f01-b1c1-0e67b9f7fe0b", "node_type": "1", "metadata": {"window": "That's an offsetting negative \nabove the line in the quarter as well.  And so, it's really the aggregation of those three things , of those \nseveral things, which led to the results for the quarter.  \n \n And you asked about the financing as well, and I should be clear on a couple of things, just as we \nthink about our models going forward.   We do have maturities coming in June and November.  We're \nassessing what our opportunities are there, nothing to announce today in that respect, but we will \naddress that at some point as we carry forward.  And it is also the case that our cash balances \nfluctuate seasonally in the back half as well.  And so, we wouldn't expect the high balance to remain \nwhere it is, just given  the seasonal demands on the business . \n \n", "original_text": "We do have maturities coming in June and November. ", "page_label": "12", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "1c3543b5de53b9f59ff5dbe81f284287ece98d759667acb6abf85f6639a2c561", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "06166617-a9b1-4983-9e8c-5316f389b8d7", "node_type": "1", "metadata": {"window": "And you asked about the financing as well, and I should be clear on a couple of things, just as we \nthink about our models going forward.   We do have maturities coming in June and November.  We're \nassessing what our opportunities are there, nothing to announce today in that respect, but we will \naddress that at some point as we carry forward.  And it is also the case that our cash balances \nfluctuate seasonally in the back half as well.  And so, we wouldn't expect the high balance to remain \nwhere it is, just given  the seasonal demands on the business . \n \n Matt Sims:  Next question, please.  \n ", "original_text": "And it is also the case that our cash balances \nfluctuate seasonally in the back half as well. "}, "hash": "e9e85a0ceccf3fd5f1b346f15cef71e35ceacc7525b66ee5a0c277b96dfa5f01", "class_name": "RelatedNodeInfo"}}, "text": "We're \nassessing what our opportunities are there, nothing to announce today in that respect, but we will \naddress that at some point as we carry forward. ", "start_char_idx": 2998, "end_char_idx": 3153, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "06166617-a9b1-4983-9e8c-5316f389b8d7": {"__data__": {"id_": "06166617-a9b1-4983-9e8c-5316f389b8d7", "embedding": null, "metadata": {"window": "And you asked about the financing as well, and I should be clear on a couple of things, just as we \nthink about our models going forward.   We do have maturities coming in June and November.  We're \nassessing what our opportunities are there, nothing to announce today in that respect, but we will \naddress that at some point as we carry forward.  And it is also the case that our cash balances \nfluctuate seasonally in the back half as well.  And so, we wouldn't expect the high balance to remain \nwhere it is, just given  the seasonal demands on the business . \n \n Matt Sims:  Next question, please.  \n ", "original_text": "And it is also the case that our cash balances \nfluctuate seasonally in the back half as well. ", "page_label": "12", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "f6aa5062-6f6b-48ce-b783-7a0df37afe92", "node_type": "4", "metadata": {"page_label": "12", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "22984b0b58240c211588ed6c0cd5e35a4a51583c2f3bfe772345b964ca16208b", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "87633704-e563-448c-959d-19a29304ef42", "node_type": "1", "metadata": {"window": "And so, it's really the aggregation of those three things , of those \nseveral things, which led to the results for the quarter.  \n \n And you asked about the financing as well, and I should be clear on a couple of things, just as we \nthink about our models going forward.   We do have maturities coming in June and November.  We're \nassessing what our opportunities are there, nothing to announce today in that respect, but we will \naddress that at some point as we carry forward.  And it is also the case that our cash balances \nfluctuate seasonally in the back half as well.  And so, we wouldn't expect the high balance to remain \nwhere it is, just given  the seasonal demands on the business . \n \n Matt Sims:  Next question, please.  \n ", "original_text": "We're \nassessing what our opportunities are there, nothing to announce today in that respect, but we will \naddress that at some point as we carry forward. ", "page_label": "12", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "5e20fe46cbc5f87e0b5a5659b40555fd96d161a9c00534e2c0ec9e3851b73f1f", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "c7b05756-88fe-468f-982a-73ed25daf215", "node_type": "1", "metadata": {"window": "We do have maturities coming in June and November.  We're \nassessing what our opportunities are there, nothing to announce today in that respect, but we will \naddress that at some point as we carry forward.  And it is also the case that our cash balances \nfluctuate seasonally in the back half as well.  And so, we wouldn't expect the high balance to remain \nwhere it is, just given  the seasonal demands on the business . \n \n Matt Sims:  Next question, please.  \n ", "original_text": "And so, we wouldn't expect the high balance to remain \nwhere it is, just given  the seasonal demands on the business . \n \n"}, "hash": "73ebbea40a8ee0ff35d22c73122006b90c571e4615ccace81db58a1f346b7430", "class_name": "RelatedNodeInfo"}}, "text": "And it is also the case that our cash balances \nfluctuate seasonally in the back half as well. ", "start_char_idx": 3153, "end_char_idx": 3248, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "c7b05756-88fe-468f-982a-73ed25daf215": {"__data__": {"id_": "c7b05756-88fe-468f-982a-73ed25daf215", "embedding": null, "metadata": {"window": "We do have maturities coming in June and November.  We're \nassessing what our opportunities are there, nothing to announce today in that respect, but we will \naddress that at some point as we carry forward.  And it is also the case that our cash balances \nfluctuate seasonally in the back half as well.  And so, we wouldn't expect the high balance to remain \nwhere it is, just given  the seasonal demands on the business . \n \n Matt Sims:  Next question, please.  \n ", "original_text": "And so, we wouldn't expect the high balance to remain \nwhere it is, just given  the seasonal demands on the business . \n \n", "page_label": "12", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "f6aa5062-6f6b-48ce-b783-7a0df37afe92", "node_type": "4", "metadata": {"page_label": "12", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "22984b0b58240c211588ed6c0cd5e35a4a51583c2f3bfe772345b964ca16208b", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "06166617-a9b1-4983-9e8c-5316f389b8d7", "node_type": "1", "metadata": {"window": "And you asked about the financing as well, and I should be clear on a couple of things, just as we \nthink about our models going forward.   We do have maturities coming in June and November.  We're \nassessing what our opportunities are there, nothing to announce today in that respect, but we will \naddress that at some point as we carry forward.  And it is also the case that our cash balances \nfluctuate seasonally in the back half as well.  And so, we wouldn't expect the high balance to remain \nwhere it is, just given  the seasonal demands on the business . \n \n Matt Sims:  Next question, please.  \n ", "original_text": "And it is also the case that our cash balances \nfluctuate seasonally in the back half as well. ", "page_label": "12", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "6031c1c898d9f1380ff6a7ef24806ae5c703687d7d9bdd1faaa49df1e016b531", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "6defb0d4-8313-476e-aa64-4ae8ad5c8f85", "node_type": "1", "metadata": {"window": "We're \nassessing what our opportunities are there, nothing to announce today in that respect, but we will \naddress that at some point as we carry forward.  And it is also the case that our cash balances \nfluctuate seasonally in the back half as well.  And so, we wouldn't expect the high balance to remain \nwhere it is, just given  the seasonal demands on the business . \n \n Matt Sims:  Next question, please.  \n ", "original_text": "Matt Sims:  Next question, please.  \n "}, "hash": "9c42d88fcf52ede2af60ba41857b6fd85230135280164ae2c0b3621dd7cd79ab", "class_name": "RelatedNodeInfo"}}, "text": "And so, we wouldn't expect the high balance to remain \nwhere it is, just given  the seasonal demands on the business . \n \n", "start_char_idx": 3248, "end_char_idx": 3370, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "6defb0d4-8313-476e-aa64-4ae8ad5c8f85": {"__data__": {"id_": "6defb0d4-8313-476e-aa64-4ae8ad5c8f85", "embedding": null, "metadata": {"window": "We're \nassessing what our opportunities are there, nothing to announce today in that respect, but we will \naddress that at some point as we carry forward.  And it is also the case that our cash balances \nfluctuate seasonally in the back half as well.  And so, we wouldn't expect the high balance to remain \nwhere it is, just given  the seasonal demands on the business . \n \n Matt Sims:  Next question, please.  \n ", "original_text": "Matt Sims:  Next question, please.  \n ", "page_label": "12", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "f6aa5062-6f6b-48ce-b783-7a0df37afe92", "node_type": "4", "metadata": {"page_label": "12", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "22984b0b58240c211588ed6c0cd5e35a4a51583c2f3bfe772345b964ca16208b", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "c7b05756-88fe-468f-982a-73ed25daf215", "node_type": "1", "metadata": {"window": "We do have maturities coming in June and November.  We're \nassessing what our opportunities are there, nothing to announce today in that respect, but we will \naddress that at some point as we carry forward.  And it is also the case that our cash balances \nfluctuate seasonally in the back half as well.  And so, we wouldn't expect the high balance to remain \nwhere it is, just given  the seasonal demands on the business . \n \n Matt Sims:  Next question, please.  \n ", "original_text": "And so, we wouldn't expect the high balance to remain \nwhere it is, just given  the seasonal demands on the business . \n \n", "page_label": "12", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "ac0c2ee2bc5d34d83ca7fa946d7c288d708a44609daf60060dd964c4008bea14", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "8743357b-ab76-40c9-bb0e-fee9746c43ab", "node_type": "1", "metadata": {"window": " \nPage 13 of 19 \n \nOperator:  Yes, sir.  Our next question is coming from Mr.  Eric Percher of Nephron Research.  Please \ngo ahead.  \n \n", "original_text": " \nPage 13 of 19 \n \nOperator:  Yes, sir. "}, "hash": "1078936195da5d6b4cac550689dbbbd86837aad51faa042fff79e5a98c4bceab", "class_name": "RelatedNodeInfo"}}, "text": "Matt Sims:  Next question, please.  \n ", "start_char_idx": 806, "end_char_idx": 844, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "8743357b-ab76-40c9-bb0e-fee9746c43ab": {"__data__": {"id_": "8743357b-ab76-40c9-bb0e-fee9746c43ab", "embedding": null, "metadata": {"window": " \nPage 13 of 19 \n \nOperator:  Yes, sir.  Our next question is coming from Mr.  Eric Percher of Nephron Research.  Please \ngo ahead.  \n \n", "original_text": " \nPage 13 of 19 \n \nOperator:  Yes, sir. ", "page_label": "13", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "8e2e64d9-3499-4495-ab28-5ac0bafd5491", "node_type": "4", "metadata": {"page_label": "13", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "1311cf71848883e159e85da50c3c3b08d1f320174a9464fade81363c5a4623dd", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "6defb0d4-8313-476e-aa64-4ae8ad5c8f85", "node_type": "1", "metadata": {"window": "We're \nassessing what our opportunities are there, nothing to announce today in that respect, but we will \naddress that at some point as we carry forward.  And it is also the case that our cash balances \nfluctuate seasonally in the back half as well.  And so, we wouldn't expect the high balance to remain \nwhere it is, just given  the seasonal demands on the business . \n \n Matt Sims:  Next question, please.  \n ", "original_text": "Matt Sims:  Next question, please.  \n ", "page_label": "12", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "bdfe9cdb4e44cd8e9daec6efe2583365392b468b8461193161e1edd9d347c507", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "1cecb194-0916-4261-9539-8196739eef0b", "node_type": "1", "metadata": {"window": " \nPage 13 of 19 \n \nOperator:  Yes, sir.  Our next question is coming from Mr.  Eric Percher of Nephron Research.  Please \ngo ahead.  \n \n Eric Percher:   Thank you. ", "original_text": "Our next question is coming from Mr. "}, "hash": "6dd3d81def4a9e455e8f2bc579373a9888c8801ee433011474be478371046047", "class_name": "RelatedNodeInfo"}}, "text": " \nPage 13 of 19 \n \nOperator:  Yes, sir. ", "start_char_idx": 0, "end_char_idx": 40, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "1cecb194-0916-4261-9539-8196739eef0b": {"__data__": {"id_": "1cecb194-0916-4261-9539-8196739eef0b", "embedding": null, "metadata": {"window": " \nPage 13 of 19 \n \nOperator:  Yes, sir.  Our next question is coming from Mr.  Eric Percher of Nephron Research.  Please \ngo ahead.  \n \n Eric Percher:   Thank you. ", "original_text": "Our next question is coming from Mr. ", "page_label": "13", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "8e2e64d9-3499-4495-ab28-5ac0bafd5491", "node_type": "4", "metadata": {"page_label": "13", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "1311cf71848883e159e85da50c3c3b08d1f320174a9464fade81363c5a4623dd", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "8743357b-ab76-40c9-bb0e-fee9746c43ab", "node_type": "1", "metadata": {"window": " \nPage 13 of 19 \n \nOperator:  Yes, sir.  Our next question is coming from Mr.  Eric Percher of Nephron Research.  Please \ngo ahead.  \n \n", "original_text": " \nPage 13 of 19 \n \nOperator:  Yes, sir. ", "page_label": "13", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "edcf0c42a17a015fc7e8c38244423e687c9d1cdc80c9def258bc7f26ab04a7b2", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "a65bd46c-268a-4135-9df0-1dd7b978c15b", "node_type": "1", "metadata": {"window": " \nPage 13 of 19 \n \nOperator:  Yes, sir.  Our next question is coming from Mr.  Eric Percher of Nephron Research.  Please \ngo ahead.  \n \n Eric Percher:   Thank you.  On the Medical side, it's hard to see through the one -time items. ", "original_text": "Eric Percher of Nephron Research. "}, "hash": "d76a5cff094b1adbd5813df217ba07731315008c45cd284709bc0a373e8fea75", "class_name": "RelatedNodeInfo"}}, "text": "Our next question is coming from Mr. ", "start_char_idx": 40, "end_char_idx": 77, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "a65bd46c-268a-4135-9df0-1dd7b978c15b": {"__data__": {"id_": "a65bd46c-268a-4135-9df0-1dd7b978c15b", "embedding": null, "metadata": {"window": " \nPage 13 of 19 \n \nOperator:  Yes, sir.  Our next question is coming from Mr.  Eric Percher of Nephron Research.  Please \ngo ahead.  \n \n Eric Percher:   Thank you.  On the Medical side, it's hard to see through the one -time items. ", "original_text": "Eric Percher of Nephron Research. ", "page_label": "13", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "8e2e64d9-3499-4495-ab28-5ac0bafd5491", "node_type": "4", "metadata": {"page_label": "13", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "1311cf71848883e159e85da50c3c3b08d1f320174a9464fade81363c5a4623dd", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "1cecb194-0916-4261-9539-8196739eef0b", "node_type": "1", "metadata": {"window": " \nPage 13 of 19 \n \nOperator:  Yes, sir.  Our next question is coming from Mr.  Eric Percher of Nephron Research.  Please \ngo ahead.  \n \n Eric Percher:   Thank you. ", "original_text": "Our next question is coming from Mr. ", "page_label": "13", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "cf5ebf9d624deeab4aaf50295de199de5e8dd93868fc1ed1f1f393265308bc42", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "e75bdab2-d675-40a5-823a-26e0594473a9", "node_type": "1", "metadata": {"window": " \nPage 13 of 19 \n \nOperator:  Yes, sir.  Our next question is coming from Mr.  Eric Percher of Nephron Research.  Please \ngo ahead.  \n \n Eric Percher:   Thank you.  On the Medical side, it's hard to see through the one -time items.  So, I want \nto ask what you can give us on the nature of those one -time items ? ", "original_text": "Please \ngo ahead.  \n \n"}, "hash": "3f0fc9bc18ff842b162d12f59b2884350c973786f7bc9c764d871dfc48144701", "class_name": "RelatedNodeInfo"}}, "text": "Eric Percher of Nephron Research. ", "start_char_idx": 77, "end_char_idx": 111, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "e75bdab2-d675-40a5-823a-26e0594473a9": {"__data__": {"id_": "e75bdab2-d675-40a5-823a-26e0594473a9", "embedding": null, "metadata": {"window": " \nPage 13 of 19 \n \nOperator:  Yes, sir.  Our next question is coming from Mr.  Eric Percher of Nephron Research.  Please \ngo ahead.  \n \n Eric Percher:   Thank you.  On the Medical side, it's hard to see through the one -time items.  So, I want \nto ask what you can give us on the nature of those one -time items ? ", "original_text": "Please \ngo ahead.  \n \n", "page_label": "13", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "8e2e64d9-3499-4495-ab28-5ac0bafd5491", "node_type": "4", "metadata": {"page_label": "13", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "1311cf71848883e159e85da50c3c3b08d1f320174a9464fade81363c5a4623dd", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "a65bd46c-268a-4135-9df0-1dd7b978c15b", "node_type": "1", "metadata": {"window": " \nPage 13 of 19 \n \nOperator:  Yes, sir.  Our next question is coming from Mr.  Eric Percher of Nephron Research.  Please \ngo ahead.  \n \n Eric Percher:   Thank you.  On the Medical side, it's hard to see through the one -time items. ", "original_text": "Eric Percher of Nephron Research. ", "page_label": "13", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "4acae9904fded8e396cf322d9a73ef0b6c76b2ef3211399462e44968a4af4ab6", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "bee18eef-db7e-421e-b317-7ed40d0007df", "node_type": "1", "metadata": {"window": "Our next question is coming from Mr.  Eric Percher of Nephron Research.  Please \ngo ahead.  \n \n Eric Percher:   Thank you.  On the Medical side, it's hard to see through the one -time items.  So, I want \nto ask what you can give us on the nature of those one -time items ?  What the trajectory looked like, \nexcluding one -timers in the quarter and any views on the exit trajectory for the year and going from \n$140 million first half to $240 million second half, how you're pacing relative to that?  \n \n", "original_text": "Eric Percher:   Thank you. "}, "hash": "9e6e68ae25e8a657be3aa7053ffabc32c33da673ae8813950c75cacb8bbd29d9", "class_name": "RelatedNodeInfo"}}, "text": "Please \ngo ahead.  \n \n", "start_char_idx": 111, "end_char_idx": 133, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "bee18eef-db7e-421e-b317-7ed40d0007df": {"__data__": {"id_": "bee18eef-db7e-421e-b317-7ed40d0007df", "embedding": null, "metadata": {"window": "Our next question is coming from Mr.  Eric Percher of Nephron Research.  Please \ngo ahead.  \n \n Eric Percher:   Thank you.  On the Medical side, it's hard to see through the one -time items.  So, I want \nto ask what you can give us on the nature of those one -time items ?  What the trajectory looked like, \nexcluding one -timers in the quarter and any views on the exit trajectory for the year and going from \n$140 million first half to $240 million second half, how you're pacing relative to that?  \n \n", "original_text": "Eric Percher:   Thank you. ", "page_label": "13", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "8e2e64d9-3499-4495-ab28-5ac0bafd5491", "node_type": "4", "metadata": {"page_label": "13", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "1311cf71848883e159e85da50c3c3b08d1f320174a9464fade81363c5a4623dd", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "e75bdab2-d675-40a5-823a-26e0594473a9", "node_type": "1", "metadata": {"window": " \nPage 13 of 19 \n \nOperator:  Yes, sir.  Our next question is coming from Mr.  Eric Percher of Nephron Research.  Please \ngo ahead.  \n \n Eric Percher:   Thank you.  On the Medical side, it's hard to see through the one -time items.  So, I want \nto ask what you can give us on the nature of those one -time items ? ", "original_text": "Please \ngo ahead.  \n \n", "page_label": "13", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "61d970a7bb9603579ab5a68a2276d35f0ff6bfe10c6a2f24eaf84ece450e2800", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "aa2ebc78-eb8e-44c4-9ae2-c1dda9eb35ff", "node_type": "1", "metadata": {"window": "Eric Percher of Nephron Research.  Please \ngo ahead.  \n \n Eric Percher:   Thank you.  On the Medical side, it's hard to see through the one -time items.  So, I want \nto ask what you can give us on the nature of those one -time items ?  What the trajectory looked like, \nexcluding one -timers in the quarter and any views on the exit trajectory for the year and going from \n$140 million first half to $240 million second half, how you're pacing relative to that?  \n \n Aaron Alt :  Thank you. ", "original_text": "On the Medical side, it's hard to see through the one -time items. "}, "hash": "9179a417a3d494d91092223c60c18b00b26d9df79ee9418263eb33a4fcd1704c", "class_name": "RelatedNodeInfo"}}, "text": "Eric Percher:   Thank you. ", "start_char_idx": 133, "end_char_idx": 160, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "aa2ebc78-eb8e-44c4-9ae2-c1dda9eb35ff": {"__data__": {"id_": "aa2ebc78-eb8e-44c4-9ae2-c1dda9eb35ff", "embedding": null, "metadata": {"window": "Eric Percher of Nephron Research.  Please \ngo ahead.  \n \n Eric Percher:   Thank you.  On the Medical side, it's hard to see through the one -time items.  So, I want \nto ask what you can give us on the nature of those one -time items ?  What the trajectory looked like, \nexcluding one -timers in the quarter and any views on the exit trajectory for the year and going from \n$140 million first half to $240 million second half, how you're pacing relative to that?  \n \n Aaron Alt :  Thank you. ", "original_text": "On the Medical side, it's hard to see through the one -time items. ", "page_label": "13", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "8e2e64d9-3499-4495-ab28-5ac0bafd5491", "node_type": "4", "metadata": {"page_label": "13", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "1311cf71848883e159e85da50c3c3b08d1f320174a9464fade81363c5a4623dd", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "bee18eef-db7e-421e-b317-7ed40d0007df", "node_type": "1", "metadata": {"window": "Our next question is coming from Mr.  Eric Percher of Nephron Research.  Please \ngo ahead.  \n \n Eric Percher:   Thank you.  On the Medical side, it's hard to see through the one -time items.  So, I want \nto ask what you can give us on the nature of those one -time items ?  What the trajectory looked like, \nexcluding one -timers in the quarter and any views on the exit trajectory for the year and going from \n$140 million first half to $240 million second half, how you're pacing relative to that?  \n \n", "original_text": "Eric Percher:   Thank you. ", "page_label": "13", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "d2f09dd063f33e0b53a6b7ebd6190a9403a980251a06fa5b9935ff2001f3af31", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "896ef14f-d281-421a-b1ae-7d60dfae0a64", "node_type": "1", "metadata": {"window": "Please \ngo ahead.  \n \n Eric Percher:   Thank you.  On the Medical side, it's hard to see through the one -time items.  So, I want \nto ask what you can give us on the nature of those one -time items ?  What the trajectory looked like, \nexcluding one -timers in the quarter and any views on the exit trajectory for the year and going from \n$140 million first half to $240 million second half, how you're pacing relative to that?  \n \n Aaron Alt :  Thank you.  We were really encouraged by the underlying performance in Q2 of the \nMedical business. ", "original_text": "So, I want \nto ask what you can give us on the nature of those one -time items ? "}, "hash": "85e2c971ad36b217ed331511009fdd03f0d9b213f9a7a3245483ffff43b814e1", "class_name": "RelatedNodeInfo"}}, "text": "On the Medical side, it's hard to see through the one -time items. ", "start_char_idx": 160, "end_char_idx": 227, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "896ef14f-d281-421a-b1ae-7d60dfae0a64": {"__data__": {"id_": "896ef14f-d281-421a-b1ae-7d60dfae0a64", "embedding": null, "metadata": {"window": "Please \ngo ahead.  \n \n Eric Percher:   Thank you.  On the Medical side, it's hard to see through the one -time items.  So, I want \nto ask what you can give us on the nature of those one -time items ?  What the trajectory looked like, \nexcluding one -timers in the quarter and any views on the exit trajectory for the year and going from \n$140 million first half to $240 million second half, how you're pacing relative to that?  \n \n Aaron Alt :  Thank you.  We were really encouraged by the underlying performance in Q2 of the \nMedical business. ", "original_text": "So, I want \nto ask what you can give us on the nature of those one -time items ? ", "page_label": "13", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "8e2e64d9-3499-4495-ab28-5ac0bafd5491", "node_type": "4", "metadata": {"page_label": "13", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "1311cf71848883e159e85da50c3c3b08d1f320174a9464fade81363c5a4623dd", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "aa2ebc78-eb8e-44c4-9ae2-c1dda9eb35ff", "node_type": "1", "metadata": {"window": "Eric Percher of Nephron Research.  Please \ngo ahead.  \n \n Eric Percher:   Thank you.  On the Medical side, it's hard to see through the one -time items.  So, I want \nto ask what you can give us on the nature of those one -time items ?  What the trajectory looked like, \nexcluding one -timers in the quarter and any views on the exit trajectory for the year and going from \n$140 million first half to $240 million second half, how you're pacing relative to that?  \n \n Aaron Alt :  Thank you. ", "original_text": "On the Medical side, it's hard to see through the one -time items. ", "page_label": "13", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "91aaae1faafc345d955e28f3114b118fc498a34f3a192142bf211695a077a515", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "384c0f53-19e5-40de-84e1-7dc37acfb21a", "node_type": "1", "metadata": {"window": "Eric Percher:   Thank you.  On the Medical side, it's hard to see through the one -time items.  So, I want \nto ask what you can give us on the nature of those one -time items ?  What the trajectory looked like, \nexcluding one -timers in the quarter and any views on the exit trajectory for the year and going from \n$140 million first half to $240 million second half, how you're pacing relative to that?  \n \n Aaron Alt :  Thank you.  We were really encouraged by the underlying performance in Q2 of the \nMedical business.  Just to restate the results. ", "original_text": "What the trajectory looked like, \nexcluding one -timers in the quarter and any views on the exit trajectory for the year and going from \n$140 million first half to $240 million second half, how you're pacing relative to that?  \n \n"}, "hash": "bad753a54506242f3794ce617d2dff385f61a892e6d99adb0d76f1dab8dbd0bb", "class_name": "RelatedNodeInfo"}}, "text": "So, I want \nto ask what you can give us on the nature of those one -time items ? ", "start_char_idx": 227, "end_char_idx": 308, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "384c0f53-19e5-40de-84e1-7dc37acfb21a": {"__data__": {"id_": "384c0f53-19e5-40de-84e1-7dc37acfb21a", "embedding": null, "metadata": {"window": "Eric Percher:   Thank you.  On the Medical side, it's hard to see through the one -time items.  So, I want \nto ask what you can give us on the nature of those one -time items ?  What the trajectory looked like, \nexcluding one -timers in the quarter and any views on the exit trajectory for the year and going from \n$140 million first half to $240 million second half, how you're pacing relative to that?  \n \n Aaron Alt :  Thank you.  We were really encouraged by the underlying performance in Q2 of the \nMedical business.  Just to restate the results. ", "original_text": "What the trajectory looked like, \nexcluding one -timers in the quarter and any views on the exit trajectory for the year and going from \n$140 million first half to $240 million second half, how you're pacing relative to that?  \n \n", "page_label": "13", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "8e2e64d9-3499-4495-ab28-5ac0bafd5491", "node_type": "4", "metadata": {"page_label": "13", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "1311cf71848883e159e85da50c3c3b08d1f320174a9464fade81363c5a4623dd", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "896ef14f-d281-421a-b1ae-7d60dfae0a64", "node_type": "1", "metadata": {"window": "Please \ngo ahead.  \n \n Eric Percher:   Thank you.  On the Medical side, it's hard to see through the one -time items.  So, I want \nto ask what you can give us on the nature of those one -time items ?  What the trajectory looked like, \nexcluding one -timers in the quarter and any views on the exit trajectory for the year and going from \n$140 million first half to $240 million second half, how you're pacing relative to that?  \n \n Aaron Alt :  Thank you.  We were really encouraged by the underlying performance in Q2 of the \nMedical business. ", "original_text": "So, I want \nto ask what you can give us on the nature of those one -time items ? ", "page_label": "13", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "98aac240aa90f8e281299744081193af4d0076c3039120a8c1477ad54a8d3610", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "6109f078-79cb-45e0-a852-54a030e02063", "node_type": "1", "metadata": {"window": "On the Medical side, it's hard to see through the one -time items.  So, I want \nto ask what you can give us on the nature of those one -time items ?  What the trajectory looked like, \nexcluding one -timers in the quarter and any views on the exit trajectory for the year and going from \n$140 million first half to $240 million second half, how you're pacing relative to that?  \n \n Aaron Alt :  Thank you.  We were really encouraged by the underlying performance in Q2 of the \nMedical business.  Just to restate the results.  The Q2 results were consistent with the expectations we \ncommunicated several weeks ago at the JPMorgan Conference, and generally consistent with Q1 \ndespite some of those adjustments that we took in the quarter.  ", "original_text": "Aaron Alt :  Thank you. "}, "hash": "5a2654df11b1252514b9d192b2c25849083ce06c05468f0d611d2ff8c628770a", "class_name": "RelatedNodeInfo"}}, "text": "What the trajectory looked like, \nexcluding one -timers in the quarter and any views on the exit trajectory for the year and going from \n$140 million first half to $240 million second half, how you're pacing relative to that?  \n \n", "start_char_idx": 308, "end_char_idx": 538, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "6109f078-79cb-45e0-a852-54a030e02063": {"__data__": {"id_": "6109f078-79cb-45e0-a852-54a030e02063", "embedding": null, "metadata": {"window": "On the Medical side, it's hard to see through the one -time items.  So, I want \nto ask what you can give us on the nature of those one -time items ?  What the trajectory looked like, \nexcluding one -timers in the quarter and any views on the exit trajectory for the year and going from \n$140 million first half to $240 million second half, how you're pacing relative to that?  \n \n Aaron Alt :  Thank you.  We were really encouraged by the underlying performance in Q2 of the \nMedical business.  Just to restate the results.  The Q2 results were consistent with the expectations we \ncommunicated several weeks ago at the JPMorgan Conference, and generally consistent with Q1 \ndespite some of those adjustments that we took in the quarter.  ", "original_text": "Aaron Alt :  Thank you. ", "page_label": "13", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "8e2e64d9-3499-4495-ab28-5ac0bafd5491", "node_type": "4", "metadata": {"page_label": "13", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "1311cf71848883e159e85da50c3c3b08d1f320174a9464fade81363c5a4623dd", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "384c0f53-19e5-40de-84e1-7dc37acfb21a", "node_type": "1", "metadata": {"window": "Eric Percher:   Thank you.  On the Medical side, it's hard to see through the one -time items.  So, I want \nto ask what you can give us on the nature of those one -time items ?  What the trajectory looked like, \nexcluding one -timers in the quarter and any views on the exit trajectory for the year and going from \n$140 million first half to $240 million second half, how you're pacing relative to that?  \n \n Aaron Alt :  Thank you.  We were really encouraged by the underlying performance in Q2 of the \nMedical business.  Just to restate the results. ", "original_text": "What the trajectory looked like, \nexcluding one -timers in the quarter and any views on the exit trajectory for the year and going from \n$140 million first half to $240 million second half, how you're pacing relative to that?  \n \n", "page_label": "13", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "f2aff12b2be7914356878c82dd6df113fcd8c3ca5879d14005192feae072a0a0", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "2d81aefd-baa3-4183-a7d3-ec96a7b3f8f3", "node_type": "1", "metadata": {"window": "So, I want \nto ask what you can give us on the nature of those one -time items ?  What the trajectory looked like, \nexcluding one -timers in the quarter and any views on the exit trajectory for the year and going from \n$140 million first half to $240 million second half, how you're pacing relative to that?  \n \n Aaron Alt :  Thank you.  We were really encouraged by the underlying performance in Q2 of the \nMedical business.  Just to restate the results.  The Q2 results were consistent with the expectations we \ncommunicated several weeks ago at the JPMorgan Conference, and generally consistent with Q1 \ndespite some of those adjustments that we took in the quarter.   I want to emphasize, as you move \naway from the adjustments that we took, the underlying elements of the Medical Improvement Plan, \nthey're on track. ", "original_text": "We were really encouraged by the underlying performance in Q2 of the \nMedical business. "}, "hash": "51ee36ac8146f0df18f8e8b7923f800602e8c14f251aa7b8b8ac42c8f920addc", "class_name": "RelatedNodeInfo"}}, "text": "Aaron Alt :  Thank you. ", "start_char_idx": 538, "end_char_idx": 562, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "2d81aefd-baa3-4183-a7d3-ec96a7b3f8f3": {"__data__": {"id_": "2d81aefd-baa3-4183-a7d3-ec96a7b3f8f3", "embedding": null, "metadata": {"window": "So, I want \nto ask what you can give us on the nature of those one -time items ?  What the trajectory looked like, \nexcluding one -timers in the quarter and any views on the exit trajectory for the year and going from \n$140 million first half to $240 million second half, how you're pacing relative to that?  \n \n Aaron Alt :  Thank you.  We were really encouraged by the underlying performance in Q2 of the \nMedical business.  Just to restate the results.  The Q2 results were consistent with the expectations we \ncommunicated several weeks ago at the JPMorgan Conference, and generally consistent with Q1 \ndespite some of those adjustments that we took in the quarter.   I want to emphasize, as you move \naway from the adjustments that we took, the underlying elements of the Medical Improvement Plan, \nthey're on track. ", "original_text": "We were really encouraged by the underlying performance in Q2 of the \nMedical business. ", "page_label": "13", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "8e2e64d9-3499-4495-ab28-5ac0bafd5491", "node_type": "4", "metadata": {"page_label": "13", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "1311cf71848883e159e85da50c3c3b08d1f320174a9464fade81363c5a4623dd", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "6109f078-79cb-45e0-a852-54a030e02063", "node_type": "1", "metadata": {"window": "On the Medical side, it's hard to see through the one -time items.  So, I want \nto ask what you can give us on the nature of those one -time items ?  What the trajectory looked like, \nexcluding one -timers in the quarter and any views on the exit trajectory for the year and going from \n$140 million first half to $240 million second half, how you're pacing relative to that?  \n \n Aaron Alt :  Thank you.  We were really encouraged by the underlying performance in Q2 of the \nMedical business.  Just to restate the results.  The Q2 results were consistent with the expectations we \ncommunicated several weeks ago at the JPMorgan Conference, and generally consistent with Q1 \ndespite some of those adjustments that we took in the quarter.  ", "original_text": "Aaron Alt :  Thank you. ", "page_label": "13", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "f3560ff8b7a5c08e82750f83410be9ea1f0af0cbb0f7adfec4f3849d96bd16cb", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "cf9b24db-5c23-4f43-9022-ee8770c6657e", "node_type": "1", "metadata": {"window": "What the trajectory looked like, \nexcluding one -timers in the quarter and any views on the exit trajectory for the year and going from \n$140 million first half to $240 million second half, how you're pacing relative to that?  \n \n Aaron Alt :  Thank you.  We were really encouraged by the underlying performance in Q2 of the \nMedical business.  Just to restate the results.  The Q2 results were consistent with the expectations we \ncommunicated several weeks ago at the JPMorgan Conference, and generally consistent with Q1 \ndespite some of those adjustments that we took in the quarter.   I want to emphasize, as you move \naway from the adjustments that we took, the underlying elements of the Medical Improvement Plan, \nthey're on track.  You heard some  of my prepared remarks relative to our progress against the \nmitigation of inflation and how our cost structure is building. ", "original_text": "Just to restate the results. "}, "hash": "c1b5285394d58719091402d2501e105d5e0c74d227b2732b660ecdd32672e8dc", "class_name": "RelatedNodeInfo"}}, "text": "We were really encouraged by the underlying performance in Q2 of the \nMedical business. ", "start_char_idx": 562, "end_char_idx": 650, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "cf9b24db-5c23-4f43-9022-ee8770c6657e": {"__data__": {"id_": "cf9b24db-5c23-4f43-9022-ee8770c6657e", "embedding": null, "metadata": {"window": "What the trajectory looked like, \nexcluding one -timers in the quarter and any views on the exit trajectory for the year and going from \n$140 million first half to $240 million second half, how you're pacing relative to that?  \n \n Aaron Alt :  Thank you.  We were really encouraged by the underlying performance in Q2 of the \nMedical business.  Just to restate the results.  The Q2 results were consistent with the expectations we \ncommunicated several weeks ago at the JPMorgan Conference, and generally consistent with Q1 \ndespite some of those adjustments that we took in the quarter.   I want to emphasize, as you move \naway from the adjustments that we took, the underlying elements of the Medical Improvement Plan, \nthey're on track.  You heard some  of my prepared remarks relative to our progress against the \nmitigation of inflation and how our cost structure is building. ", "original_text": "Just to restate the results. ", "page_label": "13", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "8e2e64d9-3499-4495-ab28-5ac0bafd5491", "node_type": "4", "metadata": {"page_label": "13", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "1311cf71848883e159e85da50c3c3b08d1f320174a9464fade81363c5a4623dd", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "2d81aefd-baa3-4183-a7d3-ec96a7b3f8f3", "node_type": "1", "metadata": {"window": "So, I want \nto ask what you can give us on the nature of those one -time items ?  What the trajectory looked like, \nexcluding one -timers in the quarter and any views on the exit trajectory for the year and going from \n$140 million first half to $240 million second half, how you're pacing relative to that?  \n \n Aaron Alt :  Thank you.  We were really encouraged by the underlying performance in Q2 of the \nMedical business.  Just to restate the results.  The Q2 results were consistent with the expectations we \ncommunicated several weeks ago at the JPMorgan Conference, and generally consistent with Q1 \ndespite some of those adjustments that we took in the quarter.   I want to emphasize, as you move \naway from the adjustments that we took, the underlying elements of the Medical Improvement Plan, \nthey're on track. ", "original_text": "We were really encouraged by the underlying performance in Q2 of the \nMedical business. ", "page_label": "13", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "9fa6b4653e0999023bfecbe273a6fbeb1ef3d9f791dc233b37971a7f099b64bb", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "6286b206-919b-4849-bd23-1c4644fdb1e6", "node_type": "1", "metadata": {"window": "Aaron Alt :  Thank you.  We were really encouraged by the underlying performance in Q2 of the \nMedical business.  Just to restate the results.  The Q2 results were consistent with the expectations we \ncommunicated several weeks ago at the JPMorgan Conference, and generally consistent with Q1 \ndespite some of those adjustments that we took in the quarter.   I want to emphasize, as you move \naway from the adjustments that we took, the underlying elements of the Medical Improvement Plan, \nthey're on track.  You heard some  of my prepared remarks relative to our progress against the \nmitigation of inflation and how our cost structure is building.  The benefits of these actions we've taken \nwill benefit our cost structure in the back half of the year. ", "original_text": "The Q2 results were consistent with the expectations we \ncommunicated several weeks ago at the JPMorgan Conference, and generally consistent with Q1 \ndespite some of those adjustments that we took in the quarter.  "}, "hash": "b7f1b4152917e9fd3c43c585fc0df05fe686d77375f0ce4db35f6f420e5508b1", "class_name": "RelatedNodeInfo"}}, "text": "Just to restate the results. ", "start_char_idx": 650, "end_char_idx": 679, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "6286b206-919b-4849-bd23-1c4644fdb1e6": {"__data__": {"id_": "6286b206-919b-4849-bd23-1c4644fdb1e6", "embedding": null, "metadata": {"window": "Aaron Alt :  Thank you.  We were really encouraged by the underlying performance in Q2 of the \nMedical business.  Just to restate the results.  The Q2 results were consistent with the expectations we \ncommunicated several weeks ago at the JPMorgan Conference, and generally consistent with Q1 \ndespite some of those adjustments that we took in the quarter.   I want to emphasize, as you move \naway from the adjustments that we took, the underlying elements of the Medical Improvement Plan, \nthey're on track.  You heard some  of my prepared remarks relative to our progress against the \nmitigation of inflation and how our cost structure is building.  The benefits of these actions we've taken \nwill benefit our cost structure in the back half of the year. ", "original_text": "The Q2 results were consistent with the expectations we \ncommunicated several weeks ago at the JPMorgan Conference, and generally consistent with Q1 \ndespite some of those adjustments that we took in the quarter.  ", "page_label": "13", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "8e2e64d9-3499-4495-ab28-5ac0bafd5491", "node_type": "4", "metadata": {"page_label": "13", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "1311cf71848883e159e85da50c3c3b08d1f320174a9464fade81363c5a4623dd", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "cf9b24db-5c23-4f43-9022-ee8770c6657e", "node_type": "1", "metadata": {"window": "What the trajectory looked like, \nexcluding one -timers in the quarter and any views on the exit trajectory for the year and going from \n$140 million first half to $240 million second half, how you're pacing relative to that?  \n \n Aaron Alt :  Thank you.  We were really encouraged by the underlying performance in Q2 of the \nMedical business.  Just to restate the results.  The Q2 results were consistent with the expectations we \ncommunicated several weeks ago at the JPMorgan Conference, and generally consistent with Q1 \ndespite some of those adjustments that we took in the quarter.   I want to emphasize, as you move \naway from the adjustments that we took, the underlying elements of the Medical Improvement Plan, \nthey're on track.  You heard some  of my prepared remarks relative to our progress against the \nmitigation of inflation and how our cost structure is building. ", "original_text": "Just to restate the results. ", "page_label": "13", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "9bd7ade6ab817453aa399bb85981bbb73e5ab0898c239a88b7432bc11974346e", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "ee618f4e-7c8c-496c-bd24-cccb7ee26798", "node_type": "1", "metadata": {"window": "We were really encouraged by the underlying performance in Q2 of the \nMedical business.  Just to restate the results.  The Q2 results were consistent with the expectations we \ncommunicated several weeks ago at the JPMorgan Conference, and generally consistent with Q1 \ndespite some of those adjustments that we took in the quarter.   I want to emphasize, as you move \naway from the adjustments that we took, the underlying elements of the Medical Improvement Plan, \nthey're on track.  You heard some  of my prepared remarks relative to our progress against the \nmitigation of inflation and how our cost structure is building.  The benefits of these actions we've taken \nwill benefit our cost structure in the back half of the year.  You heard us announce that we had \nrevenue growth for the first time in two years in the quarter as well, and we were pleased with the \nCardinal Health Brand growth that comes with that. ", "original_text": "I want to emphasize, as you move \naway from the adjustments that we took, the underlying elements of the Medical Improvement Plan, \nthey're on track. "}, "hash": "a334a90527e9eb5829e982037fd9df70e2e824961d5e5e7e2c2b9dfddaa0a0ff", "class_name": "RelatedNodeInfo"}}, "text": "The Q2 results were consistent with the expectations we \ncommunicated several weeks ago at the JPMorgan Conference, and generally consistent with Q1 \ndespite some of those adjustments that we took in the quarter.  ", "start_char_idx": 679, "end_char_idx": 893, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "ee618f4e-7c8c-496c-bd24-cccb7ee26798": {"__data__": {"id_": "ee618f4e-7c8c-496c-bd24-cccb7ee26798", "embedding": null, "metadata": {"window": "We were really encouraged by the underlying performance in Q2 of the \nMedical business.  Just to restate the results.  The Q2 results were consistent with the expectations we \ncommunicated several weeks ago at the JPMorgan Conference, and generally consistent with Q1 \ndespite some of those adjustments that we took in the quarter.   I want to emphasize, as you move \naway from the adjustments that we took, the underlying elements of the Medical Improvement Plan, \nthey're on track.  You heard some  of my prepared remarks relative to our progress against the \nmitigation of inflation and how our cost structure is building.  The benefits of these actions we've taken \nwill benefit our cost structure in the back half of the year.  You heard us announce that we had \nrevenue growth for the first time in two years in the quarter as well, and we were pleased with the \nCardinal Health Brand growth that comes with that. ", "original_text": "I want to emphasize, as you move \naway from the adjustments that we took, the underlying elements of the Medical Improvement Plan, \nthey're on track. ", "page_label": "13", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "8e2e64d9-3499-4495-ab28-5ac0bafd5491", "node_type": "4", "metadata": {"page_label": "13", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "1311cf71848883e159e85da50c3c3b08d1f320174a9464fade81363c5a4623dd", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "6286b206-919b-4849-bd23-1c4644fdb1e6", "node_type": "1", "metadata": {"window": "Aaron Alt :  Thank you.  We were really encouraged by the underlying performance in Q2 of the \nMedical business.  Just to restate the results.  The Q2 results were consistent with the expectations we \ncommunicated several weeks ago at the JPMorgan Conference, and generally consistent with Q1 \ndespite some of those adjustments that we took in the quarter.   I want to emphasize, as you move \naway from the adjustments that we took, the underlying elements of the Medical Improvement Plan, \nthey're on track.  You heard some  of my prepared remarks relative to our progress against the \nmitigation of inflation and how our cost structure is building.  The benefits of these actions we've taken \nwill benefit our cost structure in the back half of the year. ", "original_text": "The Q2 results were consistent with the expectations we \ncommunicated several weeks ago at the JPMorgan Conference, and generally consistent with Q1 \ndespite some of those adjustments that we took in the quarter.  ", "page_label": "13", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "96eea551e3a6126d9e7d08f90eb4097a46e86892668deab6494a7efe3ad6b068", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "e576ef33-8548-4237-9f70-932ce726bcb1", "node_type": "1", "metadata": {"window": "Just to restate the results.  The Q2 results were consistent with the expectations we \ncommunicated several weeks ago at the JPMorgan Conference, and generally consistent with Q1 \ndespite some of those adjustments that we took in the quarter.   I want to emphasize, as you move \naway from the adjustments that we took, the underlying elements of the Medical Improvement Plan, \nthey're on track.  You heard some  of my prepared remarks relative to our progress against the \nmitigation of inflation and how our cost structure is building.  The benefits of these actions we've taken \nwill benefit our cost structure in the back half of the year.  You heard us announce that we had \nrevenue growth for the first time in two years in the quarter as well, and we were pleased with the \nCardinal Health Brand growth that comes with that.  And the team continues to execute against the \nsimplification initiatives that have been a core  part of the Medical Improvement Plan all along. ", "original_text": "You heard some  of my prepared remarks relative to our progress against the \nmitigation of inflation and how our cost structure is building. "}, "hash": "42bb2f5367821bdc7f9c391ae3f715c4f25a543792e6fea4de565d76a7e757c2", "class_name": "RelatedNodeInfo"}}, "text": "I want to emphasize, as you move \naway from the adjustments that we took, the underlying elements of the Medical Improvement Plan, \nthey're on track. ", "start_char_idx": 893, "end_char_idx": 1043, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "e576ef33-8548-4237-9f70-932ce726bcb1": {"__data__": {"id_": "e576ef33-8548-4237-9f70-932ce726bcb1", "embedding": null, "metadata": {"window": "Just to restate the results.  The Q2 results were consistent with the expectations we \ncommunicated several weeks ago at the JPMorgan Conference, and generally consistent with Q1 \ndespite some of those adjustments that we took in the quarter.   I want to emphasize, as you move \naway from the adjustments that we took, the underlying elements of the Medical Improvement Plan, \nthey're on track.  You heard some  of my prepared remarks relative to our progress against the \nmitigation of inflation and how our cost structure is building.  The benefits of these actions we've taken \nwill benefit our cost structure in the back half of the year.  You heard us announce that we had \nrevenue growth for the first time in two years in the quarter as well, and we were pleased with the \nCardinal Health Brand growth that comes with that.  And the team continues to execute against the \nsimplification initiatives that have been a core  part of the Medical Improvement Plan all along. ", "original_text": "You heard some  of my prepared remarks relative to our progress against the \nmitigation of inflation and how our cost structure is building. ", "page_label": "13", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "8e2e64d9-3499-4495-ab28-5ac0bafd5491", "node_type": "4", "metadata": {"page_label": "13", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "1311cf71848883e159e85da50c3c3b08d1f320174a9464fade81363c5a4623dd", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "ee618f4e-7c8c-496c-bd24-cccb7ee26798", "node_type": "1", "metadata": {"window": "We were really encouraged by the underlying performance in Q2 of the \nMedical business.  Just to restate the results.  The Q2 results were consistent with the expectations we \ncommunicated several weeks ago at the JPMorgan Conference, and generally consistent with Q1 \ndespite some of those adjustments that we took in the quarter.   I want to emphasize, as you move \naway from the adjustments that we took, the underlying elements of the Medical Improvement Plan, \nthey're on track.  You heard some  of my prepared remarks relative to our progress against the \nmitigation of inflation and how our cost structure is building.  The benefits of these actions we've taken \nwill benefit our cost structure in the back half of the year.  You heard us announce that we had \nrevenue growth for the first time in two years in the quarter as well, and we were pleased with the \nCardinal Health Brand growth that comes with that. ", "original_text": "I want to emphasize, as you move \naway from the adjustments that we took, the underlying elements of the Medical Improvement Plan, \nthey're on track. ", "page_label": "13", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "68c205b003f9e6e2f79c91ae34ee8b608d04cd81fdcb92c79643765d1e56cf71", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "6b4d5dc8-6c7e-4ddf-9bc5-faddbb164216", "node_type": "1", "metadata": {"window": "The Q2 results were consistent with the expectations we \ncommunicated several weeks ago at the JPMorgan Conference, and generally consistent with Q1 \ndespite some of those adjustments that we took in the quarter.   I want to emphasize, as you move \naway from the adjustments that we took, the underlying elements of the Medical Improvement Plan, \nthey're on track.  You heard some  of my prepared remarks relative to our progress against the \nmitigation of inflation and how our cost structure is building.  The benefits of these actions we've taken \nwill benefit our cost structure in the back half of the year.  You heard us announce that we had \nrevenue growth for the first time in two years in the quarter as well, and we were pleased with the \nCardinal Health Brand growth that comes with that.  And the team continues to execute against the \nsimplification initiatives that have been a core  part of the Medical Improvement Plan all along.  So, I'm \ngoing to go back to where I started, which is we were quite pleased with the operational performance \nin the quarter.  \n \n", "original_text": "The benefits of these actions we've taken \nwill benefit our cost structure in the back half of the year. "}, "hash": "cc629363a34bfbb9929d3373ecc668205e50d24fbf474a20dcf78464dfebf797", "class_name": "RelatedNodeInfo"}}, "text": "You heard some  of my prepared remarks relative to our progress against the \nmitigation of inflation and how our cost structure is building. ", "start_char_idx": 1043, "end_char_idx": 1184, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "6b4d5dc8-6c7e-4ddf-9bc5-faddbb164216": {"__data__": {"id_": "6b4d5dc8-6c7e-4ddf-9bc5-faddbb164216", "embedding": null, "metadata": {"window": "The Q2 results were consistent with the expectations we \ncommunicated several weeks ago at the JPMorgan Conference, and generally consistent with Q1 \ndespite some of those adjustments that we took in the quarter.   I want to emphasize, as you move \naway from the adjustments that we took, the underlying elements of the Medical Improvement Plan, \nthey're on track.  You heard some  of my prepared remarks relative to our progress against the \nmitigation of inflation and how our cost structure is building.  The benefits of these actions we've taken \nwill benefit our cost structure in the back half of the year.  You heard us announce that we had \nrevenue growth for the first time in two years in the quarter as well, and we were pleased with the \nCardinal Health Brand growth that comes with that.  And the team continues to execute against the \nsimplification initiatives that have been a core  part of the Medical Improvement Plan all along.  So, I'm \ngoing to go back to where I started, which is we were quite pleased with the operational performance \nin the quarter.  \n \n", "original_text": "The benefits of these actions we've taken \nwill benefit our cost structure in the back half of the year. ", "page_label": "13", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "8e2e64d9-3499-4495-ab28-5ac0bafd5491", "node_type": "4", "metadata": {"page_label": "13", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "1311cf71848883e159e85da50c3c3b08d1f320174a9464fade81363c5a4623dd", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "e576ef33-8548-4237-9f70-932ce726bcb1", "node_type": "1", "metadata": {"window": "Just to restate the results.  The Q2 results were consistent with the expectations we \ncommunicated several weeks ago at the JPMorgan Conference, and generally consistent with Q1 \ndespite some of those adjustments that we took in the quarter.   I want to emphasize, as you move \naway from the adjustments that we took, the underlying elements of the Medical Improvement Plan, \nthey're on track.  You heard some  of my prepared remarks relative to our progress against the \nmitigation of inflation and how our cost structure is building.  The benefits of these actions we've taken \nwill benefit our cost structure in the back half of the year.  You heard us announce that we had \nrevenue growth for the first time in two years in the quarter as well, and we were pleased with the \nCardinal Health Brand growth that comes with that.  And the team continues to execute against the \nsimplification initiatives that have been a core  part of the Medical Improvement Plan all along. ", "original_text": "You heard some  of my prepared remarks relative to our progress against the \nmitigation of inflation and how our cost structure is building. ", "page_label": "13", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "2f5680154a6b38085a7311142f0eef6bfcd1ce33f78db1104534d310e02f017c", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "0a8e1d9f-0e35-4392-8c3f-68c179e0b5f7", "node_type": "1", "metadata": {"window": "I want to emphasize, as you move \naway from the adjustments that we took, the underlying elements of the Medical Improvement Plan, \nthey're on track.  You heard some  of my prepared remarks relative to our progress against the \nmitigation of inflation and how our cost structure is building.  The benefits of these actions we've taken \nwill benefit our cost structure in the back half of the year.  You heard us announce that we had \nrevenue growth for the first time in two years in the quarter as well, and we were pleased with the \nCardinal Health Brand growth that comes with that.  And the team continues to execute against the \nsimplification initiatives that have been a core  part of the Medical Improvement Plan all along.  So, I'm \ngoing to go back to where I started, which is we were quite pleased with the operational performance \nin the quarter.  \n \n I also want to point out that from a guidance perspective, while we updated the guidance for the year \nto reflect the nonrecurring , the relative impact of the nonrecurring adjustments, that was the sum \nchange of the guidance to reflect that, which is behind us, not that, which is ahead. ", "original_text": "You heard us announce that we had \nrevenue growth for the first time in two years in the quarter as well, and we were pleased with the \nCardinal Health Brand growth that comes with that. "}, "hash": "52c620217b897da72c0b08e597a1a7d263e01e1f426f4dc73b6f6afb22178745", "class_name": "RelatedNodeInfo"}}, "text": "The benefits of these actions we've taken \nwill benefit our cost structure in the back half of the year. ", "start_char_idx": 1184, "end_char_idx": 1289, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "0a8e1d9f-0e35-4392-8c3f-68c179e0b5f7": {"__data__": {"id_": "0a8e1d9f-0e35-4392-8c3f-68c179e0b5f7", "embedding": null, "metadata": {"window": "I want to emphasize, as you move \naway from the adjustments that we took, the underlying elements of the Medical Improvement Plan, \nthey're on track.  You heard some  of my prepared remarks relative to our progress against the \nmitigation of inflation and how our cost structure is building.  The benefits of these actions we've taken \nwill benefit our cost structure in the back half of the year.  You heard us announce that we had \nrevenue growth for the first time in two years in the quarter as well, and we were pleased with the \nCardinal Health Brand growth that comes with that.  And the team continues to execute against the \nsimplification initiatives that have been a core  part of the Medical Improvement Plan all along.  So, I'm \ngoing to go back to where I started, which is we were quite pleased with the operational performance \nin the quarter.  \n \n I also want to point out that from a guidance perspective, while we updated the guidance for the year \nto reflect the nonrecurring , the relative impact of the nonrecurring adjustments, that was the sum \nchange of the guidance to reflect that, which is behind us, not that, which is ahead. ", "original_text": "You heard us announce that we had \nrevenue growth for the first time in two years in the quarter as well, and we were pleased with the \nCardinal Health Brand growth that comes with that. ", "page_label": "13", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "8e2e64d9-3499-4495-ab28-5ac0bafd5491", "node_type": "4", "metadata": {"page_label": "13", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "1311cf71848883e159e85da50c3c3b08d1f320174a9464fade81363c5a4623dd", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "6b4d5dc8-6c7e-4ddf-9bc5-faddbb164216", "node_type": "1", "metadata": {"window": "The Q2 results were consistent with the expectations we \ncommunicated several weeks ago at the JPMorgan Conference, and generally consistent with Q1 \ndespite some of those adjustments that we took in the quarter.   I want to emphasize, as you move \naway from the adjustments that we took, the underlying elements of the Medical Improvement Plan, \nthey're on track.  You heard some  of my prepared remarks relative to our progress against the \nmitigation of inflation and how our cost structure is building.  The benefits of these actions we've taken \nwill benefit our cost structure in the back half of the year.  You heard us announce that we had \nrevenue growth for the first time in two years in the quarter as well, and we were pleased with the \nCardinal Health Brand growth that comes with that.  And the team continues to execute against the \nsimplification initiatives that have been a core  part of the Medical Improvement Plan all along.  So, I'm \ngoing to go back to where I started, which is we were quite pleased with the operational performance \nin the quarter.  \n \n", "original_text": "The benefits of these actions we've taken \nwill benefit our cost structure in the back half of the year. ", "page_label": "13", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "549eae7efd4f3603387904e105d0d51f8f78312c2f9eac5ca4b667487349dd99", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "2fe6127e-3443-49de-93cc-1c8a7d838070", "node_type": "1", "metadata": {"window": "You heard some  of my prepared remarks relative to our progress against the \nmitigation of inflation and how our cost structure is building.  The benefits of these actions we've taken \nwill benefit our cost structure in the back half of the year.  You heard us announce that we had \nrevenue growth for the first time in two years in the quarter as well, and we were pleased with the \nCardinal Health Brand growth that comes with that.  And the team continues to execute against the \nsimplification initiatives that have been a core  part of the Medical Improvement Plan all along.  So, I'm \ngoing to go back to where I started, which is we were quite pleased with the operational performance \nin the quarter.  \n \n I also want to point out that from a guidance perspective, while we updated the guidance for the year \nto reflect the nonrecurring , the relative impact of the nonrecurring adjustments, that was the sum \nchange of the guidance to reflect that, which is behind us, not that, which is ahead.  And if you think \nthrough how we have guided Medical for the year all along, there's always been a very back half \nfocused trajectory for our guidance here for the year, and that remains unchanged along with how \npleased we are with the core operational performance.  \n \n", "original_text": "And the team continues to execute against the \nsimplification initiatives that have been a core  part of the Medical Improvement Plan all along. "}, "hash": "ee42271f4af17a940c97c5c30f91c1b024a2262374c6cc0752a30334410bf7c4", "class_name": "RelatedNodeInfo"}}, "text": "You heard us announce that we had \nrevenue growth for the first time in two years in the quarter as well, and we were pleased with the \nCardinal Health Brand growth that comes with that. ", "start_char_idx": 1289, "end_char_idx": 1476, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "2fe6127e-3443-49de-93cc-1c8a7d838070": {"__data__": {"id_": "2fe6127e-3443-49de-93cc-1c8a7d838070", "embedding": null, "metadata": {"window": "You heard some  of my prepared remarks relative to our progress against the \nmitigation of inflation and how our cost structure is building.  The benefits of these actions we've taken \nwill benefit our cost structure in the back half of the year.  You heard us announce that we had \nrevenue growth for the first time in two years in the quarter as well, and we were pleased with the \nCardinal Health Brand growth that comes with that.  And the team continues to execute against the \nsimplification initiatives that have been a core  part of the Medical Improvement Plan all along.  So, I'm \ngoing to go back to where I started, which is we were quite pleased with the operational performance \nin the quarter.  \n \n I also want to point out that from a guidance perspective, while we updated the guidance for the year \nto reflect the nonrecurring , the relative impact of the nonrecurring adjustments, that was the sum \nchange of the guidance to reflect that, which is behind us, not that, which is ahead.  And if you think \nthrough how we have guided Medical for the year all along, there's always been a very back half \nfocused trajectory for our guidance here for the year, and that remains unchanged along with how \npleased we are with the core operational performance.  \n \n", "original_text": "And the team continues to execute against the \nsimplification initiatives that have been a core  part of the Medical Improvement Plan all along. ", "page_label": "13", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "8e2e64d9-3499-4495-ab28-5ac0bafd5491", "node_type": "4", "metadata": {"page_label": "13", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "1311cf71848883e159e85da50c3c3b08d1f320174a9464fade81363c5a4623dd", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "0a8e1d9f-0e35-4392-8c3f-68c179e0b5f7", "node_type": "1", "metadata": {"window": "I want to emphasize, as you move \naway from the adjustments that we took, the underlying elements of the Medical Improvement Plan, \nthey're on track.  You heard some  of my prepared remarks relative to our progress against the \nmitigation of inflation and how our cost structure is building.  The benefits of these actions we've taken \nwill benefit our cost structure in the back half of the year.  You heard us announce that we had \nrevenue growth for the first time in two years in the quarter as well, and we were pleased with the \nCardinal Health Brand growth that comes with that.  And the team continues to execute against the \nsimplification initiatives that have been a core  part of the Medical Improvement Plan all along.  So, I'm \ngoing to go back to where I started, which is we were quite pleased with the operational performance \nin the quarter.  \n \n I also want to point out that from a guidance perspective, while we updated the guidance for the year \nto reflect the nonrecurring , the relative impact of the nonrecurring adjustments, that was the sum \nchange of the guidance to reflect that, which is behind us, not that, which is ahead. ", "original_text": "You heard us announce that we had \nrevenue growth for the first time in two years in the quarter as well, and we were pleased with the \nCardinal Health Brand growth that comes with that. ", "page_label": "13", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "be0487d566de9c93ed7116710cde23dd3b142606b47444f7ea4b47e00d7643a4", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "0f8291b4-98b5-4597-8039-00e7bb048fa6", "node_type": "1", "metadata": {"window": "The benefits of these actions we've taken \nwill benefit our cost structure in the back half of the year.  You heard us announce that we had \nrevenue growth for the first time in two years in the quarter as well, and we were pleased with the \nCardinal Health Brand growth that comes with that.  And the team continues to execute against the \nsimplification initiatives that have been a core  part of the Medical Improvement Plan all along.  So, I'm \ngoing to go back to where I started, which is we were quite pleased with the operational performance \nin the quarter.  \n \n I also want to point out that from a guidance perspective, while we updated the guidance for the year \nto reflect the nonrecurring , the relative impact of the nonrecurring adjustments, that was the sum \nchange of the guidance to reflect that, which is behind us, not that, which is ahead.  And if you think \nthrough how we have guided Medical for the year all along, there's always been a very back half \nfocused trajectory for our guidance here for the year, and that remains unchanged along with how \npleased we are with the core operational performance.  \n \n Jason Hollar :  Yeah. ", "original_text": "So, I'm \ngoing to go back to where I started, which is we were quite pleased with the operational performance \nin the quarter.  \n \n"}, "hash": "e4550d0b15b0ba3ad152f6f027b3aa23269cea06e5e9e62ded29a3f89ad1e387", "class_name": "RelatedNodeInfo"}}, "text": "And the team continues to execute against the \nsimplification initiatives that have been a core  part of the Medical Improvement Plan all along. ", "start_char_idx": 1476, "end_char_idx": 1621, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "0f8291b4-98b5-4597-8039-00e7bb048fa6": {"__data__": {"id_": "0f8291b4-98b5-4597-8039-00e7bb048fa6", "embedding": null, "metadata": {"window": "The benefits of these actions we've taken \nwill benefit our cost structure in the back half of the year.  You heard us announce that we had \nrevenue growth for the first time in two years in the quarter as well, and we were pleased with the \nCardinal Health Brand growth that comes with that.  And the team continues to execute against the \nsimplification initiatives that have been a core  part of the Medical Improvement Plan all along.  So, I'm \ngoing to go back to where I started, which is we were quite pleased with the operational performance \nin the quarter.  \n \n I also want to point out that from a guidance perspective, while we updated the guidance for the year \nto reflect the nonrecurring , the relative impact of the nonrecurring adjustments, that was the sum \nchange of the guidance to reflect that, which is behind us, not that, which is ahead.  And if you think \nthrough how we have guided Medical for the year all along, there's always been a very back half \nfocused trajectory for our guidance here for the year, and that remains unchanged along with how \npleased we are with the core operational performance.  \n \n Jason Hollar :  Yeah. ", "original_text": "So, I'm \ngoing to go back to where I started, which is we were quite pleased with the operational performance \nin the quarter.  \n \n", "page_label": "13", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "8e2e64d9-3499-4495-ab28-5ac0bafd5491", "node_type": "4", "metadata": {"page_label": "13", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "1311cf71848883e159e85da50c3c3b08d1f320174a9464fade81363c5a4623dd", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "2fe6127e-3443-49de-93cc-1c8a7d838070", "node_type": "1", "metadata": {"window": "You heard some  of my prepared remarks relative to our progress against the \nmitigation of inflation and how our cost structure is building.  The benefits of these actions we've taken \nwill benefit our cost structure in the back half of the year.  You heard us announce that we had \nrevenue growth for the first time in two years in the quarter as well, and we were pleased with the \nCardinal Health Brand growth that comes with that.  And the team continues to execute against the \nsimplification initiatives that have been a core  part of the Medical Improvement Plan all along.  So, I'm \ngoing to go back to where I started, which is we were quite pleased with the operational performance \nin the quarter.  \n \n I also want to point out that from a guidance perspective, while we updated the guidance for the year \nto reflect the nonrecurring , the relative impact of the nonrecurring adjustments, that was the sum \nchange of the guidance to reflect that, which is behind us, not that, which is ahead.  And if you think \nthrough how we have guided Medical for the year all along, there's always been a very back half \nfocused trajectory for our guidance here for the year, and that remains unchanged along with how \npleased we are with the core operational performance.  \n \n", "original_text": "And the team continues to execute against the \nsimplification initiatives that have been a core  part of the Medical Improvement Plan all along. ", "page_label": "13", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "016a05a8c6cd95feb8ea3c0c05de90d743fda8c735663afe47c51dd5547f9c9f", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "de9bedac-31fb-471f-b4b2-c958eb673c14", "node_type": "1", "metadata": {"window": "You heard us announce that we had \nrevenue growth for the first time in two years in the quarter as well, and we were pleased with the \nCardinal Health Brand growth that comes with that.  And the team continues to execute against the \nsimplification initiatives that have been a core  part of the Medical Improvement Plan all along.  So, I'm \ngoing to go back to where I started, which is we were quite pleased with the operational performance \nin the quarter.  \n \n I also want to point out that from a guidance perspective, while we updated the guidance for the year \nto reflect the nonrecurring , the relative impact of the nonrecurring adjustments, that was the sum \nchange of the guidance to reflect that, which is behind us, not that, which is ahead.  And if you think \nthrough how we have guided Medical for the year all along, there's always been a very back half \nfocused trajectory for our guidance here for the year, and that remains unchanged along with how \npleased we are with the core operational performance.  \n \n Jason Hollar :  Yeah.  If I could just add, when you think about that first half, second half cadence and \nwhy we still anticipate the same step -up in the second half versus the first half, there's a couple of key \npoints.  \n \n", "original_text": "I also want to point out that from a guidance perspective, while we updated the guidance for the year \nto reflect the nonrecurring , the relative impact of the nonrecurring adjustments, that was the sum \nchange of the guidance to reflect that, which is behind us, not that, which is ahead. "}, "hash": "dbafb95d1e851494894052079a29433d6f55442435e03568089d480c18f29691", "class_name": "RelatedNodeInfo"}}, "text": "So, I'm \ngoing to go back to where I started, which is we were quite pleased with the operational performance \nin the quarter.  \n \n", "start_char_idx": 1621, "end_char_idx": 1752, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "de9bedac-31fb-471f-b4b2-c958eb673c14": {"__data__": {"id_": "de9bedac-31fb-471f-b4b2-c958eb673c14", "embedding": null, "metadata": {"window": "You heard us announce that we had \nrevenue growth for the first time in two years in the quarter as well, and we were pleased with the \nCardinal Health Brand growth that comes with that.  And the team continues to execute against the \nsimplification initiatives that have been a core  part of the Medical Improvement Plan all along.  So, I'm \ngoing to go back to where I started, which is we were quite pleased with the operational performance \nin the quarter.  \n \n I also want to point out that from a guidance perspective, while we updated the guidance for the year \nto reflect the nonrecurring , the relative impact of the nonrecurring adjustments, that was the sum \nchange of the guidance to reflect that, which is behind us, not that, which is ahead.  And if you think \nthrough how we have guided Medical for the year all along, there's always been a very back half \nfocused trajectory for our guidance here for the year, and that remains unchanged along with how \npleased we are with the core operational performance.  \n \n Jason Hollar :  Yeah.  If I could just add, when you think about that first half, second half cadence and \nwhy we still anticipate the same step -up in the second half versus the first half, there's a couple of key \npoints.  \n \n", "original_text": "I also want to point out that from a guidance perspective, while we updated the guidance for the year \nto reflect the nonrecurring , the relative impact of the nonrecurring adjustments, that was the sum \nchange of the guidance to reflect that, which is behind us, not that, which is ahead. ", "page_label": "13", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "8e2e64d9-3499-4495-ab28-5ac0bafd5491", "node_type": "4", "metadata": {"page_label": "13", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "1311cf71848883e159e85da50c3c3b08d1f320174a9464fade81363c5a4623dd", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "0f8291b4-98b5-4597-8039-00e7bb048fa6", "node_type": "1", "metadata": {"window": "The benefits of these actions we've taken \nwill benefit our cost structure in the back half of the year.  You heard us announce that we had \nrevenue growth for the first time in two years in the quarter as well, and we were pleased with the \nCardinal Health Brand growth that comes with that.  And the team continues to execute against the \nsimplification initiatives that have been a core  part of the Medical Improvement Plan all along.  So, I'm \ngoing to go back to where I started, which is we were quite pleased with the operational performance \nin the quarter.  \n \n I also want to point out that from a guidance perspective, while we updated the guidance for the year \nto reflect the nonrecurring , the relative impact of the nonrecurring adjustments, that was the sum \nchange of the guidance to reflect that, which is behind us, not that, which is ahead.  And if you think \nthrough how we have guided Medical for the year all along, there's always been a very back half \nfocused trajectory for our guidance here for the year, and that remains unchanged along with how \npleased we are with the core operational performance.  \n \n Jason Hollar :  Yeah. ", "original_text": "So, I'm \ngoing to go back to where I started, which is we were quite pleased with the operational performance \nin the quarter.  \n \n", "page_label": "13", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "3d351fefb43ccf15139f2bf7bcbff171ada41a2929f13ccf5a1d49f559aa30d0", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "2cac00ca-b730-4839-a939-b4bc5dd11756", "node_type": "1", "metadata": {"window": "And the team continues to execute against the \nsimplification initiatives that have been a core  part of the Medical Improvement Plan all along.  So, I'm \ngoing to go back to where I started, which is we were quite pleased with the operational performance \nin the quarter.  \n \n I also want to point out that from a guidance perspective, while we updated the guidance for the year \nto reflect the nonrecurring , the relative impact of the nonrecurring adjustments, that was the sum \nchange of the guidance to reflect that, which is behind us, not that, which is ahead.  And if you think \nthrough how we have guided Medical for the year all along, there's always been a very back half \nfocused trajectory for our guidance here for the year, and that remains unchanged along with how \npleased we are with the core operational performance.  \n \n Jason Hollar :  Yeah.  If I could just add, when you think about that first half, second half cadence and \nwhy we still anticipate the same step -up in the second half versus the first half, there's a couple of key \npoints.  \n \n First of all, inflation mitigation. ", "original_text": "And if you think \nthrough how we have guided Medical for the year all along, there's always been a very back half \nfocused trajectory for our guidance here for the year, and that remains unchanged along with how \npleased we are with the core operational performance.  \n \n"}, "hash": "2f00f656de40b3d7d4eead0716e4d83791a9bbdc68cd2376fd9a0188c5975762", "class_name": "RelatedNodeInfo"}}, "text": "I also want to point out that from a guidance perspective, while we updated the guidance for the year \nto reflect the nonrecurring , the relative impact of the nonrecurring adjustments, that was the sum \nchange of the guidance to reflect that, which is behind us, not that, which is ahead. ", "start_char_idx": 1752, "end_char_idx": 2042, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "2cac00ca-b730-4839-a939-b4bc5dd11756": {"__data__": {"id_": "2cac00ca-b730-4839-a939-b4bc5dd11756", "embedding": null, "metadata": {"window": "And the team continues to execute against the \nsimplification initiatives that have been a core  part of the Medical Improvement Plan all along.  So, I'm \ngoing to go back to where I started, which is we were quite pleased with the operational performance \nin the quarter.  \n \n I also want to point out that from a guidance perspective, while we updated the guidance for the year \nto reflect the nonrecurring , the relative impact of the nonrecurring adjustments, that was the sum \nchange of the guidance to reflect that, which is behind us, not that, which is ahead.  And if you think \nthrough how we have guided Medical for the year all along, there's always been a very back half \nfocused trajectory for our guidance here for the year, and that remains unchanged along with how \npleased we are with the core operational performance.  \n \n Jason Hollar :  Yeah.  If I could just add, when you think about that first half, second half cadence and \nwhy we still anticipate the same step -up in the second half versus the first half, there's a couple of key \npoints.  \n \n First of all, inflation mitigation. ", "original_text": "And if you think \nthrough how we have guided Medical for the year all along, there's always been a very back half \nfocused trajectory for our guidance here for the year, and that remains unchanged along with how \npleased we are with the core operational performance.  \n \n", "page_label": "13", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "8e2e64d9-3499-4495-ab28-5ac0bafd5491", "node_type": "4", "metadata": {"page_label": "13", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "1311cf71848883e159e85da50c3c3b08d1f320174a9464fade81363c5a4623dd", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "de9bedac-31fb-471f-b4b2-c958eb673c14", "node_type": "1", "metadata": {"window": "You heard us announce that we had \nrevenue growth for the first time in two years in the quarter as well, and we were pleased with the \nCardinal Health Brand growth that comes with that.  And the team continues to execute against the \nsimplification initiatives that have been a core  part of the Medical Improvement Plan all along.  So, I'm \ngoing to go back to where I started, which is we were quite pleased with the operational performance \nin the quarter.  \n \n I also want to point out that from a guidance perspective, while we updated the guidance for the year \nto reflect the nonrecurring , the relative impact of the nonrecurring adjustments, that was the sum \nchange of the guidance to reflect that, which is behind us, not that, which is ahead.  And if you think \nthrough how we have guided Medical for the year all along, there's always been a very back half \nfocused trajectory for our guidance here for the year, and that remains unchanged along with how \npleased we are with the core operational performance.  \n \n Jason Hollar :  Yeah.  If I could just add, when you think about that first half, second half cadence and \nwhy we still anticipate the same step -up in the second half versus the first half, there's a couple of key \npoints.  \n \n", "original_text": "I also want to point out that from a guidance perspective, while we updated the guidance for the year \nto reflect the nonrecurring , the relative impact of the nonrecurring adjustments, that was the sum \nchange of the guidance to reflect that, which is behind us, not that, which is ahead. ", "page_label": "13", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "abe966badaddf643bba1830b1e1f484aa8f44ed9b738662410e5fe14b668ede2", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "a6668b04-d143-4c78-b659-53cef90a138b", "node_type": "1", "metadata": {"window": "So, I'm \ngoing to go back to where I started, which is we were quite pleased with the operational performance \nin the quarter.  \n \n I also want to point out that from a guidance perspective, while we updated the guidance for the year \nto reflect the nonrecurring , the relative impact of the nonrecurring adjustments, that was the sum \nchange of the guidance to reflect that, which is behind us, not that, which is ahead.  And if you think \nthrough how we have guided Medical for the year all along, there's always been a very back half \nfocused trajectory for our guidance here for the year, and that remains unchanged along with how \npleased we are with the core operational performance.  \n \n Jason Hollar :  Yeah.  If I could just add, when you think about that first half, second half cadence and \nwhy we still anticipate the same step -up in the second half versus the first half, there's a couple of key \npoints.  \n \n First of all, inflation mitigation.  This is one where it's a significant part of that combined with Cardinal \nHealth Brand volume growth, which I'll get to in a moment. ", "original_text": "Jason Hollar :  Yeah. "}, "hash": "4d95b71982f42728929f0f23a537b8b3a5b4427ad343d3068d70122452db2e38", "class_name": "RelatedNodeInfo"}}, "text": "And if you think \nthrough how we have guided Medical for the year all along, there's always been a very back half \nfocused trajectory for our guidance here for the year, and that remains unchanged along with how \npleased we are with the core operational performance.  \n \n", "start_char_idx": 2042, "end_char_idx": 2313, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "a6668b04-d143-4c78-b659-53cef90a138b": {"__data__": {"id_": "a6668b04-d143-4c78-b659-53cef90a138b", "embedding": null, "metadata": {"window": "So, I'm \ngoing to go back to where I started, which is we were quite pleased with the operational performance \nin the quarter.  \n \n I also want to point out that from a guidance perspective, while we updated the guidance for the year \nto reflect the nonrecurring , the relative impact of the nonrecurring adjustments, that was the sum \nchange of the guidance to reflect that, which is behind us, not that, which is ahead.  And if you think \nthrough how we have guided Medical for the year all along, there's always been a very back half \nfocused trajectory for our guidance here for the year, and that remains unchanged along with how \npleased we are with the core operational performance.  \n \n Jason Hollar :  Yeah.  If I could just add, when you think about that first half, second half cadence and \nwhy we still anticipate the same step -up in the second half versus the first half, there's a couple of key \npoints.  \n \n First of all, inflation mitigation.  This is one where it's a significant part of that combined with Cardinal \nHealth Brand volume growth, which I'll get to in a moment. ", "original_text": "Jason Hollar :  Yeah. ", "page_label": "13", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "8e2e64d9-3499-4495-ab28-5ac0bafd5491", "node_type": "4", "metadata": {"page_label": "13", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "1311cf71848883e159e85da50c3c3b08d1f320174a9464fade81363c5a4623dd", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "2cac00ca-b730-4839-a939-b4bc5dd11756", "node_type": "1", "metadata": {"window": "And the team continues to execute against the \nsimplification initiatives that have been a core  part of the Medical Improvement Plan all along.  So, I'm \ngoing to go back to where I started, which is we were quite pleased with the operational performance \nin the quarter.  \n \n I also want to point out that from a guidance perspective, while we updated the guidance for the year \nto reflect the nonrecurring , the relative impact of the nonrecurring adjustments, that was the sum \nchange of the guidance to reflect that, which is behind us, not that, which is ahead.  And if you think \nthrough how we have guided Medical for the year all along, there's always been a very back half \nfocused trajectory for our guidance here for the year, and that remains unchanged along with how \npleased we are with the core operational performance.  \n \n Jason Hollar :  Yeah.  If I could just add, when you think about that first half, second half cadence and \nwhy we still anticipate the same step -up in the second half versus the first half, there's a couple of key \npoints.  \n \n First of all, inflation mitigation. ", "original_text": "And if you think \nthrough how we have guided Medical for the year all along, there's always been a very back half \nfocused trajectory for our guidance here for the year, and that remains unchanged along with how \npleased we are with the core operational performance.  \n \n", "page_label": "13", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "5fb5776b65e23e6ca128b1130cb6f0a3bf0c75450e007939aa5b96db1c328884", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "d0695bfa-5eb1-496e-9262-46cf039adcd1", "node_type": "1", "metadata": {"window": "I also want to point out that from a guidance perspective, while we updated the guidance for the year \nto reflect the nonrecurring , the relative impact of the nonrecurring adjustments, that was the sum \nchange of the guidance to reflect that, which is behind us, not that, which is ahead.  And if you think \nthrough how we have guided Medical for the year all along, there's always been a very back half \nfocused trajectory for our guidance here for the year, and that remains unchanged along with how \npleased we are with the core operational performance.  \n \n Jason Hollar :  Yeah.  If I could just add, when you think about that first half, second half cadence and \nwhy we still anticipate the same step -up in the second half versus the first half, there's a couple of key \npoints.  \n \n First of all, inflation mitigation.  This is one where it's a significant part of that combined with Cardinal \nHealth Brand volume growth, which I'll get to in a moment.  But on inflation mitigation, there's  of \ncourse  two elements . ", "original_text": "If I could just add, when you think about that first half, second half cadence and \nwhy we still anticipate the same step -up in the second half versus the first half, there's a couple of key \npoints.  \n \n"}, "hash": "c1a8e4c3695c175788b17b28955c4fe2e5f135500d58824e5e4492dd6632ffaa", "class_name": "RelatedNodeInfo"}}, "text": "Jason Hollar :  Yeah. ", "start_char_idx": 2313, "end_char_idx": 2335, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "d0695bfa-5eb1-496e-9262-46cf039adcd1": {"__data__": {"id_": "d0695bfa-5eb1-496e-9262-46cf039adcd1", "embedding": null, "metadata": {"window": "I also want to point out that from a guidance perspective, while we updated the guidance for the year \nto reflect the nonrecurring , the relative impact of the nonrecurring adjustments, that was the sum \nchange of the guidance to reflect that, which is behind us, not that, which is ahead.  And if you think \nthrough how we have guided Medical for the year all along, there's always been a very back half \nfocused trajectory for our guidance here for the year, and that remains unchanged along with how \npleased we are with the core operational performance.  \n \n Jason Hollar :  Yeah.  If I could just add, when you think about that first half, second half cadence and \nwhy we still anticipate the same step -up in the second half versus the first half, there's a couple of key \npoints.  \n \n First of all, inflation mitigation.  This is one where it's a significant part of that combined with Cardinal \nHealth Brand volume growth, which I'll get to in a moment.  But on inflation mitigation, there's  of \ncourse  two elements . ", "original_text": "If I could just add, when you think about that first half, second half cadence and \nwhy we still anticipate the same step -up in the second half versus the first half, there's a couple of key \npoints.  \n \n", "page_label": "13", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "8e2e64d9-3499-4495-ab28-5ac0bafd5491", "node_type": "4", "metadata": {"page_label": "13", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "1311cf71848883e159e85da50c3c3b08d1f320174a9464fade81363c5a4623dd", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "a6668b04-d143-4c78-b659-53cef90a138b", "node_type": "1", "metadata": {"window": "So, I'm \ngoing to go back to where I started, which is we were quite pleased with the operational performance \nin the quarter.  \n \n I also want to point out that from a guidance perspective, while we updated the guidance for the year \nto reflect the nonrecurring , the relative impact of the nonrecurring adjustments, that was the sum \nchange of the guidance to reflect that, which is behind us, not that, which is ahead.  And if you think \nthrough how we have guided Medical for the year all along, there's always been a very back half \nfocused trajectory for our guidance here for the year, and that remains unchanged along with how \npleased we are with the core operational performance.  \n \n Jason Hollar :  Yeah.  If I could just add, when you think about that first half, second half cadence and \nwhy we still anticipate the same step -up in the second half versus the first half, there's a couple of key \npoints.  \n \n First of all, inflation mitigation.  This is one where it's a significant part of that combined with Cardinal \nHealth Brand volume growth, which I'll get to in a moment. ", "original_text": "Jason Hollar :  Yeah. ", "page_label": "13", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "ab43987087d3974ccbcc0afd75b8b8578dcc5c9b9d4916f0c5d36c8f4cb12443", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "93dbad4e-6575-4b4b-8fb9-feacc180d965", "node_type": "1", "metadata": {"window": "And if you think \nthrough how we have guided Medical for the year all along, there's always been a very back half \nfocused trajectory for our guidance here for the year, and that remains unchanged along with how \npleased we are with the core operational performance.  \n \n Jason Hollar :  Yeah.  If I could just add, when you think about that first half, second half cadence and \nwhy we still anticipate the same step -up in the second half versus the first half, there's a couple of key \npoints.  \n \n First of all, inflation mitigation.  This is one where it's a significant part of that combined with Cardinal \nHealth Brand volume growth, which I'll get to in a moment.  But on inflation mitigation, there's  of \ncourse  two elements .  There\u2019s a  cost side and then there's a price side. ", "original_text": "First of all, inflation mitigation. "}, "hash": "357e9a29da6c8c77543d26071e0501886d906fa378893d2c3e77f7e82edef73b", "class_name": "RelatedNodeInfo"}}, "text": "If I could just add, when you think about that first half, second half cadence and \nwhy we still anticipate the same step -up in the second half versus the first half, there's a couple of key \npoints.  \n \n", "start_char_idx": 2335, "end_char_idx": 2540, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "93dbad4e-6575-4b4b-8fb9-feacc180d965": {"__data__": {"id_": "93dbad4e-6575-4b4b-8fb9-feacc180d965", "embedding": null, "metadata": {"window": "And if you think \nthrough how we have guided Medical for the year all along, there's always been a very back half \nfocused trajectory for our guidance here for the year, and that remains unchanged along with how \npleased we are with the core operational performance.  \n \n Jason Hollar :  Yeah.  If I could just add, when you think about that first half, second half cadence and \nwhy we still anticipate the same step -up in the second half versus the first half, there's a couple of key \npoints.  \n \n First of all, inflation mitigation.  This is one where it's a significant part of that combined with Cardinal \nHealth Brand volume growth, which I'll get to in a moment.  But on inflation mitigation, there's  of \ncourse  two elements .  There\u2019s a  cost side and then there's a price side. ", "original_text": "First of all, inflation mitigation. ", "page_label": "13", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "8e2e64d9-3499-4495-ab28-5ac0bafd5491", "node_type": "4", "metadata": {"page_label": "13", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "1311cf71848883e159e85da50c3c3b08d1f320174a9464fade81363c5a4623dd", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "d0695bfa-5eb1-496e-9262-46cf039adcd1", "node_type": "1", "metadata": {"window": "I also want to point out that from a guidance perspective, while we updated the guidance for the year \nto reflect the nonrecurring , the relative impact of the nonrecurring adjustments, that was the sum \nchange of the guidance to reflect that, which is behind us, not that, which is ahead.  And if you think \nthrough how we have guided Medical for the year all along, there's always been a very back half \nfocused trajectory for our guidance here for the year, and that remains unchanged along with how \npleased we are with the core operational performance.  \n \n Jason Hollar :  Yeah.  If I could just add, when you think about that first half, second half cadence and \nwhy we still anticipate the same step -up in the second half versus the first half, there's a couple of key \npoints.  \n \n First of all, inflation mitigation.  This is one where it's a significant part of that combined with Cardinal \nHealth Brand volume growth, which I'll get to in a moment.  But on inflation mitigation, there's  of \ncourse  two elements . ", "original_text": "If I could just add, when you think about that first half, second half cadence and \nwhy we still anticipate the same step -up in the second half versus the first half, there's a couple of key \npoints.  \n \n", "page_label": "13", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "44f9ebafe5ab0de4522a9406262ff523eff63230799c146ba27efc33076069c6", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "740c43ec-2bc8-4b31-9b05-99512d4e7323", "node_type": "1", "metadata": {"window": "Jason Hollar :  Yeah.  If I could just add, when you think about that first half, second half cadence and \nwhy we still anticipate the same step -up in the second half versus the first half, there's a couple of key \npoints.  \n \n First of all, inflation mitigation.  This is one where it's a significant part of that combined with Cardinal \nHealth Brand volume growth, which I'll get to in a moment.  But on inflation mitigation, there's  of \ncourse  two elements .  There\u2019s a  cost side and then there's a price side.  In both cases, we have very \ngood line of sight.  ", "original_text": "This is one where it's a significant part of that combined with Cardinal \nHealth Brand volume growth, which I'll get to in a moment. "}, "hash": "990e48adf334421ea9097ef6220d37525ce17f261ba2b838a6adf1033801c502", "class_name": "RelatedNodeInfo"}}, "text": "First of all, inflation mitigation. ", "start_char_idx": 2540, "end_char_idx": 2576, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "740c43ec-2bc8-4b31-9b05-99512d4e7323": {"__data__": {"id_": "740c43ec-2bc8-4b31-9b05-99512d4e7323", "embedding": null, "metadata": {"window": "Jason Hollar :  Yeah.  If I could just add, when you think about that first half, second half cadence and \nwhy we still anticipate the same step -up in the second half versus the first half, there's a couple of key \npoints.  \n \n First of all, inflation mitigation.  This is one where it's a significant part of that combined with Cardinal \nHealth Brand volume growth, which I'll get to in a moment.  But on inflation mitigation, there's  of \ncourse  two elements .  There\u2019s a  cost side and then there's a price side.  In both cases, we have very \ngood line of sight.  ", "original_text": "This is one where it's a significant part of that combined with Cardinal \nHealth Brand volume growth, which I'll get to in a moment. ", "page_label": "13", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "8e2e64d9-3499-4495-ab28-5ac0bafd5491", "node_type": "4", "metadata": {"page_label": "13", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "1311cf71848883e159e85da50c3c3b08d1f320174a9464fade81363c5a4623dd", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "93dbad4e-6575-4b4b-8fb9-feacc180d965", "node_type": "1", "metadata": {"window": "And if you think \nthrough how we have guided Medical for the year all along, there's always been a very back half \nfocused trajectory for our guidance here for the year, and that remains unchanged along with how \npleased we are with the core operational performance.  \n \n Jason Hollar :  Yeah.  If I could just add, when you think about that first half, second half cadence and \nwhy we still anticipate the same step -up in the second half versus the first half, there's a couple of key \npoints.  \n \n First of all, inflation mitigation.  This is one where it's a significant part of that combined with Cardinal \nHealth Brand volume growth, which I'll get to in a moment.  But on inflation mitigation, there's  of \ncourse  two elements .  There\u2019s a  cost side and then there's a price side. ", "original_text": "First of all, inflation mitigation. ", "page_label": "13", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "68e96c3025592b73ce68423078ca1335024fec3950c2e4f3414bfb7a882fb3c3", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "f916aa3d-2c46-41f3-a325-321e4735667a", "node_type": "1", "metadata": {"window": "If I could just add, when you think about that first half, second half cadence and \nwhy we still anticipate the same step -up in the second half versus the first half, there's a couple of key \npoints.  \n \n First of all, inflation mitigation.  This is one where it's a significant part of that combined with Cardinal \nHealth Brand volume growth, which I'll get to in a moment.  But on inflation mitigation, there's  of \ncourse  two elements .  There\u2019s a  cost side and then there's a price side.  In both cases, we have very \ngood line of sight.   On the cost side, as we've talked really for quite a while now, it's been international \nfreight and that  while we have a little bit of noise with the Red Sea, it is largely as anticipated. ", "original_text": "But on inflation mitigation, there's  of \ncourse  two elements . "}, "hash": "6ef2e3f76e6728dc2d2f10b40567dc3efb6d11aff15540f5babcd42b00406740", "class_name": "RelatedNodeInfo"}}, "text": "This is one where it's a significant part of that combined with Cardinal \nHealth Brand volume growth, which I'll get to in a moment. ", "start_char_idx": 2576, "end_char_idx": 2709, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "f916aa3d-2c46-41f3-a325-321e4735667a": {"__data__": {"id_": "f916aa3d-2c46-41f3-a325-321e4735667a", "embedding": null, "metadata": {"window": "If I could just add, when you think about that first half, second half cadence and \nwhy we still anticipate the same step -up in the second half versus the first half, there's a couple of key \npoints.  \n \n First of all, inflation mitigation.  This is one where it's a significant part of that combined with Cardinal \nHealth Brand volume growth, which I'll get to in a moment.  But on inflation mitigation, there's  of \ncourse  two elements .  There\u2019s a  cost side and then there's a price side.  In both cases, we have very \ngood line of sight.   On the cost side, as we've talked really for quite a while now, it's been international \nfreight and that  while we have a little bit of noise with the Red Sea, it is largely as anticipated. ", "original_text": "But on inflation mitigation, there's  of \ncourse  two elements . ", "page_label": "13", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "8e2e64d9-3499-4495-ab28-5ac0bafd5491", "node_type": "4", "metadata": {"page_label": "13", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "1311cf71848883e159e85da50c3c3b08d1f320174a9464fade81363c5a4623dd", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "740c43ec-2bc8-4b31-9b05-99512d4e7323", "node_type": "1", "metadata": {"window": "Jason Hollar :  Yeah.  If I could just add, when you think about that first half, second half cadence and \nwhy we still anticipate the same step -up in the second half versus the first half, there's a couple of key \npoints.  \n \n First of all, inflation mitigation.  This is one where it's a significant part of that combined with Cardinal \nHealth Brand volume growth, which I'll get to in a moment.  But on inflation mitigation, there's  of \ncourse  two elements .  There\u2019s a  cost side and then there's a price side.  In both cases, we have very \ngood line of sight.  ", "original_text": "This is one where it's a significant part of that combined with Cardinal \nHealth Brand volume growth, which I'll get to in a moment. ", "page_label": "13", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "9be02c5c0e3c288a4b4814f7809f4533dcdd229ec5886d9eaa566240eb2372c9", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "a4effb32-6707-488b-ac5a-81c401502af8", "node_type": "1", "metadata": {"window": "First of all, inflation mitigation.  This is one where it's a significant part of that combined with Cardinal \nHealth Brand volume growth, which I'll get to in a moment.  But on inflation mitigation, there's  of \ncourse  two elements .  There\u2019s a  cost side and then there's a price side.  In both cases, we have very \ngood line of sight.   On the cost side, as we've talked really for quite a while now, it's been international \nfreight and that  while we have a little bit of noise with the Red Sea, it is largely as anticipated.  And \nthat cost is already on our balance sheet and is rolling through as expected, especially given our \nvolumes have been as expected . ", "original_text": "There\u2019s a  cost side and then there's a price side. "}, "hash": "327d22f92b7eb9ad1bfd1080260be85c5f268c62dde03440768b10e4627f36f8", "class_name": "RelatedNodeInfo"}}, "text": "But on inflation mitigation, there's  of \ncourse  two elements . ", "start_char_idx": 2709, "end_char_idx": 2774, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "a4effb32-6707-488b-ac5a-81c401502af8": {"__data__": {"id_": "a4effb32-6707-488b-ac5a-81c401502af8", "embedding": null, "metadata": {"window": "First of all, inflation mitigation.  This is one where it's a significant part of that combined with Cardinal \nHealth Brand volume growth, which I'll get to in a moment.  But on inflation mitigation, there's  of \ncourse  two elements .  There\u2019s a  cost side and then there's a price side.  In both cases, we have very \ngood line of sight.   On the cost side, as we've talked really for quite a while now, it's been international \nfreight and that  while we have a little bit of noise with the Red Sea, it is largely as anticipated.  And \nthat cost is already on our balance sheet and is rolling through as expected, especially given our \nvolumes have been as expected . ", "original_text": "There\u2019s a  cost side and then there's a price side. ", "page_label": "13", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "8e2e64d9-3499-4495-ab28-5ac0bafd5491", "node_type": "4", "metadata": {"page_label": "13", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "1311cf71848883e159e85da50c3c3b08d1f320174a9464fade81363c5a4623dd", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "f916aa3d-2c46-41f3-a325-321e4735667a", "node_type": "1", "metadata": {"window": "If I could just add, when you think about that first half, second half cadence and \nwhy we still anticipate the same step -up in the second half versus the first half, there's a couple of key \npoints.  \n \n First of all, inflation mitigation.  This is one where it's a significant part of that combined with Cardinal \nHealth Brand volume growth, which I'll get to in a moment.  But on inflation mitigation, there's  of \ncourse  two elements .  There\u2019s a  cost side and then there's a price side.  In both cases, we have very \ngood line of sight.   On the cost side, as we've talked really for quite a while now, it's been international \nfreight and that  while we have a little bit of noise with the Red Sea, it is largely as anticipated. ", "original_text": "But on inflation mitigation, there's  of \ncourse  two elements . ", "page_label": "13", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "25c26e6b6396957913e392d099253c41fd2348fe6be183d871f0948b0db1a054", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "cf37ae39-a62c-4c40-83a3-f766c121e737", "node_type": "1", "metadata": {"window": "This is one where it's a significant part of that combined with Cardinal \nHealth Brand volume growth, which I'll get to in a moment.  But on inflation mitigation, there's  of \ncourse  two elements .  There\u2019s a  cost side and then there's a price side.  In both cases, we have very \ngood line of sight.   On the cost side, as we've talked really for quite a while now, it's been international \nfreight and that  while we have a little bit of noise with the Red Sea, it is largely as anticipated.  And \nthat cost is already on our balance sheet and is rolling through as expected, especially given our \nvolumes have been as expected .  So, we have a very high line of sight and confidence the cost is \ngoing to continue to step down in the second half  of the year. ", "original_text": "In both cases, we have very \ngood line of sight.  "}, "hash": "1459e6e1e58c8015f82dc410c720e9f6d5c067bb47cf4281b61161cecb6f150c", "class_name": "RelatedNodeInfo"}}, "text": "There\u2019s a  cost side and then there's a price side. ", "start_char_idx": 2774, "end_char_idx": 2826, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "cf37ae39-a62c-4c40-83a3-f766c121e737": {"__data__": {"id_": "cf37ae39-a62c-4c40-83a3-f766c121e737", "embedding": null, "metadata": {"window": "This is one where it's a significant part of that combined with Cardinal \nHealth Brand volume growth, which I'll get to in a moment.  But on inflation mitigation, there's  of \ncourse  two elements .  There\u2019s a  cost side and then there's a price side.  In both cases, we have very \ngood line of sight.   On the cost side, as we've talked really for quite a while now, it's been international \nfreight and that  while we have a little bit of noise with the Red Sea, it is largely as anticipated.  And \nthat cost is already on our balance sheet and is rolling through as expected, especially given our \nvolumes have been as expected .  So, we have a very high line of sight and confidence the cost is \ngoing to continue to step down in the second half  of the year. ", "original_text": "In both cases, we have very \ngood line of sight.  ", "page_label": "13", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "8e2e64d9-3499-4495-ab28-5ac0bafd5491", "node_type": "4", "metadata": {"page_label": "13", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "1311cf71848883e159e85da50c3c3b08d1f320174a9464fade81363c5a4623dd", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "a4effb32-6707-488b-ac5a-81c401502af8", "node_type": "1", "metadata": {"window": "First of all, inflation mitigation.  This is one where it's a significant part of that combined with Cardinal \nHealth Brand volume growth, which I'll get to in a moment.  But on inflation mitigation, there's  of \ncourse  two elements .  There\u2019s a  cost side and then there's a price side.  In both cases, we have very \ngood line of sight.   On the cost side, as we've talked really for quite a while now, it's been international \nfreight and that  while we have a little bit of noise with the Red Sea, it is largely as anticipated.  And \nthat cost is already on our balance sheet and is rolling through as expected, especially given our \nvolumes have been as expected . ", "original_text": "There\u2019s a  cost side and then there's a price side. ", "page_label": "13", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "da89c578c58ca0de18f6dfb66881152d1fbad857013ac2a365caaa21d3e202d6", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "14ce4cfc-a92d-4e6b-b5fe-d7d7476ee6b8", "node_type": "1", "metadata": {"window": "But on inflation mitigation, there's  of \ncourse  two elements .  There\u2019s a  cost side and then there's a price side.  In both cases, we have very \ngood line of sight.   On the cost side, as we've talked really for quite a while now, it's been international \nfreight and that  while we have a little bit of noise with the Red Sea, it is largely as anticipated.  And \nthat cost is already on our balance sheet and is rolling through as expected, especially given our \nvolumes have been as expected .  So, we have a very high line of sight and confidence the cost is \ngoing to continue to step down in the second half  of the year.  And then on the pricing side, as we \ntalked before, there's always the contract rolling , roll-through that we then update the pricing on, we \ndo have a little bit more at the beginning of the calendar year of some of those price adjustments. ", "original_text": "On the cost side, as we've talked really for quite a while now, it's been international \nfreight and that  while we have a little bit of noise with the Red Sea, it is largely as anticipated. "}, "hash": "77f0247906f64fd523ca5746977a3bfc40ac5c110591f7b6e24886e48ad74b3f", "class_name": "RelatedNodeInfo"}}, "text": "In both cases, we have very \ngood line of sight.  ", "start_char_idx": 2826, "end_char_idx": 2876, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "14ce4cfc-a92d-4e6b-b5fe-d7d7476ee6b8": {"__data__": {"id_": "14ce4cfc-a92d-4e6b-b5fe-d7d7476ee6b8", "embedding": null, "metadata": {"window": "But on inflation mitigation, there's  of \ncourse  two elements .  There\u2019s a  cost side and then there's a price side.  In both cases, we have very \ngood line of sight.   On the cost side, as we've talked really for quite a while now, it's been international \nfreight and that  while we have a little bit of noise with the Red Sea, it is largely as anticipated.  And \nthat cost is already on our balance sheet and is rolling through as expected, especially given our \nvolumes have been as expected .  So, we have a very high line of sight and confidence the cost is \ngoing to continue to step down in the second half  of the year.  And then on the pricing side, as we \ntalked before, there's always the contract rolling , roll-through that we then update the pricing on, we \ndo have a little bit more at the beginning of the calendar year of some of those price adjustments. ", "original_text": "On the cost side, as we've talked really for quite a while now, it's been international \nfreight and that  while we have a little bit of noise with the Red Sea, it is largely as anticipated. ", "page_label": "13", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "8e2e64d9-3499-4495-ab28-5ac0bafd5491", "node_type": "4", "metadata": {"page_label": "13", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "1311cf71848883e159e85da50c3c3b08d1f320174a9464fade81363c5a4623dd", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "cf37ae39-a62c-4c40-83a3-f766c121e737", "node_type": "1", "metadata": {"window": "This is one where it's a significant part of that combined with Cardinal \nHealth Brand volume growth, which I'll get to in a moment.  But on inflation mitigation, there's  of \ncourse  two elements .  There\u2019s a  cost side and then there's a price side.  In both cases, we have very \ngood line of sight.   On the cost side, as we've talked really for quite a while now, it's been international \nfreight and that  while we have a little bit of noise with the Red Sea, it is largely as anticipated.  And \nthat cost is already on our balance sheet and is rolling through as expected, especially given our \nvolumes have been as expected .  So, we have a very high line of sight and confidence the cost is \ngoing to continue to step down in the second half  of the year. ", "original_text": "In both cases, we have very \ngood line of sight.  ", "page_label": "13", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "dd09010c1fff79879b91580a54a937e3601a9c014c7dbbefbcd764d593710637", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "3c6dd035-4aab-4931-a463-9ee77492eeba", "node_type": "1", "metadata": {"window": "There\u2019s a  cost side and then there's a price side.  In both cases, we have very \ngood line of sight.   On the cost side, as we've talked really for quite a while now, it's been international \nfreight and that  while we have a little bit of noise with the Red Sea, it is largely as anticipated.  And \nthat cost is already on our balance sheet and is rolling through as expected, especially given our \nvolumes have been as expected .  So, we have a very high line of sight and confidence the cost is \ngoing to continue to step down in the second half  of the year.  And then on the pricing side, as we \ntalked before, there's always the contract rolling , roll-through that we then update the pricing on, we \ndo have a little bit more at the beginning of the calendar year of some of those price adjustments.  So, \nJanuary being behind us, we have really good line of sight to the pricing side as well.  \n ", "original_text": "And \nthat cost is already on our balance sheet and is rolling through as expected, especially given our \nvolumes have been as expected . "}, "hash": "021323776aa376f9197515f2ac4d8f4be295d81745c173adf4560f1a15ac15a8", "class_name": "RelatedNodeInfo"}}, "text": "On the cost side, as we've talked really for quite a while now, it's been international \nfreight and that  while we have a little bit of noise with the Red Sea, it is largely as anticipated. ", "start_char_idx": 2876, "end_char_idx": 3067, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "3c6dd035-4aab-4931-a463-9ee77492eeba": {"__data__": {"id_": "3c6dd035-4aab-4931-a463-9ee77492eeba", "embedding": null, "metadata": {"window": "There\u2019s a  cost side and then there's a price side.  In both cases, we have very \ngood line of sight.   On the cost side, as we've talked really for quite a while now, it's been international \nfreight and that  while we have a little bit of noise with the Red Sea, it is largely as anticipated.  And \nthat cost is already on our balance sheet and is rolling through as expected, especially given our \nvolumes have been as expected .  So, we have a very high line of sight and confidence the cost is \ngoing to continue to step down in the second half  of the year.  And then on the pricing side, as we \ntalked before, there's always the contract rolling , roll-through that we then update the pricing on, we \ndo have a little bit more at the beginning of the calendar year of some of those price adjustments.  So, \nJanuary being behind us, we have really good line of sight to the pricing side as well.  \n ", "original_text": "And \nthat cost is already on our balance sheet and is rolling through as expected, especially given our \nvolumes have been as expected . ", "page_label": "13", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "8e2e64d9-3499-4495-ab28-5ac0bafd5491", "node_type": "4", "metadata": {"page_label": "13", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "1311cf71848883e159e85da50c3c3b08d1f320174a9464fade81363c5a4623dd", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "14ce4cfc-a92d-4e6b-b5fe-d7d7476ee6b8", "node_type": "1", "metadata": {"window": "But on inflation mitigation, there's  of \ncourse  two elements .  There\u2019s a  cost side and then there's a price side.  In both cases, we have very \ngood line of sight.   On the cost side, as we've talked really for quite a while now, it's been international \nfreight and that  while we have a little bit of noise with the Red Sea, it is largely as anticipated.  And \nthat cost is already on our balance sheet and is rolling through as expected, especially given our \nvolumes have been as expected .  So, we have a very high line of sight and confidence the cost is \ngoing to continue to step down in the second half  of the year.  And then on the pricing side, as we \ntalked before, there's always the contract rolling , roll-through that we then update the pricing on, we \ndo have a little bit more at the beginning of the calendar year of some of those price adjustments. ", "original_text": "On the cost side, as we've talked really for quite a while now, it's been international \nfreight and that  while we have a little bit of noise with the Red Sea, it is largely as anticipated. ", "page_label": "13", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "54e4ee4d1976757f79126e9a6915b66e56e4f9ab5d8979d3d84e1450914b169f", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "27327809-f4b1-40c5-86d7-920e0ee648c7", "node_type": "1", "metadata": {"window": "In both cases, we have very \ngood line of sight.   On the cost side, as we've talked really for quite a while now, it's been international \nfreight and that  while we have a little bit of noise with the Red Sea, it is largely as anticipated.  And \nthat cost is already on our balance sheet and is rolling through as expected, especially given our \nvolumes have been as expected .  So, we have a very high line of sight and confidence the cost is \ngoing to continue to step down in the second half  of the year.  And then on the pricing side, as we \ntalked before, there's always the contract rolling , roll-through that we then update the pricing on, we \ndo have a little bit more at the beginning of the calendar year of some of those price adjustments.  So, \nJanuary being behind us, we have really good line of sight to the pricing side as well.  \n ", "original_text": "So, we have a very high line of sight and confidence the cost is \ngoing to continue to step down in the second half  of the year. "}, "hash": "058d22a74b12943aa816b8a86add807e5faf149537fe7971f75b5175ffae2c5e", "class_name": "RelatedNodeInfo"}}, "text": "And \nthat cost is already on our balance sheet and is rolling through as expected, especially given our \nvolumes have been as expected . ", "start_char_idx": 3067, "end_char_idx": 3204, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "27327809-f4b1-40c5-86d7-920e0ee648c7": {"__data__": {"id_": "27327809-f4b1-40c5-86d7-920e0ee648c7", "embedding": null, "metadata": {"window": "In both cases, we have very \ngood line of sight.   On the cost side, as we've talked really for quite a while now, it's been international \nfreight and that  while we have a little bit of noise with the Red Sea, it is largely as anticipated.  And \nthat cost is already on our balance sheet and is rolling through as expected, especially given our \nvolumes have been as expected .  So, we have a very high line of sight and confidence the cost is \ngoing to continue to step down in the second half  of the year.  And then on the pricing side, as we \ntalked before, there's always the contract rolling , roll-through that we then update the pricing on, we \ndo have a little bit more at the beginning of the calendar year of some of those price adjustments.  So, \nJanuary being behind us, we have really good line of sight to the pricing side as well.  \n ", "original_text": "So, we have a very high line of sight and confidence the cost is \ngoing to continue to step down in the second half  of the year. ", "page_label": "13", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "8e2e64d9-3499-4495-ab28-5ac0bafd5491", "node_type": "4", "metadata": {"page_label": "13", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "1311cf71848883e159e85da50c3c3b08d1f320174a9464fade81363c5a4623dd", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "3c6dd035-4aab-4931-a463-9ee77492eeba", "node_type": "1", "metadata": {"window": "There\u2019s a  cost side and then there's a price side.  In both cases, we have very \ngood line of sight.   On the cost side, as we've talked really for quite a while now, it's been international \nfreight and that  while we have a little bit of noise with the Red Sea, it is largely as anticipated.  And \nthat cost is already on our balance sheet and is rolling through as expected, especially given our \nvolumes have been as expected .  So, we have a very high line of sight and confidence the cost is \ngoing to continue to step down in the second half  of the year.  And then on the pricing side, as we \ntalked before, there's always the contract rolling , roll-through that we then update the pricing on, we \ndo have a little bit more at the beginning of the calendar year of some of those price adjustments.  So, \nJanuary being behind us, we have really good line of sight to the pricing side as well.  \n ", "original_text": "And \nthat cost is already on our balance sheet and is rolling through as expected, especially given our \nvolumes have been as expected . ", "page_label": "13", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "c678f16beabaf886b14dd5e4e2514e6298d590db11548952b810c6c36ef06a45", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "038de542-1eff-43d2-8ec4-2461758da211", "node_type": "1", "metadata": {"window": "On the cost side, as we've talked really for quite a while now, it's been international \nfreight and that  while we have a little bit of noise with the Red Sea, it is largely as anticipated.  And \nthat cost is already on our balance sheet and is rolling through as expected, especially given our \nvolumes have been as expected .  So, we have a very high line of sight and confidence the cost is \ngoing to continue to step down in the second half  of the year.  And then on the pricing side, as we \ntalked before, there's always the contract rolling , roll-through that we then update the pricing on, we \ndo have a little bit more at the beginning of the calendar year of some of those price adjustments.  So, \nJanuary being behind us, we have really good line of sight to the pricing side as well.  \n ", "original_text": "And then on the pricing side, as we \ntalked before, there's always the contract rolling , roll-through that we then update the pricing on, we \ndo have a little bit more at the beginning of the calendar year of some of those price adjustments. "}, "hash": "d8fd6bcce6cf65f92a0823954d438f536d3cb2cddc7a7f418182d21593b3d5f4", "class_name": "RelatedNodeInfo"}}, "text": "So, we have a very high line of sight and confidence the cost is \ngoing to continue to step down in the second half  of the year. ", "start_char_idx": 3204, "end_char_idx": 3334, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "038de542-1eff-43d2-8ec4-2461758da211": {"__data__": {"id_": "038de542-1eff-43d2-8ec4-2461758da211", "embedding": null, "metadata": {"window": "On the cost side, as we've talked really for quite a while now, it's been international \nfreight and that  while we have a little bit of noise with the Red Sea, it is largely as anticipated.  And \nthat cost is already on our balance sheet and is rolling through as expected, especially given our \nvolumes have been as expected .  So, we have a very high line of sight and confidence the cost is \ngoing to continue to step down in the second half  of the year.  And then on the pricing side, as we \ntalked before, there's always the contract rolling , roll-through that we then update the pricing on, we \ndo have a little bit more at the beginning of the calendar year of some of those price adjustments.  So, \nJanuary being behind us, we have really good line of sight to the pricing side as well.  \n ", "original_text": "And then on the pricing side, as we \ntalked before, there's always the contract rolling , roll-through that we then update the pricing on, we \ndo have a little bit more at the beginning of the calendar year of some of those price adjustments. ", "page_label": "13", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "8e2e64d9-3499-4495-ab28-5ac0bafd5491", "node_type": "4", "metadata": {"page_label": "13", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "1311cf71848883e159e85da50c3c3b08d1f320174a9464fade81363c5a4623dd", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "27327809-f4b1-40c5-86d7-920e0ee648c7", "node_type": "1", "metadata": {"window": "In both cases, we have very \ngood line of sight.   On the cost side, as we've talked really for quite a while now, it's been international \nfreight and that  while we have a little bit of noise with the Red Sea, it is largely as anticipated.  And \nthat cost is already on our balance sheet and is rolling through as expected, especially given our \nvolumes have been as expected .  So, we have a very high line of sight and confidence the cost is \ngoing to continue to step down in the second half  of the year.  And then on the pricing side, as we \ntalked before, there's always the contract rolling , roll-through that we then update the pricing on, we \ndo have a little bit more at the beginning of the calendar year of some of those price adjustments.  So, \nJanuary being behind us, we have really good line of sight to the pricing side as well.  \n ", "original_text": "So, we have a very high line of sight and confidence the cost is \ngoing to continue to step down in the second half  of the year. ", "page_label": "13", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "d903110d2396b6300111fed14d5ac8bde0a75cae041e035b5eca8fb4aaebebf6", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "412bf8a1-ef8f-4cc4-93bf-916b6ae4067c", "node_type": "1", "metadata": {"window": "And \nthat cost is already on our balance sheet and is rolling through as expected, especially given our \nvolumes have been as expected .  So, we have a very high line of sight and confidence the cost is \ngoing to continue to step down in the second half  of the year.  And then on the pricing side, as we \ntalked before, there's always the contract rolling , roll-through that we then update the pricing on, we \ndo have a little bit more at the beginning of the calendar year of some of those price adjustments.  So, \nJanuary being behind us, we have really good line of sight to the pricing side as well.  \n ", "original_text": "So, \nJanuary being behind us, we have really good line of sight to the pricing side as well.  \n "}, "hash": "aabd54199b719463ac91655c02e24bf1ee400ff2526b28ea61568388951b2a87", "class_name": "RelatedNodeInfo"}}, "text": "And then on the pricing side, as we \ntalked before, there's always the contract rolling , roll-through that we then update the pricing on, we \ndo have a little bit more at the beginning of the calendar year of some of those price adjustments. ", "start_char_idx": 3334, "end_char_idx": 3577, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "412bf8a1-ef8f-4cc4-93bf-916b6ae4067c": {"__data__": {"id_": "412bf8a1-ef8f-4cc4-93bf-916b6ae4067c", "embedding": null, "metadata": {"window": "And \nthat cost is already on our balance sheet and is rolling through as expected, especially given our \nvolumes have been as expected .  So, we have a very high line of sight and confidence the cost is \ngoing to continue to step down in the second half  of the year.  And then on the pricing side, as we \ntalked before, there's always the contract rolling , roll-through that we then update the pricing on, we \ndo have a little bit more at the beginning of the calendar year of some of those price adjustments.  So, \nJanuary being behind us, we have really good line of sight to the pricing side as well.  \n ", "original_text": "So, \nJanuary being behind us, we have really good line of sight to the pricing side as well.  \n ", "page_label": "13", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "8e2e64d9-3499-4495-ab28-5ac0bafd5491", "node_type": "4", "metadata": {"page_label": "13", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "1311cf71848883e159e85da50c3c3b08d1f320174a9464fade81363c5a4623dd", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "038de542-1eff-43d2-8ec4-2461758da211", "node_type": "1", "metadata": {"window": "On the cost side, as we've talked really for quite a while now, it's been international \nfreight and that  while we have a little bit of noise with the Red Sea, it is largely as anticipated.  And \nthat cost is already on our balance sheet and is rolling through as expected, especially given our \nvolumes have been as expected .  So, we have a very high line of sight and confidence the cost is \ngoing to continue to step down in the second half  of the year.  And then on the pricing side, as we \ntalked before, there's always the contract rolling , roll-through that we then update the pricing on, we \ndo have a little bit more at the beginning of the calendar year of some of those price adjustments.  So, \nJanuary being behind us, we have really good line of sight to the pricing side as well.  \n ", "original_text": "And then on the pricing side, as we \ntalked before, there's always the contract rolling , roll-through that we then update the pricing on, we \ndo have a little bit more at the beginning of the calendar year of some of those price adjustments. ", "page_label": "13", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "61e58b6b1befb837e46b244014966ceddd7c16dfa0499c6c27af502ce742a542", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "3f05051c-7f51-4210-88c3-f32a3503a2a5", "node_type": "1", "metadata": {"window": " \nPage 14 of 19 \n \nSo, there's some time now for the next couple of quarters needed to get that to roll through our \nincome statement.  But the actions now are largely behind us as it relates to inflation mitigation.  We've \nalways had confidence we  would get to this stage, but we're now at this stage and have even more \nconfidence actually seeing it start to come through in the second half of the year.  \n \n Now the other component is the Cardinal Health Brand volume. ", "original_text": " \nPage 14 of 19 \n \nSo, there's some time now for the next couple of quarters needed to get that to roll through our \nincome statement. "}, "hash": "671b36a99bf353fc8aaaef0a87575397786d40d6494b0cb54da820a9ed2cbbaf", "class_name": "RelatedNodeInfo"}}, "text": "So, \nJanuary being behind us, we have really good line of sight to the pricing side as well.  \n ", "start_char_idx": 3577, "end_char_idx": 3673, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "3f05051c-7f51-4210-88c3-f32a3503a2a5": {"__data__": {"id_": "3f05051c-7f51-4210-88c3-f32a3503a2a5", "embedding": null, "metadata": {"window": " \nPage 14 of 19 \n \nSo, there's some time now for the next couple of quarters needed to get that to roll through our \nincome statement.  But the actions now are largely behind us as it relates to inflation mitigation.  We've \nalways had confidence we  would get to this stage, but we're now at this stage and have even more \nconfidence actually seeing it start to come through in the second half of the year.  \n \n Now the other component is the Cardinal Health Brand volume. ", "original_text": " \nPage 14 of 19 \n \nSo, there's some time now for the next couple of quarters needed to get that to roll through our \nincome statement. ", "page_label": "14", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "0ac9f346-07e9-4997-8f28-e5117e7bae25", "node_type": "4", "metadata": {"page_label": "14", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "9234b4689cac640be82a7dbb5c15932ea517de37b8dfde62816f9a47fb53e9a4", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "412bf8a1-ef8f-4cc4-93bf-916b6ae4067c", "node_type": "1", "metadata": {"window": "And \nthat cost is already on our balance sheet and is rolling through as expected, especially given our \nvolumes have been as expected .  So, we have a very high line of sight and confidence the cost is \ngoing to continue to step down in the second half  of the year.  And then on the pricing side, as we \ntalked before, there's always the contract rolling , roll-through that we then update the pricing on, we \ndo have a little bit more at the beginning of the calendar year of some of those price adjustments.  So, \nJanuary being behind us, we have really good line of sight to the pricing side as well.  \n ", "original_text": "So, \nJanuary being behind us, we have really good line of sight to the pricing side as well.  \n ", "page_label": "13", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "eca5a72540841bb6baa09c79c238f7dd8672b8a808bc547d768762ad0eba1190", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "d22e444a-6136-41a3-b630-a911c2a1fc4c", "node_type": "1", "metadata": {"window": " \nPage 14 of 19 \n \nSo, there's some time now for the next couple of quarters needed to get that to roll through our \nincome statement.  But the actions now are largely behind us as it relates to inflation mitigation.  We've \nalways had confidence we  would get to this stage, but we're now at this stage and have even more \nconfidence actually seeing it start to come through in the second half of the year.  \n \n Now the other component is the Cardinal Health Brand volume.  Part of that's going to be market -\ndriven and the market volume, that utilization continues to be quite good. ", "original_text": "But the actions now are largely behind us as it relates to inflation mitigation. "}, "hash": "8eb9b4b66b64be38e17d71f11e2a284e73f486ddc862712f3f97db4bdc95afa8", "class_name": "RelatedNodeInfo"}}, "text": " \nPage 14 of 19 \n \nSo, there's some time now for the next couple of quarters needed to get that to roll through our \nincome statement. ", "start_char_idx": 0, "end_char_idx": 135, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "d22e444a-6136-41a3-b630-a911c2a1fc4c": {"__data__": {"id_": "d22e444a-6136-41a3-b630-a911c2a1fc4c", "embedding": null, "metadata": {"window": " \nPage 14 of 19 \n \nSo, there's some time now for the next couple of quarters needed to get that to roll through our \nincome statement.  But the actions now are largely behind us as it relates to inflation mitigation.  We've \nalways had confidence we  would get to this stage, but we're now at this stage and have even more \nconfidence actually seeing it start to come through in the second half of the year.  \n \n Now the other component is the Cardinal Health Brand volume.  Part of that's going to be market -\ndriven and the market volume, that utilization continues to be quite good. ", "original_text": "But the actions now are largely behind us as it relates to inflation mitigation. ", "page_label": "14", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "0ac9f346-07e9-4997-8f28-e5117e7bae25", "node_type": "4", "metadata": {"page_label": "14", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "9234b4689cac640be82a7dbb5c15932ea517de37b8dfde62816f9a47fb53e9a4", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "3f05051c-7f51-4210-88c3-f32a3503a2a5", "node_type": "1", "metadata": {"window": " \nPage 14 of 19 \n \nSo, there's some time now for the next couple of quarters needed to get that to roll through our \nincome statement.  But the actions now are largely behind us as it relates to inflation mitigation.  We've \nalways had confidence we  would get to this stage, but we're now at this stage and have even more \nconfidence actually seeing it start to come through in the second half of the year.  \n \n Now the other component is the Cardinal Health Brand volume. ", "original_text": " \nPage 14 of 19 \n \nSo, there's some time now for the next couple of quarters needed to get that to roll through our \nincome statement. ", "page_label": "14", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "5455632c526a7407f744a9d9660bda883f69b16a25587784c3db2a53b903f384", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "3357e4dc-dd4c-4885-84c7-ff75515c7dca", "node_type": "1", "metadata": {"window": " \nPage 14 of 19 \n \nSo, there's some time now for the next couple of quarters needed to get that to roll through our \nincome statement.  But the actions now are largely behind us as it relates to inflation mitigation.  We've \nalways had confidence we  would get to this stage, but we're now at this stage and have even more \nconfidence actually seeing it start to come through in the second half of the year.  \n \n Now the other component is the Cardinal Health Brand volume.  Part of that's going to be market -\ndriven and the market volume, that utilization continues to be quite good.  And what was exciting \nabout the second quarter is seeing that further inflection and actually participating in that market \ngrowth , really for the first time at the extent of what the market is growing. ", "original_text": "We've \nalways had confidence we  would get to this stage, but we're now at this stage and have even more \nconfidence actually seeing it start to come through in the second half of the year.  \n \n"}, "hash": "d875b3a6de7c7e06be45b9c1592bfcc4bfc05505506bac55eb980c8b1e5ff5c1", "class_name": "RelatedNodeInfo"}}, "text": "But the actions now are largely behind us as it relates to inflation mitigation. ", "start_char_idx": 135, "end_char_idx": 216, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "3357e4dc-dd4c-4885-84c7-ff75515c7dca": {"__data__": {"id_": "3357e4dc-dd4c-4885-84c7-ff75515c7dca", "embedding": null, "metadata": {"window": " \nPage 14 of 19 \n \nSo, there's some time now for the next couple of quarters needed to get that to roll through our \nincome statement.  But the actions now are largely behind us as it relates to inflation mitigation.  We've \nalways had confidence we  would get to this stage, but we're now at this stage and have even more \nconfidence actually seeing it start to come through in the second half of the year.  \n \n Now the other component is the Cardinal Health Brand volume.  Part of that's going to be market -\ndriven and the market volume, that utilization continues to be quite good.  And what was exciting \nabout the second quarter is seeing that further inflection and actually participating in that market \ngrowth , really for the first time at the extent of what the market is growing. ", "original_text": "We've \nalways had confidence we  would get to this stage, but we're now at this stage and have even more \nconfidence actually seeing it start to come through in the second half of the year.  \n \n", "page_label": "14", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "0ac9f346-07e9-4997-8f28-e5117e7bae25", "node_type": "4", "metadata": {"page_label": "14", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "9234b4689cac640be82a7dbb5c15932ea517de37b8dfde62816f9a47fb53e9a4", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "d22e444a-6136-41a3-b630-a911c2a1fc4c", "node_type": "1", "metadata": {"window": " \nPage 14 of 19 \n \nSo, there's some time now for the next couple of quarters needed to get that to roll through our \nincome statement.  But the actions now are largely behind us as it relates to inflation mitigation.  We've \nalways had confidence we  would get to this stage, but we're now at this stage and have even more \nconfidence actually seeing it start to come through in the second half of the year.  \n \n Now the other component is the Cardinal Health Brand volume.  Part of that's going to be market -\ndriven and the market volume, that utilization continues to be quite good. ", "original_text": "But the actions now are largely behind us as it relates to inflation mitigation. ", "page_label": "14", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "c2c3dd7e764ba7af591d7ad11d07aeffbeb6e189b5cd4ba096743cca286e0029", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "901b2bf8-7d30-47f6-8a79-03e7dd9735fa", "node_type": "1", "metadata": {"window": " \nPage 14 of 19 \n \nSo, there's some time now for the next couple of quarters needed to get that to roll through our \nincome statement.  But the actions now are largely behind us as it relates to inflation mitigation.  We've \nalways had confidence we  would get to this stage, but we're now at this stage and have even more \nconfidence actually seeing it start to come through in the second half of the year.  \n \n Now the other component is the Cardinal Health Brand volume.  Part of that's going to be market -\ndriven and the market volume, that utilization continues to be quite good.  And what was exciting \nabout the second quarter is seeing that further inflection and actually participating in that market \ngrowth , really for the first time at the extent of what the market is growing.  So that gives us much \ngreater confidence that we'll continue to see that growth and that s tep up as we get over the course of \nthe year. ", "original_text": "Now the other component is the Cardinal Health Brand volume. "}, "hash": "3193129ebf1fabac43a21f1b66e2cc72520e94c5dd4f651bbb998cc407c24fcc", "class_name": "RelatedNodeInfo"}}, "text": "We've \nalways had confidence we  would get to this stage, but we're now at this stage and have even more \nconfidence actually seeing it start to come through in the second half of the year.  \n \n", "start_char_idx": 216, "end_char_idx": 410, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "901b2bf8-7d30-47f6-8a79-03e7dd9735fa": {"__data__": {"id_": "901b2bf8-7d30-47f6-8a79-03e7dd9735fa", "embedding": null, "metadata": {"window": " \nPage 14 of 19 \n \nSo, there's some time now for the next couple of quarters needed to get that to roll through our \nincome statement.  But the actions now are largely behind us as it relates to inflation mitigation.  We've \nalways had confidence we  would get to this stage, but we're now at this stage and have even more \nconfidence actually seeing it start to come through in the second half of the year.  \n \n Now the other component is the Cardinal Health Brand volume.  Part of that's going to be market -\ndriven and the market volume, that utilization continues to be quite good.  And what was exciting \nabout the second quarter is seeing that further inflection and actually participating in that market \ngrowth , really for the first time at the extent of what the market is growing.  So that gives us much \ngreater confidence that we'll continue to see that growth and that s tep up as we get over the course of \nthe year. ", "original_text": "Now the other component is the Cardinal Health Brand volume. ", "page_label": "14", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "0ac9f346-07e9-4997-8f28-e5117e7bae25", "node_type": "4", "metadata": {"page_label": "14", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "9234b4689cac640be82a7dbb5c15932ea517de37b8dfde62816f9a47fb53e9a4", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "3357e4dc-dd4c-4885-84c7-ff75515c7dca", "node_type": "1", "metadata": {"window": " \nPage 14 of 19 \n \nSo, there's some time now for the next couple of quarters needed to get that to roll through our \nincome statement.  But the actions now are largely behind us as it relates to inflation mitigation.  We've \nalways had confidence we  would get to this stage, but we're now at this stage and have even more \nconfidence actually seeing it start to come through in the second half of the year.  \n \n Now the other component is the Cardinal Health Brand volume.  Part of that's going to be market -\ndriven and the market volume, that utilization continues to be quite good.  And what was exciting \nabout the second quarter is seeing that further inflection and actually participating in that market \ngrowth , really for the first time at the extent of what the market is growing. ", "original_text": "We've \nalways had confidence we  would get to this stage, but we're now at this stage and have even more \nconfidence actually seeing it start to come through in the second half of the year.  \n \n", "page_label": "14", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "508ad1ec945f93091963f22422466e773ba6da637221f41a02362c415e37bab6", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "6b08b11b-4232-46c8-9ef1-9400160a82c9", "node_type": "1", "metadata": {"window": "But the actions now are largely behind us as it relates to inflation mitigation.  We've \nalways had confidence we  would get to this stage, but we're now at this stage and have even more \nconfidence actually seeing it start to come through in the second half of the year.  \n \n Now the other component is the Cardinal Health Brand volume.  Part of that's going to be market -\ndriven and the market volume, that utilization continues to be quite good.  And what was exciting \nabout the second quarter is seeing that further inflection and actually participating in that market \ngrowth , really for the first time at the extent of what the market is growing.  So that gives us much \ngreater confidence that we'll continue to see that growth and that s tep up as we get over the course of \nthe year.  But there are some variables like the market itself  that will always be an impact here, good \nor bad , that we will continue to monitor and track. ", "original_text": "Part of that's going to be market -\ndriven and the market volume, that utilization continues to be quite good. "}, "hash": "22193a57b5578d049d60a0b98234017b4b8d83f57c3aba8f745e495de71a6d1c", "class_name": "RelatedNodeInfo"}}, "text": "Now the other component is the Cardinal Health Brand volume. ", "start_char_idx": 410, "end_char_idx": 471, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "6b08b11b-4232-46c8-9ef1-9400160a82c9": {"__data__": {"id_": "6b08b11b-4232-46c8-9ef1-9400160a82c9", "embedding": null, "metadata": {"window": "But the actions now are largely behind us as it relates to inflation mitigation.  We've \nalways had confidence we  would get to this stage, but we're now at this stage and have even more \nconfidence actually seeing it start to come through in the second half of the year.  \n \n Now the other component is the Cardinal Health Brand volume.  Part of that's going to be market -\ndriven and the market volume, that utilization continues to be quite good.  And what was exciting \nabout the second quarter is seeing that further inflection and actually participating in that market \ngrowth , really for the first time at the extent of what the market is growing.  So that gives us much \ngreater confidence that we'll continue to see that growth and that s tep up as we get over the course of \nthe year.  But there are some variables like the market itself  that will always be an impact here, good \nor bad , that we will continue to monitor and track. ", "original_text": "Part of that's going to be market -\ndriven and the market volume, that utilization continues to be quite good. ", "page_label": "14", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "0ac9f346-07e9-4997-8f28-e5117e7bae25", "node_type": "4", "metadata": {"page_label": "14", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "9234b4689cac640be82a7dbb5c15932ea517de37b8dfde62816f9a47fb53e9a4", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "901b2bf8-7d30-47f6-8a79-03e7dd9735fa", "node_type": "1", "metadata": {"window": " \nPage 14 of 19 \n \nSo, there's some time now for the next couple of quarters needed to get that to roll through our \nincome statement.  But the actions now are largely behind us as it relates to inflation mitigation.  We've \nalways had confidence we  would get to this stage, but we're now at this stage and have even more \nconfidence actually seeing it start to come through in the second half of the year.  \n \n Now the other component is the Cardinal Health Brand volume.  Part of that's going to be market -\ndriven and the market volume, that utilization continues to be quite good.  And what was exciting \nabout the second quarter is seeing that further inflection and actually participating in that market \ngrowth , really for the first time at the extent of what the market is growing.  So that gives us much \ngreater confidence that we'll continue to see that growth and that s tep up as we get over the course of \nthe year. ", "original_text": "Now the other component is the Cardinal Health Brand volume. ", "page_label": "14", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "4e5657dca274085190d5ed911ec2e37e25931f0aeaa7c01b2d368d2407f28d52", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "1a4a65d0-1991-4f09-90b4-08a4766d081c", "node_type": "1", "metadata": {"window": "We've \nalways had confidence we  would get to this stage, but we're now at this stage and have even more \nconfidence actually seeing it start to come through in the second half of the year.  \n \n Now the other component is the Cardinal Health Brand volume.  Part of that's going to be market -\ndriven and the market volume, that utilization continues to be quite good.  And what was exciting \nabout the second quarter is seeing that further inflection and actually participating in that market \ngrowth , really for the first time at the extent of what the market is growing.  So that gives us much \ngreater confidence that we'll continue to see that growth and that s tep up as we get over the course of \nthe year.  But there are some variables like the market itself  that will always be an impact here, good \nor bad , that we will continue to monitor and track.  So those are the key points I'd give us from the first \nhalf to the second half.  \n \n", "original_text": "And what was exciting \nabout the second quarter is seeing that further inflection and actually participating in that market \ngrowth , really for the first time at the extent of what the market is growing. "}, "hash": "2895c4c4c9daa48194846eadb0f0735b427cf5d949dc115a0416f7288992ea86", "class_name": "RelatedNodeInfo"}}, "text": "Part of that's going to be market -\ndriven and the market volume, that utilization continues to be quite good. ", "start_char_idx": 471, "end_char_idx": 582, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "1a4a65d0-1991-4f09-90b4-08a4766d081c": {"__data__": {"id_": "1a4a65d0-1991-4f09-90b4-08a4766d081c", "embedding": null, "metadata": {"window": "We've \nalways had confidence we  would get to this stage, but we're now at this stage and have even more \nconfidence actually seeing it start to come through in the second half of the year.  \n \n Now the other component is the Cardinal Health Brand volume.  Part of that's going to be market -\ndriven and the market volume, that utilization continues to be quite good.  And what was exciting \nabout the second quarter is seeing that further inflection and actually participating in that market \ngrowth , really for the first time at the extent of what the market is growing.  So that gives us much \ngreater confidence that we'll continue to see that growth and that s tep up as we get over the course of \nthe year.  But there are some variables like the market itself  that will always be an impact here, good \nor bad , that we will continue to monitor and track.  So those are the key points I'd give us from the first \nhalf to the second half.  \n \n", "original_text": "And what was exciting \nabout the second quarter is seeing that further inflection and actually participating in that market \ngrowth , really for the first time at the extent of what the market is growing. ", "page_label": "14", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "0ac9f346-07e9-4997-8f28-e5117e7bae25", "node_type": "4", "metadata": {"page_label": "14", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "9234b4689cac640be82a7dbb5c15932ea517de37b8dfde62816f9a47fb53e9a4", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "6b08b11b-4232-46c8-9ef1-9400160a82c9", "node_type": "1", "metadata": {"window": "But the actions now are largely behind us as it relates to inflation mitigation.  We've \nalways had confidence we  would get to this stage, but we're now at this stage and have even more \nconfidence actually seeing it start to come through in the second half of the year.  \n \n Now the other component is the Cardinal Health Brand volume.  Part of that's going to be market -\ndriven and the market volume, that utilization continues to be quite good.  And what was exciting \nabout the second quarter is seeing that further inflection and actually participating in that market \ngrowth , really for the first time at the extent of what the market is growing.  So that gives us much \ngreater confidence that we'll continue to see that growth and that s tep up as we get over the course of \nthe year.  But there are some variables like the market itself  that will always be an impact here, good \nor bad , that we will continue to monitor and track. ", "original_text": "Part of that's going to be market -\ndriven and the market volume, that utilization continues to be quite good. ", "page_label": "14", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "e0b262c6f2cf79c349d7417608acace5a3ba2c17f377409ab4047651b5eb5143", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "84f58ebe-9235-42a4-b2b6-24db9039b329", "node_type": "1", "metadata": {"window": "Now the other component is the Cardinal Health Brand volume.  Part of that's going to be market -\ndriven and the market volume, that utilization continues to be quite good.  And what was exciting \nabout the second quarter is seeing that further inflection and actually participating in that market \ngrowth , really for the first time at the extent of what the market is growing.  So that gives us much \ngreater confidence that we'll continue to see that growth and that s tep up as we get over the course of \nthe year.  But there are some variables like the market itself  that will always be an impact here, good \nor bad , that we will continue to monitor and track.  So those are the key points I'd give us from the first \nhalf to the second half.  \n \n Aaron Alt:   Eric, it's probably worth offering one  additional point in perspective. ", "original_text": "So that gives us much \ngreater confidence that we'll continue to see that growth and that s tep up as we get over the course of \nthe year. "}, "hash": "80de5ae073d272468d0cfe1fb57977407d9c981952043226146544e0a0cb8080", "class_name": "RelatedNodeInfo"}}, "text": "And what was exciting \nabout the second quarter is seeing that further inflection and actually participating in that market \ngrowth , really for the first time at the extent of what the market is growing. ", "start_char_idx": 582, "end_char_idx": 787, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "84f58ebe-9235-42a4-b2b6-24db9039b329": {"__data__": {"id_": "84f58ebe-9235-42a4-b2b6-24db9039b329", "embedding": null, "metadata": {"window": "Now the other component is the Cardinal Health Brand volume.  Part of that's going to be market -\ndriven and the market volume, that utilization continues to be quite good.  And what was exciting \nabout the second quarter is seeing that further inflection and actually participating in that market \ngrowth , really for the first time at the extent of what the market is growing.  So that gives us much \ngreater confidence that we'll continue to see that growth and that s tep up as we get over the course of \nthe year.  But there are some variables like the market itself  that will always be an impact here, good \nor bad , that we will continue to monitor and track.  So those are the key points I'd give us from the first \nhalf to the second half.  \n \n Aaron Alt:   Eric, it's probably worth offering one  additional point in perspective. ", "original_text": "So that gives us much \ngreater confidence that we'll continue to see that growth and that s tep up as we get over the course of \nthe year. ", "page_label": "14", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "0ac9f346-07e9-4997-8f28-e5117e7bae25", "node_type": "4", "metadata": {"page_label": "14", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "9234b4689cac640be82a7dbb5c15932ea517de37b8dfde62816f9a47fb53e9a4", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "1a4a65d0-1991-4f09-90b4-08a4766d081c", "node_type": "1", "metadata": {"window": "We've \nalways had confidence we  would get to this stage, but we're now at this stage and have even more \nconfidence actually seeing it start to come through in the second half of the year.  \n \n Now the other component is the Cardinal Health Brand volume.  Part of that's going to be market -\ndriven and the market volume, that utilization continues to be quite good.  And what was exciting \nabout the second quarter is seeing that further inflection and actually participating in that market \ngrowth , really for the first time at the extent of what the market is growing.  So that gives us much \ngreater confidence that we'll continue to see that growth and that s tep up as we get over the course of \nthe year.  But there are some variables like the market itself  that will always be an impact here, good \nor bad , that we will continue to monitor and track.  So those are the key points I'd give us from the first \nhalf to the second half.  \n \n", "original_text": "And what was exciting \nabout the second quarter is seeing that further inflection and actually participating in that market \ngrowth , really for the first time at the extent of what the market is growing. ", "page_label": "14", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "ab90aa513be36b147358c86363ef74d4f2ca2a85315cde8606069b56540fdcca", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "c49b04ba-7739-41b3-89a5-7fa712a09eca", "node_type": "1", "metadata": {"window": "Part of that's going to be market -\ndriven and the market volume, that utilization continues to be quite good.  And what was exciting \nabout the second quarter is seeing that further inflection and actually participating in that market \ngrowth , really for the first time at the extent of what the market is growing.  So that gives us much \ngreater confidence that we'll continue to see that growth and that s tep up as we get over the course of \nthe year.  But there are some variables like the market itself  that will always be an impact here, good \nor bad , that we will continue to monitor and track.  So those are the key points I'd give us from the first \nhalf to the second half.  \n \n Aaron Alt:   Eric, it's probably worth offering one  additional point in perspective.  We're not reporting on \nthe new segment structure this quarter. ", "original_text": "But there are some variables like the market itself  that will always be an impact here, good \nor bad , that we will continue to monitor and track. "}, "hash": "67f63b5c36817d34d8de12ff550e1ff79f92d2ca48ed2bb48dd810a708061796", "class_name": "RelatedNodeInfo"}}, "text": "So that gives us much \ngreater confidence that we'll continue to see that growth and that s tep up as we get over the course of \nthe year. ", "start_char_idx": 787, "end_char_idx": 926, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "c49b04ba-7739-41b3-89a5-7fa712a09eca": {"__data__": {"id_": "c49b04ba-7739-41b3-89a5-7fa712a09eca", "embedding": null, "metadata": {"window": "Part of that's going to be market -\ndriven and the market volume, that utilization continues to be quite good.  And what was exciting \nabout the second quarter is seeing that further inflection and actually participating in that market \ngrowth , really for the first time at the extent of what the market is growing.  So that gives us much \ngreater confidence that we'll continue to see that growth and that s tep up as we get over the course of \nthe year.  But there are some variables like the market itself  that will always be an impact here, good \nor bad , that we will continue to monitor and track.  So those are the key points I'd give us from the first \nhalf to the second half.  \n \n Aaron Alt:   Eric, it's probably worth offering one  additional point in perspective.  We're not reporting on \nthe new segment structure this quarter. ", "original_text": "But there are some variables like the market itself  that will always be an impact here, good \nor bad , that we will continue to monitor and track. ", "page_label": "14", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "0ac9f346-07e9-4997-8f28-e5117e7bae25", "node_type": "4", "metadata": {"page_label": "14", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "9234b4689cac640be82a7dbb5c15932ea517de37b8dfde62816f9a47fb53e9a4", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "84f58ebe-9235-42a4-b2b6-24db9039b329", "node_type": "1", "metadata": {"window": "Now the other component is the Cardinal Health Brand volume.  Part of that's going to be market -\ndriven and the market volume, that utilization continues to be quite good.  And what was exciting \nabout the second quarter is seeing that further inflection and actually participating in that market \ngrowth , really for the first time at the extent of what the market is growing.  So that gives us much \ngreater confidence that we'll continue to see that growth and that s tep up as we get over the course of \nthe year.  But there are some variables like the market itself  that will always be an impact here, good \nor bad , that we will continue to monitor and track.  So those are the key points I'd give us from the first \nhalf to the second half.  \n \n Aaron Alt:   Eric, it's probably worth offering one  additional point in perspective. ", "original_text": "So that gives us much \ngreater confidence that we'll continue to see that growth and that s tep up as we get over the course of \nthe year. ", "page_label": "14", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "756688a1ea285ac6f6f346d203610ea347b8dfbd6dda2768df89e3b381722ab0", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "c82179e8-f816-44dc-9211-ee618cff90d6", "node_type": "1", "metadata": {"window": "And what was exciting \nabout the second quarter is seeing that further inflection and actually participating in that market \ngrowth , really for the first time at the extent of what the market is growing.  So that gives us much \ngreater confidence that we'll continue to see that growth and that s tep up as we get over the course of \nthe year.  But there are some variables like the market itself  that will always be an impact here, good \nor bad , that we will continue to monitor and track.  So those are the key points I'd give us from the first \nhalf to the second half.  \n \n Aaron Alt:   Eric, it's probably worth offering one  additional point in perspective.  We're not reporting on \nthe new segment structure this quarter.  That will follow in Q3, but we can offer the observation that \nthe GMPD core part of the Medical business has operated at near breakeven levels in the first half  of \nfiscal \u201824. ", "original_text": "So those are the key points I'd give us from the first \nhalf to the second half.  \n \n"}, "hash": "6bf44acf9f0e7d44b65895d3b7eaf5b0c5de31fca998dc8bf4288e6b1faccdde", "class_name": "RelatedNodeInfo"}}, "text": "But there are some variables like the market itself  that will always be an impact here, good \nor bad , that we will continue to monitor and track. ", "start_char_idx": 926, "end_char_idx": 1074, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "c82179e8-f816-44dc-9211-ee618cff90d6": {"__data__": {"id_": "c82179e8-f816-44dc-9211-ee618cff90d6", "embedding": null, "metadata": {"window": "And what was exciting \nabout the second quarter is seeing that further inflection and actually participating in that market \ngrowth , really for the first time at the extent of what the market is growing.  So that gives us much \ngreater confidence that we'll continue to see that growth and that s tep up as we get over the course of \nthe year.  But there are some variables like the market itself  that will always be an impact here, good \nor bad , that we will continue to monitor and track.  So those are the key points I'd give us from the first \nhalf to the second half.  \n \n Aaron Alt:   Eric, it's probably worth offering one  additional point in perspective.  We're not reporting on \nthe new segment structure this quarter.  That will follow in Q3, but we can offer the observation that \nthe GMPD core part of the Medical business has operated at near breakeven levels in the first half  of \nfiscal \u201824. ", "original_text": "So those are the key points I'd give us from the first \nhalf to the second half.  \n \n", "page_label": "14", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "0ac9f346-07e9-4997-8f28-e5117e7bae25", "node_type": "4", "metadata": {"page_label": "14", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "9234b4689cac640be82a7dbb5c15932ea517de37b8dfde62816f9a47fb53e9a4", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "c49b04ba-7739-41b3-89a5-7fa712a09eca", "node_type": "1", "metadata": {"window": "Part of that's going to be market -\ndriven and the market volume, that utilization continues to be quite good.  And what was exciting \nabout the second quarter is seeing that further inflection and actually participating in that market \ngrowth , really for the first time at the extent of what the market is growing.  So that gives us much \ngreater confidence that we'll continue to see that growth and that s tep up as we get over the course of \nthe year.  But there are some variables like the market itself  that will always be an impact here, good \nor bad , that we will continue to monitor and track.  So those are the key points I'd give us from the first \nhalf to the second half.  \n \n Aaron Alt:   Eric, it's probably worth offering one  additional point in perspective.  We're not reporting on \nthe new segment structure this quarter. ", "original_text": "But there are some variables like the market itself  that will always be an impact here, good \nor bad , that we will continue to monitor and track. ", "page_label": "14", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "64607b5577f4bb2e933692081bdadc93f85d098ec655864b67033840d09b2c12", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "49c95ca7-ebc6-4fc4-bbca-1dd2935f0a29", "node_type": "1", "metadata": {"window": "So that gives us much \ngreater confidence that we'll continue to see that growth and that s tep up as we get over the course of \nthe year.  But there are some variables like the market itself  that will always be an impact here, good \nor bad , that we will continue to monitor and track.  So those are the key points I'd give us from the first \nhalf to the second half.  \n \n Aaron Alt:   Eric, it's probably worth offering one  additional point in perspective.  We're not reporting on \nthe new segment structure this quarter.  That will follow in Q3, but we can offer the observation that \nthe GMPD core part of the Medical business has operated at near breakeven levels in the first half  of \nfiscal \u201824.  And I offer you that in contrast with where they were from a fiscal \u201823 perspective, and \nwhere we're going from an overall guidance perspective, we view that as a key sign of positive \nprogress.  \n \n", "original_text": "Aaron Alt:   Eric, it's probably worth offering one  additional point in perspective. "}, "hash": "43f9e5741ec9f2fed28685203a415259d36cccf1925a2ac47562e7ba2198b8af", "class_name": "RelatedNodeInfo"}}, "text": "So those are the key points I'd give us from the first \nhalf to the second half.  \n \n", "start_char_idx": 1074, "end_char_idx": 1159, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "49c95ca7-ebc6-4fc4-bbca-1dd2935f0a29": {"__data__": {"id_": "49c95ca7-ebc6-4fc4-bbca-1dd2935f0a29", "embedding": null, "metadata": {"window": "So that gives us much \ngreater confidence that we'll continue to see that growth and that s tep up as we get over the course of \nthe year.  But there are some variables like the market itself  that will always be an impact here, good \nor bad , that we will continue to monitor and track.  So those are the key points I'd give us from the first \nhalf to the second half.  \n \n Aaron Alt:   Eric, it's probably worth offering one  additional point in perspective.  We're not reporting on \nthe new segment structure this quarter.  That will follow in Q3, but we can offer the observation that \nthe GMPD core part of the Medical business has operated at near breakeven levels in the first half  of \nfiscal \u201824.  And I offer you that in contrast with where they were from a fiscal \u201823 perspective, and \nwhere we're going from an overall guidance perspective, we view that as a key sign of positive \nprogress.  \n \n", "original_text": "Aaron Alt:   Eric, it's probably worth offering one  additional point in perspective. ", "page_label": "14", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "0ac9f346-07e9-4997-8f28-e5117e7bae25", "node_type": "4", "metadata": {"page_label": "14", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "9234b4689cac640be82a7dbb5c15932ea517de37b8dfde62816f9a47fb53e9a4", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "c82179e8-f816-44dc-9211-ee618cff90d6", "node_type": "1", "metadata": {"window": "And what was exciting \nabout the second quarter is seeing that further inflection and actually participating in that market \ngrowth , really for the first time at the extent of what the market is growing.  So that gives us much \ngreater confidence that we'll continue to see that growth and that s tep up as we get over the course of \nthe year.  But there are some variables like the market itself  that will always be an impact here, good \nor bad , that we will continue to monitor and track.  So those are the key points I'd give us from the first \nhalf to the second half.  \n \n Aaron Alt:   Eric, it's probably worth offering one  additional point in perspective.  We're not reporting on \nthe new segment structure this quarter.  That will follow in Q3, but we can offer the observation that \nthe GMPD core part of the Medical business has operated at near breakeven levels in the first half  of \nfiscal \u201824. ", "original_text": "So those are the key points I'd give us from the first \nhalf to the second half.  \n \n", "page_label": "14", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "1bc461e88ec158bef71b49642c43d778d4df8b77d73f31042f35c210b7510c34", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "7e1da58b-931a-4e7e-b6aa-745b9c0fc67b", "node_type": "1", "metadata": {"window": "But there are some variables like the market itself  that will always be an impact here, good \nor bad , that we will continue to monitor and track.  So those are the key points I'd give us from the first \nhalf to the second half.  \n \n Aaron Alt:   Eric, it's probably worth offering one  additional point in perspective.  We're not reporting on \nthe new segment structure this quarter.  That will follow in Q3, but we can offer the observation that \nthe GMPD core part of the Medical business has operated at near breakeven levels in the first half  of \nfiscal \u201824.  And I offer you that in contrast with where they were from a fiscal \u201823 perspective, and \nwhere we're going from an overall guidance perspective, we view that as a key sign of positive \nprogress.  \n \n Operator:  Thank you very much, gentlemen. ", "original_text": "We're not reporting on \nthe new segment structure this quarter. "}, "hash": "86061165189349fefee01a6c8ee90d3d99701df4fff724edc19a51e4d16caca5", "class_name": "RelatedNodeInfo"}}, "text": "Aaron Alt:   Eric, it's probably worth offering one  additional point in perspective. ", "start_char_idx": 1159, "end_char_idx": 1245, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "7e1da58b-931a-4e7e-b6aa-745b9c0fc67b": {"__data__": {"id_": "7e1da58b-931a-4e7e-b6aa-745b9c0fc67b", "embedding": null, "metadata": {"window": "But there are some variables like the market itself  that will always be an impact here, good \nor bad , that we will continue to monitor and track.  So those are the key points I'd give us from the first \nhalf to the second half.  \n \n Aaron Alt:   Eric, it's probably worth offering one  additional point in perspective.  We're not reporting on \nthe new segment structure this quarter.  That will follow in Q3, but we can offer the observation that \nthe GMPD core part of the Medical business has operated at near breakeven levels in the first half  of \nfiscal \u201824.  And I offer you that in contrast with where they were from a fiscal \u201823 perspective, and \nwhere we're going from an overall guidance perspective, we view that as a key sign of positive \nprogress.  \n \n Operator:  Thank you very much, gentlemen. ", "original_text": "We're not reporting on \nthe new segment structure this quarter. ", "page_label": "14", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "0ac9f346-07e9-4997-8f28-e5117e7bae25", "node_type": "4", "metadata": {"page_label": "14", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "9234b4689cac640be82a7dbb5c15932ea517de37b8dfde62816f9a47fb53e9a4", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "49c95ca7-ebc6-4fc4-bbca-1dd2935f0a29", "node_type": "1", "metadata": {"window": "So that gives us much \ngreater confidence that we'll continue to see that growth and that s tep up as we get over the course of \nthe year.  But there are some variables like the market itself  that will always be an impact here, good \nor bad , that we will continue to monitor and track.  So those are the key points I'd give us from the first \nhalf to the second half.  \n \n Aaron Alt:   Eric, it's probably worth offering one  additional point in perspective.  We're not reporting on \nthe new segment structure this quarter.  That will follow in Q3, but we can offer the observation that \nthe GMPD core part of the Medical business has operated at near breakeven levels in the first half  of \nfiscal \u201824.  And I offer you that in contrast with where they were from a fiscal \u201823 perspective, and \nwhere we're going from an overall guidance perspective, we view that as a key sign of positive \nprogress.  \n \n", "original_text": "Aaron Alt:   Eric, it's probably worth offering one  additional point in perspective. ", "page_label": "14", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "e36db78bcefc350886609484e220505d05bec59b248450836a6091ae7c5dfd81", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "6fe2fae4-a1b6-4454-b152-52cafdee41b0", "node_type": "1", "metadata": {"window": "So those are the key points I'd give us from the first \nhalf to the second half.  \n \n Aaron Alt:   Eric, it's probably worth offering one  additional point in perspective.  We're not reporting on \nthe new segment structure this quarter.  That will follow in Q3, but we can offer the observation that \nthe GMPD core part of the Medical business has operated at near breakeven levels in the first half  of \nfiscal \u201824.  And I offer you that in contrast with where they were from a fiscal \u201823 perspective, and \nwhere we're going from an overall guidance perspective, we view that as a key sign of positive \nprogress.  \n \n Operator:  Thank you very much, gentlemen.  Sorry to interrupt you earlier . ", "original_text": "That will follow in Q3, but we can offer the observation that \nthe GMPD core part of the Medical business has operated at near breakeven levels in the first half  of \nfiscal \u201824. "}, "hash": "30d9ec7ccf6f7de8825a8f4c0ec9585ae2b25057b14413e775d890741e13320a", "class_name": "RelatedNodeInfo"}}, "text": "We're not reporting on \nthe new segment structure this quarter. ", "start_char_idx": 1245, "end_char_idx": 1309, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "6fe2fae4-a1b6-4454-b152-52cafdee41b0": {"__data__": {"id_": "6fe2fae4-a1b6-4454-b152-52cafdee41b0", "embedding": null, "metadata": {"window": "So those are the key points I'd give us from the first \nhalf to the second half.  \n \n Aaron Alt:   Eric, it's probably worth offering one  additional point in perspective.  We're not reporting on \nthe new segment structure this quarter.  That will follow in Q3, but we can offer the observation that \nthe GMPD core part of the Medical business has operated at near breakeven levels in the first half  of \nfiscal \u201824.  And I offer you that in contrast with where they were from a fiscal \u201823 perspective, and \nwhere we're going from an overall guidance perspective, we view that as a key sign of positive \nprogress.  \n \n Operator:  Thank you very much, gentlemen.  Sorry to interrupt you earlier . ", "original_text": "That will follow in Q3, but we can offer the observation that \nthe GMPD core part of the Medical business has operated at near breakeven levels in the first half  of \nfiscal \u201824. ", "page_label": "14", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "0ac9f346-07e9-4997-8f28-e5117e7bae25", "node_type": "4", "metadata": {"page_label": "14", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "9234b4689cac640be82a7dbb5c15932ea517de37b8dfde62816f9a47fb53e9a4", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "7e1da58b-931a-4e7e-b6aa-745b9c0fc67b", "node_type": "1", "metadata": {"window": "But there are some variables like the market itself  that will always be an impact here, good \nor bad , that we will continue to monitor and track.  So those are the key points I'd give us from the first \nhalf to the second half.  \n \n Aaron Alt:   Eric, it's probably worth offering one  additional point in perspective.  We're not reporting on \nthe new segment structure this quarter.  That will follow in Q3, but we can offer the observation that \nthe GMPD core part of the Medical business has operated at near breakeven levels in the first half  of \nfiscal \u201824.  And I offer you that in contrast with where they were from a fiscal \u201823 perspective, and \nwhere we're going from an overall guidance perspective, we view that as a key sign of positive \nprogress.  \n \n Operator:  Thank you very much, gentlemen. ", "original_text": "We're not reporting on \nthe new segment structure this quarter. ", "page_label": "14", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "bab7c57b75fcb654c14ca636d1ca5ab6341a06ccaee8fa43774ed9c739181a78", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "7e300fd9-8b96-4568-8ea1-6d70f95b029a", "node_type": "1", "metadata": {"window": "Aaron Alt:   Eric, it's probably worth offering one  additional point in perspective.  We're not reporting on \nthe new segment structure this quarter.  That will follow in Q3, but we can offer the observation that \nthe GMPD core part of the Medical business has operated at near breakeven levels in the first half  of \nfiscal \u201824.  And I offer you that in contrast with where they were from a fiscal \u201823 perspective, and \nwhere we're going from an overall guidance perspective, we view that as a key sign of positive \nprogress.  \n \n Operator:  Thank you very much, gentlemen.  Sorry to interrupt you earlier .  Our next question is going \nto be coming from Erin Wright of Morgan Stanley. ", "original_text": "And I offer you that in contrast with where they were from a fiscal \u201823 perspective, and \nwhere we're going from an overall guidance perspective, we view that as a key sign of positive \nprogress.  \n \n"}, "hash": "fb126785cc0813b3d454813b7b27ae4cb1ac0c46d71efaef27a1aad44fe5db1a", "class_name": "RelatedNodeInfo"}}, "text": "That will follow in Q3, but we can offer the observation that \nthe GMPD core part of the Medical business has operated at near breakeven levels in the first half  of \nfiscal \u201824. ", "start_char_idx": 1309, "end_char_idx": 1488, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "7e300fd9-8b96-4568-8ea1-6d70f95b029a": {"__data__": {"id_": "7e300fd9-8b96-4568-8ea1-6d70f95b029a", "embedding": null, "metadata": {"window": "Aaron Alt:   Eric, it's probably worth offering one  additional point in perspective.  We're not reporting on \nthe new segment structure this quarter.  That will follow in Q3, but we can offer the observation that \nthe GMPD core part of the Medical business has operated at near breakeven levels in the first half  of \nfiscal \u201824.  And I offer you that in contrast with where they were from a fiscal \u201823 perspective, and \nwhere we're going from an overall guidance perspective, we view that as a key sign of positive \nprogress.  \n \n Operator:  Thank you very much, gentlemen.  Sorry to interrupt you earlier .  Our next question is going \nto be coming from Erin Wright of Morgan Stanley. ", "original_text": "And I offer you that in contrast with where they were from a fiscal \u201823 perspective, and \nwhere we're going from an overall guidance perspective, we view that as a key sign of positive \nprogress.  \n \n", "page_label": "14", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "0ac9f346-07e9-4997-8f28-e5117e7bae25", "node_type": "4", "metadata": {"page_label": "14", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "9234b4689cac640be82a7dbb5c15932ea517de37b8dfde62816f9a47fb53e9a4", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "6fe2fae4-a1b6-4454-b152-52cafdee41b0", "node_type": "1", "metadata": {"window": "So those are the key points I'd give us from the first \nhalf to the second half.  \n \n Aaron Alt:   Eric, it's probably worth offering one  additional point in perspective.  We're not reporting on \nthe new segment structure this quarter.  That will follow in Q3, but we can offer the observation that \nthe GMPD core part of the Medical business has operated at near breakeven levels in the first half  of \nfiscal \u201824.  And I offer you that in contrast with where they were from a fiscal \u201823 perspective, and \nwhere we're going from an overall guidance perspective, we view that as a key sign of positive \nprogress.  \n \n Operator:  Thank you very much, gentlemen.  Sorry to interrupt you earlier . ", "original_text": "That will follow in Q3, but we can offer the observation that \nthe GMPD core part of the Medical business has operated at near breakeven levels in the first half  of \nfiscal \u201824. ", "page_label": "14", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "b5b1832ea750b5c44e3691a32704b3245f6b8d0a903536809cee729665bfd476", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "cb264db5-3958-4b71-8130-a43a56b021c5", "node_type": "1", "metadata": {"window": "We're not reporting on \nthe new segment structure this quarter.  That will follow in Q3, but we can offer the observation that \nthe GMPD core part of the Medical business has operated at near breakeven levels in the first half  of \nfiscal \u201824.  And I offer you that in contrast with where they were from a fiscal \u201823 perspective, and \nwhere we're going from an overall guidance perspective, we view that as a key sign of positive \nprogress.  \n \n Operator:  Thank you very much, gentlemen.  Sorry to interrupt you earlier .  Our next question is going \nto be coming from Erin Wright of Morgan Stanley.  Please go ahead.  \n \n", "original_text": "Operator:  Thank you very much, gentlemen. "}, "hash": "4afc9ec8b515acd9708343085446662258dedfdae783eb05918362097c7adbbd", "class_name": "RelatedNodeInfo"}}, "text": "And I offer you that in contrast with where they were from a fiscal \u201823 perspective, and \nwhere we're going from an overall guidance perspective, we view that as a key sign of positive \nprogress.  \n \n", "start_char_idx": 1488, "end_char_idx": 1688, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "cb264db5-3958-4b71-8130-a43a56b021c5": {"__data__": {"id_": "cb264db5-3958-4b71-8130-a43a56b021c5", "embedding": null, "metadata": {"window": "We're not reporting on \nthe new segment structure this quarter.  That will follow in Q3, but we can offer the observation that \nthe GMPD core part of the Medical business has operated at near breakeven levels in the first half  of \nfiscal \u201824.  And I offer you that in contrast with where they were from a fiscal \u201823 perspective, and \nwhere we're going from an overall guidance perspective, we view that as a key sign of positive \nprogress.  \n \n Operator:  Thank you very much, gentlemen.  Sorry to interrupt you earlier .  Our next question is going \nto be coming from Erin Wright of Morgan Stanley.  Please go ahead.  \n \n", "original_text": "Operator:  Thank you very much, gentlemen. ", "page_label": "14", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "0ac9f346-07e9-4997-8f28-e5117e7bae25", "node_type": "4", "metadata": {"page_label": "14", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "9234b4689cac640be82a7dbb5c15932ea517de37b8dfde62816f9a47fb53e9a4", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "7e300fd9-8b96-4568-8ea1-6d70f95b029a", "node_type": "1", "metadata": {"window": "Aaron Alt:   Eric, it's probably worth offering one  additional point in perspective.  We're not reporting on \nthe new segment structure this quarter.  That will follow in Q3, but we can offer the observation that \nthe GMPD core part of the Medical business has operated at near breakeven levels in the first half  of \nfiscal \u201824.  And I offer you that in contrast with where they were from a fiscal \u201823 perspective, and \nwhere we're going from an overall guidance perspective, we view that as a key sign of positive \nprogress.  \n \n Operator:  Thank you very much, gentlemen.  Sorry to interrupt you earlier .  Our next question is going \nto be coming from Erin Wright of Morgan Stanley. ", "original_text": "And I offer you that in contrast with where they were from a fiscal \u201823 perspective, and \nwhere we're going from an overall guidance perspective, we view that as a key sign of positive \nprogress.  \n \n", "page_label": "14", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "6873e3a24e579769dd920e9434e7e03c260ae90a6e1535a897366ef9a1d7b9c0", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "7749c7ee-fae9-46b4-9db5-44960fd3aa4d", "node_type": "1", "metadata": {"window": "That will follow in Q3, but we can offer the observation that \nthe GMPD core part of the Medical business has operated at near breakeven levels in the first half  of \nfiscal \u201824.  And I offer you that in contrast with where they were from a fiscal \u201823 perspective, and \nwhere we're going from an overall guidance perspective, we view that as a key sign of positive \nprogress.  \n \n Operator:  Thank you very much, gentlemen.  Sorry to interrupt you earlier .  Our next question is going \nto be coming from Erin Wright of Morgan Stanley.  Please go ahead.  \n \n Erin Wright:  Great , thanks. ", "original_text": "Sorry to interrupt you earlier . "}, "hash": "728258e258659a804a23c1d6edfde14b3bae6db0a271247c8818e8bb1744eb78", "class_name": "RelatedNodeInfo"}}, "text": "Operator:  Thank you very much, gentlemen. ", "start_char_idx": 1688, "end_char_idx": 1731, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "7749c7ee-fae9-46b4-9db5-44960fd3aa4d": {"__data__": {"id_": "7749c7ee-fae9-46b4-9db5-44960fd3aa4d", "embedding": null, "metadata": {"window": "That will follow in Q3, but we can offer the observation that \nthe GMPD core part of the Medical business has operated at near breakeven levels in the first half  of \nfiscal \u201824.  And I offer you that in contrast with where they were from a fiscal \u201823 perspective, and \nwhere we're going from an overall guidance perspective, we view that as a key sign of positive \nprogress.  \n \n Operator:  Thank you very much, gentlemen.  Sorry to interrupt you earlier .  Our next question is going \nto be coming from Erin Wright of Morgan Stanley.  Please go ahead.  \n \n Erin Wright:  Great , thanks. ", "original_text": "Sorry to interrupt you earlier . ", "page_label": "14", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "0ac9f346-07e9-4997-8f28-e5117e7bae25", "node_type": "4", "metadata": {"page_label": "14", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "9234b4689cac640be82a7dbb5c15932ea517de37b8dfde62816f9a47fb53e9a4", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "cb264db5-3958-4b71-8130-a43a56b021c5", "node_type": "1", "metadata": {"window": "We're not reporting on \nthe new segment structure this quarter.  That will follow in Q3, but we can offer the observation that \nthe GMPD core part of the Medical business has operated at near breakeven levels in the first half  of \nfiscal \u201824.  And I offer you that in contrast with where they were from a fiscal \u201823 perspective, and \nwhere we're going from an overall guidance perspective, we view that as a key sign of positive \nprogress.  \n \n Operator:  Thank you very much, gentlemen.  Sorry to interrupt you earlier .  Our next question is going \nto be coming from Erin Wright of Morgan Stanley.  Please go ahead.  \n \n", "original_text": "Operator:  Thank you very much, gentlemen. ", "page_label": "14", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "0580dc618ab353368cc03d263cb0a5efbb96122e00a4f1ff9a719497ca222794", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "e7cf09fd-54b3-41a2-8879-5a5056a2f170", "node_type": "1", "metadata": {"window": "And I offer you that in contrast with where they were from a fiscal \u201823 perspective, and \nwhere we're going from an overall guidance perspective, we view that as a key sign of positive \nprogress.  \n \n Operator:  Thank you very much, gentlemen.  Sorry to interrupt you earlier .  Our next question is going \nto be coming from Erin Wright of Morgan Stanley.  Please go ahead.  \n \n Erin Wright:  Great , thanks.  On the drug pricing front, you do continue to mention generics as a key \ndriver. ", "original_text": "Our next question is going \nto be coming from Erin Wright of Morgan Stanley. "}, "hash": "a5d9f6ad9d09adfa112c10c9f54264675a7d19a5069af38261515aa247e6ffb4", "class_name": "RelatedNodeInfo"}}, "text": "Sorry to interrupt you earlier . ", "start_char_idx": 1731, "end_char_idx": 1764, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "e7cf09fd-54b3-41a2-8879-5a5056a2f170": {"__data__": {"id_": "e7cf09fd-54b3-41a2-8879-5a5056a2f170", "embedding": null, "metadata": {"window": "And I offer you that in contrast with where they were from a fiscal \u201823 perspective, and \nwhere we're going from an overall guidance perspective, we view that as a key sign of positive \nprogress.  \n \n Operator:  Thank you very much, gentlemen.  Sorry to interrupt you earlier .  Our next question is going \nto be coming from Erin Wright of Morgan Stanley.  Please go ahead.  \n \n Erin Wright:  Great , thanks.  On the drug pricing front, you do continue to mention generics as a key \ndriver. ", "original_text": "Our next question is going \nto be coming from Erin Wright of Morgan Stanley. ", "page_label": "14", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "0ac9f346-07e9-4997-8f28-e5117e7bae25", "node_type": "4", "metadata": {"page_label": "14", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "9234b4689cac640be82a7dbb5c15932ea517de37b8dfde62816f9a47fb53e9a4", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "7749c7ee-fae9-46b4-9db5-44960fd3aa4d", "node_type": "1", "metadata": {"window": "That will follow in Q3, but we can offer the observation that \nthe GMPD core part of the Medical business has operated at near breakeven levels in the first half  of \nfiscal \u201824.  And I offer you that in contrast with where they were from a fiscal \u201823 perspective, and \nwhere we're going from an overall guidance perspective, we view that as a key sign of positive \nprogress.  \n \n Operator:  Thank you very much, gentlemen.  Sorry to interrupt you earlier .  Our next question is going \nto be coming from Erin Wright of Morgan Stanley.  Please go ahead.  \n \n Erin Wright:  Great , thanks. ", "original_text": "Sorry to interrupt you earlier . ", "page_label": "14", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "44df6859e959672f445315e9114df8989d2d3782c692d9f90416c78f0aff1bd9", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "a9a66894-f487-46b7-a69d-f4e8ee4499cc", "node_type": "1", "metadata": {"window": "Operator:  Thank you very much, gentlemen.  Sorry to interrupt you earlier .  Our next question is going \nto be coming from Erin Wright of Morgan Stanley.  Please go ahead.  \n \n Erin Wright:  Great , thanks.  On the drug pricing front, you do continue to mention generics as a key \ndriver.  Are you still seeing that using deflationary dynamics that others have noted too? ", "original_text": "Please go ahead.  \n \n"}, "hash": "5e7609f907354a523b478e73aed6fa074a5abefea7b89a9bcadda89d4c4195cd", "class_name": "RelatedNodeInfo"}}, "text": "Our next question is going \nto be coming from Erin Wright of Morgan Stanley. ", "start_char_idx": 1764, "end_char_idx": 1841, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "a9a66894-f487-46b7-a69d-f4e8ee4499cc": {"__data__": {"id_": "a9a66894-f487-46b7-a69d-f4e8ee4499cc", "embedding": null, "metadata": {"window": "Operator:  Thank you very much, gentlemen.  Sorry to interrupt you earlier .  Our next question is going \nto be coming from Erin Wright of Morgan Stanley.  Please go ahead.  \n \n Erin Wright:  Great , thanks.  On the drug pricing front, you do continue to mention generics as a key \ndriver.  Are you still seeing that using deflationary dynamics that others have noted too? ", "original_text": "Please go ahead.  \n \n", "page_label": "14", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "0ac9f346-07e9-4997-8f28-e5117e7bae25", "node_type": "4", "metadata": {"page_label": "14", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "9234b4689cac640be82a7dbb5c15932ea517de37b8dfde62816f9a47fb53e9a4", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "e7cf09fd-54b3-41a2-8879-5a5056a2f170", "node_type": "1", "metadata": {"window": "And I offer you that in contrast with where they were from a fiscal \u201823 perspective, and \nwhere we're going from an overall guidance perspective, we view that as a key sign of positive \nprogress.  \n \n Operator:  Thank you very much, gentlemen.  Sorry to interrupt you earlier .  Our next question is going \nto be coming from Erin Wright of Morgan Stanley.  Please go ahead.  \n \n Erin Wright:  Great , thanks.  On the drug pricing front, you do continue to mention generics as a key \ndriver. ", "original_text": "Our next question is going \nto be coming from Erin Wright of Morgan Stanley. ", "page_label": "14", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "52b1b1e4addccca7419b9b3f1e7f55641c6aec9476804d742b41a99fa10667a9", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "eb1a401f-f75e-4f86-8f1e-38b58b463d8d", "node_type": "1", "metadata": {"window": "Sorry to interrupt you earlier .  Our next question is going \nto be coming from Erin Wright of Morgan Stanley.  Please go ahead.  \n \n Erin Wright:  Great , thanks.  On the drug pricing front, you do continue to mention generics as a key \ndriver.  Are you still seeing that using deflationary dynamics that others have noted too?  And how \nmaterial is that for you? ", "original_text": "Erin Wright:  Great , thanks. "}, "hash": "7d2f8647683a4c30cb8789d42764f135465ec7588318bce841d67c7d38a993e2", "class_name": "RelatedNodeInfo"}}, "text": "Please go ahead.  \n \n", "start_char_idx": 1841, "end_char_idx": 1862, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "eb1a401f-f75e-4f86-8f1e-38b58b463d8d": {"__data__": {"id_": "eb1a401f-f75e-4f86-8f1e-38b58b463d8d", "embedding": null, "metadata": {"window": "Sorry to interrupt you earlier .  Our next question is going \nto be coming from Erin Wright of Morgan Stanley.  Please go ahead.  \n \n Erin Wright:  Great , thanks.  On the drug pricing front, you do continue to mention generics as a key \ndriver.  Are you still seeing that using deflationary dynamics that others have noted too?  And how \nmaterial is that for you? ", "original_text": "Erin Wright:  Great , thanks. ", "page_label": "14", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "0ac9f346-07e9-4997-8f28-e5117e7bae25", "node_type": "4", "metadata": {"page_label": "14", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "9234b4689cac640be82a7dbb5c15932ea517de37b8dfde62816f9a47fb53e9a4", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "a9a66894-f487-46b7-a69d-f4e8ee4499cc", "node_type": "1", "metadata": {"window": "Operator:  Thank you very much, gentlemen.  Sorry to interrupt you earlier .  Our next question is going \nto be coming from Erin Wright of Morgan Stanley.  Please go ahead.  \n \n Erin Wright:  Great , thanks.  On the drug pricing front, you do continue to mention generics as a key \ndriver.  Are you still seeing that using deflationary dynamics that others have noted too? ", "original_text": "Please go ahead.  \n \n", "page_label": "14", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "4f1cb15bad5e8be2841bd415d7cd1d2e0ccfa2941b66ddcc38ad84c500c133a7", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "be8079b6-fade-497b-aa02-194ec352e7c3", "node_type": "1", "metadata": {"window": "Our next question is going \nto be coming from Erin Wright of Morgan Stanley.  Please go ahead.  \n \n Erin Wright:  Great , thanks.  On the drug pricing front, you do continue to mention generics as a key \ndriver.  Are you still seeing that using deflationary dynamics that others have noted too?  And how \nmaterial is that for you?  And also, how sustainable is it? ", "original_text": "On the drug pricing front, you do continue to mention generics as a key \ndriver. "}, "hash": "efab8e883432d2d6b8d1d5dc0ec3d62fe60ad3dcd2032a82b617031e14264fe2", "class_name": "RelatedNodeInfo"}}, "text": "Erin Wright:  Great , thanks. ", "start_char_idx": 1862, "end_char_idx": 1892, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "be8079b6-fade-497b-aa02-194ec352e7c3": {"__data__": {"id_": "be8079b6-fade-497b-aa02-194ec352e7c3", "embedding": null, "metadata": {"window": "Our next question is going \nto be coming from Erin Wright of Morgan Stanley.  Please go ahead.  \n \n Erin Wright:  Great , thanks.  On the drug pricing front, you do continue to mention generics as a key \ndriver.  Are you still seeing that using deflationary dynamics that others have noted too?  And how \nmaterial is that for you?  And also, how sustainable is it? ", "original_text": "On the drug pricing front, you do continue to mention generics as a key \ndriver. ", "page_label": "14", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "0ac9f346-07e9-4997-8f28-e5117e7bae25", "node_type": "4", "metadata": {"page_label": "14", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "9234b4689cac640be82a7dbb5c15932ea517de37b8dfde62816f9a47fb53e9a4", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "eb1a401f-f75e-4f86-8f1e-38b58b463d8d", "node_type": "1", "metadata": {"window": "Sorry to interrupt you earlier .  Our next question is going \nto be coming from Erin Wright of Morgan Stanley.  Please go ahead.  \n \n Erin Wright:  Great , thanks.  On the drug pricing front, you do continue to mention generics as a key \ndriver.  Are you still seeing that using deflationary dynamics that others have noted too?  And how \nmaterial is that for you? ", "original_text": "Erin Wright:  Great , thanks. ", "page_label": "14", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "ce94f5b2c2f78f9bd3ac368d30adff7203231276db010726f08a8dd696e088c3", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "400399f0-1f09-41b0-ba29-4ff37f0bbaa4", "node_type": "1", "metadata": {"window": "Please go ahead.  \n \n Erin Wright:  Great , thanks.  On the drug pricing front, you do continue to mention generics as a key \ndriver.  Are you still seeing that using deflationary dynamics that others have noted too?  And how \nmaterial is that for you?  And also, how sustainable is it?  What are some of the key drivers that you're \nlooking at there? ", "original_text": "Are you still seeing that using deflationary dynamics that others have noted too? "}, "hash": "8cdac582f53448dd314d5f5bbcaedf4c98d0272072f8e2275cb8682823c4a52d", "class_name": "RelatedNodeInfo"}}, "text": "On the drug pricing front, you do continue to mention generics as a key \ndriver. ", "start_char_idx": 1892, "end_char_idx": 1973, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "400399f0-1f09-41b0-ba29-4ff37f0bbaa4": {"__data__": {"id_": "400399f0-1f09-41b0-ba29-4ff37f0bbaa4", "embedding": null, "metadata": {"window": "Please go ahead.  \n \n Erin Wright:  Great , thanks.  On the drug pricing front, you do continue to mention generics as a key \ndriver.  Are you still seeing that using deflationary dynamics that others have noted too?  And how \nmaterial is that for you?  And also, how sustainable is it?  What are some of the key drivers that you're \nlooking at there? ", "original_text": "Are you still seeing that using deflationary dynamics that others have noted too? ", "page_label": "14", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "0ac9f346-07e9-4997-8f28-e5117e7bae25", "node_type": "4", "metadata": {"page_label": "14", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "9234b4689cac640be82a7dbb5c15932ea517de37b8dfde62816f9a47fb53e9a4", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "be8079b6-fade-497b-aa02-194ec352e7c3", "node_type": "1", "metadata": {"window": "Our next question is going \nto be coming from Erin Wright of Morgan Stanley.  Please go ahead.  \n \n Erin Wright:  Great , thanks.  On the drug pricing front, you do continue to mention generics as a key \ndriver.  Are you still seeing that using deflationary dynamics that others have noted too?  And how \nmaterial is that for you?  And also, how sustainable is it? ", "original_text": "On the drug pricing front, you do continue to mention generics as a key \ndriver. ", "page_label": "14", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "353d19dd22f42eb17319b407df9cb6809a195cc1ef6d79335497e190835748a8", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "e530ef42-af97-4bf6-a83e-475cc392bc8a", "node_type": "1", "metadata": {"window": "Erin Wright:  Great , thanks.  On the drug pricing front, you do continue to mention generics as a key \ndriver.  Are you still seeing that using deflationary dynamics that others have noted too?  And how \nmaterial is that for you?  And also, how sustainable is it?  What are some of the key drivers that you're \nlooking at there?  And how are you thinking about that for the balance of the year as well as we think \nabout the quarterly cadence here for th e Pharma segment, particularly with the COVID dynamics, too.  \n", "original_text": "And how \nmaterial is that for you? "}, "hash": "f906147060ac099061e24693c4addc518a19f4a6bccc43e81154a0e4a408ca7c", "class_name": "RelatedNodeInfo"}}, "text": "Are you still seeing that using deflationary dynamics that others have noted too? ", "start_char_idx": 1973, "end_char_idx": 2055, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "e530ef42-af97-4bf6-a83e-475cc392bc8a": {"__data__": {"id_": "e530ef42-af97-4bf6-a83e-475cc392bc8a", "embedding": null, "metadata": {"window": "Erin Wright:  Great , thanks.  On the drug pricing front, you do continue to mention generics as a key \ndriver.  Are you still seeing that using deflationary dynamics that others have noted too?  And how \nmaterial is that for you?  And also, how sustainable is it?  What are some of the key drivers that you're \nlooking at there?  And how are you thinking about that for the balance of the year as well as we think \nabout the quarterly cadence here for th e Pharma segment, particularly with the COVID dynamics, too.  \n", "original_text": "And how \nmaterial is that for you? ", "page_label": "14", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "0ac9f346-07e9-4997-8f28-e5117e7bae25", "node_type": "4", "metadata": {"page_label": "14", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "9234b4689cac640be82a7dbb5c15932ea517de37b8dfde62816f9a47fb53e9a4", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "400399f0-1f09-41b0-ba29-4ff37f0bbaa4", "node_type": "1", "metadata": {"window": "Please go ahead.  \n \n Erin Wright:  Great , thanks.  On the drug pricing front, you do continue to mention generics as a key \ndriver.  Are you still seeing that using deflationary dynamics that others have noted too?  And how \nmaterial is that for you?  And also, how sustainable is it?  What are some of the key drivers that you're \nlooking at there? ", "original_text": "Are you still seeing that using deflationary dynamics that others have noted too? ", "page_label": "14", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "e1965b6680aba4cf42ea866295f44fc2045e840c597b736b3f9f8d4640f53249", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "520a0f9f-e6ab-4e9a-9274-bb2667dea598", "node_type": "1", "metadata": {"window": "On the drug pricing front, you do continue to mention generics as a key \ndriver.  Are you still seeing that using deflationary dynamics that others have noted too?  And how \nmaterial is that for you?  And also, how sustainable is it?  What are some of the key drivers that you're \nlooking at there?  And how are you thinking about that for the balance of the year as well as we think \nabout the quarterly cadence here for th e Pharma segment, particularly with the COVID dynamics, too.  \n Thanks.  \n \n", "original_text": "And also, how sustainable is it? "}, "hash": "c9e54f57b76e923dc9ca5635ccdf70c58488eb701270e92f454d4bd546a8f850", "class_name": "RelatedNodeInfo"}}, "text": "And how \nmaterial is that for you? ", "start_char_idx": 2055, "end_char_idx": 2090, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "520a0f9f-e6ab-4e9a-9274-bb2667dea598": {"__data__": {"id_": "520a0f9f-e6ab-4e9a-9274-bb2667dea598", "embedding": null, "metadata": {"window": "On the drug pricing front, you do continue to mention generics as a key \ndriver.  Are you still seeing that using deflationary dynamics that others have noted too?  And how \nmaterial is that for you?  And also, how sustainable is it?  What are some of the key drivers that you're \nlooking at there?  And how are you thinking about that for the balance of the year as well as we think \nabout the quarterly cadence here for th e Pharma segment, particularly with the COVID dynamics, too.  \n Thanks.  \n \n", "original_text": "And also, how sustainable is it? ", "page_label": "14", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "0ac9f346-07e9-4997-8f28-e5117e7bae25", "node_type": "4", "metadata": {"page_label": "14", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "9234b4689cac640be82a7dbb5c15932ea517de37b8dfde62816f9a47fb53e9a4", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "e530ef42-af97-4bf6-a83e-475cc392bc8a", "node_type": "1", "metadata": {"window": "Erin Wright:  Great , thanks.  On the drug pricing front, you do continue to mention generics as a key \ndriver.  Are you still seeing that using deflationary dynamics that others have noted too?  And how \nmaterial is that for you?  And also, how sustainable is it?  What are some of the key drivers that you're \nlooking at there?  And how are you thinking about that for the balance of the year as well as we think \nabout the quarterly cadence here for th e Pharma segment, particularly with the COVID dynamics, too.  \n", "original_text": "And how \nmaterial is that for you? ", "page_label": "14", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "2ac26c47cc1d6b361b438d1889109af06a45f01b55be27a11a8dcb601c022550", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "70599055-c6f1-4ea5-96ba-542587a140d7", "node_type": "1", "metadata": {"window": "Are you still seeing that using deflationary dynamics that others have noted too?  And how \nmaterial is that for you?  And also, how sustainable is it?  What are some of the key drivers that you're \nlooking at there?  And how are you thinking about that for the balance of the year as well as we think \nabout the quarterly cadence here for th e Pharma segment, particularly with the COVID dynamics, too.  \n Thanks.  \n \n Aaron Alt :  Appreciate the question . ", "original_text": "What are some of the key drivers that you're \nlooking at there? "}, "hash": "5e6d93e0093c3cb8e12d697de21ccd6008583044ca4c9d1d1aabd9312fffebd8", "class_name": "RelatedNodeInfo"}}, "text": "And also, how sustainable is it? ", "start_char_idx": 2090, "end_char_idx": 2123, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "70599055-c6f1-4ea5-96ba-542587a140d7": {"__data__": {"id_": "70599055-c6f1-4ea5-96ba-542587a140d7", "embedding": null, "metadata": {"window": "Are you still seeing that using deflationary dynamics that others have noted too?  And how \nmaterial is that for you?  And also, how sustainable is it?  What are some of the key drivers that you're \nlooking at there?  And how are you thinking about that for the balance of the year as well as we think \nabout the quarterly cadence here for th e Pharma segment, particularly with the COVID dynamics, too.  \n Thanks.  \n \n Aaron Alt :  Appreciate the question . ", "original_text": "What are some of the key drivers that you're \nlooking at there? ", "page_label": "14", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "0ac9f346-07e9-4997-8f28-e5117e7bae25", "node_type": "4", "metadata": {"page_label": "14", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "9234b4689cac640be82a7dbb5c15932ea517de37b8dfde62816f9a47fb53e9a4", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "520a0f9f-e6ab-4e9a-9274-bb2667dea598", "node_type": "1", "metadata": {"window": "On the drug pricing front, you do continue to mention generics as a key \ndriver.  Are you still seeing that using deflationary dynamics that others have noted too?  And how \nmaterial is that for you?  And also, how sustainable is it?  What are some of the key drivers that you're \nlooking at there?  And how are you thinking about that for the balance of the year as well as we think \nabout the quarterly cadence here for th e Pharma segment, particularly with the COVID dynamics, too.  \n Thanks.  \n \n", "original_text": "And also, how sustainable is it? ", "page_label": "14", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "305b2c3d62bfe945a1a46a30e305d624d55447f58c73e1259491ef5532f8394e", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "b742bf7b-5425-460a-b17e-5a70f87545e2", "node_type": "1", "metadata": {"window": "And how \nmaterial is that for you?  And also, how sustainable is it?  What are some of the key drivers that you're \nlooking at there?  And how are you thinking about that for the balance of the year as well as we think \nabout the quarterly cadence here for th e Pharma segment, particularly with the COVID dynamics, too.  \n Thanks.  \n \n Aaron Alt :  Appreciate the question .  One of the things we  called out in commenting on the strong \nquarter that our Pharma business had was that the continued consistent market dynamics within the \ngeneric space matched with volume . ", "original_text": "And how are you thinking about that for the balance of the year as well as we think \nabout the quarterly cadence here for th e Pharma segment, particularly with the COVID dynamics, too.  \n"}, "hash": "7a7084845edeaea7e7ad0805ed41563a8a2d97f71aaa8784984b0dd2396d0da3", "class_name": "RelatedNodeInfo"}}, "text": "What are some of the key drivers that you're \nlooking at there? ", "start_char_idx": 2123, "end_char_idx": 2187, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "b742bf7b-5425-460a-b17e-5a70f87545e2": {"__data__": {"id_": "b742bf7b-5425-460a-b17e-5a70f87545e2", "embedding": null, "metadata": {"window": "And how \nmaterial is that for you?  And also, how sustainable is it?  What are some of the key drivers that you're \nlooking at there?  And how are you thinking about that for the balance of the year as well as we think \nabout the quarterly cadence here for th e Pharma segment, particularly with the COVID dynamics, too.  \n Thanks.  \n \n Aaron Alt :  Appreciate the question .  One of the things we  called out in commenting on the strong \nquarter that our Pharma business had was that the continued consistent market dynamics within the \ngeneric space matched with volume . ", "original_text": "And how are you thinking about that for the balance of the year as well as we think \nabout the quarterly cadence here for th e Pharma segment, particularly with the COVID dynamics, too.  \n", "page_label": "14", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "0ac9f346-07e9-4997-8f28-e5117e7bae25", "node_type": "4", "metadata": {"page_label": "14", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "9234b4689cac640be82a7dbb5c15932ea517de37b8dfde62816f9a47fb53e9a4", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "70599055-c6f1-4ea5-96ba-542587a140d7", "node_type": "1", "metadata": {"window": "Are you still seeing that using deflationary dynamics that others have noted too?  And how \nmaterial is that for you?  And also, how sustainable is it?  What are some of the key drivers that you're \nlooking at there?  And how are you thinking about that for the balance of the year as well as we think \nabout the quarterly cadence here for th e Pharma segment, particularly with the COVID dynamics, too.  \n Thanks.  \n \n Aaron Alt :  Appreciate the question . ", "original_text": "What are some of the key drivers that you're \nlooking at there? ", "page_label": "14", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "cc3e6f2b7d7edef56c8959b27443fe818f4088345ea69db3d757196a1399b773", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "9d4098c4-fce0-4827-90cc-f733f2f4d3d7", "node_type": "1", "metadata": {"window": "And also, how sustainable is it?  What are some of the key drivers that you're \nlooking at there?  And how are you thinking about that for the balance of the year as well as we think \nabout the quarterly cadence here for th e Pharma segment, particularly with the COVID dynamics, too.  \n Thanks.  \n \n Aaron Alt :  Appreciate the question .  One of the things we  called out in commenting on the strong \nquarter that our Pharma business had was that the continued consistent market dynamics within the \ngeneric space matched with volume .  Strong volume was a reason for one of the reasons for success \nin the business.  ", "original_text": "Thanks.  \n \n"}, "hash": "28e461078410475806f8902812ffa750c40558ffabdfad3f45896ee315bd27eb", "class_name": "RelatedNodeInfo"}}, "text": "And how are you thinking about that for the balance of the year as well as we think \nabout the quarterly cadence here for th e Pharma segment, particularly with the COVID dynamics, too.  \n", "start_char_idx": 2187, "end_char_idx": 2375, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "9d4098c4-fce0-4827-90cc-f733f2f4d3d7": {"__data__": {"id_": "9d4098c4-fce0-4827-90cc-f733f2f4d3d7", "embedding": null, "metadata": {"window": "And also, how sustainable is it?  What are some of the key drivers that you're \nlooking at there?  And how are you thinking about that for the balance of the year as well as we think \nabout the quarterly cadence here for th e Pharma segment, particularly with the COVID dynamics, too.  \n Thanks.  \n \n Aaron Alt :  Appreciate the question .  One of the things we  called out in commenting on the strong \nquarter that our Pharma business had was that the continued consistent market dynamics within the \ngeneric space matched with volume .  Strong volume was a reason for one of the reasons for success \nin the business.  ", "original_text": "Thanks.  \n \n", "page_label": "14", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "0ac9f346-07e9-4997-8f28-e5117e7bae25", "node_type": "4", "metadata": {"page_label": "14", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "9234b4689cac640be82a7dbb5c15932ea517de37b8dfde62816f9a47fb53e9a4", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "b742bf7b-5425-460a-b17e-5a70f87545e2", "node_type": "1", "metadata": {"window": "And how \nmaterial is that for you?  And also, how sustainable is it?  What are some of the key drivers that you're \nlooking at there?  And how are you thinking about that for the balance of the year as well as we think \nabout the quarterly cadence here for th e Pharma segment, particularly with the COVID dynamics, too.  \n Thanks.  \n \n Aaron Alt :  Appreciate the question .  One of the things we  called out in commenting on the strong \nquarter that our Pharma business had was that the continued consistent market dynamics within the \ngeneric space matched with volume . ", "original_text": "And how are you thinking about that for the balance of the year as well as we think \nabout the quarterly cadence here for th e Pharma segment, particularly with the COVID dynamics, too.  \n", "page_label": "14", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "90dec3534da53f1ea22be8091cfb15cb5ff30ab124e67f27b5549a608723c9a7", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "43c47f12-380d-4213-bbaf-a3d679f631f1", "node_type": "1", "metadata": {"window": "What are some of the key drivers that you're \nlooking at there?  And how are you thinking about that for the balance of the year as well as we think \nabout the quarterly cadence here for th e Pharma segment, particularly with the COVID dynamics, too.  \n Thanks.  \n \n Aaron Alt :  Appreciate the question .  One of the things we  called out in commenting on the strong \nquarter that our Pharma business had was that the continued consistent market dynamics within the \ngeneric space matched with volume .  Strong volume was a reason for one of the reasons for success \nin the business.   We often talk about the two sides of the equation being in balance. ", "original_text": "Aaron Alt :  Appreciate the question . "}, "hash": "fbcecadfc592086bf1420725c19e9d77c43c16f44aacd02492f1dfedec3fae0b", "class_name": "RelatedNodeInfo"}}, "text": "Thanks.  \n \n", "start_char_idx": 2375, "end_char_idx": 2387, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "43c47f12-380d-4213-bbaf-a3d679f631f1": {"__data__": {"id_": "43c47f12-380d-4213-bbaf-a3d679f631f1", "embedding": null, "metadata": {"window": "What are some of the key drivers that you're \nlooking at there?  And how are you thinking about that for the balance of the year as well as we think \nabout the quarterly cadence here for th e Pharma segment, particularly with the COVID dynamics, too.  \n Thanks.  \n \n Aaron Alt :  Appreciate the question .  One of the things we  called out in commenting on the strong \nquarter that our Pharma business had was that the continued consistent market dynamics within the \ngeneric space matched with volume .  Strong volume was a reason for one of the reasons for success \nin the business.   We often talk about the two sides of the equation being in balance. ", "original_text": "Aaron Alt :  Appreciate the question . ", "page_label": "14", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "0ac9f346-07e9-4997-8f28-e5117e7bae25", "node_type": "4", "metadata": {"page_label": "14", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "9234b4689cac640be82a7dbb5c15932ea517de37b8dfde62816f9a47fb53e9a4", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "9d4098c4-fce0-4827-90cc-f733f2f4d3d7", "node_type": "1", "metadata": {"window": "And also, how sustainable is it?  What are some of the key drivers that you're \nlooking at there?  And how are you thinking about that for the balance of the year as well as we think \nabout the quarterly cadence here for th e Pharma segment, particularly with the COVID dynamics, too.  \n Thanks.  \n \n Aaron Alt :  Appreciate the question .  One of the things we  called out in commenting on the strong \nquarter that our Pharma business had was that the continued consistent market dynamics within the \ngeneric space matched with volume .  Strong volume was a reason for one of the reasons for success \nin the business.  ", "original_text": "Thanks.  \n \n", "page_label": "14", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "8b73f41d84d928bf37ac1e6475749dc67a3a831f014d4805df21b26dbe6b9c18", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "3fc7508c-13c4-40ae-a13b-ac6eb9a6a8a4", "node_type": "1", "metadata": {"window": "And how are you thinking about that for the balance of the year as well as we think \nabout the quarterly cadence here for th e Pharma segment, particularly with the COVID dynamics, too.  \n Thanks.  \n \n Aaron Alt :  Appreciate the question .  One of the things we  called out in commenting on the strong \nquarter that our Pharma business had was that the continued consistent market dynamics within the \ngeneric space matched with volume .  Strong volume was a reason for one of the reasons for success \nin the business.   We often talk about the two sides of the equation being in balance.  And indeed, that's \nwhat we continue to see within our generic business, and that is indeed a core component of our \nguidance for Pharma as we carry forward. ", "original_text": "One of the things we  called out in commenting on the strong \nquarter that our Pharma business had was that the continued consistent market dynamics within the \ngeneric space matched with volume . "}, "hash": "06fb4fe9ba11fe0ecc3e52da9a81d6814243046bdb46fa7f73e64f4151407986", "class_name": "RelatedNodeInfo"}}, "text": "Aaron Alt :  Appreciate the question . ", "start_char_idx": 2387, "end_char_idx": 2426, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "3fc7508c-13c4-40ae-a13b-ac6eb9a6a8a4": {"__data__": {"id_": "3fc7508c-13c4-40ae-a13b-ac6eb9a6a8a4", "embedding": null, "metadata": {"window": "And how are you thinking about that for the balance of the year as well as we think \nabout the quarterly cadence here for th e Pharma segment, particularly with the COVID dynamics, too.  \n Thanks.  \n \n Aaron Alt :  Appreciate the question .  One of the things we  called out in commenting on the strong \nquarter that our Pharma business had was that the continued consistent market dynamics within the \ngeneric space matched with volume .  Strong volume was a reason for one of the reasons for success \nin the business.   We often talk about the two sides of the equation being in balance.  And indeed, that's \nwhat we continue to see within our generic business, and that is indeed a core component of our \nguidance for Pharma as we carry forward. ", "original_text": "One of the things we  called out in commenting on the strong \nquarter that our Pharma business had was that the continued consistent market dynamics within the \ngeneric space matched with volume . ", "page_label": "14", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "0ac9f346-07e9-4997-8f28-e5117e7bae25", "node_type": "4", "metadata": {"page_label": "14", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "9234b4689cac640be82a7dbb5c15932ea517de37b8dfde62816f9a47fb53e9a4", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "43c47f12-380d-4213-bbaf-a3d679f631f1", "node_type": "1", "metadata": {"window": "What are some of the key drivers that you're \nlooking at there?  And how are you thinking about that for the balance of the year as well as we think \nabout the quarterly cadence here for th e Pharma segment, particularly with the COVID dynamics, too.  \n Thanks.  \n \n Aaron Alt :  Appreciate the question .  One of the things we  called out in commenting on the strong \nquarter that our Pharma business had was that the continued consistent market dynamics within the \ngeneric space matched with volume .  Strong volume was a reason for one of the reasons for success \nin the business.   We often talk about the two sides of the equation being in balance. ", "original_text": "Aaron Alt :  Appreciate the question . ", "page_label": "14", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "80ac83e255b4527ff500e3abfdc420abac9e495c57c9c893128ffbe8744d0d94", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "7f805137-8557-43c3-8fd4-36f4f03d7034", "node_type": "1", "metadata": {"window": "Thanks.  \n \n Aaron Alt :  Appreciate the question .  One of the things we  called out in commenting on the strong \nquarter that our Pharma business had was that the continued consistent market dynamics within the \ngeneric space matched with volume .  Strong volume was a reason for one of the reasons for success \nin the business.   We often talk about the two sides of the equation being in balance.  And indeed, that's \nwhat we continue to see within our generic business, and that is indeed a core component of our \nguidance for Pharma as we carry forward.  One last reminder, I do want to remind that last quarter, we \nactually took our Pharma guidance up from a profit perspective to 7% to 9%. ", "original_text": "Strong volume was a reason for one of the reasons for success \nin the business.  "}, "hash": "f26a515a3aba385d74ce30a1bc1350bd0f03176ab0845e472f045c0fcf354cb6", "class_name": "RelatedNodeInfo"}}, "text": "One of the things we  called out in commenting on the strong \nquarter that our Pharma business had was that the continued consistent market dynamics within the \ngeneric space matched with volume . ", "start_char_idx": 2426, "end_char_idx": 2623, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "7f805137-8557-43c3-8fd4-36f4f03d7034": {"__data__": {"id_": "7f805137-8557-43c3-8fd4-36f4f03d7034", "embedding": null, "metadata": {"window": "Thanks.  \n \n Aaron Alt :  Appreciate the question .  One of the things we  called out in commenting on the strong \nquarter that our Pharma business had was that the continued consistent market dynamics within the \ngeneric space matched with volume .  Strong volume was a reason for one of the reasons for success \nin the business.   We often talk about the two sides of the equation being in balance.  And indeed, that's \nwhat we continue to see within our generic business, and that is indeed a core component of our \nguidance for Pharma as we carry forward.  One last reminder, I do want to remind that last quarter, we \nactually took our Pharma guidance up from a profit perspective to 7% to 9%. ", "original_text": "Strong volume was a reason for one of the reasons for success \nin the business.  ", "page_label": "14", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "0ac9f346-07e9-4997-8f28-e5117e7bae25", "node_type": "4", "metadata": {"page_label": "14", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "9234b4689cac640be82a7dbb5c15932ea517de37b8dfde62816f9a47fb53e9a4", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "3fc7508c-13c4-40ae-a13b-ac6eb9a6a8a4", "node_type": "1", "metadata": {"window": "And how are you thinking about that for the balance of the year as well as we think \nabout the quarterly cadence here for th e Pharma segment, particularly with the COVID dynamics, too.  \n Thanks.  \n \n Aaron Alt :  Appreciate the question .  One of the things we  called out in commenting on the strong \nquarter that our Pharma business had was that the continued consistent market dynamics within the \ngeneric space matched with volume .  Strong volume was a reason for one of the reasons for success \nin the business.   We often talk about the two sides of the equation being in balance.  And indeed, that's \nwhat we continue to see within our generic business, and that is indeed a core component of our \nguidance for Pharma as we carry forward. ", "original_text": "One of the things we  called out in commenting on the strong \nquarter that our Pharma business had was that the continued consistent market dynamics within the \ngeneric space matched with volume . ", "page_label": "14", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "7ee5446103a374d3deee98d16ae33fae99a8d52cea614e5715b41a7e31c575da", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "49a2968d-a6dc-4eda-8f83-78122754776d", "node_type": "1", "metadata": {"window": "Aaron Alt :  Appreciate the question .  One of the things we  called out in commenting on the strong \nquarter that our Pharma business had was that the continued consistent market dynamics within the \ngeneric space matched with volume .  Strong volume was a reason for one of the reasons for success \nin the business.   We often talk about the two sides of the equation being in balance.  And indeed, that's \nwhat we continue to see within our generic business, and that is indeed a core component of our \nguidance for Pharma as we carry forward.  One last reminder, I do want to remind that last quarter, we \nactually took our Pharma guidance up from a profit perspective to 7% to 9%.  Thank you.  \n \n", "original_text": "We often talk about the two sides of the equation being in balance. "}, "hash": "643aaa12686d75bcaed9f431563aa9f6f9b69e8c961d95a5cf9e2a9423493485", "class_name": "RelatedNodeInfo"}}, "text": "Strong volume was a reason for one of the reasons for success \nin the business.  ", "start_char_idx": 2623, "end_char_idx": 2704, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "49a2968d-a6dc-4eda-8f83-78122754776d": {"__data__": {"id_": "49a2968d-a6dc-4eda-8f83-78122754776d", "embedding": null, "metadata": {"window": "Aaron Alt :  Appreciate the question .  One of the things we  called out in commenting on the strong \nquarter that our Pharma business had was that the continued consistent market dynamics within the \ngeneric space matched with volume .  Strong volume was a reason for one of the reasons for success \nin the business.   We often talk about the two sides of the equation being in balance.  And indeed, that's \nwhat we continue to see within our generic business, and that is indeed a core component of our \nguidance for Pharma as we carry forward.  One last reminder, I do want to remind that last quarter, we \nactually took our Pharma guidance up from a profit perspective to 7% to 9%.  Thank you.  \n \n", "original_text": "We often talk about the two sides of the equation being in balance. ", "page_label": "14", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "0ac9f346-07e9-4997-8f28-e5117e7bae25", "node_type": "4", "metadata": {"page_label": "14", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "9234b4689cac640be82a7dbb5c15932ea517de37b8dfde62816f9a47fb53e9a4", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "7f805137-8557-43c3-8fd4-36f4f03d7034", "node_type": "1", "metadata": {"window": "Thanks.  \n \n Aaron Alt :  Appreciate the question .  One of the things we  called out in commenting on the strong \nquarter that our Pharma business had was that the continued consistent market dynamics within the \ngeneric space matched with volume .  Strong volume was a reason for one of the reasons for success \nin the business.   We often talk about the two sides of the equation being in balance.  And indeed, that's \nwhat we continue to see within our generic business, and that is indeed a core component of our \nguidance for Pharma as we carry forward.  One last reminder, I do want to remind that last quarter, we \nactually took our Pharma guidance up from a profit perspective to 7% to 9%. ", "original_text": "Strong volume was a reason for one of the reasons for success \nin the business.  ", "page_label": "14", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "e77722142e797ef4acbaf15592bdd4cd091080525d7d29951abc45daecc864bb", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "ed2167f4-3ac1-404f-bf75-2c0065e928eb", "node_type": "1", "metadata": {"window": "One of the things we  called out in commenting on the strong \nquarter that our Pharma business had was that the continued consistent market dynamics within the \ngeneric space matched with volume .  Strong volume was a reason for one of the reasons for success \nin the business.   We often talk about the two sides of the equation being in balance.  And indeed, that's \nwhat we continue to see within our generic business, and that is indeed a core component of our \nguidance for Pharma as we carry forward.  One last reminder, I do want to remind that last quarter, we \nactually took our Pharma guidance up from a profit perspective to 7% to 9%.  Thank you.  \n \n Operator:  Thank you, sir. ", "original_text": "And indeed, that's \nwhat we continue to see within our generic business, and that is indeed a core component of our \nguidance for Pharma as we carry forward. "}, "hash": "9d84c8bf5887ffa085a5f4d32af5498210daa2b152eb64a7f6948b3dcf21946b", "class_name": "RelatedNodeInfo"}}, "text": "We often talk about the two sides of the equation being in balance. ", "start_char_idx": 2704, "end_char_idx": 2772, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "ed2167f4-3ac1-404f-bf75-2c0065e928eb": {"__data__": {"id_": "ed2167f4-3ac1-404f-bf75-2c0065e928eb", "embedding": null, "metadata": {"window": "One of the things we  called out in commenting on the strong \nquarter that our Pharma business had was that the continued consistent market dynamics within the \ngeneric space matched with volume .  Strong volume was a reason for one of the reasons for success \nin the business.   We often talk about the two sides of the equation being in balance.  And indeed, that's \nwhat we continue to see within our generic business, and that is indeed a core component of our \nguidance for Pharma as we carry forward.  One last reminder, I do want to remind that last quarter, we \nactually took our Pharma guidance up from a profit perspective to 7% to 9%.  Thank you.  \n \n Operator:  Thank you, sir. ", "original_text": "And indeed, that's \nwhat we continue to see within our generic business, and that is indeed a core component of our \nguidance for Pharma as we carry forward. ", "page_label": "14", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "0ac9f346-07e9-4997-8f28-e5117e7bae25", "node_type": "4", "metadata": {"page_label": "14", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "9234b4689cac640be82a7dbb5c15932ea517de37b8dfde62816f9a47fb53e9a4", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "49a2968d-a6dc-4eda-8f83-78122754776d", "node_type": "1", "metadata": {"window": "Aaron Alt :  Appreciate the question .  One of the things we  called out in commenting on the strong \nquarter that our Pharma business had was that the continued consistent market dynamics within the \ngeneric space matched with volume .  Strong volume was a reason for one of the reasons for success \nin the business.   We often talk about the two sides of the equation being in balance.  And indeed, that's \nwhat we continue to see within our generic business, and that is indeed a core component of our \nguidance for Pharma as we carry forward.  One last reminder, I do want to remind that last quarter, we \nactually took our Pharma guidance up from a profit perspective to 7% to 9%.  Thank you.  \n \n", "original_text": "We often talk about the two sides of the equation being in balance. ", "page_label": "14", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "9c821725388f8df037f3f0a9cff7c1bd85dcbd392d192dce961d7dd009e1d621", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "70ca24c3-901d-4ccf-b35a-9b59b32ccdb7", "node_type": "1", "metadata": {"window": "Strong volume was a reason for one of the reasons for success \nin the business.   We often talk about the two sides of the equation being in balance.  And indeed, that's \nwhat we continue to see within our generic business, and that is indeed a core component of our \nguidance for Pharma as we carry forward.  One last reminder, I do want to remind that last quarter, we \nactually took our Pharma guidance up from a profit perspective to 7% to 9%.  Thank you.  \n \n Operator:  Thank you, sir.  We'll now move to Al len Lutz calling from Bank of America. ", "original_text": "One last reminder, I do want to remind that last quarter, we \nactually took our Pharma guidance up from a profit perspective to 7% to 9%. "}, "hash": "4a2efe06c07a384d6b2b4d2457e86376315ef20b7d32a71fe52ffab41501aeb6", "class_name": "RelatedNodeInfo"}}, "text": "And indeed, that's \nwhat we continue to see within our generic business, and that is indeed a core component of our \nguidance for Pharma as we carry forward. ", "start_char_idx": 2772, "end_char_idx": 2930, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "70ca24c3-901d-4ccf-b35a-9b59b32ccdb7": {"__data__": {"id_": "70ca24c3-901d-4ccf-b35a-9b59b32ccdb7", "embedding": null, "metadata": {"window": "Strong volume was a reason for one of the reasons for success \nin the business.   We often talk about the two sides of the equation being in balance.  And indeed, that's \nwhat we continue to see within our generic business, and that is indeed a core component of our \nguidance for Pharma as we carry forward.  One last reminder, I do want to remind that last quarter, we \nactually took our Pharma guidance up from a profit perspective to 7% to 9%.  Thank you.  \n \n Operator:  Thank you, sir.  We'll now move to Al len Lutz calling from Bank of America. ", "original_text": "One last reminder, I do want to remind that last quarter, we \nactually took our Pharma guidance up from a profit perspective to 7% to 9%. ", "page_label": "14", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "0ac9f346-07e9-4997-8f28-e5117e7bae25", "node_type": "4", "metadata": {"page_label": "14", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "9234b4689cac640be82a7dbb5c15932ea517de37b8dfde62816f9a47fb53e9a4", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "ed2167f4-3ac1-404f-bf75-2c0065e928eb", "node_type": "1", "metadata": {"window": "One of the things we  called out in commenting on the strong \nquarter that our Pharma business had was that the continued consistent market dynamics within the \ngeneric space matched with volume .  Strong volume was a reason for one of the reasons for success \nin the business.   We often talk about the two sides of the equation being in balance.  And indeed, that's \nwhat we continue to see within our generic business, and that is indeed a core component of our \nguidance for Pharma as we carry forward.  One last reminder, I do want to remind that last quarter, we \nactually took our Pharma guidance up from a profit perspective to 7% to 9%.  Thank you.  \n \n Operator:  Thank you, sir. ", "original_text": "And indeed, that's \nwhat we continue to see within our generic business, and that is indeed a core component of our \nguidance for Pharma as we carry forward. ", "page_label": "14", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "7181245947a3004cbabf219ede7e345d1fed3b0edfb2d68721ac062988d80746", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "1ff1d9de-e075-4b4c-a98b-d5531bb82408", "node_type": "1", "metadata": {"window": "We often talk about the two sides of the equation being in balance.  And indeed, that's \nwhat we continue to see within our generic business, and that is indeed a core component of our \nguidance for Pharma as we carry forward.  One last reminder, I do want to remind that last quarter, we \nactually took our Pharma guidance up from a profit perspective to 7% to 9%.  Thank you.  \n \n Operator:  Thank you, sir.  We'll now move to Al len Lutz calling from Bank of America.  Please go \nahead . \n \n", "original_text": "Thank you.  \n \n"}, "hash": "8a660c80d5b4fd38c9e6b006565e1a3d0bed4b9f8e3baa0352d09b7265cbe94c", "class_name": "RelatedNodeInfo"}}, "text": "One last reminder, I do want to remind that last quarter, we \nactually took our Pharma guidance up from a profit perspective to 7% to 9%. ", "start_char_idx": 2930, "end_char_idx": 3068, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "1ff1d9de-e075-4b4c-a98b-d5531bb82408": {"__data__": {"id_": "1ff1d9de-e075-4b4c-a98b-d5531bb82408", "embedding": null, "metadata": {"window": "We often talk about the two sides of the equation being in balance.  And indeed, that's \nwhat we continue to see within our generic business, and that is indeed a core component of our \nguidance for Pharma as we carry forward.  One last reminder, I do want to remind that last quarter, we \nactually took our Pharma guidance up from a profit perspective to 7% to 9%.  Thank you.  \n \n Operator:  Thank you, sir.  We'll now move to Al len Lutz calling from Bank of America.  Please go \nahead . \n \n", "original_text": "Thank you.  \n \n", "page_label": "14", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "0ac9f346-07e9-4997-8f28-e5117e7bae25", "node_type": "4", "metadata": {"page_label": "14", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "9234b4689cac640be82a7dbb5c15932ea517de37b8dfde62816f9a47fb53e9a4", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "70ca24c3-901d-4ccf-b35a-9b59b32ccdb7", "node_type": "1", "metadata": {"window": "Strong volume was a reason for one of the reasons for success \nin the business.   We often talk about the two sides of the equation being in balance.  And indeed, that's \nwhat we continue to see within our generic business, and that is indeed a core component of our \nguidance for Pharma as we carry forward.  One last reminder, I do want to remind that last quarter, we \nactually took our Pharma guidance up from a profit perspective to 7% to 9%.  Thank you.  \n \n Operator:  Thank you, sir.  We'll now move to Al len Lutz calling from Bank of America. ", "original_text": "One last reminder, I do want to remind that last quarter, we \nactually took our Pharma guidance up from a profit perspective to 7% to 9%. ", "page_label": "14", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "50e21218c5bdce914b16accc854bd9894980923edb0cbfaa3a0ca03afb190fec", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "c3283e31-7e49-49dc-befc-2be590f6ff46", "node_type": "1", "metadata": {"window": "And indeed, that's \nwhat we continue to see within our generic business, and that is indeed a core component of our \nguidance for Pharma as we carry forward.  One last reminder, I do want to remind that last quarter, we \nactually took our Pharma guidance up from a profit perspective to 7% to 9%.  Thank you.  \n \n Operator:  Thank you, sir.  We'll now move to Al len Lutz calling from Bank of America.  Please go \nahead . \n \n Allen Lutz:  Good morning. ", "original_text": "Operator:  Thank you, sir. "}, "hash": "7676aa2da8b271755f6d885f2fbdd51b5e1fec09c42fc8582dc6e18399925bf2", "class_name": "RelatedNodeInfo"}}, "text": "Thank you.  \n \n", "start_char_idx": 3068, "end_char_idx": 3083, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "c3283e31-7e49-49dc-befc-2be590f6ff46": {"__data__": {"id_": "c3283e31-7e49-49dc-befc-2be590f6ff46", "embedding": null, "metadata": {"window": "And indeed, that's \nwhat we continue to see within our generic business, and that is indeed a core component of our \nguidance for Pharma as we carry forward.  One last reminder, I do want to remind that last quarter, we \nactually took our Pharma guidance up from a profit perspective to 7% to 9%.  Thank you.  \n \n Operator:  Thank you, sir.  We'll now move to Al len Lutz calling from Bank of America.  Please go \nahead . \n \n Allen Lutz:  Good morning. ", "original_text": "Operator:  Thank you, sir. ", "page_label": "14", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "0ac9f346-07e9-4997-8f28-e5117e7bae25", "node_type": "4", "metadata": {"page_label": "14", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "9234b4689cac640be82a7dbb5c15932ea517de37b8dfde62816f9a47fb53e9a4", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "1ff1d9de-e075-4b4c-a98b-d5531bb82408", "node_type": "1", "metadata": {"window": "We often talk about the two sides of the equation being in balance.  And indeed, that's \nwhat we continue to see within our generic business, and that is indeed a core component of our \nguidance for Pharma as we carry forward.  One last reminder, I do want to remind that last quarter, we \nactually took our Pharma guidance up from a profit perspective to 7% to 9%.  Thank you.  \n \n Operator:  Thank you, sir.  We'll now move to Al len Lutz calling from Bank of America.  Please go \nahead . \n \n", "original_text": "Thank you.  \n \n", "page_label": "14", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "1e96ab97eaf0477c046c5265dd718cad173e2e9a236fac62afa27b8790607b8f", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "5a9b816c-bf9e-4b3c-b205-7fcb01a04871", "node_type": "1", "metadata": {"window": "One last reminder, I do want to remind that last quarter, we \nactually took our Pharma guidance up from a profit perspective to 7% to 9%.  Thank you.  \n \n Operator:  Thank you, sir.  We'll now move to Al len Lutz calling from Bank of America.  Please go \nahead . \n \n Allen Lutz:  Good morning.  Thanks for taking the question. ", "original_text": "We'll now move to Al len Lutz calling from Bank of America. "}, "hash": "1b477c8e956a0a92bfb7269e0453f65a56a8900e52ac0e04a352e0725c88ac15", "class_name": "RelatedNodeInfo"}}, "text": "Operator:  Thank you, sir. ", "start_char_idx": 3083, "end_char_idx": 3110, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "5a9b816c-bf9e-4b3c-b205-7fcb01a04871": {"__data__": {"id_": "5a9b816c-bf9e-4b3c-b205-7fcb01a04871", "embedding": null, "metadata": {"window": "One last reminder, I do want to remind that last quarter, we \nactually took our Pharma guidance up from a profit perspective to 7% to 9%.  Thank you.  \n \n Operator:  Thank you, sir.  We'll now move to Al len Lutz calling from Bank of America.  Please go \nahead . \n \n Allen Lutz:  Good morning.  Thanks for taking the question. ", "original_text": "We'll now move to Al len Lutz calling from Bank of America. ", "page_label": "14", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "0ac9f346-07e9-4997-8f28-e5117e7bae25", "node_type": "4", "metadata": {"page_label": "14", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "9234b4689cac640be82a7dbb5c15932ea517de37b8dfde62816f9a47fb53e9a4", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "c3283e31-7e49-49dc-befc-2be590f6ff46", "node_type": "1", "metadata": {"window": "And indeed, that's \nwhat we continue to see within our generic business, and that is indeed a core component of our \nguidance for Pharma as we carry forward.  One last reminder, I do want to remind that last quarter, we \nactually took our Pharma guidance up from a profit perspective to 7% to 9%.  Thank you.  \n \n Operator:  Thank you, sir.  We'll now move to Al len Lutz calling from Bank of America.  Please go \nahead . \n \n Allen Lutz:  Good morning. ", "original_text": "Operator:  Thank you, sir. ", "page_label": "14", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "a020b348a64101e241ba2b139408858de7d78b4247cd968f803295be5ad6f048", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "3e2c9d33-02f8-4a3e-bd1d-f12cf7de7811", "node_type": "1", "metadata": {"window": "Thank you.  \n \n Operator:  Thank you, sir.  We'll now move to Al len Lutz calling from Bank of America.  Please go \nahead . \n \n Allen Lutz:  Good morning.  Thanks for taking the question.  Can you talk about growth of SG&A in the \nquarter? ", "original_text": "Please go \nahead . \n \n"}, "hash": "aca7a2873d8ed4caedb9ac52a51f194d1e9ebe70c697123e28db6baf9a05e0f2", "class_name": "RelatedNodeInfo"}}, "text": "We'll now move to Al len Lutz calling from Bank of America. ", "start_char_idx": 3110, "end_char_idx": 3170, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "3e2c9d33-02f8-4a3e-bd1d-f12cf7de7811": {"__data__": {"id_": "3e2c9d33-02f8-4a3e-bd1d-f12cf7de7811", "embedding": null, "metadata": {"window": "Thank you.  \n \n Operator:  Thank you, sir.  We'll now move to Al len Lutz calling from Bank of America.  Please go \nahead . \n \n Allen Lutz:  Good morning.  Thanks for taking the question.  Can you talk about growth of SG&A in the \nquarter? ", "original_text": "Please go \nahead . \n \n", "page_label": "14", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "0ac9f346-07e9-4997-8f28-e5117e7bae25", "node_type": "4", "metadata": {"page_label": "14", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "9234b4689cac640be82a7dbb5c15932ea517de37b8dfde62816f9a47fb53e9a4", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "5a9b816c-bf9e-4b3c-b205-7fcb01a04871", "node_type": "1", "metadata": {"window": "One last reminder, I do want to remind that last quarter, we \nactually took our Pharma guidance up from a profit perspective to 7% to 9%.  Thank you.  \n \n Operator:  Thank you, sir.  We'll now move to Al len Lutz calling from Bank of America.  Please go \nahead . \n \n Allen Lutz:  Good morning.  Thanks for taking the question. ", "original_text": "We'll now move to Al len Lutz calling from Bank of America. ", "page_label": "14", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "db827c9324092a30bef96075c3777829ec824b8e0145d468d474457cc7de2cbe", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "55498f05-3c1a-45b8-ac5a-7797c29997fb", "node_type": "1", "metadata": {"window": "Operator:  Thank you, sir.  We'll now move to Al len Lutz calling from Bank of America.  Please go \nahead . \n \n Allen Lutz:  Good morning.  Thanks for taking the question.  Can you talk about growth of SG&A in the \nquarter?  You flagged incremental investments in the business and higher selling costs , can you ", "original_text": "Allen Lutz:  Good morning. "}, "hash": "144e8ac9c070a2aec619027eab734dc2db6061ccfc1d0e94f983f9f7d916448f", "class_name": "RelatedNodeInfo"}}, "text": "Please go \nahead . \n \n", "start_char_idx": 3170, "end_char_idx": 3192, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "55498f05-3c1a-45b8-ac5a-7797c29997fb": {"__data__": {"id_": "55498f05-3c1a-45b8-ac5a-7797c29997fb", "embedding": null, "metadata": {"window": "Operator:  Thank you, sir.  We'll now move to Al len Lutz calling from Bank of America.  Please go \nahead . \n \n Allen Lutz:  Good morning.  Thanks for taking the question.  Can you talk about growth of SG&A in the \nquarter?  You flagged incremental investments in the business and higher selling costs , can you ", "original_text": "Allen Lutz:  Good morning. ", "page_label": "14", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "0ac9f346-07e9-4997-8f28-e5117e7bae25", "node_type": "4", "metadata": {"page_label": "14", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "9234b4689cac640be82a7dbb5c15932ea517de37b8dfde62816f9a47fb53e9a4", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "3e2c9d33-02f8-4a3e-bd1d-f12cf7de7811", "node_type": "1", "metadata": {"window": "Thank you.  \n \n Operator:  Thank you, sir.  We'll now move to Al len Lutz calling from Bank of America.  Please go \nahead . \n \n Allen Lutz:  Good morning.  Thanks for taking the question.  Can you talk about growth of SG&A in the \nquarter? ", "original_text": "Please go \nahead . \n \n", "page_label": "14", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "ed11e8cb390b9652efe04708d0fe49dac231b2af067f9a3da403a03bd67093a3", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "14986283-48a4-43e9-a676-6c172a1c2c08", "node_type": "1", "metadata": {"window": "We'll now move to Al len Lutz calling from Bank of America.  Please go \nahead . \n \n Allen Lutz:  Good morning.  Thanks for taking the question.  Can you talk about growth of SG&A in the \nquarter?  You flagged incremental investments in the business and higher selling costs , can you ", "original_text": "Thanks for taking the question. "}, "hash": "8379d1cb99f1c5d3cf9c3cc3dcb15aacfe44e91d13cab7eab4f37b530174d91b", "class_name": "RelatedNodeInfo"}}, "text": "Allen Lutz:  Good morning. ", "start_char_idx": 3192, "end_char_idx": 3219, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "14986283-48a4-43e9-a676-6c172a1c2c08": {"__data__": {"id_": "14986283-48a4-43e9-a676-6c172a1c2c08", "embedding": null, "metadata": {"window": "We'll now move to Al len Lutz calling from Bank of America.  Please go \nahead . \n \n Allen Lutz:  Good morning.  Thanks for taking the question.  Can you talk about growth of SG&A in the \nquarter?  You flagged incremental investments in the business and higher selling costs , can you ", "original_text": "Thanks for taking the question. ", "page_label": "14", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "0ac9f346-07e9-4997-8f28-e5117e7bae25", "node_type": "4", "metadata": {"page_label": "14", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "9234b4689cac640be82a7dbb5c15932ea517de37b8dfde62816f9a47fb53e9a4", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "55498f05-3c1a-45b8-ac5a-7797c29997fb", "node_type": "1", "metadata": {"window": "Operator:  Thank you, sir.  We'll now move to Al len Lutz calling from Bank of America.  Please go \nahead . \n \n Allen Lutz:  Good morning.  Thanks for taking the question.  Can you talk about growth of SG&A in the \nquarter?  You flagged incremental investments in the business and higher selling costs , can you ", "original_text": "Allen Lutz:  Good morning. ", "page_label": "14", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "15379d8983af6ee843c4868d8575ef60e68c85de31c0c50e9a6fe73d1a3b460f", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "5045c9d5-9983-4b1f-86d0-32f8a239d857", "node_type": "1", "metadata": {"window": "Please go \nahead . \n \n Allen Lutz:  Good morning.  Thanks for taking the question.  Can you talk about growth of SG&A in the \nquarter?  You flagged incremental investments in the business and higher selling costs , can you ", "original_text": "Can you talk about growth of SG&A in the \nquarter? "}, "hash": "9ed4a896c92be88ee850d943a19d5ac774b66f67f5ed3ca8e673aa6bce74e61f", "class_name": "RelatedNodeInfo"}}, "text": "Thanks for taking the question. ", "start_char_idx": 3219, "end_char_idx": 3251, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "5045c9d5-9983-4b1f-86d0-32f8a239d857": {"__data__": {"id_": "5045c9d5-9983-4b1f-86d0-32f8a239d857", "embedding": null, "metadata": {"window": "Please go \nahead . \n \n Allen Lutz:  Good morning.  Thanks for taking the question.  Can you talk about growth of SG&A in the \nquarter?  You flagged incremental investments in the business and higher selling costs , can you ", "original_text": "Can you talk about growth of SG&A in the \nquarter? ", "page_label": "14", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "0ac9f346-07e9-4997-8f28-e5117e7bae25", "node_type": "4", "metadata": {"page_label": "14", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "9234b4689cac640be82a7dbb5c15932ea517de37b8dfde62816f9a47fb53e9a4", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "14986283-48a4-43e9-a676-6c172a1c2c08", "node_type": "1", "metadata": {"window": "We'll now move to Al len Lutz calling from Bank of America.  Please go \nahead . \n \n Allen Lutz:  Good morning.  Thanks for taking the question.  Can you talk about growth of SG&A in the \nquarter?  You flagged incremental investments in the business and higher selling costs , can you ", "original_text": "Thanks for taking the question. ", "page_label": "14", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "98da9a98f3581f0bb4f82cd10fdc68dacb29147333e3f7b099b20e447a7206eb", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "1bee3d3c-a2d6-41e5-a4a4-4a0b97d38350", "node_type": "1", "metadata": {"window": "Allen Lutz:  Good morning.  Thanks for taking the question.  Can you talk about growth of SG&A in the \nquarter?  You flagged incremental investments in the business and higher selling costs , can you ", "original_text": "You flagged incremental investments in the business and higher selling costs , can you "}, "hash": "4a510bc77ef71191871e6ec56fb82247333adab302c5bff50e78d7fd619c8462", "class_name": "RelatedNodeInfo"}}, "text": "Can you talk about growth of SG&A in the \nquarter? ", "start_char_idx": 3251, "end_char_idx": 3302, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "1bee3d3c-a2d6-41e5-a4a4-4a0b97d38350": {"__data__": {"id_": "1bee3d3c-a2d6-41e5-a4a4-4a0b97d38350", "embedding": null, "metadata": {"window": "Allen Lutz:  Good morning.  Thanks for taking the question.  Can you talk about growth of SG&A in the \nquarter?  You flagged incremental investments in the business and higher selling costs , can you ", "original_text": "You flagged incremental investments in the business and higher selling costs , can you ", "page_label": "14", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "0ac9f346-07e9-4997-8f28-e5117e7bae25", "node_type": "4", "metadata": {"page_label": "14", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "9234b4689cac640be82a7dbb5c15932ea517de37b8dfde62816f9a47fb53e9a4", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "5045c9d5-9983-4b1f-86d0-32f8a239d857", "node_type": "1", "metadata": {"window": "Please go \nahead . \n \n Allen Lutz:  Good morning.  Thanks for taking the question.  Can you talk about growth of SG&A in the \nquarter?  You flagged incremental investments in the business and higher selling costs , can you ", "original_text": "Can you talk about growth of SG&A in the \nquarter? ", "page_label": "14", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "7050be1e1619a588f657c0a78f78049e8c2e69194bcce73ac37a3476988b93ed", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "989f35b7-f155-4e88-9b3d-99dc4b82b067", "node_type": "1", "metadata": {"window": " \nPage 15 of 19 \n \nunpack exactly what those expenses are?  And then how should we think about SG&A growth for the \nremainder of the year?  Thanks.  \n \n Aaron Alt:  Happy to offer some perspective. ", "original_text": " \nPage 15 of 19 \n \nunpack exactly what those expenses are? "}, "hash": "95773043a16403ac5b3d2dc7271c3f8dfbcc87e01d70a25def6549214c461a49", "class_name": "RelatedNodeInfo"}}, "text": "You flagged incremental investments in the business and higher selling costs , can you ", "start_char_idx": 3302, "end_char_idx": 3389, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "989f35b7-f155-4e88-9b3d-99dc4b82b067": {"__data__": {"id_": "989f35b7-f155-4e88-9b3d-99dc4b82b067", "embedding": null, "metadata": {"window": " \nPage 15 of 19 \n \nunpack exactly what those expenses are?  And then how should we think about SG&A growth for the \nremainder of the year?  Thanks.  \n \n Aaron Alt:  Happy to offer some perspective. ", "original_text": " \nPage 15 of 19 \n \nunpack exactly what those expenses are? ", "page_label": "15", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "5cf92087-e35d-4fba-85d3-821d01035638", "node_type": "4", "metadata": {"page_label": "15", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "8a3bc03b84fafd2339b44712a98220bec7cd43c6e8428ad74a2f9c58c6c3dcac", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "1bee3d3c-a2d6-41e5-a4a4-4a0b97d38350", "node_type": "1", "metadata": {"window": "Allen Lutz:  Good morning.  Thanks for taking the question.  Can you talk about growth of SG&A in the \nquarter?  You flagged incremental investments in the business and higher selling costs , can you ", "original_text": "You flagged incremental investments in the business and higher selling costs , can you ", "page_label": "14", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "e058ddbebe76babf1dfc9382f18c160ecf66c46c4057f098efb6bd380dff125b", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "284a148d-feac-4eb3-a6a9-8e60321f9f1c", "node_type": "1", "metadata": {"window": " \nPage 15 of 19 \n \nunpack exactly what those expenses are?  And then how should we think about SG&A growth for the \nremainder of the year?  Thanks.  \n \n Aaron Alt:  Happy to offer some perspective.  We were pleased in the quarter to actually achieve \noperating leverage with gross profit growing faster than SG&A. ", "original_text": "And then how should we think about SG&A growth for the \nremainder of the year? "}, "hash": "36f35845d814328b12f8f9f54602c4e8f0717c2693e994b15dcdc4039589e398", "class_name": "RelatedNodeInfo"}}, "text": " \nPage 15 of 19 \n \nunpack exactly what those expenses are? ", "start_char_idx": 0, "end_char_idx": 59, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "284a148d-feac-4eb3-a6a9-8e60321f9f1c": {"__data__": {"id_": "284a148d-feac-4eb3-a6a9-8e60321f9f1c", "embedding": null, "metadata": {"window": " \nPage 15 of 19 \n \nunpack exactly what those expenses are?  And then how should we think about SG&A growth for the \nremainder of the year?  Thanks.  \n \n Aaron Alt:  Happy to offer some perspective.  We were pleased in the quarter to actually achieve \noperating leverage with gross profit growing faster than SG&A. ", "original_text": "And then how should we think about SG&A growth for the \nremainder of the year? ", "page_label": "15", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "5cf92087-e35d-4fba-85d3-821d01035638", "node_type": "4", "metadata": {"page_label": "15", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "8a3bc03b84fafd2339b44712a98220bec7cd43c6e8428ad74a2f9c58c6c3dcac", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "989f35b7-f155-4e88-9b3d-99dc4b82b067", "node_type": "1", "metadata": {"window": " \nPage 15 of 19 \n \nunpack exactly what those expenses are?  And then how should we think about SG&A growth for the \nremainder of the year?  Thanks.  \n \n Aaron Alt:  Happy to offer some perspective. ", "original_text": " \nPage 15 of 19 \n \nunpack exactly what those expenses are? ", "page_label": "15", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "c55d6c0a34e7cbc548919d0e4c2f9c857fefe9bd80df1a562c0d717383904a86", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "65dda52d-a8fd-425e-bbea-2c466aaddadf", "node_type": "1", "metadata": {"window": " \nPage 15 of 19 \n \nunpack exactly what those expenses are?  And then how should we think about SG&A growth for the \nremainder of the year?  Thanks.  \n \n Aaron Alt:  Happy to offer some perspective.  We were pleased in the quarter to actually achieve \noperating leverage with gross profit growing faster than SG&A.  SG&A did grow, of course, volume \nalso grew. ", "original_text": "Thanks.  \n \n"}, "hash": "aa4da3862b1dd5ddac7f81830524a3c8cb571154de4871e3670954f84ff660c4", "class_name": "RelatedNodeInfo"}}, "text": "And then how should we think about SG&A growth for the \nremainder of the year? ", "start_char_idx": 59, "end_char_idx": 138, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "65dda52d-a8fd-425e-bbea-2c466aaddadf": {"__data__": {"id_": "65dda52d-a8fd-425e-bbea-2c466aaddadf", "embedding": null, "metadata": {"window": " \nPage 15 of 19 \n \nunpack exactly what those expenses are?  And then how should we think about SG&A growth for the \nremainder of the year?  Thanks.  \n \n Aaron Alt:  Happy to offer some perspective.  We were pleased in the quarter to actually achieve \noperating leverage with gross profit growing faster than SG&A.  SG&A did grow, of course, volume \nalso grew. ", "original_text": "Thanks.  \n \n", "page_label": "15", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "5cf92087-e35d-4fba-85d3-821d01035638", "node_type": "4", "metadata": {"page_label": "15", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "8a3bc03b84fafd2339b44712a98220bec7cd43c6e8428ad74a2f9c58c6c3dcac", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "284a148d-feac-4eb3-a6a9-8e60321f9f1c", "node_type": "1", "metadata": {"window": " \nPage 15 of 19 \n \nunpack exactly what those expenses are?  And then how should we think about SG&A growth for the \nremainder of the year?  Thanks.  \n \n Aaron Alt:  Happy to offer some perspective.  We were pleased in the quarter to actually achieve \noperating leverage with gross profit growing faster than SG&A. ", "original_text": "And then how should we think about SG&A growth for the \nremainder of the year? ", "page_label": "15", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "2dd73142bfa3b99bc8bc672902cb4c091540d0c0effab890349d61956ae44f54", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "66bb4983-da23-4619-99dc-cc2265374dd6", "node_type": "1", "metadata": {"window": " \nPage 15 of 19 \n \nunpack exactly what those expenses are?  And then how should we think about SG&A growth for the \nremainder of the year?  Thanks.  \n \n Aaron Alt:  Happy to offer some perspective.  We were pleased in the quarter to actually achieve \noperating leverage with gross profit growing faster than SG&A.  SG&A did grow, of course, volume \nalso grew.  And so, the primary component of our increase in cost was tied to the variable cost of \nserving higher volumes. ", "original_text": "Aaron Alt:  Happy to offer some perspective. "}, "hash": "93955ccf02aebc46894897c90db15157922c4a5bf5c5f1e9c8d9680d6bddd24d", "class_name": "RelatedNodeInfo"}}, "text": "Thanks.  \n \n", "start_char_idx": 138, "end_char_idx": 150, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "66bb4983-da23-4619-99dc-cc2265374dd6": {"__data__": {"id_": "66bb4983-da23-4619-99dc-cc2265374dd6", "embedding": null, "metadata": {"window": " \nPage 15 of 19 \n \nunpack exactly what those expenses are?  And then how should we think about SG&A growth for the \nremainder of the year?  Thanks.  \n \n Aaron Alt:  Happy to offer some perspective.  We were pleased in the quarter to actually achieve \noperating leverage with gross profit growing faster than SG&A.  SG&A did grow, of course, volume \nalso grew.  And so, the primary component of our increase in cost was tied to the variable cost of \nserving higher volumes. ", "original_text": "Aaron Alt:  Happy to offer some perspective. ", "page_label": "15", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "5cf92087-e35d-4fba-85d3-821d01035638", "node_type": "4", "metadata": {"page_label": "15", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "8a3bc03b84fafd2339b44712a98220bec7cd43c6e8428ad74a2f9c58c6c3dcac", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "65dda52d-a8fd-425e-bbea-2c466aaddadf", "node_type": "1", "metadata": {"window": " \nPage 15 of 19 \n \nunpack exactly what those expenses are?  And then how should we think about SG&A growth for the \nremainder of the year?  Thanks.  \n \n Aaron Alt:  Happy to offer some perspective.  We were pleased in the quarter to actually achieve \noperating leverage with gross profit growing faster than SG&A.  SG&A did grow, of course, volume \nalso grew. ", "original_text": "Thanks.  \n \n", "page_label": "15", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "5be2705906317f2509886376030a470fbdc316614da227565235691151ea89a3", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "43569f33-965b-4263-beeb-1a03d93cc6b6", "node_type": "1", "metadata": {"window": "And then how should we think about SG&A growth for the \nremainder of the year?  Thanks.  \n \n Aaron Alt:  Happy to offer some perspective.  We were pleased in the quarter to actually achieve \noperating leverage with gross profit growing faster than SG&A.  SG&A did grow, of course, volume \nalso grew.  And so, the primary component of our increase in cost was tied to the variable cost of \nserving higher volumes.  It is also the case though that, as Jason has highlighted in his strategic \nremarks, we are investing against our business. ", "original_text": "We were pleased in the quarter to actually achieve \noperating leverage with gross profit growing faster than SG&A. "}, "hash": "3659dd10ad5c4c58db6ee7f8ada883db84b3d860167b1d8d07d91a65be6773e2", "class_name": "RelatedNodeInfo"}}, "text": "Aaron Alt:  Happy to offer some perspective. ", "start_char_idx": 150, "end_char_idx": 195, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "43569f33-965b-4263-beeb-1a03d93cc6b6": {"__data__": {"id_": "43569f33-965b-4263-beeb-1a03d93cc6b6", "embedding": null, "metadata": {"window": "And then how should we think about SG&A growth for the \nremainder of the year?  Thanks.  \n \n Aaron Alt:  Happy to offer some perspective.  We were pleased in the quarter to actually achieve \noperating leverage with gross profit growing faster than SG&A.  SG&A did grow, of course, volume \nalso grew.  And so, the primary component of our increase in cost was tied to the variable cost of \nserving higher volumes.  It is also the case though that, as Jason has highlighted in his strategic \nremarks, we are investing against our business. ", "original_text": "We were pleased in the quarter to actually achieve \noperating leverage with gross profit growing faster than SG&A. ", "page_label": "15", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "5cf92087-e35d-4fba-85d3-821d01035638", "node_type": "4", "metadata": {"page_label": "15", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "8a3bc03b84fafd2339b44712a98220bec7cd43c6e8428ad74a2f9c58c6c3dcac", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "66bb4983-da23-4619-99dc-cc2265374dd6", "node_type": "1", "metadata": {"window": " \nPage 15 of 19 \n \nunpack exactly what those expenses are?  And then how should we think about SG&A growth for the \nremainder of the year?  Thanks.  \n \n Aaron Alt:  Happy to offer some perspective.  We were pleased in the quarter to actually achieve \noperating leverage with gross profit growing faster than SG&A.  SG&A did grow, of course, volume \nalso grew.  And so, the primary component of our increase in cost was tied to the variable cost of \nserving higher volumes. ", "original_text": "Aaron Alt:  Happy to offer some perspective. ", "page_label": "15", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "766d27041d50ff1e276ba5f0da31d257d0f3cc008912dfd9b8d456c2f9ea05da", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "af2a4a68-63b8-491e-a0c5-23acb4b11f5a", "node_type": "1", "metadata": {"window": "Thanks.  \n \n Aaron Alt:  Happy to offer some perspective.  We were pleased in the quarter to actually achieve \noperating leverage with gross profit growing faster than SG&A.  SG&A did grow, of course, volume \nalso grew.  And so, the primary component of our increase in cost was tied to the variable cost of \nserving higher volumes.  It is also the case though that, as Jason has highlighted in his strategic \nremarks, we are investing against our business.  And some of the SG&A growth was purposeful \nrelative to the investments we're making in places like Navista \u2122 and other elements of our  growth \nplans. ", "original_text": "SG&A did grow, of course, volume \nalso grew. "}, "hash": "bec770dfaebf1b88a4c4005868612c4b1cc417cb127568153169329ccf0785e6", "class_name": "RelatedNodeInfo"}}, "text": "We were pleased in the quarter to actually achieve \noperating leverage with gross profit growing faster than SG&A. ", "start_char_idx": 195, "end_char_idx": 310, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "af2a4a68-63b8-491e-a0c5-23acb4b11f5a": {"__data__": {"id_": "af2a4a68-63b8-491e-a0c5-23acb4b11f5a", "embedding": null, "metadata": {"window": "Thanks.  \n \n Aaron Alt:  Happy to offer some perspective.  We were pleased in the quarter to actually achieve \noperating leverage with gross profit growing faster than SG&A.  SG&A did grow, of course, volume \nalso grew.  And so, the primary component of our increase in cost was tied to the variable cost of \nserving higher volumes.  It is also the case though that, as Jason has highlighted in his strategic \nremarks, we are investing against our business.  And some of the SG&A growth was purposeful \nrelative to the investments we're making in places like Navista \u2122 and other elements of our  growth \nplans. ", "original_text": "SG&A did grow, of course, volume \nalso grew. ", "page_label": "15", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "5cf92087-e35d-4fba-85d3-821d01035638", "node_type": "4", "metadata": {"page_label": "15", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "8a3bc03b84fafd2339b44712a98220bec7cd43c6e8428ad74a2f9c58c6c3dcac", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "43569f33-965b-4263-beeb-1a03d93cc6b6", "node_type": "1", "metadata": {"window": "And then how should we think about SG&A growth for the \nremainder of the year?  Thanks.  \n \n Aaron Alt:  Happy to offer some perspective.  We were pleased in the quarter to actually achieve \noperating leverage with gross profit growing faster than SG&A.  SG&A did grow, of course, volume \nalso grew.  And so, the primary component of our increase in cost was tied to the variable cost of \nserving higher volumes.  It is also the case though that, as Jason has highlighted in his strategic \nremarks, we are investing against our business. ", "original_text": "We were pleased in the quarter to actually achieve \noperating leverage with gross profit growing faster than SG&A. ", "page_label": "15", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "5c773679bb46b6427824f163897259ed159a9d8f5bf8db8d5433f0946cad7fe9", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "d0b877e8-2713-45b2-a7d7-46144db0af75", "node_type": "1", "metadata": {"window": "Aaron Alt:  Happy to offer some perspective.  We were pleased in the quarter to actually achieve \noperating leverage with gross profit growing faster than SG&A.  SG&A did grow, of course, volume \nalso grew.  And so, the primary component of our increase in cost was tied to the variable cost of \nserving higher volumes.  It is also the case though that, as Jason has highlighted in his strategic \nremarks, we are investing against our business.  And some of the SG&A growth was purposeful \nrelative to the investments we're making in places like Navista \u2122 and other elements of our  growth \nplans.  I will end with the fact that we are very focused on SG&A as a whole, and the team continues \nto look for further opportunities as we have  in prior years to optimize our cost structure.  \n \n", "original_text": "And so, the primary component of our increase in cost was tied to the variable cost of \nserving higher volumes. "}, "hash": "32dfec05004ec94c52e4d153555bf13c74d9a609f69bd764b5cb21c31f6da2ea", "class_name": "RelatedNodeInfo"}}, "text": "SG&A did grow, of course, volume \nalso grew. ", "start_char_idx": 310, "end_char_idx": 355, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "d0b877e8-2713-45b2-a7d7-46144db0af75": {"__data__": {"id_": "d0b877e8-2713-45b2-a7d7-46144db0af75", "embedding": null, "metadata": {"window": "Aaron Alt:  Happy to offer some perspective.  We were pleased in the quarter to actually achieve \noperating leverage with gross profit growing faster than SG&A.  SG&A did grow, of course, volume \nalso grew.  And so, the primary component of our increase in cost was tied to the variable cost of \nserving higher volumes.  It is also the case though that, as Jason has highlighted in his strategic \nremarks, we are investing against our business.  And some of the SG&A growth was purposeful \nrelative to the investments we're making in places like Navista \u2122 and other elements of our  growth \nplans.  I will end with the fact that we are very focused on SG&A as a whole, and the team continues \nto look for further opportunities as we have  in prior years to optimize our cost structure.  \n \n", "original_text": "And so, the primary component of our increase in cost was tied to the variable cost of \nserving higher volumes. ", "page_label": "15", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "5cf92087-e35d-4fba-85d3-821d01035638", "node_type": "4", "metadata": {"page_label": "15", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "8a3bc03b84fafd2339b44712a98220bec7cd43c6e8428ad74a2f9c58c6c3dcac", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "af2a4a68-63b8-491e-a0c5-23acb4b11f5a", "node_type": "1", "metadata": {"window": "Thanks.  \n \n Aaron Alt:  Happy to offer some perspective.  We were pleased in the quarter to actually achieve \noperating leverage with gross profit growing faster than SG&A.  SG&A did grow, of course, volume \nalso grew.  And so, the primary component of our increase in cost was tied to the variable cost of \nserving higher volumes.  It is also the case though that, as Jason has highlighted in his strategic \nremarks, we are investing against our business.  And some of the SG&A growth was purposeful \nrelative to the investments we're making in places like Navista \u2122 and other elements of our  growth \nplans. ", "original_text": "SG&A did grow, of course, volume \nalso grew. ", "page_label": "15", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "6620fb78256dde2696b19113b4e7062a905e6a3b24219f70bcc725d78717de02", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "2649aa6d-2acc-46ae-a7c2-61ff0360352d", "node_type": "1", "metadata": {"window": "We were pleased in the quarter to actually achieve \noperating leverage with gross profit growing faster than SG&A.  SG&A did grow, of course, volume \nalso grew.  And so, the primary component of our increase in cost was tied to the variable cost of \nserving higher volumes.  It is also the case though that, as Jason has highlighted in his strategic \nremarks, we are investing against our business.  And some of the SG&A growth was purposeful \nrelative to the investments we're making in places like Navista \u2122 and other elements of our  growth \nplans.  I will end with the fact that we are very focused on SG&A as a whole, and the team continues \nto look for further opportunities as we have  in prior years to optimize our cost structure.  \n \n Operator:  Thank you very much, sir. ", "original_text": "It is also the case though that, as Jason has highlighted in his strategic \nremarks, we are investing against our business. "}, "hash": "75f7a8554c32c6145a4c009183e12545cbd5bd8097005967f8d4047d34dd9015", "class_name": "RelatedNodeInfo"}}, "text": "And so, the primary component of our increase in cost was tied to the variable cost of \nserving higher volumes. ", "start_char_idx": 355, "end_char_idx": 467, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "2649aa6d-2acc-46ae-a7c2-61ff0360352d": {"__data__": {"id_": "2649aa6d-2acc-46ae-a7c2-61ff0360352d", "embedding": null, "metadata": {"window": "We were pleased in the quarter to actually achieve \noperating leverage with gross profit growing faster than SG&A.  SG&A did grow, of course, volume \nalso grew.  And so, the primary component of our increase in cost was tied to the variable cost of \nserving higher volumes.  It is also the case though that, as Jason has highlighted in his strategic \nremarks, we are investing against our business.  And some of the SG&A growth was purposeful \nrelative to the investments we're making in places like Navista \u2122 and other elements of our  growth \nplans.  I will end with the fact that we are very focused on SG&A as a whole, and the team continues \nto look for further opportunities as we have  in prior years to optimize our cost structure.  \n \n Operator:  Thank you very much, sir. ", "original_text": "It is also the case though that, as Jason has highlighted in his strategic \nremarks, we are investing against our business. ", "page_label": "15", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "5cf92087-e35d-4fba-85d3-821d01035638", "node_type": "4", "metadata": {"page_label": "15", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "8a3bc03b84fafd2339b44712a98220bec7cd43c6e8428ad74a2f9c58c6c3dcac", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "d0b877e8-2713-45b2-a7d7-46144db0af75", "node_type": "1", "metadata": {"window": "Aaron Alt:  Happy to offer some perspective.  We were pleased in the quarter to actually achieve \noperating leverage with gross profit growing faster than SG&A.  SG&A did grow, of course, volume \nalso grew.  And so, the primary component of our increase in cost was tied to the variable cost of \nserving higher volumes.  It is also the case though that, as Jason has highlighted in his strategic \nremarks, we are investing against our business.  And some of the SG&A growth was purposeful \nrelative to the investments we're making in places like Navista \u2122 and other elements of our  growth \nplans.  I will end with the fact that we are very focused on SG&A as a whole, and the team continues \nto look for further opportunities as we have  in prior years to optimize our cost structure.  \n \n", "original_text": "And so, the primary component of our increase in cost was tied to the variable cost of \nserving higher volumes. ", "page_label": "15", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "48526824da52f20a7f93a612dfc12bcf28533cd78b19aaa835836bd67a5a90b8", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "14e4659c-c425-4aea-9c16-7247178e524b", "node_type": "1", "metadata": {"window": "SG&A did grow, of course, volume \nalso grew.  And so, the primary component of our increase in cost was tied to the variable cost of \nserving higher volumes.  It is also the case though that, as Jason has highlighted in his strategic \nremarks, we are investing against our business.  And some of the SG&A growth was purposeful \nrelative to the investments we're making in places like Navista \u2122 and other elements of our  growth \nplans.  I will end with the fact that we are very focused on SG&A as a whole, and the team continues \nto look for further opportunities as we have  in prior years to optimize our cost structure.  \n \n Operator:  Thank you very much, sir.  We'll now move to Kevin Caliendo of UBS. ", "original_text": "And some of the SG&A growth was purposeful \nrelative to the investments we're making in places like Navista \u2122 and other elements of our  growth \nplans. "}, "hash": "a61ed3ccf43cee1e3eb703af0d859fa45b251585935b72f33298f7242f30df5e", "class_name": "RelatedNodeInfo"}}, "text": "It is also the case though that, as Jason has highlighted in his strategic \nremarks, we are investing against our business. ", "start_char_idx": 467, "end_char_idx": 591, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "14e4659c-c425-4aea-9c16-7247178e524b": {"__data__": {"id_": "14e4659c-c425-4aea-9c16-7247178e524b", "embedding": null, "metadata": {"window": "SG&A did grow, of course, volume \nalso grew.  And so, the primary component of our increase in cost was tied to the variable cost of \nserving higher volumes.  It is also the case though that, as Jason has highlighted in his strategic \nremarks, we are investing against our business.  And some of the SG&A growth was purposeful \nrelative to the investments we're making in places like Navista \u2122 and other elements of our  growth \nplans.  I will end with the fact that we are very focused on SG&A as a whole, and the team continues \nto look for further opportunities as we have  in prior years to optimize our cost structure.  \n \n Operator:  Thank you very much, sir.  We'll now move to Kevin Caliendo of UBS. ", "original_text": "And some of the SG&A growth was purposeful \nrelative to the investments we're making in places like Navista \u2122 and other elements of our  growth \nplans. ", "page_label": "15", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "5cf92087-e35d-4fba-85d3-821d01035638", "node_type": "4", "metadata": {"page_label": "15", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "8a3bc03b84fafd2339b44712a98220bec7cd43c6e8428ad74a2f9c58c6c3dcac", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "2649aa6d-2acc-46ae-a7c2-61ff0360352d", "node_type": "1", "metadata": {"window": "We were pleased in the quarter to actually achieve \noperating leverage with gross profit growing faster than SG&A.  SG&A did grow, of course, volume \nalso grew.  And so, the primary component of our increase in cost was tied to the variable cost of \nserving higher volumes.  It is also the case though that, as Jason has highlighted in his strategic \nremarks, we are investing against our business.  And some of the SG&A growth was purposeful \nrelative to the investments we're making in places like Navista \u2122 and other elements of our  growth \nplans.  I will end with the fact that we are very focused on SG&A as a whole, and the team continues \nto look for further opportunities as we have  in prior years to optimize our cost structure.  \n \n Operator:  Thank you very much, sir. ", "original_text": "It is also the case though that, as Jason has highlighted in his strategic \nremarks, we are investing against our business. ", "page_label": "15", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "e4ef62e0429f3c941819ae6a9d3cd34e02aa7738c4155e638836e3a34a7091f9", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "b60cf5a6-c47a-4d20-9e03-83fd0d70b1a7", "node_type": "1", "metadata": {"window": "And so, the primary component of our increase in cost was tied to the variable cost of \nserving higher volumes.  It is also the case though that, as Jason has highlighted in his strategic \nremarks, we are investing against our business.  And some of the SG&A growth was purposeful \nrelative to the investments we're making in places like Navista \u2122 and other elements of our  growth \nplans.  I will end with the fact that we are very focused on SG&A as a whole, and the team continues \nto look for further opportunities as we have  in prior years to optimize our cost structure.  \n \n Operator:  Thank you very much, sir.  We'll now move to Kevin Caliendo of UBS.  Please go ahead.  \n \n", "original_text": "I will end with the fact that we are very focused on SG&A as a whole, and the team continues \nto look for further opportunities as we have  in prior years to optimize our cost structure.  \n \n"}, "hash": "0c64d104e0c1cdf8a3cc0bf69f70a19a562193ce56771a454640fb52fb5fe7e2", "class_name": "RelatedNodeInfo"}}, "text": "And some of the SG&A growth was purposeful \nrelative to the investments we're making in places like Navista \u2122 and other elements of our  growth \nplans. ", "start_char_idx": 591, "end_char_idx": 743, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "b60cf5a6-c47a-4d20-9e03-83fd0d70b1a7": {"__data__": {"id_": "b60cf5a6-c47a-4d20-9e03-83fd0d70b1a7", "embedding": null, "metadata": {"window": "And so, the primary component of our increase in cost was tied to the variable cost of \nserving higher volumes.  It is also the case though that, as Jason has highlighted in his strategic \nremarks, we are investing against our business.  And some of the SG&A growth was purposeful \nrelative to the investments we're making in places like Navista \u2122 and other elements of our  growth \nplans.  I will end with the fact that we are very focused on SG&A as a whole, and the team continues \nto look for further opportunities as we have  in prior years to optimize our cost structure.  \n \n Operator:  Thank you very much, sir.  We'll now move to Kevin Caliendo of UBS.  Please go ahead.  \n \n", "original_text": "I will end with the fact that we are very focused on SG&A as a whole, and the team continues \nto look for further opportunities as we have  in prior years to optimize our cost structure.  \n \n", "page_label": "15", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "5cf92087-e35d-4fba-85d3-821d01035638", "node_type": "4", "metadata": {"page_label": "15", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "8a3bc03b84fafd2339b44712a98220bec7cd43c6e8428ad74a2f9c58c6c3dcac", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "14e4659c-c425-4aea-9c16-7247178e524b", "node_type": "1", "metadata": {"window": "SG&A did grow, of course, volume \nalso grew.  And so, the primary component of our increase in cost was tied to the variable cost of \nserving higher volumes.  It is also the case though that, as Jason has highlighted in his strategic \nremarks, we are investing against our business.  And some of the SG&A growth was purposeful \nrelative to the investments we're making in places like Navista \u2122 and other elements of our  growth \nplans.  I will end with the fact that we are very focused on SG&A as a whole, and the team continues \nto look for further opportunities as we have  in prior years to optimize our cost structure.  \n \n Operator:  Thank you very much, sir.  We'll now move to Kevin Caliendo of UBS. ", "original_text": "And some of the SG&A growth was purposeful \nrelative to the investments we're making in places like Navista \u2122 and other elements of our  growth \nplans. ", "page_label": "15", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "dfd42de193e60246323231b0c688649d5dcbbf278582c29d5eb9e9c07a49a682", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "00d39fc7-7e04-4c84-94d5-3e0bbb38193b", "node_type": "1", "metadata": {"window": "It is also the case though that, as Jason has highlighted in his strategic \nremarks, we are investing against our business.  And some of the SG&A growth was purposeful \nrelative to the investments we're making in places like Navista \u2122 and other elements of our  growth \nplans.  I will end with the fact that we are very focused on SG&A as a whole, and the team continues \nto look for further opportunities as we have  in prior years to optimize our cost structure.  \n \n Operator:  Thank you very much, sir.  We'll now move to Kevin Caliendo of UBS.  Please go ahead.  \n \n Kevin Caliendo:   Thanks. ", "original_text": "Operator:  Thank you very much, sir. "}, "hash": "d947b4569ce49834a1199caf46ef1611b458a88cf3ac960e76dfaa8438796492", "class_name": "RelatedNodeInfo"}}, "text": "I will end with the fact that we are very focused on SG&A as a whole, and the team continues \nto look for further opportunities as we have  in prior years to optimize our cost structure.  \n \n", "start_char_idx": 743, "end_char_idx": 934, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "00d39fc7-7e04-4c84-94d5-3e0bbb38193b": {"__data__": {"id_": "00d39fc7-7e04-4c84-94d5-3e0bbb38193b", "embedding": null, "metadata": {"window": "It is also the case though that, as Jason has highlighted in his strategic \nremarks, we are investing against our business.  And some of the SG&A growth was purposeful \nrelative to the investments we're making in places like Navista \u2122 and other elements of our  growth \nplans.  I will end with the fact that we are very focused on SG&A as a whole, and the team continues \nto look for further opportunities as we have  in prior years to optimize our cost structure.  \n \n Operator:  Thank you very much, sir.  We'll now move to Kevin Caliendo of UBS.  Please go ahead.  \n \n Kevin Caliendo:   Thanks. ", "original_text": "Operator:  Thank you very much, sir. ", "page_label": "15", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "5cf92087-e35d-4fba-85d3-821d01035638", "node_type": "4", "metadata": {"page_label": "15", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "8a3bc03b84fafd2339b44712a98220bec7cd43c6e8428ad74a2f9c58c6c3dcac", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "b60cf5a6-c47a-4d20-9e03-83fd0d70b1a7", "node_type": "1", "metadata": {"window": "And so, the primary component of our increase in cost was tied to the variable cost of \nserving higher volumes.  It is also the case though that, as Jason has highlighted in his strategic \nremarks, we are investing against our business.  And some of the SG&A growth was purposeful \nrelative to the investments we're making in places like Navista \u2122 and other elements of our  growth \nplans.  I will end with the fact that we are very focused on SG&A as a whole, and the team continues \nto look for further opportunities as we have  in prior years to optimize our cost structure.  \n \n Operator:  Thank you very much, sir.  We'll now move to Kevin Caliendo of UBS.  Please go ahead.  \n \n", "original_text": "I will end with the fact that we are very focused on SG&A as a whole, and the team continues \nto look for further opportunities as we have  in prior years to optimize our cost structure.  \n \n", "page_label": "15", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "d102798b59e7ecd3106d8eea39fae9f9c38135081c3121cfd4079add2c79faed", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "f357ae8a-9a96-4e19-a929-34613b60b09f", "node_type": "1", "metadata": {"window": "And some of the SG&A growth was purposeful \nrelative to the investments we're making in places like Navista \u2122 and other elements of our  growth \nplans.  I will end with the fact that we are very focused on SG&A as a whole, and the team continues \nto look for further opportunities as we have  in prior years to optimize our cost structure.  \n \n Operator:  Thank you very much, sir.  We'll now move to Kevin Caliendo of UBS.  Please go ahead.  \n \n Kevin Caliendo:   Thanks.  Thanks for taking my question. ", "original_text": "We'll now move to Kevin Caliendo of UBS. "}, "hash": "c865fa91736950b732e263a07810e1bc3733fdd4c16bb6591244e81eba23e47f", "class_name": "RelatedNodeInfo"}}, "text": "Operator:  Thank you very much, sir. ", "start_char_idx": 934, "end_char_idx": 971, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "f357ae8a-9a96-4e19-a929-34613b60b09f": {"__data__": {"id_": "f357ae8a-9a96-4e19-a929-34613b60b09f", "embedding": null, "metadata": {"window": "And some of the SG&A growth was purposeful \nrelative to the investments we're making in places like Navista \u2122 and other elements of our  growth \nplans.  I will end with the fact that we are very focused on SG&A as a whole, and the team continues \nto look for further opportunities as we have  in prior years to optimize our cost structure.  \n \n Operator:  Thank you very much, sir.  We'll now move to Kevin Caliendo of UBS.  Please go ahead.  \n \n Kevin Caliendo:   Thanks.  Thanks for taking my question. ", "original_text": "We'll now move to Kevin Caliendo of UBS. ", "page_label": "15", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "5cf92087-e35d-4fba-85d3-821d01035638", "node_type": "4", "metadata": {"page_label": "15", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "8a3bc03b84fafd2339b44712a98220bec7cd43c6e8428ad74a2f9c58c6c3dcac", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "00d39fc7-7e04-4c84-94d5-3e0bbb38193b", "node_type": "1", "metadata": {"window": "It is also the case though that, as Jason has highlighted in his strategic \nremarks, we are investing against our business.  And some of the SG&A growth was purposeful \nrelative to the investments we're making in places like Navista \u2122 and other elements of our  growth \nplans.  I will end with the fact that we are very focused on SG&A as a whole, and the team continues \nto look for further opportunities as we have  in prior years to optimize our cost structure.  \n \n Operator:  Thank you very much, sir.  We'll now move to Kevin Caliendo of UBS.  Please go ahead.  \n \n Kevin Caliendo:   Thanks. ", "original_text": "Operator:  Thank you very much, sir. ", "page_label": "15", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "e16918420c19185bb75881f9406f0cd203d235ca550ea86aac50f97f9bd33295", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "7224056f-f34c-471e-9e14-b3f8a0f7f715", "node_type": "1", "metadata": {"window": "I will end with the fact that we are very focused on SG&A as a whole, and the team continues \nto look for further opportunities as we have  in prior years to optimize our cost structure.  \n \n Operator:  Thank you very much, sir.  We'll now move to Kevin Caliendo of UBS.  Please go ahead.  \n \n Kevin Caliendo:   Thanks.  Thanks for taking my question.  I have two. ", "original_text": "Please go ahead.  \n \n"}, "hash": "ded5f68975349c492cbc15b946dd80771e94681da05984aa2de150a0d4d5c9fb", "class_name": "RelatedNodeInfo"}}, "text": "We'll now move to Kevin Caliendo of UBS. ", "start_char_idx": 971, "end_char_idx": 1012, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "7224056f-f34c-471e-9e14-b3f8a0f7f715": {"__data__": {"id_": "7224056f-f34c-471e-9e14-b3f8a0f7f715", "embedding": null, "metadata": {"window": "I will end with the fact that we are very focused on SG&A as a whole, and the team continues \nto look for further opportunities as we have  in prior years to optimize our cost structure.  \n \n Operator:  Thank you very much, sir.  We'll now move to Kevin Caliendo of UBS.  Please go ahead.  \n \n Kevin Caliendo:   Thanks.  Thanks for taking my question.  I have two. ", "original_text": "Please go ahead.  \n \n", "page_label": "15", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "5cf92087-e35d-4fba-85d3-821d01035638", "node_type": "4", "metadata": {"page_label": "15", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "8a3bc03b84fafd2339b44712a98220bec7cd43c6e8428ad74a2f9c58c6c3dcac", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "f357ae8a-9a96-4e19-a929-34613b60b09f", "node_type": "1", "metadata": {"window": "And some of the SG&A growth was purposeful \nrelative to the investments we're making in places like Navista \u2122 and other elements of our  growth \nplans.  I will end with the fact that we are very focused on SG&A as a whole, and the team continues \nto look for further opportunities as we have  in prior years to optimize our cost structure.  \n \n Operator:  Thank you very much, sir.  We'll now move to Kevin Caliendo of UBS.  Please go ahead.  \n \n Kevin Caliendo:   Thanks.  Thanks for taking my question. ", "original_text": "We'll now move to Kevin Caliendo of UBS. ", "page_label": "15", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "fab286fcf02dd5696712ef3321e7d247ea4fd66e83197000f60aac27245ae3e9", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "58a4b74f-a9b1-4c18-9515-be998860a05b", "node_type": "1", "metadata": {"window": "Operator:  Thank you very much, sir.  We'll now move to Kevin Caliendo of UBS.  Please go ahead.  \n \n Kevin Caliendo:   Thanks.  Thanks for taking my question.  I have two.  Can you give us an update on \nthe progress of the United contract renewal timing? ", "original_text": "Kevin Caliendo:   Thanks. "}, "hash": "7b9a3c01209f68590992f037ce96db31c63924593a6a9b83d05d020308985b89", "class_name": "RelatedNodeInfo"}}, "text": "Please go ahead.  \n \n", "start_char_idx": 1012, "end_char_idx": 1033, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "58a4b74f-a9b1-4c18-9515-be998860a05b": {"__data__": {"id_": "58a4b74f-a9b1-4c18-9515-be998860a05b", "embedding": null, "metadata": {"window": "Operator:  Thank you very much, sir.  We'll now move to Kevin Caliendo of UBS.  Please go ahead.  \n \n Kevin Caliendo:   Thanks.  Thanks for taking my question.  I have two.  Can you give us an update on \nthe progress of the United contract renewal timing? ", "original_text": "Kevin Caliendo:   Thanks. ", "page_label": "15", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "5cf92087-e35d-4fba-85d3-821d01035638", "node_type": "4", "metadata": {"page_label": "15", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "8a3bc03b84fafd2339b44712a98220bec7cd43c6e8428ad74a2f9c58c6c3dcac", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "7224056f-f34c-471e-9e14-b3f8a0f7f715", "node_type": "1", "metadata": {"window": "I will end with the fact that we are very focused on SG&A as a whole, and the team continues \nto look for further opportunities as we have  in prior years to optimize our cost structure.  \n \n Operator:  Thank you very much, sir.  We'll now move to Kevin Caliendo of UBS.  Please go ahead.  \n \n Kevin Caliendo:   Thanks.  Thanks for taking my question.  I have two. ", "original_text": "Please go ahead.  \n \n", "page_label": "15", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "35e0fbb68831d58518ed7e7a7448ce9c17b23f1674fef83bb53f6d36296fad50", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "e057bab2-236f-4ae9-a0cc-6e5814e3482f", "node_type": "1", "metadata": {"window": "We'll now move to Kevin Caliendo of UBS.  Please go ahead.  \n \n Kevin Caliendo:   Thanks.  Thanks for taking my question.  I have two.  Can you give us an update on \nthe progress of the United contract renewal timing?  Any updates you have there? ", "original_text": "Thanks for taking my question. "}, "hash": "c6ecc53dfb1a37bb6804f650e3e25c491bc741b83373e28f21ab6571e6feaaba", "class_name": "RelatedNodeInfo"}}, "text": "Kevin Caliendo:   Thanks. ", "start_char_idx": 1033, "end_char_idx": 1059, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "e057bab2-236f-4ae9-a0cc-6e5814e3482f": {"__data__": {"id_": "e057bab2-236f-4ae9-a0cc-6e5814e3482f", "embedding": null, "metadata": {"window": "We'll now move to Kevin Caliendo of UBS.  Please go ahead.  \n \n Kevin Caliendo:   Thanks.  Thanks for taking my question.  I have two.  Can you give us an update on \nthe progress of the United contract renewal timing?  Any updates you have there? ", "original_text": "Thanks for taking my question. ", "page_label": "15", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "5cf92087-e35d-4fba-85d3-821d01035638", "node_type": "4", "metadata": {"page_label": "15", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "8a3bc03b84fafd2339b44712a98220bec7cd43c6e8428ad74a2f9c58c6c3dcac", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "58a4b74f-a9b1-4c18-9515-be998860a05b", "node_type": "1", "metadata": {"window": "Operator:  Thank you very much, sir.  We'll now move to Kevin Caliendo of UBS.  Please go ahead.  \n \n Kevin Caliendo:   Thanks.  Thanks for taking my question.  I have two.  Can you give us an update on \nthe progress of the United contract renewal timing? ", "original_text": "Kevin Caliendo:   Thanks. ", "page_label": "15", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "bad95344890acf5f2fbafa8fb1eb8a048b5753284dcd1a37ce8e601619cf2a0e", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "fb4c981c-8420-47a8-adb8-058da50f0a3c", "node_type": "1", "metadata": {"window": "Please go ahead.  \n \n Kevin Caliendo:   Thanks.  Thanks for taking my question.  I have two.  Can you give us an update on \nthe progress of the United contract renewal timing?  Any updates you have there?  And just to follow \nup on that SG&A question. ", "original_text": "I have two. "}, "hash": "548df39433e4882733c8219e1fe0765816df22d04201f970a6000517b835fdfc", "class_name": "RelatedNodeInfo"}}, "text": "Thanks for taking my question. ", "start_char_idx": 1059, "end_char_idx": 1090, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "fb4c981c-8420-47a8-adb8-058da50f0a3c": {"__data__": {"id_": "fb4c981c-8420-47a8-adb8-058da50f0a3c", "embedding": null, "metadata": {"window": "Please go ahead.  \n \n Kevin Caliendo:   Thanks.  Thanks for taking my question.  I have two.  Can you give us an update on \nthe progress of the United contract renewal timing?  Any updates you have there?  And just to follow \nup on that SG&A question. ", "original_text": "I have two. ", "page_label": "15", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "5cf92087-e35d-4fba-85d3-821d01035638", "node_type": "4", "metadata": {"page_label": "15", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "8a3bc03b84fafd2339b44712a98220bec7cd43c6e8428ad74a2f9c58c6c3dcac", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "e057bab2-236f-4ae9-a0cc-6e5814e3482f", "node_type": "1", "metadata": {"window": "We'll now move to Kevin Caliendo of UBS.  Please go ahead.  \n \n Kevin Caliendo:   Thanks.  Thanks for taking my question.  I have two.  Can you give us an update on \nthe progress of the United contract renewal timing?  Any updates you have there? ", "original_text": "Thanks for taking my question. ", "page_label": "15", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "989a48b876d311ed1a4c147790f6b162f9e1ac5a20663bc2aa44447d685916ee", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "d8f9cd1e-ea46-43fc-98f0-fd6818dc49b2", "node_type": "1", "metadata": {"window": "Kevin Caliendo:   Thanks.  Thanks for taking my question.  I have two.  Can you give us an update on \nthe progress of the United contract renewal timing?  Any updates you have there?  And just to follow \nup on that SG&A question.  W ere there purposeful investments made when you saw upside from \ninterest and other things in SG&A in the quarter ? ", "original_text": "Can you give us an update on \nthe progress of the United contract renewal timing? "}, "hash": "561680d0fed3c10b1677f26386521708b9bf7c9ace46c2eb0c9b2473b732a255", "class_name": "RelatedNodeInfo"}}, "text": "I have two. ", "start_char_idx": 1090, "end_char_idx": 1102, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "d8f9cd1e-ea46-43fc-98f0-fd6818dc49b2": {"__data__": {"id_": "d8f9cd1e-ea46-43fc-98f0-fd6818dc49b2", "embedding": null, "metadata": {"window": "Kevin Caliendo:   Thanks.  Thanks for taking my question.  I have two.  Can you give us an update on \nthe progress of the United contract renewal timing?  Any updates you have there?  And just to follow \nup on that SG&A question.  W ere there purposeful investments made when you saw upside from \ninterest and other things in SG&A in the quarter ? ", "original_text": "Can you give us an update on \nthe progress of the United contract renewal timing? ", "page_label": "15", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "5cf92087-e35d-4fba-85d3-821d01035638", "node_type": "4", "metadata": {"page_label": "15", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "8a3bc03b84fafd2339b44712a98220bec7cd43c6e8428ad74a2f9c58c6c3dcac", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "fb4c981c-8420-47a8-adb8-058da50f0a3c", "node_type": "1", "metadata": {"window": "Please go ahead.  \n \n Kevin Caliendo:   Thanks.  Thanks for taking my question.  I have two.  Can you give us an update on \nthe progress of the United contract renewal timing?  Any updates you have there?  And just to follow \nup on that SG&A question. ", "original_text": "I have two. ", "page_label": "15", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "329acdb6a5afe4f253c8e86a18f6fedac91bb97024b117559c9e7654f1785687", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "eb3c614a-b681-4851-a036-22dfe438bfae", "node_type": "1", "metadata": {"window": "Thanks for taking my question.  I have two.  Can you give us an update on \nthe progress of the United contract renewal timing?  Any updates you have there?  And just to follow \nup on that SG&A question.  W ere there purposeful investments made when you saw upside from \ninterest and other things in SG&A in the quarter ?  I'm trying to quantify how much was in the original \nplan versus maybe how much is incremental given some of the upside that you saw below the line?  \n \n", "original_text": "Any updates you have there? "}, "hash": "e13685c87df853d590bbeb1d9c2293ff450579081f0b6a9d4d2d8e861591a5b5", "class_name": "RelatedNodeInfo"}}, "text": "Can you give us an update on \nthe progress of the United contract renewal timing? ", "start_char_idx": 1102, "end_char_idx": 1184, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "eb3c614a-b681-4851-a036-22dfe438bfae": {"__data__": {"id_": "eb3c614a-b681-4851-a036-22dfe438bfae", "embedding": null, "metadata": {"window": "Thanks for taking my question.  I have two.  Can you give us an update on \nthe progress of the United contract renewal timing?  Any updates you have there?  And just to follow \nup on that SG&A question.  W ere there purposeful investments made when you saw upside from \ninterest and other things in SG&A in the quarter ?  I'm trying to quantify how much was in the original \nplan versus maybe how much is incremental given some of the upside that you saw below the line?  \n \n", "original_text": "Any updates you have there? ", "page_label": "15", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "5cf92087-e35d-4fba-85d3-821d01035638", "node_type": "4", "metadata": {"page_label": "15", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "8a3bc03b84fafd2339b44712a98220bec7cd43c6e8428ad74a2f9c58c6c3dcac", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "d8f9cd1e-ea46-43fc-98f0-fd6818dc49b2", "node_type": "1", "metadata": {"window": "Kevin Caliendo:   Thanks.  Thanks for taking my question.  I have two.  Can you give us an update on \nthe progress of the United contract renewal timing?  Any updates you have there?  And just to follow \nup on that SG&A question.  W ere there purposeful investments made when you saw upside from \ninterest and other things in SG&A in the quarter ? ", "original_text": "Can you give us an update on \nthe progress of the United contract renewal timing? ", "page_label": "15", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "4974fdbb1fc18bbf1c690bdaf9aa01229906c2181f422ebc667c1994aa920ad3", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "4d535836-2f25-4c28-b7ce-90bfcbba3675", "node_type": "1", "metadata": {"window": "I have two.  Can you give us an update on \nthe progress of the United contract renewal timing?  Any updates you have there?  And just to follow \nup on that SG&A question.  W ere there purposeful investments made when you saw upside from \ninterest and other things in SG&A in the quarter ?  I'm trying to quantify how much was in the original \nplan versus maybe how much is incremental given some of the upside that you saw below the line?  \n \n Jason Hollar:  Yeah, sure. ", "original_text": "And just to follow \nup on that SG&A question. "}, "hash": "a451377257cf417a17a76ff8e68f0d8b15a78949f5908dc9d42da45a8f7f9046", "class_name": "RelatedNodeInfo"}}, "text": "Any updates you have there? ", "start_char_idx": 1184, "end_char_idx": 1212, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "4d535836-2f25-4c28-b7ce-90bfcbba3675": {"__data__": {"id_": "4d535836-2f25-4c28-b7ce-90bfcbba3675", "embedding": null, "metadata": {"window": "I have two.  Can you give us an update on \nthe progress of the United contract renewal timing?  Any updates you have there?  And just to follow \nup on that SG&A question.  W ere there purposeful investments made when you saw upside from \ninterest and other things in SG&A in the quarter ?  I'm trying to quantify how much was in the original \nplan versus maybe how much is incremental given some of the upside that you saw below the line?  \n \n Jason Hollar:  Yeah, sure. ", "original_text": "And just to follow \nup on that SG&A question. ", "page_label": "15", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "5cf92087-e35d-4fba-85d3-821d01035638", "node_type": "4", "metadata": {"page_label": "15", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "8a3bc03b84fafd2339b44712a98220bec7cd43c6e8428ad74a2f9c58c6c3dcac", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "eb3c614a-b681-4851-a036-22dfe438bfae", "node_type": "1", "metadata": {"window": "Thanks for taking my question.  I have two.  Can you give us an update on \nthe progress of the United contract renewal timing?  Any updates you have there?  And just to follow \nup on that SG&A question.  W ere there purposeful investments made when you saw upside from \ninterest and other things in SG&A in the quarter ?  I'm trying to quantify how much was in the original \nplan versus maybe how much is incremental given some of the upside that you saw below the line?  \n \n", "original_text": "Any updates you have there? ", "page_label": "15", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "2dd12d52a618934389ba33c3451f8d59c40047a38a34d33eb89918e59583a5a5", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "e4589d49-b52e-4fdd-8058-f96abae1be02", "node_type": "1", "metadata": {"window": "Can you give us an update on \nthe progress of the United contract renewal timing?  Any updates you have there?  And just to follow \nup on that SG&A question.  W ere there purposeful investments made when you saw upside from \ninterest and other things in SG&A in the quarter ?  I'm trying to quantify how much was in the original \nplan versus maybe how much is incremental given some of the upside that you saw below the line?  \n \n Jason Hollar:  Yeah, sure.  I'll touch on both points here. ", "original_text": "W ere there purposeful investments made when you saw upside from \ninterest and other things in SG&A in the quarter ? "}, "hash": "1087840620e1a9f372e4347ed00b1dd0bcb05362f29d05adb0f58ac8b27c5a88", "class_name": "RelatedNodeInfo"}}, "text": "And just to follow \nup on that SG&A question. ", "start_char_idx": 1212, "end_char_idx": 1258, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "e4589d49-b52e-4fdd-8058-f96abae1be02": {"__data__": {"id_": "e4589d49-b52e-4fdd-8058-f96abae1be02", "embedding": null, "metadata": {"window": "Can you give us an update on \nthe progress of the United contract renewal timing?  Any updates you have there?  And just to follow \nup on that SG&A question.  W ere there purposeful investments made when you saw upside from \ninterest and other things in SG&A in the quarter ?  I'm trying to quantify how much was in the original \nplan versus maybe how much is incremental given some of the upside that you saw below the line?  \n \n Jason Hollar:  Yeah, sure.  I'll touch on both points here. ", "original_text": "W ere there purposeful investments made when you saw upside from \ninterest and other things in SG&A in the quarter ? ", "page_label": "15", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "5cf92087-e35d-4fba-85d3-821d01035638", "node_type": "4", "metadata": {"page_label": "15", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "8a3bc03b84fafd2339b44712a98220bec7cd43c6e8428ad74a2f9c58c6c3dcac", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "4d535836-2f25-4c28-b7ce-90bfcbba3675", "node_type": "1", "metadata": {"window": "I have two.  Can you give us an update on \nthe progress of the United contract renewal timing?  Any updates you have there?  And just to follow \nup on that SG&A question.  W ere there purposeful investments made when you saw upside from \ninterest and other things in SG&A in the quarter ?  I'm trying to quantify how much was in the original \nplan versus maybe how much is incremental given some of the upside that you saw below the line?  \n \n Jason Hollar:  Yeah, sure. ", "original_text": "And just to follow \nup on that SG&A question. ", "page_label": "15", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "85e24a7dff9fc34a2a88cdfed5f99bf524f2e0ade64012343aacefe7bf0a09e2", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "c59c3428-8f76-4308-b58a-9e36d67c97cc", "node_type": "1", "metadata": {"window": "Any updates you have there?  And just to follow \nup on that SG&A question.  W ere there purposeful investments made when you saw upside from \ninterest and other things in SG&A in the quarter ?  I'm trying to quantify how much was in the original \nplan versus maybe how much is incremental given some of the upside that you saw below the line?  \n \n Jason Hollar:  Yeah, sure.  I'll touch on both points here.  There \u2019s no updates with the Optum contract \nthat goes through this fiscal year. ", "original_text": "I'm trying to quantify how much was in the original \nplan versus maybe how much is incremental given some of the upside that you saw below the line?  \n \n"}, "hash": "9fa21526f7c1bef6fd6efd6716b65f5a49d48626ccf94602ff5f7cbf05a8ddef", "class_name": "RelatedNodeInfo"}}, "text": "W ere there purposeful investments made when you saw upside from \ninterest and other things in SG&A in the quarter ? ", "start_char_idx": 1258, "end_char_idx": 1375, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "c59c3428-8f76-4308-b58a-9e36d67c97cc": {"__data__": {"id_": "c59c3428-8f76-4308-b58a-9e36d67c97cc", "embedding": null, "metadata": {"window": "Any updates you have there?  And just to follow \nup on that SG&A question.  W ere there purposeful investments made when you saw upside from \ninterest and other things in SG&A in the quarter ?  I'm trying to quantify how much was in the original \nplan versus maybe how much is incremental given some of the upside that you saw below the line?  \n \n Jason Hollar:  Yeah, sure.  I'll touch on both points here.  There \u2019s no updates with the Optum contract \nthat goes through this fiscal year. ", "original_text": "I'm trying to quantify how much was in the original \nplan versus maybe how much is incremental given some of the upside that you saw below the line?  \n \n", "page_label": "15", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "5cf92087-e35d-4fba-85d3-821d01035638", "node_type": "4", "metadata": {"page_label": "15", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "8a3bc03b84fafd2339b44712a98220bec7cd43c6e8428ad74a2f9c58c6c3dcac", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "e4589d49-b52e-4fdd-8058-f96abae1be02", "node_type": "1", "metadata": {"window": "Can you give us an update on \nthe progress of the United contract renewal timing?  Any updates you have there?  And just to follow \nup on that SG&A question.  W ere there purposeful investments made when you saw upside from \ninterest and other things in SG&A in the quarter ?  I'm trying to quantify how much was in the original \nplan versus maybe how much is incremental given some of the upside that you saw below the line?  \n \n Jason Hollar:  Yeah, sure.  I'll touch on both points here. ", "original_text": "W ere there purposeful investments made when you saw upside from \ninterest and other things in SG&A in the quarter ? ", "page_label": "15", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "32559f711e919c8eb92e28a001d1e6f32ebce7c363bae11db405097d6827d1a0", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "c8dfa6c5-4323-4c4f-8bf7-ac582a8f435b", "node_type": "1", "metadata": {"window": "And just to follow \nup on that SG&A question.  W ere there purposeful investments made when you saw upside from \ninterest and other things in SG&A in the quarter ?  I'm trying to quantify how much was in the original \nplan versus maybe how much is incremental given some of the upside that you saw below the line?  \n \n Jason Hollar:  Yeah, sure.  I'll touch on both points here.  There \u2019s no updates with the Optum contract \nthat goes through this fiscal year.  And as I highlighted before, they are a great customer of ours, long -\nstanding customer, one that brings a lot of innovation to healthcare and one that we've worked very \nhard over the y ears to attempt to exceed their expectations, and we think we're doing a great job of \nthat and we'd love to keep working with them, of course.  ", "original_text": "Jason Hollar:  Yeah, sure. "}, "hash": "911395c95552ceaf48a129292ef3db4605227fb99f5690faacad95a2694099d9", "class_name": "RelatedNodeInfo"}}, "text": "I'm trying to quantify how much was in the original \nplan versus maybe how much is incremental given some of the upside that you saw below the line?  \n \n", "start_char_idx": 1375, "end_char_idx": 1528, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "c8dfa6c5-4323-4c4f-8bf7-ac582a8f435b": {"__data__": {"id_": "c8dfa6c5-4323-4c4f-8bf7-ac582a8f435b", "embedding": null, "metadata": {"window": "And just to follow \nup on that SG&A question.  W ere there purposeful investments made when you saw upside from \ninterest and other things in SG&A in the quarter ?  I'm trying to quantify how much was in the original \nplan versus maybe how much is incremental given some of the upside that you saw below the line?  \n \n Jason Hollar:  Yeah, sure.  I'll touch on both points here.  There \u2019s no updates with the Optum contract \nthat goes through this fiscal year.  And as I highlighted before, they are a great customer of ours, long -\nstanding customer, one that brings a lot of innovation to healthcare and one that we've worked very \nhard over the y ears to attempt to exceed their expectations, and we think we're doing a great job of \nthat and we'd love to keep working with them, of course.  ", "original_text": "Jason Hollar:  Yeah, sure. ", "page_label": "15", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "5cf92087-e35d-4fba-85d3-821d01035638", "node_type": "4", "metadata": {"page_label": "15", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "8a3bc03b84fafd2339b44712a98220bec7cd43c6e8428ad74a2f9c58c6c3dcac", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "c59c3428-8f76-4308-b58a-9e36d67c97cc", "node_type": "1", "metadata": {"window": "Any updates you have there?  And just to follow \nup on that SG&A question.  W ere there purposeful investments made when you saw upside from \ninterest and other things in SG&A in the quarter ?  I'm trying to quantify how much was in the original \nplan versus maybe how much is incremental given some of the upside that you saw below the line?  \n \n Jason Hollar:  Yeah, sure.  I'll touch on both points here.  There \u2019s no updates with the Optum contract \nthat goes through this fiscal year. ", "original_text": "I'm trying to quantify how much was in the original \nplan versus maybe how much is incremental given some of the upside that you saw below the line?  \n \n", "page_label": "15", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "f04d5b264f7510496ff9be8879214419a3fa71f35ac4eaaf27f5a276312bff52", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "3a30fe86-63e1-406a-8ee3-5004fd6963dc", "node_type": "1", "metadata": {"window": "W ere there purposeful investments made when you saw upside from \ninterest and other things in SG&A in the quarter ?  I'm trying to quantify how much was in the original \nplan versus maybe how much is incremental given some of the upside that you saw below the line?  \n \n Jason Hollar:  Yeah, sure.  I'll touch on both points here.  There \u2019s no updates with the Optum contract \nthat goes through this fiscal year.  And as I highlighted before, they are a great customer of ours, long -\nstanding customer, one that brings a lot of innovation to healthcare and one that we've worked very \nhard over the y ears to attempt to exceed their expectations, and we think we're doing a great job of \nthat and we'd love to keep working with them, of course.   Now I do get a lot of questions around the \norder of magnitude of this, and I'm not going to go into details. ", "original_text": "I'll touch on both points here. "}, "hash": "c55fd356db95d09812eea65e189734b6496d5106faf0c1a3cfaaa215097f6c61", "class_name": "RelatedNodeInfo"}}, "text": "Jason Hollar:  Yeah, sure. ", "start_char_idx": 1528, "end_char_idx": 1555, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "3a30fe86-63e1-406a-8ee3-5004fd6963dc": {"__data__": {"id_": "3a30fe86-63e1-406a-8ee3-5004fd6963dc", "embedding": null, "metadata": {"window": "W ere there purposeful investments made when you saw upside from \ninterest and other things in SG&A in the quarter ?  I'm trying to quantify how much was in the original \nplan versus maybe how much is incremental given some of the upside that you saw below the line?  \n \n Jason Hollar:  Yeah, sure.  I'll touch on both points here.  There \u2019s no updates with the Optum contract \nthat goes through this fiscal year.  And as I highlighted before, they are a great customer of ours, long -\nstanding customer, one that brings a lot of innovation to healthcare and one that we've worked very \nhard over the y ears to attempt to exceed their expectations, and we think we're doing a great job of \nthat and we'd love to keep working with them, of course.   Now I do get a lot of questions around the \norder of magnitude of this, and I'm not going to go into details. ", "original_text": "I'll touch on both points here. ", "page_label": "15", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "5cf92087-e35d-4fba-85d3-821d01035638", "node_type": "4", "metadata": {"page_label": "15", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "8a3bc03b84fafd2339b44712a98220bec7cd43c6e8428ad74a2f9c58c6c3dcac", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "c8dfa6c5-4323-4c4f-8bf7-ac582a8f435b", "node_type": "1", "metadata": {"window": "And just to follow \nup on that SG&A question.  W ere there purposeful investments made when you saw upside from \ninterest and other things in SG&A in the quarter ?  I'm trying to quantify how much was in the original \nplan versus maybe how much is incremental given some of the upside that you saw below the line?  \n \n Jason Hollar:  Yeah, sure.  I'll touch on both points here.  There \u2019s no updates with the Optum contract \nthat goes through this fiscal year.  And as I highlighted before, they are a great customer of ours, long -\nstanding customer, one that brings a lot of innovation to healthcare and one that we've worked very \nhard over the y ears to attempt to exceed their expectations, and we think we're doing a great job of \nthat and we'd love to keep working with them, of course.  ", "original_text": "Jason Hollar:  Yeah, sure. ", "page_label": "15", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "91989a25934c315f648ecea43866f165f30217823ece6bb151cdbdcc250cc867", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "08277890-3d82-4e84-ad09-c197ac32b72d", "node_type": "1", "metadata": {"window": "I'm trying to quantify how much was in the original \nplan versus maybe how much is incremental given some of the upside that you saw below the line?  \n \n Jason Hollar:  Yeah, sure.  I'll touch on both points here.  There \u2019s no updates with the Optum contract \nthat goes through this fiscal year.  And as I highlighted before, they are a great customer of ours, long -\nstanding customer, one that brings a lot of innovation to healthcare and one that we've worked very \nhard over the y ears to attempt to exceed their expectations, and we think we're doing a great job of \nthat and we'd love to keep working with them, of course.   Now I do get a lot of questions around the \norder of magnitude of this, and I'm not going to go into details.  But just a couple of points, given the \nnumber of questions I've received is we have disclosed in the past, and I think it comes through in \nevery K, just the order of magnitude.  ", "original_text": "There \u2019s no updates with the Optum contract \nthat goes through this fiscal year. "}, "hash": "2b37f09689c10443cf4b34f9f89770f8edaad73576e32dd7cf50c90020969622", "class_name": "RelatedNodeInfo"}}, "text": "I'll touch on both points here. ", "start_char_idx": 1555, "end_char_idx": 1587, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "08277890-3d82-4e84-ad09-c197ac32b72d": {"__data__": {"id_": "08277890-3d82-4e84-ad09-c197ac32b72d", "embedding": null, "metadata": {"window": "I'm trying to quantify how much was in the original \nplan versus maybe how much is incremental given some of the upside that you saw below the line?  \n \n Jason Hollar:  Yeah, sure.  I'll touch on both points here.  There \u2019s no updates with the Optum contract \nthat goes through this fiscal year.  And as I highlighted before, they are a great customer of ours, long -\nstanding customer, one that brings a lot of innovation to healthcare and one that we've worked very \nhard over the y ears to attempt to exceed their expectations, and we think we're doing a great job of \nthat and we'd love to keep working with them, of course.   Now I do get a lot of questions around the \norder of magnitude of this, and I'm not going to go into details.  But just a couple of points, given the \nnumber of questions I've received is we have disclosed in the past, and I think it comes through in \nevery K, just the order of magnitude.  ", "original_text": "There \u2019s no updates with the Optum contract \nthat goes through this fiscal year. ", "page_label": "15", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "5cf92087-e35d-4fba-85d3-821d01035638", "node_type": "4", "metadata": {"page_label": "15", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "8a3bc03b84fafd2339b44712a98220bec7cd43c6e8428ad74a2f9c58c6c3dcac", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "3a30fe86-63e1-406a-8ee3-5004fd6963dc", "node_type": "1", "metadata": {"window": "W ere there purposeful investments made when you saw upside from \ninterest and other things in SG&A in the quarter ?  I'm trying to quantify how much was in the original \nplan versus maybe how much is incremental given some of the upside that you saw below the line?  \n \n Jason Hollar:  Yeah, sure.  I'll touch on both points here.  There \u2019s no updates with the Optum contract \nthat goes through this fiscal year.  And as I highlighted before, they are a great customer of ours, long -\nstanding customer, one that brings a lot of innovation to healthcare and one that we've worked very \nhard over the y ears to attempt to exceed their expectations, and we think we're doing a great job of \nthat and we'd love to keep working with them, of course.   Now I do get a lot of questions around the \norder of magnitude of this, and I'm not going to go into details. ", "original_text": "I'll touch on both points here. ", "page_label": "15", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "6a06fe0dcd97ab4717603b5bc62169c5592f700c7618edb486a8291472bec23f", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "3050c150-95ed-4d9e-8d7e-a356dbd02b1a", "node_type": "1", "metadata": {"window": "Jason Hollar:  Yeah, sure.  I'll touch on both points here.  There \u2019s no updates with the Optum contract \nthat goes through this fiscal year.  And as I highlighted before, they are a great customer of ours, long -\nstanding customer, one that brings a lot of innovation to healthcare and one that we've worked very \nhard over the y ears to attempt to exceed their expectations, and we think we're doing a great job of \nthat and we'd love to keep working with them, of course.   Now I do get a lot of questions around the \norder of magnitude of this, and I'm not going to go into details.  But just a couple of points, given the \nnumber of questions I've received is we have disclosed in the past, and I think it comes through in \nevery K, just the order of magnitude.   So last year, they were over a $30 billion customer of ours. ", "original_text": "And as I highlighted before, they are a great customer of ours, long -\nstanding customer, one that brings a lot of innovation to healthcare and one that we've worked very \nhard over the y ears to attempt to exceed their expectations, and we think we're doing a great job of \nthat and we'd love to keep working with them, of course.  "}, "hash": "bd11a55a79ae3e2eb77b5119f9811ce0c7db4870dc582e92633b0c5254f56c8a", "class_name": "RelatedNodeInfo"}}, "text": "There \u2019s no updates with the Optum contract \nthat goes through this fiscal year. ", "start_char_idx": 1587, "end_char_idx": 1668, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "3050c150-95ed-4d9e-8d7e-a356dbd02b1a": {"__data__": {"id_": "3050c150-95ed-4d9e-8d7e-a356dbd02b1a", "embedding": null, "metadata": {"window": "Jason Hollar:  Yeah, sure.  I'll touch on both points here.  There \u2019s no updates with the Optum contract \nthat goes through this fiscal year.  And as I highlighted before, they are a great customer of ours, long -\nstanding customer, one that brings a lot of innovation to healthcare and one that we've worked very \nhard over the y ears to attempt to exceed their expectations, and we think we're doing a great job of \nthat and we'd love to keep working with them, of course.   Now I do get a lot of questions around the \norder of magnitude of this, and I'm not going to go into details.  But just a couple of points, given the \nnumber of questions I've received is we have disclosed in the past, and I think it comes through in \nevery K, just the order of magnitude.   So last year, they were over a $30 billion customer of ours. ", "original_text": "And as I highlighted before, they are a great customer of ours, long -\nstanding customer, one that brings a lot of innovation to healthcare and one that we've worked very \nhard over the y ears to attempt to exceed their expectations, and we think we're doing a great job of \nthat and we'd love to keep working with them, of course.  ", "page_label": "15", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "5cf92087-e35d-4fba-85d3-821d01035638", "node_type": "4", "metadata": {"page_label": "15", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "8a3bc03b84fafd2339b44712a98220bec7cd43c6e8428ad74a2f9c58c6c3dcac", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "08277890-3d82-4e84-ad09-c197ac32b72d", "node_type": "1", "metadata": {"window": "I'm trying to quantify how much was in the original \nplan versus maybe how much is incremental given some of the upside that you saw below the line?  \n \n Jason Hollar:  Yeah, sure.  I'll touch on both points here.  There \u2019s no updates with the Optum contract \nthat goes through this fiscal year.  And as I highlighted before, they are a great customer of ours, long -\nstanding customer, one that brings a lot of innovation to healthcare and one that we've worked very \nhard over the y ears to attempt to exceed their expectations, and we think we're doing a great job of \nthat and we'd love to keep working with them, of course.   Now I do get a lot of questions around the \norder of magnitude of this, and I'm not going to go into details.  But just a couple of points, given the \nnumber of questions I've received is we have disclosed in the past, and I think it comes through in \nevery K, just the order of magnitude.  ", "original_text": "There \u2019s no updates with the Optum contract \nthat goes through this fiscal year. ", "page_label": "15", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "7267df7d4ddb8e4ea83a7a7d233a2079d5763e8c8c14903e999c8b011590cd56", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "909afeea-cfae-40c9-89a2-4817f915f180", "node_type": "1", "metadata": {"window": "I'll touch on both points here.  There \u2019s no updates with the Optum contract \nthat goes through this fiscal year.  And as I highlighted before, they are a great customer of ours, long -\nstanding customer, one that brings a lot of innovation to healthcare and one that we've worked very \nhard over the y ears to attempt to exceed their expectations, and we think we're doing a great job of \nthat and we'd love to keep working with them, of course.   Now I do get a lot of questions around the \norder of magnitude of this, and I'm not going to go into details.  But just a couple of points, given the \nnumber of questions I've received is we have disclosed in the past, and I think it comes through in \nevery K, just the order of magnitude.   So last year, they were over a $30 billion customer of ours.  And \nI see a lot of people attempting to try to model out impacts and things of that nature. ", "original_text": "Now I do get a lot of questions around the \norder of magnitude of this, and I'm not going to go into details. "}, "hash": "164765dc6124aa6cad3bb495ecec49e06e57f376ea96df81b378c1e132d13cca", "class_name": "RelatedNodeInfo"}}, "text": "And as I highlighted before, they are a great customer of ours, long -\nstanding customer, one that brings a lot of innovation to healthcare and one that we've worked very \nhard over the y ears to attempt to exceed their expectations, and we think we're doing a great job of \nthat and we'd love to keep working with them, of course.  ", "start_char_idx": 1668, "end_char_idx": 2001, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "909afeea-cfae-40c9-89a2-4817f915f180": {"__data__": {"id_": "909afeea-cfae-40c9-89a2-4817f915f180", "embedding": null, "metadata": {"window": "I'll touch on both points here.  There \u2019s no updates with the Optum contract \nthat goes through this fiscal year.  And as I highlighted before, they are a great customer of ours, long -\nstanding customer, one that brings a lot of innovation to healthcare and one that we've worked very \nhard over the y ears to attempt to exceed their expectations, and we think we're doing a great job of \nthat and we'd love to keep working with them, of course.   Now I do get a lot of questions around the \norder of magnitude of this, and I'm not going to go into details.  But just a couple of points, given the \nnumber of questions I've received is we have disclosed in the past, and I think it comes through in \nevery K, just the order of magnitude.   So last year, they were over a $30 billion customer of ours.  And \nI see a lot of people attempting to try to model out impacts and things of that nature. ", "original_text": "Now I do get a lot of questions around the \norder of magnitude of this, and I'm not going to go into details. ", "page_label": "15", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "5cf92087-e35d-4fba-85d3-821d01035638", "node_type": "4", "metadata": {"page_label": "15", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "8a3bc03b84fafd2339b44712a98220bec7cd43c6e8428ad74a2f9c58c6c3dcac", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "3050c150-95ed-4d9e-8d7e-a356dbd02b1a", "node_type": "1", "metadata": {"window": "Jason Hollar:  Yeah, sure.  I'll touch on both points here.  There \u2019s no updates with the Optum contract \nthat goes through this fiscal year.  And as I highlighted before, they are a great customer of ours, long -\nstanding customer, one that brings a lot of innovation to healthcare and one that we've worked very \nhard over the y ears to attempt to exceed their expectations, and we think we're doing a great job of \nthat and we'd love to keep working with them, of course.   Now I do get a lot of questions around the \norder of magnitude of this, and I'm not going to go into details.  But just a couple of points, given the \nnumber of questions I've received is we have disclosed in the past, and I think it comes through in \nevery K, just the order of magnitude.   So last year, they were over a $30 billion customer of ours. ", "original_text": "And as I highlighted before, they are a great customer of ours, long -\nstanding customer, one that brings a lot of innovation to healthcare and one that we've worked very \nhard over the y ears to attempt to exceed their expectations, and we think we're doing a great job of \nthat and we'd love to keep working with them, of course.  ", "page_label": "15", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "563d84ef7b1adeb946291b4d03cb64deddc9aef73b4afc7e34648904c1e8acdb", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "da612441-8817-43e0-8189-50323c9099c5", "node_type": "1", "metadata": {"window": "There \u2019s no updates with the Optum contract \nthat goes through this fiscal year.  And as I highlighted before, they are a great customer of ours, long -\nstanding customer, one that brings a lot of innovation to healthcare and one that we've worked very \nhard over the y ears to attempt to exceed their expectations, and we think we're doing a great job of \nthat and we'd love to keep working with them, of course.   Now I do get a lot of questions around the \norder of magnitude of this, and I'm not going to go into details.  But just a couple of points, given the \nnumber of questions I've received is we have disclosed in the past, and I think it comes through in \nevery K, just the order of magnitude.   So last year, they were over a $30 billion customer of ours.  And \nI see a lot of people attempting to try to model out impacts and things of that nature.  And just a couple \nof things that I'm not sure it's real clear about the scope of business we have with them today. ", "original_text": "But just a couple of points, given the \nnumber of questions I've received is we have disclosed in the past, and I think it comes through in \nevery K, just the order of magnitude.  "}, "hash": "f1b3a01ad67c785abbe9754e0190a1a696e9a9b465a4d5d596e5395f20845276", "class_name": "RelatedNodeInfo"}}, "text": "Now I do get a lot of questions around the \norder of magnitude of this, and I'm not going to go into details. ", "start_char_idx": 2001, "end_char_idx": 2111, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "da612441-8817-43e0-8189-50323c9099c5": {"__data__": {"id_": "da612441-8817-43e0-8189-50323c9099c5", "embedding": null, "metadata": {"window": "There \u2019s no updates with the Optum contract \nthat goes through this fiscal year.  And as I highlighted before, they are a great customer of ours, long -\nstanding customer, one that brings a lot of innovation to healthcare and one that we've worked very \nhard over the y ears to attempt to exceed their expectations, and we think we're doing a great job of \nthat and we'd love to keep working with them, of course.   Now I do get a lot of questions around the \norder of magnitude of this, and I'm not going to go into details.  But just a couple of points, given the \nnumber of questions I've received is we have disclosed in the past, and I think it comes through in \nevery K, just the order of magnitude.   So last year, they were over a $30 billion customer of ours.  And \nI see a lot of people attempting to try to model out impacts and things of that nature.  And just a couple \nof things that I'm not sure it's real clear about the scope of business we have with them today. ", "original_text": "But just a couple of points, given the \nnumber of questions I've received is we have disclosed in the past, and I think it comes through in \nevery K, just the order of magnitude.  ", "page_label": "15", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "5cf92087-e35d-4fba-85d3-821d01035638", "node_type": "4", "metadata": {"page_label": "15", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "8a3bc03b84fafd2339b44712a98220bec7cd43c6e8428ad74a2f9c58c6c3dcac", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "909afeea-cfae-40c9-89a2-4817f915f180", "node_type": "1", "metadata": {"window": "I'll touch on both points here.  There \u2019s no updates with the Optum contract \nthat goes through this fiscal year.  And as I highlighted before, they are a great customer of ours, long -\nstanding customer, one that brings a lot of innovation to healthcare and one that we've worked very \nhard over the y ears to attempt to exceed their expectations, and we think we're doing a great job of \nthat and we'd love to keep working with them, of course.   Now I do get a lot of questions around the \norder of magnitude of this, and I'm not going to go into details.  But just a couple of points, given the \nnumber of questions I've received is we have disclosed in the past, and I think it comes through in \nevery K, just the order of magnitude.   So last year, they were over a $30 billion customer of ours.  And \nI see a lot of people attempting to try to model out impacts and things of that nature. ", "original_text": "Now I do get a lot of questions around the \norder of magnitude of this, and I'm not going to go into details. ", "page_label": "15", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "141eb390a6aa3bfac216e4f45c47cab598b52a499a9b8f35a502cacb731a5863", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "caefe377-afb4-4ec0-85a0-9b66a041ccfd", "node_type": "1", "metadata": {"window": "And as I highlighted before, they are a great customer of ours, long -\nstanding customer, one that brings a lot of innovation to healthcare and one that we've worked very \nhard over the y ears to attempt to exceed their expectations, and we think we're doing a great job of \nthat and we'd love to keep working with them, of course.   Now I do get a lot of questions around the \norder of magnitude of this, and I'm not going to go into details.  But just a couple of points, given the \nnumber of questions I've received is we have disclosed in the past, and I think it comes through in \nevery K, just the order of magnitude.   So last year, they were over a $30 billion customer of ours.  And \nI see a lot of people attempting to try to model out impacts and things of that nature.  And just a couple \nof things that I'm not sure it's real clear about the scope of business we have with them today.  The \nmajority of the revenue we have with them is through our base PD business, and a lot of that is mail \norder volume. ", "original_text": "So last year, they were over a $30 billion customer of ours. "}, "hash": "00c02b8b2f13f0f0797482285f6cc7499e325539b2e9ed9d7a2f961eb3402336", "class_name": "RelatedNodeInfo"}}, "text": "But just a couple of points, given the \nnumber of questions I've received is we have disclosed in the past, and I think it comes through in \nevery K, just the order of magnitude.  ", "start_char_idx": 2111, "end_char_idx": 2291, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "caefe377-afb4-4ec0-85a0-9b66a041ccfd": {"__data__": {"id_": "caefe377-afb4-4ec0-85a0-9b66a041ccfd", "embedding": null, "metadata": {"window": "And as I highlighted before, they are a great customer of ours, long -\nstanding customer, one that brings a lot of innovation to healthcare and one that we've worked very \nhard over the y ears to attempt to exceed their expectations, and we think we're doing a great job of \nthat and we'd love to keep working with them, of course.   Now I do get a lot of questions around the \norder of magnitude of this, and I'm not going to go into details.  But just a couple of points, given the \nnumber of questions I've received is we have disclosed in the past, and I think it comes through in \nevery K, just the order of magnitude.   So last year, they were over a $30 billion customer of ours.  And \nI see a lot of people attempting to try to model out impacts and things of that nature.  And just a couple \nof things that I'm not sure it's real clear about the scope of business we have with them today.  The \nmajority of the revenue we have with them is through our base PD business, and a lot of that is mail \norder volume. ", "original_text": "So last year, they were over a $30 billion customer of ours. ", "page_label": "15", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "5cf92087-e35d-4fba-85d3-821d01035638", "node_type": "4", "metadata": {"page_label": "15", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "8a3bc03b84fafd2339b44712a98220bec7cd43c6e8428ad74a2f9c58c6c3dcac", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "da612441-8817-43e0-8189-50323c9099c5", "node_type": "1", "metadata": {"window": "There \u2019s no updates with the Optum contract \nthat goes through this fiscal year.  And as I highlighted before, they are a great customer of ours, long -\nstanding customer, one that brings a lot of innovation to healthcare and one that we've worked very \nhard over the y ears to attempt to exceed their expectations, and we think we're doing a great job of \nthat and we'd love to keep working with them, of course.   Now I do get a lot of questions around the \norder of magnitude of this, and I'm not going to go into details.  But just a couple of points, given the \nnumber of questions I've received is we have disclosed in the past, and I think it comes through in \nevery K, just the order of magnitude.   So last year, they were over a $30 billion customer of ours.  And \nI see a lot of people attempting to try to model out impacts and things of that nature.  And just a couple \nof things that I'm not sure it's real clear about the scope of business we have with them today. ", "original_text": "But just a couple of points, given the \nnumber of questions I've received is we have disclosed in the past, and I think it comes through in \nevery K, just the order of magnitude.  ", "page_label": "15", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "2d297f94c86532aa052f79c76982564ef5ea2bb7529c37562ff6ce581bd25dc3", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "e3ed3339-96fd-4c8b-9b78-9cdd14be00ec", "node_type": "1", "metadata": {"window": "Now I do get a lot of questions around the \norder of magnitude of this, and I'm not going to go into details.  But just a couple of points, given the \nnumber of questions I've received is we have disclosed in the past, and I think it comes through in \nevery K, just the order of magnitude.   So last year, they were over a $30 billion customer of ours.  And \nI see a lot of people attempting to try to model out impacts and things of that nature.  And just a couple \nof things that I'm not sure it's real clear about the scope of business we have with them today.  The \nmajority of the revenue we have with them is through our base PD business, and a lot of that is mail \norder volume.  So, what you have here are the typical markers of large customer, PD majority and \nmail orders. ", "original_text": "And \nI see a lot of people attempting to try to model out impacts and things of that nature. "}, "hash": "ddf1a2d7e28438c48493a27cf045d9ab88292ec858d723a75f24916e368a4985", "class_name": "RelatedNodeInfo"}}, "text": "So last year, they were over a $30 billion customer of ours. ", "start_char_idx": 2291, "end_char_idx": 2352, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "e3ed3339-96fd-4c8b-9b78-9cdd14be00ec": {"__data__": {"id_": "e3ed3339-96fd-4c8b-9b78-9cdd14be00ec", "embedding": null, "metadata": {"window": "Now I do get a lot of questions around the \norder of magnitude of this, and I'm not going to go into details.  But just a couple of points, given the \nnumber of questions I've received is we have disclosed in the past, and I think it comes through in \nevery K, just the order of magnitude.   So last year, they were over a $30 billion customer of ours.  And \nI see a lot of people attempting to try to model out impacts and things of that nature.  And just a couple \nof things that I'm not sure it's real clear about the scope of business we have with them today.  The \nmajority of the revenue we have with them is through our base PD business, and a lot of that is mail \norder volume.  So, what you have here are the typical markers of large customer, PD majority and \nmail orders. ", "original_text": "And \nI see a lot of people attempting to try to model out impacts and things of that nature. ", "page_label": "15", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "5cf92087-e35d-4fba-85d3-821d01035638", "node_type": "4", "metadata": {"page_label": "15", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "8a3bc03b84fafd2339b44712a98220bec7cd43c6e8428ad74a2f9c58c6c3dcac", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "caefe377-afb4-4ec0-85a0-9b66a041ccfd", "node_type": "1", "metadata": {"window": "And as I highlighted before, they are a great customer of ours, long -\nstanding customer, one that brings a lot of innovation to healthcare and one that we've worked very \nhard over the y ears to attempt to exceed their expectations, and we think we're doing a great job of \nthat and we'd love to keep working with them, of course.   Now I do get a lot of questions around the \norder of magnitude of this, and I'm not going to go into details.  But just a couple of points, given the \nnumber of questions I've received is we have disclosed in the past, and I think it comes through in \nevery K, just the order of magnitude.   So last year, they were over a $30 billion customer of ours.  And \nI see a lot of people attempting to try to model out impacts and things of that nature.  And just a couple \nof things that I'm not sure it's real clear about the scope of business we have with them today.  The \nmajority of the revenue we have with them is through our base PD business, and a lot of that is mail \norder volume. ", "original_text": "So last year, they were over a $30 billion customer of ours. ", "page_label": "15", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "6cf1a129c7eb74c80b224ed9948d518b1d261725ea46e367da7dc7e824423518", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "4dbaec66-07d5-4f16-b8c1-71e8404463c5", "node_type": "1", "metadata": {"window": "But just a couple of points, given the \nnumber of questions I've received is we have disclosed in the past, and I think it comes through in \nevery K, just the order of magnitude.   So last year, they were over a $30 billion customer of ours.  And \nI see a lot of people attempting to try to model out impacts and things of that nature.  And just a couple \nof things that I'm not sure it's real clear about the scope of business we have with them today.  The \nmajority of the revenue we have with them is through our base PD business, and a lot of that is mail \norder volume.  So, what you have here are the typical markers of large customer, PD majority and \nmail orders.  So , those are all markers of lower -than-average  margin type of business.  ", "original_text": "And just a couple \nof things that I'm not sure it's real clear about the scope of business we have with them today. "}, "hash": "9bc840bf06f3862167e5bd6e516e36ec529b86c7046a86ed9a27f101aa88effb", "class_name": "RelatedNodeInfo"}}, "text": "And \nI see a lot of people attempting to try to model out impacts and things of that nature. ", "start_char_idx": 2352, "end_char_idx": 2445, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "4dbaec66-07d5-4f16-b8c1-71e8404463c5": {"__data__": {"id_": "4dbaec66-07d5-4f16-b8c1-71e8404463c5", "embedding": null, "metadata": {"window": "But just a couple of points, given the \nnumber of questions I've received is we have disclosed in the past, and I think it comes through in \nevery K, just the order of magnitude.   So last year, they were over a $30 billion customer of ours.  And \nI see a lot of people attempting to try to model out impacts and things of that nature.  And just a couple \nof things that I'm not sure it's real clear about the scope of business we have with them today.  The \nmajority of the revenue we have with them is through our base PD business, and a lot of that is mail \norder volume.  So, what you have here are the typical markers of large customer, PD majority and \nmail orders.  So , those are all markers of lower -than-average  margin type of business.  ", "original_text": "And just a couple \nof things that I'm not sure it's real clear about the scope of business we have with them today. ", "page_label": "15", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "5cf92087-e35d-4fba-85d3-821d01035638", "node_type": "4", "metadata": {"page_label": "15", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "8a3bc03b84fafd2339b44712a98220bec7cd43c6e8428ad74a2f9c58c6c3dcac", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "e3ed3339-96fd-4c8b-9b78-9cdd14be00ec", "node_type": "1", "metadata": {"window": "Now I do get a lot of questions around the \norder of magnitude of this, and I'm not going to go into details.  But just a couple of points, given the \nnumber of questions I've received is we have disclosed in the past, and I think it comes through in \nevery K, just the order of magnitude.   So last year, they were over a $30 billion customer of ours.  And \nI see a lot of people attempting to try to model out impacts and things of that nature.  And just a couple \nof things that I'm not sure it's real clear about the scope of business we have with them today.  The \nmajority of the revenue we have with them is through our base PD business, and a lot of that is mail \norder volume.  So, what you have here are the typical markers of large customer, PD majority and \nmail orders. ", "original_text": "And \nI see a lot of people attempting to try to model out impacts and things of that nature. ", "page_label": "15", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "a0792d3b0da44bae073d92ce088eb5c2f6fefeb580b63716b933b3abb82ba661", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "bdbadb6b-bcb8-4f6a-b12c-5bd8302a6780", "node_type": "1", "metadata": {"window": "So last year, they were over a $30 billion customer of ours.  And \nI see a lot of people attempting to try to model out impacts and things of that nature.  And just a couple \nof things that I'm not sure it's real clear about the scope of business we have with them today.  The \nmajority of the revenue we have with them is through our base PD business, and a lot of that is mail \norder volume.  So, what you have here are the typical markers of large customer, PD majority and \nmail orders.  So , those are all markers of lower -than-average  margin type of business.   And so, we do \nhave other business with them, of course, too, they are very large and have a lot of breadth into \nvarious parts of the industry. ", "original_text": "The \nmajority of the revenue we have with them is through our base PD business, and a lot of that is mail \norder volume. "}, "hash": "5a46ab7f78decd055576c972343de30c04f056ffc94faca354b07561785a8b75", "class_name": "RelatedNodeInfo"}}, "text": "And just a couple \nof things that I'm not sure it's real clear about the scope of business we have with them today. ", "start_char_idx": 2445, "end_char_idx": 2561, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "bdbadb6b-bcb8-4f6a-b12c-5bd8302a6780": {"__data__": {"id_": "bdbadb6b-bcb8-4f6a-b12c-5bd8302a6780", "embedding": null, "metadata": {"window": "So last year, they were over a $30 billion customer of ours.  And \nI see a lot of people attempting to try to model out impacts and things of that nature.  And just a couple \nof things that I'm not sure it's real clear about the scope of business we have with them today.  The \nmajority of the revenue we have with them is through our base PD business, and a lot of that is mail \norder volume.  So, what you have here are the typical markers of large customer, PD majority and \nmail orders.  So , those are all markers of lower -than-average  margin type of business.   And so, we do \nhave other business with them, of course, too, they are very large and have a lot of breadth into \nvarious parts of the industry. ", "original_text": "The \nmajority of the revenue we have with them is through our base PD business, and a lot of that is mail \norder volume. ", "page_label": "15", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "5cf92087-e35d-4fba-85d3-821d01035638", "node_type": "4", "metadata": {"page_label": "15", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "8a3bc03b84fafd2339b44712a98220bec7cd43c6e8428ad74a2f9c58c6c3dcac", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "4dbaec66-07d5-4f16-b8c1-71e8404463c5", "node_type": "1", "metadata": {"window": "But just a couple of points, given the \nnumber of questions I've received is we have disclosed in the past, and I think it comes through in \nevery K, just the order of magnitude.   So last year, they were over a $30 billion customer of ours.  And \nI see a lot of people attempting to try to model out impacts and things of that nature.  And just a couple \nof things that I'm not sure it's real clear about the scope of business we have with them today.  The \nmajority of the revenue we have with them is through our base PD business, and a lot of that is mail \norder volume.  So, what you have here are the typical markers of large customer, PD majority and \nmail orders.  So , those are all markers of lower -than-average  margin type of business.  ", "original_text": "And just a couple \nof things that I'm not sure it's real clear about the scope of business we have with them today. ", "page_label": "15", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "999d7bb89358500e10263428b18a5120afb80421d9812642845257037f2e4c2a", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "c2b6b96f-4761-4bb5-9ac7-4ddc64285109", "node_type": "1", "metadata": {"window": "And \nI see a lot of people attempting to try to model out impacts and things of that nature.  And just a couple \nof things that I'm not sure it's real clear about the scope of business we have with them today.  The \nmajority of the revenue we have with them is through our base PD business, and a lot of that is mail \norder volume.  So, what you have here are the typical markers of large customer, PD majority and \nmail orders.  So , those are all markers of lower -than-average  margin type of business.   And so, we do \nhave other business with them, of course, too, they are very large and have a lot of breadth into \nvarious parts of the industry.  But for us, those tend to be a little bit of the overweight of how we \nsupport them.  \n \n", "original_text": "So, what you have here are the typical markers of large customer, PD majority and \nmail orders. "}, "hash": "93c5c4d7748a6efec0e51f2128c889cc074df35c1f10750d42cf0613446979af", "class_name": "RelatedNodeInfo"}}, "text": "The \nmajority of the revenue we have with them is through our base PD business, and a lot of that is mail \norder volume. ", "start_char_idx": 2561, "end_char_idx": 2682, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "c2b6b96f-4761-4bb5-9ac7-4ddc64285109": {"__data__": {"id_": "c2b6b96f-4761-4bb5-9ac7-4ddc64285109", "embedding": null, "metadata": {"window": "And \nI see a lot of people attempting to try to model out impacts and things of that nature.  And just a couple \nof things that I'm not sure it's real clear about the scope of business we have with them today.  The \nmajority of the revenue we have with them is through our base PD business, and a lot of that is mail \norder volume.  So, what you have here are the typical markers of large customer, PD majority and \nmail orders.  So , those are all markers of lower -than-average  margin type of business.   And so, we do \nhave other business with them, of course, too, they are very large and have a lot of breadth into \nvarious parts of the industry.  But for us, those tend to be a little bit of the overweight of how we \nsupport them.  \n \n", "original_text": "So, what you have here are the typical markers of large customer, PD majority and \nmail orders. ", "page_label": "15", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "5cf92087-e35d-4fba-85d3-821d01035638", "node_type": "4", "metadata": {"page_label": "15", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "8a3bc03b84fafd2339b44712a98220bec7cd43c6e8428ad74a2f9c58c6c3dcac", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "bdbadb6b-bcb8-4f6a-b12c-5bd8302a6780", "node_type": "1", "metadata": {"window": "So last year, they were over a $30 billion customer of ours.  And \nI see a lot of people attempting to try to model out impacts and things of that nature.  And just a couple \nof things that I'm not sure it's real clear about the scope of business we have with them today.  The \nmajority of the revenue we have with them is through our base PD business, and a lot of that is mail \norder volume.  So, what you have here are the typical markers of large customer, PD majority and \nmail orders.  So , those are all markers of lower -than-average  margin type of business.   And so, we do \nhave other business with them, of course, too, they are very large and have a lot of breadth into \nvarious parts of the industry. ", "original_text": "The \nmajority of the revenue we have with them is through our base PD business, and a lot of that is mail \norder volume. ", "page_label": "15", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "81b1499c31579ae8141507d5806a6d7165188cabd03ed69e18c10ece8cff2f0a", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "2b28cded-3168-47be-a75a-04ba7ff7503b", "node_type": "1", "metadata": {"window": "And just a couple \nof things that I'm not sure it's real clear about the scope of business we have with them today.  The \nmajority of the revenue we have with them is through our base PD business, and a lot of that is mail \norder volume.  So, what you have here are the typical markers of large customer, PD majority and \nmail orders.  So , those are all markers of lower -than-average  margin type of business.   And so, we do \nhave other business with them, of course, too, they are very large and have a lot of breadth into \nvarious parts of the industry.  But for us, those tend to be a little bit of the overweight of how we \nsupport them.  \n \n As it relates to the SG&A, the only thing I would say is, no, it's not like that. ", "original_text": "So , those are all markers of lower -than-average  margin type of business.  "}, "hash": "703444707e84ff34644ae9245294f7527dbf328ed8e3bf338b129a23eefb5cbf", "class_name": "RelatedNodeInfo"}}, "text": "So, what you have here are the typical markers of large customer, PD majority and \nmail orders. ", "start_char_idx": 2682, "end_char_idx": 2778, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "2b28cded-3168-47be-a75a-04ba7ff7503b": {"__data__": {"id_": "2b28cded-3168-47be-a75a-04ba7ff7503b", "embedding": null, "metadata": {"window": "And just a couple \nof things that I'm not sure it's real clear about the scope of business we have with them today.  The \nmajority of the revenue we have with them is through our base PD business, and a lot of that is mail \norder volume.  So, what you have here are the typical markers of large customer, PD majority and \nmail orders.  So , those are all markers of lower -than-average  margin type of business.   And so, we do \nhave other business with them, of course, too, they are very large and have a lot of breadth into \nvarious parts of the industry.  But for us, those tend to be a little bit of the overweight of how we \nsupport them.  \n \n As it relates to the SG&A, the only thing I would say is, no, it's not like that. ", "original_text": "So , those are all markers of lower -than-average  margin type of business.  ", "page_label": "15", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "5cf92087-e35d-4fba-85d3-821d01035638", "node_type": "4", "metadata": {"page_label": "15", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "8a3bc03b84fafd2339b44712a98220bec7cd43c6e8428ad74a2f9c58c6c3dcac", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "c2b6b96f-4761-4bb5-9ac7-4ddc64285109", "node_type": "1", "metadata": {"window": "And \nI see a lot of people attempting to try to model out impacts and things of that nature.  And just a couple \nof things that I'm not sure it's real clear about the scope of business we have with them today.  The \nmajority of the revenue we have with them is through our base PD business, and a lot of that is mail \norder volume.  So, what you have here are the typical markers of large customer, PD majority and \nmail orders.  So , those are all markers of lower -than-average  margin type of business.   And so, we do \nhave other business with them, of course, too, they are very large and have a lot of breadth into \nvarious parts of the industry.  But for us, those tend to be a little bit of the overweight of how we \nsupport them.  \n \n", "original_text": "So, what you have here are the typical markers of large customer, PD majority and \nmail orders. ", "page_label": "15", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "98c3cfb6348252c35968faed66f84b2395f3e99f8ce4530b24d7190cbc4ec8eb", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "c1c69078-3694-480a-995d-4fc91698e90a", "node_type": "1", "metadata": {"window": "The \nmajority of the revenue we have with them is through our base PD business, and a lot of that is mail \norder volume.  So, what you have here are the typical markers of large customer, PD majority and \nmail orders.  So , those are all markers of lower -than-average  margin type of business.   And so, we do \nhave other business with them, of course, too, they are very large and have a lot of breadth into \nvarious parts of the industry.  But for us, those tend to be a little bit of the overweight of how we \nsupport them.  \n \n As it relates to the SG&A, the only thing I would say is, no, it's not like that.  What we do is we look at \nthe capabilities and the necessities needed both short -term and long -term. ", "original_text": "And so, we do \nhave other business with them, of course, too, they are very large and have a lot of breadth into \nvarious parts of the industry. "}, "hash": "0cb55f36182ab7ee533874b6cd61e74f8682563298cb6b4244f04ec4d55cdfdb", "class_name": "RelatedNodeInfo"}}, "text": "So , those are all markers of lower -than-average  margin type of business.  ", "start_char_idx": 2778, "end_char_idx": 2855, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "c1c69078-3694-480a-995d-4fc91698e90a": {"__data__": {"id_": "c1c69078-3694-480a-995d-4fc91698e90a", "embedding": null, "metadata": {"window": "The \nmajority of the revenue we have with them is through our base PD business, and a lot of that is mail \norder volume.  So, what you have here are the typical markers of large customer, PD majority and \nmail orders.  So , those are all markers of lower -than-average  margin type of business.   And so, we do \nhave other business with them, of course, too, they are very large and have a lot of breadth into \nvarious parts of the industry.  But for us, those tend to be a little bit of the overweight of how we \nsupport them.  \n \n As it relates to the SG&A, the only thing I would say is, no, it's not like that.  What we do is we look at \nthe capabilities and the necessities needed both short -term and long -term. ", "original_text": "And so, we do \nhave other business with them, of course, too, they are very large and have a lot of breadth into \nvarious parts of the industry. ", "page_label": "15", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "5cf92087-e35d-4fba-85d3-821d01035638", "node_type": "4", "metadata": {"page_label": "15", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "8a3bc03b84fafd2339b44712a98220bec7cd43c6e8428ad74a2f9c58c6c3dcac", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "2b28cded-3168-47be-a75a-04ba7ff7503b", "node_type": "1", "metadata": {"window": "And just a couple \nof things that I'm not sure it's real clear about the scope of business we have with them today.  The \nmajority of the revenue we have with them is through our base PD business, and a lot of that is mail \norder volume.  So, what you have here are the typical markers of large customer, PD majority and \nmail orders.  So , those are all markers of lower -than-average  margin type of business.   And so, we do \nhave other business with them, of course, too, they are very large and have a lot of breadth into \nvarious parts of the industry.  But for us, those tend to be a little bit of the overweight of how we \nsupport them.  \n \n As it relates to the SG&A, the only thing I would say is, no, it's not like that. ", "original_text": "So , those are all markers of lower -than-average  margin type of business.  ", "page_label": "15", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "93706ec5263051b85f3f7d97fd9680231630d1f809d605109f0927664c576019", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "18c8f6e5-05c5-41c9-9729-896c46c0cba3", "node_type": "1", "metadata": {"window": "So, what you have here are the typical markers of large customer, PD majority and \nmail orders.  So , those are all markers of lower -than-average  margin type of business.   And so, we do \nhave other business with them, of course, too, they are very large and have a lot of breadth into \nvarious parts of the industry.  But for us, those tend to be a little bit of the overweight of how we \nsupport them.  \n \n As it relates to the SG&A, the only thing I would say is, no, it's not like that.  What we do is we look at \nthe capabilities and the necessities needed both short -term and long -term.  Short-term is going to be \non volume and making sure we can support our customers in getting that strong volume growth \nacross the enterprise in place.  ", "original_text": "But for us, those tend to be a little bit of the overweight of how we \nsupport them.  \n \n"}, "hash": "7ef0f32a44dbc9072af4e9c7113b443ef9f0ec5164894b36f93e8669730d9f66", "class_name": "RelatedNodeInfo"}}, "text": "And so, we do \nhave other business with them, of course, too, they are very large and have a lot of breadth into \nvarious parts of the industry. ", "start_char_idx": 2855, "end_char_idx": 3000, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "18c8f6e5-05c5-41c9-9729-896c46c0cba3": {"__data__": {"id_": "18c8f6e5-05c5-41c9-9729-896c46c0cba3", "embedding": null, "metadata": {"window": "So, what you have here are the typical markers of large customer, PD majority and \nmail orders.  So , those are all markers of lower -than-average  margin type of business.   And so, we do \nhave other business with them, of course, too, they are very large and have a lot of breadth into \nvarious parts of the industry.  But for us, those tend to be a little bit of the overweight of how we \nsupport them.  \n \n As it relates to the SG&A, the only thing I would say is, no, it's not like that.  What we do is we look at \nthe capabilities and the necessities needed both short -term and long -term.  Short-term is going to be \non volume and making sure we can support our customers in getting that strong volume growth \nacross the enterprise in place.  ", "original_text": "But for us, those tend to be a little bit of the overweight of how we \nsupport them.  \n \n", "page_label": "15", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "5cf92087-e35d-4fba-85d3-821d01035638", "node_type": "4", "metadata": {"page_label": "15", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "8a3bc03b84fafd2339b44712a98220bec7cd43c6e8428ad74a2f9c58c6c3dcac", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "c1c69078-3694-480a-995d-4fc91698e90a", "node_type": "1", "metadata": {"window": "The \nmajority of the revenue we have with them is through our base PD business, and a lot of that is mail \norder volume.  So, what you have here are the typical markers of large customer, PD majority and \nmail orders.  So , those are all markers of lower -than-average  margin type of business.   And so, we do \nhave other business with them, of course, too, they are very large and have a lot of breadth into \nvarious parts of the industry.  But for us, those tend to be a little bit of the overweight of how we \nsupport them.  \n \n As it relates to the SG&A, the only thing I would say is, no, it's not like that.  What we do is we look at \nthe capabilities and the necessities needed both short -term and long -term. ", "original_text": "And so, we do \nhave other business with them, of course, too, they are very large and have a lot of breadth into \nvarious parts of the industry. ", "page_label": "15", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "95db4852c4e87205d65b0fc521111850d57de297400e13461ff8f57a1d23ef10", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "542f85ec-3ab4-4e77-baeb-148fc11a703c", "node_type": "1", "metadata": {"window": "So , those are all markers of lower -than-average  margin type of business.   And so, we do \nhave other business with them, of course, too, they are very large and have a lot of breadth into \nvarious parts of the industry.  But for us, those tend to be a little bit of the overweight of how we \nsupport them.  \n \n As it relates to the SG&A, the only thing I would say is, no, it's not like that.  What we do is we look at \nthe capabilities and the necessities needed both short -term and long -term.  Short-term is going to be \non volume and making sure we can support our customers in getting that strong volume growth \nacross the enterprise in place.   We are then looking to balance that with longer -term investments, \nwhether it's the Navista \u2122 Network we've called out before as investments. ", "original_text": "As it relates to the SG&A, the only thing I would say is, no, it's not like that. "}, "hash": "9e97ad2af02e26f661357ec17c1a4bd5e2d16b05bb2561842a37a5cc7a1264a4", "class_name": "RelatedNodeInfo"}}, "text": "But for us, those tend to be a little bit of the overweight of how we \nsupport them.  \n \n", "start_char_idx": 3000, "end_char_idx": 3089, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "542f85ec-3ab4-4e77-baeb-148fc11a703c": {"__data__": {"id_": "542f85ec-3ab4-4e77-baeb-148fc11a703c", "embedding": null, "metadata": {"window": "So , those are all markers of lower -than-average  margin type of business.   And so, we do \nhave other business with them, of course, too, they are very large and have a lot of breadth into \nvarious parts of the industry.  But for us, those tend to be a little bit of the overweight of how we \nsupport them.  \n \n As it relates to the SG&A, the only thing I would say is, no, it's not like that.  What we do is we look at \nthe capabilities and the necessities needed both short -term and long -term.  Short-term is going to be \non volume and making sure we can support our customers in getting that strong volume growth \nacross the enterprise in place.   We are then looking to balance that with longer -term investments, \nwhether it's the Navista \u2122 Network we've called out before as investments. ", "original_text": "As it relates to the SG&A, the only thing I would say is, no, it's not like that. ", "page_label": "15", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "5cf92087-e35d-4fba-85d3-821d01035638", "node_type": "4", "metadata": {"page_label": "15", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "8a3bc03b84fafd2339b44712a98220bec7cd43c6e8428ad74a2f9c58c6c3dcac", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "18c8f6e5-05c5-41c9-9729-896c46c0cba3", "node_type": "1", "metadata": {"window": "So, what you have here are the typical markers of large customer, PD majority and \nmail orders.  So , those are all markers of lower -than-average  margin type of business.   And so, we do \nhave other business with them, of course, too, they are very large and have a lot of breadth into \nvarious parts of the industry.  But for us, those tend to be a little bit of the overweight of how we \nsupport them.  \n \n As it relates to the SG&A, the only thing I would say is, no, it's not like that.  What we do is we look at \nthe capabilities and the necessities needed both short -term and long -term.  Short-term is going to be \non volume and making sure we can support our customers in getting that strong volume growth \nacross the enterprise in place.  ", "original_text": "But for us, those tend to be a little bit of the overweight of how we \nsupport them.  \n \n", "page_label": "15", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "cdf1922708f1f9616d6ec7a8954f8ad8eba8cf0902499ae993500a7a451e5895", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "aa064d45-ec4c-46da-8395-970deaf301f6", "node_type": "1", "metadata": {"window": "And so, we do \nhave other business with them, of course, too, they are very large and have a lot of breadth into \nvarious parts of the industry.  But for us, those tend to be a little bit of the overweight of how we \nsupport them.  \n \n As it relates to the SG&A, the only thing I would say is, no, it's not like that.  What we do is we look at \nthe capabilities and the necessities needed both short -term and long -term.  Short-term is going to be \non volume and making sure we can support our customers in getting that strong volume growth \nacross the enterprise in place.   We are then looking to balance that with longer -term investments, \nwhether it's the Navista \u2122 Network we've called out before as investments.  But we also have others \nthat we went through during Investor Day and have had a number of updates even today. ", "original_text": "What we do is we look at \nthe capabilities and the necessities needed both short -term and long -term. "}, "hash": "a03427185d0ac28480329a8f0371c0f22c2a22d5b18b1666a27bdeef9b4cf026", "class_name": "RelatedNodeInfo"}}, "text": "As it relates to the SG&A, the only thing I would say is, no, it's not like that. ", "start_char_idx": 3089, "end_char_idx": 3171, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "aa064d45-ec4c-46da-8395-970deaf301f6": {"__data__": {"id_": "aa064d45-ec4c-46da-8395-970deaf301f6", "embedding": null, "metadata": {"window": "And so, we do \nhave other business with them, of course, too, they are very large and have a lot of breadth into \nvarious parts of the industry.  But for us, those tend to be a little bit of the overweight of how we \nsupport them.  \n \n As it relates to the SG&A, the only thing I would say is, no, it's not like that.  What we do is we look at \nthe capabilities and the necessities needed both short -term and long -term.  Short-term is going to be \non volume and making sure we can support our customers in getting that strong volume growth \nacross the enterprise in place.   We are then looking to balance that with longer -term investments, \nwhether it's the Navista \u2122 Network we've called out before as investments.  But we also have others \nthat we went through during Investor Day and have had a number of updates even today. ", "original_text": "What we do is we look at \nthe capabilities and the necessities needed both short -term and long -term. ", "page_label": "15", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "5cf92087-e35d-4fba-85d3-821d01035638", "node_type": "4", "metadata": {"page_label": "15", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "8a3bc03b84fafd2339b44712a98220bec7cd43c6e8428ad74a2f9c58c6c3dcac", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "542f85ec-3ab4-4e77-baeb-148fc11a703c", "node_type": "1", "metadata": {"window": "So , those are all markers of lower -than-average  margin type of business.   And so, we do \nhave other business with them, of course, too, they are very large and have a lot of breadth into \nvarious parts of the industry.  But for us, those tend to be a little bit of the overweight of how we \nsupport them.  \n \n As it relates to the SG&A, the only thing I would say is, no, it's not like that.  What we do is we look at \nthe capabilities and the necessities needed both short -term and long -term.  Short-term is going to be \non volume and making sure we can support our customers in getting that strong volume growth \nacross the enterprise in place.   We are then looking to balance that with longer -term investments, \nwhether it's the Navista \u2122 Network we've called out before as investments. ", "original_text": "As it relates to the SG&A, the only thing I would say is, no, it's not like that. ", "page_label": "15", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "cba2a79d7ba58c7f089c58c975a02196118c418b5b49208152c70b104515a0c5", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "7a750335-3830-47b4-9fad-a07a8a833139", "node_type": "1", "metadata": {"window": "But for us, those tend to be a little bit of the overweight of how we \nsupport them.  \n \n As it relates to the SG&A, the only thing I would say is, no, it's not like that.  What we do is we look at \nthe capabilities and the necessities needed both short -term and long -term.  Short-term is going to be \non volume and making sure we can support our customers in getting that strong volume growth \nacross the enterprise in place.   We are then looking to balance that with longer -term investments, \nwhether it's the Navista \u2122 Network we've called out before as investments.  But we also have others \nthat we went through during Investor Day and have had a number of updates even today.  Within our \nat-Home business, we have three new facilities that  we're bringing online over the course of the next \nyear or two, within the Medical distribution three facilities I talked about today. ", "original_text": "Short-term is going to be \non volume and making sure we can support our customers in getting that strong volume growth \nacross the enterprise in place.  "}, "hash": "334abd0ed32cf6a788efc3e883bc064c02247e583ed2d3d338f9930bc1038c78", "class_name": "RelatedNodeInfo"}}, "text": "What we do is we look at \nthe capabilities and the necessities needed both short -term and long -term. ", "start_char_idx": 3171, "end_char_idx": 3274, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "7a750335-3830-47b4-9fad-a07a8a833139": {"__data__": {"id_": "7a750335-3830-47b4-9fad-a07a8a833139", "embedding": null, "metadata": {"window": "But for us, those tend to be a little bit of the overweight of how we \nsupport them.  \n \n As it relates to the SG&A, the only thing I would say is, no, it's not like that.  What we do is we look at \nthe capabilities and the necessities needed both short -term and long -term.  Short-term is going to be \non volume and making sure we can support our customers in getting that strong volume growth \nacross the enterprise in place.   We are then looking to balance that with longer -term investments, \nwhether it's the Navista \u2122 Network we've called out before as investments.  But we also have others \nthat we went through during Investor Day and have had a number of updates even today.  Within our \nat-Home business, we have three new facilities that  we're bringing online over the course of the next \nyear or two, within the Medical distribution three facilities I talked about today. ", "original_text": "Short-term is going to be \non volume and making sure we can support our customers in getting that strong volume growth \nacross the enterprise in place.  ", "page_label": "15", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "5cf92087-e35d-4fba-85d3-821d01035638", "node_type": "4", "metadata": {"page_label": "15", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "8a3bc03b84fafd2339b44712a98220bec7cd43c6e8428ad74a2f9c58c6c3dcac", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "aa064d45-ec4c-46da-8395-970deaf301f6", "node_type": "1", "metadata": {"window": "And so, we do \nhave other business with them, of course, too, they are very large and have a lot of breadth into \nvarious parts of the industry.  But for us, those tend to be a little bit of the overweight of how we \nsupport them.  \n \n As it relates to the SG&A, the only thing I would say is, no, it's not like that.  What we do is we look at \nthe capabilities and the necessities needed both short -term and long -term.  Short-term is going to be \non volume and making sure we can support our customers in getting that strong volume growth \nacross the enterprise in place.   We are then looking to balance that with longer -term investments, \nwhether it's the Navista \u2122 Network we've called out before as investments.  But we also have others \nthat we went through during Investor Day and have had a number of updates even today. ", "original_text": "What we do is we look at \nthe capabilities and the necessities needed both short -term and long -term. ", "page_label": "15", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "f6525627305dec593372a976b6aacc758c6ac2ce1fb7dd0fc9ea731630d42821", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "a0a3addc-273b-4c68-a6d2-c960baf2ac0a", "node_type": "1", "metadata": {"window": "As it relates to the SG&A, the only thing I would say is, no, it's not like that.  What we do is we look at \nthe capabilities and the necessities needed both short -term and long -term.  Short-term is going to be \non volume and making sure we can support our customers in getting that strong volume growth \nacross the enterprise in place.   We are then looking to balance that with longer -term investments, \nwhether it's the Navista \u2122 Network we've called out before as investments.  But we also have others \nthat we went through during Investor Day and have had a number of updates even today.  Within our \nat-Home business, we have three new facilities that  we're bringing online over the course of the next \nyear or two, within the Medical distribution three facilities I talked about today.  We have on the ", "original_text": "We are then looking to balance that with longer -term investments, \nwhether it's the Navista \u2122 Network we've called out before as investments. "}, "hash": "1e5fe05b892f93d3dac0346916016d28d86d555b3bb68b5e908fae537324e638", "class_name": "RelatedNodeInfo"}}, "text": "Short-term is going to be \non volume and making sure we can support our customers in getting that strong volume growth \nacross the enterprise in place.  ", "start_char_idx": 3274, "end_char_idx": 3427, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "a0a3addc-273b-4c68-a6d2-c960baf2ac0a": {"__data__": {"id_": "a0a3addc-273b-4c68-a6d2-c960baf2ac0a", "embedding": null, "metadata": {"window": "As it relates to the SG&A, the only thing I would say is, no, it's not like that.  What we do is we look at \nthe capabilities and the necessities needed both short -term and long -term.  Short-term is going to be \non volume and making sure we can support our customers in getting that strong volume growth \nacross the enterprise in place.   We are then looking to balance that with longer -term investments, \nwhether it's the Navista \u2122 Network we've called out before as investments.  But we also have others \nthat we went through during Investor Day and have had a number of updates even today.  Within our \nat-Home business, we have three new facilities that  we're bringing online over the course of the next \nyear or two, within the Medical distribution three facilities I talked about today.  We have on the ", "original_text": "We are then looking to balance that with longer -term investments, \nwhether it's the Navista \u2122 Network we've called out before as investments. ", "page_label": "15", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "5cf92087-e35d-4fba-85d3-821d01035638", "node_type": "4", "metadata": {"page_label": "15", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "8a3bc03b84fafd2339b44712a98220bec7cd43c6e8428ad74a2f9c58c6c3dcac", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "7a750335-3830-47b4-9fad-a07a8a833139", "node_type": "1", "metadata": {"window": "But for us, those tend to be a little bit of the overweight of how we \nsupport them.  \n \n As it relates to the SG&A, the only thing I would say is, no, it's not like that.  What we do is we look at \nthe capabilities and the necessities needed both short -term and long -term.  Short-term is going to be \non volume and making sure we can support our customers in getting that strong volume growth \nacross the enterprise in place.   We are then looking to balance that with longer -term investments, \nwhether it's the Navista \u2122 Network we've called out before as investments.  But we also have others \nthat we went through during Investor Day and have had a number of updates even today.  Within our \nat-Home business, we have three new facilities that  we're bringing online over the course of the next \nyear or two, within the Medical distribution three facilities I talked about today. ", "original_text": "Short-term is going to be \non volume and making sure we can support our customers in getting that strong volume growth \nacross the enterprise in place.  ", "page_label": "15", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "49e77002d3e2ff8e29a04ec3010c8a1306b6025cc71b6521c3eb3e4d83458c80", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "3ab7afeb-5439-4b4c-be1b-e6006f6be773", "node_type": "1", "metadata": {"window": "What we do is we look at \nthe capabilities and the necessities needed both short -term and long -term.  Short-term is going to be \non volume and making sure we can support our customers in getting that strong volume growth \nacross the enterprise in place.   We are then looking to balance that with longer -term investments, \nwhether it's the Navista \u2122 Network we've called out before as investments.  But we also have others \nthat we went through during Investor Day and have had a number of updates even today.  Within our \nat-Home business, we have three new facilities that  we're bringing online over the course of the next \nyear or two, within the Medical distribution three facilities I talked about today.  We have on the ", "original_text": "But we also have others \nthat we went through during Investor Day and have had a number of updates even today. "}, "hash": "acc6d48bd34ab0a8e2cce1ee5ab37cbe144f7a2e982fcdccaa8b0ec73eb589cb", "class_name": "RelatedNodeInfo"}}, "text": "We are then looking to balance that with longer -term investments, \nwhether it's the Navista \u2122 Network we've called out before as investments. ", "start_char_idx": 3427, "end_char_idx": 3570, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "3ab7afeb-5439-4b4c-be1b-e6006f6be773": {"__data__": {"id_": "3ab7afeb-5439-4b4c-be1b-e6006f6be773", "embedding": null, "metadata": {"window": "What we do is we look at \nthe capabilities and the necessities needed both short -term and long -term.  Short-term is going to be \non volume and making sure we can support our customers in getting that strong volume growth \nacross the enterprise in place.   We are then looking to balance that with longer -term investments, \nwhether it's the Navista \u2122 Network we've called out before as investments.  But we also have others \nthat we went through during Investor Day and have had a number of updates even today.  Within our \nat-Home business, we have three new facilities that  we're bringing online over the course of the next \nyear or two, within the Medical distribution three facilities I talked about today.  We have on the ", "original_text": "But we also have others \nthat we went through during Investor Day and have had a number of updates even today. ", "page_label": "15", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "5cf92087-e35d-4fba-85d3-821d01035638", "node_type": "4", "metadata": {"page_label": "15", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "8a3bc03b84fafd2339b44712a98220bec7cd43c6e8428ad74a2f9c58c6c3dcac", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "a0a3addc-273b-4c68-a6d2-c960baf2ac0a", "node_type": "1", "metadata": {"window": "As it relates to the SG&A, the only thing I would say is, no, it's not like that.  What we do is we look at \nthe capabilities and the necessities needed both short -term and long -term.  Short-term is going to be \non volume and making sure we can support our customers in getting that strong volume growth \nacross the enterprise in place.   We are then looking to balance that with longer -term investments, \nwhether it's the Navista \u2122 Network we've called out before as investments.  But we also have others \nthat we went through during Investor Day and have had a number of updates even today.  Within our \nat-Home business, we have three new facilities that  we're bringing online over the course of the next \nyear or two, within the Medical distribution three facilities I talked about today.  We have on the ", "original_text": "We are then looking to balance that with longer -term investments, \nwhether it's the Navista \u2122 Network we've called out before as investments. ", "page_label": "15", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "7be101edc506f3e08b68797bca8b062451a6a4c3c69614d7ec7189a6ffcf717b", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "b2914adc-8dc7-4f7f-99c8-2d6181827e10", "node_type": "1", "metadata": {"window": "Short-term is going to be \non volume and making sure we can support our customers in getting that strong volume growth \nacross the enterprise in place.   We are then looking to balance that with longer -term investments, \nwhether it's the Navista \u2122 Network we've called out before as investments.  But we also have others \nthat we went through during Investor Day and have had a number of updates even today.  Within our \nat-Home business, we have three new facilities that  we're bringing online over the course of the next \nyear or two, within the Medical distribution three facilities I talked about today.  We have on the ", "original_text": "Within our \nat-Home business, we have three new facilities that  we're bringing online over the course of the next \nyear or two, within the Medical distribution three facilities I talked about today. "}, "hash": "1fd6d9a1eb96cf7a5589e7909f51b1fd4bb4488fa7d3d7fdbfb10b80c9bd6067", "class_name": "RelatedNodeInfo"}}, "text": "But we also have others \nthat we went through during Investor Day and have had a number of updates even today. ", "start_char_idx": 3570, "end_char_idx": 3681, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "b2914adc-8dc7-4f7f-99c8-2d6181827e10": {"__data__": {"id_": "b2914adc-8dc7-4f7f-99c8-2d6181827e10", "embedding": null, "metadata": {"window": "Short-term is going to be \non volume and making sure we can support our customers in getting that strong volume growth \nacross the enterprise in place.   We are then looking to balance that with longer -term investments, \nwhether it's the Navista \u2122 Network we've called out before as investments.  But we also have others \nthat we went through during Investor Day and have had a number of updates even today.  Within our \nat-Home business, we have three new facilities that  we're bringing online over the course of the next \nyear or two, within the Medical distribution three facilities I talked about today.  We have on the ", "original_text": "Within our \nat-Home business, we have three new facilities that  we're bringing online over the course of the next \nyear or two, within the Medical distribution three facilities I talked about today. ", "page_label": "15", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "5cf92087-e35d-4fba-85d3-821d01035638", "node_type": "4", "metadata": {"page_label": "15", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "8a3bc03b84fafd2339b44712a98220bec7cd43c6e8428ad74a2f9c58c6c3dcac", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "3ab7afeb-5439-4b4c-be1b-e6006f6be773", "node_type": "1", "metadata": {"window": "What we do is we look at \nthe capabilities and the necessities needed both short -term and long -term.  Short-term is going to be \non volume and making sure we can support our customers in getting that strong volume growth \nacross the enterprise in place.   We are then looking to balance that with longer -term investments, \nwhether it's the Navista \u2122 Network we've called out before as investments.  But we also have others \nthat we went through during Investor Day and have had a number of updates even today.  Within our \nat-Home business, we have three new facilities that  we're bringing online over the course of the next \nyear or two, within the Medical distribution three facilities I talked about today.  We have on the ", "original_text": "But we also have others \nthat we went through during Investor Day and have had a number of updates even today. ", "page_label": "15", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "877a74fa6fb41402752c4c75635700e161597a378749ef429375be82a8a4f1d6", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "ac853a32-bdf8-4a8e-a3f4-457b62da9b47", "node_type": "1", "metadata": {"window": "We are then looking to balance that with longer -term investments, \nwhether it's the Navista \u2122 Network we've called out before as investments.  But we also have others \nthat we went through during Investor Day and have had a number of updates even today.  Within our \nat-Home business, we have three new facilities that  we're bringing online over the course of the next \nyear or two, within the Medical distribution three facilities I talked about today.  We have on the ", "original_text": "We have on the "}, "hash": "b3b1229fe9ec666ef4c732d88afe5aa75e273ea8c246297e146d6beeabb18cab", "class_name": "RelatedNodeInfo"}}, "text": "Within our \nat-Home business, we have three new facilities that  we're bringing online over the course of the next \nyear or two, within the Medical distribution three facilities I talked about today. ", "start_char_idx": 3681, "end_char_idx": 3881, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "ac853a32-bdf8-4a8e-a3f4-457b62da9b47": {"__data__": {"id_": "ac853a32-bdf8-4a8e-a3f4-457b62da9b47", "embedding": null, "metadata": {"window": "We are then looking to balance that with longer -term investments, \nwhether it's the Navista \u2122 Network we've called out before as investments.  But we also have others \nthat we went through during Investor Day and have had a number of updates even today.  Within our \nat-Home business, we have three new facilities that  we're bringing online over the course of the next \nyear or two, within the Medical distribution three facilities I talked about today.  We have on the ", "original_text": "We have on the ", "page_label": "15", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "5cf92087-e35d-4fba-85d3-821d01035638", "node_type": "4", "metadata": {"page_label": "15", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "8a3bc03b84fafd2339b44712a98220bec7cd43c6e8428ad74a2f9c58c6c3dcac", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "b2914adc-8dc7-4f7f-99c8-2d6181827e10", "node_type": "1", "metadata": {"window": "Short-term is going to be \non volume and making sure we can support our customers in getting that strong volume growth \nacross the enterprise in place.   We are then looking to balance that with longer -term investments, \nwhether it's the Navista \u2122 Network we've called out before as investments.  But we also have others \nthat we went through during Investor Day and have had a number of updates even today.  Within our \nat-Home business, we have three new facilities that  we're bringing online over the course of the next \nyear or two, within the Medical distribution three facilities I talked about today.  We have on the ", "original_text": "Within our \nat-Home business, we have three new facilities that  we're bringing online over the course of the next \nyear or two, within the Medical distribution three facilities I talked about today. ", "page_label": "15", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "f7937302eac0c90299d13d226121193ea78f69e739914dbd8c213a0dc61414f7", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "12653169-53f1-41ac-8f73-976b95773fd3", "node_type": "1", "metadata": {"window": " \nPage 16 of 19 \n \nPharma side, the consumer health new logistics center.   So, and I also made some comments around \nsome of the IT capabilities within Pharma and the e -commerce and Intelogix \u2122 capability.  So, we are \ninvesting where it makes sense, efficiently, very well -aligned to our strategy.  And these are not \ninvestments that you can just turn on and off. ", "original_text": " \nPage 16 of 19 \n \nPharma side, the consumer health new logistics center.  "}, "hash": "d39aafb506240e532d4a1f104bb87d169cadadfde13bd82c1b70496fdf79442f", "class_name": "RelatedNodeInfo"}}, "text": "We have on the ", "start_char_idx": 3881, "end_char_idx": 3896, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "12653169-53f1-41ac-8f73-976b95773fd3": {"__data__": {"id_": "12653169-53f1-41ac-8f73-976b95773fd3", "embedding": null, "metadata": {"window": " \nPage 16 of 19 \n \nPharma side, the consumer health new logistics center.   So, and I also made some comments around \nsome of the IT capabilities within Pharma and the e -commerce and Intelogix \u2122 capability.  So, we are \ninvesting where it makes sense, efficiently, very well -aligned to our strategy.  And these are not \ninvestments that you can just turn on and off. ", "original_text": " \nPage 16 of 19 \n \nPharma side, the consumer health new logistics center.  ", "page_label": "16", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "6d5ec7f6-bdd6-41b2-9b56-d1f2960aaef4", "node_type": "4", "metadata": {"page_label": "16", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "b0205224430b7dfc9e84da67be2109c44a567f4dad70817a17b38328d6416b9b", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "ac853a32-bdf8-4a8e-a3f4-457b62da9b47", "node_type": "1", "metadata": {"window": "We are then looking to balance that with longer -term investments, \nwhether it's the Navista \u2122 Network we've called out before as investments.  But we also have others \nthat we went through during Investor Day and have had a number of updates even today.  Within our \nat-Home business, we have three new facilities that  we're bringing online over the course of the next \nyear or two, within the Medical distribution three facilities I talked about today.  We have on the ", "original_text": "We have on the ", "page_label": "15", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "ad783d838b10ed68488dfdce5c3fc0612b076929117d935bcc0416cdfa860b5d", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "13622462-122e-4de3-8c44-6798bdc46e4c", "node_type": "1", "metadata": {"window": " \nPage 16 of 19 \n \nPharma side, the consumer health new logistics center.   So, and I also made some comments around \nsome of the IT capabilities within Pharma and the e -commerce and Intelogix \u2122 capability.  So, we are \ninvesting where it makes sense, efficiently, very well -aligned to our strategy.  And these are not \ninvestments that you can just turn on and off.  So, it's something that we're going to invest as \nappropriate, but only what we have to do as well. ", "original_text": "So, and I also made some comments around \nsome of the IT capabilities within Pharma and the e -commerce and Intelogix \u2122 capability. "}, "hash": "d7a4053f88ae87c515b902730423ff2d073a10623623404611d0cea84c755f82", "class_name": "RelatedNodeInfo"}}, "text": " \nPage 16 of 19 \n \nPharma side, the consumer health new logistics center.  ", "start_char_idx": 0, "end_char_idx": 75, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "13622462-122e-4de3-8c44-6798bdc46e4c": {"__data__": {"id_": "13622462-122e-4de3-8c44-6798bdc46e4c", "embedding": null, "metadata": {"window": " \nPage 16 of 19 \n \nPharma side, the consumer health new logistics center.   So, and I also made some comments around \nsome of the IT capabilities within Pharma and the e -commerce and Intelogix \u2122 capability.  So, we are \ninvesting where it makes sense, efficiently, very well -aligned to our strategy.  And these are not \ninvestments that you can just turn on and off.  So, it's something that we're going to invest as \nappropriate, but only what we have to do as well. ", "original_text": "So, and I also made some comments around \nsome of the IT capabilities within Pharma and the e -commerce and Intelogix \u2122 capability. ", "page_label": "16", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "6d5ec7f6-bdd6-41b2-9b56-d1f2960aaef4", "node_type": "4", "metadata": {"page_label": "16", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "b0205224430b7dfc9e84da67be2109c44a567f4dad70817a17b38328d6416b9b", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "12653169-53f1-41ac-8f73-976b95773fd3", "node_type": "1", "metadata": {"window": " \nPage 16 of 19 \n \nPharma side, the consumer health new logistics center.   So, and I also made some comments around \nsome of the IT capabilities within Pharma and the e -commerce and Intelogix \u2122 capability.  So, we are \ninvesting where it makes sense, efficiently, very well -aligned to our strategy.  And these are not \ninvestments that you can just turn on and off. ", "original_text": " \nPage 16 of 19 \n \nPharma side, the consumer health new logistics center.  ", "page_label": "16", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "109daa890f428929527df5cca921cfee016cb8575c76d94575cc95dad669efee", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "b29222ba-64b7-4ba8-a35a-da18b620af59", "node_type": "1", "metadata": {"window": " \nPage 16 of 19 \n \nPharma side, the consumer health new logistics center.   So, and I also made some comments around \nsome of the IT capabilities within Pharma and the e -commerce and Intelogix \u2122 capability.  So, we are \ninvesting where it makes sense, efficiently, very well -aligned to our strategy.  And these are not \ninvestments that you can just turn on and off.  So, it's something that we're going to invest as \nappropriate, but only what we have to do as well.  We want to take away waste and invest it where \nthere's growth is the key objective.  \n \n", "original_text": "So, we are \ninvesting where it makes sense, efficiently, very well -aligned to our strategy. "}, "hash": "93a2cda84eb696f05e7f4dc15212eb93a228414347141b8d3f4af2f82f3e3196", "class_name": "RelatedNodeInfo"}}, "text": "So, and I also made some comments around \nsome of the IT capabilities within Pharma and the e -commerce and Intelogix \u2122 capability. ", "start_char_idx": 75, "end_char_idx": 207, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "b29222ba-64b7-4ba8-a35a-da18b620af59": {"__data__": {"id_": "b29222ba-64b7-4ba8-a35a-da18b620af59", "embedding": null, "metadata": {"window": " \nPage 16 of 19 \n \nPharma side, the consumer health new logistics center.   So, and I also made some comments around \nsome of the IT capabilities within Pharma and the e -commerce and Intelogix \u2122 capability.  So, we are \ninvesting where it makes sense, efficiently, very well -aligned to our strategy.  And these are not \ninvestments that you can just turn on and off.  So, it's something that we're going to invest as \nappropriate, but only what we have to do as well.  We want to take away waste and invest it where \nthere's growth is the key objective.  \n \n", "original_text": "So, we are \ninvesting where it makes sense, efficiently, very well -aligned to our strategy. ", "page_label": "16", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "6d5ec7f6-bdd6-41b2-9b56-d1f2960aaef4", "node_type": "4", "metadata": {"page_label": "16", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "b0205224430b7dfc9e84da67be2109c44a567f4dad70817a17b38328d6416b9b", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "13622462-122e-4de3-8c44-6798bdc46e4c", "node_type": "1", "metadata": {"window": " \nPage 16 of 19 \n \nPharma side, the consumer health new logistics center.   So, and I also made some comments around \nsome of the IT capabilities within Pharma and the e -commerce and Intelogix \u2122 capability.  So, we are \ninvesting where it makes sense, efficiently, very well -aligned to our strategy.  And these are not \ninvestments that you can just turn on and off.  So, it's something that we're going to invest as \nappropriate, but only what we have to do as well. ", "original_text": "So, and I also made some comments around \nsome of the IT capabilities within Pharma and the e -commerce and Intelogix \u2122 capability. ", "page_label": "16", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "6e743ba995aa9b942fde741e5fbd5db46e68ebe4bea87095c4c7eed21efabbf2", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "1ef60e61-99b2-40d0-9ae3-fec5bd874e47", "node_type": "1", "metadata": {"window": " \nPage 16 of 19 \n \nPharma side, the consumer health new logistics center.   So, and I also made some comments around \nsome of the IT capabilities within Pharma and the e -commerce and Intelogix \u2122 capability.  So, we are \ninvesting where it makes sense, efficiently, very well -aligned to our strategy.  And these are not \ninvestments that you can just turn on and off.  So, it's something that we're going to invest as \nappropriate, but only what we have to do as well.  We want to take away waste and invest it where \nthere's growth is the key objective.  \n \n Aaron Alt:  For those working on their models, it's probably worth pointing out that with respect to the \nQ2 profitability in the business, it was the case that last year, we called out unusual strength in the \noverall Pharma demand, particularly from large customers, as well as very strong cough, cold and flu \nseason. ", "original_text": "And these are not \ninvestments that you can just turn on and off. "}, "hash": "d6d6aba3ac43046ad20fd8b7d3a8cf8aaf655128d63fa1f18759152874536852", "class_name": "RelatedNodeInfo"}}, "text": "So, we are \ninvesting where it makes sense, efficiently, very well -aligned to our strategy. ", "start_char_idx": 207, "end_char_idx": 300, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "1ef60e61-99b2-40d0-9ae3-fec5bd874e47": {"__data__": {"id_": "1ef60e61-99b2-40d0-9ae3-fec5bd874e47", "embedding": null, "metadata": {"window": " \nPage 16 of 19 \n \nPharma side, the consumer health new logistics center.   So, and I also made some comments around \nsome of the IT capabilities within Pharma and the e -commerce and Intelogix \u2122 capability.  So, we are \ninvesting where it makes sense, efficiently, very well -aligned to our strategy.  And these are not \ninvestments that you can just turn on and off.  So, it's something that we're going to invest as \nappropriate, but only what we have to do as well.  We want to take away waste and invest it where \nthere's growth is the key objective.  \n \n Aaron Alt:  For those working on their models, it's probably worth pointing out that with respect to the \nQ2 profitability in the business, it was the case that last year, we called out unusual strength in the \noverall Pharma demand, particularly from large customers, as well as very strong cough, cold and flu \nseason. ", "original_text": "And these are not \ninvestments that you can just turn on and off. ", "page_label": "16", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "6d5ec7f6-bdd6-41b2-9b56-d1f2960aaef4", "node_type": "4", "metadata": {"page_label": "16", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "b0205224430b7dfc9e84da67be2109c44a567f4dad70817a17b38328d6416b9b", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "b29222ba-64b7-4ba8-a35a-da18b620af59", "node_type": "1", "metadata": {"window": " \nPage 16 of 19 \n \nPharma side, the consumer health new logistics center.   So, and I also made some comments around \nsome of the IT capabilities within Pharma and the e -commerce and Intelogix \u2122 capability.  So, we are \ninvesting where it makes sense, efficiently, very well -aligned to our strategy.  And these are not \ninvestments that you can just turn on and off.  So, it's something that we're going to invest as \nappropriate, but only what we have to do as well.  We want to take away waste and invest it where \nthere's growth is the key objective.  \n \n", "original_text": "So, we are \ninvesting where it makes sense, efficiently, very well -aligned to our strategy. ", "page_label": "16", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "488da19695f709a02939f916ac5e68122dbc3ddab02bb241ac7334e288fc9143", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "a8d9531e-d9ca-460f-8733-a8d9f10aced1", "node_type": "1", "metadata": {"window": "So, and I also made some comments around \nsome of the IT capabilities within Pharma and the e -commerce and Intelogix \u2122 capability.  So, we are \ninvesting where it makes sense, efficiently, very well -aligned to our strategy.  And these are not \ninvestments that you can just turn on and off.  So, it's something that we're going to invest as \nappropriate, but only what we have to do as well.  We want to take away waste and invest it where \nthere's growth is the key objective.  \n \n Aaron Alt:  For those working on their models, it's probably worth pointing out that with respect to the \nQ2 profitability in the business, it was the case that last year, we called out unusual strength in the \noverall Pharma demand, particularly from large customers, as well as very strong cough, cold and flu \nseason.  So, as you're looking at your comparisons, keep that in mind.  \n \n", "original_text": "So, it's something that we're going to invest as \nappropriate, but only what we have to do as well. "}, "hash": "b2853c485f83de8dab882650a844351e176c5a726a9ee65bb99a88830078d961", "class_name": "RelatedNodeInfo"}}, "text": "And these are not \ninvestments that you can just turn on and off. ", "start_char_idx": 300, "end_char_idx": 366, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "a8d9531e-d9ca-460f-8733-a8d9f10aced1": {"__data__": {"id_": "a8d9531e-d9ca-460f-8733-a8d9f10aced1", "embedding": null, "metadata": {"window": "So, and I also made some comments around \nsome of the IT capabilities within Pharma and the e -commerce and Intelogix \u2122 capability.  So, we are \ninvesting where it makes sense, efficiently, very well -aligned to our strategy.  And these are not \ninvestments that you can just turn on and off.  So, it's something that we're going to invest as \nappropriate, but only what we have to do as well.  We want to take away waste and invest it where \nthere's growth is the key objective.  \n \n Aaron Alt:  For those working on their models, it's probably worth pointing out that with respect to the \nQ2 profitability in the business, it was the case that last year, we called out unusual strength in the \noverall Pharma demand, particularly from large customers, as well as very strong cough, cold and flu \nseason.  So, as you're looking at your comparisons, keep that in mind.  \n \n", "original_text": "So, it's something that we're going to invest as \nappropriate, but only what we have to do as well. ", "page_label": "16", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "6d5ec7f6-bdd6-41b2-9b56-d1f2960aaef4", "node_type": "4", "metadata": {"page_label": "16", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "b0205224430b7dfc9e84da67be2109c44a567f4dad70817a17b38328d6416b9b", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "1ef60e61-99b2-40d0-9ae3-fec5bd874e47", "node_type": "1", "metadata": {"window": " \nPage 16 of 19 \n \nPharma side, the consumer health new logistics center.   So, and I also made some comments around \nsome of the IT capabilities within Pharma and the e -commerce and Intelogix \u2122 capability.  So, we are \ninvesting where it makes sense, efficiently, very well -aligned to our strategy.  And these are not \ninvestments that you can just turn on and off.  So, it's something that we're going to invest as \nappropriate, but only what we have to do as well.  We want to take away waste and invest it where \nthere's growth is the key objective.  \n \n Aaron Alt:  For those working on their models, it's probably worth pointing out that with respect to the \nQ2 profitability in the business, it was the case that last year, we called out unusual strength in the \noverall Pharma demand, particularly from large customers, as well as very strong cough, cold and flu \nseason. ", "original_text": "And these are not \ninvestments that you can just turn on and off. ", "page_label": "16", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "d7edefbb7bbf036ffb15fb99ccabf31531fbf994da028c3807dae46a763c1993", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "d31dc993-aecd-49b4-a9d4-97605fb5c8a1", "node_type": "1", "metadata": {"window": "So, we are \ninvesting where it makes sense, efficiently, very well -aligned to our strategy.  And these are not \ninvestments that you can just turn on and off.  So, it's something that we're going to invest as \nappropriate, but only what we have to do as well.  We want to take away waste and invest it where \nthere's growth is the key objective.  \n \n Aaron Alt:  For those working on their models, it's probably worth pointing out that with respect to the \nQ2 profitability in the business, it was the case that last year, we called out unusual strength in the \noverall Pharma demand, particularly from large customers, as well as very strong cough, cold and flu \nseason.  So, as you're looking at your comparisons, keep that in mind.  \n \n Operator:  Thanks a lot sir. ", "original_text": "We want to take away waste and invest it where \nthere's growth is the key objective.  \n \n"}, "hash": "fd8c1440c6d0a4a08cec92ce067335b3b13da91229ab63c53cf93a4f1d58a2bb", "class_name": "RelatedNodeInfo"}}, "text": "So, it's something that we're going to invest as \nappropriate, but only what we have to do as well. ", "start_char_idx": 366, "end_char_idx": 466, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "d31dc993-aecd-49b4-a9d4-97605fb5c8a1": {"__data__": {"id_": "d31dc993-aecd-49b4-a9d4-97605fb5c8a1", "embedding": null, "metadata": {"window": "So, we are \ninvesting where it makes sense, efficiently, very well -aligned to our strategy.  And these are not \ninvestments that you can just turn on and off.  So, it's something that we're going to invest as \nappropriate, but only what we have to do as well.  We want to take away waste and invest it where \nthere's growth is the key objective.  \n \n Aaron Alt:  For those working on their models, it's probably worth pointing out that with respect to the \nQ2 profitability in the business, it was the case that last year, we called out unusual strength in the \noverall Pharma demand, particularly from large customers, as well as very strong cough, cold and flu \nseason.  So, as you're looking at your comparisons, keep that in mind.  \n \n Operator:  Thanks a lot sir. ", "original_text": "We want to take away waste and invest it where \nthere's growth is the key objective.  \n \n", "page_label": "16", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "6d5ec7f6-bdd6-41b2-9b56-d1f2960aaef4", "node_type": "4", "metadata": {"page_label": "16", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "b0205224430b7dfc9e84da67be2109c44a567f4dad70817a17b38328d6416b9b", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "a8d9531e-d9ca-460f-8733-a8d9f10aced1", "node_type": "1", "metadata": {"window": "So, and I also made some comments around \nsome of the IT capabilities within Pharma and the e -commerce and Intelogix \u2122 capability.  So, we are \ninvesting where it makes sense, efficiently, very well -aligned to our strategy.  And these are not \ninvestments that you can just turn on and off.  So, it's something that we're going to invest as \nappropriate, but only what we have to do as well.  We want to take away waste and invest it where \nthere's growth is the key objective.  \n \n Aaron Alt:  For those working on their models, it's probably worth pointing out that with respect to the \nQ2 profitability in the business, it was the case that last year, we called out unusual strength in the \noverall Pharma demand, particularly from large customers, as well as very strong cough, cold and flu \nseason.  So, as you're looking at your comparisons, keep that in mind.  \n \n", "original_text": "So, it's something that we're going to invest as \nappropriate, but only what we have to do as well. ", "page_label": "16", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "3267b71b3a7d5b140d0596ce71dffe082e03b44952ddd3066b71bac68fd0ab3b", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "e95281c1-c6ff-4650-ac92-369a8444afa2", "node_type": "1", "metadata": {"window": "And these are not \ninvestments that you can just turn on and off.  So, it's something that we're going to invest as \nappropriate, but only what we have to do as well.  We want to take away waste and invest it where \nthere's growth is the key objective.  \n \n Aaron Alt:  For those working on their models, it's probably worth pointing out that with respect to the \nQ2 profitability in the business, it was the case that last year, we called out unusual strength in the \noverall Pharma demand, particularly from large customers, as well as very strong cough, cold and flu \nseason.  So, as you're looking at your comparisons, keep that in mind.  \n \n Operator:  Thanks a lot sir.  Ladies and gentlemen, if your question has been answered you may \nremove yourself from the queue by pressing star two.  ", "original_text": "Aaron Alt:  For those working on their models, it's probably worth pointing out that with respect to the \nQ2 profitability in the business, it was the case that last year, we called out unusual strength in the \noverall Pharma demand, particularly from large customers, as well as very strong cough, cold and flu \nseason. "}, "hash": "472ac93ba47a133971296f0865772bc6ab3e074e78be26623a91608dd8a4bb89", "class_name": "RelatedNodeInfo"}}, "text": "We want to take away waste and invest it where \nthere's growth is the key objective.  \n \n", "start_char_idx": 466, "end_char_idx": 555, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "e95281c1-c6ff-4650-ac92-369a8444afa2": {"__data__": {"id_": "e95281c1-c6ff-4650-ac92-369a8444afa2", "embedding": null, "metadata": {"window": "And these are not \ninvestments that you can just turn on and off.  So, it's something that we're going to invest as \nappropriate, but only what we have to do as well.  We want to take away waste and invest it where \nthere's growth is the key objective.  \n \n Aaron Alt:  For those working on their models, it's probably worth pointing out that with respect to the \nQ2 profitability in the business, it was the case that last year, we called out unusual strength in the \noverall Pharma demand, particularly from large customers, as well as very strong cough, cold and flu \nseason.  So, as you're looking at your comparisons, keep that in mind.  \n \n Operator:  Thanks a lot sir.  Ladies and gentlemen, if your question has been answered you may \nremove yourself from the queue by pressing star two.  ", "original_text": "Aaron Alt:  For those working on their models, it's probably worth pointing out that with respect to the \nQ2 profitability in the business, it was the case that last year, we called out unusual strength in the \noverall Pharma demand, particularly from large customers, as well as very strong cough, cold and flu \nseason. ", "page_label": "16", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "6d5ec7f6-bdd6-41b2-9b56-d1f2960aaef4", "node_type": "4", "metadata": {"page_label": "16", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "b0205224430b7dfc9e84da67be2109c44a567f4dad70817a17b38328d6416b9b", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "d31dc993-aecd-49b4-a9d4-97605fb5c8a1", "node_type": "1", "metadata": {"window": "So, we are \ninvesting where it makes sense, efficiently, very well -aligned to our strategy.  And these are not \ninvestments that you can just turn on and off.  So, it's something that we're going to invest as \nappropriate, but only what we have to do as well.  We want to take away waste and invest it where \nthere's growth is the key objective.  \n \n Aaron Alt:  For those working on their models, it's probably worth pointing out that with respect to the \nQ2 profitability in the business, it was the case that last year, we called out unusual strength in the \noverall Pharma demand, particularly from large customers, as well as very strong cough, cold and flu \nseason.  So, as you're looking at your comparisons, keep that in mind.  \n \n Operator:  Thanks a lot sir. ", "original_text": "We want to take away waste and invest it where \nthere's growth is the key objective.  \n \n", "page_label": "16", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "d1d05852d551f80d28fc095588327422289fab515fc54e053b8a47ade3a00687", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "ea70d62a-d14e-4e09-8213-cbeea8029853", "node_type": "1", "metadata": {"window": "So, it's something that we're going to invest as \nappropriate, but only what we have to do as well.  We want to take away waste and invest it where \nthere's growth is the key objective.  \n \n Aaron Alt:  For those working on their models, it's probably worth pointing out that with respect to the \nQ2 profitability in the business, it was the case that last year, we called out unusual strength in the \noverall Pharma demand, particularly from large customers, as well as very strong cough, cold and flu \nseason.  So, as you're looking at your comparisons, keep that in mind.  \n \n Operator:  Thanks a lot sir.  Ladies and gentlemen, if your question has been answered you may \nremove yourself from the queue by pressing star two.   We'll now move to Mr. ", "original_text": "So, as you're looking at your comparisons, keep that in mind.  \n \n"}, "hash": "7904c3d02ad69fd82bb0b7d9c29878d1197d6b55cc9ad77c31423721c48fda8c", "class_name": "RelatedNodeInfo"}}, "text": "Aaron Alt:  For those working on their models, it's probably worth pointing out that with respect to the \nQ2 profitability in the business, it was the case that last year, we called out unusual strength in the \noverall Pharma demand, particularly from large customers, as well as very strong cough, cold and flu \nseason. ", "start_char_idx": 555, "end_char_idx": 876, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "ea70d62a-d14e-4e09-8213-cbeea8029853": {"__data__": {"id_": "ea70d62a-d14e-4e09-8213-cbeea8029853", "embedding": null, "metadata": {"window": "So, it's something that we're going to invest as \nappropriate, but only what we have to do as well.  We want to take away waste and invest it where \nthere's growth is the key objective.  \n \n Aaron Alt:  For those working on their models, it's probably worth pointing out that with respect to the \nQ2 profitability in the business, it was the case that last year, we called out unusual strength in the \noverall Pharma demand, particularly from large customers, as well as very strong cough, cold and flu \nseason.  So, as you're looking at your comparisons, keep that in mind.  \n \n Operator:  Thanks a lot sir.  Ladies and gentlemen, if your question has been answered you may \nremove yourself from the queue by pressing star two.   We'll now move to Mr. ", "original_text": "So, as you're looking at your comparisons, keep that in mind.  \n \n", "page_label": "16", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "6d5ec7f6-bdd6-41b2-9b56-d1f2960aaef4", "node_type": "4", "metadata": {"page_label": "16", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "b0205224430b7dfc9e84da67be2109c44a567f4dad70817a17b38328d6416b9b", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "e95281c1-c6ff-4650-ac92-369a8444afa2", "node_type": "1", "metadata": {"window": "And these are not \ninvestments that you can just turn on and off.  So, it's something that we're going to invest as \nappropriate, but only what we have to do as well.  We want to take away waste and invest it where \nthere's growth is the key objective.  \n \n Aaron Alt:  For those working on their models, it's probably worth pointing out that with respect to the \nQ2 profitability in the business, it was the case that last year, we called out unusual strength in the \noverall Pharma demand, particularly from large customers, as well as very strong cough, cold and flu \nseason.  So, as you're looking at your comparisons, keep that in mind.  \n \n Operator:  Thanks a lot sir.  Ladies and gentlemen, if your question has been answered you may \nremove yourself from the queue by pressing star two.  ", "original_text": "Aaron Alt:  For those working on their models, it's probably worth pointing out that with respect to the \nQ2 profitability in the business, it was the case that last year, we called out unusual strength in the \noverall Pharma demand, particularly from large customers, as well as very strong cough, cold and flu \nseason. ", "page_label": "16", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "ce29c865d63ba2663693ad27b42123e50123528592c3008e39b7b4e62bd1e4a5", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "de7cdfed-11e3-4c2e-8af1-d2268ae2dae7", "node_type": "1", "metadata": {"window": "We want to take away waste and invest it where \nthere's growth is the key objective.  \n \n Aaron Alt:  For those working on their models, it's probably worth pointing out that with respect to the \nQ2 profitability in the business, it was the case that last year, we called out unusual strength in the \noverall Pharma demand, particularly from large customers, as well as very strong cough, cold and flu \nseason.  So, as you're looking at your comparisons, keep that in mind.  \n \n Operator:  Thanks a lot sir.  Ladies and gentlemen, if your question has been answered you may \nremove yourself from the queue by pressing star two.   We'll now move to Mr.  George Hill of Deutsche \nBank. ", "original_text": "Operator:  Thanks a lot sir. "}, "hash": "09b55c1dd31db1b3109df03284a197830508c6b0539da523a79db949342cabc7", "class_name": "RelatedNodeInfo"}}, "text": "So, as you're looking at your comparisons, keep that in mind.  \n \n", "start_char_idx": 876, "end_char_idx": 942, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "de7cdfed-11e3-4c2e-8af1-d2268ae2dae7": {"__data__": {"id_": "de7cdfed-11e3-4c2e-8af1-d2268ae2dae7", "embedding": null, "metadata": {"window": "We want to take away waste and invest it where \nthere's growth is the key objective.  \n \n Aaron Alt:  For those working on their models, it's probably worth pointing out that with respect to the \nQ2 profitability in the business, it was the case that last year, we called out unusual strength in the \noverall Pharma demand, particularly from large customers, as well as very strong cough, cold and flu \nseason.  So, as you're looking at your comparisons, keep that in mind.  \n \n Operator:  Thanks a lot sir.  Ladies and gentlemen, if your question has been answered you may \nremove yourself from the queue by pressing star two.   We'll now move to Mr.  George Hill of Deutsche \nBank. ", "original_text": "Operator:  Thanks a lot sir. ", "page_label": "16", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "6d5ec7f6-bdd6-41b2-9b56-d1f2960aaef4", "node_type": "4", "metadata": {"page_label": "16", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "b0205224430b7dfc9e84da67be2109c44a567f4dad70817a17b38328d6416b9b", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "ea70d62a-d14e-4e09-8213-cbeea8029853", "node_type": "1", "metadata": {"window": "So, it's something that we're going to invest as \nappropriate, but only what we have to do as well.  We want to take away waste and invest it where \nthere's growth is the key objective.  \n \n Aaron Alt:  For those working on their models, it's probably worth pointing out that with respect to the \nQ2 profitability in the business, it was the case that last year, we called out unusual strength in the \noverall Pharma demand, particularly from large customers, as well as very strong cough, cold and flu \nseason.  So, as you're looking at your comparisons, keep that in mind.  \n \n Operator:  Thanks a lot sir.  Ladies and gentlemen, if your question has been answered you may \nremove yourself from the queue by pressing star two.   We'll now move to Mr. ", "original_text": "So, as you're looking at your comparisons, keep that in mind.  \n \n", "page_label": "16", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "02cc655b9f3bdb520dc4527f5e4af1928d05a1f74bdfd2c9f65584ec80451b62", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "e8869165-9c6f-4cef-b3a7-468f8215efa0", "node_type": "1", "metadata": {"window": "Aaron Alt:  For those working on their models, it's probably worth pointing out that with respect to the \nQ2 profitability in the business, it was the case that last year, we called out unusual strength in the \noverall Pharma demand, particularly from large customers, as well as very strong cough, cold and flu \nseason.  So, as you're looking at your comparisons, keep that in mind.  \n \n Operator:  Thanks a lot sir.  Ladies and gentlemen, if your question has been answered you may \nremove yourself from the queue by pressing star two.   We'll now move to Mr.  George Hill of Deutsche \nBank.  Please go ahead.  \n \n", "original_text": "Ladies and gentlemen, if your question has been answered you may \nremove yourself from the queue by pressing star two.  "}, "hash": "124d87489e431df9c4fbfa9a9283acacbe87eca4a1bb25e43361cabca7c90173", "class_name": "RelatedNodeInfo"}}, "text": "Operator:  Thanks a lot sir. ", "start_char_idx": 942, "end_char_idx": 971, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "e8869165-9c6f-4cef-b3a7-468f8215efa0": {"__data__": {"id_": "e8869165-9c6f-4cef-b3a7-468f8215efa0", "embedding": null, "metadata": {"window": "Aaron Alt:  For those working on their models, it's probably worth pointing out that with respect to the \nQ2 profitability in the business, it was the case that last year, we called out unusual strength in the \noverall Pharma demand, particularly from large customers, as well as very strong cough, cold and flu \nseason.  So, as you're looking at your comparisons, keep that in mind.  \n \n Operator:  Thanks a lot sir.  Ladies and gentlemen, if your question has been answered you may \nremove yourself from the queue by pressing star two.   We'll now move to Mr.  George Hill of Deutsche \nBank.  Please go ahead.  \n \n", "original_text": "Ladies and gentlemen, if your question has been answered you may \nremove yourself from the queue by pressing star two.  ", "page_label": "16", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "6d5ec7f6-bdd6-41b2-9b56-d1f2960aaef4", "node_type": "4", "metadata": {"page_label": "16", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "b0205224430b7dfc9e84da67be2109c44a567f4dad70817a17b38328d6416b9b", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "de7cdfed-11e3-4c2e-8af1-d2268ae2dae7", "node_type": "1", "metadata": {"window": "We want to take away waste and invest it where \nthere's growth is the key objective.  \n \n Aaron Alt:  For those working on their models, it's probably worth pointing out that with respect to the \nQ2 profitability in the business, it was the case that last year, we called out unusual strength in the \noverall Pharma demand, particularly from large customers, as well as very strong cough, cold and flu \nseason.  So, as you're looking at your comparisons, keep that in mind.  \n \n Operator:  Thanks a lot sir.  Ladies and gentlemen, if your question has been answered you may \nremove yourself from the queue by pressing star two.   We'll now move to Mr.  George Hill of Deutsche \nBank. ", "original_text": "Operator:  Thanks a lot sir. ", "page_label": "16", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "bc497956f3845373359dd8d06d918cce8ccab8b8618198f1754659b3114031a5", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "87e200f6-bc57-420f-a871-b3afd1d21a23", "node_type": "1", "metadata": {"window": "So, as you're looking at your comparisons, keep that in mind.  \n \n Operator:  Thanks a lot sir.  Ladies and gentlemen, if your question has been answered you may \nremove yourself from the queue by pressing star two.   We'll now move to Mr.  George Hill of Deutsche \nBank.  Please go ahead.  \n \n George Hill:  Yeah. ", "original_text": "We'll now move to Mr. "}, "hash": "90f277bb0c937ec1f130f5265028c9b778047910b9c740d7bcb965bb08cd42c3", "class_name": "RelatedNodeInfo"}}, "text": "Ladies and gentlemen, if your question has been answered you may \nremove yourself from the queue by pressing star two.  ", "start_char_idx": 971, "end_char_idx": 1091, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "87e200f6-bc57-420f-a871-b3afd1d21a23": {"__data__": {"id_": "87e200f6-bc57-420f-a871-b3afd1d21a23", "embedding": null, "metadata": {"window": "So, as you're looking at your comparisons, keep that in mind.  \n \n Operator:  Thanks a lot sir.  Ladies and gentlemen, if your question has been answered you may \nremove yourself from the queue by pressing star two.   We'll now move to Mr.  George Hill of Deutsche \nBank.  Please go ahead.  \n \n George Hill:  Yeah. ", "original_text": "We'll now move to Mr. ", "page_label": "16", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "6d5ec7f6-bdd6-41b2-9b56-d1f2960aaef4", "node_type": "4", "metadata": {"page_label": "16", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "b0205224430b7dfc9e84da67be2109c44a567f4dad70817a17b38328d6416b9b", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "e8869165-9c6f-4cef-b3a7-468f8215efa0", "node_type": "1", "metadata": {"window": "Aaron Alt:  For those working on their models, it's probably worth pointing out that with respect to the \nQ2 profitability in the business, it was the case that last year, we called out unusual strength in the \noverall Pharma demand, particularly from large customers, as well as very strong cough, cold and flu \nseason.  So, as you're looking at your comparisons, keep that in mind.  \n \n Operator:  Thanks a lot sir.  Ladies and gentlemen, if your question has been answered you may \nremove yourself from the queue by pressing star two.   We'll now move to Mr.  George Hill of Deutsche \nBank.  Please go ahead.  \n \n", "original_text": "Ladies and gentlemen, if your question has been answered you may \nremove yourself from the queue by pressing star two.  ", "page_label": "16", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "7f27a5bc77f98948bf9677c965679192f41b6db3a66b1011d002819d2befad8c", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "0b8bbc53-2dd6-4657-ae4f-bf816fb159c2", "node_type": "1", "metadata": {"window": "Operator:  Thanks a lot sir.  Ladies and gentlemen, if your question has been answered you may \nremove yourself from the queue by pressing star two.   We'll now move to Mr.  George Hill of Deutsche \nBank.  Please go ahead.  \n \n George Hill:  Yeah.  Good morning, Jason  and Aaron . ", "original_text": "George Hill of Deutsche \nBank. "}, "hash": "13beef63b340f2bf691ab39458af3140ddd1764220e21faea80adb8bcf5e05a0", "class_name": "RelatedNodeInfo"}}, "text": "We'll now move to Mr. ", "start_char_idx": 1091, "end_char_idx": 1113, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "0b8bbc53-2dd6-4657-ae4f-bf816fb159c2": {"__data__": {"id_": "0b8bbc53-2dd6-4657-ae4f-bf816fb159c2", "embedding": null, "metadata": {"window": "Operator:  Thanks a lot sir.  Ladies and gentlemen, if your question has been answered you may \nremove yourself from the queue by pressing star two.   We'll now move to Mr.  George Hill of Deutsche \nBank.  Please go ahead.  \n \n George Hill:  Yeah.  Good morning, Jason  and Aaron . ", "original_text": "George Hill of Deutsche \nBank. ", "page_label": "16", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "6d5ec7f6-bdd6-41b2-9b56-d1f2960aaef4", "node_type": "4", "metadata": {"page_label": "16", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "b0205224430b7dfc9e84da67be2109c44a567f4dad70817a17b38328d6416b9b", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "87e200f6-bc57-420f-a871-b3afd1d21a23", "node_type": "1", "metadata": {"window": "So, as you're looking at your comparisons, keep that in mind.  \n \n Operator:  Thanks a lot sir.  Ladies and gentlemen, if your question has been answered you may \nremove yourself from the queue by pressing star two.   We'll now move to Mr.  George Hill of Deutsche \nBank.  Please go ahead.  \n \n George Hill:  Yeah. ", "original_text": "We'll now move to Mr. ", "page_label": "16", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "173274b6310ca8d9d6502ab40ad611555cb8a696adbb3d144e8d09314fd949f1", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "38d3e55b-7ab5-48a1-aec9-7281b73f295c", "node_type": "1", "metadata": {"window": "Ladies and gentlemen, if your question has been answered you may \nremove yourself from the queue by pressing star two.   We'll now move to Mr.  George Hill of Deutsche \nBank.  Please go ahead.  \n \n George Hill:  Yeah.  Good morning, Jason  and Aaron .  And forgive me if I kind of missed this or if you \nguys talked through this already. ", "original_text": "Please go ahead.  \n \n"}, "hash": "ee61f62b3defbbfcba35a71fb103af2acd7ee79d47ac191e3196a37e87553b6a", "class_name": "RelatedNodeInfo"}}, "text": "George Hill of Deutsche \nBank. ", "start_char_idx": 1113, "end_char_idx": 1144, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "38d3e55b-7ab5-48a1-aec9-7281b73f295c": {"__data__": {"id_": "38d3e55b-7ab5-48a1-aec9-7281b73f295c", "embedding": null, "metadata": {"window": "Ladies and gentlemen, if your question has been answered you may \nremove yourself from the queue by pressing star two.   We'll now move to Mr.  George Hill of Deutsche \nBank.  Please go ahead.  \n \n George Hill:  Yeah.  Good morning, Jason  and Aaron .  And forgive me if I kind of missed this or if you \nguys talked through this already. ", "original_text": "Please go ahead.  \n \n", "page_label": "16", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "6d5ec7f6-bdd6-41b2-9b56-d1f2960aaef4", "node_type": "4", "metadata": {"page_label": "16", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "b0205224430b7dfc9e84da67be2109c44a567f4dad70817a17b38328d6416b9b", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "0b8bbc53-2dd6-4657-ae4f-bf816fb159c2", "node_type": "1", "metadata": {"window": "Operator:  Thanks a lot sir.  Ladies and gentlemen, if your question has been answered you may \nremove yourself from the queue by pressing star two.   We'll now move to Mr.  George Hill of Deutsche \nBank.  Please go ahead.  \n \n George Hill:  Yeah.  Good morning, Jason  and Aaron . ", "original_text": "George Hill of Deutsche \nBank. ", "page_label": "16", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "2e472619d13ee27749195bfd96a93d348d53a4e4fc6891d4a43d2bb7c4c9d358", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "87197485-940e-409d-a9ea-731c2f35657f", "node_type": "1", "metadata": {"window": "We'll now move to Mr.  George Hill of Deutsche \nBank.  Please go ahead.  \n \n George Hill:  Yeah.  Good morning, Jason  and Aaron .  And forgive me if I kind of missed this or if you \nguys talked through this already.  But as it relates to the planned restatement of the other segment, it \nlooks like the growth in the near -term is coming in  [inaudible] but kind of the long -term targets and \nwhich I kind of wonder if you could address kind of or disaggregate in which sub -segments you're \nseeing with softness relative to the long -term expectations for the balance of the year or this year \nversus what you think ki nd of accelerates coming out and kind of closes the gap in the longer -term \nguidance?  \n \n", "original_text": "George Hill:  Yeah. "}, "hash": "1b316cd6d0522151c0e81c6807e1189a41b23887a20bb95b93fad7cc45558dd3", "class_name": "RelatedNodeInfo"}}, "text": "Please go ahead.  \n \n", "start_char_idx": 1144, "end_char_idx": 1165, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "87197485-940e-409d-a9ea-731c2f35657f": {"__data__": {"id_": "87197485-940e-409d-a9ea-731c2f35657f", "embedding": null, "metadata": {"window": "We'll now move to Mr.  George Hill of Deutsche \nBank.  Please go ahead.  \n \n George Hill:  Yeah.  Good morning, Jason  and Aaron .  And forgive me if I kind of missed this or if you \nguys talked through this already.  But as it relates to the planned restatement of the other segment, it \nlooks like the growth in the near -term is coming in  [inaudible] but kind of the long -term targets and \nwhich I kind of wonder if you could address kind of or disaggregate in which sub -segments you're \nseeing with softness relative to the long -term expectations for the balance of the year or this year \nversus what you think ki nd of accelerates coming out and kind of closes the gap in the longer -term \nguidance?  \n \n", "original_text": "George Hill:  Yeah. ", "page_label": "16", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "6d5ec7f6-bdd6-41b2-9b56-d1f2960aaef4", "node_type": "4", "metadata": {"page_label": "16", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "b0205224430b7dfc9e84da67be2109c44a567f4dad70817a17b38328d6416b9b", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "38d3e55b-7ab5-48a1-aec9-7281b73f295c", "node_type": "1", "metadata": {"window": "Ladies and gentlemen, if your question has been answered you may \nremove yourself from the queue by pressing star two.   We'll now move to Mr.  George Hill of Deutsche \nBank.  Please go ahead.  \n \n George Hill:  Yeah.  Good morning, Jason  and Aaron .  And forgive me if I kind of missed this or if you \nguys talked through this already. ", "original_text": "Please go ahead.  \n \n", "page_label": "16", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "8d24855f07b5a23c435067f15de1adf8bf89762544b28314720f6ff62f962f96", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "30affc97-ddce-40da-a4bb-c83b55a92fcd", "node_type": "1", "metadata": {"window": "George Hill of Deutsche \nBank.  Please go ahead.  \n \n George Hill:  Yeah.  Good morning, Jason  and Aaron .  And forgive me if I kind of missed this or if you \nguys talked through this already.  But as it relates to the planned restatement of the other segment, it \nlooks like the growth in the near -term is coming in  [inaudible] but kind of the long -term targets and \nwhich I kind of wonder if you could address kind of or disaggregate in which sub -segments you're \nseeing with softness relative to the long -term expectations for the balance of the year or this year \nversus what you think ki nd of accelerates coming out and kind of closes the gap in the longer -term \nguidance?  \n \n Aaron Alt :  The businesses that report through Other for us going forward will be our at -Home \nbusiness, our Nuclear Precision Health business  and our OptiFreight\u00ae business. ", "original_text": "Good morning, Jason  and Aaron . "}, "hash": "cffe38dde7a3f8473adc06877bc99d8549f2dc446be788b1ff0bdb03e9ffaa86", "class_name": "RelatedNodeInfo"}}, "text": "George Hill:  Yeah. ", "start_char_idx": 1165, "end_char_idx": 1185, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "30affc97-ddce-40da-a4bb-c83b55a92fcd": {"__data__": {"id_": "30affc97-ddce-40da-a4bb-c83b55a92fcd", "embedding": null, "metadata": {"window": "George Hill of Deutsche \nBank.  Please go ahead.  \n \n George Hill:  Yeah.  Good morning, Jason  and Aaron .  And forgive me if I kind of missed this or if you \nguys talked through this already.  But as it relates to the planned restatement of the other segment, it \nlooks like the growth in the near -term is coming in  [inaudible] but kind of the long -term targets and \nwhich I kind of wonder if you could address kind of or disaggregate in which sub -segments you're \nseeing with softness relative to the long -term expectations for the balance of the year or this year \nversus what you think ki nd of accelerates coming out and kind of closes the gap in the longer -term \nguidance?  \n \n Aaron Alt :  The businesses that report through Other for us going forward will be our at -Home \nbusiness, our Nuclear Precision Health business  and our OptiFreight\u00ae business. ", "original_text": "Good morning, Jason  and Aaron . ", "page_label": "16", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "6d5ec7f6-bdd6-41b2-9b56-d1f2960aaef4", "node_type": "4", "metadata": {"page_label": "16", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "b0205224430b7dfc9e84da67be2109c44a567f4dad70817a17b38328d6416b9b", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "87197485-940e-409d-a9ea-731c2f35657f", "node_type": "1", "metadata": {"window": "We'll now move to Mr.  George Hill of Deutsche \nBank.  Please go ahead.  \n \n George Hill:  Yeah.  Good morning, Jason  and Aaron .  And forgive me if I kind of missed this or if you \nguys talked through this already.  But as it relates to the planned restatement of the other segment, it \nlooks like the growth in the near -term is coming in  [inaudible] but kind of the long -term targets and \nwhich I kind of wonder if you could address kind of or disaggregate in which sub -segments you're \nseeing with softness relative to the long -term expectations for the balance of the year or this year \nversus what you think ki nd of accelerates coming out and kind of closes the gap in the longer -term \nguidance?  \n \n", "original_text": "George Hill:  Yeah. ", "page_label": "16", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "a211577c5c422d025f3f9f81c9f4dab8d89e6ec57949a7a545b466d75ff67a70", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "c1471836-60f0-4660-8568-c56311933c5a", "node_type": "1", "metadata": {"window": "Please go ahead.  \n \n George Hill:  Yeah.  Good morning, Jason  and Aaron .  And forgive me if I kind of missed this or if you \nguys talked through this already.  But as it relates to the planned restatement of the other segment, it \nlooks like the growth in the near -term is coming in  [inaudible] but kind of the long -term targets and \nwhich I kind of wonder if you could address kind of or disaggregate in which sub -segments you're \nseeing with softness relative to the long -term expectations for the balance of the year or this year \nversus what you think ki nd of accelerates coming out and kind of closes the gap in the longer -term \nguidance?  \n \n Aaron Alt :  The businesses that report through Other for us going forward will be our at -Home \nbusiness, our Nuclear Precision Health business  and our OptiFreight\u00ae business.  Those  are what we \nhave traditionally called our growth businesses as part of other segments.  ", "original_text": "And forgive me if I kind of missed this or if you \nguys talked through this already. "}, "hash": "61208bd68f9a48a391b778a3afcd6f5915204078cc7be6095bcd29adaa62668c", "class_name": "RelatedNodeInfo"}}, "text": "Good morning, Jason  and Aaron . ", "start_char_idx": 1185, "end_char_idx": 1218, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "c1471836-60f0-4660-8568-c56311933c5a": {"__data__": {"id_": "c1471836-60f0-4660-8568-c56311933c5a", "embedding": null, "metadata": {"window": "Please go ahead.  \n \n George Hill:  Yeah.  Good morning, Jason  and Aaron .  And forgive me if I kind of missed this or if you \nguys talked through this already.  But as it relates to the planned restatement of the other segment, it \nlooks like the growth in the near -term is coming in  [inaudible] but kind of the long -term targets and \nwhich I kind of wonder if you could address kind of or disaggregate in which sub -segments you're \nseeing with softness relative to the long -term expectations for the balance of the year or this year \nversus what you think ki nd of accelerates coming out and kind of closes the gap in the longer -term \nguidance?  \n \n Aaron Alt :  The businesses that report through Other for us going forward will be our at -Home \nbusiness, our Nuclear Precision Health business  and our OptiFreight\u00ae business.  Those  are what we \nhave traditionally called our growth businesses as part of other segments.  ", "original_text": "And forgive me if I kind of missed this or if you \nguys talked through this already. ", "page_label": "16", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "6d5ec7f6-bdd6-41b2-9b56-d1f2960aaef4", "node_type": "4", "metadata": {"page_label": "16", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "b0205224430b7dfc9e84da67be2109c44a567f4dad70817a17b38328d6416b9b", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "30affc97-ddce-40da-a4bb-c83b55a92fcd", "node_type": "1", "metadata": {"window": "George Hill of Deutsche \nBank.  Please go ahead.  \n \n George Hill:  Yeah.  Good morning, Jason  and Aaron .  And forgive me if I kind of missed this or if you \nguys talked through this already.  But as it relates to the planned restatement of the other segment, it \nlooks like the growth in the near -term is coming in  [inaudible] but kind of the long -term targets and \nwhich I kind of wonder if you could address kind of or disaggregate in which sub -segments you're \nseeing with softness relative to the long -term expectations for the balance of the year or this year \nversus what you think ki nd of accelerates coming out and kind of closes the gap in the longer -term \nguidance?  \n \n Aaron Alt :  The businesses that report through Other for us going forward will be our at -Home \nbusiness, our Nuclear Precision Health business  and our OptiFreight\u00ae business. ", "original_text": "Good morning, Jason  and Aaron . ", "page_label": "16", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "0a2eaf0a1450c92708ff7068984160a356b99574cff5a8f9ffc14fd245732a6b", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "ab0c38fa-505f-45fb-9a3b-7f65eceb7977", "node_type": "1", "metadata": {"window": "George Hill:  Yeah.  Good morning, Jason  and Aaron .  And forgive me if I kind of missed this or if you \nguys talked through this already.  But as it relates to the planned restatement of the other segment, it \nlooks like the growth in the near -term is coming in  [inaudible] but kind of the long -term targets and \nwhich I kind of wonder if you could address kind of or disaggregate in which sub -segments you're \nseeing with softness relative to the long -term expectations for the balance of the year or this year \nversus what you think ki nd of accelerates coming out and kind of closes the gap in the longer -term \nguidance?  \n \n Aaron Alt :  The businesses that report through Other for us going forward will be our at -Home \nbusiness, our Nuclear Precision Health business  and our OptiFreight\u00ae business.  Those  are what we \nhave traditionally called our growth businesses as part of other segments.   And indeed, over the long \nterm, we expect the CAGR on their collective growth to be 8% to 10%. ", "original_text": "But as it relates to the planned restatement of the other segment, it \nlooks like the growth in the near -term is coming in  [inaudible] but kind of the long -term targets and \nwhich I kind of wonder if you could address kind of or disaggregate in which sub -segments you're \nseeing with softness relative to the long -term expectations for the balance of the year or this year \nversus what you think ki nd of accelerates coming out and kind of closes the gap in the longer -term \nguidance?  \n \n"}, "hash": "80bcd45cd417c94f65a36ce0af94fdca8ea61be130b46caa7c885eefee7f15b9", "class_name": "RelatedNodeInfo"}}, "text": "And forgive me if I kind of missed this or if you \nguys talked through this already. ", "start_char_idx": 1218, "end_char_idx": 1303, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "ab0c38fa-505f-45fb-9a3b-7f65eceb7977": {"__data__": {"id_": "ab0c38fa-505f-45fb-9a3b-7f65eceb7977", "embedding": null, "metadata": {"window": "George Hill:  Yeah.  Good morning, Jason  and Aaron .  And forgive me if I kind of missed this or if you \nguys talked through this already.  But as it relates to the planned restatement of the other segment, it \nlooks like the growth in the near -term is coming in  [inaudible] but kind of the long -term targets and \nwhich I kind of wonder if you could address kind of or disaggregate in which sub -segments you're \nseeing with softness relative to the long -term expectations for the balance of the year or this year \nversus what you think ki nd of accelerates coming out and kind of closes the gap in the longer -term \nguidance?  \n \n Aaron Alt :  The businesses that report through Other for us going forward will be our at -Home \nbusiness, our Nuclear Precision Health business  and our OptiFreight\u00ae business.  Those  are what we \nhave traditionally called our growth businesses as part of other segments.   And indeed, over the long \nterm, we expect the CAGR on their collective growth to be 8% to 10%. ", "original_text": "But as it relates to the planned restatement of the other segment, it \nlooks like the growth in the near -term is coming in  [inaudible] but kind of the long -term targets and \nwhich I kind of wonder if you could address kind of or disaggregate in which sub -segments you're \nseeing with softness relative to the long -term expectations for the balance of the year or this year \nversus what you think ki nd of accelerates coming out and kind of closes the gap in the longer -term \nguidance?  \n \n", "page_label": "16", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "6d5ec7f6-bdd6-41b2-9b56-d1f2960aaef4", "node_type": "4", "metadata": {"page_label": "16", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "b0205224430b7dfc9e84da67be2109c44a567f4dad70817a17b38328d6416b9b", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "c1471836-60f0-4660-8568-c56311933c5a", "node_type": "1", "metadata": {"window": "Please go ahead.  \n \n George Hill:  Yeah.  Good morning, Jason  and Aaron .  And forgive me if I kind of missed this or if you \nguys talked through this already.  But as it relates to the planned restatement of the other segment, it \nlooks like the growth in the near -term is coming in  [inaudible] but kind of the long -term targets and \nwhich I kind of wonder if you could address kind of or disaggregate in which sub -segments you're \nseeing with softness relative to the long -term expectations for the balance of the year or this year \nversus what you think ki nd of accelerates coming out and kind of closes the gap in the longer -term \nguidance?  \n \n Aaron Alt :  The businesses that report through Other for us going forward will be our at -Home \nbusiness, our Nuclear Precision Health business  and our OptiFreight\u00ae business.  Those  are what we \nhave traditionally called our growth businesses as part of other segments.  ", "original_text": "And forgive me if I kind of missed this or if you \nguys talked through this already. ", "page_label": "16", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "d57886c62123bfb0363d82c999bf50ce09b4a15eeac627799b2b548691cd1c40", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "8e971903-8b92-41d6-ad4b-dfa11c01f956", "node_type": "1", "metadata": {"window": "Good morning, Jason  and Aaron .  And forgive me if I kind of missed this or if you \nguys talked through this already.  But as it relates to the planned restatement of the other segment, it \nlooks like the growth in the near -term is coming in  [inaudible] but kind of the long -term targets and \nwhich I kind of wonder if you could address kind of or disaggregate in which sub -segments you're \nseeing with softness relative to the long -term expectations for the balance of the year or this year \nversus what you think ki nd of accelerates coming out and kind of closes the gap in the longer -term \nguidance?  \n \n Aaron Alt :  The businesses that report through Other for us going forward will be our at -Home \nbusiness, our Nuclear Precision Health business  and our OptiFreight\u00ae business.  Those  are what we \nhave traditionally called our growth businesses as part of other segments.   And indeed, over the long \nterm, we expect the CAGR on their collective growth to be 8% to 10%.  The disconnect you're \nreferencing, which is the 6% to 8% in fiscal \u201824, is only driven by the impact of the non -recurring \nadjustments from Q2 on the at -Home business that we referenced a couple of weeks ago as we \ntalked about our expectations for Q2.  ", "original_text": "Aaron Alt :  The businesses that report through Other for us going forward will be our at -Home \nbusiness, our Nuclear Precision Health business  and our OptiFreight\u00ae business. "}, "hash": "ee8a881ee933a39c7c9907ce256634b724c98cfba791a2bca075de6e504a68ab", "class_name": "RelatedNodeInfo"}}, "text": "But as it relates to the planned restatement of the other segment, it \nlooks like the growth in the near -term is coming in  [inaudible] but kind of the long -term targets and \nwhich I kind of wonder if you could address kind of or disaggregate in which sub -segments you're \nseeing with softness relative to the long -term expectations for the balance of the year or this year \nversus what you think ki nd of accelerates coming out and kind of closes the gap in the longer -term \nguidance?  \n \n", "start_char_idx": 1303, "end_char_idx": 1798, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "8e971903-8b92-41d6-ad4b-dfa11c01f956": {"__data__": {"id_": "8e971903-8b92-41d6-ad4b-dfa11c01f956", "embedding": null, "metadata": {"window": "Good morning, Jason  and Aaron .  And forgive me if I kind of missed this or if you \nguys talked through this already.  But as it relates to the planned restatement of the other segment, it \nlooks like the growth in the near -term is coming in  [inaudible] but kind of the long -term targets and \nwhich I kind of wonder if you could address kind of or disaggregate in which sub -segments you're \nseeing with softness relative to the long -term expectations for the balance of the year or this year \nversus what you think ki nd of accelerates coming out and kind of closes the gap in the longer -term \nguidance?  \n \n Aaron Alt :  The businesses that report through Other for us going forward will be our at -Home \nbusiness, our Nuclear Precision Health business  and our OptiFreight\u00ae business.  Those  are what we \nhave traditionally called our growth businesses as part of other segments.   And indeed, over the long \nterm, we expect the CAGR on their collective growth to be 8% to 10%.  The disconnect you're \nreferencing, which is the 6% to 8% in fiscal \u201824, is only driven by the impact of the non -recurring \nadjustments from Q2 on the at -Home business that we referenced a couple of weeks ago as we \ntalked about our expectations for Q2.  ", "original_text": "Aaron Alt :  The businesses that report through Other for us going forward will be our at -Home \nbusiness, our Nuclear Precision Health business  and our OptiFreight\u00ae business. ", "page_label": "16", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "6d5ec7f6-bdd6-41b2-9b56-d1f2960aaef4", "node_type": "4", "metadata": {"page_label": "16", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "b0205224430b7dfc9e84da67be2109c44a567f4dad70817a17b38328d6416b9b", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "ab0c38fa-505f-45fb-9a3b-7f65eceb7977", "node_type": "1", "metadata": {"window": "George Hill:  Yeah.  Good morning, Jason  and Aaron .  And forgive me if I kind of missed this or if you \nguys talked through this already.  But as it relates to the planned restatement of the other segment, it \nlooks like the growth in the near -term is coming in  [inaudible] but kind of the long -term targets and \nwhich I kind of wonder if you could address kind of or disaggregate in which sub -segments you're \nseeing with softness relative to the long -term expectations for the balance of the year or this year \nversus what you think ki nd of accelerates coming out and kind of closes the gap in the longer -term \nguidance?  \n \n Aaron Alt :  The businesses that report through Other for us going forward will be our at -Home \nbusiness, our Nuclear Precision Health business  and our OptiFreight\u00ae business.  Those  are what we \nhave traditionally called our growth businesses as part of other segments.   And indeed, over the long \nterm, we expect the CAGR on their collective growth to be 8% to 10%. ", "original_text": "But as it relates to the planned restatement of the other segment, it \nlooks like the growth in the near -term is coming in  [inaudible] but kind of the long -term targets and \nwhich I kind of wonder if you could address kind of or disaggregate in which sub -segments you're \nseeing with softness relative to the long -term expectations for the balance of the year or this year \nversus what you think ki nd of accelerates coming out and kind of closes the gap in the longer -term \nguidance?  \n \n", "page_label": "16", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "ea45af9083f80684f8689bd9a6d6dc69791ebb1807c46f17a27bd58bc8e7221d", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "2b4cbce0-912e-42dd-8a8f-9ff1d1a8945b", "node_type": "1", "metadata": {"window": "And forgive me if I kind of missed this or if you \nguys talked through this already.  But as it relates to the planned restatement of the other segment, it \nlooks like the growth in the near -term is coming in  [inaudible] but kind of the long -term targets and \nwhich I kind of wonder if you could address kind of or disaggregate in which sub -segments you're \nseeing with softness relative to the long -term expectations for the balance of the year or this year \nversus what you think ki nd of accelerates coming out and kind of closes the gap in the longer -term \nguidance?  \n \n Aaron Alt :  The businesses that report through Other for us going forward will be our at -Home \nbusiness, our Nuclear Precision Health business  and our OptiFreight\u00ae business.  Those  are what we \nhave traditionally called our growth businesses as part of other segments.   And indeed, over the long \nterm, we expect the CAGR on their collective growth to be 8% to 10%.  The disconnect you're \nreferencing, which is the 6% to 8% in fiscal \u201824, is only driven by the impact of the non -recurring \nadjustments from Q2 on the at -Home business that we referenced a couple of weeks ago as we \ntalked about our expectations for Q2.   Each of the businesses contribute to the revenue and profit \ngrowth for Other for us as we carry forward. ", "original_text": "Those  are what we \nhave traditionally called our growth businesses as part of other segments.  "}, "hash": "5880b5e3466ded778907bbcd5737d342e0ce1568e9e526ad606132d851e39e6d", "class_name": "RelatedNodeInfo"}}, "text": "Aaron Alt :  The businesses that report through Other for us going forward will be our at -Home \nbusiness, our Nuclear Precision Health business  and our OptiFreight\u00ae business. ", "start_char_idx": 1798, "end_char_idx": 1975, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "2b4cbce0-912e-42dd-8a8f-9ff1d1a8945b": {"__data__": {"id_": "2b4cbce0-912e-42dd-8a8f-9ff1d1a8945b", "embedding": null, "metadata": {"window": "And forgive me if I kind of missed this or if you \nguys talked through this already.  But as it relates to the planned restatement of the other segment, it \nlooks like the growth in the near -term is coming in  [inaudible] but kind of the long -term targets and \nwhich I kind of wonder if you could address kind of or disaggregate in which sub -segments you're \nseeing with softness relative to the long -term expectations for the balance of the year or this year \nversus what you think ki nd of accelerates coming out and kind of closes the gap in the longer -term \nguidance?  \n \n Aaron Alt :  The businesses that report through Other for us going forward will be our at -Home \nbusiness, our Nuclear Precision Health business  and our OptiFreight\u00ae business.  Those  are what we \nhave traditionally called our growth businesses as part of other segments.   And indeed, over the long \nterm, we expect the CAGR on their collective growth to be 8% to 10%.  The disconnect you're \nreferencing, which is the 6% to 8% in fiscal \u201824, is only driven by the impact of the non -recurring \nadjustments from Q2 on the at -Home business that we referenced a couple of weeks ago as we \ntalked about our expectations for Q2.   Each of the businesses contribute to the revenue and profit \ngrowth for Other for us as we carry forward. ", "original_text": "Those  are what we \nhave traditionally called our growth businesses as part of other segments.  ", "page_label": "16", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "6d5ec7f6-bdd6-41b2-9b56-d1f2960aaef4", "node_type": "4", "metadata": {"page_label": "16", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "b0205224430b7dfc9e84da67be2109c44a567f4dad70817a17b38328d6416b9b", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "8e971903-8b92-41d6-ad4b-dfa11c01f956", "node_type": "1", "metadata": {"window": "Good morning, Jason  and Aaron .  And forgive me if I kind of missed this or if you \nguys talked through this already.  But as it relates to the planned restatement of the other segment, it \nlooks like the growth in the near -term is coming in  [inaudible] but kind of the long -term targets and \nwhich I kind of wonder if you could address kind of or disaggregate in which sub -segments you're \nseeing with softness relative to the long -term expectations for the balance of the year or this year \nversus what you think ki nd of accelerates coming out and kind of closes the gap in the longer -term \nguidance?  \n \n Aaron Alt :  The businesses that report through Other for us going forward will be our at -Home \nbusiness, our Nuclear Precision Health business  and our OptiFreight\u00ae business.  Those  are what we \nhave traditionally called our growth businesses as part of other segments.   And indeed, over the long \nterm, we expect the CAGR on their collective growth to be 8% to 10%.  The disconnect you're \nreferencing, which is the 6% to 8% in fiscal \u201824, is only driven by the impact of the non -recurring \nadjustments from Q2 on the at -Home business that we referenced a couple of weeks ago as we \ntalked about our expectations for Q2.  ", "original_text": "Aaron Alt :  The businesses that report through Other for us going forward will be our at -Home \nbusiness, our Nuclear Precision Health business  and our OptiFreight\u00ae business. ", "page_label": "16", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "1be431bd92109dd9aef6455fef3b28b02c53442249a161566875cd4837d5242e", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "4fef81fe-fd48-497d-b6b2-7ac2ababd63f", "node_type": "1", "metadata": {"window": "But as it relates to the planned restatement of the other segment, it \nlooks like the growth in the near -term is coming in  [inaudible] but kind of the long -term targets and \nwhich I kind of wonder if you could address kind of or disaggregate in which sub -segments you're \nseeing with softness relative to the long -term expectations for the balance of the year or this year \nversus what you think ki nd of accelerates coming out and kind of closes the gap in the longer -term \nguidance?  \n \n Aaron Alt :  The businesses that report through Other for us going forward will be our at -Home \nbusiness, our Nuclear Precision Health business  and our OptiFreight\u00ae business.  Those  are what we \nhave traditionally called our growth businesses as part of other segments.   And indeed, over the long \nterm, we expect the CAGR on their collective growth to be 8% to 10%.  The disconnect you're \nreferencing, which is the 6% to 8% in fiscal \u201824, is only driven by the impact of the non -recurring \nadjustments from Q2 on the at -Home business that we referenced a couple of weeks ago as we \ntalked about our expectations for Q2.   Each of the businesses contribute to the revenue and profit \ngrowth for Other for us as we carry forward.  In our earlier disclosures, I think you can get pretty close, \nwe disclosed the revenue of the individual pieces. ", "original_text": "And indeed, over the long \nterm, we expect the CAGR on their collective growth to be 8% to 10%. "}, "hash": "7749b128bbd71d6d460ffb235c6ac4e1aa745dce2392aeef76f71e1e2a93508c", "class_name": "RelatedNodeInfo"}}, "text": "Those  are what we \nhave traditionally called our growth businesses as part of other segments.  ", "start_char_idx": 1975, "end_char_idx": 2071, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "4fef81fe-fd48-497d-b6b2-7ac2ababd63f": {"__data__": {"id_": "4fef81fe-fd48-497d-b6b2-7ac2ababd63f", "embedding": null, "metadata": {"window": "But as it relates to the planned restatement of the other segment, it \nlooks like the growth in the near -term is coming in  [inaudible] but kind of the long -term targets and \nwhich I kind of wonder if you could address kind of or disaggregate in which sub -segments you're \nseeing with softness relative to the long -term expectations for the balance of the year or this year \nversus what you think ki nd of accelerates coming out and kind of closes the gap in the longer -term \nguidance?  \n \n Aaron Alt :  The businesses that report through Other for us going forward will be our at -Home \nbusiness, our Nuclear Precision Health business  and our OptiFreight\u00ae business.  Those  are what we \nhave traditionally called our growth businesses as part of other segments.   And indeed, over the long \nterm, we expect the CAGR on their collective growth to be 8% to 10%.  The disconnect you're \nreferencing, which is the 6% to 8% in fiscal \u201824, is only driven by the impact of the non -recurring \nadjustments from Q2 on the at -Home business that we referenced a couple of weeks ago as we \ntalked about our expectations for Q2.   Each of the businesses contribute to the revenue and profit \ngrowth for Other for us as we carry forward.  In our earlier disclosures, I think you can get pretty close, \nwe disclosed the revenue of the individual pieces. ", "original_text": "And indeed, over the long \nterm, we expect the CAGR on their collective growth to be 8% to 10%. ", "page_label": "16", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "6d5ec7f6-bdd6-41b2-9b56-d1f2960aaef4", "node_type": "4", "metadata": {"page_label": "16", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "b0205224430b7dfc9e84da67be2109c44a567f4dad70817a17b38328d6416b9b", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "2b4cbce0-912e-42dd-8a8f-9ff1d1a8945b", "node_type": "1", "metadata": {"window": "And forgive me if I kind of missed this or if you \nguys talked through this already.  But as it relates to the planned restatement of the other segment, it \nlooks like the growth in the near -term is coming in  [inaudible] but kind of the long -term targets and \nwhich I kind of wonder if you could address kind of or disaggregate in which sub -segments you're \nseeing with softness relative to the long -term expectations for the balance of the year or this year \nversus what you think ki nd of accelerates coming out and kind of closes the gap in the longer -term \nguidance?  \n \n Aaron Alt :  The businesses that report through Other for us going forward will be our at -Home \nbusiness, our Nuclear Precision Health business  and our OptiFreight\u00ae business.  Those  are what we \nhave traditionally called our growth businesses as part of other segments.   And indeed, over the long \nterm, we expect the CAGR on their collective growth to be 8% to 10%.  The disconnect you're \nreferencing, which is the 6% to 8% in fiscal \u201824, is only driven by the impact of the non -recurring \nadjustments from Q2 on the at -Home business that we referenced a couple of weeks ago as we \ntalked about our expectations for Q2.   Each of the businesses contribute to the revenue and profit \ngrowth for Other for us as we carry forward. ", "original_text": "Those  are what we \nhave traditionally called our growth businesses as part of other segments.  ", "page_label": "16", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "8576e2faeec0bca75db873fab797c03f26bb73ed3672c35591b2167e306eb95f", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "db2ea73b-b0f0-4fb0-a5c1-6e520da845a5", "node_type": "1", "metadata": {"window": "Aaron Alt :  The businesses that report through Other for us going forward will be our at -Home \nbusiness, our Nuclear Precision Health business  and our OptiFreight\u00ae business.  Those  are what we \nhave traditionally called our growth businesses as part of other segments.   And indeed, over the long \nterm, we expect the CAGR on their collective growth to be 8% to 10%.  The disconnect you're \nreferencing, which is the 6% to 8% in fiscal \u201824, is only driven by the impact of the non -recurring \nadjustments from Q2 on the at -Home business that we referenced a couple of weeks ago as we \ntalked about our expectations for Q2.   Each of the businesses contribute to the revenue and profit \ngrowth for Other for us as we carry forward.  In our earlier disclosures, I think you can get pretty close, \nwe disclosed the revenue of the individual pieces.  And indeed, we've talked about Nuclear  doubling \nits profit off of its fiscal \u201821 baseline by fiscal \u201826 as well, I believe, and so you're able to get to that \ncomponent of Other through that.  \n \n", "original_text": "The disconnect you're \nreferencing, which is the 6% to 8% in fiscal \u201824, is only driven by the impact of the non -recurring \nadjustments from Q2 on the at -Home business that we referenced a couple of weeks ago as we \ntalked about our expectations for Q2.  "}, "hash": "96255b07186c192c973b1e1de54d60ddfb460fa6ec7eb9a3927a476fd218acc5", "class_name": "RelatedNodeInfo"}}, "text": "And indeed, over the long \nterm, we expect the CAGR on their collective growth to be 8% to 10%. ", "start_char_idx": 2071, "end_char_idx": 2167, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "db2ea73b-b0f0-4fb0-a5c1-6e520da845a5": {"__data__": {"id_": "db2ea73b-b0f0-4fb0-a5c1-6e520da845a5", "embedding": null, "metadata": {"window": "Aaron Alt :  The businesses that report through Other for us going forward will be our at -Home \nbusiness, our Nuclear Precision Health business  and our OptiFreight\u00ae business.  Those  are what we \nhave traditionally called our growth businesses as part of other segments.   And indeed, over the long \nterm, we expect the CAGR on their collective growth to be 8% to 10%.  The disconnect you're \nreferencing, which is the 6% to 8% in fiscal \u201824, is only driven by the impact of the non -recurring \nadjustments from Q2 on the at -Home business that we referenced a couple of weeks ago as we \ntalked about our expectations for Q2.   Each of the businesses contribute to the revenue and profit \ngrowth for Other for us as we carry forward.  In our earlier disclosures, I think you can get pretty close, \nwe disclosed the revenue of the individual pieces.  And indeed, we've talked about Nuclear  doubling \nits profit off of its fiscal \u201821 baseline by fiscal \u201826 as well, I believe, and so you're able to get to that \ncomponent of Other through that.  \n \n", "original_text": "The disconnect you're \nreferencing, which is the 6% to 8% in fiscal \u201824, is only driven by the impact of the non -recurring \nadjustments from Q2 on the at -Home business that we referenced a couple of weeks ago as we \ntalked about our expectations for Q2.  ", "page_label": "16", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "6d5ec7f6-bdd6-41b2-9b56-d1f2960aaef4", "node_type": "4", "metadata": {"page_label": "16", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "b0205224430b7dfc9e84da67be2109c44a567f4dad70817a17b38328d6416b9b", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "4fef81fe-fd48-497d-b6b2-7ac2ababd63f", "node_type": "1", "metadata": {"window": "But as it relates to the planned restatement of the other segment, it \nlooks like the growth in the near -term is coming in  [inaudible] but kind of the long -term targets and \nwhich I kind of wonder if you could address kind of or disaggregate in which sub -segments you're \nseeing with softness relative to the long -term expectations for the balance of the year or this year \nversus what you think ki nd of accelerates coming out and kind of closes the gap in the longer -term \nguidance?  \n \n Aaron Alt :  The businesses that report through Other for us going forward will be our at -Home \nbusiness, our Nuclear Precision Health business  and our OptiFreight\u00ae business.  Those  are what we \nhave traditionally called our growth businesses as part of other segments.   And indeed, over the long \nterm, we expect the CAGR on their collective growth to be 8% to 10%.  The disconnect you're \nreferencing, which is the 6% to 8% in fiscal \u201824, is only driven by the impact of the non -recurring \nadjustments from Q2 on the at -Home business that we referenced a couple of weeks ago as we \ntalked about our expectations for Q2.   Each of the businesses contribute to the revenue and profit \ngrowth for Other for us as we carry forward.  In our earlier disclosures, I think you can get pretty close, \nwe disclosed the revenue of the individual pieces. ", "original_text": "And indeed, over the long \nterm, we expect the CAGR on their collective growth to be 8% to 10%. ", "page_label": "16", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "d24d249bc882b13a89c890a62b7552d63550ef9cbb1db437273b8f5f6c29cdd3", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "f47bf491-0436-45ac-aa5f-93cf985c17e5", "node_type": "1", "metadata": {"window": "Those  are what we \nhave traditionally called our growth businesses as part of other segments.   And indeed, over the long \nterm, we expect the CAGR on their collective growth to be 8% to 10%.  The disconnect you're \nreferencing, which is the 6% to 8% in fiscal \u201824, is only driven by the impact of the non -recurring \nadjustments from Q2 on the at -Home business that we referenced a couple of weeks ago as we \ntalked about our expectations for Q2.   Each of the businesses contribute to the revenue and profit \ngrowth for Other for us as we carry forward.  In our earlier disclosures, I think you can get pretty close, \nwe disclosed the revenue of the individual pieces.  And indeed, we've talked about Nuclear  doubling \nits profit off of its fiscal \u201821 baseline by fiscal \u201826 as well, I believe, and so you're able to get to that \ncomponent of Other through that.  \n \n Matt Sims:  Next question, please.  \n \n", "original_text": "Each of the businesses contribute to the revenue and profit \ngrowth for Other for us as we carry forward. "}, "hash": "89f9643fac87108ad9fa2bc61c858359ffaf3ef83be34add4789323d367f46ee", "class_name": "RelatedNodeInfo"}}, "text": "The disconnect you're \nreferencing, which is the 6% to 8% in fiscal \u201824, is only driven by the impact of the non -recurring \nadjustments from Q2 on the at -Home business that we referenced a couple of weeks ago as we \ntalked about our expectations for Q2.  ", "start_char_idx": 2167, "end_char_idx": 2424, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "f47bf491-0436-45ac-aa5f-93cf985c17e5": {"__data__": {"id_": "f47bf491-0436-45ac-aa5f-93cf985c17e5", "embedding": null, "metadata": {"window": "Those  are what we \nhave traditionally called our growth businesses as part of other segments.   And indeed, over the long \nterm, we expect the CAGR on their collective growth to be 8% to 10%.  The disconnect you're \nreferencing, which is the 6% to 8% in fiscal \u201824, is only driven by the impact of the non -recurring \nadjustments from Q2 on the at -Home business that we referenced a couple of weeks ago as we \ntalked about our expectations for Q2.   Each of the businesses contribute to the revenue and profit \ngrowth for Other for us as we carry forward.  In our earlier disclosures, I think you can get pretty close, \nwe disclosed the revenue of the individual pieces.  And indeed, we've talked about Nuclear  doubling \nits profit off of its fiscal \u201821 baseline by fiscal \u201826 as well, I believe, and so you're able to get to that \ncomponent of Other through that.  \n \n Matt Sims:  Next question, please.  \n \n", "original_text": "Each of the businesses contribute to the revenue and profit \ngrowth for Other for us as we carry forward. ", "page_label": "16", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "6d5ec7f6-bdd6-41b2-9b56-d1f2960aaef4", "node_type": "4", "metadata": {"page_label": "16", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "b0205224430b7dfc9e84da67be2109c44a567f4dad70817a17b38328d6416b9b", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "db2ea73b-b0f0-4fb0-a5c1-6e520da845a5", "node_type": "1", "metadata": {"window": "Aaron Alt :  The businesses that report through Other for us going forward will be our at -Home \nbusiness, our Nuclear Precision Health business  and our OptiFreight\u00ae business.  Those  are what we \nhave traditionally called our growth businesses as part of other segments.   And indeed, over the long \nterm, we expect the CAGR on their collective growth to be 8% to 10%.  The disconnect you're \nreferencing, which is the 6% to 8% in fiscal \u201824, is only driven by the impact of the non -recurring \nadjustments from Q2 on the at -Home business that we referenced a couple of weeks ago as we \ntalked about our expectations for Q2.   Each of the businesses contribute to the revenue and profit \ngrowth for Other for us as we carry forward.  In our earlier disclosures, I think you can get pretty close, \nwe disclosed the revenue of the individual pieces.  And indeed, we've talked about Nuclear  doubling \nits profit off of its fiscal \u201821 baseline by fiscal \u201826 as well, I believe, and so you're able to get to that \ncomponent of Other through that.  \n \n", "original_text": "The disconnect you're \nreferencing, which is the 6% to 8% in fiscal \u201824, is only driven by the impact of the non -recurring \nadjustments from Q2 on the at -Home business that we referenced a couple of weeks ago as we \ntalked about our expectations for Q2.  ", "page_label": "16", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "f6590dec8c31eb8751ff7ee106d44cdaec3127afe0bb9f3c958aecc1011b4b1e", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "4521b31b-30eb-412a-bb80-8cc034b4ead6", "node_type": "1", "metadata": {"window": "And indeed, over the long \nterm, we expect the CAGR on their collective growth to be 8% to 10%.  The disconnect you're \nreferencing, which is the 6% to 8% in fiscal \u201824, is only driven by the impact of the non -recurring \nadjustments from Q2 on the at -Home business that we referenced a couple of weeks ago as we \ntalked about our expectations for Q2.   Each of the businesses contribute to the revenue and profit \ngrowth for Other for us as we carry forward.  In our earlier disclosures, I think you can get pretty close, \nwe disclosed the revenue of the individual pieces.  And indeed, we've talked about Nuclear  doubling \nits profit off of its fiscal \u201821 baseline by fiscal \u201826 as well, I believe, and so you're able to get to that \ncomponent of Other through that.  \n \n Matt Sims:  Next question, please.  \n \n Operator:  Yes, sir. ", "original_text": "In our earlier disclosures, I think you can get pretty close, \nwe disclosed the revenue of the individual pieces. "}, "hash": "3faed9a50dc798b2e558c30cbf88bef8c500914fea64b582cdff7492f318363a", "class_name": "RelatedNodeInfo"}}, "text": "Each of the businesses contribute to the revenue and profit \ngrowth for Other for us as we carry forward. ", "start_char_idx": 2424, "end_char_idx": 2530, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "4521b31b-30eb-412a-bb80-8cc034b4ead6": {"__data__": {"id_": "4521b31b-30eb-412a-bb80-8cc034b4ead6", "embedding": null, "metadata": {"window": "And indeed, over the long \nterm, we expect the CAGR on their collective growth to be 8% to 10%.  The disconnect you're \nreferencing, which is the 6% to 8% in fiscal \u201824, is only driven by the impact of the non -recurring \nadjustments from Q2 on the at -Home business that we referenced a couple of weeks ago as we \ntalked about our expectations for Q2.   Each of the businesses contribute to the revenue and profit \ngrowth for Other for us as we carry forward.  In our earlier disclosures, I think you can get pretty close, \nwe disclosed the revenue of the individual pieces.  And indeed, we've talked about Nuclear  doubling \nits profit off of its fiscal \u201821 baseline by fiscal \u201826 as well, I believe, and so you're able to get to that \ncomponent of Other through that.  \n \n Matt Sims:  Next question, please.  \n \n Operator:  Yes, sir. ", "original_text": "In our earlier disclosures, I think you can get pretty close, \nwe disclosed the revenue of the individual pieces. ", "page_label": "16", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "6d5ec7f6-bdd6-41b2-9b56-d1f2960aaef4", "node_type": "4", "metadata": {"page_label": "16", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "b0205224430b7dfc9e84da67be2109c44a567f4dad70817a17b38328d6416b9b", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "f47bf491-0436-45ac-aa5f-93cf985c17e5", "node_type": "1", "metadata": {"window": "Those  are what we \nhave traditionally called our growth businesses as part of other segments.   And indeed, over the long \nterm, we expect the CAGR on their collective growth to be 8% to 10%.  The disconnect you're \nreferencing, which is the 6% to 8% in fiscal \u201824, is only driven by the impact of the non -recurring \nadjustments from Q2 on the at -Home business that we referenced a couple of weeks ago as we \ntalked about our expectations for Q2.   Each of the businesses contribute to the revenue and profit \ngrowth for Other for us as we carry forward.  In our earlier disclosures, I think you can get pretty close, \nwe disclosed the revenue of the individual pieces.  And indeed, we've talked about Nuclear  doubling \nits profit off of its fiscal \u201821 baseline by fiscal \u201826 as well, I believe, and so you're able to get to that \ncomponent of Other through that.  \n \n Matt Sims:  Next question, please.  \n \n", "original_text": "Each of the businesses contribute to the revenue and profit \ngrowth for Other for us as we carry forward. ", "page_label": "16", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "2cc3d2f3916246ff2aa6aacb23f722e8c65727e8dde7489fb5a84ff716465af1", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "17d5ae9c-86bc-4f28-bace-78574ee1b645", "node_type": "1", "metadata": {"window": "The disconnect you're \nreferencing, which is the 6% to 8% in fiscal \u201824, is only driven by the impact of the non -recurring \nadjustments from Q2 on the at -Home business that we referenced a couple of weeks ago as we \ntalked about our expectations for Q2.   Each of the businesses contribute to the revenue and profit \ngrowth for Other for us as we carry forward.  In our earlier disclosures, I think you can get pretty close, \nwe disclosed the revenue of the individual pieces.  And indeed, we've talked about Nuclear  doubling \nits profit off of its fiscal \u201821 baseline by fiscal \u201826 as well, I believe, and so you're able to get to that \ncomponent of Other through that.  \n \n Matt Sims:  Next question, please.  \n \n Operator:  Yes, sir.  Will now take Stephen Baxter of Wells Fargo. ", "original_text": "And indeed, we've talked about Nuclear  doubling \nits profit off of its fiscal \u201821 baseline by fiscal \u201826 as well, I believe, and so you're able to get to that \ncomponent of Other through that.  \n \n"}, "hash": "38cfd21c5e19568083d353bbeb198e4b64609ed0bc15da3e3a2540c7029b07bb", "class_name": "RelatedNodeInfo"}}, "text": "In our earlier disclosures, I think you can get pretty close, \nwe disclosed the revenue of the individual pieces. ", "start_char_idx": 2530, "end_char_idx": 2644, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "17d5ae9c-86bc-4f28-bace-78574ee1b645": {"__data__": {"id_": "17d5ae9c-86bc-4f28-bace-78574ee1b645", "embedding": null, "metadata": {"window": "The disconnect you're \nreferencing, which is the 6% to 8% in fiscal \u201824, is only driven by the impact of the non -recurring \nadjustments from Q2 on the at -Home business that we referenced a couple of weeks ago as we \ntalked about our expectations for Q2.   Each of the businesses contribute to the revenue and profit \ngrowth for Other for us as we carry forward.  In our earlier disclosures, I think you can get pretty close, \nwe disclosed the revenue of the individual pieces.  And indeed, we've talked about Nuclear  doubling \nits profit off of its fiscal \u201821 baseline by fiscal \u201826 as well, I believe, and so you're able to get to that \ncomponent of Other through that.  \n \n Matt Sims:  Next question, please.  \n \n Operator:  Yes, sir.  Will now take Stephen Baxter of Wells Fargo. ", "original_text": "And indeed, we've talked about Nuclear  doubling \nits profit off of its fiscal \u201821 baseline by fiscal \u201826 as well, I believe, and so you're able to get to that \ncomponent of Other through that.  \n \n", "page_label": "16", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "6d5ec7f6-bdd6-41b2-9b56-d1f2960aaef4", "node_type": "4", "metadata": {"page_label": "16", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "b0205224430b7dfc9e84da67be2109c44a567f4dad70817a17b38328d6416b9b", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "4521b31b-30eb-412a-bb80-8cc034b4ead6", "node_type": "1", "metadata": {"window": "And indeed, over the long \nterm, we expect the CAGR on their collective growth to be 8% to 10%.  The disconnect you're \nreferencing, which is the 6% to 8% in fiscal \u201824, is only driven by the impact of the non -recurring \nadjustments from Q2 on the at -Home business that we referenced a couple of weeks ago as we \ntalked about our expectations for Q2.   Each of the businesses contribute to the revenue and profit \ngrowth for Other for us as we carry forward.  In our earlier disclosures, I think you can get pretty close, \nwe disclosed the revenue of the individual pieces.  And indeed, we've talked about Nuclear  doubling \nits profit off of its fiscal \u201821 baseline by fiscal \u201826 as well, I believe, and so you're able to get to that \ncomponent of Other through that.  \n \n Matt Sims:  Next question, please.  \n \n Operator:  Yes, sir. ", "original_text": "In our earlier disclosures, I think you can get pretty close, \nwe disclosed the revenue of the individual pieces. ", "page_label": "16", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "eabe4c1c971b6471c5ddbc521c4b1e38eb4f27c653be2fe979b84c8985add1bb", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "c8857409-c8ac-4d47-bff4-46b02417919c", "node_type": "1", "metadata": {"window": "Each of the businesses contribute to the revenue and profit \ngrowth for Other for us as we carry forward.  In our earlier disclosures, I think you can get pretty close, \nwe disclosed the revenue of the individual pieces.  And indeed, we've talked about Nuclear  doubling \nits profit off of its fiscal \u201821 baseline by fiscal \u201826 as well, I believe, and so you're able to get to that \ncomponent of Other through that.  \n \n Matt Sims:  Next question, please.  \n \n Operator:  Yes, sir.  Will now take Stephen Baxter of Wells Fargo.  Please go ahead, sir.  \n \n", "original_text": "Matt Sims:  Next question, please.  \n \n"}, "hash": "3e22e729133e7b644d297b63a5838f01658a7e3b515806e49eb221c931a8c8b9", "class_name": "RelatedNodeInfo"}}, "text": "And indeed, we've talked about Nuclear  doubling \nits profit off of its fiscal \u201821 baseline by fiscal \u201826 as well, I believe, and so you're able to get to that \ncomponent of Other through that.  \n \n", "start_char_idx": 2644, "end_char_idx": 2842, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "c8857409-c8ac-4d47-bff4-46b02417919c": {"__data__": {"id_": "c8857409-c8ac-4d47-bff4-46b02417919c", "embedding": null, "metadata": {"window": "Each of the businesses contribute to the revenue and profit \ngrowth for Other for us as we carry forward.  In our earlier disclosures, I think you can get pretty close, \nwe disclosed the revenue of the individual pieces.  And indeed, we've talked about Nuclear  doubling \nits profit off of its fiscal \u201821 baseline by fiscal \u201826 as well, I believe, and so you're able to get to that \ncomponent of Other through that.  \n \n Matt Sims:  Next question, please.  \n \n Operator:  Yes, sir.  Will now take Stephen Baxter of Wells Fargo.  Please go ahead, sir.  \n \n", "original_text": "Matt Sims:  Next question, please.  \n \n", "page_label": "16", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "6d5ec7f6-bdd6-41b2-9b56-d1f2960aaef4", "node_type": "4", "metadata": {"page_label": "16", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "b0205224430b7dfc9e84da67be2109c44a567f4dad70817a17b38328d6416b9b", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "17d5ae9c-86bc-4f28-bace-78574ee1b645", "node_type": "1", "metadata": {"window": "The disconnect you're \nreferencing, which is the 6% to 8% in fiscal \u201824, is only driven by the impact of the non -recurring \nadjustments from Q2 on the at -Home business that we referenced a couple of weeks ago as we \ntalked about our expectations for Q2.   Each of the businesses contribute to the revenue and profit \ngrowth for Other for us as we carry forward.  In our earlier disclosures, I think you can get pretty close, \nwe disclosed the revenue of the individual pieces.  And indeed, we've talked about Nuclear  doubling \nits profit off of its fiscal \u201821 baseline by fiscal \u201826 as well, I believe, and so you're able to get to that \ncomponent of Other through that.  \n \n Matt Sims:  Next question, please.  \n \n Operator:  Yes, sir.  Will now take Stephen Baxter of Wells Fargo. ", "original_text": "And indeed, we've talked about Nuclear  doubling \nits profit off of its fiscal \u201821 baseline by fiscal \u201826 as well, I believe, and so you're able to get to that \ncomponent of Other through that.  \n \n", "page_label": "16", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "acb929f46fcad57d6eed05ceeccbeddd8b95f6b604f1e90eb204c1fe2d5f85ba", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "5c659247-40d2-4e0c-b196-b301cd218cb3", "node_type": "1", "metadata": {"window": "In our earlier disclosures, I think you can get pretty close, \nwe disclosed the revenue of the individual pieces.  And indeed, we've talked about Nuclear  doubling \nits profit off of its fiscal \u201821 baseline by fiscal \u201826 as well, I believe, and so you're able to get to that \ncomponent of Other through that.  \n \n Matt Sims:  Next question, please.  \n \n Operator:  Yes, sir.  Will now take Stephen Baxter of Wells Fargo.  Please go ahead, sir.  \n \n Stephen Baxter:   Yes. ", "original_text": "Operator:  Yes, sir. "}, "hash": "f39189824cf477ba9a83d2b70e5f225f731fa30fa1a449c671a9116c2898d30f", "class_name": "RelatedNodeInfo"}}, "text": "Matt Sims:  Next question, please.  \n \n", "start_char_idx": 2842, "end_char_idx": 2881, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "5c659247-40d2-4e0c-b196-b301cd218cb3": {"__data__": {"id_": "5c659247-40d2-4e0c-b196-b301cd218cb3", "embedding": null, "metadata": {"window": "In our earlier disclosures, I think you can get pretty close, \nwe disclosed the revenue of the individual pieces.  And indeed, we've talked about Nuclear  doubling \nits profit off of its fiscal \u201821 baseline by fiscal \u201826 as well, I believe, and so you're able to get to that \ncomponent of Other through that.  \n \n Matt Sims:  Next question, please.  \n \n Operator:  Yes, sir.  Will now take Stephen Baxter of Wells Fargo.  Please go ahead, sir.  \n \n Stephen Baxter:   Yes. ", "original_text": "Operator:  Yes, sir. ", "page_label": "16", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "6d5ec7f6-bdd6-41b2-9b56-d1f2960aaef4", "node_type": "4", "metadata": {"page_label": "16", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "b0205224430b7dfc9e84da67be2109c44a567f4dad70817a17b38328d6416b9b", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "c8857409-c8ac-4d47-bff4-46b02417919c", "node_type": "1", "metadata": {"window": "Each of the businesses contribute to the revenue and profit \ngrowth for Other for us as we carry forward.  In our earlier disclosures, I think you can get pretty close, \nwe disclosed the revenue of the individual pieces.  And indeed, we've talked about Nuclear  doubling \nits profit off of its fiscal \u201821 baseline by fiscal \u201826 as well, I believe, and so you're able to get to that \ncomponent of Other through that.  \n \n Matt Sims:  Next question, please.  \n \n Operator:  Yes, sir.  Will now take Stephen Baxter of Wells Fargo.  Please go ahead, sir.  \n \n", "original_text": "Matt Sims:  Next question, please.  \n \n", "page_label": "16", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "fc78045641392a257a61103bd3ba607c1f174a80efaabe9888e2014b81a3e95c", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "8d92e2f5-73df-4bf8-b7bf-7fbcbff943d0", "node_type": "1", "metadata": {"window": "And indeed, we've talked about Nuclear  doubling \nits profit off of its fiscal \u201821 baseline by fiscal \u201826 as well, I believe, and so you're able to get to that \ncomponent of Other through that.  \n \n Matt Sims:  Next question, please.  \n \n Operator:  Yes, sir.  Will now take Stephen Baxter of Wells Fargo.  Please go ahead, sir.  \n \n Stephen Baxter:   Yes.  Hi, good morning. ", "original_text": "Will now take Stephen Baxter of Wells Fargo. "}, "hash": "07028acf19b075c05505aa31dc629ab0fbb0e77e60d0016816673fce5b8c990e", "class_name": "RelatedNodeInfo"}}, "text": "Operator:  Yes, sir. ", "start_char_idx": 2881, "end_char_idx": 2902, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "8d92e2f5-73df-4bf8-b7bf-7fbcbff943d0": {"__data__": {"id_": "8d92e2f5-73df-4bf8-b7bf-7fbcbff943d0", "embedding": null, "metadata": {"window": "And indeed, we've talked about Nuclear  doubling \nits profit off of its fiscal \u201821 baseline by fiscal \u201826 as well, I believe, and so you're able to get to that \ncomponent of Other through that.  \n \n Matt Sims:  Next question, please.  \n \n Operator:  Yes, sir.  Will now take Stephen Baxter of Wells Fargo.  Please go ahead, sir.  \n \n Stephen Baxter:   Yes.  Hi, good morning. ", "original_text": "Will now take Stephen Baxter of Wells Fargo. ", "page_label": "16", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "6d5ec7f6-bdd6-41b2-9b56-d1f2960aaef4", "node_type": "4", "metadata": {"page_label": "16", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "b0205224430b7dfc9e84da67be2109c44a567f4dad70817a17b38328d6416b9b", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "5c659247-40d2-4e0c-b196-b301cd218cb3", "node_type": "1", "metadata": {"window": "In our earlier disclosures, I think you can get pretty close, \nwe disclosed the revenue of the individual pieces.  And indeed, we've talked about Nuclear  doubling \nits profit off of its fiscal \u201821 baseline by fiscal \u201826 as well, I believe, and so you're able to get to that \ncomponent of Other through that.  \n \n Matt Sims:  Next question, please.  \n \n Operator:  Yes, sir.  Will now take Stephen Baxter of Wells Fargo.  Please go ahead, sir.  \n \n Stephen Baxter:   Yes. ", "original_text": "Operator:  Yes, sir. ", "page_label": "16", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "dbdecff8cbc37aa14b6365596c23a7f6ad237c2772b466db66d568ad26752d08", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "4a933b8b-e029-4ef6-9703-837a74507525", "node_type": "1", "metadata": {"window": "Matt Sims:  Next question, please.  \n \n Operator:  Yes, sir.  Will now take Stephen Baxter of Wells Fargo.  Please go ahead, sir.  \n \n Stephen Baxter:   Yes.  Hi, good morning.  Thanks for the questions. ", "original_text": "Please go ahead, sir.  \n \n"}, "hash": "250421c93a8b2b014a93ac3d59f5771dcc1acec6bd263065079d380ac8886e73", "class_name": "RelatedNodeInfo"}}, "text": "Will now take Stephen Baxter of Wells Fargo. ", "start_char_idx": 2902, "end_char_idx": 2947, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "4a933b8b-e029-4ef6-9703-837a74507525": {"__data__": {"id_": "4a933b8b-e029-4ef6-9703-837a74507525", "embedding": null, "metadata": {"window": "Matt Sims:  Next question, please.  \n \n Operator:  Yes, sir.  Will now take Stephen Baxter of Wells Fargo.  Please go ahead, sir.  \n \n Stephen Baxter:   Yes.  Hi, good morning.  Thanks for the questions. ", "original_text": "Please go ahead, sir.  \n \n", "page_label": "16", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "6d5ec7f6-bdd6-41b2-9b56-d1f2960aaef4", "node_type": "4", "metadata": {"page_label": "16", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "b0205224430b7dfc9e84da67be2109c44a567f4dad70817a17b38328d6416b9b", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "8d92e2f5-73df-4bf8-b7bf-7fbcbff943d0", "node_type": "1", "metadata": {"window": "And indeed, we've talked about Nuclear  doubling \nits profit off of its fiscal \u201821 baseline by fiscal \u201826 as well, I believe, and so you're able to get to that \ncomponent of Other through that.  \n \n Matt Sims:  Next question, please.  \n \n Operator:  Yes, sir.  Will now take Stephen Baxter of Wells Fargo.  Please go ahead, sir.  \n \n Stephen Baxter:   Yes.  Hi, good morning. ", "original_text": "Will now take Stephen Baxter of Wells Fargo. ", "page_label": "16", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "e70a64c068791863d6d423241a01a3ea8b94baf90dbc157ecda5acd2988d238d", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "8e487d6f-16db-4d2b-8645-9ef5403e7bd4", "node_type": "1", "metadata": {"window": "Operator:  Yes, sir.  Will now take Stephen Baxter of Wells Fargo.  Please go ahead, sir.  \n \n Stephen Baxter:   Yes.  Hi, good morning.  Thanks for the questions.  A couple of quick ones. ", "original_text": "Stephen Baxter:   Yes. "}, "hash": "29dc96a54dcea600c7b5532184bd11f5fa6f2cdabe47c8d466765b90cb3951f8", "class_name": "RelatedNodeInfo"}}, "text": "Please go ahead, sir.  \n \n", "start_char_idx": 2947, "end_char_idx": 2973, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "8e487d6f-16db-4d2b-8645-9ef5403e7bd4": {"__data__": {"id_": "8e487d6f-16db-4d2b-8645-9ef5403e7bd4", "embedding": null, "metadata": {"window": "Operator:  Yes, sir.  Will now take Stephen Baxter of Wells Fargo.  Please go ahead, sir.  \n \n Stephen Baxter:   Yes.  Hi, good morning.  Thanks for the questions.  A couple of quick ones. ", "original_text": "Stephen Baxter:   Yes. ", "page_label": "16", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "6d5ec7f6-bdd6-41b2-9b56-d1f2960aaef4", "node_type": "4", "metadata": {"page_label": "16", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "b0205224430b7dfc9e84da67be2109c44a567f4dad70817a17b38328d6416b9b", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "4a933b8b-e029-4ef6-9703-837a74507525", "node_type": "1", "metadata": {"window": "Matt Sims:  Next question, please.  \n \n Operator:  Yes, sir.  Will now take Stephen Baxter of Wells Fargo.  Please go ahead, sir.  \n \n Stephen Baxter:   Yes.  Hi, good morning.  Thanks for the questions. ", "original_text": "Please go ahead, sir.  \n \n", "page_label": "16", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "d7855916720ba5585ca9e04bd0229451dd0874bf88c2b87d96ae64dbf95d79e2", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "1290d304-e8be-48bf-ad8a-7c92fc8aefa7", "node_type": "1", "metadata": {"window": "Will now take Stephen Baxter of Wells Fargo.  Please go ahead, sir.  \n \n Stephen Baxter:   Yes.  Hi, good morning.  Thanks for the questions.  A couple of quick ones.  On \nCOVID vaccine commercial channel, I think last quarter, you kind of indicated or implied that the \ncontribution was around $25 million. ", "original_text": "Hi, good morning. "}, "hash": "4e2cec30ed32a60821afdfe6baceef4cc8e3033241257061433fbfe3337c3e4a", "class_name": "RelatedNodeInfo"}}, "text": "Stephen Baxter:   Yes. ", "start_char_idx": 2973, "end_char_idx": 2996, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "1290d304-e8be-48bf-ad8a-7c92fc8aefa7": {"__data__": {"id_": "1290d304-e8be-48bf-ad8a-7c92fc8aefa7", "embedding": null, "metadata": {"window": "Will now take Stephen Baxter of Wells Fargo.  Please go ahead, sir.  \n \n Stephen Baxter:   Yes.  Hi, good morning.  Thanks for the questions.  A couple of quick ones.  On \nCOVID vaccine commercial channel, I think last quarter, you kind of indicated or implied that the \ncontribution was around $25 million. ", "original_text": "Hi, good morning. ", "page_label": "16", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "6d5ec7f6-bdd6-41b2-9b56-d1f2960aaef4", "node_type": "4", "metadata": {"page_label": "16", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "b0205224430b7dfc9e84da67be2109c44a567f4dad70817a17b38328d6416b9b", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "8e487d6f-16db-4d2b-8645-9ef5403e7bd4", "node_type": "1", "metadata": {"window": "Operator:  Yes, sir.  Will now take Stephen Baxter of Wells Fargo.  Please go ahead, sir.  \n \n Stephen Baxter:   Yes.  Hi, good morning.  Thanks for the questions.  A couple of quick ones. ", "original_text": "Stephen Baxter:   Yes. ", "page_label": "16", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "35e961583fd7251b2682745d0fd28bd805ac475c1d9e5ef03e00c6aaede37468", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "294d0bf8-f62f-4bd3-b414-a6d312edabc0", "node_type": "1", "metadata": {"window": "Please go ahead, sir.  \n \n Stephen Baxter:   Yes.  Hi, good morning.  Thanks for the questions.  A couple of quick ones.  On \nCOVID vaccine commercial channel, I think last quarter, you kind of indicated or implied that the \ncontribution was around $25 million.  I was hoping you could update us on what the performance was \nthis quarter and whether you factor anything in for the balance of the year? ", "original_text": "Thanks for the questions. "}, "hash": "1689cc1142ba2895a14b310eee861f0809e0680041781eaf3a77be1cf28909d3", "class_name": "RelatedNodeInfo"}}, "text": "Hi, good morning. ", "start_char_idx": 2996, "end_char_idx": 3014, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "294d0bf8-f62f-4bd3-b414-a6d312edabc0": {"__data__": {"id_": "294d0bf8-f62f-4bd3-b414-a6d312edabc0", "embedding": null, "metadata": {"window": "Please go ahead, sir.  \n \n Stephen Baxter:   Yes.  Hi, good morning.  Thanks for the questions.  A couple of quick ones.  On \nCOVID vaccine commercial channel, I think last quarter, you kind of indicated or implied that the \ncontribution was around $25 million.  I was hoping you could update us on what the performance was \nthis quarter and whether you factor anything in for the balance of the year? ", "original_text": "Thanks for the questions. ", "page_label": "16", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "6d5ec7f6-bdd6-41b2-9b56-d1f2960aaef4", "node_type": "4", "metadata": {"page_label": "16", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "b0205224430b7dfc9e84da67be2109c44a567f4dad70817a17b38328d6416b9b", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "1290d304-e8be-48bf-ad8a-7c92fc8aefa7", "node_type": "1", "metadata": {"window": "Will now take Stephen Baxter of Wells Fargo.  Please go ahead, sir.  \n \n Stephen Baxter:   Yes.  Hi, good morning.  Thanks for the questions.  A couple of quick ones.  On \nCOVID vaccine commercial channel, I think last quarter, you kind of indicated or implied that the \ncontribution was around $25 million. ", "original_text": "Hi, good morning. ", "page_label": "16", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "4e50143c22d98bae6121df1d1503addeadb11292de7ab4b91ade5d9f9d910819", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "ea97ddd3-ba21-48fc-88b0-acceb624cfcc", "node_type": "1", "metadata": {"window": "Stephen Baxter:   Yes.  Hi, good morning.  Thanks for the questions.  A couple of quick ones.  On \nCOVID vaccine commercial channel, I think last quarter, you kind of indicated or implied that the \ncontribution was around $25 million.  I was hoping you could update us on what the performance was \nthis quarter and whether you factor anything in for the balance of the year?  And then just to try one \nmore time on the non -recurring Medical adjustments. ", "original_text": "A couple of quick ones. "}, "hash": "62ec4d5a249a9124b5aa6b6fd1abf25261e53be0972734fbb9276b085d945760", "class_name": "RelatedNodeInfo"}}, "text": "Thanks for the questions. ", "start_char_idx": 3014, "end_char_idx": 3040, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "ea97ddd3-ba21-48fc-88b0-acceb624cfcc": {"__data__": {"id_": "ea97ddd3-ba21-48fc-88b0-acceb624cfcc", "embedding": null, "metadata": {"window": "Stephen Baxter:   Yes.  Hi, good morning.  Thanks for the questions.  A couple of quick ones.  On \nCOVID vaccine commercial channel, I think last quarter, you kind of indicated or implied that the \ncontribution was around $25 million.  I was hoping you could update us on what the performance was \nthis quarter and whether you factor anything in for the balance of the year?  And then just to try one \nmore time on the non -recurring Medical adjustments. ", "original_text": "A couple of quick ones. ", "page_label": "16", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "6d5ec7f6-bdd6-41b2-9b56-d1f2960aaef4", "node_type": "4", "metadata": {"page_label": "16", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "b0205224430b7dfc9e84da67be2109c44a567f4dad70817a17b38328d6416b9b", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "294d0bf8-f62f-4bd3-b414-a6d312edabc0", "node_type": "1", "metadata": {"window": "Please go ahead, sir.  \n \n Stephen Baxter:   Yes.  Hi, good morning.  Thanks for the questions.  A couple of quick ones.  On \nCOVID vaccine commercial channel, I think last quarter, you kind of indicated or implied that the \ncontribution was around $25 million.  I was hoping you could update us on what the performance was \nthis quarter and whether you factor anything in for the balance of the year? ", "original_text": "Thanks for the questions. ", "page_label": "16", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "a5b88968c03843ecf25e705feb28877b99cb81f5e3aba722298c388a61090855", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "d434d266-6de5-44d3-869d-e213e6694d75", "node_type": "1", "metadata": {"window": "Hi, good morning.  Thanks for the questions.  A couple of quick ones.  On \nCOVID vaccine commercial channel, I think last quarter, you kind of indicated or implied that the \ncontribution was around $25 million.  I was hoping you could update us on what the performance was \nthis quarter and whether you factor anything in for the balance of the year?  And then just to try one \nmore time on the non -recurring Medical adjustments.  Can you just tell us on the $20 million , like what ", "original_text": "On \nCOVID vaccine commercial channel, I think last quarter, you kind of indicated or implied that the \ncontribution was around $25 million. "}, "hash": "8c13b73fba868edf9f2249eec52c38b77ebaab0c55b00e3220c0bbb3f57081f5", "class_name": "RelatedNodeInfo"}}, "text": "A couple of quick ones. ", "start_char_idx": 3040, "end_char_idx": 3064, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "d434d266-6de5-44d3-869d-e213e6694d75": {"__data__": {"id_": "d434d266-6de5-44d3-869d-e213e6694d75", "embedding": null, "metadata": {"window": "Hi, good morning.  Thanks for the questions.  A couple of quick ones.  On \nCOVID vaccine commercial channel, I think last quarter, you kind of indicated or implied that the \ncontribution was around $25 million.  I was hoping you could update us on what the performance was \nthis quarter and whether you factor anything in for the balance of the year?  And then just to try one \nmore time on the non -recurring Medical adjustments.  Can you just tell us on the $20 million , like what ", "original_text": "On \nCOVID vaccine commercial channel, I think last quarter, you kind of indicated or implied that the \ncontribution was around $25 million. ", "page_label": "16", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "6d5ec7f6-bdd6-41b2-9b56-d1f2960aaef4", "node_type": "4", "metadata": {"page_label": "16", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "b0205224430b7dfc9e84da67be2109c44a567f4dad70817a17b38328d6416b9b", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "ea97ddd3-ba21-48fc-88b0-acceb624cfcc", "node_type": "1", "metadata": {"window": "Stephen Baxter:   Yes.  Hi, good morning.  Thanks for the questions.  A couple of quick ones.  On \nCOVID vaccine commercial channel, I think last quarter, you kind of indicated or implied that the \ncontribution was around $25 million.  I was hoping you could update us on what the performance was \nthis quarter and whether you factor anything in for the balance of the year?  And then just to try one \nmore time on the non -recurring Medical adjustments. ", "original_text": "A couple of quick ones. ", "page_label": "16", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "e9a4d1e45227276f4ff3388b434ef7b56e124dccdb469286c8d6ceb8a7d95940", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "64dc31a6-6d0f-472d-9ce8-754c469b53f4", "node_type": "1", "metadata": {"window": "Thanks for the questions.  A couple of quick ones.  On \nCOVID vaccine commercial channel, I think last quarter, you kind of indicated or implied that the \ncontribution was around $25 million.  I was hoping you could update us on what the performance was \nthis quarter and whether you factor anything in for the balance of the year?  And then just to try one \nmore time on the non -recurring Medical adjustments.  Can you just tell us on the $20 million , like what ", "original_text": "I was hoping you could update us on what the performance was \nthis quarter and whether you factor anything in for the balance of the year? "}, "hash": "d8d852186d582b74bf230a75c075658a7d7206b43b91d39ed25b50953696a5ae", "class_name": "RelatedNodeInfo"}}, "text": "On \nCOVID vaccine commercial channel, I think last quarter, you kind of indicated or implied that the \ncontribution was around $25 million. ", "start_char_idx": 3064, "end_char_idx": 3204, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "64dc31a6-6d0f-472d-9ce8-754c469b53f4": {"__data__": {"id_": "64dc31a6-6d0f-472d-9ce8-754c469b53f4", "embedding": null, "metadata": {"window": "Thanks for the questions.  A couple of quick ones.  On \nCOVID vaccine commercial channel, I think last quarter, you kind of indicated or implied that the \ncontribution was around $25 million.  I was hoping you could update us on what the performance was \nthis quarter and whether you factor anything in for the balance of the year?  And then just to try one \nmore time on the non -recurring Medical adjustments.  Can you just tell us on the $20 million , like what ", "original_text": "I was hoping you could update us on what the performance was \nthis quarter and whether you factor anything in for the balance of the year? ", "page_label": "16", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "6d5ec7f6-bdd6-41b2-9b56-d1f2960aaef4", "node_type": "4", "metadata": {"page_label": "16", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "b0205224430b7dfc9e84da67be2109c44a567f4dad70817a17b38328d6416b9b", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "d434d266-6de5-44d3-869d-e213e6694d75", "node_type": "1", "metadata": {"window": "Hi, good morning.  Thanks for the questions.  A couple of quick ones.  On \nCOVID vaccine commercial channel, I think last quarter, you kind of indicated or implied that the \ncontribution was around $25 million.  I was hoping you could update us on what the performance was \nthis quarter and whether you factor anything in for the balance of the year?  And then just to try one \nmore time on the non -recurring Medical adjustments.  Can you just tell us on the $20 million , like what ", "original_text": "On \nCOVID vaccine commercial channel, I think last quarter, you kind of indicated or implied that the \ncontribution was around $25 million. ", "page_label": "16", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "9f354db69bde5d02ff44f30f7f0ba99c41f2e5b5ef6ea3ca462be34967777aee", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "11dfc159-cd50-49ee-b47e-84d816a98128", "node_type": "1", "metadata": {"window": "A couple of quick ones.  On \nCOVID vaccine commercial channel, I think last quarter, you kind of indicated or implied that the \ncontribution was around $25 million.  I was hoping you could update us on what the performance was \nthis quarter and whether you factor anything in for the balance of the year?  And then just to try one \nmore time on the non -recurring Medical adjustments.  Can you just tell us on the $20 million , like what ", "original_text": "And then just to try one \nmore time on the non -recurring Medical adjustments. "}, "hash": "5166c7c893f0b67236ff3c6dc43752b1d147c445405031c8d45b72c1466e4832", "class_name": "RelatedNodeInfo"}}, "text": "I was hoping you could update us on what the performance was \nthis quarter and whether you factor anything in for the balance of the year? ", "start_char_idx": 3204, "end_char_idx": 3343, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "11dfc159-cd50-49ee-b47e-84d816a98128": {"__data__": {"id_": "11dfc159-cd50-49ee-b47e-84d816a98128", "embedding": null, "metadata": {"window": "A couple of quick ones.  On \nCOVID vaccine commercial channel, I think last quarter, you kind of indicated or implied that the \ncontribution was around $25 million.  I was hoping you could update us on what the performance was \nthis quarter and whether you factor anything in for the balance of the year?  And then just to try one \nmore time on the non -recurring Medical adjustments.  Can you just tell us on the $20 million , like what ", "original_text": "And then just to try one \nmore time on the non -recurring Medical adjustments. ", "page_label": "16", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "6d5ec7f6-bdd6-41b2-9b56-d1f2960aaef4", "node_type": "4", "metadata": {"page_label": "16", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "b0205224430b7dfc9e84da67be2109c44a567f4dad70817a17b38328d6416b9b", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "64dc31a6-6d0f-472d-9ce8-754c469b53f4", "node_type": "1", "metadata": {"window": "Thanks for the questions.  A couple of quick ones.  On \nCOVID vaccine commercial channel, I think last quarter, you kind of indicated or implied that the \ncontribution was around $25 million.  I was hoping you could update us on what the performance was \nthis quarter and whether you factor anything in for the balance of the year?  And then just to try one \nmore time on the non -recurring Medical adjustments.  Can you just tell us on the $20 million , like what ", "original_text": "I was hoping you could update us on what the performance was \nthis quarter and whether you factor anything in for the balance of the year? ", "page_label": "16", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "81a3484f0689d6f6aee6b437931bfbe6b55eea8be3bb08cf76392113d7df98eb", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "0205b7fa-c0df-462b-9137-39a9c11521da", "node_type": "1", "metadata": {"window": "On \nCOVID vaccine commercial channel, I think last quarter, you kind of indicated or implied that the \ncontribution was around $25 million.  I was hoping you could update us on what the performance was \nthis quarter and whether you factor anything in for the balance of the year?  And then just to try one \nmore time on the non -recurring Medical adjustments.  Can you just tell us on the $20 million , like what ", "original_text": "Can you just tell us on the $20 million , like what "}, "hash": "e21c5ba67301fa531c744e232ebbda359ca73319e9fd1d1388ec4624bf5638f2", "class_name": "RelatedNodeInfo"}}, "text": "And then just to try one \nmore time on the non -recurring Medical adjustments. ", "start_char_idx": 3343, "end_char_idx": 3422, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "0205b7fa-c0df-462b-9137-39a9c11521da": {"__data__": {"id_": "0205b7fa-c0df-462b-9137-39a9c11521da", "embedding": null, "metadata": {"window": "On \nCOVID vaccine commercial channel, I think last quarter, you kind of indicated or implied that the \ncontribution was around $25 million.  I was hoping you could update us on what the performance was \nthis quarter and whether you factor anything in for the balance of the year?  And then just to try one \nmore time on the non -recurring Medical adjustments.  Can you just tell us on the $20 million , like what ", "original_text": "Can you just tell us on the $20 million , like what ", "page_label": "16", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "6d5ec7f6-bdd6-41b2-9b56-d1f2960aaef4", "node_type": "4", "metadata": {"page_label": "16", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "b0205224430b7dfc9e84da67be2109c44a567f4dad70817a17b38328d6416b9b", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "11dfc159-cd50-49ee-b47e-84d816a98128", "node_type": "1", "metadata": {"window": "A couple of quick ones.  On \nCOVID vaccine commercial channel, I think last quarter, you kind of indicated or implied that the \ncontribution was around $25 million.  I was hoping you could update us on what the performance was \nthis quarter and whether you factor anything in for the balance of the year?  And then just to try one \nmore time on the non -recurring Medical adjustments.  Can you just tell us on the $20 million , like what ", "original_text": "And then just to try one \nmore time on the non -recurring Medical adjustments. ", "page_label": "16", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "8736fb7ae396b416ba80365ed9303b14320293dfc6cf82aeccc59f2a39824a2e", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "6956d2b9-4838-4559-a7a2-1fee8635ef82", "node_type": "1", "metadata": {"window": " \nPage 17 of 19 \n \ndoes that actually represent in terms of the underlying accounting and our business activity.  Thank \nyou. \n \n Jason Hollar:  Yes.  So, for the vaccines, let me  just kind of walk through the last couple of quarters, \nand that will give you a flavor of the benefits and the trends and such. ", "original_text": " \nPage 17 of 19 \n \ndoes that actually represent in terms of the underlying accounting and our business activity. "}, "hash": "dbbae39292cb372186b48e5f3b8cb48095dda808036ba15d94071cb0eed8fe22", "class_name": "RelatedNodeInfo"}}, "text": "Can you just tell us on the $20 million , like what ", "start_char_idx": 3422, "end_char_idx": 3474, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "6956d2b9-4838-4559-a7a2-1fee8635ef82": {"__data__": {"id_": "6956d2b9-4838-4559-a7a2-1fee8635ef82", "embedding": null, "metadata": {"window": " \nPage 17 of 19 \n \ndoes that actually represent in terms of the underlying accounting and our business activity.  Thank \nyou. \n \n Jason Hollar:  Yes.  So, for the vaccines, let me  just kind of walk through the last couple of quarters, \nand that will give you a flavor of the benefits and the trends and such. ", "original_text": " \nPage 17 of 19 \n \ndoes that actually represent in terms of the underlying accounting and our business activity. ", "page_label": "17", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "0d51f961-2630-4f26-b63f-20378f90e37c", "node_type": "4", "metadata": {"page_label": "17", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "d4da2bed8eff879df87258e89f1a6ffb2fba7017447c2029bdfc31ee753c79f9", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "0205b7fa-c0df-462b-9137-39a9c11521da", "node_type": "1", "metadata": {"window": "On \nCOVID vaccine commercial channel, I think last quarter, you kind of indicated or implied that the \ncontribution was around $25 million.  I was hoping you could update us on what the performance was \nthis quarter and whether you factor anything in for the balance of the year?  And then just to try one \nmore time on the non -recurring Medical adjustments.  Can you just tell us on the $20 million , like what ", "original_text": "Can you just tell us on the $20 million , like what ", "page_label": "16", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "7d1615347920d7fb9936cc844ce72e86a41b2f39cf91eff98df8ad97775ff00a", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "8b8ff68d-b80a-4a3e-8be3-771c67db055e", "node_type": "1", "metadata": {"window": " \nPage 17 of 19 \n \ndoes that actually represent in terms of the underlying accounting and our business activity.  Thank \nyou. \n \n Jason Hollar:  Yes.  So, for the vaccines, let me  just kind of walk through the last couple of quarters, \nand that will give you a flavor of the benefits and the trends and such.  When we talked last quarter, \nwe've highlighted in Q1, with the FDA approval at the beginning of September, we were staged to hit \nthe ground running, and we had fairly significant volume in that first quarter. ", "original_text": "Thank \nyou. \n \n"}, "hash": "c86c6fd383e1965205df2b53cbcbd803dc17f40aa7fb440968888f5694eb4fae", "class_name": "RelatedNodeInfo"}}, "text": " \nPage 17 of 19 \n \ndoes that actually represent in terms of the underlying accounting and our business activity. ", "start_char_idx": 0, "end_char_idx": 113, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "8b8ff68d-b80a-4a3e-8be3-771c67db055e": {"__data__": {"id_": "8b8ff68d-b80a-4a3e-8be3-771c67db055e", "embedding": null, "metadata": {"window": " \nPage 17 of 19 \n \ndoes that actually represent in terms of the underlying accounting and our business activity.  Thank \nyou. \n \n Jason Hollar:  Yes.  So, for the vaccines, let me  just kind of walk through the last couple of quarters, \nand that will give you a flavor of the benefits and the trends and such.  When we talked last quarter, \nwe've highlighted in Q1, with the FDA approval at the beginning of September, we were staged to hit \nthe ground running, and we had fairly significant volume in that first quarter. ", "original_text": "Thank \nyou. \n \n", "page_label": "17", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "0d51f961-2630-4f26-b63f-20378f90e37c", "node_type": "4", "metadata": {"page_label": "17", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "d4da2bed8eff879df87258e89f1a6ffb2fba7017447c2029bdfc31ee753c79f9", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "6956d2b9-4838-4559-a7a2-1fee8635ef82", "node_type": "1", "metadata": {"window": " \nPage 17 of 19 \n \ndoes that actually represent in terms of the underlying accounting and our business activity.  Thank \nyou. \n \n Jason Hollar:  Yes.  So, for the vaccines, let me  just kind of walk through the last couple of quarters, \nand that will give you a flavor of the benefits and the trends and such. ", "original_text": " \nPage 17 of 19 \n \ndoes that actually represent in terms of the underlying accounting and our business activity. ", "page_label": "17", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "97c33e4c92f51e5893b57b2d6b2a384cef9b27e4ad137767cb138f5aee535331", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "678fdc7f-8185-4c8f-9573-4d3c150b20da", "node_type": "1", "metadata": {"window": " \nPage 17 of 19 \n \ndoes that actually represent in terms of the underlying accounting and our business activity.  Thank \nyou. \n \n Jason Hollar:  Yes.  So, for the vaccines, let me  just kind of walk through the last couple of quarters, \nand that will give you a flavor of the benefits and the trends and such.  When we talked last quarter, \nwe've highlighted in Q1, with the FDA approval at the beginning of September, we were staged to hit \nthe ground running, and we had fairly significant volume in that first quarter.  But as anticipated, we \nindicated at that point t hat we would expect it to peak within Q2. ", "original_text": "Jason Hollar:  Yes. "}, "hash": "85f8dfde789ab5875af0ffd0ff620cd44df6589cc46b6d6949ea125ccb5d0983", "class_name": "RelatedNodeInfo"}}, "text": "Thank \nyou. \n \n", "start_char_idx": 113, "end_char_idx": 128, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "678fdc7f-8185-4c8f-9573-4d3c150b20da": {"__data__": {"id_": "678fdc7f-8185-4c8f-9573-4d3c150b20da", "embedding": null, "metadata": {"window": " \nPage 17 of 19 \n \ndoes that actually represent in terms of the underlying accounting and our business activity.  Thank \nyou. \n \n Jason Hollar:  Yes.  So, for the vaccines, let me  just kind of walk through the last couple of quarters, \nand that will give you a flavor of the benefits and the trends and such.  When we talked last quarter, \nwe've highlighted in Q1, with the FDA approval at the beginning of September, we were staged to hit \nthe ground running, and we had fairly significant volume in that first quarter.  But as anticipated, we \nindicated at that point t hat we would expect it to peak within Q2. ", "original_text": "Jason Hollar:  Yes. ", "page_label": "17", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "0d51f961-2630-4f26-b63f-20378f90e37c", "node_type": "4", "metadata": {"page_label": "17", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "d4da2bed8eff879df87258e89f1a6ffb2fba7017447c2029bdfc31ee753c79f9", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "8b8ff68d-b80a-4a3e-8be3-771c67db055e", "node_type": "1", "metadata": {"window": " \nPage 17 of 19 \n \ndoes that actually represent in terms of the underlying accounting and our business activity.  Thank \nyou. \n \n Jason Hollar:  Yes.  So, for the vaccines, let me  just kind of walk through the last couple of quarters, \nand that will give you a flavor of the benefits and the trends and such.  When we talked last quarter, \nwe've highlighted in Q1, with the FDA approval at the beginning of September, we were staged to hit \nthe ground running, and we had fairly significant volume in that first quarter. ", "original_text": "Thank \nyou. \n \n", "page_label": "17", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "263d970de3619497e63455b7e53c78a3e4ee5ddfd6443ed2f9377a88a3604d74", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "2131668c-e803-4490-bd4b-a661ad485016", "node_type": "1", "metadata": {"window": " \nPage 17 of 19 \n \ndoes that actually represent in terms of the underlying accounting and our business activity.  Thank \nyou. \n \n Jason Hollar:  Yes.  So, for the vaccines, let me  just kind of walk through the last couple of quarters, \nand that will give you a flavor of the benefits and the trends and such.  When we talked last quarter, \nwe've highlighted in Q1, with the FDA approval at the beginning of September, we were staged to hit \nthe ground running, and we had fairly significant volume in that first quarter.  But as anticipated, we \nindicated at that point t hat we would expect it to peak within Q2.  And so, we expected higher volume, \nhigher contribution in Q2 versus Q1. ", "original_text": "So, for the vaccines, let me  just kind of walk through the last couple of quarters, \nand that will give you a flavor of the benefits and the trends and such. "}, "hash": "c75a2a1cb9769351033e05f800a04a60e3cb0d1e28bb186a0d06c169d753702d", "class_name": "RelatedNodeInfo"}}, "text": "Jason Hollar:  Yes. ", "start_char_idx": 128, "end_char_idx": 148, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "2131668c-e803-4490-bd4b-a661ad485016": {"__data__": {"id_": "2131668c-e803-4490-bd4b-a661ad485016", "embedding": null, "metadata": {"window": " \nPage 17 of 19 \n \ndoes that actually represent in terms of the underlying accounting and our business activity.  Thank \nyou. \n \n Jason Hollar:  Yes.  So, for the vaccines, let me  just kind of walk through the last couple of quarters, \nand that will give you a flavor of the benefits and the trends and such.  When we talked last quarter, \nwe've highlighted in Q1, with the FDA approval at the beginning of September, we were staged to hit \nthe ground running, and we had fairly significant volume in that first quarter.  But as anticipated, we \nindicated at that point t hat we would expect it to peak within Q2.  And so, we expected higher volume, \nhigher contribution in Q2 versus Q1. ", "original_text": "So, for the vaccines, let me  just kind of walk through the last couple of quarters, \nand that will give you a flavor of the benefits and the trends and such. ", "page_label": "17", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "0d51f961-2630-4f26-b63f-20378f90e37c", "node_type": "4", "metadata": {"page_label": "17", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "d4da2bed8eff879df87258e89f1a6ffb2fba7017447c2029bdfc31ee753c79f9", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "678fdc7f-8185-4c8f-9573-4d3c150b20da", "node_type": "1", "metadata": {"window": " \nPage 17 of 19 \n \ndoes that actually represent in terms of the underlying accounting and our business activity.  Thank \nyou. \n \n Jason Hollar:  Yes.  So, for the vaccines, let me  just kind of walk through the last couple of quarters, \nand that will give you a flavor of the benefits and the trends and such.  When we talked last quarter, \nwe've highlighted in Q1, with the FDA approval at the beginning of September, we were staged to hit \nthe ground running, and we had fairly significant volume in that first quarter.  But as anticipated, we \nindicated at that point t hat we would expect it to peak within Q2. ", "original_text": "Jason Hollar:  Yes. ", "page_label": "17", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "0d7d8d5186cb5c836ee143faefa006661f9845845c61620c349b903e58cc0229", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "8df6e9a1-eb18-48b3-8cee-86797c1e7349", "node_type": "1", "metadata": {"window": "Thank \nyou. \n \n Jason Hollar:  Yes.  So, for the vaccines, let me  just kind of walk through the last couple of quarters, \nand that will give you a flavor of the benefits and the trends and such.  When we talked last quarter, \nwe've highlighted in Q1, with the FDA approval at the beginning of September, we were staged to hit \nthe ground running, and we had fairly significant volume in that first quarter.  But as anticipated, we \nindicated at that point t hat we would expect it to peak within Q2.  And so, we expected higher volume, \nhigher contribution in Q2 versus Q1.  And that was because we saw October as the largest month \nwithin that season.  ", "original_text": "When we talked last quarter, \nwe've highlighted in Q1, with the FDA approval at the beginning of September, we were staged to hit \nthe ground running, and we had fairly significant volume in that first quarter. "}, "hash": "347036c49cdbe31cc28ef3103ebefcc82a106f0fc785b74751263098419fe52f", "class_name": "RelatedNodeInfo"}}, "text": "So, for the vaccines, let me  just kind of walk through the last couple of quarters, \nand that will give you a flavor of the benefits and the trends and such. ", "start_char_idx": 148, "end_char_idx": 307, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "8df6e9a1-eb18-48b3-8cee-86797c1e7349": {"__data__": {"id_": "8df6e9a1-eb18-48b3-8cee-86797c1e7349", "embedding": null, "metadata": {"window": "Thank \nyou. \n \n Jason Hollar:  Yes.  So, for the vaccines, let me  just kind of walk through the last couple of quarters, \nand that will give you a flavor of the benefits and the trends and such.  When we talked last quarter, \nwe've highlighted in Q1, with the FDA approval at the beginning of September, we were staged to hit \nthe ground running, and we had fairly significant volume in that first quarter.  But as anticipated, we \nindicated at that point t hat we would expect it to peak within Q2.  And so, we expected higher volume, \nhigher contribution in Q2 versus Q1.  And that was because we saw October as the largest month \nwithin that season.  ", "original_text": "When we talked last quarter, \nwe've highlighted in Q1, with the FDA approval at the beginning of September, we were staged to hit \nthe ground running, and we had fairly significant volume in that first quarter. ", "page_label": "17", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "0d51f961-2630-4f26-b63f-20378f90e37c", "node_type": "4", "metadata": {"page_label": "17", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "d4da2bed8eff879df87258e89f1a6ffb2fba7017447c2029bdfc31ee753c79f9", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "2131668c-e803-4490-bd4b-a661ad485016", "node_type": "1", "metadata": {"window": " \nPage 17 of 19 \n \ndoes that actually represent in terms of the underlying accounting and our business activity.  Thank \nyou. \n \n Jason Hollar:  Yes.  So, for the vaccines, let me  just kind of walk through the last couple of quarters, \nand that will give you a flavor of the benefits and the trends and such.  When we talked last quarter, \nwe've highlighted in Q1, with the FDA approval at the beginning of September, we were staged to hit \nthe ground running, and we had fairly significant volume in that first quarter.  But as anticipated, we \nindicated at that point t hat we would expect it to peak within Q2.  And so, we expected higher volume, \nhigher contribution in Q2 versus Q1. ", "original_text": "So, for the vaccines, let me  just kind of walk through the last couple of quarters, \nand that will give you a flavor of the benefits and the trends and such. ", "page_label": "17", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "84049843c625c1c9f4941e74dc92699538aebf05690c0d37318148263eaedd7c", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "0fc3ade2-4d5b-4668-94a8-b6a4484d5dc4", "node_type": "1", "metadata": {"window": "Jason Hollar:  Yes.  So, for the vaccines, let me  just kind of walk through the last couple of quarters, \nand that will give you a flavor of the benefits and the trends and such.  When we talked last quarter, \nwe've highlighted in Q1, with the FDA approval at the beginning of September, we were staged to hit \nthe ground running, and we had fairly significant volume in that first quarter.  But as anticipated, we \nindicated at that point t hat we would expect it to peak within Q2.  And so, we expected higher volume, \nhigher contribution in Q2 versus Q1.  And that was because we saw October as the largest month \nwithin that season.   And then as expected, we saw that wind down over the course of November and \nDecember . ", "original_text": "But as anticipated, we \nindicated at that point t hat we would expect it to peak within Q2. "}, "hash": "bcec98e77c67d578952f99a44abc89ba770278182e5bddd27809018cf9018bc0", "class_name": "RelatedNodeInfo"}}, "text": "When we talked last quarter, \nwe've highlighted in Q1, with the FDA approval at the beginning of September, we were staged to hit \nthe ground running, and we had fairly significant volume in that first quarter. ", "start_char_idx": 307, "end_char_idx": 518, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "0fc3ade2-4d5b-4668-94a8-b6a4484d5dc4": {"__data__": {"id_": "0fc3ade2-4d5b-4668-94a8-b6a4484d5dc4", "embedding": null, "metadata": {"window": "Jason Hollar:  Yes.  So, for the vaccines, let me  just kind of walk through the last couple of quarters, \nand that will give you a flavor of the benefits and the trends and such.  When we talked last quarter, \nwe've highlighted in Q1, with the FDA approval at the beginning of September, we were staged to hit \nthe ground running, and we had fairly significant volume in that first quarter.  But as anticipated, we \nindicated at that point t hat we would expect it to peak within Q2.  And so, we expected higher volume, \nhigher contribution in Q2 versus Q1.  And that was because we saw October as the largest month \nwithin that season.   And then as expected, we saw that wind down over the course of November and \nDecember . ", "original_text": "But as anticipated, we \nindicated at that point t hat we would expect it to peak within Q2. ", "page_label": "17", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "0d51f961-2630-4f26-b63f-20378f90e37c", "node_type": "4", "metadata": {"page_label": "17", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "d4da2bed8eff879df87258e89f1a6ffb2fba7017447c2029bdfc31ee753c79f9", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "8df6e9a1-eb18-48b3-8cee-86797c1e7349", "node_type": "1", "metadata": {"window": "Thank \nyou. \n \n Jason Hollar:  Yes.  So, for the vaccines, let me  just kind of walk through the last couple of quarters, \nand that will give you a flavor of the benefits and the trends and such.  When we talked last quarter, \nwe've highlighted in Q1, with the FDA approval at the beginning of September, we were staged to hit \nthe ground running, and we had fairly significant volume in that first quarter.  But as anticipated, we \nindicated at that point t hat we would expect it to peak within Q2.  And so, we expected higher volume, \nhigher contribution in Q2 versus Q1.  And that was because we saw October as the largest month \nwithin that season.  ", "original_text": "When we talked last quarter, \nwe've highlighted in Q1, with the FDA approval at the beginning of September, we were staged to hit \nthe ground running, and we had fairly significant volume in that first quarter. ", "page_label": "17", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "9cfd32166f0f882496d999523b9bea8bda3dccc6f83261a9374330310df250e7", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "a53d491a-ca38-496c-91dd-c2efaca5039c", "node_type": "1", "metadata": {"window": "So, for the vaccines, let me  just kind of walk through the last couple of quarters, \nand that will give you a flavor of the benefits and the trends and such.  When we talked last quarter, \nwe've highlighted in Q1, with the FDA approval at the beginning of September, we were staged to hit \nthe ground running, and we had fairly significant volume in that first quarter.  But as anticipated, we \nindicated at that point t hat we would expect it to peak within Q2.  And so, we expected higher volume, \nhigher contribution in Q2 versus Q1.  And that was because we saw October as the largest month \nwithin that season.   And then as expected, we saw that wind down over the course of November and \nDecember .  Still seeing some level of volume in Q3, but I would expect it to be quite insignificant \ncompared to what we saw in Q1 and then Q2.  \n \n", "original_text": "And so, we expected higher volume, \nhigher contribution in Q2 versus Q1. "}, "hash": "042b8c7dc122e18bf88352149a11ac8229c0656949f56de53fa9f245ba02e0a2", "class_name": "RelatedNodeInfo"}}, "text": "But as anticipated, we \nindicated at that point t hat we would expect it to peak within Q2. ", "start_char_idx": 518, "end_char_idx": 610, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "a53d491a-ca38-496c-91dd-c2efaca5039c": {"__data__": {"id_": "a53d491a-ca38-496c-91dd-c2efaca5039c", "embedding": null, "metadata": {"window": "So, for the vaccines, let me  just kind of walk through the last couple of quarters, \nand that will give you a flavor of the benefits and the trends and such.  When we talked last quarter, \nwe've highlighted in Q1, with the FDA approval at the beginning of September, we were staged to hit \nthe ground running, and we had fairly significant volume in that first quarter.  But as anticipated, we \nindicated at that point t hat we would expect it to peak within Q2.  And so, we expected higher volume, \nhigher contribution in Q2 versus Q1.  And that was because we saw October as the largest month \nwithin that season.   And then as expected, we saw that wind down over the course of November and \nDecember .  Still seeing some level of volume in Q3, but I would expect it to be quite insignificant \ncompared to what we saw in Q1 and then Q2.  \n \n", "original_text": "And so, we expected higher volume, \nhigher contribution in Q2 versus Q1. ", "page_label": "17", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "0d51f961-2630-4f26-b63f-20378f90e37c", "node_type": "4", "metadata": {"page_label": "17", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "d4da2bed8eff879df87258e89f1a6ffb2fba7017447c2029bdfc31ee753c79f9", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "0fc3ade2-4d5b-4668-94a8-b6a4484d5dc4", "node_type": "1", "metadata": {"window": "Jason Hollar:  Yes.  So, for the vaccines, let me  just kind of walk through the last couple of quarters, \nand that will give you a flavor of the benefits and the trends and such.  When we talked last quarter, \nwe've highlighted in Q1, with the FDA approval at the beginning of September, we were staged to hit \nthe ground running, and we had fairly significant volume in that first quarter.  But as anticipated, we \nindicated at that point t hat we would expect it to peak within Q2.  And so, we expected higher volume, \nhigher contribution in Q2 versus Q1.  And that was because we saw October as the largest month \nwithin that season.   And then as expected, we saw that wind down over the course of November and \nDecember . ", "original_text": "But as anticipated, we \nindicated at that point t hat we would expect it to peak within Q2. ", "page_label": "17", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "ec23538651c7f7d7e2bffd80073e086e58939692a7509644ce3de8aaaeeba8aa", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "d69e54a2-d7db-4330-9f87-fbcb39c98b8f", "node_type": "1", "metadata": {"window": "When we talked last quarter, \nwe've highlighted in Q1, with the FDA approval at the beginning of September, we were staged to hit \nthe ground running, and we had fairly significant volume in that first quarter.  But as anticipated, we \nindicated at that point t hat we would expect it to peak within Q2.  And so, we expected higher volume, \nhigher contribution in Q2 versus Q1.  And that was because we saw October as the largest month \nwithin that season.   And then as expected, we saw that wind down over the course of November and \nDecember .  Still seeing some level of volume in Q3, but I would expect it to be quite insignificant \ncompared to what we saw in Q1 and then Q2.  \n \n Overall, I think the key message is that this is consistent with our expectations. ", "original_text": "And that was because we saw October as the largest month \nwithin that season.  "}, "hash": "223a9fd9a067a8fe46fe96a09d970df266cbb80f0274b94752f4fd840b8c55ae", "class_name": "RelatedNodeInfo"}}, "text": "And so, we expected higher volume, \nhigher contribution in Q2 versus Q1. ", "start_char_idx": 610, "end_char_idx": 683, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "d69e54a2-d7db-4330-9f87-fbcb39c98b8f": {"__data__": {"id_": "d69e54a2-d7db-4330-9f87-fbcb39c98b8f", "embedding": null, "metadata": {"window": "When we talked last quarter, \nwe've highlighted in Q1, with the FDA approval at the beginning of September, we were staged to hit \nthe ground running, and we had fairly significant volume in that first quarter.  But as anticipated, we \nindicated at that point t hat we would expect it to peak within Q2.  And so, we expected higher volume, \nhigher contribution in Q2 versus Q1.  And that was because we saw October as the largest month \nwithin that season.   And then as expected, we saw that wind down over the course of November and \nDecember .  Still seeing some level of volume in Q3, but I would expect it to be quite insignificant \ncompared to what we saw in Q1 and then Q2.  \n \n Overall, I think the key message is that this is consistent with our expectations. ", "original_text": "And that was because we saw October as the largest month \nwithin that season.  ", "page_label": "17", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "0d51f961-2630-4f26-b63f-20378f90e37c", "node_type": "4", "metadata": {"page_label": "17", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "d4da2bed8eff879df87258e89f1a6ffb2fba7017447c2029bdfc31ee753c79f9", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "a53d491a-ca38-496c-91dd-c2efaca5039c", "node_type": "1", "metadata": {"window": "So, for the vaccines, let me  just kind of walk through the last couple of quarters, \nand that will give you a flavor of the benefits and the trends and such.  When we talked last quarter, \nwe've highlighted in Q1, with the FDA approval at the beginning of September, we were staged to hit \nthe ground running, and we had fairly significant volume in that first quarter.  But as anticipated, we \nindicated at that point t hat we would expect it to peak within Q2.  And so, we expected higher volume, \nhigher contribution in Q2 versus Q1.  And that was because we saw October as the largest month \nwithin that season.   And then as expected, we saw that wind down over the course of November and \nDecember .  Still seeing some level of volume in Q3, but I would expect it to be quite insignificant \ncompared to what we saw in Q1 and then Q2.  \n \n", "original_text": "And so, we expected higher volume, \nhigher contribution in Q2 versus Q1. ", "page_label": "17", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "6eed8b5ad9ea796c730cf11a5af4cd0a55ea2ba80cc45a8b96fd12d91b2aba90", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "f9ea1971-7c70-4470-b5e7-e5488bd80f02", "node_type": "1", "metadata": {"window": "But as anticipated, we \nindicated at that point t hat we would expect it to peak within Q2.  And so, we expected higher volume, \nhigher contribution in Q2 versus Q1.  And that was because we saw October as the largest month \nwithin that season.   And then as expected, we saw that wind down over the course of November and \nDecember .  Still seeing some level of volume in Q3, but I would expect it to be quite insignificant \ncompared to what we saw in Q1 and then Q2.  \n \n Overall, I think the key message is that this is consistent with our expectations.  As Aaron highlighted \nin his comments already, we had multiple drivers of growth for the Pharma segment in the second \nquarter. ", "original_text": "And then as expected, we saw that wind down over the course of November and \nDecember . "}, "hash": "b1f37d08a19aff0742b8a8a4e7050d5e4f1b37b384711db180a82d8a5dceeecc", "class_name": "RelatedNodeInfo"}}, "text": "And that was because we saw October as the largest month \nwithin that season.  ", "start_char_idx": 683, "end_char_idx": 762, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "f9ea1971-7c70-4470-b5e7-e5488bd80f02": {"__data__": {"id_": "f9ea1971-7c70-4470-b5e7-e5488bd80f02", "embedding": null, "metadata": {"window": "But as anticipated, we \nindicated at that point t hat we would expect it to peak within Q2.  And so, we expected higher volume, \nhigher contribution in Q2 versus Q1.  And that was because we saw October as the largest month \nwithin that season.   And then as expected, we saw that wind down over the course of November and \nDecember .  Still seeing some level of volume in Q3, but I would expect it to be quite insignificant \ncompared to what we saw in Q1 and then Q2.  \n \n Overall, I think the key message is that this is consistent with our expectations.  As Aaron highlighted \nin his comments already, we had multiple drivers of growth for the Pharma segment in the second \nquarter. ", "original_text": "And then as expected, we saw that wind down over the course of November and \nDecember . ", "page_label": "17", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "0d51f961-2630-4f26-b63f-20378f90e37c", "node_type": "4", "metadata": {"page_label": "17", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "d4da2bed8eff879df87258e89f1a6ffb2fba7017447c2029bdfc31ee753c79f9", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "d69e54a2-d7db-4330-9f87-fbcb39c98b8f", "node_type": "1", "metadata": {"window": "When we talked last quarter, \nwe've highlighted in Q1, with the FDA approval at the beginning of September, we were staged to hit \nthe ground running, and we had fairly significant volume in that first quarter.  But as anticipated, we \nindicated at that point t hat we would expect it to peak within Q2.  And so, we expected higher volume, \nhigher contribution in Q2 versus Q1.  And that was because we saw October as the largest month \nwithin that season.   And then as expected, we saw that wind down over the course of November and \nDecember .  Still seeing some level of volume in Q3, but I would expect it to be quite insignificant \ncompared to what we saw in Q1 and then Q2.  \n \n Overall, I think the key message is that this is consistent with our expectations. ", "original_text": "And that was because we saw October as the largest month \nwithin that season.  ", "page_label": "17", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "ad93b8d8582ca805ca8ec036a4ce96889865396583d315678c8dd1761891de94", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "7d2467da-d112-4a32-9a01-23f14cf8a1fc", "node_type": "1", "metadata": {"window": "And so, we expected higher volume, \nhigher contribution in Q2 versus Q1.  And that was because we saw October as the largest month \nwithin that season.   And then as expected, we saw that wind down over the course of November and \nDecember .  Still seeing some level of volume in Q3, but I would expect it to be quite insignificant \ncompared to what we saw in Q1 and then Q2.  \n \n Overall, I think the key message is that this is consistent with our expectations.  As Aaron highlighted \nin his comments already, we had multiple drivers of growth for the Pharma segment in the second \nquarter.  It was strength with the generics program withi n brand, it was COVID driving that component. \n", "original_text": "Still seeing some level of volume in Q3, but I would expect it to be quite insignificant \ncompared to what we saw in Q1 and then Q2.  \n \n"}, "hash": "e60a14bb6c8e065c700d107ffc4aabd921b90552b7ae6d42994a175ff29c63e7", "class_name": "RelatedNodeInfo"}}, "text": "And then as expected, we saw that wind down over the course of November and \nDecember . ", "start_char_idx": 762, "end_char_idx": 850, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "7d2467da-d112-4a32-9a01-23f14cf8a1fc": {"__data__": {"id_": "7d2467da-d112-4a32-9a01-23f14cf8a1fc", "embedding": null, "metadata": {"window": "And so, we expected higher volume, \nhigher contribution in Q2 versus Q1.  And that was because we saw October as the largest month \nwithin that season.   And then as expected, we saw that wind down over the course of November and \nDecember .  Still seeing some level of volume in Q3, but I would expect it to be quite insignificant \ncompared to what we saw in Q1 and then Q2.  \n \n Overall, I think the key message is that this is consistent with our expectations.  As Aaron highlighted \nin his comments already, we had multiple drivers of growth for the Pharma segment in the second \nquarter.  It was strength with the generics program withi n brand, it was COVID driving that component. \n", "original_text": "Still seeing some level of volume in Q3, but I would expect it to be quite insignificant \ncompared to what we saw in Q1 and then Q2.  \n \n", "page_label": "17", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "0d51f961-2630-4f26-b63f-20378f90e37c", "node_type": "4", "metadata": {"page_label": "17", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "d4da2bed8eff879df87258e89f1a6ffb2fba7017447c2029bdfc31ee753c79f9", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "f9ea1971-7c70-4470-b5e7-e5488bd80f02", "node_type": "1", "metadata": {"window": "But as anticipated, we \nindicated at that point t hat we would expect it to peak within Q2.  And so, we expected higher volume, \nhigher contribution in Q2 versus Q1.  And that was because we saw October as the largest month \nwithin that season.   And then as expected, we saw that wind down over the course of November and \nDecember .  Still seeing some level of volume in Q3, but I would expect it to be quite insignificant \ncompared to what we saw in Q1 and then Q2.  \n \n Overall, I think the key message is that this is consistent with our expectations.  As Aaron highlighted \nin his comments already, we had multiple drivers of growth for the Pharma segment in the second \nquarter. ", "original_text": "And then as expected, we saw that wind down over the course of November and \nDecember . ", "page_label": "17", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "42a8b4fe26dda33135def57da9bd824c69b15dcffcea17f83aaa4ef29828f55a", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "2ec08fa5-29f0-42d9-9080-1d2fb799eaa6", "node_type": "1", "metadata": {"window": "And that was because we saw October as the largest month \nwithin that season.   And then as expected, we saw that wind down over the course of November and \nDecember .  Still seeing some level of volume in Q3, but I would expect it to be quite insignificant \ncompared to what we saw in Q1 and then Q2.  \n \n Overall, I think the key message is that this is consistent with our expectations.  As Aaron highlighted \nin his comments already, we had multiple drivers of growth for the Pharma segment in the second \nquarter.  It was strength with the generics program withi n brand, it was COVID driving that component. \n And then we have these investments and primarily the cost to serve a partial offset to those other two \ndrivers. ", "original_text": "Overall, I think the key message is that this is consistent with our expectations. "}, "hash": "774a3ee9b3db1fbed32bbd110635523528fce7a21fcf047e9fb25577faca4d5f", "class_name": "RelatedNodeInfo"}}, "text": "Still seeing some level of volume in Q3, but I would expect it to be quite insignificant \ncompared to what we saw in Q1 and then Q2.  \n \n", "start_char_idx": 850, "end_char_idx": 987, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "2ec08fa5-29f0-42d9-9080-1d2fb799eaa6": {"__data__": {"id_": "2ec08fa5-29f0-42d9-9080-1d2fb799eaa6", "embedding": null, "metadata": {"window": "And that was because we saw October as the largest month \nwithin that season.   And then as expected, we saw that wind down over the course of November and \nDecember .  Still seeing some level of volume in Q3, but I would expect it to be quite insignificant \ncompared to what we saw in Q1 and then Q2.  \n \n Overall, I think the key message is that this is consistent with our expectations.  As Aaron highlighted \nin his comments already, we had multiple drivers of growth for the Pharma segment in the second \nquarter.  It was strength with the generics program withi n brand, it was COVID driving that component. \n And then we have these investments and primarily the cost to serve a partial offset to those other two \ndrivers. ", "original_text": "Overall, I think the key message is that this is consistent with our expectations. ", "page_label": "17", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "0d51f961-2630-4f26-b63f-20378f90e37c", "node_type": "4", "metadata": {"page_label": "17", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "d4da2bed8eff879df87258e89f1a6ffb2fba7017447c2029bdfc31ee753c79f9", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "7d2467da-d112-4a32-9a01-23f14cf8a1fc", "node_type": "1", "metadata": {"window": "And so, we expected higher volume, \nhigher contribution in Q2 versus Q1.  And that was because we saw October as the largest month \nwithin that season.   And then as expected, we saw that wind down over the course of November and \nDecember .  Still seeing some level of volume in Q3, but I would expect it to be quite insignificant \ncompared to what we saw in Q1 and then Q2.  \n \n Overall, I think the key message is that this is consistent with our expectations.  As Aaron highlighted \nin his comments already, we had multiple drivers of growth for the Pharma segment in the second \nquarter.  It was strength with the generics program withi n brand, it was COVID driving that component. \n", "original_text": "Still seeing some level of volume in Q3, but I would expect it to be quite insignificant \ncompared to what we saw in Q1 and then Q2.  \n \n", "page_label": "17", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "8ed862b0ebb64bf5958aeedc3278344954ba6e69730f0d45b854d69160c40c4c", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "b5d73c51-2c59-4478-899a-346e90c2dfa7", "node_type": "1", "metadata": {"window": "And then as expected, we saw that wind down over the course of November and \nDecember .  Still seeing some level of volume in Q3, but I would expect it to be quite insignificant \ncompared to what we saw in Q1 and then Q2.  \n \n Overall, I think the key message is that this is consistent with our expectations.  As Aaron highlighted \nin his comments already, we had multiple drivers of growth for the Pharma segment in the second \nquarter.  It was strength with the generics program withi n brand, it was COVID driving that component. \n And then we have these investments and primarily the cost to serve a partial offset to those other two \ndrivers.  So overall, feel good about the overall health of the business and the contribution of COVID \nwithin it. ", "original_text": "As Aaron highlighted \nin his comments already, we had multiple drivers of growth for the Pharma segment in the second \nquarter. "}, "hash": "fe92420598d30d83d1274eb4250ff82003dd5647af59f983eeba0e636dde5c76", "class_name": "RelatedNodeInfo"}}, "text": "Overall, I think the key message is that this is consistent with our expectations. ", "start_char_idx": 987, "end_char_idx": 1070, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "b5d73c51-2c59-4478-899a-346e90c2dfa7": {"__data__": {"id_": "b5d73c51-2c59-4478-899a-346e90c2dfa7", "embedding": null, "metadata": {"window": "And then as expected, we saw that wind down over the course of November and \nDecember .  Still seeing some level of volume in Q3, but I would expect it to be quite insignificant \ncompared to what we saw in Q1 and then Q2.  \n \n Overall, I think the key message is that this is consistent with our expectations.  As Aaron highlighted \nin his comments already, we had multiple drivers of growth for the Pharma segment in the second \nquarter.  It was strength with the generics program withi n brand, it was COVID driving that component. \n And then we have these investments and primarily the cost to serve a partial offset to those other two \ndrivers.  So overall, feel good about the overall health of the business and the contribution of COVID \nwithin it. ", "original_text": "As Aaron highlighted \nin his comments already, we had multiple drivers of growth for the Pharma segment in the second \nquarter. ", "page_label": "17", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "0d51f961-2630-4f26-b63f-20378f90e37c", "node_type": "4", "metadata": {"page_label": "17", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "d4da2bed8eff879df87258e89f1a6ffb2fba7017447c2029bdfc31ee753c79f9", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "2ec08fa5-29f0-42d9-9080-1d2fb799eaa6", "node_type": "1", "metadata": {"window": "And that was because we saw October as the largest month \nwithin that season.   And then as expected, we saw that wind down over the course of November and \nDecember .  Still seeing some level of volume in Q3, but I would expect it to be quite insignificant \ncompared to what we saw in Q1 and then Q2.  \n \n Overall, I think the key message is that this is consistent with our expectations.  As Aaron highlighted \nin his comments already, we had multiple drivers of growth for the Pharma segment in the second \nquarter.  It was strength with the generics program withi n brand, it was COVID driving that component. \n And then we have these investments and primarily the cost to serve a partial offset to those other two \ndrivers. ", "original_text": "Overall, I think the key message is that this is consistent with our expectations. ", "page_label": "17", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "555f6726676c168b87e35351414a0212b713386209a8be642eba07cc8e23ef98", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "019a0f8c-4027-49d6-bbd8-df5982e10f6c", "node_type": "1", "metadata": {"window": "Still seeing some level of volume in Q3, but I would expect it to be quite insignificant \ncompared to what we saw in Q1 and then Q2.  \n \n Overall, I think the key message is that this is consistent with our expectations.  As Aaron highlighted \nin his comments already, we had multiple drivers of growth for the Pharma segment in the second \nquarter.  It was strength with the generics program withi n brand, it was COVID driving that component. \n And then we have these investments and primarily the cost to serve a partial offset to those other two \ndrivers.  So overall, feel good about the overall health of the business and the contribution of COVID \nwithin it.  Aaron , any comments from that?  \n \n", "original_text": "It was strength with the generics program withi n brand, it was COVID driving that component. \n"}, "hash": "2bd965f45530f6f9b85d94ad7e2ffefa5d014863e3eff8762a9764ba9abdf0fb", "class_name": "RelatedNodeInfo"}}, "text": "As Aaron highlighted \nin his comments already, we had multiple drivers of growth for the Pharma segment in the second \nquarter. ", "start_char_idx": 1070, "end_char_idx": 1198, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "019a0f8c-4027-49d6-bbd8-df5982e10f6c": {"__data__": {"id_": "019a0f8c-4027-49d6-bbd8-df5982e10f6c", "embedding": null, "metadata": {"window": "Still seeing some level of volume in Q3, but I would expect it to be quite insignificant \ncompared to what we saw in Q1 and then Q2.  \n \n Overall, I think the key message is that this is consistent with our expectations.  As Aaron highlighted \nin his comments already, we had multiple drivers of growth for the Pharma segment in the second \nquarter.  It was strength with the generics program withi n brand, it was COVID driving that component. \n And then we have these investments and primarily the cost to serve a partial offset to those other two \ndrivers.  So overall, feel good about the overall health of the business and the contribution of COVID \nwithin it.  Aaron , any comments from that?  \n \n", "original_text": "It was strength with the generics program withi n brand, it was COVID driving that component. \n", "page_label": "17", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "0d51f961-2630-4f26-b63f-20378f90e37c", "node_type": "4", "metadata": {"page_label": "17", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "d4da2bed8eff879df87258e89f1a6ffb2fba7017447c2029bdfc31ee753c79f9", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "b5d73c51-2c59-4478-899a-346e90c2dfa7", "node_type": "1", "metadata": {"window": "And then as expected, we saw that wind down over the course of November and \nDecember .  Still seeing some level of volume in Q3, but I would expect it to be quite insignificant \ncompared to what we saw in Q1 and then Q2.  \n \n Overall, I think the key message is that this is consistent with our expectations.  As Aaron highlighted \nin his comments already, we had multiple drivers of growth for the Pharma segment in the second \nquarter.  It was strength with the generics program withi n brand, it was COVID driving that component. \n And then we have these investments and primarily the cost to serve a partial offset to those other two \ndrivers.  So overall, feel good about the overall health of the business and the contribution of COVID \nwithin it. ", "original_text": "As Aaron highlighted \nin his comments already, we had multiple drivers of growth for the Pharma segment in the second \nquarter. ", "page_label": "17", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "bc0f226e1168eaae67e693832e93b247f0a97daa901db5661f46b86e7f43dc6a", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "65abbdb0-7509-4798-8524-d99e6dcf1b3c", "node_type": "1", "metadata": {"window": "Overall, I think the key message is that this is consistent with our expectations.  As Aaron highlighted \nin his comments already, we had multiple drivers of growth for the Pharma segment in the second \nquarter.  It was strength with the generics program withi n brand, it was COVID driving that component. \n And then we have these investments and primarily the cost to serve a partial offset to those other two \ndrivers.  So overall, feel good about the overall health of the business and the contribution of COVID \nwithin it.  Aaron , any comments from that?  \n \n Aaron Alt:  With respect to the non -recurring adjustments, we previewed this back at the JPMorgan \nConference when we updated our commentary around the Medical business. ", "original_text": "And then we have these investments and primarily the cost to serve a partial offset to those other two \ndrivers. "}, "hash": "f455b785d08d1509ec1b7353574794859d14e6aa4a896ac6d9d5b3b92aac3e0a", "class_name": "RelatedNodeInfo"}}, "text": "It was strength with the generics program withi n brand, it was COVID driving that component. \n", "start_char_idx": 1198, "end_char_idx": 1293, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "65abbdb0-7509-4798-8524-d99e6dcf1b3c": {"__data__": {"id_": "65abbdb0-7509-4798-8524-d99e6dcf1b3c", "embedding": null, "metadata": {"window": "Overall, I think the key message is that this is consistent with our expectations.  As Aaron highlighted \nin his comments already, we had multiple drivers of growth for the Pharma segment in the second \nquarter.  It was strength with the generics program withi n brand, it was COVID driving that component. \n And then we have these investments and primarily the cost to serve a partial offset to those other two \ndrivers.  So overall, feel good about the overall health of the business and the contribution of COVID \nwithin it.  Aaron , any comments from that?  \n \n Aaron Alt:  With respect to the non -recurring adjustments, we previewed this back at the JPMorgan \nConference when we updated our commentary around the Medical business. ", "original_text": "And then we have these investments and primarily the cost to serve a partial offset to those other two \ndrivers. ", "page_label": "17", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "0d51f961-2630-4f26-b63f-20378f90e37c", "node_type": "4", "metadata": {"page_label": "17", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "d4da2bed8eff879df87258e89f1a6ffb2fba7017447c2029bdfc31ee753c79f9", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "019a0f8c-4027-49d6-bbd8-df5982e10f6c", "node_type": "1", "metadata": {"window": "Still seeing some level of volume in Q3, but I would expect it to be quite insignificant \ncompared to what we saw in Q1 and then Q2.  \n \n Overall, I think the key message is that this is consistent with our expectations.  As Aaron highlighted \nin his comments already, we had multiple drivers of growth for the Pharma segment in the second \nquarter.  It was strength with the generics program withi n brand, it was COVID driving that component. \n And then we have these investments and primarily the cost to serve a partial offset to those other two \ndrivers.  So overall, feel good about the overall health of the business and the contribution of COVID \nwithin it.  Aaron , any comments from that?  \n \n", "original_text": "It was strength with the generics program withi n brand, it was COVID driving that component. \n", "page_label": "17", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "b25f784574e5a1e8fe1f6bb227fca7b82a69586d4a36bcfd7d49648216055371", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "a6f2297f-cb23-41f1-936d-c8b8427e3e2f", "node_type": "1", "metadata": {"window": "As Aaron highlighted \nin his comments already, we had multiple drivers of growth for the Pharma segment in the second \nquarter.  It was strength with the generics program withi n brand, it was COVID driving that component. \n And then we have these investments and primarily the cost to serve a partial offset to those other two \ndrivers.  So overall, feel good about the overall health of the business and the contribution of COVID \nwithin it.  Aaron , any comments from that?  \n \n Aaron Alt:  With respect to the non -recurring adjustments, we previewed this back at the JPMorgan \nConference when we updated our commentary around the Medical business.  And our comment that \nis our comment now, which is as we have continued to dig deep across the portfolio, we've taken a \ndecision to take some nonrecurring adjustments, which , the majority of which hit the at -Home \nbusiness, which now reports or will report as part of Other in Q3 . ", "original_text": "So overall, feel good about the overall health of the business and the contribution of COVID \nwithin it. "}, "hash": "e486cb66787ff86074fa62d4ed4e5dca1f6c4f3aeb786ea35d0f7b85dc2b5a7f", "class_name": "RelatedNodeInfo"}}, "text": "And then we have these investments and primarily the cost to serve a partial offset to those other two \ndrivers. ", "start_char_idx": 1293, "end_char_idx": 1406, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "a6f2297f-cb23-41f1-936d-c8b8427e3e2f": {"__data__": {"id_": "a6f2297f-cb23-41f1-936d-c8b8427e3e2f", "embedding": null, "metadata": {"window": "As Aaron highlighted \nin his comments already, we had multiple drivers of growth for the Pharma segment in the second \nquarter.  It was strength with the generics program withi n brand, it was COVID driving that component. \n And then we have these investments and primarily the cost to serve a partial offset to those other two \ndrivers.  So overall, feel good about the overall health of the business and the contribution of COVID \nwithin it.  Aaron , any comments from that?  \n \n Aaron Alt:  With respect to the non -recurring adjustments, we previewed this back at the JPMorgan \nConference when we updated our commentary around the Medical business.  And our comment that \nis our comment now, which is as we have continued to dig deep across the portfolio, we've taken a \ndecision to take some nonrecurring adjustments, which , the majority of which hit the at -Home \nbusiness, which now reports or will report as part of Other in Q3 . ", "original_text": "So overall, feel good about the overall health of the business and the contribution of COVID \nwithin it. ", "page_label": "17", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "0d51f961-2630-4f26-b63f-20378f90e37c", "node_type": "4", "metadata": {"page_label": "17", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "d4da2bed8eff879df87258e89f1a6ffb2fba7017447c2029bdfc31ee753c79f9", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "65abbdb0-7509-4798-8524-d99e6dcf1b3c", "node_type": "1", "metadata": {"window": "Overall, I think the key message is that this is consistent with our expectations.  As Aaron highlighted \nin his comments already, we had multiple drivers of growth for the Pharma segment in the second \nquarter.  It was strength with the generics program withi n brand, it was COVID driving that component. \n And then we have these investments and primarily the cost to serve a partial offset to those other two \ndrivers.  So overall, feel good about the overall health of the business and the contribution of COVID \nwithin it.  Aaron , any comments from that?  \n \n Aaron Alt:  With respect to the non -recurring adjustments, we previewed this back at the JPMorgan \nConference when we updated our commentary around the Medical business. ", "original_text": "And then we have these investments and primarily the cost to serve a partial offset to those other two \ndrivers. ", "page_label": "17", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "c36650d363a004fe3c78e218b3d66d44fbc0745a0c521ba3765195ec4efdeec3", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "c11849f7-7cab-49c7-ae10-3ce7140a5846", "node_type": "1", "metadata": {"window": "It was strength with the generics program withi n brand, it was COVID driving that component. \n And then we have these investments and primarily the cost to serve a partial offset to those other two \ndrivers.  So overall, feel good about the overall health of the business and the contribution of COVID \nwithin it.  Aaron , any comments from that?  \n \n Aaron Alt:  With respect to the non -recurring adjustments, we previewed this back at the JPMorgan \nConference when we updated our commentary around the Medical business.  And our comment that \nis our comment now, which is as we have continued to dig deep across the portfolio, we've taken a \ndecision to take some nonrecurring adjustments, which , the majority of which hit the at -Home \nbusiness, which now reports or will report as part of Other in Q3 .  As well as component hitting the \nWaveMark business, which is par t of the new GMPD business.  ", "original_text": "Aaron , any comments from that?  \n \n"}, "hash": "f78496b56e6e8065e2be1c371284fa39b3bfc9721b649e6b6a88d6cdf9c3fd29", "class_name": "RelatedNodeInfo"}}, "text": "So overall, feel good about the overall health of the business and the contribution of COVID \nwithin it. ", "start_char_idx": 1406, "end_char_idx": 1511, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "c11849f7-7cab-49c7-ae10-3ce7140a5846": {"__data__": {"id_": "c11849f7-7cab-49c7-ae10-3ce7140a5846", "embedding": null, "metadata": {"window": "It was strength with the generics program withi n brand, it was COVID driving that component. \n And then we have these investments and primarily the cost to serve a partial offset to those other two \ndrivers.  So overall, feel good about the overall health of the business and the contribution of COVID \nwithin it.  Aaron , any comments from that?  \n \n Aaron Alt:  With respect to the non -recurring adjustments, we previewed this back at the JPMorgan \nConference when we updated our commentary around the Medical business.  And our comment that \nis our comment now, which is as we have continued to dig deep across the portfolio, we've taken a \ndecision to take some nonrecurring adjustments, which , the majority of which hit the at -Home \nbusiness, which now reports or will report as part of Other in Q3 .  As well as component hitting the \nWaveMark business, which is par t of the new GMPD business.  ", "original_text": "Aaron , any comments from that?  \n \n", "page_label": "17", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "0d51f961-2630-4f26-b63f-20378f90e37c", "node_type": "4", "metadata": {"page_label": "17", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "d4da2bed8eff879df87258e89f1a6ffb2fba7017447c2029bdfc31ee753c79f9", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "a6f2297f-cb23-41f1-936d-c8b8427e3e2f", "node_type": "1", "metadata": {"window": "As Aaron highlighted \nin his comments already, we had multiple drivers of growth for the Pharma segment in the second \nquarter.  It was strength with the generics program withi n brand, it was COVID driving that component. \n And then we have these investments and primarily the cost to serve a partial offset to those other two \ndrivers.  So overall, feel good about the overall health of the business and the contribution of COVID \nwithin it.  Aaron , any comments from that?  \n \n Aaron Alt:  With respect to the non -recurring adjustments, we previewed this back at the JPMorgan \nConference when we updated our commentary around the Medical business.  And our comment that \nis our comment now, which is as we have continued to dig deep across the portfolio, we've taken a \ndecision to take some nonrecurring adjustments, which , the majority of which hit the at -Home \nbusiness, which now reports or will report as part of Other in Q3 . ", "original_text": "So overall, feel good about the overall health of the business and the contribution of COVID \nwithin it. ", "page_label": "17", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "e4bec623b5e7376453fb33fa8fe5c042e1d77a2bf6bc77a033c9e7ef15918bc1", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "ff75ffb2-8fec-40a9-b880-12d1034fca6b", "node_type": "1", "metadata": {"window": "And then we have these investments and primarily the cost to serve a partial offset to those other two \ndrivers.  So overall, feel good about the overall health of the business and the contribution of COVID \nwithin it.  Aaron , any comments from that?  \n \n Aaron Alt:  With respect to the non -recurring adjustments, we previewed this back at the JPMorgan \nConference when we updated our commentary around the Medical business.  And our comment that \nis our comment now, which is as we have continued to dig deep across the portfolio, we've taken a \ndecision to take some nonrecurring adjustments, which , the majority of which hit the at -Home \nbusiness, which now reports or will report as part of Other in Q3 .  As well as component hitting the \nWaveMark business, which is par t of the new GMPD business.   So, if you read through the update to \nour guidance for the year where we moved from approximately $400 million  to approximately $380 \nmillion driven by the impact of the nonrecurring adjustments, you can reach your own conclusions as \nto the relative quantification and the distribution given those comments. ", "original_text": "Aaron Alt:  With respect to the non -recurring adjustments, we previewed this back at the JPMorgan \nConference when we updated our commentary around the Medical business. "}, "hash": "19031187f19ac0e0333ada9f0823f4f36e7e31a05318225a7ee108ed97ee1aa6", "class_name": "RelatedNodeInfo"}}, "text": "Aaron , any comments from that?  \n \n", "start_char_idx": 1511, "end_char_idx": 1547, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "ff75ffb2-8fec-40a9-b880-12d1034fca6b": {"__data__": {"id_": "ff75ffb2-8fec-40a9-b880-12d1034fca6b", "embedding": null, "metadata": {"window": "And then we have these investments and primarily the cost to serve a partial offset to those other two \ndrivers.  So overall, feel good about the overall health of the business and the contribution of COVID \nwithin it.  Aaron , any comments from that?  \n \n Aaron Alt:  With respect to the non -recurring adjustments, we previewed this back at the JPMorgan \nConference when we updated our commentary around the Medical business.  And our comment that \nis our comment now, which is as we have continued to dig deep across the portfolio, we've taken a \ndecision to take some nonrecurring adjustments, which , the majority of which hit the at -Home \nbusiness, which now reports or will report as part of Other in Q3 .  As well as component hitting the \nWaveMark business, which is par t of the new GMPD business.   So, if you read through the update to \nour guidance for the year where we moved from approximately $400 million  to approximately $380 \nmillion driven by the impact of the nonrecurring adjustments, you can reach your own conclusions as \nto the relative quantification and the distribution given those comments. ", "original_text": "Aaron Alt:  With respect to the non -recurring adjustments, we previewed this back at the JPMorgan \nConference when we updated our commentary around the Medical business. ", "page_label": "17", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "0d51f961-2630-4f26-b63f-20378f90e37c", "node_type": "4", "metadata": {"page_label": "17", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "d4da2bed8eff879df87258e89f1a6ffb2fba7017447c2029bdfc31ee753c79f9", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "c11849f7-7cab-49c7-ae10-3ce7140a5846", "node_type": "1", "metadata": {"window": "It was strength with the generics program withi n brand, it was COVID driving that component. \n And then we have these investments and primarily the cost to serve a partial offset to those other two \ndrivers.  So overall, feel good about the overall health of the business and the contribution of COVID \nwithin it.  Aaron , any comments from that?  \n \n Aaron Alt:  With respect to the non -recurring adjustments, we previewed this back at the JPMorgan \nConference when we updated our commentary around the Medical business.  And our comment that \nis our comment now, which is as we have continued to dig deep across the portfolio, we've taken a \ndecision to take some nonrecurring adjustments, which , the majority of which hit the at -Home \nbusiness, which now reports or will report as part of Other in Q3 .  As well as component hitting the \nWaveMark business, which is par t of the new GMPD business.  ", "original_text": "Aaron , any comments from that?  \n \n", "page_label": "17", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "5c8bbc701d6335bea7f86753841fd8b9997dead1a72cb8e277338f8b51b54071", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "63fc2bb7-dea5-4c7d-a1c1-43098f1b3eb6", "node_type": "1", "metadata": {"window": "So overall, feel good about the overall health of the business and the contribution of COVID \nwithin it.  Aaron , any comments from that?  \n \n Aaron Alt:  With respect to the non -recurring adjustments, we previewed this back at the JPMorgan \nConference when we updated our commentary around the Medical business.  And our comment that \nis our comment now, which is as we have continued to dig deep across the portfolio, we've taken a \ndecision to take some nonrecurring adjustments, which , the majority of which hit the at -Home \nbusiness, which now reports or will report as part of Other in Q3 .  As well as component hitting the \nWaveMark business, which is par t of the new GMPD business.   So, if you read through the update to \nour guidance for the year where we moved from approximately $400 million  to approximately $380 \nmillion driven by the impact of the nonrecurring adjustments, you can reach your own conclusions as \nto the relative quantification and the distribution given those comments.  Thanks.  \n \n", "original_text": "And our comment that \nis our comment now, which is as we have continued to dig deep across the portfolio, we've taken a \ndecision to take some nonrecurring adjustments, which , the majority of which hit the at -Home \nbusiness, which now reports or will report as part of Other in Q3 . "}, "hash": "33aa658c7bc64a479b5e3078291dbd19fca0c7dc7a86dff7b568df1cdb663e92", "class_name": "RelatedNodeInfo"}}, "text": "Aaron Alt:  With respect to the non -recurring adjustments, we previewed this back at the JPMorgan \nConference when we updated our commentary around the Medical business. ", "start_char_idx": 1547, "end_char_idx": 1718, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "63fc2bb7-dea5-4c7d-a1c1-43098f1b3eb6": {"__data__": {"id_": "63fc2bb7-dea5-4c7d-a1c1-43098f1b3eb6", "embedding": null, "metadata": {"window": "So overall, feel good about the overall health of the business and the contribution of COVID \nwithin it.  Aaron , any comments from that?  \n \n Aaron Alt:  With respect to the non -recurring adjustments, we previewed this back at the JPMorgan \nConference when we updated our commentary around the Medical business.  And our comment that \nis our comment now, which is as we have continued to dig deep across the portfolio, we've taken a \ndecision to take some nonrecurring adjustments, which , the majority of which hit the at -Home \nbusiness, which now reports or will report as part of Other in Q3 .  As well as component hitting the \nWaveMark business, which is par t of the new GMPD business.   So, if you read through the update to \nour guidance for the year where we moved from approximately $400 million  to approximately $380 \nmillion driven by the impact of the nonrecurring adjustments, you can reach your own conclusions as \nto the relative quantification and the distribution given those comments.  Thanks.  \n \n", "original_text": "And our comment that \nis our comment now, which is as we have continued to dig deep across the portfolio, we've taken a \ndecision to take some nonrecurring adjustments, which , the majority of which hit the at -Home \nbusiness, which now reports or will report as part of Other in Q3 . ", "page_label": "17", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "0d51f961-2630-4f26-b63f-20378f90e37c", "node_type": "4", "metadata": {"page_label": "17", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "d4da2bed8eff879df87258e89f1a6ffb2fba7017447c2029bdfc31ee753c79f9", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "ff75ffb2-8fec-40a9-b880-12d1034fca6b", "node_type": "1", "metadata": {"window": "And then we have these investments and primarily the cost to serve a partial offset to those other two \ndrivers.  So overall, feel good about the overall health of the business and the contribution of COVID \nwithin it.  Aaron , any comments from that?  \n \n Aaron Alt:  With respect to the non -recurring adjustments, we previewed this back at the JPMorgan \nConference when we updated our commentary around the Medical business.  And our comment that \nis our comment now, which is as we have continued to dig deep across the portfolio, we've taken a \ndecision to take some nonrecurring adjustments, which , the majority of which hit the at -Home \nbusiness, which now reports or will report as part of Other in Q3 .  As well as component hitting the \nWaveMark business, which is par t of the new GMPD business.   So, if you read through the update to \nour guidance for the year where we moved from approximately $400 million  to approximately $380 \nmillion driven by the impact of the nonrecurring adjustments, you can reach your own conclusions as \nto the relative quantification and the distribution given those comments. ", "original_text": "Aaron Alt:  With respect to the non -recurring adjustments, we previewed this back at the JPMorgan \nConference when we updated our commentary around the Medical business. ", "page_label": "17", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "4308aa7c920c815e65157597cb9538631036d1301ddca6110b93f30c481ec2c3", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "80c6ec03-2a40-4124-b02d-cc9ff20bf222", "node_type": "1", "metadata": {"window": "Aaron , any comments from that?  \n \n Aaron Alt:  With respect to the non -recurring adjustments, we previewed this back at the JPMorgan \nConference when we updated our commentary around the Medical business.  And our comment that \nis our comment now, which is as we have continued to dig deep across the portfolio, we've taken a \ndecision to take some nonrecurring adjustments, which , the majority of which hit the at -Home \nbusiness, which now reports or will report as part of Other in Q3 .  As well as component hitting the \nWaveMark business, which is par t of the new GMPD business.   So, if you read through the update to \nour guidance for the year where we moved from approximately $400 million  to approximately $380 \nmillion driven by the impact of the nonrecurring adjustments, you can reach your own conclusions as \nto the relative quantification and the distribution given those comments.  Thanks.  \n \n Operator:  Thank you very much sir. ", "original_text": "As well as component hitting the \nWaveMark business, which is par t of the new GMPD business.  "}, "hash": "100c5c68705a42d0ae372ca6d761eb430fb8fb402c80b3b672b62d279465480e", "class_name": "RelatedNodeInfo"}}, "text": "And our comment that \nis our comment now, which is as we have continued to dig deep across the portfolio, we've taken a \ndecision to take some nonrecurring adjustments, which , the majority of which hit the at -Home \nbusiness, which now reports or will report as part of Other in Q3 . ", "start_char_idx": 1718, "end_char_idx": 2003, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "80c6ec03-2a40-4124-b02d-cc9ff20bf222": {"__data__": {"id_": "80c6ec03-2a40-4124-b02d-cc9ff20bf222", "embedding": null, "metadata": {"window": "Aaron , any comments from that?  \n \n Aaron Alt:  With respect to the non -recurring adjustments, we previewed this back at the JPMorgan \nConference when we updated our commentary around the Medical business.  And our comment that \nis our comment now, which is as we have continued to dig deep across the portfolio, we've taken a \ndecision to take some nonrecurring adjustments, which , the majority of which hit the at -Home \nbusiness, which now reports or will report as part of Other in Q3 .  As well as component hitting the \nWaveMark business, which is par t of the new GMPD business.   So, if you read through the update to \nour guidance for the year where we moved from approximately $400 million  to approximately $380 \nmillion driven by the impact of the nonrecurring adjustments, you can reach your own conclusions as \nto the relative quantification and the distribution given those comments.  Thanks.  \n \n Operator:  Thank you very much sir. ", "original_text": "As well as component hitting the \nWaveMark business, which is par t of the new GMPD business.  ", "page_label": "17", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "0d51f961-2630-4f26-b63f-20378f90e37c", "node_type": "4", "metadata": {"page_label": "17", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "d4da2bed8eff879df87258e89f1a6ffb2fba7017447c2029bdfc31ee753c79f9", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "63fc2bb7-dea5-4c7d-a1c1-43098f1b3eb6", "node_type": "1", "metadata": {"window": "So overall, feel good about the overall health of the business and the contribution of COVID \nwithin it.  Aaron , any comments from that?  \n \n Aaron Alt:  With respect to the non -recurring adjustments, we previewed this back at the JPMorgan \nConference when we updated our commentary around the Medical business.  And our comment that \nis our comment now, which is as we have continued to dig deep across the portfolio, we've taken a \ndecision to take some nonrecurring adjustments, which , the majority of which hit the at -Home \nbusiness, which now reports or will report as part of Other in Q3 .  As well as component hitting the \nWaveMark business, which is par t of the new GMPD business.   So, if you read through the update to \nour guidance for the year where we moved from approximately $400 million  to approximately $380 \nmillion driven by the impact of the nonrecurring adjustments, you can reach your own conclusions as \nto the relative quantification and the distribution given those comments.  Thanks.  \n \n", "original_text": "And our comment that \nis our comment now, which is as we have continued to dig deep across the portfolio, we've taken a \ndecision to take some nonrecurring adjustments, which , the majority of which hit the at -Home \nbusiness, which now reports or will report as part of Other in Q3 . ", "page_label": "17", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "3c0115330245869f59a733301515723399ffcb89d760da41b24de5e571a03446", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "0a5a1648-6d22-4e4d-b1ec-1dffda1ec6f1", "node_type": "1", "metadata": {"window": "Aaron Alt:  With respect to the non -recurring adjustments, we previewed this back at the JPMorgan \nConference when we updated our commentary around the Medical business.  And our comment that \nis our comment now, which is as we have continued to dig deep across the portfolio, we've taken a \ndecision to take some nonrecurring adjustments, which , the majority of which hit the at -Home \nbusiness, which now reports or will report as part of Other in Q3 .  As well as component hitting the \nWaveMark business, which is par t of the new GMPD business.   So, if you read through the update to \nour guidance for the year where we moved from approximately $400 million  to approximately $380 \nmillion driven by the impact of the nonrecurring adjustments, you can reach your own conclusions as \nto the relative quantification and the distribution given those comments.  Thanks.  \n \n Operator:  Thank you very much sir.  Our next question is coming from Charles Rhyee of TD Cowen. \n", "original_text": "So, if you read through the update to \nour guidance for the year where we moved from approximately $400 million  to approximately $380 \nmillion driven by the impact of the nonrecurring adjustments, you can reach your own conclusions as \nto the relative quantification and the distribution given those comments. "}, "hash": "8f2817b47d726a82069611378a36fb73f3c6e3ccb6cf72668ee9db4a7d721d94", "class_name": "RelatedNodeInfo"}}, "text": "As well as component hitting the \nWaveMark business, which is par t of the new GMPD business.  ", "start_char_idx": 2003, "end_char_idx": 2098, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "0a5a1648-6d22-4e4d-b1ec-1dffda1ec6f1": {"__data__": {"id_": "0a5a1648-6d22-4e4d-b1ec-1dffda1ec6f1", "embedding": null, "metadata": {"window": "Aaron Alt:  With respect to the non -recurring adjustments, we previewed this back at the JPMorgan \nConference when we updated our commentary around the Medical business.  And our comment that \nis our comment now, which is as we have continued to dig deep across the portfolio, we've taken a \ndecision to take some nonrecurring adjustments, which , the majority of which hit the at -Home \nbusiness, which now reports or will report as part of Other in Q3 .  As well as component hitting the \nWaveMark business, which is par t of the new GMPD business.   So, if you read through the update to \nour guidance for the year where we moved from approximately $400 million  to approximately $380 \nmillion driven by the impact of the nonrecurring adjustments, you can reach your own conclusions as \nto the relative quantification and the distribution given those comments.  Thanks.  \n \n Operator:  Thank you very much sir.  Our next question is coming from Charles Rhyee of TD Cowen. \n", "original_text": "So, if you read through the update to \nour guidance for the year where we moved from approximately $400 million  to approximately $380 \nmillion driven by the impact of the nonrecurring adjustments, you can reach your own conclusions as \nto the relative quantification and the distribution given those comments. ", "page_label": "17", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "0d51f961-2630-4f26-b63f-20378f90e37c", "node_type": "4", "metadata": {"page_label": "17", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "d4da2bed8eff879df87258e89f1a6ffb2fba7017447c2029bdfc31ee753c79f9", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "80c6ec03-2a40-4124-b02d-cc9ff20bf222", "node_type": "1", "metadata": {"window": "Aaron , any comments from that?  \n \n Aaron Alt:  With respect to the non -recurring adjustments, we previewed this back at the JPMorgan \nConference when we updated our commentary around the Medical business.  And our comment that \nis our comment now, which is as we have continued to dig deep across the portfolio, we've taken a \ndecision to take some nonrecurring adjustments, which , the majority of which hit the at -Home \nbusiness, which now reports or will report as part of Other in Q3 .  As well as component hitting the \nWaveMark business, which is par t of the new GMPD business.   So, if you read through the update to \nour guidance for the year where we moved from approximately $400 million  to approximately $380 \nmillion driven by the impact of the nonrecurring adjustments, you can reach your own conclusions as \nto the relative quantification and the distribution given those comments.  Thanks.  \n \n Operator:  Thank you very much sir. ", "original_text": "As well as component hitting the \nWaveMark business, which is par t of the new GMPD business.  ", "page_label": "17", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "65a7d131949580e022eee5bd3ef98223671012fadc62f2a5ec7d33159fce54f4", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "2c6e7904-ef9b-4745-aa79-195d0768634c", "node_type": "1", "metadata": {"window": "And our comment that \nis our comment now, which is as we have continued to dig deep across the portfolio, we've taken a \ndecision to take some nonrecurring adjustments, which , the majority of which hit the at -Home \nbusiness, which now reports or will report as part of Other in Q3 .  As well as component hitting the \nWaveMark business, which is par t of the new GMPD business.   So, if you read through the update to \nour guidance for the year where we moved from approximately $400 million  to approximately $380 \nmillion driven by the impact of the nonrecurring adjustments, you can reach your own conclusions as \nto the relative quantification and the distribution given those comments.  Thanks.  \n \n Operator:  Thank you very much sir.  Our next question is coming from Charles Rhyee of TD Cowen. \n Please go ahead.  \n \n", "original_text": "Thanks.  \n \n"}, "hash": "6fdeb1fe44fd26a583c84f71450a8532c556eeb4e0d7f19bc95c9b5f919151af", "class_name": "RelatedNodeInfo"}}, "text": "So, if you read through the update to \nour guidance for the year where we moved from approximately $400 million  to approximately $380 \nmillion driven by the impact of the nonrecurring adjustments, you can reach your own conclusions as \nto the relative quantification and the distribution given those comments. ", "start_char_idx": 2098, "end_char_idx": 2409, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "2c6e7904-ef9b-4745-aa79-195d0768634c": {"__data__": {"id_": "2c6e7904-ef9b-4745-aa79-195d0768634c", "embedding": null, "metadata": {"window": "And our comment that \nis our comment now, which is as we have continued to dig deep across the portfolio, we've taken a \ndecision to take some nonrecurring adjustments, which , the majority of which hit the at -Home \nbusiness, which now reports or will report as part of Other in Q3 .  As well as component hitting the \nWaveMark business, which is par t of the new GMPD business.   So, if you read through the update to \nour guidance for the year where we moved from approximately $400 million  to approximately $380 \nmillion driven by the impact of the nonrecurring adjustments, you can reach your own conclusions as \nto the relative quantification and the distribution given those comments.  Thanks.  \n \n Operator:  Thank you very much sir.  Our next question is coming from Charles Rhyee of TD Cowen. \n Please go ahead.  \n \n", "original_text": "Thanks.  \n \n", "page_label": "17", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "0d51f961-2630-4f26-b63f-20378f90e37c", "node_type": "4", "metadata": {"page_label": "17", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "d4da2bed8eff879df87258e89f1a6ffb2fba7017447c2029bdfc31ee753c79f9", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "0a5a1648-6d22-4e4d-b1ec-1dffda1ec6f1", "node_type": "1", "metadata": {"window": "Aaron Alt:  With respect to the non -recurring adjustments, we previewed this back at the JPMorgan \nConference when we updated our commentary around the Medical business.  And our comment that \nis our comment now, which is as we have continued to dig deep across the portfolio, we've taken a \ndecision to take some nonrecurring adjustments, which , the majority of which hit the at -Home \nbusiness, which now reports or will report as part of Other in Q3 .  As well as component hitting the \nWaveMark business, which is par t of the new GMPD business.   So, if you read through the update to \nour guidance for the year where we moved from approximately $400 million  to approximately $380 \nmillion driven by the impact of the nonrecurring adjustments, you can reach your own conclusions as \nto the relative quantification and the distribution given those comments.  Thanks.  \n \n Operator:  Thank you very much sir.  Our next question is coming from Charles Rhyee of TD Cowen. \n", "original_text": "So, if you read through the update to \nour guidance for the year where we moved from approximately $400 million  to approximately $380 \nmillion driven by the impact of the nonrecurring adjustments, you can reach your own conclusions as \nto the relative quantification and the distribution given those comments. ", "page_label": "17", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "5d911e70371f962b23dd4d6cce92fdbe8d0da5e5c5c77c37ba077c35a66dd328", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "73436123-325b-4a00-b7ea-cef9b942348c", "node_type": "1", "metadata": {"window": "As well as component hitting the \nWaveMark business, which is par t of the new GMPD business.   So, if you read through the update to \nour guidance for the year where we moved from approximately $400 million  to approximately $380 \nmillion driven by the impact of the nonrecurring adjustments, you can reach your own conclusions as \nto the relative quantification and the distribution given those comments.  Thanks.  \n \n Operator:  Thank you very much sir.  Our next question is coming from Charles Rhyee of TD Cowen. \n Please go ahead.  \n \n Charles Rhyee:  Yeah, thanks for taking the question. ", "original_text": "Operator:  Thank you very much sir. "}, "hash": "e5d52ec3fc4f7198307e39a226369772eab6b968978ccb00183db6604a59f5ca", "class_name": "RelatedNodeInfo"}}, "text": "Thanks.  \n \n", "start_char_idx": 2409, "end_char_idx": 2421, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "73436123-325b-4a00-b7ea-cef9b942348c": {"__data__": {"id_": "73436123-325b-4a00-b7ea-cef9b942348c", "embedding": null, "metadata": {"window": "As well as component hitting the \nWaveMark business, which is par t of the new GMPD business.   So, if you read through the update to \nour guidance for the year where we moved from approximately $400 million  to approximately $380 \nmillion driven by the impact of the nonrecurring adjustments, you can reach your own conclusions as \nto the relative quantification and the distribution given those comments.  Thanks.  \n \n Operator:  Thank you very much sir.  Our next question is coming from Charles Rhyee of TD Cowen. \n Please go ahead.  \n \n Charles Rhyee:  Yeah, thanks for taking the question. ", "original_text": "Operator:  Thank you very much sir. ", "page_label": "17", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "0d51f961-2630-4f26-b63f-20378f90e37c", "node_type": "4", "metadata": {"page_label": "17", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "d4da2bed8eff879df87258e89f1a6ffb2fba7017447c2029bdfc31ee753c79f9", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "2c6e7904-ef9b-4745-aa79-195d0768634c", "node_type": "1", "metadata": {"window": "And our comment that \nis our comment now, which is as we have continued to dig deep across the portfolio, we've taken a \ndecision to take some nonrecurring adjustments, which , the majority of which hit the at -Home \nbusiness, which now reports or will report as part of Other in Q3 .  As well as component hitting the \nWaveMark business, which is par t of the new GMPD business.   So, if you read through the update to \nour guidance for the year where we moved from approximately $400 million  to approximately $380 \nmillion driven by the impact of the nonrecurring adjustments, you can reach your own conclusions as \nto the relative quantification and the distribution given those comments.  Thanks.  \n \n Operator:  Thank you very much sir.  Our next question is coming from Charles Rhyee of TD Cowen. \n Please go ahead.  \n \n", "original_text": "Thanks.  \n \n", "page_label": "17", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "c2bf3f1c5c9e2edb7ccc0464116e904d6bfaa5d4064624b63ee746ceb61da859", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "9d2e8dc8-263a-4514-8dd9-01baa0b096a4", "node_type": "1", "metadata": {"window": "So, if you read through the update to \nour guidance for the year where we moved from approximately $400 million  to approximately $380 \nmillion driven by the impact of the nonrecurring adjustments, you can reach your own conclusions as \nto the relative quantification and the distribution given those comments.  Thanks.  \n \n Operator:  Thank you very much sir.  Our next question is coming from Charles Rhyee of TD Cowen. \n Please go ahead.  \n \n Charles Rhyee:  Yeah, thanks for taking the question.  Just wanted to follow -up on a [inaudible]  there \non the vaccine impact. ", "original_text": "Our next question is coming from Charles Rhyee of TD Cowen. \n"}, "hash": "cfd64d5670c3eef423d795dd19e83f2d096be9a3423d696ec1de6b38879af458", "class_name": "RelatedNodeInfo"}}, "text": "Operator:  Thank you very much sir. ", "start_char_idx": 2421, "end_char_idx": 2457, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "9d2e8dc8-263a-4514-8dd9-01baa0b096a4": {"__data__": {"id_": "9d2e8dc8-263a-4514-8dd9-01baa0b096a4", "embedding": null, "metadata": {"window": "So, if you read through the update to \nour guidance for the year where we moved from approximately $400 million  to approximately $380 \nmillion driven by the impact of the nonrecurring adjustments, you can reach your own conclusions as \nto the relative quantification and the distribution given those comments.  Thanks.  \n \n Operator:  Thank you very much sir.  Our next question is coming from Charles Rhyee of TD Cowen. \n Please go ahead.  \n \n Charles Rhyee:  Yeah, thanks for taking the question.  Just wanted to follow -up on a [inaudible]  there \non the vaccine impact. ", "original_text": "Our next question is coming from Charles Rhyee of TD Cowen. \n", "page_label": "17", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "0d51f961-2630-4f26-b63f-20378f90e37c", "node_type": "4", "metadata": {"page_label": "17", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "d4da2bed8eff879df87258e89f1a6ffb2fba7017447c2029bdfc31ee753c79f9", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "73436123-325b-4a00-b7ea-cef9b942348c", "node_type": "1", "metadata": {"window": "As well as component hitting the \nWaveMark business, which is par t of the new GMPD business.   So, if you read through the update to \nour guidance for the year where we moved from approximately $400 million  to approximately $380 \nmillion driven by the impact of the nonrecurring adjustments, you can reach your own conclusions as \nto the relative quantification and the distribution given those comments.  Thanks.  \n \n Operator:  Thank you very much sir.  Our next question is coming from Charles Rhyee of TD Cowen. \n Please go ahead.  \n \n Charles Rhyee:  Yeah, thanks for taking the question. ", "original_text": "Operator:  Thank you very much sir. ", "page_label": "17", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "4a21fd6035441f63ac6219a9c699c6a78e442c202a4a6e236d0d8fa88e564bc1", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "4237d889-7794-4b67-85b7-935a956624bc", "node_type": "1", "metadata": {"window": "Thanks.  \n \n Operator:  Thank you very much sir.  Our next question is coming from Charles Rhyee of TD Cowen. \n Please go ahead.  \n \n Charles Rhyee:  Yeah, thanks for taking the question.  Just wanted to follow -up on a [inaudible]  there \non the vaccine impact.  I understand you're saying that you expected to peak in the December quarter. \n", "original_text": "Please go ahead.  \n \n"}, "hash": "30aceac12cdeba5c0d82c2d5a1237f6480c28161b678ef2c1b0a7b81f7ec4b86", "class_name": "RelatedNodeInfo"}}, "text": "Our next question is coming from Charles Rhyee of TD Cowen. \n", "start_char_idx": 2457, "end_char_idx": 2518, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "4237d889-7794-4b67-85b7-935a956624bc": {"__data__": {"id_": "4237d889-7794-4b67-85b7-935a956624bc", "embedding": null, "metadata": {"window": "Thanks.  \n \n Operator:  Thank you very much sir.  Our next question is coming from Charles Rhyee of TD Cowen. \n Please go ahead.  \n \n Charles Rhyee:  Yeah, thanks for taking the question.  Just wanted to follow -up on a [inaudible]  there \non the vaccine impact.  I understand you're saying that you expected to peak in the December quarter. \n", "original_text": "Please go ahead.  \n \n", "page_label": "17", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "0d51f961-2630-4f26-b63f-20378f90e37c", "node_type": "4", "metadata": {"page_label": "17", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "d4da2bed8eff879df87258e89f1a6ffb2fba7017447c2029bdfc31ee753c79f9", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "9d2e8dc8-263a-4514-8dd9-01baa0b096a4", "node_type": "1", "metadata": {"window": "So, if you read through the update to \nour guidance for the year where we moved from approximately $400 million  to approximately $380 \nmillion driven by the impact of the nonrecurring adjustments, you can reach your own conclusions as \nto the relative quantification and the distribution given those comments.  Thanks.  \n \n Operator:  Thank you very much sir.  Our next question is coming from Charles Rhyee of TD Cowen. \n Please go ahead.  \n \n Charles Rhyee:  Yeah, thanks for taking the question.  Just wanted to follow -up on a [inaudible]  there \non the vaccine impact. ", "original_text": "Our next question is coming from Charles Rhyee of TD Cowen. \n", "page_label": "17", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "7dc7ab2076e9c27862a67f243a8b3c1b746ab6ca12921e56ec566a319a739b2d", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "a54a84f8-7455-48ff-80bf-7aec9afec552", "node_type": "1", "metadata": {"window": "Operator:  Thank you very much sir.  Our next question is coming from Charles Rhyee of TD Cowen. \n Please go ahead.  \n \n Charles Rhyee:  Yeah, thanks for taking the question.  Just wanted to follow -up on a [inaudible]  there \non the vaccine impact.  I understand you're saying that you expected to peak in the December quarter. \n Would you say that the contribution, though, from vaccine was higher than in the first quarter given \nthat you had still three months overall ? ", "original_text": "Charles Rhyee:  Yeah, thanks for taking the question. "}, "hash": "5f6fcfa995269d4d2af4685dbd9ede8179ca5a1fb042caf729d4e300fe36b999", "class_name": "RelatedNodeInfo"}}, "text": "Please go ahead.  \n \n", "start_char_idx": 2518, "end_char_idx": 2539, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "a54a84f8-7455-48ff-80bf-7aec9afec552": {"__data__": {"id_": "a54a84f8-7455-48ff-80bf-7aec9afec552", "embedding": null, "metadata": {"window": "Operator:  Thank you very much sir.  Our next question is coming from Charles Rhyee of TD Cowen. \n Please go ahead.  \n \n Charles Rhyee:  Yeah, thanks for taking the question.  Just wanted to follow -up on a [inaudible]  there \non the vaccine impact.  I understand you're saying that you expected to peak in the December quarter. \n Would you say that the contribution, though, from vaccine was higher than in the first quarter given \nthat you had still three months overall ? ", "original_text": "Charles Rhyee:  Yeah, thanks for taking the question. ", "page_label": "17", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "0d51f961-2630-4f26-b63f-20378f90e37c", "node_type": "4", "metadata": {"page_label": "17", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "d4da2bed8eff879df87258e89f1a6ffb2fba7017447c2029bdfc31ee753c79f9", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "4237d889-7794-4b67-85b7-935a956624bc", "node_type": "1", "metadata": {"window": "Thanks.  \n \n Operator:  Thank you very much sir.  Our next question is coming from Charles Rhyee of TD Cowen. \n Please go ahead.  \n \n Charles Rhyee:  Yeah, thanks for taking the question.  Just wanted to follow -up on a [inaudible]  there \non the vaccine impact.  I understand you're saying that you expected to peak in the December quarter. \n", "original_text": "Please go ahead.  \n \n", "page_label": "17", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "9909360879d025240e4e4f5a9f9d67dd53a74ff745496d238f56e65cf5b15aed", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "349bda6a-857e-4f34-974f-97ce681608a6", "node_type": "1", "metadata": {"window": "Our next question is coming from Charles Rhyee of TD Cowen. \n Please go ahead.  \n \n Charles Rhyee:  Yeah, thanks for taking the question.  Just wanted to follow -up on a [inaudible]  there \non the vaccine impact.  I understand you're saying that you expected to peak in the December quarter. \n Would you say that the contribution, though, from vaccine was higher than in the first quarter given \nthat you had still three months overall ?  And if we look at that, relative to what you had expected, the \nhigher costs that you incurred, did you use that to fund those  kind investments? ", "original_text": "Just wanted to follow -up on a [inaudible]  there \non the vaccine impact. "}, "hash": "6c2fe85754c268608675779986ab13a6d2140e22132914d3466066a4bda90d9c", "class_name": "RelatedNodeInfo"}}, "text": "Charles Rhyee:  Yeah, thanks for taking the question. ", "start_char_idx": 2539, "end_char_idx": 2593, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "349bda6a-857e-4f34-974f-97ce681608a6": {"__data__": {"id_": "349bda6a-857e-4f34-974f-97ce681608a6", "embedding": null, "metadata": {"window": "Our next question is coming from Charles Rhyee of TD Cowen. \n Please go ahead.  \n \n Charles Rhyee:  Yeah, thanks for taking the question.  Just wanted to follow -up on a [inaudible]  there \non the vaccine impact.  I understand you're saying that you expected to peak in the December quarter. \n Would you say that the contribution, though, from vaccine was higher than in the first quarter given \nthat you had still three months overall ?  And if we look at that, relative to what you had expected, the \nhigher costs that you incurred, did you use that to fund those  kind investments? ", "original_text": "Just wanted to follow -up on a [inaudible]  there \non the vaccine impact. ", "page_label": "17", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "0d51f961-2630-4f26-b63f-20378f90e37c", "node_type": "4", "metadata": {"page_label": "17", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "d4da2bed8eff879df87258e89f1a6ffb2fba7017447c2029bdfc31ee753c79f9", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "a54a84f8-7455-48ff-80bf-7aec9afec552", "node_type": "1", "metadata": {"window": "Operator:  Thank you very much sir.  Our next question is coming from Charles Rhyee of TD Cowen. \n Please go ahead.  \n \n Charles Rhyee:  Yeah, thanks for taking the question.  Just wanted to follow -up on a [inaudible]  there \non the vaccine impact.  I understand you're saying that you expected to peak in the December quarter. \n Would you say that the contribution, though, from vaccine was higher than in the first quarter given \nthat you had still three months overall ? ", "original_text": "Charles Rhyee:  Yeah, thanks for taking the question. ", "page_label": "17", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "c11a6111ded4d5ff7dfa72d2313a5fc8b7a26a6a2e92efb1ec50b267fdba0b25", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "06bdfb1f-7d00-4026-807d-278c784f1241", "node_type": "1", "metadata": {"window": "Please go ahead.  \n \n Charles Rhyee:  Yeah, thanks for taking the question.  Just wanted to follow -up on a [inaudible]  there \non the vaccine impact.  I understand you're saying that you expected to peak in the December quarter. \n Would you say that the contribution, though, from vaccine was higher than in the first quarter given \nthat you had still three months overall ?  And if we look at that, relative to what you had expected, the \nhigher costs that you incurred, did you use that to fund those  kind investments?  Just wanted to get a \nsense on relative contribution.  \n \n", "original_text": "I understand you're saying that you expected to peak in the December quarter. \n"}, "hash": "adf17be6b584d42971c5bd9f2e3ddbd27af801de42f779318910c8df06e5f89c", "class_name": "RelatedNodeInfo"}}, "text": "Just wanted to follow -up on a [inaudible]  there \non the vaccine impact. ", "start_char_idx": 2593, "end_char_idx": 2667, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "06bdfb1f-7d00-4026-807d-278c784f1241": {"__data__": {"id_": "06bdfb1f-7d00-4026-807d-278c784f1241", "embedding": null, "metadata": {"window": "Please go ahead.  \n \n Charles Rhyee:  Yeah, thanks for taking the question.  Just wanted to follow -up on a [inaudible]  there \non the vaccine impact.  I understand you're saying that you expected to peak in the December quarter. \n Would you say that the contribution, though, from vaccine was higher than in the first quarter given \nthat you had still three months overall ?  And if we look at that, relative to what you had expected, the \nhigher costs that you incurred, did you use that to fund those  kind investments?  Just wanted to get a \nsense on relative contribution.  \n \n", "original_text": "I understand you're saying that you expected to peak in the December quarter. \n", "page_label": "17", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "0d51f961-2630-4f26-b63f-20378f90e37c", "node_type": "4", "metadata": {"page_label": "17", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "d4da2bed8eff879df87258e89f1a6ffb2fba7017447c2029bdfc31ee753c79f9", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "349bda6a-857e-4f34-974f-97ce681608a6", "node_type": "1", "metadata": {"window": "Our next question is coming from Charles Rhyee of TD Cowen. \n Please go ahead.  \n \n Charles Rhyee:  Yeah, thanks for taking the question.  Just wanted to follow -up on a [inaudible]  there \non the vaccine impact.  I understand you're saying that you expected to peak in the December quarter. \n Would you say that the contribution, though, from vaccine was higher than in the first quarter given \nthat you had still three months overall ?  And if we look at that, relative to what you had expected, the \nhigher costs that you incurred, did you use that to fund those  kind investments? ", "original_text": "Just wanted to follow -up on a [inaudible]  there \non the vaccine impact. ", "page_label": "17", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "07bb58b32b32fc444d65edc08627b63d3f1b44e4577acb42b6ff7bbc55dc6928", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "e8ff7435-dc0b-4422-be69-9ea3731dc20e", "node_type": "1", "metadata": {"window": "Charles Rhyee:  Yeah, thanks for taking the question.  Just wanted to follow -up on a [inaudible]  there \non the vaccine impact.  I understand you're saying that you expected to peak in the December quarter. \n Would you say that the contribution, though, from vaccine was higher than in the first quarter given \nthat you had still three months overall ?  And if we look at that, relative to what you had expected, the \nhigher costs that you incurred, did you use that to fund those  kind investments?  Just wanted to get a \nsense on relative contribution.  \n \n Jason Hollar:  Yes. ", "original_text": "Would you say that the contribution, though, from vaccine was higher than in the first quarter given \nthat you had still three months overall ? "}, "hash": "9dbcf2e456f053eae813f45f1ac09ead3590b239e57cdb0a679b33929f0894a3", "class_name": "RelatedNodeInfo"}}, "text": "I understand you're saying that you expected to peak in the December quarter. \n", "start_char_idx": 2667, "end_char_idx": 2746, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "e8ff7435-dc0b-4422-be69-9ea3731dc20e": {"__data__": {"id_": "e8ff7435-dc0b-4422-be69-9ea3731dc20e", "embedding": null, "metadata": {"window": "Charles Rhyee:  Yeah, thanks for taking the question.  Just wanted to follow -up on a [inaudible]  there \non the vaccine impact.  I understand you're saying that you expected to peak in the December quarter. \n Would you say that the contribution, though, from vaccine was higher than in the first quarter given \nthat you had still three months overall ?  And if we look at that, relative to what you had expected, the \nhigher costs that you incurred, did you use that to fund those  kind investments?  Just wanted to get a \nsense on relative contribution.  \n \n Jason Hollar:  Yes. ", "original_text": "Would you say that the contribution, though, from vaccine was higher than in the first quarter given \nthat you had still three months overall ? ", "page_label": "17", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "0d51f961-2630-4f26-b63f-20378f90e37c", "node_type": "4", "metadata": {"page_label": "17", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "d4da2bed8eff879df87258e89f1a6ffb2fba7017447c2029bdfc31ee753c79f9", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "06bdfb1f-7d00-4026-807d-278c784f1241", "node_type": "1", "metadata": {"window": "Please go ahead.  \n \n Charles Rhyee:  Yeah, thanks for taking the question.  Just wanted to follow -up on a [inaudible]  there \non the vaccine impact.  I understand you're saying that you expected to peak in the December quarter. \n Would you say that the contribution, though, from vaccine was higher than in the first quarter given \nthat you had still three months overall ?  And if we look at that, relative to what you had expected, the \nhigher costs that you incurred, did you use that to fund those  kind investments?  Just wanted to get a \nsense on relative contribution.  \n \n", "original_text": "I understand you're saying that you expected to peak in the December quarter. \n", "page_label": "17", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "837a58899fd3728ef138bf455a4417976f1870d556d1747b31dfc030c46408f9", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "72df9eee-d456-4278-af7e-cf75f7203c81", "node_type": "1", "metadata": {"window": "Just wanted to follow -up on a [inaudible]  there \non the vaccine impact.  I understand you're saying that you expected to peak in the December quarter. \n Would you say that the contribution, though, from vaccine was higher than in the first quarter given \nthat you had still three months overall ?  And if we look at that, relative to what you had expected, the \nhigher costs that you incurred, did you use that to fund those  kind investments?  Just wanted to get a \nsense on relative contribution.  \n \n Jason Hollar:  Yes.  As I highlighted, October was the peak month and since we only had a partial \nSeptember, it's clearly higher in Q2 than in Q1. ", "original_text": "And if we look at that, relative to what you had expected, the \nhigher costs that you incurred, did you use that to fund those  kind investments? "}, "hash": "75cf7f572ad55980227e7dd1c8d3c427dbcd8ec674e0546fac9d56432035025a", "class_name": "RelatedNodeInfo"}}, "text": "Would you say that the contribution, though, from vaccine was higher than in the first quarter given \nthat you had still three months overall ? ", "start_char_idx": 2746, "end_char_idx": 2890, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "72df9eee-d456-4278-af7e-cf75f7203c81": {"__data__": {"id_": "72df9eee-d456-4278-af7e-cf75f7203c81", "embedding": null, "metadata": {"window": "Just wanted to follow -up on a [inaudible]  there \non the vaccine impact.  I understand you're saying that you expected to peak in the December quarter. \n Would you say that the contribution, though, from vaccine was higher than in the first quarter given \nthat you had still three months overall ?  And if we look at that, relative to what you had expected, the \nhigher costs that you incurred, did you use that to fund those  kind investments?  Just wanted to get a \nsense on relative contribution.  \n \n Jason Hollar:  Yes.  As I highlighted, October was the peak month and since we only had a partial \nSeptember, it's clearly higher in Q2 than in Q1. ", "original_text": "And if we look at that, relative to what you had expected, the \nhigher costs that you incurred, did you use that to fund those  kind investments? ", "page_label": "17", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "0d51f961-2630-4f26-b63f-20378f90e37c", "node_type": "4", "metadata": {"page_label": "17", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "d4da2bed8eff879df87258e89f1a6ffb2fba7017447c2029bdfc31ee753c79f9", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "e8ff7435-dc0b-4422-be69-9ea3731dc20e", "node_type": "1", "metadata": {"window": "Charles Rhyee:  Yeah, thanks for taking the question.  Just wanted to follow -up on a [inaudible]  there \non the vaccine impact.  I understand you're saying that you expected to peak in the December quarter. \n Would you say that the contribution, though, from vaccine was higher than in the first quarter given \nthat you had still three months overall ?  And if we look at that, relative to what you had expected, the \nhigher costs that you incurred, did you use that to fund those  kind investments?  Just wanted to get a \nsense on relative contribution.  \n \n Jason Hollar:  Yes. ", "original_text": "Would you say that the contribution, though, from vaccine was higher than in the first quarter given \nthat you had still three months overall ? ", "page_label": "17", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "5ad9e002cac4b319f4a1c45c7da87be5ff88fe9dbc7bbc574796350e4431d0a7", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "d83a5a3f-f739-4f23-81e6-2ac536c19a7f", "node_type": "1", "metadata": {"window": "I understand you're saying that you expected to peak in the December quarter. \n Would you say that the contribution, though, from vaccine was higher than in the first quarter given \nthat you had still three months overall ?  And if we look at that, relative to what you had expected, the \nhigher costs that you incurred, did you use that to fund those  kind investments?  Just wanted to get a \nsense on relative contribution.  \n \n Jason Hollar:  Yes.  As I highlighted, October was the peak month and since we only had a partial \nSeptember, it's clearly higher in Q2 than in Q1.  We did have November, December contributions as \nwell, but it r eally tailed off by the time we got to the end of the quarter, and that's why you would \nexpect there to be very little. ", "original_text": "Just wanted to get a \nsense on relative contribution.  \n \n"}, "hash": "61381c4b3049f9a40adba19275e51235b440da95764cdc882e1dec1ceba2889c", "class_name": "RelatedNodeInfo"}}, "text": "And if we look at that, relative to what you had expected, the \nhigher costs that you incurred, did you use that to fund those  kind investments? ", "start_char_idx": 2890, "end_char_idx": 3036, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "d83a5a3f-f739-4f23-81e6-2ac536c19a7f": {"__data__": {"id_": "d83a5a3f-f739-4f23-81e6-2ac536c19a7f", "embedding": null, "metadata": {"window": "I understand you're saying that you expected to peak in the December quarter. \n Would you say that the contribution, though, from vaccine was higher than in the first quarter given \nthat you had still three months overall ?  And if we look at that, relative to what you had expected, the \nhigher costs that you incurred, did you use that to fund those  kind investments?  Just wanted to get a \nsense on relative contribution.  \n \n Jason Hollar:  Yes.  As I highlighted, October was the peak month and since we only had a partial \nSeptember, it's clearly higher in Q2 than in Q1.  We did have November, December contributions as \nwell, but it r eally tailed off by the time we got to the end of the quarter, and that's why you would \nexpect there to be very little. ", "original_text": "Just wanted to get a \nsense on relative contribution.  \n \n", "page_label": "17", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "0d51f961-2630-4f26-b63f-20378f90e37c", "node_type": "4", "metadata": {"page_label": "17", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "d4da2bed8eff879df87258e89f1a6ffb2fba7017447c2029bdfc31ee753c79f9", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "72df9eee-d456-4278-af7e-cf75f7203c81", "node_type": "1", "metadata": {"window": "Just wanted to follow -up on a [inaudible]  there \non the vaccine impact.  I understand you're saying that you expected to peak in the December quarter. \n Would you say that the contribution, though, from vaccine was higher than in the first quarter given \nthat you had still three months overall ?  And if we look at that, relative to what you had expected, the \nhigher costs that you incurred, did you use that to fund those  kind investments?  Just wanted to get a \nsense on relative contribution.  \n \n Jason Hollar:  Yes.  As I highlighted, October was the peak month and since we only had a partial \nSeptember, it's clearly higher in Q2 than in Q1. ", "original_text": "And if we look at that, relative to what you had expected, the \nhigher costs that you incurred, did you use that to fund those  kind investments? ", "page_label": "17", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "fc1f3c93172d5becdff78dd6d66b5d98ebe7eb7b6f006ad4894237289e5d3279", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "23b72e29-c5a5-4ae7-a84c-26e6a57a09b1", "node_type": "1", "metadata": {"window": "Would you say that the contribution, though, from vaccine was higher than in the first quarter given \nthat you had still three months overall ?  And if we look at that, relative to what you had expected, the \nhigher costs that you incurred, did you use that to fund those  kind investments?  Just wanted to get a \nsense on relative contribution.  \n \n Jason Hollar:  Yes.  As I highlighted, October was the peak month and since we only had a partial \nSeptember, it's clearly higher in Q2 than in Q1.  We did have November, December contributions as \nwell, but it r eally tailed off by the time we got to the end of the quarter, and that's why you would \nexpect there to be very little.  It's just typical for vaccines in general. ", "original_text": "Jason Hollar:  Yes. "}, "hash": "066ae8d81bda50046c7e23496be191c8788cf3e989cf5cffb03d4f115d58c66d", "class_name": "RelatedNodeInfo"}}, "text": "Just wanted to get a \nsense on relative contribution.  \n \n", "start_char_idx": 3036, "end_char_idx": 3094, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "23b72e29-c5a5-4ae7-a84c-26e6a57a09b1": {"__data__": {"id_": "23b72e29-c5a5-4ae7-a84c-26e6a57a09b1", "embedding": null, "metadata": {"window": "Would you say that the contribution, though, from vaccine was higher than in the first quarter given \nthat you had still three months overall ?  And if we look at that, relative to what you had expected, the \nhigher costs that you incurred, did you use that to fund those  kind investments?  Just wanted to get a \nsense on relative contribution.  \n \n Jason Hollar:  Yes.  As I highlighted, October was the peak month and since we only had a partial \nSeptember, it's clearly higher in Q2 than in Q1.  We did have November, December contributions as \nwell, but it r eally tailed off by the time we got to the end of the quarter, and that's why you would \nexpect there to be very little.  It's just typical for vaccines in general. ", "original_text": "Jason Hollar:  Yes. ", "page_label": "17", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "0d51f961-2630-4f26-b63f-20378f90e37c", "node_type": "4", "metadata": {"page_label": "17", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "d4da2bed8eff879df87258e89f1a6ffb2fba7017447c2029bdfc31ee753c79f9", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "d83a5a3f-f739-4f23-81e6-2ac536c19a7f", "node_type": "1", "metadata": {"window": "I understand you're saying that you expected to peak in the December quarter. \n Would you say that the contribution, though, from vaccine was higher than in the first quarter given \nthat you had still three months overall ?  And if we look at that, relative to what you had expected, the \nhigher costs that you incurred, did you use that to fund those  kind investments?  Just wanted to get a \nsense on relative contribution.  \n \n Jason Hollar:  Yes.  As I highlighted, October was the peak month and since we only had a partial \nSeptember, it's clearly higher in Q2 than in Q1.  We did have November, December contributions as \nwell, but it r eally tailed off by the time we got to the end of the quarter, and that's why you would \nexpect there to be very little. ", "original_text": "Just wanted to get a \nsense on relative contribution.  \n \n", "page_label": "17", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "17ac7cb55a0ef8c4e10aa30420d7d9129ba03767435c71e56f406ef5e130c6d3", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "31acdef2-19e9-48f2-9b84-ebf773f1b34a", "node_type": "1", "metadata": {"window": "And if we look at that, relative to what you had expected, the \nhigher costs that you incurred, did you use that to fund those  kind investments?  Just wanted to get a \nsense on relative contribution.  \n \n Jason Hollar:  Yes.  As I highlighted, October was the peak month and since we only had a partial \nSeptember, it's clearly higher in Q2 than in Q1.  We did have November, December contributions as \nwell, but it r eally tailed off by the time we got to the end of the quarter, and that's why you would \nexpect there to be very little.  It's just typical for vaccines in general.  So, there's nothing we're seeing \nthere.  ", "original_text": "As I highlighted, October was the peak month and since we only had a partial \nSeptember, it's clearly higher in Q2 than in Q1. "}, "hash": "197c2aca837f1702562803522bf505a756ec2c5acd54373d1b9b4c71c6d104b2", "class_name": "RelatedNodeInfo"}}, "text": "Jason Hollar:  Yes. ", "start_char_idx": 128, "end_char_idx": 148, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "31acdef2-19e9-48f2-9b84-ebf773f1b34a": {"__data__": {"id_": "31acdef2-19e9-48f2-9b84-ebf773f1b34a", "embedding": null, "metadata": {"window": "And if we look at that, relative to what you had expected, the \nhigher costs that you incurred, did you use that to fund those  kind investments?  Just wanted to get a \nsense on relative contribution.  \n \n Jason Hollar:  Yes.  As I highlighted, October was the peak month and since we only had a partial \nSeptember, it's clearly higher in Q2 than in Q1.  We did have November, December contributions as \nwell, but it r eally tailed off by the time we got to the end of the quarter, and that's why you would \nexpect there to be very little.  It's just typical for vaccines in general.  So, there's nothing we're seeing \nthere.  ", "original_text": "As I highlighted, October was the peak month and since we only had a partial \nSeptember, it's clearly higher in Q2 than in Q1. ", "page_label": "17", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "0d51f961-2630-4f26-b63f-20378f90e37c", "node_type": "4", "metadata": {"page_label": "17", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "d4da2bed8eff879df87258e89f1a6ffb2fba7017447c2029bdfc31ee753c79f9", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "23b72e29-c5a5-4ae7-a84c-26e6a57a09b1", "node_type": "1", "metadata": {"window": "Would you say that the contribution, though, from vaccine was higher than in the first quarter given \nthat you had still three months overall ?  And if we look at that, relative to what you had expected, the \nhigher costs that you incurred, did you use that to fund those  kind investments?  Just wanted to get a \nsense on relative contribution.  \n \n Jason Hollar:  Yes.  As I highlighted, October was the peak month and since we only had a partial \nSeptember, it's clearly higher in Q2 than in Q1.  We did have November, December contributions as \nwell, but it r eally tailed off by the time we got to the end of the quarter, and that's why you would \nexpect there to be very little.  It's just typical for vaccines in general. ", "original_text": "Jason Hollar:  Yes. ", "page_label": "17", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "c5b2b972de15b36872454dd736999888a30394eccfe87d02361258abbe904a80", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "4acb7a18-3f3f-48d4-8fee-803d6f659e14", "node_type": "1", "metadata": {"window": "Just wanted to get a \nsense on relative contribution.  \n \n Jason Hollar:  Yes.  As I highlighted, October was the peak month and since we only had a partial \nSeptember, it's clearly higher in Q2 than in Q1.  We did have November, December contributions as \nwell, but it r eally tailed off by the time we got to the end of the quarter, and that's why you would \nexpect there to be very little.  It's just typical for vaccines in general.  So, there's nothing we're seeing \nthere.   And again, I think the way you asked the question around the funding of investments; I'll just go ", "original_text": "We did have November, December contributions as \nwell, but it r eally tailed off by the time we got to the end of the quarter, and that's why you would \nexpect there to be very little. "}, "hash": "1f78de014ec3ac897f9eb0b619be01cae3a3581a1f0e8de3869a2c1339a5e720", "class_name": "RelatedNodeInfo"}}, "text": "As I highlighted, October was the peak month and since we only had a partial \nSeptember, it's clearly higher in Q2 than in Q1. ", "start_char_idx": 3114, "end_char_idx": 3241, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "4acb7a18-3f3f-48d4-8fee-803d6f659e14": {"__data__": {"id_": "4acb7a18-3f3f-48d4-8fee-803d6f659e14", "embedding": null, "metadata": {"window": "Just wanted to get a \nsense on relative contribution.  \n \n Jason Hollar:  Yes.  As I highlighted, October was the peak month and since we only had a partial \nSeptember, it's clearly higher in Q2 than in Q1.  We did have November, December contributions as \nwell, but it r eally tailed off by the time we got to the end of the quarter, and that's why you would \nexpect there to be very little.  It's just typical for vaccines in general.  So, there's nothing we're seeing \nthere.   And again, I think the way you asked the question around the funding of investments; I'll just go ", "original_text": "We did have November, December contributions as \nwell, but it r eally tailed off by the time we got to the end of the quarter, and that's why you would \nexpect there to be very little. ", "page_label": "17", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "0d51f961-2630-4f26-b63f-20378f90e37c", "node_type": "4", "metadata": {"page_label": "17", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "d4da2bed8eff879df87258e89f1a6ffb2fba7017447c2029bdfc31ee753c79f9", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "31acdef2-19e9-48f2-9b84-ebf773f1b34a", "node_type": "1", "metadata": {"window": "And if we look at that, relative to what you had expected, the \nhigher costs that you incurred, did you use that to fund those  kind investments?  Just wanted to get a \nsense on relative contribution.  \n \n Jason Hollar:  Yes.  As I highlighted, October was the peak month and since we only had a partial \nSeptember, it's clearly higher in Q2 than in Q1.  We did have November, December contributions as \nwell, but it r eally tailed off by the time we got to the end of the quarter, and that's why you would \nexpect there to be very little.  It's just typical for vaccines in general.  So, there's nothing we're seeing \nthere.  ", "original_text": "As I highlighted, October was the peak month and since we only had a partial \nSeptember, it's clearly higher in Q2 than in Q1. ", "page_label": "17", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "b58fa17747693657953c4e56927294a8ac5c9108613cbe3eac9b052eaf366518", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "014d7f31-af18-4ae8-ae10-a7c229c786a4", "node_type": "1", "metadata": {"window": "Jason Hollar:  Yes.  As I highlighted, October was the peak month and since we only had a partial \nSeptember, it's clearly higher in Q2 than in Q1.  We did have November, December contributions as \nwell, but it r eally tailed off by the time we got to the end of the quarter, and that's why you would \nexpect there to be very little.  It's just typical for vaccines in general.  So, there's nothing we're seeing \nthere.   And again, I think the way you asked the question around the funding of investments; I'll just go ", "original_text": "It's just typical for vaccines in general. "}, "hash": "3083fee1adde552f37cba793211c26c800bbedee34064d7b7b76dda83dd4dd99", "class_name": "RelatedNodeInfo"}}, "text": "We did have November, December contributions as \nwell, but it r eally tailed off by the time we got to the end of the quarter, and that's why you would \nexpect there to be very little. ", "start_char_idx": 3241, "end_char_idx": 3426, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "014d7f31-af18-4ae8-ae10-a7c229c786a4": {"__data__": {"id_": "014d7f31-af18-4ae8-ae10-a7c229c786a4", "embedding": null, "metadata": {"window": "Jason Hollar:  Yes.  As I highlighted, October was the peak month and since we only had a partial \nSeptember, it's clearly higher in Q2 than in Q1.  We did have November, December contributions as \nwell, but it r eally tailed off by the time we got to the end of the quarter, and that's why you would \nexpect there to be very little.  It's just typical for vaccines in general.  So, there's nothing we're seeing \nthere.   And again, I think the way you asked the question around the funding of investments; I'll just go ", "original_text": "It's just typical for vaccines in general. ", "page_label": "17", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "0d51f961-2630-4f26-b63f-20378f90e37c", "node_type": "4", "metadata": {"page_label": "17", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "d4da2bed8eff879df87258e89f1a6ffb2fba7017447c2029bdfc31ee753c79f9", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "4acb7a18-3f3f-48d4-8fee-803d6f659e14", "node_type": "1", "metadata": {"window": "Just wanted to get a \nsense on relative contribution.  \n \n Jason Hollar:  Yes.  As I highlighted, October was the peak month and since we only had a partial \nSeptember, it's clearly higher in Q2 than in Q1.  We did have November, December contributions as \nwell, but it r eally tailed off by the time we got to the end of the quarter, and that's why you would \nexpect there to be very little.  It's just typical for vaccines in general.  So, there's nothing we're seeing \nthere.   And again, I think the way you asked the question around the funding of investments; I'll just go ", "original_text": "We did have November, December contributions as \nwell, but it r eally tailed off by the time we got to the end of the quarter, and that's why you would \nexpect there to be very little. ", "page_label": "17", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "5f68d84d784aa97f9738bb449e0c90e5a8706ad875e8c3f5f19b3bd4f52773e2", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "fd97a8d1-76fa-46dd-b7c5-266c7fe1e0e1", "node_type": "1", "metadata": {"window": "As I highlighted, October was the peak month and since we only had a partial \nSeptember, it's clearly higher in Q2 than in Q1.  We did have November, December contributions as \nwell, but it r eally tailed off by the time we got to the end of the quarter, and that's why you would \nexpect there to be very little.  It's just typical for vaccines in general.  So, there's nothing we're seeing \nthere.   And again, I think the way you asked the question around the funding of investments; I'll just go ", "original_text": "So, there's nothing we're seeing \nthere.  "}, "hash": "d0f5105439ef65279f2d529b5f28a8553cc477aa0d0d212a6d7444cc8bacb116", "class_name": "RelatedNodeInfo"}}, "text": "It's just typical for vaccines in general. ", "start_char_idx": 3426, "end_char_idx": 3469, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "fd97a8d1-76fa-46dd-b7c5-266c7fe1e0e1": {"__data__": {"id_": "fd97a8d1-76fa-46dd-b7c5-266c7fe1e0e1", "embedding": null, "metadata": {"window": "As I highlighted, October was the peak month and since we only had a partial \nSeptember, it's clearly higher in Q2 than in Q1.  We did have November, December contributions as \nwell, but it r eally tailed off by the time we got to the end of the quarter, and that's why you would \nexpect there to be very little.  It's just typical for vaccines in general.  So, there's nothing we're seeing \nthere.   And again, I think the way you asked the question around the funding of investments; I'll just go ", "original_text": "So, there's nothing we're seeing \nthere.  ", "page_label": "17", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "0d51f961-2630-4f26-b63f-20378f90e37c", "node_type": "4", "metadata": {"page_label": "17", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "d4da2bed8eff879df87258e89f1a6ffb2fba7017447c2029bdfc31ee753c79f9", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "014d7f31-af18-4ae8-ae10-a7c229c786a4", "node_type": "1", "metadata": {"window": "Jason Hollar:  Yes.  As I highlighted, October was the peak month and since we only had a partial \nSeptember, it's clearly higher in Q2 than in Q1.  We did have November, December contributions as \nwell, but it r eally tailed off by the time we got to the end of the quarter, and that's why you would \nexpect there to be very little.  It's just typical for vaccines in general.  So, there's nothing we're seeing \nthere.   And again, I think the way you asked the question around the funding of investments; I'll just go ", "original_text": "It's just typical for vaccines in general. ", "page_label": "17", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "906f0dc8bc89b46ff5f36a2cf440ff490084a6652c309317648d1bb53c8fd44b", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "50cd9dfc-9e14-4d52-97dc-0f01f9b5ff97", "node_type": "1", "metadata": {"window": "We did have November, December contributions as \nwell, but it r eally tailed off by the time we got to the end of the quarter, and that's why you would \nexpect there to be very little.  It's just typical for vaccines in general.  So, there's nothing we're seeing \nthere.   And again, I think the way you asked the question around the funding of investments; I'll just go ", "original_text": "And again, I think the way you asked the question around the funding of investments; I'll just go "}, "hash": "d37fbb044181381883b1b952da73a42f79d263d85dff0bbb7432db99d4924cf5", "class_name": "RelatedNodeInfo"}}, "text": "So, there's nothing we're seeing \nthere.  ", "start_char_idx": 3469, "end_char_idx": 3511, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "50cd9dfc-9e14-4d52-97dc-0f01f9b5ff97": {"__data__": {"id_": "50cd9dfc-9e14-4d52-97dc-0f01f9b5ff97", "embedding": null, "metadata": {"window": "We did have November, December contributions as \nwell, but it r eally tailed off by the time we got to the end of the quarter, and that's why you would \nexpect there to be very little.  It's just typical for vaccines in general.  So, there's nothing we're seeing \nthere.   And again, I think the way you asked the question around the funding of investments; I'll just go ", "original_text": "And again, I think the way you asked the question around the funding of investments; I'll just go ", "page_label": "17", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "0d51f961-2630-4f26-b63f-20378f90e37c", "node_type": "4", "metadata": {"page_label": "17", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "d4da2bed8eff879df87258e89f1a6ffb2fba7017447c2029bdfc31ee753c79f9", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "fd97a8d1-76fa-46dd-b7c5-266c7fe1e0e1", "node_type": "1", "metadata": {"window": "As I highlighted, October was the peak month and since we only had a partial \nSeptember, it's clearly higher in Q2 than in Q1.  We did have November, December contributions as \nwell, but it r eally tailed off by the time we got to the end of the quarter, and that's why you would \nexpect there to be very little.  It's just typical for vaccines in general.  So, there's nothing we're seeing \nthere.   And again, I think the way you asked the question around the funding of investments; I'll just go ", "original_text": "So, there's nothing we're seeing \nthere.  ", "page_label": "17", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "109bac6dd19cde31c231369d57ccd7558791f4dc62d0469b985e28f981d6348f", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "c351a89d-353e-481d-84d9-f3966c0ca6c8", "node_type": "1", "metadata": {"window": " \nPage 18 of 19 \n \nback to my prior answer to that question.  There were costs associated with the vaccine rollout.  As \nyou can imagine, that's a lot of volume to ramp up for really two months' worth of support.  Our team \ndid a fantastic job working with the manufacturers and our customers to play that role when we were \nnot involved in the vaccine discret ion before COVID.  ", "original_text": " \nPage 18 of 19 \n \nback to my prior answer to that question. "}, "hash": "f2815927d7295a59cebd476d3c7b56d2a29a5261e97ef040e4c74b5d3022d5ed", "class_name": "RelatedNodeInfo"}}, "text": "And again, I think the way you asked the question around the funding of investments; I'll just go ", "start_char_idx": 3511, "end_char_idx": 3609, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "c351a89d-353e-481d-84d9-f3966c0ca6c8": {"__data__": {"id_": "c351a89d-353e-481d-84d9-f3966c0ca6c8", "embedding": null, "metadata": {"window": " \nPage 18 of 19 \n \nback to my prior answer to that question.  There were costs associated with the vaccine rollout.  As \nyou can imagine, that's a lot of volume to ramp up for really two months' worth of support.  Our team \ndid a fantastic job working with the manufacturers and our customers to play that role when we were \nnot involved in the vaccine discret ion before COVID.  ", "original_text": " \nPage 18 of 19 \n \nback to my prior answer to that question. ", "page_label": "18", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "0deec662-07aa-4179-9d25-c20d9a0a3f6c", "node_type": "4", "metadata": {"page_label": "18", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "f11e4d47d1a17013e15f5609bc3c17fa461213c2b0fd0db015679c7e48260aaa", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "50cd9dfc-9e14-4d52-97dc-0f01f9b5ff97", "node_type": "1", "metadata": {"window": "We did have November, December contributions as \nwell, but it r eally tailed off by the time we got to the end of the quarter, and that's why you would \nexpect there to be very little.  It's just typical for vaccines in general.  So, there's nothing we're seeing \nthere.   And again, I think the way you asked the question around the funding of investments; I'll just go ", "original_text": "And again, I think the way you asked the question around the funding of investments; I'll just go ", "page_label": "17", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "cbc7c1c387d89f3dde76f0d0dfffa904b88553519eb3318c11cfd8351dd8e21c", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "c423abd1-d9ed-47b9-adab-7ee047c21c4e", "node_type": "1", "metadata": {"window": " \nPage 18 of 19 \n \nback to my prior answer to that question.  There were costs associated with the vaccine rollout.  As \nyou can imagine, that's a lot of volume to ramp up for really two months' worth of support.  Our team \ndid a fantastic job working with the manufacturers and our customers to play that role when we were \nnot involved in the vaccine discret ion before COVID.   So, I feel very good about our role, and we did \nhave to incur costs associated with the ramp -up and ramp -down in such a short period of time. ", "original_text": "There were costs associated with the vaccine rollout. "}, "hash": "72d3ceea220673ba4aac0c264c625d5605e25affdbc96f33051c06bc29ab836c", "class_name": "RelatedNodeInfo"}}, "text": " \nPage 18 of 19 \n \nback to my prior answer to that question. ", "start_char_idx": 0, "end_char_idx": 61, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "c423abd1-d9ed-47b9-adab-7ee047c21c4e": {"__data__": {"id_": "c423abd1-d9ed-47b9-adab-7ee047c21c4e", "embedding": null, "metadata": {"window": " \nPage 18 of 19 \n \nback to my prior answer to that question.  There were costs associated with the vaccine rollout.  As \nyou can imagine, that's a lot of volume to ramp up for really two months' worth of support.  Our team \ndid a fantastic job working with the manufacturers and our customers to play that role when we were \nnot involved in the vaccine discret ion before COVID.   So, I feel very good about our role, and we did \nhave to incur costs associated with the ramp -up and ramp -down in such a short period of time. ", "original_text": "There were costs associated with the vaccine rollout. ", "page_label": "18", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "0deec662-07aa-4179-9d25-c20d9a0a3f6c", "node_type": "4", "metadata": {"page_label": "18", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "f11e4d47d1a17013e15f5609bc3c17fa461213c2b0fd0db015679c7e48260aaa", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "c351a89d-353e-481d-84d9-f3966c0ca6c8", "node_type": "1", "metadata": {"window": " \nPage 18 of 19 \n \nback to my prior answer to that question.  There were costs associated with the vaccine rollout.  As \nyou can imagine, that's a lot of volume to ramp up for really two months' worth of support.  Our team \ndid a fantastic job working with the manufacturers and our customers to play that role when we were \nnot involved in the vaccine discret ion before COVID.  ", "original_text": " \nPage 18 of 19 \n \nback to my prior answer to that question. ", "page_label": "18", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "a7dc23126f0e0f76e4402b24f1f0a7a4d7b92b3c4ab90095abf1aefe23c42069", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "744e9bb2-3701-4ce3-8b17-ede2ce4f85d1", "node_type": "1", "metadata": {"window": " \nPage 18 of 19 \n \nback to my prior answer to that question.  There were costs associated with the vaccine rollout.  As \nyou can imagine, that's a lot of volume to ramp up for really two months' worth of support.  Our team \ndid a fantastic job working with the manufacturers and our customers to play that role when we were \nnot involved in the vaccine discret ion before COVID.   So, I feel very good about our role, and we did \nhave to incur costs associated with the ramp -up and ramp -down in such a short period of time.  But \nthat was not necessarily used as currency to fund other programs . ", "original_text": "As \nyou can imagine, that's a lot of volume to ramp up for really two months' worth of support. "}, "hash": "9df86470d5ebf2b99f08b3d4a5b60b90fdf418a43f0ed789b88fb9b7a115ee7f", "class_name": "RelatedNodeInfo"}}, "text": "There were costs associated with the vaccine rollout. ", "start_char_idx": 61, "end_char_idx": 115, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "744e9bb2-3701-4ce3-8b17-ede2ce4f85d1": {"__data__": {"id_": "744e9bb2-3701-4ce3-8b17-ede2ce4f85d1", "embedding": null, "metadata": {"window": " \nPage 18 of 19 \n \nback to my prior answer to that question.  There were costs associated with the vaccine rollout.  As \nyou can imagine, that's a lot of volume to ramp up for really two months' worth of support.  Our team \ndid a fantastic job working with the manufacturers and our customers to play that role when we were \nnot involved in the vaccine discret ion before COVID.   So, I feel very good about our role, and we did \nhave to incur costs associated with the ramp -up and ramp -down in such a short period of time.  But \nthat was not necessarily used as currency to fund other programs . ", "original_text": "As \nyou can imagine, that's a lot of volume to ramp up for really two months' worth of support. ", "page_label": "18", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "0deec662-07aa-4179-9d25-c20d9a0a3f6c", "node_type": "4", "metadata": {"page_label": "18", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "f11e4d47d1a17013e15f5609bc3c17fa461213c2b0fd0db015679c7e48260aaa", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "c423abd1-d9ed-47b9-adab-7ee047c21c4e", "node_type": "1", "metadata": {"window": " \nPage 18 of 19 \n \nback to my prior answer to that question.  There were costs associated with the vaccine rollout.  As \nyou can imagine, that's a lot of volume to ramp up for really two months' worth of support.  Our team \ndid a fantastic job working with the manufacturers and our customers to play that role when we were \nnot involved in the vaccine discret ion before COVID.   So, I feel very good about our role, and we did \nhave to incur costs associated with the ramp -up and ramp -down in such a short period of time. ", "original_text": "There were costs associated with the vaccine rollout. ", "page_label": "18", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "abd29860b77b0d897e0e236e1975f530639687ac2505f8c33611285307f4b904", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "d48bb228-ebc8-4384-bfb8-8ad64388b724", "node_type": "1", "metadata": {"window": " \nPage 18 of 19 \n \nback to my prior answer to that question.  There were costs associated with the vaccine rollout.  As \nyou can imagine, that's a lot of volume to ramp up for really two months' worth of support.  Our team \ndid a fantastic job working with the manufacturers and our customers to play that role when we were \nnot involved in the vaccine discret ion before COVID.   So, I feel very good about our role, and we did \nhave to incur costs associated with the ramp -up and ramp -down in such a short period of time.  But \nthat was not necessarily used as currency to fund other programs .  Those programs are importa nt \nstrategically and all very consistent with the plans and the actions and the forecast we've laid out \nhere. ", "original_text": "Our team \ndid a fantastic job working with the manufacturers and our customers to play that role when we were \nnot involved in the vaccine discret ion before COVID.  "}, "hash": "a9ab2978f6c379f2bb9e3fce366cde192cfd8b113054fc3e3288564dffee4358", "class_name": "RelatedNodeInfo"}}, "text": "As \nyou can imagine, that's a lot of volume to ramp up for really two months' worth of support. ", "start_char_idx": 115, "end_char_idx": 211, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "d48bb228-ebc8-4384-bfb8-8ad64388b724": {"__data__": {"id_": "d48bb228-ebc8-4384-bfb8-8ad64388b724", "embedding": null, "metadata": {"window": " \nPage 18 of 19 \n \nback to my prior answer to that question.  There were costs associated with the vaccine rollout.  As \nyou can imagine, that's a lot of volume to ramp up for really two months' worth of support.  Our team \ndid a fantastic job working with the manufacturers and our customers to play that role when we were \nnot involved in the vaccine discret ion before COVID.   So, I feel very good about our role, and we did \nhave to incur costs associated with the ramp -up and ramp -down in such a short period of time.  But \nthat was not necessarily used as currency to fund other programs .  Those programs are importa nt \nstrategically and all very consistent with the plans and the actions and the forecast we've laid out \nhere. ", "original_text": "Our team \ndid a fantastic job working with the manufacturers and our customers to play that role when we were \nnot involved in the vaccine discret ion before COVID.  ", "page_label": "18", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "0deec662-07aa-4179-9d25-c20d9a0a3f6c", "node_type": "4", "metadata": {"page_label": "18", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "f11e4d47d1a17013e15f5609bc3c17fa461213c2b0fd0db015679c7e48260aaa", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "744e9bb2-3701-4ce3-8b17-ede2ce4f85d1", "node_type": "1", "metadata": {"window": " \nPage 18 of 19 \n \nback to my prior answer to that question.  There were costs associated with the vaccine rollout.  As \nyou can imagine, that's a lot of volume to ramp up for really two months' worth of support.  Our team \ndid a fantastic job working with the manufacturers and our customers to play that role when we were \nnot involved in the vaccine discret ion before COVID.   So, I feel very good about our role, and we did \nhave to incur costs associated with the ramp -up and ramp -down in such a short period of time.  But \nthat was not necessarily used as currency to fund other programs . ", "original_text": "As \nyou can imagine, that's a lot of volume to ramp up for really two months' worth of support. ", "page_label": "18", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "0a2c96bc07e4ab25d64f85a40c4dddda0bffb86a7d6a826f3e90f8914cc97b2e", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "b6da76c2-fbe6-44ab-b276-23c9605a7145", "node_type": "1", "metadata": {"window": "There were costs associated with the vaccine rollout.  As \nyou can imagine, that's a lot of volume to ramp up for really two months' worth of support.  Our team \ndid a fantastic job working with the manufacturers and our customers to play that role when we were \nnot involved in the vaccine discret ion before COVID.   So, I feel very good about our role, and we did \nhave to incur costs associated with the ramp -up and ramp -down in such a short period of time.  But \nthat was not necessarily used as currency to fund other programs .  Those programs are importa nt \nstrategically and all very consistent with the plans and the actions and the forecast we've laid out \nhere.  So, there's no changes as it relates to how we're approaching these both short -term \nrequirements as well as long -term investments.  \n \n", "original_text": "So, I feel very good about our role, and we did \nhave to incur costs associated with the ramp -up and ramp -down in such a short period of time. "}, "hash": "8d13a963440fac521a74a70d4b086cf7d4a1dd63e2840b31521252b53ea17434", "class_name": "RelatedNodeInfo"}}, "text": "Our team \ndid a fantastic job working with the manufacturers and our customers to play that role when we were \nnot involved in the vaccine discret ion before COVID.  ", "start_char_idx": 211, "end_char_idx": 377, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "b6da76c2-fbe6-44ab-b276-23c9605a7145": {"__data__": {"id_": "b6da76c2-fbe6-44ab-b276-23c9605a7145", "embedding": null, "metadata": {"window": "There were costs associated with the vaccine rollout.  As \nyou can imagine, that's a lot of volume to ramp up for really two months' worth of support.  Our team \ndid a fantastic job working with the manufacturers and our customers to play that role when we were \nnot involved in the vaccine discret ion before COVID.   So, I feel very good about our role, and we did \nhave to incur costs associated with the ramp -up and ramp -down in such a short period of time.  But \nthat was not necessarily used as currency to fund other programs .  Those programs are importa nt \nstrategically and all very consistent with the plans and the actions and the forecast we've laid out \nhere.  So, there's no changes as it relates to how we're approaching these both short -term \nrequirements as well as long -term investments.  \n \n", "original_text": "So, I feel very good about our role, and we did \nhave to incur costs associated with the ramp -up and ramp -down in such a short period of time. ", "page_label": "18", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "0deec662-07aa-4179-9d25-c20d9a0a3f6c", "node_type": "4", "metadata": {"page_label": "18", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "f11e4d47d1a17013e15f5609bc3c17fa461213c2b0fd0db015679c7e48260aaa", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "d48bb228-ebc8-4384-bfb8-8ad64388b724", "node_type": "1", "metadata": {"window": " \nPage 18 of 19 \n \nback to my prior answer to that question.  There were costs associated with the vaccine rollout.  As \nyou can imagine, that's a lot of volume to ramp up for really two months' worth of support.  Our team \ndid a fantastic job working with the manufacturers and our customers to play that role when we were \nnot involved in the vaccine discret ion before COVID.   So, I feel very good about our role, and we did \nhave to incur costs associated with the ramp -up and ramp -down in such a short period of time.  But \nthat was not necessarily used as currency to fund other programs .  Those programs are importa nt \nstrategically and all very consistent with the plans and the actions and the forecast we've laid out \nhere. ", "original_text": "Our team \ndid a fantastic job working with the manufacturers and our customers to play that role when we were \nnot involved in the vaccine discret ion before COVID.  ", "page_label": "18", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "28059cc72ac7befbb60893c82365b1d027f1c3090ca0e075ac06e4b0b585dc02", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "6b6bd3ae-2aa2-412f-8541-5321c99eb11c", "node_type": "1", "metadata": {"window": "As \nyou can imagine, that's a lot of volume to ramp up for really two months' worth of support.  Our team \ndid a fantastic job working with the manufacturers and our customers to play that role when we were \nnot involved in the vaccine discret ion before COVID.   So, I feel very good about our role, and we did \nhave to incur costs associated with the ramp -up and ramp -down in such a short period of time.  But \nthat was not necessarily used as currency to fund other programs .  Those programs are importa nt \nstrategically and all very consistent with the plans and the actions and the forecast we've laid out \nhere.  So, there's no changes as it relates to how we're approaching these both short -term \nrequirements as well as long -term investments.  \n \n Aaron Alt:  Probably worth emphasizing that Jason's point is that September and October were the \nhigh points for COVID for  us from a distribution perspective, quickly tailing off thereafter.  \n \n", "original_text": "But \nthat was not necessarily used as currency to fund other programs . "}, "hash": "0cb5c925e5b3eec0569643f592af3f1f07382434e2ce0a8d77c12b9ca6d90686", "class_name": "RelatedNodeInfo"}}, "text": "So, I feel very good about our role, and we did \nhave to incur costs associated with the ramp -up and ramp -down in such a short period of time. ", "start_char_idx": 377, "end_char_idx": 522, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "6b6bd3ae-2aa2-412f-8541-5321c99eb11c": {"__data__": {"id_": "6b6bd3ae-2aa2-412f-8541-5321c99eb11c", "embedding": null, "metadata": {"window": "As \nyou can imagine, that's a lot of volume to ramp up for really two months' worth of support.  Our team \ndid a fantastic job working with the manufacturers and our customers to play that role when we were \nnot involved in the vaccine discret ion before COVID.   So, I feel very good about our role, and we did \nhave to incur costs associated with the ramp -up and ramp -down in such a short period of time.  But \nthat was not necessarily used as currency to fund other programs .  Those programs are importa nt \nstrategically and all very consistent with the plans and the actions and the forecast we've laid out \nhere.  So, there's no changes as it relates to how we're approaching these both short -term \nrequirements as well as long -term investments.  \n \n Aaron Alt:  Probably worth emphasizing that Jason's point is that September and October were the \nhigh points for COVID for  us from a distribution perspective, quickly tailing off thereafter.  \n \n", "original_text": "But \nthat was not necessarily used as currency to fund other programs . ", "page_label": "18", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "0deec662-07aa-4179-9d25-c20d9a0a3f6c", "node_type": "4", "metadata": {"page_label": "18", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "f11e4d47d1a17013e15f5609bc3c17fa461213c2b0fd0db015679c7e48260aaa", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "b6da76c2-fbe6-44ab-b276-23c9605a7145", "node_type": "1", "metadata": {"window": "There were costs associated with the vaccine rollout.  As \nyou can imagine, that's a lot of volume to ramp up for really two months' worth of support.  Our team \ndid a fantastic job working with the manufacturers and our customers to play that role when we were \nnot involved in the vaccine discret ion before COVID.   So, I feel very good about our role, and we did \nhave to incur costs associated with the ramp -up and ramp -down in such a short period of time.  But \nthat was not necessarily used as currency to fund other programs .  Those programs are importa nt \nstrategically and all very consistent with the plans and the actions and the forecast we've laid out \nhere.  So, there's no changes as it relates to how we're approaching these both short -term \nrequirements as well as long -term investments.  \n \n", "original_text": "So, I feel very good about our role, and we did \nhave to incur costs associated with the ramp -up and ramp -down in such a short period of time. ", "page_label": "18", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "b8942c1d0dbb9636f6d04e4fd62437845667329cc1ac207c1c6714bd826f4cff", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "2ca25976-3146-4672-90ac-64e4c0a302e5", "node_type": "1", "metadata": {"window": "Our team \ndid a fantastic job working with the manufacturers and our customers to play that role when we were \nnot involved in the vaccine discret ion before COVID.   So, I feel very good about our role, and we did \nhave to incur costs associated with the ramp -up and ramp -down in such a short period of time.  But \nthat was not necessarily used as currency to fund other programs .  Those programs are importa nt \nstrategically and all very consistent with the plans and the actions and the forecast we've laid out \nhere.  So, there's no changes as it relates to how we're approaching these both short -term \nrequirements as well as long -term investments.  \n \n Aaron Alt:  Probably worth emphasizing that Jason's point is that September and October were the \nhigh points for COVID for  us from a distribution perspective, quickly tailing off thereafter.  \n \n Matt Sims:  Next question, please.  \n \n", "original_text": "Those programs are importa nt \nstrategically and all very consistent with the plans and the actions and the forecast we've laid out \nhere. "}, "hash": "7cfb42d723156656ffa19d8cf5c80f2acee6cbf0e54392bc73363704c623bb71", "class_name": "RelatedNodeInfo"}}, "text": "But \nthat was not necessarily used as currency to fund other programs . ", "start_char_idx": 522, "end_char_idx": 594, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "2ca25976-3146-4672-90ac-64e4c0a302e5": {"__data__": {"id_": "2ca25976-3146-4672-90ac-64e4c0a302e5", "embedding": null, "metadata": {"window": "Our team \ndid a fantastic job working with the manufacturers and our customers to play that role when we were \nnot involved in the vaccine discret ion before COVID.   So, I feel very good about our role, and we did \nhave to incur costs associated with the ramp -up and ramp -down in such a short period of time.  But \nthat was not necessarily used as currency to fund other programs .  Those programs are importa nt \nstrategically and all very consistent with the plans and the actions and the forecast we've laid out \nhere.  So, there's no changes as it relates to how we're approaching these both short -term \nrequirements as well as long -term investments.  \n \n Aaron Alt:  Probably worth emphasizing that Jason's point is that September and October were the \nhigh points for COVID for  us from a distribution perspective, quickly tailing off thereafter.  \n \n Matt Sims:  Next question, please.  \n \n", "original_text": "Those programs are importa nt \nstrategically and all very consistent with the plans and the actions and the forecast we've laid out \nhere. ", "page_label": "18", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "0deec662-07aa-4179-9d25-c20d9a0a3f6c", "node_type": "4", "metadata": {"page_label": "18", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "f11e4d47d1a17013e15f5609bc3c17fa461213c2b0fd0db015679c7e48260aaa", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "6b6bd3ae-2aa2-412f-8541-5321c99eb11c", "node_type": "1", "metadata": {"window": "As \nyou can imagine, that's a lot of volume to ramp up for really two months' worth of support.  Our team \ndid a fantastic job working with the manufacturers and our customers to play that role when we were \nnot involved in the vaccine discret ion before COVID.   So, I feel very good about our role, and we did \nhave to incur costs associated with the ramp -up and ramp -down in such a short period of time.  But \nthat was not necessarily used as currency to fund other programs .  Those programs are importa nt \nstrategically and all very consistent with the plans and the actions and the forecast we've laid out \nhere.  So, there's no changes as it relates to how we're approaching these both short -term \nrequirements as well as long -term investments.  \n \n Aaron Alt:  Probably worth emphasizing that Jason's point is that September and October were the \nhigh points for COVID for  us from a distribution perspective, quickly tailing off thereafter.  \n \n", "original_text": "But \nthat was not necessarily used as currency to fund other programs . ", "page_label": "18", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "d197db88d5510248253eba9cdafa88cf4f0d014b2a0a57ed9227c08b73e83e6a", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "4f7bca5b-929e-4069-82b1-18c3e131e9e9", "node_type": "1", "metadata": {"window": "So, I feel very good about our role, and we did \nhave to incur costs associated with the ramp -up and ramp -down in such a short period of time.  But \nthat was not necessarily used as currency to fund other programs .  Those programs are importa nt \nstrategically and all very consistent with the plans and the actions and the forecast we've laid out \nhere.  So, there's no changes as it relates to how we're approaching these both short -term \nrequirements as well as long -term investments.  \n \n Aaron Alt:  Probably worth emphasizing that Jason's point is that September and October were the \nhigh points for COVID for  us from a distribution perspective, quickly tailing off thereafter.  \n \n Matt Sims:  Next question, please.  \n \n Operator:  Thank you very much, gentlemen. ", "original_text": "So, there's no changes as it relates to how we're approaching these both short -term \nrequirements as well as long -term investments.  \n \n"}, "hash": "8e34c85fd175e82c3ced6ce0da8763e67c30af5a572fa50d4c9cb7025272c64b", "class_name": "RelatedNodeInfo"}}, "text": "Those programs are importa nt \nstrategically and all very consistent with the plans and the actions and the forecast we've laid out \nhere. ", "start_char_idx": 594, "end_char_idx": 733, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "4f7bca5b-929e-4069-82b1-18c3e131e9e9": {"__data__": {"id_": "4f7bca5b-929e-4069-82b1-18c3e131e9e9", "embedding": null, "metadata": {"window": "So, I feel very good about our role, and we did \nhave to incur costs associated with the ramp -up and ramp -down in such a short period of time.  But \nthat was not necessarily used as currency to fund other programs .  Those programs are importa nt \nstrategically and all very consistent with the plans and the actions and the forecast we've laid out \nhere.  So, there's no changes as it relates to how we're approaching these both short -term \nrequirements as well as long -term investments.  \n \n Aaron Alt:  Probably worth emphasizing that Jason's point is that September and October were the \nhigh points for COVID for  us from a distribution perspective, quickly tailing off thereafter.  \n \n Matt Sims:  Next question, please.  \n \n Operator:  Thank you very much, gentlemen. ", "original_text": "So, there's no changes as it relates to how we're approaching these both short -term \nrequirements as well as long -term investments.  \n \n", "page_label": "18", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "0deec662-07aa-4179-9d25-c20d9a0a3f6c", "node_type": "4", "metadata": {"page_label": "18", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "f11e4d47d1a17013e15f5609bc3c17fa461213c2b0fd0db015679c7e48260aaa", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "2ca25976-3146-4672-90ac-64e4c0a302e5", "node_type": "1", "metadata": {"window": "Our team \ndid a fantastic job working with the manufacturers and our customers to play that role when we were \nnot involved in the vaccine discret ion before COVID.   So, I feel very good about our role, and we did \nhave to incur costs associated with the ramp -up and ramp -down in such a short period of time.  But \nthat was not necessarily used as currency to fund other programs .  Those programs are importa nt \nstrategically and all very consistent with the plans and the actions and the forecast we've laid out \nhere.  So, there's no changes as it relates to how we're approaching these both short -term \nrequirements as well as long -term investments.  \n \n Aaron Alt:  Probably worth emphasizing that Jason's point is that September and October were the \nhigh points for COVID for  us from a distribution perspective, quickly tailing off thereafter.  \n \n Matt Sims:  Next question, please.  \n \n", "original_text": "Those programs are importa nt \nstrategically and all very consistent with the plans and the actions and the forecast we've laid out \nhere. ", "page_label": "18", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "72a1bace54996f437799f468fe0507fa2a6493d8a75359851733b25e4948cab2", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "ea4685da-3f85-46c4-9d22-42c1f2a1d067", "node_type": "1", "metadata": {"window": "But \nthat was not necessarily used as currency to fund other programs .  Those programs are importa nt \nstrategically and all very consistent with the plans and the actions and the forecast we've laid out \nhere.  So, there's no changes as it relates to how we're approaching these both short -term \nrequirements as well as long -term investments.  \n \n Aaron Alt:  Probably worth emphasizing that Jason's point is that September and October were the \nhigh points for COVID for  us from a distribution perspective, quickly tailing off thereafter.  \n \n Matt Sims:  Next question, please.  \n \n Operator:  Thank you very much, gentlemen.  And our last question today will be coming from Mr. \n", "original_text": "Aaron Alt:  Probably worth emphasizing that Jason's point is that September and October were the \nhigh points for COVID for  us from a distribution perspective, quickly tailing off thereafter.  \n \n"}, "hash": "13bbe3dbd5b1e6eba35c69c94bc99d26dcb71f05984a59249c2bbeb28de35cd2", "class_name": "RelatedNodeInfo"}}, "text": "So, there's no changes as it relates to how we're approaching these both short -term \nrequirements as well as long -term investments.  \n \n", "start_char_idx": 733, "end_char_idx": 871, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "ea4685da-3f85-46c4-9d22-42c1f2a1d067": {"__data__": {"id_": "ea4685da-3f85-46c4-9d22-42c1f2a1d067", "embedding": null, "metadata": {"window": "But \nthat was not necessarily used as currency to fund other programs .  Those programs are importa nt \nstrategically and all very consistent with the plans and the actions and the forecast we've laid out \nhere.  So, there's no changes as it relates to how we're approaching these both short -term \nrequirements as well as long -term investments.  \n \n Aaron Alt:  Probably worth emphasizing that Jason's point is that September and October were the \nhigh points for COVID for  us from a distribution perspective, quickly tailing off thereafter.  \n \n Matt Sims:  Next question, please.  \n \n Operator:  Thank you very much, gentlemen.  And our last question today will be coming from Mr. \n", "original_text": "Aaron Alt:  Probably worth emphasizing that Jason's point is that September and October were the \nhigh points for COVID for  us from a distribution perspective, quickly tailing off thereafter.  \n \n", "page_label": "18", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "0deec662-07aa-4179-9d25-c20d9a0a3f6c", "node_type": "4", "metadata": {"page_label": "18", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "f11e4d47d1a17013e15f5609bc3c17fa461213c2b0fd0db015679c7e48260aaa", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "4f7bca5b-929e-4069-82b1-18c3e131e9e9", "node_type": "1", "metadata": {"window": "So, I feel very good about our role, and we did \nhave to incur costs associated with the ramp -up and ramp -down in such a short period of time.  But \nthat was not necessarily used as currency to fund other programs .  Those programs are importa nt \nstrategically and all very consistent with the plans and the actions and the forecast we've laid out \nhere.  So, there's no changes as it relates to how we're approaching these both short -term \nrequirements as well as long -term investments.  \n \n Aaron Alt:  Probably worth emphasizing that Jason's point is that September and October were the \nhigh points for COVID for  us from a distribution perspective, quickly tailing off thereafter.  \n \n Matt Sims:  Next question, please.  \n \n Operator:  Thank you very much, gentlemen. ", "original_text": "So, there's no changes as it relates to how we're approaching these both short -term \nrequirements as well as long -term investments.  \n \n", "page_label": "18", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "e066f08b6f46705230ccdd07fdb2d0f3b07a85efc30aa920e79f4bb3255c5809", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "2239daae-a42f-4daf-9a34-afe95092a964", "node_type": "1", "metadata": {"window": "Those programs are importa nt \nstrategically and all very consistent with the plans and the actions and the forecast we've laid out \nhere.  So, there's no changes as it relates to how we're approaching these both short -term \nrequirements as well as long -term investments.  \n \n Aaron Alt:  Probably worth emphasizing that Jason's point is that September and October were the \nhigh points for COVID for  us from a distribution perspective, quickly tailing off thereafter.  \n \n Matt Sims:  Next question, please.  \n \n Operator:  Thank you very much, gentlemen.  And our last question today will be coming from Mr. \n Daniel Grosslight of Citi. ", "original_text": "Matt Sims:  Next question, please.  \n \n"}, "hash": "54e5e88d5916d6d6997808bea52976439231ba2451397ef6f0cc697c92d1485d", "class_name": "RelatedNodeInfo"}}, "text": "Aaron Alt:  Probably worth emphasizing that Jason's point is that September and October were the \nhigh points for COVID for  us from a distribution perspective, quickly tailing off thereafter.  \n \n", "start_char_idx": 871, "end_char_idx": 1068, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "2239daae-a42f-4daf-9a34-afe95092a964": {"__data__": {"id_": "2239daae-a42f-4daf-9a34-afe95092a964", "embedding": null, "metadata": {"window": "Those programs are importa nt \nstrategically and all very consistent with the plans and the actions and the forecast we've laid out \nhere.  So, there's no changes as it relates to how we're approaching these both short -term \nrequirements as well as long -term investments.  \n \n Aaron Alt:  Probably worth emphasizing that Jason's point is that September and October were the \nhigh points for COVID for  us from a distribution perspective, quickly tailing off thereafter.  \n \n Matt Sims:  Next question, please.  \n \n Operator:  Thank you very much, gentlemen.  And our last question today will be coming from Mr. \n Daniel Grosslight of Citi. ", "original_text": "Matt Sims:  Next question, please.  \n \n", "page_label": "18", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "0deec662-07aa-4179-9d25-c20d9a0a3f6c", "node_type": "4", "metadata": {"page_label": "18", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "f11e4d47d1a17013e15f5609bc3c17fa461213c2b0fd0db015679c7e48260aaa", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "ea4685da-3f85-46c4-9d22-42c1f2a1d067", "node_type": "1", "metadata": {"window": "But \nthat was not necessarily used as currency to fund other programs .  Those programs are importa nt \nstrategically and all very consistent with the plans and the actions and the forecast we've laid out \nhere.  So, there's no changes as it relates to how we're approaching these both short -term \nrequirements as well as long -term investments.  \n \n Aaron Alt:  Probably worth emphasizing that Jason's point is that September and October were the \nhigh points for COVID for  us from a distribution perspective, quickly tailing off thereafter.  \n \n Matt Sims:  Next question, please.  \n \n Operator:  Thank you very much, gentlemen.  And our last question today will be coming from Mr. \n", "original_text": "Aaron Alt:  Probably worth emphasizing that Jason's point is that September and October were the \nhigh points for COVID for  us from a distribution perspective, quickly tailing off thereafter.  \n \n", "page_label": "18", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "6d4482e739ac3e13999b062b3c3798ab0ecd47098e80de7980ec577f1c6d86aa", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "79abe1c7-9c4b-43d5-85db-6d199c3df288", "node_type": "1", "metadata": {"window": "So, there's no changes as it relates to how we're approaching these both short -term \nrequirements as well as long -term investments.  \n \n Aaron Alt:  Probably worth emphasizing that Jason's point is that September and October were the \nhigh points for COVID for  us from a distribution perspective, quickly tailing off thereafter.  \n \n Matt Sims:  Next question, please.  \n \n Operator:  Thank you very much, gentlemen.  And our last question today will be coming from Mr. \n Daniel Grosslight of Citi.  Please go ahead , sir. \n \n", "original_text": "Operator:  Thank you very much, gentlemen. "}, "hash": "2c0dc61400b7359ef0b7c57ef9550e7bd9b9f3028ef5a95eb2a2449181a5b634", "class_name": "RelatedNodeInfo"}}, "text": "Matt Sims:  Next question, please.  \n \n", "start_char_idx": 1068, "end_char_idx": 1107, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "79abe1c7-9c4b-43d5-85db-6d199c3df288": {"__data__": {"id_": "79abe1c7-9c4b-43d5-85db-6d199c3df288", "embedding": null, "metadata": {"window": "So, there's no changes as it relates to how we're approaching these both short -term \nrequirements as well as long -term investments.  \n \n Aaron Alt:  Probably worth emphasizing that Jason's point is that September and October were the \nhigh points for COVID for  us from a distribution perspective, quickly tailing off thereafter.  \n \n Matt Sims:  Next question, please.  \n \n Operator:  Thank you very much, gentlemen.  And our last question today will be coming from Mr. \n Daniel Grosslight of Citi.  Please go ahead , sir. \n \n", "original_text": "Operator:  Thank you very much, gentlemen. ", "page_label": "18", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "0deec662-07aa-4179-9d25-c20d9a0a3f6c", "node_type": "4", "metadata": {"page_label": "18", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "f11e4d47d1a17013e15f5609bc3c17fa461213c2b0fd0db015679c7e48260aaa", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "2239daae-a42f-4daf-9a34-afe95092a964", "node_type": "1", "metadata": {"window": "Those programs are importa nt \nstrategically and all very consistent with the plans and the actions and the forecast we've laid out \nhere.  So, there's no changes as it relates to how we're approaching these both short -term \nrequirements as well as long -term investments.  \n \n Aaron Alt:  Probably worth emphasizing that Jason's point is that September and October were the \nhigh points for COVID for  us from a distribution perspective, quickly tailing off thereafter.  \n \n Matt Sims:  Next question, please.  \n \n Operator:  Thank you very much, gentlemen.  And our last question today will be coming from Mr. \n Daniel Grosslight of Citi. ", "original_text": "Matt Sims:  Next question, please.  \n \n", "page_label": "18", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "842163ff173391cd8208405d7792f667c130e7c32c4fe3a47644c80a2e5cb477", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "2117cc69-f7e4-44dc-b626-c1f2b431ef74", "node_type": "1", "metadata": {"window": "Aaron Alt:  Probably worth emphasizing that Jason's point is that September and October were the \nhigh points for COVID for  us from a distribution perspective, quickly tailing off thereafter.  \n \n Matt Sims:  Next question, please.  \n \n Operator:  Thank you very much, gentlemen.  And our last question today will be coming from Mr. \n Daniel Grosslight of Citi.  Please go ahead , sir. \n \n Daniel Grosslight:  Hi guys. ", "original_text": "And our last question today will be coming from Mr. \n"}, "hash": "9b43d7868840d5c8b4b8ec83076c429e70534b244da84f7af76ec5748c4fc774", "class_name": "RelatedNodeInfo"}}, "text": "Operator:  Thank you very much, gentlemen. ", "start_char_idx": 1107, "end_char_idx": 1150, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "2117cc69-f7e4-44dc-b626-c1f2b431ef74": {"__data__": {"id_": "2117cc69-f7e4-44dc-b626-c1f2b431ef74", "embedding": null, "metadata": {"window": "Aaron Alt:  Probably worth emphasizing that Jason's point is that September and October were the \nhigh points for COVID for  us from a distribution perspective, quickly tailing off thereafter.  \n \n Matt Sims:  Next question, please.  \n \n Operator:  Thank you very much, gentlemen.  And our last question today will be coming from Mr. \n Daniel Grosslight of Citi.  Please go ahead , sir. \n \n Daniel Grosslight:  Hi guys. ", "original_text": "And our last question today will be coming from Mr. \n", "page_label": "18", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "0deec662-07aa-4179-9d25-c20d9a0a3f6c", "node_type": "4", "metadata": {"page_label": "18", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "f11e4d47d1a17013e15f5609bc3c17fa461213c2b0fd0db015679c7e48260aaa", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "79abe1c7-9c4b-43d5-85db-6d199c3df288", "node_type": "1", "metadata": {"window": "So, there's no changes as it relates to how we're approaching these both short -term \nrequirements as well as long -term investments.  \n \n Aaron Alt:  Probably worth emphasizing that Jason's point is that September and October were the \nhigh points for COVID for  us from a distribution perspective, quickly tailing off thereafter.  \n \n Matt Sims:  Next question, please.  \n \n Operator:  Thank you very much, gentlemen.  And our last question today will be coming from Mr. \n Daniel Grosslight of Citi.  Please go ahead , sir. \n \n", "original_text": "Operator:  Thank you very much, gentlemen. ", "page_label": "18", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "23904de929b022f3416430426bf8cc13c7a101e83e108e71f13dd4b2226df9c0", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "5f00cd55-801f-4309-a8e5-11e73a2bc731", "node_type": "1", "metadata": {"window": "Matt Sims:  Next question, please.  \n \n Operator:  Thank you very much, gentlemen.  And our last question today will be coming from Mr. \n Daniel Grosslight of Citi.  Please go ahead , sir. \n \n Daniel Grosslight:  Hi guys.  Thanks for taking the question. ", "original_text": "Daniel Grosslight of Citi. "}, "hash": "7f8f093c22de63ab2dddbfafcd1aa71ac85625d38aa6c965fd08d5e573b906db", "class_name": "RelatedNodeInfo"}}, "text": "And our last question today will be coming from Mr. \n", "start_char_idx": 1150, "end_char_idx": 1203, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "5f00cd55-801f-4309-a8e5-11e73a2bc731": {"__data__": {"id_": "5f00cd55-801f-4309-a8e5-11e73a2bc731", "embedding": null, "metadata": {"window": "Matt Sims:  Next question, please.  \n \n Operator:  Thank you very much, gentlemen.  And our last question today will be coming from Mr. \n Daniel Grosslight of Citi.  Please go ahead , sir. \n \n Daniel Grosslight:  Hi guys.  Thanks for taking the question. ", "original_text": "Daniel Grosslight of Citi. ", "page_label": "18", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "0deec662-07aa-4179-9d25-c20d9a0a3f6c", "node_type": "4", "metadata": {"page_label": "18", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "f11e4d47d1a17013e15f5609bc3c17fa461213c2b0fd0db015679c7e48260aaa", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "2117cc69-f7e4-44dc-b626-c1f2b431ef74", "node_type": "1", "metadata": {"window": "Aaron Alt:  Probably worth emphasizing that Jason's point is that September and October were the \nhigh points for COVID for  us from a distribution perspective, quickly tailing off thereafter.  \n \n Matt Sims:  Next question, please.  \n \n Operator:  Thank you very much, gentlemen.  And our last question today will be coming from Mr. \n Daniel Grosslight of Citi.  Please go ahead , sir. \n \n Daniel Grosslight:  Hi guys. ", "original_text": "And our last question today will be coming from Mr. \n", "page_label": "18", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "c7e94fe773f1a9822a672ccf4c1f0e909d5da632659e1745ae46db9a6a742ed2", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "4bcaee50-97bc-4aec-9204-00b35a49192d", "node_type": "1", "metadata": {"window": "Operator:  Thank you very much, gentlemen.  And our last question today will be coming from Mr. \n Daniel Grosslight of Citi.  Please go ahead , sir. \n \n Daniel Grosslight:  Hi guys.  Thanks for taking the question.  I wanted to just go back quickly to the \nMedical profitability question and confirm one thing. ", "original_text": "Please go ahead , sir. \n \n"}, "hash": "803a6f457b05a572f6a14ae5f34f64527017527c41111126d5f7eb51877336fc", "class_name": "RelatedNodeInfo"}}, "text": "Daniel Grosslight of Citi. ", "start_char_idx": 1203, "end_char_idx": 1230, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "4bcaee50-97bc-4aec-9204-00b35a49192d": {"__data__": {"id_": "4bcaee50-97bc-4aec-9204-00b35a49192d", "embedding": null, "metadata": {"window": "Operator:  Thank you very much, gentlemen.  And our last question today will be coming from Mr. \n Daniel Grosslight of Citi.  Please go ahead , sir. \n \n Daniel Grosslight:  Hi guys.  Thanks for taking the question.  I wanted to just go back quickly to the \nMedical profitability question and confirm one thing. ", "original_text": "Please go ahead , sir. \n \n", "page_label": "18", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "0deec662-07aa-4179-9d25-c20d9a0a3f6c", "node_type": "4", "metadata": {"page_label": "18", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "f11e4d47d1a17013e15f5609bc3c17fa461213c2b0fd0db015679c7e48260aaa", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "5f00cd55-801f-4309-a8e5-11e73a2bc731", "node_type": "1", "metadata": {"window": "Matt Sims:  Next question, please.  \n \n Operator:  Thank you very much, gentlemen.  And our last question today will be coming from Mr. \n Daniel Grosslight of Citi.  Please go ahead , sir. \n \n Daniel Grosslight:  Hi guys.  Thanks for taking the question. ", "original_text": "Daniel Grosslight of Citi. ", "page_label": "18", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "0ff74de156f5988762478e0bc09137b1e881c7c7be9abe5f539c72fd42c8bab7", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "b2afa807-8304-4a24-817a-52f4ed6d422d", "node_type": "1", "metadata": {"window": "And our last question today will be coming from Mr. \n Daniel Grosslight of Citi.  Please go ahead , sir. \n \n Daniel Grosslight:  Hi guys.  Thanks for taking the question.  I wanted to just go back quickly to the \nMedical profitability question and confirm one thing.  That $20 million one -time item, that was wholly \nconcentrated this quarter. ", "original_text": "Daniel Grosslight:  Hi guys. "}, "hash": "4f1048b5f3abd3e29b4ec83a8b0320300da2605ba325dc9afb2a5390fd3bfc7f", "class_name": "RelatedNodeInfo"}}, "text": "Please go ahead , sir. \n \n", "start_char_idx": 1230, "end_char_idx": 1256, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "b2afa807-8304-4a24-817a-52f4ed6d422d": {"__data__": {"id_": "b2afa807-8304-4a24-817a-52f4ed6d422d", "embedding": null, "metadata": {"window": "And our last question today will be coming from Mr. \n Daniel Grosslight of Citi.  Please go ahead , sir. \n \n Daniel Grosslight:  Hi guys.  Thanks for taking the question.  I wanted to just go back quickly to the \nMedical profitability question and confirm one thing.  That $20 million one -time item, that was wholly \nconcentrated this quarter. ", "original_text": "Daniel Grosslight:  Hi guys. ", "page_label": "18", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "0deec662-07aa-4179-9d25-c20d9a0a3f6c", "node_type": "4", "metadata": {"page_label": "18", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "f11e4d47d1a17013e15f5609bc3c17fa461213c2b0fd0db015679c7e48260aaa", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "4bcaee50-97bc-4aec-9204-00b35a49192d", "node_type": "1", "metadata": {"window": "Operator:  Thank you very much, gentlemen.  And our last question today will be coming from Mr. \n Daniel Grosslight of Citi.  Please go ahead , sir. \n \n Daniel Grosslight:  Hi guys.  Thanks for taking the question.  I wanted to just go back quickly to the \nMedical profitability question and confirm one thing. ", "original_text": "Please go ahead , sir. \n \n", "page_label": "18", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "fd4de68fdf6a533a8c797aa92edd112ed0aa813a181ef791677c8bec8c655518", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "5950d0db-b458-464c-9730-76ac2dab6003", "node_type": "1", "metadata": {"window": "Daniel Grosslight of Citi.  Please go ahead , sir. \n \n Daniel Grosslight:  Hi guys.  Thanks for taking the question.  I wanted to just go back quickly to the \nMedical profitability question and confirm one thing.  That $20 million one -time item, that was wholly \nconcentrated this quarter.  So, without that, the Medical profitability would have been around $90 \nmillion . ", "original_text": "Thanks for taking the question. "}, "hash": "fcbe7d5aed8718bd2cf9dd19bcdfe35b1c9f0c48b853ea9d4eb71ee8c90e7d37", "class_name": "RelatedNodeInfo"}}, "text": "Daniel Grosslight:  Hi guys. ", "start_char_idx": 1256, "end_char_idx": 1285, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "5950d0db-b458-464c-9730-76ac2dab6003": {"__data__": {"id_": "5950d0db-b458-464c-9730-76ac2dab6003", "embedding": null, "metadata": {"window": "Daniel Grosslight of Citi.  Please go ahead , sir. \n \n Daniel Grosslight:  Hi guys.  Thanks for taking the question.  I wanted to just go back quickly to the \nMedical profitability question and confirm one thing.  That $20 million one -time item, that was wholly \nconcentrated this quarter.  So, without that, the Medical profitability would have been around $90 \nmillion . ", "original_text": "Thanks for taking the question. ", "page_label": "18", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "0deec662-07aa-4179-9d25-c20d9a0a3f6c", "node_type": "4", "metadata": {"page_label": "18", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "f11e4d47d1a17013e15f5609bc3c17fa461213c2b0fd0db015679c7e48260aaa", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "b2afa807-8304-4a24-817a-52f4ed6d422d", "node_type": "1", "metadata": {"window": "And our last question today will be coming from Mr. \n Daniel Grosslight of Citi.  Please go ahead , sir. \n \n Daniel Grosslight:  Hi guys.  Thanks for taking the question.  I wanted to just go back quickly to the \nMedical profitability question and confirm one thing.  That $20 million one -time item, that was wholly \nconcentrated this quarter. ", "original_text": "Daniel Grosslight:  Hi guys. ", "page_label": "18", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "d2c98b4efde0d982d6cdcf75f0a1ff573b80a42201114e7464d4ac41c1c71dd7", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "6a828dd6-af56-4f37-8e93-96a60843bd30", "node_type": "1", "metadata": {"window": "Please go ahead , sir. \n \n Daniel Grosslight:  Hi guys.  Thanks for taking the question.  I wanted to just go back quickly to the \nMedical profitability question and confirm one thing.  That $20 million one -time item, that was wholly \nconcentrated this quarter.  So, without that, the Medical profitability would have been around $90 \nmillion .  And then on your commentary around shipping rates coming down and benefiting you and the \nvolatility in the Red Sea , if you look at the China to West Coast shipping rates, they have spiked \nmaterially in January. ", "original_text": "I wanted to just go back quickly to the \nMedical profitability question and confirm one thing. "}, "hash": "1f5979e83fc6b709f0325aff8e3f926145de36135adc18d027f062759c90f787", "class_name": "RelatedNodeInfo"}}, "text": "Thanks for taking the question. ", "start_char_idx": 1285, "end_char_idx": 1317, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "6a828dd6-af56-4f37-8e93-96a60843bd30": {"__data__": {"id_": "6a828dd6-af56-4f37-8e93-96a60843bd30", "embedding": null, "metadata": {"window": "Please go ahead , sir. \n \n Daniel Grosslight:  Hi guys.  Thanks for taking the question.  I wanted to just go back quickly to the \nMedical profitability question and confirm one thing.  That $20 million one -time item, that was wholly \nconcentrated this quarter.  So, without that, the Medical profitability would have been around $90 \nmillion .  And then on your commentary around shipping rates coming down and benefiting you and the \nvolatility in the Red Sea , if you look at the China to West Coast shipping rates, they have spiked \nmaterially in January. ", "original_text": "I wanted to just go back quickly to the \nMedical profitability question and confirm one thing. ", "page_label": "18", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "0deec662-07aa-4179-9d25-c20d9a0a3f6c", "node_type": "4", "metadata": {"page_label": "18", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "f11e4d47d1a17013e15f5609bc3c17fa461213c2b0fd0db015679c7e48260aaa", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "5950d0db-b458-464c-9730-76ac2dab6003", "node_type": "1", "metadata": {"window": "Daniel Grosslight of Citi.  Please go ahead , sir. \n \n Daniel Grosslight:  Hi guys.  Thanks for taking the question.  I wanted to just go back quickly to the \nMedical profitability question and confirm one thing.  That $20 million one -time item, that was wholly \nconcentrated this quarter.  So, without that, the Medical profitability would have been around $90 \nmillion . ", "original_text": "Thanks for taking the question. ", "page_label": "18", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "a97414f17317ffd35ce97d33d98662c9985e2bff36ac5e5867e538f65377a599", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "be0ce916-bc5b-492e-8459-6c92501bd2bd", "node_type": "1", "metadata": {"window": "Daniel Grosslight:  Hi guys.  Thanks for taking the question.  I wanted to just go back quickly to the \nMedical profitability question and confirm one thing.  That $20 million one -time item, that was wholly \nconcentrated this quarter.  So, without that, the Medical profitability would have been around $90 \nmillion .  And then on your commentary around shipping rates coming down and benefiting you and the \nvolatility in the Red Sea , if you look at the China to West Coast shipping rates, they have spiked \nmaterially in January.  So, I'm won dering how , I guess a couple of things there. ", "original_text": "That $20 million one -time item, that was wholly \nconcentrated this quarter. "}, "hash": "079d6e86e33aca1a6f8f042db7cbd6ef697b3c15654d4528de5787882dc0aed1", "class_name": "RelatedNodeInfo"}}, "text": "I wanted to just go back quickly to the \nMedical profitability question and confirm one thing. ", "start_char_idx": 1317, "end_char_idx": 1412, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "be0ce916-bc5b-492e-8459-6c92501bd2bd": {"__data__": {"id_": "be0ce916-bc5b-492e-8459-6c92501bd2bd", "embedding": null, "metadata": {"window": "Daniel Grosslight:  Hi guys.  Thanks for taking the question.  I wanted to just go back quickly to the \nMedical profitability question and confirm one thing.  That $20 million one -time item, that was wholly \nconcentrated this quarter.  So, without that, the Medical profitability would have been around $90 \nmillion .  And then on your commentary around shipping rates coming down and benefiting you and the \nvolatility in the Red Sea , if you look at the China to West Coast shipping rates, they have spiked \nmaterially in January.  So, I'm won dering how , I guess a couple of things there. ", "original_text": "That $20 million one -time item, that was wholly \nconcentrated this quarter. ", "page_label": "18", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "0deec662-07aa-4179-9d25-c20d9a0a3f6c", "node_type": "4", "metadata": {"page_label": "18", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "f11e4d47d1a17013e15f5609bc3c17fa461213c2b0fd0db015679c7e48260aaa", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "6a828dd6-af56-4f37-8e93-96a60843bd30", "node_type": "1", "metadata": {"window": "Please go ahead , sir. \n \n Daniel Grosslight:  Hi guys.  Thanks for taking the question.  I wanted to just go back quickly to the \nMedical profitability question and confirm one thing.  That $20 million one -time item, that was wholly \nconcentrated this quarter.  So, without that, the Medical profitability would have been around $90 \nmillion .  And then on your commentary around shipping rates coming down and benefiting you and the \nvolatility in the Red Sea , if you look at the China to West Coast shipping rates, they have spiked \nmaterially in January. ", "original_text": "I wanted to just go back quickly to the \nMedical profitability question and confirm one thing. ", "page_label": "18", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "8f516c269cdd5728c495730bfa10a2f277dd39a623d02110abe4822b8899e136", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "329d1330-4598-45a4-bd08-470e72579014", "node_type": "1", "metadata": {"window": "Thanks for taking the question.  I wanted to just go back quickly to the \nMedical profitability question and confirm one thing.  That $20 million one -time item, that was wholly \nconcentrated this quarter.  So, without that, the Medical profitability would have been around $90 \nmillion .  And then on your commentary around shipping rates coming down and benefiting you and the \nvolatility in the Red Sea , if you look at the China to West Coast shipping rates, they have spiked \nmaterially in January.  So, I'm won dering how , I guess a couple of things there.  One, how that may \nkind of roll through your contracts? ", "original_text": "So, without that, the Medical profitability would have been around $90 \nmillion . "}, "hash": "ad24a999b05fc8ebf14286bde4afce895de94d2fe5f7a8e4f38ef056245ba018", "class_name": "RelatedNodeInfo"}}, "text": "That $20 million one -time item, that was wholly \nconcentrated this quarter. ", "start_char_idx": 1412, "end_char_idx": 1489, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "329d1330-4598-45a4-bd08-470e72579014": {"__data__": {"id_": "329d1330-4598-45a4-bd08-470e72579014", "embedding": null, "metadata": {"window": "Thanks for taking the question.  I wanted to just go back quickly to the \nMedical profitability question and confirm one thing.  That $20 million one -time item, that was wholly \nconcentrated this quarter.  So, without that, the Medical profitability would have been around $90 \nmillion .  And then on your commentary around shipping rates coming down and benefiting you and the \nvolatility in the Red Sea , if you look at the China to West Coast shipping rates, they have spiked \nmaterially in January.  So, I'm won dering how , I guess a couple of things there.  One, how that may \nkind of roll through your contracts? ", "original_text": "So, without that, the Medical profitability would have been around $90 \nmillion . ", "page_label": "18", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "0deec662-07aa-4179-9d25-c20d9a0a3f6c", "node_type": "4", "metadata": {"page_label": "18", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "f11e4d47d1a17013e15f5609bc3c17fa461213c2b0fd0db015679c7e48260aaa", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "be0ce916-bc5b-492e-8459-6c92501bd2bd", "node_type": "1", "metadata": {"window": "Daniel Grosslight:  Hi guys.  Thanks for taking the question.  I wanted to just go back quickly to the \nMedical profitability question and confirm one thing.  That $20 million one -time item, that was wholly \nconcentrated this quarter.  So, without that, the Medical profitability would have been around $90 \nmillion .  And then on your commentary around shipping rates coming down and benefiting you and the \nvolatility in the Red Sea , if you look at the China to West Coast shipping rates, they have spiked \nmaterially in January.  So, I'm won dering how , I guess a couple of things there. ", "original_text": "That $20 million one -time item, that was wholly \nconcentrated this quarter. ", "page_label": "18", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "0a115acac9c36dee128fed2417c7a32a788dea7eff1b9a6c73d9e5c785fff3ed", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "426e93f2-f383-4950-a373-772f8cbb37f2", "node_type": "1", "metadata": {"window": "I wanted to just go back quickly to the \nMedical profitability question and confirm one thing.  That $20 million one -time item, that was wholly \nconcentrated this quarter.  So, without that, the Medical profitability would have been around $90 \nmillion .  And then on your commentary around shipping rates coming down and benefiting you and the \nvolatility in the Red Sea , if you look at the China to West Coast shipping rates, they have spiked \nmaterially in January.  So, I'm won dering how , I guess a couple of things there.  One, how that may \nkind of roll through your contracts?  And then given that you capitalize those costs and then expense it \nover two to three quarters post those costs being capitalized, how that might impact the cadence of \nyour Medical Improvement Plan in fiscal \u201825. ", "original_text": "And then on your commentary around shipping rates coming down and benefiting you and the \nvolatility in the Red Sea , if you look at the China to West Coast shipping rates, they have spiked \nmaterially in January. "}, "hash": "20bcb5afb335e90bb6255f6f1e76191528c9b5652f395e8fe64da150d943ce1d", "class_name": "RelatedNodeInfo"}}, "text": "So, without that, the Medical profitability would have been around $90 \nmillion . ", "start_char_idx": 1489, "end_char_idx": 1571, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "426e93f2-f383-4950-a373-772f8cbb37f2": {"__data__": {"id_": "426e93f2-f383-4950-a373-772f8cbb37f2", "embedding": null, "metadata": {"window": "I wanted to just go back quickly to the \nMedical profitability question and confirm one thing.  That $20 million one -time item, that was wholly \nconcentrated this quarter.  So, without that, the Medical profitability would have been around $90 \nmillion .  And then on your commentary around shipping rates coming down and benefiting you and the \nvolatility in the Red Sea , if you look at the China to West Coast shipping rates, they have spiked \nmaterially in January.  So, I'm won dering how , I guess a couple of things there.  One, how that may \nkind of roll through your contracts?  And then given that you capitalize those costs and then expense it \nover two to three quarters post those costs being capitalized, how that might impact the cadence of \nyour Medical Improvement Plan in fiscal \u201825. ", "original_text": "And then on your commentary around shipping rates coming down and benefiting you and the \nvolatility in the Red Sea , if you look at the China to West Coast shipping rates, they have spiked \nmaterially in January. ", "page_label": "18", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "0deec662-07aa-4179-9d25-c20d9a0a3f6c", "node_type": "4", "metadata": {"page_label": "18", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "f11e4d47d1a17013e15f5609bc3c17fa461213c2b0fd0db015679c7e48260aaa", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "329d1330-4598-45a4-bd08-470e72579014", "node_type": "1", "metadata": {"window": "Thanks for taking the question.  I wanted to just go back quickly to the \nMedical profitability question and confirm one thing.  That $20 million one -time item, that was wholly \nconcentrated this quarter.  So, without that, the Medical profitability would have been around $90 \nmillion .  And then on your commentary around shipping rates coming down and benefiting you and the \nvolatility in the Red Sea , if you look at the China to West Coast shipping rates, they have spiked \nmaterially in January.  So, I'm won dering how , I guess a couple of things there.  One, how that may \nkind of roll through your contracts? ", "original_text": "So, without that, the Medical profitability would have been around $90 \nmillion . ", "page_label": "18", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "8d2f084de94211ce5ff1d8fd07dadd5650bc0e014515e0246e89959a61f35124", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "befcdd3f-9d7a-4c3a-bbcc-ce554b595f11", "node_type": "1", "metadata": {"window": "That $20 million one -time item, that was wholly \nconcentrated this quarter.  So, without that, the Medical profitability would have been around $90 \nmillion .  And then on your commentary around shipping rates coming down and benefiting you and the \nvolatility in the Red Sea , if you look at the China to West Coast shipping rates, they have spiked \nmaterially in January.  So, I'm won dering how , I guess a couple of things there.  One, how that may \nkind of roll through your contracts?  And then given that you capitalize those costs and then expense it \nover two to three quarters post those costs being capitalized, how that might impact the cadence of \nyour Medical Improvement Plan in fiscal \u201825.  Thank you.  \n \n", "original_text": "So, I'm won dering how , I guess a couple of things there. "}, "hash": "5348867b2fbcfcf504f2208bd2a3835174c750cbcb028383974586b7eaaea6d8", "class_name": "RelatedNodeInfo"}}, "text": "And then on your commentary around shipping rates coming down and benefiting you and the \nvolatility in the Red Sea , if you look at the China to West Coast shipping rates, they have spiked \nmaterially in January. ", "start_char_idx": 1571, "end_char_idx": 1785, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "befcdd3f-9d7a-4c3a-bbcc-ce554b595f11": {"__data__": {"id_": "befcdd3f-9d7a-4c3a-bbcc-ce554b595f11", "embedding": null, "metadata": {"window": "That $20 million one -time item, that was wholly \nconcentrated this quarter.  So, without that, the Medical profitability would have been around $90 \nmillion .  And then on your commentary around shipping rates coming down and benefiting you and the \nvolatility in the Red Sea , if you look at the China to West Coast shipping rates, they have spiked \nmaterially in January.  So, I'm won dering how , I guess a couple of things there.  One, how that may \nkind of roll through your contracts?  And then given that you capitalize those costs and then expense it \nover two to three quarters post those costs being capitalized, how that might impact the cadence of \nyour Medical Improvement Plan in fiscal \u201825.  Thank you.  \n \n", "original_text": "So, I'm won dering how , I guess a couple of things there. ", "page_label": "18", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "0deec662-07aa-4179-9d25-c20d9a0a3f6c", "node_type": "4", "metadata": {"page_label": "18", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "f11e4d47d1a17013e15f5609bc3c17fa461213c2b0fd0db015679c7e48260aaa", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "426e93f2-f383-4950-a373-772f8cbb37f2", "node_type": "1", "metadata": {"window": "I wanted to just go back quickly to the \nMedical profitability question and confirm one thing.  That $20 million one -time item, that was wholly \nconcentrated this quarter.  So, without that, the Medical profitability would have been around $90 \nmillion .  And then on your commentary around shipping rates coming down and benefiting you and the \nvolatility in the Red Sea , if you look at the China to West Coast shipping rates, they have spiked \nmaterially in January.  So, I'm won dering how , I guess a couple of things there.  One, how that may \nkind of roll through your contracts?  And then given that you capitalize those costs and then expense it \nover two to three quarters post those costs being capitalized, how that might impact the cadence of \nyour Medical Improvement Plan in fiscal \u201825. ", "original_text": "And then on your commentary around shipping rates coming down and benefiting you and the \nvolatility in the Red Sea , if you look at the China to West Coast shipping rates, they have spiked \nmaterially in January. ", "page_label": "18", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "acb60255ef7c8aab97aef06f832a0fb64f2e0ed4b6b16bcdb9e247ff4c643c2f", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "a004ad39-b1cd-48d9-a1a7-5e2ffdf5117f", "node_type": "1", "metadata": {"window": "So, without that, the Medical profitability would have been around $90 \nmillion .  And then on your commentary around shipping rates coming down and benefiting you and the \nvolatility in the Red Sea , if you look at the China to West Coast shipping rates, they have spiked \nmaterially in January.  So, I'm won dering how , I guess a couple of things there.  One, how that may \nkind of roll through your contracts?  And then given that you capitalize those costs and then expense it \nover two to three quarters post those costs being capitalized, how that might impact the cadence of \nyour Medical Improvement Plan in fiscal \u201825.  Thank you.  \n \n Aaron Alt:  I'll start with the first half of that question. ", "original_text": "One, how that may \nkind of roll through your contracts? "}, "hash": "8274e4cc610ab4a126142f6988b7b6e9b06308f5dbf9768c2050a68513fd080c", "class_name": "RelatedNodeInfo"}}, "text": "So, I'm won dering how , I guess a couple of things there. ", "start_char_idx": 1785, "end_char_idx": 1844, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "a004ad39-b1cd-48d9-a1a7-5e2ffdf5117f": {"__data__": {"id_": "a004ad39-b1cd-48d9-a1a7-5e2ffdf5117f", "embedding": null, "metadata": {"window": "So, without that, the Medical profitability would have been around $90 \nmillion .  And then on your commentary around shipping rates coming down and benefiting you and the \nvolatility in the Red Sea , if you look at the China to West Coast shipping rates, they have spiked \nmaterially in January.  So, I'm won dering how , I guess a couple of things there.  One, how that may \nkind of roll through your contracts?  And then given that you capitalize those costs and then expense it \nover two to three quarters post those costs being capitalized, how that might impact the cadence of \nyour Medical Improvement Plan in fiscal \u201825.  Thank you.  \n \n Aaron Alt:  I'll start with the first half of that question. ", "original_text": "One, how that may \nkind of roll through your contracts? ", "page_label": "18", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "0deec662-07aa-4179-9d25-c20d9a0a3f6c", "node_type": "4", "metadata": {"page_label": "18", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "f11e4d47d1a17013e15f5609bc3c17fa461213c2b0fd0db015679c7e48260aaa", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "befcdd3f-9d7a-4c3a-bbcc-ce554b595f11", "node_type": "1", "metadata": {"window": "That $20 million one -time item, that was wholly \nconcentrated this quarter.  So, without that, the Medical profitability would have been around $90 \nmillion .  And then on your commentary around shipping rates coming down and benefiting you and the \nvolatility in the Red Sea , if you look at the China to West Coast shipping rates, they have spiked \nmaterially in January.  So, I'm won dering how , I guess a couple of things there.  One, how that may \nkind of roll through your contracts?  And then given that you capitalize those costs and then expense it \nover two to three quarters post those costs being capitalized, how that might impact the cadence of \nyour Medical Improvement Plan in fiscal \u201825.  Thank you.  \n \n", "original_text": "So, I'm won dering how , I guess a couple of things there. ", "page_label": "18", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "f0042537beb611e9a9ec52ef714a0e6b3a3404ee388a1499aafe36fb311524a8", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "7a9bda51-e8e1-4933-afe3-062ff35af2f9", "node_type": "1", "metadata": {"window": "And then on your commentary around shipping rates coming down and benefiting you and the \nvolatility in the Red Sea , if you look at the China to West Coast shipping rates, they have spiked \nmaterially in January.  So, I'm won dering how , I guess a couple of things there.  One, how that may \nkind of roll through your contracts?  And then given that you capitalize those costs and then expense it \nover two to three quarters post those costs being capitalized, how that might impact the cadence of \nyour Medical Improvement Plan in fiscal \u201825.  Thank you.  \n \n Aaron Alt:  I'll start with the first half of that question.  You are thinking about things correctly. ", "original_text": "And then given that you capitalize those costs and then expense it \nover two to three quarters post those costs being capitalized, how that might impact the cadence of \nyour Medical Improvement Plan in fiscal \u201825. "}, "hash": "90bc95137234ea75ab75ff8d7b57168176556dbfb720e2e8ba0edffb2d99432f", "class_name": "RelatedNodeInfo"}}, "text": "One, how that may \nkind of roll through your contracts? ", "start_char_idx": 1844, "end_char_idx": 1900, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "7a9bda51-e8e1-4933-afe3-062ff35af2f9": {"__data__": {"id_": "7a9bda51-e8e1-4933-afe3-062ff35af2f9", "embedding": null, "metadata": {"window": "And then on your commentary around shipping rates coming down and benefiting you and the \nvolatility in the Red Sea , if you look at the China to West Coast shipping rates, they have spiked \nmaterially in January.  So, I'm won dering how , I guess a couple of things there.  One, how that may \nkind of roll through your contracts?  And then given that you capitalize those costs and then expense it \nover two to three quarters post those costs being capitalized, how that might impact the cadence of \nyour Medical Improvement Plan in fiscal \u201825.  Thank you.  \n \n Aaron Alt:  I'll start with the first half of that question.  You are thinking about things correctly. ", "original_text": "And then given that you capitalize those costs and then expense it \nover two to three quarters post those costs being capitalized, how that might impact the cadence of \nyour Medical Improvement Plan in fiscal \u201825. ", "page_label": "18", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "0deec662-07aa-4179-9d25-c20d9a0a3f6c", "node_type": "4", "metadata": {"page_label": "18", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "f11e4d47d1a17013e15f5609bc3c17fa461213c2b0fd0db015679c7e48260aaa", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "a004ad39-b1cd-48d9-a1a7-5e2ffdf5117f", "node_type": "1", "metadata": {"window": "So, without that, the Medical profitability would have been around $90 \nmillion .  And then on your commentary around shipping rates coming down and benefiting you and the \nvolatility in the Red Sea , if you look at the China to West Coast shipping rates, they have spiked \nmaterially in January.  So, I'm won dering how , I guess a couple of things there.  One, how that may \nkind of roll through your contracts?  And then given that you capitalize those costs and then expense it \nover two to three quarters post those costs being capitalized, how that might impact the cadence of \nyour Medical Improvement Plan in fiscal \u201825.  Thank you.  \n \n Aaron Alt:  I'll start with the first half of that question. ", "original_text": "One, how that may \nkind of roll through your contracts? ", "page_label": "18", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "18387aa22019ea99ad68ff29f11763f3a3bfd8a6228ab3efa0429a6dfcad1cf3", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "ffa75df3-eb8d-4d72-8167-2ee14f2e2d2c", "node_type": "1", "metadata": {"window": "So, I'm won dering how , I guess a couple of things there.  One, how that may \nkind of roll through your contracts?  And then given that you capitalize those costs and then expense it \nover two to three quarters post those costs being capitalized, how that might impact the cadence of \nyour Medical Improvement Plan in fiscal \u201825.  Thank you.  \n \n Aaron Alt:  I'll start with the first half of that question.  You are thinking about things correctly.  I'll go \nback and emphasize we were really pleased with the operational performance of the business. ", "original_text": "Thank you.  \n \n"}, "hash": "557804cae8737021ae23285805f7b77e1caf07411949a505d3a40afe9138ff31", "class_name": "RelatedNodeInfo"}}, "text": "And then given that you capitalize those costs and then expense it \nover two to three quarters post those costs being capitalized, how that might impact the cadence of \nyour Medical Improvement Plan in fiscal \u201825. ", "start_char_idx": 1900, "end_char_idx": 2114, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "ffa75df3-eb8d-4d72-8167-2ee14f2e2d2c": {"__data__": {"id_": "ffa75df3-eb8d-4d72-8167-2ee14f2e2d2c", "embedding": null, "metadata": {"window": "So, I'm won dering how , I guess a couple of things there.  One, how that may \nkind of roll through your contracts?  And then given that you capitalize those costs and then expense it \nover two to three quarters post those costs being capitalized, how that might impact the cadence of \nyour Medical Improvement Plan in fiscal \u201825.  Thank you.  \n \n Aaron Alt:  I'll start with the first half of that question.  You are thinking about things correctly.  I'll go \nback and emphasize we were really pleased with the operational performance of the business. ", "original_text": "Thank you.  \n \n", "page_label": "18", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "0deec662-07aa-4179-9d25-c20d9a0a3f6c", "node_type": "4", "metadata": {"page_label": "18", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "f11e4d47d1a17013e15f5609bc3c17fa461213c2b0fd0db015679c7e48260aaa", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "7a9bda51-e8e1-4933-afe3-062ff35af2f9", "node_type": "1", "metadata": {"window": "And then on your commentary around shipping rates coming down and benefiting you and the \nvolatility in the Red Sea , if you look at the China to West Coast shipping rates, they have spiked \nmaterially in January.  So, I'm won dering how , I guess a couple of things there.  One, how that may \nkind of roll through your contracts?  And then given that you capitalize those costs and then expense it \nover two to three quarters post those costs being capitalized, how that might impact the cadence of \nyour Medical Improvement Plan in fiscal \u201825.  Thank you.  \n \n Aaron Alt:  I'll start with the first half of that question.  You are thinking about things correctly. ", "original_text": "And then given that you capitalize those costs and then expense it \nover two to three quarters post those costs being capitalized, how that might impact the cadence of \nyour Medical Improvement Plan in fiscal \u201825. ", "page_label": "18", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "ade958c838ea39c933eb38caf4bba2db5ff4a98d2390b0a3afc97a99262ef2c7", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "830ae623-4c88-4e2a-91aa-202d3e3f48fd", "node_type": "1", "metadata": {"window": "One, how that may \nkind of roll through your contracts?  And then given that you capitalize those costs and then expense it \nover two to three quarters post those costs being capitalized, how that might impact the cadence of \nyour Medical Improvement Plan in fiscal \u201825.  Thank you.  \n \n Aaron Alt:  I'll start with the first half of that question.  You are thinking about things correctly.  I'll go \nback and emphasize we were really pleased with the operational performance of the business.  And \ngiven that we've adjusted our yearly guidance just to reflect the impact of the non -recurring \nadjustments in Q2, your conclusion on the math would be reasonable.  \n \n", "original_text": "Aaron Alt:  I'll start with the first half of that question. "}, "hash": "19795a42981ef0bafec55f7f619d23b305bea9ec9cefb94b50cb105b71dfbb71", "class_name": "RelatedNodeInfo"}}, "text": "Thank you.  \n \n", "start_char_idx": 2114, "end_char_idx": 2129, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "830ae623-4c88-4e2a-91aa-202d3e3f48fd": {"__data__": {"id_": "830ae623-4c88-4e2a-91aa-202d3e3f48fd", "embedding": null, "metadata": {"window": "One, how that may \nkind of roll through your contracts?  And then given that you capitalize those costs and then expense it \nover two to three quarters post those costs being capitalized, how that might impact the cadence of \nyour Medical Improvement Plan in fiscal \u201825.  Thank you.  \n \n Aaron Alt:  I'll start with the first half of that question.  You are thinking about things correctly.  I'll go \nback and emphasize we were really pleased with the operational performance of the business.  And \ngiven that we've adjusted our yearly guidance just to reflect the impact of the non -recurring \nadjustments in Q2, your conclusion on the math would be reasonable.  \n \n", "original_text": "Aaron Alt:  I'll start with the first half of that question. ", "page_label": "18", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "0deec662-07aa-4179-9d25-c20d9a0a3f6c", "node_type": "4", "metadata": {"page_label": "18", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "f11e4d47d1a17013e15f5609bc3c17fa461213c2b0fd0db015679c7e48260aaa", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "ffa75df3-eb8d-4d72-8167-2ee14f2e2d2c", "node_type": "1", "metadata": {"window": "So, I'm won dering how , I guess a couple of things there.  One, how that may \nkind of roll through your contracts?  And then given that you capitalize those costs and then expense it \nover two to three quarters post those costs being capitalized, how that might impact the cadence of \nyour Medical Improvement Plan in fiscal \u201825.  Thank you.  \n \n Aaron Alt:  I'll start with the first half of that question.  You are thinking about things correctly.  I'll go \nback and emphasize we were really pleased with the operational performance of the business. ", "original_text": "Thank you.  \n \n", "page_label": "18", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "c86d586d1f01cba37c48bef21c121eb78fa654df52ccfd0a084818a136f1e191", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "29fad6a0-0a46-412b-a1e1-11318294c102", "node_type": "1", "metadata": {"window": "And then given that you capitalize those costs and then expense it \nover two to three quarters post those costs being capitalized, how that might impact the cadence of \nyour Medical Improvement Plan in fiscal \u201825.  Thank you.  \n \n Aaron Alt:  I'll start with the first half of that question.  You are thinking about things correctly.  I'll go \nback and emphasize we were really pleased with the operational performance of the business.  And \ngiven that we've adjusted our yearly guidance just to reflect the impact of the non -recurring \nadjustments in Q2, your conclusion on the math would be reasonable.  \n \n Jason Hollar:  Yeah, o n the second component, you are correct that shipping rates have spiked. ", "original_text": "You are thinking about things correctly. "}, "hash": "255ca4218542f588523015121d5c5a2ae575b630f876149d0d5ebb37c4e43424", "class_name": "RelatedNodeInfo"}}, "text": "Aaron Alt:  I'll start with the first half of that question. ", "start_char_idx": 2129, "end_char_idx": 2190, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "29fad6a0-0a46-412b-a1e1-11318294c102": {"__data__": {"id_": "29fad6a0-0a46-412b-a1e1-11318294c102", "embedding": null, "metadata": {"window": "And then given that you capitalize those costs and then expense it \nover two to three quarters post those costs being capitalized, how that might impact the cadence of \nyour Medical Improvement Plan in fiscal \u201825.  Thank you.  \n \n Aaron Alt:  I'll start with the first half of that question.  You are thinking about things correctly.  I'll go \nback and emphasize we were really pleased with the operational performance of the business.  And \ngiven that we've adjusted our yearly guidance just to reflect the impact of the non -recurring \nadjustments in Q2, your conclusion on the math would be reasonable.  \n \n Jason Hollar:  Yeah, o n the second component, you are correct that shipping rates have spiked. ", "original_text": "You are thinking about things correctly. ", "page_label": "18", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "0deec662-07aa-4179-9d25-c20d9a0a3f6c", "node_type": "4", "metadata": {"page_label": "18", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "f11e4d47d1a17013e15f5609bc3c17fa461213c2b0fd0db015679c7e48260aaa", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "830ae623-4c88-4e2a-91aa-202d3e3f48fd", "node_type": "1", "metadata": {"window": "One, how that may \nkind of roll through your contracts?  And then given that you capitalize those costs and then expense it \nover two to three quarters post those costs being capitalized, how that might impact the cadence of \nyour Medical Improvement Plan in fiscal \u201825.  Thank you.  \n \n Aaron Alt:  I'll start with the first half of that question.  You are thinking about things correctly.  I'll go \nback and emphasize we were really pleased with the operational performance of the business.  And \ngiven that we've adjusted our yearly guidance just to reflect the impact of the non -recurring \nadjustments in Q2, your conclusion on the math would be reasonable.  \n \n", "original_text": "Aaron Alt:  I'll start with the first half of that question. ", "page_label": "18", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "f54313ff19a89460b707a99aa8b3eba349d655d01c76a373b4c31a035d5735b1", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "2722cd83-e05d-490a-bec2-ad3fded20d27", "node_type": "1", "metadata": {"window": "Thank you.  \n \n Aaron Alt:  I'll start with the first half of that question.  You are thinking about things correctly.  I'll go \nback and emphasize we were really pleased with the operational performance of the business.  And \ngiven that we've adjusted our yearly guidance just to reflect the impact of the non -recurring \nadjustments in Q2, your conclusion on the math would be reasonable.  \n \n Jason Hollar:  Yeah, o n the second component, you are correct that shipping rates have spiked.  I \nthink the word use was materially and how I would characterize it is, yes, that's accurate, but \nsubstantially less materially than where they were in the past. ", "original_text": "I'll go \nback and emphasize we were really pleased with the operational performance of the business. "}, "hash": "58ecb05a13612f2a9734aa707dffdc39234b788a84f9fdbe6951fbca8be602ca", "class_name": "RelatedNodeInfo"}}, "text": "You are thinking about things correctly. ", "start_char_idx": 2190, "end_char_idx": 2231, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "2722cd83-e05d-490a-bec2-ad3fded20d27": {"__data__": {"id_": "2722cd83-e05d-490a-bec2-ad3fded20d27", "embedding": null, "metadata": {"window": "Thank you.  \n \n Aaron Alt:  I'll start with the first half of that question.  You are thinking about things correctly.  I'll go \nback and emphasize we were really pleased with the operational performance of the business.  And \ngiven that we've adjusted our yearly guidance just to reflect the impact of the non -recurring \nadjustments in Q2, your conclusion on the math would be reasonable.  \n \n Jason Hollar:  Yeah, o n the second component, you are correct that shipping rates have spiked.  I \nthink the word use was materially and how I would characterize it is, yes, that's accurate, but \nsubstantially less materially than where they were in the past. ", "original_text": "I'll go \nback and emphasize we were really pleased with the operational performance of the business. ", "page_label": "18", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "0deec662-07aa-4179-9d25-c20d9a0a3f6c", "node_type": "4", "metadata": {"page_label": "18", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "f11e4d47d1a17013e15f5609bc3c17fa461213c2b0fd0db015679c7e48260aaa", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "29fad6a0-0a46-412b-a1e1-11318294c102", "node_type": "1", "metadata": {"window": "And then given that you capitalize those costs and then expense it \nover two to three quarters post those costs being capitalized, how that might impact the cadence of \nyour Medical Improvement Plan in fiscal \u201825.  Thank you.  \n \n Aaron Alt:  I'll start with the first half of that question.  You are thinking about things correctly.  I'll go \nback and emphasize we were really pleased with the operational performance of the business.  And \ngiven that we've adjusted our yearly guidance just to reflect the impact of the non -recurring \nadjustments in Q2, your conclusion on the math would be reasonable.  \n \n Jason Hollar:  Yeah, o n the second component, you are correct that shipping rates have spiked. ", "original_text": "You are thinking about things correctly. ", "page_label": "18", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "8c5310cb153cf85869b97584a4a325ae8773ad2662eb7ddf93e438fd00654edb", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "20599250-aecd-4ff8-85ba-5ea98f0735ba", "node_type": "1", "metadata": {"window": "Aaron Alt:  I'll start with the first half of that question.  You are thinking about things correctly.  I'll go \nback and emphasize we were really pleased with the operational performance of the business.  And \ngiven that we've adjusted our yearly guidance just to reflect the impact of the non -recurring \nadjustments in Q2, your conclusion on the math would be reasonable.  \n \n Jason Hollar:  Yeah, o n the second component, you are correct that shipping rates have spiked.  I \nthink the word use was materially and how I would characterize it is, yes, that's accurate, but \nsubstantially less materially than where they were in the past.  So, the order of magnitude we're \ntalking about is vastly smaller. ", "original_text": "And \ngiven that we've adjusted our yearly guidance just to reflect the impact of the non -recurring \nadjustments in Q2, your conclusion on the math would be reasonable.  \n \n"}, "hash": "859118e8a211cf4030ba343b2b76f9b93f92994c3a2a95bb2d34222f61304aba", "class_name": "RelatedNodeInfo"}}, "text": "I'll go \nback and emphasize we were really pleased with the operational performance of the business. ", "start_char_idx": 2231, "end_char_idx": 2332, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "20599250-aecd-4ff8-85ba-5ea98f0735ba": {"__data__": {"id_": "20599250-aecd-4ff8-85ba-5ea98f0735ba", "embedding": null, "metadata": {"window": "Aaron Alt:  I'll start with the first half of that question.  You are thinking about things correctly.  I'll go \nback and emphasize we were really pleased with the operational performance of the business.  And \ngiven that we've adjusted our yearly guidance just to reflect the impact of the non -recurring \nadjustments in Q2, your conclusion on the math would be reasonable.  \n \n Jason Hollar:  Yeah, o n the second component, you are correct that shipping rates have spiked.  I \nthink the word use was materially and how I would characterize it is, yes, that's accurate, but \nsubstantially less materially than where they were in the past.  So, the order of magnitude we're \ntalking about is vastly smaller. ", "original_text": "And \ngiven that we've adjusted our yearly guidance just to reflect the impact of the non -recurring \nadjustments in Q2, your conclusion on the math would be reasonable.  \n \n", "page_label": "18", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "0deec662-07aa-4179-9d25-c20d9a0a3f6c", "node_type": "4", "metadata": {"page_label": "18", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "f11e4d47d1a17013e15f5609bc3c17fa461213c2b0fd0db015679c7e48260aaa", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "2722cd83-e05d-490a-bec2-ad3fded20d27", "node_type": "1", "metadata": {"window": "Thank you.  \n \n Aaron Alt:  I'll start with the first half of that question.  You are thinking about things correctly.  I'll go \nback and emphasize we were really pleased with the operational performance of the business.  And \ngiven that we've adjusted our yearly guidance just to reflect the impact of the non -recurring \nadjustments in Q2, your conclusion on the math would be reasonable.  \n \n Jason Hollar:  Yeah, o n the second component, you are correct that shipping rates have spiked.  I \nthink the word use was materially and how I would characterize it is, yes, that's accurate, but \nsubstantially less materially than where they were in the past. ", "original_text": "I'll go \nback and emphasize we were really pleased with the operational performance of the business. ", "page_label": "18", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "0fca16e5a05a1cde6c3cd79e5cad92f4c4ad9a06d4fbbd06c34c617c544b46f4", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "8c34ad96-1c1f-4b01-a70c-0679d5398877", "node_type": "1", "metadata": {"window": "You are thinking about things correctly.  I'll go \nback and emphasize we were really pleased with the operational performance of the business.  And \ngiven that we've adjusted our yearly guidance just to reflect the impact of the non -recurring \nadjustments in Q2, your conclusion on the math would be reasonable.  \n \n Jason Hollar:  Yeah, o n the second component, you are correct that shipping rates have spiked.  I \nthink the word use was materially and how I would characterize it is, yes, that's accurate, but \nsubstantially less materially than where they were in the past.  So, the order of magnitude we're \ntalking about is vastly smaller.  It is also something that we do not believe that that will be the \npermanent level.  ", "original_text": "Jason Hollar:  Yeah, o n the second component, you are correct that shipping rates have spiked. "}, "hash": "3e58492e95ac2f4eb3eae5a5b7ee85fe6c06d9ee58e824a726890f6afdc2f440", "class_name": "RelatedNodeInfo"}}, "text": "And \ngiven that we've adjusted our yearly guidance just to reflect the impact of the non -recurring \nadjustments in Q2, your conclusion on the math would be reasonable.  \n \n", "start_char_idx": 2332, "end_char_idx": 2505, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "8c34ad96-1c1f-4b01-a70c-0679d5398877": {"__data__": {"id_": "8c34ad96-1c1f-4b01-a70c-0679d5398877", "embedding": null, "metadata": {"window": "You are thinking about things correctly.  I'll go \nback and emphasize we were really pleased with the operational performance of the business.  And \ngiven that we've adjusted our yearly guidance just to reflect the impact of the non -recurring \nadjustments in Q2, your conclusion on the math would be reasonable.  \n \n Jason Hollar:  Yeah, o n the second component, you are correct that shipping rates have spiked.  I \nthink the word use was materially and how I would characterize it is, yes, that's accurate, but \nsubstantially less materially than where they were in the past.  So, the order of magnitude we're \ntalking about is vastly smaller.  It is also something that we do not believe that that will be the \npermanent level.  ", "original_text": "Jason Hollar:  Yeah, o n the second component, you are correct that shipping rates have spiked. ", "page_label": "18", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "0deec662-07aa-4179-9d25-c20d9a0a3f6c", "node_type": "4", "metadata": {"page_label": "18", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "f11e4d47d1a17013e15f5609bc3c17fa461213c2b0fd0db015679c7e48260aaa", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "20599250-aecd-4ff8-85ba-5ea98f0735ba", "node_type": "1", "metadata": {"window": "Aaron Alt:  I'll start with the first half of that question.  You are thinking about things correctly.  I'll go \nback and emphasize we were really pleased with the operational performance of the business.  And \ngiven that we've adjusted our yearly guidance just to reflect the impact of the non -recurring \nadjustments in Q2, your conclusion on the math would be reasonable.  \n \n Jason Hollar:  Yeah, o n the second component, you are correct that shipping rates have spiked.  I \nthink the word use was materially and how I would characterize it is, yes, that's accurate, but \nsubstantially less materially than where they were in the past.  So, the order of magnitude we're \ntalking about is vastly smaller. ", "original_text": "And \ngiven that we've adjusted our yearly guidance just to reflect the impact of the non -recurring \nadjustments in Q2, your conclusion on the math would be reasonable.  \n \n", "page_label": "18", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "4381fb59ff533978e3d91712c206ace583372e2442d52eb3a5a914beab3f5070", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "dd09368c-b0db-4893-a3c8-afce7c937dd2", "node_type": "1", "metadata": {"window": "I'll go \nback and emphasize we were really pleased with the operational performance of the business.  And \ngiven that we've adjusted our yearly guidance just to reflect the impact of the non -recurring \nadjustments in Q2, your conclusion on the math would be reasonable.  \n \n Jason Hollar:  Yeah, o n the second component, you are correct that shipping rates have spiked.  I \nthink the word use was materially and how I would characterize it is, yes, that's accurate, but \nsubstantially less materially than where they were in the past.  So, the order of magnitude we're \ntalking about is vastly smaller.  It is also something that we do not believe that that will be the \npermanent level.   Yes, we have more flexibility in our contracts, and that will continue to be a lever \nand a component that we'll be evaluating determining on whether , how permanent these are or not. ", "original_text": "I \nthink the word use was materially and how I would characterize it is, yes, that's accurate, but \nsubstantially less materially than where they were in the past. "}, "hash": "5a1f99ac45c7805758923cc39e6aa753d5aedbdda74957951ee64a3ea0f7195c", "class_name": "RelatedNodeInfo"}}, "text": "Jason Hollar:  Yeah, o n the second component, you are correct that shipping rates have spiked. ", "start_char_idx": 2505, "end_char_idx": 2601, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "dd09368c-b0db-4893-a3c8-afce7c937dd2": {"__data__": {"id_": "dd09368c-b0db-4893-a3c8-afce7c937dd2", "embedding": null, "metadata": {"window": "I'll go \nback and emphasize we were really pleased with the operational performance of the business.  And \ngiven that we've adjusted our yearly guidance just to reflect the impact of the non -recurring \nadjustments in Q2, your conclusion on the math would be reasonable.  \n \n Jason Hollar:  Yeah, o n the second component, you are correct that shipping rates have spiked.  I \nthink the word use was materially and how I would characterize it is, yes, that's accurate, but \nsubstantially less materially than where they were in the past.  So, the order of magnitude we're \ntalking about is vastly smaller.  It is also something that we do not believe that that will be the \npermanent level.   Yes, we have more flexibility in our contracts, and that will continue to be a lever \nand a component that we'll be evaluating determining on whether , how permanent these are or not. ", "original_text": "I \nthink the word use was materially and how I would characterize it is, yes, that's accurate, but \nsubstantially less materially than where they were in the past. ", "page_label": "18", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "0deec662-07aa-4179-9d25-c20d9a0a3f6c", "node_type": "4", "metadata": {"page_label": "18", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "f11e4d47d1a17013e15f5609bc3c17fa461213c2b0fd0db015679c7e48260aaa", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "8c34ad96-1c1f-4b01-a70c-0679d5398877", "node_type": "1", "metadata": {"window": "You are thinking about things correctly.  I'll go \nback and emphasize we were really pleased with the operational performance of the business.  And \ngiven that we've adjusted our yearly guidance just to reflect the impact of the non -recurring \nadjustments in Q2, your conclusion on the math would be reasonable.  \n \n Jason Hollar:  Yeah, o n the second component, you are correct that shipping rates have spiked.  I \nthink the word use was materially and how I would characterize it is, yes, that's accurate, but \nsubstantially less materially than where they were in the past.  So, the order of magnitude we're \ntalking about is vastly smaller.  It is also something that we do not believe that that will be the \npermanent level.  ", "original_text": "Jason Hollar:  Yeah, o n the second component, you are correct that shipping rates have spiked. ", "page_label": "18", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "98ae792e8981141ea8f800cb4df9cc69934857fa9f48d64d34c79ce14c38aa1d", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "5d32ffae-30e3-41af-84c8-69b1cc437fbf", "node_type": "1", "metadata": {"window": "And \ngiven that we've adjusted our yearly guidance just to reflect the impact of the non -recurring \nadjustments in Q2, your conclusion on the math would be reasonable.  \n \n Jason Hollar:  Yeah, o n the second component, you are correct that shipping rates have spiked.  I \nthink the word use was materially and how I would characterize it is, yes, that's accurate, but \nsubstantially less materially than where they were in the past.  So, the order of magnitude we're \ntalking about is vastly smaller.  It is also something that we do not believe that that will be the \npermanent level.   Yes, we have more flexibility in our contracts, and that will continue to be a lever \nand a component that we'll be evaluating determining on whether , how permanent these are or not.  I \nwould also say that our maturity, our capability within this space has substantially improved as well as \nwe've invested in the underlying processes and procedures to manage through these types of , that \ntype of volatility. ", "original_text": "So, the order of magnitude we're \ntalking about is vastly smaller. "}, "hash": "3bf625d57c565d1f3f8b64056868759bf60d6ce25c0d115fb8a4d37e73df63f9", "class_name": "RelatedNodeInfo"}}, "text": "I \nthink the word use was materially and how I would characterize it is, yes, that's accurate, but \nsubstantially less materially than where they were in the past. ", "start_char_idx": 2601, "end_char_idx": 2765, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "5d32ffae-30e3-41af-84c8-69b1cc437fbf": {"__data__": {"id_": "5d32ffae-30e3-41af-84c8-69b1cc437fbf", "embedding": null, "metadata": {"window": "And \ngiven that we've adjusted our yearly guidance just to reflect the impact of the non -recurring \nadjustments in Q2, your conclusion on the math would be reasonable.  \n \n Jason Hollar:  Yeah, o n the second component, you are correct that shipping rates have spiked.  I \nthink the word use was materially and how I would characterize it is, yes, that's accurate, but \nsubstantially less materially than where they were in the past.  So, the order of magnitude we're \ntalking about is vastly smaller.  It is also something that we do not believe that that will be the \npermanent level.   Yes, we have more flexibility in our contracts, and that will continue to be a lever \nand a component that we'll be evaluating determining on whether , how permanent these are or not.  I \nwould also say that our maturity, our capability within this space has substantially improved as well as \nwe've invested in the underlying processes and procedures to manage through these types of , that \ntype of volatility. ", "original_text": "So, the order of magnitude we're \ntalking about is vastly smaller. ", "page_label": "18", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "0deec662-07aa-4179-9d25-c20d9a0a3f6c", "node_type": "4", "metadata": {"page_label": "18", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "f11e4d47d1a17013e15f5609bc3c17fa461213c2b0fd0db015679c7e48260aaa", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "dd09368c-b0db-4893-a3c8-afce7c937dd2", "node_type": "1", "metadata": {"window": "I'll go \nback and emphasize we were really pleased with the operational performance of the business.  And \ngiven that we've adjusted our yearly guidance just to reflect the impact of the non -recurring \nadjustments in Q2, your conclusion on the math would be reasonable.  \n \n Jason Hollar:  Yeah, o n the second component, you are correct that shipping rates have spiked.  I \nthink the word use was materially and how I would characterize it is, yes, that's accurate, but \nsubstantially less materially than where they were in the past.  So, the order of magnitude we're \ntalking about is vastly smaller.  It is also something that we do not believe that that will be the \npermanent level.   Yes, we have more flexibility in our contracts, and that will continue to be a lever \nand a component that we'll be evaluating determining on whether , how permanent these are or not. ", "original_text": "I \nthink the word use was materially and how I would characterize it is, yes, that's accurate, but \nsubstantially less materially than where they were in the past. ", "page_label": "18", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "38df45687b3ac423a214db4d739acaec3bb30cf556bf709f245574d9279cbf4b", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "687939ab-d703-4c12-b8a3-90a3967e1c6e", "node_type": "1", "metadata": {"window": "Jason Hollar:  Yeah, o n the second component, you are correct that shipping rates have spiked.  I \nthink the word use was materially and how I would characterize it is, yes, that's accurate, but \nsubstantially less materially than where they were in the past.  So, the order of magnitude we're \ntalking about is vastly smaller.  It is also something that we do not believe that that will be the \npermanent level.   Yes, we have more flexibility in our contracts, and that will continue to be a lever \nand a component that we'll be evaluating determining on whether , how permanent these are or not.  I \nwould also say that our maturity, our capability within this space has substantially improved as well as \nwe've invested in the underlying processes and procedures to manage through these types of , that \ntype of volatility.  So overall, we feel very good about where we stand and generally don't see this \nbeing as a material item, but we'll continue to watch it closely.  \n ", "original_text": "It is also something that we do not believe that that will be the \npermanent level.  "}, "hash": "b3ebb6a9ee87d39dfb55b26e4d4cefbad625973a6b0c9ad2f29617b00724111b", "class_name": "RelatedNodeInfo"}}, "text": "So, the order of magnitude we're \ntalking about is vastly smaller. ", "start_char_idx": 2765, "end_char_idx": 2832, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "687939ab-d703-4c12-b8a3-90a3967e1c6e": {"__data__": {"id_": "687939ab-d703-4c12-b8a3-90a3967e1c6e", "embedding": null, "metadata": {"window": "Jason Hollar:  Yeah, o n the second component, you are correct that shipping rates have spiked.  I \nthink the word use was materially and how I would characterize it is, yes, that's accurate, but \nsubstantially less materially than where they were in the past.  So, the order of magnitude we're \ntalking about is vastly smaller.  It is also something that we do not believe that that will be the \npermanent level.   Yes, we have more flexibility in our contracts, and that will continue to be a lever \nand a component that we'll be evaluating determining on whether , how permanent these are or not.  I \nwould also say that our maturity, our capability within this space has substantially improved as well as \nwe've invested in the underlying processes and procedures to manage through these types of , that \ntype of volatility.  So overall, we feel very good about where we stand and generally don't see this \nbeing as a material item, but we'll continue to watch it closely.  \n ", "original_text": "It is also something that we do not believe that that will be the \npermanent level.  ", "page_label": "18", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "0deec662-07aa-4179-9d25-c20d9a0a3f6c", "node_type": "4", "metadata": {"page_label": "18", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "f11e4d47d1a17013e15f5609bc3c17fa461213c2b0fd0db015679c7e48260aaa", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "5d32ffae-30e3-41af-84c8-69b1cc437fbf", "node_type": "1", "metadata": {"window": "And \ngiven that we've adjusted our yearly guidance just to reflect the impact of the non -recurring \nadjustments in Q2, your conclusion on the math would be reasonable.  \n \n Jason Hollar:  Yeah, o n the second component, you are correct that shipping rates have spiked.  I \nthink the word use was materially and how I would characterize it is, yes, that's accurate, but \nsubstantially less materially than where they were in the past.  So, the order of magnitude we're \ntalking about is vastly smaller.  It is also something that we do not believe that that will be the \npermanent level.   Yes, we have more flexibility in our contracts, and that will continue to be a lever \nand a component that we'll be evaluating determining on whether , how permanent these are or not.  I \nwould also say that our maturity, our capability within this space has substantially improved as well as \nwe've invested in the underlying processes and procedures to manage through these types of , that \ntype of volatility. ", "original_text": "So, the order of magnitude we're \ntalking about is vastly smaller. ", "page_label": "18", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "83222b9db79fe3c4161f58195ea9f1e0159ae35203e3c6c25a153dee54ebd377", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "18230539-18b0-4170-b469-4e8b96b68371", "node_type": "1", "metadata": {"window": "I \nthink the word use was materially and how I would characterize it is, yes, that's accurate, but \nsubstantially less materially than where they were in the past.  So, the order of magnitude we're \ntalking about is vastly smaller.  It is also something that we do not believe that that will be the \npermanent level.   Yes, we have more flexibility in our contracts, and that will continue to be a lever \nand a component that we'll be evaluating determining on whether , how permanent these are or not.  I \nwould also say that our maturity, our capability within this space has substantially improved as well as \nwe've invested in the underlying processes and procedures to manage through these types of , that \ntype of volatility.  So overall, we feel very good about where we stand and generally don't see this \nbeing as a material item, but we'll continue to watch it closely.  \n ", "original_text": "Yes, we have more flexibility in our contracts, and that will continue to be a lever \nand a component that we'll be evaluating determining on whether , how permanent these are or not. "}, "hash": "79b027597ba82929e58b465dc3a32aebb030dccb0ac271baab107d434f176080", "class_name": "RelatedNodeInfo"}}, "text": "It is also something that we do not believe that that will be the \npermanent level.  ", "start_char_idx": 2832, "end_char_idx": 2917, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "18230539-18b0-4170-b469-4e8b96b68371": {"__data__": {"id_": "18230539-18b0-4170-b469-4e8b96b68371", "embedding": null, "metadata": {"window": "I \nthink the word use was materially and how I would characterize it is, yes, that's accurate, but \nsubstantially less materially than where they were in the past.  So, the order of magnitude we're \ntalking about is vastly smaller.  It is also something that we do not believe that that will be the \npermanent level.   Yes, we have more flexibility in our contracts, and that will continue to be a lever \nand a component that we'll be evaluating determining on whether , how permanent these are or not.  I \nwould also say that our maturity, our capability within this space has substantially improved as well as \nwe've invested in the underlying processes and procedures to manage through these types of , that \ntype of volatility.  So overall, we feel very good about where we stand and generally don't see this \nbeing as a material item, but we'll continue to watch it closely.  \n ", "original_text": "Yes, we have more flexibility in our contracts, and that will continue to be a lever \nand a component that we'll be evaluating determining on whether , how permanent these are or not. ", "page_label": "18", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "0deec662-07aa-4179-9d25-c20d9a0a3f6c", "node_type": "4", "metadata": {"page_label": "18", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "f11e4d47d1a17013e15f5609bc3c17fa461213c2b0fd0db015679c7e48260aaa", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "687939ab-d703-4c12-b8a3-90a3967e1c6e", "node_type": "1", "metadata": {"window": "Jason Hollar:  Yeah, o n the second component, you are correct that shipping rates have spiked.  I \nthink the word use was materially and how I would characterize it is, yes, that's accurate, but \nsubstantially less materially than where they were in the past.  So, the order of magnitude we're \ntalking about is vastly smaller.  It is also something that we do not believe that that will be the \npermanent level.   Yes, we have more flexibility in our contracts, and that will continue to be a lever \nand a component that we'll be evaluating determining on whether , how permanent these are or not.  I \nwould also say that our maturity, our capability within this space has substantially improved as well as \nwe've invested in the underlying processes and procedures to manage through these types of , that \ntype of volatility.  So overall, we feel very good about where we stand and generally don't see this \nbeing as a material item, but we'll continue to watch it closely.  \n ", "original_text": "It is also something that we do not believe that that will be the \npermanent level.  ", "page_label": "18", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "9a7c636fe92cf548b40a5c25c0bdc1c3d61224454ede54fa97f7c9733db101a3", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "65552542-c9cd-4c0e-b631-1e685ff9dd2e", "node_type": "1", "metadata": {"window": "So, the order of magnitude we're \ntalking about is vastly smaller.  It is also something that we do not believe that that will be the \npermanent level.   Yes, we have more flexibility in our contracts, and that will continue to be a lever \nand a component that we'll be evaluating determining on whether , how permanent these are or not.  I \nwould also say that our maturity, our capability within this space has substantially improved as well as \nwe've invested in the underlying processes and procedures to manage through these types of , that \ntype of volatility.  So overall, we feel very good about where we stand and generally don't see this \nbeing as a material item, but we'll continue to watch it closely.  \n ", "original_text": "I \nwould also say that our maturity, our capability within this space has substantially improved as well as \nwe've invested in the underlying processes and procedures to manage through these types of , that \ntype of volatility. "}, "hash": "7630419ba8ee8ad58e0c73a64ce333840f862a76398b9483eb0729969c4e5ec9", "class_name": "RelatedNodeInfo"}}, "text": "Yes, we have more flexibility in our contracts, and that will continue to be a lever \nand a component that we'll be evaluating determining on whether , how permanent these are or not. ", "start_char_idx": 2917, "end_char_idx": 3101, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "65552542-c9cd-4c0e-b631-1e685ff9dd2e": {"__data__": {"id_": "65552542-c9cd-4c0e-b631-1e685ff9dd2e", "embedding": null, "metadata": {"window": "So, the order of magnitude we're \ntalking about is vastly smaller.  It is also something that we do not believe that that will be the \npermanent level.   Yes, we have more flexibility in our contracts, and that will continue to be a lever \nand a component that we'll be evaluating determining on whether , how permanent these are or not.  I \nwould also say that our maturity, our capability within this space has substantially improved as well as \nwe've invested in the underlying processes and procedures to manage through these types of , that \ntype of volatility.  So overall, we feel very good about where we stand and generally don't see this \nbeing as a material item, but we'll continue to watch it closely.  \n ", "original_text": "I \nwould also say that our maturity, our capability within this space has substantially improved as well as \nwe've invested in the underlying processes and procedures to manage through these types of , that \ntype of volatility. ", "page_label": "18", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "0deec662-07aa-4179-9d25-c20d9a0a3f6c", "node_type": "4", "metadata": {"page_label": "18", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "f11e4d47d1a17013e15f5609bc3c17fa461213c2b0fd0db015679c7e48260aaa", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "18230539-18b0-4170-b469-4e8b96b68371", "node_type": "1", "metadata": {"window": "I \nthink the word use was materially and how I would characterize it is, yes, that's accurate, but \nsubstantially less materially than where they were in the past.  So, the order of magnitude we're \ntalking about is vastly smaller.  It is also something that we do not believe that that will be the \npermanent level.   Yes, we have more flexibility in our contracts, and that will continue to be a lever \nand a component that we'll be evaluating determining on whether , how permanent these are or not.  I \nwould also say that our maturity, our capability within this space has substantially improved as well as \nwe've invested in the underlying processes and procedures to manage through these types of , that \ntype of volatility.  So overall, we feel very good about where we stand and generally don't see this \nbeing as a material item, but we'll continue to watch it closely.  \n ", "original_text": "Yes, we have more flexibility in our contracts, and that will continue to be a lever \nand a component that we'll be evaluating determining on whether , how permanent these are or not. ", "page_label": "18", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "ce26834911769ecfba7939f57300131c32b16bb85f53420bca59c4de39b8d59e", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "b0f50702-52d6-4dc1-9b1d-ea2d14f1307e", "node_type": "1", "metadata": {"window": "It is also something that we do not believe that that will be the \npermanent level.   Yes, we have more flexibility in our contracts, and that will continue to be a lever \nand a component that we'll be evaluating determining on whether , how permanent these are or not.  I \nwould also say that our maturity, our capability within this space has substantially improved as well as \nwe've invested in the underlying processes and procedures to manage through these types of , that \ntype of volatility.  So overall, we feel very good about where we stand and generally don't see this \nbeing as a material item, but we'll continue to watch it closely.  \n ", "original_text": "So overall, we feel very good about where we stand and generally don't see this \nbeing as a material item, but we'll continue to watch it closely.  \n "}, "hash": "4356f329daa8a355def0b184ba062d25c054efe972e59c395a83b3aa9d5ec0b9", "class_name": "RelatedNodeInfo"}}, "text": "I \nwould also say that our maturity, our capability within this space has substantially improved as well as \nwe've invested in the underlying processes and procedures to manage through these types of , that \ntype of volatility. ", "start_char_idx": 3101, "end_char_idx": 3329, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "b0f50702-52d6-4dc1-9b1d-ea2d14f1307e": {"__data__": {"id_": "b0f50702-52d6-4dc1-9b1d-ea2d14f1307e", "embedding": null, "metadata": {"window": "It is also something that we do not believe that that will be the \npermanent level.   Yes, we have more flexibility in our contracts, and that will continue to be a lever \nand a component that we'll be evaluating determining on whether , how permanent these are or not.  I \nwould also say that our maturity, our capability within this space has substantially improved as well as \nwe've invested in the underlying processes and procedures to manage through these types of , that \ntype of volatility.  So overall, we feel very good about where we stand and generally don't see this \nbeing as a material item, but we'll continue to watch it closely.  \n ", "original_text": "So overall, we feel very good about where we stand and generally don't see this \nbeing as a material item, but we'll continue to watch it closely.  \n ", "page_label": "18", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "0deec662-07aa-4179-9d25-c20d9a0a3f6c", "node_type": "4", "metadata": {"page_label": "18", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "f11e4d47d1a17013e15f5609bc3c17fa461213c2b0fd0db015679c7e48260aaa", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "65552542-c9cd-4c0e-b631-1e685ff9dd2e", "node_type": "1", "metadata": {"window": "So, the order of magnitude we're \ntalking about is vastly smaller.  It is also something that we do not believe that that will be the \npermanent level.   Yes, we have more flexibility in our contracts, and that will continue to be a lever \nand a component that we'll be evaluating determining on whether , how permanent these are or not.  I \nwould also say that our maturity, our capability within this space has substantially improved as well as \nwe've invested in the underlying processes and procedures to manage through these types of , that \ntype of volatility.  So overall, we feel very good about where we stand and generally don't see this \nbeing as a material item, but we'll continue to watch it closely.  \n ", "original_text": "I \nwould also say that our maturity, our capability within this space has substantially improved as well as \nwe've invested in the underlying processes and procedures to manage through these types of , that \ntype of volatility. ", "page_label": "18", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "794029954c7c8ff058abb6105177f173d4d9d2d6485e7f62a1193b7612cda728", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "315be810-f70c-4406-86c2-ed1cabceb7d0", "node_type": "1", "metadata": {"window": " \nPage 19 of 19 \n \nOperator:  Thank you very much, sir.  Ladies and gentlemen, that will conclude today's Q&A session. \n I'd like to turn the call back over to Mr.  Jason Holl ar for the additional or closing remarks. ", "original_text": " \nPage 19 of 19 \n \nOperator:  Thank you very much, sir. "}, "hash": "1a56cc3b315ad4a8401c71d50537f1e759b9e4fbbcf7f15f0cb401565b04ab19", "class_name": "RelatedNodeInfo"}}, "text": "So overall, we feel very good about where we stand and generally don't see this \nbeing as a material item, but we'll continue to watch it closely.  \n ", "start_char_idx": 3329, "end_char_idx": 3479, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "315be810-f70c-4406-86c2-ed1cabceb7d0": {"__data__": {"id_": "315be810-f70c-4406-86c2-ed1cabceb7d0", "embedding": null, "metadata": {"window": " \nPage 19 of 19 \n \nOperator:  Thank you very much, sir.  Ladies and gentlemen, that will conclude today's Q&A session. \n I'd like to turn the call back over to Mr.  Jason Holl ar for the additional or closing remarks. ", "original_text": " \nPage 19 of 19 \n \nOperator:  Thank you very much, sir. ", "page_label": "19", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "269e28ab-8278-4b1f-8f4a-d4f82d6c333a", "node_type": "4", "metadata": {"page_label": "19", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "c70b6bf73838ffa217ef857e5fc9e229fb7778e2448a2c23654ffb4f4e19bfc4", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "b0f50702-52d6-4dc1-9b1d-ea2d14f1307e", "node_type": "1", "metadata": {"window": "It is also something that we do not believe that that will be the \npermanent level.   Yes, we have more flexibility in our contracts, and that will continue to be a lever \nand a component that we'll be evaluating determining on whether , how permanent these are or not.  I \nwould also say that our maturity, our capability within this space has substantially improved as well as \nwe've invested in the underlying processes and procedures to manage through these types of , that \ntype of volatility.  So overall, we feel very good about where we stand and generally don't see this \nbeing as a material item, but we'll continue to watch it closely.  \n ", "original_text": "So overall, we feel very good about where we stand and generally don't see this \nbeing as a material item, but we'll continue to watch it closely.  \n ", "page_label": "18", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "129c5b365830e4f0e3a4004573bbff85a3c5990919412d4fceec75d5cf3a8630", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "03ec4e6b-6407-4b43-83a4-184007bffbef", "node_type": "1", "metadata": {"window": " \nPage 19 of 19 \n \nOperator:  Thank you very much, sir.  Ladies and gentlemen, that will conclude today's Q&A session. \n I'd like to turn the call back over to Mr.  Jason Holl ar for the additional or closing remarks.  Thank you.  \n \n", "original_text": "Ladies and gentlemen, that will conclude today's Q&A session. \n"}, "hash": "9d19f287297655038a510a7d701a34fc033eda03f5696106ae8c0d3544be9a3d", "class_name": "RelatedNodeInfo"}}, "text": " \nPage 19 of 19 \n \nOperator:  Thank you very much, sir. ", "start_char_idx": 0, "end_char_idx": 56, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "03ec4e6b-6407-4b43-83a4-184007bffbef": {"__data__": {"id_": "03ec4e6b-6407-4b43-83a4-184007bffbef", "embedding": null, "metadata": {"window": " \nPage 19 of 19 \n \nOperator:  Thank you very much, sir.  Ladies and gentlemen, that will conclude today's Q&A session. \n I'd like to turn the call back over to Mr.  Jason Holl ar for the additional or closing remarks.  Thank you.  \n \n", "original_text": "Ladies and gentlemen, that will conclude today's Q&A session. \n", "page_label": "19", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "269e28ab-8278-4b1f-8f4a-d4f82d6c333a", "node_type": "4", "metadata": {"page_label": "19", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "c70b6bf73838ffa217ef857e5fc9e229fb7778e2448a2c23654ffb4f4e19bfc4", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "315be810-f70c-4406-86c2-ed1cabceb7d0", "node_type": "1", "metadata": {"window": " \nPage 19 of 19 \n \nOperator:  Thank you very much, sir.  Ladies and gentlemen, that will conclude today's Q&A session. \n I'd like to turn the call back over to Mr.  Jason Holl ar for the additional or closing remarks. ", "original_text": " \nPage 19 of 19 \n \nOperator:  Thank you very much, sir. ", "page_label": "19", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "4822e66c72d3104162eb7ce5ca17bfa60203aaed84ae884a54665e4f09d565ed", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "2e2a9366-80a3-44ce-9157-ddc5fc39046e", "node_type": "1", "metadata": {"window": " \nPage 19 of 19 \n \nOperator:  Thank you very much, sir.  Ladies and gentlemen, that will conclude today's Q&A session. \n I'd like to turn the call back over to Mr.  Jason Holl ar for the additional or closing remarks.  Thank you.  \n \n Jason Hollar:  Yeah, thanks  everyone, for joining us this morning. ", "original_text": "I'd like to turn the call back over to Mr. "}, "hash": "8d30a1df918e0820a2c80d5c14e288e960a2edb49c13089a949ca97d04002642", "class_name": "RelatedNodeInfo"}}, "text": "Ladies and gentlemen, that will conclude today's Q&A session. \n", "start_char_idx": 56, "end_char_idx": 119, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "2e2a9366-80a3-44ce-9157-ddc5fc39046e": {"__data__": {"id_": "2e2a9366-80a3-44ce-9157-ddc5fc39046e", "embedding": null, "metadata": {"window": " \nPage 19 of 19 \n \nOperator:  Thank you very much, sir.  Ladies and gentlemen, that will conclude today's Q&A session. \n I'd like to turn the call back over to Mr.  Jason Holl ar for the additional or closing remarks.  Thank you.  \n \n Jason Hollar:  Yeah, thanks  everyone, for joining us this morning. ", "original_text": "I'd like to turn the call back over to Mr. ", "page_label": "19", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "269e28ab-8278-4b1f-8f4a-d4f82d6c333a", "node_type": "4", "metadata": {"page_label": "19", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "c70b6bf73838ffa217ef857e5fc9e229fb7778e2448a2c23654ffb4f4e19bfc4", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "03ec4e6b-6407-4b43-83a4-184007bffbef", "node_type": "1", "metadata": {"window": " \nPage 19 of 19 \n \nOperator:  Thank you very much, sir.  Ladies and gentlemen, that will conclude today's Q&A session. \n I'd like to turn the call back over to Mr.  Jason Holl ar for the additional or closing remarks.  Thank you.  \n \n", "original_text": "Ladies and gentlemen, that will conclude today's Q&A session. \n", "page_label": "19", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "5b8b49a3fb8cf98c513c0b99a7905df8df17b7a198a2b53d70365180752e6589", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "4b09cbc6-a9b1-45f8-b55b-fc3a00aa2751", "node_type": "1", "metadata": {"window": " \nPage 19 of 19 \n \nOperator:  Thank you very much, sir.  Ladies and gentlemen, that will conclude today's Q&A session. \n I'd like to turn the call back over to Mr.  Jason Holl ar for the additional or closing remarks.  Thank you.  \n \n Jason Hollar:  Yeah, thanks  everyone, for joining us this morning.  We're clearly excited about the \nmomentum that we have in our business . ", "original_text": "Jason Holl ar for the additional or closing remarks. "}, "hash": "e992742628a75edad9af97d305b4801df750dd9e367aa84e65321626034f0209", "class_name": "RelatedNodeInfo"}}, "text": "I'd like to turn the call back over to Mr. ", "start_char_idx": 119, "end_char_idx": 162, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "4b09cbc6-a9b1-45f8-b55b-fc3a00aa2751": {"__data__": {"id_": "4b09cbc6-a9b1-45f8-b55b-fc3a00aa2751", "embedding": null, "metadata": {"window": " \nPage 19 of 19 \n \nOperator:  Thank you very much, sir.  Ladies and gentlemen, that will conclude today's Q&A session. \n I'd like to turn the call back over to Mr.  Jason Holl ar for the additional or closing remarks.  Thank you.  \n \n Jason Hollar:  Yeah, thanks  everyone, for joining us this morning.  We're clearly excited about the \nmomentum that we have in our business . ", "original_text": "Jason Holl ar for the additional or closing remarks. ", "page_label": "19", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "269e28ab-8278-4b1f-8f4a-d4f82d6c333a", "node_type": "4", "metadata": {"page_label": "19", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "c70b6bf73838ffa217ef857e5fc9e229fb7778e2448a2c23654ffb4f4e19bfc4", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "2e2a9366-80a3-44ce-9157-ddc5fc39046e", "node_type": "1", "metadata": {"window": " \nPage 19 of 19 \n \nOperator:  Thank you very much, sir.  Ladies and gentlemen, that will conclude today's Q&A session. \n I'd like to turn the call back over to Mr.  Jason Holl ar for the additional or closing remarks.  Thank you.  \n \n Jason Hollar:  Yeah, thanks  everyone, for joining us this morning. ", "original_text": "I'd like to turn the call back over to Mr. ", "page_label": "19", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "1653704bba1d4c8b7a1c08f939077f819f258366be19998f44d21f91526c49ec", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "4fcd9ef9-5c30-44c5-aba3-f7a6acbd24f7", "node_type": "1", "metadata": {"window": "Ladies and gentlemen, that will conclude today's Q&A session. \n I'd like to turn the call back over to Mr.  Jason Holl ar for the additional or closing remarks.  Thank you.  \n \n Jason Hollar:  Yeah, thanks  everyone, for joining us this morning.  We're clearly excited about the \nmomentum that we have in our business .  Both the shorter -term operational elements that we've \ntalked a lot about today , but also about the longer -term strategy with the announcement of specialty \nnetworks this week, it just highlights that we're looking and acting both short -term and long -term and \nare really excited about the opportunities still in front of us. ", "original_text": "Thank you.  \n \n"}, "hash": "494f581a921182f518071f8712032c7788d79f84caa03078852356b1d7b1611d", "class_name": "RelatedNodeInfo"}}, "text": "Jason Holl ar for the additional or closing remarks. ", "start_char_idx": 162, "end_char_idx": 215, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "4fcd9ef9-5c30-44c5-aba3-f7a6acbd24f7": {"__data__": {"id_": "4fcd9ef9-5c30-44c5-aba3-f7a6acbd24f7", "embedding": null, "metadata": {"window": "Ladies and gentlemen, that will conclude today's Q&A session. \n I'd like to turn the call back over to Mr.  Jason Holl ar for the additional or closing remarks.  Thank you.  \n \n Jason Hollar:  Yeah, thanks  everyone, for joining us this morning.  We're clearly excited about the \nmomentum that we have in our business .  Both the shorter -term operational elements that we've \ntalked a lot about today , but also about the longer -term strategy with the announcement of specialty \nnetworks this week, it just highlights that we're looking and acting both short -term and long -term and \nare really excited about the opportunities still in front of us. ", "original_text": "Thank you.  \n \n", "page_label": "19", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "269e28ab-8278-4b1f-8f4a-d4f82d6c333a", "node_type": "4", "metadata": {"page_label": "19", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "c70b6bf73838ffa217ef857e5fc9e229fb7778e2448a2c23654ffb4f4e19bfc4", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "4b09cbc6-a9b1-45f8-b55b-fc3a00aa2751", "node_type": "1", "metadata": {"window": " \nPage 19 of 19 \n \nOperator:  Thank you very much, sir.  Ladies and gentlemen, that will conclude today's Q&A session. \n I'd like to turn the call back over to Mr.  Jason Holl ar for the additional or closing remarks.  Thank you.  \n \n Jason Hollar:  Yeah, thanks  everyone, for joining us this morning.  We're clearly excited about the \nmomentum that we have in our business . ", "original_text": "Jason Holl ar for the additional or closing remarks. ", "page_label": "19", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "81c1ffeee4762750a8831717a81827b418106f15b884dd062bc81a1eb2ce6b21", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "d60bbae8-2270-49dd-add8-34b9dedf6a5f", "node_type": "1", "metadata": {"window": "I'd like to turn the call back over to Mr.  Jason Holl ar for the additional or closing remarks.  Thank you.  \n \n Jason Hollar:  Yeah, thanks  everyone, for joining us this morning.  We're clearly excited about the \nmomentum that we have in our business .  Both the shorter -term operational elements that we've \ntalked a lot about today , but also about the longer -term strategy with the announcement of specialty \nnetworks this week, it just highlights that we're looking and acting both short -term and long -term and \nare really excited about the opportunities still in front of us.  So, thanks again for joining us today, and \nhave a g reat day.  \n \n", "original_text": "Jason Hollar:  Yeah, thanks  everyone, for joining us this morning. "}, "hash": "0b0665878a54e212b4b9e62a23360a483ecbad8641c43504f1456bdd95f5ab85", "class_name": "RelatedNodeInfo"}}, "text": "Thank you.  \n \n", "start_char_idx": 215, "end_char_idx": 230, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "d60bbae8-2270-49dd-add8-34b9dedf6a5f": {"__data__": {"id_": "d60bbae8-2270-49dd-add8-34b9dedf6a5f", "embedding": null, "metadata": {"window": "I'd like to turn the call back over to Mr.  Jason Holl ar for the additional or closing remarks.  Thank you.  \n \n Jason Hollar:  Yeah, thanks  everyone, for joining us this morning.  We're clearly excited about the \nmomentum that we have in our business .  Both the shorter -term operational elements that we've \ntalked a lot about today , but also about the longer -term strategy with the announcement of specialty \nnetworks this week, it just highlights that we're looking and acting both short -term and long -term and \nare really excited about the opportunities still in front of us.  So, thanks again for joining us today, and \nhave a g reat day.  \n \n", "original_text": "Jason Hollar:  Yeah, thanks  everyone, for joining us this morning. ", "page_label": "19", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "269e28ab-8278-4b1f-8f4a-d4f82d6c333a", "node_type": "4", "metadata": {"page_label": "19", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "c70b6bf73838ffa217ef857e5fc9e229fb7778e2448a2c23654ffb4f4e19bfc4", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "4fcd9ef9-5c30-44c5-aba3-f7a6acbd24f7", "node_type": "1", "metadata": {"window": "Ladies and gentlemen, that will conclude today's Q&A session. \n I'd like to turn the call back over to Mr.  Jason Holl ar for the additional or closing remarks.  Thank you.  \n \n Jason Hollar:  Yeah, thanks  everyone, for joining us this morning.  We're clearly excited about the \nmomentum that we have in our business .  Both the shorter -term operational elements that we've \ntalked a lot about today , but also about the longer -term strategy with the announcement of specialty \nnetworks this week, it just highlights that we're looking and acting both short -term and long -term and \nare really excited about the opportunities still in front of us. ", "original_text": "Thank you.  \n \n", "page_label": "19", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "015b5ca847bf647c92e6e5182af92d0bb6aec2ebc1560b181dc78e6851671318", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "6290f6af-acdc-4c2f-9f82-ac1b5f6df889", "node_type": "1", "metadata": {"window": "Jason Holl ar for the additional or closing remarks.  Thank you.  \n \n Jason Hollar:  Yeah, thanks  everyone, for joining us this morning.  We're clearly excited about the \nmomentum that we have in our business .  Both the shorter -term operational elements that we've \ntalked a lot about today , but also about the longer -term strategy with the announcement of specialty \nnetworks this week, it just highlights that we're looking and acting both short -term and long -term and \nare really excited about the opportunities still in front of us.  So, thanks again for joining us today, and \nhave a g reat day.  \n \n Operator:  Thank you very much, sir. ", "original_text": "We're clearly excited about the \nmomentum that we have in our business . "}, "hash": "8ea126c35dc6894dde38e85b2b57c61f0f67b2e9540ded746de3e0d23250c72d", "class_name": "RelatedNodeInfo"}}, "text": "Jason Hollar:  Yeah, thanks  everyone, for joining us this morning. ", "start_char_idx": 230, "end_char_idx": 298, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "6290f6af-acdc-4c2f-9f82-ac1b5f6df889": {"__data__": {"id_": "6290f6af-acdc-4c2f-9f82-ac1b5f6df889", "embedding": null, "metadata": {"window": "Jason Holl ar for the additional or closing remarks.  Thank you.  \n \n Jason Hollar:  Yeah, thanks  everyone, for joining us this morning.  We're clearly excited about the \nmomentum that we have in our business .  Both the shorter -term operational elements that we've \ntalked a lot about today , but also about the longer -term strategy with the announcement of specialty \nnetworks this week, it just highlights that we're looking and acting both short -term and long -term and \nare really excited about the opportunities still in front of us.  So, thanks again for joining us today, and \nhave a g reat day.  \n \n Operator:  Thank you very much, sir. ", "original_text": "We're clearly excited about the \nmomentum that we have in our business . ", "page_label": "19", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "269e28ab-8278-4b1f-8f4a-d4f82d6c333a", "node_type": "4", "metadata": {"page_label": "19", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "c70b6bf73838ffa217ef857e5fc9e229fb7778e2448a2c23654ffb4f4e19bfc4", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "d60bbae8-2270-49dd-add8-34b9dedf6a5f", "node_type": "1", "metadata": {"window": "I'd like to turn the call back over to Mr.  Jason Holl ar for the additional or closing remarks.  Thank you.  \n \n Jason Hollar:  Yeah, thanks  everyone, for joining us this morning.  We're clearly excited about the \nmomentum that we have in our business .  Both the shorter -term operational elements that we've \ntalked a lot about today , but also about the longer -term strategy with the announcement of specialty \nnetworks this week, it just highlights that we're looking and acting both short -term and long -term and \nare really excited about the opportunities still in front of us.  So, thanks again for joining us today, and \nhave a g reat day.  \n \n", "original_text": "Jason Hollar:  Yeah, thanks  everyone, for joining us this morning. ", "page_label": "19", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "3dc556cb2f334d3b369b58ba62f0836b6b20e786a2c8b07f0fa19e6c7d3a70a9", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "aba47aa3-1b7f-4864-b5f9-63a0f06f66bf", "node_type": "1", "metadata": {"window": "Thank you.  \n \n Jason Hollar:  Yeah, thanks  everyone, for joining us this morning.  We're clearly excited about the \nmomentum that we have in our business .  Both the shorter -term operational elements that we've \ntalked a lot about today , but also about the longer -term strategy with the announcement of specialty \nnetworks this week, it just highlights that we're looking and acting both short -term and long -term and \nare really excited about the opportunities still in front of us.  So, thanks again for joining us today, and \nhave a g reat day.  \n \n Operator:  Thank you very much, sir.  Ladies and gentlemen, that will conclude today's conference. \n", "original_text": "Both the shorter -term operational elements that we've \ntalked a lot about today , but also about the longer -term strategy with the announcement of specialty \nnetworks this week, it just highlights that we're looking and acting both short -term and long -term and \nare really excited about the opportunities still in front of us. "}, "hash": "a0877d7fbd78f59fbec2060b7ac04d50105ddbe0f9753449fb6443041cd1b332", "class_name": "RelatedNodeInfo"}}, "text": "We're clearly excited about the \nmomentum that we have in our business . ", "start_char_idx": 298, "end_char_idx": 371, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "aba47aa3-1b7f-4864-b5f9-63a0f06f66bf": {"__data__": {"id_": "aba47aa3-1b7f-4864-b5f9-63a0f06f66bf", "embedding": null, "metadata": {"window": "Thank you.  \n \n Jason Hollar:  Yeah, thanks  everyone, for joining us this morning.  We're clearly excited about the \nmomentum that we have in our business .  Both the shorter -term operational elements that we've \ntalked a lot about today , but also about the longer -term strategy with the announcement of specialty \nnetworks this week, it just highlights that we're looking and acting both short -term and long -term and \nare really excited about the opportunities still in front of us.  So, thanks again for joining us today, and \nhave a g reat day.  \n \n Operator:  Thank you very much, sir.  Ladies and gentlemen, that will conclude today's conference. \n", "original_text": "Both the shorter -term operational elements that we've \ntalked a lot about today , but also about the longer -term strategy with the announcement of specialty \nnetworks this week, it just highlights that we're looking and acting both short -term and long -term and \nare really excited about the opportunities still in front of us. ", "page_label": "19", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "269e28ab-8278-4b1f-8f4a-d4f82d6c333a", "node_type": "4", "metadata": {"page_label": "19", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "c70b6bf73838ffa217ef857e5fc9e229fb7778e2448a2c23654ffb4f4e19bfc4", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "6290f6af-acdc-4c2f-9f82-ac1b5f6df889", "node_type": "1", "metadata": {"window": "Jason Holl ar for the additional or closing remarks.  Thank you.  \n \n Jason Hollar:  Yeah, thanks  everyone, for joining us this morning.  We're clearly excited about the \nmomentum that we have in our business .  Both the shorter -term operational elements that we've \ntalked a lot about today , but also about the longer -term strategy with the announcement of specialty \nnetworks this week, it just highlights that we're looking and acting both short -term and long -term and \nare really excited about the opportunities still in front of us.  So, thanks again for joining us today, and \nhave a g reat day.  \n \n Operator:  Thank you very much, sir. ", "original_text": "We're clearly excited about the \nmomentum that we have in our business . ", "page_label": "19", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "242dd8489544889669568cdfcfab69f03831a659a477183d25b495d21063517c", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "3a5bc759-4aa8-4451-bbd5-4423ad922c86", "node_type": "1", "metadata": {"window": "Jason Hollar:  Yeah, thanks  everyone, for joining us this morning.  We're clearly excited about the \nmomentum that we have in our business .  Both the shorter -term operational elements that we've \ntalked a lot about today , but also about the longer -term strategy with the announcement of specialty \nnetworks this week, it just highlights that we're looking and acting both short -term and long -term and \nare really excited about the opportunities still in front of us.  So, thanks again for joining us today, and \nhave a g reat day.  \n \n Operator:  Thank you very much, sir.  Ladies and gentlemen, that will conclude today's conference. \n Thank for your attendance. ", "original_text": "So, thanks again for joining us today, and \nhave a g reat day.  \n \n"}, "hash": "dfc9e152bcd0ed3c39dc95673eea2447ad4f741b6395c8adca3cf812c52038e9", "class_name": "RelatedNodeInfo"}}, "text": "Both the shorter -term operational elements that we've \ntalked a lot about today , but also about the longer -term strategy with the announcement of specialty \nnetworks this week, it just highlights that we're looking and acting both short -term and long -term and \nare really excited about the opportunities still in front of us. ", "start_char_idx": 371, "end_char_idx": 702, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "3a5bc759-4aa8-4451-bbd5-4423ad922c86": {"__data__": {"id_": "3a5bc759-4aa8-4451-bbd5-4423ad922c86", "embedding": null, "metadata": {"window": "Jason Hollar:  Yeah, thanks  everyone, for joining us this morning.  We're clearly excited about the \nmomentum that we have in our business .  Both the shorter -term operational elements that we've \ntalked a lot about today , but also about the longer -term strategy with the announcement of specialty \nnetworks this week, it just highlights that we're looking and acting both short -term and long -term and \nare really excited about the opportunities still in front of us.  So, thanks again for joining us today, and \nhave a g reat day.  \n \n Operator:  Thank you very much, sir.  Ladies and gentlemen, that will conclude today's conference. \n Thank for your attendance. ", "original_text": "So, thanks again for joining us today, and \nhave a g reat day.  \n \n", "page_label": "19", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "269e28ab-8278-4b1f-8f4a-d4f82d6c333a", "node_type": "4", "metadata": {"page_label": "19", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "c70b6bf73838ffa217ef857e5fc9e229fb7778e2448a2c23654ffb4f4e19bfc4", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "aba47aa3-1b7f-4864-b5f9-63a0f06f66bf", "node_type": "1", "metadata": {"window": "Thank you.  \n \n Jason Hollar:  Yeah, thanks  everyone, for joining us this morning.  We're clearly excited about the \nmomentum that we have in our business .  Both the shorter -term operational elements that we've \ntalked a lot about today , but also about the longer -term strategy with the announcement of specialty \nnetworks this week, it just highlights that we're looking and acting both short -term and long -term and \nare really excited about the opportunities still in front of us.  So, thanks again for joining us today, and \nhave a g reat day.  \n \n Operator:  Thank you very much, sir.  Ladies and gentlemen, that will conclude today's conference. \n", "original_text": "Both the shorter -term operational elements that we've \ntalked a lot about today , but also about the longer -term strategy with the announcement of specialty \nnetworks this week, it just highlights that we're looking and acting both short -term and long -term and \nare really excited about the opportunities still in front of us. ", "page_label": "19", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "fcedbefb1bea6890532b4232c56124e71b16d9881aa28d7acf797b15c0877ff7", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "e3ec08d4-8fc2-4fb1-9477-0841d4be4e5f", "node_type": "1", "metadata": {"window": "We're clearly excited about the \nmomentum that we have in our business .  Both the shorter -term operational elements that we've \ntalked a lot about today , but also about the longer -term strategy with the announcement of specialty \nnetworks this week, it just highlights that we're looking and acting both short -term and long -term and \nare really excited about the opportunities still in front of us.  So, thanks again for joining us today, and \nhave a g reat day.  \n \n Operator:  Thank you very much, sir.  Ladies and gentlemen, that will conclude today's conference. \n Thank for your attendance.  You may now disconnect. ", "original_text": "Operator:  Thank you very much, sir. "}, "hash": "433e3c25d36b1fedfcc9223d4609f540b9ea0e5ece6e57ce1535b4eddebf89e2", "class_name": "RelatedNodeInfo"}}, "text": "So, thanks again for joining us today, and \nhave a g reat day.  \n \n", "start_char_idx": 702, "end_char_idx": 769, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "e3ec08d4-8fc2-4fb1-9477-0841d4be4e5f": {"__data__": {"id_": "e3ec08d4-8fc2-4fb1-9477-0841d4be4e5f", "embedding": null, "metadata": {"window": "We're clearly excited about the \nmomentum that we have in our business .  Both the shorter -term operational elements that we've \ntalked a lot about today , but also about the longer -term strategy with the announcement of specialty \nnetworks this week, it just highlights that we're looking and acting both short -term and long -term and \nare really excited about the opportunities still in front of us.  So, thanks again for joining us today, and \nhave a g reat day.  \n \n Operator:  Thank you very much, sir.  Ladies and gentlemen, that will conclude today's conference. \n Thank for your attendance.  You may now disconnect. ", "original_text": "Operator:  Thank you very much, sir. ", "page_label": "19", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "269e28ab-8278-4b1f-8f4a-d4f82d6c333a", "node_type": "4", "metadata": {"page_label": "19", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "c70b6bf73838ffa217ef857e5fc9e229fb7778e2448a2c23654ffb4f4e19bfc4", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "3a5bc759-4aa8-4451-bbd5-4423ad922c86", "node_type": "1", "metadata": {"window": "Jason Hollar:  Yeah, thanks  everyone, for joining us this morning.  We're clearly excited about the \nmomentum that we have in our business .  Both the shorter -term operational elements that we've \ntalked a lot about today , but also about the longer -term strategy with the announcement of specialty \nnetworks this week, it just highlights that we're looking and acting both short -term and long -term and \nare really excited about the opportunities still in front of us.  So, thanks again for joining us today, and \nhave a g reat day.  \n \n Operator:  Thank you very much, sir.  Ladies and gentlemen, that will conclude today's conference. \n Thank for your attendance. ", "original_text": "So, thanks again for joining us today, and \nhave a g reat day.  \n \n", "page_label": "19", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "e15410197ffcb048a20af773a67103076a83b766fcb17f1b20acd9c656abf626", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "76984402-1833-4729-9c30-d510b2882fa3", "node_type": "1", "metadata": {"window": "Both the shorter -term operational elements that we've \ntalked a lot about today , but also about the longer -term strategy with the announcement of specialty \nnetworks this week, it just highlights that we're looking and acting both short -term and long -term and \nare really excited about the opportunities still in front of us.  So, thanks again for joining us today, and \nhave a g reat day.  \n \n Operator:  Thank you very much, sir.  Ladies and gentlemen, that will conclude today's conference. \n Thank for your attendance.  You may now disconnect.  Good day , and goodbye.  \n ", "original_text": "Ladies and gentlemen, that will conclude today's conference. \n"}, "hash": "996dfac34a568854e797de9bda9fd022938bdefd303edfda5db01b43c8203ebe", "class_name": "RelatedNodeInfo"}}, "text": "Operator:  Thank you very much, sir. ", "start_char_idx": 19, "end_char_idx": 56, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "76984402-1833-4729-9c30-d510b2882fa3": {"__data__": {"id_": "76984402-1833-4729-9c30-d510b2882fa3", "embedding": null, "metadata": {"window": "Both the shorter -term operational elements that we've \ntalked a lot about today , but also about the longer -term strategy with the announcement of specialty \nnetworks this week, it just highlights that we're looking and acting both short -term and long -term and \nare really excited about the opportunities still in front of us.  So, thanks again for joining us today, and \nhave a g reat day.  \n \n Operator:  Thank you very much, sir.  Ladies and gentlemen, that will conclude today's conference. \n Thank for your attendance.  You may now disconnect.  Good day , and goodbye.  \n ", "original_text": "Ladies and gentlemen, that will conclude today's conference. \n", "page_label": "19", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "269e28ab-8278-4b1f-8f4a-d4f82d6c333a", "node_type": "4", "metadata": {"page_label": "19", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "c70b6bf73838ffa217ef857e5fc9e229fb7778e2448a2c23654ffb4f4e19bfc4", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "e3ec08d4-8fc2-4fb1-9477-0841d4be4e5f", "node_type": "1", "metadata": {"window": "We're clearly excited about the \nmomentum that we have in our business .  Both the shorter -term operational elements that we've \ntalked a lot about today , but also about the longer -term strategy with the announcement of specialty \nnetworks this week, it just highlights that we're looking and acting both short -term and long -term and \nare really excited about the opportunities still in front of us.  So, thanks again for joining us today, and \nhave a g reat day.  \n \n Operator:  Thank you very much, sir.  Ladies and gentlemen, that will conclude today's conference. \n Thank for your attendance.  You may now disconnect. ", "original_text": "Operator:  Thank you very much, sir. ", "page_label": "19", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "9b42974a1b1f09ff9089052f374839de60b21145ed44e6ccd9de61204dde0b56", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "effaa786-cbc2-4692-8f66-5d1470e46276", "node_type": "1", "metadata": {"window": "So, thanks again for joining us today, and \nhave a g reat day.  \n \n Operator:  Thank you very much, sir.  Ladies and gentlemen, that will conclude today's conference. \n Thank for your attendance.  You may now disconnect.  Good day , and goodbye.  \n ", "original_text": "Thank for your attendance. "}, "hash": "28fe0d4d26ba94d5d4a6454a11ccc043545b1082691408f427ff19d65565a31e", "class_name": "RelatedNodeInfo"}}, "text": "Ladies and gentlemen, that will conclude today's conference. \n", "start_char_idx": 806, "end_char_idx": 868, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "effaa786-cbc2-4692-8f66-5d1470e46276": {"__data__": {"id_": "effaa786-cbc2-4692-8f66-5d1470e46276", "embedding": null, "metadata": {"window": "So, thanks again for joining us today, and \nhave a g reat day.  \n \n Operator:  Thank you very much, sir.  Ladies and gentlemen, that will conclude today's conference. \n Thank for your attendance.  You may now disconnect.  Good day , and goodbye.  \n ", "original_text": "Thank for your attendance. ", "page_label": "19", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "269e28ab-8278-4b1f-8f4a-d4f82d6c333a", "node_type": "4", "metadata": {"page_label": "19", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "c70b6bf73838ffa217ef857e5fc9e229fb7778e2448a2c23654ffb4f4e19bfc4", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "76984402-1833-4729-9c30-d510b2882fa3", "node_type": "1", "metadata": {"window": "Both the shorter -term operational elements that we've \ntalked a lot about today , but also about the longer -term strategy with the announcement of specialty \nnetworks this week, it just highlights that we're looking and acting both short -term and long -term and \nare really excited about the opportunities still in front of us.  So, thanks again for joining us today, and \nhave a g reat day.  \n \n Operator:  Thank you very much, sir.  Ladies and gentlemen, that will conclude today's conference. \n Thank for your attendance.  You may now disconnect.  Good day , and goodbye.  \n ", "original_text": "Ladies and gentlemen, that will conclude today's conference. \n", "page_label": "19", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "0184c86ecba1dacc2b527f5146b956b69ee8adbda8638e512dee3d7af7b326ef", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "e788ae7a-4203-4c3f-ba68-c28469df465c", "node_type": "1", "metadata": {"window": "Operator:  Thank you very much, sir.  Ladies and gentlemen, that will conclude today's conference. \n Thank for your attendance.  You may now disconnect.  Good day , and goodbye.  \n ", "original_text": "You may now disconnect. "}, "hash": "1745723396aec2dded03a3508f1dee06125afd677939a6a9878e69d046b5f1b2", "class_name": "RelatedNodeInfo"}}, "text": "Thank for your attendance. ", "start_char_idx": 868, "end_char_idx": 895, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "e788ae7a-4203-4c3f-ba68-c28469df465c": {"__data__": {"id_": "e788ae7a-4203-4c3f-ba68-c28469df465c", "embedding": null, "metadata": {"window": "Operator:  Thank you very much, sir.  Ladies and gentlemen, that will conclude today's conference. \n Thank for your attendance.  You may now disconnect.  Good day , and goodbye.  \n ", "original_text": "You may now disconnect. ", "page_label": "19", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "269e28ab-8278-4b1f-8f4a-d4f82d6c333a", "node_type": "4", "metadata": {"page_label": "19", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "c70b6bf73838ffa217ef857e5fc9e229fb7778e2448a2c23654ffb4f4e19bfc4", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "effaa786-cbc2-4692-8f66-5d1470e46276", "node_type": "1", "metadata": {"window": "So, thanks again for joining us today, and \nhave a g reat day.  \n \n Operator:  Thank you very much, sir.  Ladies and gentlemen, that will conclude today's conference. \n Thank for your attendance.  You may now disconnect.  Good day , and goodbye.  \n ", "original_text": "Thank for your attendance. ", "page_label": "19", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "d19b79259d86405ccdf70218fdc6931eb8d19cde7ec4387d06b08275caaa9085", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "8059ec2f-7c0a-4d46-ad87-508f624e497b", "node_type": "1", "metadata": {"window": "Ladies and gentlemen, that will conclude today's conference. \n Thank for your attendance.  You may now disconnect.  Good day , and goodbye.  \n ", "original_text": "Good day , and goodbye.  \n "}, "hash": "694c90f157bfad95fae3f8f9813fb9acc32854b028304ae6eda1085260974750", "class_name": "RelatedNodeInfo"}}, "text": "You may now disconnect. ", "start_char_idx": 895, "end_char_idx": 919, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "8059ec2f-7c0a-4d46-ad87-508f624e497b": {"__data__": {"id_": "8059ec2f-7c0a-4d46-ad87-508f624e497b", "embedding": null, "metadata": {"window": "Ladies and gentlemen, that will conclude today's conference. \n Thank for your attendance.  You may now disconnect.  Good day , and goodbye.  \n ", "original_text": "Good day , and goodbye.  \n ", "page_label": "19", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "269e28ab-8278-4b1f-8f4a-d4f82d6c333a", "node_type": "4", "metadata": {"page_label": "19", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "c70b6bf73838ffa217ef857e5fc9e229fb7778e2448a2c23654ffb4f4e19bfc4", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "e788ae7a-4203-4c3f-ba68-c28469df465c", "node_type": "1", "metadata": {"window": "Operator:  Thank you very much, sir.  Ladies and gentlemen, that will conclude today's conference. \n Thank for your attendance.  You may now disconnect.  Good day , and goodbye.  \n ", "original_text": "You may now disconnect. ", "page_label": "19", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "0cbd0c6e8df7f4f29a6d7856b202b766f1d2f723844a7d12754229610eb3e3a1", "class_name": "RelatedNodeInfo"}}, "text": "Good day , and goodbye.  \n ", "start_char_idx": 919, "end_char_idx": 946, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}}, "docstore/metadata": {"2b35cef7-27ec-4c77-8741-7536e1b99e5c": {"doc_hash": "5885b3ee05bdef57a81dcf35e5f40b2e2baa987f12dc97197cfd431cc53d13f9", "ref_doc_id": "a4414d54-6710-431a-9934-c424ca18a68a"}, "53c01b19-2681-45a7-9265-bb1f9166ed3e": {"doc_hash": "f3d4911e66b0f663f8639b0bc9ae3abf3c54393ee026af5a0121028d0edc5405", "ref_doc_id": "a4414d54-6710-431a-9934-c424ca18a68a"}, "24cde944-6af4-4357-9a9d-9b91e6aa55a6": {"doc_hash": "da2c2a392694e2b87f703b8934245aaf91b73b81feba4bbff97100e121d7b80e", "ref_doc_id": "a4414d54-6710-431a-9934-c424ca18a68a"}, "e91ab319-1bc7-40c3-9b80-2d2fb51957a3": {"doc_hash": "2439fb859f3d60ec28944ca473f9aaab9929df5dea19204fa9ff40afa9876e7d", "ref_doc_id": "a4414d54-6710-431a-9934-c424ca18a68a"}, "a0d3e3d1-e0ef-4ae0-b22f-afc8bf26f8da": {"doc_hash": "23e4adbffb4bff3dbb436febb68bdc627acb82ba1dc3698c59904e1362879196", "ref_doc_id": "a4414d54-6710-431a-9934-c424ca18a68a"}, "1196d81d-6394-4c13-9b9f-480c3a22c0b9": {"doc_hash": "e6a7d239b193e1a9f4e8442f08f2dbf30011efc9e03ebb1cf2af3913d48d085c", "ref_doc_id": "a4414d54-6710-431a-9934-c424ca18a68a"}, "4008df93-4537-40d8-91ae-415cfaa5a9b1": {"doc_hash": "4bfeffd624f1b533a23cf4514f8f15a7181965c76f04f2c321941e5f0830141a", "ref_doc_id": "a4414d54-6710-431a-9934-c424ca18a68a"}, "e46986a0-30bf-4a26-80ba-59f84910c16f": {"doc_hash": "b605c81e035d07996a6758829dff119b52b9b292175801870b2df6309fe4784a", "ref_doc_id": "a4414d54-6710-431a-9934-c424ca18a68a"}, "5cf2fec5-897e-46dc-93e9-e0e4cf2073d2": {"doc_hash": "ba489be32d08ba5357dad166ee72d96a437cdbed1c4a21718db968b7b5285a2d", "ref_doc_id": "a4414d54-6710-431a-9934-c424ca18a68a"}, "967afa49-7711-4b8c-99a9-115f90bbf988": {"doc_hash": "cf01f64ac21530ff1fd1e0d8d346a44bd232a19abee63c1d67a707b65e409763", "ref_doc_id": "a4414d54-6710-431a-9934-c424ca18a68a"}, "e79bc945-1e39-4012-86ed-5c9e820d4aaa": {"doc_hash": "57dc1949405e678f0557bbfc91f14dbcf6e784b41ccd0d65067fb3f7580314af", "ref_doc_id": "a4414d54-6710-431a-9934-c424ca18a68a"}, "09e57fcf-706b-4cb2-a4b9-3813e5addea2": {"doc_hash": "acf796e25cceb2f1a8259d9f93b4a2e1f521a094cf1d319cc214c0f047b729aa", "ref_doc_id": "a4414d54-6710-431a-9934-c424ca18a68a"}, "274bc5da-dda3-48c6-8987-840e2328437c": {"doc_hash": "b2b801745b5f06216cb5caf1c40c5cc8fea7bdadfa934edd2cd29068331a7a5e", "ref_doc_id": "a4414d54-6710-431a-9934-c424ca18a68a"}, "a3e1ec3a-bfd0-4115-8490-2dcb20fd628c": {"doc_hash": "ec9fa38f6eb1c84572fe5263bcda77bad4d95274ed37d45c3fad8d8743013e80", "ref_doc_id": "a4414d54-6710-431a-9934-c424ca18a68a"}, "dd1de457-b343-4ca4-80a4-73f4381940c9": {"doc_hash": "d4aeb3df3fd1bc3b6433eaa0e06d615f2a9a4d60b2b3c98207d3475d59b73be8", "ref_doc_id": "a4414d54-6710-431a-9934-c424ca18a68a"}, "4590692e-1b0d-486c-a06b-0a6895dfe8f3": {"doc_hash": "ef2b4aa31ef771593f5d2b7f39e05b494b4356d841658050a341ab3c5930c933", "ref_doc_id": "a4414d54-6710-431a-9934-c424ca18a68a"}, "11b83ae2-f338-4180-a308-8be35d719626": {"doc_hash": "d69db7f79393b5b9605b9979640e90d45bbf8cb8889e7c333b2803f0534cb08e", "ref_doc_id": "a4414d54-6710-431a-9934-c424ca18a68a"}, "e52c54aa-0a67-432f-90da-19c152aa1675": {"doc_hash": "0671975c17b4d2a4be467d347f10883327047640ce2fe77c486fae5713ead4d5", "ref_doc_id": "a4414d54-6710-431a-9934-c424ca18a68a"}, "c86e8138-f341-46f7-bd9e-228d5ec6da37": {"doc_hash": "4de43c82590fca1a7f23175dd96d9f8de70b588930d0157428989527edfa1a78", "ref_doc_id": "a4414d54-6710-431a-9934-c424ca18a68a"}, "80d29dbf-ec98-4263-90d8-4bfb52bc361d": {"doc_hash": "ca6940624b2d998d12ea0c686f737a5917408dcf2629fbb0bb196501afb24a45", "ref_doc_id": "af1efd63-b407-4e15-8b8e-7fdf94ed494d"}, "8f0d3214-ac5b-429d-b6fc-02705e9e0bcc": {"doc_hash": "c9b9bcf0a84b66af173cdaf1d8ec0a0488e5a606175b960ff6078b370e1f0186", "ref_doc_id": "af1efd63-b407-4e15-8b8e-7fdf94ed494d"}, "cd18a014-c4a5-4969-b568-746db62905d4": {"doc_hash": "1f414a457adf451242f787ebc84ef9c99fb4c1640dfa752c33579750b2b35d04", "ref_doc_id": "af1efd63-b407-4e15-8b8e-7fdf94ed494d"}, "318d0436-6633-4dba-b681-532a2164ab96": {"doc_hash": "ee5e2f57c4cc7e1fa2036fccbce3ed7a1f54797740aa405be53f81477a7a4608", "ref_doc_id": "af1efd63-b407-4e15-8b8e-7fdf94ed494d"}, "c2b7f78f-aa18-4197-afcd-c1f9505155b3": {"doc_hash": "e1cc633cc487f5520b9e774dfdf063b1750a832eea2fd84e435cb28b96091d46", "ref_doc_id": "af1efd63-b407-4e15-8b8e-7fdf94ed494d"}, "177cb92a-0319-41d5-a36e-14c0b22250d4": {"doc_hash": "2fc02489cf58a43067016ee45396b4f7c9b899ce0f482243873dd31e9282ba99", "ref_doc_id": "af1efd63-b407-4e15-8b8e-7fdf94ed494d"}, "7d704305-bc7c-40ff-ae2e-e9ef20103ddc": {"doc_hash": "730782c0b03b80ed2ba97f9839744156678c47c01075c5ee6b523409fd0a0698", "ref_doc_id": "af1efd63-b407-4e15-8b8e-7fdf94ed494d"}, "e97e4010-193f-4cfa-966a-6b5b2abcf674": {"doc_hash": "47a327c967bbe06fae86cbbb104f624266041d935d6a0db41527a296c956adea", "ref_doc_id": "af1efd63-b407-4e15-8b8e-7fdf94ed494d"}, "c728b342-573c-4be8-b137-48d1ebf80374": {"doc_hash": "b9753973a2e73e28b14e5af735d133de8b9c34cddaa44b200c661375e87f455a", "ref_doc_id": "af1efd63-b407-4e15-8b8e-7fdf94ed494d"}, "51a565bd-a823-4759-bc5b-294bd6433331": {"doc_hash": "33d722573cb11d59025527cd594ccb7e9486121a36574a4e0dfe589a9543a2d8", "ref_doc_id": "af1efd63-b407-4e15-8b8e-7fdf94ed494d"}, "569a3639-3901-41ed-98e1-576e40a12866": {"doc_hash": "a65bfaf03f50f03856a78ecf9fe4c2a690871719188478f41c0b8fd7530f3b03", "ref_doc_id": "af1efd63-b407-4e15-8b8e-7fdf94ed494d"}, "0bf3b072-85eb-47ee-a21e-69474ff15fe4": {"doc_hash": "d0b786e5807e200305b4b065307f7e489aec5cd0a6008b418826ede90431a540", "ref_doc_id": "af1efd63-b407-4e15-8b8e-7fdf94ed494d"}, "54a85354-6242-4d48-90e3-38c742368493": {"doc_hash": "b48eb9c6f232bcd340c7e98ee7a26f3c4ec9c7d88395caf9693ee10b2c3a3ca2", "ref_doc_id": "af1efd63-b407-4e15-8b8e-7fdf94ed494d"}, "54700922-67e0-469f-91dc-556eba18af73": {"doc_hash": "2eb937cd7ee2251a2f727f6e24b0780695b10887734b0bbcaaf9e3dfe053d067", "ref_doc_id": "af1efd63-b407-4e15-8b8e-7fdf94ed494d"}, "9e0f4328-cd45-4fb0-9d26-0922be4544d1": {"doc_hash": "cbae4509d8d381c46ea4becbc22187c6660a8b8aed5d8c94d28b17a1ed62e15f", "ref_doc_id": "af1efd63-b407-4e15-8b8e-7fdf94ed494d"}, "54702bd4-4c68-4a9a-866b-09341a069377": {"doc_hash": "be1114c2f831703790447142a19a011803b0c032182ea0fc52501e809e39f198", "ref_doc_id": "af1efd63-b407-4e15-8b8e-7fdf94ed494d"}, "b9db02c7-8674-4358-bb73-1eb1f7de88c4": {"doc_hash": "e7674b5c7eb7f9bff2933e28db081eb3f3b59817349e11a2d28ec776a36c62c0", "ref_doc_id": "2122bb61-73c3-4261-85c0-fd8e84992ea1"}, "fbcbb01a-e3e2-439a-9c9b-4c15ccf177fa": {"doc_hash": "80b843d21803e6aa20c7cbabce8224d3068ad5bd67fba5dbf4cd274c31db4991", "ref_doc_id": "2122bb61-73c3-4261-85c0-fd8e84992ea1"}, "85445337-5676-4544-a161-7696b355e4e2": {"doc_hash": "9e244f17d9d72c3a4af5b6632d02d0109f7c0f31f1015b0e8f3a979a5f9ca7ea", "ref_doc_id": "2122bb61-73c3-4261-85c0-fd8e84992ea1"}, "a7a62310-92aa-46eb-9ff3-25983a54528f": {"doc_hash": "b8448cbfcd64914878f09665784c90e999dbc51f1fdcfaedd9cedeab9e7d1ebb", "ref_doc_id": "2122bb61-73c3-4261-85c0-fd8e84992ea1"}, "2fb1baaa-0fb9-4468-bef1-512693d62a5c": {"doc_hash": "a726a8e9bac5cd7ddc7f12a1e5ce3322f18242e2bf5a5bc609d67d45b4101218", "ref_doc_id": "2122bb61-73c3-4261-85c0-fd8e84992ea1"}, "3baca8c7-8b24-4a8b-b306-78907a252595": {"doc_hash": "2cb5eb0f4cf779067b36f91a5af6dd6bd2a8615bb6f81ea7919f7066f636eed3", "ref_doc_id": "2122bb61-73c3-4261-85c0-fd8e84992ea1"}, "7bb4c23a-8a23-48a2-b691-3bc70a1fa455": {"doc_hash": "624123dc98b99f1a24e59a9574349e097cba952e1670195bd1fb1c7376b307c2", "ref_doc_id": "2122bb61-73c3-4261-85c0-fd8e84992ea1"}, "6a39ae9e-bb88-44e8-8eaf-8ce398f2dde6": {"doc_hash": "6efa672e7410b2e8a78eb6ae02820d9934716da459f7aa5e79fdfb20ded25f5c", "ref_doc_id": "2122bb61-73c3-4261-85c0-fd8e84992ea1"}, "ebb3a8d1-f6c1-47a3-a8b0-891c7f93e772": {"doc_hash": "5fc955e8aa48f0d7549ae416226c7c4e762ae8e32415163dc28c8a6aae8a468b", "ref_doc_id": "2122bb61-73c3-4261-85c0-fd8e84992ea1"}, "f68fdfaa-a54e-4e67-910e-5f58d594c53a": {"doc_hash": "9e54fd5873eac0558272939ad93df73b16be4f36ec8beaa0515714d964255c4e", "ref_doc_id": "2122bb61-73c3-4261-85c0-fd8e84992ea1"}, "20afa8b3-5b25-4805-9f52-3c22c3e1a93c": {"doc_hash": "d2a0d0fca58324e22efbd7b65b41e5f4f4b9597e34f36eeed30061a5723af4da", "ref_doc_id": "2122bb61-73c3-4261-85c0-fd8e84992ea1"}, "7c26fc13-57e5-4d66-a324-05bd3fa4e265": {"doc_hash": "a1241867f3b97f189c1cd5c724ae46d2e5b799f6d0aee0f125da7529d5e53d2b", "ref_doc_id": "2122bb61-73c3-4261-85c0-fd8e84992ea1"}, "e70b5174-1312-4a64-99b0-c0aa1e9e5ea6": {"doc_hash": "18d0108d3c47d7002dd0ae9af7233a67a0ee60dc728dcfc128616da9e23b6c97", "ref_doc_id": "2122bb61-73c3-4261-85c0-fd8e84992ea1"}, "0a6a206f-0137-4f43-89e6-7e83f68a9a7e": {"doc_hash": "f473c97fdb28c37993a199bbf1a5795922114e5de80a97c1199f7d426ec44359", "ref_doc_id": "2122bb61-73c3-4261-85c0-fd8e84992ea1"}, "f222a1fc-f336-4364-bfff-4d3c1508e67f": {"doc_hash": "0a8f24af471c01c0bab75654488b3993986deba6fc94871afe4abfff397a65bb", "ref_doc_id": "2122bb61-73c3-4261-85c0-fd8e84992ea1"}, "65c867c2-3756-4791-a720-5d9a93794014": {"doc_hash": "1f34709443d4ed08585615acf77634f50162305567458524676d0ccaf6473755", "ref_doc_id": "2122bb61-73c3-4261-85c0-fd8e84992ea1"}, "329bf0ef-b5d2-42c6-9bc7-888b9d4160e7": {"doc_hash": "c1d06ab1aeef390e56468d365e116cf217f81a06bda6d6b691e0c8badca4812d", "ref_doc_id": "2122bb61-73c3-4261-85c0-fd8e84992ea1"}, "6c28b2fe-9db4-4844-8b46-f59b5a7118e5": {"doc_hash": "4027da73881eb5857cecb94cedb697219ac739d3d934c3b45a2fe881bfd7474b", "ref_doc_id": "51bcdcef-b372-404b-848b-774d2abd5d5e"}, "0b96bdc3-ca6f-40ab-b4e1-57d54e9c8665": {"doc_hash": "fe98e773b7a267fc61d549ceb23701966e810ec4bfb8cda78d7418fd668dd21d", "ref_doc_id": "51bcdcef-b372-404b-848b-774d2abd5d5e"}, "af324dab-1977-4096-a25b-7d45113c31a9": {"doc_hash": "bb1fdf2a26477ee396d0a211c41a4e8adba92d7205577d54ae64d7aab93f6924", "ref_doc_id": "51bcdcef-b372-404b-848b-774d2abd5d5e"}, "1e89ed48-e4be-42bd-bb93-1b6caf1dbe81": {"doc_hash": "b3deed9d28a3f507b1a5aa6330d706f37638703681ec8c7cd31778d51e319d6d", "ref_doc_id": "51bcdcef-b372-404b-848b-774d2abd5d5e"}, "d31cacf4-758c-4c4a-a6ad-52d8a4941119": {"doc_hash": "9697047d923f0c146ee719e584f899a06b26b64e399caa5b2ba5613dd056573b", "ref_doc_id": "51bcdcef-b372-404b-848b-774d2abd5d5e"}, "f5268ec7-350b-477d-9200-de8b834ff2b4": {"doc_hash": "f647de7f4c34dfbfffbbd4867b70e0e7a5ae193acdd57dfe1e67225308258b8c", "ref_doc_id": "51bcdcef-b372-404b-848b-774d2abd5d5e"}, "9e2a6610-8446-42d7-8a65-c4259a34cc69": {"doc_hash": "c8b2d908a14475abd3bd0d8d098dc0361833cb234f0d54c2b021e2a4633bb71c", "ref_doc_id": "51bcdcef-b372-404b-848b-774d2abd5d5e"}, "46f78cd2-c7c3-4138-bdfc-ba91d6eb1f91": {"doc_hash": "2343c6e995b820f1fccba2f0ec8214471d8ef833cc0531f4760d1e843082d98b", "ref_doc_id": "51bcdcef-b372-404b-848b-774d2abd5d5e"}, "e925b52e-478e-4246-96fa-fd5a30ca965a": {"doc_hash": "7d00260477e323e802bc4fb3932067b342dafbc5db3c5e04ae15d6b4e410d700", "ref_doc_id": "51bcdcef-b372-404b-848b-774d2abd5d5e"}, "100fe8a3-fb7d-4c06-b8ac-0001a8df6441": {"doc_hash": "b659eeebfd276ba16f4bf0382c86f16720a76bc6bf1da868b17ef4ad746a4643", "ref_doc_id": "51bcdcef-b372-404b-848b-774d2abd5d5e"}, "fdd8b160-64c4-4ecc-b50a-6e8a9cae9229": {"doc_hash": "81a3380f3969e73975b4832b5282ebc31aca4c4b86127017f66bac0c2d77db39", "ref_doc_id": "51bcdcef-b372-404b-848b-774d2abd5d5e"}, "7ce4eff2-694d-4a81-9819-a222670a7016": {"doc_hash": "e1b4584a1fff67b82341f2a5c4b690ae038b0bfcdf0d41a38e14ca7fc86d99b2", "ref_doc_id": "51bcdcef-b372-404b-848b-774d2abd5d5e"}, "142bb824-5ad1-4276-8bec-90b909ce04a4": {"doc_hash": "4a60a27a3e0b9f31d64a237d27523a6ba9c41897784c2f0b52e4dea7c264af4b", "ref_doc_id": "51bcdcef-b372-404b-848b-774d2abd5d5e"}, "8cf35c63-710f-4195-9cd1-f5b72a74a031": {"doc_hash": "96d7f33421bd0a5e22646f34eb3792dd8d5e36e6407493c11268b506ffcd36a0", "ref_doc_id": "51bcdcef-b372-404b-848b-774d2abd5d5e"}, "fc9cd0e3-9257-436b-8135-16618a3f52c2": {"doc_hash": "03a0a7b8b9685346746731d3a4ab195f8e9c1184492dc67d764187704197e146", "ref_doc_id": "51bcdcef-b372-404b-848b-774d2abd5d5e"}, "6cd6e370-3396-4492-94e7-eea8f8d3b7a8": {"doc_hash": "852149fc175d550c8d53d64bdec443cdc75907b3964c125b8d4fa8d9f18fcadf", "ref_doc_id": "51bcdcef-b372-404b-848b-774d2abd5d5e"}, "51447f56-c89d-426b-9ebb-f47b55070fb8": {"doc_hash": "0c91f072d7fdc47271bd4d2e3fa7c1d3e8dd76cb0d0a434b25c6cbdd5d2b663c", "ref_doc_id": "62106fa2-0df0-4578-a53e-51fe39997eca"}, "3f9525f0-c979-46da-bc32-6d4316b606f0": {"doc_hash": "f9583e3adef90be40c7fdfe9d83942c429dee58273c5f7d37fdce363857b722f", "ref_doc_id": "62106fa2-0df0-4578-a53e-51fe39997eca"}, "845b711d-e7c3-4266-a749-e55edef2018d": {"doc_hash": "ccdb0eec17e1cd844980854bf1fdc0a3781b89ab9c097b7afb0cba6e80af45eb", "ref_doc_id": "62106fa2-0df0-4578-a53e-51fe39997eca"}, "50bbe4bf-3394-4964-b6e0-777e431d8be2": {"doc_hash": "1f8540678635b75e0ce02c9255e9385ebf57d482a72731c1769452c0b4f607cf", "ref_doc_id": "62106fa2-0df0-4578-a53e-51fe39997eca"}, "c3300713-1e8a-4a75-9a5c-5cd03f601d1b": {"doc_hash": "38419f4a7047b5bfd0bd88583fb55e43294aabd544a926177bbc9ec60d59f47f", "ref_doc_id": "62106fa2-0df0-4578-a53e-51fe39997eca"}, "8ed0be0e-8c45-47d2-998e-7fc2b18f4c1e": {"doc_hash": "07d927f0e735adf8d4483ebeb40995dbf0751d50a3762527f25b65fffa13084b", "ref_doc_id": "62106fa2-0df0-4578-a53e-51fe39997eca"}, "d99c283d-39fb-4ede-ad2b-761d0ff95a09": {"doc_hash": "4774ad50a94740bd28269ebe0191f3239b1f5b950970af1b2f038600cfa825ab", "ref_doc_id": "62106fa2-0df0-4578-a53e-51fe39997eca"}, "f505ce80-d147-4e10-9208-8cfde73127c6": {"doc_hash": "0220bcb0d0a86a11758e98d374a05284f3308ed6285f38f3b2e71b7296f8bd3c", "ref_doc_id": "62106fa2-0df0-4578-a53e-51fe39997eca"}, "8aced6b5-70df-4f2f-90a0-dec3434d1674": {"doc_hash": "d5d48417cb82ea749c69fe3969d792bbd82c4ef121ae633208cfc1ea872a3d23", "ref_doc_id": "62106fa2-0df0-4578-a53e-51fe39997eca"}, "84891518-fc6a-440d-9b0e-3062fe707d85": {"doc_hash": "55930f4924fa6fb0630b53603859984f76d55b8e3386aadfc60afff6a9f98454", "ref_doc_id": "62106fa2-0df0-4578-a53e-51fe39997eca"}, "259ae151-bf33-4e47-b5e6-b80de93b2640": {"doc_hash": "6f5d491174201db6d65ae56a197c9c61e175d3262d7bd49bbcb2badbdaaefb01", "ref_doc_id": "62106fa2-0df0-4578-a53e-51fe39997eca"}, "0b065238-292f-42a7-b83b-ad904a6d0e35": {"doc_hash": "65d2fcbf8f2ac1a1d45319ceb86040c5e5496b8d87376a9938b2c422259e82aa", "ref_doc_id": "62106fa2-0df0-4578-a53e-51fe39997eca"}, "444d3782-2c0f-45f3-b8a6-efa202d674ac": {"doc_hash": "0cd58bc5d8ac6672dbb5ef66dbc60f20e729856ef114ad32f888444bdffd6f53", "ref_doc_id": "62106fa2-0df0-4578-a53e-51fe39997eca"}, "97a7d4ed-7b2e-4b13-b635-5630ea1fbde8": {"doc_hash": "b81b1e22e652c13d1999e751f1f8e472eb13ed3e2b38dc184caf458f42268917", "ref_doc_id": "62106fa2-0df0-4578-a53e-51fe39997eca"}, "f0431abd-d0d2-4bb0-8e12-76be35f49076": {"doc_hash": "b673d1c76f11b23856846e47764f48f8e15196f196ee121e696ba537a695cd1c", "ref_doc_id": "62106fa2-0df0-4578-a53e-51fe39997eca"}, "c1e144ad-3728-4823-b118-610959f97a50": {"doc_hash": "a45768c56ece803f01ba32f2a805189fd9bb55eff3f599cf4ba597529639ae77", "ref_doc_id": "62106fa2-0df0-4578-a53e-51fe39997eca"}, "f4559797-4e0e-4ca1-84d0-7dac65822cd9": {"doc_hash": "516682f25b55c31945f8b9d0523a6a58d9b785a36abbc4b980ca5a49fdf91b48", "ref_doc_id": "62106fa2-0df0-4578-a53e-51fe39997eca"}, "99ecc5ee-0622-4ac5-9dd0-90959df9d26e": {"doc_hash": "721f43b152300d33ddb5b2d1066eef411f07e55210fed408fa49a692ce420015", "ref_doc_id": "62106fa2-0df0-4578-a53e-51fe39997eca"}, "35a4c3d9-7aa2-4a29-9409-d3131eed678e": {"doc_hash": "8ffb3bbc1189754cb7957b298e0f6adff4d59d4c63b2b1639fd0997b9ac66dc4", "ref_doc_id": "62106fa2-0df0-4578-a53e-51fe39997eca"}, "9e7b4c27-a664-49b6-aeb1-73c837d86154": {"doc_hash": "3f32eb072b465a8f39d091030277175f7b44516f344f471f257b8183f1946bc6", "ref_doc_id": "62106fa2-0df0-4578-a53e-51fe39997eca"}, "cd9ffd1c-3051-43c8-8973-0721d0ed2a41": {"doc_hash": "75a6f6fe6d06c35b780d6dc17064eeea97ecfb871efb362f2b3aae0dda2a6e0b", "ref_doc_id": "46b2014a-9df1-4279-a34f-4fd4570310ad"}, "7b13b2d1-a32a-429a-9adc-a33549f9c50a": {"doc_hash": "3bf754a91a71ffec39797fdc6fd353c07e4b48c0a64e0240a95b961ea13ce766", "ref_doc_id": "46b2014a-9df1-4279-a34f-4fd4570310ad"}, "ae6163ac-8069-4006-9dd6-8e2b56faf487": {"doc_hash": "c06e693f0d71448d6302840931f883f4d23882825c5694c0bec1139d323b6330", "ref_doc_id": "46b2014a-9df1-4279-a34f-4fd4570310ad"}, "5446d953-c24c-47fe-ac1b-aeae0abed8d8": {"doc_hash": "57eb502fc9773416e8114905ea600cb67c01cf9dbf3e4598ff10d04b3e1e5e77", "ref_doc_id": "46b2014a-9df1-4279-a34f-4fd4570310ad"}, "c7af42ad-d22e-4f3c-a1d0-4763722b42ff": {"doc_hash": "3b039db82a5bbb4234f8082b7ea79595c47de1ee95314c80053b573e1a3bd9d1", "ref_doc_id": "46b2014a-9df1-4279-a34f-4fd4570310ad"}, "95f3cf67-4d72-4239-aaf7-d941f75ba82c": {"doc_hash": "cb4b21848f926167cc6b536f5bab9834ea512291d743dda8807ea626644f152a", "ref_doc_id": "46b2014a-9df1-4279-a34f-4fd4570310ad"}, "d9a6e026-62f5-4aee-9629-39693977650d": {"doc_hash": "402fa908dc7b35a82a2bfc2ae7a00172311c131944b1a84c175a9e97a232b92f", "ref_doc_id": "46b2014a-9df1-4279-a34f-4fd4570310ad"}, "1aabddb0-4bf0-4325-bdd2-fe279f7dc2c4": {"doc_hash": "6e8305b0f175f2552edac0994f3c0df9e39325a78e8d552c56e10ef8385367f9", "ref_doc_id": "46b2014a-9df1-4279-a34f-4fd4570310ad"}, "e2921bc5-1dbd-4321-a278-af9075c70edc": {"doc_hash": "edc022f6ffd2ca0dd8b65b6bf6f4501529158bbb0d2c3a0d5dbf4d2999873a70", "ref_doc_id": "46b2014a-9df1-4279-a34f-4fd4570310ad"}, "263863e6-1476-467c-8b8c-378eb99caafc": {"doc_hash": "a6960a79479edaecb298dad49eba064f7e72eeffefa9fdd2173f9e60e9e5e325", "ref_doc_id": "46b2014a-9df1-4279-a34f-4fd4570310ad"}, "5b35f39e-be52-4d19-a5e3-d34eca4912e8": {"doc_hash": "c98820b525630f346084d541731a219cb320b2d40719c1008e2d2fe65d62f2de", "ref_doc_id": "46b2014a-9df1-4279-a34f-4fd4570310ad"}, "e69f4c27-e107-447b-a9cc-047ac7eb4ce7": {"doc_hash": "6e09ce18206feaf59d657c6be966f3569dcca9321c79bd264a2ef80c651510ba", "ref_doc_id": "46b2014a-9df1-4279-a34f-4fd4570310ad"}, "72bdbffe-4370-40a8-8f76-17ddf47a4ca3": {"doc_hash": "252e748ba69cf66047ef33ab78a579997863699897ec44903470a6c32fd6c9e3", "ref_doc_id": "46b2014a-9df1-4279-a34f-4fd4570310ad"}, "a9b343e5-cc6a-4b4d-962e-27a7a7f9fbb4": {"doc_hash": "6156c3c852a3022be5811ac986f77f92b04d092d091b99aa06966a22fb8411f7", "ref_doc_id": "46b2014a-9df1-4279-a34f-4fd4570310ad"}, "0a41d06e-0eac-41ed-aeda-ed197836524c": {"doc_hash": "8b765916286c351030bc4ddb0fbc4a629ddc8b6d2acb327bb49f4feec0a63b11", "ref_doc_id": "46b2014a-9df1-4279-a34f-4fd4570310ad"}, "97cd6209-6d07-4d02-b974-5a85cd437508": {"doc_hash": "7ed5c2ec4bf5fa50acda4336d6b4e402e1cc2f5b656a2a32507ac8a31578b897", "ref_doc_id": "46b2014a-9df1-4279-a34f-4fd4570310ad"}, "ad9d6ef1-7c96-4a27-8281-7a9dc5149181": {"doc_hash": "64a9e1f5528733be273630cacc790c3982005eac5e1bae110789b20e5cd567c7", "ref_doc_id": "46b2014a-9df1-4279-a34f-4fd4570310ad"}, "2a71b444-048a-462c-ba74-d888f19a31b5": {"doc_hash": "e16adc6643b15aac97ddd6c886ad45a9bd7712e77341edc5b512321f891171a1", "ref_doc_id": "46b2014a-9df1-4279-a34f-4fd4570310ad"}, "9d10591e-f12b-4a3b-b537-a4c0749764bd": {"doc_hash": "52bb0f4ac94cdc856ea0dcf50c7982e64ef0db4b7887797b15b0ddd3ca9c7ab3", "ref_doc_id": "46b2014a-9df1-4279-a34f-4fd4570310ad"}, "63307908-cd19-4691-b35f-5935607f9bd7": {"doc_hash": "d6b4de7e97d72a590ebd974ebf65da8ad84d13b3d6c63c2a4691493e34503e26", "ref_doc_id": "46b2014a-9df1-4279-a34f-4fd4570310ad"}, "9311ff59-9c98-412a-af59-fd30396a3efb": {"doc_hash": "17b406abb0c8dfa7ce48862a121c18924b1ced0eee0e73d6f1699cdb73e2357a", "ref_doc_id": "1b974c9c-bb8b-435a-a421-b84d1956e255"}, "c5bbf16b-6a43-44f4-b569-d5218dd4e002": {"doc_hash": "abf79b81e399cf8f376368783eee6bb6f9f134f57ce0eaff30afa78601d54bc4", "ref_doc_id": "1b974c9c-bb8b-435a-a421-b84d1956e255"}, "555af6c8-b890-43f8-bd19-f70e84e98f81": {"doc_hash": "209e70a8084d0b88100ab77728a4b2ba81a3578e2e739dc576ba469c8dfff975", "ref_doc_id": "1b974c9c-bb8b-435a-a421-b84d1956e255"}, "32f990db-1f0d-4a5c-a7f1-d8bdbe511d8d": {"doc_hash": "c0c575a2a7eae74106318ac7cabf7969acb8af02a49ad8597b77b1d21fbaaf99", "ref_doc_id": "1b974c9c-bb8b-435a-a421-b84d1956e255"}, "b23e0dca-b34b-4549-bbfa-c2b29152ded9": {"doc_hash": "159606b89bd0de3298e3ff09e56397a90d2533fc4e9661fd431aeeac70543618", "ref_doc_id": "1b974c9c-bb8b-435a-a421-b84d1956e255"}, "43c9c340-ad6b-4c38-a400-5dd92022bcde": {"doc_hash": "52e72ef8464b8877925a786dd7bbc881f6d2d87d6af3ace4a69de60ba457b8e0", "ref_doc_id": "1b974c9c-bb8b-435a-a421-b84d1956e255"}, "db807c40-67e7-414e-8cca-6e520497267f": {"doc_hash": "74c2fca4a9e40e282dec23eae2ea8d48a52bbb55699304f1a40749f51c3b2b55", "ref_doc_id": "1b974c9c-bb8b-435a-a421-b84d1956e255"}, "84ec9b09-9ab2-4292-9ed6-8bd5278c659a": {"doc_hash": "89b5d5c88f41a72c76c3e2f023d952bfb942a9e92fb8a93fd46f5f60317a05d2", "ref_doc_id": "1b974c9c-bb8b-435a-a421-b84d1956e255"}, "90c0d51f-d87d-4bab-8c9b-eaa7b87c5748": {"doc_hash": "bb21efee6c2794f038c786b067d550305fd894a7e76c3ed20ef00b9dff708cbf", "ref_doc_id": "1b974c9c-bb8b-435a-a421-b84d1956e255"}, "58fd92b4-fe36-4a8a-8069-136bcfce7545": {"doc_hash": "9ebe884344b5914adb6a694bd6c48e3f0cbeff897e56849308876a28d9723a3f", "ref_doc_id": "1b974c9c-bb8b-435a-a421-b84d1956e255"}, "46b4ddac-e273-4879-8fb3-22a7003d1469": {"doc_hash": "ebd3e20c32af0c3c2793039baf4d1dd49090aa39aa320e90085236b366cfc5f4", "ref_doc_id": "1b974c9c-bb8b-435a-a421-b84d1956e255"}, "40f76173-5e11-4d91-bdaf-4ad7a4a47228": {"doc_hash": "75d30462b21e1b788e0e9e6f9b38382807f348bf2850f44b2e98f68e7cef2c58", "ref_doc_id": "1b974c9c-bb8b-435a-a421-b84d1956e255"}, "63206695-382c-4390-ab68-6767f4a298b4": {"doc_hash": "dc71940f6428422aa1f639ad887c0f2d950bc7b59f5fc93f3fb664af84928ec8", "ref_doc_id": "1b974c9c-bb8b-435a-a421-b84d1956e255"}, "130dbcf6-273c-4d68-bd50-976970d187b5": {"doc_hash": "bba9bae95bc8b1b07dbe59bf8e6421bd24f0956d2dac5d777261b27494c5564d", "ref_doc_id": "1b974c9c-bb8b-435a-a421-b84d1956e255"}, "7e1af22d-b54b-482f-94b9-c3d133b1afe4": {"doc_hash": "6b527b47c944a8b05dd694cecca666d6c1be28a8052ac74ac999ab2b68f828bf", "ref_doc_id": "1b974c9c-bb8b-435a-a421-b84d1956e255"}, "c33602cb-89eb-451f-94bf-70ab19a4d642": {"doc_hash": "bd8605272fc4ceca734a8ebbcb141464dacd99c3ab1753eb770a4f5152209479", "ref_doc_id": "1b974c9c-bb8b-435a-a421-b84d1956e255"}, "652887f1-8aa3-4232-9fdb-42fd4cd75192": {"doc_hash": "98764b1849d00c2b1ed229fe9ffae8cc7560bc9471457ea36024ca3176f48e37", "ref_doc_id": "1b974c9c-bb8b-435a-a421-b84d1956e255"}, "b23c1a75-8def-4517-a27c-2dc6b7461557": {"doc_hash": "229680a5e4ad84cc2d3abe72decaa60824478eca5bb528716687b6bbae93046f", "ref_doc_id": "1b974c9c-bb8b-435a-a421-b84d1956e255"}, "50e5df59-c1a0-4d5a-ac2e-b392237e6679": {"doc_hash": "ee98fc848fdbda87c4e1393898b778b744f75bb97ebd4fe54275f9efb94bce19", "ref_doc_id": "cb248949-64fc-498f-a357-322668a33cd9"}, "0168fae5-1479-4543-8914-0603c1531c2a": {"doc_hash": "ea77144fd59020a832fce5c68ad7268f176005965b5bc40538852cb24c8ffc81", "ref_doc_id": "cb248949-64fc-498f-a357-322668a33cd9"}, "fac20d16-66f2-4c74-ab36-21cb576bc156": {"doc_hash": "ad2e6a3333ea3b199a57e5a24565343552869eccb490023f8891369d972d853a", "ref_doc_id": "cb248949-64fc-498f-a357-322668a33cd9"}, "fef2fae6-e748-4e2e-89d6-932a0c437e4a": {"doc_hash": "8f8288b4b661de3c4073e9ea3a689a5deaf5da943158d9e6b08936f90e237cc1", "ref_doc_id": "cb248949-64fc-498f-a357-322668a33cd9"}, "70f9f2dc-967c-4d32-96e8-a68529ef5810": {"doc_hash": "08015cc2af2287b23e460002d567744cb8183638af969c68f66a5ada19e40114", "ref_doc_id": "cb248949-64fc-498f-a357-322668a33cd9"}, "cf63d8bb-5614-4279-9b1a-a22515f68f70": {"doc_hash": "026ea339ea765ad9634451d7ddabc655221a6d6b99b8e789c67981add696daec", "ref_doc_id": "cb248949-64fc-498f-a357-322668a33cd9"}, "1e571f78-4a3b-4f2d-b96f-e70ce603ce9a": {"doc_hash": "97c77f3bc1e5c4df80e4b63c70ca8eef60c8c31a6a37425b633b7b7b183324f6", "ref_doc_id": "cb248949-64fc-498f-a357-322668a33cd9"}, "be104b7c-4278-4375-9ab8-849b1958bb4e": {"doc_hash": "05d05dcd5a924c6bf07090d43eb5dbedd6f035c888195e52eb47af837816dcc4", "ref_doc_id": "cb248949-64fc-498f-a357-322668a33cd9"}, "3c290084-9a7a-43a9-93bb-3f3b237848fa": {"doc_hash": "f314bc8dbd347d15f7d8066c34d216144b6369839bdd7f0770fda11ac8cd5cc2", "ref_doc_id": "cb248949-64fc-498f-a357-322668a33cd9"}, "8f8cc612-ecf4-4442-b705-62e0522aa90b": {"doc_hash": "4035847f797162a82cf8c207d815be469569e9fccb3bcca3cb7c22c823b3ab40", "ref_doc_id": "cb248949-64fc-498f-a357-322668a33cd9"}, "5d079ed4-7dc3-4f4b-9ea1-fc1a99f369af": {"doc_hash": "72d14e0214a697c4c0fc8000832d96aa9017a90654e2b2f2601d8853636b6f5e", "ref_doc_id": "cb248949-64fc-498f-a357-322668a33cd9"}, "b58873c8-367d-452f-a56c-fce70ecbbce2": {"doc_hash": "5a5094911ce155a78fbb5179435a5b1ad5a85177ef6145fd4a5a59ee7092f54f", "ref_doc_id": "cb248949-64fc-498f-a357-322668a33cd9"}, "a73a1c4e-bd86-475b-b6be-4b4366cdddcf": {"doc_hash": "a43f47dda48086ebd46d1e7938ccf0dea91651e6c901bd259b620129fc0d0d9f", "ref_doc_id": "cb248949-64fc-498f-a357-322668a33cd9"}, "cf35929c-ff61-4f37-875c-986901a68dc4": {"doc_hash": "8ca5a1b9f53c46076d5ab4a5880be38947d0f06d7d703c4f046ba54e898f996a", "ref_doc_id": "cb248949-64fc-498f-a357-322668a33cd9"}, "ee05a25c-dbb9-4803-a0a1-4def30f01f77": {"doc_hash": "429dd17055d1b74864dafec8c6e9fa30c18982e58d98f38a9fcdf998dc97c27d", "ref_doc_id": "cb248949-64fc-498f-a357-322668a33cd9"}, "3946df4e-2014-4b39-9403-1767aaed4df7": {"doc_hash": "b2626f029b127747d218680f0f90b13f2b5b453bcbe349dadaadce4e591c7b4d", "ref_doc_id": "cb248949-64fc-498f-a357-322668a33cd9"}, "47895c88-6bc4-43aa-8edf-9adc38447bd9": {"doc_hash": "01d46006db9536e0ab1fd6c5af30b0dc6996c09434092ffc11ccf30d3334f2fa", "ref_doc_id": "cb248949-64fc-498f-a357-322668a33cd9"}, "af491530-c3ad-45bf-ace6-d7d2671965b9": {"doc_hash": "6d8b1f70372dd042ccc9f774036021b98dae81ada3ca41ed5f5beb63467ad35a", "ref_doc_id": "dd0c036b-c7ea-4c12-b21f-2c88607b8c5c"}, "8a90e4e0-eacd-4a83-8ae2-0cf30c0bab42": {"doc_hash": "dca7a57a33f043665f452411972cb9ffa9c8189c0e2062084048aa26e63d42ed", "ref_doc_id": "dd0c036b-c7ea-4c12-b21f-2c88607b8c5c"}, "304ac4bc-a541-4424-9b4c-b8b64313dcd6": {"doc_hash": "1178ff741f47e457ee590e531310901a89873544c83ac84ce249d32310f2d37c", "ref_doc_id": "dd0c036b-c7ea-4c12-b21f-2c88607b8c5c"}, "b37b57a5-942d-4a57-b3f4-412b40b20176": {"doc_hash": "f8a11e928cb209a78412ef348e8046cef18ebaea8746c0e9651f4051c856e489", "ref_doc_id": "dd0c036b-c7ea-4c12-b21f-2c88607b8c5c"}, "3a1862bc-a495-4847-b59d-66aad3b43d88": {"doc_hash": "5974e8456bd661a39cb32234b3f9348aea85afb1c491a8f40452386e1ac35465", "ref_doc_id": "dd0c036b-c7ea-4c12-b21f-2c88607b8c5c"}, "9f9bc403-b149-4043-90c5-9634d43a9840": {"doc_hash": "76f16f8163ad6ff33b122ed14d01ac3ebbed981d7d5c812dd30af51ad79f1a77", "ref_doc_id": "dd0c036b-c7ea-4c12-b21f-2c88607b8c5c"}, "fbff49a6-910a-448d-a85a-f02c8e203f8d": {"doc_hash": "18f1536aed49f4e27b114874f86f02934a39392bd682c3c94b53f85263945242", "ref_doc_id": "dd0c036b-c7ea-4c12-b21f-2c88607b8c5c"}, "70600a73-fa6b-40b3-ae8c-c00996535c0a": {"doc_hash": "09ec19e069ecac43c68a8d22dc561af5f422d1b84d24a752b649d68952877e5b", "ref_doc_id": "dd0c036b-c7ea-4c12-b21f-2c88607b8c5c"}, "e3c4e1d9-0abe-423f-a6f2-4bce556e2ea9": {"doc_hash": "32fd531b1f67af411ead8f43c47345d548a8770a6a3710731d97d40bd7663b85", "ref_doc_id": "dd0c036b-c7ea-4c12-b21f-2c88607b8c5c"}, "2a79b74f-9962-4f38-bc50-7da567f207ee": {"doc_hash": "09249753275511519cbf344ab2356f47c1aff88546896d06143580255dc0e51a", "ref_doc_id": "dd0c036b-c7ea-4c12-b21f-2c88607b8c5c"}, "951bda90-1220-4014-8f81-a3412d4a53aa": {"doc_hash": "650a2eeaaf422ea5a740ccc13cc16968fcc87ac6de27cbde79812a9f6fcd967f", "ref_doc_id": "dd0c036b-c7ea-4c12-b21f-2c88607b8c5c"}, "cc01a675-e4e0-41c8-a5b2-6b3b3b99c275": {"doc_hash": "0a3b38916f165c1c17e334d9898f1bb5bee9631720fa1d5367d122b609d23b22", "ref_doc_id": "dd0c036b-c7ea-4c12-b21f-2c88607b8c5c"}, "31223a1c-a92c-4967-bff0-460eca6132b7": {"doc_hash": "774689fe49a49c682a745830c8c123ffa30f33fa832293bc460485334879c941", "ref_doc_id": "dd0c036b-c7ea-4c12-b21f-2c88607b8c5c"}, "77180a31-af95-41e7-b5b3-5cd49290594f": {"doc_hash": "0bd50164cb540c5d7d5c789a7c73f1c872963ab982a688c903e4e51ffb961714", "ref_doc_id": "dd0c036b-c7ea-4c12-b21f-2c88607b8c5c"}, "69c10b64-a513-48d0-886b-9224b26b8499": {"doc_hash": "255f3f9f4b95a92a03a78bff415a3995387498bfc9cad9649a3a483885be8e4e", "ref_doc_id": "dd0c036b-c7ea-4c12-b21f-2c88607b8c5c"}, "c6f577c9-834a-4a47-9a77-4edd826aa38a": {"doc_hash": "d608faf7e5e1adcdefd2fe5ebde4909ab84f9f5ae85a26ef5077cbed49416527", "ref_doc_id": "dd0c036b-c7ea-4c12-b21f-2c88607b8c5c"}, "b1e4b3b3-3aaa-4055-89c1-aa346bfc7db7": {"doc_hash": "7cde88442d1251de4d35a1c0211e38c28ca91cc8c0fb21ade602da19f5ac856e", "ref_doc_id": "dd0c036b-c7ea-4c12-b21f-2c88607b8c5c"}, "cee6f8f3-e90f-4ee9-bd47-b2dcca2dc6c2": {"doc_hash": "5895ee01e72afa798f2c43af820ae1d85bb9159b74b99a123bbe68ec3837f78e", "ref_doc_id": "dd0c036b-c7ea-4c12-b21f-2c88607b8c5c"}, "c0bfa657-e3c6-4f06-9052-a0603618d961": {"doc_hash": "a53bd68646b287458f8d2cd370b410fa2dca01d3bfeb8d34da01f8d5f0d59a7f", "ref_doc_id": "dd0c036b-c7ea-4c12-b21f-2c88607b8c5c"}, "3aed3ca6-89b2-46ee-923d-6c9579add71d": {"doc_hash": "dce149408e7caa373e9f062d6b5f770ec896280f4766b29c2ca93a1321afb7ed", "ref_doc_id": "0be51136-ae11-430d-b0c4-8d03b6d16d4c"}, "35182a77-950e-40b7-a41c-1143adcc3c0e": {"doc_hash": "0a360f7b3c7cc1740dccffafbe754ed2cea1929eafa98fd22e8d0ff1926c8fa8", "ref_doc_id": "0be51136-ae11-430d-b0c4-8d03b6d16d4c"}, "d03b695a-7b1a-48db-88cc-b7c26078cbcd": {"doc_hash": "ac6bbc449855e8b7f8ed3542156da961391ed2928f5fdced687fe18bea5f360e", "ref_doc_id": "0be51136-ae11-430d-b0c4-8d03b6d16d4c"}, "f0476995-35cc-4a40-b7ea-6891e8a891bd": {"doc_hash": "834f46fbeaedad716a425d058347e0496f77ed0bf7472abb52ce14f86ac4111f", "ref_doc_id": "0be51136-ae11-430d-b0c4-8d03b6d16d4c"}, "886dcbad-98e1-4c45-9054-2b18d1274bb8": {"doc_hash": "419d1a332f236142790394c4550e421603632e243ce489e8edb5596776665d8d", "ref_doc_id": "0be51136-ae11-430d-b0c4-8d03b6d16d4c"}, "1dff6ac6-9a19-4836-8cb6-0ad19efec4cf": {"doc_hash": "bf5134b284202e7d117093e352cc29f691aabb5923a90badad0b0cdb8c251d47", "ref_doc_id": "0be51136-ae11-430d-b0c4-8d03b6d16d4c"}, "2e5006eb-a0b6-48fd-9f66-61d790060772": {"doc_hash": "2d7219aa1674aa73ba29a518112f58a374c2b88125c5b01bc47ab5761248e834", "ref_doc_id": "0be51136-ae11-430d-b0c4-8d03b6d16d4c"}, "7c2a3a7f-3b94-4533-8b92-ec86c669eaa8": {"doc_hash": "e0eca3f0f96fc77b545a3c78556b55b4b4e4001755c909046d5081ea41aeda5e", "ref_doc_id": "0be51136-ae11-430d-b0c4-8d03b6d16d4c"}, "62176bcb-4113-4dbe-bd59-063def3f2b1a": {"doc_hash": "632fb3962416f3cec95b6c6fd1db80763febff0637baaf55db4ad2ac8180499a", "ref_doc_id": "0be51136-ae11-430d-b0c4-8d03b6d16d4c"}, "9cf1b625-527a-4cfe-af44-9b91586cc312": {"doc_hash": "345c1a515140a1ad5a6a0e8e0f38639cbf14d88c9515b38293df1f8c623f477f", "ref_doc_id": "0be51136-ae11-430d-b0c4-8d03b6d16d4c"}, "e3e87f39-2f8c-4161-a3a6-0b73b52ffc0b": {"doc_hash": "cc41d4d91bdb92c9ae79ac10c4532e2d33ccb99478f75a732db98a9f186e5d37", "ref_doc_id": "0be51136-ae11-430d-b0c4-8d03b6d16d4c"}, "1d5099cc-e8c8-4b54-993f-3454efabda9d": {"doc_hash": "4dfb2e12d151c9e18cd7b328a64cc29e54b50731d8e4c5ab7f98d4b13705dc3a", "ref_doc_id": "0be51136-ae11-430d-b0c4-8d03b6d16d4c"}, "19fa639b-9bae-4312-ba26-a23e7e3945e7": {"doc_hash": "1c4ad9c0fdbcceb46bcc474413cfc559733cae54c654d421de7e45a33401008d", "ref_doc_id": "0be51136-ae11-430d-b0c4-8d03b6d16d4c"}, "00d6f413-0d3a-4dfe-ae32-c4f468cc1746": {"doc_hash": "69b3c929553824232eea2b9f8397ef34f97239a7e08e989f3b93aaa1b6aac055", "ref_doc_id": "0be51136-ae11-430d-b0c4-8d03b6d16d4c"}, "7efe25dc-48fc-42f2-b2a8-15752901612b": {"doc_hash": "11b9dd2cb5b500c317182f54f93571fcb0e8ce1bad3f7842ed1eb94d8af05dd0", "ref_doc_id": "0be51136-ae11-430d-b0c4-8d03b6d16d4c"}, "e013b527-1b94-4fc2-a7ae-b35abc2b6eae": {"doc_hash": "fbe3295230f94624091cb4070e33c79a6b37ff20d6eec2346fa1af20ccc4418c", "ref_doc_id": "0be51136-ae11-430d-b0c4-8d03b6d16d4c"}, "75bbcc61-ac12-4770-8da9-5fb27af869f7": {"doc_hash": "0993022e19c75663b7b9dac0e5909a85dbac7ca24d0962f53c28cf393a01d4aa", "ref_doc_id": "0be51136-ae11-430d-b0c4-8d03b6d16d4c"}, "e5e8352a-8e14-4201-8c26-a96be3fa17e0": {"doc_hash": "7a69bc3a01396f63495aa642db77921bb77f0d6442c5fae0e1ef1a0ce1c25d09", "ref_doc_id": "0be51136-ae11-430d-b0c4-8d03b6d16d4c"}, "588b9c19-8c10-456d-ab55-ea023d7d318d": {"doc_hash": "58ef2805ce0d2ae8d3fe3302931c55d93eaf37c0bfe6387538e9910f89162800", "ref_doc_id": "0be51136-ae11-430d-b0c4-8d03b6d16d4c"}, "da5dc87a-5381-4245-ac99-f47e3baa2b9f": {"doc_hash": "26faebbd5b68f6a0809787abea5a1a985e148e90c6ee2bf50ce5b893da89e020", "ref_doc_id": "0be51136-ae11-430d-b0c4-8d03b6d16d4c"}, "cd7454c5-91b8-442d-b376-8e74bb217dc4": {"doc_hash": "c26e1e9333168db52bfb4b30a6f5e38876b1ccc76bced6fceeea1ade069ac13f", "ref_doc_id": "0be51136-ae11-430d-b0c4-8d03b6d16d4c"}, "9a77fa52-81e9-43f7-b119-832f43f6201e": {"doc_hash": "1c7cf4e4f899807b79098c086fb9c9631e9289c12fb4bf96fc0796355e120ddf", "ref_doc_id": "0be51136-ae11-430d-b0c4-8d03b6d16d4c"}, "de100211-e95f-48b2-8829-e9daea52cede": {"doc_hash": "132a544f72e083023bf906662fd5c7bd52c838c0a9308eadc7ae0464867b540f", "ref_doc_id": "0be51136-ae11-430d-b0c4-8d03b6d16d4c"}, "01a973ec-6ff2-440a-92db-8fa255c01bbc": {"doc_hash": "6e6c36cb434cc0d44baa11d962d6f7d6761ba460a9605a8df19f7d2840e358fa", "ref_doc_id": "0be51136-ae11-430d-b0c4-8d03b6d16d4c"}, "1742b17b-20ce-43a7-bb47-274ab10fc2bf": {"doc_hash": "988d9068f4155c33231dcc47bd89daa91d9312db6d4fcc65596b2c2a1c764466", "ref_doc_id": "0be51136-ae11-430d-b0c4-8d03b6d16d4c"}, "da8c225f-2dc1-4dab-9bb7-0d2d0aa6adc6": {"doc_hash": "3df1d88d39e4ac89155633903ed8e7eb3026692cc7d9a3d546761e5b4766a665", "ref_doc_id": "b4407d4d-b563-4c08-aa98-9c55aec1911f"}, "7897b9a9-e59a-4e0d-94aa-4f66487a6334": {"doc_hash": "e74a6d43a8bbf637233184fb7055fd006c81cdfa6b52a3a3b5346fe957f9c30f", "ref_doc_id": "b4407d4d-b563-4c08-aa98-9c55aec1911f"}, "d6b208c8-07c9-4624-8baf-63f6c6ced31f": {"doc_hash": "ceb6dcfc5ef987eb14970f590f3d711c0d7078cd447e2a4d968902fecfea353c", "ref_doc_id": "b4407d4d-b563-4c08-aa98-9c55aec1911f"}, "41da7205-52a9-45ed-b750-0c39e3b0a248": {"doc_hash": "b57050467d8f8c54bfb7a2defe845865043a9624e06b55c8d36a84bc111fb17e", "ref_doc_id": "b4407d4d-b563-4c08-aa98-9c55aec1911f"}, "0ebbb8aa-93ef-4691-b413-d9e82728b5c5": {"doc_hash": "b0b70f32d97b39c587dd73b30d5de0dd19c73c0ec9b434c1a266dee9898308cf", "ref_doc_id": "b4407d4d-b563-4c08-aa98-9c55aec1911f"}, "7525efe1-c12b-441c-9624-b8865f30aa32": {"doc_hash": "a5ccde625ec2c9c6599052a99cee36cb984d2904b17c2012db7c0f0816c1e7e4", "ref_doc_id": "b4407d4d-b563-4c08-aa98-9c55aec1911f"}, "db85f13a-5c9f-4676-b788-eeb119826fe2": {"doc_hash": "a81128588c22555cd5f111f7ac5605eb809cbac235d6f2495c0a7878ba3dda15", "ref_doc_id": "b4407d4d-b563-4c08-aa98-9c55aec1911f"}, "481dd25a-a48f-467d-abc8-8c7f00c10400": {"doc_hash": "dcc5d3a8595a9cbc9e462340759b2ad2e27f187012e661df46658f8beb83dd0b", "ref_doc_id": "b4407d4d-b563-4c08-aa98-9c55aec1911f"}, "e05c2758-a557-4cc8-95f7-8721e3831a4e": {"doc_hash": "6fabe046b51d1f0399994d89641799e42b5d9c936df663e8dd193b14f9604eb7", "ref_doc_id": "b4407d4d-b563-4c08-aa98-9c55aec1911f"}, "4f673dfa-ee43-4082-9091-67651040c039": {"doc_hash": "1972e5eed8da13e47d86388c96a6cabc92618d7e30d466c8cd1972a576502afc", "ref_doc_id": "b4407d4d-b563-4c08-aa98-9c55aec1911f"}, "458dbdf3-09fa-4c9e-ba92-8519ea6a1df5": {"doc_hash": "c38e357de1b3325e587c3bd44b67b213b6ac82f9e7bfb9d39c7f97eb09cd1133", "ref_doc_id": "b4407d4d-b563-4c08-aa98-9c55aec1911f"}, "46667162-05bd-4bce-be1d-abd52f201488": {"doc_hash": "228c7d659c210b3bcc7741e2f8fcc7524741ab1e00c7d32f9776bbadcc9263ca", "ref_doc_id": "b4407d4d-b563-4c08-aa98-9c55aec1911f"}, "ca2880cd-622f-4084-9382-3ceb3e291910": {"doc_hash": "310d5d1f864162a8d4cc930aa8c3098f8e4443cf40750fc27bea650273dda69a", "ref_doc_id": "b4407d4d-b563-4c08-aa98-9c55aec1911f"}, "b62b2866-0edf-4585-bf8a-04fa73151984": {"doc_hash": "23239473814768b2f4b681b9fbdf24220c0474669427fa61f16ccf9a7f976e94", "ref_doc_id": "b4407d4d-b563-4c08-aa98-9c55aec1911f"}, "3d832961-1de6-41df-b9f7-8fcee26e3bc9": {"doc_hash": "0a2f2a58a8547d1be29451589932a17e071d5d6f06b0eda4bb9c6cef9cf57321", "ref_doc_id": "b4407d4d-b563-4c08-aa98-9c55aec1911f"}, "ec908560-986a-4256-9e9e-fa0292bd2a3c": {"doc_hash": "1c9ab20088110d25280247c9e142893123b643c2820cadef1e3753a26b90793f", "ref_doc_id": "b4407d4d-b563-4c08-aa98-9c55aec1911f"}, "03ab3e2f-3931-41b6-b691-1718e5d2ede2": {"doc_hash": "ddf24e8056a8649d950ecbb7612940f97b3d1bfb1e4dbc99f722ed2349b0a2a4", "ref_doc_id": "b4407d4d-b563-4c08-aa98-9c55aec1911f"}, "b3304d79-f196-409e-b3a8-fbe621a7a113": {"doc_hash": "68daa7217ffc185ef6a9690c1015862bdbb11a048009028166656fc25d70edd6", "ref_doc_id": "b4407d4d-b563-4c08-aa98-9c55aec1911f"}, "b647a521-8609-4b97-ae49-6af447026582": {"doc_hash": "81f2f069f1416e62f369a70c8622ca50db70c1b490e0f913d9c5ae6db6623491", "ref_doc_id": "b4407d4d-b563-4c08-aa98-9c55aec1911f"}, "cca5ad36-2127-463f-be4b-4ad243e9df99": {"doc_hash": "9a897515bcc2900d2a06dab2fc5ed8116d596d768bdeb1af990bf341317f9a69", "ref_doc_id": "b4407d4d-b563-4c08-aa98-9c55aec1911f"}, "9b99e806-62e9-434d-9ae5-9a6fdb561630": {"doc_hash": "ec0461296a6b385125800a2c718f5b4d47ed4db42ca5db7d6cd952db398eacb7", "ref_doc_id": "b4407d4d-b563-4c08-aa98-9c55aec1911f"}, "6a73f8c1-43fa-49ea-8528-5ad6dea2421e": {"doc_hash": "f0f5292fb00b214dea7d15d90f2351529587cd5891c9b4774a55e5bd42959ab8", "ref_doc_id": "b4407d4d-b563-4c08-aa98-9c55aec1911f"}, "4d028826-cb65-4f5c-8b3d-51a1ccc5f21e": {"doc_hash": "6cd6c95a657a4a268f682836d0788f4178dd2aca794caa3d651a226fdbe9acf2", "ref_doc_id": "b4407d4d-b563-4c08-aa98-9c55aec1911f"}, "11c2f803-5bdf-450e-834f-eca7bfaec6ff": {"doc_hash": "a6c4d46c20a3e93dd0e3d014ba1ebb319489540c39f25c64323a34d28d030657", "ref_doc_id": "b4407d4d-b563-4c08-aa98-9c55aec1911f"}, "6051638b-89fb-4e3d-9d88-ccce6b72047b": {"doc_hash": "830ff2112a5625b8adc5d4bc740deeb8335e9d7b0d6be19498735027a498a473", "ref_doc_id": "b4407d4d-b563-4c08-aa98-9c55aec1911f"}, "6f3fce4d-c647-4c1b-9960-0b518a758cb3": {"doc_hash": "0a05330a96dbdde7a411b6a13bd7fb7ee597fe1873ff93c247ceedab98bfe560", "ref_doc_id": "b4407d4d-b563-4c08-aa98-9c55aec1911f"}, "7ff8ca1a-21e3-40f3-b3d1-eaed2971ef62": {"doc_hash": "7846e6912e215b7aafc3cb604ae93f4e8005fe4ea6061f06c2d34ae126762b89", "ref_doc_id": "b4407d4d-b563-4c08-aa98-9c55aec1911f"}, "5cab21a6-25a8-4e3a-9b70-c66ac5a3edc5": {"doc_hash": "b38b00b26eb644b1503974bfbdfa9ed7a4d4e8740d15c9cf3bdec9a3b9c84cec", "ref_doc_id": "b4407d4d-b563-4c08-aa98-9c55aec1911f"}, "ce4ae115-06fa-4dcf-ac79-41aa04c03004": {"doc_hash": "2502b43ba07440363176a67152fb687194ce815e33c467a2bf34d2a2d0e2c5d2", "ref_doc_id": "b4407d4d-b563-4c08-aa98-9c55aec1911f"}, "4e802994-243b-44e0-95c5-5c6a0a563285": {"doc_hash": "23462e14e8eef49477fd6756d308018ca66244f824b74d4ff7c15e18ce648f24", "ref_doc_id": "b4407d4d-b563-4c08-aa98-9c55aec1911f"}, "87f572ce-aa8f-45db-8e49-184000e38a43": {"doc_hash": "7b7d13b8c40100451a8fcfb6c8a90b114fee29cfa21ca65cc50f3d60c628edfb", "ref_doc_id": "b4407d4d-b563-4c08-aa98-9c55aec1911f"}, "59085e65-3a54-4079-9170-ad230a2b1dea": {"doc_hash": "d9e6af86e8ce320a04b32d144ea0a60bcab10381a8113ee11eecfaf780b102f7", "ref_doc_id": "b4407d4d-b563-4c08-aa98-9c55aec1911f"}, "72b690d9-0331-4411-9347-932df9e5a9ef": {"doc_hash": "e3f5fe0dfb3bd837292647416c9f67f33d8a18a93a504afdc419cac5ae55edce", "ref_doc_id": "b4407d4d-b563-4c08-aa98-9c55aec1911f"}, "a9c7e98d-0b9d-4c98-ad09-8c94ce597237": {"doc_hash": "cce879c02c7c9bef0a107b874e34c59c6d10ad8b15561e99d903f439adb06cd3", "ref_doc_id": "b4407d4d-b563-4c08-aa98-9c55aec1911f"}, "16a1d2e2-21e3-42cf-8377-47742de8a75b": {"doc_hash": "1301ffbfb9177893acec81b838cec230905ca4d0bc1b3e33c2939631d01f7ed8", "ref_doc_id": "b4407d4d-b563-4c08-aa98-9c55aec1911f"}, "7eab7704-61ea-4c02-9f86-416fac68fee1": {"doc_hash": "21954772aca0b56db1706aa421a2dd1923c7eba427a0c38af17e6c255a063664", "ref_doc_id": "f6aa5062-6f6b-48ce-b783-7a0df37afe92"}, "6c9340db-3e8e-4ab4-a8ba-625ed62d3398": {"doc_hash": "5bea363f7aeabe641ed42b8888b85cfb23c0a78fff7da3013f38e02d6ad13d7b", "ref_doc_id": "f6aa5062-6f6b-48ce-b783-7a0df37afe92"}, "8a18a009-f699-4f8b-b756-23a321d8e9ed": {"doc_hash": "46158e27d14929f11d5da7fd48e76d4e70a15ab786337b197f69bf2a0f20f9e8", "ref_doc_id": "f6aa5062-6f6b-48ce-b783-7a0df37afe92"}, "9629e9ef-fe06-41bf-bb6d-1fe5be376d7a": {"doc_hash": "aba6b249245323bbac07333c9fabfcba4a98d46133c9ae0575866952839ed7ba", "ref_doc_id": "f6aa5062-6f6b-48ce-b783-7a0df37afe92"}, "6fbaf010-4d69-403d-9007-f0c00a132875": {"doc_hash": "a45fc755c4a9cd6fbb69f94d4568c12b850b508c6fb4098d991d2465c27c17aa", "ref_doc_id": "f6aa5062-6f6b-48ce-b783-7a0df37afe92"}, "67c3b1a7-1db3-464c-86d3-3e7271c18d23": {"doc_hash": "81f46bfc82552d34d3c96f9af7f10239d5323efb80ccbe5ec79fcad8b6728d95", "ref_doc_id": "f6aa5062-6f6b-48ce-b783-7a0df37afe92"}, "ae89a610-3160-48d5-b8ae-bd508f2defff": {"doc_hash": "60f11f9b45aba76a0312d5f4289aa127f4a4b46fd8a1d5239b2f1803da2d2985", "ref_doc_id": "f6aa5062-6f6b-48ce-b783-7a0df37afe92"}, "167dc050-c078-48f9-b264-69ae17ca8ab8": {"doc_hash": "3d23145931840d0eb2a48188d5737a1ad827272986397090f9fe52c41bc3054c", "ref_doc_id": "f6aa5062-6f6b-48ce-b783-7a0df37afe92"}, "bf4e18c6-44e8-4231-be5b-b8ce6fae391b": {"doc_hash": "66abeb5cd8a25b94a2aca0e36168f274b340c19f65648633dcd46c63d295ee20", "ref_doc_id": "f6aa5062-6f6b-48ce-b783-7a0df37afe92"}, "b2d2c856-c1a9-4be6-8c70-290dcc72c675": {"doc_hash": "0ecff71b7f9fe7419e115480d3437942666d4c7bda6b605227e2f63364e90572", "ref_doc_id": "f6aa5062-6f6b-48ce-b783-7a0df37afe92"}, "4840c105-9d65-4c00-bee1-8624d6039756": {"doc_hash": "19f781c258fceba070da8d8462b7e8b54b41f7f5e7a63a53857f7d262153bbdf", "ref_doc_id": "f6aa5062-6f6b-48ce-b783-7a0df37afe92"}, "600de59c-58aa-422d-a43c-d19840fa4c8f": {"doc_hash": "818470980633cfd1d18831bff77edb16d7c7828887e0e8cd209ed1570deabf04", "ref_doc_id": "f6aa5062-6f6b-48ce-b783-7a0df37afe92"}, "364ea9e2-e7a6-461b-ae2d-a0cdaa895fe2": {"doc_hash": "9e2a63917114ff95ed87e51538dc286689ac105759e445c40a70530174479e75", "ref_doc_id": "f6aa5062-6f6b-48ce-b783-7a0df37afe92"}, "63b97613-ed15-43de-9ba6-6394455b8cab": {"doc_hash": "5c154c8cd8126bd998dbd3325f214aae5d1bdb7ccff652fec642bc8dae6f1e9d", "ref_doc_id": "f6aa5062-6f6b-48ce-b783-7a0df37afe92"}, "72f07ada-7aee-4d9b-9da4-82b9adbead4b": {"doc_hash": "d770ab2a3127cf624e024de19fd0dd986a8cb67a93fee2e181f4ff94a843714f", "ref_doc_id": "f6aa5062-6f6b-48ce-b783-7a0df37afe92"}, "16149aa9-a975-411f-a12b-96ad49e97df0": {"doc_hash": "9043d058ff021ffe91e4984e326f7b2fffb28ffcbdd607be7ad9d5dd0e229751", "ref_doc_id": "f6aa5062-6f6b-48ce-b783-7a0df37afe92"}, "3bca1532-55b2-443e-9585-cd8bf53c8bf7": {"doc_hash": "bd186d0b162bac45be971eec71da19ec1b93503ebb929e8397f3d94e342f6c38", "ref_doc_id": "f6aa5062-6f6b-48ce-b783-7a0df37afe92"}, "eb93f940-44f9-4914-80a9-5845b2f7e70c": {"doc_hash": "df2c724a7f6be3a5f3fbc8ad69fc4e6ba8c4b7637fda91e55e00670b18a95f13", "ref_doc_id": "f6aa5062-6f6b-48ce-b783-7a0df37afe92"}, "b843e5c0-4471-45d5-a108-da28578569d4": {"doc_hash": "6ca96bc4285de00ae0f35eb295862570098ab01c03263d2599992a210b9513fc", "ref_doc_id": "f6aa5062-6f6b-48ce-b783-7a0df37afe92"}, "c01ccf74-6dd5-47fa-b795-4d40809dbd96": {"doc_hash": "957074bc6d79418f6fb31dcff26a155a0ab9350a1ae322a4cc5efa89d5e00880", "ref_doc_id": "f6aa5062-6f6b-48ce-b783-7a0df37afe92"}, "20654277-bde5-4825-b8a7-739f3512ad7c": {"doc_hash": "53ece92250d881271813e2f3c92d49d07485c7b7a0d75824ce30e403cf367141", "ref_doc_id": "f6aa5062-6f6b-48ce-b783-7a0df37afe92"}, "c2a29d29-99ce-4ba1-a30e-b10420669489": {"doc_hash": "d70ce440692385382c3213c4a97841691e309327e393d906a83fa3fe6b599d34", "ref_doc_id": "f6aa5062-6f6b-48ce-b783-7a0df37afe92"}, "daf05f0c-1d53-4e7b-8b84-5a08476fd49d": {"doc_hash": "32a44fb5c135618ebd6476fe398f35c8e31d82d7d814cb7b97f703f036bdc07a", "ref_doc_id": "f6aa5062-6f6b-48ce-b783-7a0df37afe92"}, "6ce3c768-7bad-480d-aea6-0082550df34c": {"doc_hash": "e766bc2b76ffc3e8b410a9bd5f953f86b1c4e827cdea6b603fe41896a08df8ee", "ref_doc_id": "f6aa5062-6f6b-48ce-b783-7a0df37afe92"}, "39229aaf-89d2-4a27-a73c-56c3931ebbe8": {"doc_hash": "389f07ccb4caa96a58f55228a4b9d45ed55be201f7b1e9ccb897282b961cbb55", "ref_doc_id": "f6aa5062-6f6b-48ce-b783-7a0df37afe92"}, "224eb121-5ae3-48c8-b111-a421cc33b0f9": {"doc_hash": "cbf7de343d27e364ffc497e04aafd7ba4b646f87180d82aee4920d43be285b91", "ref_doc_id": "f6aa5062-6f6b-48ce-b783-7a0df37afe92"}, "7f1fbbd9-bace-4242-b340-6c1929f61d16": {"doc_hash": "76c1e2104275b9fac2f166278b8bd08eedc79203f2a042cabe24ac40f729d730", "ref_doc_id": "f6aa5062-6f6b-48ce-b783-7a0df37afe92"}, "bf21d441-4922-4ec7-8b35-6b7c66115a5c": {"doc_hash": "303641badcebdadf045bd9daca05aa066f734899e63b002554720f26231dc26a", "ref_doc_id": "f6aa5062-6f6b-48ce-b783-7a0df37afe92"}, "8c048a3c-f8ea-4b9a-94f0-b96222c3a02a": {"doc_hash": "a7f2d1d41ee1b0d27fb6803fe8acee2719052a680e08d5c7d976162ada727899", "ref_doc_id": "f6aa5062-6f6b-48ce-b783-7a0df37afe92"}, "07dff0cf-9e28-4f4d-a388-cc54d670d1ec": {"doc_hash": "032a6dc7e3e6eacdcdda126f7c7a24394c19dc1692459dfd85b39adb90cd9dd1", "ref_doc_id": "f6aa5062-6f6b-48ce-b783-7a0df37afe92"}, "a47431fd-b28e-4608-968b-fcea260d5b5f": {"doc_hash": "06db9544f41f31d56a2a3f4a6d9d8965214d046442f90a06a5c943edd19ccd81", "ref_doc_id": "f6aa5062-6f6b-48ce-b783-7a0df37afe92"}, "0bfe42aa-9cd0-4f01-b1c1-0e67b9f7fe0b": {"doc_hash": "1c3543b5de53b9f59ff5dbe81f284287ece98d759667acb6abf85f6639a2c561", "ref_doc_id": "f6aa5062-6f6b-48ce-b783-7a0df37afe92"}, "87633704-e563-448c-959d-19a29304ef42": {"doc_hash": "5e20fe46cbc5f87e0b5a5659b40555fd96d161a9c00534e2c0ec9e3851b73f1f", "ref_doc_id": "f6aa5062-6f6b-48ce-b783-7a0df37afe92"}, "06166617-a9b1-4983-9e8c-5316f389b8d7": {"doc_hash": "6031c1c898d9f1380ff6a7ef24806ae5c703687d7d9bdd1faaa49df1e016b531", "ref_doc_id": "f6aa5062-6f6b-48ce-b783-7a0df37afe92"}, "c7b05756-88fe-468f-982a-73ed25daf215": {"doc_hash": "ac0c2ee2bc5d34d83ca7fa946d7c288d708a44609daf60060dd964c4008bea14", "ref_doc_id": "f6aa5062-6f6b-48ce-b783-7a0df37afe92"}, "6defb0d4-8313-476e-aa64-4ae8ad5c8f85": {"doc_hash": "bdfe9cdb4e44cd8e9daec6efe2583365392b468b8461193161e1edd9d347c507", "ref_doc_id": "f6aa5062-6f6b-48ce-b783-7a0df37afe92"}, "8743357b-ab76-40c9-bb0e-fee9746c43ab": {"doc_hash": "edcf0c42a17a015fc7e8c38244423e687c9d1cdc80c9def258bc7f26ab04a7b2", "ref_doc_id": "8e2e64d9-3499-4495-ab28-5ac0bafd5491"}, "1cecb194-0916-4261-9539-8196739eef0b": {"doc_hash": "cf5ebf9d624deeab4aaf50295de199de5e8dd93868fc1ed1f1f393265308bc42", "ref_doc_id": "8e2e64d9-3499-4495-ab28-5ac0bafd5491"}, "a65bd46c-268a-4135-9df0-1dd7b978c15b": {"doc_hash": "4acae9904fded8e396cf322d9a73ef0b6c76b2ef3211399462e44968a4af4ab6", "ref_doc_id": "8e2e64d9-3499-4495-ab28-5ac0bafd5491"}, "e75bdab2-d675-40a5-823a-26e0594473a9": {"doc_hash": "61d970a7bb9603579ab5a68a2276d35f0ff6bfe10c6a2f24eaf84ece450e2800", "ref_doc_id": "8e2e64d9-3499-4495-ab28-5ac0bafd5491"}, "bee18eef-db7e-421e-b317-7ed40d0007df": {"doc_hash": "d2f09dd063f33e0b53a6b7ebd6190a9403a980251a06fa5b9935ff2001f3af31", "ref_doc_id": "8e2e64d9-3499-4495-ab28-5ac0bafd5491"}, "aa2ebc78-eb8e-44c4-9ae2-c1dda9eb35ff": {"doc_hash": "91aaae1faafc345d955e28f3114b118fc498a34f3a192142bf211695a077a515", "ref_doc_id": "8e2e64d9-3499-4495-ab28-5ac0bafd5491"}, "896ef14f-d281-421a-b1ae-7d60dfae0a64": {"doc_hash": "98aac240aa90f8e281299744081193af4d0076c3039120a8c1477ad54a8d3610", "ref_doc_id": "8e2e64d9-3499-4495-ab28-5ac0bafd5491"}, "384c0f53-19e5-40de-84e1-7dc37acfb21a": {"doc_hash": "f2aff12b2be7914356878c82dd6df113fcd8c3ca5879d14005192feae072a0a0", "ref_doc_id": "8e2e64d9-3499-4495-ab28-5ac0bafd5491"}, "6109f078-79cb-45e0-a852-54a030e02063": {"doc_hash": "f3560ff8b7a5c08e82750f83410be9ea1f0af0cbb0f7adfec4f3849d96bd16cb", "ref_doc_id": "8e2e64d9-3499-4495-ab28-5ac0bafd5491"}, "2d81aefd-baa3-4183-a7d3-ec96a7b3f8f3": {"doc_hash": "9fa6b4653e0999023bfecbe273a6fbeb1ef3d9f791dc233b37971a7f099b64bb", "ref_doc_id": "8e2e64d9-3499-4495-ab28-5ac0bafd5491"}, "cf9b24db-5c23-4f43-9022-ee8770c6657e": {"doc_hash": "9bd7ade6ab817453aa399bb85981bbb73e5ab0898c239a88b7432bc11974346e", "ref_doc_id": "8e2e64d9-3499-4495-ab28-5ac0bafd5491"}, "6286b206-919b-4849-bd23-1c4644fdb1e6": {"doc_hash": "96eea551e3a6126d9e7d08f90eb4097a46e86892668deab6494a7efe3ad6b068", "ref_doc_id": "8e2e64d9-3499-4495-ab28-5ac0bafd5491"}, "ee618f4e-7c8c-496c-bd24-cccb7ee26798": {"doc_hash": "68c205b003f9e6e2f79c91ae34ee8b608d04cd81fdcb92c79643765d1e56cf71", "ref_doc_id": "8e2e64d9-3499-4495-ab28-5ac0bafd5491"}, "e576ef33-8548-4237-9f70-932ce726bcb1": {"doc_hash": "2f5680154a6b38085a7311142f0eef6bfcd1ce33f78db1104534d310e02f017c", "ref_doc_id": "8e2e64d9-3499-4495-ab28-5ac0bafd5491"}, "6b4d5dc8-6c7e-4ddf-9bc5-faddbb164216": {"doc_hash": "549eae7efd4f3603387904e105d0d51f8f78312c2f9eac5ca4b667487349dd99", "ref_doc_id": "8e2e64d9-3499-4495-ab28-5ac0bafd5491"}, "0a8e1d9f-0e35-4392-8c3f-68c179e0b5f7": {"doc_hash": "be0487d566de9c93ed7116710cde23dd3b142606b47444f7ea4b47e00d7643a4", "ref_doc_id": "8e2e64d9-3499-4495-ab28-5ac0bafd5491"}, "2fe6127e-3443-49de-93cc-1c8a7d838070": {"doc_hash": "016a05a8c6cd95feb8ea3c0c05de90d743fda8c735663afe47c51dd5547f9c9f", "ref_doc_id": "8e2e64d9-3499-4495-ab28-5ac0bafd5491"}, "0f8291b4-98b5-4597-8039-00e7bb048fa6": {"doc_hash": "3d351fefb43ccf15139f2bf7bcbff171ada41a2929f13ccf5a1d49f559aa30d0", "ref_doc_id": "8e2e64d9-3499-4495-ab28-5ac0bafd5491"}, "de9bedac-31fb-471f-b4b2-c958eb673c14": {"doc_hash": "abe966badaddf643bba1830b1e1f484aa8f44ed9b738662410e5fe14b668ede2", "ref_doc_id": "8e2e64d9-3499-4495-ab28-5ac0bafd5491"}, "2cac00ca-b730-4839-a939-b4bc5dd11756": {"doc_hash": "5fb5776b65e23e6ca128b1130cb6f0a3bf0c75450e007939aa5b96db1c328884", "ref_doc_id": "8e2e64d9-3499-4495-ab28-5ac0bafd5491"}, "a6668b04-d143-4c78-b659-53cef90a138b": {"doc_hash": "ab43987087d3974ccbcc0afd75b8b8578dcc5c9b9d4916f0c5d36c8f4cb12443", "ref_doc_id": "8e2e64d9-3499-4495-ab28-5ac0bafd5491"}, "d0695bfa-5eb1-496e-9262-46cf039adcd1": {"doc_hash": "44f9ebafe5ab0de4522a9406262ff523eff63230799c146ba27efc33076069c6", "ref_doc_id": "8e2e64d9-3499-4495-ab28-5ac0bafd5491"}, "93dbad4e-6575-4b4b-8fb9-feacc180d965": {"doc_hash": "68e96c3025592b73ce68423078ca1335024fec3950c2e4f3414bfb7a882fb3c3", "ref_doc_id": "8e2e64d9-3499-4495-ab28-5ac0bafd5491"}, "740c43ec-2bc8-4b31-9b05-99512d4e7323": {"doc_hash": "9be02c5c0e3c288a4b4814f7809f4533dcdd229ec5886d9eaa566240eb2372c9", "ref_doc_id": "8e2e64d9-3499-4495-ab28-5ac0bafd5491"}, "f916aa3d-2c46-41f3-a325-321e4735667a": {"doc_hash": "25c26e6b6396957913e392d099253c41fd2348fe6be183d871f0948b0db1a054", "ref_doc_id": "8e2e64d9-3499-4495-ab28-5ac0bafd5491"}, "a4effb32-6707-488b-ac5a-81c401502af8": {"doc_hash": "da89c578c58ca0de18f6dfb66881152d1fbad857013ac2a365caaa21d3e202d6", "ref_doc_id": "8e2e64d9-3499-4495-ab28-5ac0bafd5491"}, "cf37ae39-a62c-4c40-83a3-f766c121e737": {"doc_hash": "dd09010c1fff79879b91580a54a937e3601a9c014c7dbbefbcd764d593710637", "ref_doc_id": "8e2e64d9-3499-4495-ab28-5ac0bafd5491"}, "14ce4cfc-a92d-4e6b-b5fe-d7d7476ee6b8": {"doc_hash": "54e4ee4d1976757f79126e9a6915b66e56e4f9ab5d8979d3d84e1450914b169f", "ref_doc_id": "8e2e64d9-3499-4495-ab28-5ac0bafd5491"}, "3c6dd035-4aab-4931-a463-9ee77492eeba": {"doc_hash": "c678f16beabaf886b14dd5e4e2514e6298d590db11548952b810c6c36ef06a45", "ref_doc_id": "8e2e64d9-3499-4495-ab28-5ac0bafd5491"}, "27327809-f4b1-40c5-86d7-920e0ee648c7": {"doc_hash": "d903110d2396b6300111fed14d5ac8bde0a75cae041e035b5eca8fb4aaebebf6", "ref_doc_id": "8e2e64d9-3499-4495-ab28-5ac0bafd5491"}, "038de542-1eff-43d2-8ec4-2461758da211": {"doc_hash": "61e58b6b1befb837e46b244014966ceddd7c16dfa0499c6c27af502ce742a542", "ref_doc_id": "8e2e64d9-3499-4495-ab28-5ac0bafd5491"}, "412bf8a1-ef8f-4cc4-93bf-916b6ae4067c": {"doc_hash": "eca5a72540841bb6baa09c79c238f7dd8672b8a808bc547d768762ad0eba1190", "ref_doc_id": "8e2e64d9-3499-4495-ab28-5ac0bafd5491"}, "3f05051c-7f51-4210-88c3-f32a3503a2a5": {"doc_hash": "5455632c526a7407f744a9d9660bda883f69b16a25587784c3db2a53b903f384", "ref_doc_id": "0ac9f346-07e9-4997-8f28-e5117e7bae25"}, "d22e444a-6136-41a3-b630-a911c2a1fc4c": {"doc_hash": "c2c3dd7e764ba7af591d7ad11d07aeffbeb6e189b5cd4ba096743cca286e0029", "ref_doc_id": "0ac9f346-07e9-4997-8f28-e5117e7bae25"}, "3357e4dc-dd4c-4885-84c7-ff75515c7dca": {"doc_hash": "508ad1ec945f93091963f22422466e773ba6da637221f41a02362c415e37bab6", "ref_doc_id": "0ac9f346-07e9-4997-8f28-e5117e7bae25"}, "901b2bf8-7d30-47f6-8a79-03e7dd9735fa": {"doc_hash": "4e5657dca274085190d5ed911ec2e37e25931f0aeaa7c01b2d368d2407f28d52", "ref_doc_id": "0ac9f346-07e9-4997-8f28-e5117e7bae25"}, "6b08b11b-4232-46c8-9ef1-9400160a82c9": {"doc_hash": "e0b262c6f2cf79c349d7417608acace5a3ba2c17f377409ab4047651b5eb5143", "ref_doc_id": "0ac9f346-07e9-4997-8f28-e5117e7bae25"}, "1a4a65d0-1991-4f09-90b4-08a4766d081c": {"doc_hash": "ab90aa513be36b147358c86363ef74d4f2ca2a85315cde8606069b56540fdcca", "ref_doc_id": "0ac9f346-07e9-4997-8f28-e5117e7bae25"}, "84f58ebe-9235-42a4-b2b6-24db9039b329": {"doc_hash": "756688a1ea285ac6f6f346d203610ea347b8dfbd6dda2768df89e3b381722ab0", "ref_doc_id": "0ac9f346-07e9-4997-8f28-e5117e7bae25"}, "c49b04ba-7739-41b3-89a5-7fa712a09eca": {"doc_hash": "64607b5577f4bb2e933692081bdadc93f85d098ec655864b67033840d09b2c12", "ref_doc_id": "0ac9f346-07e9-4997-8f28-e5117e7bae25"}, "c82179e8-f816-44dc-9211-ee618cff90d6": {"doc_hash": "1bc461e88ec158bef71b49642c43d778d4df8b77d73f31042f35c210b7510c34", "ref_doc_id": "0ac9f346-07e9-4997-8f28-e5117e7bae25"}, "49c95ca7-ebc6-4fc4-bbca-1dd2935f0a29": {"doc_hash": "e36db78bcefc350886609484e220505d05bec59b248450836a6091ae7c5dfd81", "ref_doc_id": "0ac9f346-07e9-4997-8f28-e5117e7bae25"}, "7e1da58b-931a-4e7e-b6aa-745b9c0fc67b": {"doc_hash": "bab7c57b75fcb654c14ca636d1ca5ab6341a06ccaee8fa43774ed9c739181a78", "ref_doc_id": "0ac9f346-07e9-4997-8f28-e5117e7bae25"}, "6fe2fae4-a1b6-4454-b152-52cafdee41b0": {"doc_hash": "b5b1832ea750b5c44e3691a32704b3245f6b8d0a903536809cee729665bfd476", "ref_doc_id": "0ac9f346-07e9-4997-8f28-e5117e7bae25"}, "7e300fd9-8b96-4568-8ea1-6d70f95b029a": {"doc_hash": "6873e3a24e579769dd920e9434e7e03c260ae90a6e1535a897366ef9a1d7b9c0", "ref_doc_id": "0ac9f346-07e9-4997-8f28-e5117e7bae25"}, "cb264db5-3958-4b71-8130-a43a56b021c5": {"doc_hash": "0580dc618ab353368cc03d263cb0a5efbb96122e00a4f1ff9a719497ca222794", "ref_doc_id": "0ac9f346-07e9-4997-8f28-e5117e7bae25"}, "7749c7ee-fae9-46b4-9db5-44960fd3aa4d": {"doc_hash": "44df6859e959672f445315e9114df8989d2d3782c692d9f90416c78f0aff1bd9", "ref_doc_id": "0ac9f346-07e9-4997-8f28-e5117e7bae25"}, "e7cf09fd-54b3-41a2-8879-5a5056a2f170": {"doc_hash": "52b1b1e4addccca7419b9b3f1e7f55641c6aec9476804d742b41a99fa10667a9", "ref_doc_id": "0ac9f346-07e9-4997-8f28-e5117e7bae25"}, "a9a66894-f487-46b7-a69d-f4e8ee4499cc": {"doc_hash": "4f1cb15bad5e8be2841bd415d7cd1d2e0ccfa2941b66ddcc38ad84c500c133a7", "ref_doc_id": "0ac9f346-07e9-4997-8f28-e5117e7bae25"}, "eb1a401f-f75e-4f86-8f1e-38b58b463d8d": {"doc_hash": "ce94f5b2c2f78f9bd3ac368d30adff7203231276db010726f08a8dd696e088c3", "ref_doc_id": "0ac9f346-07e9-4997-8f28-e5117e7bae25"}, "be8079b6-fade-497b-aa02-194ec352e7c3": {"doc_hash": "353d19dd22f42eb17319b407df9cb6809a195cc1ef6d79335497e190835748a8", "ref_doc_id": "0ac9f346-07e9-4997-8f28-e5117e7bae25"}, "400399f0-1f09-41b0-ba29-4ff37f0bbaa4": {"doc_hash": "e1965b6680aba4cf42ea866295f44fc2045e840c597b736b3f9f8d4640f53249", "ref_doc_id": "0ac9f346-07e9-4997-8f28-e5117e7bae25"}, "e530ef42-af97-4bf6-a83e-475cc392bc8a": {"doc_hash": "2ac26c47cc1d6b361b438d1889109af06a45f01b55be27a11a8dcb601c022550", "ref_doc_id": "0ac9f346-07e9-4997-8f28-e5117e7bae25"}, "520a0f9f-e6ab-4e9a-9274-bb2667dea598": {"doc_hash": "305b2c3d62bfe945a1a46a30e305d624d55447f58c73e1259491ef5532f8394e", "ref_doc_id": "0ac9f346-07e9-4997-8f28-e5117e7bae25"}, "70599055-c6f1-4ea5-96ba-542587a140d7": {"doc_hash": "cc3e6f2b7d7edef56c8959b27443fe818f4088345ea69db3d757196a1399b773", "ref_doc_id": "0ac9f346-07e9-4997-8f28-e5117e7bae25"}, "b742bf7b-5425-460a-b17e-5a70f87545e2": {"doc_hash": "90dec3534da53f1ea22be8091cfb15cb5ff30ab124e67f27b5549a608723c9a7", "ref_doc_id": "0ac9f346-07e9-4997-8f28-e5117e7bae25"}, "9d4098c4-fce0-4827-90cc-f733f2f4d3d7": {"doc_hash": "8b73f41d84d928bf37ac1e6475749dc67a3a831f014d4805df21b26dbe6b9c18", "ref_doc_id": "0ac9f346-07e9-4997-8f28-e5117e7bae25"}, "43c47f12-380d-4213-bbaf-a3d679f631f1": {"doc_hash": "80ac83e255b4527ff500e3abfdc420abac9e495c57c9c893128ffbe8744d0d94", "ref_doc_id": "0ac9f346-07e9-4997-8f28-e5117e7bae25"}, "3fc7508c-13c4-40ae-a13b-ac6eb9a6a8a4": {"doc_hash": "7ee5446103a374d3deee98d16ae33fae99a8d52cea614e5715b41a7e31c575da", "ref_doc_id": "0ac9f346-07e9-4997-8f28-e5117e7bae25"}, "7f805137-8557-43c3-8fd4-36f4f03d7034": {"doc_hash": "e77722142e797ef4acbaf15592bdd4cd091080525d7d29951abc45daecc864bb", "ref_doc_id": "0ac9f346-07e9-4997-8f28-e5117e7bae25"}, "49a2968d-a6dc-4eda-8f83-78122754776d": {"doc_hash": "9c821725388f8df037f3f0a9cff7c1bd85dcbd392d192dce961d7dd009e1d621", "ref_doc_id": "0ac9f346-07e9-4997-8f28-e5117e7bae25"}, "ed2167f4-3ac1-404f-bf75-2c0065e928eb": {"doc_hash": "7181245947a3004cbabf219ede7e345d1fed3b0edfb2d68721ac062988d80746", "ref_doc_id": "0ac9f346-07e9-4997-8f28-e5117e7bae25"}, "70ca24c3-901d-4ccf-b35a-9b59b32ccdb7": {"doc_hash": "50e21218c5bdce914b16accc854bd9894980923edb0cbfaa3a0ca03afb190fec", "ref_doc_id": "0ac9f346-07e9-4997-8f28-e5117e7bae25"}, "1ff1d9de-e075-4b4c-a98b-d5531bb82408": {"doc_hash": "1e96ab97eaf0477c046c5265dd718cad173e2e9a236fac62afa27b8790607b8f", "ref_doc_id": "0ac9f346-07e9-4997-8f28-e5117e7bae25"}, "c3283e31-7e49-49dc-befc-2be590f6ff46": {"doc_hash": "a020b348a64101e241ba2b139408858de7d78b4247cd968f803295be5ad6f048", "ref_doc_id": "0ac9f346-07e9-4997-8f28-e5117e7bae25"}, "5a9b816c-bf9e-4b3c-b205-7fcb01a04871": {"doc_hash": "db827c9324092a30bef96075c3777829ec824b8e0145d468d474457cc7de2cbe", "ref_doc_id": "0ac9f346-07e9-4997-8f28-e5117e7bae25"}, "3e2c9d33-02f8-4a3e-bd1d-f12cf7de7811": {"doc_hash": "ed11e8cb390b9652efe04708d0fe49dac231b2af067f9a3da403a03bd67093a3", "ref_doc_id": "0ac9f346-07e9-4997-8f28-e5117e7bae25"}, "55498f05-3c1a-45b8-ac5a-7797c29997fb": {"doc_hash": "15379d8983af6ee843c4868d8575ef60e68c85de31c0c50e9a6fe73d1a3b460f", "ref_doc_id": "0ac9f346-07e9-4997-8f28-e5117e7bae25"}, "14986283-48a4-43e9-a676-6c172a1c2c08": {"doc_hash": "98da9a98f3581f0bb4f82cd10fdc68dacb29147333e3f7b099b20e447a7206eb", "ref_doc_id": "0ac9f346-07e9-4997-8f28-e5117e7bae25"}, "5045c9d5-9983-4b1f-86d0-32f8a239d857": {"doc_hash": "7050be1e1619a588f657c0a78f78049e8c2e69194bcce73ac37a3476988b93ed", "ref_doc_id": "0ac9f346-07e9-4997-8f28-e5117e7bae25"}, "1bee3d3c-a2d6-41e5-a4a4-4a0b97d38350": {"doc_hash": "e058ddbebe76babf1dfc9382f18c160ecf66c46c4057f098efb6bd380dff125b", "ref_doc_id": "0ac9f346-07e9-4997-8f28-e5117e7bae25"}, "989f35b7-f155-4e88-9b3d-99dc4b82b067": {"doc_hash": "c55d6c0a34e7cbc548919d0e4c2f9c857fefe9bd80df1a562c0d717383904a86", "ref_doc_id": "5cf92087-e35d-4fba-85d3-821d01035638"}, "284a148d-feac-4eb3-a6a9-8e60321f9f1c": {"doc_hash": "2dd73142bfa3b99bc8bc672902cb4c091540d0c0effab890349d61956ae44f54", "ref_doc_id": "5cf92087-e35d-4fba-85d3-821d01035638"}, "65dda52d-a8fd-425e-bbea-2c466aaddadf": {"doc_hash": "5be2705906317f2509886376030a470fbdc316614da227565235691151ea89a3", "ref_doc_id": "5cf92087-e35d-4fba-85d3-821d01035638"}, "66bb4983-da23-4619-99dc-cc2265374dd6": {"doc_hash": "766d27041d50ff1e276ba5f0da31d257d0f3cc008912dfd9b8d456c2f9ea05da", "ref_doc_id": "5cf92087-e35d-4fba-85d3-821d01035638"}, "43569f33-965b-4263-beeb-1a03d93cc6b6": {"doc_hash": "5c773679bb46b6427824f163897259ed159a9d8f5bf8db8d5433f0946cad7fe9", "ref_doc_id": "5cf92087-e35d-4fba-85d3-821d01035638"}, "af2a4a68-63b8-491e-a0c5-23acb4b11f5a": {"doc_hash": "6620fb78256dde2696b19113b4e7062a905e6a3b24219f70bcc725d78717de02", "ref_doc_id": "5cf92087-e35d-4fba-85d3-821d01035638"}, "d0b877e8-2713-45b2-a7d7-46144db0af75": {"doc_hash": "48526824da52f20a7f93a612dfc12bcf28533cd78b19aaa835836bd67a5a90b8", "ref_doc_id": "5cf92087-e35d-4fba-85d3-821d01035638"}, "2649aa6d-2acc-46ae-a7c2-61ff0360352d": {"doc_hash": "e4ef62e0429f3c941819ae6a9d3cd34e02aa7738c4155e638836e3a34a7091f9", "ref_doc_id": "5cf92087-e35d-4fba-85d3-821d01035638"}, "14e4659c-c425-4aea-9c16-7247178e524b": {"doc_hash": "dfd42de193e60246323231b0c688649d5dcbbf278582c29d5eb9e9c07a49a682", "ref_doc_id": "5cf92087-e35d-4fba-85d3-821d01035638"}, "b60cf5a6-c47a-4d20-9e03-83fd0d70b1a7": {"doc_hash": "d102798b59e7ecd3106d8eea39fae9f9c38135081c3121cfd4079add2c79faed", "ref_doc_id": "5cf92087-e35d-4fba-85d3-821d01035638"}, "00d39fc7-7e04-4c84-94d5-3e0bbb38193b": {"doc_hash": "e16918420c19185bb75881f9406f0cd203d235ca550ea86aac50f97f9bd33295", "ref_doc_id": "5cf92087-e35d-4fba-85d3-821d01035638"}, "f357ae8a-9a96-4e19-a929-34613b60b09f": {"doc_hash": "fab286fcf02dd5696712ef3321e7d247ea4fd66e83197000f60aac27245ae3e9", "ref_doc_id": "5cf92087-e35d-4fba-85d3-821d01035638"}, "7224056f-f34c-471e-9e14-b3f8a0f7f715": {"doc_hash": "35e0fbb68831d58518ed7e7a7448ce9c17b23f1674fef83bb53f6d36296fad50", "ref_doc_id": "5cf92087-e35d-4fba-85d3-821d01035638"}, "58a4b74f-a9b1-4c18-9515-be998860a05b": {"doc_hash": "bad95344890acf5f2fbafa8fb1eb8a048b5753284dcd1a37ce8e601619cf2a0e", "ref_doc_id": "5cf92087-e35d-4fba-85d3-821d01035638"}, "e057bab2-236f-4ae9-a0cc-6e5814e3482f": {"doc_hash": "989a48b876d311ed1a4c147790f6b162f9e1ac5a20663bc2aa44447d685916ee", "ref_doc_id": "5cf92087-e35d-4fba-85d3-821d01035638"}, "fb4c981c-8420-47a8-adb8-058da50f0a3c": {"doc_hash": "329acdb6a5afe4f253c8e86a18f6fedac91bb97024b117559c9e7654f1785687", "ref_doc_id": "5cf92087-e35d-4fba-85d3-821d01035638"}, "d8f9cd1e-ea46-43fc-98f0-fd6818dc49b2": {"doc_hash": "4974fdbb1fc18bbf1c690bdaf9aa01229906c2181f422ebc667c1994aa920ad3", "ref_doc_id": "5cf92087-e35d-4fba-85d3-821d01035638"}, "eb3c614a-b681-4851-a036-22dfe438bfae": {"doc_hash": "2dd12d52a618934389ba33c3451f8d59c40047a38a34d33eb89918e59583a5a5", "ref_doc_id": "5cf92087-e35d-4fba-85d3-821d01035638"}, "4d535836-2f25-4c28-b7ce-90bfcbba3675": {"doc_hash": "85e24a7dff9fc34a2a88cdfed5f99bf524f2e0ade64012343aacefe7bf0a09e2", "ref_doc_id": "5cf92087-e35d-4fba-85d3-821d01035638"}, "e4589d49-b52e-4fdd-8058-f96abae1be02": {"doc_hash": "32559f711e919c8eb92e28a001d1e6f32ebce7c363bae11db405097d6827d1a0", "ref_doc_id": "5cf92087-e35d-4fba-85d3-821d01035638"}, "c59c3428-8f76-4308-b58a-9e36d67c97cc": {"doc_hash": "f04d5b264f7510496ff9be8879214419a3fa71f35ac4eaaf27f5a276312bff52", "ref_doc_id": "5cf92087-e35d-4fba-85d3-821d01035638"}, "c8dfa6c5-4323-4c4f-8bf7-ac582a8f435b": {"doc_hash": "91989a25934c315f648ecea43866f165f30217823ece6bb151cdbdcc250cc867", "ref_doc_id": "5cf92087-e35d-4fba-85d3-821d01035638"}, "3a30fe86-63e1-406a-8ee3-5004fd6963dc": {"doc_hash": "6a06fe0dcd97ab4717603b5bc62169c5592f700c7618edb486a8291472bec23f", "ref_doc_id": "5cf92087-e35d-4fba-85d3-821d01035638"}, "08277890-3d82-4e84-ad09-c197ac32b72d": {"doc_hash": "7267df7d4ddb8e4ea83a7a7d233a2079d5763e8c8c14903e999c8b011590cd56", "ref_doc_id": "5cf92087-e35d-4fba-85d3-821d01035638"}, "3050c150-95ed-4d9e-8d7e-a356dbd02b1a": {"doc_hash": "563d84ef7b1adeb946291b4d03cb64deddc9aef73b4afc7e34648904c1e8acdb", "ref_doc_id": "5cf92087-e35d-4fba-85d3-821d01035638"}, "909afeea-cfae-40c9-89a2-4817f915f180": {"doc_hash": "141eb390a6aa3bfac216e4f45c47cab598b52a499a9b8f35a502cacb731a5863", "ref_doc_id": "5cf92087-e35d-4fba-85d3-821d01035638"}, "da612441-8817-43e0-8189-50323c9099c5": {"doc_hash": "2d297f94c86532aa052f79c76982564ef5ea2bb7529c37562ff6ce581bd25dc3", "ref_doc_id": "5cf92087-e35d-4fba-85d3-821d01035638"}, "caefe377-afb4-4ec0-85a0-9b66a041ccfd": {"doc_hash": "6cf1a129c7eb74c80b224ed9948d518b1d261725ea46e367da7dc7e824423518", "ref_doc_id": "5cf92087-e35d-4fba-85d3-821d01035638"}, "e3ed3339-96fd-4c8b-9b78-9cdd14be00ec": {"doc_hash": "a0792d3b0da44bae073d92ce088eb5c2f6fefeb580b63716b933b3abb82ba661", "ref_doc_id": "5cf92087-e35d-4fba-85d3-821d01035638"}, "4dbaec66-07d5-4f16-b8c1-71e8404463c5": {"doc_hash": "999d7bb89358500e10263428b18a5120afb80421d9812642845257037f2e4c2a", "ref_doc_id": "5cf92087-e35d-4fba-85d3-821d01035638"}, "bdbadb6b-bcb8-4f6a-b12c-5bd8302a6780": {"doc_hash": "81b1499c31579ae8141507d5806a6d7165188cabd03ed69e18c10ece8cff2f0a", "ref_doc_id": "5cf92087-e35d-4fba-85d3-821d01035638"}, "c2b6b96f-4761-4bb5-9ac7-4ddc64285109": {"doc_hash": "98c3cfb6348252c35968faed66f84b2395f3e99f8ce4530b24d7190cbc4ec8eb", "ref_doc_id": "5cf92087-e35d-4fba-85d3-821d01035638"}, "2b28cded-3168-47be-a75a-04ba7ff7503b": {"doc_hash": "93706ec5263051b85f3f7d97fd9680231630d1f809d605109f0927664c576019", "ref_doc_id": "5cf92087-e35d-4fba-85d3-821d01035638"}, "c1c69078-3694-480a-995d-4fc91698e90a": {"doc_hash": "95db4852c4e87205d65b0fc521111850d57de297400e13461ff8f57a1d23ef10", "ref_doc_id": "5cf92087-e35d-4fba-85d3-821d01035638"}, "18c8f6e5-05c5-41c9-9729-896c46c0cba3": {"doc_hash": "cdf1922708f1f9616d6ec7a8954f8ad8eba8cf0902499ae993500a7a451e5895", "ref_doc_id": "5cf92087-e35d-4fba-85d3-821d01035638"}, "542f85ec-3ab4-4e77-baeb-148fc11a703c": {"doc_hash": "cba2a79d7ba58c7f089c58c975a02196118c418b5b49208152c70b104515a0c5", "ref_doc_id": "5cf92087-e35d-4fba-85d3-821d01035638"}, "aa064d45-ec4c-46da-8395-970deaf301f6": {"doc_hash": "f6525627305dec593372a976b6aacc758c6ac2ce1fb7dd0fc9ea731630d42821", "ref_doc_id": "5cf92087-e35d-4fba-85d3-821d01035638"}, "7a750335-3830-47b4-9fad-a07a8a833139": {"doc_hash": "49e77002d3e2ff8e29a04ec3010c8a1306b6025cc71b6521c3eb3e4d83458c80", "ref_doc_id": "5cf92087-e35d-4fba-85d3-821d01035638"}, "a0a3addc-273b-4c68-a6d2-c960baf2ac0a": {"doc_hash": "7be101edc506f3e08b68797bca8b062451a6a4c3c69614d7ec7189a6ffcf717b", "ref_doc_id": "5cf92087-e35d-4fba-85d3-821d01035638"}, "3ab7afeb-5439-4b4c-be1b-e6006f6be773": {"doc_hash": "877a74fa6fb41402752c4c75635700e161597a378749ef429375be82a8a4f1d6", "ref_doc_id": "5cf92087-e35d-4fba-85d3-821d01035638"}, "b2914adc-8dc7-4f7f-99c8-2d6181827e10": {"doc_hash": "f7937302eac0c90299d13d226121193ea78f69e739914dbd8c213a0dc61414f7", "ref_doc_id": "5cf92087-e35d-4fba-85d3-821d01035638"}, "ac853a32-bdf8-4a8e-a3f4-457b62da9b47": {"doc_hash": "ad783d838b10ed68488dfdce5c3fc0612b076929117d935bcc0416cdfa860b5d", "ref_doc_id": "5cf92087-e35d-4fba-85d3-821d01035638"}, "12653169-53f1-41ac-8f73-976b95773fd3": {"doc_hash": "109daa890f428929527df5cca921cfee016cb8575c76d94575cc95dad669efee", "ref_doc_id": "6d5ec7f6-bdd6-41b2-9b56-d1f2960aaef4"}, "13622462-122e-4de3-8c44-6798bdc46e4c": {"doc_hash": "6e743ba995aa9b942fde741e5fbd5db46e68ebe4bea87095c4c7eed21efabbf2", "ref_doc_id": "6d5ec7f6-bdd6-41b2-9b56-d1f2960aaef4"}, "b29222ba-64b7-4ba8-a35a-da18b620af59": {"doc_hash": "488da19695f709a02939f916ac5e68122dbc3ddab02bb241ac7334e288fc9143", "ref_doc_id": "6d5ec7f6-bdd6-41b2-9b56-d1f2960aaef4"}, "1ef60e61-99b2-40d0-9ae3-fec5bd874e47": {"doc_hash": "d7edefbb7bbf036ffb15fb99ccabf31531fbf994da028c3807dae46a763c1993", "ref_doc_id": "6d5ec7f6-bdd6-41b2-9b56-d1f2960aaef4"}, "a8d9531e-d9ca-460f-8733-a8d9f10aced1": {"doc_hash": "3267b71b3a7d5b140d0596ce71dffe082e03b44952ddd3066b71bac68fd0ab3b", "ref_doc_id": "6d5ec7f6-bdd6-41b2-9b56-d1f2960aaef4"}, "d31dc993-aecd-49b4-a9d4-97605fb5c8a1": {"doc_hash": "d1d05852d551f80d28fc095588327422289fab515fc54e053b8a47ade3a00687", "ref_doc_id": "6d5ec7f6-bdd6-41b2-9b56-d1f2960aaef4"}, "e95281c1-c6ff-4650-ac92-369a8444afa2": {"doc_hash": "ce29c865d63ba2663693ad27b42123e50123528592c3008e39b7b4e62bd1e4a5", "ref_doc_id": "6d5ec7f6-bdd6-41b2-9b56-d1f2960aaef4"}, "ea70d62a-d14e-4e09-8213-cbeea8029853": {"doc_hash": "02cc655b9f3bdb520dc4527f5e4af1928d05a1f74bdfd2c9f65584ec80451b62", "ref_doc_id": "6d5ec7f6-bdd6-41b2-9b56-d1f2960aaef4"}, "de7cdfed-11e3-4c2e-8af1-d2268ae2dae7": {"doc_hash": "bc497956f3845373359dd8d06d918cce8ccab8b8618198f1754659b3114031a5", "ref_doc_id": "6d5ec7f6-bdd6-41b2-9b56-d1f2960aaef4"}, "e8869165-9c6f-4cef-b3a7-468f8215efa0": {"doc_hash": "7f27a5bc77f98948bf9677c965679192f41b6db3a66b1011d002819d2befad8c", "ref_doc_id": "6d5ec7f6-bdd6-41b2-9b56-d1f2960aaef4"}, "87e200f6-bc57-420f-a871-b3afd1d21a23": {"doc_hash": "173274b6310ca8d9d6502ab40ad611555cb8a696adbb3d144e8d09314fd949f1", "ref_doc_id": "6d5ec7f6-bdd6-41b2-9b56-d1f2960aaef4"}, "0b8bbc53-2dd6-4657-ae4f-bf816fb159c2": {"doc_hash": "2e472619d13ee27749195bfd96a93d348d53a4e4fc6891d4a43d2bb7c4c9d358", "ref_doc_id": "6d5ec7f6-bdd6-41b2-9b56-d1f2960aaef4"}, "38d3e55b-7ab5-48a1-aec9-7281b73f295c": {"doc_hash": "8d24855f07b5a23c435067f15de1adf8bf89762544b28314720f6ff62f962f96", "ref_doc_id": "6d5ec7f6-bdd6-41b2-9b56-d1f2960aaef4"}, "87197485-940e-409d-a9ea-731c2f35657f": {"doc_hash": "a211577c5c422d025f3f9f81c9f4dab8d89e6ec57949a7a545b466d75ff67a70", "ref_doc_id": "6d5ec7f6-bdd6-41b2-9b56-d1f2960aaef4"}, "30affc97-ddce-40da-a4bb-c83b55a92fcd": {"doc_hash": "0a2eaf0a1450c92708ff7068984160a356b99574cff5a8f9ffc14fd245732a6b", "ref_doc_id": "6d5ec7f6-bdd6-41b2-9b56-d1f2960aaef4"}, "c1471836-60f0-4660-8568-c56311933c5a": {"doc_hash": "d57886c62123bfb0363d82c999bf50ce09b4a15eeac627799b2b548691cd1c40", "ref_doc_id": "6d5ec7f6-bdd6-41b2-9b56-d1f2960aaef4"}, "ab0c38fa-505f-45fb-9a3b-7f65eceb7977": {"doc_hash": "ea45af9083f80684f8689bd9a6d6dc69791ebb1807c46f17a27bd58bc8e7221d", "ref_doc_id": "6d5ec7f6-bdd6-41b2-9b56-d1f2960aaef4"}, "8e971903-8b92-41d6-ad4b-dfa11c01f956": {"doc_hash": "1be431bd92109dd9aef6455fef3b28b02c53442249a161566875cd4837d5242e", "ref_doc_id": "6d5ec7f6-bdd6-41b2-9b56-d1f2960aaef4"}, "2b4cbce0-912e-42dd-8a8f-9ff1d1a8945b": {"doc_hash": "8576e2faeec0bca75db873fab797c03f26bb73ed3672c35591b2167e306eb95f", "ref_doc_id": "6d5ec7f6-bdd6-41b2-9b56-d1f2960aaef4"}, "4fef81fe-fd48-497d-b6b2-7ac2ababd63f": {"doc_hash": "d24d249bc882b13a89c890a62b7552d63550ef9cbb1db437273b8f5f6c29cdd3", "ref_doc_id": "6d5ec7f6-bdd6-41b2-9b56-d1f2960aaef4"}, "db2ea73b-b0f0-4fb0-a5c1-6e520da845a5": {"doc_hash": "f6590dec8c31eb8751ff7ee106d44cdaec3127afe0bb9f3c958aecc1011b4b1e", "ref_doc_id": "6d5ec7f6-bdd6-41b2-9b56-d1f2960aaef4"}, "f47bf491-0436-45ac-aa5f-93cf985c17e5": {"doc_hash": "2cc3d2f3916246ff2aa6aacb23f722e8c65727e8dde7489fb5a84ff716465af1", "ref_doc_id": "6d5ec7f6-bdd6-41b2-9b56-d1f2960aaef4"}, "4521b31b-30eb-412a-bb80-8cc034b4ead6": {"doc_hash": "eabe4c1c971b6471c5ddbc521c4b1e38eb4f27c653be2fe979b84c8985add1bb", "ref_doc_id": "6d5ec7f6-bdd6-41b2-9b56-d1f2960aaef4"}, "17d5ae9c-86bc-4f28-bace-78574ee1b645": {"doc_hash": "acb929f46fcad57d6eed05ceeccbeddd8b95f6b604f1e90eb204c1fe2d5f85ba", "ref_doc_id": "6d5ec7f6-bdd6-41b2-9b56-d1f2960aaef4"}, "c8857409-c8ac-4d47-bff4-46b02417919c": {"doc_hash": "fc78045641392a257a61103bd3ba607c1f174a80efaabe9888e2014b81a3e95c", "ref_doc_id": "6d5ec7f6-bdd6-41b2-9b56-d1f2960aaef4"}, "5c659247-40d2-4e0c-b196-b301cd218cb3": {"doc_hash": "dbdecff8cbc37aa14b6365596c23a7f6ad237c2772b466db66d568ad26752d08", "ref_doc_id": "6d5ec7f6-bdd6-41b2-9b56-d1f2960aaef4"}, "8d92e2f5-73df-4bf8-b7bf-7fbcbff943d0": {"doc_hash": "e70a64c068791863d6d423241a01a3ea8b94baf90dbc157ecda5acd2988d238d", "ref_doc_id": "6d5ec7f6-bdd6-41b2-9b56-d1f2960aaef4"}, "4a933b8b-e029-4ef6-9703-837a74507525": {"doc_hash": "d7855916720ba5585ca9e04bd0229451dd0874bf88c2b87d96ae64dbf95d79e2", "ref_doc_id": "6d5ec7f6-bdd6-41b2-9b56-d1f2960aaef4"}, "8e487d6f-16db-4d2b-8645-9ef5403e7bd4": {"doc_hash": "35e961583fd7251b2682745d0fd28bd805ac475c1d9e5ef03e00c6aaede37468", "ref_doc_id": "6d5ec7f6-bdd6-41b2-9b56-d1f2960aaef4"}, "1290d304-e8be-48bf-ad8a-7c92fc8aefa7": {"doc_hash": "4e50143c22d98bae6121df1d1503addeadb11292de7ab4b91ade5d9f9d910819", "ref_doc_id": "6d5ec7f6-bdd6-41b2-9b56-d1f2960aaef4"}, "294d0bf8-f62f-4bd3-b414-a6d312edabc0": {"doc_hash": "a5b88968c03843ecf25e705feb28877b99cb81f5e3aba722298c388a61090855", "ref_doc_id": "6d5ec7f6-bdd6-41b2-9b56-d1f2960aaef4"}, "ea97ddd3-ba21-48fc-88b0-acceb624cfcc": {"doc_hash": "e9a4d1e45227276f4ff3388b434ef7b56e124dccdb469286c8d6ceb8a7d95940", "ref_doc_id": "6d5ec7f6-bdd6-41b2-9b56-d1f2960aaef4"}, "d434d266-6de5-44d3-869d-e213e6694d75": {"doc_hash": "9f354db69bde5d02ff44f30f7f0ba99c41f2e5b5ef6ea3ca462be34967777aee", "ref_doc_id": "6d5ec7f6-bdd6-41b2-9b56-d1f2960aaef4"}, "64dc31a6-6d0f-472d-9ce8-754c469b53f4": {"doc_hash": "81a3484f0689d6f6aee6b437931bfbe6b55eea8be3bb08cf76392113d7df98eb", "ref_doc_id": "6d5ec7f6-bdd6-41b2-9b56-d1f2960aaef4"}, "11dfc159-cd50-49ee-b47e-84d816a98128": {"doc_hash": "8736fb7ae396b416ba80365ed9303b14320293dfc6cf82aeccc59f2a39824a2e", "ref_doc_id": "6d5ec7f6-bdd6-41b2-9b56-d1f2960aaef4"}, "0205b7fa-c0df-462b-9137-39a9c11521da": {"doc_hash": "7d1615347920d7fb9936cc844ce72e86a41b2f39cf91eff98df8ad97775ff00a", "ref_doc_id": "6d5ec7f6-bdd6-41b2-9b56-d1f2960aaef4"}, "6956d2b9-4838-4559-a7a2-1fee8635ef82": {"doc_hash": "97c33e4c92f51e5893b57b2d6b2a384cef9b27e4ad137767cb138f5aee535331", "ref_doc_id": "0d51f961-2630-4f26-b63f-20378f90e37c"}, "8b8ff68d-b80a-4a3e-8be3-771c67db055e": {"doc_hash": "263d970de3619497e63455b7e53c78a3e4ee5ddfd6443ed2f9377a88a3604d74", "ref_doc_id": "0d51f961-2630-4f26-b63f-20378f90e37c"}, "678fdc7f-8185-4c8f-9573-4d3c150b20da": {"doc_hash": "0d7d8d5186cb5c836ee143faefa006661f9845845c61620c349b903e58cc0229", "ref_doc_id": "0d51f961-2630-4f26-b63f-20378f90e37c"}, "2131668c-e803-4490-bd4b-a661ad485016": {"doc_hash": "84049843c625c1c9f4941e74dc92699538aebf05690c0d37318148263eaedd7c", "ref_doc_id": "0d51f961-2630-4f26-b63f-20378f90e37c"}, "8df6e9a1-eb18-48b3-8cee-86797c1e7349": {"doc_hash": "9cfd32166f0f882496d999523b9bea8bda3dccc6f83261a9374330310df250e7", "ref_doc_id": "0d51f961-2630-4f26-b63f-20378f90e37c"}, "0fc3ade2-4d5b-4668-94a8-b6a4484d5dc4": {"doc_hash": "ec23538651c7f7d7e2bffd80073e086e58939692a7509644ce3de8aaaeeba8aa", "ref_doc_id": "0d51f961-2630-4f26-b63f-20378f90e37c"}, "a53d491a-ca38-496c-91dd-c2efaca5039c": {"doc_hash": "6eed8b5ad9ea796c730cf11a5af4cd0a55ea2ba80cc45a8b96fd12d91b2aba90", "ref_doc_id": "0d51f961-2630-4f26-b63f-20378f90e37c"}, "d69e54a2-d7db-4330-9f87-fbcb39c98b8f": {"doc_hash": "ad93b8d8582ca805ca8ec036a4ce96889865396583d315678c8dd1761891de94", "ref_doc_id": "0d51f961-2630-4f26-b63f-20378f90e37c"}, "f9ea1971-7c70-4470-b5e7-e5488bd80f02": {"doc_hash": "42a8b4fe26dda33135def57da9bd824c69b15dcffcea17f83aaa4ef29828f55a", "ref_doc_id": "0d51f961-2630-4f26-b63f-20378f90e37c"}, "7d2467da-d112-4a32-9a01-23f14cf8a1fc": {"doc_hash": "8ed862b0ebb64bf5958aeedc3278344954ba6e69730f0d45b854d69160c40c4c", "ref_doc_id": "0d51f961-2630-4f26-b63f-20378f90e37c"}, "2ec08fa5-29f0-42d9-9080-1d2fb799eaa6": {"doc_hash": "555f6726676c168b87e35351414a0212b713386209a8be642eba07cc8e23ef98", "ref_doc_id": "0d51f961-2630-4f26-b63f-20378f90e37c"}, "b5d73c51-2c59-4478-899a-346e90c2dfa7": {"doc_hash": "bc0f226e1168eaae67e693832e93b247f0a97daa901db5661f46b86e7f43dc6a", "ref_doc_id": "0d51f961-2630-4f26-b63f-20378f90e37c"}, "019a0f8c-4027-49d6-bbd8-df5982e10f6c": {"doc_hash": "b25f784574e5a1e8fe1f6bb227fca7b82a69586d4a36bcfd7d49648216055371", "ref_doc_id": "0d51f961-2630-4f26-b63f-20378f90e37c"}, "65abbdb0-7509-4798-8524-d99e6dcf1b3c": {"doc_hash": "c36650d363a004fe3c78e218b3d66d44fbc0745a0c521ba3765195ec4efdeec3", "ref_doc_id": "0d51f961-2630-4f26-b63f-20378f90e37c"}, "a6f2297f-cb23-41f1-936d-c8b8427e3e2f": {"doc_hash": "e4bec623b5e7376453fb33fa8fe5c042e1d77a2bf6bc77a033c9e7ef15918bc1", "ref_doc_id": "0d51f961-2630-4f26-b63f-20378f90e37c"}, "c11849f7-7cab-49c7-ae10-3ce7140a5846": {"doc_hash": "5c8bbc701d6335bea7f86753841fd8b9997dead1a72cb8e277338f8b51b54071", "ref_doc_id": "0d51f961-2630-4f26-b63f-20378f90e37c"}, "ff75ffb2-8fec-40a9-b880-12d1034fca6b": {"doc_hash": "4308aa7c920c815e65157597cb9538631036d1301ddca6110b93f30c481ec2c3", "ref_doc_id": "0d51f961-2630-4f26-b63f-20378f90e37c"}, "63fc2bb7-dea5-4c7d-a1c1-43098f1b3eb6": {"doc_hash": "3c0115330245869f59a733301515723399ffcb89d760da41b24de5e571a03446", "ref_doc_id": "0d51f961-2630-4f26-b63f-20378f90e37c"}, "80c6ec03-2a40-4124-b02d-cc9ff20bf222": {"doc_hash": "65a7d131949580e022eee5bd3ef98223671012fadc62f2a5ec7d33159fce54f4", "ref_doc_id": "0d51f961-2630-4f26-b63f-20378f90e37c"}, "0a5a1648-6d22-4e4d-b1ec-1dffda1ec6f1": {"doc_hash": "5d911e70371f962b23dd4d6cce92fdbe8d0da5e5c5c77c37ba077c35a66dd328", "ref_doc_id": "0d51f961-2630-4f26-b63f-20378f90e37c"}, "2c6e7904-ef9b-4745-aa79-195d0768634c": {"doc_hash": "c2bf3f1c5c9e2edb7ccc0464116e904d6bfaa5d4064624b63ee746ceb61da859", "ref_doc_id": "0d51f961-2630-4f26-b63f-20378f90e37c"}, "73436123-325b-4a00-b7ea-cef9b942348c": {"doc_hash": "4a21fd6035441f63ac6219a9c699c6a78e442c202a4a6e236d0d8fa88e564bc1", "ref_doc_id": "0d51f961-2630-4f26-b63f-20378f90e37c"}, "9d2e8dc8-263a-4514-8dd9-01baa0b096a4": {"doc_hash": "7dc7ab2076e9c27862a67f243a8b3c1b746ab6ca12921e56ec566a319a739b2d", "ref_doc_id": "0d51f961-2630-4f26-b63f-20378f90e37c"}, "4237d889-7794-4b67-85b7-935a956624bc": {"doc_hash": "9909360879d025240e4e4f5a9f9d67dd53a74ff745496d238f56e65cf5b15aed", "ref_doc_id": "0d51f961-2630-4f26-b63f-20378f90e37c"}, "a54a84f8-7455-48ff-80bf-7aec9afec552": {"doc_hash": "c11a6111ded4d5ff7dfa72d2313a5fc8b7a26a6a2e92efb1ec50b267fdba0b25", "ref_doc_id": "0d51f961-2630-4f26-b63f-20378f90e37c"}, "349bda6a-857e-4f34-974f-97ce681608a6": {"doc_hash": "07bb58b32b32fc444d65edc08627b63d3f1b44e4577acb42b6ff7bbc55dc6928", "ref_doc_id": "0d51f961-2630-4f26-b63f-20378f90e37c"}, "06bdfb1f-7d00-4026-807d-278c784f1241": {"doc_hash": "837a58899fd3728ef138bf455a4417976f1870d556d1747b31dfc030c46408f9", "ref_doc_id": "0d51f961-2630-4f26-b63f-20378f90e37c"}, "e8ff7435-dc0b-4422-be69-9ea3731dc20e": {"doc_hash": "5ad9e002cac4b319f4a1c45c7da87be5ff88fe9dbc7bbc574796350e4431d0a7", "ref_doc_id": "0d51f961-2630-4f26-b63f-20378f90e37c"}, "72df9eee-d456-4278-af7e-cf75f7203c81": {"doc_hash": "fc1f3c93172d5becdff78dd6d66b5d98ebe7eb7b6f006ad4894237289e5d3279", "ref_doc_id": "0d51f961-2630-4f26-b63f-20378f90e37c"}, "d83a5a3f-f739-4f23-81e6-2ac536c19a7f": {"doc_hash": "17ac7cb55a0ef8c4e10aa30420d7d9129ba03767435c71e56f406ef5e130c6d3", "ref_doc_id": "0d51f961-2630-4f26-b63f-20378f90e37c"}, "23b72e29-c5a5-4ae7-a84c-26e6a57a09b1": {"doc_hash": "c5b2b972de15b36872454dd736999888a30394eccfe87d02361258abbe904a80", "ref_doc_id": "0d51f961-2630-4f26-b63f-20378f90e37c"}, "31acdef2-19e9-48f2-9b84-ebf773f1b34a": {"doc_hash": "b58fa17747693657953c4e56927294a8ac5c9108613cbe3eac9b052eaf366518", "ref_doc_id": "0d51f961-2630-4f26-b63f-20378f90e37c"}, "4acb7a18-3f3f-48d4-8fee-803d6f659e14": {"doc_hash": "5f68d84d784aa97f9738bb449e0c90e5a8706ad875e8c3f5f19b3bd4f52773e2", "ref_doc_id": "0d51f961-2630-4f26-b63f-20378f90e37c"}, "014d7f31-af18-4ae8-ae10-a7c229c786a4": {"doc_hash": "906f0dc8bc89b46ff5f36a2cf440ff490084a6652c309317648d1bb53c8fd44b", "ref_doc_id": "0d51f961-2630-4f26-b63f-20378f90e37c"}, "fd97a8d1-76fa-46dd-b7c5-266c7fe1e0e1": {"doc_hash": "109bac6dd19cde31c231369d57ccd7558791f4dc62d0469b985e28f981d6348f", "ref_doc_id": "0d51f961-2630-4f26-b63f-20378f90e37c"}, "50cd9dfc-9e14-4d52-97dc-0f01f9b5ff97": {"doc_hash": "cbc7c1c387d89f3dde76f0d0dfffa904b88553519eb3318c11cfd8351dd8e21c", "ref_doc_id": "0d51f961-2630-4f26-b63f-20378f90e37c"}, "c351a89d-353e-481d-84d9-f3966c0ca6c8": {"doc_hash": "a7dc23126f0e0f76e4402b24f1f0a7a4d7b92b3c4ab90095abf1aefe23c42069", "ref_doc_id": "0deec662-07aa-4179-9d25-c20d9a0a3f6c"}, "c423abd1-d9ed-47b9-adab-7ee047c21c4e": {"doc_hash": "abd29860b77b0d897e0e236e1975f530639687ac2505f8c33611285307f4b904", "ref_doc_id": "0deec662-07aa-4179-9d25-c20d9a0a3f6c"}, "744e9bb2-3701-4ce3-8b17-ede2ce4f85d1": {"doc_hash": "0a2c96bc07e4ab25d64f85a40c4dddda0bffb86a7d6a826f3e90f8914cc97b2e", "ref_doc_id": "0deec662-07aa-4179-9d25-c20d9a0a3f6c"}, "d48bb228-ebc8-4384-bfb8-8ad64388b724": {"doc_hash": "28059cc72ac7befbb60893c82365b1d027f1c3090ca0e075ac06e4b0b585dc02", "ref_doc_id": "0deec662-07aa-4179-9d25-c20d9a0a3f6c"}, "b6da76c2-fbe6-44ab-b276-23c9605a7145": {"doc_hash": "b8942c1d0dbb9636f6d04e4fd62437845667329cc1ac207c1c6714bd826f4cff", "ref_doc_id": "0deec662-07aa-4179-9d25-c20d9a0a3f6c"}, "6b6bd3ae-2aa2-412f-8541-5321c99eb11c": {"doc_hash": "d197db88d5510248253eba9cdafa88cf4f0d014b2a0a57ed9227c08b73e83e6a", "ref_doc_id": "0deec662-07aa-4179-9d25-c20d9a0a3f6c"}, "2ca25976-3146-4672-90ac-64e4c0a302e5": {"doc_hash": "72a1bace54996f437799f468fe0507fa2a6493d8a75359851733b25e4948cab2", "ref_doc_id": "0deec662-07aa-4179-9d25-c20d9a0a3f6c"}, "4f7bca5b-929e-4069-82b1-18c3e131e9e9": {"doc_hash": "e066f08b6f46705230ccdd07fdb2d0f3b07a85efc30aa920e79f4bb3255c5809", "ref_doc_id": "0deec662-07aa-4179-9d25-c20d9a0a3f6c"}, "ea4685da-3f85-46c4-9d22-42c1f2a1d067": {"doc_hash": "6d4482e739ac3e13999b062b3c3798ab0ecd47098e80de7980ec577f1c6d86aa", "ref_doc_id": "0deec662-07aa-4179-9d25-c20d9a0a3f6c"}, "2239daae-a42f-4daf-9a34-afe95092a964": {"doc_hash": "842163ff173391cd8208405d7792f667c130e7c32c4fe3a47644c80a2e5cb477", "ref_doc_id": "0deec662-07aa-4179-9d25-c20d9a0a3f6c"}, "79abe1c7-9c4b-43d5-85db-6d199c3df288": {"doc_hash": "23904de929b022f3416430426bf8cc13c7a101e83e108e71f13dd4b2226df9c0", "ref_doc_id": "0deec662-07aa-4179-9d25-c20d9a0a3f6c"}, "2117cc69-f7e4-44dc-b626-c1f2b431ef74": {"doc_hash": "c7e94fe773f1a9822a672ccf4c1f0e909d5da632659e1745ae46db9a6a742ed2", "ref_doc_id": "0deec662-07aa-4179-9d25-c20d9a0a3f6c"}, "5f00cd55-801f-4309-a8e5-11e73a2bc731": {"doc_hash": "0ff74de156f5988762478e0bc09137b1e881c7c7be9abe5f539c72fd42c8bab7", "ref_doc_id": "0deec662-07aa-4179-9d25-c20d9a0a3f6c"}, "4bcaee50-97bc-4aec-9204-00b35a49192d": {"doc_hash": "fd4de68fdf6a533a8c797aa92edd112ed0aa813a181ef791677c8bec8c655518", "ref_doc_id": "0deec662-07aa-4179-9d25-c20d9a0a3f6c"}, "b2afa807-8304-4a24-817a-52f4ed6d422d": {"doc_hash": "d2c98b4efde0d982d6cdcf75f0a1ff573b80a42201114e7464d4ac41c1c71dd7", "ref_doc_id": "0deec662-07aa-4179-9d25-c20d9a0a3f6c"}, "5950d0db-b458-464c-9730-76ac2dab6003": {"doc_hash": "a97414f17317ffd35ce97d33d98662c9985e2bff36ac5e5867e538f65377a599", "ref_doc_id": "0deec662-07aa-4179-9d25-c20d9a0a3f6c"}, "6a828dd6-af56-4f37-8e93-96a60843bd30": {"doc_hash": "8f516c269cdd5728c495730bfa10a2f277dd39a623d02110abe4822b8899e136", "ref_doc_id": "0deec662-07aa-4179-9d25-c20d9a0a3f6c"}, "be0ce916-bc5b-492e-8459-6c92501bd2bd": {"doc_hash": "0a115acac9c36dee128fed2417c7a32a788dea7eff1b9a6c73d9e5c785fff3ed", "ref_doc_id": "0deec662-07aa-4179-9d25-c20d9a0a3f6c"}, "329d1330-4598-45a4-bd08-470e72579014": {"doc_hash": "8d2f084de94211ce5ff1d8fd07dadd5650bc0e014515e0246e89959a61f35124", "ref_doc_id": "0deec662-07aa-4179-9d25-c20d9a0a3f6c"}, "426e93f2-f383-4950-a373-772f8cbb37f2": {"doc_hash": "acb60255ef7c8aab97aef06f832a0fb64f2e0ed4b6b16bcdb9e247ff4c643c2f", "ref_doc_id": "0deec662-07aa-4179-9d25-c20d9a0a3f6c"}, "befcdd3f-9d7a-4c3a-bbcc-ce554b595f11": {"doc_hash": "f0042537beb611e9a9ec52ef714a0e6b3a3404ee388a1499aafe36fb311524a8", "ref_doc_id": "0deec662-07aa-4179-9d25-c20d9a0a3f6c"}, "a004ad39-b1cd-48d9-a1a7-5e2ffdf5117f": {"doc_hash": "18387aa22019ea99ad68ff29f11763f3a3bfd8a6228ab3efa0429a6dfcad1cf3", "ref_doc_id": "0deec662-07aa-4179-9d25-c20d9a0a3f6c"}, "7a9bda51-e8e1-4933-afe3-062ff35af2f9": {"doc_hash": "ade958c838ea39c933eb38caf4bba2db5ff4a98d2390b0a3afc97a99262ef2c7", "ref_doc_id": "0deec662-07aa-4179-9d25-c20d9a0a3f6c"}, "ffa75df3-eb8d-4d72-8167-2ee14f2e2d2c": {"doc_hash": "c86d586d1f01cba37c48bef21c121eb78fa654df52ccfd0a084818a136f1e191", "ref_doc_id": "0deec662-07aa-4179-9d25-c20d9a0a3f6c"}, "830ae623-4c88-4e2a-91aa-202d3e3f48fd": {"doc_hash": "f54313ff19a89460b707a99aa8b3eba349d655d01c76a373b4c31a035d5735b1", "ref_doc_id": "0deec662-07aa-4179-9d25-c20d9a0a3f6c"}, "29fad6a0-0a46-412b-a1e1-11318294c102": {"doc_hash": "8c5310cb153cf85869b97584a4a325ae8773ad2662eb7ddf93e438fd00654edb", "ref_doc_id": "0deec662-07aa-4179-9d25-c20d9a0a3f6c"}, "2722cd83-e05d-490a-bec2-ad3fded20d27": {"doc_hash": "0fca16e5a05a1cde6c3cd79e5cad92f4c4ad9a06d4fbbd06c34c617c544b46f4", "ref_doc_id": "0deec662-07aa-4179-9d25-c20d9a0a3f6c"}, "20599250-aecd-4ff8-85ba-5ea98f0735ba": {"doc_hash": "4381fb59ff533978e3d91712c206ace583372e2442d52eb3a5a914beab3f5070", "ref_doc_id": "0deec662-07aa-4179-9d25-c20d9a0a3f6c"}, "8c34ad96-1c1f-4b01-a70c-0679d5398877": {"doc_hash": "98ae792e8981141ea8f800cb4df9cc69934857fa9f48d64d34c79ce14c38aa1d", "ref_doc_id": "0deec662-07aa-4179-9d25-c20d9a0a3f6c"}, "dd09368c-b0db-4893-a3c8-afce7c937dd2": {"doc_hash": "38df45687b3ac423a214db4d739acaec3bb30cf556bf709f245574d9279cbf4b", "ref_doc_id": "0deec662-07aa-4179-9d25-c20d9a0a3f6c"}, "5d32ffae-30e3-41af-84c8-69b1cc437fbf": {"doc_hash": "83222b9db79fe3c4161f58195ea9f1e0159ae35203e3c6c25a153dee54ebd377", "ref_doc_id": "0deec662-07aa-4179-9d25-c20d9a0a3f6c"}, "687939ab-d703-4c12-b8a3-90a3967e1c6e": {"doc_hash": "9a7c636fe92cf548b40a5c25c0bdc1c3d61224454ede54fa97f7c9733db101a3", "ref_doc_id": "0deec662-07aa-4179-9d25-c20d9a0a3f6c"}, "18230539-18b0-4170-b469-4e8b96b68371": {"doc_hash": "ce26834911769ecfba7939f57300131c32b16bb85f53420bca59c4de39b8d59e", "ref_doc_id": "0deec662-07aa-4179-9d25-c20d9a0a3f6c"}, "65552542-c9cd-4c0e-b631-1e685ff9dd2e": {"doc_hash": "794029954c7c8ff058abb6105177f173d4d9d2d6485e7f62a1193b7612cda728", "ref_doc_id": "0deec662-07aa-4179-9d25-c20d9a0a3f6c"}, "b0f50702-52d6-4dc1-9b1d-ea2d14f1307e": {"doc_hash": "129c5b365830e4f0e3a4004573bbff85a3c5990919412d4fceec75d5cf3a8630", "ref_doc_id": "0deec662-07aa-4179-9d25-c20d9a0a3f6c"}, "315be810-f70c-4406-86c2-ed1cabceb7d0": {"doc_hash": "4822e66c72d3104162eb7ce5ca17bfa60203aaed84ae884a54665e4f09d565ed", "ref_doc_id": "269e28ab-8278-4b1f-8f4a-d4f82d6c333a"}, "03ec4e6b-6407-4b43-83a4-184007bffbef": {"doc_hash": "5b8b49a3fb8cf98c513c0b99a7905df8df17b7a198a2b53d70365180752e6589", "ref_doc_id": "269e28ab-8278-4b1f-8f4a-d4f82d6c333a"}, "2e2a9366-80a3-44ce-9157-ddc5fc39046e": {"doc_hash": "1653704bba1d4c8b7a1c08f939077f819f258366be19998f44d21f91526c49ec", "ref_doc_id": "269e28ab-8278-4b1f-8f4a-d4f82d6c333a"}, "4b09cbc6-a9b1-45f8-b55b-fc3a00aa2751": {"doc_hash": "81c1ffeee4762750a8831717a81827b418106f15b884dd062bc81a1eb2ce6b21", "ref_doc_id": "269e28ab-8278-4b1f-8f4a-d4f82d6c333a"}, "4fcd9ef9-5c30-44c5-aba3-f7a6acbd24f7": {"doc_hash": "015b5ca847bf647c92e6e5182af92d0bb6aec2ebc1560b181dc78e6851671318", "ref_doc_id": "269e28ab-8278-4b1f-8f4a-d4f82d6c333a"}, "d60bbae8-2270-49dd-add8-34b9dedf6a5f": {"doc_hash": "3dc556cb2f334d3b369b58ba62f0836b6b20e786a2c8b07f0fa19e6c7d3a70a9", "ref_doc_id": "269e28ab-8278-4b1f-8f4a-d4f82d6c333a"}, "6290f6af-acdc-4c2f-9f82-ac1b5f6df889": {"doc_hash": "242dd8489544889669568cdfcfab69f03831a659a477183d25b495d21063517c", "ref_doc_id": "269e28ab-8278-4b1f-8f4a-d4f82d6c333a"}, "aba47aa3-1b7f-4864-b5f9-63a0f06f66bf": {"doc_hash": "fcedbefb1bea6890532b4232c56124e71b16d9881aa28d7acf797b15c0877ff7", "ref_doc_id": "269e28ab-8278-4b1f-8f4a-d4f82d6c333a"}, "3a5bc759-4aa8-4451-bbd5-4423ad922c86": {"doc_hash": "e15410197ffcb048a20af773a67103076a83b766fcb17f1b20acd9c656abf626", "ref_doc_id": "269e28ab-8278-4b1f-8f4a-d4f82d6c333a"}, "e3ec08d4-8fc2-4fb1-9477-0841d4be4e5f": {"doc_hash": "9b42974a1b1f09ff9089052f374839de60b21145ed44e6ccd9de61204dde0b56", "ref_doc_id": "269e28ab-8278-4b1f-8f4a-d4f82d6c333a"}, "76984402-1833-4729-9c30-d510b2882fa3": {"doc_hash": "0184c86ecba1dacc2b527f5146b956b69ee8adbda8638e512dee3d7af7b326ef", "ref_doc_id": "269e28ab-8278-4b1f-8f4a-d4f82d6c333a"}, "effaa786-cbc2-4692-8f66-5d1470e46276": {"doc_hash": "d19b79259d86405ccdf70218fdc6931eb8d19cde7ec4387d06b08275caaa9085", "ref_doc_id": "269e28ab-8278-4b1f-8f4a-d4f82d6c333a"}, "e788ae7a-4203-4c3f-ba68-c28469df465c": {"doc_hash": "0cbd0c6e8df7f4f29a6d7856b202b766f1d2f723844a7d12754229610eb3e3a1", "ref_doc_id": "269e28ab-8278-4b1f-8f4a-d4f82d6c333a"}, "8059ec2f-7c0a-4d46-ad87-508f624e497b": {"doc_hash": "28fea5afee0f1837b6f8d795c32064fb6dbcd1bb59aa18192ec2ea2eea70dd5c", "ref_doc_id": "269e28ab-8278-4b1f-8f4a-d4f82d6c333a"}}, "docstore/ref_doc_info": {"a4414d54-6710-431a-9934-c424ca18a68a": {"node_ids": ["2b35cef7-27ec-4c77-8741-7536e1b99e5c", "53c01b19-2681-45a7-9265-bb1f9166ed3e", "24cde944-6af4-4357-9a9d-9b91e6aa55a6", "e91ab319-1bc7-40c3-9b80-2d2fb51957a3", "a0d3e3d1-e0ef-4ae0-b22f-afc8bf26f8da", "1196d81d-6394-4c13-9b9f-480c3a22c0b9", "4008df93-4537-40d8-91ae-415cfaa5a9b1", "e46986a0-30bf-4a26-80ba-59f84910c16f", "5cf2fec5-897e-46dc-93e9-e0e4cf2073d2", "967afa49-7711-4b8c-99a9-115f90bbf988", "e79bc945-1e39-4012-86ed-5c9e820d4aaa", "09e57fcf-706b-4cb2-a4b9-3813e5addea2", "274bc5da-dda3-48c6-8987-840e2328437c", "a3e1ec3a-bfd0-4115-8490-2dcb20fd628c", "dd1de457-b343-4ca4-80a4-73f4381940c9", "4590692e-1b0d-486c-a06b-0a6895dfe8f3", "11b83ae2-f338-4180-a308-8be35d719626", "e52c54aa-0a67-432f-90da-19c152aa1675", "c86e8138-f341-46f7-bd9e-228d5ec6da37"], "metadata": {"window": " \nPage 1 of 19 \n \nQ2 FY24 Cardinal Health, Inc.  Earnings \nConference Call  \nFebruary 1, 2024 , 8:30AM Eastern  \n \nOperator :  Good day , and welcome to today's Second Quarter Financial Year 2024 Cardinal Health \nEarnings Conference Call.  This meeting is being recorded.  At this time, I'd like to hand the call over to \nMatt Sims, Vice President of Investor Relations. ", "original_text": " \nPage 1 of 19 \n \nQ2 FY24 Cardinal Health, Inc. ", "page_label": "1", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}}, "af1efd63-b407-4e15-8b8e-7fdf94ed494d": {"node_ids": ["80d29dbf-ec98-4263-90d8-4bfb52bc361d", "8f0d3214-ac5b-429d-b6fc-02705e9e0bcc", "cd18a014-c4a5-4969-b568-746db62905d4", "318d0436-6633-4dba-b681-532a2164ab96", "c2b7f78f-aa18-4197-afcd-c1f9505155b3", "177cb92a-0319-41d5-a36e-14c0b22250d4", "7d704305-bc7c-40ff-ae2e-e9ef20103ddc", "e97e4010-193f-4cfa-966a-6b5b2abcf674", "c728b342-573c-4be8-b137-48d1ebf80374", "51a565bd-a823-4759-bc5b-294bd6433331", "569a3639-3901-41ed-98e1-576e40a12866", "0bf3b072-85eb-47ee-a21e-69474ff15fe4", "54a85354-6242-4d48-90e3-38c742368493", "54700922-67e0-469f-91dc-556eba18af73", "9e0f4328-cd45-4fb0-9d26-0922be4544d1", "54702bd4-4c68-4a9a-866b-09341a069377"], "metadata": {"window": " \nPage 2 of 19 \n \nPharma again delivered strong performance.  Overall, the business is performing consistent with our \nexpectations, and we\u2019re pleased to reiterate our outlook for 7% to 9% segment profit growth in fiscal \n\u201824. \n \n We\u2019ve seen ongoing stability in macro trends, including in our generics program, and continued \nbroad -based strength in overall pharmaceutical demand.  \n \n Our Specialty Distribution business also continued to see strong demand, including with COVID -19 \nvaccines in the first part of the quarter.  \n \n", "original_text": " \nPage 2 of 19 \n \nPharma again delivered strong performance. ", "page_label": "2", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}}, "2122bb61-73c3-4261-85c0-fd8e84992ea1": {"node_ids": ["b9db02c7-8674-4358-bb73-1eb1f7de88c4", "fbcbb01a-e3e2-439a-9c9b-4c15ccf177fa", "85445337-5676-4544-a161-7696b355e4e2", "a7a62310-92aa-46eb-9ff3-25983a54528f", "2fb1baaa-0fb9-4468-bef1-512693d62a5c", "3baca8c7-8b24-4a8b-b306-78907a252595", "7bb4c23a-8a23-48a2-b691-3bc70a1fa455", "6a39ae9e-bb88-44e8-8eaf-8ce398f2dde6", "ebb3a8d1-f6c1-47a3-a8b0-891c7f93e772", "f68fdfaa-a54e-4e67-910e-5f58d594c53a", "20afa8b3-5b25-4805-9f52-3c22c3e1a93c", "7c26fc13-57e5-4d66-a324-05bd3fa4e265", "e70b5174-1312-4a64-99b0-c0aa1e9e5ea6", "0a6a206f-0137-4f43-89e6-7e83f68a9a7e", "f222a1fc-f336-4364-bfff-4d3c1508e67f", "65c867c2-3756-4791-a720-5d9a93794014", "329bf0ef-b5d2-42c6-9bc7-888b9d4160e7"], "metadata": {"window": " \nPage 3 of 19 \n \nWe also delivered strong cash flow and ended the quarter with $4.6  billion  of cash, even following \nincremental share repurchase activity in the quarter.  \n \n As seen on slide 4 , total company revenue increased 12% to $57.4 billion, reflecting growth in both \nthe Pharma and Medical segments.  \n \n We drove operating leverage for the enterprise, despite incremental investments in the business and \nhigher costs to support sales growth.  \n \n Gross margin increased 11% to $1.8 billion, driven by both segments, and consolidated SG&A \nincreased 8% to $1.3 billion.   \n \n", "original_text": " \nPage 3 of 19 \n \nWe also delivered strong cash flow and ended the quarter with $4.6  billion  of cash, even following \nincremental share repurchase activity in the quarter.  \n \n", "page_label": "3", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}}, "51bcdcef-b372-404b-848b-774d2abd5d5e": {"node_ids": ["6c28b2fe-9db4-4844-8b46-f59b5a7118e5", "0b96bdc3-ca6f-40ab-b4e1-57d54e9c8665", "af324dab-1977-4096-a25b-7d45113c31a9", "1e89ed48-e4be-42bd-bb93-1b6caf1dbe81", "d31cacf4-758c-4c4a-a6ad-52d8a4941119", "f5268ec7-350b-477d-9200-de8b834ff2b4", "9e2a6610-8446-42d7-8a65-c4259a34cc69", "46f78cd2-c7c3-4138-bdfc-ba91d6eb1f91", "e925b52e-478e-4246-96fa-fd5a30ca965a", "100fe8a3-fb7d-4c06-b8ac-0001a8df6441", "fdd8b160-64c4-4ecc-b50a-6e8a9cae9229", "7ce4eff2-694d-4a81-9819-a222670a7016", "142bb824-5ad1-4276-8bec-90b909ce04a4", "8cf35c63-710f-4195-9cd1-f5b72a74a031", "fc9cd0e3-9257-436b-8135-16618a3f52c2", "6cd6e370-3396-4492-94e7-eea8f8d3b7a8"], "metadata": {"window": " \nPage 4 of 19 \n \nWith respect to COVID -19 vaccines, we saw the strength in demand from September for the fall \nimmunization season carry into October, before peaking mid -month and trending to a much lower run \nrate as we exited the second quarter.  \n \n The Q2 increase in segment profit includes a partial offset from higher costs to support sales growth, \ndriven by increased pharmaceutical volumes.  \n \n Turning to the Medical segment on slide 6 . \n \n Second quarter revenue increased 3% to $3.9 billion, which as Jason alluded to, reflects quarterly \nrevenue growth for the Medical segment for the first time in over two years. ", "original_text": " \nPage 4 of 19 \n \nWith respect to COVID -19 vaccines, we saw the strength in demand from September for the fall \nimmunization season carry into October, before peaking mid -month and trending to a much lower run \nrate as we exited the second quarter.  \n \n", "page_label": "4", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}}, "62106fa2-0df0-4578-a53e-51fe39997eca": {"node_ids": ["51447f56-c89d-426b-9ebb-f47b55070fb8", "3f9525f0-c979-46da-bc32-6d4316b606f0", "845b711d-e7c3-4266-a749-e55edef2018d", "50bbe4bf-3394-4964-b6e0-777e431d8be2", "c3300713-1e8a-4a75-9a5c-5cd03f601d1b", "8ed0be0e-8c45-47d2-998e-7fc2b18f4c1e", "d99c283d-39fb-4ede-ad2b-761d0ff95a09", "f505ce80-d147-4e10-9208-8cfde73127c6", "8aced6b5-70df-4f2f-90a0-dec3434d1674", "84891518-fc6a-440d-9b0e-3062fe707d85", "259ae151-bf33-4e47-b5e6-b80de93b2640", "0b065238-292f-42a7-b83b-ad904a6d0e35", "444d3782-2c0f-45f3-b8a6-efa202d674ac", "97a7d4ed-7b2e-4b13-b635-5630ea1fbde8", "f0431abd-d0d2-4bb0-8e12-76be35f49076", "c1e144ad-3728-4823-b118-610959f97a50", "f4559797-4e0e-4ca1-84d0-7dac65822cd9", "99ecc5ee-0622-4ac5-9dd0-90959df9d26e", "35a4c3d9-7aa2-4a29-9409-d3131eed678e", "9e7b4c27-a664-49b6-aeb1-73c837d86154"], "metadata": {"window": " \nPage 5 of 19 \n \nWith our strong first half performance and positive outlook, we are again raising our fiscal \u2018 24 EPS \nguidance.  Our new range of $7.20 to $7.35 reflects a $0.45 increase at the bottom end and $0.35 \nincrease at the top end from our Q1 guidance range, and a mid -point which is 26% above our fiscal \n\u201823 EPS results.  We are encouraged by the operating performance of our businesses, and our strong \ncash flow generation, which is certainly contributing to the improvements below the line.  \n \n Interest and Other is reduced to a range of $50  million  to $65 million, which primarily reflects \nincreased interest income from higher -than-anticipated cash balances. ", "original_text": " \nPage 5 of 19 \n \nWith our strong first half performance and positive outlook, we are again raising our fiscal \u2018 24 EPS \nguidance. ", "page_label": "5", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}}, "46b2014a-9df1-4279-a34f-4fd4570310ad": {"node_ids": ["cd9ffd1c-3051-43c8-8973-0721d0ed2a41", "7b13b2d1-a32a-429a-9adc-a33549f9c50a", "ae6163ac-8069-4006-9dd6-8e2b56faf487", "5446d953-c24c-47fe-ac1b-aeae0abed8d8", "c7af42ad-d22e-4f3c-a1d0-4763722b42ff", "95f3cf67-4d72-4239-aaf7-d941f75ba82c", "d9a6e026-62f5-4aee-9629-39693977650d", "1aabddb0-4bf0-4325-bdd2-fe279f7dc2c4", "e2921bc5-1dbd-4321-a278-af9075c70edc", "263863e6-1476-467c-8b8c-378eb99caafc", "5b35f39e-be52-4d19-a5e3-d34eca4912e8", "e69f4c27-e107-447b-a9cc-047ac7eb4ce7", "72bdbffe-4370-40a8-8f76-17ddf47a4ca3", "a9b343e5-cc6a-4b4d-962e-27a7a7f9fbb4", "0a41d06e-0eac-41ed-aeda-ed197836524c", "97cd6209-6d07-4d02-b974-5a85cd437508", "ad9d6ef1-7c96-4a27-8281-7a9dc5149181", "2a71b444-048a-462c-ba74-d888f19a31b5", "9d10591e-f12b-4a3b-b537-a4c0749764bd", "63307908-cd19-4691-b35f-5935607f9bd7"], "metadata": {"window": " \nPage 6 of 19 \n \nat-Home and OptiFreight\u00ae aggregated in Other.  At that time,  we also plan to provide a recast of the \nresults for fiscals \u201822 to \u201824 on the new segmentation.  \n \n Beginning with the Pharmaceutical and Specialty Solutions segment, the guidance ranges are \nconsistent with the former Pharma segment, even excluding our higher -growth Nuclear business.  We \nexpect 10% to 12% revenue growth and 7% to 9% segment profit outlook  for fiscal \u201824, and a 4% to \n6% segment profit growth CAGR over the long term.  \n \n", "original_text": " \nPage 6 of 19 \n \nat-Home and OptiFreight\u00ae aggregated in Other. ", "page_label": "6", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}}, "1b974c9c-bb8b-435a-a421-b84d1956e255": {"node_ids": ["9311ff59-9c98-412a-af59-fd30396a3efb", "c5bbf16b-6a43-44f4-b569-d5218dd4e002", "555af6c8-b890-43f8-bd19-f70e84e98f81", "32f990db-1f0d-4a5c-a7f1-d8bdbe511d8d", "b23e0dca-b34b-4549-bbfa-c2b29152ded9", "43c9c340-ad6b-4c38-a400-5dd92022bcde", "db807c40-67e7-414e-8cca-6e520497267f", "84ec9b09-9ab2-4292-9ed6-8bd5278c659a", "90c0d51f-d87d-4bab-8c9b-eaa7b87c5748", "58fd92b4-fe36-4a8a-8069-136bcfce7545", "46b4ddac-e273-4879-8fb3-22a7003d1469", "40f76173-5e11-4d91-bdaf-4ad7a4a47228", "63206695-382c-4390-ab68-6767f4a298b4", "130dbcf6-273c-4d68-bd50-976970d187b5", "7e1af22d-b54b-482f-94b9-c3d133b1afe4", "c33602cb-89eb-451f-94bf-70ab19a4d642", "652887f1-8aa3-4232-9fdb-42fd4cd75192", "b23c1a75-8def-4517-a27c-2dc6b7461557"], "metadata": {"window": " \nPage 7 of 19 \n \nThough this segment\u2019s structure has slightly changed, our focus on executing in the core remains . \n We\u2019re building upon our strong foundation, while investing to accelerate growth in Specialty both \ndownstream and upstream.  \n \n We believe that this new segment structure further enables those efforts, by enhancing management \nfocus, leveraging the connectivity between Pharmaceutical Distribution and Specialty,  and positioning \nthe business for long -term growth and investment.  More on that front shortly.       \n \n", "original_text": " \nPage 7 of 19 \n \nThough this segment\u2019s structure has slightly changed, our focus on executing in the core remains . \n", "page_label": "7", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}}, "cb248949-64fc-498f-a357-322668a33cd9": {"node_ids": ["50e5df59-c1a0-4d5a-ac2e-b392237e6679", "0168fae5-1479-4543-8914-0603c1531c2a", "fac20d16-66f2-4c74-ab36-21cb576bc156", "fef2fae6-e748-4e2e-89d6-932a0c437e4a", "70f9f2dc-967c-4d32-96e8-a68529ef5810", "cf63d8bb-5614-4279-9b1a-a22515f68f70", "1e571f78-4a3b-4f2d-b96f-e70ce603ce9a", "be104b7c-4278-4375-9ab8-849b1958bb4e", "3c290084-9a7a-43a9-93bb-3f3b237848fa", "8f8cc612-ecf4-4442-b705-62e0522aa90b", "5d079ed4-7dc3-4f4b-9ea1-fc1a99f369af", "b58873c8-367d-452f-a56c-fce70ecbbce2", "a73a1c4e-bd86-475b-b6be-4b4366cdddcf", "cf35929c-ff61-4f37-875c-986901a68dc4", "ee05a25c-dbb9-4803-a0a1-4def30f01f77", "3946df4e-2014-4b39-9403-1767aaed4df7", "47895c88-6bc4-43aa-8edf-9adc38447bd9"], "metadata": {"window": " \nPage 8 of 19 \n \nSecond, c reating a platform for our expansion across specialty therapeutic areas.  The company\u2019s \nPPS Analytics solution is a subscription -based advanced technology platform that utilizes artificial \nintelligence, such as continuous learning algorithms and natural lan guage processing, to analyze data \nfrom electronic medical records, practice management, imaging and dispensing systems and \ntransform it into actionable insights for providers and other stakeholders.  We see this complementing \nour suite of clinical,  practice management and distribution solutions to specialty practices nationwide. \n Specialty Networks experience and capabilities in clinical engagement are robust, which also \naccelerates our upstream data and research opportunities with biopharma manufact urers.    \n \n", "original_text": " \nPage 8 of 19 \n \nSecond, c reating a platform for our expansion across specialty therapeutic areas. ", "page_label": "8", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}}, "dd0c036b-c7ea-4c12-b21f-2c88607b8c5c": {"node_ids": ["af491530-c3ad-45bf-ace6-d7d2671965b9", "8a90e4e0-eacd-4a83-8ae2-0cf30c0bab42", "304ac4bc-a541-4424-9b4c-b8b64313dcd6", "b37b57a5-942d-4a57-b3f4-412b40b20176", "3a1862bc-a495-4847-b59d-66aad3b43d88", "9f9bc403-b149-4043-90c5-9634d43a9840", "fbff49a6-910a-448d-a85a-f02c8e203f8d", "70600a73-fa6b-40b3-ae8c-c00996535c0a", "e3c4e1d9-0abe-423f-a6f2-4bce556e2ea9", "2a79b74f-9962-4f38-bc50-7da567f207ee", "951bda90-1220-4014-8f81-a3412d4a53aa", "cc01a675-e4e0-41c8-a5b2-6b3b3b99c275", "31223a1c-a92c-4967-bff0-460eca6132b7", "77180a31-af95-41e7-b5b3-5cd49290594f", "69c10b64-a513-48d0-886b-9224b26b8499", "c6f577c9-834a-4a47-9a77-4edd826aa38a", "b1e4b3b3-3aaa-4055-89c1-aa346bfc7db7", "cee6f8f3-e90f-4ee9-bd47-b2dcca2dc6c2", "c0bfa657-e3c6-4f06-9052-a0603618d961"], "metadata": {"window": " \nPage 9 of 19 \n \nWe are also continuing to invest in new product innovation and portfolio expansion in key categories, \nin alignment with our disciplined portfolio management approach.  \n \n As a result of our team\u2019s collective efforts, we\u2019re seeing our 5 -point plan to grow Cardinal Health \nBrand volume result in improvements in our leading indicators, and most importantly, strong customer \nretention and product volume growth.  \n \n Finally, we continue to drive simplification and optimize our cost structure by exiting non -core product \nlines, rationalizing our network , and streamlining our international footprint.  \n \n We believe our new structure will further enable our Medical Improvement Plan efforts, as we \ncontinue to execute the plan and deliver value for customers.  \n \n", "original_text": " \nPage 9 of 19 \n \nWe are also continuing to invest in new product innovation and portfolio expansion in key categories, \nin alignment with our disciplined portfolio management approach.  \n \n", "page_label": "9", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}}, "0be51136-ae11-430d-b0c4-8d03b6d16d4c": {"node_ids": ["3aed3ca6-89b2-46ee-923d-6c9579add71d", "35182a77-950e-40b7-a41c-1143adcc3c0e", "d03b695a-7b1a-48db-88cc-b7c26078cbcd", "f0476995-35cc-4a40-b7ea-6891e8a891bd", "886dcbad-98e1-4c45-9054-2b18d1274bb8", "1dff6ac6-9a19-4836-8cb6-0ad19efec4cf", "2e5006eb-a0b6-48fd-9f66-61d790060772", "7c2a3a7f-3b94-4533-8b92-ec86c669eaa8", "62176bcb-4113-4dbe-bd59-063def3f2b1a", "9cf1b625-527a-4cfe-af44-9b91586cc312", "e3e87f39-2f8c-4161-a3a6-0b73b52ffc0b", "1d5099cc-e8c8-4b54-993f-3454efabda9d", "19fa639b-9bae-4312-ba26-a23e7e3945e7", "00d6f413-0d3a-4dfe-ae32-c4f468cc1746", "7efe25dc-48fc-42f2-b2a8-15752901612b", "e013b527-1b94-4fc2-a7ae-b35abc2b6eae", "75bbcc61-ac12-4770-8da9-5fb27af869f7", "e5e8352a-8e14-4201-8c26-a96be3fa17e0", "588b9c19-8c10-456d-ab55-ea023d7d318d", "da5dc87a-5381-4245-ac99-f47e3baa2b9f", "cd7454c5-91b8-442d-b376-8e74bb217dc4", "9a77fa52-81e9-43f7-b119-832f43f6201e", "de100211-e95f-48b2-8829-e9daea52cede", "01a973ec-6ff2-440a-92db-8fa255c01bbc", "1742b17b-20ce-43a7-bb47-274ab10fc2bf"], "metadata": {"window": " \nPage 10 of 19 \n \nprevalence, emerging Alzheimer\u2019s therapy availability and reimbursement, and increasing clinical trial \nneeds.  \n \n Finally, priority number four , maximizing shareholder value creation . \n \n We\u2019re continuing to maximize shareholder value creation through our improved operational \nperformance, robust cash flow and responsible allocation of capital.  \n   \n As Aaron noted, our robust cash flow generation is not only driving benefits below the operating line, \nit is enabling our opportunistic capital deployment , with additional share repurchases in the quarter \nbeyond our baseline plan and our ability to pursue value -creating M&A in Specialty.   \n \n", "original_text": " \nPage 10 of 19 \n \nprevalence, emerging Alzheimer\u2019s therapy availability and reimbursement, and increasing clinical trial \nneeds.  \n \n", "page_label": "10", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}}, "b4407d4d-b563-4c08-aa98-9c55aec1911f": {"node_ids": ["da8c225f-2dc1-4dab-9bb7-0d2d0aa6adc6", "7897b9a9-e59a-4e0d-94aa-4f66487a6334", "d6b208c8-07c9-4624-8baf-63f6c6ced31f", "41da7205-52a9-45ed-b750-0c39e3b0a248", "0ebbb8aa-93ef-4691-b413-d9e82728b5c5", "7525efe1-c12b-441c-9624-b8865f30aa32", "db85f13a-5c9f-4676-b788-eeb119826fe2", "481dd25a-a48f-467d-abc8-8c7f00c10400", "e05c2758-a557-4cc8-95f7-8721e3831a4e", "4f673dfa-ee43-4082-9091-67651040c039", "458dbdf3-09fa-4c9e-ba92-8519ea6a1df5", "46667162-05bd-4bce-be1d-abd52f201488", "ca2880cd-622f-4084-9382-3ceb3e291910", "b62b2866-0edf-4585-bf8a-04fa73151984", "3d832961-1de6-41df-b9f7-8fcee26e3bc9", "ec908560-986a-4256-9e9e-fa0292bd2a3c", "03ab3e2f-3931-41b6-b691-1718e5d2ede2", "b3304d79-f196-409e-b3a8-fbe621a7a113", "b647a521-8609-4b97-ae49-6af447026582", "cca5ad36-2127-463f-be4b-4ad243e9df99", "9b99e806-62e9-434d-9ae5-9a6fdb561630", "6a73f8c1-43fa-49ea-8528-5ad6dea2421e", "4d028826-cb65-4f5c-8b3d-51a1ccc5f21e", "11c2f803-5bdf-450e-834f-eca7bfaec6ff", "6051638b-89fb-4e3d-9d88-ccce6b72047b", "6f3fce4d-c647-4c1b-9960-0b518a758cb3", "7ff8ca1a-21e3-40f3-b3d1-eaed2971ef62", "5cab21a6-25a8-4e3a-9b70-c66ac5a3edc5", "ce4ae115-06fa-4dcf-ac79-41aa04c03004", "4e802994-243b-44e0-95c5-5c6a0a563285", "87f572ce-aa8f-45db-8e49-184000e38a43", "59085e65-3a54-4079-9170-ad230a2b1dea", "72b690d9-0331-4411-9347-932df9e5a9ef", "a9c7e98d-0b9d-4c98-ad09-8c94ce597237", "16a1d2e2-21e3-42cf-8377-47742de8a75b"], "metadata": {"window": " \nPage 11 of 19 \n \nSo, that was really exciting to us and it's certainly a key part of the value.  So, we definitely attributed \ngood value to that technology and where we believe that can go.  And not only is that good for our \nbusiness, but importantly, we see that technology is really solving a lot of customer, both provider and \nmanufacturer challenges , and ultimately giving a much better solutions to the end patient.  \n So, it's a win -win across the industry and one that plugs in nicely to our strategy and to be throughout \nthe specialty space. ", "original_text": " \nPage 11 of 19 \n \nSo, that was really exciting to us and it's certainly a key part of the value. ", "page_label": "11", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}}, "f6aa5062-6f6b-48ce-b783-7a0df37afe92": {"node_ids": ["7eab7704-61ea-4c02-9f86-416fac68fee1", "6c9340db-3e8e-4ab4-a8ba-625ed62d3398", "8a18a009-f699-4f8b-b756-23a321d8e9ed", "9629e9ef-fe06-41bf-bb6d-1fe5be376d7a", "6fbaf010-4d69-403d-9007-f0c00a132875", "67c3b1a7-1db3-464c-86d3-3e7271c18d23", "ae89a610-3160-48d5-b8ae-bd508f2defff", "167dc050-c078-48f9-b264-69ae17ca8ab8", "bf4e18c6-44e8-4231-be5b-b8ce6fae391b", "b2d2c856-c1a9-4be6-8c70-290dcc72c675", "4840c105-9d65-4c00-bee1-8624d6039756", "600de59c-58aa-422d-a43c-d19840fa4c8f", "364ea9e2-e7a6-461b-ae2d-a0cdaa895fe2", "63b97613-ed15-43de-9ba6-6394455b8cab", "72f07ada-7aee-4d9b-9da4-82b9adbead4b", "16149aa9-a975-411f-a12b-96ad49e97df0", "3bca1532-55b2-443e-9585-cd8bf53c8bf7", "eb93f940-44f9-4914-80a9-5845b2f7e70c", "b843e5c0-4471-45d5-a108-da28578569d4", "c01ccf74-6dd5-47fa-b795-4d40809dbd96", "20654277-bde5-4825-b8a7-739f3512ad7c", "c2a29d29-99ce-4ba1-a30e-b10420669489", "daf05f0c-1d53-4e7b-8b84-5a08476fd49d", "6ce3c768-7bad-480d-aea6-0082550df34c", "39229aaf-89d2-4a27-a73c-56c3931ebbe8", "224eb121-5ae3-48c8-b111-a421cc33b0f9", "7f1fbbd9-bace-4242-b340-6c1929f61d16", "bf21d441-4922-4ec7-8b35-6b7c66115a5c", "8c048a3c-f8ea-4b9a-94f0-b96222c3a02a", "07dff0cf-9e28-4f4d-a388-cc54d670d1ec", "a47431fd-b28e-4608-968b-fcea260d5b5f", "0bfe42aa-9cd0-4f01-b1c1-0e67b9f7fe0b", "87633704-e563-448c-959d-19a29304ef42", "06166617-a9b1-4983-9e8c-5316f389b8d7", "c7b05756-88fe-468f-982a-73ed25daf215", "6defb0d4-8313-476e-aa64-4ae8ad5c8f85"], "metadata": {"window": " \nPage 12 of 19 \n \noperational performance of the business is exactly how we've laid it out.  So, the only update that \nwe've had today were in recognition of some of those non -recurring items.  But the plan in the fiscal \nyear \u201826 aggregate targets that we're going after are absolutely unchanged to this re -segmentation.  \n \n We did have to bucket the Medical Improvement Plan into the various buckets because we did have \nthe growth businesses that were a component of that. ", "original_text": " \nPage 12 of 19 \n \noperational performance of the business is exactly how we've laid it out. ", "page_label": "12", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}}, "8e2e64d9-3499-4495-ab28-5ac0bafd5491": {"node_ids": ["8743357b-ab76-40c9-bb0e-fee9746c43ab", "1cecb194-0916-4261-9539-8196739eef0b", "a65bd46c-268a-4135-9df0-1dd7b978c15b", "e75bdab2-d675-40a5-823a-26e0594473a9", "bee18eef-db7e-421e-b317-7ed40d0007df", "aa2ebc78-eb8e-44c4-9ae2-c1dda9eb35ff", "896ef14f-d281-421a-b1ae-7d60dfae0a64", "384c0f53-19e5-40de-84e1-7dc37acfb21a", "6109f078-79cb-45e0-a852-54a030e02063", "2d81aefd-baa3-4183-a7d3-ec96a7b3f8f3", "cf9b24db-5c23-4f43-9022-ee8770c6657e", "6286b206-919b-4849-bd23-1c4644fdb1e6", "ee618f4e-7c8c-496c-bd24-cccb7ee26798", "e576ef33-8548-4237-9f70-932ce726bcb1", "6b4d5dc8-6c7e-4ddf-9bc5-faddbb164216", "0a8e1d9f-0e35-4392-8c3f-68c179e0b5f7", "2fe6127e-3443-49de-93cc-1c8a7d838070", "0f8291b4-98b5-4597-8039-00e7bb048fa6", "de9bedac-31fb-471f-b4b2-c958eb673c14", "2cac00ca-b730-4839-a939-b4bc5dd11756", "a6668b04-d143-4c78-b659-53cef90a138b", "d0695bfa-5eb1-496e-9262-46cf039adcd1", "93dbad4e-6575-4b4b-8fb9-feacc180d965", "740c43ec-2bc8-4b31-9b05-99512d4e7323", "f916aa3d-2c46-41f3-a325-321e4735667a", "a4effb32-6707-488b-ac5a-81c401502af8", "cf37ae39-a62c-4c40-83a3-f766c121e737", "14ce4cfc-a92d-4e6b-b5fe-d7d7476ee6b8", "3c6dd035-4aab-4931-a463-9ee77492eeba", "27327809-f4b1-40c5-86d7-920e0ee648c7", "038de542-1eff-43d2-8ec4-2461758da211", "412bf8a1-ef8f-4cc4-93bf-916b6ae4067c"], "metadata": {"window": " \nPage 13 of 19 \n \nOperator:  Yes, sir.  Our next question is coming from Mr.  Eric Percher of Nephron Research.  Please \ngo ahead.  \n \n", "original_text": " \nPage 13 of 19 \n \nOperator:  Yes, sir. ", "page_label": "13", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}}, "0ac9f346-07e9-4997-8f28-e5117e7bae25": {"node_ids": ["3f05051c-7f51-4210-88c3-f32a3503a2a5", "d22e444a-6136-41a3-b630-a911c2a1fc4c", "3357e4dc-dd4c-4885-84c7-ff75515c7dca", "901b2bf8-7d30-47f6-8a79-03e7dd9735fa", "6b08b11b-4232-46c8-9ef1-9400160a82c9", "1a4a65d0-1991-4f09-90b4-08a4766d081c", "84f58ebe-9235-42a4-b2b6-24db9039b329", "c49b04ba-7739-41b3-89a5-7fa712a09eca", "c82179e8-f816-44dc-9211-ee618cff90d6", "49c95ca7-ebc6-4fc4-bbca-1dd2935f0a29", "7e1da58b-931a-4e7e-b6aa-745b9c0fc67b", "6fe2fae4-a1b6-4454-b152-52cafdee41b0", "7e300fd9-8b96-4568-8ea1-6d70f95b029a", "cb264db5-3958-4b71-8130-a43a56b021c5", "7749c7ee-fae9-46b4-9db5-44960fd3aa4d", "e7cf09fd-54b3-41a2-8879-5a5056a2f170", "a9a66894-f487-46b7-a69d-f4e8ee4499cc", "eb1a401f-f75e-4f86-8f1e-38b58b463d8d", "be8079b6-fade-497b-aa02-194ec352e7c3", "400399f0-1f09-41b0-ba29-4ff37f0bbaa4", "e530ef42-af97-4bf6-a83e-475cc392bc8a", "520a0f9f-e6ab-4e9a-9274-bb2667dea598", "70599055-c6f1-4ea5-96ba-542587a140d7", "b742bf7b-5425-460a-b17e-5a70f87545e2", "9d4098c4-fce0-4827-90cc-f733f2f4d3d7", "43c47f12-380d-4213-bbaf-a3d679f631f1", "3fc7508c-13c4-40ae-a13b-ac6eb9a6a8a4", "7f805137-8557-43c3-8fd4-36f4f03d7034", "49a2968d-a6dc-4eda-8f83-78122754776d", "ed2167f4-3ac1-404f-bf75-2c0065e928eb", "70ca24c3-901d-4ccf-b35a-9b59b32ccdb7", "1ff1d9de-e075-4b4c-a98b-d5531bb82408", "c3283e31-7e49-49dc-befc-2be590f6ff46", "5a9b816c-bf9e-4b3c-b205-7fcb01a04871", "3e2c9d33-02f8-4a3e-bd1d-f12cf7de7811", "55498f05-3c1a-45b8-ac5a-7797c29997fb", "14986283-48a4-43e9-a676-6c172a1c2c08", "5045c9d5-9983-4b1f-86d0-32f8a239d857", "1bee3d3c-a2d6-41e5-a4a4-4a0b97d38350"], "metadata": {"window": " \nPage 14 of 19 \n \nSo, there's some time now for the next couple of quarters needed to get that to roll through our \nincome statement.  But the actions now are largely behind us as it relates to inflation mitigation.  We've \nalways had confidence we  would get to this stage, but we're now at this stage and have even more \nconfidence actually seeing it start to come through in the second half of the year.  \n \n Now the other component is the Cardinal Health Brand volume. ", "original_text": " \nPage 14 of 19 \n \nSo, there's some time now for the next couple of quarters needed to get that to roll through our \nincome statement. ", "page_label": "14", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}}, "5cf92087-e35d-4fba-85d3-821d01035638": {"node_ids": ["989f35b7-f155-4e88-9b3d-99dc4b82b067", "284a148d-feac-4eb3-a6a9-8e60321f9f1c", "65dda52d-a8fd-425e-bbea-2c466aaddadf", "66bb4983-da23-4619-99dc-cc2265374dd6", "43569f33-965b-4263-beeb-1a03d93cc6b6", "af2a4a68-63b8-491e-a0c5-23acb4b11f5a", "d0b877e8-2713-45b2-a7d7-46144db0af75", "2649aa6d-2acc-46ae-a7c2-61ff0360352d", "14e4659c-c425-4aea-9c16-7247178e524b", "b60cf5a6-c47a-4d20-9e03-83fd0d70b1a7", "00d39fc7-7e04-4c84-94d5-3e0bbb38193b", "f357ae8a-9a96-4e19-a929-34613b60b09f", "7224056f-f34c-471e-9e14-b3f8a0f7f715", "58a4b74f-a9b1-4c18-9515-be998860a05b", "e057bab2-236f-4ae9-a0cc-6e5814e3482f", "fb4c981c-8420-47a8-adb8-058da50f0a3c", "d8f9cd1e-ea46-43fc-98f0-fd6818dc49b2", "eb3c614a-b681-4851-a036-22dfe438bfae", "4d535836-2f25-4c28-b7ce-90bfcbba3675", "e4589d49-b52e-4fdd-8058-f96abae1be02", "c59c3428-8f76-4308-b58a-9e36d67c97cc", "c8dfa6c5-4323-4c4f-8bf7-ac582a8f435b", "3a30fe86-63e1-406a-8ee3-5004fd6963dc", "08277890-3d82-4e84-ad09-c197ac32b72d", "3050c150-95ed-4d9e-8d7e-a356dbd02b1a", "909afeea-cfae-40c9-89a2-4817f915f180", "da612441-8817-43e0-8189-50323c9099c5", "caefe377-afb4-4ec0-85a0-9b66a041ccfd", "e3ed3339-96fd-4c8b-9b78-9cdd14be00ec", "4dbaec66-07d5-4f16-b8c1-71e8404463c5", "bdbadb6b-bcb8-4f6a-b12c-5bd8302a6780", "c2b6b96f-4761-4bb5-9ac7-4ddc64285109", "2b28cded-3168-47be-a75a-04ba7ff7503b", "c1c69078-3694-480a-995d-4fc91698e90a", "18c8f6e5-05c5-41c9-9729-896c46c0cba3", "542f85ec-3ab4-4e77-baeb-148fc11a703c", "aa064d45-ec4c-46da-8395-970deaf301f6", "7a750335-3830-47b4-9fad-a07a8a833139", "a0a3addc-273b-4c68-a6d2-c960baf2ac0a", "3ab7afeb-5439-4b4c-be1b-e6006f6be773", "b2914adc-8dc7-4f7f-99c8-2d6181827e10", "ac853a32-bdf8-4a8e-a3f4-457b62da9b47"], "metadata": {"window": " \nPage 15 of 19 \n \nunpack exactly what those expenses are?  And then how should we think about SG&A growth for the \nremainder of the year?  Thanks.  \n \n Aaron Alt:  Happy to offer some perspective. ", "original_text": " \nPage 15 of 19 \n \nunpack exactly what those expenses are? ", "page_label": "15", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}}, "6d5ec7f6-bdd6-41b2-9b56-d1f2960aaef4": {"node_ids": ["12653169-53f1-41ac-8f73-976b95773fd3", "13622462-122e-4de3-8c44-6798bdc46e4c", "b29222ba-64b7-4ba8-a35a-da18b620af59", "1ef60e61-99b2-40d0-9ae3-fec5bd874e47", "a8d9531e-d9ca-460f-8733-a8d9f10aced1", "d31dc993-aecd-49b4-a9d4-97605fb5c8a1", "e95281c1-c6ff-4650-ac92-369a8444afa2", "ea70d62a-d14e-4e09-8213-cbeea8029853", "de7cdfed-11e3-4c2e-8af1-d2268ae2dae7", "e8869165-9c6f-4cef-b3a7-468f8215efa0", "87e200f6-bc57-420f-a871-b3afd1d21a23", "0b8bbc53-2dd6-4657-ae4f-bf816fb159c2", "38d3e55b-7ab5-48a1-aec9-7281b73f295c", "87197485-940e-409d-a9ea-731c2f35657f", "30affc97-ddce-40da-a4bb-c83b55a92fcd", "c1471836-60f0-4660-8568-c56311933c5a", "ab0c38fa-505f-45fb-9a3b-7f65eceb7977", "8e971903-8b92-41d6-ad4b-dfa11c01f956", "2b4cbce0-912e-42dd-8a8f-9ff1d1a8945b", "4fef81fe-fd48-497d-b6b2-7ac2ababd63f", "db2ea73b-b0f0-4fb0-a5c1-6e520da845a5", "f47bf491-0436-45ac-aa5f-93cf985c17e5", "4521b31b-30eb-412a-bb80-8cc034b4ead6", "17d5ae9c-86bc-4f28-bace-78574ee1b645", "c8857409-c8ac-4d47-bff4-46b02417919c", "5c659247-40d2-4e0c-b196-b301cd218cb3", "8d92e2f5-73df-4bf8-b7bf-7fbcbff943d0", "4a933b8b-e029-4ef6-9703-837a74507525", "8e487d6f-16db-4d2b-8645-9ef5403e7bd4", "1290d304-e8be-48bf-ad8a-7c92fc8aefa7", "294d0bf8-f62f-4bd3-b414-a6d312edabc0", "ea97ddd3-ba21-48fc-88b0-acceb624cfcc", "d434d266-6de5-44d3-869d-e213e6694d75", "64dc31a6-6d0f-472d-9ce8-754c469b53f4", "11dfc159-cd50-49ee-b47e-84d816a98128", "0205b7fa-c0df-462b-9137-39a9c11521da"], "metadata": {"window": " \nPage 16 of 19 \n \nPharma side, the consumer health new logistics center.   So, and I also made some comments around \nsome of the IT capabilities within Pharma and the e -commerce and Intelogix \u2122 capability.  So, we are \ninvesting where it makes sense, efficiently, very well -aligned to our strategy.  And these are not \ninvestments that you can just turn on and off. ", "original_text": " \nPage 16 of 19 \n \nPharma side, the consumer health new logistics center.  ", "page_label": "16", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}}, "0d51f961-2630-4f26-b63f-20378f90e37c": {"node_ids": ["6956d2b9-4838-4559-a7a2-1fee8635ef82", "8b8ff68d-b80a-4a3e-8be3-771c67db055e", "678fdc7f-8185-4c8f-9573-4d3c150b20da", "2131668c-e803-4490-bd4b-a661ad485016", "8df6e9a1-eb18-48b3-8cee-86797c1e7349", "0fc3ade2-4d5b-4668-94a8-b6a4484d5dc4", "a53d491a-ca38-496c-91dd-c2efaca5039c", "d69e54a2-d7db-4330-9f87-fbcb39c98b8f", "f9ea1971-7c70-4470-b5e7-e5488bd80f02", "7d2467da-d112-4a32-9a01-23f14cf8a1fc", "2ec08fa5-29f0-42d9-9080-1d2fb799eaa6", "b5d73c51-2c59-4478-899a-346e90c2dfa7", "019a0f8c-4027-49d6-bbd8-df5982e10f6c", "65abbdb0-7509-4798-8524-d99e6dcf1b3c", "a6f2297f-cb23-41f1-936d-c8b8427e3e2f", "c11849f7-7cab-49c7-ae10-3ce7140a5846", "ff75ffb2-8fec-40a9-b880-12d1034fca6b", "63fc2bb7-dea5-4c7d-a1c1-43098f1b3eb6", "80c6ec03-2a40-4124-b02d-cc9ff20bf222", "0a5a1648-6d22-4e4d-b1ec-1dffda1ec6f1", "2c6e7904-ef9b-4745-aa79-195d0768634c", "73436123-325b-4a00-b7ea-cef9b942348c", "9d2e8dc8-263a-4514-8dd9-01baa0b096a4", "4237d889-7794-4b67-85b7-935a956624bc", "a54a84f8-7455-48ff-80bf-7aec9afec552", "349bda6a-857e-4f34-974f-97ce681608a6", "06bdfb1f-7d00-4026-807d-278c784f1241", "e8ff7435-dc0b-4422-be69-9ea3731dc20e", "72df9eee-d456-4278-af7e-cf75f7203c81", "d83a5a3f-f739-4f23-81e6-2ac536c19a7f", "23b72e29-c5a5-4ae7-a84c-26e6a57a09b1", "31acdef2-19e9-48f2-9b84-ebf773f1b34a", "4acb7a18-3f3f-48d4-8fee-803d6f659e14", "014d7f31-af18-4ae8-ae10-a7c229c786a4", "fd97a8d1-76fa-46dd-b7c5-266c7fe1e0e1", "50cd9dfc-9e14-4d52-97dc-0f01f9b5ff97"], "metadata": {"window": " \nPage 17 of 19 \n \ndoes that actually represent in terms of the underlying accounting and our business activity.  Thank \nyou. \n \n Jason Hollar:  Yes.  So, for the vaccines, let me  just kind of walk through the last couple of quarters, \nand that will give you a flavor of the benefits and the trends and such. ", "original_text": " \nPage 17 of 19 \n \ndoes that actually represent in terms of the underlying accounting and our business activity. ", "page_label": "17", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}}, "0deec662-07aa-4179-9d25-c20d9a0a3f6c": {"node_ids": ["c351a89d-353e-481d-84d9-f3966c0ca6c8", "c423abd1-d9ed-47b9-adab-7ee047c21c4e", "744e9bb2-3701-4ce3-8b17-ede2ce4f85d1", "d48bb228-ebc8-4384-bfb8-8ad64388b724", "b6da76c2-fbe6-44ab-b276-23c9605a7145", "6b6bd3ae-2aa2-412f-8541-5321c99eb11c", "2ca25976-3146-4672-90ac-64e4c0a302e5", "4f7bca5b-929e-4069-82b1-18c3e131e9e9", "ea4685da-3f85-46c4-9d22-42c1f2a1d067", "2239daae-a42f-4daf-9a34-afe95092a964", "79abe1c7-9c4b-43d5-85db-6d199c3df288", "2117cc69-f7e4-44dc-b626-c1f2b431ef74", "5f00cd55-801f-4309-a8e5-11e73a2bc731", "4bcaee50-97bc-4aec-9204-00b35a49192d", "b2afa807-8304-4a24-817a-52f4ed6d422d", "5950d0db-b458-464c-9730-76ac2dab6003", "6a828dd6-af56-4f37-8e93-96a60843bd30", "be0ce916-bc5b-492e-8459-6c92501bd2bd", "329d1330-4598-45a4-bd08-470e72579014", "426e93f2-f383-4950-a373-772f8cbb37f2", "befcdd3f-9d7a-4c3a-bbcc-ce554b595f11", "a004ad39-b1cd-48d9-a1a7-5e2ffdf5117f", "7a9bda51-e8e1-4933-afe3-062ff35af2f9", "ffa75df3-eb8d-4d72-8167-2ee14f2e2d2c", "830ae623-4c88-4e2a-91aa-202d3e3f48fd", "29fad6a0-0a46-412b-a1e1-11318294c102", "2722cd83-e05d-490a-bec2-ad3fded20d27", "20599250-aecd-4ff8-85ba-5ea98f0735ba", "8c34ad96-1c1f-4b01-a70c-0679d5398877", "dd09368c-b0db-4893-a3c8-afce7c937dd2", "5d32ffae-30e3-41af-84c8-69b1cc437fbf", "687939ab-d703-4c12-b8a3-90a3967e1c6e", "18230539-18b0-4170-b469-4e8b96b68371", "65552542-c9cd-4c0e-b631-1e685ff9dd2e", "b0f50702-52d6-4dc1-9b1d-ea2d14f1307e"], "metadata": {"window": " \nPage 18 of 19 \n \nback to my prior answer to that question.  There were costs associated with the vaccine rollout.  As \nyou can imagine, that's a lot of volume to ramp up for really two months' worth of support.  Our team \ndid a fantastic job working with the manufacturers and our customers to play that role when we were \nnot involved in the vaccine discret ion before COVID.  ", "original_text": " \nPage 18 of 19 \n \nback to my prior answer to that question. ", "page_label": "18", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}}, "269e28ab-8278-4b1f-8f4a-d4f82d6c333a": {"node_ids": ["315be810-f70c-4406-86c2-ed1cabceb7d0", "03ec4e6b-6407-4b43-83a4-184007bffbef", "2e2a9366-80a3-44ce-9157-ddc5fc39046e", "4b09cbc6-a9b1-45f8-b55b-fc3a00aa2751", "4fcd9ef9-5c30-44c5-aba3-f7a6acbd24f7", "d60bbae8-2270-49dd-add8-34b9dedf6a5f", "6290f6af-acdc-4c2f-9f82-ac1b5f6df889", "aba47aa3-1b7f-4864-b5f9-63a0f06f66bf", "3a5bc759-4aa8-4451-bbd5-4423ad922c86", "e3ec08d4-8fc2-4fb1-9477-0841d4be4e5f", "76984402-1833-4729-9c30-d510b2882fa3", "effaa786-cbc2-4692-8f66-5d1470e46276", "e788ae7a-4203-4c3f-ba68-c28469df465c", "8059ec2f-7c0a-4d46-ad87-508f624e497b"], "metadata": {"window": " \nPage 19 of 19 \n \nOperator:  Thank you very much, sir.  Ladies and gentlemen, that will conclude today's Q&A session. \n I'd like to turn the call back over to Mr.  Jason Holl ar for the additional or closing remarks. ", "original_text": " \nPage 19 of 19 \n \nOperator:  Thank you very much, sir. ", "page_label": "19", "file_name": "CAH-Q2-FY24-ECT.pdf", "file_path": "pdfs\\CAH-Q2-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 209786, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}}}}